Patent Publication Number: US-2004043382-A1

Title: Novel proteins and nucleic acids encoding same

Description:
RELATED APPLICATIONS  
     [0001] This is a request for filing a new nonprovisional application under 37 C.F.R. §1.53(b). This application claims priority to U.S. S. No. 60/274,322 filed on Mar. 8, 2001 (Cura 590); U.S. S. No. 60/283,675 filed on Apr. 13, 2001 (Cura 590D1); U.S. S. No. 60/338,092 filed on Dec. 3, 2001 (Cura 590D2); U.S. S. No. 60/274,281 filed on Mar. 8, 2001 (Cura 591); U.S. S. No. 60/274,101 filed on Mar. 8, 2001 (Cura 592); U.S. S. No. 60/325,681 filed on Sep. 27, 2001 (Cura 592J1); U.S. S. No. 60/304,354 filed on Jul. 10, 2001 (Cura 592I1); U.S. S. No. 60/279,995 filed on Mar. 30, 2001 (Cura 592H1); U.S. S. No. 60/294,899 filed on May 31, 2001 (Cura 592E1); U.S. S. No. 60/287,424 filed on Apr. 30, 2001 (Cura 592D1); U.S. S. No. 60/299,027 filed on Jun. 18, 2001 (Cura 592D2); U.S. S. No. 60/309,198 filed on Jul. 31, 2001 (Cura 592C1); U.S. S. No. 60/281,194 filed on Apr. 4, 2001 (Cura 592A1); U.S. S. No. 60/274,194 filed on Mar. 8, 2001 (Cura 593); U.S. S. No. 60/274,849 filed on Mar. 9, 2001 (Cura 594); U.S. S. No. 60/330,380 filed on Oct. 18, 2001 (Cura 594C1); U.S. S. No. 60/275,235 filed on Mar. 12, 2001 (Cura 595); U.S. S. No. 60/288,342 filed on May 3, 2001 (Cura 595J1); U.S. S. No. 60/275,578 filed on Mar. 13, 2001 (Cura 596); U.S. S. No. 60/291,240 filed on May 16, 2001 (Cura 596I1); U.S. S. No. 60/294,485 filed on May 30, 2001 (Cura 596B1); U.S. S. No. 60/299,310 filed on Jun. 19, 2001 (Cura 596A1); U.S. S. No. 60/275,579 filed on Mar. 13, 2001 (Cura 597); U.S. S. No. 60/275,601 filed on Mar. 13, 2001 (Cura 598); U.S. S. No. 60/276,000 filed on Mar. 14, 2001 (Cura 599); U.S. S. No. 60/280,900 filed on Apr. 2, 2001 (Cura 599E1); U.S. S. No. 60/276,776 filed on Mar. 16, 2001 (Cura 600); U.S. S. No. 60/294,889 filed on May 31, 2001 (Cura 600G 1); U.S. S. No. 60/318,770 filed on Sep. 12, 2001 (Cura 600E1); U.S. S. No. 60/276,994 filed on Mar. 19, 2001 (Cura 604); U.S. S. No. 60/277,338 filed on Mar. 20, 2001 (Cura 607); U.S. S. No. 60/325,430 filed on Sep. 27, 2001 (Cura 607J1); U.S. S. No. 60/332,094 filed on Nov. 21, 2001 (Cura 607C1); U.S. S. No. 60/299,303 filed on Jun. 19, 2001 (Cura 607B1); U.S. S. No. 60/288,066 filed on May 2, 2001 (Cura 607A1); U.S. S. No. 60/277,321 filed on Mar. 20, 2001 (Cura 608); U.S. S. No. 60/280,822 filed on Apr. 2, 2001 (Cura 608A); U.S. S. No. 60/277,239 filed on Mar. 20, 2001 (Cura 609); U.S. S. No. 60/277,327 filed on Mar. 20, 2001 (Cura 610); U.S. S. No. 60/277,791 filed on Mar. 21, 2001 (Cura 611); U.S. S. No. 60/333,184 filed on Nov. 14, 2001 (Cura 611H1); U.S. S. No. 60/277,833 filed on Mar. 22, 2001 (Cura 612); U.S. S. No. 60/318,462 filed on Sep. 10, 2001 (Cura 612J1); U.S. S. No. 60/288,528 filed on May 3, 2001 (Cura 612A1); U.S. S. No. 60/278,152 filed on Mar. 23, 2001 (Cura 613); U.S. S. No. 60/332,272 filed on Nov. 14, 2001 (Cura 613D1); U.S. S. No. 60/278,894 filed on Mar. 26, 2001 (Cura 614); U.S. S. No. 60/312,903 filed on Aug. 16, 2001 (Cura 614C1); U.S. S. No. 60/333,272 filed on Nov. 14, 2001 (Cura 614C2); U.S. S. No. 60/279,036 filed on Mar. 27, 2001 (Cura 615); U.S. S. No. 60/332,172 filed on Nov. 14, 2001 (Cura 615I1); U.S. S. No. 60/337,426 filed on Dec. 3, 2001 (Cura 615I2); U.S. S. No. 60/278,999 filed on Mar. 27, 2001 (Cura 616); U.S. S. No. 60/279,344 filed on Mar. 28, 2001 (Cura 617); U.S. S. No. 60/332,271 filed on Nov. 14, 2001 (Cura 617J1); U.S. S. No. 60/291,099 filed on May 16, 2001 (Cura 617H1); U.S. S. No. 60/291,190 filed on May 15, 2001 (Cura 617E1); U.S. S. No. 60/280,233 filed on Mar. 30, 2001 (Cura 618); U.S. S. No. 60/280,802 filed on Apr. 2, 2001 (Cura 621); U.S. S. No. 60/335,301 filed on Oct. 31, 2001 (Cura 621 F1); U.S. S. No. 60/337,185 filed on Dec. 4, 2001 (Cura 621D1); and U.S. S. No. 60/345,705 filed on Jan. 3, 2002 (Cura 621B1). 
    
    
     
       FIELD OF THE INVENTION  
       [0002] The present invention relates to novel polypeptides that are targets of small molecule drugs and that have properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions. The present invention discloses novel associations of proteins and polypeptides and the nucleic acids that encode them with various diseases or pathologies. The proteins and related proteins that are similar to them, are encoded by a cDNA and/or by genomic DNA. The proteins, polypeptides and their cognate nucleic acids were identified by Curagen Corporation in certain cases. The XYZase-encoded protein and any variants, thereof, are suitable as diagnostic markers, targets for an antibody therapeutic and targets for small molecule drugs. As such the current invention embodies the use of recombinantly expressed and/or endogenously expressed protein in various screens to identify such therapeutic antibodies and/or therapeutic small molecules.  
       BACKGROUND  
       [0003] Eukaryotic cells are characterized by biochemical and physiological processes which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular organisms such as vertebrates, or more particularly organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways are constituted of extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells.  
       [0004] Signaling proteins may be classified as endocrine effectors, paracrine effectors or autocrine effectors. Endocrine effectors are signaling molecules secreted by a given organ into the circulatory system, which are then transported to a distant target organ or tissue. The target cells include the receptors for the endocrine effector, and when the endocrine effector binds, a signaling cascade is induced. Paracrine effectors involve secreting cells and receptor cells in close proximity to each other, for example two different classes of cells in the same tissue or organ. One class of cells secretes the paracrine effector, which then reaches the second class of cells, for example by diffusion through the extracellular fluid. The second class of cells contains the receptors for the paracrine effector; binding of the effector results in induction of the signaling cascade that elicits the corresponding biochemical or physiological effect. Autocrine effectors are highly analogous to paracrine effectors, except that the same cell type that secretes the autocrine effector also contains the receptor. Thus the autocrine effector binds to receptors on the same cell, or on identical neighboring cells. The binding process then elicits the characteristic biochemical or physiological effect.  
       [0005] Signaling processes may elicit a variety of effects on cells and tissues including by way of nonlimiting example induction of cell or tissue proliferation, suppression of growth or proliferation, induction of differentiation or maturation of a cell or tissue, and suppression of differentiation or maturation of a cell or tissue.  
       [0006] Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as diminished or suppressed level of synthesis and secretion protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by diminished or suppressed levels of a protein effector of interest. Therefore there is a need to be able to assay for the level of the protein effector of interest in a biological sample from such a subject, and to compare the level with that characteristic of a nonpathological condition. There further is a need to provide the protein effector as a product of manufacture. Administration of the effector to a subject in need thereof is useful in treatment of the pathological condition, or the protein effector deficiency or suppression may be favorably acted upon by the administration of another small molecule drug product. Accordingly, there is a need for a method of treatment of a pathological condition brought on by a diminished or suppressed levels of the protein effector of interest.  
       [0007] Small molecule targets have been implicated in various disease states or pathologies. These targets may be proteins, and particularly enzymatic proteins, which are acted upon by small molecule drugs for the purpose of altering target function and achieving a desired result. Cellular, animal and clinical studies can be performed to elucidate the genetic contribution to the etiology and pathogenesis of conditions in which small molecule targets are implicated in a variety of physiologic, pharmacologic or native states. These studies utilize the core technologies at CuraGen Corporation to look at differential gene expression, protein-protein interactions, large-scale sequencing of expressed genes and the association of genetic variations such as, but not limited to, single nucleotide polymorphisms (SNPs) or splice variants in and between biological samples from experimental and control groups. The goal of such studies is to identify potential avenues for therapeutic intervention in order to prevent, treat the consequences or cure the conditions.  
       [0008] In order to treat diseases, pathologies and other abnormal states or conditions in which a mammalian organism has been diagnosed as being, or as being at risk for becoming, other than in a normal state or condition, it is important to identify new therapeutic agents. Such a procedure includes at least the steps of identifying a target component within an affected tissue or organ, and identifying a candidate therapeutic agent that modulates the functional attributes of the target. The target component may be any biological macromolecule implicated in the disease or pathology. Commonly the target is a polypeptide or protein with specific functional attributes. Other classes of macromolecule may be a nucleic acid, a polysaccharide, a lipid such as a complex lipid or a glycolipid; in addition a target may be a sub-cellular structure or extra-cellular structure that is comprised of more than one of these classes of macromolecule. Once such a target has been identified, it may be employed in a screening assay in order to identify favorable candidate therapeutic agents from among a large population of substances or compounds.  
       [0009] In many cases the objective of such screening assays is to identify small molecule candidates; this is commonly approached by the use of combinatorial methodologies to develop the population of substances to be tested. The implementation of high throughput screening methodologies is advantageous when working with large, combinatorial libraries of compounds.  
       [0010] It is an objective of this invention to provide at least one target biopolymer that is intended to serve as the macromolecular component in a screening assay for identifying candidate pharmaceutical agents.  
       [0011] It is another objective of the present invention to provide screening assays that positively identify candidate pharmaceutical agents from among a combinatorial library of low molecular weight substances or compounds.  
       [0012] It is still a further objective of this invention to employ the candidate pharmaceutical agents in any of a variety of in vitro, ex vivo and in vivo assays in order to identify pharmaceutical agents with advantageous therapeutic applications in the treatment of a disease, pathology, or abnormal state or condition in a mammal.  
       SUMMARY OF THE INVENTION  
       [0013] The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as “NOVX” nucleic acid, which represents the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, or polypeptide sequences, which represents the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 178.  
       [0014] In one aspect, the invention provides an isolated polypeptide comprising a mature form of a NOVX amino acid. One example is a variant of a mature form of a NOVX amino acid sequence, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. The amino acid can be, for example, a NOVX amino acid sequence or a variant of a NOVX amino acid sequence, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed. The invention also includes fragments of any of these. In another aspect, the invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof.  
       [0015] Also included in the invention is a NOVX polypeptide that is a naturally occurring allelic variant of a NOVX sequence. In one embodiment, the allelic variant includes an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a NOVX nucleic acid sequence. In another embodiment, the NOVX polypeptide is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution. In one embodiment, the invention discloses a method for determining the presence or amount of the NOVX polypeptide in a sample. The method involves the steps of: providing a sample; introducing the sample to an antibody that binds immunospecifically to the polypeptide; and determining the presence or amount of antibody bound to the NOVX polypeptide, thereby determining the presence or amount of the NOVX polypeptide in the sample. In another embodiment, the invention provides a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide in a mammalian subject. This method involves the steps of: measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and comparing the amount of the polypeptide in the sample of the first step to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.  
       [0016] In a further embodiment, the invention includes a method of identifying an agent that binds to a NOVX polypeptide. This method involves the steps of: introducing the polypeptide to the agent; and determining whether the agent binds to the polypeptide. In various embodiments, the agent is a cellular receptor or a downstream effector.  
       [0017] In another aspect, the invention provides a method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of a NOVX polypeptide. The method involves the steps of: providing a cell expressing the NOVX polypeptide and having a property or function ascribable to the polypeptide; contacting the cell with a composition comprising a candidate substance; and determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent. In another aspect, the invention describes a method for screening for a modulator of activity or of latency or predisposition to a pathology associated with the NOVX polypeptide. This method involves the following steps: administering a test compound to a test animal at increased risk for a pathology associated with the NOVX polypeptide, wherein the test animal recombinantly expresses the NOVX polypeptide. This method involves the steps of measuring the activity of the NOVX polypeptide in the test animal after administering the compound of step; and comparing the activity of the protein in the test animal with the activity of the NOVX polypeptide in a control animal not administered the polypeptide, wherein a change in the activity of the NOVX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of, or predisposition to, a pathology associated with the NOVX polypeptide. In one embodiment, the test animal is a recombinant test animal that expresses a test protein transgene or expresses the transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein the promoter is not the native gene promoter of the transgene. In another aspect, the invention includes a method for modulating the activity of the NOVX polypeptide, the method comprising introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide.  
       [0018] The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. In a preferred embodiment, the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant. In another embodiment, the nucleic acid encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence. In one embodiment, the NOVX nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, or a complement of the nucleotide sequence. In another aspect, the invention provides a vector or a cell expressing a NOVX nucleotide sequence.  
       [0019] In one embodiment, the invention discloses a method for modulating the activity of a NOVX polypeptide. The method includes the steps of: introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide. In another embodiment, the invention includes an isolated NOVX nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising a NOVX amino acid sequence or a variant of a mature form of the NOVX amino acid sequence, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. In another embodiment, the invention includes an amino acid sequence that is a variant of the NOVX amino acid sequence, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed.  
       [0020] In one embodiment, the invention discloses a NOVX nucleic acid fragment encoding at least a portion of a NOVX polypeptide or any variant of the polypeptide, wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed. In another embodiment, the invention includes the complement of any of the NOVX nucleic acid molecules or a naturally occurring allelic nucleic acid variant. In another embodiment, the invention discloses a NOVX nucleic acid molecule that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the invention discloses a NOVX nucleic acid, wherein the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence.  
       [0021] In another aspect, the invention includes a NOVX nucleic acid, wherein one or more nucleotides in the NOVX nucleotide sequence is changed to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In one embodiment, the invention discloses a nucleic acid fragment of the NOVX nucleotide sequence and a nucleic acid fragment wherein one or more nucleotides in the NOVX nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In another embodiment, the invention includes a nucleic acid molecule wherein the nucleic acid molecule hybridizes under stringent conditions to a NOVX nucleotide sequence or a complement of the NOVX nucleotide sequence. In one embodiment, the invention includes a nucleic acid molecule, wherein the sequence is changed such that no more than 15% of the nucleotides in the coding sequence differ from the NOVX nucleotide sequence or a fragment thereof.  
       [0022] In a further aspect, the invention includes a method for determining the presence or amount of the NOVX nucleic acid in a sample. The method involves the steps of: providing the sample; introducing the sample to a probe that binds to the nucleic acid molecule; and determining the presence or amount of the probe bound to the NOVX nucleic acid molecule, thereby determining the presence or amount of the NOVX nucleic acid molecule in the sample. In one embodiment, the presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.  
       [0023] In another aspect, the invention discloses a method for determining the presence of or predisposition to a disease associated with altered levels of the NOVX nucleic acid molecule of in a first mammalian subject. The method involves the steps of: measuring the amount of NOVX nucleic acid in a sample from the first mammalian subject; and comparing the amount of the nucleic acid in the sample of step (a) to the amount of NOVX nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.  
       [0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.  
       [0025] Other features and advantages of the invention will be apparent from the following detailed description and claims.  
       DETAILED DESCRIPTION OF THE INVENTION  
       [0026] The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as “NOVX nucleic acids” or “NOVX polynucleotides” and the corresponding encoded polypeptides are referred to as “NOVX polypeptides” or “NOVX proteins.” Unless indicated otherwise, “NOVX” is meant to refer to any of the novel sequences disclosed herein. Table 1 provides a summary of the NOVX nucleic acids and their encoded polypeptides.  
               TABLE 1                          Sequences and Corresponding SEQ ID Numbers                                         Nucleic   Amino                   Acid   Acid               SEQ   SEQ       NOVX   Internal   ID   ID       No.   Acc. No.   NO.   NO.   Homology                                          1a   CG58522-01   1   2   human platelet                       activating factor                       acetylhydrolase        2a   CG58520-01   3   4   GABA(A) receptor        2b   CG58520-02   5   6   GABA(A) receptor        2c   CG58520-03   7   8   GABA(A) receptor        3a   CG58518-01   9   10   GABA(A) receptor        4a   CG58516-01   11   12   Beta transducin        5a   CG58473-01   13   14   Protein kinase        6a   CG58470-01   15   16   UDP-N-                       acetylhexosamine                       pyrophosphorylase        7a   CG58593-01   17   18   ubiquitin 52 like        8a   CG57871-01   19   20   tousled like kinase like        9a   CG58590-01   21   22   guanylate kinase like        9b   CG58590-02   23   24   guanylate kinase like        10a   CG58572-01   25   26   glucosamine phosphate                       N acetyltransferase like        10b   CG58572-02   27   28   glucosamine phosphate                       N acetyltransferase like        11a   CG58564-01   29   30   Protein tyrosine                       phosphatase like        11b   CG58564-02   31   32   Protein tyrosine                       phosphatase like        11c   CG58564-03   33   34   Dual-Specificity                       phosphatase like        11d   CG58564-04   35   36   Dual-Specificity                       phosphatase like        12a   CG57819-01   37   38   RPGR interacting                       protein 1 like        13a   CG57789-01   39   40   RAS like protein                       RRP22 like        13b   CG57789-02   41   42   RAS like protein                       RRP22 like        14a   CG57758-01   43   44   sodium/lithium                       dependent                       dicarboxylate                       transporter like        14b   CG57758-02   45   46   sodium/lithium                       dependent                       dicarboxylate                       transporter like        14c   CG57758-03   47   48   sodium/lithium                       dependent                       dicarboxylate                       transporter like        14d   CG57758-04   49   50   sodium/lithium                       dependent                       dicarboxylate                       transporter like        14e   CG57758-05   51   52   sodium/lithium                       dependent                       dicarboxylate                       transporter like        15a   CG57732-01   53   54   Ca 2 + calmodulin                       dependent protein                       kinase IV kinase like        15b   CG57732-02   55   56   Ca 2 + calmodulin                       dependent protein                       kinase IV kinase like        15c   CG57732-03   57   58   Ca 2 + calmodulin                       dependent protein                       kinase IV kinase like        16a   CG57709-01   59   60   TCE2 like        17a   CG57700-01   61   62   hydoxyacylglutathione                       hydrolase like        17b   CG57700-02   63   64   hydoxyacylglutathione                       hydrolase like        17c   CG57700-03   65   66   hydoxyacylglutathione                       hydrolase like        17d   CG57700-04   67   68   hydoxyacylglutathione                       hydrolase like        18a   CG58553-01   69   70   vasopressin receptor                       like        19a   CG58626-01   71   72   phosphatidic acid                       preferring                       phospholipase A1 like        20a   CG57597-01   73   74   hypothetical protein                       like        21a   CG57804-01   75   76   Talin like        22a   CG57551-01   77   78   NAC-1 like        23a   CG57411-01   79   80   Kelch like        24a   CG57399-01   81   82   phospholipase                       ADRAB-B precursor                       like        24b   CG57399-02   83   84   phospholipase                       ADRAB-B precursor                       like        24c   CG57399-03   85   86   phospholipase                       ADRAB-B precursor                       like        25a   CG59311-01   87   88   acyl-coenzyme A                       thioester hydrolase        25b   CG59311-02   89   90   peroxisomal acyl-                       coenzyme A thioeseter                       hydrolase like        25c   CG59311-03   91   92   peroxisomal acyl-                       coenzyme A thioeseter                       hydrolase like        26a   CG59309-01   93   94   acyl-coenzyme A                       thioester hydrolase        27a   CG57364-01   95   96   CG6896        28a   CG59348-01   97   98   cytoplasmic protein                       (patent calls this Cyclin                       L-like)        29a   CG59245-01   99   100   glucose 6-phosphatase        29b   CG59245-02   101   102   glucose 6-phosphatase        30a   CG59241-01   103   104   Amiloride-sensitive                       sodium channel        31a   CG58602-01   105   106   FAD binding domain                       containing protein        32a   CG58468-01   107   108   Serum Amyloid Protein        33a   CG58183-01   109   110   N-Methyl-D-Aspartate                       receptor        34a   CG59315-01   111   112   Connexin        35a   CG59203-01   113   114   lysozyme C        35b   CG59203-02   115   116   lysozyme C        36a   CG58662-01   117   118   cytoplasmic protein        36b   CG58662-02   119   120   cytoplasmic protein        37a   CG58584-01   121   122   405 ribosomal protein                       S29 like        38a   CG58538-01   123   124   Histone deacetylase                       complex protein 66 like        39a   CG59371-01   125   126   expressed cytoplasmic                       protein like        40a   CG59346-01   127   128   cortactin binding                       protein 1 like        41a   CG57814-01   129   130   Basic I 19 like  homo                           sapiens          41b   CG57814-02   131   132   Basic I 19 like  homo                           sapiens          42a   CG59327-01   133   134   Monocarboxylate                       transporter 1 like        43a   CG59494-01   135   136   myelin P2 like        44a   CG59432-0l   137   138   chloride channel like        44b   CG59432-02   139   140   chloride channel like        45a   CG59394-01   141   142   GPCR like        46a   CG59383-01   143   144   D6MM5E PROTEIN                       like        46b   CG59383-02   145   146   D6MM5E PROTEIN                       like        47a   CG58526-01   147   148   scramblase like        48a   CG57851-01   149   150   sulfotransferase like        49a   CG59377-01   151   152   epsin like        50a   CG59258-01   153   154   transcriptional activator                       like        51a   CG59492-01   155   156   Myosin Head (Motor                       Domain) like        52a   CG59564-01   157   158   Sorting nexin 6 like        53a   CG59553-01   159   160   Secretory protein SECS                       like        54a   CG59545-01   161   162   Placental protein 13                       like        55a   CG59435-01   163   164   Nedd-1 like        55b   CG59435-02   165   166   Nedd-1 like        56a   CG59439-01   167   168   Xenobiotic/medium-                       chain fatty acid: CoA                       ligase form XL-III like        56b   CG59439-02   169   170   Xenobiotic/medium-                       chain fatty acid: CoA                       ligase form XL-III like        57a   CG59354-01   171   172   phosducin like        57b   CG59354-02   173   174   phosducin like        57c   CG59354-03   175   176   phosducin like        58a   CG59319-01   177   178   phosducin like        58b   CG59319-02   179   180   phosducin like        59a   CG59576-01   181   182   GPCR like        60a   CG59557-01   183   184   GPCR like        61a   CG59555-01   185   186   GPCR like        62a   CG59551-01   187   188   GPCR like        63a   CG59540-01   189   190   GPCR like        64a   CG59280-01   191   192   GPCR like        64b   CG59280-02   193   194   GPCR like        65a   CG59568-01   195   196   GPCR like        66a   CG59224-01   197   198   GPCR like        67a   CG59222-01   199   200   GPCR like        68a   CG59220-01   201   202   GPCR like        69a   CG59218-0l   203   204   GPCR like        70a   CG59216-01   205   206   GPCR like        71a   CG59214-01   207   208   GPCR like        72a   CG59211-01   209   210   GPCR like        73a   CG59276-01   211   212   Dihydroorotate                       dehydrogenase like        74a   CG59268-01   213   214   monooxygenase like        75a   CG59549-01   215   216   H326 like (cytoplasmic                       protein with WD repeat                       domain)        76a   CG59641-01   217   218   Acetyl-CoA                       Carboxylase 2 like        77a   CG59630-01   219   220   Midnolin like        78a   CG59561-01   221   222   ACYL COENZYME A                       THIOESTER                       HYDROLASE like        79a   CG59452-01   223   224   CELL                       PROLIFERATION                       RELATED PROTEIN                       CAP like        80a   CG59572-01   225   226   Pseudouridine Synthase                       3 like        80b   CG59572-02   227   228   Pseudouridine Synthase                       3 like        81a   CG59522-01   229   230   Myosin like        82a   CG59520-01   231   232   Farnesyl-                       pyrophosphate                       synthetase like        83a   CG59758-01   233   234   UBIQUITIN like        83b   CG59758-02   235   236   UBIQUITIN like        84a   CG59586-01   237   238   glucokinase like        85a   CG59704-01   239   240   serine/threonine kinase                       like        86a   CG59628-01   241   242   Short-chain                       dehydrogenase like        87a   CG59516-01   243   244   Calponin like        87b   CG59516-02   245   246   Calponin like        88a   CG59671-02   247   248   acyl-coenzyme A                       thioester hydrolase        89a   CG56870-01   249   250   NDRG3 like        89b   CG56870-02   251   252   NDRG3 like        89c   CG56870-03   253   254   NDRG3 like        89d   CG56870-04   255   256   NDRG3 like        89e   CG56870-05   257   258   NDRG3 like        90a   CG59764-01   259   260   Ferritin like        91a   CG59710-01   261   262   P14 like        92a   CG59754-02   263   264   Downs syndrome cell                       adhesion molecule like        92b   CG59754-01   265   266   Downs syndrome cell                       adhesion molecule like        93a   CG59800-01   267   268   HEPARAN SULFATE                       D-GLUCOSAMINYL                       3-O-                       SULFOTRANSFERASE-3B                       like        94a   CG59761-01   269   270   AXIN I (AXIS                       INHIBITION                       PROTEIN I) (HAXIN)                       like        95a   CG59756-01   271   272   JUNCTOPHILIN                       TYPE 2 like        96a   CG59708-01   273   274   Ubiquitin carboxyl-                       terminal hydrolase 21                       like        96b   CG59708-02   275   276   Ubiquitin carboxyl-                       terminal hydrolase 21                       like        96c   CG59708-03   277   278   Ubiquitin carboxyl-                       terminal hydrolase 21                       like        97a   CG59559-01   279   280   BA12M19.1.3 like        98a   CG59669-01   281   282   carbonyl reductase                       (called NADPH-                       dependent carbonyl                       reductase-like in                       patent)        99a   CG58624-01   283   284   metal transporter       100a   CG59679-01   285   286   carbonyl reductase       101a   CG59644-01   287   288   CG12091 (putative                       protein phosphatase)       102a   CG59662-01   289   290   Cyclophilin       103a   CG59773-01   291   292   Myomegalin       103b   CG59773-02   293   294   Myomegalin       103c   CG59773-03   295   296   Myomegalin       104a   CG57460-01   297   298   PEPTIDYL-PROLYL                       CIS-TRANS                       ISOMERASE like       105a   CG57464-01   299   300   N-                       ACETYLTRANSFER                       ASE like       106a   CG57466-01   301   302   Acetylglucosaminyl-                       transferase like       107a   CG57468-01   303   304   ABC transporter like                         homo sapiens         108a   CG59609-01   305   306   PEPTIDYL-PROLYL                       CIS-TRANS                       ISOMERASE A like       109a   CG59613-01   307   308   Proliferating cell                       nuclear antigen like       110a   CG59619-01   309   310   CYTOPLASMIC                       ACTIN 2 like       111a   CG59621-01   311   312   SELENOPHOSPHATE                       SYNTHETASE like       112a   CG59625-01   313   314   glucose transporter like       113a   CG59887-0l   315   316   Amino Acid/Metabolite                       Permease like       113b   CG59887-02   317   318   Amino Acid/Metabolite                       Permease like       114a   CG59861-01   319   320   RIBULOSE-5-                       PHOSPHATE                       EPIMERASE like       114b   CG59861-02   321   322   RIBULOSE-5-                       PHOSPHATE                       EPIMERASE like       115a   CG59857-01   323   324   Rhotekin like  homo                           sapiens         116a   CG59855-0l   325   326   ATP SYNTHASE                       SUBUNIT C lik       116b   CG59855-02   327   328   ATP SYNTHASE                       SUBUNIT C like       117a   CG59807-01   329   330   Zinc finger like       118a   CG59805-01   331   332   Zinc finger like       119a   CG59928-01   333   334   Universal Stress (USP)                       Domain Containing                       Protein like       120a   CG59947-01   335   336   VOLTAGE-GATED                       POTASSIUM                       CHANNEL PROTEIN                       KV3.3 (KSHIIID) like       121a   CG59938-0l   337   338   arylsulfatase like  homo                           sapiens         122a   CG59746-01   339   340   ubiguitin-specific                       processing protease                       like  homo sapiens         123a   CG88613-01   341   342   INOSITOL 1,4,5-                       TRISPHOSPHATE 3-                       KINASE                       ISOENZYME like       124a   CG59993-01   343   344   synaptotagmin II like       124b   CG59993-02   345   346   synaptotagmin 11 like       125a   CG59991-01   347   348   ooplasm specific                       protein like       126a   CG59987-01   349   350   GTP-RHO binding                       protein 1 (rhophilin)                       like       126b   CG59987-02   351   352   GTP-RHO binding                       protein 1 (rhophilin)                       like       127a   CG59971-01   353   354   Leucine rich repeat                       (LRR) like       127b   CG59971-02   355   356   Leucine rich repeat                       (LRR) like                  
 
       [0027] Table 1 indicates homology of NOVX nucleic acids to known protein families. Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table 1 will be useful in therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table 1.  
       [0028] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.  
       [0029] Consistent with other known members of the family of proteins, identified in column 5 of Table 1, the NOVX polypeptides of the present invention show homology to, and contain domains that are characteristic of, other members of such protein families. Details of the sequence relatedness and domain analysis for each NOVX are presented in Example A.  
       [0030] The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit diseases associated with the protein families listed in Table 1.  
       [0031] The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are presented in Example C. Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g. a variety of cancers.  
       [0032] Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein.  
       [0033] The present invention is based on the identification of biological macromolecules differentially modulated in a pathologic state, disease, or an abnormal condition or state. Among the pathologies or diseases of present interest include metabolic diseases including those related to endocrinologic disorders, cancers, various tumors and neoplasias, inflammatory disorders, central nervous system disorders, and similar abnormal conditions or states. In very significant embodiments of the present invention, the biological macromolecules implicated in the pathologies and conditions are proteins and polypeptides, and in such cases the present invention is related as well to the nucleic acids that encode them. Methods that may be employed to identify relevant biological macromolecules include any procedures that detect differential expression of nucleic acids encoding proteins and polypeptides associated with the disorder, as well as procedures that detect the respective proteins and polypeptides themselves. Significant methods that have been employed by the present inventors, include GeneCalling® technology and SeqCalling TM technology, disclosed respectively, in U.S. Pat. No. 5,871,697, and in U. S. Ser. No. 09/417,386, filed Oct. 13, 1999, each of which is incorporated herein by reference in its entirety. GeneCalling® is also described in Shimkets, et al., “Gene expression analysis by transcript profiling coupled to a gene database query” Nature Biotechnology 17:198-803 (1999).  
       [0034] The invention provides polypeptides and nucleotides encoded thereby that have been identified as having novel associations with a disease or pathology, or an abnormal state or condition, in a mammal. The present invention further identifies a set of proteins and polypeptides, including naturally occurring polypeptides, precursor forms or proproteins, or mature forms of the polypeptides or proteins, which are implicated as targets for therapeutic agents in the treatment of various diseases, pathologies, abnormal states and conditions. A target may be employed in any of a variety of screening methodologies in order to identify candidate therapeutic agents which interact with the target and in so doing exert a desired or favorable effect. The candidate therapeutic agent is identified by screening a large collection of substances or compounds in an important embodiment of the invention. Such a collection may comprise a combinatorial library of substances or compounds in which, in at least one subset of substances or compounds, the individual members are related to each other by simple structural variations based on a particular canonical or basic chemical structure. The variations may include, by way of nonlimiting example, changes in length or identity of a basic framework of bonded atoms; changes in number, composition and disposition of ringed structures, bridge structures, alicyclic rings, and aromatic rings; and changes in pendent or substituents atoms or groups that are bonded at particular positions to the basic framework of bonded atoms or to the ringed structures, the bridge structures, the alicyclic structures, or the aromatic structures.  
       [0035] A polypeptide or protein described herein, and that serves as a target in the screening procedure, includes the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, e.g., the full-length gene product, encoded by the corresponding gene. The naturally occurring polypeptide also includes the polypeptide, precursor or proprotein encoded by an open reading frame described herein. A “mature” form of a polypeptide or protein arises as a result of one or more naturally occurring processing steps as they may occur within the cell, including a host cell. The processing steps occur as the gene product arises, e.g., via cleavage of the amino-terminal methionine residue encoded by the initiation codon of an open reading frame, or the proteolytic cleavage of a signal peptide or leader sequence. Thus, a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an amino-terminal signal sequence from residue 1 to residue M is cleaved, includes the residues from residue M+1 to residue N remaining. A “mature” form of a polypeptide or protein may also arise from non-proteolytic post-translational modification. Such non-proteolytic processes include, e.g., glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or the combination of any of them.  
       [0036] As used herein, “identical” residues correspond to those residues in a comparison between two sequences where the equivalent nucleotide base or amino acid residue in an alignment of two sequences is the same residue. Residues are alternatively described as “similar” or “positive” when the comparisons between two sequences in an alignment show that residues in an equivalent position in a comparison are either the same amino acid or a conserved amino acid as defined below.  
       [0037] As used herein, a “chemical composition” relates to a composition including at least one compound that is either synthesized or extracted from a natural source. A chemical compound may be the product of a defined synthetic procedure. Such a synthesized compound is understood herein to have defined properties in terms of molecular formula, molecular structure relating the association of bonded atoms to each other, physical properties such as chromatographic or spectroscopic characterizations, and the like. A compound extracted from a natural source is advantageously analyzed by chemical and physical methods in order to provide a representation of its defined properties, including its molecular formula, molecular structure relating the association of bonded atoms to each other, physical properties such as chromatographic or spectroscopic characterizations, and the like.  
       [0038] As used herein, a “candidate therapeutic agent” is a chemical compound that includes at least one substance shown to bind to a target biopolymer. In important embodiments of the invention, the target biopolymer is a protein or polypeptide, a nucleic acid, a polysaccharide or proteoglycan, or a lipid such as a complex lipid. The method of identifying compounds that bind to the target effectively eliminates compounds with little or no binding affinity, thereby increasing the potential that the identified chemical compound may have beneficial therapeutic applications. In cases where the “candidate therapeutic agent” is a mixture of more than one chemical compound, subsequent screening procedures may be carried out to identify the particular substance in the mixture that is the binding compound, and that is to be identified as a candidate therapeutic agent.  
       [0039] As used herein, a “pharmaceutical agent” is provided by screening a candidate therapeutic agent using models for a disease state or pathology in order to identify a candidate exerting a desired or beneficial therapeutic effect with relation to the disease or pathology. Such a candidate that successfully provides such an effect is termed a pharmaceutical agent herein. Nonlimiting examples of model systems that may be used in such screens include particular cell lines, cultured cells, tissue preparations, whole tissues, organ preparations, intact organs, and nonhuman mammals. Screens employing at least one system, and preferably more than one system, may be employed in order to identify a pharmaceutical agent. Any pharmaceutical agent so identified may be pursued in further investigation using human subjects.  
       [0040] NOVX Nucleic Acids and Polypeptides  
       [0041] NOVX Clones  
       [0042] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.  
       [0043] The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders.  
       [0044] The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.  
       [0045] In one specific embodiment, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 178; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 178, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 178; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 178 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d).  
       [0046] In another specific embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence given SEQ ID NO: 2n, wherein n is an integer between 1 and 178; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 178 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 178; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 178, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 178 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules.  
       [0047] In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178; and (d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.  
       [0048] One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.  
       [0049] An NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product “mature” form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a “mature” form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a “mature” form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.  
       [0050] The term “probes”, as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.  
       [0051] The term “isolated” nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′- and 3′-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.  
       [0052] A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2 nd  Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; and Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, New York, N.Y., 1993.)  
       [0053] A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, erg., using an automated DNA synthesizer.  
       [0054] As used herein, the term “oligonucleotide” refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.  
       [0055] In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of an NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 is one that is sufficiently complementary to the nucleotide sequence from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 that it can hydrogen bond with little or no mismatches to the nucleotide sequence from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, thereby forming a stable duplex.  
       [0056] As used herein, the term “complementary” refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term “binding” means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.  
       [0057] Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.  
       [0058] A full-length NOVX clone is identified as containing an ATG translation start codon and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 5′ direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 3′ direction of the disclosed sequence.  
       [0059] Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, New York, N.Y., 1993, and below.  
       [0060] A “homologous nucleic acid sequence” or “homologous amino acid sequence,” or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for an NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.  
       [0061] An NOVX polypeptide is encoded by the open reading frame (“ORF”) of an NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG “start” codon and terminates with one of the three “stop” codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bonafide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.  
       [0062] The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178; or an anti-sense strand nucleotide sequence of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178.  
       [0063] Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express an NOVX protein, such as by measuring a level of an NOVX-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.  
       [0064] “A polypeptide having a biologically-active portion of an NOVX polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a “biologically-active portion of NOVX” can be prepared by isolating a portion SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, that encodes a polypeptide having an NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOVX.  
       [0065] NOVX Nucleic Acid and Polypeptide Variants  
       [0066] The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences shown in SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO: 2n, wherein n is an integer between 1 and 178.  
       [0067] In addition to the human NOVX nucleotide sequences shown in SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame (ORF) encoding an NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.  
       [0068] Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from the human SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.  
       [0069] Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.  
       [0070] Homologs (i.e., nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.  
       [0071] As used herein, the phrase “stringent hybridization conditions” refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at  
       [0072] pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60° C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.  
       [0073] Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6×SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65° C., followed by one or more washes in 0.2×SSC, 0.01% BSA at 50° C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).  
       [0074] In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6×SSC, 5× Denhardt&#39;s solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55° C., followed by one or more washes in 1×SSC, 0.1% SDS at 37° C. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, NY, and Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.  
       [0075] In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5×SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40° C., followed by one or more washes in 2×SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50° C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981 . Proc Natl Acad Sci USA  78: 6789-6792.  
       [0076] Conservative Mutations  
       [0077] In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of said NOVX proteins. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in the sequence SEQ ID NO: 2n, wherein n is an integer between 1 and 178. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an “essential” amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.  
       [0078] Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences SEQ ID NO: 2n, wherein n is an integer between 1 and 178. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 178; more preferably at least about 70% homologous SEQ ID NO: 2n, wherein n is an integer between 1 and 178; still more preferably at least about 80% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 178; even more preferably at least about 90% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 178; and most preferably at least about 95% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 178.  
       [0079] An isolated nucleic acid molecule encoding an NOVX protein homologous to the protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 178 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.  
       [0080] Mutations can be introduced into SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.  
       [0081] The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved “strong” residues or fully conserved “weak” residues. The “strong” group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the “weak” group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, HFY, wherein the letters within each group represent the single letter amino acid code.  
       [0082] In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and an NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).  
       [0083] In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).  
       [0084] Antisense Nucleic Acids  
       [0085] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, or fragments, analogs or derivatives thereof. An “antisense” nucleic acid comprises a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of an NOVX protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 178, or antisense nucleic acids complementary to an NOVX nucleic acid sequence of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, are additionally provided.  
       [0086] In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence encoding an NOVX protein. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence encoding the NOVX protein. The term “noncoding region” refers to 5′ and 3′ sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).  
       [0087] Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).  
       [0088] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N-6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).  
       [0089] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an NOVX protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.  
       [0090] In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987 . Nucl. Acids Res.  15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (See, e.g., Inoue, et al. 1987 . Nucl. Acids Res.  15: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, et al., 1987 . FEBS Lett.  215: 327-330.  
       [0091] Ribozymes and PNA Moieties  
       [0092] Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.  
       [0093] In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988 . Nature  334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for an NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of an NOVX cDNA disclosed herein (i.e., SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an NOVX-encoding mRNA. See, e.g., U.S. Pat. No. 4,987,071 to Cech, et al. and U.S. Pat. No. 5,116,742 to Cech, et al. NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993)  Science  261:1411-1418.  
       [0094] Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991 . Anticancer Drug Des.  6: 569-84; Helene, et al. 1992 . Ann. N. Y Acad. Sci.  660: 27-36; Maher, 1992 . Bioassays  14: 807-15.  
       [0095] In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996 . Bioorg Med Chem  4: 5-23. As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra; Perry-O&#39;Keefe, et al., 1996 . Proc. Natl. Acad. Sci. USA  93:14670-14675.  
       [0096] PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S 1  nucleases (See, Hyrup, et al., 1996.supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O&#39;Keefe, et al., 1996. supra).  
       [0097] In another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996 . Nucl Acids Res  24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5′-(4-methoxytrityl)amino-5′-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5′ end of DNA. See, e.g., Mag, et al., 1989 . Nucl Acid Res  17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment. See, e.g., Finn, et al., 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment. See, e.g., Petersen, et al., 1975 . Bioorg. Med. Chem. Lett.  5: 1119-11124.  
       [0098] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989 . Proc. Natl. Acad. Sci. U.S.A.  86: 6553-6556; Lemaitre, et al., 1987 . Proc. Natl. Acad. Sci.  84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (see, e.g., Krol, et al., 1988 . BioTechniques  6:958-976) or intercalating agents (see, e.g., Zon, 1988 . Pharm. Res.  5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.  
       [0099] NOVX Polypeptides  
       [0100] A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in SEQ ID NO: 2n, wherein n is an integer between 1 and 178. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NO: 2n, wherein n is an integer between 1 and 178 while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.  
       [0101] In general, an NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.  
       [0102] One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.  
       [0103] An “isolated” or “purified” polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language “substantially free of cellular material” includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a “contaminating protein”), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.  
       [0104] The language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.  
       [0105] Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e.g., the amino acid sequence shown in SEQ ID NO: 2n, wherein n is an integer between 1 and 178) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of an NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of an NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.  
       [0106] Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.  
       [0107] In an embodiment, the NOVX protein has an amino acid sequence shown SEQ ID NO: 2n, wherein n is an integer between 1 and 178. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 178, and retains the functional activity of the protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 178, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ ID NO: 2n, wherein n is an integer between 1 and 178, and retains the functional activity of the NOVX proteins of SEQ ID NO: 2n, wherein n is an integer between 1 and 178.  
       [0108] Determining Homology Between Two or More Sequences  
       [0109] To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid “homology” is equivalent to amino acid or nucleic acid “identity”).  
       [0110] The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970 . J Mol Biol  48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178.  
       [0111] The term “sequence identity” refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term “substantial identity” as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.  
       [0112] Chimeric and Fusion Proteins  
       [0113] The invention also provides NOVX chimeric or fusion proteins. As used herein, an A NOVX “chimeric protein” or “fusion protein” comprises an NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An “NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to an NOVX protein SEQ ID NO: 2n, wherein n is an integer between 1 and 178, whereas a “non-NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, e.g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within an NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of an NOVX protein. In one embodiment, an NOVX fusion protein comprises at least one biologically-active portion of an NOVX protein. In another embodiment, an NOVX fusion protein comprises at least two biologically-active portions of an NOVX protein. In yet another embodiment, an NOVX fusion protein comprises at least three biologically-active portions of an NOVX protein. Within the fusion protein, the term “operatively-linked” is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.  
       [0114] In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.  
       [0115] In another embodiment, the fusion protein is an NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.  
       [0116] In yet another embodiment, the fusion protein is an NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between an NOVX ligand and an NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of an NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with an NOVX ligand.  
       [0117] An NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &amp; Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.  
       [0118] NOVX Agonists and Antagonists  
       [0119] The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (e.g., discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.  
       [0120] Variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (e.g., truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e.g., Narang, 1983 . Tetrahedron  39: 3; Itakura, et al., 1984 . Annu. Rev. Biochem.  53: 323; Itakura, et al., 1984 . Science  198: 1056; Ike, et al., 1983 . Nucl. Acids Res.  11: 477.  
       [0121] Polypeptide Libraries  
       [0122] In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of an NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1  nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.  
       [0123] Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992 . Proc. Natl. Acad. Sci. USA  89: 7811-7815; Delgrave, et al., 1993 . Protein Engineering  6:327-331.  
       [0124] NOVX Antibodies  
       [0125] The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F ab , F ab , and F (ab)2  fragments, and an F ab  expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG 1 , IgG 2 , and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.  
       [0126] An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence shown in SEQ ID NO: 2n, wherein n is an integer between 1 and 178, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.  
       [0127] In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will indicate which regions of a NOVX polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981 , Proc. Nat. Acad. Sci. USA  78: 3824-3828; Kyte and Doolittle 1982 , J. Mol. Biol.  157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.  
       [0128] A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.  
       [0129] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., incorporated herein by reference). Some of these antibodies are discussed below.  
       [0130] Polyclonal Antibodies  
       [0131] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund&#39;s (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and  Corynebacterium parvum , or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).  
       [0132] The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).  
       [0133] Monoclonal Antibodies  
       [0134] The term “monoclonal antibody” (MAb) or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.  
       [0135] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein,  Nature,  256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.  
       [0136] The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding,  Monoclonal Antibodies: Principles and Practice , Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells. Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Va. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor,  J. Immunol.,  133:3001 (1984); Brodeur et al.,  Monoclonal Antibody Production Techniques and Applications , Marcel Dekker, Inc., New York, (1987) pp. 51-63].  
       [0137] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard,  Anal. Biochem.,  107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.  
       [0138] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, 1986). Suitable culture media for this purpose include, for example, Dulbecco&#39;s Modified Eagle&#39;s Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.  
       [0139] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.  
       [0140] The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison,  Nature  368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.  
       [0141] Humanized Antibodies  
       [0142] The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′) 2  or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al.,  Nature,  321:522-525 (1986); Riechmann et al.,  Nature,  332:323-327 (1988); Verhoeyen et al.,  Science,  239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Pat. No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta,  Curr. Op. Struct. Biol.,  2:593-596 (1992)).  
       [0143] Human Antibodies  
       [0144] Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed “human antibodies”, or “fully human antibodies” herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).  
       [0145] In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter,  J. Mol. Biol.,  227:381 (1991); Marks et al.,  J. Mol. Biol.,  222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. ( Bio/Technology  10, 779-783 (1992)); Lonberg et al.  Nature  368 856-859 (1994)); Morrison ( Nature  368, 812-13 (1994)); Fishwild et al, ( Nature Biotechnology  1, 845-51 (1996)); Neuberger ( Nature Biotechnology  14, 826 (1996)); and Lonberg and Huszar ( Intern. Rev. Immunol.  13 65-93 (1995)).  
       [0146] Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal&#39;s endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host&#39;s genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.  
       [0147] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Pat. No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.  
       [0148] A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Pat. No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.  
       [0149] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.  
       [0150] Fab Fragments and Single Chain Antibodies  
       [0151] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Pat. No. 4,946,778). In addition, methods can be adapted for the construction of F ab  expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F (ab′)2  fragment produced by pepsin digestion of an antibody molecule; (ii) an F ab  fragment generated by reducing the disulfide bridges of an F (ab′)2  fragment; (iii) an F ab  fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F v  fragments.  
       [0152] Bispecific Antibodies  
       [0153] Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.  
       [0154] Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello,  Nature,  305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published May 13, 1993, and in Traunecker et al.,  EMBO J.  10:3655-3659 (1991).  
       [0155] Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al.,  Methods in Enzymology,  121:210 (1986).  
       [0156] According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.  
       [0157] Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab′) 2  bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al.,  Science  229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab′) 2  fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab′ fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives is then reconverted to the Fab′-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab′-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.  
       [0158] Additionally, Fab′ fragments can be directly recovered from  E. coli  and chemically coupled to form bispecific antibodies. Shalaby et al.,  J. Exp. Med.  175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab′) 2  molecule. Each Fab′ fragment was separately secreted from  E. coli  and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.  
       [0159] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al.,  J. Immunol.  148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab′ portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al.,  Proc. Natl. Acad. Sci. USA  90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H  and V L  domains of one fragment are forced to pair with the complementary V L  and V H  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al.,  J. Immunol.  152:5368 (1994).  
       [0160] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al.,  J. Immunol.  147:60 (1991).  
       [0161] Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).  
       [0162] Heteroconjugate Antibodies  
       [0163] Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Pat. No. 4,676,980.  
       [0164] Effector Function Engineering  
       [0165] It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al.,  J. Exp Med.,  176: 1191-1195 (1992) and Shopes,  J. Immunol.,  148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al.  Cancer Research,  53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al.,  Anti - Cancer Drug Design,  3: 219-230 (1989).  
       [0166] Immunoconjugates  
       [0167] The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).  
       [0168] Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from  Pseudomonas aeruginosa ), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin,  Aleurites fordii  proteins, dianthin proteins,  Phytolaca americana  proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  212 Bi, 131i,  131 In,  90 Y, and  18 Re.  
       [0169] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al.,  Science,  238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.  
       [0170] In another embodiment, the antibody can be conjugated to a “receptor” (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a “ligand” (e.g., avidin) that is in turn conjugated to a cytotoxic agent.  
       [0171] Immunoliposomes  
       [0172] The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al.,  Proc. Natl. Acad. Sci. USA,  82: 3688 (1985); Hwang et al.,  Proc. Natl. Acad. Sci. USA,  77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.  
       [0173] Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab′ fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al.,  J. Biol. Chem.,  257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al.,  J. National Cancer Inst.,  81(19): 1484 (1989).  
       [0174] Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention  
       [0175] Antibodies directed against a protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of the protein (e.g., for use in measuring levels of the protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies against the proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antigen binding domain, are utilized as pharmacologically-active compounds (see below).  
       [0176] An antibody specific for a protein of the invention can be used to isolate the protein by standard techniques, such as immunoaffinity chromatography or immunoprecipitation. Such an antibody can facilitate the purification of the natural protein antigen from cells and of recombinantly produced antigen expressed in host cells. Moreover, such an antibody can be used to detect the antigenic protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic protein. Antibodies directed against the protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  125 I,  131 I,  35 S or  3 H.  
       [0177] Antibody Therapeutics  
       [0178] Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.  
       [0179] Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.  
       [0180] A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.  
       [0181] Pharmaceutical Compositions of Antibodies  
       [0182] Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.  
       [0183] If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.  
       [0184] The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.  
       [0185] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.  
       [0186] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.  
       [0187] ELISA Assay  
       [0188] An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., F ab  or F (ab)2 ) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term “biological sample”, therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in “ELISA: Theory and Practice: Methods in Molecular Biology”, Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, N.J., 1995; “Immunoassay”, E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, Calif., 1996; and “Practice and Thory of Enzyme Immunoassays”, P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.  
       [0189] NOVX Recombinant Expression Vectors and Host Cells  
       [0190] Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.  
       [0191] The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably-linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).  
       [0192] The term “regulatory sequence” is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).  
       [0193] The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as  Escherichia coli , insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.  
       [0194] Expression of proteins in prokaryotes is most often carried out in  Escherichia coli  with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988 . Gene  67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion  E. coli  expression vectors include pTrc (Amrann et al., (1988)  Gene  69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).  
       [0195] One strategy to maximize recombinant protein expression in  E. coli  is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in  E. coli  (see, e.g., Wada, et al., 1992 . Nucl. Acids Res.  20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.  
       [0196] In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast  Saccharomyces cerivisae  include pYepSecI (Baldari, et al., 1987 . EMBO J.  6: 229-234), pMFa (Kurjan and Herskowitz, 1982 . Cell  30: 933-943), pJRY88 (Schultz et al., 1987 . Gene  54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.). Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983 . Mol. Cell. Biol.  3: 2156-2165) and the pVL series (Lucklow and Summers, 1989 . Virology  170: 31-39).  
       [0197] In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987 . Nature  329: 840) and pMT2PC (Kaufman, et al., 1987 . EMBO J.  6: 187-195). When used in mammalian cells, the expression vector&#39;s control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.  
       [0198] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987 . Genes Dev.  1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988 . Adv. Immunol.  43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989 . EMBO J.  8: 729-733) and immunoglobulins (Banedji, et al., 1983 . Cell  33: 729-740; Queen and Baltimore, 1983 . Cell  33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989 . Proc. Natl. Acad. Sci. USA  86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985 . Science  230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990 . Science  249: 374-379) and the α-fetoprotein promoter (Campes and Tilghman, 1989 . Genes Dev.  3: 537-546).  
       [0199] The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., “Antisense RNA as a molecular tool for genetic analysis,”  Reviews - Trends in Genetics , Vol. 1(1) 1986.  
       [0200] Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as  E. coli , insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.  
       [0201] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.  
       [0202] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).  
       [0203] A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.  
       [0204] Transgenic NOVX Animals  
       [0205] The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.  
       [0206] A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.  
       [0207] To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e.g., the cDNA of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector).  
       [0208] Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5′- and 3′-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′- and 3′-termini) are included in the vector. See, e.g., Thomas, et al., 1987 . Cell  51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. See, e.g., Li, et al., 1992 . Cell  69: 915.  
       [0209] The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TETRATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991 . Curr. Opin. Biotechnol.  2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.  
       [0210] In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al., 1992 . Proc. Natl. Acad. Sci. USA  89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of  Saccharomyces cerevisiae . See, O&#39;Gorman, et al., 1991 . Science  251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.  
       [0211] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997 . Nature  385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G 0  phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.  
       [0212] Pharmaceutical Compositions  
       [0213] The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as “active compounds”) of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington&#39;s Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger&#39;s solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.  
       [0214] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.  
       [0215] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.  
       [0216] Sterile injectable solutions can be prepared by incorporating the active compound (e.g., an NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.  
       [0217] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.  
       [0218] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.  
       [0219] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.  
       [0220] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.  
       [0221] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.  
       [0222] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.  
       [0223] The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994 . Proc. Natl. Acad. Sci. USA  91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, orcan comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.  
       [0224] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.  
       [0225] Screening and Detection Methods  
       [0226] The isolated nucleic acid molecules of the invention can be used to express NOVX protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (e.g., in a biological sample) or a genetic lesion in an NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.  
       [0227] The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.  
       [0228] Screening Assays  
       [0229] The invention provides a method (also referred to herein as a “screening assay”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, e.g., NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.  
       [0230] In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of an NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997 . Anticancer Drug Design  12: 145.  
       [0231] A “small molecule” as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.  
       [0232] Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993 . Proc. Natl. Acad. Sci. U.S.A.  90: 6909; Erb, et al., 1994 . Proc. Natl. Acad. Sci. U.S.A.  91: 11422; Zuckermann, et al., 1994 . J. Med. Chem.  37: 2678; Cho, et al., 1993 . Science  261: 1303; Carrell, et al., 1994 . Angew. Chem. Int. Ed. Engl.  33: 2059; Carell, et al., 1994 . Angew. Chem. Int. Ed. Engl.  33: 2061; and Gallop, et al., 1994 . J. Med. Chem.  37:1233.  
       [0233] Libraries of compounds may be presented in solution (e.g., Houghten, 1992 . Biotechniques  13: 412-421), or on beads (Lam, 1991 . Nature  354: 82-84), on chips (Fodor, 1993 . Nature  364: 555-556), bacteria (Ladner, U.S. Pat. No. 5,223,409), spores (Ladner, U.S. Pat. No. 5,233,409), plasmids (Cull, et al., 1992 . Proc. Natl. Acad. Sci. USA  89: 1865-1869) or on phage (Scott and Smith, 1990 . Science  249: 386-390; Devlin, 1990 . Science  249: 404-406; Cwirla, et al., 1990 . Proc. Natl. Acad. Sci. U.S.A.  87: 6378-6382; Felici, 1991 . J. Mol. Biol.  222: 301-310; Ladner, U.S. Pat. No. 5,233,409.).  
       [0234] In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to an NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with  125 I,  35 S,  14 C, or  3 H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.  
       [0235] In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule. As used herein, a “target molecule” is a molecule with which an NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses an NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. An NOVX target molecule can be a non-NOVX molecule or an NOVX protein or polypeptide of the invention. In one embodiment, an NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.  
       [0236] Determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e. intracellular Ca 2+ , diacylglycerol, IP 3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising an NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.  
       [0237] In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting an NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.  
       [0238] In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to an NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate an NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra.  
       [0239] In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of an NOVX target molecule.  
       [0240] The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether) n , N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).  
       [0241] In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.  
       [0242] Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.  
       [0243] In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (ie., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.  
       [0244] In yet another aspect of the invention, the NOVX proteins can be used as “bait proteins” in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos, et al., 1993 . Cell  72: 223-232; Madura, et al., 1993 . J. Biol. Chem.  268: 12046-12054; Bartel, et al., 1993 . Biotechniques  14: 920-924; Iwabuchi, et al., 1993 . Oncogene  8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX (“NOVX-binding proteins” or “NOVX-bp”) and modulate NOVX activity. Such NOVX-binding proteins are also likely to be involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.  
       [0245] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GALA). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming an NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.  
       [0246] The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.  
       [0247] Detection Assays  
       [0248] Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.  
       [0249] Chromosome Mapping  
       [0250] Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences, SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.  
       [0251] Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.  
       [0252] Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D&#39;Eustachio, et al., 1983 . Science  220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.  
       [0253] PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.  
       [0254] Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal 0.4 z spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).  
       [0255] Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.  
       [0256] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e.g., in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, et al., 1987 . Nature,  325: 783-787.  
       [0257] Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.  
       [0258] Tissue Typing  
       [0259] The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual&#39;s genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP (“restriction fragment length polymorphisms,” described in U.S. Pat. No. 5,272,057).  
       [0260] Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual&#39;s genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5′- and 3′-termini of the sequences. These primers can then be used to amplify an individual&#39;s DNA and subsequently sequence it.  
       [0261] Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).  
       [0262] Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.  
       [0263] Predictive Medicine  
       [0264] The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer&#39;s Disease, Parkinson&#39;s Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in an NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.  
       [0265] Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as “pharmacogenomics”). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)  
       [0266] Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials.  
       [0267] These and other agents are described in further detail in the following sections.  
       [0268] Diagnostic Assays  
       [0269] An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 178, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.  
       [0270] An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′) 2 ) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (ie., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOVX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.  
       [0271] In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.  
       [0272] In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.  
       [0273] The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.  
       [0274] Prognostic Assays  
       [0275] The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a “test sample” refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.  
       [0276] Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).  
       [0277] The methods of the invention can also be used to detect genetic lesions in an NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding an NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from an NOVX gene; (ii) an addition of one or more nucleotides to an NOVX gene; (iii) a substitution of one or more nucleotides of an NOVX gene, (iv) a chromosomal rearrangement of an NOVX gene; (v) an alteration in the level of a messenger RNA transcript of an NOVX gene, (vi) aberrant modification of an NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of an NOVX gene, (viii) a non-wild-type level of an NOVX protein, (ix) allelic loss of an NOVX gene, and (x) inappropriate post-translational modification of an NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in an NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.  
       [0278] In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al., 1988 . Science  241: 1077-1080; and Nakazawa, et al., 1994 . Proc. Natl. Acad. Sci. USA  91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al., 1995 . Nucl. Acids Res.  23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to an NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.  
       [0279] Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990 . Proc. Natl. Acad. Sci. USA  87: 1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989 . Proc. Natl. Acad. Sci. USA  86: 1173-1177); Qβ Replicase (see, Lizardi, et al, 1988 . BioTechnology  6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.  
       [0280] In an alternative embodiment, mutations in an NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.  
       [0281] In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996 . Human Mutation  7: 244-255; Kozal, et al., 1996 . Nat. Med.  2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.  
       [0282] In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977 . Proc. Natl. Acad. Sci. USA  74: 560 or Sanger, 1977 . Proc. Natl. Acad. Sci. USA  74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995 . Biotechniques  19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al., 1996 . Adv. Chromatography  36: 127-162; and Griffin, et al., 1993 . Appl. Biochem. Biotechnol.  38: 147-159).  
       [0283] Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985 . Science  230: 1242. In general, the art technique of “mismatch cleavage” starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S 1  nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988 . Proc. Natl. Acad. Sci. USA  85: 4397; Saleeba, et al., 1992 . Methods Enzymol.  217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.  
       [0284] In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called “DNA mismatch repair” enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of  E. coli  cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994 . Carcinogenesis  15: 1657-1662. According to an exemplary embodiment, a probe based on an NOVX sequence, e.g. a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.  
       [0285] In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989 . Proc. Natl. Acad. Sci. USA:  86: 2766; Cotton, 1993 . Mutat. Res.  285: 125-144; Hayashi, 1992 . Genet. Anal. Tech. Appl.  9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991 . Trends Genet.  7: 5.  
       [0286] In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985 . Nature  313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987 . Biophys. Chem.  265: 12753.  
       [0287] Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986 . Nature  324: 163; Saiki, et al., 1989 . Proc. Natl. Acad. Sci. USA  86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.  
       [0288] Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989 . Nucl. Acids Res.  17: 2437-2448) or at the extreme 3′-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993 . Tibtech.  11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992 . Mol. Cell Probes  6: 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991 . Proc. Natl. Acad. Sci. USA  88: 189. In such cases, ligation will occur only if there is a perfect match at the 3′-terminus of the 5′ sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.  
       [0289] The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an NOVX gene.  
       [0290] Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.  
       [0291] Pharmacogenomics  
       [0292] Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g., NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer&#39;s Disease, Parkinson&#39;s Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual&#39;s genotype and that individual&#39;s response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual&#39;s genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.  
       [0293] Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996 . Clin. Exp. Pharmacol. Physiol.,  23: 983-985; Linder, 1997 . Clin. Chem.,  43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.  
       [0294] As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome PREGNANCY ZONE PROTEIN PRECURSOR enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C 19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification. Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual&#39;s drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.  
       [0295] Monitoring of Effects During Clinical Trials  
       [0296] Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials.  
       [0297] For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a “read out” or markers of the immune responsiveness of a particular cell.  
       [0298] By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.  
       [0299] In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i.e., to decrease the effectiveness of the agent.  
       [0300] Methods of Treatment  
       [0301] The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn&#39;s disease; multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, and other diseases, disorders and conditions of the like.  
       [0302] These methods of treatment will be discussed more fully, below.  
       [0303] Disease and Disorders  
       [0304] Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are “dysfunctional” (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to “knockout” endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989 . Science  244: 1288-1292); or (v) modulators (i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.  
       [0305] Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (ie., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.  
       [0306] Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).  
       [0307] Prophylactic Methods  
       [0308] In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, an NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.  
       [0309] Therapeutic Methods  
       [0310] Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of an NOVX protein, a peptide, an NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of an NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering an NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.  
       [0311] Stimulation of NOVX activity is desirable in situations in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).  
       [0312] Determination of the Biological Effect of the Therapeutic  
       [0313] In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.  
       [0314] In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient&#39;s disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.  
       [0315] Prophylactic and Therapeutic Uses of the Compositions of the Invention  
       [0316] The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer&#39;s Disease, Parkinson&#39;s Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.  
       [0317] As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer&#39;s Disease, Parkinson&#39;s Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.  
       [0318] Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (i.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.  
       [0319] Sequence Analyses  
       [0320] The sequence of NOVX was derived by laboratory cloning of cDNA fragments, by in silico prediction of the sequence. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. In silico prediction was based on sequences available in CuraGen&#39;s proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.  
       [0321] The laboratory cloning was performed using one or more of the methods summarized below:  
       [0322] SeqCalling™Technology: cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then sequenced using CuraGen Corporation&#39;s SeqCalling technology which is disclosed in full in U.S. Ser. No. 09/417,386 filed Oct. 13, 1999, and Ser. No. 09/614,505 filed Jul. 11, 2000. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatics programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation&#39;s database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.  
       [0323] Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a “cSNP” to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.  
       [0324] Presented information includes that associated with genomic clones, public genes and ESTs sharing sequence identity with the disclosed sequence and CuraGen Corporation&#39;s Electronic Northern bioinformatic tool. 
     
    
    
     EXAMPLES  
     Example A  
     Sequence related information  
     [0325] The NOV1 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 1A.  
               TABLE 1A                       NOV1 Sequence Analysis                                                SEQ ID NO:1   711 bp                     NOV1a,     TGCAGA   ATG AACCAAGGAGACTCAAACCCAGCAGCTACTCCGCATGCGGCAGAAGACA       CG582522-01 DNA Sequence           TTCAAGGAGATGACAGATGGATGTGTCAGCACAACAGATTTGTTTTGGACTGTAAAGA                   CAAACAGCCTGATGTACCATTTGCGGGAGGCTCCGTGGTGCAGTTACTGCAGCCATAT                   GAGATATGGCGAGAGCTTTTTTCCCCACTTCATGCACTGAATTTTGGAACTGGGGGAG                   ATACAACAAGACATGTTTTGTGGAGACTAAAGAGCGGAGAACTGGGGAATACTAAGCC                   TAAGGTCATTGTTTTCTGGCTAGGAAGAAACAACCATGAAAATATGGCAGAAGAGGTA                   GCAGGTGGTATGGCGGCCATCGTACAACTTATCAACACAAGGCAGCCACAGGCCAAAA                   TCATTGTATTTGATCTGTTACCTCAAGGTGAGAAACCCAACCCTTTGAGGCAAAAGAA                   CGCCAAGGTGAACCCACTCGTCAAGATTTCGCTGCTGAAACTTACCAACGTGCAGCTC                   CTGGATACTGACAGGGGTTTCGTGCACTCCGACCGTGCCATCTCCTGCCACGACATGT                   TTGATTTTCTGCATTTGACAGGAGGTGGCTACTCAAAGGTCTGCAAACCCTTGAATGA                   ACTGATCATGCAGTTGTTGGAGGAAACACCTGAGGAGAAACAAACCACCATTGCC TGA                       CTGGCTCCCATGAGT                                           ORF STart: ATG at 7       ORF Stop: TGA at 694           SEQ ID NO:2   229 aa   MW at 25656.2 kD                     NOV1a,   MNQGDSNPAATPHAAEDIQGDDRWMCQHNRFVLDCKDKQPDVPFAGGSVVQLLQPYEI       CG58522-01 Protein Sequence           WRELFSPLHALNFGTGGDTTRHVLWRLKSGELGNTKPKVIVFWLGRNMAEEVAG                   GMAAIVQLINTRQPQAKIIVFDLLPQGEKPNPLRQKNAKVNPLVKISLLKLTNVQLLD                   TDRGFVHSDRAISCHDMFDELHLTGGGYSKVCKPLNELIMQLLEETPEEEQTTIA                  
 
     [0326] Further analysis of the NOV1a protein yielded the following properties shown in Table 1B.  
               TABLE 1B                       Protein Sequence Properties NOV1a                                        Psort   0.6500 probability located in cytoplasm; 0.2340 probability       analysis:   located in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space; 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0327] A search of the NOV1a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1C.  
               TABLE 1C                          Geneseq Results for NOV1a                                             Identities/                   NOV1a   Similarites               Residues/   for the       Geneseq   Protein/Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB49433   Human beta platelet   1 . . . 229   196/229    e−114           activating factor   1 . . . 229   (85%)           acetylhydrolase -  Homo         209/229             sapiens , 229 aa. [U.S.       (90%)           Pat. No. 6146868-A,           14 NOV. 2000]       AAB49432   Rat beta platelet   1 . . . 229   195/229    e−114           activating factor   1 . . . 229   (85%)           acetylhydrolase -  Rattus         208/229             norvegicus , 229 aa. [U.S.       (90%)           Pat. No. 6146868-A,           14 NOV. 2000]       AAB49434   Murine beta platelet   1 . . . 229   192/229    e−111           activating factor   1 . . . 229   (83%)           acetylhydrolase -  Mus         205/229             musculus , 229 aa. [U.S.       (88%)           Pat. No. 6146868-A,           14 NOV. 2000]       AAB49436   Bovine gamma platelet   4 . . . 219   124/216   5e−74           activating factor   3 . . . 218   (57%)           acetylhydrolase -  Bos         165/216           taurus, 1232 aa. [U.S.       (75%)           Pat. No. 6146868-A,           14 NOV. 2000]       AAB49435   Human gamma platelet   4 . . . 219   124/216   2e−73           activating factor   3 . . . 218   (57%)           acetylhydrolase -  Homo         164/216             sapiens , 231 aa. [U.S.       (75%)           Pat. No. 6146868-A,           14 NOV. 2000]                  
 
     [0328] In a BLAST search of public sequence databases, the NOV1a protein was found to have homology to the proteins shown in the BLASTP data in Table 1D.  
               TABLE 1D                          Public BLASTP Results for NOV1a                                         NOV1a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/Organism/   Match   the Matched   Expect       Number   Length   Residues   Portion   Value               Q29459   Platelet-activating   1 . . . 229   196/229 (85%)    e−114           factor acetylhydrolase   1 . . . 229   209/229 (90%)           IB beta subunit           (EC 3.1.1.47) (PAF           acetylhydrolase 30           kDa subunit)           (PAF-AH 30 kDa           subunit) (PAF-AH           beta subunit)           (PAFAH beta           subunit) -  Homo               sapiens  (Human),           and, 229 aa.       O35264   Platelet-activating   1 . . . 229   195/229 (85%)    e−113           factor acetylhydrolase   1 . . . 229   208/229 (90%)           IB beta subunit (EC           3.1.1.47) (PAF           acetylhydrolase 30           kDa subunit)           (PAF-AH beta           subunit) (PAFAH           beta subunit)           (Platelet-           activating factor           acetylhydrolase alpha,           2 subunit) (PAF-AH           alpha 2) -  Rattus               norvegicus  (Rat),           229 aa.       Q61206   Platelet-activating   1 . . . 229   192/229 (83%)    e−111           factor acetylhydrolase   1 . . . 229   205/229 (88%)           IB beta subunit (EC           3.1.1.47) (PAF           acetylhydrolase 30           kDa subunit)           (PAF-AH 30 kDa           subunit) (PAF-AH           beta subunit)           (PAFAH beta           subunit) -  Mus               musculus  (Mouse),           229 aa.       Q29460   Platelet-activating   4 . . . 219   125/216 (57%)   8e−74           factor acetylhydrolase   3 . . . 218   165/216 (75%)           IB gamma subunit           (EC 3.1.1.47)           (PAF acetylhydrolase           29 kDa subunit)           (PAF-AH 29 kDa           subunit) (PAF-AH           gamma subunit)           (PAFAH gamma           subunit) -  Bos taurus             (Bovine), 232 aa.       Q15102   Platelet-activating   4 . . . 219   124/216 (57%)   7e−73           factor acetyl-   3 . . . 218   164/216 (75%)           hydrolase IB           gamma subunit           (EC 3.1.1.47)           (PAF acetylhydrolase           29 kDa subunit)           (PAF-AH 29 kDa           subunit) (PAF-AH           gamma subunit)           (PAFAH gamma           subunit) -  Homo               sapiens  (Human),           231 aa.                  
 
     [0329] PFam analysis predicts that the NOV1a protein contains the domains shown in the Table 1E.  
               TABLE 1E                          Domain Analysis of NOV1a                                 NOV1a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value               PAF-AH:   7 . . . 221   150/215 (70%)   6e−147       domain 1 of 1       186/215 (87%)                  
 
     Example 2  
     [0330] The NOV2 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 2A.  
               TABLE 2A                       NOV2 Sequence Analysis                                                SEQ ID NO:3   1457 bp                     NOV2a,     CGATTCCG   ATG GGTCCTTTGAAAGCTTTTCTCTTCTCCCCTTTTCTTCTGCGGAGTCA       CG58520-01 DNA Sequence           AAGTAGAGGGGTGAGGTTGGTCTTCTTGTTACTGACCCTGCATTTGGGAAACGTTGAT                   AAGGCAGATGATGAAGATGATGAGGATTTAACGGTGAACAAAACCTGGGTCTTGGCCC                   CAAAAATTCATGAAGGAGATATCACACAAATTCTGAATTCATTGCTTCAAGGCTATGA                   CAATAAACTTCGTCCAGATATAGGAGTGAGGCCCACAGTAATTGAAACTGATGTTTAT                   GTAAACAGCATTGGACCAGTTGATCCAATTAATATGGAATATACAATAGATATAATTT                   TTGCCCAAACCTGGTTTGACAGTCGTTTAAAATTCAATAGTACCATGAAAGTGCTTAT                   GCTTAACAGTAATATGGTTGGAAAAATTTGGATTCCTGACACTTTCTTCAGAAACTCA                   AGAAAATCTGATGCTCACTGGATAACAACTCCTAATCGTCTGCTTCGAATTTGGAATG                   ATAGATGGATACCCTAAAAATGAAATTGAGTTATCAATGGAAGCGAAGTTCTGTGGAA                   GTGGGCGACACAAGATCCGGAGATTATATCAGTTTGCATTTGTAGGGTTACGGAACTC                   AACTGAAATCACTCACACGATCTCTGGGGATTATGTTATCATGACAATTTTTTTTGAC                   CTGAGCAGAAGAATGGGATATTTCACTATTCAGACCTACATTCCATGCATTCTGACAG                   TTGTTCTTTCTTGGGTGTCTTTTTGGATCAATAAAGATGCAGTGCCTGCAAGAACATC                   GTTGGGTATGACATCTATAGGTATCACTACAGTTCTGACTATGACAACCCTGAGTACA                   ATTGCCAGGAAGTCTTTACCTAAGGTTTCTTATGTGACTGCGATGGATCTCTTTGTTT                   CTGTTTGTTTCATTTTTGTTTTTGCAGCCTTGATGGAATATGGAACCTTGCATTATTT                   TACCAGCAACCAAAAAGGAAAGACTGCTACTAAAGACAGAAAGCTAAAAAATAAAGCC                   TCGACTCCTGGTCTCCATCCTGGATCCACTCTGATTCCAATGAATAATATTTCTGTGC                   CGCAAGAAGATGATTATGGGTATCAGTGTTTGGAGGGCAAAGATTGTGCCAGCTTCTT                   CTGTTGCTTTGAAGACTGCAGAACAGGATCTTGGAGGGAAGGAAGGATACACATACGC                   ATTGCCAAAATTGACTCTTATTCTAGAATATTTTTCCCAACCGCTTTTGCCCTGTTCA                   ACTTGGTTTATTGGGTTGGCTATCTTTACTTA TAA   AATCTACTTCATAAGCAAAAATC                       AAAAGAA                                           ORF Start: ATG at 9       ORF Stop: TAA at 1425           SEQ ID NO:4   472 aa   MW at 54100.9 kD                     NOV2a,   MGPLKAFLFSPELLRSQSRGVRLVFLLLTLHLGNVDKADDEDDEDLTVNKTWVLAPKI       CG58520-01 Protein Sequence           HEGDITQILNSLLQGYDNKLRPDIGVRPTVIETDVYVNSIGPVDPINMEYTIDIIFAQ                   TWFDSRLKFNSTMKVLMLNSNMVGKIWIPDTFFRNSRKSDAHWITTPNRLLRIWNDGR                   VLYTLRRLTINAECYLQLHNFPMDEHSCPLEFSSFSIDGYPKNEIELSMEAKFCGSGR                   HKIRRLYQFAFVGLRNSTEITHTISGDYVIMTIFFDLSRRMGYFTIQTYIPCILTVVL                   SWVSFWINKDAVPARTSLGMTSIGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVC                   FIFVFAALMEYGTLHYFTSNQKGKTATKDRKLKNKASTPGLHPGSTLIPMNNISVPQE                   DDYGYQCLEGKDCASFFCCFEDCRTGSWREGRIHIRIAKIDSYSRIFFPTAFALFNLV                   YWVGYLYL                                     SEQ ID NO:5   1521 bp                     NOV2b,     CAACCAAGAGGCAAGAGGCGAGAGAAGGAAAAAAAAAAAAGCG   ATG AGTTCGCCAAAT       CG58520-02 DNA Sequence           ATATGGAGCACAGGAAGCTCAGTCTACTCGACTCCTGTATTTTCACAGAAAATGACGG                   TGTGGATTCTGCTCCTGCTGTCGCTCTACCCTGGCTTCACTAGCCAGAAATCTGATGA                   TGACTATGAAGATTATGCTTCTAACAAAACATGGGTCTTGACTCCAAAAGTTCCTGAG                   GGTGATGTCACTGTCATCTTAAACAACCTGCTGGAAGGATATGACAATAAACTTCGGC                   CTGATATAGGAGTGAAGCCAACGTTAATTCACACAGACATGTATGTGAATAGCATTGG                   TCCAGTGAACGCTATCAATATGGAATACACTATTGATATATTTTTTGCGCAAACGTGG                   TATGACAGACGTTTGAAATTTAACAGCACCATTAAAGTCCTCCGATTGAACAGCAACA                   TGGTGGGGAAAATCTGGATTCCAGACACTTTCTTCAGAAATTCCAAAAAAGCTGATGC                   ACACTGGATCACCACCCCCAACAGGATGCTGAGAATTTGGAATGATGGTCGAGTGCTC                   TACACCCTAAGGTTGACAATTGATGCTGAGTGCCAATTACAATTGCACAACTTTCCAA                   TGGATGAACACTCCTGCCCCTTGGAGTTCTCCAGTTATGGCTATCCACGTGAAGAAAT                   TGTTTATCAATGGAAGCGAAGTTCTGTTGAAGTGGGCGACACAAGATCCTGGAGGCTT                   TATCAATTCTCATTTGTTGGTCTAAGAAATACCACCGAAGTAGTGAAGACAACTTCCG                   GAGATTATGTGGTCATGTCTGTCTACTTTGATCTGAGCAGAAGAATGGGATACTTTAC                   CATCCAGACCTATATCCCCTGCACACTCATTGTCGTCCTATCCTGGGTGTCTTTCTGG                   ATCAATAAGGATGCTGTTCCAGCCAGAACATCTTTAGGTATCACCACTGTCCTGACAA                   TGACCACCCTCAGCACCATTGCCCGGAAATCGCTCCCCAAGGTCTCCTATGTCACAGC                   GATGGATCTCTTTGTATCTGTTTGTTTCATCTTTGTCTTCTCTGCTCTGGTGGAGTAT                   GGCACCTTGCATTATTTTGTCAGCAACCGGAAACCAAGCAAGGACAAAGATAAAAAGA                   AGAAAAACCCTCTTCTTCGGATGTTTTCCTTCAAGGCCCCTACCATTGATATCCGCCC                   AAGATCAGCAACCATTCAAATGAATAATGCTACACACCTTCAAGAGAGAGATGAAGAG                   TACGGCTATGAGTGTCTGGACGGCAAGGACTGTGCCAGTTTTTTCTGCTGTTTTGAAG                   ATTGTCGAACAGGAGCTTGGAGACATGGGAGGATACATATCCGCATTGCCAAAATGGA                   CTCCTATGCTCGGATCTTCTTCCCCACTGCCTTCTGCCTGTTTAATCTGGTCTATTGG                   GTCTCCTACCTCTACCTG TGA   GGAGGTATGGGTTTTACTGATATGGTTCTTATTCACT                       GAGTCTCATGGAG                                           ORF Start ATG at 44       ORF Stop: TGA at 1469           SEQ ID NO:6   475 aa   MW at 55184.9 kD                     NOV2b,   MSSPNIWSTGSSVYSTPVFSQKMTVWILLLLSLYPGFTSQKSDDDYEDYASNKTWVLT       CG58520-02 Protein Sequence           PKVPEGDVTVILNNLLEGYDNKLRPDIGVKPTLIHTDMYVNSIGPVNAINMEYTIDIF                   FAQTWYDRRLKFNSTIKVLRLNSNMVGKIWIPDTFFRNSKKADAHWITTPNRMLRIWN                   DGRVLYTLRLTIDAECQLQLHNFPMDEHSCPLEFSSYGYPREEIVYQWKRSSVEVGDT                   RSWRLYQFSFVGLRNTTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVLS                   WVSFWINKDAVPARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFS                   ALVEYGTLHYFVSNRKPSKDKDKKKKNPLLRMFSFKAPTIDIRPRSATIQMNNATHLQ                   ERDEEYGYECLDGKDCASFFCCFEDCRTGAWRHGRIHIRIAKMDSYARIFFPTAFCLF                   NLVYWVSYLYL                                     SEQ ID NO:7   1455 bp                     NOV2c,     TAGTGCAGCACACGTAAAAAAGCGATTCCG   ATG GGTCCTTTGAAAGCTTTTCTCTTCT       CG58520-03 DNA Sequence           CCCCTTTTCTTCTGCGGAGTCAAAGTAGAGGGGTGAGGTTGGTCTTCTTGTTACTGAC                   CCTGCATTTGGGAAACTGGGTTGATAAGGCAGATGATGAAGATGATGAGGATTTAACG                   GTGAACAAAACCTGGGTCTTGGCCCCAAAAATTCATGAAGGAGATATCACACAAATTC                   TGAATTCATTGCTTCAAGGCTATGACAATAAACTTCGTCCAGATATAGGAGTGAGGCC                   CACAGTAATTGAAACTGATGTTTATGTAAACAGCATTGGACCAGTTGATCCAATTAAT                   ATGGAATATACAATAGATATAATTTTTGCCCAAACCTGGTTTGACAGTCGTTTAAAAT                   TCAATAGTACCATGAAAGTGCTTATGCTTAACAGTAATATGGTTGGAAAAATTTGGAT                   TCCTGACACTTTCTTCAGAAACTCAAGAAAATCTGATGCTCACTGGATAACAACTCCT                   AATCGTCTGCTTCGAATTTGGAATGATGGACGAGTTCTGTATACTCTAAGGTTGACAA                   TTAATGCAGAATGTTATCTTCAGCTTCATAACTTTCCCATGGATGAACATTCCTGTCC                   ACTGGAATTTTCAAGCGATGGATACCCTAAAAATGAAATTGAGTATAAGTGGAAAAAG                   CCCTCCGTAGAAGTGGCTGATCCTAAATACTGGAGATTATATCAGTTTGCATTTGTAG                   GGTTACGGAACTCAACTGAAATCACTCACACGATCTCTGGTGATTATGTTATCATGAC                   AATTTTTTTTGACCTGAGCAGAAGAATGGGATATTTCACTATTCAGACCTACATTCCA                   TGCATTCTGACAGTTGTTCTTTCTTGGGTGTCTTTTTGGATCAATAAAGATGCAGTGC                   CTGCAAGAACATCGTTGGGTATCACTACAGTTCTGACTATGACAACCCTGAGTACAAT                   TGCCAGGAAGTCTTTACCTAAGGTTTCTTATGTGACTGCGATGGATCTCTTTGTTTCT                   GTTTGTTTCATTTTTGTTTTTGCAGCCTTGATGGAATATGGAACCTTGCATTATTTTA                   CCAGCAACCAAAAAGGAAAGACTGCTACTAAAGACAGAAAGCTAAAAAATAAAGCCTC                   GGTAACTCCTGGTCTCCATCCTGGATCCACTCTGATTCCAATGAATAATATTTCTGTG                   CCGCAAGAAGATGATTATGGGTATCAGTGTTTGGAGGGCAAAGATTGTGCCAGCTTCT                   TCTGTTGCTTTGAAGACTGCAGAACAGGATCTTGGAGGGAAGGAAGGATACACATACG                   CATTGCCAAAATTGACTCTTATTCTAGAATATTTTTCCCAACCGCTTTTGCCCTGTTC                   AACTTGGTTTATTGGGTTGGCTATCTTTTACTTAT AA   AATCTACTTCATAAGCAAAAAT                       CAAAA                                           ORF Start: ATG at 31       ORF Stop: TAA at 1426           SEQ ID NO:8   465 aa   MW at 53597.3 kD                     NOV2c,   MGPLKAFLFSPFLLRSQSRGVRLVFLLLTLHLGNWVDKADDEDDEDLTVNKTWVLAPK       CG58520-03 Protein Sequence           IHEGDITQILNSLLQGYDNKLRPDIGVRPTVIETDVYVNSIGPVDPINMEYTIDIIFA                   QTWFDSRLKFNSTMKVLMLNSNMVGKIWIPDTFFRNSRKSDAHWITTPNRLLRIWNDG                   RVLYTLRLTINAECYLQLHNFPMDEHSCPLEFSSDGYPKNEIEYKWKKPSVEVADPKY                   WRLYQFAFVGLRNSTEITHTISGDYVIMTIFFDLSRRMGYFTIQTYIPCILTVVLSWV                   SFWINKDAVPARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVSVCFIFVFAAL                   MEYGTLHYFTSNQKGKTATKDRKLKNKASVTPGLHPGSTLIPMNNISVPQEDDYGYQC                   LEGKDCASFFCCFEDCRTGSWREGRIHIRIAKIDSYSRIFFPTAFALFNLVYWVGYLYL                  
 
     [0331] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 2B.  
               TABLE 2B                          Comparison of NOV2a against NOV2b through NOV2c.                         Protein   NOV2a Residues/   Identities/       Sequence   Match Residues   Similarities for the Matched Region               NOV2b   24 . . . 472   311/458 (67%)           27 . . . 475   352/458 (75%)       NOV2c    1 . . . 472   414/474 (87%)            1 . . . 465   415/474 (87%)                  
 
     [0332] Further analysis of the NOV2a protein yielded the following properties shown in Table 2C.  
               TABLE 2C                       Protein Sequence Properties NOV2a                                        Psort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability located           in endoplasmic reticulum (membrane); 0.1000 probability           located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 38 and 39       analysis:                  
 
     [0333] A search of the NOV2a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2D.  
               TABLE 2D                          Geneseq Results for NOV2a                                             Identities/                   NOV2a   Similarites           Protein/   Residues/   for the       Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAM41007   Human polypeptide   24 . . . 472   334/451   0.0           SEQ ID NO 5938 -   49 . . . 489   (74%)             Homo sapiens , 489 aa.       379/451           [WO200153312-A1,       (83%)           26 JUL. 2001]       AAM39221   Human polypeptide   24 . . . 472   334/451   0.0           SEQ ID NO 2366       (74%)             Homo sapiens , 467 aa.   27 . . . 467   379/451           [WO200153312-A1,       (83%)           26 JUL. 2001]       AAR83968   GABA-A receptor   24 . . . 472   300/472   e−169           gamma-3 subunit -    5 . . . 467   (63%)             Homo sapiens , 467 aa.       356/472           [WO9529234-A1,       (74%)           02 NOV. 1995]       AAW59048   GABA-A receptor   62 . . . 472   193/448   e−102           epsilon sub-unit   70 . . . 506   (43%)           related protein -       274/448           Mammalia, 506 aa.       (61%)           [DE19644501-A1,           30 APR. 1998]       AAW61045   Human GABA   62 . . . 472   193/448   e−102           receptor epsilon   70 . . . 506   (43%)           subunit -  Homo         274/448             sapiens , 506 aa.       (61%)           [WO9823742-A1,           04 JUN. 1998]                  
 
     [0334] In a BLAST search of public sequence databases, the NOV2a protein was found to have homology to the proteins shown in the BLASTP data in Table 2E.  
               TABLE 2E                          Public BLASTP Results for NOV2a                                         NOV2a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/Organism/   Match   the Matched   Expect       Number   Length   Residues   Portion   Value               P23574   Gamma-amino-    1 . . . 472   426/475 (89%)   0.0           butyric-acid    1 . . . 465   440/475 (91%)           receptor gamma-1           subunit precursor           (GABA(A)           receptor) -             Rattus norvegicus             (Rat), 465 aa.       Q9R0Y8   Gamma-amino-    1 . . . 472   420/477 (88%)   0.0           butyric-acid    1 . . . 465   434/477 (90%)           receptor gamma-1           subunit precursor           (GABA(A)           receptor) -             Mus musculus             (Mouse), 465 aa.       JH0824   gamma-amino-   16 . . . 472   390/463 (84%)   0.0           butyric acid A   12 . . . 464   416/463 (89%)           receptor gamma 1           chain precursor -           chicken, 464 aa.       JH0316   gamma-amino-   24 . . . 472   336/451 (74%)   0.0           butyric acid A   26 . . . 466   380/451 (83%)           receptor gamma 2           chain alternatively           spliced precursor -           mouse, 466 aa.       P18508   Gamma-amino-   24 . . . 472   335/451 (74%)   0.0           butyric-acid receptor   26 . . . 466   379/451 (83%)           gamma-2 subnuit           precursor           (GABA(A)           receptor) -             Rattus norvegicus             (Rat), 466 aa.                  
 
     [0335] PFam analysis predicts that the NOV2a protein contains the domains shown in the Table 2F.  
               TABLE 2F                          Domain Analysis of NOV2a                                 NOV2a                   Match   Identities/Similarities   Expect       Pfam Domain   Region   for the Matched Region   Value               Neur_chan_LBD:    63 . . . 273    66/271 (24%)   2.7e−56       domain 1 of 1       162/271 (60%)       Cys-protease-3C:   363 . . . 369    4/7 (57%)   5.2       domain 1 of 1        6/7 (86%)       Neur_chan_memb:   280 . . . 466    44/297 (15%)   1.2e−60       domain 1 of 1       164/297 (55%)                  
 
     Example 3  
     [0336] The NOV3 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 3A.  
               TABLE 3A                       NOV3 Sequence Analysis                                                SEQ ID NO:9   1440 bp                     NOV3a,     GAAGAG   ATG GTCCTGGCTTTCCAGTTAGTCTCCTTCACCTACATCTGGATCATATTGA       CG58518-01 DNA Sequence           AACCAAATGTTTGTGCTGCTTCTAACATCAAGATGACACACCAGCGGTGCTCCTCTTC                   AATGAAACAAACCTGGAAACAAGAAACTAGAATGAAGAAAGATGACAGTACCAAAGCG                   CGGCCTCAGAAATATGAGCAACTTCTCCATATAGAGGACAACGATTTCGCAATGAGAC                   CTGGATTTGGAGGTGAGTATTATCCTCTCAAAATTGGGTCTCCAGTGCCAGTAGGTAT                   AGATGTCCATGTTGAAAGCATTGACAGCATTTCAGAGACTAACATGGTAAGTTTCTTC                   ATGGGATATGACTTTACAATGACTTTTTATCTCAGGCATTACTGGAAAGACGAGAGGC                   TCTCCTTTCCTAGCACAGCAAACAAAAGCATGACATTTGATCATAGATTGACCAGAAA                   GATCTGGGTGCCTGATATCTTTTTTGTCCACTCTAAAAGATCCTTCATCCATGATACA                   ACTATGGAGAATATCATGCTGCGCGTACACCCTGATGGAAACGTCCTCCTAAGTCTCA                   GGAGGATAACGGTTTCGGCCATGTGCTTTATGGATTTCAGCAGGTTTCCTCTTGACAC                   TCAAAATTGTTCTCTTGAACTGGAAAGCGCCTACAATGAGGATGACCTAATGCTATAC                   TGGAAACACGGAAACAAGTCCTTAAATACTGAAGAACATATGTCCCTTTCTCAGTTCT                   TCATTGAAGACTTCAGTGCATCTAGTGGATTAGCTTTCTATAGCAGCACAGGTTGGTA                   CAATAGGCTTTTCATCAACTTTGTGCTAAGGAGGCATGTTTTCTTCTTTGTGCTGCAA                   ACCTATTTCCCAGCCATATTGATGGTGATGCTTTCATGGGTTTCATTTTGGATTGACC                   GAAGAGCTGTTCCTGCAAGAGTTTCCCTGGGTGGAATCACCACAGTGCTGACCATGTC                   CACAATCATCACTGCTGTGAGCGCCTCCATGCCCCAGGTGTCCTACCTCAAGGCTGTG                   GATGTGTACCTGTGGGTCAGCTCCCTCTTTGTGTTCCTGTCAGTCATTGAGTATGCAG                   CTGTGAACTACCTCACCACAGTGGAAGAGCGGAAACAATTCAAGAAGACAGGAAAGGT                   ACAGATTTCTAGGATGTACAATATTGATGCAGTTCAAGCTATGGCCTTTGATGGTTGT                   TACCATGACAGCGAGATTGACATGGACCAGACTTCCCTCTCTCTAAACTCAGAAGACT                   TCATGAGAAGAAAATCGATATGCAGCCCCAGCACCGATTCATCTCGGATAAAGAGAAG                   AAAATCCCTAGGAGGACATGTTGGTAGAATCATTCTGGAAAACAACCATGTCATTGAC                   ACCTATTCTAGGATTTTATTCCCCATTGTGTATATCTTTATTTAA TTT                                           ORF Start: ATG at 7       ORF Stop: TAA at 1435           SEQ ID NO:10   476 aa   MW at 55285.2 kD                     NOV3a,   MVLAFQLVSFTYIWIILKPNVCAASNIKMTHQRCSSSMKQTWKQETRMKKDDSTKARP       CG58518-01 Protein Sequence           QKYEQLLHIEDNDFAMRPGFGGEYYPLKIGSPVPVGIDVHVESIDSISETNMVSFFMG                   YDFIMTFYLRHYWKDERLSFPSTANKSMTFDHRLTRKIWVPDIFFVHSKRSFIHDTTM                   ENIMLRVHPDGNVLLSLRRITVSAMCFMDFSRFPLDTQNCSLELESAYNEDDLMLYWK                   HGNKSLNTEEHMSLSQFFIEDFSASSGLAFYSSTGWYNRLFINFVLRRHVFFFVLQTY                   FPAILMVMLSWVSFWIDRRAVPARVSLGGITTVLTMSTIITAVSASMPQVSYLKAVDV                   YLWVSSLFVFLSVIEYAAVNYLTTVEERKQFKKTGKVQISRMYNIDAVQAMAFDGCYH                   DSEIDMDQTSLSLNSEDFMRRKSICSPSTDSSRIKRRKSLGGHVGRIILENNHVIDTY                   SRILFPIVYIFI                  
 
     [0337] Further analysis of the NOV3a protein yielded the following properties shown in Table 3B.  
               TABLE 3B                       Protein Sequence Properties NOV3a                                        PSort   0.6850 probability located in endoplasmic reticulum       analysis:   (membrane); 0.6400 probability located in plasma membrane;           0.4600 probability located in Golgi body; 0.2400 probability           located in nucleus       SignalP   Likely cleavage site between residues 25 and 26       analysis:                  
 
     [0338] A search of the NOV3a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3C.  
               TABLE 3C                          Geneseq Results for NOV3a                                             Identities/                   NOV3a   Similarites           Protein/   Residues/   for the       Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAU04467   Human gamma-amino    1 . . . 474   454/475   0.0           butyric acid (GABA)    1 . . . 456   (95%)           receptor protein #1 -       454/475             Homo sapiens , 467 aa.       (95%)           [WO200153489-A1,           26 JUL. 2001]       AAU04470   Human gamma-amino   48 . . . 474   408/428   0.0           butyric acid (GABA)    1 . . . 409   (95%)           receptor protein #4 -       408/428             Homo sapiens , 420 aa.       (95%)           [WO200153489-A1,           26 JUL. 2001]       AAU04468   Human gamma-amino    1 . . . 393   370/394   0.0           butyric acid (GABA)    1 . . . 377   (93%)           receptor protein #2       370/394             Homo sapiens , 392 aa.       (93%)           [WO200153489-A1,           26 JUL. 2001]       AAU04471   Human gamma-amino   48 . . . 393   324/347   e−180           butyric acid (GABA)    1 . . . 330   (93%)           receptor protein #5 -       (93%)           [WO200153489-A1,           26 JUL. 2001]       AAU04469   Human gamma-amino    1 . . . 192   176/192   2e−96           butyric acid (GABA)    1 . . . 177   (91%)               receptor protein #3 -       176/192             Homo sapiens , 180 aa.       (91%)           [WO200153489-A1,           26 JUL. 2001]                  
 
     [0339] In a BLAST search of public sequence databases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table 3D.  
               TABLE 3D                          Public BLASTP Results for NOV3a                                         NOV3a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/Organism/   Match   the Matched   Expect       Number   Length   Residues   Portion   Value               P50573   Gamma-amino-    1 . . . 474   383/476 (80%)   0.0           butyric-acid    1 . . . 453   407/476 (85%)           receptor rho-3           subunit precursor           (GABA(A)           receptor) -  Rattus               norvegicus  (Rat),           464 aa.       Q9YGQ2   GAMMA-AMINO-    1 . . . 474   293/485 (60%)   e−153           BUTYRIC-ACID    4 . . . 459   363/485 (74%)           RECEPTOR RHO-3           SUBUNIT -  Morone               americana             (White perch),           470 aa.       P50572   Gamma-amino-   49 . . . 474   270/427 (63%)   e−144           butyric-acid   58 . . . 463   317/427 (74%)           receptor rho-1           subunit precursor           (GABA(A)           receptor) -  Rattus               norvegicus  (Rat),           474 aa.       P56475   Gamma-amino-   49 . . . 474   270/427 (63%)   e−143           butyric-acid   58 . . . 463   317/427 (74%)           receptor rho-1           subunit precursor           (GABA(A)           receptor) -  Mus               musculus  (Mouse),           474 aa.       P24046   Gamma-amino-   49 . . . 474   268/427 (62%)   e−143           butyric-acid   57 . . . 462   317/427 (73%)           receptor rho-1           subunit precursor           (GABA(A)           receptor) -             Homo sapiens             (Human), 473 aa.                  
 
     [0340] PFam analysis predicts that the NOV3a protein contains the domains shown in the Table 3E.  
               TABLE 3E                          Domain Analysis of NOV3a                                 NOV3a                   Match   Identities/Similarities   Expect       Pfam Domain   Region   for the Matched Region   Value               Neur_chan_LBD:    88 . . . 282    70/250 (28%)   1.2e−54       domain 1 of 1       165/250 (66%)       Neur_chan_memb:   289 . . . 475    44/292 (15%)   7.6e−28       domain 1 of 1       141/292(48%)                  
 
     Example 4  
     [0341] The NOV4 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 4A.  
               TABLE 4A                       NOV4 Sequence Analysis                                                SEQ ID NO:11   1587 bp                     NOV4a,     GAACAGAA   ATG AATAAAAGTCGCTGGCAGAGTAGAAGACGACATGGGAGAAGAAGCCA       CG58516-01 DNA Sequence           CCAGCAGAACCCTTGGTTCAGACTCCGTGATTCTGAAGACAGGTCTGACTCCCGGGCA                   GCACAGCCCGCTCACGATTCCGGCCACGGTGATGACGAGTCTCCGTCAACCTCGTCTG                   GCACAGCTGGGACCTCCTCTGTGCCAGAGCTACCTGGGTTTTACTTTGACCCTGAAAA                   GAAACGCTACTTCCGCTTGCTCCCTGGACATAACAACTGCAACCCCCTGACGAAAGAG                   AGCATCCGGCAGAAGGAGATGGAGAGCAAGAGACTGCGGCTGCTCCAGGAAGAAGACA                   GACGGAAAAAGATTGCCAGGATGGGATTTAATGCATCTTCCATGCTACGAAAAAGCCA                   GCTGGGTTTTCTCAACGTCACCAATTACTGCCATTTAGCCCACGAGCTGCGTCTCAGC                   TGCATGGAGAGGAAAAAGGTCCAGATTCGAAGCATGGATCCCTCCGCCTTGGCAAGCG                   ACCGATTTAACCTCATACTGGCAGATACCAACAGTGACCGGCTCTTCACAGTGAACGA                   TGTTACAGTTGGAGGCTCCAAGTATGGTATCATCAACCTGCAAGTCTGAAGACCCCT                   ACGCTCAAGGTGTTCATGCCACGAAAACCTCCGATTCTCACCAACCGGAAGGTGAACA                   CTTCGGTGTGCTGGGCCTCGCTGAATCACTTGGATTCCCACATTCTGCTATGCCTCAT                   GGGACTCGCAGAGACTCCAGGCTGTGCCACCCTGCTCCCAGCATCACTGTTCGTCAAT                   AGTCCCCACCCAGGAATAGACCGGCCTGGCATGCTCTGCAGTTTCCGGATCCCTGGGG                   GTGCCTGGTCCTGTGCCTGGTCCCTGAATATCCAAGCAAATAACTGCTTCAGTACAGG                   CTTGTCTCGGCGGGTCCTGTTGACCAACGTGGTGACGGGACACCGGCAGTCCTTTGGG                   ACCAACAGTGATGTCTTGGCCCAGCAGTTTGCTCTCATGGCTCCTCTGCTGTTTAATG                   GCTGCCGCTCTGGGGAAATCTTTGCCATTGATCTGCGTTGTGGAAATCAAGGCAAGGG                   ATGGAAGGCCACCCGCCTGTTTCATGATTCAGCAGTGACCTCTGTGCGGATCCTCCAA                   GATGAGCAATACCTGATGGCTTCAGACATGGCTGGAAAGATCAAGCTGTGGGACCTGA                   GGACCACGAAGTGCGTAAGGCAGTACGAAGGCCACGTGAATGAGTACGCCTACCTGCC                   CCTGCATGTGCACGAGGAAGAAGGAATCCTGGTGGCAGTGGGCCAGGACTGCTACACG                   AGAATCTGGAGCCTCCACGATGCCCGCCTACTGAGAACCATACCCTCCCCGTACCCTG                   CCTCCAAGGCCGACATTCCCAGTGTGGCCTTCTCGTCGCGGCTGGGGGGCTCCCGGGG                   AGAATCTGGAGCCTCCACGATGCCCGCCTACTGAGAACCATACCCTCCCCGTACCCTG                   CCTCCAAGGCCGACATTCCCAGTGTGGCCTTCTCGTCGCGGCTGGGGGGCTCCCGGGG                   GCGCGCCGGGGCTGCTCATGGCTGTCGGGCAGGACCTTTACTGTTACTCCTACAGCTA                   ATTCTGCAGGGCACAGCCCAGAGCCATGTGGATTTGACTTACGGGAGTAAAGCG TAA   C                       TTTTTACTGCATCTAATGAGG                                           ORF Start: ATG at 9       ORF Stop: TAA at 1563           SEQ ID NO:12   518 aa   MW at 57769.3 kD                     NOV4a,   MNKSRWQSRRHGRRSHQQNPWFRLRDSEDRSDSRAAQPAHDSGHGDDESPSTSSGTA       CG58516-01 Protein Sequence           GTSSVPELPGFYFDPEKKRYFRLLPGENNCNPLTKESIRQKEMESKRLRLLQEEDRRK                   KIARMGFNASSMLRKSQLGFLNVTNYCHLAHELRLSCMERKKVQIRSMDPSALASDRF                   NLILADTNSDRLFTVNDVTVGGSKYGIINLQSLKTPTLKVFMPRKPPILTNRKVNTSV                   CWASLNHLDSHILICLMGLAETPGCATLLPASLFVNSPHPGIDRPGMLCSFRIPGGAW                   SCAWSLNIQANNCFSTGLSRRVLLTNVVTGHRQSFGTNSDVLAQQFALMAPLLFNGCR                   SGEIFAIDLRCGNQGKGWKATRLFHDSAVTSVRILQDEQYLMASDMAGKIKLWDLRTT                   KCVRQYEGHVNEYAYLPLHVHEEEGILVAVGQDCYTRIWSLHDARLLRTIPSPYPASK                   ADIPSVAFSSRLGGSRGRAGAAHGCRAGPLLLLLQLILQGTAQSHVDLTYGSKA                  
 
     [0342] Further analysis of the NOV4a protein yielded the following properties shown in Table 4B.  
               TABLE 4B                       Protein Sequence Properties NOV4a                                        Psort   0.9600 probability located in nucleus; 0.4776 probability       analysis:   located in mitochondrial matrix space; 0.3000 probability           located in microbody (peroxisome); 0.1837 probability located           in mitochondrial inner membrane       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0343] A search of the NOV4a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4C.  
               TABLE 4C                          Geneseq Results for NOV4a                                         NOV4a   Identities/               Protein/   Residues/   Similarities       Geneseq   Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               ABB11794   Human secreted   1 . . . 484   470/484 (97%)   0.0           protein   5 . . . 485   471/484 (97%)           homologue SEQ           ID NO:2164—             Homo sapiens,             500 aa.           [WO200157188-           A2, Aug. 9,           2001]       AAM79804   Human protein   1 . . . 484   470/484 (97%)   0.0           SEQ ID NO   5 . . . 485   471/484 (97%)           3450— Homo               sapiens,  500 aa.           [WO200157190-           A2, Aug. 9,           2001]       AAM41122   Human poly-   1 . . . 484   470/484 (97%)   0.0           peptide SEQ ID   5 . . . 485   471/484 (97%)           NO 6053— Homo               sapiens,  500 aa.           [WO200153312-           A1, Jul. 26,           2001]       AAG67256   Amino acid   1 . . . 484   459/484 (94%)   0.0           sequence of a   1 . . . 474   462/484 (94%)           human liver-           associated gene—             Homo sapiens,             489 aa.           [WO200109318-           A1, Feb. 8,           2001]       AAB94587   Human protein   1 . . . 484   459/484 (94%)   0.0           sequence SEQ ID   1 . . . 474   462/484 (94%)           NO:15389—             Homo sapiens ,           489 aa.           [EP1074617-A2,           Feb. 7, 2001]                  
 
     [0344] In a BLAST search of public sequence databases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table 4D.  
               TABLE 4D                          Public BLASTP Results for NOV4a                                             Identities/                   NOV4a   Similarities       Protein       Residues/   for the       Accession   Protein/   Match   Matched   Expect       Number   Organism/Length   Residues   Portion   Value               AAH18979   HYPOTHETICAL    1 . . . 484   470/484   0.0           55.7 KDA       (97%)           PROTEIN—    1 . . . 480   471/484             Homo sapiens         (97%)           (Human), 495 aa.       Q96K22   CDNA FLJ14839    1 . . . 484   459/484   0.0           FIS, CLONE       (94%)           OVARC1001791—    1 . . . 474   462/484             Homo sapiens         (94%)           (Human), 489 aa.       Q9Y4P5   HYPOTHETICAL    5 . . . 435   420/431   0.0           48.5 KDA       (97%)           PROTEIN—    2 . . . 428   421/431             Homo sapiens         (97%)           (Human), 430 aa           (fragment).       Q99LF7   HYPOTHETICAL    1 . . . 484   378/485   0.0           58.1 KDA       (77%)           PROTEIN—    1 . . . 481   423/485             Mus musculus         (86%)           (Mouse), 519 aa.       Q9UF10   HYPOTHETICAL   269 . . . 483   175/215   4e−99           26.0 KDA       (81%)           PROTEIN—    4 . . . 217   193/215             Homo sapiens         (89%)           (Human), 234 aa           (fragment).                  
 
     [0345] PFam analysis predicts that the NOV4a protein contains the domains shown in the Table 4E.  
               TABLE 4E                          Domain Analysis of NOV4a                                     Identities/               NOV4a   Similarities for       Pfam Domain   Match Region   the Matched Region   Expect Value               WD40: domain   281 . . . 316    2/37 (5%)    5.8e+02       1 of 3       26/37 (70%)       WD40: domain   367 . . . 402   10/37 (27%)   6.1       2 of 3       27/37 (73%)       WD40: domain   408 . . . 446   10/39 (26%)   13       3 of 3       23/39 (59%)                  
 
     Example 5  
     [0346] The NOV5 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 5A.  
               TABLE 5A                       NOV5 Sequence Analysis                                                SEQ ID NO:13   1081 bp                     NOV5a,     AGG   ATG GCCCAGAAGGAGAACAGTTATCCCTGGCCCTATGGCAAGCAGACGGCTCCAG       CG58473-01 DNA Sequence           CCGGCCTGAGTACCCTGCTCCCGCGAGTCCTCCCGAGGATCCCCACCGAAGCTGCGCG                   TGAGCTCCCGAGCTGCGCAGACCCACAGCCCGCAGCGGCCCCTGGCCATGAGGTGGTA                   GAGAACAGTTGTGGGAAGCGCAGCATCTTAACGCGGCCCTTCCTGGTCGACGACCTTG                   AGACTGGGCGTCCCCTGGGCAAAGACAAGTTTGTACATGTGTACTTGGCTCGAAAGAA                   GACAAGCCATTTCATCGTGGCCCTCAAGGCCTTCAAGTCTCAGATAGAGGAGGGCGTG                   GAGCACCAGATGCGCAGGCAGATGGAAATCCAGGCCCCCTTTCAGCATCCCAACATAT                   TGAGTCTCTACAACTATTTTTATGACCTGAGAAAAATCTACTGGATTCTAGAGTACGC                   CCCCGCCACCCCTACCCCCGAGGAGCTGTACCAGGAGCTGCGAAAGAGCCGCACCTTT                   GACAAGAAGCCAACAGCCACCATCACGGGGGAGGTGGCAGATGCTCTGATGTACTGCC                   GAGCACCAGATGCGCAGGCAGATGGAAATCCAGGCCCCCTTTCAGCATCCCAACATAT                   TGAGTCTCTACAACTATTTTTATGACCTGAGAAAAATCTACTGGATTCTAGAGTACGC                   CCCCGCCACCCCTACCCCCGAGGAGCTGTACCAGGAGCTGCGAAAGAGCCGCACCTTT                   GACAAGAAGCCAACAGCCACCATCACGGGGGAGGTGGCAGATGCTCTGATGTACTGCC                   ACGGGAAGAAGGTGACTCCCAGAGACATGAAGCCAGATAATCTACTCTCAGGGCTTGA                   GGGCGAGCTGAAAGTTGCCGACTTCGGCTGCCCTGTGCACGCCCCCTCACTGAGGAGG                   AAGACAAGACAAATGTGTGGCACCCTGGACTACCTGTCCCCAGAGACAATTGAGGGGC                   GCGCGCACACCGAGAAGGTGGATTTGTGGTACATCGGAGCACTCGGCTATGAGCCGCT                   GGTGGGGAACCCCACACACAATGAGGCCTATGGGCGAATCGTCAAGGTGGCCCTAAAA                   TTCCCCCTTCTGTGCCCAGGAGAGCCCCAGGACCTCATCTCCAAGCTGCTTAGGCATA                   ACCCCTCAGAACGGCTGCCCCTGGCCCAGGTCTCAGCCCACCCTGGGATCCTGGCCCA                   TTCTCGGAGGGTTTTGCCTCCCTCTGCCCATCAGTCTGTCCCCTGGTGGTCCCTGACA                   TTCACTCGGGGGCGTCTGTGTTTG TAA   GTCTGCATAT                                           ORF Start: ATG at 4       ORF Stop: TAA at 1069           SEQ ID NO:14   355 aa   MW at 40012.7 kD                     NOV5a,   MAQKENSYPWPYGKQTAPAGLSTLLPRVLPRIPTEAARELPSCADPQPAAAPGHEVVE       CG58473-01 Protein Sequence           NSCGKRSILTRPFLVDDLETGRPLGKDKFVHVYLARKKTSHFIVALKAFKSQIEEGVE                   HQMRRQMEIQAPFQHPNILSLYNYFYDLRKIYWILEYAPATPTPEELYQELRKSRTFD                   KKPTATITGEVADALMYCHGKKVTPRDMKPDNTLLSGLEGELKVADFGCPVHAPSLRRK                   TRQMCGTLDYLSPETIEGRAHTEKVDLWYIGALGYEPLVGNPTHNEAYGRIVKVALKF                   PLLCPGEPQDLISKLLRHNPSERLPLAQVSAHPGILAHSRRVLPPSAHQSVPWWSLTF                   TRGRLCL                  
 
     [0347] Further analysis of the NOV5a protein yielded the following properties shown in Table 5B1 
               TABLE 5B                       Protein Sequence Properties NOV5a                                        Psort   0.4500 probability located in cytoplasm; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1897 probability located           in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0348] A search of the NOV5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5C.  
               TABLE 5C                          Geneseq Results for NOV5a                                         NOV5a   Identities/               Protein/   Residues/   Similarities       Genseq   Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAG67615   Amino acid   1 . . . 341   247/349 (70%)   e−129           sequence of   1 . . . 343   274/349 (77%)           a human           [WO200109316-           A1, Feb. 8, 2001]       AAG67436   Amino acid   1 . . . 341   247/349 (70%)   e−129           sequence of a   1 . . . 343   274/349 (77%)           human poly-           peptide— Homo               sapiens , 344 aa.           [WO200109345-           A1, Feb. 8, 2001]       AAY22475   Human AUR1   1 . . . 341   247/349 (70%)   e−129           protein   1 . . . 343   274/349 (77%)           sequence— Homo               sapiens , 344 aa.           [WO9937788-A2,           Jul. 29, 1999]       AAW18083   Human Aurora-   1 . . . 341   247/349 (70%)   e−129           1— Homo     1 . . . 343   274/349 (77%)             sapiens , 344 aa.           [WO9722702-A1,           Jun. 26, 1997]       AAY27052   Human protein   1 . . . 341   246/352 (69%)   e−127           kinase (HPKM)-1   1 . . . 346   274/352 (76%)           (clone ID           2940)— Homo               sapiens , 347 aa.           [WO9938981-A2,           Aug. 5, 1999]                  
 
     [0349] In a BLAST search of public sequence databases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table 5D.  
               TABLE 5D                          Public BLASTP Results for NOV5a                                         NOV5a   Identities/           Protein       Residues/   Similarities       Accession   Protein/   Match   for the   Expect       Number   Organism/Length   Residues   Matched Portion   Value               O60446   AURORA-   1 . . . 341   247/349 (70%)   e−128           RELATED   1 . . . 343   274/349 (77%)           KINASE 2           (SERINE/           THREONINE           KINASE 12)—             Homo sapiens              (Human), 344 aa.       Q96GD4   UNKNOWN   1 . . . 341   247/349 (70%)   e−128           (PROTEIN FOR   1 . . . 343   274/349 (77%)           MGC:11031)—             Homo sapiens             (Human), 344 aa.       Q96DV5   UNKNOWN   1 . . . 341   247/350 (70%)   e−126           (PROTEIN FOR   1 . . . 344   274/350 (77%)           MGC:4243)—             Homo sapiens             (Human), 345 aa.       Q9UQ46   AIK2— Homo     1 . . . 341   245/348 (70%)   e−126             sapiens  (Human),   1 . . . 342   272/348 (77%)           343 aa.       O14630   PROTEIN   1 . . . 341   245/352 (69%)   e−125           KINASE— Homo     1 . . . 346   272/352 (76%)             sapiens  (Human),           347 aa.                  
 
     [0350] PFam analysis predicts that the NOV5a protein contains the domains shown in the Table SE.  
               TABLE 5E                          Domain Analysis of NOV5a                                     Identities/               NOV5a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               Pkinase: domain   76 . . . 325    81/293 (28%)   6.5e−36       1 of 1       184/293 (63%)                  
 
     Example 6  
     [0351] The NOV6 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 6A.  
               TABLE 6A                       NOV6 Sequence Analysis                                                SEQ ID NO:15   1524 bp                     NOV6a,     AGCATT   ATG AACACTAATGACCTTAAACTCAGGTTGTCCAAAGCTGAGCAAGAACACC       CG58470-01 DNA Sequence           CACTACGTTTCTGGAATGAGCTTGAAGAAGCCCGACAGGTAGAACTTTATGCAGAGCT                   CCAGGCCATCGACTTTCAGGAACTGAACTTCTTTTTCCAAAAGGCCATTGAAGGATTT                   AACCAGTCCTCTCATCAAGAAAAGGTGGATGCGGGAATGGAACCTGTCCCTCGAGAAG                   TACTGGGCAGTGCTGCAGGGAAGCTAGATCAGCTCCAGGCCTGGGAAAGCAAAGTTTT                   CCAGATTTCTGAGAACAAAGTCACAGTTGTTCTAGCTGGTGGGCAGGGGACTAGACTC                   GTTGCATATCCAAAGGGGATGTATGATGTTGGTTTGCCATCCCATAAGACACTTTTTC                   AGATTCAAGCAGAGCATATCCTGAAGCTACAACAGTTAGCTGAAAAATATTATGGCAA                   CAAATGCATTATTCCATATTACGTCATGACCAGCGAGTTCACTCTGGGGCCCACGGCC                   GAGTTCTTCAGGGAGCACAACTTCTTCCACCTGGACCCCGCCAACGTGGTCATGTTTG                   AGCAGCGCCTGCTGCCTGCTGTGACCTTTGATGGCAAGGTTATCCTGGAGCGGAAAGA                   CAAAGTTGCCATGGCCCCAGACGGCAACGGGGGCCTCTACTGCGCGCTGGAGGACCAC                   AAGATCCTGGAGGACATGGAGCGCCGGGGAGTGGAGTTTGTGCACGTGTACTGTGTGG                   ACAACATCCTGGTGCGGCTGGCGGACCCTGTCTTCATCGGCTTCTGTGTGTTGCAGGG                   CGCAGACTGTGGCGCCAAGGTGGTGGAAAAGGCATACCCCGAGGAGCCCGTGGGCGTG                   GTGTGCCAGGTGGACGGTGTCCCCCAGGTGGTGGAGTACAGCGAGATCAGTCCTGAGA                   CCGCACAGCTACGTGTCTCCGACGGGAGCCTGCTGTACAATGCAGGCAACATCTGCAA                   CCACTTCTTCACCCGAGGCTTCCTTAAGGCGGTCACCAGGGAGTTTGAGCCTTTGCTG                   AAGCCACACGTGGCTGTGAAGAAGGTCCCGTATGTGGATGAGGAGGGGAATCTGGTAA                   AGCCGCTAAAACCGAACGGGATAAAGATGGAGAAGTTTGTGTTTGATGTGTTCCGGTT                   TGCTAAGAACTTTGCTGCCTTGGAAGTGCTGCGGGAGGAGGAATTTTCCCCACTGAAG                   AACGCAGAGCCAGCCGACAGGGACAGTCCCCGCACCGCTCGCCAGGCCCTGCTCACCC                   AGCACTACCGGTGGGCTCTGCGGGCCGGGGCCCGCTTCCTGGATGCCCATGGGGCCCG                   GCTCCCAGAGCTGCCCAGCTTGCCCCCAAATGGAGACCCTCCGGCCATCTGTGAGATA                   TCGCCCTTGGTGTCTTACTCTGGAGAGGGTTTAGAAGTGTACCTGCAAGGCCGGGAGT                   TCCAGTCCCCGCTCATCCTGGATGAAGACCAGGCCAGGGAGCTGGTGAAAAATGGTAT                   A TGA   ACCTGATACCAA                                           ORF Start: ATG at 7       ORF Stop: TGA at 1510           SEQ ID NO:16   501 aa   MW at 56461.0 kD                     NOV6a,   MNTNDLKLRLSKAEQEHPLRFWNELEEARQVELYAELQAIDFQELNFFFQKAIEGFNQ       CG58470-01 Protein Sequence           SSHQEKVDAGMEPVPREVLGSAAGKLDQLQAWESKVFQISENKVTVVLAGGQGTRLVA                   YPKGMYDVGLPSHKTLFQIQAEHILKLQQLAEKYYGNKCIIPYYVMTSEFTLGPTAEF                   FREHNFFHLDPANVVMFEQRLLPAVTFDGKVILERKDKVAMAPDGNGGLYCALEDHKI                   LEDMERRGVEFVHVYCVDNILVRLADPVFIGFCVLQGADCGAKVVEKAYPEEPVGVVC                   QVDGVPQVVEYSEISPETAQLRVSDGSLLYNAGNICNHFFTRGFLKAVTREFEPLLKP                   HVAVKKVPYVDEEGNLVKPLKPNGIKMEKFVFDVFRFAKNFAALEVLREEEFSPLKNA                   EPADRDSPRTARQALLTQHYRWALRAGARFLDAHGARLPELPSLPPNGDPPAICEISP                   LVSYSGEGLEVYLQGREFQSPLILDEDQARELVKNGI                  
 
     [0352] Further analysis of the NOV6a protein yielded the following properties shown in Table 6B.  
               TABLE 6B                       Protein Sequence Properties NOV6a                                        PSort   0.4500 probability located in cytoplasm; 0.3490 probability       analysis:   located in microbody (peroxisome); 0.1000 probability located           in mitochondrial matrix space; 0.1000 probability located           in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0353] A search of the NOV6a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6C.  
               TABLE 6C                          Geneseq Results for NOV6a                                         NOV6a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB56960   Human prostate    1 . . . 501   353/522 (67%)   0.0           cancer antigen    3 . . . 524   413/522 (78%)           protein sequence           SEQ ID NO:           1538— Homo               sapiens , 524 aa.           [WO200055174-           A1, Sep. 21,           2000]       AAG32392     Arabidopsis      9 . . . 485   194/489 (39%)   3e−84             thaliana  protein   36 . . . 497   275/489 (55%)           fragment SEQ ID           NO: 39067—             Arabidopsis               thaliana , 502 aa.           [EP1033405-A2,           Sep. 6, 2000]       AAG40236     Arabidopsis      9 . . . 485   193/488 (39%)   3e−82             thaliana  protein   12 . . . 472   272/488 (55%)           fragment SEQ ID           NO: 49896—             Arabidopsis               thaliana , 477 aa.           [EP1033405-A2,           Sep. 6, 2000]       AAG40235     Arabidopsis      9 . . . 485   193/488 (39%)   3e−82             thaliana  protein   35 . . . 495   272/488 (55%)           fragment SEQ ID           NO: 49895—             Arabidopsis               thaliana , 500 aa.           [EP1033405-A2,           Sep. 6, 2000]       AAG40234     Arabidopsis      9 . . . 485   193/488 (39%)   3e−82             thaliana  protein   40 . . . 500   272/488 (55%)           fragment SEQ ID           NO: 49894—             Arabidopsis               thaliana , 505 aa.           [EP1033405-A2,           Sep. 6, 2000]                  
 
     [0354] In a BLAST search of public sequence databases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table 6D.  
               TABLE 6D                          Public BLASTP Results for NOV6a                                         NOV6a   Identities/           Protein       Residues/   Similarities for           Accession   Protein/   Matched   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q96GM2   UDP-N-    1 . . . 501   351/505 (69%)   0.0           ACTEYL-    1 . . . 505   412/505 (81%)           GLUCOSAMINE           PYROPHOS-           PHORYLASE           1— Homo sapiens             (Human), 505 aa.       Q16222   UDP-N-acetyl-    1 . . . 501   352/522 (67%)   0.0           hexosamine pyro-    1 . . . 522   412/522 (78%)           phosphorylase           (Antigen X)           (AGX) (Sperm-           associated           antigen 2)           [Includes: UDP-           N-acetylgalactos-           amine pyro-           phosphorylase           (EC 2.7.7.-)           (AGX-1); UDP-           N-acetylglucos-           amine pyro-           phosphorylase           (EC 2.7.7.23)           (AGX-2)]—             Homo sapiens             (Human), 522 aa.       Q91YN5   HYPO-    1 . . . 501   342/522 (65%)   0.0           THETICAL    1 . . . 522   407/522 (77%)           58.6 KDA           PROTEIN—             Mus musculus             (Mouse), 522 aa.       AAH17547   HYPO-    1 . . . 501   341/521 (65%)   0.0           THETICAL    1 . . . 521   407/521 (77%)           58.5 KDA           PROTEIN—             Mus musculus             (Mouse), 521 aa.       Q9Y0Z0   BCDNA:    6 . . . 492   236/491 (48%)   e−124           LD24639   44 . . . 513   330/491 (67%)           PROTEIN—             Drosophila               melanogaster             (Fruit fly),           520 aa.                  
 
     [0355] PFam analysis predicts that the NOV6a protein contains the domains shown in the Table 6E.  
               TABLE 6E                          Domain Analysis of NOV6a                                     Identities/               NOV6a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               UDPGP: domain   40 . . . 434   108/428 (25%)   8.4e−111       1 of 1       324/428 (76%)                  
 
     Example 7  
     [0356] The NOV7 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 7A.  
               TABLE 7A                       NOV7 Sequence Analysis                                                SEQ ID NO:17   461 bp                     NOV7a,     ACGCAGAG   ATG CAGATCTTTGTGAAGACCCTCACGGGCAAGACCATCACCCTTGAGGT       CG58593-01 DNA Sequence           CAAGCCCACCGACACCATTGAGAATGTCAAAACCAAAATTCAGGACAAGGAGGGTATC                   CCACCTGACCAGCAGCGTCTGATATTTGCTGGGAAACGGCTGGAGGATGGCCACACTC                   TCTCAGGCTACAACATCCAGAAAGAGTCCACCCTAAACCTGGTGCTGCGCCTGCGAGG                   TGGCATTACTGAGCCTTCCCTCCGCCAGCTCGTCCAGAAATACAACTGCGACGAGATG                   ATCTGCTGCAAGTGCTATGCTTGCCTGCACCCCGGTGCTATCAACTGCCACAAGAAGA                   AATGCGGCCACACCAACAACCTGTACCCCAGGAAGAAGGTCAAA TAA   GGCTCTTCCTT                       CCTTGAAGGGCAGCAGCCTTCTGCCCAGGCCCCATGGCCCTGGGGCCTCAATAAA                                           ORF Start: ATG at 9       ORF Stop: TAA at 393           SEQ ID NO:18   128 aa   MW at 14540.9 kD                     NOV7a,   MQIFVKTLTGKTITLEVKPTDTIENVKTKIQDKEGIPPDQQRLIFAGKRLEDGHTLSG       CG58593-01 Protein Sequence           YNIQKESTLNLVLRLRGGITEPSLRQLVQKYNCDEMICCKCYACLHPGAINCHKKKCG                   HTNNLYPRKKVK                  
 
     [0357] Further analysis of the NOV7a protein yielded the following properties shown in Table 7B.  
               TABLE 7B                       Protein Sequence Properties NOV7a                                        PSort   0.9800 probability located in nucleus; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0358] A search of the NOV7a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7C.  
               TABLE 7C                          Geneseq Results for NOV7a                                             Identities/                   NOV7a   Similarities           Protein/   Residues/   for the           Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB52080   Gene 16 human    1 . . . 128   111/128   7e−61           secreted protein       (86%)           homologous amino    1 . . . 128   118/128           acid sequence       (91%)           #129— Sus scrofa ,           128 aa.           [WO200061596-A1,           Oct. 19, 2000]       AAG43861     Arabidopsis      1 . . . 128   101/128   9e−55             thaliana  protein       (78%)           fragment SEQ ID    1 . . . 128   113/128           NO: 54871—       (87%)             Arabidopsis               thaliana , 128 aa.           [EP1033405-A2,           Sep. 6, 2000]       AAG36188     Arabidopsis      1 . . . 128   101/128   9e−55             thaliana  protein       (78%)           fragment SEQ ID   122 . . . 249   113/128           NO: 44314—       (87%)             Arabidopsis               thaliana , 249 aa.           [EP1033405-A2,           Sep. 6, 2000]       AAG36187     Arabidopsis      1 . . . 128   101/128   9e−55             thaliana  protein       (78%)           fragment SEQ ID   137 . . . 264   113/128           NO: 44313—       (87%)             Arabidopsis               thaliana , 264 aa.           [EP1033405-A2,           Sep. 6, 2000]       AAG36186     Arabidopsis      1 . . . 128   101/128   9e−55             thaliana  protein       (78%)           fragment SEQ ID   195 . . . 322   113/128           NO: 44312—       (87%)             Arabidopsis               thaliana , 322 aa.           [EP1033405-A2,           Sep. 6, 2000]                  
 
     [0359] In a BLAST search of public sequence databases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table 7D.  
               TABLE 7D                          Public BLASTP Results for NOV7a                                         NOV7a   Identities/           Protein       Residues/   Similarities       Accession   Protein/   Match   for the   Expect       Number   Organism/Length   Residues   Matched Portion   Value               Q9BX98   UBIQUITIN    1 . . . 128   111/128 (86%)   3e−60           A-52 RESIDUE   14 . . . 141   118/128 (91%)           RIBOSOMAL           PROTEIN           FUSION           PRODUCT 1—             Homo sapiens             (Human), 141 aa           (fragment).       Q9UPK7   UBIQUITIN-52    1 . . . 128   111/128 (86%)   3e−60           AMINO ACID    1 . . . 128   118/128 (91%)           FUSION           PROTEIN—             Homo sapiens             (Human), 128 aa.       Q9PT09   UBIQUITIN—    1 . . . 128   110/128 (85%)   6e−60             Oncorhynchus      1 . . . 128   118/128 (91%)             mykiss  (Rainbow           trout) ( Salmo               gairdneri ),           128 aa.       O42388   UBIQUITIN-    1 . . . 128   110/128 (85%)   7e−60           RIBOSOMAL    1 . . . 128   117/128 (90%)           PROTEIN           FUSION           PROTEIN—             Gallus gallus             (Chicken),           128 aa.       Q9XSV1   UBIQUITIN-    1 . . . 128   110/128 (85%)   1e−59           RIBOSOMAL    1 . . . 128   117/128 (90%)           PROTEIN L40           FUSION           PROTEIN—             Canis               familiaris             (Dog), 128 aa.                  
 
     [0360] PFam analysis predicts that the NOV7a protein contains the domains shown in the Table 7E.  
               TABLE 7E                          Domain Analysis of NOV7a                                     Identities/               NOV7a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               ubiquitin: domain   1 . . . 74   54/83 (65%)   1.9e−38       1 of 1       72/83 (87%)       Ribosomal_L40e:   77 . . . 128   30/52 (58%)   7.3e−20       domain 1 of 1       42/52 (81%)                  
 
     Example 8  
     [0361] The NOV8 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 8A.  
               TABLE 8A                       NOV8 Sequence Analysis                                                SEQ ID NO:19   2296 bp                     NOV8a,     CGGCGGCGGCGGCAGTAGAAATG   ATG GAAGAATTGCATAGCCTGGACCCACGACGGCA       CG57871-01 DNA Sequence           GAAATTATTGGAGGCCAGGTTTACTGGAGTAGGTGTTAGTAAGGGACCACTTAATAGT                   GAGTCTTCCAACCAGAGCTTGTGCAGCGTCGGATCCTTGAGTGATAAAGAAGTAGAGA                   CTCCCAAGAAAAAGCAGAATGACCAGCGAAATCGGAAAAGAAAAGCTGAACCATATGA                   AAGTAGCCAAGGGAAAGGCACTCCTAGGGGACATAAAATTAGTGATTACTTTGAGTTT                   GCTGGGGGAAGCGGGCCGGGAACCAGCCCTGGCAGAAGTGTTCCACCAGTTGCACGAT                   CCTCACTGCAACATTCTTTATCCAATCCCTTACCGCGACGAGTAGAACAGCCCCTCTA                   TGGTTTAGATGGCAGTGCTGCAAAGGAGGCAACGGAGGAGCAGTCTGCTCTGCCAACC                   CTCATGTCAGTGATGCTAGCAAAACCTCGGCTTGACACAGAGCAGCTGGCGCAAAGGG                   GAGCTGGCCTCTGCTTCACTTTTGTTTCAGCTCAGCAAAACAGTCCCTCATCTACGGG                   ATCTGGCAACACAGAGCATTCCTGCAGCTCCCAAAAACAGATCTCCATCCAGCACAGA                   CAGACCCAGTCCGACCTCACAATAGAAAAAATATCTGCACTAGAAAACAGTAAGAATT                   CTGACTTAGAGAAGAAGGAGGGAAGAATAGATGATTTATTAAGAGCCATCTGTGATTT                   GAGACGGCAGATTGATGAACAGCAAAAGATGCTAGAGAAATACAAGGAACGATTAAAT                   AGATGTGTGACAATGAGCAAGAAACTCCTTATAGAAAAGTCAAAACAAGAGAAGATGG                   CGTGTAGAGATAAGAGCATGCAAGACCGCTTGAGACTGGGCCACTTTACTACGTCTGA                   CCACGGAGCCAAATTTACTGAGCAGTGGACAGATGGTTATGCTTTTCAGAATCTTATC                   AAGCAACAGGAAAGGATAAATTCACAGAGGGAAGAGATAGAAAGACAACGGAAAATGT                   TAGCAAAGCGGAAACCTCCTGCCATGGGTCAGGCCCCTCCTGCAACCAATGAGCAGAA                   ACAGTGGAAAAGCAAGACCAATGGAGCTGAAAATGAAACGTTAACGTTAAAAGAATAC                   CATGAACAAGAAGAAATCTTCAAACTCAGATTAGGTCATCTTAAAAAGGAGGAAGCAG                   AGATCCAGGCAGAGCTGGAGAGGCTAGAAAGGGTTAGAAAACTACATATCAGGGAAGT                   AAAAAGGATACATAATGAAGATAATTCACAATTTAAATATCATCCAACGCTAAATGAC                   AGATATTTGTTGTTACATCTTTTGGGTAGAGGAGGTTTCAGTGAAGTTTACAAGGCAT                   TTGATCTAACAGAGCAAAGATACGTAGCTGTGAAAATTCACCAGTTAAATAAAAACTG                   GAGAGATGAGAAAAAGGAGAATTACCACAAGCATGCATGTAGGGAATACCGGATTCAT                   AAAGAGCTGGACCATCCCAGAATAGTTAAGCTGTATGATTACTTTTCACTGGATACTG                   ACTCGTTTTGTACAGTATTAGAATACTGTGAGGGAAATGATCTGGACTTCTACCTGAA                   ACAGCACAAATTAATGTCAGAGAAAGAGGCCCGGTCCATTATCATGCAGATTGTGAAT                   GCTTTAAAGTACTTAAATGAAATAAAACCTCCCATCATACACTATGACCTCAAACCAG                   GTAATATTCTTTTAGAAAATGGTACAGCGTGTGGAGAGATAAAAATTACAGATTTTGG                   TCTTTCGAAGATCATGGATGATGATAGCTACAATTCAGTGGATGGCATGGAGCTAACA                   TCACAAGGTGCTGGTACTTATTGGTATTTACCACCAGAGTGTTTTGTGGTTGGGAAAG                   AACCACCAAAGATCTCAAATAAAGTTGATGTGTGGTCGGTGGGTGTGATCTTCTATCA                   GTGTCTTTATGGAAGGAAGCCTTTTGGCCATAACCAGTCTCAGCAAGACATCCTACAA                   GAGAATACGATTCTTAAAGCTACTGAAGTGCAGTTCCCGCCAAAGCCGGTAGTAACAC                   CTGAAGCAAAGGCGTTGATTCGACGATGCTTGGCCTACCGAAAGGAGGACCGCATTGA                   TGTCCAGCAGCTGGCCTGTGATCCCTACTTGTTGCCTCACATCCGAAAGTCAGTCTCT                   ACGAGTAGCCCTGCTGGAGCTGCTATTGCATCAACCTCTGGGGCGTCCAATAACAGTT                   CTTCTAAT TGA   GACTGACTCCAAGGCCACAAACT                                           ORF Start: ATG at 24       ORF Stop: TGA at 2271           SEQ ID NO:20   749 aa   MW at 8545.8 kD                     NOV8a,   MEELHSLDPRRQKLLEARFTGVGVSKGPLNSESSNQSLCSVGSLSDKEVETPKKKQND       CG57871-01 Protein Sequence           QRNRKRKAEPYESSQGKGTPRGHKISDYFEFAGGSGPGTSPGRSVPPVARSSLQHSLS                   NPLPRRVEQPLYGLDGSAAKEATEEQSALPTLMSVMLAKPRLDTEQLAQRGAGLCFTF                   VSAQQNSPSSTGSGNTEHSCSSQKQISIQHRQTQSDLTIEKISALENSKNSDLEKKEG                   RIDDLLRAICDLRRQIDEQQKMLEKYKERLNRCVTMSKKLLIEKSKQEKMACRDKSMQ                   DRLRLGHFTTSDHGAKFTEQWTDGYAFQNLIKQQERINSQREEIERQRKMLAKRKPPA                   MGQAPPATNEQKQWKSKTNGAENETLTLKEYHEQEEIFKLRLGHLKKEEAEIQAELER                   LERVRKLHIREVKRIHNEDNSQFKYHPTLNDRYLLLHLLGRGGFSEVYKAFDLTEQRY                   VAVKIHQLNKNWRDEKKENYHKHACREYRIHKELDHPRIVKLYDYFSLDTDSFCTVLE                   YCEGNDLDFYLKQHKLMSEKEARSIIMQIVNALKYLNEIKPPIIHYDLKPGNILLENG                   TACGEIKITDFGLSKIMDDDSYNSVDGMELTSQGAGTYWYLPPECFVVGKEPPKISNK                   VDVWSVGVIFYQCLYGRKPFGHNQSQQDILQENTILKATEVQFPPKPVVTPEAKALIR                   RCLAYRKEDRIDVQQLACDPYLLPHIRKSVSTSSPAGAAIASTSGASNNSSSN                  
 
     [0362] Further analysis of the NOV8a protein yielded the following properties shown in Table 8B.  
               TABLE 8B                       Protein Sequence Properties NOV8a                                        PSort   0.9600 probability located in nucleus; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located           in endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0363] A search of the NOV8a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8C.  
               TABLE 8C                          Geneseq Results for NOV8a                                         NOV8a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value                                             AAM39278   Human polypeptide SEQ ID NO   1 . . . 749   703/749   (93%)   0.0           2423 -  Homo sapiens , 718 aa.   2 . . . 718   707/749   (93%)           [WO200153312-A1, 26 JUL           2001]       AAM41064   Human polypeptide SEQ ID NO   1 . . . 749   695/750   (92%)   0.0           5995 -  Homo sapiens , 809 aa.   92 . . . 809    701/750   (92%)           [WO200153312-A1, 26 JUL           2001]       AAR76062   Protein kinase PKU beta -  Homo     210 . . . 749    525/540   (97%)   0.0             sapiens , 540 aa. [JP07132093-A,   1 . . . 540   527/540   (97%)           23 MAY 1995]       AAR76061   Protein kinase PKU alpha -  Homo     1 . . . 744   537/794   (67%)   0.0             sapiens , 787 aa. [JP07132093-A,   49 . . . 783    592/794   (73%)           23 MAY 1995]       ABB20910   Protein #2909 encoded by probe   346 . . . 749    404/404   (100%)   0.0           expression -  Homo sapiens , 404   1 . . . 404   404/404   (100%)           aa. [WO200157274-A2, 09 AUG           2001]                  
 
     [0364] In a BLAST search of public sequence databases, the NOV8a protein was found to have homology to the proteins shown in the BLASTP data in Table 8D.  
               TABLE 8D                          Public BLASTP Results for NOV8a                                         NOV8a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9UK17   TOUSLED-LIKE KINASE 2 -   1 . . . 749   731/749 (97%)   0.0             Homo sapiens  (Human), 749 aa.   1 . . . 749   736/749 (97%)       O55047   TOUSLED-LIKE KINASE -  Mus     1 . . . 749   699/749 (93%)   0.0             musculus  (Mouse), 717 aa.   1 . . . 717   705/749 (93%)       Q9Y4F7   PKU-ALPHA -  Homo sapiens     1 . . . 749   700/749 (93%)   0.0           (Human), 719 aa (fragment).   3 . . . 719   705/749 (93%)       Q9D5Y5   TOUSLED-LIKE KINASE 2   1 . . . 656   629/656 (95%)   0.0           (ARABIDOPSIS) -  Mus musculus     1 . . . 656   640/656 (96%)           (Mouse), 696 aa.       Q90ZY7   PKU-ALPHA PROTEIN KINASE -   1 . . . 749   580/753 (77%)   0.0             Brachydanio rerio  (Zebrafish)   2 . . . 697   626/753 (83%)           ( Zebra danio ), 697 aa.                  
 
     [0365] PFam analysis predicts that the NOV8a protein contains the domains shown in the Table 8E.  
               TABLE 8E                          Domain Analysis of NOV8a                                     Identities/                   Similarities       Pfam Domain   NOV8a Match Region   for the Matched Region   Expect Value                                         A2M: domain 1 of 1   501 . . . 523   10/23   (43%)   4.6               20/23   (87%)       Pkinase: domain 1 of   439 . . . 718   96/316   (30%)   5.4e−70       1       213/316   (67%)                  
 
     Example 9  
     [0366] The NOV9 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 9A.  
               TABLE 9A                       NOV9 Sequence Analysis                                                SEQ ID NO:21   2060 bp                     NOV9a,     GTTTTCATAGATAACC   ATG CAACATCCCATATGAATGGGCATGTTACAGAGGAATCA       CG58590-01 DNA Sequence           GACAGCGAAGTAAAAAATGTTGATCTTGCATCACCAGAGGAACATCAGAAGCACCGAG                   AGATGGCTGTTGACTGCCCTGGAGATTTGGGCACCAGGATGATGCCAATACGTCGAAG                   TGCACAGTTGGAGCGTATTCGGCAACAACAGGAGGACATGAGGCGTAGGAGAGAGGAA                   GAAGGGAAAAAGCAAGAACTTGACCTTAATTCTTCCATGAGACTTAAGAAACTAGCCC                   AAATTCCTCCAAAGACCGGAATAGATAACCCTATGTTTGATACAGAGGAAGGAATTGT                   CTTAGAAAGTCCTCATTATGCTGTGAAAATATTAGAAATAGAAGACTTGTTTTCTTCA                   CTTAAACATATCCAACATACTTTGGTAGATTCTCAGAGCCAGGAGGATATTTCACTGC                   TTTTACAACTTGTTCAAAATAAGGATTTCCAGAATGCATTTAAGATACACAATGCCAT                   CACAGTACACATGAACAAGGCCAGTCCTCCATTTCCTCTTATCTCCAACGCACAAGAT                   CTTGCTCAAGAGGTACAAACTGTTTTGAAGCCAGTTCATCATAAGGAAGGACAAGAAC                   TAACTGCTTTGCTGAATACTCCACATATTCAGGCACTTTTACTGGCCCACGATAAGGT                   TGCTGAGCAGGAAATGCAGCTAGAGCCCATTACAGATGAGAGAGTTTATGAAAGTATT                   GGCCAGTATGGAGGAGAAACTGTAAAAATAGTTCGTATAGAAAAGGCTCGTGATATTC                   CGTTGGGTGCTACAGTTCGTAATGAAATGGACTCTGTCATCATTAGCCGGATAGTAAA                   AGGGGGTGCTGCAGAGAAAAGTGGTCTGTTGCATGAAGGAGATGAAGTTCTAGAGATT                   AATGGCATTGAAATTCGGGGGAAAGATGTCAATGAGGTTTTTGACTTGTTGTCTGATA                   TGCATGGTACTTTGACTTTTGTCCTGATTCCCAGTCAACAGATCAAGCCGCCTCCTGC                   CAAGGAAACAGTAATCCATGTAAAAGCTCATTTTGACTATGACCCCTCAGATGACCCT                   TATGTTCCATGTCGAGAGTTAGGTCTGTCTTTTCAAAAAGGTGATATACTTCATGTGA                   TCAGTCAAGAAGATCCAAACTGGTGGCAGGCCTACAGGGAAGGGGACGAAGATAATCA                   ACCTCTAGCCGGGCTTGTTCCAGGGAAAAGCTTTCAGCAGCAAAGGGAAGCCATGAAA                   CAAACCATAGAAGAAGATAAGGAGCCAGAAAAATCAGGTAAACTGTGGTGTGCAAAGA                   AGAATAAAAAGAAGAGGAAAAAGGTTTTATATAATGCCAATAAAAATGATGATTATGA                   CAACGAGGAGATCTTAACCTATGAGGAAATGTCACTTTATCATCAGCCAGCAAATAGG                   AAGAGACCTATCATCTTGATTGGTCCACAGAACTGTGGCCAGAATGAATTGCGTCAGA                   GGCTCATGAACAAAGAAAAGGACCGCTTTGCATCTGCAGTTCCTCGTACAACCCGGAG                   TAGGCGAGACCAAGAAGTAGCCGGTAGAGATTACCACTTTGTTTCGCGGCAAGCATTC                   GAGGCAGACATAGCAGCTGGAAAGTTCATTGAGCATGGTGAATTTGAGAAGAATTTGT                   ATGGAACTAGCATAGATTCTGTACGGCAAGTGATCAACTCTGGCAAAATATGTCTTTT                   AAGTCTTCGTACACAGTCATTGAAGACTCTCCGGAATTCAGATTTGAAACCATATATT                   ATCTTCATTGCACCCCCTTCACAAGAAAGACTTCGGGCATTATTGGCCAAAGAAGGCA                   AGAATCCAAAGCCTGAAGAGTTGAGAGAAATCATTGAGAAGACAAGAGAGATGGAGCA                   GAACAATGGCCACTACTTTGATACGGCAATTGTGAATTCCGATCTTGATAAAGCCTAT                   CAGGAATTGCTTAGGTTAATTAACAAACTTGATACTGAACCTCAGTGGGTACCATCCA                   CTTGGCTGAGG TGA   AAGAAACATCCATTCT                                           ORF Start: ATG at 17       ORF Stop: TGA at 2042           SEQ ID NO:22   675 aa   MW at 77311.8 kD                     NOV9a,   MTTSHMNGHVTEESDSEVKNVDLASPEEHQKHREMAVDCPGDLGTRMMPIRRSAQLER       CG58590-01 Protein Sequence           IRQQQEDMRRRREEEGKKQELDLNSSMRLKKLAQIPPKTGIDNPMFDTEEGIVLESPH                   YAVKILEIEDLFSSLKHIQHTLVDSQSDEDISLLLQLVQNKDFQNAFKIHNAITVHMN                   KASPPFPLISNAQDLAQEVQTVLKPVHHKEGQELTALLNTPHIQALLLAHDKVAEQEM                   QLEPITDERVYESIGQYGGETVKIVRIEKARDIPLGATVRNEMDSVIISRIVKGGAAE                   KSGLLHEGDEVLEINGIEIRGKDVNEVFDLLSDMHGTLTFVLIPSQQIKPPPAKETVI                   HVKAHFDYDPSDDPYVPCRELGLSFQKGDILHVISQEDPNWWQAYREGDEDNQPLAGL                   VPGKSFQQQREAMKQTIEEDKEPEKSGKLWCAKKNKKKRKKVLYNANKNDDYDNEEIL                   TYEEMSLYHQPANRKRPIILIGPQNCGQNELRQRLMNKEKDRFASAVPRTTRSRRDQE                   VAGRDYHFVSRQAFEADIAAGKFIEHGEFEKNLYGTSIDSVRQVINSGKICLLSLRTQ                   SLKTLRNSDLKPYIIFIAPPSQERLRALLAKEGKNPKPEELREIIEKTREMEQNNGHY                   FDTAIVNSDLDKAYQELLRLINKLDTEPQWVPSTWLR                                     SEQ ID NO:23   2030 bp                     NOV9b,     CC ATGACAACATCCCATATGAATGGGCATGTTACAGAGGAATCAGACAGCGAAGTAAA       CG58590-02 DNA Sequence           AAATGTTGATCTTGCATCACCAGAGGAACATCAGAAGCACCGAGAGATGGCTGTTGAC                   TGCCCTGGAGATTTGGGCACCAGGATGATGCCAATACGTCGAAGTGCACAGTTGGAGC                   GTATTCGGCAACAACAGGAGGACATGAGGCGTAGGAGAGAGGAAGAAGGGAAAAAGCA                   AGAACTTGACCTTAATTCTTCCATGAGACTTAAGAAACTAGCCCAAATTCCTCCAAAG                   ACCGGAATAGATAACCCTATGTTTGATACAGAGGAAGGAATTGTCTTAGAAAGTCCTC                   ATTATGCTGTGAAAATATTAGAAATAGAAGACTTGTTTTCTTCACTTAAACATATCCA                   ACATACTTTGGTAGATTCTCAGAGCCAGGAGGATATTTCACTGCTTTTACAACTTGTT                   CAAAATAAGGATTTCCAGAATGCATTTAAGATACACAATGCCATCACAGTACATATGA                   ACAAGGCCAGTCCTCCATTTCCTCTTATCTCCAACGCACAAGATCTTGCTCAAGAGGT                   ACAAACTGTTTTGAAGCCAGTTCATCATAAGGAAGGACAAGAACTAACTGCTTTGCTG                   AATACTCCACATATTCAGGCACTTTTACTGGCCCACGATAAGGTTGCTGAGCAGGAAA                   TGCAGCTAGAGCCCATTACAGATGAGAGAGTTTATGAAAGTATTGGCCAGTATGGAGG                   AGAAACTGTAAAAATAGTTCGTATAGAAAAGGCTCGTGATATTCCGTTGGGTGCTACA                   GTTCGTAATGAAATGGACTCTGTCATCATTAGCCGGATAGTAAAAGGGGGTGCTGCAG                   AGAAAAGTGGTCTGTTGCATGAAGGAGATGAAGTTCTAGAGATTAATGGCATTGAAAT                   TCGGGGGAAAGATGTCAATGAGGTTTTTGACCTGTTGTCTGATATGCATGGTACTTTG                   ACTTTTGTCCTGATTCCCAGTCAACAGATCAAGCCGCCTCCTGCCAAGGAAACAGTAA                   TCCATGTAAAAGCTCATTTTGACTATGACCCCTCAGATGACCCTTATGTTCCATGTCG                   AGAGTTAGGTCTGTCTTTTCAAAAAGGTGATATACTTCATGTGATCAGTCAAGAAGAT                   CCAAACTGGTGGCAGGCCTACAGGGAAGGGGACGAAGATAATCAACCTCTAGCCGGGC                   TTGTTCCAGGGAAAAGCTTTCAGCAGCAAAGGGAAGCCATGAAACAAACCATAGAAGA                   AGATAAGGAGCCAGAAAAATCAGGAAAACTGTGGTGTGCAAAGAAGAATAAAAAGAAG                   AGGAAAAAGGTTTTATATAATGCCAATAAAAATGATGATTATGACAACGAGGAGATCT                   TAACCTATGAGGAAATGTCACTTTATCATCAGCCAGCAAATAGGAAGAGACCTATCAT                   CTTGATTGGTCCACAGAACTGTGGCCAGAATGAATTGCGTCAGAGGCTCATGAACAAA                   GAAAAGGACCGCTTTGCATCTGCAGTTCCTCATACAACCCGGAGTAGGCGAGACCAAG                   AAGTAGCCGGTAGAGATTACCACTTTGTTTCGCGGCAAGCATTCGAGGCAGACATAGC                   AGCTGGAAAGTTCATTGAGCATGGTGAATTTGAGAAGAATTTGTATGGAACTAGCATA                   GATTCTGTACGGCAAGTGATCAACTCTGGCAAAATATGTCTTTTAAGTCTTCGTACAC                   AGTCATTGAAGACTCTCCGGAATTCAGATTTGAAACCATATATTATCTTCATTGCACC                   CCCTTCACAAGAAAGACTTCGGGCATTATTGGCCAAAGAAGGCAAGAATCCAAAGCCT                   GAAGAGTTGAGAGAAATCATTGAGAAGACAAGAGAGATGGAGCAGAACAATGGCCACT                   ACTTTGATACGGCAATTGTGAATTCCGATCTTGATAAAGCCTATCAGGAATTGCTTAG                   GTTAATTAACAAACTTGATACTGAACCTCAGTGGGTACCATCCACTTGGCTGAGG TGA                                           ORF Start: ATG at 3       ORF Stop: TGA at 2028           SEQ ID NO:24   675 aa   MW at 77292.8 kD                     NOV9b,   MTTSEMNGEVTEESDSEVKNVDLASPEEHQKHREMAVDCPGDLGTRMMPIRRSAQLER       CG58590-02 Protein Sequence           IRQQQEDMRRRREEEGKKQELDLNSSMRLKKLAQIPPKTGIDNPMFDTEEGIVLESPH                   YAVKILEIEDLFSSLKHIQHTLVDSQSDEDISLLLQLVQNKDFQNAFKIHNAITVHMN                   KASPPFPLISNAQDLAQEVQTVLKPVHHKEGQELTALLNTPHIQALLLAHDKVAEQEM                   QLEPITDERVYESIGQYGGETVKIVRIEKARDIPLGATVRNEMDSVIISRIVKGGAAE                   KSGLLHEGDEVLEINGIEIRGKDVNEVFDLLSDMHGTLTFVLIPSQQIKPPPAKETVI                   HVKAHFDYDPSDDPYVPCRELGLSFQKGDILHVISQEDPNWWQAYREGDEDNQPLAGL                   VPGKSFQQQREAMKQTIEEDKEPEKSGKLWCAKKNKKKRKKVLYNANKNDDYDNEEIL                   TYEEMSLYHQPANRKRPIILIGPQNCGQNELRQRLMNKEKDRFASAVPHTTRSRRDQE                   VAGRDYHFVSRQAFEADIAAGKFIEHGEFEKNLYGTSIDSVRQVINSGKICLLSLRTQ                   SLKTLRNSDLKPYIIFIAPPSQERLRALLAKEGKNPKPEELREIIEKTREMEQNNGHY                   FDTAIVNSDLDKAYQELLRLINKLDTEPQWVPSTWLR                  
 
     [0367] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 9B.  
               TABLE 9B                          Comparison of NOV9a against NOV9b.                                 Identities/       Protein   NOV9a Residues/   Similarities for       Sequence   Match Residues   the Matched Region               NOV9b   1 . . . 675   636/675 (94%)           1 . . . 675   636/675 (94%)                  
 
     [0368] Further analysis of the NOV9a protein yielded the following properties shown in Table 9C.  
               TABLE 9C                       Protein Sequence Properties NOV9a                                        PSort   0.7000 probability located in nucleus; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located           in endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0369] A search of the NOV9a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9D.  
               TABLE 9D                          Geneseq Results for NOV9a                                         NOV9a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB94180   Human protein sequence SEQ ID   173 . . . 675   501/503 (99%)   0.0           NO:14494 -  Homo sapiens , 503 aa.    1 . . . 503   501/503 (99%)           [EP1074617-A2, 7 FEB 2001]       AAB41921   Human ORFX ORF1685   406 . . . 675   261/270 (96%)   e−147           polypeptide sequence SEQ ID    1 . . . 269   264/270 (97%)           NO:3370 -  Homo sapiens , 269 aa.           [WO200058473-A2, 5 OCT 2000]       AAU07123   Human novel human protein, NHP   143 . . . 674   224/564 (39%)   e−109           #23 -  Homo sapiens , 576 aa.    31 . . . 574   339/564 (59%)           [WO200161016-A2, 23 AUG 2001]       AAU07119   Human novel human protein, NHP   143 . . . 654   213/544 (39%)   e−102           #19 -  Homo sapiens , 560 aa.    31 . . . 554   327/544 (59%)           [WO200161016-A2, 23 AUG 2001]       AAU07115   Human novel human protein, NHP   143 . . . 606   196/481 (40%)   5e−97            #15 -  Homo sapiens , 520 aa.    31 . . . 495   300/481 (61%)           [WO200161016-A2, 23 AUG 2001]                  
 
     [0370] In a BLAST search of public sequence databases, the NOV9a protein was found to have homology to the proteins shown in the BLASTP data in Table 9E.  
               TABLE 9E                          Public BLASTP Results for NOV9a                                             Identities/                   NOV9a   Similarities       Protein       Residues/   for the       Accession       Match   Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9JLB2   PALS1 -  Mus musculus  (Mouse),    1 . . . 675   652/675 (96%)   0.0           675 aa.    1 . . . 675   665/675 (97%)       Q9H9Q0   CDNA FLJ12615 FIS, CLONE   173 . . . 675   501/503 (99%)   0.0           NT2RM4001629, WEAKLY    1 . . . 503   501/503 (99%)           SIMILAR TO MAGUK P55           SUBFAMILY MEMBER 3 -  Homo               sapiens  (Human), 503 aa.       AAL40935   STARDUST PROTEIN MAGUK1   252 . . . 674   252/460 (54%)   e−140           ISOFORM -  Drosophila      829 . . . 1282   327/460 (70%)             melanogaster  (Fruit fly), 1289 aa.       Q9W3H6   CG1617 PROTEIN -  Drosophila     252 . . . 674   252/500 (50%)   e−132             melanogaster  (Fruit fly), 794 aa.   294 . . . 787   327/500 (65%)       Q9W7F1   P55-RELATED MAGUK   142 . . . 673   209/556 (37%)   e−105           PROTEIN DLG3 -  Brachydanio      30 . . . 573   335/556 (59%)             rerio  (Zebrafish) ( Zebra danio ), 576            aa.                  
 
     [0371] PFam analysis predicts that the NOV9a protein contains the domains shown in the Table 9F.  
               TABLE 9F                          Domain Analysis of NOV9a                                     Identities/                   Similarities       Pfam Domain   NOV9a Match Region   for the Matched Region   Expect Value                                         L27: domain 1 of 1   186 . . . 238   19/56   (34%)   0.049               39/56   (70%)       PDZ: domain 1 of 1   256 . . . 335   21/83   (25%)   9.7e−12               58/83   (70%)       SH3: domain 1 of 1   348 . . . 415   19/68   (28%)   0.026               46/68   (68%)       Guanylate_kin: domain 1   515 . . . 624   54/113   (48%)   6.2e−38       of 1       87/113   (77%)       Peptidase_S15: domain 1   642 . . . 658   6/17   (35%)   8.2       of 1       13/17   (76%)       Caulimo_mov: domain 1   420 . . . 673   59/335   (18%)   6.1       of 1       156/335   (47%)                  
 
     Example 10  
     [0372] The NOV10 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 10A.  
               TABLE 10A                       NOV10 Sequence Analysis                                                SEQ ID NO:25   576 bp                     NOV10a,     ACCTTACTAGAAAA   ATG AAACCTGATGAAACTCCTATGTTTGACCCAAGTCTACTCAA       CG58572-01 DNA Sequence           AGAAGTGGACTGGAGTCAGAATACAGCTACATTTTCTCCAGCCATTTCCCCAACACAT                   CCTGGAGAAGGCTTGGTTTTGAGGCCTCTTTGTACTGCTGACTTAAATAGAGGTTTTT                   TTAAGGTATTGGGTCAGCTAACAGAGACTGGAGTTGTCAGCCCTGAACAATTTATGGA                   ATCTTTTGAGCATATGAAGAAATCTGGGGATTATTATGTTACAGTTGTAGAAGATGTG                   ACTCTAGGACAGATTGTTGCTACGGCAACTCTGATTATAGAACATAAATTCATCCATT                   CCTGTGCTAAGAGAGGAAGAGTAGAAGATGTTGTTGTTAGTGATGAATGCAGAGGAAA                   GCAGCTTGGCAAATTGTTATTATCAACCCTTACTTTGCTAAGCAAGAAACTGAACTGT                   TACAAGATTACCCTTGAATGTCTACCACAAAATGTTGGTTTCTATAAAAAGTTTGGAT                   ATACTGTATCTGAAGAAAACTACATGTGTCGGAGGTTTCTAAAGTAA AAATCTT                                           ORF Start: ATG at 15       ORF Stop: TAA at 567           SEQ ID NO:26   184 aa   MW at 2079.9 kD                     NOV10a,   MKPDETPMFDPSLLKEVDWSQNTATFSPAISPTHPGEGLVLRPLCTADLNRGFFKVLG       CG58572-01 Protein Sequence           QLTETGVVSPEQFMESFEHMKKSGDYYVTVVEDVTLGQIVATATLIEHKFIHSCAKR                   GRVEDVVVSDECRGKQLGKLLLSTLTLLSKKLNCYKITLECLPQNVGFYKKFGYTVSE                   ENYMCRRFLK                                     SEQ ID NO:27   560 bp                     NOV10b,     ATG AAACCTGATGAAACTCCTATGTTTGACCCAAGTCTACTCAAAGAAGTGGACTGGA       CG58572-02 DNA Sequence           GTCAGAATACAGCTACATTTTCTCCAGCCATTTCCCCAACACATCCTGGAGAAGGCTT                   GGTTTTGGGGCCTCTTTGTACTGCTGACTTAAATAGAGGTTTTTTTAAGGTATTGGGT                   CAGCTAACAGAGACTGGAGTTGTCAGCCCTGAACAATTTATGAAATCTTTTGAGCATA                   TGAAGAAATCTGGGGATTATTATGTTACAGTTGTAGAAGATGTGACTCTAGGACAGAT                   TGTTGCTACGGCAACTCTGATTATAGAACATAAATTCATCCATTCCTGTGCTAAGAGA                   GGAAGAGTAGAAGATGTTGTTGTTAGTGATGAATGCAGAGGAAAGCAGCTTGGCAAAT                   TGTTATTATCAACCCTTACTTTGCTAAGCAAGAAACTGAACTGTTACAAGATTACCCT                   TGAATGTCTACCACAAAATGTTGGTTTCTATAAAAAGTTTGGATATACTGTATCTGAA                   GAAAACTACATGTGTCGGAGGTTTCTAAAG TAA   AAATC                                           ORF Start: ATG at 1       ORF Stop: TAA at 553           SEQ ID NO:28   184 aa   MW at 20649.8 kD                     NOV10b,   MKPDETPMFDPSLLKEVDWSQNTATFSPAISPTHPGEGLVLGPLCTADLNRGFFKVLG       CG5872-02 Protein Sequence           QLTETGVVSPEQFMKSFEHMKKSGDYYVTVVEDVTLGQIVATATLIIEHKFIHSCAKR                   GRVEDVVVSDECRGKQLGKLLLSTLTLLSKKLNCYKITLECLPQNVGFYKKFGYTVSE                   ENYMCRRFLK                  
 
     [0373] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 10B.  
               TABLE 10B                          Comparison of NOV10a against NOV10b.                                 Identities/       Protein   NOV10a Residues/   Similarities for       Sequence   Match Residues   the Matched Region               NOV10b   1 . . . 184   163/184 (88%)           1 . . . 184   164/184 (88%)                  
 
     [0374] Further analysis of the NOV10a protein yielded the following properties shown in Table 10C.  
               TABLE 10C                       Protein Sequence Properties NOV10a                                        PSort   0.4500 probability located in cytoplasm; 0.1206 probability       analysis:   located in microbody (peroxisome); 0.1000 probability located           in mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0375] A search of the NOV10a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 10D.  
               TABLE 10D                          Geneseq Results for NOV10a                                         NOV10a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG67123   Amino acid sequence of human   1 . . . 184   183/184 (99%)   e−105           50287 transferase -  Homo sapiens ,   1 . . . 184   184/184 (99%)           184 aa. [WO200164904-A2,           7 SEP 2001]       AAB73505   Human transferase HTFS-12, SEQ   1 . . . 184   183/184 (99%)   e−105           ID NO: 12 -  Homo sapiens , 184 aa.   1 . . . 184   184/184 (99%)           [WO200132888-A2, 10 MAY           2001]       AAB63700   Human gastric cancer associated   1 . . . 184   183/184 (99%)   e−105           antigen protein sequence SEQ ID   17 . . . 200    184/184 (99%)           NO:1062 -  Homo sapiens , 200 aa.           [WO200073801-A2, 7 DEC           2000]       AAU07779   Human novel transferase protein,   1 . . . 184   182/184 (98%)   e−104           NHP #22 -  Homo sapiens , 184 aa.   1 . . . 184   183/184 (98%)           [WO200164903-A2, 7 SEP 2001]       AAM79992   Human protein SEQ ID NO 3638 -   1 . . . 184   181/184 (98%)   e−104             Homo sapiens , 206 aa.   23 . . . 206    183/184 (99%)           [WO200157190-A2, 9 AUG           2001]                  
 
     [0376] In a BLAST search of public sequence databases, the NOV10a protein was found to have homology to the proteins shown in the BLASTP data in Table 10E.  
               TABLE 10E                          Public BLASTP Results for NOV10a                                             Identities/                   NOV10a   Similarities       Protein       Residues/   for the       Accession       Match   Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                             Q96EK6   SIMILAR TO GLUCOSAMINE-   1 . . . 184   183/184   (99%)    e−104           PHOSPHATE N-   1 . . . 184   184/184   (99%)           ACETYLTRANSFERASE -  Homo               sapiens  (Human), 184 aa.       Q9JK38   EMEG32 PROTEIN   1 . . . 184   180/184   (97%)    e−102           (GLUCOSAMINE-PHOSPHATE N-   1 . . . 184   182/184   (98%)           ACETYLTRANSFERASE) -  Mus               musculus  (Mouse), 184 aa.       Q9VAI0   Probable glucosamine-phosphate N-   4 . . . 176   84/174   (48%)   2e−43           acetyltransferase (EC 2.3.1.4)   6 . . . 179   123/174   (70%)           (Phosphoglucosamine transacetylase)           (Phosphoglucosamine acetylase) -             Drosophila melanogaster  (Fruit fly),           219 aa.       Q17427   Probable glucosamine-phosphate N-   32 . . . 182    65/152   (42%)   1e−28           acetyltransferase (EC 2.3.1.4)   15 . . . 165    98/152   (63%)           (Phosphoglucosamine transacetylase)           (Phosphoglucosamine acetylase) -             Caenorhabditis elegans , 165 aa.       O45811   T23G11.2PROTEIN -   42 . . . 184    63/143   (44%)   3e−26             Caenorhabditis elegans , 347 aa.   201 . . . 340    88/143   (61%)                  
 
     [0377] PFam analysis predicts that the NOV10a protein contains the domains shown in the Table 10F.  
               TABLE 10F                          Domain Analysis of NOV10a                                     Identities/                   Similarities       Pfam Domain   NOV10a Match Region   for the Matched Region   Expect Value               Acetyltransf: domain 1   89 . . . 171   22/87 (25%)   6.5e−13       of 1       62/87 (71%)                  
 
     Example 11  
     [0378] The NOV11 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 11A.  
               TABLE 11A                       NOV11 Sequence Analysis                                                SEQ ID NO:29   7098 bp                     NOV11a,     CCCGCGGGCCAGCACC   ATG GAGGACGTGAAGCTGGAGTTCCCTTCCCTTCCACAGTGC       CG58564-01 DNA Sequence           AAGGAAGACGCCGAGGAGTGGACCTACCCTATGAGACGAGAGATGCAGGAAATTTTAC                   CTGGATTGTTCTTAGGCCCATATTCATCTGCTATGAAAAGCAAGCTACCTGTACTACA                   GAAACATGGAATAACCCATATAATATGCATACGACAAAATATTGAAGCAAACTTTATT                   AAACCAAACTTTCAGCAGTTATTTAGGTATTTAGTCCTGGATATTGCAGATAATCCAG                   TTGAAAATATAATACGTTTTTTCCCTATGACTAAGGAATTTATTGATGGGAGCTTACA                   AATGGGAGGTAAAGTTCTTGTGCATGGAAATGCAGGGATCTCCAGAAGTGCAGCCTTT                   GTTATTGCATACATTATGGAAACATTTGGAATGAAGTACAGGGATGCTTTTGCTTATG                   TTCAAGAAAGAAGATTTTGTATTAATCCTAATGCTGGATTTGTCCATCAACTTCAGGA                   ATATGAAGCCATCTACCTAGCAAAATTAACAATACAGATGATGTCACCACTCCAGATA                   GAAAGGTCATTATCTGTTCATTCTGGTACCACAGGTAGTTTGAAGAGAACACATGAAG                   AAGAGGATGATTTTGGAACCATGCAAGTGGCGACTGCACAGAATGGC TGA   CTTGAAGA                       GCAACATCATAGA                                           ORF Start: ATG at 17       ORF Stop: TGA at 686           SEQ ID NO:30   223 aa   MW at 25492.2 kD                     NOV11a,   MEDVKLEFPSLPQCKEDAEEWTYPMRREMQEILPGLEFLGPYSSAMKSKLPVLQKHGIT       CG58564-01 Protein Sequence           HIICIRQNIEANFIKPNFQQLFRYLVLDIADNPVENIIRFFPMTKEFIDGSLQMGGKV                   LVHGNAGISRSAAFVIAYIMETFGMKYRDAFAYVQERRFCINPNAGFVHQLQEYEAIY                   LAKLTIQMMSPLQIERSLSVHSGTTGSLKRTHEEEDDPGTMQVATAQNG                                     SEQ ID NO:31   724 bp                     NOV 11b,     ACTCTCCCACCCCACCCACCAGAATGGCGGGCCAGCACC ATG GAGGACGTGAAGCTGG         CG58564-02 DNA Sequence           AGTTCCCTTCCCTTCCACAGTGCAAGGAAGACGCCGAGGAGTGGACCTACCCTATGAG                   ACGAGAGATGCAGGAAATTTTATCTGGATTGTTCTTAGGCCCATATTCATCTGCTATG                   AAAAGCAAGCTACCTGTACTACAGAAACATGGAATAACCCATATAATATGCATACGAC                   AAAATATTGAAGCAAACTTTATTAAACCAAACTTTCAGCAGTTATTTAGATATTTAGT                   CCTGGATATTGCAGATAATCCAGTTGAAAATATAATACGTTTTTTCCCTATGACTAAG                   GAATTTATTGATGGGAGCTTACAAATGGGAGGAAAAGTTCTTGTGCATGGAAATGCAG                   GGATCTCCAGAAGTGCAGCCTTTGTTATTGCATACATTATGGAAACATTTGGAATGAA                   GTACAGAGATGCTTTTGCTTATGTTCAAGAAAGAAGATTTTGTATTAATCCTAATGCT                   GGATTTGTCCATCAACTTCAGGAATATGAAGCCATCTACCTAGCAAAATTAACAATAC                   AGATGATGTCACCACTCCAGATAGAAAGGTCATTATCTGTTCATTCTGGTACCACAGG                   CAGTTTGAAGAGAACACATGAAGAAGAGGATGATTTTGGAACCATGCAAGTGGCGACT                   GCACAGAATGG TGA   CTTGAAGAGCAAC                                           ORF Start: ATG at 40       ORF Stop: TGA at 709           SEQ ID NO:32   223 aa   MW at 25482.1 kD                     NOV11b,   MEDVKLEFPSLPQCKEDAEEWTYPMRREMQEILSGLFLGPYSSAMKSKLPVLQKHGIT       CG58564-02 Protein Sequence           HIICIRQNIEANFIKPNFQQLFRYLVLDIADNPVENIIRFFPMTKEFIDGSLQMGGKV                   LVHGNAGISRSAAFVIAYIMETFGMKYRDAFAYVQERRFCINPNAGFVHQLQEYEAIY                   LAKLTIQMMSPLQIERSLSVHSGTTGSLKRTHEEEDDFGTMQVATAQNG                                     SEQ ID NO:33   545 bp                     NOV11c,     ACTCTCCCACCCCACCCACCAGCCCGCGGGCCAGCACC   ATG GAGGACGTGAAGCTGGA       CG58564-03 DNA Sequence           GTTCCCTTCCCTTCCACAGTGCAAGGAAGACGCCGAGGAGTGGACCTACCCTATGAGA                   CGAGAGATGCAGGAAATTTTACCTGGATTGTTCTTAGGCCCATATTCATCTGCTATGA                   AAAGCAAGCTACCTGTACTACAGAAACATTTGGAA TGA   AGTACAGAGATGCTTTTGCT                       TATGTTCAAGAAAGAAGATTTTGTATTAATCCTAATGCTGGATTTGTCCATCAACTTC                       AGGAATATGAAGCCATCTACCTAGCAAAATTAACAATACAGATGATGTCACCACTCCA                       GATAGAAAGGTCATTATCTGTTCATTCTGGTACCACAGGCAGTTTGAAGAGAACACAT                       GAGGAAGAGGATGATTTTGGAACCATGCAAGTGGCGACTGCACAGAATGGCTGACTTG                       AAGAGCAACATCATAGAGTGTGAATTTCTATTTGGGAAGGAGAAAATACAAGAGAAAA                       TTATAATGTAAAATGGTAAAAAA                                           ORF Start: ATG at 39       ORF Stop: TGA at 210           SEQ ID NO:34   57 aa   MW at 6695.7 kD                     NOV11c,   MEDVKLEFPSLPQCKEDAEEWTYPMRREMQEILPGLFLGPYSSAMKSKLPVLQKHLE       CG58564-03 DNA Sequence                                     SEQ ID NO:35   663 bp                     NOV11d,     ACTCTCCCACCCCACCCACCAGCCCGCGGGCCAGCACC   ATG GAGGACGTGAAGCTGGA       CG58564-04 DNA Sequence           GTTCCCTTCCCTTCCACAGTGCAAGGAAGACGCCGAGGAGTGGACCTACCCTATGAGA                   CGAGAGATGCAGGAAATTTTACCTGGATTGTTCTTAGGCCCATATTCATCTGCTATGA                   AAAGCAAGCTACCTGTACTACAGAAACATGGAATAACCCATATAATATGCATACGACA                   AAATATTGAAGCAAACTTTATTAAACCAAACTTTCAGCAGTTATTTAGACTAAGGAAT                   TTATTGATGGGAGCTTACAAATGGGAGGAAAAGTTCTTGTGCATGGAAATGCAGGGAT                   CTCCAGAAGTGCAGCCTTTGTTATTGCATACATTATGGAAACATTTGGAA TGA   AGTAC                       AGAGATGCTTTTGCTTATGTTCAAGAAAGAAGATTTTGTATTAATCCTAATGCTGGAT                       TTGTCCATCAACTTCAGGAATATGAAGCCATCTACCTAGCAAAATTAACAATACAGAT                       GATGTCACCACTCCAGATAGAAAGGTCATTATCTGTTCATTCTGGTACCACAGGCAGT                       TTGAAGAGAACACATGAAGAAGAGGATGATTTTGGAACCATGCAAGTGGCGACTGCAC                       AGAATGGCTGACTTGAAGAGCAACT                                           ORF Start: ATG at 39       ORF Stop: TGA at 399           SEQ ID NO:36   120 aa   MW at 14245.6 kD                     NOV11d,   MEDVKLEFPSLPQCKEDAEEWTYPMRREMQEILPGLFLGPYSSAMKSKLPVLQKHGIT       CG58564-04 Protein Sequence           HIICIRQNIEANFIKPNFQQLEFRLRNLLMGAYKWEEKFLCMEMQGSPEVQPLLLHTLW                   KHLE                  
 
     [0379] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 11B.  
               TABLE 11B                          Comparison of NOV11a against NOV11b through NOV11d.                                         Identities/               NOV11a Residues/   Similarities for           Protein Sequence   Match Residues   the Matched Region                                                 NOV11b   1 . . . 223   222/223   (99%)               1 . . . 223   222/223   (99%)           NOV11c   1 . . . 55    55/55   (100%)               1 . . . 55    55/55   (100%)           NOV11d   1 . . . 81    81/81   (100%)               1 . . . 81    81/81   (100%)                      
 
     [0380] Further analysis of the NOV11a protein yielded the following properties shown in Table 11C.  
               TABLE 11C                       Protein Sequence Properties NOV11a                                        PSort   0.4698 probability located in microbody (peroxisome); 0.4500       analysis:   probability located in cytoplasm; 0.1958 probability located in           lysosome (lumen); 0.1000 probability located in mitochondrial           matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0381] A search of the NOV11a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 11D.  
               TABLE 11D                          Geneseq Results for NOV11a                                             Identities/                   NOV11a   Similarities           Protein/   Residues/   for the       Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAU09017   Human dual    1 . . . 223   223/223   e−128           specificity       (100%)           phosphatase    1 . . . 223   223/223           38692— Homo         (100%)             sapiens , 223 aa.           [WO200173059-           A2, Oct. 4, 2001]       AAE08552   Human    1 . . . 223   223/223   e−128           phosphatase       (100%)           protein— Homo      1 . . . 223   223/223             sapiens , 223 aa.       (100%)           [WO200160992-           A2, Aug. 23,           2001]       AAM41520   Human poly-    1 . . . 223   223/223   e−128           peptide SEQ ID       (100%)           NO 6451— Homo     14 . . . 236   223/223             sapiens , 236 aa.       (100%)           [WO200153312-           A1, Jul. 26, 2001]       AAM39734   Human poly-    1 . . . 223   223/223   e−128           peptide SEQ ID       (100%)           NO 2879— Homo      1 . . . 223   223/223             sapiens , 223 aa.       (100%)           [WO200153312-           A1, Jul. 26, 2001]       AAU23521   Novel human   25 . . . 171    55/147   1e−18            enzyme poly-        (37%)           peptide #607—    7 . . . 145    80/147             Homo sapiens ,        (54%)           190 aa.           [WO200155301-           A2, Aug. 2,           2001]                  
 
     [0382] In a BLAST search of public sequence databases, the NOV11a protein was found to have homology to the proteins shown in the BLASTP data in Table 11E.  
               TABLE 11E                          Public BLASTP Results for NOV11a                                             Identities/                   NOV11a   Similarities       Protein       Residues/   for the       Accession   Protein/   Match   Matched   Expect       Number   Organism/Length   Residues   Portion   Value               CAD10219   SEQUENCE 4    1 . . . 223   223/223   e−127           FROM PATENT       (100%)            WO0173059—    1 . . . 223   223/223             Homo sapiens         (100%)            (Human), 223 aa.       Q9DCF8   0610039A20RIK    1 . . . 223   215/223   e−124           PROTEIN— Mus         (96%)             musculus      1 . . . 223   221/223           (Mouse), 223 aa.       (98%)       Q60970   PROTEIN    1 . . . 223   214/223   e−124           TYROSINE       (95%)           PHOSPHATASE-    1 . . . 223   221/223           LIKE— Mus         (98%)             musculus             (Mouse), 223 aa.       Q60969   PROTEIN    1 . . . 168   163/168   2e−93            TYROSINE       (97%)           PHOSPHATASE-    1 . . . 168   167/168           LIKE— Mus         (99%)             musculus             (Mouse), 205 aa.       Q99850   TYROSINE   116 . . . 181   66/66   3e−31            PHOSPHATASE-       (100%)            LIKE PROTEIN    1 . . . 66   66/66           HOMOLOG       (100%)            HSTYXB—             Homo sapiens             (Human), 66 aa           (fragment).                  
 
     [0383] PFam analysis predicts that the NOV11a protein contains the domains shown in the Table 11F.  
               TABLE 11F                          Domain Analysis of NOV11a                                     Identities/               NOV11a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               DSPc: domain   28 . . . 173    64/172 (37%)   2.2e−63       1 of 1       127/172 (74%)       Y_phosphatase:   35 . . . 179    35/279 (13%)   1.7       domain 1 of 1        93/279 (33%)                  
 
     Example 12  
     [0384] The NOV12 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 12A.  
               TABLE 12A                       NOV12 Sequence Analysis                                                SEQ ID NO:37   3696 bp                     NOV12a,     GTGTAAAAATACTGTCCATTTA   ATG TTTTCTGGGACTTTAGGTAAGAATATGAAAACT       CG57819-01 DNA Sequence           CAACCACCCTTGAGCAGGATGAACCGGGAGGAATTGGAGGACAGTTTCTTTCGACTTC                   GCGAAGATCACATGTTGGTGAAGGAGCTTTCTTGGAAGCAACAGGATGAGATCAAAAG                   GCTGAGGACCACCTTGCTGCGGTTGACCGCTGCTGGCCGGGACCTGCGGGTCGCGGAG                   GAGGCGGCGCCGCTCTCGGAGACCGCAAGGCGCGGGCAGAAGGCGGGATGGCGGCAGC                   GCCTCTCCATGCACCAGCGCCCCCAGATGCACCGACTGCAAGGGCATTTCCACTGCGT                   CGGCCCTGCCAGCCCCCGCCGCGCCCAGCCTCGCGTCCAAGTGGGACACAGACAGCTC                   CACACAGCCGGTGCACCGGTGCCGGAGAAACCCAAGAGGGGTAGGGACAGGCTGAGCT                   ACACAGCCCCTCCATCGTTTAAGGAGCATGCGACAAATGAAAACAGAGGTGAAGTAGC                   CAGTAAACCCAGTGAACTGGCCCACATCATGGCCAGCAATACCATGCAAGTGGAAGAG                   CCACCCAAGTCTCCTGAGAAAATGTGGCCTAAAGATGAAAATTTTGAACAGAGAAGCT                   CATTGGAGTGTGCTCAGAAGGCTGCAGAGCTTCGGGCTTCCATTAAAGAGAAGGTAGA                   GCTGATTCGACTTAAGAAGCTCTTACATGAAAGAAATGCTTCATTGGTTATGACAAAA                   GCACAATTAACAGAAGTTCAAGAGGTGAGTTGCCATCTTTTGACCCAGAATCAGGGAA                   TCCTGAGTGCAGCCCATGAGGCCCTCCTCAAGCAAGTGAATGAGCTCAGGGCAGAGCT                   GAAGGAAGAAAGCAAGAAGGCTGTGAGCTTGAAGAGCCAACTGGAAGATGTGTCTATC                   TTGCAGATGACTCTGAAGGAGTTTCAGGAGAGAGTTGAAGATTTGGAAAAAGAACGAA                   AATTGCTGAATGACAATTATGACAAACTCTTAGAAAGCAGTGACAGCTCCAGTCAGCC                   CCACTGGAGCAACGAGCTCATAGCGGAACAGCTACAGCAGCAAGTCTCTCAGCTGCAG                   GATCAGCTGGATGCTGAGCTGGAGGACAAGAGAAAAGTTTTACTTGAGCTGTCCAGGG                   AGAAAGCCCAAAATGAGGATCTGAAGCTTGAAGTCACCAACATACTTCAGAAGCATAA                   ACAGGAAGTAGAGCTCCTCCAAAATGCAGCCACAATTTCCCAACCTCCTGACAGGCAA                   TCTGAACCAGCCACTCACCCAGCTGTATTGCAAGAGAACACTCAGATCCAGCCAAGTG                   AACCCAAAAACCAAGAAGAAAAGAAACTGTCCCAGGTGCTAAATGAGTTGCAAGTATC                   ACACGCAGAGACCACATTGGAACTAGAAAAGACCAGGGACATGCTTATTCTGCAGCGC                   AAAATCAACGTGTGTTATCAGGAGGAACTGGAGGCAATGATGACAAAAGCTGACAATG                   ATAATAGAGATCACAAAGAAAAGCTGGAGAGGTTGACTCGACTACTAGACCTCAAGAA                   TAACCGTATCAAGCAGCTGGAAGAACAGCTCAAAGATGTTGCTTATGGCACCCGACCG                   TTGTCGTTATGTTTGGAAACACTGCCAGCCCATGGAGATGAGGATAAAGTGGATATTT                   CTCTGCTGCATCAGGGTGAGAATCTTTTTGAACTGCACATCCACCAGGCCTTCCTGAC                   ATCTGCCGCCCTAGCTCAGGCTGGAGATACCCAACCTACCACTTTCTGCACCTATTCC                   TTCTATGACTTTGAAACCCACTGTACCCCATTATCTGTGGGGCCACAGCCCCTCTATG                   ACTTCACCTCCCAGTATGTGATGGAGACAGATTCGCTTTTCTTACACTACCTTCAAGA                   GGCTTCAGCCCGGCTTGACATACACCAGGCCATGGCCAGTGAACACAGCACTCTTGCT                   GCAGGATGGATTTGCTTTGACAGGGTGCTAGAGACTGTGGAGAAAGTCCATGGCTTGG                   CCACACTGATTGGTGCTGGTGGAGAAGAGTTCGGGGTTCTAGAGTACTGGATGAGGCT                   GCGTTTCCCCATAAAACCCAGCCTACAGGCGTGCAATAAACGAAAGAAAGCCCAGGTC                   TACCTGTCAACCGATGTGCTTGGAGGCCGGAAGGCCCAGGAAGAGGAGGTGAGATCGG                   AGTCTTGGGAACCTCAGAACGAGCTGTGGATTGAAATCACCAAGTGCTGTGGCCTCCG                   GAGTCGATGGCTGGGAACTCAACCCAGTCCATATGCTGTGTACCGCTTCTTCACCTTT                   TCTGACCATGACACTGCCATCATTCCAGCCAGTAACAACCCCTACTTTAGAGACCAGG                   CTCGATTCCCAGTGCTTGTGACCTCTGACCTGGACCATTATCTGAGACGGGAGGCCTT                   GTCTATACATGTTTTTGATGATGAAGACTTAGAGCCTGGCTCGTATCTTGGCCGAGCC                   CGAGTGCCTTTACTGCCTCTTGCAAAAAATGAATCTATCAAAGGTGATTTTAACCTCA                   CTGACCCTGCAGAGAAACCCAACGGATCTATTCAAGTGCAACTGGATTGGAAGTTTCC                   CTACATACCCCCTGAGAGCTTCCTGAAACCAGAAGCTCAGACTAAGGGGAAGGATACC                   AAGGACAGTTCAAAGATCTCATCTGAAGAGGAAAAGGCTTCATTTCCTTCCCAGGATC                   AGATGGCATCTCCTGAGGTTCCCATTGAAGCTGGCCAGTATCGATCTAAGAGAAAACC                   TCCTCATGGGGGAGAAAGAAAGGAGAAGGAGCACCAGGTTGTGAGCTACTCAAGAAGA                   AAACATGGCAAAAGAATAGGTGTTCAAGGAAAGAATAGAATGGAGTATCTTAGCCTTA                   ACATCTTAAATGGAAATACACTGAAGCAGGTGAATTACACTGAGTGGAAGTTCTCAGA                   GACTAACAGCTTCATAGGTGATGGCTTTAAAAATCAGCACGAGGAAGAGGAAATGACA                   TTATCCCATTCAGCACTGAAACAGAAGGAACCTCTACATCCTGTAAATGACAAAGAAT                   CCTCTGAACAAGGTTCTGAAGTCAGTGAAGCACAAACTACCGACAGTGATGATGTCAT                   AGTGCCACCCATGTCTCAGAAATATCCTAAGGCAGATTCAGAGAAGATGTGCATTGAA                   ATTGTCTCCCTGGCCTTCTACCCAGAGGCAGAAGTGATGTCTGATGAGAACATAAAAC                   AGGTGTATGTGGAGTACAAATTCTACGACCTACCCTTGTCGGAGACAGAGACTCCAGT                   GTCCCTAAGGAAGCCTAGGGCAGGAGAAGAAATCCACTTTCACTTTAGCAAGGTAATA                   GACCTGGACCCACAGGAGCAGCAAGGCCGAAGGCGGTTTCTGTTCGACATGCTGAATG                   GACAAGATCCTGATCAAGGACAGTTAAAGTTTACAGTGGTAAGTGATCCTCTGGATGA                   AGAAAAGAAAGAATGTGAAGAAGTGGGATATGCATATCTTCAACTGTGGCAGATCCTG                   GAGTCAGGAAGAGATATTCTAGAGCAAGAGCTAGACGTTGTTAGCCCTGAAGATCTGG                   CTACCCCAATAGGAAGGCTGAAGGTTTCCCTTCAAGCAGCTGCTGTCCTCCATGCTAT                   TTACAAGGAGATGACTGAAGATTTGTTTTCA TGA   AGGAACAA                                           ORF Start: ATG at 23       ORF Stop: TGA at 3686           SEQ ID NO:38   1221 aa   MW at 139825.2 kD                     NOV12a,   MFSGTLGKNMKTQPPLSRMNREELEDSFFRLREDHMLVKELSWKQQDEIKRLRTTLLR       CG57819-01 Protein           LTAAGRDLRVAEEAAPLSETARRGQKAGWRQRLSMHQRPQMHRLQGHFHCVGPASPRR                   AQPRVQVGHRQLHTAGAPVPEKPKRGRDRLSYTAPPSFKEHATNENRGEVASKPSELA                   HIMASNTMQVEEPPKSPEKMWPKDENFEQRSSLECAQKAAELRASIKEKVELIRLKKL                   LHERNASLVMTKAQLTEVQEVSCHLLTQNQGILSAAHEALLKQVNELRAELKEESKKA                   VSLKSQLEDVSILQMTLKEFQERVEDLEKERKLLNDNYDKLLESSDSSSQPHWSNELT                   AEQLQQQVSQLQDQLDAELEDKRKVLLELSREKAQNEDLKLEVTNILQKHKQEVELLQ                   NAATISQPPDRQSEPATHPAVLQENTQIQPSEPKNQEEKKLSQVLNELQVSHAETTLE                   LEKTRDMLILQRKINVCYQEELEAMMTKADNDNRDHKEKLERLTRLLDLKNNRIKQLE                   EQLKDVAYGTRPLSLCLETLPAHGDEDKVDISLLHQGENLFELHIHQAFLTSAALAQA                   GDTQPTTFCTYSFYDFETHCTPLSVGPQPLYDFTSQYVMETDSLFLHYLQEASARLDI                   HQAMASEHSTLAAGWICFDRVLETVEKVHGLATLIGAGGEEFGVLEYWMRLRFPIKPS                   LQACNKRKKAQVYLSTDVLGGRKAQEEEVRSESWEPQNELWIEITKCCGLRSRWLGTQ                   PSPYAVYRFFTFSDHDTAIIPASNNPYFRDQARFPVLVTSDLDHYLRREALSIHVFDD                   EDLEPGSYLGRARVPLLPLAKNESIKGDFNLTDPAEKPNGSIQVQLDWKFPYIPPESF                   LKPEAQTKGKDTKDSSKISSEEEKASFPSQDQMASPEVPIEAGQYRSKRKPPHGGERK                   EKEHQVVSYSRRKHGKRIGVQGKNRMEYLSLNILNGNTLKQVNYTEWKFSETNSFIGD                   GFKNQHEEEEMTLSHSALKQKEPLHPVNDKESSEQGSEVSEAQTTDSDDVIVPPMSQK                   YPKADSEKMCIEIVSLAFYPEAEVMSDENIKQVYVEYKFYDLPLSETETPVSLRKPRA                   GEEIHFHFSKVIDLDPQEQQGRRRFLFDMLNGQDPDQGQLKFTVVSDPLDEEKKECEE                   VGYAYLQLWQILESGRDILEQELDVVSPEDLATPIGRLKVSLQAAAVLHAIYKEMTED                   LFS                  
 
     [0385] Further analysis of the NOV12a protein yielded the following properties shown in Table 12B.  
               TABLE 12B                       Protein Sequence Properties NOV12a                                        PSort   0.9600 probability located in nucleus; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1000 probability located           in mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0386] A search of the NOV12a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12C.  
               TABLE 12C                          Geneseq Results for NOV12a                                             Identities/                   NOV12a   Similarities           Protein/   Residues/   for the       Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAM78558   Human protein   63 . . . 1219   400/1193    e−172           SEQ ID NO       (33%)           1220— Homo     47 . . . 1177   640/1193             sapiens , 1179 aa.       (53%)           [WO200157190-           A2, Aug. 9,           2001]       AAM79542   Human protein   63 . . . 1219   400/1193    e−172           SEQ ID NO       (33%)           3188— Homo     28 . . . 1158   640/1193             sapiens , 1160 aa.       (53%)           [WO200157190-           A2, Aug. 9,           2001]       AAM41414   Human poly-   63 . . . 1219   400/1193    e−172           peptide SEQ ID       (33%)           NO 6345— Homo     28 . . . 1158   640/1193             sapiens , 1160 aa.       (53%)           [WO200153312-           A1, Jul. 26, 2001]       AAM39628   Human poly-   118 . . . 1219    390/1138    e−171           peptide SEQ ID       (34%)           NO 2773— Homo     47 . . . 1126   623/1138             sapiens , 1128 aa.       (54%)           [WO200153312-           A1, Jul. 26, 2001]       AAG75661   Human colon   445 . . . 523    40/79    1e−13            cancer antigen       (50%)           protein SEQ ID   33 . . . 111    56/79            NO:6425— Homo         (70%)           sapiens, 118 aa.           [WO200122920-           A2, Apr. 5, 2001]                  
 
     [0387] In a BLAST search of public sequence databases, the NOV12a protein was found to have homology to the proteins shown in the BLASTP data in Table 12D.  
               TABLE 12D                          Public BLASTP Results for NOV12a                                             Identities/                   NOV12a   Similarities       Protein       Residues/   for the       Accession   Protein/   Match   Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q96KN7   RPGR-    7 . . . 1221   1203/1258   0.0           INTERACTING       (95%)           PROTEIN 1—   29 . . . 1286   1207/1258             Homo sapiens         (95%)           (Human), 1286 aa.       Q96QA8   RPGR-    7 . . . 1221   1203/1258   0.0           INTERACTING       (95%)           PROTEIN 1—   29 . . . 1286   1207/1258             Homo sapiens         (95%)           (Human), 1286 aa.       Q9GLM3   RPGR-    1 . . . 1221    922/1234   0.0           INTERACTING       (74%)           PROTEIN-1—    1 . . . 1221   1031/1234             Bos taurus         (82%)           (Bovine), 1221 aa.       Q9NR40   RPGR-   331 . . . 1221    883/902   0.0           INTERACTING       (97%)           PROTEIN—   1 . . . 902   888/902             Homo sapiens         (97%)           (Human), 902 aa.       Q9HBK6   RPGR-   471 . . . 1221    742/763   0.0           INTERACTING       (97%)           PROTEIN-1—   1 . . . 762   746/763                 Homo sapiens         (97%)           (Human), 762 aa.                  
 
     [0388] PFam analysis predicts that the NOV12a protein contains the domains shown in the Table 12E.  
               TABLE 12E                          Domain Analysis of NOV12a                                 NOV12a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value               PFEMP: domain   293 . . . 413   23/176 (13%)   7.9       1 of 1       82/176 (47%)       C2: domain   736 . . . 825   14/101 (14%)   1.4       1 of 1       54/101 (53%)                  
 
     Example 13  
     [0389] The NOV13 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 13A.  
               TABLE 13A                       NOV13 Sequence Analysis                                                SEQ ID NO:39   678 bp                     NOV13a,     TGGGGCGGGAGGC   ATG GTCTCCACCTACCGGGTGGCCGTGCTGGGGGCGCGAGGTGTG       CG57789-01 DNA Sequence           GGCAAGAGTGCCATCGTGCGCCAGTTCTTGTACAACGAGTTCAGCGAGGTCTGCGTCC                   CCACCACCGCCCGCCGCCTTTACCTGCCTGCTGTCGTCATGAACGGCCACGTGCACGA                   CCTCCAGATCCTCGACTTTCCACCCATCAGCGCCTTCCCTGTCAATACGCTCCAGGAG                   TGGGCAGACACCTGCTGCAGGGGACTCCGGAGTGTCCACGCCTACATCCTGGTCTACG                   ACATCTGCTGCTTTGACAGCTTTGAGTACGTCAAGACCATCCGCCAGCAGATCCTGGA                   GACGAGGGTGATCGGAACCTCAGAGACGCCCATCATCATCGTGGGCAACAAGCGGGAC                   CTGCAGCGCGGACGCGTGATCCCGCGCTGGAACGTGTCGCACCTGGTACGCAAGACCT                   GGAAGTGCGGCTACGTGGAATGCTCGGCCAAGTACAACTGGCACATCCTGCTGCTCTT                   CAGCGAGCTGCTCAAGAGCGTCGGCTGCGCCCGTTGCAAGCACGTGCACGCTGCCCTG                   CGCTTCCAGGGCGCGCTGCGCCGCAACCGCTGCGCCATCATG TGA   CGCCTGCGCGCCC                       CTCGGGCTGCACCGGCACTGGCCGAGCGGAGGGCGGGGCC                                           ORF Start: ATG at 14       ORF Stop: TGA at 623           SEQ ID NO:40   203 aa   MW at 23229.0 kD                     NOV13a,   MVSTYRVAVLGARGVGKSAIVRQFLYNEFSEVCVPTTARRLYLPAVVMNGHVHDLQIL       CG57789-01 Protein Sequence           DFPPISAFPVNTLQEWADTCCRGLRSVHAYILVYDICCFDSFEYVKTIRQQILETRVI                   GTSETPIIIVGNKRDLQRGRVIPRWNVSHLVRKTWKCGYVECSAKYNWHILLLFSELL                   KSVGCARCKHVHAALRFQGALRRNRCAIM                                     SEQ ID NO:41   682 bp                     NOV13b,     TGGGAGGC   ATG GTCTCCACCTACCGGGTGGCCGTGCTGGGGGCGCGAGGTGTGGGCAA       CG57789-02 DNA Sequence           GAGTGCCATCGTGCGCCAGTTCTTGTACAACGAGTTCAGCGAGGTCTGCGTCCCCACC                   ACCGCCCGCCGCCTTTACCTGCCTGCTGTCGTCATGAACGGCCACGTGCACGACCTCC                   AGATCCTCGACTTTCCACCCATCAGCGCCTTCCCTGTCAATACGCTCCAGGAGTGGGC                   AGACACCTGCTGCAGGGGACTCCGGAGTGTCCACGCCTACATCCTGGTCTACGACATC                   TGCTGCTTTGACAGCTTTGAGTACGTCAAGACCATCCGCCAGCAGATCCTGGAGACGA                   GGGTGATCGGAACCTCAGAGACGCCCATCATCATCGTGGGCAACAAGCGGGACCTGCA                   GCGCGGACGCGTGATCCCGCGCTGGAACGTGTCGCACCTGGTACGCAAGACCTGGAAG                   TGCGGCTACGTGGAATGCTCGGCCAAGTACAACTGGCACATCCTGCTGCTCTTCAGCG                   AGCTGCTCAAGAGCGTCGGCTGCGCCCGTTGCAAGCACGTGCACGCTGCCCTGCGCTT                   CCAGGGCGCGCTGCGCCGCAACCGCTGCGCCATCATG TGA   CGCCTGCGCGCCCCTCGG                       GCTGCACCGGCACTGGCCGAGCGGAGGGCACTGGCCGAGCGGAG                                           ORF Start: ATG at 9       ORF Stop: TGA at 618           SEQ ID NO:42   203 aa   MW at 23229.0 kD                     NOV13b,   MVSTYRVAVLGARGVGKSAIVRQFLYNEFSEVCVPTTARRLYLPAVVMNGHVHDLQIL       CG57789-02 Protein Sequence           DFPPISAFPVNTLQEWADTCCRGLRSVHAYILVYDICCFDSFEYVKTIRQQILETRVI                   GTSETPIIIVGNKRDLQRGRVIPRWNVSHLVRKTWKCGYVECSAKYNWHILLLFSELL                   KSVGCARCKHVHAALRFQGALRRNRCAIM                  
 
     [0390] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 13B.  
               TABLE 13B                          Comparison of NOV13a against NOV13b.                                 Protein   NOV13a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV13b   1 . . . 203   203/203 (100%)               1 . . . 203   203/203 (100%)                      
 
     [0391] Further analysis of the NOV13a protein yielded the following properties shown in Table 13C.  
               TABLE 13C                       Protein Sequence Properties NOV13a                                        PSort   0.6500 probability located in plasma membrane; 0.5064       analysis:   probability located in mitochondrial matrix space; 0.3844           probability located in microbody (peroxisome); 0.2556           probability located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0392] A search of the NOV13a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13D.  
               TABLE 13D                          Geneseq Results for NOV13a                                             Identities/                   NOV13a   Similarities           Protein/   Residues/   for the       Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB42840   Human ORFX   1 . . . 136   136/136   2e−75           ORF2604 poly-       (100%)            peptide sequence   1 . . . 136   136/136           SEQ ID NO:5208—       (100%)              Homo sapiens ,           136 aa.           [WO200058473-A2,           Oct. 5, 2000]       AAM41682   Human polypeptide   5 . . . 174    66/171   4e−18           SEQ ID NO 6613—       (38%)             Homo sapiens ,   15 . . . 173    189/171           206 aa.       (51%)           [WO200153312-A1,           Jul. 26, 2001]       AAM39896   Human polypeptide   5 . . . 174    66/171   4e−18           SEQ ID NO 3041—       (38%)             Homo sapiens ,   8 . . . 166    89/171           199 aa.       (51%)           [WO200153312-A1,           Jul. 26, 2001]       AAY99656   Human GTPase   5 . . . 173    59/179   3e−14           associated protein-       (32%)           7— Homo sapiens ,   25 . . . 191     87/179           281 aa.       (47%)           WO200031263-A2,           Jun. 2, 2000]       AAR05075   RAP1A Gene   5 . . . 177    57/175   5e-14           product       (32%)           incorporating at   4 . . . 165    90/175           least one peptide       (50%)           associated with ras           oncogene—           Synthetic, 184 aa.           [WO9000179-A,           Jan. 11, 1990]                  
 
     [0393] In a BLAST search of public sequence databases, the NOV13a protein was found to have homology to the proteins shown in the BLASTP data in Table 13E.  
               TABLE 13E                          Public BLASTP Results for NOV13a                                         NOV13a   Identities/           Protein       Residues/   Similarities       Accession   Protein/   Match   for the   Expect       Number   Organism/Length   Residues   Matched Portion   Value               Q96S79   RAS-LIKE   1 . . . 203   203/203 (100%)    e−118           PROTEIN/   1 . . . 203   203/203 (100%)           VTS58635—             Homo sapiens             (Human), 203 aa.       Q92737   Ras-like protein   1 . . . 203   105/204 (51%)    3e−50            RRP22 (RAS-   1 . . . 203   134/204 (65%)            related protein           on chromosome           22)— Homo               sapiens  (Human),           203 aa.       Q95KD9   HYPO-   5 . . . 174   66/171 (38%)   1e−17            THETICAL   8 . . . 166   89/171 (51%)           22.5 KDA           PROTEIN—             Macaca               fascicularis             (Crab eating           macaque)           (Cynomolgus           monkey), 199 aa.       Q96HU8   SIMILAR TO   5 . . . 174   66/171 (38%)   1e−17            CG8500 GENE   8 . . . 166   89/171 (51%)           PRODUCT—             Homo sapiens             (Human), 199 aa.       Q9NF75   EG:BACR37P7.8   5 . . . 174   61/174 (35%)   4e−16            PROTEIN—   48 . . . 210    88/174 (50%)             Drosophila               melanogaster             (Fruit fly),           306 aa.                  
 
     [0394] PFam analysis predicts that the NOV13a protein contains the domains shown in the Table 13F.  
               TABLE 13F                          Domain Analysis of NOV13a                                 NOV13a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value               Semialdhyde_dh:   4 . . . 14     4/11 (36%)   0.75       domain 1 of 1        11/11 (100%)       ras: domain 1 of 1   6 . . . 203   56/224 (25%)   1.2e−12               125/224 (56%)                   
 
     Example 14  
     [0395] The NOV14 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 14A.  
               TABLE 14A                       NOV14 Sequence Analysis                                                SEQ ID NO:43   1790 bp                     NOV14a,     TCTCCCTCCCGCGCG   ATG GCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCG       CG57758-01 DNA Sequence           TGATCTTGTTCGTCACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAA                   GGTCAGTTGTGCCTACGTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATC                   CCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGG                   ACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCCTGGGCGG                   CCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGC                   ACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCA                   CAGCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCAT                   CGTGGAGGCCATATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTG                   GAGCTGGTGGACAAGGGCAAGGCCAAGGAGCTGCCAGGGAGTCAAGTGATTTTTGAAG                   GCCCCACTCTGGGGCAGCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGAC                   CCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGA                   CCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCG                   TGAACTTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTT                   CGCCTGGCTGTGGCTCCAGTTTGTTTACATGTTCTCCAGTTTTAAAAAGTCCTGGGGC                   TGCGGGCTAGAGAGCAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGT                   ACCGGAAGCTGGGGCCCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCT                   GCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTT                   GCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTGTGG                   CCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGAC                   TGAGGAAGGTAAGTCTCCTGTTCTGATCGCCCCCCCTCCCCTGCTGGATTGGAAGGTA                   ACCCAGGAGAAAGTGCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGG                   CTAAAGGATCCGAGGCCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTT                   GCACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTC                   ACTGAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCA                   TGTCTCGCTCCATCGGCCTCAATCCGCTGTACATCATGCTGCCCTGTACCCTGAGTGC                   CTCCTTTGCCTTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTAT                   GGGCACCTCAAGGTTGCTGACATGGTGAAAACAGGAGTCATAATGAACATAATTGGAG                   TCTTCTGTGTGTTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCA                   TTTCCCTGACTGGGCTAATGTGACACATATTGAGACT TAG   GAAGAGCCACAAGACCAC                       ACACACAGCCCTTACCCTCCTCAGGACTACCGAACCTTCTGGCACACCTT                                           ORF Start: ATG at 16       ORF Stop: TAG at 1720           SEQ ID NO:44   568 aa   MW at 62592.9 kD                     NOV14a,   MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVSCAYVIILMAIYWCTEVIPLAVT       CG57758-01 Protein Sequence           SLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWV                   GAKPARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDK                   GKAKELPGSQVIFEGPTLGQQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVL                   LGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMFSSFKKSWGCGLES                   KKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEG                   ETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKV                   PWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTS                   NVATTTLFLPIFASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKV                   ADMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIET                                     SEQ ID NO:45   1899 bp                     NOV14b,     CGTCTCGCCCGCCAGTCTCCCTCCCGCGCG   ATG GCCTCGGCGCTGAGCTATGTCTCCA       CG57758-02 DNA Sequence           AGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCCTGCTGCTGCCACTCGTCAT                   TCTGATGCCCGCCAAGGTCAGTTGCTGTGCCTACGTCATCATCCTCATGGCCATTTAC                   TGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCC                   CACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAA                   CATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCAC                   AAGAGGATCGCCCTGCGCACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGC                   TGGGCTTCATGGGCGTCACAGCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCAC                   GGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGATGGAAGCCACAAGCGCA                   GCCACCGAGGCCGGCCTGGAGGGACAAGGTACCACAATAAACAACCTGAATGCACTGG                   AGGATGATACAGTGAAAGCAGTACTAGGAGGAAAGTGTGTAGCTATAATAAGCACTTA                   CGTCAAAAAAGTAGAAAAACTTCAAATAAACAATCTAATGACACCTCTTAAAAAACTA                   GAAAAGCAAGAGCAACAGGACCTAGGGCCTGGCATCAGGCCTCAGGACTCTGCCCAGT                   GCCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTA                   CGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGTGCTC                   CTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCTTCCT                   GGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCT                   CCAGTTTGTTTACATGTTCTCCAGTTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGC                   AAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGCTGGGGC                   CCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTG                   GTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGAGGGT                   GAGACAAAGTCAGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTATTCA                   TTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGGTAAGTC                   TCCTGTTCTGATCGCCCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTG                   CCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGG                   CCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCC                   GGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAGC                   AACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGTCTCGCTCCATCG                   GCCTCAATCCGCTGTACATCATGCTGCCCTGTACCCTGAGTGCCTCCTTTGCCTTCAT                   GTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTCAAGGTT                   GCTGACATGGTAAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTT                   TGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGC                   TAATGTGACACATATTGAGACT TAG   GAAGAGCCACAAGACCAC                                           ORF Start: ATG at 31       ORF Stop: TAG at 1879           SEQ ID NO:46   616 aa   MW at 67816.9 kD                     NOV14b,   MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVSCCAYVIILMAIYWCTEVIPLAV       CG57758-02 Protein Sequence           TSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLW                   VGAKPARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLEGQG                   TTINNLNALEDDTVKAVLGGKCVAIISTYVKKVEKLQINNLMTPLKKLEKQEQQDLGP                   GIRPQDSAQCQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPD                   SKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMFSSFKKSWGCGLESKKNEKAALKV                   LQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKSVSDATV                   AIFVATLLFIVPSQKPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKVPWGIVLLLGG                   GFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLP                   IFASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIM                   NIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIET                                     SEQ ID NO:47   1899 bp                     NOV14c,     CGTCTCGCCCGCCAGTCTCCCTCCCGCGCG   ATG GCCTCGGCGCTGAGCTATGTCTCCA       CG57758-03 DNA Sequence           AGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCCTGCTGCTGCCACTCGTCAT                   TCTGATGCCCGCCAAGGTCAGTTGCTGTGCCTACGTCATCATCCTCATGGCCATTTAC                   TGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCC                   CACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAA                   CATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCAC                   AAGAGGATCGCCCTGCGCACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGC                   TGGGCTTCATGGGCGTCACAGCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCAC                   GGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGATGGAAGCCACAAGCGCA                   GCCACCGAGGCCGGCCTGGAGGGACAAGGTACCACAATAAACAACCTGAATGCACTGG                   AGGATGATACAGTGAAAGCAGTACTAGGAGGAAAGTGTGTAGCTATAATAAGCACTTA                   CGTCAAAAAAGTAGAAAAACTTCAAATAAACAATCTAATGACACCTCTTAAAAAACTA                   GAAAAGCAAGAGCAACAGGACCTAGGGCCTGGCATCAGGCCTCAGGACTCTGCCCAGT                   GCCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTA                   CGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGTGCTC                   CTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCTTCCT                   GGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCT                   CCAGTTTGTTTACATGTTCTCCAGTTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGC                   AAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGCTGGGGC                   CCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTG                   GTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGAGGGT                   GAGACAAAGTCAGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTATTCA                   TTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGGTAAGTC                   TCCTGTTCTGATCGCCCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTG                   CCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGG                   CCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCC                   GGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAGC                   AACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGTCTCGCTCCATCG                   GCCTCAATCCGCTGTACATCATGCTGCCCTGTACCCTGAGTGCCTCCTTTGCCTTCAT                   GTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTCAAGGTT                   GCTGACATGGTAAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTT                   TGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGC                   TAATGTGACACATATTGAGACT TAG   GAAGAGCCACAAGACCAC                                           ORF Start: ATG at 31       ORF Stop: TAG at 1879           SEQ ID NO:48   616 aa   MW at 67816.9 kD                     NOV14c,   MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVSCCAYVIILMAIYWCTEVIPLAV       CG57758-03 Protein Sequence           TSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLW                   VGAKPARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLEGQG                   TTINNLNALEDDTVKAVLGGKCVAIISTYVKKVEKLQINNLMTPLKKLEKQEQQDLGP                   GIRPQDSAQCQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPD                   SKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMFSSFKKSWGCGLESKKNEKAALKV                   LQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKSVSDATV                   AIFVATLLFIVPSQKPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKVPWGIVLLLGG                   GFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLP                   IFASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIM                   NIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIET                                     SEQ ID NO:49   1606 bp                     NOV14d,     G   ATG GCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTC       CG57758-04 DNA Sequence           ACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGTTTGTCAGGTGTG                   CCTACGTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGT                   CACCTCTCTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAG                   GTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCCTGGGCGGCCTCATCGTGG                   CCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACGCTCCTCTG                   GGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTG                   TCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCA                   TATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGA                   CAAGGGCAAGGCCAAGGAGCTGCCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTG                   GGGCAGCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCT                   GCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGT                   GCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCT                   TCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGT                   GGCTCCAGTTTGTTTACATGAGATTCAATTTTAAAAAGTCCTGGGGCTGCGGGCTAGA                   GAGCAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGTTG                   GGGCCCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCC                   TGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGA                   GGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTA                   TTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGAAA                   GGAAAACTCCATTTTATCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGT                   GCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAG                   GCCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCC                   CGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAG                   CAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGGTGAAAACAGGA                   GTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGTCAACACCTGGGGAC                   GGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAATGTGACACATATTGAGAC                   T TAG   GAAGAGCCACAAGACCACACACATAGCCCTTACCCT                                           ORF Start: ATG at 2       ORF Stop: TAG at 1568           SEQ ID NO:50   522 aa   MW at 58109.6 kD                     NOV14d,   MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAV       CG57758-04 Protein Sequence           TSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLW                   VGAKPARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVD                   KGKAKELPGSQVIFEGPTLGQQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVV                   LLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMRFNFKKSWGCGLE                   SKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVE                   GETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKV                   PWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTS                   NVATTTLFLPIFASMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIET                                     SEQ ID NO:51   1781 BP                     NOV14e,     G   ATG GCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTC       CG57758-05 DNA Sequence           ACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGTTTGTCAGGTGTG                   CCTACGTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGT                   CACCTCTCTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAG                   GTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCCTGGGCGGCCTCATCGTGG                   CCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACGCTCCTCTG                   GGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTG                   TCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCA                   TATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGA                   CAAGGGCAAGGCCAAGGAGCTGCCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTG                   GGGCAGCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCT                   GCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGT                   GCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCT                   TCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGT                   GGCTCCAGTTTGTTTACATGAGATTCAATTTTAAAAAGTCCTGGGGCTGCGGGCTAGA                   GAGCAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGTTG                   GGGCCCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCC                   TGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGA                   GGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTA                   TTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGAAA                   GGAAAACTCCATTTTATCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGT                   GCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAG                   GCCTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCC                   CGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAG                   CAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGAATCACGTCCCC                   AAGAGCTTCTGTGTTCTGTACGGTGATGTTGCAGTGCTGTCTTTCCGCAGTCTCGCTC                   CATCGGCCTCAATCCGCTGTACATCATGCTGCCCTGTACCC TGA   GTGCCTCCTTTGCC                       TTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTCA                       AGGTTGCTGACATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGT                       GTTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGAC                       TGGGCTAATGTGACACATATTGAGACTTAGGAAGAGCCACA                                           ORF Start: ATG at 2       ORF Stop: TGA at 1550           SEQ ID NO:52   516 aa   MW at 57173.5 kD                     NOV14e,   MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVILMAIYWCTEVIPLAV       CG57758-05 Protein Sequence           TSLMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLW                   VGAKPARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVD                   KGKAKELPGSQVIFEGPTLGQQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVV                   LLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMRFNFKKSWGCGLE                   SKKNEKAALEVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVE                   GETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKV                   PWGIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTS                   NVATTTLFLPIFAS                  
 
     [0396] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 14B.  
               TABLE 14B                          Comparison of NOV14a against NOV14b through NOV14e.                                 Protein   NOV14a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV14b   1 . . . 568   519/616 (84%)               1 . . . 616   524/616 (84%)           NOV14c   1 . . . 568   519/616 (84%)               1 . . . 616   524/616 (84%)           NOV14d   1 . . . 568   483/570 (84%)               1 . . . 522   485/570 (84%)           NOV14e   1 . . . 480   440/482 (91%)               1 . . . 480   443/482 (91%)                      
 
     [0397] Further analysis of the NOV14a protein yielded the following properties shown in Table 14C.  
               TABLE 14C                       Protein Sequence Properties NOV14a                                        PSort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability located           in endoplasmic reticulum (membrane); 0.1000 probability           located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 38 and 39       analysis:                  
 
     [0398] A search of the NOV14a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14D.  
               TABLE 14D                          Geneseq Results for NOV14a                                             Identities/                   NOV14a   Similarities           Protein/   Residues/   for the       Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB23625   Human secreted   10 . . . 566    256/623   e−137           protein SEQ ID NO:       (41%)           50— Homo sapiens ,   9 . . . 623   386/623           627 aa.       (61%)           [WO200049134-A1,           Aug. 24, 2000]       AAB36158   Novel human   10 . . . 566    256/623   e−137           transporter protein       (41%)           SEQ ID NO: 2—   9 . . . 623   386/623             Homo sapiens ,       (61%)           627 aa.           [WO200065055-A2,           Nov. 2, 2000]       AAB42213   Human ORFX   10 . . . 566    256/623   e−136           ORF1977 poly-       (41%)           peptide sequence   9 . . . 623   386/623           SEQ ID NO:       (61%)           3954— Homo               sapiens , 627 aa.           [WO200058473-A2,           Oct. 5, 2000]       AAB36164   Novel human   10 . . . 566    252/623   e−136           transporter protein       (40%)           SEQ ID NO: 14—   9 . . . 622   382/623             Homo sapiens ,       (60%)           626 aa.           [WO200065055-A2,           Nov. 2, 2000]       AAB36159   Novel human   10 . . . 566    256/623   e−136           transporter protein       (41%)           SEQ ID NO: 4—   9 . . . 623   385/623             Homo sapiens ,       (61%)           627 aa.           [WO200065055-A2,           Nov. 2, 2000]                  
 
     [0399] In a BLAST search of public sequence databases, the NOV14a protein was found to have homology to the proteins shown in the BLASTP data in Table 14E.  
               TABLE 14E                          Public BLASTP Results for NOV14a                                         NOV14a   Identities/           Protein       Residues/   Similarities       Accession   Protein/   Match   for the   Expect       Number   Organism/Length   Residues   Matched Portion   Value               O57661   INTESTINAL   1 . . . 564   336/619 (54%)   0.0           SODIUM/   1 . . . 619   444/619 (71%)           LITHIUM           DEPENDENT DI-           CARBOXYLATE           TRANSPORTER           (NA(+)/DI-           CARBOXYLATE           COTRANS-           PORTER)—             Xenopus laevis             (African clawed           frog), 622 aa.       Q9ES88   NA/DICARB-   1 . . . 561   311/572 (54%)   e−179           OXYLATE CO-   1 . . . 567   421/572 (73%)           TRANSPORTER           (SOLUTE           CARRIER           FAMILY 13           (SODIUM-           TRANSPORTER),           MEMBER 2)—             Mus musculus             (Mouse), 586 aa.       O35055   SODIUM/DI-   1 . . . 562   311/572 (54%)   e−179           CARBOXYLATE   1 . . . 568   419/572 (72%)           COTRANS-           PORTER 1           (NA(+)/DI-           CARBOXYLATE           COTRANS-           PORTER 1)           (KIDNEY DI-           CARBOXYLATE           TRANSPORTER)           (SDCT1)           (ORGANIC ANION           TRANSPORTER 1)           (OAT1)— Rattus               norvegicus  (Rat),           587 aa.       Q13183   Renal sodium/   1 . . . 561   318/581 (54%)   e−179           dicarboxylate   1 . . . 572   428/581 (72%)           cotransporter           (Na(+)/           dicarboxylate           cotransporter)—             Homo sapiens             (Human), 592 aa.       Q28615   Renal sodium/   1 . . . 562   300/586 (51%)   e−172           dicarboxylate   1 . . . 576   418/586 (71%)           cotransporter           (Na(+)/           dicarboxylate           cotransporter)—             Oryctolagus               cuniculus  (Rabbit),           593 aa.                  
 
     [0400] PFam analysis predicts that the NOV14a protein contains the domains shown in the Table 14F.  
               TABLE 14F                          Domain Analysis of NOV14a                                 NOV14a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value               Na_sulph_symp:   6 . . . 554   163/604 (27%)   8.3e−140       domain 1 of 1       424/604 (70%)                  
 
     Example 15  
     [0401] The NOV15 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 15A.  
               TABLE 15A                       NOV15 Sequence Analysis                                                SEQ ID NO:53   1547 bp                     NOV15a,     AACCCCCTTGACTGAAGCA   ATG GAGGGGGGTCCAGCTGTCTGCTGCCAGGATCCTCGG       CG57732-01 DNA Sequence           GCAGAGCTGGTAGAACGGGTGGCAGCCATCGATGTGACTCACTTGGAGGAGGCAGATG                   GTGGCCCAGAGCCTACTAGAAACGGTGTGGACCCCCCACCACGGGCCAGAGCTGCCTC                   TGTGATCCCTGGCAGTACTTCAAGACTGCTCCCAGCCCGGCCTAGCCTCTCAGCCAGG                   AAGCTTTCCCTACAGGAGCGGCCAGCAGGAAGCTATCTGGAGGCGCAGGCTGGGCCTT                   ATGCCACGGGGCCTGCCAGCCACATCTCCCCCCGGGCCTGGCGGAGGCCCACCATCGA                   GTCCCACCACGTGGCCATCTCAGATGCAGAGGACTGCGTGCAGCTGAACCAGTACAAG                   CTGCAGAGTGAGATTGGCAAGGGTGCCTACGGTGTGGTGAGGCTGGCCTACAACGAAA                   GTGAAGACAGACACTATGCAATGAAAGTCCTTTCCAAAAAGAAGTTACTGAAGCAGTA                   TGGCTTTCCACGTCGCCCTCCCCCGAGAGGGTCCCAGGCTGCCCAGGGAGGACCAGCC                   AAGCAGCTGCTGCCCCTGGAGCGGGTGTACCAGGAGATTGCCATCCTGAAGAAGCTGG                   ACCACGTGAATGTGGTCAAACTGATCGAGGTACTGGATGACCCAGCTGAGGACAACCT                   CTATTTGCCCCGCATCCTTCTCCATAGGCCCGTCATGGAAGTGCCCTGTGACAAGCCC                   TTCTCGGAGGAGCAAGCTCGCCTCTACCTGCGGGACGTCATCCTGGGCCTCGAGTACG                   TGCACTGCCAGAAGATCGTCCACAGGGACATCAAGCCATCCAACCTGCTCCTGGGGGA                   TGATGGGCACGTGAAGATCGCCGACTTTGGCGTCAGCAACCAGTTTGAGGGGAACGAC                   GCTCAGCTGTCCAGCACGGCGGGAACCCCAGCATTCATGGCCCCCGAGGCCATTTCTG                   ATTCCGGCCAGAGCTTCAGTGGGAAGTTGGATGTATGGGCCACTGGCGTCACGTTGTA                   CTGCTTTGTCTATGGGAAGTGCCCATTCATCGACGATTTCATCCTGGCCCTCCACAGG                   AAGATCAAGAATGAGCCCGTGGTGTTTCCTGAGGAGCCAGAAATCAGCGAGGAGCTCA                   AGGACCTGATCCTGAAGATGTTAGACAAGAATCCCGAGACGAGAATTGGGGTGCCAGA                   CATCAAGTTGCACCCTTGGGTGACCAAGAACGGGGAGGAGCCCCTTCCTTCGGAGGAG                   GAGCACTGCAGCGTGGTGGAGGTGACAGAGGAGGAGGTTAAGAACTCAGTCAGGCTCA                   TCCCCAGCTGGACCACGGTGATCCTGGTGAAGTCCATGCTGAGGAAGCGTTCCTTTGG                   GAACCCGTTTGAGCCCCAAGCACGGAGGGAAGAGCGATCCATGTCTGCTCCAGGAAAC                   CTACTGGTGAAAGAAGGGTTTGGTGAAGGGGGCAAGAGCCCAGAGCTCCCCGGCGTCC                   AGGAAGACGAGGCTGCATCC TGA   GCCCCTGCATGCACCC                                           ORF Start: ATG at 20       ORF Stop: TGA at 1529           SEQ ID NO:54   503 aa   MW at 55606.7 kD                     NOV15a,   MEGGPAVCCQDPRAELVERVAAIDVTHLEEADGGPEPTRNGVDPPPRARAASVIPGST       CG57732-01 Protein Sequence           SRLLPARPSLSARKLSLQERPAGSYLEAQAGPYATGPASHISPRAWRRPTIESHHVAI                   SDAEDCVQLNQYKLQSEIGKGAYGVVRLAYNESEDRHYAMKVLSKKKLLKQYGFPRRP                   PPRGSQAAQGGPAKQLLPLERVYQEIAILKKLDHVNVVKLIEVLDDPAEDNLYLPRIL                   LERPVMEVPCDKPFSEEQARLYLRDVILGLEYVHCQKIVHRDIKPSNLLLGDDGHVKI                   ADFGVSNQFEGNDAQLSSTAGTPAFMAPEAISDSGQSFSGKLDVWATGVTLYCFVYGK                   CPFIDDFILALHRKIKNEPVVFPEEPEISEELKDLILKMLDKNPETRIGVPDIKLHPW                   VTKNGEEPLPSEEEHCSVVEVTEEEVKNSVRLIPSWTTVILVKSMLRKRSFGNPFEPQ                   ARREERSMSAPGNLLVKEGFGEGGKSPELPGVQEDEAAS                                     SEQ ID NO:55   1611 bp                     NOV15b,     GCGCCCAGGTTCCCAACAAGGCTACGCAGAAGAACCCCCTTGACTGAAGCA ATG GAGG         CG57732-02 DNA Sequence           GGGGTCCAGCTGTCTGCTGCCAGGATCCTCGGGCAGAGCTGGTAGAACGGGTGGCAGC                   CATCGATGTGACTCACTTGGAGGAGGCAGATGGTGGCCCAGAGCCTACTAGAAACGGT                   GTGGACCCCCCACCACGGGCCAGAGCTGCCTCTGTGATCCCTGGCAGTACTTTAAGAC                   TGCTCCCAGCCCGGCCTAGCCTCTCAGCCAGGAAGCTTTCCCTACAGGAGCGGCCAGC                   AGGAAGCTATCTGGAGGCGCAGGCTGGGCCTTATGCCACGGGGCCTGCCAGCCACATC                   TCCCCCCGGGCCTGGCGGAGGCCCACCATCGAGTCCCACCACGTGGCCATCTCAGATG                   CAGAGGACTGCGTGCAGCTGAACCAGTACAAGCTGCAGAGTGAGATTGGCAAGGGTGC                   CTACGGTGTGGTGAGGCTGGCCTACAACGAAAGTGAAGACAGACACTATGCAATGAAA                   GTCCTTTCCAAAAAGAAGTTACTGAAGCAGTATGGCTTTCCACGTCGCCCTCCCCCGA                   GAGGGTCCCAGGCTGCCCAGGGAGGACCAGCCAAGCAGCTGCTGCCCCTGGAGCGGGT                   GTACCAGGAGATTGCCATCCTGAAGAAGCTGGACCACGTGAATGTGGTCAAACTGATC                   GAGGTCCTGGATGACCCAGCTGAGGACAACCTCTATTTGGTGTTTGACCTCCTGAGAA                   AGGGGCCCGTCATGGAAGTGCCCTGTGACAAGTCCTTCTCGGAGGAGCAAGCTCGCCT                   CTACCTGCGGGACGTCATCCTGGGCCTCGAGTACTTGCACTGCCAGAAGATCSTCCAC                   AGGGACATCAAGCCATCCAACCTGCTCCTGGGGGATGATGGGCACGTGAAGATCGCCG                   ACTTTGGCGTCAGCAACCAGTTTGAGGGGAACGACGCTCAGCTGTCCAGCACGGCGGG                   AACCCCAGCATTCATGGCCCCCGAGGCCATTTCTGATTCCGGCCAGAGCTTCAGTGGG                   AAGGCCTTGGATGTATGGGCCACTGGCGTCACGCTGTACTGCTTTGTCTATGGGAAGT                   GCCCGTTCATCGACGATTTCATCCTGGCCCTCCACAGGAAGATCAAGAATGAGCCCGT                   GGTGTTTCCTGAGGGGCCAGAAATCAGCGAGGAGCTCAAGGACCTGATCCTGAAGATG                   ATCCTGGTGAAGTCCATGCTGAGGAAGCGTTCCTTTGGGAACCCGTTTGAGCCCCAAG                   CACGGAGGGAAGAGCGATCCATGTCTGCTCCAGGAAACCTACTGGTGAAAGAAGGGTT                   TGGTGAAGGGGGCAAGAGCCCAGAGCTCCCCGGCGTCCAGGAAGACGAGGCTGCATCC                     TGA   GCCCCTGCATGCACCCAGGGCCACCCGGCAGCACACTCATCC                                           ORF Start: ATG at 52       ORF Stop: TGA at 1567           SEQ ID NO:56   505 aa   MW at 55652.7 kD                     NOV15b,   MEGGPAVDDQDPRAELVERVAAIDVTHLEEADGGPEPTRNGVDPPPRARAASVIPGST       CG57732-02 Protein Sequence           SRLLPARPSLSARKLSLQERPAGSYLEAQAGPYATGPASHISPRAWRRPTIESHHVAI                   SDAEDCVQLNQYKLQSEIGKGAYGVVRLAYNESEDRHYAMKVLSKKKLLKQYGFPRRP                   PPRGSQAAQGGPAEQLLPLERVYQEIAILKKLDHVNVVKLIEVLDDPAEDNLYLVFDL                   LRKGPVMEVPCDKSFSEEQARLYLRDVILGLEYLHCQKIVHRDIKPSNLLLGDDGHVK                   IADFGVSNQFEGNDAQLSSTAGTPAFMAPEAISDSGQSFSGKALDVWATGVTLYCFVY                   GKCPFIDDFILALHRKIKNEPVVFPEGPEISEELKDLILKMLDKNPETRIGVPDIKLH                   PWVTKNGEEPLPSEEEHCSVVEVTEEEVKNSVRLIPSWTTVILVKSMLRKRSFGNPPE                   PQARREERSMSAPGNLLVKEGFGEGGKSPELPGVQEDEAAS                                     SEQ ID NO:57   1725 bp                     NOV15c,     GCGCCCAGGTTCCCAACAAGGCTACGCAGAAGAACCCCCTTGACTGAAGTA   ATG GAGG       CG57732-03 DNA Sequence           GGGGTCCAGCTGTCTGCTGCCAGGATCCTCGGGCAGAGCTGGTAGAACGGGTGGCAGC                   CATCGATGTGACTCACTTGGAGGAGGCAGATGGTGGCCCAGAGCCTACTAGAAACGGT                   GTGGACCCCCCACCACGGGCCAGAGCTGCCTCTGTGATCCCTGGCAGTACTTCAAGAC                   TGCTCCCAGCCCGGCCTAGCCTCTCAGCCAGGAAGCTTTCCCTACAGGAGCGGCCAGC                   AGGAAGCTATCTGGAGGCGCAGGCTGGGCCTTATGCCACGGGGCCTGCCAGCCACATC                   TCCCCCCGGGCCTGGCGGAGGCCCACCATCGAGTCCCACCACGTGGCCATCTCAGATG                   CAGAGGACTGCGTGCAGCTGAACCAGTACAAGCTGCAGAGTGAGATTGGCAAGGGTGC                   CTACGGTGTGGTGAGGCTGGCCTACAACGAAAGTGAAGACAGACACTATGCAATGAAA                   GTCCTTTCCAAAAAGAAGTTACTGAAGCAGTATGGCTTTCCACGTCGCCCTCCCCCGA                   GAGGGTCCCAGGCTGCCCAGGGAGGACCAGCCAAGCAGCTGCTGCCCCTGGAGCGGGT                   GTACCAGGAGATTGCCATCCTGAAGAAGCTGGACCACGTGAATGTGGTCAAACTGATC                   GAGGTCCTGGATGACCCGGCTGAGGACAACCTCTATTTGGCCCTGCAGAACCAGGCCC                   AGAATATCCAGTTAGATTCAACAAATATCGCCAAGTCCCACTCCCTGCTTCCCTCTGA                   GCAGCAAGACAGTGGATCCACGTGGGCTGCGCGCTCAGTGTTTGACCTCCTGAGAAAG                   GGGCCCGTCATGGAAGTGCCCTGTGACAAGCCCTTCTCGGAGGAGCAAGCTCGCCTCT                   ACCTGCGGGACGTCATCCTGGGCCTCGAGTACTTGCACTGCCAGAAGATCGTCCACAG                   GGACATCAAGCCATCCAACCTGCTCCTGGGGGATGATGGGCACGTGAAGATCGCCGAC                   TTTGGCGTCAGCAACCAGTTTGAGGGGAACGACGCTCAGCTGTCCAGCACGGCGGGAA                   CCCCAGCATTCATGGCCCCCGAGGCCATTTCTGATTCCGGCCAGAGCTTCAGTGGGAA                   GGCCTTGGATGTATGGGCCACTGGCGTCACGTTGTACTGCTTTGTCTATGGGAAGTGC                   CCGTTCATCGACGATTTCATCCTGGCCCTCCACAGGAAGACCAAGAATGAGCCCGTGG                   TGTTTCCTGAGGGGCCAGAAATCAGCGAGGAGCTCAAGGACCTGATCCTGAAGATGTT                   AGACAAGAATCCCGAGACGAGAATTGGGGTGCCAGACATCAAGTTGCACCCTTGGGTG                   ACCAAGAACGGGGAGGAGCCCCTTCCTTCGGAGGAGGAGCACTGCAGCGTGGTGGAGG                   TGACAGAGGAGGAGGTTAAGAACTCAGTCAGGCTCATCCCCAGCTGGACCACGGTGAT                   CCTGGTGAAGTCCATGCTGAGGAAGCGTTCCTTTGGGAACCCGTTTGAGCCCCAAGCA                   CGGAGGGAAGAGCGATCCATGTCTGCTCCAGGAAACCTACTGGTGAAAGAAGGGTTTG                   GTGAAGGGGGCAAGAGCCCAGAGCTCCCCGGCGTCCAGGAAGACGAGGCTGCATCCTG                   A GCCCCTGCATGCACCCAGGGCCACCCGGCAGCACACTCATCC                                           ORF Start: ATG at 52       ORF Stop: TGA at 1681           SEQ ID NO:58   543 aa   MW at 59729.0 kD                     NOV15c,   MEGGPAVCCQDPRAELVERVAAIDVTHLEEADGGPEPTRNGVDPPPRARAASVIPGST       CG57732-03 Protein Sequence           SRLLPARPSLSARKLSLQERPAGSYLEAQAGPYATGPASHISPRAWRRPTIESHHVAI                   SDAEDCVQLNQYKLQSEIGKGAYGVVRLAYNESEDRHYAMKVLSKKKLLKQYGFPRRP                   PPRGSQAAQGGPAKQLLPLERVYQEIAILKKLDHVNVVKLIEVLDDPAEDNLYLALQN                   QAQNIQLDSTNIAKSHSLLPSEQQDSGSTWAARSVFDLLRKGPVMEVPCDKPFSEEQA                   RLYLRDVILGLEYLHCQKIVHRDIKPSNLLLGDDGHVKIADFGVSNQFEGNDAQLSST                   AGTPAFMAPEAISDSGQSFSGKALDVWATGVTLYCFVYGKCPPIDDFILALHRKTKNE                   PVVFPEGPEISEELKDLILKMLDKNPETRIGVPDIKLHPWVTKNGEEPLPSEEEHCSY                   VEVTEEEVKNSVRLIPSWTTVILVKSMLRKRSFGNPFEPQARREERSMSAPGNLLVKE                   GFGEGGKSPELPGVQEDEAAS                  
 
     [0402] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 15B.  
               TABLE 15B                          Comparison of NOV15a against NOV15b through NOV15c.                                 Protein   NOV15a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV15b   1 . . . 503   495/505 (98%)               1 . . . 505   497/505 (98%)           NOV15c   1 . . . 503   492/543 (90%)               1 . . . 543   495/543 (90%)                      
 
     [0403] Further analysis of the NOV15a protein yielded the following properties shown in Table 15C.  
               TABLE 15C                       Protein Sequence Properties NOV15a                                        PSort   0.7600 probability located in nucleus; 0.3000 probability located in       analysis:   microbody (peroxisome); 0.1000 probability located in mitochondrial           matrix space; 0.1000 probability located in lysosome (lumen)               SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0404] A search of the NOV15a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15D.  
               TABLE 15D                          Geneseq Results for NOV15a                                             Identities/                   NOV15a   Similarities           Protein/   Residues/   for the       Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAU03510   Human protein    1 . . . 503   496/513   0.0           kinase #10— Homo         (96%)             sapiens , 513 aa.    1 . . . 513   498/513           [WO200138503-A2,       (96%)           May 31, 2001]       AAE04361   Human kinase    1 . . . 503   496/513   0.0           (PKIN)-2— Homo         (96%)             sapiens , 513 aa.    1 . . . 513   498/513           [WO200146397-A2,       (96%)           Jun. 28, 2001]       AAY44239   Human cell    64 . . . 500   289/450   e−165           signalling protein-       (64%)           2— Homo sapiens ,    90 . . . 538   367/450           540 aa.       (81%)           [WO9958558-A2,           Nov. 18, 1999]       AAM40450   Human polypeptide    64 . . . 482   283/432   e−162           SEQ ID NO 5381—       (65%)             Homo sapiens ,   128 . . . 558   356/432           680 aa.       (81%)           [WO200153312-A1,           Jul. 26, 2001]       AAM40449   Human polypeptide    64 . . . 482   283/432   e−162           SEQ ID NO 5380—       (65%)             Homo sapiens ,   128 . . . 558   356/432           680 aa.       (81%)           [WO200153312-A1,           Jul. 26, 2001]                  
 
     [0405] In a BLAST search of public sequence databases, the NOV15a protein was found to have homology to the proteins shown in the BLASTP data in Table 15E.  
               TABLE 15E                          Public BLASTP Results for NOV15a                                         NOV15a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9BQH3   HYPOTHETICAL   1 . . . 503   497/505 (98%)   0.0           55.7 KDA   1 . . . 505   499/505 (98%)           PROTEIN— Homo               sapiens  (Human),           505 aa.       P97756   CA2+/   1 . . . 503   465/505 (92%)   0.0           CALMODULIN-   1 . . . 505   478/505 (94%)           DEPENDENT           PROTEIN KINASE           IV KINASE           ISOFORM— Rattus               norvegicus  (Rat),           505 aa.       AAH17529   SIMILAR TO   1 . . . 503   464/505 (91%)   0.0           CALCIUM/   1 . . . 505   478/505 (93%)           CALMODULIN-           DEPENDENT           PROTEIN KINASE           KINASE 1,           ALPHA— Mus               musculus  (Mouse),           505 aa.       Q64572   CA2+/   1 . . . 503   463/505 (91%)   0.0           CALMODULIN-   1 . . . 505   476/505 (93%)           DEPENDENT           PROTEIN KINASE           KINASE (EC           2.7.1.37)— Rattus               norvegicus  (Rat),           505 aa.       Q9R054   CALCIUM/   1 . . . 503   454/505 (89%)   0.0           CALMODULIN   1 . . . 505   471/505 (92%)           DEPENDENT           PROTEIN KINASE           KINASE ALPHA—             Mus musculus             (Mouse), 505 aa.                  
 
     [0406] PFam analysis predicts that the NOV15a protein contains the domains shown in the Table 15F.  
               TABLE 15F                          Domain Analysis of NOV15a                                 NOV15a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value               Pkinase: domain   128 . . . 228    28/101 (28%)   8.4e−16       1 of 2        81/101 (80%)       Pkinase: domain   245 . . . 407    70/201 (35%)   1.7e−52       1 of 2       129/201 (64%)                  
 
     Example 16  
     [0407] The NOV16 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 16A.  
               TABLE 16A                       NOV16 Sequence Analysis                                                SEQ ID NO:59   688 bp                     NOV16a     GACGCGGACCCGCC   ATG GCGCGGAAGAAGGTGCGTCCGCGGCTGATCGCGGAGCTGGC       CG57709-01 DNA Sequence           CCGCCGCGTGCGCGCCCTGCGGGAGCAACTGAACAGGCCGCGCGACTCCCAGCTCTAC                   GCGGTGGACTACGAGACCTTGACGCGGCCGTTCTCTGGACGCCGGCTGCCGGTCCGGG                   CCTGGGCCGACGTGCGCCGCGAGAGCCGCCTCTTGCAGCTGCTCGGCCGCCTCCCGCT                   CTTCGGCCTGGGCCGCCTGGTCACGCGCAAGTCCTGGCTGTGGCAGCACGACGAGCCG                   TGCTACTGGCGCCTCACGCGGGTGCGGCCCGACTACACGGCGCAGAACTTGGACCACG                   GGAAGGCCTGGGGCATCCTGACCTTCAAAGGTAAGGCTCGGGAGAGCGCGCGGGAGAT                   CGAACACGTCATGTACCATGACTGGCGGCTGGTGCCCAAGCACGAGGAGGAGGCCTTC                   ACCGCGTTCACGCCGGCGCCGGAAGACAGCCTGGCCTCCGTGCCGTACCCGCCTCTCC                   TCCGGGCCATGATTATCGCAGAACGACAGAAAAATGGAGACACAAGCACCGAGGAGCC                   CATGCTGAATGTGCAGAGGATACGCATGGAACCCTGGGATTACCCTGCAAAACAGGAA                   GACAAAGGAAGGGCCAAGGGCACCCCCGTC TAG   AATGCCAGAACCAGCGG                                           ORF Start: ATG at 15       ORF Stop: TAG at 669           SEQ ID NO:60   218 aa   MW at 25647.2 kD                     NOV16a,   MARKKVRPRLIAELARRVRALREQLNRPRDSQLYAVDYETLTRPFSGRRLPVRAWADV       CG57709-01 Protein Sequence           RRESRLLQLLGRLPLFGLGRLVTRKSWLWQHDEPCYWRLTRVRPDYTAQNLDHGKAWG                   ILTFKGKARESAREIEHVMYHDWRLVPKHEEEAFTAFTPAPEDSLASVPYPPLLRAMI                   IAEROKNGDTSTEEPMLNVORIRMEPWDYPAKOEDKGRAKGTPV                  
 
     [0408] Further analysis of the NOV16a protein yielded the following properties shown in Table 16B.  
               TABLE 16B                       Protein Sequence Properties NOV16a                                        PSort   0.9081 probability located in mitochondrial matrix space;       analysis:   0.6000 probability located in mitochondrial inner membrane;           0.6000 probability located in mitochondrial intermembrane           space; 0.6000 probability located in mitochondrial outer           membrane       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0409] A search of the NOV16a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16C.  
               TABLE 16C                          Geneseq Results for NOV16a                                         NOV16a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG81356   Human AFP    1 . . . 218   212/218    e−125           protein sequence        (97%)           SEQ ID NO:    1 . . . 218   212/218           230— Homo          (97%)             sapiens , 18 aa.           [WO200129221-           A2, Apr. 26,           2001]       AAU30525   Novel human   135 . . . 218   84/84   3e−45            secreted protein       (100%)           [WO200179449-    1 . . . 84   84/84           A2, Oct. 25,       (100%)           2001]       AAU30526   Novel human   187 . . . 217   31/31   4e−12            secreted protein       (100%)           #1017— Homo     12 . . . 42   31/31             sapiens , 62 aa.       (100%)           [WO200179449-           A2, Oct. 25,           2001]                  
 
     [0410] In a BLAST search of public sequence databases, the NOV16a protein was found to have homology to the proteins shown in the BLASTP data in Table 16D.  
               TABLE 16D                          Public BLASTP Results for NOV16a                                         NOV16a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9BV17   HYPOTHETICAL   1 . . . 218   214/218 (98%)   e−125           25.7 KDA   1 . . . 218   214/218 (98%)           PROTEIN— Homo               sapiens  (Human),           218 aa.       P82930   MITO-   1 . . . 218   213/218 (97%)   e−124           CHONDRIAL 28S   1 . . . 218   213/218 (97%)           RIBOSOMAL           PROTEIN S34           (MRP-S34)— Homo               sapiens  (Human),           218 aa.       CAC38606   SEQUENCE 229   1 . . . 218   212/218 (97%)   e−124           FROM PATENT   1 . . . 218   212/218 (97%)           WO0129221—             Homo sapiens             (Human), 218 aa.       Q9JIK9   TCE2   1 . . . 218   194/218 (88%)   e−114           (0610007F04RIK   1 . . . 218   205/218 (93%)           PROTEIN)—             Mus musculus             (Mouse), 218 aa.       Q9D957   0610007F04R1K   1 . . . 218   193/218 (88%)   e−114           PROTEN—   1 . . . 218   205/218 (93%)             Mus musculus             (Mouse), 218 aa.                  
 
     [0411] PFam analysis predicts that the NOV16a protein contains the domains shown in the Table 16E.  
               TABLE 16E                          Domain Analysis of NOV16a                                 NOV16a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value                         No Significant Matches Found                  
 
     Example 17  
     [0412] The NOV17 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 17A.  
               TABLE 17A                       NOV17 Sequence Analysis                                                SEQ ID NO:61   894 bp                     NOV17a,     CTCCGTGACC   ATG AAGGTCAAGGTCATCCCCGTGCTCGAGGACAACTACATGTACCTG       CG57700-01 DNA Sequence           GTCATCGAGGAGCTCACGCGCGAGGCGGTGGCCGTGGACGTGGCTGTGCCCAAGAGGC                   TGCTGGAGATCGTGGGCCGGGAGGGGGTGTCTCTGACCGCTGTGCTGACCACCCACCA                   TCACTGGGACCACGCGCGGGGAAACCCGGAGCTGGCGCGGCTTCGTCCCGGGCTGGCG                   GTGCTGGGCGCGGACGAGCGCATCTTCTCGCTGACGCGCAGGCTGGCGCACGGCGAGG                   AGCTGCAGTTCGGGGCCATCCACGTGCGTTGCCTCCTGACGCCCGGCCACACCGCCCG                   CCACATGAGCTACTTCCTGTGGGAGGACGATTGCCCGGACCCACCCGCCCTGTTCTCG                   GGTGGCGACGCGCTGTCGGTGGCCGGCTGCGGCTCGTGCCTGGAGGGCAGCGCCCAGC                   AGATGTACCAGAGCCTGGCCGAGCTGGGTACCCTGCCCCCCGAGACGAAGGTGTTCTG                   CGGCCACGAGCACACGCTTAGCAACCTGGAGTTTGCCCAGAAAGTGGAGCCCTGCAAC                   GACCACGTGAGAGCCAAGCTGTCCTGGGCTCAGAAGAGGGATGAGGATGACGTGCCCA                   CTGTGCCGTCGACTCTGGGCGAGGAGCGCCTCTACAACCCCTTCCTGCGGGTGGCGGA                   GGAGCCGGTGCGCAAGTTCACGGGCAAGGCGGTCCCCGCCGACGTCCTGGAGGCGCTA                   TGCAAGGAGCGGGCGCGCTTCGAACAGGCGGGCGAGCCGCGGCAGCCACAGGCGCGGG                   CCCTCCTTGCGCTGCAGTGGGGGCTCCTGAGTGCAGCCCCACACGAC TGA   GCCACCCA                       GACCCTCACAGGGCTGGGGCCTGC                                           ORF Start: ATG at 11       ORF Stop: TGA at 860           SEQ ID NO:62   283 aa   MW at 31262.3 kD                     NOV17a,   MKVKVIPVLEDNYMYLVIEELTREAVAVDVAVPKRLLEIVGREGVSLTAVLTTHHHWD       CG57700-01 Protein Sequence           HARGNPELARLRPGLAVLGADERIFSLTRRLAHGEELQFGAIHVRCLLTPGHTAGHMS                   YFLWEDDCPDPPALFSGGDALSVAGCGSCLEGSAQQMYQSLAELGTLPPETKVFCGHE                   HTLSNLEFAQKVEPCNDHVRAKLSWAQKRDEDDVPTVPSTLGEERLYNPFLRVAEEPV                   RKFTGKAVPADVLEALCKERARFEQAGEPRQPQARALLALQWGLLSAAPHD                                     SEQ ID NO:63   888 bp                     NOV17b,     CTCCGTGACC   ATG AAGGTCAAGGTCATCCCCGTGCTCGAGGACAACTACATGTACCTG       CG57700-02 DNA Sequence           GTCATCGAGGAGCTCACGCGCGAGGCGGTGGCCGTGGACGTGGCTGTGCCCAAGAGGC                   TGCTGGAGATCGTGGGCCGGGAGGGGGTGTCTCTGACCGCTGTGCTGACCACCCACCA                   TCACTGGGACCACGCGCGGGGAAACCCGGAGCTGGCGCGGCTTCGTCCCGGGCTGGCG                   GTGCTGGGCGCGGACGAGCGCATCTTCTCGCTGACGCGCAGGCTGGCGCACGGCGAGG                   AGCTGCAGTTCGGGGCCATCCACGTGCGTTGCCTCCTGACGCCCGGCCACACCGCCGG                   CCACATGAGCTACTTCCTGTGGGAGGACGATTGCCCGGACCCACCCGCCCTGTTCTCG                   GGCGACGCGCTGTCGGTGGCCGGCTGCGGCTCGTGCCTGGAGGGCAGCGCCCAGCAGA                   TGTACCAGAGCCTGGCCGAGCTGGGTACCCTGCCCCCCGAGACGAAGGTGTTCTGCGG                   CCACGAGCACACACTTAGCAACCTGGAGTTTGCCCAGAAAGTGGAGCCCTGCAACGAC                   CACGTGAGAGCCAAGCTGTCCTGGGCTAAGAAGAGGGATGAGGATGACGTGCCCACTG                   TGCCGTCGACTCTGGGCGAGGAGCGCCTCTACAACCCCTTCCTGCGGGTGGCAGAGGA                   GCCGGTGCGCAAGTTCACGGGCAAGGCGGTCCCCGCCGACGTCCTGGAGGCGCTATGC                   AAGGAGCGGGCGCGCTTCGAACAGGCGGGCGAGCCGCGGCAGCCACAGGCGCGGGCCC                   TCCTTGCGCTGCAGTGGGGGCTCCTGAGTGCAGCCCCACACGAC TGA   GCCACCCAGAC                       CCTCACAGGGCTGGGCCT                                           ORF Start: ATG at 11       ORF Stop: TGA at 857           SEQ ID NO:64   282 aa   MW at 31205.3 kD                     NOV17b,   MKVKVIPVLEDNYMYLVIEELTREAVAVDVAVPKRLLEIVGREGVSLTAVLTTHHHWD       CG57700-02 Protein Sequence           HARGNPELARLRPGLAVLGADERIFSLTRRLAHGEELQFGAIHVRCLLTPGHTAGHMS                   YFLWEDDCPDPPALFSGDALSVAGCGSCLEGSAQQMYQSLAELGTLPPETKVFCGHEH                   TLSNLEFAQKVEPCNDHVRAKLSWAKKRDEDDVPTVPSTLGEERLYNPFLRVAEEPVR                   KFTGKAVPADVLEALCKERARFEQAGEPRQPQARALLALQWGLLSAAPHD                                     SEQ ID NO:65   882 bp                     NOV17c,     ACC   ATG AAGGTCAAGGTCATCCCCGTGCTCGAGGACAACTACATGTACCTGGTCATCG       CG57700-03 DNA Sequence           AGGAGCTCACGCGCGAGGCGGTGGCCGTGGACGTGGCTGTGCCCAAGAGGCTGCTGGA                   GATCGTGGGCCGGGAGGGGGTGTCTCTGACCGCTGTGCTGACCACCCACCATCACTGG                   GACCACGCGCGGGGAAACCCGGAGCTGGCGCGGCTTCGTCCCGGGCTGGCGGTGCTGG                   GCGCGGACGAGCGCATCTTCTCGCTGACGCGCAGGCTGGCGCACGGCGAGGAGCTGCG                   GTTCGGGGCCATCCACGTGCGTTGCCTCCTGACGCCCGGCCACACCGCCGGCCACATG                   AGCTACTTCCTGTGGGAGGACGATTGCCCGGACCCACCCGCCCTGTTCTCGGGCGACG                   CGCTGTCGGTGGCCGGCTGCGGCTGGTCCGTGGAGGGCAGCCCCCAGGACATCTACCA                   GAGCCTGGCCGAGCTGGGTACCCTGCCCCCCGAGACGAAGGTGTTCTGCGGCCACGAG                   CACACGCTTAGCAACCTGGAGTTTGCCCAGAAAGTGGAGCCCTGCAACGACCACGTGA                   GAGCCAAGCTGTCCTGGGCTAAGAAGAGGGATGAGGATGACGTGCCCACTGTGCCGTC                   GACTCTGGGCGAGGAGCGCCTCTACAACCCCTTCCTGCGGGTGGCAGAGGAGCCGGTG                   CGCAAGTTCACGGGCAAGGCGGTCCCCGCCGACGTCCTGGAGGCGCTATGCAAGGAGC                   GGGCGCGCTCCGAACAGGCGGGCGAGCCGCGGCAGCCACAGGCGCGGGCCCTCCTTGC                   GCTGCAGTGGGGGCTCCTGAGTGCAGCCCCACACGAC TGA   GCCACCCAGACCCTCACA                       GGGCTGGGGCCT                                           ORF Start: ATG at 4       ORF Stop: TGA at 850           SEQ ID NO:66   282 aa   MW at 31173.2 kD                     NOV17c,   MKVKVIPVLEDNYMYLVIEELTREAVAVDVAVPKRLLEIVGREGVSLTAVLTTHHHWD       CG57700-03 Protein Sequence           HARGNPELARLRPGLAVLGADERIFSLTRRLAHGEELRFGAIHVRCLLTPGHTAGHMS                   YFLWEDDCPDPPALFSGDALSVAGCGSCLEGSAQQMYQSLAELGTLPPETKVFCGHEH                   TLSNLEFAQKVEPCNDHVRAKLSWAKKRDEDDVPTVPSTLGEERLYNPFLRVAEEPVR                   KFTGKAVPADVLEALCKERARSEQAGEPRQPQARALLALQWGLLSAAPHD                                     SEQ ID NO:67   855 bp                     NOV17d,     ACC   ATG AAGGTCAAGGTCATCCCCGTGCTCGAGGACAACTACATGTACCTGGTCATCG       CG57700-04 DNA Sequence           AGGAGCTCACGCGCGAGGCGGTGGCCGTGGACGTGGCTGTGCCCAAGAGGCTGCTGGA                   GATCGTGGGCCGGGAGGGGGTGTCTCTGACCGCTGTGCTGACCACCCACTATCACTGG                   GACCACGCGCGGGGAAACCCGGAGCTGGCGCGGCTTCGTCCCGGGCTGGCGGTGCTGG                   GCGCGGACGAGCGCATCTTCTCGCTGACGCGCAGGCTGGCGCACGGCGAGGAGCTGCG                   GTTCGGGGCCATCCACGTGCGTTGCCTCCTGACGCCCGGCCACACCGCCGGCCACATG                   AGCTACTTCCTGTGGGAGGACGATTGCCCGGACCCACCCGCCCTGTTCTCGGGCGACG                   CGCTGTCGGTGGCCGGCTGCGGCTCGTGCCTGGAGGGCAGCGCCCAGCAGATGTACCA                   GAGCCTGGCCGAGCTGGGTACCCTGCCCCCCGAGACGAAGGTGTTCTGCGGCCACGAG                   CACACGCTTAGCAACCTGGAGTTTGCCCAGAAAGTGGAGCCCTGCAACGACCACAAGA                   GGGATGAGGATGACGTGCCCACTGTGCCGTCGACTCTGGGCGAGGAGCGCCTCTACAA                   CCCCTTCCTGCGGGTGGCAGAGGAGCCGGTGCGCAAGTTCACGGGCAAGGCGGTCCCC                   GCCGACGTCCTGGAGGCGCTATGCAAGGAGCGGGCGCGCTTCGAACAGGCGGGCGAGC                   CGCGGCAGCCACAGGCGCGGGCCCTCCTTGCGCTGCAGTGGGGGCTCCTGAGTGCAGC                   CCCACACGAC TGA   GCCACCCAGACCCTCACAGGGCTGGGGCCT                                           ORF Start: ATG at 4       ORF Stop: TGA at 823           SEQ ID NO:68   273 aa   MW at 30219.1 kD                     NOV17d,   MKVKVIPVLEDNYMYLVIEELTREAVAVDVAVPKRLLEIVGREGVSLTAVLTTHYHWD       CG57700-04 Protein Sequence           HARGNPELARLRPGLAVLGADERIFSLTRRLAHGEELRFGAIHVRCLLTPGHTAGHMS                   YFLWEDDCPDPPALFSGDALSVAGCGSCLEGSAQQMYQSLAELGTLPPETKVFCGHEH                   TLSNLEFAQKVEPCNDHKRDEDDVPTVPSTLGEERLYNPFLRVAEEPVRKFTGKAVPA                   DVLEALCKERARFEQAGEPRQPQARALLALQWGLLSAAPHD                  
 
     [0413] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 17B.  
               TABLE 17B                          Comparison of NOV17a against NOV17b through NOV17d.                                 Protein   NOV17a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV17b   1 . . . 283   281/283 (99%)               1 . . . 282   282/283 (99%)           NOV17c   1 . . . 283   279/283 (98%)               1 . . . 282   281/283 (98%)           NOV17d   1 . . . 283   271/283 (95%)               1 . . . 273   273/283 (95%)                      
 
     [0414] Further analysis of the NOV17a protein yielded the following properties shown in Table 17C.  
               TABLE 17C                       Protein Sequence Properties NOV17a                                        PSort   0.4500 probability located in cytoplasm; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1682 probability located           in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0415] A search of the NOV17a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17D.  
               TABLE 17D                          Geneseq Results for NOV17a                                         NOV17a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAW80783   Human bisphos-    1 . . . 256   128/257 (49%)   6e−72           phonate binding    1 . . . 256   184/257 (70%)           protein, DP1           (hDP1)— Homo               sapiens , 260 aa.           [WO9836064-A1,           Aug. 20, 1998]       AAG10987     Arabidopsis      1 . . . 245   107/248 (43%)   5e−53             thaliana  protein    1 . . . 246   160/248 (64%)           fragment SEQ ID           NO: 9531—             Arabidopsis               thaliana , 258 aa.           [EP1033405-A2,           Sep. 6, 2000]       AAG10986     Arabidopsis      1 . . . 245   107/248 (43%)   5e−53             thaliana  protein    11 . . . 256   160/248 (64%)           fragment SEQ ID           NO: 9530—             Arabidopsis               thaliana , 268 aa.           [EP1033405-A2,           Sep. 6, 2000]       AAM78721   Human protein    1 . . . 226   100/227 (44%)   6e−45           SEQ ID NO   119 . . . 344   135/227 (59%)           1383— Homo               sapiens , 385 aa.           [WO200157190-           A2, Aug. 9,           2001]       AAY71110   Human Hydrolase    1 . . . 226   100/227 (44%)   6e−45           protein-8    95 . . . 320   135/227 (59%)           (HYDRL-8)—             Homo sapiens ,           361 aa.           [WO200028045-           A2, May 18,           2000]                  
 
     [0416] In a BLAST search of public sequence databases, the NOV17a protein was found to have homology to the proteins shown in the BLASTP data in Table 17E.  
               TABLE 17E                          Public BLASTP Results for NOV17a                                         NOV17a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9BT45   SIMILAR TO RIKEN   1 . . . 283   280/283 (98%)    e−163           CDNA 1500017E18   1 . . . 282   282/283 (98%)           GENE— Homo sapiens             (Human), 282 aa.       Q9DB32   1500017E18R1K   1 . . . 278   231/279 (82%)    e−133           PROTEIN— Mus     1 . . . 278   251/279 (89%)             musculus  (Mouse),           283 aa.       Q96S11   SIMILAR TO   1 . . . 128   217/228 (95%)    e−123           HAGH— Homo     1 . . . 218   218/228 (95%)             sapiens  (Human),           218 aa.       Q96NR5   CDNA FLJ30279   1 . . . 133   132/133 (99%)   3e−73            FIS, CLONE   1 . . . 133   133/133 (99%)           BRACE2002772,           MODERATELY           SIMILAR TO           HYDROXYACYL-           GLUTATHIONE           HYDROLASE           (BC 3.1.2.6)— Homo               sapiens  (Human),           202 aa.       O35952   Hydroxyacyl-   1 . . . 256   128/257 (49%)   1e−71            glutathione hydrolase   1 . . . 256   184/257 (70%)           (EC 3.1.2.6)           (Glyoxalase II) (Glx           II) (Round spermatid           protein RSP29)—             Rattus norvegicus             (Rat), 260 aa.                  
 
     [0417] PFam analysis predicts that the NOV17a protein contains the domains shown in the Table 17F.  
               TABLE 17F                          Domain Analysis of NOV17a                                 NOV17a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value               lactamase_B:   7 . . . 173    55/221 (25%)   5.8e−32       domain 1 of 1       129/221 (58%)                  
 
     Example 18  
     [0418] The NOV18 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 18A.  
               TABLE 18A                       NOV18 Sequence Analysis                                                SEQ ID NO:69   2109 bp                     NOV18a,     GGGTCCGGCGGGCATCGGCAAGACC   ATG GCGGCCAAAAATATCCTGTACGACTGGGCG       CG58553-01 DNA Sequence           GCGGGCAAGCTGTACCAGGGCCAGGTGGACTTCGCCTTCTTCATGCCCTGCGGCGAGC                   TGCTGGAGAGGCCGGGCACGCGCAGCCTGGCTGACCTGATCCTGGACCAGTGCCCCGA                   CCGCGGCGCGCCGGTGCCGCAGATGCTGGCCCAGCCGCAGCGGCTGCTCTTCATCCTG                   GACGGCGCGGACGAGCTGCCGGCGCTGGGGGGCCCCGAGGCCGCGCCCTGCACAGACC                   CCTTCGAGGCGGCGAGCGGCGCGCGGGTGCTAGGCGGGCTGCTGAGTAAGGCGCTGCT                   GCCCACGGCCCTCCTGCTGGTGACCACGCGCGCCGCCGCCCCCGGGAGGCTGCAGGGC                   CGCCTGTGTTCCCCGCAGTGCGCCGAGGTGCGCGGCTTCTCCGACAAGGACAAGAAGA                   AGTATTTCTACAAGTTCTTCCGGGATGAGAGGAGGGCCGAGCGCGCCTACCGCTTCGT                   GAAGGAGAACGAGACGCTGTTCGCGCTGTGCTTCGTGCCCTTCGTGTGCTGGATCGTG                   TGCACCGTGCTGCGCCAGCAGCTGGAGCTCGGTCGGGACCTGTCGCGCACGTCCAAGA                   CCACCACGTCAGTGTACCTGCTTTTCATCACCAGCGTTCTGAGCTCGGCTCCGGTAGC                   CGACGGGCCCCGGTTGCAGGGCGACCTGCGCAATCTGTGCCGCCTGGCCCGCGAGGGC                   GTCCTCGGACGCAGGGCGCAGTTTGCCGAGAAGGAACTGGAGCAACTGGAGCTTCGTG                   GCTCCAAAGTGCAGACGCTGTTTCTCAGCAAAAAGGAGCTGCCGGGCGTGCTGGAGAC                   AGAGGTCACCTACCAGTTCATCGACCAGAGCTTCCAGGAGTCCTTCGCGGCACTGTCC                   TACCTGCTGGAGGACGGCGGGGTGCCCAGGACCGCGGCTGGCGGCGTTGGGACACTCC                   TGCGTGGGGACGCCCAGCCGCACAGCCACTTGGTGCTCACCACGCGCTTCCTCTTCGG                   ACTGCTGAGCGCGGAGCGGATGCGCGACATCGAGCGCCACTTCGGCTGCATGGTTTCA                   GAGCGTGTGAAGCAGGAGGCCCTGCGGTGGGTGCAGGGACAGGGACAGGGCTGCCCCG                   GAGTGGCACCAGAGGTGACCGAGGGGGCCAAAGGGCTCGAGGACACCGAAGAGCCAGA                   GGAGGAGGAGGAGGGAGAGGAGCCCAACTACCCACTGGAGTTGCTGTACTGCCTGTAC                   GAGACGCAGGAGGACGCGTTTGTGCGCCAAGCCCTGGGCCGGTTCCCGGAGCTGGCGC                   TGCAGCGAGTGCGCTTCTGCCGCATGGACGTGGCTGTTCTGAGCTACTGCGTGAGGTG                   CTGCCCTGCTGCACAGGCACTGCGGCTGATCAGCTGCAGATTGGTTGCTGCGCAGGAG                   AAGAAGAAGAAGAGCCTGGGGAAGCGGCTCCAGGCCAGCCTGGGCACCACAAAACAAC                   TGCCAGCCTCCCTTCTTCATCCACTCTTTCAGGCAATGACTGACCCACTGTGCCATCT                   GAGCAGCCTCACGCTGTCCCACTGCAAACTCCCTGACGCGGTCTGCCGAGACCTTTCT                   GAGGCCCTGAGGGCAGCCCCCGCACTGACGGAGCTGGGCCTCCTCCACAACAGGCTCA                   GTGAGGCAGGACTGCGTATGCTGAGTGAGGGCCTAGCCTGGCCGCAGTGCAGGGTGCA                   GACGGTCAGGGTACAGCTGCCTGACCCCCAGCGAGGGCTCCAGTACCTGGTGGGTATG                   CTTCGGCAGAGCCCTGCCCTGACCACCCTGGATCTCAGCGGCTGCCAACTGCCCGCCC                   CCATGGTGACCTACCTGTGTGCAGTCCTGCAGCACCAGGGATGCGGCCTGCAGACCCT                   CAGTCTGGCCTCTGTGGAGCTGAGCGAGCAGTCACTACAGGAGCTTCAGGCTGTGAAG                   AGAGCAAAGCCGGATCTGGTCATCACACACCCAGCGCTGGACGGCCACCCACAACCTC                   CCAAGGAACTCATCTCGACCTTC TGA   GGCTCTGGTGGCCAGAGCAGGGTGGAAGACCC                       TAGTCAAAGTCCCTGTGGAGA                                           ORF Start: ATG at 26       ORF Stop: TGA at 2054           SEQ ID NO:70   676 aa   MW at 74650.3 kD                     NOV18a,   MAAKNILYDWAAGKLYQGQVDFAFFMPCGELLERPGTRSLADLILDQCPDRGAPVPQM       CG58553-01 Protein Sequence           LAQPQRLLFILDGADELPALGGPEAAPCTDPFEAASGARVLGGLLSKALLPTALLLVT                   TRAAAPGRLQGRLCSPQCAEVRGFSDKDKKKYFYKFFRDERRAERAYRFVKENETLFA                   LCFVPFVCWIVCTVLRQQLELGRDLSRTSKTTTSVYLLFITSVLSSAPVADGPRLQGD                   LRNLCRLAREGVLGRRAQFAEKELEQLELRGSKVQTLFLSKKELPGVLETEVTYQFID                   QSFQESFAALSYLLEDGGVPRTAAGGVGTLLRGDAQPHSHLVLTTRFLFGLLSAERMR                   DIERHFGCMVSERVKQEALRWVQGQGQGCPGVAPEVTEGAKGLEDTEEPEEEEEGEEP                   NYPLELLYCLYETQEDAFVRQALGRFPELALQRVRFCRMDVAVLSYCVRCCPAAQALR                   LISCRLVAAQEKKKKSLGKRLQASLGTTKQLPASLLHPLFQAMTDPLCHLSSLTLSHC                   KLPDAVCRDLSEALRAAPALTELGLLHNRLSEAGLRMLSEGLAWPQCRVQTVRVQLPD                   PQRGLQYLVGMLRQSPALTTLDLSGCQLPAPMVTYLCAVLQHQGCGLQTLSLASVELS                   EQSLQELQAVKRAKPDLVITHPALDGHPQPPKELISTF                  
 
     [0419] Further analysis of the NOV18a protein yielded the following properties shown in Table 18B.  
               TABLE 18B                       Protein Sequence Properties NOV18a                                        Psort   0.7400 probability located in nucleus; 0.6000 probability       analysis:   located in endoplasmic reticulum (membrane); 0.3000           probability located in microbody (peroxisome); 0.1000           probability located in mitochondrial inner membrane       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0420] A search of the NOV18a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18C.  
               TABLE 18C                          Geneseq Results for NOV18a                                         NOV18a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAE04546   Human G-protein    1 . . . 676   671/682 (98%)   0.0           coupled receptor-   210 . . . 891   671/682 (98%)           2 (GCREC-2)           protein— Homo               sapiens , 891 aa.           [WO200142288-           A2, Jun. 14,           2001]       AAU00023   Human activated    1 . . . 633   605/695 (87%)   0.0           T-lymphocyte   210 . . . 904   610/695 (87%)           associated           sequence 2,           ATLAS-2—             Homo sapiens ,           1851 aa.           [WO200114564-           A2, Mar. 1, 2001]       ABB11735   Human vaso-    1 . . . 490   485/490 (98%)   0.0           pressin receptor   106 . . . 595   485/490 (98%)           homologue, SEQ           ID NO:2105—             Homo sapiens ,           597 aa.           [WO200157188-           A2, Aug. 9,           2001]       AAR33389   AII/AVPv2   193 . . . 670   322/481 (66%)   e−174           receptor—    1 . . . 480   371/481 (76%)           Synthetic, 481 aa.           [WO9305073-A,           Mar. 18, 1993]       AAM89960   Human immune/    1 . . . 274   265/274 (96%)   e−151           haematopoietic    9 . . . 282   266/274 (96%)           antigen SEQ ID           NO:17553—             Homo sapiens ,           329 aa.           [WO200157182-           A2, Aug. 9,           2001]                  
 
     [0421] In a BLAST search of public sequence databases, the NOV18a protein was found to have homology to the proteins shown in the BLASTP data in Table 18D.  
               TABLE 18D                          Public BLASTP Results for NOV18a                                         NOV18a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               CAC34689   SEQUENCE 3    1 . . . 633   605/695 (87%)   0.0           FROM PATENT   210 . . . 904   610/695 (87%)           WO0114564—             Homo sapiens             (Human),           1851 aa.       Q91WS2   HYPO-   107 . . . 659   390/557 (70%)   0.0           THETICAL    1 . . . 554   450/557 (80%)           62.5 KDA           PROTEIN—             Mus musculus             (Mouse), 556 aa           (fragment).       Q63035   VASOPRESSIN   193 . . . 670   324/483 (67%)    e−173           RECEPTOR—    1 . . . 482   372/483 (76%)             Rattus norvegicus             (Rat), 483 aa.       AAL12498   CRYOPYRIN—    3 . . . 657   232/709 (32%)   5e−94              Homo sapiens     234 . . . 914   355/709 (49%)           (Human), 920 aa.       AAL12497   CRYOPYRIN—    3 . . . 648   223/658 (33%)   6e−93              Homo sapiens     234 . . . 848   344/658 (51%)           (Human), 1034           aa.                  
 
     [0422] PFam analysis predicts that the NOV18a protein contains the domains shown in the Table 18E.  
               TABLE 18E                          Domain Analysis of NOV18a                                 NOV18a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value                         No Significant Matches Found                  
 
     Example 19  
     [0423] The NOV19 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 19A.  
               TABLE 19A                       NOV19 Sequence Analysis                                                SEQ ID NO:71   2686 bp                     NOV19a,     CCGGCGGCGTCTCCACAGC   ATG AATTACCCGGGCCGCGGGTCCCCACGGAGCCCCGAG       CG58626-01 DNA Sequence           CATAACGGCCGAGGCGGCGGCGGCGGCGCCTGGGAGCTGGGCTCAGACGCGAGGCCAG                   CGTTCGGCGGCGGCGTCTGCTGCTTCGAGCACCTGCCCGGCGGGGACCCGGACGACGG                   CGACGTGCCCCTGGCCCTGCTGCGCGGGGAACCCGGGCTGCATTTGGCGCCGGGCACC                   GACGACCACAACCACCACCTCGCGCTGGACCCCTGCCTCAGTGACGAGAACTATGACT                   TCAGCTCCGCCGAGTCGGGCTCCTCGCTGCGCTACTACAGCGAGGGTGAGAGCGGCGG                   CGGCGGCAGCTCCTTGTCGCTGCACCCGCCGCAGCAGCCTCCGCTGGTCCCGACGAAC                   TCGGGGGGCGGCGGCGCGACAGGAGGGTCCCCCGGGGAAAGGAAACGTACCCGCCTTG                   GCGGCCCGGCGGCCCGGCACCGCTATGAGGTAGTGACGGAGCTGGGCCCGGAGGAGGT                   ACGCTGGTTCTACAAGGAGGACAAGAAGACCTGGAAGCCCTTCATCGGCTACGACTCG                   CTCCGCATCGAGCTCGCCTTCCGGACCCTGCTGCAGACCACGGGTGCCCGGCCCCAGG                   GCGGGGACCGGGACGGCGACCATGTGTGCTCCCCCACGGGCCCAGCCTCCAGTTCCGG                   AGAAGATGACGATGAGGACCGCGCCTGCGGCTTCTGCCAGAGTACGACGGGGCACGAG                   CCGGAGATGGTGGAGCTTGTGAACATCGAGCCTGTGTGCGTGCGGGGCGGCCTCTACG                   AGGTGGATGTGACCCAAGGAGAGTGCTACCCGGTGTACTGGAACCGTGCTGATAAAAT                   ACCAGTAATGCGTGGACAGTGGTTTATTGACGGCACTTGGCAGCCTCTAGAAGAGGAA                   GAAAGTAATTTAATTGAGCAAGAACATCTCAATTGTTTTAGGGGCCAGCAGATGCAGG                   AAAATTTCGATATTGAAGTGTCAAAATCCATAGATGGAAAAGATGCTGTTCATAGTTT                   CAAGTTGAGTCGAAACCATGTGGACTGGCACAGTGTGGATGAAGTATATCTTTATAGT                   GATGCAACAACATCTAAAATTGCAAGAACAGTTACCCAAAAACTGGGATTTTCTAAAG                   CATCAAGTAGTGGTACCAGACTTCATAGAGGTTATGTAGAAGAAGCCACATTAGAAGA                   CAAGCCATCACAGACTACCCATATTGTATTTGTTGTGCATGGCATTGGGCAGAAAATG                   GACCAAGGAAGAATTATCAAAAATACAGCTATGATGAGAGAAGCTGCAAGAAAAATAG                   AAGAAAGGCATTTTTCCAACCATGCAACACATGTTGAATTTCTGCCTGTTGAGTGGCG                   GTCAAAACTTACTCTTGATGGAGACACTGTTGATTCCATTACTCCTGACAAAGTACGA                   GGTTTAAGGGATATGCTGAACAGCAGTGCAATGGACATAATGTATTATACTAGTCCAC                   TTTATAGAGATGAACTAGTTAAAGGCCTTCAGCAAGAGCTGAATCGATTGTATTCCCT                   TTTCTGTTCTCGGAATCCAGACTTTGAAGAAAAAGGGGGTAAAGTCTCAATAGTATCA                   CATTCCTTGGGATGTGTAATTACTTATGACATAATGACTGGCTGGAATCCAGTTCGGC                   TGTATGAACAGTTGCTGCAAAAGGAAGAAGAGTTGCCTGATGAACGATGGATGAGCTA                   TGAAGAACGACATCTTCTTGATGAACTCTATATAACTAAACGACGGCTGAAGGAAATA                   GAAGAACGGCTTCACGGATTGAAAGCATCATCTATGACACAAACACCTGCCTTAAAAT                   TTAAGGTAGAGAATTTCTTCTGTATGGGATCCCCATTAGCAGTTTTCTTGGCGTTGCG                   TGGCATCCGCCCAGGAAATACTGGAAGTCAAGACCATATTTTGCCTAGAGAGATTTGT                   AACCGGTTACTAAATATTTTTCATCCTACAGATCCAGTGGCTTATAGATTAGAACCAT                   TAATACTGAAACACTACAGCAACATTTCACCTGTCCAGATCCACTGGTACAATACTTC                   AAATCCTTTACCTTATGAACATATGAAGCCAAGCTTTCTCAACCCAGCTAAAGAACCT                   ACCTCAGTTTCAGAGAATGAAGGCATTTCAACCATACCAAGCCCTGTGACCTCACCAG                   TTTTGTCCCGCCGACACTATGGAGAATCTATAACAAATATAGGCAAAGCAAGCATATT                   AGGTGCTGCTAGCATTGGAAAGGGACTTGGAGGAATGTTGTTCTCAAGATTTGGACGT                   TCATCTACAACACAGTCATCTGAAACATCAAAAGACTCAATGGAAGATGAGAAGAAGC                   CAGTTGCCTCACCTTCTGCTACCACCGTAGGGACACAGACCCTTCCACATAGCAGTTC                   TGGCTTCCTCGATTCTGCAGTGGAGTTGGATCACAGGATTGATTTTGAACTCAGAGAA                   GGCCTTGTGGAGAGCCGCTATTGGTCAGCTGTCACGTCGCATACTGCCTATTGGTCAT                   CCTTGGATGTTGCCCTTTTTCTTTTAACCTTCATGTATAAACATGAGCACGATGATGA                   TGCAAAACCCAATTTAGATCCAATC TGA   ACTCTCTTGAAGGACATGAATGGCCTAAAA                       CTGATTTTTTTTTTTTCC                                           ORF Start: ATG at 20       ORF Stop: TGA at 2636           SEQ ID NO:72   872 aa   MW at 97063.4 kD                     NOV19a,   MNYPGRGSPRSPEHNGRGGGGGAWELGSDARPAFGGGVCCFEHLPGGDPDDGDVPLAL       CG58626-01 Protein Sequence           LRGEPGLHLAPGTDDHNHHLALDPCLSDENYDFSSAESGSSLRYYSEGESGGGGSSLS                   LHPPQQPPLVPTNSGGGGATGGSPGERKRTRLGGPAARHRYEVVTELGPEEVRWFYKE                   DKKTWKPFIGYDSLRIELAFRTLLQTTGARPQGGDRDGDHVCSPTGPASSSGEDDDED                   RACGFCQSTTGHEPEMVELVNIEPVCVRGGLYEVDVTQGECYPVYWNRADKIPVMRGQ                   WFIDGTWQPLEEEESNLIEQEHLNCFRGQQMQENFDIEVSKSIDGKDAVHSFKLSRNH                   VDWHSVDEVYLYSDATTSKIARTVTQKLGFSKASSSGTRLHRGYVEEATLEDKPSQTT                   HIVFVVHGIGQKMDQGRIIKNTAMMREAARKIEERHFSNHATHVEFLPVEWRSKLTLD                   GDTVDSITPDKVRGLRDMLNSSAMDIMYYTSPLYRDELVKGLQQELNRLYSLFCSRNP                   DFEEKGGKVSIVSHSLGCVITYDIMTGWNPVRLYEQLLQKEEELPDERWMSYEERHLL                   DELYITKRRLKEIEERLHGLKASSMTQTPALKFKVENFFCMGSPLAVFLALRGIRPGN                   TGSQDHILPREICNRLLNIFHPTDPVAYRLEPLILKHYSNISPVQIHWYNTSNPLPYE                   HMKPSFLNPAKEPTSVSENEGISTIPSPVTSPVLSRRHYGESITNIGKASILGAASIG                   KGLGGMLFSRFGRSSTTQSSETSKDSMEDEKKPVASPSATTVGTQTLPHSSSGFLDSA                   VELDHRIDFELREGLVESRYWSAVTSHTAYWSSLDVALFLLTFMYKHEHDDDAKPNLD                   PI                  
 
     [0424] Further analysis of the NOV19a protein yielded the following properties shown in Table 19B.  
               TABLE 19B                       Protein Sequence Properties NOV19a                                        PSort   0.4555 probability located in microbody (peroxisome); 0.4500       analysis:   probability located in cytoplasm; 0.1000 probability located in           mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0425] A search of the NOV19a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 19C.  
               TABLE 19C                          Geneseq Results for NOV19a                                         NOV19a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG64151     Arabidopsis     257 . . . 547   104/316 (32%)   1e−38             thaliana     156 . . . 454   156/316 (48%)           gravitropism           protein—             Arabidopsis               thaliana , 933 aa.           [JP2001120279-           A, May 8, 2001]       AAM41595   Human poly-   261 . . . 548    94/301 (31%)   6e−25           peptide SEQ ID    52 . . . 328   138/301 (45%)           NO 6526− Homo               sapiens , 677 aa.           [WO200153312-           A1, Jul. 26, 2001]       AAB92643   Human protein   119 . . . 608   132/524 (25%)   2e−24           sequence SEQ ID   226 . . . 664   204/524 (38%)           NO:10972—             Homo sapiens ,           1000 aa.           [EP1074617-A2,           Feb. 7, 2001]       AAM39809   Human poly-   274 . . . 548    90/288 (31%)   4e−23           peptide SEQ ID    3 . . . 266   131/288 (45%)           NO 2954— Homo               sapiens , 615 aa.           [WO200153312-           A1, Jul. 26, 2001]       AAB93825   Human protein   404 . . . 608    76/229 (33%)   6e−23           sequence SEQ ID   227 . . . 449   113/229 (49%)           NO:13636—             Homo sapiens ,           694 aa.           [EP1074617-A2,           Feb. 7, 2001]                  
 
     [0426] In a BLAST search of public sequence databases, the NOV19a protein was found to have homology to the proteins shown in the BLASTP data in Table 19D.  
               TABLE 19D                          Public BLASTP Results for NOV19a                                         NOV19a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               O46606   PHOSPHATIDIC    1 . . . 872   802/876 (91%)   0.0           ACID-    1 . . . 875   829/876 (94%)           PREFERRING           PHOSPHO-           LIPASE A1—             Bos taurus             (Bovine), 875 aa.       Q9C0F8   KIAA1705   378 . . . 872   493/495 (99%)   0.0           PROTEIN—    4 . . . 498   494/495 (99%)             Homo sapiens             (Human), 498 aa           (fragment).       Q96LL2   CDNA FLJ25408   419 . . . 872   453/454 (99%)   0.0           FIS, CLONE    1 . . . 454   454/454 (99%)           TST02965,           HIGHLY           SIMILAR TO             BOS TAURUS             PHOSPHATIDIC           ACID-           PREFERRING           PHOSPHO-           LIPASE A1           MRNA— Homo               sapiens  (Human),           454 aa.       AAH18552   HYPO-   624 . . . 869   224/246 (91%)    e−130           THETICAL    1 . . . 246   236/246 (95%)           27.3 KDA           PROTEIN— Mus               musculus             (Mouse), 249 aa           (fragment).       AAL32232   HYPO-   122 . . . 867   255/794 (32%)   6e−91            THETICAL    11 . . . 750   374/794 (46%)           85.1 KDA           PROTEIN—             Caenorhabditis               elegans , 753 aa.                  
 
     [0427] PFam analysis predicts that the NOV19a protein contains the domains shown in the Table 19E.  
               TABLE 19E                          Domain Analysis of NOV19a                                 NOV19a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value               DUF203: domain   252 . . . 458    42/219 (19%)   7.5       1 of 1       105/219 (48%)       DDHD: domain   611 . . . 858    96/266 (36%)   3.3e−116       1 of 1       236/266 (89%)                  
 
     Example 20  
     [0428] The NOV20 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 20A.  
               TABLE 20A                       NOV20 Sequence Analysis                                                SEQ ID NO:73   773 bp                     NOV20a,     GGTAAGGACACAAG   ATG CCAAATAGGGTAAGGAATGGTCCAGAAACCTGTGAACTCTG       CG57597-01 DNA Sequence           CATTGCAGGCATGCACCACCACTCCTGGCTAATTTTTTGTATTTTTAGTGCCATCGAA                   TCCGGCTCAAACCTTTTATTTCTCTTATGTAAAAGCTGTGTACTTCAGAAAAACATGT                   ACAGTTATCCCTGGCAGTGCCGGGGTGGGGTCTGCGCGGCCCTGGAGGCCTGGCCGGC                   CTTGCAGATCGCTGTGGAGAATGGCTTCGGGGGTGTGCACAGCCAGGAGAAGGCCAAG                   TGGCTGGGGGGTGCAGTGGAGGATTACTTCATGCGCAATGCTGACTTGGAGCTAGATG                   AGGTGGAAGACTTCCTTGGAGAGCTGTTGACCAACGAGTTTGATACAGTTGTGGAAGA                   CGGGAGTCTGCCCCAGGTGAGCCAGCAACTGCAGACCATGTTCCACCACTTCCAGAGG                   GGTGATGGGGCTGCTCTGAGGGAGATGGCCTCCTGCATCACTCAGAGAAAATGCAAGG                   TCACAGCCACTGCACTTAAGACAGCTAGAGAGACTGATGAGGATGAAGATGATGTGGA                   CAGTGTGGAAGAGATGGAGGTCACAGCTACGAATGATGGGGCTGCTACAGATGGGGTC                   TGCCCCCAGCCTGAACCCTCTGATCCAGACGCTCAGACTATTAAGGAAGAGGATATAG                   TGGAAGATGGCTGGACCATTGTCCGGAGAAAAAAA TGA   GTGGGGATGATTGGAAATGG                       CTTTGGGCCCTTATTTGCT                                           ORF Start: ATG at 15       ORF Stop: TGA at 732           SEQ ID NO:74   239 aa   MW at 26579.5 kD                     NOV20a,   MPNRVRNGPETCELCIAGMHHHSWLIFCIFSAIESGSNLLFLLCKSCVLQKNMYSYPW       CG57597-O1 Protein Sequence           QCRGGVCAALEAWPALQIAVENGFGGVHSQEKAKWLGGAVEDYFMRNADLELDEVEDF                   LGELLTNEFDTVVEDGSLPQVSQQLQTMFHHFQRGDGAALREMASCITQRKCKVTATA                   LKTARETDEDEDDVDSVEEMEVTATNDGAATDGVCPQPEPSDPDAQTIKEEDIVEDGW                   TIVRRKK                  
 
     [0429] Further analysis of the NOV20a protein yielded the following properties shown in Table 20B.  
               TABLE 20B                       Protein Sequence Properties NOV20a                                        PSort   0.3000 probability located in nucleus; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0430] A search of the NOV20a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 20C.  
               TABLE 20C                          Geneseq Results for NOV20a                                         NOV20a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG81374   Human AFP   61 . . . 239   178/179 (99%)    e−101           protein sequence   13 . . . 191   178/179 (99%)           SEQ ID NO:           266— Homo               sapiens , 191 aa.           [WO200129221-           A2, Apr. 26,           2001]       AAG57770     Arabidopsis     63 . . . 239    56/182 (30%)   1e−13              thaliana  protein   18 . . . 178    94/182 (50%)             Arabidopsis               thaliana , 184 aa.           [EP1033405-A2,           Sep. 6, 2000]       AAG57771     Arabidopsis     74 . . . 239    52/171 (30%)   2e−11              thaliana  protein    1 . . . 150    89/171 (51%)           fragment SEQ ID           NO:74487—             Arabidopsis               thaliana , 156 aa.           [EP1033405-A2,           Sep. 6, 2000]                  
 
     [0431] In a BLAST search of public sequence databases, the NOV20a protein was found to have homology to the proteins shown in the BLASTP data in Table 20D.  
               TABLE 20D                          Public BLASTP Results for NOV20a                                         NOV20a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q969E8   UNKNOWN   61 . . . 239   178/179 (99%)    e−101           (PROTEIN FOR   13 . . . 191   178/179 (99%)           MGC:20451)           (PROTEIN FOR           IMAGE:3953868)—             Homo sapiens             (Human), 191 aa.       Q9NAD8   Y51H4A.15    1 . . . 239    66/239 (27%)   5e−23            PROTEIN—    1 . . . 225   122/239 (50%)             Caenorhabditis               elegans , 225 aa.       Q06672   HIGHLY ACIDIC   63 . . . 238    46/177 (25%)   5e−11            C-TERMINUS—   79 . . . 244    82/177 (45%)             Saccharomyces               cerevisiae  (Baker&#39;s           yeast), 249 aa.       Q9VB10   CG14543   71 . . . 238    49/174 (28%)   2e−10            PROTEIN—   24 . . . 195    81/174 (46%)             Drosophila               melanogaster             (Fruit fly), 195 aa.       Q9UUA9   HYPOTHETICAL   70 . . . 239    42/172 (24%)   2e−06            HIGHLY ACIDIC   22 . . . 178    83/172 (47%)           C-TERMINUS           PROTEIN—             Schizosaccharo-               myces pombe             (Fission yeast),           179 aa.                  
 
     [0432] PFam analysis predicts that the NOV20a protein contains the domains shown in the Table 20E.  
               TABLE 20E                          Domain Analysis of NOV20a                                 NOV20a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value                         No Significant Matches Found                  
 
     Example 21  
     [0433] The NOV21 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 21A.  
               TABLE 21A                       NOV21 Sequence Analysis                                                SEQ ID NO:75   7741 bp                     NOV21a,     TTGTCTCTTTGTGTTTTCCAGACATTCTAAGTGAGACTGTCCACATCATCTAGGAAA   A         CG57804-01 DNA Sequence             TG GTGGCCCTGTCCTTAAAGATTTGTGTGCGCCACTGCAACGTGGTGAAGACCATGCA                   GTTTGAACCATCTACAGCTGTGTACGATGCGTGTCGAGTCATTCGGGAACGGGTGCCT                   GAGGCACAAACTGGGCAAGCTTCTGACTATGGACTCTTTCTTTCGGATGAAGACCCGA                   GGAAAGGGATTTGGCTGGAAGCGGGCAGAACACTGGATTACTACATGTTGCGGAATGG                   GGATATTTTGGAATATAAAAAGAAACAGAGACCTCAGAAAATCCGGATGCTGGATGGA                   TCTGTGAAGACAGTGATGGTGGATGATTCCAAGACTGTGGGGGAGCTCCTGGTCACTA                   TTTGTAGCAGAATAGGAATAACAAATTATGAAGAATACTCCTTAATCCAAGAAACTAT                   TGAAGAAAAGAAAGAGGAAGGAACGGGCACACTCAAAAAAGACAGGACACTGTTACGA                   GATGAGAGGAAAATGGAGAAGTTGAAGGCCAAGCTGCACACAGATGATGACCTAAATT                   GGCTGGATCACAGCCGAACATTCAGAGAACAAGGAGTAGATGAAAACGAAACGTTGCT                   GCTTAGACGGAAGTTCTTTTACTCTGATCAGAATGTAGATTCGAGAGACCCCGTGCAG                   CTGAACTTGCTTTATGTTCAGGCACGGGATGACATCCTGAATGGCTCTCACCCTGTCT                   CCTTCGAGAAACCTTGTGAGTTTGGTGGATTTCAAGCCCAGATACAATTTGGACCTCA                   TGTGGAACATAAACACAAACCTGGATTTTTAGATCTGAAGGAATTCCTGCCCAAAGAA                   TATATCAAGCAGAGAGGAGCTGAAAAGAGGATCTTTCAGGAGCATAAGAACTGCGGAG                   AGATGAGTGAGATAGAAGCCAAGGTCAAGTACGTCAAACTCGCACGGTCCCTCCGCAC                   ATATGGCGTGTCCTTCTTCCTGGTGAAGGAGAAGATGAAAGGCAAGAACAAGCTGGTG                   CCTCGCCTGCTGGGGATCACCAAAGACTCGGTGATGCGCGTGGATGAGAAGACCAAGG                   AAGTGCTGCAGGAGTGGCCCCTCACCACCGTCAAGCGCTGGGCAGCCTCACCCAAGAG                   CTTCACACTGGATTTTGGGGAGTATCAGGAAAGCTACTATTCAGTACAAACCACCGAG                   GGAGAGCAGATATCCCAGCTGATTGCAGGCTACATTGACATCATCCTGAAAAAGGGAA                   CATACGTGACATCTGTGGGGTCTCCTCATTGCACTCCACATGGCTGGTGTTCTCTCAG                   TGACCAAACCACTTTTCCCGGCAGGTCCACCATCTTGCAGCAGCAGTTCAACCGGACC                   GGGAAGGCAGAGCACGGCTCAGTGGCGCTGCCGGCCGTGATGCGCTCGGGCTCCAGCG                   GGCCTGAGACCTTCAACGTTGGCAGCATGCCCTCGCCACAGCAGCAGGTCATGGTTGG                   GCAGATGCACCGAGGCCACATGCCGCCACTGACCTCAGCCCAGCAGGCCCTGATGGGG                   ACCATCAACACAAGCATGCACGCCGTCCAGCAGGCCCAGGATGATCTCAGTGAGCTCG                   ACTCGCTGCCACCTCTCGGCCAGGATATGGCATCTAGGGTATGGGTTCAGAACAAAGT                   CGACGAATCCAAACACGAAATCCATTCTCAAGTTGATGCTATCACGGCCGGAACGGCT                   TCAGTTGTTAACCTCACAGCTGGTGACCCTGCAGACACTGACTACACAGCTGTGGGAT                   GTGCGATCACCACTATTTCTTCCAACCTGACGGAGATGTCCAAGGGTGTGAAGCTATT                   GGCCGCCCTCATGGATGATGAGGTGGGCAGCGGGGAGGACTTGCTCAGAGCTGCCAGG                   ACCCTCGCTGGGGCGGTGTCAGACTTGCTGAAAGCTGTGCAGCCTACTTCTGGAGAGC                   CTCGACAGACAGTTTTGACTGCTGCTGGCAGCATCGGACAAGCCAGTGGGGATCTTCT                   GAGACAGATTGGAGAGAATGAGACTGATGAGCGATTCCAGGATGTTTTAATGAGTTTG                   GCCAAAGCTGTTGCCAATGCAGCTGCCATGTTGGTACTAAAGGCAAAGAATGTTGCCC                   AAGTGGCCGAAGACACTGTCCTACAGAACAGGGTAATTGCTGCTGCCACCCAGTGTGC                   CCTCTCCACCTCCCAGCTTGTGGCATGTGCCAAGGTTGTGAGCCCCACTATTAGCTCC                   CCTGTGTGCCAGGAGCAGCTGATTGAAGCAGGGAAGCTGGTGGACCGCTCGGTGGAGA                   ACTGTGTCCGTGCCTGCCAGGCGGCCACTACCGATAGTGAGCTCCTGAAGCAGGTCAG                   CGCAGCGGCCAGCGTGGTCAGCCAGGCCCTCCATGATCTCCTGCAGCATGTGCGGCAG                   TTTGCCAGCCGAGGCGAGCCCATCGGCCGCTACGACCAGGCTACTGACACCATCATGT                   GTGTCACCGAGAGCATCTTCAGCTCCATGGGTGACGCTGGTGAAATGGTGCGCCAGGC                   GCGGGTTCTGGCCCAAGCCACATCAGACCTCGTCAATGCCATGAGGTCAGATGCAGAA                   GCCGAAATCGACATGGAGAATTCAAAGAAGCTCCTGGCAGCAGCAAAACTCTTAGCTG                   ACTCCACTGCTCGCATGGTGGAAGCTGCAAAGGGGGCTGCAGCCAACCCAGAGAATGA                   GGACCAGCAGCAAAGGCTGAGAGAAGCTGCAGAAGGCCTCCGGGTAGCAACCAACGCA                   GCTGCCCAGAATGCTATTAAGAAAAAAATTGTCAACCGACTGGAGGTTGCAGCCAAGC                   AGGCCGCAGCGGCAGCCACACAGACCATCGCCGCCTCCCAGAATGCAGCTGTTTCCAA                   CAAGAACCCTGCGGCCCAGCAGCAGCTGGTCCAGAGTTGCAAGGCAGTGGCTGATCAC                   ATCCCTCAGCTGGTCCAGGGAGTGAGGGGGAGCCAAGCTCAAGCTGAAGACCTGAGTG                   CCCAGCTGGCTCTCATCATCTCCAGCCAGAACTTCCTCCAGCCTGGAAGCAAGATGGT                   GTCCTCTGCCAAAGCCGCAGTGCCCACCGTGAGTGACCAGGCCGCAGCCATGCAGCTG                   AGCCAGTGTGCCAAGAACCTGGCCACCAGCTTGGCGGAGCTGCGTACCGCCTCGCAGA                   AGGCCCATGAAGCTTGTGGTCCGATGGAAATCGATTCAGCTCTGAATACGGTGCAGAC                   GCTTAAGAATGAACTGCAGGATGCCAAGATGGCAGCCGTGGAGAGCCAGCTGAAGCCA                   CTTCCAGGGGAAACGCTGGAAAAATGTGCTCAGGACCTGGGAAGCACATCCAAGGCGG                   TGGGCTCCTCCATGGCACAGCTGCTGACCTGTGCTGCTCAAGGCAACGAACACTACAC                   AGGGGTGGCTGCTAGAGAGACGGCCCAAGCTCTGAAAACACTGGCCCAGGCCGCCCGT                   GGAGTGGCTGCATCGACAACCGACCCCGCGGCCGCCCATGCCATGTTAGATTCTGCTC                   GAGACGTGATGGAGGGCTCCGCCATGCTCATTCAAGAGGCCAAGCAGGCCCTGATTGC                   ACCTGGAGATGCAGAGCGTCAACAAAGACTGGCTCAGGTGGCTAAAGCCGTCTCACAC                   TCCTTGAATAACTGCGTAAATTGCCTCCCTGGGCAGAAGGATGTGGACGTGGCCTTGA                   AGAGCATCGGGGAGTCCAGCAAGAAGCTQCTTGTGGATTCGCTACCTCCAAGCACGAA                   GCCTTTCCAGGAAGCCCAGAGTGAACTGAACCAGGCAGCAGCTGATCTGAACCAGTCT                   GCTGGGGAAGTGGTCCATGCCACCCGGGGCCAGAGTGGACAGTTGGCTGCAGCCTCTG                   GAAAGTTCAGTGATGATTTTGGTGAATTCCTCGATGCTGGCATTGAGATGGCTGGCCA                   AGCTCAGACAAAAGAAGACCAGATCCAAGTGATAGGGAACCTCAAGAATATCTCGATG                   GCATCCAGCAAGCTGCTGTTAGCTGCCAAGTCTCTCTCTGTAGATCCAGGAGCTCCCA                   ATGCGAAAAATCTCCTGGCTGCAGCTGCAAGAGCTGTGACAGAGAGCATCAATCAACT                   CATCACTCTGTGTACCCAACAAGCTCCGGGCCAGAAAGAGTGCGATAATGCCCTGCGG                   GAGCTCGAGACTGTGAAGGGGATGTTGGACAATCCTAATGAACCTGTTAGTGACCTCT                   CTTACTTTGACTGCATTGAGAGTGTGATGGAAAACTCCAAGGTTCTGGGTGAATCGAT                   GGCAGGGATTTCACAGAATGCCAAGACCGGAGACCTCCCTGCCTTTGGGGAATGTGTG                   GGGATTGCATCCAAGGCTCTCTGTGGGCTGACAGAGGCTGCAGCCCAGGCTGCATACT                   TGGTTGGCATCTCTGATCCAAACAGCCAGGCAGGCCACCAGGGCCTGGTGGACCCCAT                   CCAGTTTGCCAGGGCTAACCAGGCCATCCAGATGGCATGCCAGAACTTGGTGGACCCT                   GGCAGCAGCCCATCACAGGTCCTGTCAGCCGCCACAATTGTTGCCAAGCACACGTCAG                   CCTTGTGCAATGCCTGCCGCATCGCCTCATCCAAGACGGCCAACCCAGTAGCCAAGAG                   GCACTTCGTCCAGTCAGCCAAGGAAGTCGCCAACAGCACTGCCAACCTGGTGAAGACC                   ATCAAGGCCCTGGATGGGGATTTCTCTGAAGACAACCGCAATAAGTGTCGCATCGCCA                   CCGCACCCTTGATTGAAGCTGTGGAGAACCTGACAGCGTTCGCCTCAAACCCTGAGTT                   TGTCAGCATTCCTGCCCAGATCAGCTCCGAGGGTTCCCAGGCACAGGAACCAATCCTG                   GTCTCAGCCAAGACCATGCTGGAGAGTTCATCGTACCTCATTCGCACTGCACGCTCTC                   TGGCCATCAACCCCAAAGACCCACCCACCTGGTCTGTACTGGCTGGACATTCCCATAC                   AGTGTCCGACTCCATCAAGAGTCTCATCACTTCTATCAGGGACAAGGCCCCTGGACAG                   AGGGAGTGTGATTACTCCATCGATGGCATCAACCGGTGCATCCGGGACATCGAGCAGG                   CCTCGCTGGCCGCCGTCAGCCAGAGCCTGGCCACGAGGGACGACATCTCTGTGGAGGC                   CCTGCAGGAGCAGCTGACTTCGGTGGTCCAGGAAATCGGACACCTTATCGATCCCATC                   GCCACAGCGGCTCGGGGAGAAGCAGCTCAGCTGGGACATAAGGTGACACAACTGGCAA                   GCTATTTTGAGCCCTTGATCTTAGCCGCAGTTGGTGTGGCCTCCAAGATTCTTGATCA                   TCAGCAGCAGATGACGGTGCTGGACCAGACCAAGACTCTCGCAGAGTCTGCCTTGCAG                   ATGTTGTATGCAGCCAAAGAAGGTGGCGGAAACCCCAAGGCACAACACACCCATGACG                   CCATCACAGAGGCCGCCCAGTTGATGAAGGAAGCCGTGGATGACATCATGGTGACGCT                   GAACGAAGCTGCCAGTGAAGTGGGGCTGGTTGGGGGCATGGTGGACGCCATTGCAGAA                   GCCATGAGCAAGCTGGATGAAGGCACTCCTCCAGAACCAAAGGGAACATTTGTCGACT                   ATCAGACGACTGTGGTTAAATACTCCAAAGCCATTGCGGTGACAGCTCAGGAAATGAT                   GACTAAGTCGGTTACTAACCCGGAGGAGTTGGGAGGACTGGCTTCACAAATGACCAGT                   GACTATGGGCACCTGGCTTTCCAGGGCCAGATGGCAGCAGCCACGGCGGAACCAGAGG                   AGATCGGATTCCAGATTCGCACTCGTGTGCAGGACCTGGGCCACGGCTGTATCTTCCT                   GGTGCAGAAGGCAGGGGCCCTCCAGGTCTGCCCCACAGACAGCTACACCAAGAGGGAG                   CTGATCGAATGCGCCCGTGCCGTCACGGAAAAGGTCTCCTTGGTGCTCTCGGCTCTCC                   AGGCCGGGAACAAAGGAACCCAGGCATGCATTACAGCCGCCACCGCTGTGTCTGGGAT                   CATTGCCGACCTGGACACCACCATTATGTTTGCAACAGCGGGGACGCTGAATGCAGAG                   AACAGTGAGACCTTCGCAGACCACAGGGAGAACATTCTCAAGACGGCCAAGGCCTTGG                   TAGAAGACACGAAACTACTTGTGTCAGGAGCTGCGTCCACTCCTGACAAGCTGGCCCA                   GGCGGCCCAGTCCTCAGCAGCCACCATCACCCAGCTCGCAGAAGTGGTCAAGCTGGGG                   GCAGCCAGCCTGGGCTCCGACGACCCCGAGACCCAGGTGGATTTGATCAATGCCATCA                   AAGATGTGGCCAAGGCCCTTTCTGATCTCATCAGTGCTACCAAGGGAGCTGCCAGCAA                   GCCAGTGGACGACCCTTCCATGTACCAGCTCAAGGGGGCTGCCAAGGTGATGGTGACC                   AATGTCACCTCGCTCCTCAAGACTGTAAAGGCAGTGGAGGATGAGGCCACCCGGGGCA                   CCAGGGCGCTTGAGGCCACAATTGAATGCATAAAGCAGGAGCTTACGGTGTTCCAGTC                   AAAAGACGTACCTGAAAAGACATCATCACCTGAAGAATCCATAAGGATGACGAAAGGC                   ATCACCATGGCAACAGCCAAAGCCGTGGCAGCTGGGAACTCATGTAGACAGGAGGACG                   TGATTGCTACTGCCAACCTGAGCCGGAAAGCCGTGTCAGATATGTTGACGGCTTGCAA                   GCAAGCATCCTTCCACCCCGATGTCAGTGACGAGGTGAGAACCAGAGCCTTGCGTTTC                   GGGACGGAGTGCACCCTTGGCTACTTGGACCTCCTGGAGCACGTCTTGGTGATTCTTC                   AGAAACCAACCCCAGAATTCAAGCAGCAGCTGGCCGCTTTCTCCAAGCGAGTCGCCGG                   CGCTGTGACAGAGCTCATCCAGGCGGCGGAAGCCATGAAAGGAACAGAGTGGGTGGAT                   CCAGAAGACCCAACTGTCATTGCAGAAACAGAGTTACTGGGGGCTGCAGCATCCATCG                   AAGCTGCTGCTAAGAAGTTAGAGCAACTGAAGCCAAGAGCAAAACCAAAACAAGCGGA                   TGAGACCCTGGACTTTGAGGAACAGATCTTGGAAGCTGCTAAATCCATTGCTGCTGCC                   ACAAGCGCCCTGGTCAAATCGGCCTCAGCAGCCCAGAGGGAGCTGGTGGCCCAAGGAA                   AGGTGGGCTCCATCCCTGCCAATGCTGCAGACGACGGACAGTGGTCACAGGGGCTGAT                   TTCTGCTGCCCGGATGGTGGCGGCTGCGACCAGCAGTCTCTGTGAGGCGGCCAATGCC                   TCCGTTCAGGGACACGCCAGCGAGGAGAAGCTCATCTCATCTGCCAAGCAGGTCGCCG                   CTTCCACGGCTCAGCTGCTGGTGGCCTGCAAGGTGAAGGCCGACCAGGATTCAGAGGC                   CATGAGGCGGCTACAGGCGGCAGGAAATGCTGTGAAAAGAGCCTCAGACAATCTTGTC                   CGTGCAGCCCAGAAGGCAGCTTTTGGCAAAGCTGATGACGACGATGTTGTAGTGGAAA                   CCAAGTTTGTGGGGGGCATTGCTCAGATCATCGCCGCCCAGGAAGAAATGCTAAAGAA                   AGAGCGAGAACTGGAAGAAGCAAGGAAAAAACTGGCCCAAATCCGCCAGCAGCAGTAT                   AAGTTTTTACCCACCGAGCTGAGGGAAGATGAGGGC TAA   AGGTGCGAGCCCAGATGGC                       GAGCCCCAGGGGATGGCCCTGGCTGAA                                           ORF Start: ATG at 58       ORF Stop: TAA at 7693           SEQ ID NO:76   2545 aa   MW at 271692.8 kD                     NOV21a,   MVALSLKICVRHCNVVKTMQFEPSTAVYDACRVIRERVPEAQTGQASDYGLFLSDEDP       CG57804-01 Protein       Sequence   RKGIWLEAGRTLDYYMLRNGDILEYKKKQRPQKIRMLDGSVKTVMVDDSKTVGELLVT                   ICSRIGITNYEEYSLIQETIEEKKEEGTGTLKKDRTLLRDERKMEKLKAKLHTDDDLN                   WLDHSRTFREQGVDENETLLLRRKFFYSDQNVDSRDPVQLNLLYVQARDDILNGSHPV                   SFEKACEFGGFQAQIQFGPHVEHKHKPGFLDLKEFLPKEYIKQRGAEKRIFQEHKNCG                   EMSEIEAKVKYVKLARSLRTYGVSFFLVKEKMKGKNKLVPRLLGITKDSVMRVDEKTK                   EVLQEWPLTTVKRWAASPKSFTLDFGEYQESYYSVQTTEGEQISQLIAGYIDIILKKG                   TYVTSVGSPHCTPHGWCSLSDQTTFPGRSTILQQQFNRTGKAEHGSVALPAVMRSGSS                   GPSTFNVGSMPSPQQQVMVGQMHRGHMPPLTSAQQALMGTINTSMHAVQQAQDDLSEL                   DSLPPLGQDMASRVWVQNKVDESKHEIHSQVDAITAGTASVVNLTAGDPADTDYTAVG                   CAITTISSNLTEMSKGVKLLAALMDDEVGSGEDLLRAARTLAGAVSDLLKAVQPTSGE                   PRQTVLTAAGSIGQASGDLLRQIGENETDERFQDVLMSLAKAVANAAAMLVLKAKNVA                   QVAEDTVLQNRVIAAATQCALSTSQLVACAKVVSPTISSPVCQEQLIEAGKLVDRSVE                   NCVRACQAATTDSELLKQVSAAASVVSQALHDLLQHVRQFASRGEPIGRYDQATDTIM                   CVTESIFSSMGDAGEMVRQARVLAQATSDLVNAMRSDAEAEIDMENSKKLLAAAKLLA                   DSTARMVEAAKGAAANPENEDQQQRLREAAEGLRVATNAAAQNAIKKKIVNRLEVAAK                   QAAAAATQTIAASQNAAVSNKNPAAQQQLVQSCKAVADHIPQLVQGVRGSQAQAEDLS                   AQLALIISSQNFLQPGSKMVSSAKAAVPTVSDQAAAMQLSQCAKNLATSLAELRTASQ                   KAHEACGPMEIDSALNTVQTLKNELQDAKMAAVESQLKPLPGETLEKCAQDLGSTSKA                   VGSSMAQLLTCAAQGNEHYTGVAARETAQALKTLAQAARGVAASTTDPAAAHAMKDSA                   RDVMEGSAMLIQEAKQALIAPGDAERQQRLAQVAKAVSHSLNNCVNCLPGQKDVDVAL                   KSIGESSKKLLVDSLPPSTKPFQEAQSELNQAAADLNQSAGEVVHATRGQSGELAAAS                   GKFSDDFGEFLDAGIEMAGQAQTKEDQIQVIGNLKNISMASSKLLLAAKSLSVDPGAP                   NAKNLLAAAARAVTESINQLITLCTQQAPGQKECDNALRELETVKGMLDNPNEPVSDL                   SYFDCIESVMENSKVLGESMAGISQNAKTGDLPAFGECVGIASKALCGLTEAAAQAAY                   LVGISDPNSQAGHQGLVDPIQFARANQAIQMACQNLVDPGSSPSQVLSAATIVAKHTS                   ALCNACRIASSKTANPVAKRHFVQSAKEVANSTANLVKTIKALDGDFSEDNRNKCRIA                   TAPLIEAVENLTAFASNPEFVSIPAQISSEGSQAQEPILVSAKTMLESSSYLIRTARS                   LAINPKDPPTWSVLAGHSHTVSDSIKSLITSIRDKAPGQRECDYSIDGINRCIRDIEQ                   ASLAAVSQSLATRDDISVEALQEQLTSVVQEIGHLIDPIATAARGEAAQLGHKVTQLA                   SYFEPLILAAVGVASKILDHQQQMTVLDQTKTLAESALQMLYAAKEGGGNPKAQHTHD                   AITEAAQLMKEAVDDIMVTLNEAASEVGLVGGMVDAIAEAMSKLDEGTPPEPKGTFVD                   YQTTVVKYSKAIAVTAQEMMTKSVTNPEELGGLASQMTSDYGHLAFQGQMAAATAEPE                   EIGFQIRTRVQDLGHGCIFLVQKAGALQVCPTDSYTKRELIECARAVTEKVSLVLSAL                   QAGNKGTQACITAATAVSGIIADLDTTIMFATAGTLNAENSETFADHRENILKTAKAL                   VEDTKLLVSGAASTPDKLAQAAQSSAATITQLAEVVKLGAASLGSDDPETQVDLINAI                   KDVAKALSDLISATKGAASKPVDDPSMYQLKGAAKVMVTNVTSLLKTVKAVEDEATRG                   TRALEATIECIKQELTVFQSKDVPEKTSSPEESIRMTKGITMATAKAVAAGNSCRQED                   VIATANLSRKAVSDMLTACKQASFHPDVSDEVRTRALRFGTECTLGYLDLLEHVLVIL                   QKPTPEFKQQLAAFSKRVAGAVTELIQAAEAMKGTEWVDPEDPTVIAETELLGAAASI                   EAAAKKLEQLKPRAKPKQADETLDFEEQILEAAKSIAAATSALVKSASAAQRELVAQG                   KVGSIPANAADDGQWSQSLISAARMVAAATSSLCEAANASVQGHASEEKLISSAKQVA                   ASTAQLLVACKVKADQDSEAMRRLQAAGNAVKRASDNLVRAAQKAAFGKADDDDVVVE                   TKFVGGIAQIIAAQEEMLKKERELEEARKKLAQIRQQQYKFLPTELREDEG                  
 
     [0434] Further analysis of the NOV21a protein yielded the following properties shown in Table 21B.  
               TABLE 21B                       Protein Sequence Properties NOV21a                                        PSort   0.5964 probability located in mitochondrial matrix space;       analysis:   0.3037 probability located in mitochondrial inner membrane;           0.3037 probability located in mitochondrial intermembrane           space; 0.3037 probability located in mitochondrial outer           membrane       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0435] A search of the NOV21a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 21C.  
               TABLE 21C                          Geneseq Results for NOV21a                                             Identities/                   NOV21a   Similarities           Protein/   Residues/   for the       Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB41087   Human ORFX     1 . . . 2543   1913/2546   0.0           ORF851 poly-       (75%)           peptide sequence     1 . . . 2540   2231/2546           SEQ ID NO:       (87%)           1702— Homo               sapiens ,           2541 aa.           [WO200058473-           A2, Oct. 5, 2000]       AAM39312   Human poly-   1381 . . . 2545   1161/1165   0.0           peptide SEQ ID       (99%)           NO 2457— Homo       1 . . . 1165   1163/1165             sapiens , 1165 aa.       (99%)           [WO200153312-           A1, Jul. 26, 2001]       AAM79794   Human protein   1378 . . . 2545   1156/1168   0.0           SEQ ID NO       (98%)           3440— Homo      10 . . . 1177   1160/1168             sapiens , 1177 aa.       (98%)           [WO200157190-           A2, Aug. 9,           2001]       AAM41098   Human poly-   1378 . . . 2545   1156/1168   0.0           peptide SEQ ID       (98%)           NO 6029— Homo      10 . . . 1177   1160/1168             sapiens , 1177 aa.       (98%)           [WO200153312-           A1, Jul. 26, 2001]       AAM41079   Human poly-   1378 . . . 2545   1156/1168   0.0           peptide SEQ ID       (98%)           NO 6010— Homo      10 . . . 1177   1160/1168             sapiens , 1177 aa.       (98%)           [WO200153312-           A1, Jul. 26, 2001]                  
 
     [0436] In a BLAST search of public sequence databases, the NOV21a protein was found to have homology to the proteins shown in the BLASTP data in Table 21D.  
               TABLE 21D                          Public BLASTP Results for NOV21a                                             Identities/                   NOV21a   Similarities       Protein       Residues/   for the       Accession   Protein/   Match   Matched   Value       Number   Organism/Length   Residues   Portion   Expect               Q9Y490   Talin— Homo       1 . . . 2543   1910/2546   0.0             sapiens  (Human),       (75%)           2541 aa.     1 . . . 2540   2230/2546                   (87%)       P26039   Talin— Mus       1 . . . 2543   1907/2546   0.0             musculus         (74%)           (Mouse), 2541 aa.     1 . . . 2540   2230/2546                   (86%)       Q9UPX3   KIAA1027    853 . . . 2543   1262/1694   0.0           PROTEIN—       (74%)           Homo (fragment).     1 . . . 1694   1483/1694                   (87%)       Q9VSL8   CG6831     1 . . . 2532   1197/2563   0.0           PROTEIN       (46%)           (TALIN)—     1 . . . 2534   1707/2563             Drosophila         (65%)             melanogaster             (Fruit fly),           2836 aa.       Q9Y4G6   KIAA0320   1597 . . . 2545   947/949   0.0           PROTEIN—       (99%)             Homo sapiens      1 . . . 949   948/949           (Human), 949 aa       (99%)           (fragment).                  
 
     [0437] PFam analysis predicts that the NOV21a protein contains the domains shown in the Table 21E.  
               TABLE 21E                          Domain Analysis of NOV21a                                     Identities/                   Similarities           NOV21a   for the   Expect       Pfam Domain   Match Region   Matched Region   Value                                     ubiquitin: domain 1 of 1   64 . . . 88     8/27 (30%)   4.3                20/27 (74%)       Band_41: domain 1 of 1   123 . . . 316    67/211 (32%)   1.3e−92               172/211 (82%)       IRS: domain 1 of 1   312 . . . 404    19/109 (17%)   1.2                46/109 (42%)       I_LWEQ: domain 1 of 5   674 . . . 768    31/98 (32%)   11                59/98 (60%)       transport_prot: domain   667 . . . 814    24/182 (13%)   10       1 of 1        88/182 (48%)       I_LWEQ: domain 2 of 5   852 . . . 894    18/47 (38%)   2.4e+02                31/47 (66%)       Vinculin: domain 1 of 1   860 . . . 903    12/48 (25%)   1.3                30/48 (62%)       I_LWEQ: domain 3 of 5   925 . . . 984    21/62 (34%)   5.9e+04                37/62 (60%)       TP_methylase: domain    861 . . . 1036    26/226 (12%)   8       1 of 1       105/226 (46%)       Apolipoprotein: domain    981 . . . 1229    48/288 (17%)   3.5       1 of 1       141/288 (49%)       CAP: domain 1 of 1    917 . . . 1354    94/557 (17%)   4.4               209/557 (38%)       I_LWEQ: domain 4 of 5   1529 . . . 1545    10/17 (59%)   56                13/17 (76%)       STAT: domain 1 of 1   1660 . . . 1821    35/211 (17%)   8.2                95/211 (45%)       LEA: domain 1 of 1   1768 . . . 1834    15/76 (20%)   7                42/76 (55%)       Histone_HNS: domain   2232 . . . 2356    29/143 (20%)   3.7       1 of 1        63/143 (44%)       I_LWEQ: domain 5 of 5   2345 . . . 2536   100/202 (50%)    2e−101               183/202 (91%)                  
 
     Example 22  
     [0438] The NOV22 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 22A.  
               TABLE 22A                       NOV22 Sequence Analysis                                                SEQ ID NO:77   2214 bp                     NOV22a,     ATTCCTCCCTGCCCCTCGTGCAGCCGCTGCC   ATG GCCCAGACACTGCAGATGGAGATC       CG57551-01 DNA Sequence           CCGAACTTCGGCAACAGCATCCTGGAGTGCCTCAATGAACAGCGGCTGCAGGGCCTGT                   ACTGTGACGTGTCAGTGGTGGTCAAGGGCCATGCCTTCAAGGCCCACCGGGCCGTGCT                   TGCTGCCAGCAGCTCCTACTTCCGGGACCTGTTCAACAACAGCCGCAGCGCCGTGGTG                   GAGCTGCCGCCGGCTGTGCAGCCCCAGTCTTTCCAGCAGATCCTCAGCTTCTGCTACA                   CGGGCCGGCTGAGCATGAACGTGGGCGACCAGTTCCTGCTCATGTACACGGCTGGCTT                   CCTGCAGATCCAGGAGATCATGGAGAAGGGCACCGAGTTCTTCCTCAAGGTGAGCTCC                   CCGAGCTGCGACTCCCAGGGCCTGCATGCGGAGGAGGCCCCATCGTCGGAGCCCCAGA                   GCCCCGTGGCGCAGACATCGGGCTGGCCAGCCTGTAGCACCCCGCTGCCCCTCGTGTC                   GCGGGTGAAGACGGAGCAGCAGGAGTCGGACTCCGTGCAGTGCATGCCCGTGGCCAAG                   CGGCTGTGGGACAGTGGCCAGAAGGAGGCTGGGGGCGGCGGCAATGGCAGCCGCAAGA                   TGGCCAAGTTCTCCACGCCGGACCTGGCTGCCAACCGGCCTCACCAGCCCCCGCCACC                   CCAACAGGCTCCGGTGGTGGCAGCAGCCCAGCCCGCCGTGGCTGCGGGAGCAGGGCAG                   CCAGCCGGTGGGGTGGCAGCAGCAGGGGGTGTGGTGAGTGGGCCCAGCACGTCGGAGC                   GGACCAGCCCAGGCACCTCAAGCGCCTACACCAGCGACAGCCCTGGCTCCTACCACAA                   TGAGGAGGACGAGGAGGAGGATGGTGGCGAGGAGGGCATGGATGAGCAGTACCGGCAG                   ATCTGCAACATGTACACCATGTACAGCATGATGAACGTCGGCCAGACAGCCGAGAAGG                   TGGAGGCCCTCCCGGAGCAGGTAGCCCCCGAGTCCCGAAATCGCATCCGGGTTCGGCA                   AGACCTGGCGTCTCTCCCGGCTGAACTTATCAACCAGATTGGGAACCGCTGCCACCCC                   AAGCTCTACGACGAGGGCGACCCCTCTGAGAAGCTGGAGCTGGTGACAGGCACCAACG                   TGTACATCACAAGGGCGCAGCTGATGAACTGCCACGTCAGCGCAGGCACGCGGCACAA                   GGTCCTACTGCGGCGGCTCCTGGCCTCCTTCTTTGACCGGAACACGCTGGCCAACAGC                   TGCGGCACCGGCATCCGCTCTTCTACCAACGATCCCCGTCGGAAGCCCCTGGACAGCC                   GCGTGCTCCACGCTGTCAAGTACTACTGCCAGAACTTCGCCCCCAACTTCAAGGAGAG                   CGAGATGAATGCCATCGCGGCCGACATGTGCACCAACGCCCGCCGCGTCGTGCGCAAG                   AGCTGGATGCCCAAGGTCAAGGTGCTCAAGGCTGAGGATGACGCCTACACCACCTTCA                   TCAGTGAAACGGGCAAGATCGAGCCGGACATGATGGGTGTGGAGCATGGCTTCGAGAC                   CGCCAGCCACGAGGGCGAGGCGGGTCCCATCGCTGAAGCCCTGCAG TAA   CCCGCCCAG                       CCTCCCGCGGGGCCGCACACTTCCCCTCCCAACACACACACACACCTGCCATCTTGGT                       CATGAGCTACTGTCTGTCCCTCCCCAGGACCCGCGGTGGGTGCTGCATGTTCCCGGCC                       CTCTGCCCCTCCTGTCCTACCCCCTTTCCCCACCGAGAGCTGGGCCGGGAGAGGACCG                       CAGGGCAGGTGGCGTGAGGTCCGTGTTGCCTTCTTTAACACACACTCGTGCAGTGGGG                       GAGTTCTGGCTCCCCAACCTAACCCCTAGCCGTCATCTCCACACTCACCAGGCCCACC                       AGGGGAGGGGGCTGGCCTGGGGGTCTTGGGAAGGCCCCTCCCCAGGCCTTAGGCCACC                       TCGCGGAAGCCTTCAGCCTCCGCCCCTCACTGCAGCCCCTTGGGACTTGAGGGGGGCC                       CCAGGGGTTCTCAGGACCCCTCCCACCACCTCCCAGTGCTTCCACGTCTCCAAAAGCG                       CCTTCCTGTCACCCTCGTCTATCCCTGCGCCTGGGGGCTGGGGTAGGCGAGGCCGTGG                       GGACTACCCATTTTATAGCTGGGGAAACAGGCTCCGAGAAATTGCACAACCGACCTCA                       GGTGGCCGGC                                           ORF Start: ATG at 32       ORF Stop: TAA at 1613           SEQ ID NO:78   527 aa   MW at 57283.8 kD                     NOV22a,   MAQTLQMEIPNFGNSILECLNEQRLQGLYCDVSVVVKGHAFKAHRAVLAASSSYFRDL       CG57551-01 Protein Sequence           FNNSRSAVVELPAAVQPQSFQQILSFCYTGRLSMNVGDQFLLMYTAGFLQIQEIMEKG                   TEFFLKVSSPSCDSQGLHAEEAPSSEPQSPVAQTSGWPACSTPLPLVSRVKTEQOESD                   SVQCMPVAKRLWDSGQKEAGGGGNGSRKMAKFSTPDLAANRPHQPPPPQQAPVVAAAQ                   PAVAAGAGQPAGGVAAAGGVVSGPSTSERTSPGTSSAYTSDSPGSYHNEEDEEEDGGE                   EGMDEQYRQICNMYTMYSMMNVGQTAEKVEALPEQVAPESRNRIRVRQDLASLPAELI                   NQIGNRCHPKLYDEGDPSEKLELVTGTNVYITRAQLMNCHVSAGTRHKVLLRRLLASF                   FDRNTLANSCGTGIRSSTNDPRRKPLDSRVLHAVKYYCQNFAPNFKESEMNAIAADMC                   TNARRVVRKSWMPKVKVLKAEDDAYTTFISETGKIEPDMMGVEHGFETASHEGEAGPI                   AEALQ                  
 
     [0439] Further analysis of the NOV22a protein yielded the following properties shown in Table 22B.  
               TABLE 22B                       Protein Sequence Properties NOV22a                                        PSort   0.6000 probability located in nucleus; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0440] A search of the NOV22a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 22C.  
               TABLE 22C                          Geneseq Results for NOV22a                                         NOV22a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB41621   Human ORFX   300 . . . 527   228/228    e−131           ORF1385 poly-       (100%)           peptide sequence    1 . . . 228   228/228           SEQ ID NO:       (100%)           2770— Homo               sapiens , 228 aa.           [WO200058473-           A2, Oct. 5, 2000]       ABB17117   Human nervous   409 . . . 501   64/94   7e−29            system related       (68%)           polypeptide SEQ    1 . . . 93   73/94           ID NO 5774—       (77%)             Homo sapiens ,           190 aa.           [WO200159063-           A2, Aug. 16,           2001]       AAG78615   Human zinc    5 . . . 159    62/164   2e−25            finger tran-       (37%)           scription factor    7 . . . 170    92/164           BioZFTF45—       (55%)             Homo sapiens ,           413 aa.           [CN1299825-A,           Jun. 20, 2001]       AAY73351   HTRM clone    7 . . . 291    83/291   8e−18            1484257 protein       (28%)           [WO9957144-A2,    1 . . . 277   124/291           Nov. 11, 1999]       (42%)       AAM41058   Human poly-    7 . . . 291    84/295   2e−17            peptide SEQ ID       (28%)           NO 5989— Homo      2 . . . 271   123/295             sapiens , 804 aa.       (41%)           [WO200153312-           A1, Jul. 26, 2001]                  
 
     [0441] In a BLAST search of public sequence databases, the NOV22a protein was found to have homology to the proteins shown in the BLASTP data in Table 22D.  
               TABLE 22D                          Public BLASTP Results for NOV22a                                         NOV22a   Identities/           Protein       Residues/   Similarities       Accession   Protein/   Match   for the   Expect       Number   Organism/Length   Residues   Matched Portion   Value               Q96RE7   NAC1   1 . . . 527   526/527 (99%)   0.0           PROTEIN—   1 . . . 527   526/527 (99%)             Homo sapiens             (Human), 527 aa.       O35260   NAC-1    1 . . . 527   462/530 (87%)   0.0           PROTEIN—   1 . . . 514   475/530 (89%)             Rattus norvegicus             (Rat), 514 aa.       Q9CZ72   4930511N13R1K   1 . . . 527   462/530 (87%)   0.0           PROTEIN— Mus     1 . . . 514   476/530 (89%)             musculus             (Mouse), 514 aa.       Q96BF6   SIMILAR TO   1 . . . 501   289/522 (55%)   e−140           RIKEN CDNA   1 . . . 478   335/522 (63%)           0610020I02           GENE— Homo               sapiens  (Human),           587 aa.       AAH22103   RIKEN CDNA   1 . . . 485   281/502 (55%)   e−139           0610020I02   1 . . . 459   327/502 (64%)           GENE— Mus               musculus             (Mouse), 586 aa.                  
 
     [0442] PFam analysis predicts that the NOV22a protein contains the domains shown in the Table 22E.  
               TABLE 22E                          Domain Analysis of NOV22a                                     Identities/               NOV22a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               BTB: domain 1 of 1   14 . . . 124   40/143 (28%)   6.2e−23               88/143 (62%)                  
 
     Example 23  
     [0443] The NOV23 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 23A.  
               TABLE 23A                       NOV23 Sequence Analysis                                                SEQ ID NO:79   1497 bp                     NOV23a,   b ATGGCCACTGCACAGGTGGAACTGGTGCAGGGTGGTCCCCGGGCTCCAGTAGGGGAGA       CG57411-01 DNA Sequence           AGCTGGAGCTCGTCCTGTCGAACCTGCAGGCAGACGTCCTGGAGTTGCTGCTGGAGTT                   TGTCTACACGGGCTCCCTGGTCATCGACTCGGCCAACGCCAAGACACTGCTGGAGGCG                   GCCAGCAAGTTCCAGTTCCACACCTTCTGCAAAGTCTGCGTGTCCTTTCTCGAGAAGC                   AGCTGACGGCCAGCAACTGCCTGGGCGTGCTGGCCATGGCCGAGGCCATGCAGTGCAG                   CGAGCTCTACCACATGGCCAAGGCCTTCGCGCTGCAGATCTTCCCCGAGGTGGCCGCC                   CAGGAGGAGATCCTCAGCATCTCCAAGGACGACTTCATCGCCTACGTCTCCAACGACA                   GCCTCAACACCAAGGCTGAGGAGCTGGTGTACGAGACAGTCATCAAGTGGATCAAGAA                   GGACCCCGCGACACGCACACAGCTGCAGTACGCGGCTGAGCTCCTGGCCGTGGTCCGC                   CTCCCCTTCATCCACCCCAGCTACCTGCTCAATGTGGTTGACAATGAAGAGCTGATCA                   AGTCATCAGAAGCCTGCCGGGACCTGGTGAACGAGGCCAAACGCTACCATATGCTGCC                   CCACGCCCGCCAGGAGATGCAGACGCCCCGAACCCGGCCGCGCGTCCCTGCAGGTGTG                   GCTGAGGTCATCGTCTTGGTTGGGGGCCGTCAGATGGTGGGGATGACCCAGCGCTCGC                   TGGTGGCCGTCACCTGCTGGAACCCGCAGAACAACAAGTGGTACCCCTTGGCCTCGCT                   GCCCTTCTATGACCGCGAGTTCTTCAGTGTAGTGAGTGCAGGGGACAACATCTACCTC                   TCAGGTGGGATGGAATCAGGGGTGACGCTGGCTGATGTCTGGTGCTACATGTCCCTGC                   TTGATAACTGGAACCTCGTCTCCAGAATGACAGTCCCCCGCTGTCGGCACAATAGCCT                   CGTCTACGATGGGAAGATTTACACCCTCGGGGGACTTGGCGTGGCAGGCAACGTGGAC                   CACGTGGAGGTCCCTGCAGGTGTGGCTGAGGTCATCGTCTTGGTTGGGGGCCGTCAGA                   TGGTGGGGATGACCCAGCGCTCGCTGGTGGCCGTCACCTGCTGGAACCCGCAGAACAA                   CAAGTGGTACCCCTTGGCCTCGCTGGGTGGGATGGAATCAGGGGTGACGCTGGCTGAT                   GTCTGGTGCTACATGTCCCTGCTTGATAACTGGAACCTCGTCTCCAGAATGACAGTCC                   CCCGCTGTCGGCACAATAGCCTCGTCTACGATGGGAAGATTTACACCCTCGGGGGACT                   TGGCGTGGCAGGCAACGTGGACCACGTGGAGGCCTACGAGCCCACAACCAACACATGG                   ACCCTCCTCCCCCACATGCCCTGCCCTGTGTTCAGACACGGCTGCGTCGTGATAAAGA                   AATATATTCAAAGCGGC TGA   CATCAGCAGAAAGCCCACGATAAGACT                                           ORF Start: ATG at 1       ORF Stop: TGA at 1468           SEQ ID NO:80   489 aa   MW at 54208.2 kD                     NOV23a,   MATAQVELVQGGPRAPVGEKLELVLSNLQADVLELLLEFVYTGSLVIDSANAKTLLEA       CG57411-01 Protein Sequence           ASKFQFHTFCKVCVSFLEKQLTASNCLGVLAMAEAMQCSELYHMAKAFALQIFPEVAA                   QEEILSISKDDFIAYVSNDSLNTKAEELVYETVIKWIKKDPATRTQLQYAAELLAVVR                   LPFIHPSYLLNVVDNEELIKSSEACRDLVNEAKRYHMLPHARQEMQTPRTRPRVPAGV                   AEVIVLVGGRQMVGMTQRSLVAVTCWNPQNNKWYPLASLPFYDREFFSVVSAGDNIYL                   SGGMESGVTLADVWCYMSLLDNWNLVSRMTVPRCRHNSLVYDGKIYTLGGLGVAGNVD                   HVEVPAGVAEVIVLVGGRQMVGMTQRSLVAVTCWNPQNNKWYPLASLGGMESGVTLAD                   VWCYMSLLDNWNLVSRMTVPRCRHNSLVYDGKIYTLGGLGVAGNVDHVEAYEPTTNTW                   TLLPHMPCPVFRHGCVVIKKYIQSG                  
 
     [0444] Further analysis of the NOV23a protein yielded the following properties shown in Table 23B.  
               TABLE 23B                       Protein Sequence Properties NOV23a                                        PSort   0.6500 probability located in cytoplasm; 0.2271 probability       analysis:   located in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space; 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0445] A search of the NOV23a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 23C.  
               TABLE 23C                          Geneseq Results for NOV23a                                         NOV23a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB40940   Human ORFX   19 . . . 351   317/333 (95%)    e−180           ORF704 poly-    4 . . . 334   320/333 (95%)           peptide sequence           SEQ ID NO:           1408— Homo               sapiens , 335 aa.           [WO200058473-           A2, Oct. 5, 2000]       AAM38711   Human poly-   22 . . . 472   151/488 (30%)   2e−61            peptide SEQ ID   78 . . . 559   222/488 (44%)           NO 1856— Homo               sapiens , 574 aa.           [WO200153312-           A1, Jul. 26, 2001]       AAB43090   Human ORFX   22 . . . 468   150/491 (30%)   3e−59            ORF2854 poly-    9 . . . 487   241/491 (48%)           peptide sequence           SEQ ID NO:           5708— Homo               sapiens , 506 aa.           [WO200058473-           A2, Oct. 5, 2000]       AAM38956   Human poly-   22 . . . 468   149/491 (30%)   1e−58            peptide SEQ ID    90 . . . 568   240/491 (48%)           NO 2101— Homo               sapiens , 587 aa.           [WO200153312-           A1, Jul. 26, 2001]       AAM94018   Human stomach   25 . . . 470   148/490 (30%)   3e−56            cancer expressed   76 . . . 553   231/490 (46%)           polypeptide SEQ           ID NO 106—             Homo sapiens ,           568 aa.           [WO200109317-           A1, Feb. 8, 2001]                  
 
     [0446] In a BLAST search of public sequence databases, the NOV23a protein was found to have homology to the proteins shown in the BLASTP data in Table 23D.  
               TABLE 23D                          Public BLASTP Results for NOV23a                                         NOV23a   Identities/           Protein       Residues/   Similarities       Accession   Protein/   Match   for the   Expect       Number   Organism/Length   Residues   Matched Portion   Value               Q96CT2   HYPO-    19 . . . 489   390/507 (76%)   0.0           THETICAL   203 . . . 707   406/507 (79%)           76.8 KDA           PROTEIN—             Homo sapiens             (Human), 707 aa           (fragment).       Q96PW7   KIAA1921    19 . . . 489   390/507 (76%)   0.0           PROTEIN—    41 . . . 545   406/507 (79%)             Homo sapiens             (Human), 545 aa           (fragment).       Q96BF0   SIMILAR    19 . . . 351   329/333 (98%)   0.0           TO HYPO-   172 . . . 502   330/333 (98%)           THETICAL           PROTEIN           FLJ14106—             Homo sapiens              (Human), 503 aa.       Q9D5K3   4930429H24RIK    33 . . . 485   165/492 (33%)   2e−66           PROTEIN—    1 . . . 477   248/492 (49%)             Mus musculus             (Mouse), 484 aa.       Q9UH77   Kelch-like protein    22 . . . 468   150/491 (30%)   1e−58           3— Homo sapiens      90 . . . 568   241/491 (48%)           (Human), 587 aa.                  
 
     [0447] PFam analysis predicts that the NOV23a protein contains the domains shown in the Table 23E.  
               TABLE 23E                          Domain Analysis of NOV23a                                     Identities/               NOV23a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               BTB: domain 1 of 1    4 . . . 79   24/143 (17%)   3.7                53/143 (37%)       Kelch: domain 1 of 4   223 . . . 272    9/50 (18%)   0.94                 28/50 (56%)       Kelch: domain 2 of 4   275 . . . 320    11/47 (23%)   0.016                27/47 (57%)       Kelch: domain 3 of 4   322 . . . 396    14/75 (19%)   3.3e−05                44/75 (59%)       Kelch: domain 4 of 4   426 . . . 471    19/47 (40%)   7.2e−10                35/47 (74%)                  
 
     Example 24  
     [0448] The NOV24 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 24A.  
               TABLE 24A                       NOV24 Sequence Analysis                                                SEQ ID NO:81   4268 bp                     NOV24a,     ATG ACCTGGGACACAGCTCTCTGGACCTCAGTTTTTCTGATTGGGCTCCTTCCTACCC       CG57399-01 DNA Sequence           TTGGTTTCGCTAATTGCATCCTCCAGACTTCTGGTAAAATGTGTACTTTAAGAGGTAG                   ATACCCCCAGCCCCCACAACCACCTCTCTGCTTGTCTCCCCTAGTCCACCAGCTCCGA                   CCAGCAGACATCAAAGTGGTGGCCGCCCTGGGTAATGATGAAACCTTCCAGGAAAGTG                   GTGCAGGGCAGCTAAGTGAGCCTGACCCCAGGCAGTGGTCCTGGCCACAGGCCTGCTT                   GCCTGGGGTAAAAAAGGAAATGCAAGATGTGGTAGGTGAGAGAACGCCGAGCCGTCGC                   CGCAGCCTCCGCCGCCGAGAAGCCCTTGTTCCCGCTGCTGGGAAGGAGAGTCTGTGCC                   GACAAGATATTTTCATTTCCTTGTTGGAAATTATCAAGCATTTTCCTCCCTCCCCTCA                   GGACATCAACCTGGAGAAAGACTGGAAGCTGGTCACACTCTTCATTGGGGTCAACGAC                   TTGTGTCATTACTGTCCACTTGTTCAGGGCCCCGTTATAGACCTGGGTGGGATGGATA                   CCCTCCACTCCCTGCAGCTCCCAAGGGCTTTCGTCAACGTGGTGGAGGTCATGGAGCT                   GGCTAGCCTGTACCAGGGCCAAGGCGGGAAATGTGCCATGCTGGCAGCTCAGGAAGCC                   TGGAACAGCCTCCTGGCCTCCAGCAGGTACAGTGAGCAGGAGTCCTTCACCGTGGTTT                   TCCAGCCTTTCTTCTATGAGACCACCCCATCTGACCCCCGACTCCAGGATTCTACCAC                   GCTGGCCTGGCATCTCTGGAATAGGATGATGGAGCCAGCAGGAGAGAAAGATGAGCCA                   TTGAGTGTAAAACACGGGAGGCCAATGAAGTGTCCCTCTCAGGAGAGCCCCTATCTGT                   TCAGCTACAGAAACAGCAACTACCTGACCAGACTGCAGAAACCCCAAGACAAGCTTGT                   AAGAGAAGGAGCGGAAATCAGATGTCCTGACAAAGACCCCTCCGATACGGTTCCCACC                   TCAGTTCATAGGCTGAAGCCGGCTGACATCAACGTAATTGGAGCCCTGGGTGACTCTC                   TCACGGCAGGCAATGGGGCCGGGTCCACACCTGGGAACGTCTTGGACGTCTTGACTCA                   GTACCGAGGCCTGTCCTGGAGCGTCGGCGGAGATGAGAACATCGGCACCGTTACCACC                   CTGGCAGACATCCTCCGGGAATTCAACCCTTCCCTGAAGGGCTTCTCTGTTGGCACTG                   GGAAAGAAACCAGTCCTAATGCCTTCTTAAACCAGGCTGTGGCAGGAGGCCGAGCTGA                   GCAGGCCAGGAGGCTGGTGGACCTGATGAAGAATGACACGAGGATACACTTTCAGGAA                   GACTGGAAGATAATAACCCTGTTTATAGGCGGCAATGACCTCTGTGATTTCTGCAATG                   ATCTGGTACACTATTCTCCCCAGAACTTCACAGACAACATTGGAAAGGCCCTGGACAT                   CCTCCATGCTGAGTCTCAGGTTCCTCGGGCATTTGTGAACCTGGTGACGGTGCTTGAG                   ATCGTCAACCTGAGGGAGCTGTACCAGGAGAAAAAAGTCTACTGCCCAAGGATGATCC                   TCAGGTCACTGTGTCCCTGTGTCCTGAAGTTTGATGATAACTCAACAGAACTTGCTAC                   CCTCATCGAATTCAACAAGAAGTTTCAGGAGAAGACCCACCAACTGATTGAGAGTGGG                   CGATATGACACAAGGGAAGATTTTACTGTGGTTGTGCAGCCGTTCTTTGAAAACGTGG                   ACATGCCAAAGACCCAGGAAGGATTGCCTGACAACTCTTTCTTCGCTCCTGACTGTTT                   CCACTTCAGCAGCAAGTCTCACTCCCGAGCAGCCAGTGCTCTCTGGAACAATATGCTG                   GAGCCTGTTGGCCAGAAGACGACTCGTCATAAGTTTGAAAACAAGATCAATATCACAT                   GTCCGTCACAGGTCCAGCCGTTTCTGAGGACCTACAAGAACAGCATGCAGGGTCATGG                   GACCTGGCTGCCATGCAGGGACAGAGCCCCTTCTGCCTTGCACCCTACCTCAGTGCAT                   GCCCTGAGACCTGCAGACATCCAAGTTGTGGCTGCTCTGGGGGATTCTCTGACCGCTG                   GCAATGGAATTGGCTCCAAACCAGACGACCTCCCCGATGTCACCACACAGTATCGGGG                   ACTGTCATACAGTGCAGGAGGGGACGGCTCCCTGGAGAATGTCACCACCTTACCTAGT                   TCTATCCTTCGCGAGTTTAACAGAAACCTCACAGGCTACGCCGTCGGCACGGGTGATG                   CCAATGACACGAATGCATTCCTCAATCAAGCTGTTCCCGGAGCAAAGGCTAGGGATCT                   TATGAGCCAAGTCCAAACTCTGATGCAGAAGATGAAAGATGATCATAGAGTAAATTTC                   CATGAAGACTGGAAGGTCATCACAGTGCTGATCGGAGGCAGCGATTTATGTGACTACT                   GCACAGATTCGAATCTGTATTCTGCAGCCAACTTTGTTCACCATCTCCGCAATGCCTT                   GGACGTCCTCCATAGAGAGGTGCCCAGAGTCCTGGTCAACCTCGTGGACTTCCTGAAC                   CCCACTATCATGCGGCAGGTGTTCCTGGGAAACCCAGACAAGTGCCCAGTGCAGCAGG                   CCAGCGTTTTGTGTAACTGCGTTCTGACCCTGCGGGAGAACTCCCAAGAGCTAGCCAG                   GCTGGAGGCCTTCAGCCGAGCCTACCAGAGCAGCATGCGCGAGCTGGTGGGGTCAGGC                   CGCTATGACACGCAGGAGGACTTCTCTGTGGTGCTGCAGCCCTTCTTCCAGAACATCC                   AGCTCCCTGTCCTGCAGGATGGGCTCCCAGATACGTCCTTCTTTGCCCCAGACTGCAT                   CCACCCAAATCAGAAATTCCACTCCCAGCTGGCCAGACCCCTTTGGACCAATATGCTT                   GAACCACTTGGAAGCAAAACAGAGACCCTGGACCTGAGAGCAGAGATGCCCATCACCT                   GTCCCACTCAGAATGAGCCCTTCCTGAGAACCCCTCGGAATAGTAACTACACGTACCC                   CATCAAGCCAGCCATTGAGAACTGGGGCAGTGACTTCCTGTGTACAGAGTGGAAGGCT                   TCCAATAGTGTTCCAACCTCTGTCCACCAGCTCCGACCAGCAGACATCAAAGTGGTGG                   CCGCCCTGGGTGACTCTCTGACTACAGCAGTGGGAGCTCGACCAAACAACTCCAGTGA                   CCTACCCACATCTTGGAGGGGACTCTCTTGGAGCATTGGAGGGGATGGGAACTTGGAG                   ACTCACACCACACTGCCCAGTATTCTGAAGAAGTTCAACCCTTACCTCCTTGGCTTCT                   CTACCAGCACCTGGGAGGGGACAGCAGGACTAAATGTGGCAGCGGAAGGGGCCAGAGC                   TAGGAGGGACATGCCAGCCCAGGCCTGGGACCTGGTAGAGCGAATGAAAAACAGCCCC                   ATACACTTTCAGGAAGACTGGAAGATAATAACCCTGTTTATAGGCGGCAATGACCTCT                   GTGATTTCTGCAATGATCTGGTAGGTGAATATGTTCAGCACATCCAACAGGCCCTGGA                   CATCCTCTCTGAGGAGCTCCCAAGGGCTTTCGTCAACGTGGTGGAGGTCATGGAGCTG                   GCTAGCCTGTACCAGGGCCAAGGCGGGAAATGTGCCATGCTGGCAGCTCAGAACAACT                   GCACTTGCCTCAGACACTCGCAAAGCTCCCTGGAGAAGCAAGAACTGAAGAAAGTGAA                   CTGGAACCTCCAGCATGGCATCTCCAGTTTCTCCTACTGGCACCAATACACACAGCGT                   GAGGACTTTGCGGTTGTGGTGCAGCCTTTCTTCCAAAACACACTCACCCCACTGAACA                   GAGGGGACACTGACCTCACCTTCTTCTCCGAGGACTGTTTTCACTTCTCAGACCGCGG                   GCATGCCGAGATGGCCATCGCACTCTGGAACAACATGCTGGAACCAGTGGGCCGCAAG                   ACTACCTCCAACAACTTCACCCACAGCCGAGCCAAACTCAAGTGCCCCTCTCCTGTGA                   GTCCTTACCTCTACACCCTGCGGAACAGCCGATTGCTCCCAGACCAGGCTGAAGAAGC                   CCCCGAGGTGCTCTACTGGGCTGTCCCAGTGGCAGCGGGAGTCGGCCTTGTGGTGGGC                   ATCATCGGGACAGTGGTCTGGAGGTGCAGGAGAGGTGGCCGGAGGGAAGATCCTCCAA                   TGAGCCTGCGCACTGTGGCCCTC TAG   GCCCGGGG                                           ORF Start: ATG at 1       ORF Stop: TAG at 4258           SEQ ID NO:82   1419 aa   MW at 158435.1 kD                     NOV24a,   MTWDTALWTSVFLIGLLPTLGFANCILQTSGKMCTLRGRYPQPPQPPLCLSPLVHQLR       CG57399-01 Protein       Sequence   PADIKVVAALGNDETFQESGAGQLSEPDPRQWSWPQACLPGVKKEMQDVVGERTPSRR                   RSLRRREALVPAAGKESLCRQDIFISLLEIIKHFPPSPQDINLEKDWKLVTLFIGVND                   LCHYCPLVQGPVIDLGGMDTLHSLQLPRAFVNVVEVMELASLYQGQGGKCAMLAAQEA                   WNSLLASSRYSEQESFTVVFQPFFYETTPSDPRLQDSTTLAWHLWNRMMEPAGEKDEP                   LSVKHGRPMKCPSQESPYLFSYRNSNYLTRLQKPQDKLVREGAEIRCPDKDPSDTVPT                   SVHRLKPADINVIGALGDSLTAGNGAGSTPGNVLDVLTQYRGLSWSVGGDENIGTVTT                   LADILREFNPSLKGFSVGTGKETSPNAFLNQAVAGGRAEQARRLVDLMKNDTRIHFQE                   DWKIITLFIGGNDLCDETNDLVHYSPQNFTDNTGKALDILHAESQVPRAFVNLVTVLE                   IVNLRELYQEKKVYCPRMILRSLCPCVLKFDDNSTELATLIEFNKKFQEKTHQLIESG                   RYDTREDFTVVVQPFFENVDMPKTQEGLPDNSFFAPDCFHFSSKSHSRAASALWNNML                   EPVGQKTTRHKFENKINITCPSQVQPFLRTYKNSMQGHGTWLPCRDRAPSALHPTSVH                   ALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYSAGGDGSLENVTTLPS                   SILREFNRNLTGYAVGTGDANDTNAFLNQAVPGAKARDLMSQVQTLMQKMKDDHRVNF                   HEDWKVITVLIGGSDLCDYCTDSNLYDAANFVHHLRNALDVLHREVPRVLVNLVDFLN                   PTIMRQVFLGNPDKCPVQQASVLCNCVLTLRENSQELARLEAFSRAYQSSMRELVGSG                   RYDTQEDFSVVLQPFFQNIQLPVLQDGLPDTSFFAPDCIHPNQKFHSQLARALWTNML                   EPLGSKTETLDLRAEMPITCPTQNEPFLRTPRNSNYTYPIKPAIENWGSDFLCTEWKA                   SNSVPTSVHQLRPADIKVVAALGDSLTTAVGARPNNSSDLPTSWRGLSWSIGGDGNLE                   THTTLPSILKKFNPYLLGFSTSTWEGTAGLNVAAEGARARRDMPAQAWDLVERMKNSP                   IHFQEDWKIITLFIGGNDLCDFCNDLVGEYVQHIQQALDILSEELPRAFVNVVEVMEL                   ASLYQGQGGKCAMLAAQNNCTCLRHSQSSLEKQELKKVNWNLQHGISSFSYWHQYTQR                   EDFAVVVQPFFQNTLTPLNRGDTDLTFFSEDCFHFSDRGHAEMAIALWNNMLEPVGRK                   TTSNNFTHSRAKLKCPSPVSPYLYTLRNSRLLPDQAEEAPEVLYWAVPVAAGVGLVVG                   IIGTVVWRCRRGGRREDPPMSLRTVAL                                         SEQ ID NO:83       1624 bp                     NOV24b,     GCCGGCTGACATCAATGTAATTGGAGCCCTGGGTGACTCTCTCACGGCAGGCAATGGG         CG57399-02 DNA Sequence             GCCGGGTCCACACCTGGGAACGTCTTGGACGTCTTGACTCAGTACCGAGGCCTGTCCT                       GGAGCGTCGGCGGAGATGAGAACATCGGCACCGTTACCACCCTGGCGAACATCCTCCG                       GGAATTCAACCCTTCCCTGAAGGGCTTCTCTGTTGGCACTGGGAAAGAAACCAGTCCT                       AATGCCTTCTTAAACCAGGCTGTGGCAGGAGGCCGAGCTGAGGATCTACCTGTCCAGG                       CCAGGAGGCTGGTGGACCTG   ATG AAGAATGACACGAGGATACACTTTCAGGAAGACTG                   GAAGATAATAACCCTGTTTATAGGCGGCAATGACCTCTGTGATTTCTGCAATGATCTG                   GTCCACTATTCCCCCCAGAACTTCACAGACAACATTGGAAAGGCCCTGGACATCCTCC                   ATGCTGAGGTTCCTCGGGCATTTGTGAACCTGGTGACGGTGCTTGAGATCGTCAACCT                   GAGGGAGCTGTACCAGGAGAAAAAAGTCTACTGCCCAAGGATGATCCTCAGGTCTCTG                   TGTCCCTGTGTCCTGAAGTTTGATGATAACTCAACAGAACTTGCTACCCTCATCGAAT                   TCAACAAGAAGTTTCAGGAGAAGACCCACCAACTGATTGAGAGTGGGCGATATGACAC                   AAGGGAAGATTTTACTGTGGTTGTGCAGCCGTTCTTTGAAAACGTGGACATGCCAAAG                   ACCTCGGAAGGATTGCCTGACAACTCTTTCTTCGCTCCTGACTGTTTCCACTTCAGCA                   GCAAGTCTCACTCCCGAGCAGCCAGTGCTCTCTGGAACAATATGCTGGAGCCTGTTGG                   CCAGAAGACGACTCGTCATAAGTTTGAAAACAAGATCAATATCACATGTCCGAACCAG                   GTCCAGCCGTTTCTGAGGACCTACAAGAACAGCATGCAGGGTCATGGGACCTGGCTGC                   CATGCAGGGACAGAGCCCCTTCTGCCTTGCACCCTACCTCAGTGCATGCCCTGAGACC                   TGCAGACATCCAAGTTGTGGCTGCTCTGGGGGATTCTCTGACCGCTGGCAATGGAATT                   GGCTCCAAACCAGACGACCTCCCCGATGTCACCACACAGTATCGGGGACTGTCATACA                   GAGAAAGTAAACCAGGGTTCTTATCAGACTCCTGGGTCAGCAAATCCAACAGGAAATG                   CACCAGAAAAGCACCAAATCCCTGAATCTTCACCTCCCCGCTTGCATGTATACGTGTA                   CACGTGGTGTTCCTACGTCTCTGTTTACTGTCTTTATGTGTTTATTCATGTTGTCTTG                   TAGTCACACAGCTGCCTTTACATATATGTACACATCTGCACAGAAAACCTCTGAAACC                   CATCGCACACTTCGAGAGGCCATAACCAAGACACAATCACAATCAGCCATGTCTTGAA                   AGATTAGCAATTCGACAAGAGGAAAGGGTGAGAAAGGGCATCCCGAACACGGAAGTGG                   AGAAGCTCAGGGTGTGTCAGGCGAGCGGTTGCGTGTAGATATTCTCAAGTTTCTTTCT                   CTCCTAATAAAGTTCTCATTCCTGTAGGCTTCAAAGTAAGTGGCGAGTAGCTCAGAAT                                         ORF Start: ATG at 311       ORF Stop: TGA at 1241           SEQ ID NO:84   310 aa   MW at 35240.6 kD                     NOV24b,   MKNDTRIHFQEDWKIITLFIGGNDLCHFCNDLVHYSPQNFTDNIGKALDILHAEVPRA       CG57399-02 Protein       Sequence   FVNLVTVLEIVNLRELYQEKKVYCPRMILRSLCPCVLKFDDNSTELATLIEFNKKFQE                   KTHQLIESGRYDTREDPTVVVQPFFENVDMPKTSEGLPDNSFFAPDCFHFSSKSHSRA                   ASALWNNMLEPVGQKTTRHKFENKINITCPNQVQPFLRTYKNSMQGHGTWLPCRDRAP                   SALHPTSVHALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYRESKPGF                   LSDSWVSKSNRKCTRKAPNP                                     SEQ ID NO:85   4425 bp                     NOV24c,     CTGGAGCATTCTGGC   ATG GGGCTGCGGCCAGGCATTTTCCTCCTGGAGCTGCTGCTGC       CG57399-03 DNA Sequence           TTCTGGGGCAAGGTACCCCTCAGATCCATACCTCTCCTAGAAAGAGTACATTGGAAGG                   GCAGCTATGGCCAGAGACAGTTCACTCTCTGAAGCCTTCTGATATTAAATTTGTGGCA                   GCCATTGGCAATCTGGAAATTGTGCCAGACCCAGGGACGGGCGATCTGGAGAAGCAAG                   ACGAAAGGCCACAGCAGGTGTGCATGGGAGTGATGACAGTCCTTTCAGACATCATCAG                   ATATTTCAGTCCTTCTGTTCCAATGCCTGTGTGCCACACTGGAAAGAGAGTCATACCC                   CACGATGGTGCTGAGGACTTGTGGATTCAGGCTCAAGAACTGGTGAGAAACATGAAAG                   AGAACCAACTTGACTTTCAATTTGACTGGAAGCTCATCAATGTGTTCTTCAGTAATGC                   AAGCCAGTGTTACCTGTGCCCCTCTGCTCAACAGAATGCGCTTGCGGCGGGCGGCGTG                   GATGAGCTGATGGGGGTGCTGGACTACCTGCAGCAGGAGGTGCCCAGAGCATTTGTAA                   ACCTGGTGGACCTCTCTGAGGTTGCAGAGGTCTCTCGTCAGTATCACGGCACTTGGCT                   CAGCCCTGCACCAGAGCCCTGTAATTGCTCAGAGGAGACCACCCGGCTGGCCAAGGTG                   GTGATGCAGTGGTCTTATCAGGAAGCCTGGAACAGCCTCCTGGCCTCCAGCAGGTACA                   GTGAGCAGGAGTCCTTCACCGTGGTTTTCCAGCCTTTCTTCTATGAGACCACCCCATC                   TGACCCCCGACTCCAGGATTCTACCACGCTGGCCTGGCATCTCTGGAATAGGATGATG                   GAGCCAGCAGGAGAGAAGATGAGCCATTGAGTGTAAAACACGGGAGGCCAAATGAAGT                   GTCCCTCTCAGGAGAGCCCCTATCTGTTCAGCTACAGAAACAGCAACTACCTGACCAG                   ACTGCAGAAACCCCAAGACAAGCTTGAGGTAAGAGAAGGAGCGGAAATCAGATGTCCT                   GACAAAGACCCCTCCGATACGGTTCCCACCTCAGTTCATAGGCTGAAGCCGGCTGACA                   TCAACGTAATTGGAGCCCTGGGTGACTCTCTCACGGCAGGCAATGGGGCCGGGTCCAC                   ACCTGGGAACCTCTTGGACGTCTTGACTCAGTACCGAGGCCTGTCCTGGAGCGTCGGC                   GGAGATGAGAACATCGGCACCGTTACCACCCTGGCGGACATCCTCCGGGAATTCAACC                   CTTCCCTGAAGGGCTTCTCTGTTGGCACTGGGAAAGAAACCAGTCCTAATGCCTTCTT                   AAACCAGGCTGTGGCAGGAGGCCGAGCTGAGCAGGCCAGGAGGCTGGTGGACCTGATG                   AAGAATGACACGAGGATACACTTTCAGGAAGACTCCAACATAATAACCCTGTTTATAG                   GCGGCAATGACCTCTGTGATTTCTGCAATGATCTGGTACACTATTCTCCCCAGAACTT                   CACAGACAACATTGGAAAGGCCCTGGACATCCTCCATGCTGAGGTTCCTCGGGCATTT                   GTGAACCTGGTGACGGTGCTTGAGATCGTCAACCTGAGGGAGCTGTACCAGGACAAAA                   AAGTCTACTGCCCAAGGATGATCCTCAGGTCACTGTGTCCCTGTGTCCTGAAGTTTGA                   TGATAACTCAACAGAACTTGCTACCCTCATCGAATTCAACAACAAGTTTCAGGAGAAG                   ACCCACCAACTGATTGAGAGTGGGCGATATGACACAAGGGAAGATTTTACTGTGGTTG                   TGCAGCCGTTCTTTGAAAACGTGCACATGCCAAAGACCCAGGAAGGATTGCCTGACAA                   CTCTTTCTTCGCTCCTGACTGTTTCCACTTCAGCAGCAAGTCTCACTCCCGAGCAGCC                   AGTGCTCTCTGGAACAATATGCTGGAGCCTGTTOCCCAGAAGACGACTCGTCATAAGT                   TTGAAAACAAGATCAATATCACATGTCCGAACCACGTAGAGTGGCCGTTTCTGAGGAC                   CTACAAGAACAGCATGCAGGGTCATGGGACCTGGCTGCCATGCAGGGACAGAGCCCCT                   TCTGCCTTGCACCCTACCTCAGTCCATGCCCTGAGACCTGCAGACATCCAAGTTGTGG                   CTGCTCTGGGGGATTCTCTGACCGCTGGCAATGGAATTGGCTCCAAACCAGACGACCT                   CCCCGATGTCACCACACAGTATCGGGGACTGTCATACAGTGCAGGAGGGGACGGCTCC                   CTGGAGAATGTGACCACCTTACCTGATATCCTTCGGGAGTTTAACAGAAACCTCACAG                   GCTACGCCGTGGGCACGGGTGATCCCAATGACACGAATGCATTCCTCAATCAAGCTGT                   TCCCGGAGCAAAGGCTAGGGATCTTATGAGCCAAGTCCAAACTCTGATGCACAAGATG                   AAAGATGATCATAGAGTAAATTTCCATGAAGACTGGAAGGTCATCACAGTGCTGATCG                   GAGGCAGCGATTTATGTGACTACTGCACAGATTCGAATCTGTATTCTGCAGCCAACTT                   TGTTCACCATCTCCGCAATGCCTTGGACGTCCTGCATAGAGAGGTGCCCAGAGTCCTG                   GTCAACCTCGTCGACTTCCTGAACCCCACTATCATGCGGCAGGTGTTCCTGGGAAACC                   CAGACAAGTGCCCAGTGCAGCAGGCCAGCGTTTTGTGTAACTGCGTTCTGACCCTGCG                   GGAGAACTCCCAAGAGCTAGCCAGGCTGGAGGCCTTCAGCCGACCCTACCAGAGCAGC                   ATGCGCGAGCTGGTGGGGTCAGGCCGCTATGACACGCAGGAGGACTTCTCTGTGGTGC                   TGCAGCCCTTCTTCCAGAACATCCAGCTCCCTGTCCTGCAGGATGGGCTCCCAGATAC                   GTCCTTCTTTGCCCCAGACTGCATCCACCCAAATCAGAAATTCCACTCCCAGCTGGCC                   AGAGCCCTTTGGACCAATATGCTTGAACCACTTGGAAGCAAAACAGAGACCCTGGACC                   TGAGAGCAGAGATGCCCATCACCTGTCCCACTCAGAATGAGCCCTTCCTGAGAACCCC                   TCGGAATAGTAACTACACGTACCCCATCAAGCCAGCCATTGAGAACTGGGGCAGTGAC                   TTCCTGTGTACAGAGTGGAAGGCTTCCAATAGTGTTCCAACCTCTGTCCACCAGCTCC                   CACCAGCAGACATCAAAGTGGTGGCCGCCCTGGGTGACTCTCTGACTGTGGCAGTGGG                   AGCTCGACCAAACAACTCCAGTGACCTACCCACATCTTGGAGGGGACTCTCTTGGAGC                   ATTGGAGGGGATGGGAACTTGGAGACTCACACCACACTGCCCGACATTCTGAAGAAGT                   TCAACCCTTACCTCCTTGGCTTCTCTACCAGCACCTGGGAGGGGACAGCAGGACTAAA                   TGTGGCAGCGGAAGGGGCCAGAGCTAGGGACATGCCAGCCCAGGCCTGGGACCTGGTA                   GAGCGAATGAAAAACAGCCCCCAGGACATCAACCTGGAGAAAGACTGGAAGCTGGTCA                   CACTCTTCATTGGGGTCAACGACTTGTGTCATTACTGTGAGAATCCGGTAGGCGAATA                   TGTTCAGCACATCCAACAGGCCCTGGACATCCTCTCTGAGGAGCTCCCAAGGGCTTTC                   GTCAACGTGGTGGAGGTCATGGAGCTGGCTAGCCTGTACCAGGGCCAAGGCGGGAAAT                   GTGCCATGCTGGCAGCTCAGAACAACTGCACTTGCCTCAGACACTCGCAAAGCTCCCT                   GGAGAAGCAAGAACTGAAGAAAGTGAACTGGAACCTCCAGCATGGCATCTCCAGTTTC                   TCCTACTGGCACCAATACACACAGCGTGAGGACTTTGCGGTTGTGGTGCAGCCTTTCT                   TCCAAAACACACTCACCCCACTGAACAGAGGGGACACTGACCTCACCTTCTTCTCCGA                   GGACTGTTTTCACTTCTCAGACCGCGGGCATGCCGAGATGGCCATCGCACTCTGGAAC                   AACATGCTGGAACCAGTGGGCCGCAAGACTACCTCCAACAACTTCACCCACAGCCGAG                   CCAAACTCAAGTGCCCCTCTCCTGAGAGCCCTTACCTCTACACCCTGCGGAACAGCCG                   ATTGCTCCCAGACCAGGCTGAAGAAGCCCCCGAGGTGCTCTACTGGGCTGTCCCAGTG                   GCAGCGGGAGTCGGCCTTGTGGTGGGCATCATCGGGACAGTGGTCTGGAGGTGCAGGA                   GAGGTGGCCGGAGGGAAGATCCTCCAATGAGCCTGCGCACTGTGGCCCTC TAG   GCCCG                       GGGGTGGGTCCTCACCCTAAACTCCCTATAGCCACTCTCTTCACCGCCCTCTGCCCCA                       GCCACTCCCGGCCACCAGGACATGCTTCAATGCCTGGTGCCATAGGAAGCCCAGGGGA                       CAGTCACAACTTCTTGG                                           ORF Start ATG at 16       ORF Stop: TAG at 4285           SEQ ID NO:86   1423 aa   MW at 159352.7 kD                     NOV24c,   MGLRPGIFLLELLLLLGQGTPQIHTSPRKSTLEGQLWPETVHSLKPSKIKFVAAIGNL       CG57399-03 Protein       Sequence   EIVPDPGTGDLEKQDERPQQVCMGVMTVLSDIIRYFSPSVPMPVCHTGKRVIPHDGAE                   DLWIQAQELVRNMKENQLDFQFDWKLINVFFSNASQCYLCPSAQQNGLAAGGVDELMG                   VLDYLQQEVPRAFVNLVDLSEVAEVSRQYHGTWLSPAPEPCNCSEETTRLAKVVMQWS                   YQEAWNSLLASSRYSEQESFTVVFQPFFYETTPSDPRLQDSTTLAWHLWNRMMEPAGE                   KDEPLSVKHGRPMKCPSQESPYLFSYRNSNYLTRLQKPQDKLEVREGAEIRCPDKDPS                   DTVPTSVHRLKPADINVIGALGDSLTAGNGAGSTPGNVLDVLTQYRGLSWSVGGDENI                   GTVTTLADILREFNPSLKGFSVGTGKETSPNAFLNQAVAGGRAEQARRLVDLMKNDTR                   IHFQEDWKIITLFIGGNDLCDFCNDLVHYSPQNFTDNIGKALDILHAEVPRAFVNIVT                   VLEIVNLRELYQEKKVYCPRMILRSLCPCVLKFDDNSTELATLIEFWKKFQEKTHQLI                   ESGRYDTREDFTVVVQPFFENVDMPKTQEGLPDNSFFAPDCFHFSSKSHSRAASALWN                   NMLEPVGQKTTRHKFENKINITCPNQVEWPFLRTYKNSMQGHGTWLPCRDRAPSAIHP                   TSVHALRPADIQVVAALGDSLTAGNGIGSKPDDLPDVTTQYRGLSYSAGGDGSLENVT                   TLPDILREFNRNLTGYAVGTGDANDTNAFLNQAVPGAKARDLMSQVQTLMQKMKDDHR                   VNFHEDWKVITVLIGGSDLCDYCTDSNLYSAANFVHHLRNALDVLHREVPRVLVNLVD                   FLNPTIMRQVFLGNPDKCPVQQASVLCNCVLTLRENSQELARLEAFSRAYQSSMRELV                   GSGRYDTQEDFSVVLQPFFQNIQLPVLQDGLPDTSFFAPDCIHPNQKFHSQLARALWT                   NNLEPLGSKTETLDLRAEMPITCPTQNEPFLRTPRNSNYTYPIKPAIENWGSDFLCTE                   WKASNSVPTSVHQLRPADIKVVAALGDSLTVAVGARPNNSSDLPTSWRGLSWSIGGDG                   NLETHTTLPDILKKPNPYLLGPSTSTWEGTAGLNVAAEGARARDMPAQAWDLVERMKN                   SPQDINLEKDWKLVTLFIGVNDLCHYCENPVGEYVQHIQQALDILSEELPRAFVNVVE                   VMELASLYQGQGGKCAMLAAQNNCTCLRHSQSSLEKQELKKVNWNLQHGISSFSYWHQ                   YTQREDFAVVVQPFFQNTLTPLNRGDTDLTFFSEDCFHFSDRGHAEMAIALWNNMLEP                   VGRKTTSNNFTHSRAKLKCPSPESPYLYTLRNSRLLPDQAEEAPEVLYWAVPVAAGVG                   LVVGIIGTVVWRCRRGGRREDPPMSLRTVAL                  
 
     [0449] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 24B.  
               TABLE 24B                          Comparison of NOV24a against NOV24b through NOV24c.                                 Protein   NOV24a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV24b   454 . . . 748    283/295 (95%)                1 . . . 293    285/295 (95%)           NOV24c    27 . . . 1419   1211/1426 (84%)                23 . . . 1423   1261/1426 (87%)                      
 
     [0450] Further analysis of the NOV24a protein yielded the following properties shown in Table 24C.  
               TABLE 24C                       Protein Sequence Properties NOV24a                                        PSort   0.6850 probability located in endoplasmic reticulum       analysis:   (membrane); 0.6400 probability located in plasma membrane;           0.4600 probability located in Golgi body; 0.1080 probability           located in nucleus       SignalP   Likely cleavage site between residues 24 and 25       analysis:                  
 
     [0451] A search of the NOV24a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 24D.  
               TABLE 24D                          Geneseq Results for NOV24a                                             Identities/                   NOV24a   Similarities           Protein/   Residues/   for the       Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAW30751   Rat phospho-    50 . . . 1403    911/1404   0.0           lipase-B/lipase—       (64%)             Rattus rattus      60 . . . 1447   1077/1404           1450 aa.       (75%)           [JP09248190-A,           Sep. 22, 1997]       ABB11053   Human phospho-   985 . . . 1203   205/224    e−117           lipase B  Homo         (91%)             sapiens , 267 aa.   45 . . . 267   213/224           [WO200157188-       (94%)           A2, Aug. 9,           2001]       AAM25824   Human protein   985 . . . 1203   205/224    e−117           sequence SEQ ID       (91%)           NO:1339— Homo     45 . . . 267   213/224             sapiens , 267 aa.       (94%)           [WO200153455-           A2, Jul. 26, 2001]       AAM95420   Human   979 . . . 1106   110/130   3e−56            reproductive       (84%)           system related    4 . . . 133   117/130           antigen SEQ ID       (89%)           NO:4078— Homo               sapiens , 148 aa.           [WO200155320-           A2, Aug. 2,           2001]       ABB11237   Human phospho-   393 . . . 478    84/90   3e−40            lipase homologue,       (93%)           SEQ ID NO:   43 . . . 132   86/90           1607— Homo         (95%)             sapiens , 132 aa.           [WO200157188-           A2, Aug. 9,           2001]                  
 
     [0452] In a BLAST search of public sequence databases, the NOV24a protein was found to have homology to the proteins shown in the BLASTP data in Table 24E.  
               TABLE 24E                          Public BLASTP Results for NOV24a                                         NOV24a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q05017   Phospholipase    6 . . . 1416   1042/1466   0.0           ADRAB-B       (71%)           precursor    2 . . . 1456   1179/1466           (EC 3.1.-.-)—       (80%)             Oryctolagus               cuniculus             (Rabbit), 1458 aa.       O70320   PHOSPHO-    7 . . . 1414    965/1474   0.0           LIPASE B—       (65%)             Cavia porcellus      3 . . . 1458   1135/1474           (Guinea pig),       (76%)           1463 aa.       O54728   PHOSPHO-    50 . . . 1403    911/1404   0.0           LIPASE B—       (64%)             Rattus norvegicus      60 . . . 1447   1077/1404           (Rat), 1450 aa.       (75%)       Q96DP9   CDNA FLJ30866   454 . . . 714    257/261    e−151           FIS, CLONE       (98%)           FEBRA2004110,    1 . . . 259   258/261           HIGHLY       (98%)           SIMILAR TO           PHOSPHO-           LIPASE           ADRAB-B           PRECURSOR           (EC 3.1.-.-)—             Homo sapiens             (Human), 270 aa.       Q9N2Z4   HYPO-   343 . . . 673    130/343   1e−59            THETICAL       (37%)           41.4 KDA   37 . . . 369   202/343           PROTEIN—       (57%)             Caenorhabditis               elegans , 377 aa.                  
 
     [0453] PFam analysis predicts that the NOV24a protein contains the domains shown in the Table 24F.  
               TABLE 24F                          Domain Analysis of NOV24a                                     Identities/               NOV24a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               Lipase_GDSL: domain   360 . . . 484    54/147 (37%)   4.8e−42       1 of 3       116/147 (79%)       Lipase_GDSL: domain   705 . . . 834    57/147 (39%)   4.5e−44       2 of 3       116/147 (79%)       SecA_protein: domain   834 . . . 851    10/20 (50%)   4.9       1 of 1        17/20 (85%)       Vitellogenin_N: domain   1107 . . . 1124     8/18 (44%)   3.8       1 of 1        17/18 (94%)       Lipase_GDSL: domain   1062 . . . 1185    48/147 (33%)   6.3e−37       3 of 3       114/147 (78%)                  
 
     Example 25  
     [0454] The NOV25 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 25A.  
               TABLE 25A                       NOV25 Sequence Analysis                                                SEQ ID NO:87   1348 bp                     NOV25a,     CTGGGTCGCCCCTGTTCTACCCAGATTGGG   ATG GCAGCGACGCTGATCCTGGAGCCCG       CG59311-01 DNA Sequence           CGGGCCGCTGCTGCTGGGACGAGCCGCTGCGCATCGCAGTGCGCGGCCTGGCCCCGGA                   GCAGCCAGTCACGCTGCGCACGTCCCTGCGCGACGAAGAGGGCGCGCTCTTCCGGGCC                   CACGCGCGCTACCGTGCCGACGCCCGCGACGAGCTGGACCTGGAGCGCGCGCCCGCGC                   TGGGAGGCAGCTTCGCGGGGCTCCAGCCCATGGGGCTGCTGTGGGCGTTGGAGCCCGA                   GAAAGCCTTGGTGCGGCTGGTGAAGCGCGACGTGCGGACGCCCTTCGCCGTGGAGCTG                   GAAGTGCTGGACGGCCACGACACCGAGCCCGGGCGGCTGCTGTGCCTGGCGCAGAACA                   AGCGCGACTTTCTCCGGCCGGGGGTGCGGCGCGAGCCGGTGCGCGCGGGCCCGGTGCG                   CGCCGCGCTCTTCCTGCCGCCGGATAGGGGGCCCTTTCCTGGGATCATTGATCTGTTT                   GGGAGCAGCAGGGGCCTTTGTGAATACAGGGCCAGCCTCCTGGCCGGACATGGTTTTG                   CTGTGCTTGCCCTGGCTTATTTCAGATTTGAAGACCTCCCCGAAGATCTGAATGATGT                   ACATCTGGAGTACTTTGAAGAAGCCGTGGACTTTATGCTGCAGCATCCAAAGGTGAAA                   GGTCCTAGTATTGCGCTTCTTGGATTTTCCAAAGGAGGTGACCTGTGTCTCTCAATGG                   CTTCTTTCTTGAAGGGCATCACAGCCACTGTACTTATCAATGCCTGTGTAGCCAACAC                   AGTAGCTCCTCTACATTACAAGGATATGATTATTCCTAAACTTGTCGATGATCTAGGA                   AAAGTAAAAATCACTAAGTCAGGATTTCTCACTTTTATGGACACTTGGAGCAATCCAC                   TGGAGGAACACAATCACCAAAGTCTTGTTCCATTGGAAAAGGCGCAGGTGCCCTTCTT                   GTTTATTGTTGGCATGGATGATCAAAGCTGGAAGAGTGAATTCTATGCTCAGATAGCC                   TCTGAAAGGCTACAAGCTCATGGGAAAGAAAGACCCCAGATAATCTGTTACCCAGAAA                   CTGGTCACTGTATTGACCCACCTTATTTTCCTCCTTCTAGAGCTTCTGTGCACGCTGT                   TTTGGGTGAGGCAATATTCTATGGAGGTGAGCCAAAGGCTCACTCAAAGGCACAGGTA                   GATGCCTGGCAGCAAATTCAAACTTTCTTCCATAAACATCTCAATGGTAAAAAATCTG                   TCAAGCACAGCAAAATA TAA   CATTGTAGCCACAGACCAGATACCATTAATAAAAATCC                       TATTCATACAACTT                                           ORF Start: ATG at 31       ORF Stop: TAA at 1294           SEQ ID NO:88   421 aa   MW at 46815.4 kD                     NOV25a,   MAATLILEPAGRCCWDEPLRIAVRGLAPEQPVTLRTSLRDEEGALFRAHARYRADARD       CG59311-01 Protein Sequnce           ELDLERAPALGGSFAGLQPMGLLWALEPEKALVRLVKRDVRTPFAVELEVLDGHDTEP                   GRLLCLAQNKRDFLRPGVRREPVRAGPVRAALFLPPDRGPFPFIIDLFGSSRGLCEYR                   ASLLAGHGFAVLALAYFRFEDLPEDLNDVHLEYFEEAVDFMLQHPKVKGPSIALLGFS                   KGGDLCLSMASFLKGITATVLINACVANTVAPLHYKDMIIPKLVDDLGKVKITKSGFL                   TFMDTWSNPLEEHNHQSLVPLEKAQVPFLFIVGMDDQSWKSEFYAQIASERLQAHGKE                   RPQIICYPETGHCIDPPYFPPSRASVHAVLGEAIFYGGEPKAHSKAQVDAWQQIQTFF                   HKHLNGKKSVKHSKI                                     SEQ ID NO:89   1021 bp                     NOV25b,     AGATTGGG   ATG GCAGCGACGCTGATCCTGGAGCCCGCGGGCCGCTGCTGCTGGGACGA       CG59311-01 DNA Sequence           GCCGCTGCGCATCGCAGTGCGCGGCCTGGCCCCGGAGCAGCCAGTCACGCTGCGCACG                   TCCCTGCGCGACGAAGAGGGCGCGCTCTTCCGGGCCCACGCGCGCTACCGTGCCGACG                   CCTCTAATCCCGGCACTTTGGGGGGCCAAGGCAGGGGGCCCTTTCCTGGGATCATTGA                   TCTGTTTGGGAGCAGCAGGGGCCTTTGTGAATACAGGGCCAGCCTCCTGGCCGGACAT                   GGTTTTGCTGTGCTTGCCCTGGCTTATTTCAGATTTGAAGACCTCCCCGAAGATCTGA                   ATGATGTACATCTGGAGTACTTTGAAGAAGCCGTGGACTTTATGCTGCAGCATCCAAA                   GGTGAAAGGTCCTAGTATTGCGCTTCTTGGATTTTCCAAAGGAGGTGACCTGTGTCTC                   TCAATGGCTTCTTTCTTGAAGGGCATCACAGCCACTGTACTTATCAATGCCTGTGTAG                   CCAACACAGTAGCTCCTCTACATTACAAGGATATGATTATTCCTAAACTTGTCGATGA                   TCTAGGAAAAGTAAAAATCACTAAGTCAGGATTTCTCACTTTTATGGACACTTGGAGC                   AATCCACTGGAGGAACACAATCACCAAAGTCTTGTTCCATTGGAAAAGGCGCAGGTGC                   CCTTCTTGTTTATTGTTGGCATGGATGATCAAAGCTGGAAGAGTGAATTCTATGCTCA                   GATAGCCTCTGAAAGGCTACAAGCTCATGGGAAAGAAAGACCCCAGATAATCTGTTAC                   CCAGAAACTGGTCACTGTATTGACCCACCTTATTTTCCTCCTTCTAGAGCTTCTGTGC                   ACGCTGTTTTGGGTGAGGCAATATTCTATGGAGGTGAGCCAAAGGCTCACTCAAAGGC                   ACAGGTAGATGCCTGGCAGCAAATTCAAACTTTCTTCCATAAACATCTCAATGGTAAA                   AAATCTGTCAAGCACAGCAAAATA TAA   CATTGTAG                                           ORF Start: ATG at 9       ORF Stop: TAA at 1011           SEQ ID NO:90   334 aa   MW at 36926.0 kD                     NOV25b,   MAATLILEPAGRCCWDEPLRIAVRGLAPEQPVTLRTSLRDEEGALFRAHARYRADASN       CG59311-02 Protein Sequence           PGTLGGQGRGPFPGIIDLFGSSRGLCEYRASLLAGHGFAVLALAYFRFEDLPEDLNDV                   HLEYFEEAVDFMLQHPKVKGPSIALLGFSKGGDLCLSMASFLKGITATVLINACVANT                   VAPLHYKDMIIPKLVDDLGKVKITKSGFLTFMDTWSNPLEEHNHQSLVPLEKAQVPFL                   FIVGMDDQSWKSEFYAQIASERLQAHGKERPQIICYPETGHCIDPPYFPPSRASVHAV                   LGEAIFYGGEPKAHSKAQVDAWQQIQTFFHKHLNGKKSVKHSKI                                     SEQ ID NO:91   1021 bp                     NOV25c,     AGATTGGG   ATG GCAGCGACGCTGATCCTGGAGCCCGCGGGCCGCTGCTGCTGGGACGA       CG59311-03 DNA Sequence           GCCGCTGCGCATCGCAGTGCGCGGCCTGGCCCCGGAGCAGCCAGTCACGCTGCGCACG                   TCCCTGCGCGACGAAGAGGGCGCGCTCTTCCGGGCCCACGCGCGCTACCGTGCCGACG                   CCTCTAATCCCGGCACTTTGGGAGGCCAAGGCAGGGGGCCCTTTCCTGGGATCATTGA                   TCTGTTTGGGAGCAGCAGGGGCCTTTGTGAATACAGGGCCAGCCTCCTGGCCGGACAT                   GGTTTTGCTGTGCTTGCCCTGGCTTATTTCAGATTTGAAGACCTCCCCGAAGATCTGA                   ATGATGTACATCTGGAGTACTTTGAAGAAGCCGTGGACTTTATGCTGCAGCATCCAAA                   GGTGAAAGGTCCTAGTATTGCGCTTCTTGGATTTTCCAAAGGAGGTGACCTGTGTCTC                   TCAATGGCTTCTTTCTTGAAGGGCATCACAGCCACTGTACTTATCAATGCCTGTGTAG                   CCAACACAGTAGCTCCTCTACATTACAAGGATATGATTATTCCTAAACTTGTCGATGA                   TCTAGGAAAAGTAAAAATCACTAAGTCAGGATTTCTCACTTTTATGGACACTTGGAGC                   AATCCACTGGAGGAACACAATCACCAAAGTCTTGTTCCATTGOAAAAGGCGCAGGTGC                   CCTTCTTGTTTATTGTTGGCATGGATGATCAAAGCTGGAAGAGTGAATTCTATGCTCA                   GATAGCCTCTGAAAGGCTACAAGCTCATGGGAAAGAAAGACCCCAGATAATCTGTTAC                   CCAGAAACTGGTCACTGTATTGACCCACCTTATTTTCCTCCTTCTAGAGCTTCTGTGC                   ACGCTGTTTTGGGTGAGGCAATATTCTATGGAGGTGAGCCAAAGGCTCACTCAAAGGC                   ACAGGTAGATGCCTGGCAGCAAATTCAAACTTTCTTCCATAAACATCTCAATGGTAAA                   AAATCTGTCAAGCACAGCAAAATA TAA   CATTGTAG                                           ORF Start: ATG at 9       ORF Stop: TAA at 1011           SEQ ID NO:92   334 aa   MW at 36926.0 kD                     NOV25c,   MAATLILEPAGRCCWDEPLRIAVRGLAPEQPVTLRTSLRDEEGALFRAHARYRADASN       CG59311-03 Protein Sequence           PGTLGGQGRGPFPGIIDLFGSSRGLCEYRASLLAGHGFAVLALAYFRFEDLPEDLNDV                   HLEYFEEAVDFMLQHPKVKGPSIALLGFSKGGDLCLSMASFLKGITATVLINACVANT                   VAPLHYKDMIIPKLVDDLGKVKITKSGFLTFMDTWSNPLEEHNHQSLVPLEKAQVPFL                   FIVGMDDQSWKSEFYAQIASERLQAHGKERPQIICYPETGHCIDPPYFPPSRASVHAV                   LGEAIFYGGEPKAHSKAQVDAWQQIQTFFHKHLNGKKSVKHSKI                  
 
     [0455] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 25B.  
               TABLE 25B                          Comparison of NOV25a against NOV25b through NOV25c.                                 Protein   NOV25a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV25b   154 . . . 421   268/268 (100%)                67 . . . 334   268/268 (100%)           NOV25c   154 . . . 421   268/268 (100%)                67 . . . 334   268/268 (100%)                      
 
     [0456] Further analysis of the NOV25a protein yielded the following properties shown in Table 25C.  
               TABLE 25C                       Protein Sequence Properties NOV25a                                        PSort   0.4500 probability located in cytoplasm; 0.3630 probability       analysis:   located in microbody (peroxisome); 0.1958 probability located           in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0457] A search of the NOV25a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 25D.  
               TABLE 25D                          Geneseq Results for NOV25a                                         NOV25a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAM41490   Human poly-    1 . . . 421   288/421   e−175           peptide SEQ ID       (68%)           NO 6421— Homo      74 . . . 494   347/421             sapiens , 494 aa.       (82%)           Jul. 26, 2001]       AAM39704   Human poly-    1 . . . 421   288/421   e−175           peptide SEQ ID       (68%)           NO 2849— Homo      63 . . . 483   346/421             sapiens , 483 aa.       (81%)           [WO200153312-           A1, Jul. 26, 2001]       AAY71112   Human Hydrolase    1 . . . 421   288/421   e−175           protein-10       (68%)           (HYDRL-10)—    63 . . . 483   346/421             Homo sapiens ,       (81%)           483 aa.           [WO200028045-           A2, May 18,           2000]       AAB93479   Human protein    1 . . . 421   287/421   e−175           sequence SEQ ID       (68%)           NO:12766—    63 . . . 483   346/421             Homo sapiens ,       (82%)           483 aa.           [EP1074617-A2,           Feb. 7, 2001]       AAY07932   Human secreted   241 . . . 421    181/181   e−105           protein fragment       (100%)           encoded from    1 . . . 181    181/181           gene 81— Homo         (100%)             sapiens , 182 aa.           [WO9918208-A1,           Apr. 15, 1999]                  
 
     [0458] In a BLAST search of public sequence databases, the NOV25a protein was found to have homology to the proteins shown in the BLASTP data in Table 25E.  
               TABLE 25E                          Public BLASTP Results for NOV25a                                         NOV25a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               P49753   Peroxisomal acyl-    1 . . . 421   288/421 (68%)   e−175           coenzyme A    1 . . . 421   347/421 (82%)           thioester hydrolase           2 (EC 3.1.2.2)           (Peroxisomal long-           chain acyl-coA           thioesterase 2)           (ZAP128)— Homo               sapiens  (Human),           421 aa.       Q9QYR7   Peroxisomal acyl-    1 . . . 421   264/421 (62%)   e−157           coenzyme A   12 . . . 432   331/421 (77%)           thioester hydrolase           2 (EC 3.1.2.2)           (Peroxisomal long-           chain acyl-coA           thioesterase 2)           (PTE-Ia)— Mus               musculus  (Mouse),           432 aa.       O88267   Cytosolic acyl    1 . . . 421   268/421 (63%)   e−153           coenzyme A    1 . . . 419   318/421 (74%)           thioester hydrolase,           inducible           (EC 3.1.2.2) (Long           chain acyl-CoA           thioester hydrolase)           (Long chain acyl-           CoA hydrolase)           (CTE-I) (LACH2)           (ACH2)  Rattus               norvegicus  (Rat),           419 aa.       Q9QYR9   Acyl coenzyme A    3 . . . 413   264/411 (64%)   e−153           thioester hydrolase,   44 . . . 452   321/411 (77%)           mitochondrial           precursor           (EC 3.1.2.2) (Very-           long-chain acyl-           CoA thioesterase)           (MTE-I)— Mus               musculus  (Mouse),           453 aa.       O55137   Cytosolic acyl    1 . . . 413   262/413 (63%)   e−153           coenzyme A    1 . . . 411   319/413 (76%)           thioester (Long           chain acyl-CoA           thioester hydrolase)           (Long chain acyl-           CoA hydrolase)           (CTE-I)— Mus               musculus  (Mouse),           419 aa.                  
 
     [0459] PFam analysis predicts that the NOV25a protein contains the domains shown in the Table 25F.  
               TABLE 25F                          Domain Analysis of NOV25a                                 NOV25a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value                         No Significant Matches Found                  
 
     Example 26  
     [0460] The NOV26 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 26A.  
               TABLE 26A                       NOV26 Sequence Analysis                                                SEQ ID NO:93   1375 bp                     NOV26a,     GGGACGCCGGACGCCGTCCGGACATTCGGCGCGCTTGCCACGATCTTGGACGGGTCTC         CG59309-01 DNA Sequence             GGGCCTCGACCTTTGAATTCCCCGCTCCGGCTCCAAG   ATG TCAGCAACGCTGATCCTG                   GAGCCCCCAGGCCGCTGCTGCTGGAACGAGCCGGTGCGCATTGCCGTGCGCGGCCTGG                   CCCCGGAGCAGCGGGTTACGCTGCGCGCGTCCCTGCGCGACGAGAAGGGCGCGCTCTT                   CCGGGCCCACGCGCGCTACTGCGCCGACGCCCGCGGCGAGCTGGACCTGGAGCGCGCA                   CCCGCGCTGGGCGGCAGCTTCGCGGGACTCGAGCCCATGGGGCTGCTCTGGGCCCTGG                   AACCCGAGAAGCCTTTTTGGCGCTTCCTGAAGCGGGACGTACAGATTCCTTTTGTCGT                   GGAGTTGGAGGTGCTGGACGGCCACGACCCCGAGCCTGGACGGCTGCTGTGCCAGGCG                   CAGCACGAGCGCCACTTCCTCCCGCCAGGGGTGCGGCGCCAGTCGGTGCGAGCGGGCC                   GGGTGCGCGCCACGCTCTTCCTGCCGCCAGGTGAGCCTGGACCCTTCCCAGGGATCAT                   TGACATCTTTGGTATTGGAGGGGGCCTCTTGGAATATCGAGCCAGCCTCCTTGCTGGC                   CATGGCTTTGCCACGTTGGCTCTAGCTTATTATAACTTTGAAGATCTCCCCAATAACA                   TGGACAACATATCCCTGGAGTACTTCGAAGAAGCCGTATGCTACATGCTTCAACATCC                   CCAGGTTAAAGGCCCAGGCATTGGGCTTTTGGGCATTTCTCTAGGAGCTGATATTTGT                   CTCTCAATGGCCTCATTCTTGAAGAATGTCTCAGCCACAGTTTCCATCAATGGATCTG                   GGATCAGTGGGAACACAGCCATCAACTATAAGCACAGTAGCATTCCACCATTGGGCTA                   TGACCTGAGGAGAATCAAGGTAGCTTTCTCAGGCCTCGTGGACATTGTGGATATAAGG                   AATGCTCTCGTAGGAGGGTACAAGAACCCCAGCATGATTCCAATAGAGAAGGCCCAGG                   GGCCCATCCTGCTCATTGTTGGTCAGGATGACCATAACTGGAGAAGTGAGTTGTATGC                   CCAAACAGTCTCTGAACGGTTACAGGCCCATGGAAAGGAAAAACCCCAGATCATCTGT                   TACCCTGGGACTGGGCATTACATCGAGCCTCCTTACTTCCCCCTGTGCCCAGCTTCCC                   TTCACAGATTACTGAACAAACATGTTATATGGGGTGGGGAGCCCAGGGCTCATTCTAA                   GGCCCAGGAAGATGCCTGGAAGCAAATTCTAGCCTTCTTCTGCAAACACCTGGGAGGT                   ACCCAGAAAACAGCTGTCCCTAAATTG TAA   TGCATTTGTCT                                           ORF Start: ATG at 96       ORF Stop: TAA at 1362           SEQ ID NO:94   422 aa   MW at 46455.1 kD                     NOV26a,   MSATLILEPPGRCCWNEPVRIAVRGLAPEQRVTLRASLRDEKGALFRAHARYCADARG       CG59309-01 Protein Sequence           ELDLERAPALGGSFAGLEPMGLLWALEPEKPFWRFLKRDVQIPFVVELEVLDGHDPEP                   GRLLCQAQHERHFLPPGVRRQSVRAGRVRATLFLPPGEPGPFPGIIDIFGIGGGLLEY                   RASLLAGHGFATLALAYYNFEDLPNNMDNISLEYFEEAVCYMLQHPQVKGPGIGLLGI                   SLGADICLSMASFLKNVSATVSINGSGISGNTAINYKHSSIPPLGYDLRRIKVAFSGL                   VDIVDIRNALVGGYKNPSMIPIEKAQGPILLIVGQDDHNWRSELYAQTVSERLQAHGK                   EKPQIICYPGTGHYIEPPYFPLCPASLHRLLNKHVIWGGEPRAHSKAQEDAWKQILAF                   FCKHLGGTQKTAVPKL                  
 
     [0461] Further analysis of the NOV26a protein yielded the following properties shown in Table 26B.  
               TABLE 26B                       Protein Sequence Properties NOV26a                                        PSort   0.4500 probability located in cytoplasm; 0.2585 probability       analysis:   located in lysosome (lumen); 0.1940 probability located in           microbody (peroxisome); 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0462] A search of the NOV26a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 26C.  
               TABLE 26C                          Geneseq Results for NOV26a                                         NOV26a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAM41490   Human poly-    1 . . . 422   296/422 (70%)    e−179           peptide SEQ ID    74 . . . 494   341/422 (80%)           NO 6421— Homo               sapiens , 494 aa.           [WO200153312-           A1, Jul. 26, 2001]       AAM39704   Human poly-    1 . . . 422   296/422 (70%)    e−179           peptide SEQ ID    63 . . . 483   341/422 (80%)           NO 2849— Homo               sapiens , 483 aa.           [WO200153312-           A1, Jul. 26, 2001]       AAY71112   Human Hydrolase    1 . . . 422   296/422 (70%)    e−179           protein-10    63 . . . 483   341/422 (80%)           (HYDRL-10)—             Homo sapiens ,           483 aa.           [WO200028045-           A2, May 18,           2000]       AAB93479   Human protein    1 . . . 422   295/422 (69%)    e−178           sequence SEQ ID    63 . . . 483   340/422 (79%)           NO:12766—             Homo sapiens ,           483 aa.           [EP1074617-A2,           Feb. 7, 2001]       AAY07932   Human secreted   242 . . . 422    93/181 (51%)   2e−48            protein fragment    1 . . . 181   123/181 (67%)           encoded from           gene 81— Homo               sapiens , 182 aa.           [WO9918208-A1,           Apr. 15, 1999]                  
 
     [0463] In a BLAST search of public sequence databases, the NOV26a protein was found to have homology to the proteins shown in the BLASTP data in Table 26D.  
               TABLE 26D                          Public BLASTP Results for NOV26a                                         NOV26a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9QYR8   PEROXISOMAL    1 . . . 422   312/422 (73%)   0.0           LONG CHAIN    1 . . . 421   362/422 (84%)           ACYL-COA THIO-           ESTERASE IB—             Mus musculus             (Mouse), 421 aa.       P49753   Peroxisomal acyl-    1 . . . 422   296/422 (70%)   e−178           coenzyme A    1 . . . 421   341/422 (80%)           thioester hydrolase           2 (EC 3.1.2.2)           (Peroxisomal long-           chain acyl-coA           thioesterase 2)           (ZAP128)— Homo               sapiens  (Human),           421 aa.       Q9QYR7   Peroxisomal acyl-    1 . . . 422   281/424 (66%)   e−163           coenzyme A   12 . . . 432   333/424 (78%)           thioester hydrolase           2 (EC 3.1.2.2)           (Peroxisomal long-           chain acyl-coA           thioesterase 2)           (PTE-Ia)— Mus               musculus  (Mouse),           432 aa.       O55137   Cytosolic acyl    1 . . . 422   275/423 (65%)   e−162           coenzyme A    1 . . . 419   330/423 (78%)           thioester hydrolase,           inducible           (EC 3.1.2.2) (Long           chain acyl-CoA           thioester hydrolase)           (Long chain acyl-           CoA hydrolase)           (CTE-I)— Mus               musculus  (Mouse),           419 aa.       O88267   Cytosolic acyl    1 . . . 422   276/423 (65%)   e−162           coenzyme A    1 . . . 419   329/423 (77%)           thioester hydrolase,           inducible           (EC 3.1.2.2) (Long           chain acyl-CoA           thioester hydrolase)           (Long chain acyl-           CoA hydrolase)           (CTE-I) (LACH2)           (ACH2)  Rattus               norvegicus  (Rat),           419 aa.                  
 
     [0464] PFam analysis predicts that the NOV26a protein contains the domains shown in the Table 26E.  
               TABLE 26E                          Domain Analysis of NOV26a                                     Identities/               NOV26a   Similarities           Match   for the       Pfam Domain   Region   Matched Region   Expect Value                                     DLH: domain 1 of 2   144 . . . 188   17/52 (33%)   63               32/52 (62%)       DLH: domain 2 of 2   394 . . . 411    9/18 (50%)   2.6               13/18 (72%)                  
 
     Example 27  
     [0465] The NOV27 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 27A.  
               TABLE 27A                       NOV27 Sequence Analysis                                                SEQ ID NO:95   1333 bp                     NOV27a,     CCTGGCCCCCAAGCTCCCCACTCTGGTGCCCCGAGCAGCCCTGTGGGCAAGCAGCCGC         CG57364-01 DNA Sequence             CGCC   ATG GCCGAGCACCTGGAGCTGCTGGCAGAGATGCCCATGGTGGGCAGGATGAGC                   ACACAGGAGCGGCTGAAGCATGCCCAGAAGCGGCGCGCCCAGCAGGTGAAGATGTGGG                   CCCAGGCTGAGAAGGAGGCCCAGGGCAAGAAGGGTCCTGGGGAGCGTCCCCGGAAGGA                   GGCAGCCAGCCAAGGGCTCCTGAAGCAGGTCCTCTTCCCTCCCAGTGTTGTCCTTCTG                   GAGGCCGCTGCCCGAAATGACCTGGAAGAAGTCCGCCAGTTCCTTGGGAGTGGGGTCA                   GCCCTGACTTGGCCAACGAGGACGGCCTGACGGCCCTGCACCAGTGCTGCATTGATGA                   TTTCCGAGAGATGGTGCAGCAGCTCCTGGAGGCTGGGGCCAACATCAATGCCTGTGAC                   AGTGAGTGCTGGACGCCTCTGCATGCTGCGGCCACCTGCGGCCACCTGCACCTGGTGG                   AGCTGCTCATCGCCAGTGGCGCCAATCTCCTGGCGGTCAACACCGACGGGAACATGCC                   CTATGACCTGTGTGATGATGAGCAGACGCTGGACTGCCTGGAGACTGCCATGGCCGAC                   CGTGGCATCACCCAGGACAGCATCGAGGCCGCCCGGGCCGTGCCAGAACTGCGCATGC                   TGGACGACATCCGGAGCCGGCTGCAGGCCGGGGCAGACCTCCATGCCCCCCTGGACCA                   CGGGGCCACGCTGCTGCACGTCGCAGCCGCCAACGGGTTCAGCGAGGCGGCTGCCCTG                   CTGCTGGAACACCGAGCCAGCCTGAGCGCTAAGGACCAAGACGGCTGGGAGCCGCTGC                   ACGCCGCGGCCTACTGGGGCCAGGTGCCCCTGGTGGAGCTGCTCGTGGCGCACGGGGC                   CGACCTGAACGCAAAGTCCCTGATGGACGAGACGCCCCTTGATGTGTGCGGGGACGAG                   GAGGTGCGGGCCAAGCTGCTGGAGCTGAAGCACAAGCACGACGCCCTCCTGCGCGCCC                   AGAGCCGCCAGCGCTCCTTGCTGCGCCGCCGCACCTCCAGCGCCGGCAGCCGCGGGAA                   GGTGGTGAGGCGGGATGAGCCTAACCCAGCGCAGCGGCTGACGCATGTCCCAGAAGCG                   GCGCGCCCAGCAGGTGAAGATGTGGGCCCAGGC TGA   GAAGGAGGCCCAGGGCAAGAAG                       GGTCCTGGGGAGCGTCCCCGGAAGGAGGCAGCCAGCCAAGGGCTCCTGAAGCAGGTCC                       TCTTCCCTCCCAGTGTTGTCCTTCTGGAGGCCGCTGCCCGAAATGACCTGGAAGAAG                                           ORF Start: ATG at 63       ORF Stop: TGA at 1194           SEQ ID NO:96   377 aa   MW at 41019.9 kD                     NOV27a,   MAEHLELLAEMPMVGRMSTQERLKHAQKRRAQQVKMWAQAEKEAQGKKGPGERPRKEA       CG57364-01 Protein Sequence           ASQGLLKQVLFPPSVVLLEAAARNDLEEVRQFLGSGVSPDLANEDGLTALHQCCIDDF                   REMVQQLLEAGANINACDSECWTPLHAAATCGHLHLVELLIASGANLLAVNTDGNMPY                   DLCDDEQTLDCLETAMADRGITQDSIEAARAVPELRMLDDIRSRLQAGADLHAPLDHG                   ATLLHVAAANGFSEAAALLLEHRASLSAKDQDGWEPLHAAAYWGQVPLVELLVAHGAD                   LNAKSLMDETPLDVCGDEEVRAKLLELKHKHDALLRAQSRQRSLLRRRTSSAGSRGKV                   VRRDEPNPAQRLTHVPEAARPAGEDVGPG                  
 
     [0466] Further analysis of the NOV27a protein yielded the following properties shown in Table 27B.  
               TABLE 27B                       Protein Sequence Properties NOV27a                                        PSort   0.3000 probability located in microbody (peroxisome); 0.3000       analysis:   probability located in nucleus; 0.1547 probability located in           lysosome (lumen); 0.1000 probability located in mitochondrial           matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0467] A search of the NOV27a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 27C.  
               TABLE 27C                          Geneseq Results for NOV27a                                             Identities/                   NOV27a   Similarities           Protein/   Residues/   for the       Geneseq   Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAM40636   Human polypeptide    89 . . . 351   262/263    e−151           SEQ ID NO 5567—        (99%)             Homo sapiens ,    1 . . . 263   263/263           440 aa.        (99%)           [WO200153312-A1,           Jul. 26, 2001]       AAM38850   Human polypeptide   119 . . . 351   233/233    e−132           SEQ ID NO 1995—       (100%)             Homo sapiens ,    1 . . . 233   233/233           410 aa.       (100%)           [WO200153312-A1,           Jul. 26, 2001]       AAM78864   Human protein SEQ    1 . . . 351   209/351    e−118           ID NO 1526—        (59%)             Homo sapiens ,    1 . . . 348   265/351           567 aa.        (74%)           [WO200157190-A2,           Aug. 9, 2001]       ABB11817   Human KIAA0823    45 . . . 354   173/316   3e−94            protein homologue,        (54%)           SEQ ID NO:    3 . . . 318   226/316           2187— Homo          (70%)             sapiens , 536 aa.           [WO200157188-A2,           Aug. 9, 2001]       AAM79848   Human protein    45 . . . 354   173/316   3e−94            SEQ ID NO 3494—        (54%)             Homo sapiens ,    3 . . . 318   226/316           536 aa.        (70%)           [WO200157190-A2,           Aug. 9, 2001]                  
 
     [0468] In a BLAST search of public sequence databases, the NOV27a protein was found to have homology to the proteins shown in the BLASTP data in Table 27D.  
               TABLE 27D                          Public BLASTP Results for NOV27a                                         NOV27a   Identities/           Protein       Residues/   Similarities       Accession   Protein/   Match   for the   Expect       Number   Organism/Length   Residues   Matched Portion   Value               Q96134   UNKNOWN   1 . . . 351   351/351 (100%)   0.0           (PROTEIN FOR   1 . . . 351   351/351 (100%)           MGC:14333)—             Homo sapiens             (Human), 528 aa.       Q923M0   MYOSIN   1 . . . 351   301/351 (85%)    e−171           PHOSPHATASE   1 . . . 351   320/351 (90%)            TARGETING           SUBUNIT 3           MYPT3— Mus               musculus             (Mouse), 524 aa           (fragment).       AAL62093   PROTEIN PHOS-   1 . . . 351   210/351 (59%)    e−118           PHATASE 1   1 . . . 348   266/351 (74%)            REGULATORY           SUBUNIT 16B—             Mus musculus             (Mouse), 568 aa.       Q95N27   CAAX BOX   1 . . . 351   210/351 (59%)    e−118           PROTEIN   1 . . . 348   266/351 (74%)            TIMAP— Bos               taurus  (Bovine),           568 aa.       Q96T49   CAAX BOX   1 . . . 351   209/351 (59%)    e−117           PROTEIN   1 . . . 348   265/351 (74%)            TIMAP— Homo               sapiens  (Human),           567 aa.                  
 
     [0469] PFam analysis predicts that the NOV27a protein contains the domains shown in the Table 27E.  
               TABLE 27E                          Domain Analysis of NOV27a                                 NOV27a   Identities/Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value               ank: domain 1 of 5    70 . . . 102    8/33 (24%)   99               20/33 (61%)       ank: domain 2 of 5   103 . . . 135   16/33 (48%)   7.1e−08               26/33 (79%)       ank: domain 3 of 5   136 . . . 168   15/33 (45%)   2.9e−07               26/33 (79%)       ank: domain 4 of 5   231 . . . 263   16/33 (48%)     2e−06               24/33 (73%)       ank: domain 5 of 5   264 . . . 296   16/33 (48%)   2.7e−08               27/33 (82%)                  
 
     Example 28  
     [0470] The NOV28 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 28A.  
               TABLE 28A                       NOV28 Sequence Analysis                                                SEQ ID NO:97   1719 bp                     NOV28a,   CGGGCACAGGCTCACCCTCGAGTGGCACAGGAATCCCAGGTAGATGACGGCGGCCGCG       CG59348-01 DNA Sequence           GCTGGTGCTGCAGGGTCGCCAGCTCCCGCGGCAGCGGCCGGCGCCCCGGGATCTGGGG                   GCGCACCCTCAGGGTCGCAGGGGGTGCTGATCGGGGACAGGCTGTACTCCGGGGTGCT                   CATCACCTTGGAGAACTGCCTCCTGCCTGACGACAAGCTCCGTTTCACGCCGTCCATG                   TCGAGCGGCCTCGACACCGACACAGAGACCGACCTCCGCGTGGTGGGCTGCGAGCTCA                   TCCAGGCGGCCGGTATCCTGCTCCGCCTGCCGCAGGTGGCCATGGCTACCGGGCAGGT                   GTTGTTCCAGCGGTTCTTTTATACCAAGTCCTTCGTGAAGCACTCCATGGAGCATGTG                   TCAATGGCCTGTGTCCACCTGGCTTCCAAGATAGAAGAGGCCCCAAGACGCATACGGG                   ACGTCATCAATGTGTTTCACCGCCTTCGACAGCTGAGAGACAAAAAGAAGCCCGTGCC                   TCTACTACTGGATCAAGATTATGTTAATTTAAAGAACCAAATTATAAAGGCGGAAAGA                   CGAGTTCTCAAAGAGTTGGGTTTCTGCGTCCATGTGAAGCATCCTCATAAGATAATCG                   TTATGTACCTTCAGGTGTTAGAGTGTGAGCGTAACCAACACCTGGTCCAGACCTCATG                   GAATTACATGAACGACAGCCTTCGCACCGACGTCTTCGTGCGGTTCCAGCCAGAGAGC                   ATCGCCTGTGCCTGCATTTATCTTGCTGCCCGGACGCTGGAGATCCCTTTGCCCAATC                   GTCCCCATTGGTTTCTTTTGTTTGGAGCAACTGAAGAAGAAATTCAGGAAATCTGCTT                   AAAGATCTTGCAGCTTTATGCTCGGAAAAAGGTTGATCTCACACACCTGGAGGGTGAA                   GTGGAAAAAAGAAAGCACGCTATCGAAGAGGCAAAGGCCCAAGCCCGGGGCCTGTTGC                   CTGGGGGCACACAGGTGCTGGATGGTACCTCGGGGTTCTCTCCTGCCCCCAAGCTGGT                   GGAATCCCCCAAAGAAGGTAAAGGGAGCAAGCCTTCCCCACTGTCTGTGAAGAACACC                   AAGAGGAGGCTGGAGGGCGCCAAGAAAGCCAAGGCGGACAGCCCCGTGAACGGCTTGC                   CAAAGGGGCGAGAGAGTCGGAGTCGGAGCCGGAGCCGTGAGCAGAGCTACTCGAGGTC                   CCCATCCCGATCAGCGTCTCCTAAGAGGAGGAAAAGTGACAGCGGCTCCACATCTGGT                   GGGTCCAAGTCGCAGAGCCGCTCCCGGAGCAGGAGTGACTCCCCACCGAGACAGGCCC                   CCCGCAGCGCTCCCTACAAAGGCTCTGAGATTCGGGGCTCCCGGAAGTCCAAGGACTG                   CAAGTACCCCCAGAAGCCACACAAGTCTCGGAGCCGGAGTTCTTCCCGTTCTCGAAGC                   AGGTCACGGGAGCGGGCGGATAATCCGGGAAAATACAAGAAGAAAAGTCATTACTACA                   GAGATCAGCGACGAGAGCGCTCGAGGTCGTATGAACGCACAGGCCGTCGCTATGAGCG                   GGACCACCCTGGGCACAGCAGGCATCGGAGGTGACACGTGCTTCAGACCGGTCTGGGG                   TGCGGCGCACACCTGGGCCCGTGCAGGGCTCAGCTCGGCAGCAGCTCTGAGGGCAGCT                   CAATGAAAAAGTGAATGCACACGCCCTTGTTGGCGTG                                         ORF Start: ATG at 44       ORF Stop: TGA at 1598           SEQ ID NO:98   518 aa   MW at 58034.5 kD                     NOV28a,   MTAAAAGAAGSAAPAAAAGAPGSGGAPSGSQGVLIGDRLYSGVLITLENCLLPDDKLR       CG59348-01 Protein Sequence           FTPSMSSGLDTDTETDLRVVGCELIQAAGILLRLPQVAMATGQVLFQRFFYTKSFVKH                   SMEHVSMACVHLASKIEEAPRRIRDVINVFHRLRQLRDKKKPVPLLLDQDYVNLKNQI                   IKAERRVLKELGFCVHVKHPHKIIVMYLQVLECERNQHLVQTSWNYMNDSLRTDVFVR                   FQPESIACACIYLAARTLEIPLPNRPHWFLLFGATEEEIQEICLKILQLYARKKVDLT                   HLEGEVEKRKHAIEEAKAQARGLLPGGTQVLDGTSGFSPAPKLVESPKEGKGSKPSPL                   SVKNTKRRLEGAKKAKADSPVNGLPKGRESRSRSRSREQSYSRSPSRSASPKRRKSDS                   GSTSGGSKSQSRSRSRSDSPPRQAPRSAPYKGSEIRGSRKSKDCKYPQKPHKSRSRSS                   SRSRSRSRERADNPGKYKKKSHYYRDQRRERSRSYERTGRRYERDHPGHSRHRR                  
 
     [0471] Further analysis of the NOV28a protein yielded the following properties shown in Table 28B.  
               TABLE 28B                       Protein Sequence Properties NOV28a                                        Psort   0.5500 probability located in endoplasmic reticulum       analysis:   (membrane); 0.2400 probability located in nucleus; 0.1900           probability located in lysosome (lumen); 0.1000 probability           located in endoplasmic reticulum (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0472] A search of the NOV28a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 28C.  
               TABLE 28C                          Geneseq Results for NOV28a                                         NOV28a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAM94028   Human stomach   221 . . . 518   298/298   e−172           cancer expressed       (100%)           polypeptide SEQ    1 . . . 298   298/298           ID NO 126—       (100%)             Homo sapiens ,           298 aa.           [WO200109317-           A1, Feb. 8, 2001]       AAG64403   Human paneth   221 . . . 518   298/298   e−172           cell enhanced       (100%)           expression-like    1 . . . 298   298/298           protein— Homo         (100%)             sapiens , 298 aa.           [WO200138372-           A1, May 31,           2001]       AAB94641   Human protein   221 . . . 518   298/298   e−172           sequence SEQ ID       (100%)           NO:15526—    1 . . . 298   298/298             Homo sapiens ,       (100%)           298 aa.           [EP1074617-A2,           Feb. 7, 2001]       AAM78533   Human protein    2 . . . 518   316/526   e−168           SEQ ID NO        (60%)           1195— Homo      8 . . . 526   390/526             sapiens , 526 aa.        (74%)           [WO200157190-           A2, Aug. 9,           2001]       AAB94371   Human protein    2 . . . 518   316/526   e−168           sequence SEQ ID        (60%)           NO:14909—    8 . . . 526   390/526             Homo sapiens ,        (74%)           526 aa.           [EP1074617-A2,           Feb. 7, 2001]                  
 
     [0473] In a BLAST search of public sequence databases, the NOV28a protein was found to have homology to the proteins shown in the BLASTP data in Table 28D.  
               TABLE 28D                          Public BLASTP Results for NOV28a                                         NOV28a   Identities/           Protein       Residues/   Similarities       Accession   Protein/   Match   for the   Expect       Number   Organism/Length   Residues   Matched Portion   Value               Q96S94   HYPO-    3 . . . 518   516/516 (100%)   0.0           THETICAL    5 . . . 520   516/516 (100%)           58.1 KDA           PROTEIN—             Homo sapiens             (Human), 520 aa.       Q9JJA7   BRAIN CDNA,    1 . . . 518   466/519 (89%)    0.0           CLONE MNCB-    1 . . . 518   482/519 (92%)            5160, SIMILAR           TO  MUS               MUSCULUS             PANETH CELL           ENHANCED           EXPRESSION           PCEE MRNA—             Mus musculus             (Mouse), 518 aa.       Q9UK58   CYCLIN L    2 . . . 518   316/526 (60%)    e−167           ANIA-6A—    8 . . . 526   390/526 (74%)              Homo sapiens             (Human), 526 aa.       Q9R1Q2   CYCLIN ANIA-    2 . . . 518   312/526 (59%)    e−165           6A— Rattus      9 . . . 527   391/526 (74%)              norvegicus             (Rat), 527 aa.       Q9WV44   CYCLIN ANIA-    3 . . . 518   314/526 (59%)    e−162           6A— Mus     15 . . . 531   385/526 (72%)              musculus             (Mouse), 531 aa.                  
 
     [0474] PFam analysis predicts that the NOV28a protein contains the domains shown in the Table 28E.  
               TABLE 28E                          Domain Analysis of NOV28a                                     Identities/               NOV28a   Similarities for           Match   the Matched   Expect       Pfam Domain   Region   Region   Value                                         cyclin: domain 1 of 1    46 . . . 190   28/163   (17%)   0.0022               86/163   (53%)       Srg: domain 1 of 1   221 . . . 230   4/10   (40%)   6.7               10/10   (100%)       transcript_fac2: domain 1   235 . . . 253   12/19   (63%)   0.86       of 1       15/19   (79%)       cyclin_C: domain 1 of 1   196 . . . 311   22/139   (16%)   2.6               65/139   (47%)                  
 
     Example 29  
     [0475] The NOV29 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 29A.  
               TABLE 29A                       NOV29 Sequence Analysis                                                SEQ ID NO:99   1069 bp                     NOV29a,     CGGGGCCTGGTCGGCAGCTGGGCCGCC   ATG GAGTCCACGCTGGGCGCGGGCATCGTGA       CG59245-01 DNA Sequence           TAGCCGAGGCGCTACAGAACCAGCTAGCCTGGCTGGAGAACGTGTGGCTCTGGATCAC                   CTTTCTGGGCGATCCCAAGATCCTCTTTCTGTTCTACTTCCCCGCGGCCTACTACGCC                   TCCCGCCGTGTGGGCATCGCGGTGCTCTGGATCAGCCTCATCACCGAGTGGCTCAACC                   TCATCTTCAAGTGGTTTCTTTTTGGAGACAGGCCCTTTTGGTGGGTCCATGAGTCTGG                   TTACTACAGCCAGGCTCCAGCCCAGGTTCACCAGTTCCCCTCTTCTTGTGAGACTGGT                   CCAGGTGGCAGCCCTTCTGGACACTGCATGATCACAGGAGCAGCCCTCTGGCCCATAA                   TGACGGCCCTGTCTTCGCAGGTGCGCTGGGTAAGGGTGATGCCTAGCCTGGCTTATTG                   CACCTTCCTTTTGGCGGTTGGCTTGTCGCGAATCTTCATCTTAGCACATTTCCCTCAC                   CAGGTGCTGGCTGGCCTAATAACTGGTTGGCTGATGACTCCCCGAGTGCCTATGGAGC                   GGGAGCTAAGCTTCTATGGGTTGACTGCACTGGCCCTCATGCTAGGCACCAGCCTCAT                   CTATTGGACCCTCTTTACACTGGGCCTGGATCTTTCTTGGTCCATCAGCCTAGCCTTC                   AAGTGGTGTGAGCGGCCTGAGTGGATACACGTGGATAGCCGGCCCTTTGCCTCCCTGA                   GCCGTGACTCAGGGGCTGCCCTGGGCCTGGGCATTGCCTTGCACTCTCCCTGCTATGC                   CCAGGTGCGTCGGGCACAGCTGGGAAATGGCCAGAAGATAGCCTGCCTTGTGCTGGCC                   ATGGGGCTGCTGGGCCCCCTGGACTGGCTGGGCCACCCCCCTCAGATCAGCCTCTTCT                   ACATTTTCAATTTCCTCAAGTACACCCTCTGGCCATGCCTAGTCCTGGCCCTCGTGCC                   CTGGGCAGTGCACATGTTCAGTGCCCAGGAAGCACCGCCCATCCACTCTTCC TGA   CTT                       CTTGTGTGCCTCCCTTTCCTTTCCC                                           ORF Start: ATG at 28       ORF Stop: TGA at 1039           SEQ ID NO:100   337 aa   MW at 37808.0 kD                     NOV29a,   MESTLGAGIVIAEALQNQLAWLENVWLWITFLGDPKILFLFYFPAAYYASRRVGIAVL       CG59245-01 Protein Sequence           WISLITEWLNLIFKWFLFGDRPFWWVHESGYYSQAPAQVHQFPSSCETGPGGSPSGHC                   MITGAALWPIMTALSSQVRWVRVMPSLAYCTFLLAVGLSRIFILAHFPHQVLAGLITG                   WLMTPRVPMERELSFYGLTALALMLGTSLIYWTLFTLGLDLSWSISLAFKWCERPEWI                   HVDSRPFASLSRDSGAALGLGIALHSPCYAQVRRAQLGNGQKIACLVLAMGLLGPLDW                   LGHPPQISLFYIFNFLKYTLWPCLVLALVPWAVEMFSAQEAPPIHSS                                     SEQ ID NO:101   1386 bp                     NOV29b,     TGAGTCTGTACTTTCCGCCCTGGAGCAAGCCGGGGCCTGGTCGGCAGCTGGGCCGCC   A         CG59245-01 DNA Sequence             TG GAGTCCACGCTGGGCGCGGGCATCGTGATAGCCGAGGCGCTACAGAACCAGCTAGC                   CTGGCTGGAGAACGTGTGGCTCTGGATCACCTTTCTGGGCGATCCCAAGATCCTCTTT                   CTGTTCTACTTCCCCGCGGCCTACTACGCCTCCCGCCGTGTGGGCATCGCGGTGCTCT                   GGATCAGCCTCATCACCGAGTGGCTCAACCTCATCTTCAAGTGGTTTCTTTTTGGAGA                   CAGGCCCTTTTGGTGGGTCCATGAGTCTGGTTACTACAGCCAGGCTCCAGCCCAGGTT                   CACCAGTTCCCCTCTTCTTGTGAGACTGGTCCAGGCAGCCCTTCTGGACACTGCATGA                   TCACAGGAGCAGCCCTCTGGCCCATAATGACGGCCCTGTCTTCGCAGGTGGCCACTCG                   GGCCCGCAGCCGCTGGGTAAGGGTGATGCCTAGCCTGGCTTATTGCACCTTCCTTTTG                   GCGGTTGGCTTGTCGCGAATCTTCATCTTAGCACATTTCCCTCACCAGGTGCTGGCTG                   GCCTAATAACTGGCGCTGTCCTGGGCTGGCTGATGACTCCCCGAGTGCCTATGGAGCG                   GGAGCTAAGCTTCTATGGGTTGACTGCACTGGCCCTCATGCTAGGCACCAGCCTCATC                   TATTGGACCCTCTTTACACTGGGCCTGGATCTTTCTTGGTCCATCAGCCTAGCCTTCA                   AGTGGTGTGAGCGGCCTGAGTGGATACACGTGGATAGCCGGCCCTTTGCCTCCCTGAG                   CCGTGACTCAGGGGCTGCCCTGGGCCTGGGCATTGCCTTGCACTCTCCCTGCTATGCC                   CAGGTGCGTCGGGCACAGCTGGGAAATGGCCAGAAGATAGCCTGCCTTGTGCTGGCCA                   TGGGGCTGCTGGGCCCCCTGGACTGGCTGGGCCACCCCCCTCAGATCAGCCTCTTCTA                   CATTTTCAATTTCCTCAAGTACACCCTCTGGCCATGCCCAGTCCTGGCCCTCGTGCCC                   TGGGCAGTGCACATGTTCAGTGCCCAGGAAGCACCGCCCATCCACTCTTCCTGACTTC                   TTGTGTGCCTCCCTTTCCTTTCCCTCCCACAAAGCCAACACTCTGTGACCACCACACT                   CCAGGAGGCAGCCCCATCCCCTTCCAGCCCCTAAGTAGGCCCTCCCCTCCCTAAATCT                   GCTTCCGCACCACCTGGTCTTAGCCCCAAAGATGGGCCTTCTCTCTCCCAGATAAGTT                   GGTCCTCCCTCTGCCTTTCCTCTCAAGCCCCCAAAGAGCAAAGGCAACAGCAAGACCA                   GCGGGTTCTTGCAACACTGTGAGGGGCAGCCAGGGCGGAAAGTACAGACTCA                                         ORF Start: ATG at 58       ORF Stop: TGA at 1096           SEQ ID NO:102   346 aa   MW at 38718.0 kD                     NOV29b,   MESTLGAGIVIAEALQNQLAWLENVWLWITFLGDPKILFLFYFPAAYYASRRVGIAVL       CG59245-01 Protein Sequence           WISLITEWLNLIFKWFLFGDRPFWWVHESGYYSQAPAQVHQFPSSCETGPGSPSGHCM                   ITGAALWPIMTALSSQVATRARSRWVRVMPSLAYCTFLLAVGLSRIFILAHFPHQVLA                   GLITGAVLGWLMTPRVPMERELSFYGLTALALMLGTSLIYWTLFTLGLDLSWSISLAF                   KWCERPEWIHVDSRPFASLSRDSGAALGLGIALHSPCYAQVRRAQLGNGQKIACLVLA                   MGLLGPLDWLGHPPQISLFYIFNFLKYTLWPCPVLALVPWAVHMFSAQEAPPIHSS                  
 
     [0476] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 29B.  
               TABLE 29B                          Comparison of NOV29a against NOV29b.                             NOV29a   Identities/           Residues/   Similarities for       Protein   Match   the Matched       Sequence   Residues   Region               NOV29b   1 . . . 337   335/347 (96%)           1 . . . 346   335/347 (96%)                  
 
     [0477] Further analysis of the NOV29a protein yielded the following properties shown in Table 29C.  
               TABLE 29C                       Protein Sequence Properties NOV29a                                        PSort   0.6850 probability located in endoplasmic reticulum       analysis:   (membrane); 0.6400 probability located in plasma           membrane; 0.4600 probability located in Golgi body;           0.1000 probability located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 41 and 42       analysis:                  
 
     [0478] A search of the NOV29a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 29D.  
               TABLE 29D                          Geneseq Results for NOV29a                                         NOV29a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAM79500   Human protein SEQ ID NO 3146 -   1 . . . 337   336/347 (96%)   0.0             Homo sapiens , 382 aa.   37 . . . 382    336/347 (96%)           [WO200157190-A2, 9 AUG           2001]       AAB42637   Human ORFX ORF2401   1 . . . 337   328/348 (94%)   0.0           polypeptide sequence SEQ ID   31 . . . 377    328/348 (94%)           NO:4802 -  Homo sapiens , 377 aa.           [WO200058473-A2, 5 OCT           2000]       AAB85355   Human phosphatase (PP) (clone ID   1 . . . 305   297/315 (94%)    e−174           1269556CD1) -  Homo sapiens , 385   1 . . . 314   298/315 (94%)           aa. [WO200153469-A2, 26 JUL           2001]       AAM78516   Human protein SEQ ID NO 1178 -   1 . . . 337   266/341 (78%)    e−146             Homo sapiens , 404 aa.   125 . . . 404    272/341 (79%)           [WO200157190-A2, 9 AUG           2001]       AAB25679   Human secreted protein sequence   198 . . . 337    140/140 (100%)   6e−81           encoded by gene 15 SEQ ID   1 . . . 140   140/140 (100%)           NO:68 -  Homo sapiens , 141 aa.           [WO200043495-A2, 27 JUL 2000]                  
 
     [0479] In a BLAST search of public sequence databases, the NOV29a protein was found to have homology to the proteins shown in the BLASTP data in Table 29E.  
               TABLE 29E                          Public BLASTP Results for NOV29a                                             Identities/                   NOV29a   Similarities       Protein       Residues/   for the       Accession       Match   Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               AAH21574   HYPOTHETICAL 38.7 KDA   1 . . . 337   336/347 (96%)   0.0           PROTEIN -  Homo sapiens     1 . . . 346   336/347 (96%)           (Human), 346 aa.       Q9BUM1   HYPOTHETICAL 40.1 KDA   1 . . . 337   336/347 (96%)   0.0           PROTEIN -  Homo sapiens     15 . . . 360    336/347 (96%)           (Human), 360 aa (fragment).       O42153   Glucose-6-phosphatase (EC   8 . . . 323   127/333 (38%)   1e−59           3.1.3.9) (G6Pase) (G-6-Pase) -   8 . . . 339   184/333 (55%)             Haplochromis nubilus , 352 aa.       Q98UF8   GLUCOSE-6-PHOSPHATASE -   8 . . . 323   123/333 (36%)   2e−57             Sparus aurata  (Gilthead sea   8 . . . 337   185/333 (54%)           bream), 350 aa.       Q9Z186   GLUCOSE-6-PHOSPHATASE -   7 . . . 325   128/343 (37%)   5e−56             Mus musculus  (Mouse), 355 aa.   7 . . . 345   188/343 (54%)                  
 
     [0480] PFam analysis predicts that the NOV29a protein contains the domains shown in the Table 29F.  
               TABLE 29F                          Domain Analysis of NOV29a                                     Identities/                   Similarities       Pfam   NOV29a   for the   Expect       Domain   Match Region   Matched Region   Value               PAP2: domain 1 of 1   51 . . . 190   38/175 (22%)   0.00037               95/175 (54%)                  
 
     Example 30  
     [0481] The NOV30 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 30A.  
               TABLE 30A                       NOV39 Sequence Analysis                                                SEQ ID NO:103   1624 bp                     NOV30a,     ATG GAACTGAAGGCCGAGGAGGAGGAGGTGGGTGGCGTCCAGCCGGTGGACTTGGTGG       CG59241-01 DNA Sequence           CCTTTGCCAACAGCTGCACCCTCCATGGCACCAACCACATTTTTGTGGAGGGGGGTCC                   AGGGCCAAGGCAGGTGCTGTGGGCGGTGGCCTTTGTCCTGGCACTGGGTGCCTTCCTG                   TGCCAGGTAGGGGACCGCGTTGCTTATTACCTCAGCTACCCACACGTGACCCTTCTAA                   ACGAAGTGGCCACCACGGAGCTGGCCTTCCCGGCAGTCACCCTCTGCAACACTAATGC                   TGTGCGGCTGTCCCAGCTCAGCTACCCTGACTTGCTTTATTTGGCCCCCATGCTGGGA                   CTGGATGAAAGTGATGACCCCGGGGTGCCCCTCGCTCCACCGGGCCCTGAGGCCTTCT                   CTGGGGAGCCCTTTAACCTGCACCGCTTCTACAATCGCTCCTGCCACCGGCTGGAGGA                   CATGCTGCTCTATTGCTCCTACCAAGGGGGACCCTGCGGCCCTCACAACTTCTCAGTG                   GTGTTCACACGCTATGGAAAGTGCTACACGTTCAACTCGGGCCGAGATGGGCGGCCGC                   GGCTGAAGACCATGAAGGGTGGGACGGGCAATGGGCTGGAAATCATGCTGGACATCCA                   GCAGGACGAGTACCTGCCTGTGTGGGGGGAGACTGACGAGACGTCCTTCGAAGCAGGC                   ATCAAAGTGCAGATCCATAGTCAGGATGAACCTCCTTTCATCGACCAGCTGGGCTTTG                   GCGTGGCCCCAGGCTTCCAGACCTTTGTGGCCTGCCAGGAGCAGCGGATCTACCTGCC                   CCCACCCTGGGGCACCTGCAAAGCTGTTACCATGGACTCGGATTTCTTCGACTCCTAC                   AGCATCACTGCCTGCCGCATCGACTGTGAGACGCGCTACCTGGTGGAGAACTGCAACT                   GCCGCATGGTGCACATGCCAGGTGATGCCCCATACTGTACTCCAGAGCAGTACAAGGA                   GTGTGCAGATCCTGCTCTGGACTTCCTGGTGGAGAAGGACCAGGAGTACTGCGTGTGT                   GAAATGCCTTGCAACCTGACCCGCTATGGCAAAGAGCTGTCCATGGTCAAGATCCCCA                   GCAAAGCCTCAGCCAAGTACCTGGCCAAGAAGTTCAACAAATCTGAGCAATACATAGG                   GGAGAACATCCTGGTGCTGGACATTTTCTTTGAAGTCCTCAACTATGAGACCATTGAA                   CAGAAGAAGGCCTATGAGATTGCAGGGCTCCTGGGTGACATCGGGGGCCAGATGGGGC                   TGTTCATCGGGGCCAGCATCCTCACGGTGCTGGAGCTCTTTGACTACGCCTACGAGGT                   AGTCATTAAGCACAAGCTGTGCCGACGAGGAAAATGCCAGAAGGAGGCCAAAAGGAGC                   AGTGCGGACAAGGGCGTGGCCCTCAGCCTGGACGACGTCAAAAGACACAACCCGTGCG                   AGAGCCTTCGGGGCCACCCTGCCGGGATGACATACGCTGCCAACATCCTACCTCACCA                   TCCGGCCCGAGGCACGTTCGAGGACTTTACCTGC TGA   GCCCCGCAGGCCGCTGAACCA                       AAGGCCTAGATGGGGAGGACTAGGAGAGCGAGGGGGCCCCCAGCTGCCTCCTCACATC                                           ORF Start: ATG at 1       ORF Stop: TGA at 1543           SEQ ID NO:104   514 aa   MW at 57221.7 kD                     NOV3a,   MELKAEEEEVGGVQPVDLVAFANSCTLHGTNHIFVEGGPGPRQVLWAVAFVLALGAFL       CG59241-01 Protein Sequence           CQVGDRVAYYLSYPHVTLLNEVATTELAFPAVTLCNTNAVRLSQLSYPDLLYLAPMLG                   LDESDDPGVPLAPPGPEAFSGEPFNLHRFYNRSCHRLEDMLLYCSYQGGPCGPHNFSV                   VFTRYGKCYTFNSGRDGRPRLKTMKGGTGNGLEIMLDIQQDEYLPVWGETDETSFEAG                   IKVQIHSQDEPPFIDQLGFGVAPGFQTFVACQEQRIYLPPPWGTCKAVTMDSDFFDSY                   SITACRIDCETRYLVENCNCRMVHMPGDAPTCTPEQYKECADPALDFLVEKDQEYCVC                   EMPCNLTRYGKELSMVKIPSKASAKYLAKKFNKSEQYIGENILVLDIFFEVLNYETIE                   QKKAYEIAGLLGDIGGQMGLFIGASILTVLELFDYAYEVVIKHKLCRRGKCQKEAKRS                   SADKGVALSLDDVKRHNPCESLRGHPAGMTYAANILPHHPARGTFEDFTC                  
 
     [0482] Further analysis of the NOV30a protein yielded the following properties shown in Table 30B.  
               TABLE 30B                       Protein Sequence Properties NOV30a                                        PSort   0.7900 probability located in plasma membrane; 0.3000       analysis:   probability located in Golgi body; 0.2000 probability           located in endoplasmic reticulum (membrane);           0.1000 probability located in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 60 and 61       analysis:                  
 
     [0483] A search of the NOV30a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 30C.  
               TABLE 30C                          Geneseq Results for NOV30a                                         NOV30a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAY69178   A rat acid-sensitive cationic    1 . . . 514   488/515 (94%)   0.0           channel 1B (rASIC1B) - Rattus sp,   47 . . . 559   497/515 (95%)           559 aa. [WO200008149-A2, 17               FEB 2000]           AAY03186   Rat Acid sensitive ion channel    1 . . . 514   488/515 (94%)   0.0           protein sequence - Rattus sp, 513    1 . . . 513   498/515 (95%)           aa. [WO9911784-A1, 11 MAR           1999]       AAW68507   Rat acid sensing ionic channel 1B -    1 . . . 514   488/515 (94%)   0.0           Rattus sp, 559 aa. [WO9835034-   47 . . . 559   497/515 (95%)           A1, 13 AUG 1998]       AAY69175   A rat acid-sensitive cationic    1 . . . 514   416/527 (78%)   0.0           526 aa. [WO200008149-A2, 17    1 . . . 526   445/527 (83%)           FEB 2000]       AAY03188   Rat Acid sensitive ion channel    1 . . . 514   416/527 (78%)   0.0           alpha protein sequence - Rattus sp,    1 . . . 526   445/527 (83%)           526 aa. [WO9911784-A1, 11           MAR 1999]                  
 
     [0484] In a BLAST search of public sequence databases, the NOV30a protein was found to have homology to the proteins shown in the BLASTP data in Table 30D.  
               TABLE 30D                          Public BLASTP Results for NOV30a                                             Identities/                   NOV30a   Similarities       Protein       Residues/   for the       Accession       Match   Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q91YB8   ION CHANNEL -  Rattus norvegicus     1 . . . 514   489/515 (94%)   0.0           (Rat), 559 aa.   47 . . . 559    498/515 (95%)       O88762   ASIC-BETA -  Rattus norvegicus     1 . . . 514   488/515 (94%)   0.0           (Rat), 513 aa.   1 . . . 513   498/515 (95%)       P55926   Amiloride-sensitive brain sodium   1 . . . 514   416/527 (78%)   0.0           channel BNaC2 (Amiloride-sensitive   1 . . . 526   445/527 (83%)           cation channel neuronal 2) (Proton           gated cation channel ASIC1) -  Rattus               norvegicus  (Rat), 526 aa.       P78348   Amiloride-sensitive brain sodium   1 . . . 514   421/575 (73%)   0.0           channel BNaC2 (Amiloride-sensitive   1 . . . 574   447/575 (77%)           cation channel neuronal 2) -  Homo               sapiens  (Human), 574 aa.       Q99NA1   PROTON-GATED CATION   175 . . . 514    334/341 (97%)   0.0           CHANNEL SUBUNIT ASIC-   86 . . . 425    337/341 (97%)           BETA2 -  Rattus norvegicus  (Rat),           425 aa.                  
 
     [0485] PFam analysis predicts that the NOV30a protein contains the domains shown in the Table 30E.  
               TABLE 30E                          Domain Analysis of NOV30a                                     Identities/                   Similarities       Pfam   NOV30a   for the   Expect       Domain   Match Region   Matched Region   Value                                         ASC: domain 1 of 2    21 . . . 118   34/106   (32%)   1.6e−29                79/106   (75%)       ASC: domain 2 of 2   145 . . . 442   133/351   (38%)   2.1e−139               281/351   (80%)                  
 
     Example 31  
     [0486] The NOV31 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 31A.  
               TABLE 31A                       NOV31 Sequence Analysis                                                SEQ ID NO:105   1949 bp                     NOV31a,     TGCCTGGCT   ATG GCCCGACTGCTCAGGTCTGCAACCTGGGAGCTGTTCCCCTGGAGGG       CG58602-01 DNA Sequence           GCTACTGCTCCCAGTCCCTGCAGGGAGAGCTCTGCAGGGACTTCGTAGAGGCTCTGAA                   GGCCGTGGTGGGCGGCTCCCACGTGTCCACTGCCGCGGTGGTCCGAGAGCAGCACGGG                   CGCGATGAGTCGGTGCACAGGTGCGAACCTCCTGATGCTGTGGTGTGGCCCCAGAACG                   TGGAGCAGGTCAGCCGGCTGGCAGCCCTGTGCTATCGCCAAGGTGTGCCCATCATCCC                   ATTCGGCACCGGCACCGGGCTTGAGGGTGGCGTCTGTGCTGTGCAGGGCGGCGTCTGC                   GTTAACCTGACGCATATGGACCGAATCCTGGAGCTGAACCAGGAGGACTTCTCTGTGG                   TGGTGGAGCCAGGTGTCACCCGCAAAGCCCTCAACGCCAACCTGCGGGACAGCGGCCT                   CTGGTTTCCTCCAGACCCAGGCGCGGACGCCTCTCTCTGTGGCATGGCGGCCACCGGG                   GCGTCGGGGACCAACGCGGTCCGCTACGGCACCATGCGGGACAACGTGCTCAACCTGG                   AGGTGGTGCTGCCCGACGGGCGGCTGCTGCACACGGCGGGCCGAGGCCTCATCACAGA                   TTCCACTGCTGCATTCCCCCACATCAGCCCCACTGAGTGCTTTTCCCAGGGGCCAGGG                   CCTCATGTCAATTCTCCTCACCCTGCCCCTGAGGCCACAGTGGCCGCCACGTGTGCGT                   TCCCCAGTGTCCAGGCTGCTGTGGACAGCACTGTACACATCCTCCAGGCTGCAGTGCC                   CGTAGCCCGCATTGAGTTCCTGGATGAAGTCATGATGGATGCCTGCAACAGGTACAGC                   AAGCTGAATTGCTTAGTGGCGCCCACACTCTTCCTGGAGTTCCATGGCTCCCAGCAGG                   CACTGGAGGAGCAGCTGCAGCGCACAGAGGAGATAGTCCAGCAGAACGGAGCCTCTGA                   CTTCTCCTGGGCCAAGGAGGCCGAGGAGCGCAGCCGGCTTTGGACAGCACGGCACAAT                   GCCTGGTACGCAGCCCTGGCCACGCGGCCAGGCTGCAAGGGCTACTCCACGGATGTGT                   GTGTGCCCATCTCCCGGCTGCCGGAGATCGTGGTGCAGACCAAGGAGGATCTGAATGC                   CTCAGGACTCACAGGAAGCATTGTCGGGCATGTGGGTGACGGCAACTTCCACTGCATC                   CTGCTGGTCAACCCTGATGACGCCGAGGAACTGGGCAGGGTCAAGGCTTTTGCAGAAC                   AGCTGGGCAGGCGGGCACTGGCTCTCCACGGAACGTGCACCGGGGGAGCATGGCATGG                   AATGGGCAAGCGGCAGCTGCTGCAGGAGGAGGTGGGCGCCGTGGGCGTGGAGACCATG                   CGGCAGCTCAAGGCCGTGCTAGACCCCCAAGGCCTCATGAATCCAGGCAAAGTGCTG T                       GA   AGGGGGTCTGAGCACTTAGCCCACAAGTTCCCTGACTACGGAGCCGGTTCTGGAAC                       TTTTCTTCATGCCACGGCCCCTGCAAGGAAATAGATGCTGAGGCAGTCTTCCTGCCAG                       CGAGCCCACTGTATCTGGGCCCAAGGCCAGAGGGCCCAGAGAGAAGCCTGAGCACCGT                       GTTACCTCCCTGGCCCTCTGGCTGGCCCCAGGAGCCTTTGGTTCAGTAAACGACCCAG                       GGTGGTTCCCAGCAAAGCTGCTTCCTCTCTGCTCCTACGCATCCTGTCCTGGCGGGAA                       GAGAGCGTCTGGGTCCATTCAAGACTCTGATGACACCCCTCCCCGAGGCCTCCCACTG                       CCGGGGTCCCAGGACCCTTCCCCCTTCACCTGGTGACAGGAACACTCCTTTCCTGGTA                       TGGAACGTGAGCTCCCGTGACATGATGATAGGTCTTCTCCTTGGGGCCTCCCCCAATA                       AATCTGTAATAAACCTGAAACCCACCTACAGCTAA                                           ORF Start: ATG at 10       ORF Stop: TGA at 1450           SEQ ID NO:106   480 aa   MW at 51629.1 kD                     NOV31a,   MARLLRSATWELFPWRGYCSQSLQGELCRDFVEALKAVVGGSHVSTAAVVREQHGRDE       CG58602-01 Protein Sequence           SVHRCEPPDAVVWPQNVEQVSRLAALCYRQGVPIIPFGTGTGLEGGVCAVQGGVCVNL                   THMDRILELNQEDFSVVVEPGVTRKALNAHLRDSGLWFPPDPGADASLCGMAATGASG                   TNAVRYGTMRDNVLNLEVVLPDGRLLHTAGRGLITDSTAAFPHISPTECFSQGPGPHV                   NSPHPAPEATVAATCAFPSVQAAVDSTVHILQAAVPVARIEFLDEVMMDACNRYSKLN                   CLVAPTLFLEFHGSQQALEEQLQRTEEIVQQNGASDFSWAKEAEERSRLWTARHNAWY                   AALATRPGCKGYSTDVCVPISRLPEIVVQTKEDLNASGLTGSIVGHVGDGNFHCILLV                   NPDDAEELGRVKAFAEQLGRRALALHGTCTGEHGIGMGKRQLLQEEVGAVGVETMRQL                   KAVLDPQGLMNPGKVL                  
 
     [0487] Further analysis of the NOV31a protein yielded the following properties shown in Table 31B.  
               TABLE 31B                       Protein Sequence Properties NOV31a                                        PSort   0.6574 probability located in mitochondrial matrix space;       analysis:   0.3502 probability located in mitochondrial inner membrane;           0.3502 probability located in mitochondrial intermembrane           space; 0.3502 probability located in mitochondrial outer           membrane       SignalP   Likely cleavage site between residues 20 and 21       analysis:                  
 
     [0488] A search of the NOV31a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 31C.  
               TABLE 31C                          Geneseq Results for NOV31a                                         NOV31a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value                                             ABB10446   Human cDNA SEQ ID NO: 754 -   1 . . . 96   91/96   (94%)   8e−49             Homo sapiens , 115 aa.   15 . . . 110   92/96   (95%)           [WO200154474-A2, 2 AUG 2001]       AAE09597   Human gene 5 encoded novel   1 . . . 96   91/96   (94%)   8e−49           protein HDPMT22, SEQ ID NO:33 -   15 . . . 110   92/96   (95%)             Homo sapiens , 115 aa.           [WO200155311-A2, 2 AUG 2001]       AAM52368   GIP12-C4 protein -  Arabidopsis     66 . . . 203   69/138   (50%)   9e−34             thaliana , 159 aa. [FR2806095-A1,    3 . . . 140   98/138   (71%)           14 SEP 2001]       AAG92286   C glutamicum protein fragment SEQ   46 . . . 477   108/486   (22%)   2e−22           ID NO: 6040 - Corynebacterium   25 . . . 502   186/486   (38%)           glutamicum, 948 aa. [EP1108790-           A2, 20 JUN 2001]       AAB79309   Corynebacterium glutamicum SMP   46 . . . 477   108/486   (22%)   2e−22           protein sequence SEQ ID NO:134 -   22 . . . 499   186/486   (38%)           Corynebacterium glutamicum, 945           aa. [WO200100844-A2, 4 JAN           2001]                  
 
     [0489] In a BLAST search of public sequence databases, the NOV31a protein was found to have homology to the proteins shown in the BLASTP data in Table 31D.  
               TABLE 31D                          Public BLASTP Results for NOV31a                                             Identities/                   NOV31a   Similarities       Protein       Residues/   for the       Accession       Match   Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9D635   4733401P21RIK PROTEIN -  Mus      1 . . . 480   394/483 (81%)   0.0             musculus  (Mouse), 481 aa.    1 . . . 481   423/483 (87%)       Q19965   F32D8.4 PROTEIN -  Caenorhabditis     20 . . . 480   221/466 (47%)   e−121             elegans , 912 aa.   445 . . . 909    307/466 (65%)       CAD16371   PUTATIVE D-LACTATE   32 . . . 479   226/454 (49%)   e−119           DEHYDROGENASE   20 . . . 469   300/454 (65%)           (CYTOCHROME)           OXIDOREDUCTASE PROTEIN           (EC 1.1.2.4) -  Ralstonia               solanacearum  ( Pseudomonas               solanacearum ), 472 aa.       A89201   protein F32D8.4 [imported] -   30 . . . 480   214/469 (45%)   e−115             Caenorhabditis elegans , 870 aa.   399 . . . 867    296/469 (62%)       AAL51780   D-LACTATE DEHYDROGENASE   41 . . . 480   209/444 (47%)   e−114           (CYTOCHROME) (EC 1.1.2.4) -   28 . . . 467   286/444 (64%)             Brucella melitensis , 468 aa.                  
 
     [0490] PFam analysis predicts that the NOV31a protein contains the domains shown in the Table 31E.  
               TABLE 31E                          Domain Analysis of NOV31a                                     Identities/                   Similarities       Pfam   NOV31a   for the   Expect       Domain   Match Region   Matched Region   Value                                         FAD_binding_4:    33 . . . 214   70/208   (34%)   3.7e−56       domain 1 of 1       154/208   (74%)       FAD-oxidase_C:   206 . . . 479   91/307   (30%)   1.3e−58       domain 1 of 1       210/307   (68%)                  
 
     Example 32  
     [0491] The NOV32 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 32A.  
               TABLE 32A                       NOV32 Sequence Analysis                                                SEQ ID NO:107   698 bp                     NOV32a,     CTCCTTCCTGTGCTCTTTAT   ATG GACCAACAACTTCTCGTCCTTGGGGTCTCTGTGCA       CG58468-01 DNA Sequence           AATATCAATTTTTTCACATTATCTTTTCTCCACAGACATGAGAGGGAAGGCATTTATT                   TTCCCTCAAGAATCAGCTACAGTCTATGTGTCCCTGATCCCCAAGGTGAAGAAGCCCC                   TGAAGAACTTCAAGCTTTGCCTGAAAACCTTCACAGACTTCACCTGCCCTTATAGCCT                   CTTCTACAGCACTCCGTCCCAGGACAATGAGCTGCTTCTCCTTGTCAACAAAATGGGA                   ATGTATCTGCTGCACATTGGAAATGCTGCGGTCACTTTCAATGGCCCCACCCCCTGCC                   CTCGATCTCCTTATGCTTCGACCCATGTCAATGTGAGCTGGGAGTCTGCCTCTGGAAT                   TGCTACACTCTGGGCAAATGGGAAGCTGGTGGGGAGGAAGGGTGTGTGGAAGGGGTAC                   TCTGTGGGAGAAGAGGCTAAGATCATCCTGGGACAAGAGCAGGATTCCTTTGGGGGAC                   ATTTTGATGAAAATCAATCCTTTGTTGGGGTGATATGGGATGTGTTTTTGTGGGATCA                   TGTGCTCCCTCCAAAGGAGATGTGTGACTCCTGTTACAGCGGCAGCCTCCTGAATCGG                   CATACCCTGACTTATGAAGATAATGGCTATGTGGTAACTAAGCCCAAGGTGTGGGCT T                       AA                                           ORF Start: ATG at 21       ORF Stop: TAA at 696           SEQ ID NO:108   225 aa   MW at 25265.8 kD                     NOV32a,   MDQQLLVLGVSVQISIFSHYLFSTDMRGKAFIFPQESATVYVSLIPKVKKPLKNFKLC       CG58468-01 Protein Sequence           LKTFTDFTCPYSLFYSTRSQDNELLLLVNKMGMYLLHIGNAAVTFNGPTPCPRSPYAS                   THVNVSWESASGIATLWANGKLVGRKGVWKGYSVGEEAKIILGQEQDSFGGHFDENQS                   FVGVIWDVFLWDHVLPPKEMCDSCYSGSLLNRHTLTYEDNGYVVTKPKVWA                  
 
     [0492] Further analysis of the NOV32a protein yielded the following properties shown in Table 32B.  
               TABLE 32B                       Protein Sequence Properties NOV32a                                        PSort   0.5500 probability located in endoplasmic reticulum       analysis:   (membrane); 0.3200 probability located in microbody           (peroxisome); 0.2368 probability located in lysosome           (lumen); 0.1000 probability located in endoplasmic           reticulum (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0493] A search of the NOV32a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 32C.  
               TABLE 32C                          Geneseq Results for NOV32a                                         NOV32a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAR74763   Sermun amyloid P component,   24 . . . 224    98/207 (47%)   4e−48           promoter sapm- Homo sapiens ,    2 . . . 203   136/207 (65%)           204 aa. [WO9505394-A,           23 Feb. 1995]       AAR29923   SAP- Homo sapiens , 223 aa.    7 . . . 224   101/224 (45%)   3e−47           [WO9221364-A, 10 DEC. 1992]    5 . . . 222   143/224 (63%)       AAR29922   CRP- Homo sapiens , 225 aa.   14 . . . 224   100/218 (45%)   2e−43           [WO9221364-A, 10 DEC. 1992]   11 . . . 224   132/218 (59%)       AAR74769   Female hamster protein, 1 fhp-   24 . . . 222    95/206 (46%)   6e−43             Cricetus cricetus , 210 aa.    1 . . . 199   132/206 (63%)           [WO9505394-A, 23 FEB. 1995]       AAY76844   Human C reactive protein (CRP)   24 . . . 224    98/208 (47%)   1e−42           sequence- Homo sapiens , 206 aa.    2 . . . 205   128/208 (61%)           [JP2000014388-A,           18 JAN. 2000]                  
 
     [0494] In a BLAST search of public sequence databases, the NOV32a protein was found to have homology to the proteins shown in the BLASTP data in Table 32D.  
               TABLE 32D                          Public BLASTP Results for NOV32a                                         NOV32a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9D8J8   1810030J14RIK PROTEIN- Mus      6 . . . 224   130/220 (59%)   5e−72             musculus  (Mouse), 219 aa.    4 . . . 218   166/220 (75%)       Q9D8V2   1810030J14RIK PROTEIN- Mus      6 . . . 190   110/186 (59%)   2e−58             musculus  (Mouse), 200 aa.   20 . . . 200   139/186 (74%)       Q63913   SERUM AMYLOID P- Cricetulus      1 . . . 224   109/231 (47%)   4e−51             migratorius  (Armenian hamster),    1 . . . 222   152/231 (65%)           223 aa.       P23680   Serum amyloid P-component    6 . . . 224   105/224 (46%)   7e−50           precursor (SAP)- Rattus norvegicus      4 . . . 223   145/224 (63%)           (Rat), 228 aa.       P15697   Female protein precursor (FP)    1 . . . 222   108/229 (47%)   7e−50           (Serum amyloid P-component)-    1 . . . 220   151/229 (65%)             Cricetulus migratorius  (Armenian           hamster), 231 aa.                  
 
     [0495] PFam analysis predicts that the NOV32a protein contains the domains shown in the Table 32E.  
               TABLE 32E                          Domain Analysis of NOV32a                                     Identities/           Pfam   NOV32a Match   Similarities for   Expect       Domain   Region   the Matched Region   Value               pentaxin: domain 1 of   29 . . . 221   103/214 (48%)   8e−76       1       156/214 (73%)                  
 
     Example 33  
     [0496] The NOV33 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 33A.  
               TABLE 33A                       NOV33 Sequence Analysis                                                SEQ ID NO:109   3350 bp                     NOV33a,     TA   ATG AGGAGACTGAGTTTGTGGTGGCTGCTGAGCAGGGTCTGTCTGCTGTTGCCGCC       CG58183-01 DNA Sequence           GCCCTGCGCACTGGTGCTGGCCGGGGTGCCCAGCTCCTCCTCGCACCCGCAGCCCTGC                   CAGATCCTCAAGCGCATCGGGCACGCGGTGAGGGTGGGCGCGGTGCACTTGCAGCCCT                   GGACCACCGCCCCCCGCGCGGCCAGCCGCGCTCCGGACGACAGCCGAGCAGGAGCCCA                   GAGGGATGAGCCGGAGCCAGGGACTAGGCGGTCCCCGGCGCCCTCGCCGGGCGCACGC                   TGGTTGGGGAGCACCCTGCATGGCCGGGGGCCGCCGGGCTCCCGTAAGCCCGGGGAGG                   GCGCCAGGGCGGAGGCCCTGTGGCCACGGGACGCCCTCCTATTTGCCGTGGACAACCT                   GAACCGCGTGGAAGGGCTGCTACCCTACAACCTGTCTTTGGAAGTAGTGATGGCCATC                   GAGGCAGGCCTGGGCGATCTGCCACTTTTGCCCTTCTCCTCCCCTAGTTCGCCATGGA                   GCAGTGACCCTTTCTCCTTCCTGCAAAGTGTGTGCCATACCGTGGTGGTGCAAGGGGT                   GTCGGCGCTGCTCGCCTTCCCCCAGAGCCAGGGCGAAATGATGGAGCTCGACTTGGTC                   AGCTTAGTCCTGCACATTCCAGTGATCAGCATCGTGCGCCACGAGTTTCCACGGGAGA                   GTCAGAATCCCCTTCACCTACAACTGAGTTTAGAAAATTCATTAAGTTCTGATGCTGA                   TGTCACTGTCTCAATCCTGACCATGAACAACTGGTACAATTTTAGCTTGTTGCTGTGC                   CAGGAAGACTGGAACATCACCGACTTCCTCCTCCTTACCCAGAATAATTCCAAGTTCC                   ACCTTGGTTCTATCATCAACATCACCGCTAACCTCCCCTCCACCCAGGACCTCTTGAG                   CTTCCTACAGATCCAGCTTGAGAGTATTAAGAACAGCACACCCACAGTGGTGATGTTT                   GGCTGCGACATGGAAAGTATCCGGCGGATTTTCGAAATTACAACCCAGTTTGGGGTCA                   TGCCCCCTGAACTTCGTTGGGTGCTGGGAGATTCCCAGAATGTGGAGGAACTGAGGAC                   AGAGGGTCTGCCCTTAGGGCTCATTGCTCATGGAAAAACAACACAGTCTGTCTTTGAG                   CACTACGTACAAGATGCTATGGAGCTGGTCGCAAGAGCTGTAGCCACAGCCACCATGA                   TCCAACCAGAACTTGCTCTCATTCCCAGCACGATGAACTGCATGGAGGTGGAAACTAC                   AAATCTCACTTCAGGACAATATTTATCAAGGTTTCTAGCCAATACCACTTTCAGAGGC                   CTCAGTGGTTCCATCAGAGTAAAAGGTTCCACCATCGTCAGCTCAGAAAACAACTTTT                   TCATCTGGAATCTTCAACATCACCCCATGGGAAAGCCAATGTGGACCCGCTTGGGCAG                   CTGGCAGGGGGGAAAGATTGTCATGGACTATGGAATATGGCCAGAGCAGGCCCAGAGA                   CACAAAACCCACTTCCAACATCCAAGTAAGCTACACTTGAGAGTGGTTACCCTGATTG                   AGCATCCTTTTGTCTTCACAAGGGAGGTAGATGATGAAGGCTTGTGCCCTGCTGGCCA                   ACTCTGTCTAGACCCCATGACTAATGACTCTTCCACATTGGACAGCCTTTTTAGCAGC                   CTCCATAGCAGTAATGATACAGTGCCCATTAAATTCAAGAAGTGCTGCTATGGATATT                   GCATTGATCTGCTGGAAAAGATAGCAGAAGACATGAACTTTGACTTCGACCTCTATAT                   TGTAGGGGATGGAAAGTATGGAGCATGGAAAAATGGGCACTGGACTGGGCTAGTGGGT                   GATCTCCTGAGAGGGACTGCCCACATGGCAGTCACTTCCTTTAGCATCAATACTGCAC                   GGAGCCAGGTGATAGATTTCACCAGCCCTTTCTTCTCCACCAGCTTGGGCATCTTAGT                   GAGGACCCGAGATACAGCAGCTCCCATTGGAGCCTTCATGTGGCCACTCCACTGGACA                   ATGTGGCTGGGGATTTTTGTGGCTCTGCACATCACTGCCGTCTTCCTCACTCTGTATG                   AATGGAAGAGTCCATTTGGTTTGACTTCCAAGGCGCGAAATAGAAGTAAAGTCTTCTC                   CTTTTCTTCAGCCTTGAACATCTGTTATGCCCTCTTGTTTGGCAGAACAGTGGCCATC                   AAACCTCCAAAATGTTGGACTGGAAGGTTTCTAATGAACCTTTGGGCCATTTTCTGTA                   TGTTTTGCCTTTCCACATACACGGCAAACTTGCCTGCTGTCATGGTAGGTGAGAAGAT                   CTATGAAGAGCTTTCTGGAATACATGACCCCAAGTTACATCATCCTTCCCAAGGATTC                   CGCTTTGGAACTGTCCGAGAAAGCAGTGCTGAAGATTATGTGAGACAAAGTTTCCCAG                   AGATGCATGAATATATGAGAAGGTACAATGTTCCAGCCACCCCTGATGGAGTGGAGTA                   TCTGAAGAATGATCCAGAGAAACTAGACGCCTTCATCATGGACAAAGCCCTTCTGGAT                   TATGAAGTGTCAATAGATGCTGACTGCAAACTTCTCACTGTGGGGAAGCCATTTGCCA                   TAGAAGGTTACGGCATTGGCCTCCCACCCAACTCTCCATTGACCGCCAACATATCCGA                   GCTAATCAGTCAATACAAGTCACATGGGTTTATGGATATGCTCCATGACAAGTGGTAC                   AGGGTGGTTCCCTGTGGCAAGAGAAGTTTTGCTGTCACGGAGACTTTGCAAATGGGCA                   TCAAACACTTCTCTGGGCTCTTTGTGCTGCTGTGCATTGGATTTGGTCTGTCCATTTT                   GACCACCATTGGTGAGCACATAGTATACAGGCTGCTGCTACCACGAATCAAAAACAAA                   TCCAAGCTGCAATACTGGCTCCACACCAGCCAGAGATTACACAGAGCAATAAATACAT                   CATTTATAGAGGAAAAGCAGCAGCATTTCAAGACCAAACGTGTGGAAAAGAGATCTAA                   TGTGGGACCCCGTCAGCTTACCGTATGGAATACTTCCAATCTGAGTCATGACAACCGA                   CGGAAATACATCTTTAGTGATGAGGAAGGACAAAACCAGCTGGGCATCCGGATCCACC                   AGGACATCCCCCTCCCTCCAAGGAGAAGAGAGCTCCCTGCCTTGCGGACCACCAATGG                   GAAAGCAGACTCCCTAAATGTATCTCGGAACTCAGTGATGCAGGAACTCTCAGAGCTC                   GAGAAGCAGATTCAGGTGATCCGTCAGGAGCTGCAGCTGGCTGTGAGCAGGAAAACGG                   AGCTGGAGGAGTATCAAAGGACAAGTCGGACTTGTGAGTCC TAG                                           ORF Start: ATG at 3       ORF Stop: TAG at 3348           SEQ ID NO:110   1115 aa   MW at 125453.7 kD                     NOV33a,   MRRLSLWWLLSRVCLLLPPPCALVLAGVPSSSSHPQPCQILKRIGHAVRVGAVHLQPW       CG58183-01 Protein Sequence           TTAPRAASRAPDDSRAGAQRDEPEPGTRRSTAPSPGARWLGSTLHGRGPPGSRKPGEG                   ARAEALWPRDALLFAVDNLNRVEGLLPYNLSLEVVNAIEAGLGDLPLLPFSSPSSPWS                   SDPFSFLQSVCHTVVVQGVSALLAFPQSQGEMMELDLVSLVLHIPVISIVRHEFPRES                   QNPLHLQLSLENSLSSDADVTVSILTMNNWYNFSLLLCQEDWNITDFLLLTQNNSKFH                   LGSIINITANLPSTQDLLSFLQIQLESIKNSTPTVVMFGCDMESIRRIFEITTQFGVM                   PPELRWVLGDSQNVEELRTEGLPLGLIAHGKTTQSVFEHYVQDAMELVARAVATATMI                   QPELALIPSTMNCMEVETTNLTSGQYLSRFLANTTFRGLSGSIRVKGSTIVSSENNFF                   IWNLQHDPMGKPMWTRLGSWQGCKIVMDYGIWPEQAQRNKTHFQHPSKLHLRVVTLIE                   HPFVFTREVDDEGLCPAGQLCLDPMTNDSSTLDSLFSSLHSSNDTVPIKFKKCCYGYC                   IDLLEKIAEDMNFDFDLYIVGDGKYGAWKNGHWTGLVGDLLRGTAHMAVTSFSINTAR                   SQVIDFTSPFFSTSLGILVRTRDTAAPIGAFMWPLHWTMWLGIFVALHITAVFLTLYE                   WKSPFGLTSKGRNRSKVFSFSSALNICYALLFGRTVAIKPPKCWTGRFLMNLWAIFCM                   FCLSTYTANLAAVMVGEKIYEELSGIHDPKLNHPSQGFRFGTVRESSAEDYVRQSFPE                   MHEYMRRYNVPATPDGVEYLKNDPEKLDAFIMDKALLDYEVSIDADCKLLTVGKPFAI                   EGYGIGLPPNSPLTANISELISQYKSHGFMDMLHDKWYRVVPCGKRSFAVTETLQNGI                   KHFSGLFVLLCIGFGLSILTTIGEHIVYRLLLPRIKNKSKLQYWLHTSQRLHRAINTS                   FIEEKQQHFKTKRVEKRSNVGPRQLTVWNTSNLSHDNRRKYIFSDEEGQNQLGIRIHQ                   DIPLPPRRRELPALRTTNGKADSLNVSRNSVMQELSELEKQIQVIRQELQLAVSRKTE                   LEEYQRTSRTCES                  
 
     [0497] Further analysis of the NOV33a protein yielded the following properties shown in Table 33B.  
               TABLE 33B                       Protein Sequence Properties NOV33a                                        PSort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability           located in endoplasmic reticulum (membrane); 0.1000           probability located in endoplasmic           reticulum (lumen)       SignalP   Likely cleavage site between residues 34 and 35       analysis:                  
 
     [0498] A search of the NOV33a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 33C.  
               TABLE 33C                          Geneseq Results for NOV33a                                         NOV33a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAU02199   Human glutamate receptor-like    95 . . . 1103   508/1047 (48%)   0.0           protein, MEM4- Homo sapiens ,    6 . . . 1007   680/1047 (64%)           1043 aa. [WO200144473-A2,           21 JUN. 2001]       AAB42494   Human ORFX ORF2258    95 . . . 985   484/912 (53%)   0.0           polypeptide sequence SEQ ID    6 . . . 885   635/912 (69%)           NO: 4516- Homo sapiens ,           901 aa. [WO200058473-A2,           5 OCT. 2000]       AAU02198   Human glutamate receptor-like   532 . . . 1103   361/579 (62%)   0.0           protein, MEM3- Homo sapiens ,   362 . . . 935   448/579 (77%)           971 aa. [WO200144473-A2,           21 JUN. 2001]       AAU02197   Human glutamate receptor-like   532 . . . 1103   352/579 (60%)   0.0           protein, MEM2- Homo sapiens ,   362 . . . 929   437/579 (74%)           965 aa. [WO200144473-A2,           21 JUN. 2001]       AAR44192   Rat NMDA receptor subunit,   175 . . . 1023   245/873 (28%)   2e−83           NR2A- Rattus rattus , 1464 aa.    77 . . . 911   425/873 (48%)           [DE4216321-A, 18-NOV. 1993]                  
 
     [0499] In a BLAST search of public sequence databases, the NOV33a protein was found to have homology to the proteins shown in the BLASTP data in Table 33D.  
               TABLE 33D                          Public BLASTP Results for NOV33a                                         NOV33a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               AAL40734   N-METHYL-D-ASPARTATE    1 . . . 1115   1110/1115 (99%)   0.0           RECEPTOR 3A- Homo sapiens      1 . . . 1115   1112/1115 (99%)           (Human), 1115 aa.       Q62800   IONOTROPIC GLUTAMATE    1 . . . 1115   1032/1115 (92%)   0.0           RECEPTOR- Rattus norvegicus      1 . . . 1115   1083/1115 (96%)           (Rat), 1115 aa.       Q9R1M7   N-METHYL-D-ASPARTATE    1 . . . 1115   1032/1135 (90%)   0.0           RECEPTOR SPLICE    1 . . . 1135   1083/1135 (94%)           VARIANT NR3A-2- Rattus               norvegicus  (Rat), 1135 aa.       CAC69380   SEQUENCE 7 FROM PATENT    95 . . . 1103    508/1047 (48%)   0.0           WO0144473- Homo sapiens      6 . . . 1007    680/1047 (64%)           (Human), 1043 aa.       Q91ZU9   NMDA-TYPE GLUTAMATE   112 . . . 1103    510/1001 (50%)   0.0           RECEPTOR SUBUNIT NR3B    34 . . . 980    669/1001 (65%)           PRECURSOR- Mus musculus             (Mouse), 1003 aa.                  
 
     [0500] PFam analysis predicts that the NOV33a protein contains the domains shown in the Table 33E.  
               TABLE 33E                          Domain Analysis of NOV33a                                     Identities/           Pfam   NOV33a Match   Similarities for   Expect       Domain   Region   the Matched Region   Value               lig_chan: domain 1 of   674 . . . 952    81/323 (25%)   4e−95       1       232/323 (72%)                  
 
     Example 34  
     [0501] The NOV34 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 34A.  
               TABLE 34A                       NOV34 Sequence Analysis                                                SEQ ID NO:111   1253 bp                     NOV34a,     CCCAGCGCC   ATG GGGGAGTGGGCGTTCCTGGGCTCGCTGCTGGACGCCGTGCAGCTGC       CG59315-01 DNA Sequence           AGTCGCCGCTCGTGGGCCGCCTCTGGCTGGTGGTCATGCTGATCTTCCGCATCCTGGT                   GCTGGCCACGGTGGGCGGCGCCGTGTTCGAGGACGAGCAAGAGGAGTTCGTGTGCAAC                   ACGCTGCAGCCGGGCTGTCGCCAGACCTGCTACGACCGCGCCTTCCCGGTCTCCCACT                   ACCGCTTCTGGCTCTTCCACATCCTGCTGCTCTCCGCGCCCCCGGTGCTGTTCGTCGT                   CTACTCCATGCACCGGGCAGGCAAGGAGGCGGGCGGCGCTGAGGCGGCGGCGCAGTGC                   GCCCCCGGACTGCCCGAGGCCCAGTGCGCGCCGTGCGCCCTGCGCGCCCGCCGCGCGC                   GCCGCTGCTACCTGCTGAGCGTGGCGCTGCGCCTGCTGGCCGAGCTGACCTTCCTGGG                   CGGCCAGGCGCTGCTCTACGGCTTCCGCGTGGCCCCGCACTTCGCGTGCGCCGGTCCG                   CCCTGCCCGCACACGGTCGACTGCTTCGTGAGCCGCCCCACCGAGAAGACCGTCTTCG                   TGCTCTTCTATTTCGCGGTGGGGCTGCTGTCGGCGCTGCTCAGCGTAGCCGAGCTGGG                   CCACCTGCTCTGGAAGGGCCGCCCGCGCGCCGGGGAGCGTGACAACCGCTGCAACCGT                   GCACACGAAGAGGCGCAGAAGCTGCTCCCGCCGCCGCCGCCGCCACCTCCCCCACCGG                   CCCTGCCCTCCCGGCGCCCCGGCCCCGAGCCGTGCGCCCCGCCGGCCTATGCGCACCC                   GGCGCCGGCCAGCCTCCGCGAGTGCGGCAGCGGCCGCGGCAGGAATGCGCCAATGGCT                   CCCAGATGTGGACCCCACCGCTTAACCCCTTACCCCCCAGCCGCGCTCCCCCAAGGGC                   CTTCCAGCCTGAGCCCCGCCAACAGCAGGGAGCTCTGCCCAGGTGAGAACCAGCCCAG                   GACTGGAGTCAGCGCCAGCCCGCCCCTAGTGCCCACGGACACCTCCCAACCTAGATCC                   TACCTGTCTTCCTTCCTTGAGGCTGGAGGGGAAGGCTCATGGACACAAGAATGCAAGC                   ATGCATGCACACAGCTACACTGCCTCCCATCCCCTCCCGCCGACGCTGCCAGGGTGCC                   CCTCCCTCGCTCCCCATCCTGGCAGGGCGGGCGGCGCAGAGCGCTCCACTCCGGATTC                   CCCACGCCCCCGAGCCGTTCGCAGGCTCGCAC AAG                                           ORF Start: ATG at 10       ORF Stop: AG at 1252           SEQ ID NO:112   414 aa   MW at 44773.0 kD                     NOV34a,   MGEWAFLGSLLDAVQLQSPLVGRLWLVVMLIFRILVLATVGGAVFEDEQEEFVCNTLQ       CG59315-01 Protein Sequence           PGCRQTCYDRAFPVSHYRFWLFHILLLSAPPVLFVVYSMHRAGKEAGGAEAAAQCAPG                   LPEAQCAPCALRARRARRCYLLSVALRLLAELTFLGGQALLYGFRVAPHFACAGPPCP                   HTVDCFVSRPTEKTVFVLFYFAVGLLSALLSVAELGHLLWKGRPRAGERDNRCNRAHE                   EAQKLLPPPPPPPPPPALPSRRPGPEPCAPPAYAHPAPASLRECGSGRGRNAPMAPRC                   GRHRLTPYPPAALPQGPSSLSPANSRELCPGENQPRTGVSASPPLVPTDTSQPRSYLS                   SFLEAGGEGSWTQECKHACTQLHCLPSPPADAARVPLPRSPSWQGGRRRALHSGFPTP                   PSRSQART                  
 
     [0502] Further analysis of the NOV34a protein yielded the following properties shown in Table 34B.  
               TABLE 34B                       Protein Sequence Properties NOV34a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability           located in endoplasmic reticulum (membrane);           0.0300 probability located in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 39 and 40       analysis:                  
 
     [0503] A search of the NOV34a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 34C.  
               TABLE 34C                          Geneseq Results for NOV34a                                         NOV34a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAW49009   Mouse alpha 3 connexin protein-   1 . . . 296   121/334 (36%)   5e−52           Mus sp, 417 aa. [WO9830677-A1,   1 . . . 327   169/334 (50%)           16 JUL. 1998]       AAW23968   Connexin protein Cx40- Homo     1 . . . 215    93/233 (39%)   9e−46             sapiens , 358 aa. [WO9802150-A1,   1 . . . 232   133/233 (56%)           22 JAN. 1998]       AAW23970   Connexin protein Cx45- Homo     4 . . . 212    93/252 (36%)   3e−43             sapiens , 396 aa. [WO9802150-A1,   3 . . . 253   137/252 (53%)           22 JAN. 1998]       AAW23969   Connexin protein Cx43- Homo     1 . . . 216    86/235 (36%)   1e−42             sapiens , 382 aa. [WO9802150-A1,   1 . . . 235   130/235 (54%)           22 JAN. 1998]       AAM93194   Human polypeptide, SEQ ID NO:   7 . . . 384   129/409 (31%)   8e−38           [EP1130094-A2, 5 SEP. 2001]   7 . . . 360   169/409 (40%)                  
 
     [0504] In a BLAST search of public sequence databases, the NOV34a protein was found to have homology to the proteins shown in the BLASTP data in Table 34D.  
               TABLE 34D                          Public BLASTP Results for NOV34a                                         NOV34a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q91YD1   CONNEXIN30.2- Mus musculus     1 . . . 283   228/283 (80%)    e−129           (Mouse), 278 aa.   1 . . . 265   240/283 (84%)       I46053   connexin44-bovine, 402 aa.   1 . . . 397   151/418 (36%)   1e−62               1 . . . 396   207/418 (49%)       P41987   Gap junction alpha-3 protein   2 . . . 397   150/417 (35%)   4e−62           (Connexin 44) (Cx44)- Bos     1 . . . 395   206/417 (48%)             taurus  (Bovine), 401 aa.       AAA50954   CONNEXIN44- Bos taurus     1 . . . 398   154/429 (35%)   1e−60           (Bovine), 407 aa.   1 . . . 402   214/429 (48%)       Q9TU17   GAP JUNCTION PROTEIN   1 . . . 398   147/415 (35%)   1e−60           (CONNEXIN)- Ovis aries     1 . . . 408   204/415 (48%)           (Sheep), 413 aa.                  
 
     [0505] PFam analysis predicts that the NOV34a protein contains the domains shown in the  
               TABLE 34E                          Domain Analysis of NOV34a                                     Identities/           Pfam   NOV34a Match   Similarities for   Expect       Domain   Region   the Matched Region   Value               DUF26: domain 1 of 1   107 . . . 152    12/56 (21%)   1.4                27/56 (48%)       connexin: domain 1 of    1 . . . 212   101/247 (41%)   6.5e−75       1       150/247 (61%)                  
 
     Example 35  
     [0506] The NOV35 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 35A.  
               TABLE 35A                       NOV35 Sequence Analysis                                                SEQ ID NO:113   724 bp                     NOV35a,     TAAATTCGCGGCCGCGTCGACCTTCCGCAGACTCAACTGAGAAGTCAGCCTCTGCGGC         CG59203-01 DNA Sequence             AGGCACCAGGAATCTGCCTTTTCAGTTCTGTCTCCGGCAGGCTTTGAGG   ATG AAGGCT                   GCGGGCATTCTGACCCTCATTGGCTGCCTGGTCACAGGCGCCGAGTCCAAAATCTACA                   CTCGTTGCAAACTGGCAAAAATATTCTCGAGGGCTGGCCTGGACAATTACTGGGGCTT                   CAGCCTTGGAAACTGGATCTGCATGGCGTATTATGAGAGCGGCTACAACACCACAGCC                   CAGACGGTCCTGGATGACGGCAGCATCGACTACGGCATCTTCCAGATCAACAGCTTCG                   CGTGGTGCAGACGCGGAAAGCTGAAGGAGAACAACCACTGCCACGTCGCCTGCTCAGC                   CTTGGTCACTGATGACCTCACAGATGCGATTATCTGTGCCAAGAAAATTGTTAAAGAG                   ACACAAGGAATGAACTATTGGCAAGGCTGGAAGAAACACTGTGAGGGGAGAGACCTGT                   CCGACTGGAAAAAAGACTGTGAGGTTTCC TAA   ACTGGAACTGGACCCAGGATGCTTTG                       CAGCAACGCCCTAGGGTTTGCAGTGAATGTCCAAATGCCTGTGTCATCTTGTCCCGTT                       TCCTCCCAATATTCCTTCTCAAACTTGGAGAGGGAAAATTAAGCTATACTTTTAAGAA                       AATAAATATTTCCATTTAAATGTCAAAA                                           ORF Start: ATG at 108       ORF Stop: TAA at 552           SEQ ID NO:114   148 aa   MW at 16655.9 kD                     NOV35a,   MKAAGILTLIGCLVTGAESKIYTRCKLAKIFSRAGLDNYWGFSLGNWICMAYYESGYN       CG59203-01 Protein Sequence           TTAQTVLDDGSIDYGIFQINSFAWCRRGKLKENNHCHVACSALVTDDLTDAIICAKKI                   VKETQGMNYWQGWKKHCEGRDLSDWKKDCEVS                                     SEQ ID NO:115   453 bp                     NOV35b,     CATTCTGACCCTCATTGGCTGCCTGGTCACAGGCGCCGAGTCCAAAATCTACACTCGT         CG59203-02 DNA Sequence             TGCAAACTGGCAAAAATATTCTCGAGGGCTGGCCTGGACAATTACTGGGGCTTCAGCC                       TTGGAAACTGGATCTGC   ATG GCGTATTATGAGAGCGGCTACAACACCACAGCCCAGAC                   GGTCCTGGATGACGGCAGCATCGACTACGGCATCTTCCAGATCAACAGCTTCGCGTGG                   TGCAGACGCGGAAAGCTGAAGGAGAACAACCACTGCCACGTCGCCTGCTCAGCCTTGG                   TCACTGATGACCTCACAGATGCAATTATCTGTGCCAGGAAAATTGTTAAAGAGACACA                   AGGAATGAATTATTGGCAAGGCTGGAAGAAACATTGTGAGGGCAGAGACCTGTCCGAC                   TGGAAAAAAGGCTGTGAGGTTTCC TAA   ACTGGAACTGGACCCAGGAT                                           ORF Start: ATG at 134       ORF Stop: TAA at 431           SEQ ID NO:116   99 aa   MW at 11288.6 kD                     NOV35b,   MAYYESGYNTTAQTVLDDGSIDYGIFQINSFAWCRRGKLKENNHCHVACSALVTDDLT       CG59203-02 Protein Sequence           DAIICARKIVKETQGMNYWQGWKKHCEGRDLSDWKKGCEVS                  
 
     [0507] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 35B.  
               TABLE 35B                          Comparison of NOV35a against NOV35b.                                         Identities/           Protein   NOV35a Residues/   Similarities for           Sequence   Match Residues   the Matched Region                       NOV35b   50 . . . 148   97/99 (97%)                1 . . . 99   98/99 (98%)                      
 
     [0508] Further analysis of the NOV35a protein yielded the following properties shown in Table 35C.  
               TABLE 35C                       Protein Sequence Properties NOV35a                                        Psort   0.3700 probability located in outside; 0.1697 probability       analysis:   located in microbody (peroxisome); 0.1000 probability located           in endoplasmic reticulum (membrane); 0.1000 probability           located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 20 and 21       analysis:                  
 
     [0509] A search of the NOV35a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 35D.  
               TABLE 35D                          Geneseq Results for NOV35a                                         NOV35a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAY57399   Human lysoenzyme LYC2    1 . . . 148   143/148 (96%)   3e−86           polypeptide- Homo sapiens , 148 aa.    1 . . . 148   147/148 (98%)           [WO200012722-A1,           9 MAR. 2000]       AAU29169   Human PRO polypeptide sequence    1 . . . 148   143/148 (96%)   6e−86           #146- Homo sapiens , 148 aa.    1 . . . 148   146/148 (98%)           [WO200168848-A2,           20 SEP. 2001]       AAB66145   Protein of the invention #57-    1 . . . 148   143/148 (96%)   6e−86           Unidentified, 148 aa.    1 . . . 148   146/148 (98%)           [WO200078961-A1,           28 DEC. 2000]       AAY99396   Human PRO1278 (UNQ648)    1 . . . 148   143/148 (96%)   6e−86           amino acid sequence SEQ ID NO:    1 . . . 148   146/148 (98%)           203- Homo sapiens , 148 aa.           [WO200012708-A2,           9 MAR. 2000]       AAY71109   Human Hydrolase protein-7    1 . . . 148   142/148 (95%)   1e−85           (HYDRL-7)- Homo sapiens , 194   47 . . . 194   146/148 (97%)           aa. [WO200028045-A2,           18 MAY 2000]                  
 
     [0510] In a BLAST search of public sequence databases, the NOV35a protein was found to have homology to the proteins shown in the BLASTP data in Table 35E.  
               TABLE 35E                          Public BLASTP Results for NOV35a                                         NOV35a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96LF2   BA14C22.1 (NOVEL PROTEIN    1 . . . 148   148/148 (100%)   7e−88           SIMILAR TO LYSOZYME)-    1 . . . 148   148/148 (100%)             Homo sapiens  (Human), 148 aa.       Q9H1R9   BA534G20.1.1 (NOVEL PROTEIN    1 . . . 148   144/148 (97%)   4e−86           SIMILAR TO LYSOZYME C-1    1 . . . 148   147/148 (99%)           (1,4-BETA-N-           ACYLMURAMIDASE C, EC           3.2.1.17) (ISOFORM 1))- Homo               sapiens  (Human), 148 aa.       AAH21730   HYPOTHETICAL 21.6 KDA    1 . . . 148   143/148 (96%)   2e−85           PROTEIN- Homo sapiens     47 . . . 194   146/148 (98%)           (Human), 194 aa.       Q9CPX3   1700038F02RIK PROTEIN- Mus      1 . . . 148   110/148 (74%)   3e−66             musculus  (Mouse), 148 aa.    1 . . . 148   127/148 (85%)       Q9H1R8   BA534G20.1.2 (NOVEL PROTEIN   20 . . . 125   104/106 (98%)   1e−59           SIMILAR TO LYSOZYME C-1    1 . . . 106   106/106 (99%)           (1,4-BETA-N-           ACYLMURAMIDASE C, EC           3.2.1.17) (ISOFORM 2))- Homo               sapiens  (Human), 106 aa (fragment).                  
 
     [0511] PFam analysis predicts that the NOV35a protein contains the domains shown in the Table 35F.  
               TABLE 35F                          Domain Analysis of NOV35a                                     Identities/           Pfam   NOV35a Match   Similarities for   Expect       Domain   Region   the Matched Region   Value               lys: domain 1 of 1   20 . . . 145    68/129 (53%)   8e−58               107/129 (83%)                  
 
     Example 36  
     [0512] The NOV36 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 36A.  
               TABLE 36A                       NOV36 Sequence Analysis                                                SEQ ID NO:117   712 bp                     NOV36a,     GCAGCTATTGCACTTAATCGCGGCTGCTAGCACC   ATG TCCCGCGTTTTGGTGCCTTGC       CG58662-01 DNA Sequence           CATGTGAAAGGCACCGTAGCCCTGCAGGTGGGGGACGTATGGACCTCCCAAGGCCGGC                   CTAGTGTGCTGGTCATTGATGTCACCTTCCCCTGTGTCACTCCGTTCGAGGGGATCAC                   ATTTAAGAATTATTACACAGCGTTTTTTGAGCATCCTGTCTGTCAGCACACCTCAGCA                   CACACACCGGCCAAGTGGGTGACCTGCCTGTGGGACTACTGTCTGATGCCCGACCCAC                   ACAGTGAGGAGGGAGCCCAGGAGTATGTGTCGCTGTTCAAGCAACAGATACTGTGTGA                   CATGGCCAGAATATCGGACCTACACCTGATTCTGCAGCAGCCATCACCACTGTGGCTG                   TCTTTCACAGTGGACGAGCTGCAGATCTATCAGCAGGGACCAAAGAGCCCCTCCATGA                   TCTTCCCCAAGTGGCTCTCCCACCCAGTGCCCTGTGAGCAACCTGCACTCCTCCATGA                   GGGTCTCCCAGACCCCAGCAGGGTATCCTCTGAGGTGCAGCAGATGTGGGCACTGACA                   GAGATGATCCGGGCCAGTCACACCTCCGCGAGGATAGGCCACTTTGATGTAGATGGCT                   GTTATGACCTGAACTTACTCTCCTACACT TGA   GTGGTGGCTCCTAGCCAAGATGTTGG                       CCTTTCTGTGCCCACT                                           ORF Start: ATG at 35       ORF Stop: TGA at 668           SEQ ID NO:118   211 aa   MW at 23932.3 kD                     NOV36a,   MSRVLVPCHVKGTVALQVGDVWTSQCRPSVLVIDVTFPCVTPFEGITFKNYYTAFFEH       CG58662-01 Protein Sequence           PVCQETSAHTPAKWVTCLWDYCLMPDPHSEEGAQEYVSLPKQQILCDMARISELHLIL                   QQPSPLWLSFTVEELQIYQQGPKSPSMIFPKWLSHPVPCEQPALLHEGLPDPSRVSSE                   VQQMWALTEMIRASRTSARIGEFDVDGCYDLNLLSYT                                     SEQ ID NO:119   843 bp                     NOV36b,     CTGGCCTGAAGCCATGTCCCGCGTTCTAGCACCATGTCCCGCGTCTAGCACCATGTCC         CG58662-02 DNA Sequence             CGCGTCTAGCACCATGTCCCGCGTTCTAGCACCATGTCCCGCGTTCTAGCACCATGTC                       CCGCGTTCTAGCACC ATGTCCCGCGTTTTGGTGCCTTGCCATGTGAAAGGCTCCGTAG                   CCCTCCAGGTGGGCGACGTGCGGACCTCCCAAGGCCGGCCTGGCGTGCTGGTCATCGA                   TGTCACCTTCCCCAGCGTCGCTCCCTTCGAGTTGCAGGAAATCACGTTTAAGAATTAC                   TACACAGCTTTTTTGAGCATCCGTGTCCGTCAGTACACCTCAGCACACACACCTGCCA                   AGTGGGTGACCTGCCTTCGGGACTACTGCCTGATGCCTGACCCACACAGTGAAGAGGG                   AGCCCAGGAGTATGTATCGCTGTTCAAGCATCAGATGCTATGTGACATGGCTAGAATA                   TCGGAGCTACGCCTGATTCTGCGGCAGCCATCACCACTGTGGCTGTCTTTCACAGTGG                   AGGAGCTGCAGATCTATCAGCAGGGACCAAAGAGCCCCTCCGTGACCTTTCCCAAGTG                   GCTCTCCCACCCAGTGCCCTGTGAGCAACCTGCACTCCTCCGTGAGGGTTTCCCAGAC                   CCCAGCAGGGTATCCTCCGAGGTGCAGCAGATGTGGGCACTGACAGAGATGATCCGGG                   CCAGTCACACCTCCGCAAGGATCGGCCGCTTTGATGTGGATGGCTGTTATGACCTGAC                   CTTGCTCTCCTACACT TGA   ATGGTTGCTCTTAGCCAAGATGTTGGCCTTTTTGTGGGC                       ACAGAAAGGCCAACGCGGGACATGGTGCTAG                                           ORF Start: ATG at 132       Stop: TGA at 771           SEQ ID NO:120   213 aa   MW at 24222.6 kD                     NOV36b,   MSRVLVPCHVKGSVALQVGDVRTSQGRPGVLVIDVTFPSVAPFELQEITFKNYYTAFL       CG58662-02 Protein Sequence           SIRVRQYTSAHTPAKWVTCLRDYCLMPDPHSEEGAQEYVLSFKHQMLCDMARISELRL                   ILRQPSPLWLSFTVEELQIYQQGPKSPSVTFPKWLSHPVPCEQPALLREGFPDPSRVS                   SEVQQMWALTEMIRASHTSARIGRFDVDGCYDLTLLSYT                  
 
     [0513] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 36B.  
               TABLE 36B                          Comparison of NOV36a against NOV36b.                                         Identities/           Protein   NOV36a Residues/   Similarities for           Sequence   Match Residues   the Matched Region                       NOV36b   1 . . . 211   188/213 (88%)               1 . . . 213   193/213 (90%)                      
 
     [0514] Further analysis of the NOV36a protein yielded the following properties shown in Table 36C.  
               TABLE 36C                       Protein Sequence Properties NOV36a                                        PSort   0.5666 probability located in microbody (peroxisome);       analysis:   0.4500 probability located in cytoplasm; 0.1562           probability located in lysosome (lumen); 0.1000           probability located in mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0515] A search of the NOV36a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 36D.  
               TABLE 36D                          Geneseq Results for NOV36a                                         NOV36a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAG04038   Human secreted protein, SEQ ID   1 . . . 103   82/105 (78%)   1e−39           NO: 8119- Homo sapiens , 115 aa.   1 . . . 105   85/105 (80%)           [EP1033401-A2, 6 SEP. 2000]                  
 
     [0516] In a BLAST search of public sequence databases, the NOV36a protein was found to have homology to the proteins shown in the BLASTP data in Table 36E.  
               TABLE 36E                          Public BLASTP Results for NOV36a                                         NOV36a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9BSH3   SIMILAR TO RIKEN CDNA   1 . . . 211   190/213 (89%)    e−107           1500032A17 GENE- Homo     1 . . . 213   195/213 (91%)             sapiens  (Human), 213 aa.       Q9CQM0   1500032A17RIK PROTEIN-   1 . . . 211   174/213 (81%)   4e−97             Mus musculus  (Mouse),   1 . . . 213   183/213 (85%)           213 aa.                  
 
     [0517] PFam analysis predicts that the NOV36a protein contains the domains shown in the Table 36F.  
               TABLE 36F                          Domain Analysis of NOV36a                                             Identities/               Pfam   NOV36a   Similarities for   Expect           Domain   Match Region   the Matched Region   Value                             No Significant Matches Found                  
 
     Example 37  
     [0518] The NOV37 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 37A.  
               TABLE 37A                       NOV37 Sequence Analysis                                                SEQ ID NO:121   520 bp                     NOV37a,     CA   TTT GCTGTCTCCTCTGCTCACCAGCAGCTGTACTGGAGCCACCCGCGAAAATTCGG       CG58584-01 DNA Sequence           CCAGGGTTCTCGCTCTTGTCGTGTCTGTTCAAACCGGCACGGTCTGATCCGGAAATAT                   GGCCTCAATATGTGCCGCCAGTGTTTCCGTCAGTACGCGAAGGATATCGGTTTCATTA                   AGAAAGACCTGAGCTGTCTTCCTTGGCACTGCCTATGGAGG TGA   CACCCATCTCCTCC                       ATCATGGCCATCCTGAGACCGCTCGCGAAGCCCAAGATCATCAAAAAGAGCACCAAGT                       TCACTGGGAACCAGTCAGACTGATATGTCAAAATTAAGGGTAACTGGTGGAAACACAG                       AGGTATTGACAACAGGGTTCATAGAAGGTTTGAGGGCCAGATCTATGCCCAACATTGG                       TTATGGGAGAAACAAAAAGACAAAGCACATACTGCCCAGTGGCTTCTGGAAGTTCCTC                       GTCCACAACGTTAAGGAGCTGGAAGTACTGCTGGTGAGCAGAGGAGACAGCAAATG                                           ORF Start: TTT at 3       ORF Stop: TGA at 216           SEQ ID NO:122   71 aa   MW at 8461.8 kD                     NOV37a,   FAVSSAHQQLYWSHPRKFGQGSRSCRVCSNRHGLIRKYGLNMCRQCFRQYAKDIGFIK       CG58584-01 Protein Sequence           KDLSCLPWHCLWR                  
 
     [0519] Further analysis of the NOV37a protein yielded the following properties shown in Table 37B.  
               TABLE 37B                       Protein Sequence Properties NOV37a                                        PSort   0.6400 probability located in microbody (peroxisome);       analysis:   0.4500 probability located in cytoplasm; 0.1000           probability located in mitochondrial matrix           space; 0.1000 probability located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0520] A search of the NOV37a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 37C.  
               TABLE 37C                          Geneseq Results for NOV37a                                         NOV37a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAG76128   Human colon cancer antigen    7 . . . 60   46/54 (85%)   4e−24           protein SEQ ID NO: 6892- Homo      2 . . . 55   48/54 (88%)             sapiens , 80 aa. [WO200122920-           A2, 5 APR. 2001]       AAM79084   Human protein SEQ ID NO 1746-    7 . . . 60   39/54 (72%)   2e−18             Homo sapiens , 56 aa.    3 . . . 56   43/54 (79%)           [WO200157190-A2,           9 AUG. 2001]       AAG39921     Arabidopsis thaliana  protein    7 . . . 63   40/57 (70%)   2e−18           fragment SEQ ID NO: 49464-    3 . . . 58   45/57 (78%)             Arabidopsis thaliana , 637 aa.           [EP1033405-A2, 6 SEP. 2000]       AAM80068   Human protein SEQ ID NO 3714-    7 . . . 58   38/52 (73%)   5e−18             Homo sapiens , 74 aa.   22 . . . 73   42/52 (80%)           [WO200157190-A2,           9 AUG. 2001]       AAG34802     Arabidopsis thaliana  protein    7 . . . 58   37/52 (71%)   1e−17           fragment SEQ ID NO: 42406-    3 . . . 54   42/52 (80%)             Arabidopsis thaliana , 56 aa.           [EP1033405-A2, 6 SEP. 2000]                  
 
     [0521] In a BLAST search of public sequence databases, the NOV37a protein was found to have homology to the proteins shown in the BLASTP data in Table 37D.  
               TABLE 37D                          Public BLASTP Results for NOV37a                                         NOV37a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               BAB79485   RIBOSOMAL PROTEIN S29-    7 . . . 60   53/54 (98%)   1e−27             Homo sapiens  (Human), 56 aa.    3 . . . 56   53/54 (98%)       P30054   40S ribosomal protein S29- Homo      7 . . . 60   53/54 (98%)   1e−27             sapiens  (Human),, 55 aa.    2 . . . 55   53/54 (98%)       Q9OYP2   40S RIBOSOMAL PROTEIN S29-    7 . . . 60   52/54 (96%)   2e−27             Ictalurus punctatus  (Channel    3 . . . 56   53/54 (97%)           catfish), 56 aa.       AAL62474   RIBOSOMAL PROTEIN S29-    7 . . . 60   41/54 (75%)   6e−21             Spodoptera frugiperda  (Fall    3 . . . 56   48/54 (87%)           armyworm), 56 aa.       Q9VH69   CG8495 PROTEIN- Drosophila     10 . . . 60   41/51 (80%)   3e−20             melanogaster  (Fruit fly), 56 aa.    6 . . . 56   46/51 (89%)                  
 
     [0522] PFam analysis predicts that the NOV37a protein contains the domains shown in the Table 37E.  
               TABLE 37E                          Domain Analysis of NOV37a                                     Identities/           Pfam   NOV37a Match   Similarities for   Expect       Domain   Region   the Matched Region   Value               Ribosomal_S14:   7 . . . 61   17/60 (28%)   7.5e−20       domain 1 of 1       51/60 (85%)                  
 
     Example 38  
     [0523] The NOV38 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 38A.  
               TABLE 38A                       NOV38 Sequence Analysis                                                SEQ ID NO:123   2039 bp                     NOV38a,     GCAGCACACCTGCTCTGTGACTGACACTCTTGCAGAAGTGGGGCCACTTCAGGGACAT         CG58538-01 DNA Sequence             GGACAAGGTGTTGTACCTGCTGTCACAGAGCCTGTTATCTGTTCAGA   ATG ACCGAAGA                   AGCATGCCGAACACGGAGTCAGAAACGAGCGCTTGAACGGGACCCAACAGAGGACGAT                   GTGGAGAGCAAGAAAATAAAAATGGAGAGAGGATTGTTGGCTTCAGATTTAAACACTG                   ACGGAGACATGAGGGTGACACCTGAGCCCGCAGCAGGTCCAACCCAAGCATTGCTGAG                   GGCAACAGAGGCCACGGCCATGGCCATGGGCAGAGGCGAAGGGCTGGTGGGCGATGGG                   CCCGTGGACATGCGCACCTCACACAGTGACATGAAGTCCGAGAGGAGACCCCCCTCAC                   CTGACGTGATTGTGCTCTCCGACAACGAGCAGCCCTCGAGCCCGAGAGTGAATGGGCT                   GACCACCGTGGCCTTGAAGGAGACTAGCACCGAGGCCCTCATGAAAAGCAGTCCTGAA                   GAACGAGAAAGGATGATCAAGCAGCTGAAGGAAGAATTGAGGTTAGAAGAAGCAAAAC                   TCGTGTTGTTGAAAAAGTTGCGGCAGAGTCAAATACAAAAGGAAGCCACCGCCCAGAA                   GCCCACAGGTTCTGTTGGGAGCACCGTGACCACCCCTCCCCCGCTTGTTCGGGGCACT                   CAGAACATTCCTGCTGGCAAGCCATCACTCCAGACCTCTTCAGCTCGGATGCCCGGCA                   GTGTCATACCCCCGCCCCTGGTCCGAGGTGGGCAGCAGGCGTCCTCGAAGCTGGGGCC                   ACAGGCGAGCTCACAGGTCGTCATGCCCCCACTCGTCAGGGGGGCTCAGCAAATCCAC                   AGCATTAGGCAACATTCCAGCACAGGGCCACCGCCCCTCCTCCTGGCCCCCCGGGCGT                   CGGTGCCCAGTGTGCAGATTCAGGGACAGAGGATCATCCAGCAGGGCCTCATCCGCGT                   CGCCAATGTTCCCAACACCAGCCTGCTCGTCAACATCCCACAGCCCACCCCAGCATCA                   CTGAAGGGGACAACAGCCACCTCCGCTCAGGCCAACTCCACCCCCACTAGTGTGGCCT                   CTGTGGTCACCTCTGCCGAGTCTCCAGCAAGCCGACAGGCGGCCGCCAAGCTGGCGCT                   GCGCAAACAGCTGGAGAAGACGCTACTCGAGATCCCCCCACCCAAGCCCCCAGCCCCA                   GAGATGAACTTCCTGCCCAGCGCCGCCAACAACGAGTTCATCTACCTGGTCGGCCTGG                   AGGAGGTGGTGCAGAACCTACTGGAGACACAAGCAGGCAGGATGTCGGCCGCCACTGT                   GCTGTCCCGGGAGCCCTACATGTGTGCACAGTGCAAGACGGACTTCACGTGCCGCTGG                   CGGGAGGAGAAGAGCGGCGCCATCATGTGTGAGAACTGCATGACAACCAACCAGAAGA                   AGGCGCTCAAGGTGGAGCACACCAGCCGGCTGAAGGCCGCCTTTGTGAAGGCGCTGCA                   GCAGGAACAGGAGATTGAGCAGCGGCTCCTGCAGCAGGGCACGGCCCCTGCACAGGCC                   AAGGCCGAGCCCACCGCTGCCCCACACCCCGTGCTGAAGCAGGCCTCCAGCCAGCTGT                   CCCGGGGTTCGGCCACGACGCCCCGAGGTGTCCTGCACACGTTCAGTCCGTCACCCAA                   ACTGCAGAACTCAGCCTCGGCCACAGCCCTGGTCAGCAGGACCGGCAGACATTCTGAG                   AGAACCGTGAGCGCCGGCAAGGGCAGCGCCACCTCCAACTGGAAGAAGACGCCCCTCA                   GCACAGGCGGGACCCTTGCGTTTGTCAGCCCAAGCCTGGCGGTGCACAAGAGCTCCTC                   GGCCGTGGACCGCCAGCGAGAGTACCTCCTGGACATGATCCCACCCCGCTCCATCCCC                   CAGTCAGCCACGTGGAAA TAG   TGCGAGCCAGGCCCCGTGGAAGACGGGCTCCCTCCTC                       CCCCACCTGGCCCCTGGTCTAGAAGGACCCACTGCACCACCCTCCGCTGGCTCGGGAA                       GACACCGTG                                           ORF Start: ATG at 106       ORF Stop: TAG at 1933           SEQ ID NO:124   609 aa   MW at 65295.8 kD                     NOV38a,   MTEEACRTRSQKRALERDPTEDDVESKKIKMERGLLASDLNTDGDMRVTPEPGAGPTQ       CG58538-01 Protein Sequence           GLLRATEATAMAMGRGEGLVGDGPVDMRTSHSDMKSERRPPSPDVIVLSDNSQPSSPR                   VNGLTTVAIKETSTEALMKSSPEERERNIKQLKEELRLEEAKLVLLKKLRQSQIQKEA                   TAQKPTGSVGSTVTTPPPLVRGTQNIPAGKPSLQTSSARMPGSVIPPPLVRGGQQASS                   KLGPQASSQVVMPPLVRGAQQIHSIRQHSSTGPPPLLLAPRASVPSVQIQGQRIIQQG                   LIRVANVPNTSLLVNIPQPTPASLKGTTATSAQANSTPTSVASVVTSAESPASRQAAA                   KLALRKQLEKTLLEIPPPKPPAPEMNFLPSAANNEFIYLVGLEEVVQNLLETQAGRMS                   AATVLSREPYMCAQCKTDFTCRWREEKSGAIMCENCMTTNQKKALKVEHTSRLKAAEV                   KALQQEQEIEQRLLQQGTAFAQAKAEPTAAPHPVLKQASSQLSRGSATTPRGVLHTFS                   PSPKLQNSASATALVSRTGRHSERTVSAGKGSATSNWKKTPLSTGGTLAFVSPSLAVH                   KSSSAVDRQREYLLDMIPPRSIPQSATWK                  
 
     [0524] Further analysis of the NOV38a protein yielded the following properties shown in Table 38B.  
               TABLE 38B                       Protein Sequence Properties NOV38a                                        PSort   0.4404 probability located in mitochondrial matrix space;       analysis:   0.3000 probability located in microbody (peroxisome); 0.1257           probability located in mitochondrial inner membrane; 0.1257           probability located in mitochondrial intermembrane space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0525] A search of the NOV38a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 38C.  
               TABLE 38C                          Geneseq Results for NOV38a                                         NOV38a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAM00991   Human bone marrow protein, SEQ    1 . . . 471   217/504 (43%)   2e−87           ID NO: 492- Homo sapiens , 502    4 . . . 473   290/504 (57%)           aa. [WO200153453-A2,           26 JUL. 2001]       AAM00944   Human bone marrow protein, SEQ    1 . . . 471   217/504 (43%)   2e−87           ID NO: 420- Homo sapiens , 546    48 . . . 517   290/504 (57%)           aa. [WO200153453-A2,           26 JUL. 2001]       AAM00831   Human bone marrow protein, SEQ    1 . . . 197    84/217 (38%)   1e−23           ID NO: 194- Homo sapiens , 266    47 . . . 262   110/217 (49%)           aa. [WO200153453-A2,           26 JUL. 2001]       AAM85818   Human immune/haematopoietic   417 . . . 471    41/55 (74%)   7e−19           antigen SEQ ID NO: 13411- Homo      1 . . . 55    49/55 (88%)             sapiens , 84 aa. [WO200157182-           A2, 9 AUG. 2001]                  
 
     [0526] In a BLAST search of public sequence databases, the NOV38a protein was found to have homology to the proteins shown in the BLASTP data in Table 38D.  
               TABLE 38D                          Public BLASTP Results for NOV38a                                         NOV38a               Protein   Protein/   Residues/   Identities/       Accession   Organism/   Match   Similarities for   Expect       Number   Length   Residues   the Matched Portion   Value                         No Significant Matches Found                  
 
     [0527] PFam analysis predicts that the NOV38a protein contains the domains shown in the Table 38E.  
               TABLE 38E                          Domain Analysis of NOV38a                                     Identities/           Pfam   NOV38a Match   Similarities for   Expect       Domain   Region   the Matched Region   Value               GATA: domain 1 of 1   414 . . . 453   12/43 (28%)   1.1               17/43 (40%)                  
 
     Example 39  
     [0528] The NOV39 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 39A.  
               TABLE 39A                       NOV39 Sequence Analysis                                                SEQ ID NO:125   1421 bp                     NOV39a,     ACCATTTCAGAG   ATG TCTTCCAGAAGTACCAAAGATTTAATTAAAAGTAAGTGGGGAT       CG59371-01 DNA Sequence           CGAAGCCTAGTAACTCCAAATCCGAAACTACATTAGAAAAATTAAAGGGAGAAATTGC                   ACACTTAAAGACATCAGTGGATGAAATCACAAGTGGGAAAGGAAAGCTGACTGATAAA                   GAGAGACACAGACTTTTGGAGAAAATTCGAGTCCTTGAGGCTGAGAAGGAGAAGAATG                   CTTATCAACTCACAGAGAAGGACAAAGAAATACAGCGACTGAGAGACCAACTGAAGGC                   CAGATATAGTACTACCACATTGCTTGAACAGCTGGAAGAGACAACGAGAGAAGGAGAA                   AGGAGGGAGCAGGTGTTGAAAGCCTTATCTGAAGAGAAAGACGTATTGAAACAACAGT                   TGTCTGCTGCAACCTCACGAATTGCTGAACTTGAAAGCAAAACCAATACACTCCGTTT                   ATCACAGACTGTGGCTCCAAACTGCTTCAACTCATCAATAAATAATATTCATGAAATG                   GAAATACAGCTGAAAGATGCTCTGGAGAAAAATCAGCAGTGGCTCGTGTATGATCAGC                   AGCGGGAAGTCTATGTAAAAGGACTTTTAGCAAAGATCTTTGAGTTGGAAAAGAAAAC                   GGAAACAGCTGCTCATTCACTCCCACAGCAGACAAAAAAGCCTGAATCAGAAGGTTAT                   CTTCAAGAAGAGAAGCAGAAATGTTACAACGATCTCTTGGCAACTGCAAAAAAAGATC                   TTGAGGTTGAACGACAAACCATAACTCAGCTGAGTTTTGAACTGAGTGAATTTCGAAG                   AAAATATGAAGAAACCCAAAAAGAAGTTCACAATTTAAATCAGCTGTTGTATTCACAA                   AGAAGGGCAGATGTGCAACATCTGGAAGATGATAGGCATAAAACAGAGAAGATACAAA                   AACTCAGGGAAGAGAATGATATTGCTAGGGGAAAACTTGAAGAAGAGAAGAAGAGATC                   CGAAGAGCTCTTATCTCAGGTCCAGTCTCTTTACACATCTCTGCTAAACCAGCAAGAA                   GAACAAACAAGGGTAGCTCTGTTGGAACAACAGATGCAGGCATGTACTTTAGACTTTG                   AAAATGAAAAACTCGACCGTCAACATGTGCAGCATCAATTGCATGTAATTCTTAAGGA                   GCTCCGAAAAGCAAGAAAAAATATAACACAGTTGGAATCCTTGAAACAGCTTCATGAG                   TTTGCCATCACAGAGCCATTAGTCACTTTCCAAGGAGAGACTGAAAACAGAGAAAAAG                   TTGCCGCCTCACCAAAAAGTCCCACTGCTGCACTCAATGGAAGCCTGGTGGAATGTCC                   CAAGTGCAATATACAGTATCCAGCCACTGAGCATCGCGATCTGCTTGTCCATGTGGAA                   TACTGTTCAAAG TAG   CAAAATAAGTATTT                                           ORF Start: ATG at 13       ORF Stop: TAG at 1405           SEQ ID NO:126   464 aa   MW at 54045.6 kD                     NOV39a,   MSSRSTKDLIKSKWGSKPSNSKSETTLEKLKGEIAHLKTSVDEITSGKGKLTDKERHR       CG59371-01 Protein Sequence           LLEKIRVLEAEKEKNAYQLTEKDKEIQRLRDQLKARYSTTTLLEQLEETTREGERREQ                   VLKALSEEKDVLKQQLSAATSRIAELESKTNTLRLSQTVAPNCFNSSINNIHEMEIQL                   KDALEKNQQWLVYDQQREVYVKGLLAKTFELEKKTETAAHSLPQQTKKPSSEGYLQEE                   KQKCYNDLLASAKKDLEVERQTITQLSFELSEFRRKYEETQKEVHNLNQLLYSQRRAD                   VQHLEDDRHKTEKIQKLREENDIARGKLEEEKKRSEELLSQVQSLYTSLLKQQEEQTR                   VALLEQQAQACTLDFENEKLDRQHVQHQLNVILKELRKARKNITQLESLKQLHEFAIT                   EPLVTFQGETENREKVAASPKSPTAALNGSLVECPKCNIQYPATEHRDLLVHVEYCSK                  
 
     [0529] Further analysis of the NOV39a protein yielded the following properties shown in Table 39B.  
               TABLE 39B                       Protein Sequence Properties NOV39a                                        PSort   0.4500 probability located in cytoplasm; 0.3000       analysis:   probability located in microbody (peroxisome);           0.1000 probability located in mitochondrial matrix           space; 0.1000 probability located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0530] A search of the NOV39a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 39C.  
               TABLE 39C                          Geneseq Results for NOV39a                                         NOV39a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAB92925   Human protein sequence SEQ ID   170 . . . 392   222/223 (99%)    e−122           NO: 11576- Homo sapiens , 231 aa.    1 . . . 223   222/223 (99%)           [EP1074617-A2, 7 FEB. 2001]       AAG75490   Human colon cancer antigen    1 . . . 67    64/67 (95%)   1e−28           protein SEQ ID NO: 6254- Homo      99 . . . 165    64/67 (95%)             sapiens , 165 aa. [WO200122920-           A2, 5 APR. 2001]       AAM78520   Human protein SEQ ID NO 1182-    6 . . . 394    96/421 (22%)   3e−12             Homo sapiens , 990 aa.   515 . . . 929   182/421 (42%)           [WO200157190-A2,           9 AUG. 2001]       AAM41000   Human polypeptide SEQ ID NO    70 . . . 420    90/384 (23%)   3e−12           5931- Homo sapiens , 1988 aa.   852 . . . 1203   161/384 (41%)           [WO200153312-A1,           26 JUL. 2001]       AAM40999   Human polypeptide SEQ ID NO    70 . . . 420    90/384 (23%)   3e−12           5930- Homo sapiens , 1988 aa.   852 . . . 1203   161/384 (41%)           [WO200153312-A1,           26 JUL. 2001]                  
 
     [0531] In a BLAST search of public sequence databases, the NOV39a protein was found to have homology to the proteins shown in the BLASTP data in Table 39D.  
               TABLE 39D                          Public BLASTP Results for NOV39a                                         NOV39a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q96H32   SIMILAR TO RIKEN CDNA   1 . . . 464   458/464 (98%)   0.0           1200008O12 GENE -  Homo     1 . . . 464   458/464 (98%)           sapiens (Human), 464 aa.       Q9DBZ8   1200008O12RIK PROTEIN -    1 . . . 464   348/464 (75%)   0.0             Mus musculus  (Mouse), 462 aa.   1 . . . 462   401/464 (86%)       Q9NVS7   CDNA FLJ10540 FIS, CLONE   170 . . . 392    222/223 (99%)    e−122           NT2RP2001245 -  Homo sapiens     1 . . . 223   222/223 (99%)           (Human), 231 aa.       Q9CZP8   2700032M20RIK PROTEIN -   1 . . . 176   121/176 (68%)   3e−63             Mus musculus  (Mouse), 189 aa.   1 . . . 176   150/176 (84%)       Q9VJE5   CLIP-190 PROTEIN -  Drosophila     4 . . . 439   108/461 (23%)   2e−16             melanogaster  (Fruit fly), 1690 aa.   675 . . . 1118    203/461 (43%)                  
 
     [0532] PFam analysis predicts that the NOV39a protein contains the domains shown in the Table 39E.  
                           TABLE 39E                               Identities/               NOV39a   Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value                                    No Significant Matches Found                  
 
     [0533] Table 39E. Domain Analysis of NOV39a Identities Pfam Domain NOV39a Match Region Similarities Expect Value for the Matched Region No Significant Matches Found  
     Example 40  
     [0534] The NOV40 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 40A.  
               TABLE 40A                       NOV40 Sequence Analysis                                                SEQ ID NO:127   3955 bp                     NOV40a,     TGCACCCTCGCTGCCTCCTTTCCTCCATGCTGCCTGGATCTGGCGAGCTGGGGTGATT         CG59346.01 DNA Sequence             AATTGGCT   ATG ATGATGAACGTCCCCGGCGGAGGAGCGGCCGCGGTGATGATGACGGG                   CTACAATAATGGTCGCTGTCCCCGGAATTCTCTCTACAGTGACTGCATTATTGAGGAG                   AAGACGGTGGTCCTGCAGAAAAAAGACAATGAGGGCTTTGGATTCGTGCTTCGAGGGG                   CCAAAGCTGACACACCCATTGAAGAATTCACACCAACACCGGCTTTCCCAGCCCTACA                   GTACCTGGAGTCCGTGGATGAAGGTGGGGTGGCGTGGCAAGCCCGACTAAGGACCGGG                   GACTTCTTGATTGAGGTTAACAATGAGAATGTTGTCAAAGTCGGCCACAGGCAGGTGG                   TGAACATGATCCGGCAGGGAGGGAATCACCTGGTCCTTAAGGTGGTCACGGTGACCAG                   GAATCTGGACCCCGACGACACCGCCAGGAAGAAAGCTCCCCCGCCTCCAAAGCGGGCA                   CCGACCACAGCCCTCACCCTGCGCTCCAAGTCCATGACCTCGGAGCTGGAGGAGCTCG                   ATAAACCCGAGGAGATAGTCCCGGCCTCCAAGCCCTCCCGCGCTGCTGAGAACATGGC                   TGTGGAACCGAGGGTGGCGACCATCAAGCAGCGGCCCAGCAGCCGGTGCTTCCCGGCG                   GGCTCAGACATGAACGTGAGTGGCCGTACCTTGGGACCACGAGGGCGGGGGCCGACGG                   TGCCCCCTAGGCTCTCTGGTTTGCAGTCTGTGTACGAACGCCAAGGAATCGCCGTGAT                   GACGCCCACTGTTCCTGGGAGCCCAAAAGCCCCGTTTCTGGGCATCCCTCGAGGTACG                   ATGCGAAGGCAGAAATCAATAGGAATAACAGAGGAAGAGCGGCAGTTTCTGGCTCCTC                   CAATGCTGAAGTTCACCAGAAGCCTGTCCATGCCGGACACCTCTGAGGACATCCCCCC                   TCCACCGCAGTCTGTGCCCCCGTCCCCACCACCACCTTCCCCAACCACTTACAACTGC                   CCCAAGTCCCCAACTCCAAGAGTCTACGGGACGATTAAGCCTGCGTTCAATCAGAATT                   CTGCCGCCAAGGTGTCCCCCGCCACCAGGTCCGACACCGTGGCCACCATGATGAGGGA                   GAAGGGGATGTACTTCAGGAGAGAGCTGGACCGCTACTCCTTGGACTCTGAAGACCTC                   TACAGTCGGAATGCCGGCCCGCAAGCCAACTTCCGCAACAAGAGAGGCCAGATGCCAG                   AAAACCCATACTCAGACGTGGGGAAGATCGCCAGCAAAGCCGTCTACGTCCCCGCCAA                   GCCCGCCAGGCGGAAGGGGATGCTGGTGAAGCAGTCCAACGTGGAGGACAGCCCCGAG                   AAGACGTGCTCCATCCCTATCCCGACCATCATCGTGAAGGAGCCGTCCACCAGCAGCA                   GCGGCAAGAGCAGCCAGGGCAGCAGCATGGAGATCGACCCCCAGGCCCCGGAGCCACC                   GAGCCAGCTGCGGCCTGACGAAAGCCTCACCGTCAGCAGCCCCTTTGCCGCCGCCATC                   GCCGGAGCCGTCCGCGACCGTGAGAAGCGGCTGGAAGCCAGGAGGAACTCCCCGGCCT                   TCCTCTCCACAGACCTGGGGGATGAGGATGTGGGCCTGGGGCCACCCGCCCCCAGGAC                   GCGGCCCTCCATGTTCCCCGAGGAGGGGGATTTTGCTGACGAGGACAGCGCTGAGCAG                   CTGTCATCCCCCATGCCGAGTGCCACGCCCAGGGAGCCCGAAAACCATTTCGTGGGTG                   GCGCCGAGGCCAGTGCTCCGGGTGAGGCTGGGAGGCCGCTGAATTCCACGTCCAAAGC                   CCAGGGGCCCGAGAGCAGCCCAGCAGTGCCCTCCGCGAGCAGCGGCACAGCCGGCCCC                   GGGAATTATGTCCACCCACTCACAGGGCGGCTGCTTGATCCCAGCTCCCCGCTGGCCC                   TGGCACTCTCCGCAAGGGACCCAGCCATGAAGGAGTCTCAACAGGGACCCAAAGGGGA                   GGCCCCCAAGGCCGACCTCAACAAACCTCTTTACATTGATACCAAAATGCGGCCCAGC                   CTGGATGCCGGCTTCCCTACGGTCACCAGGCAGAACACCCGGGGACCCCTGAGGCGGC                   AGGAGACGGAGAACAAGTACGAGACCGACCTGGGCCGAGACCGGAAAGGCGATGACAA                   GAAGAACATGCTGATCGACATCATGGACACGTCCCAGCAGAAGTCGGCTGGCCTGCTG                   ATGGTGCACACCGTGGACGCCACTAAGCTGGACAACGCCCTGCAGGAAGAGGACGAGA                   AGGCAGAGGTGGAGATGAAGCCAGACAGCTCGCCGTCCGAGGTGCCAGAAGGTGTTTC                   CGAAACCGAAGGTGCTTTACAGATCTCCGCTGCCCCCGAGCCCACCACCGTGCCCGGC                   AGAACCATCGTCGCGGTGGGCTCCATGGAAGAGGCGGTGATTTTGCCATTCCGCATCC                   CTCCTCCCCCTCTGGCATCCGTGGACTTGGATGAGGATTTTATTTTTACAGAGCCATT                   GCCTCCTCCCCTGGAATTTGCAAATAGTTTTGATATCCCCGATGACCGGGCAGCTTCT                   GTCCCGGCTCTCTCAGACTTAGTGAAGCAGAACAAAAGCGACACCCCTCAGTCCCCTT                   CGTTGAACTCCAGCCAACCAACCAACTCTGCAGACAGCAAGAAGCCAGCCAGTCTTTC                   AAACTGTCTGCCTGCCTCATTCCTGCCACCCCCTGAAAGCTTTGACGCCGTCGCCGAC                   TCTGGGATCGAGGAGGTGGACAGCCGGAGTAGCAGCGACCACCACCTCGAGACGACCA                   GCACTATCTCCACCGTGTCTAGCATCTCCACCCTGTCTTCCGAAGGTGGAGAGAATGT                   GGACACCTGCACAGTCTATGCAGATGGGCAAGCATTTATGGTTGACAAACCCCCAGTA                   CCTCCTAAGCCAAAAATGAAGCCCATCATTCACAAAAGCAATGCACTTTATCAAGACG                   CGCTCGTGGAAGAAGATGTAGATAGCTTTGTTATCCCCCCGCCCGCTCCCCCGCCCCC                   GCCGGGCAGTGCCCAGCCTGGGATGGCCAAGGTTCTCCAGCCAAGGACCTCCAAGTTG                   TGGGGCGACGTCACAGAGATCAAAAGCCCGATTCTCTCAGGCCCAAAGGCAAACGTTA                   TTAGTGAATTGAACTCTATCCTACAGCAAATGAACCGAGAGAAATTGGCAAAGCCGGG                   GGAAGGACTGGATTCACCAATGGGAGCCAAGTCCGCCAGCCTCGCTCCAAGAAGCCCG                   GAGATCATGAGCACCATCTCAGGTACACGGAGCACGACGGTCACCTTCACTGTTCGCC                   CCGGCACCTCCCAGCCCATCACCCTGCAGAGCCGGCCCCCCGACTATGAAAGCAGGAC                   CTCAGGAACAAGACGTGCCCCAAGCCCTGTGGTCTCGCCAACACAGATGAACAAAGAG                   ACCCTGCCCGCCCCCCTGTCTGCTGCCACCGCCTCTCCTTCTCCCGCTCTCTCAGATG                   TCTTTAGCCTTCCAAGCCAGCCCCCTTCTGGGGATCTATTTGGCTTGAACCCAGCGGG                   ACGCAGTAGGTCGCCATCCCCCTCGATACTGCAACAGCCAATCTCAAATAAGCCTTTT                   ACAACTAAACCTGTCCACCTGTGGACTAAACCAGATGTGGCCGATTGGCTGGAAAGTC                   TAAACTTGGGTGAACATAAAGAGGCCTTCATGGACAATGAGATCGATGGCAGTCACTT                   ACCAAACCTGCAGAAGGAGGACCTCATCGATCTTGGGGTAACTCGAGTCGGGCACAGA                   ATGAACATAGAAAGGGCTTTGAAACAGCTGCTGGACAGA TAA   GGACGGCTGCTCTCCA                       CCTCGCAGACTGCTCTTGTTATAAGTAGAGATGGGCTCGTGCTGAAACATCTGAATGC                       CAAGCGAAGTC                                           ORF Start: ATG at 67       ORF Stop: TAA at 3868           SEQ ID NO:128   1267 aa   MW at 136108.7 kD                     NOV40a,   MMMNVPGGGAAAVMNTGYNNGRCPRNSLYSDCIIEEKTVVLQKKDNEGFGFVLRGAKA       CG59346-01 Protein       Sequence   DTPIEEFTPTPAFPALQYLESVDEGGVAWQAGLRTGDFLIEVNNENVVKVGHRQVVNM                   IRQGGNHLVLKVVTVTRNLDPDDTARKKAPPPPKRAPTTALTLRSKSMTSELEELDKP                   EEIVPASKPSRAAENMAVEPRVATIKQRPSSRCFPAGSDNNVSGRTLGPRGRGPTVPP                   RLSGLQSVYERQGIAVMTPTVPGSPKAPFLGIPRGTMRRQKSTGTTEEERQFLAPPML                   KFTRSLSMPDTSEDIPPPPQSVPPSPFPPSPTTYNCPKSPTPRVYGTIKPAFNQNSAA                   KVSPATRSDTVATMMREKGMYFRRELDRYSLDSEDLYSRNAGPQANFRNKRGQMPENP                   YSEVGKIASKAVYVPAKPARRKGMLVKQSNVEDSPEKTCSIPTPTIIVKEPSTSSSGK                   SSQGSSMEIDPQAPEPPSQLRPDESLTVSSPFAAAIAGAVRDREKRLEARRNSPAFLS                   TDLGDEDVGLGPPAPRTRPSMFPEEGDFADEDSAEQLSSPMPSATPREPENHFVGGAE                   ASAPGEAGRPLNSTSKAQGPESSPAVPSASSGTAGPGNYVHPLTGRLLDPSSPLALAL                   SARDRAMKESQQGPKGEAPKADLNKPLYIDTKMRPSLDAGFPTVTRQNTRGPLRRQET                   ENKYETDLGRDRKGDDKKNNLIDIMDTSQQKSAGLLMVHTVDATKLDNALQEEDEKAE                   VEMKPDSSPSEVPEGVSETEGALQISAAPEPTTVPGRTIVAVGSMEEAVILPFRIPPP                   PLASVDLDEDFIFTEPLPPPLEFANSFDIPDDRAASVPALSDLVKQRKSDTPQSPSLN                   SSQPTNSADSKKPASLSNCLPASFLPPPESFDAVADSGIEEVDSRSSSDHHLETTSTI                   STVSSISTLSSEGGENVDTCTVYADGQAFMVDKPPVPPKPKNKPIIHKSNALYQDALV                   EEDVDSFVIPPPAPPPPPGSAQPGMAKVLQPRTSKLWGDVTEIKSPILSGPKANVISE                   LNSILQQMNREKLAKPGEGLDSPMGAKSASLAPRSPEIMSTISGTRSTTVTFTVRPGT                   SQPITLQSRPPDYESRTSGTRRAPSPVVSPTEMNKETLPAPLSAATASPSPALSDVFS                   LPSQPPSGDLFGLNPAGRSRSPSPSILQQPISNKPFTTKPVHLWTKPDVADWLESLNL                   GEHKEAFMDNEIDGSHLPNLQKEDLIDLGVTRVGHRMNIERALKQLLDR                  
 
     [0535] Further analysis of the NOV40a protein yielded the following properties shown in Table 40B.  
               TABLE 40B                       Protein Sequence Properties NOV40a                                        PSort   0.4500 probability located in cytoplasm; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1000 probability           located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0536] A search of the NOV40a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 40C.  
               TABLE 40C                          Geneseq Results for NOV40a                                         NOV40a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Data]   Residues   Region   Value                                             AAM79240   Human protein SEQ ID NO 1902 -   14 . . . 1267   1231/1271   (96%)   0.0             Homo sapiens , 1248 aa.    1 . . . 1248   1231/1271   (96%)           [WO200157190-A2, 9 AUG            2001]       AAB31518   Amino acid sequence of the rat   30 . . . 1267   1078/1255   (85%)   0.0           Shank2 polypeptide - Rattus sp,   240 . . . 1470    1132/1255   (89%)           1470 aa. [WO200078921-A2,           28 DEC 2000]       AAM80224   Human protein SEQ ID NO 3870 -   172 . . . 1267    1071/1103   (97%)   0.0             Homo sapiens , 1161 aa.   82 . . . 1161   1071/1103   (97%)           [WO200157190-A2, 9 AUG           2001]       AAB31517   Amino acid sequence of the rat   18 . . . 1264   496/1349   (36%)   0.0           Shank3a polypeptide - Rattus sp,   550 . . . 1737    673/1349   (49%)           1740 aa. [WO200078921-A2,           28 DEC 2000]       AAY83017   Rat shank 3a -  Rattus rattus , 1740   18 . . . 1264   496/1349   (36%)   0.0           aa. [WO200011204-A2,   550 . . . 1737    673/1349   (49%)           2 MAR 2000]                  
 
     [0537] In a BLAST search of public sequence databases, the NOV40a protein was found to have homology to the proteins shown in the BLASTP data in Table 40D.  
               TABLE 40D                          Public BLASTP Results for NOV40a                                         NOV40a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9UPX8   KIAA1022 PROTEIN -  Homo     124 . . . 1267    1121/1154 (97%)   0.0             sapiens  (Human), 1131 aa   1 . . . 1131   1121/1154 (97%)           (fragment).       Q9QX93   PROLINE RICH SYNAPSE   2 . . . 1267   1103/1276 (86%)   0.0           ASSOCIATED PROTEIN 1 -   1 . . . 1252   1158/1276 (90%)             Rattus norvegicus  (Rat), 1252 aa.       O70470   CORTACTIN-BINDING   2 . . . 1267   1102/1276 (86%)   0.0           PROTEIN 1 -  Rattus norvegicus     1 . . . 1252   1158/1276 (90%)           (Rat), 1252 aa.       Q9WUV9   PROLINE RICH SYNAPSE   2 . . . 1267   1103/1283 (85%)   0.0           ASSOCIATED PROTEIN 1 -   1 . . . 1259   1158/1283 (89%)             Rattus norvegicus  (Rat), 1259 aa.       Q9WUW0   PROLINE RICH SYNAPSE   2 . . . 1267   1095/1276 (85%)   0.0           ASSOCIATED PROTEIN 1 -   1 . . . 1250   1151/1276 (89%)             Rattus norvegicus  (Rat), 1250 aa.                  
 
     [0538] PFam analysis predicts that the NOV40a protein contains the domains shown in the Table 40E.  
               TABLE 40E                          Domain Analysis of NOV40a                                     Identities/                   Similarities           NOV40a   for the   Expect       Pfam Domain   Match Region   Matched Region   Value               PDZ: domain 1 of 1    38 . . . 131   23/97 (24%)     1e−07               70/97 (72%)       SAM: domain 1 of 1   1202 . . . 1265   27/68 (40%)   9.8e−22               53/68 (78%)                  
 
     Example 41  
     [0539] The NOV41 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 41A.  
               TABLE 41A                       NOV41 Sequence Analysis                                                SEQ ID NO:129   2069 bp                     NOV41a,     GGACACTGACATGGACTGAAGGAGTAGAAAGCACTATAAATGTCTTTCCTTATCTGTG         CG57814-01 DNA Sequence             TGTACTCTTATCTCACTGTTCTATTTTTTCTCCTCATTTATATTAACTCTTTCTTACC                       TTTTTTTCTGAACTTCTAGGCCTTCTCTTTCCAGAACTGGTGGAAGACAAATGAAACG                       GCCAAGATGGTAAGAAACAAGCCGCATTTCTCCTTGGGGAGACTGATAATTTAAAAGG                       TTTGTTGTGTCAGAAACATTCCCAGCTTCATCACCAACCCTTTCCTTCCACCTCTGCC                       CACTGGAGACCACTTACATCCCGAAGCGGACGCGGCAGCTGAAGTCAGGAAACCATGC                       ATCACATTAGCAGGAGCCAACTGCAGACTTTAAACTCCGTTCAACATGTGGATGCGGC                       AGAGAA   ATG ACCTGTCCAGACAAGCCGGGGCAGCTCATAAACTGGTTCATCTGCTCCC                   TGTGCGTCCCGCGGGTGCGTAAGCTCTGGAGCAGCCGGCGTCCAAGGACCCGGAGAAA                   CCTTCTGCTGGGCACTGCGTGTGCCATCTACTTGGGCTTCCTGGTGAGCCAGGTGGGG                   AGGGCCTCTCTCCAGCATGGACAGGCGGCTGAGAAGGGGCCACATCGCAGCCGCGACA                   CCGCCGAGCCATCCTTCCCTGAGATACCCCTGGATGGTACCCTGGCCCCTCCAGAGTC                   CCAGGGCAATGGGTCCACTCTGCAGCCCAATGTGGTGTACATTACCCTACGCTCCGAG                   CGCAGCAAGCCGGCCAATATCCGTGGCACCGTGAAGCCCAAGCGCAGGAAAAAGCATG                   CAGTGGCATCGGCTGCCCCAGGGCAGGAGGCTTTGGTCGGACCATCCCTTCAGCCGCA                   GGAAGCGGCAAGGGAAGCTGATGCTGTAGCACCTGGGTACGCTCAGGGAGCAAACCTG                   GTTAAGATTGGAGAGCGACCCTGGAGGTTGGTGCGGGGTCCGGGAGTGCGAGCCGGGG                   GCCCAGACTTCCTGCAGCCCAGCTCCAGGGAGAGCAACATTAGGATCTACAGCGAGAG                   CGCCCCCTCCTGGCTGAGCAAAGATGACATCCGAAGAATGCGACTCTTGGCGGACAGC                   GCAGTGGCAGGGCTCCGGCCTGTGTCCTCTAGGAGCGGAGCCCGTTTGCTGGTGCTGG                   AGGGGGGCGCACCTGGCGCTGTGCTCCGCTGTGGCCCTAGCCCCTGTGGGCTTCTCAA                   GCAGCCCTTGGACATGAGTGAGGTGTTTGCCTTCCACCTAGACAGGATCCTGGGGCTC                   AACAGGACCCTGCCGTCTGTGAGCAGGAAAGCAGAGTTCATCCAAGATGCCCGCCCAT                   GCCCCATCATTCTTTGGGATGCATCTTTATCTTCAGCAAGTAATGACACCCATTCTTC                   TGTTAAGCTCACCTGGGGAACTTATCAGCAGTTGCTGAAACAGAAATGCTGGCAGAAT                   GGCCGAGTACCCAAGCCTGAATCAGGTTGTACTGAAATACATCATCATGAGTGGTCCA                   AGATGGCACTCTTTGATTTTTTGTTACAGATTTATAATCGCTTAGATACAAATTGCTG                   TGGATTCAGACCTCGCAAGGAAGATGCCTGTGTACAGAATGGATTGAGGCCAAAATGT                   GATGACCAAGGTTCTGCGGCTCTAGCACACATTATCCAGCGAAAGCATGACCCAAGGC                   ATTTGGTTTTTATAGACAACAAGGGTTTCTTTGACAGGAGTGAAGATAACTTAAACTT                   CAAATTGTTAGAAGGCATCAAAGAGTTTCCAGCTTCTGCAGTTTCTGTTTTGAAGAGC                   CAGCACTTACGGCAGAAACTTCTTCAGTCTCTGTTTCTTGATAAAGTGTATTGGGAAA                   GTCAAGGAGGTAGACAAGGAATTGAAAAGCTTATCGATGTAATAGAACACAGAGCCAA                   AATTCTTATCACCTATATCAATGCACACGGGGTCAAAGTATTACCTATGAATGAA TGA                       CAAAAGAATCTTCTGGCTAGGGTGTTAGATATATTTATGCATTTTTGGTTTTGTTTTT                       AAATCAAGCACATCAACCTCAAGCCCGTTTAGCAATGAG                                           ORF Start: ATG at 413       ORF Stop: TGA at 1970           SEQ ID NO:130   519 aa   MW at 57552.4 kD                     NOV41a,   MTCPDKPGQLINWFICSLCVPRVRRLWSSRRPRTRRNLLLGTACAIYLGFLVSQVGRA       CG57814-01 Protein Sequence           SLQHGQAAEKGPHRSRDTAEPSFPEIPLDGTLAPPESQGNGSTLQPNVVYITLRSERS                   KPANIRGTVKPKRRKKHAVASAAPGQEALVGPSLQPQEAAREADAVAPGYAQGANLVK                   IGERPWRLVRGPGVRAGGPDFLQPSSRESNIRIYSESAPSWLSKDDIRRMRLLADSAV                   AGLRPVSSRSGARLLVLEGGAPGAVLRCGPSPCGLLKQPLDMSEVFAFHLDRILGLNR                   TLPSVSRKAEFIQDGRPCPIILWDASLSSASNDTHSSVKLTWGTYQQLLKQKCWQNGR                   VPKPESGCTEIHHHEWSKMALFDFLLQIYNRLDTNCCGFRPRKEDACVQNGLRPKCDD                   QGSAALAHIIQRKHDPRHLVFTDNKGFFDRSEDNLNFKLLEGIKEFPASAVSVLKSQH                   LRQKLLQSLFLDKVYWESQGGRQGIEKLIDVIEHRAKILITYINAHGVKVLPMNE                                     SEQ ID NO:131   1740 bp                     NOV41b,     GGCAGCTGAAGTCAGGAAACCATGCATCACATTAGCAGGAGCCAACTGCAGACTTTAA         CG57814-02 DNA Sequence             ACTCCGTTCAACATGTGGATGCGGCAGAGAA   ATG ACCTGTCCAGACAAGCCGGGGCAG                   CTCATAAACTGGTTCATCTGCTCCCTGTGCGTCCCGCGGGTGCGTAAGCTCTGGAGCA                   GCCGGCGTCCAAGGACCCGGAGAAACCTTCTGCTGGGCACTGCGTGTGCCATCTACTT                   GGGCTTCCTGGTGAGCCAGGTGGGGAGGGCCTCTCTCCAGCATGGACAGGCGGCTGAG                   AAGGGGCCACATCGCAGCCGCGACACCGCCGAGCCATCCTTCCCTGAGATACCCCTGG                   ATGGTACCCTGGCCCCTCCAGAGTCCCAGGGCAATGGGTCCACTCTGCAGCCCAATGT                   GGTGTACATTACCCTACGCTCCAAGCGCAGCAAGCCGGCCAATATCCGTGGCACCGTG                   AAGCCCAAGCGCAGGAAAAAGCATGCAGTGGCATCGGCTGCCCAAGGGCAGGAGGCTT                   TGGTCGGACCATCCCTTCAGCCGCAAGAAGCGGCAAGGGAAGCTGATGCTGTAGCACT                   GGGTACGCTCAGGAGCAAACTGGTTAAGATGGAGAGCGACCCTGAAGGTGGTGCGGGG                   TCGGGAGTGCGAGCCGGGGGCCCAGACTTCCTGCAGCCCAGCTCCAGGGAGAGCAACA                   TTAGGATCTACAGCGAGAGCGCCCCCTCCTGGCTGAGCAAAGATGACATCCGAAGAAT                   GCGACTCTTGGCGGAGAGCGCAGTGGCAGGGCTCCGGCCTGTGTCCTCTAGGAGCGGA                   GCCCGTTTGCTGGTGCTGGAGGGGGGCGCACCTGGCGCTGTGCTCCGCTGTGGCCCTA                   GCCCCTGTGGGCTTCTCAAGCAGCCCTTGGACATGAGTGAGGTGTTTGCCTTCCACCT                   AGACAGGATCCTGGGGCTCAACAGGACCCTGCCGTCTGTGAGCAGGAAAGCAGAGTTC                   ATCCAAGATGGCCGCCCATGCCCCATCATTCTTTGGCATGCATCTTTATCTTCAGCAA                   GTAATGACACCCATTCTTCTGTTAAGCTCACCTGGGGAACTTATCAGCAGTTGCTGAA                   ACAGAAATGCTGGCAGAATGGCCGAGTACCCAAGCCTGAATCAGGTTGTACTGAAATA                   CATCATCATGAGTGGTCCAAGATGGCACTCTTTGATTTTTTGTTACAGATTTATAATC                   GCTTAGATACAAATTGCTGTGGATTCAGACCTCGCAACGAAGATGCCTGTGTACAGAA                   TGGATTGAGGCCAAAATGTGATGACCAAGGTTCTGCGGCTCTAGCACACATTATCCAG                   CGAAAGCATGACCCAAGGCATTTGGTTTTTATAGACAACAAGGGTTTCTTTGACAGGA                   GTGAAGATAACTTAAACTTCAAATTGTTAGAAGGCATCAAAGAGTTTCCAGCTTCTGC                   AGTTTCTGTTTTGAAGAGCCAGCACTTACGGCAGAAACTTCTTCAGTCTCTGTTTCTT                   GATAAAGTGTATTGGGAAAGTCAAGGAGGTAGACAAGGAATTGAAAAGCTTATCGATG                   TAATAGAACACAGAGCCAAAATTCTTATCACCTATATCAATGCACACGGGGTCAAAGT                   ATTACCTATGAATGAA TGA   CAAAAGAATCTTCTGGCTAGCGTGTTAGATATATTTATG                       CATTTTTGGTTTTGTTTTTAAATCAAGCACATCAACCTCAAGCCCGTTTAGCAATGAG                                           ORF Start: ATG at 90       ORF Stop: TGA at 1641           SEQ ID NO:132   517 aa   MW at 57179.9 kD                     NOV41b,   MTCPDKPGQLINWFICSLCVPRVRKLWSSRRPRTRRNLLLGTACAIYLGFLVSQVGRA       CG57814-02 Protein Sequence           SLQHGQAAEKGPHRSRDTAEPSFPEIPLDGTLAPPESQGNGSTLQPNVVYITLRSKRS                   KPANIRGTVKPKRRKKHAVASAAQGQEALVGPSLQPQEAAREADAVALGTLRSKLVKM                   ESDPEGGAGSGVRAGGPDFLQPSSRESNIRIYSESAPSWLSKDDIRRMRLLADSAVAG                   LRPVSSRSGARLLVLEGGAPGAVLRCGPSPCGLLKQPLDMSEVFAFHLDRILGLNRTL                   PSVSRKAEFIQDGRPCPIILWDASLSSASNDTHSSVKLTWGTYQQLLKQKCWQNGRVP                   KPESGCTEIHHHEWSKMALFDFLLQIYNRLDTNCCGFRPRKEDACVQNGLRPKCDDQG                   SAALAHIIQRKHDPRHLVFIDNKGFFDRSEDNLNFKLLEGIKEFPASAVSVLKSQHLR                   QKLLQSLFLDKVYWESQGGRQGIEKLIDVIEHRAKILITYINAHGVKVLPMNE                  
 
     [0540] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 41B.  
               TABLE 41B                          Comparison of NOV41a against NOV41b.                                 Identities/           NOV41a Residues/   Similarities for       Protein Sequence   Match Residues   the Matched Region               NOV41b   1 . . . 519   493/519 (94%)           1 . . . 517   497/519 (94%)                  
 
     [0541] Further analysis of the NOV41a protein yielded the following properties shown in Table 41C.  
               TABLE 41C                       Protein Sequence Properties NOV41a                                        PSort   0.5500 probability located in endoplasmic reticulum       analysis:   (membrane); 0.2404 probability located in lysosome           (lumen); 0.1000 probability located in endoplasmic           reticulum (lumen); 0.1000 probability located in outside       SignalP   Likely cleavage site between residues 59 and 60       analysis:                  
 
     [0542] A search of the NOV41a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 41D.  
               TABLE 41D                          Geneseq Results for NOV41a                                         NOV41a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Data]   Residues   Region   Value               AAU12276   Human PRO6001 polypeptide   1 . . . 519   518/519 (99%)   0.0           sequence -  Homo sapiens , 519 aa.   1 . . . 519   519/519 (99%)           [WO200140466-A2, 7 JUN            2001]       AAM39125   Human polypeptide SEQ ID NO   1 . . . 519   518/519 (99%)   0.0           2270 -  Homo sapiens , 519 aa.   1 . . . 519   519/519 (99%)           [WO200153312-A1, 26 JUL            2001]       AAM40911   Human polypeptide SEQ ID NO   1 . . . 519   491/527 (93%)   0.0           5842 -  Homo sapiens , 537 aa.   19 . . . 537    495/527 (93%)           [WO200153312-A1, 26 JUL            2001]       AAM41373   Human polypeptide SEQ ID NO   212 . . . 512    130/316 (41%)   1e−64           6304 -  Homo sapiens , 479 aa.   161 . . . 471    180/316 (56%)           [WO200153312-A1, 26 JUL            2001]       AAM39587   Human polypeptide SEQ ID NO   212 . . . 512    130/316 (41%)   1e−64           2732 -  Homo sapiens , 397 aa.   79 . . . 389    180/316 (56%)           [WO200153312-A1, 26 JUL 2001]                  
 
     [0543] In a BLAST search of public sequence databases, the NOV41a protein was found to have homology to the proteins shown in the BLASTP data in Table 41E.  
               TABLE 41E                          Public BLASTP Results for NOV41a                                         NOV41a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                             Q9ET25   HYPOTHETICAL BASIC    1 . . . 519   431/519   (83%)   0.0           PROTEIN I-19 -  Mus musculus      1 . . . 517   462/519   (88%)           (Mouse), 517 aa.       Q9NYZ0   AD021 PROTEIN -  Homo     274 . . . 519   246/246   (100%)    e−145             sapiens  (Human), 246 aa.    1 . . . 246   246/246   (100%)       Q9UFP1   HYPOTHETICAL 49.5 KDA   212 . . . 512   129/316   (40%)   2e−63           PROTEIN -  Homo sapiens     130 . . . 440   179/316   (55%)           (Human), 448 aa (fragment).                  
 
     [0544] PFam analysis predicts that the NOV41a protein contains the domains shown in the Table 41F.  
               TABLE 41F                          Domain Analysis of NOV41a                                     Identities/                   Similarities           NOV41a   for the   Expect       Pfam Domain   Match Region   Matched Region   Value                                         SQS_PSY:   109 . . . 145   8/37   (22%)   9.9       domain 1 of 1       29/37   (78%)                  
 
     Example 42  
     [0545] The NOV42 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 42A.  
               TABLE 42A                       NOV42 Sequence Analysis                                                SEQ ID NO:133   1294 bp                     NOV42a,     G   ATG GCCACCTTGAACGTTGTACTGATGTTGATGCCCCTTGCCCAGTACATTTTCCAT       CG59327-01 DNA Sequence           TGTTTTATAACTGTGCTACTGAAGTACTTGTGTGCAGAGTATGGCTGGAGGAATGCCA                   TGTTGATCCAAGICCCCGTTTCCTTAAACCTGTTTGTTTTTGGGACCCTCATGAGGCC                   CCTCCCTCCTGGGAAAAACCCAAATGACCCAGAAGAGAAAGATCTGCGCGTCCTGCCC                   GCGCACTCCACAGAGTCTGTAATGTCAAATGGACAGCAGGGAAGAATAGAAGAGAAGG                   ATGGCGGGTCTGGGAACGAGGAGACCCTCTGTGACCTGCAAGCCCAGGAGTGCAAGCC                   CAGGAGTGCCCCGATCAGGCCAGATCATGTGCGCTTTCCGGTTCTGAAGACGGTCAGC                   TGGCTCATTATGAGAGTCAAGAAGGGCTTCGAGGATTGGTACTCAGGCTATTTTGGGA                   CAGCCAGCCTATTTACAAATCGAATGTTTGTAGCCTTTGTTTTCTGGGCTTCATTTGC                   ATACAGCAGCTTTGTCATCTCCTTTATTCATCTCCCAGAAATCGTCAATTTGTATAAC                   TTATTGGAGCAAACGAAGGTTTTCCCTCTGACTTCAATTATAGCAATAGTTCACATTG                   TTGGAAAAGTGATCCTGGGCGTCATAGCTGACTTACCTTGCATCAGTGTTTGGAATGT                   CTTCCTGTTGGCCAGCTTCGTTCTTGTCCTCAGTATTTTTGTTTTGCTGCCTTTGATG                   CATATGTACGCTGGCCTGGTGGTCATCTGCACACTGACAGGGTTTTCCAGCGGTTATT                   TCTCCCTAATGCCCATAGTGACTGAAGACTTGGTTGGCATTGAACATTTGGCCAATGC                   CTACGGCATCATCATCTGTGCTAATGGCATCTCTGCGTTGTTGGGACCACCTTTTGCA                   GGTAAACTGTCTGAGGTTTTAAGAGTTCATAGTGCATATAGATACGGTGTGTTAGCTC                   TGCGAGGAGACGGATGCAGAGCACTCACATCTTCTCTTATACATAGAAGTGAAATGGC                   TTTC TAA   AGTTAGATCACTGGCCAGAGTTTTTGAGTCACAAGAGCTATTCCACAGATT                       TCCTTTAGAAAAACAATCACCACTGGCAGTCCACTTCAGTGACACAGAATGGGTTGCA                       GAACTTGCTTACTTATGTGACACATTCAACCTGCTCAATGAACTCAATCTGTCACTTC                       AGGGGAGAAGGACAACTGTGTTCAAGTCAGCAAATAAAGTGGCTACATTCAAAACCAA                       ACTGGAATTACGGGGGTG                                           ORF Start: ATG at 2       Stop: TAA at 1049           SEQ ID NO:134   349 aa   MW at 38694.2 kD                     NOV42a,   MATLNVVLMLNPLAQYIFHCFITVLLKYLCAEYGWRNAMLIQGAVSLNLFVFGTLMRP       CG59327-01 Protein Sequence           LPPGKNPNDPEEKDLRVLPAHSTESVNSNGQQGRIEEKDGGSGNEETLCDLQAQECKP                   RSAPIRPDHVRFPVLKTVSWLIMRVKKGFEDWYSGYFGTASLFTNRMFVAFVFWASFA                   YSSFVISFIHLPEIVNLYNLLEQTKVFFLTSIIAIVHIVGKVILGVIADLPCISVWNV                   FLLASFVLVLSIFVLLPLMHMYAGLVVICTLTGFSSGYFSLMPIVTEDLVGIEHLANA                   YGIIICANGISALLGPPFAGKLSEVLRVHSAYRYGVLALRGDGCRALTSSLIHRSEMAF                  
 
     [0546] Further analysis of the NOV42a protein yielded the following properties shown in Table 42B.  
               TABLE 42B                       Protein Sequence Properties NOV42a                                                PSort   0.6850 probability located in endoplasmic reticulum           analysis:   (membrane); 0.6400 probability located in plasma               membrane; 0.4600 probability located in Golgi               body; 0.1000 probability located in endoplasmic               reticulum (lumen)           SignalP   Likely cleavage site between residues 32 and 33           analysis:                      
 
     [0547] A search of the NOV42a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 42C.  
               TABLE 42C                          Geneseq Results for NOV42a                                         NOV42a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Data]   Residues   Matched Region   Value                                             AAO07132   Human polypeptide SEQ ID NO   257 . . . 331   49/77   (63%)   6e−20           21024 -  Homo sapiens , 107 aa.    5 . . . 81   58/77   (74%)           [WO200164835-A2, 7 SEP 2001]       AAY31642   Human transport-associated protein-   157 . . . 342   54/197   (27%)   1e−07           4 (TRANP-4) -  Homo sapiens , 465   221 . . . 401   86/197   (43%)           aa. [WO9941373-A2, 19 AUG            1999]       AAY02737   Human secreted protein encoded by   198 . . . 342   41/147   (27%)   9e−06           gene 88 clone HKAFB88 -  Homo      24 . . . 164   65/147   (43%)             sapiens , 229 aa. [WO9902546-A1,           21 JAN 1999]                  
 
     [0548] In a BLAST search of public sequence databases, the NOV42a protein was found to have homology to the proteins shown in the BLASTP data in Table 42D.  
               TABLE 42D                          Public BLASTP Results for NOV42a                                             Identities/           Protein           Similarities       Accession       NOV42a Residues/   for the    Expect       Number   Protein/Organism/Length   Match Residues   Matched Portion   Value                                             Q96NI7   CDNA FLJ30794 FIS, CLONE    22 . . . 331   250/312   (80%)    e−138           FEBRA2001093, WEAKLY    1 . . . 310   266/312   (85%)           SIMILAR TO           MONOCARBOXYLATE           (Human), 336 aa.       Q9D1K0   1110004H10RIK PROTEIN -  Mus      22 . . . 331   220/312   (70%)    e−119             musculus  (Mouse), 336 aa.    1 . . . 310   250/312   (79%)       AAL39716   LD30953P -  Drosophila     142 . . . 314   50/180   (27%)   2e−15             melanogaster  (Fruit fly), 894 aa.   665 . . . 843   89/180   (48%)       Q9V9B3   CG3409 PROTEIN -  Drosophila     142 . . . 314   50/180   (27%)   2e−15             melanogaster  (Fruit fly), 800 aa.   571 . . . 749   89/180   (48%)       Q9W0L6   CG13907 PROTEIN -  Drosophila     157 . . . 331   55/178   (30%)   1e−14             melanogaster  (Fruit fly), 816 aa.   565 . . . 738   91/178   (50%)                  
 
     [0549] PFam analysis predicts that the NOV42a protein contains the domains shown in the Table 42E.  
               TABLE 42E                          Domain Analysis of NOV42a                                     Identities/                   Similarities           NOV42a   for the   Expect       Pfam Domain   Match Region   Matched Region   Value               oxidored_q3:   197 . . . 314   25/177 (14%)   9.1       domain 1 of 1       73/177 (41%)                  
 
     Example 43  
     [0550] The NOV43 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 43A.  
               TABLE 43A                       NOV43 Sequence Analysis                                                SEQ ID NO:135   455 bp                     NOV43a,     TAGAACTGTGTTGAGCTCTCACCCATCACG   ATG AGCAACAAATTCTTGGGAACCTGGA       CG59494-01 DNA Sequence           AGCTGGTCTCCAGTGAAAACTTTGAGGATTACATGAAAGAACTGGGAGTGAATTTCGC                   AGCCCGGAACATGGCAGGGTTAGTGAAACCGACAGTAACTATTAGTGTTGATGGGAAA                   ATGATGACCATAAGAACAGAAAGTTCTTTCCAGGACACTAAGATCTCCTTCAAGCTGG                   GGGAAGAATTTGATGAAACTACAGCAGACAACCGGAAAGTAAAGAGCACCATAACATT                   AGAGAATGGCTCAATGATTCACGTCCAAAAATGGCTTGGCAAAGAGACAACAATCAAA                   AGAAAAATTGTGGATGAAAAAATGGTAGTGGAATGTAAAATGAATAATATTGTCAGCA                   CCAGAATCTACGAAAAGGTC TGA   AAAATCATTTCTTCATTGAAGTGGCT                                           ORF Start: ATG at 31       ORF Stop: TGA at 427           SEQ ID NO:136   132 aa   MW at 15096.4 kD                     NOV43a,   MSNKFLGTWKLVSSENFEDYMKELGVNFAARNMAGLVKPTVTISVDGKMMTIRTESSF       CG59494-01 Protein Sequence           QDTKISFKLGEEPDETTADNRRVKSTITLENGSMIHVQKWLGKETTIKRKIVDEKMVV                   ECKMNNIVSTRIYEKV                  
 
     [0551] Further analysis of the NOV43a protein yielded the following properties shown in Table 43B.  
               TABLE 43B                       Protein Sequence Properties NOV43a                                        PSort   0.6500 probability located in cytoplasm; 0.1000       analysis:   probability located in mitochondrial matrix space;           0.1000 probability located in lysosome (lumen);           0.0053 probability located in microbody (peroxisome)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0552] A search of the NOV43a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 43C.  
               TABLE 43C                          Geneseq Results for NOV43a                                         NOV43a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAW40227   Human myelin P2 protein- Homo     1 . . . 130    89/130 (68%)   2e−47             sapiens , 136 aa. [WO9803647-A2,   1 . . . 130   107/130 (81%)           29 JAN. 1998]       AAW40228   Bovine myelin P2 protein- Bos     1 . . . 130    89/130 (68%)   9e−47             taurus , 136 aa. [WO9803647-A2,   1 . . . 130   106/130 (81%)           29 JAN. 1998]       AAY90320   Human AFABP protein sequence-   1 . . . 131    84/131 (64%)   3e−46             Homo sapiens , 132 aa.   1 . . . 131   110/131 (83%)           [WO200047734-A1,           17 AUG. 2000]       AAY90319   Mouse AFABP protein sequence-   1 . . . 131    83/131 (63%)   7e−45           Mus sp, 132 aa. [WO200047734-   1 . . . 131   108/131 (82%)           A1, 17 AUG. 2000]       AAG66576   Mouse MDGI polypeptide-Mus   1 . . . 131    73/131 (55%)   6e−40           sp, 133 aa. [U.S. Pat.   1 . . . 131   103/131 (77%)           No. 6232291-B1, 15 MAY 2001]                  
 
     [0553] In a BLAST search of public sequence databases, the NOV43a protein was found to have homology to the proteins shown in the BLASTP data in Table 43D.  
               TABLE 43D                          Public BLASTP Results for NOV43a                                         NOV43a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               MPRB2   myelin P2 protein-rabbit, 132 aa.   1 . . . 132    95/132 (71%)   3e−49               1 . . . 132   109/132 (81%)       P02691   Myelin P2 protein- Oryctolagus     2 . . . 132    94/131 (71%)   1e−48             cuniculus  (Rabbit), 131 aa.   1 . . . 131   108/131 (81%)       MPHU2   myelin P2 protein [validated]-   1 . . . 132    92/132 (69%)   3e−48           human, 132 aa.   1 . . . 132   109/132 (81%)       Q90X56   ADIPOCYTE FATTY ACID   1 . . . 131    86/131 (65%)   1e−47           BINDING PROTEIN- Gallus     1 . . . 131   113/131 (85%)             gallus  (Chicken), 132 aa.       P02689   Myelin P2 protein- Homo sapiens     2 . . . 132    91/131 (69%)   1e−47           (Human), 131 aa.   1 . . . 131   108/131 (81%)                  
 
     [0554] PFam analysis predicts that the NOV43a protein contains the domains shown in the Table 43E.  
               TABLE 43E                          Domain Analysis of NOV43a                                     Identities/           Pfam   NOV43a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               lipocalin: domain 1 of   4 . . . 132    45/157 (29%)   3.2e−36       1       113/157 (72%)                  
 
     Example 44  
     [0555] The NOV44 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 44A.  
               TABLE 44A                       NOV44 Sequence Analysis                                                SEQ ID NO:137   1561 bp                     NOV44a,     AAGAATTGTAGCTCTCCACTGAATTGCAGGGGTTCTTGAATGTTGTCAACATTTGGAG         CG59432-01 DNA Sequence             GCAGTTGGAGGAGGGAGCTCTATTGATGAAAAATGGCTACATATTCAAAATTTCAGTG                       TATACCAGGAAGATAATTCAATTCAATCTCTGGCTTACCCAAAGAATCTTGGAGTTAC                       TGCCAATGAGGAAATCCCCAGGGTCTAATAAAAATATCTTTAGGAGTGAAGGAGTTAA                       CTGAGTGTGTAAGCTTTATCTTCTGTCCAATGGACTTGTGGTTTGCTTATAAAACTCT                       CCAGTAAATAATTGTTAGAGACCTGTCATTGATAGCAGTTGCTAGTTGCTGCCTTTTA                       AGAGCTCGTTGATTCCTCTGCAAGGTGGTGCAGCATCCTCTGTCCCTTCATTCATTTC                       AGATCTACTCAGGTCTCCCTGTAAACAGATCTCTCGGATCAATAAGC   ATG AATGACGA                   AGACTACACCACCATCTATGACACAATCCAAAATGAGAGGACGTATGAGGTTCCAGAC                   CAGCCAGAAGAAAATGAAAGTCCCCATTATGATGATGTCCATGAGTACTTAAGGCCAG                   AAAATGATTTATATGCCACTCAGCTGAATACCCATGAGTATGATTTTGTGTCAGTCTA                   TACCATTAAGGGTGAAGAGACCAGCTTGGCCTCTGTCCAGTCAGAAGACAGAGGCTAC                   CTCCTGCCTGATGAGATATACTCTGAACTCCAGGAGGCTCATCCAGGTGAGCCCCAGG                   AGGACAGGGGCATCTCAATGGAAGGGTTATATTCATCAACCCAGGACCAGCAACTCTG                   CGCAGCAGAACTCCAGGAGAATGGGAGTGTGATGAAGGAAGATCTGCCTTCTCCTTCA                   AGCTTCACCATTCAGCACAGTAAGGCCTTCTCTACCACCAAGTATTCCTGCTATTCTG                   ATGCTGAAGGTTTGGAAGAAAAGGAGGCAGCTCACATGAACCCTGAGATTTACCTCTT                   TGTGAAGGTAAGGTCTGCCTCTGACAGGCATACCCTGTTCATGCAGATATTATGGCTG                   GTGTTTTATTTTGCTCTGAATGACCAGGGAAAGATTCATAATGCCATGGTCCTTGGAT                   CTCAATACATATTCAGGAGTCGGAGGGAC TAA   ATCAGTCATTAGAGTGTACTCAGCTC                       TTCACAAAATTAGAGGAATTGGAAGGTGCATTTAAAGCACGTATTTAATCACTGACTT                       TTACATACCATGGGCAAAGTATTTTTCAAAACGGTTCACATAAGTGAGCCATAACTGC                       TGCCCAAATCCTTGCCATTGTGGCTGACATTAAGTACATTTTTCTGTCTGGTTAAATT                       TCCTTTGTCGACATGTTTAAAAGTGAAACCAAAGCTTGTGAAAGAAAGACCTTCTTGT                       GCTTCTAAGGTCACAGATTTGTCAGATAGGTGGTCAATAAAGGCTATCTCTGTCACTA                       GCTTGCCCCTTTGGCACCAATATAACTAAAAATTTGATGAAGTCAAATGATTTCAGTA                       GTAGTAAGACACTACCAGTGTTAATGTTTAATACTTACGATATCTAAACAGAA                                           ORF Start: ATG at 454       ORF Stop: TAA at 1132           SEQ ID NO:138   226 aa   MW at 26132.2 kD                     NOV44a,   MNDEDYSTIYDTIQNERTYEVPDQPEENESPHYDDVHEYLRPENDLYATQLNTHEYDF       CG59432-01 Protein Sequence           VSVYTIKGEETSLASVQSEDRGYLLPDEIYSELQEAHPGEPQEDRGISMEGLYSSTQD                   QQLCAAELQENGSVMKEDLPSPSSFTIQHSKAFSTTKYSCYSDAEGLEEKEGAHMNPE                   IYLFVKVRSASDRHTLFMQILWLVFYFALNDQGKIHNAMVLGSQYIFRSRRD                                     SEQ ID NO:139   809 bp                     NOV44b,     ATCCTCTGTCCCTTCATTCATTTCAGATCTACTCAGGTCTCCCTGTAAACAGATCTCT         CG59432-02 DNA Sequence             CGGATCAATAAGC   ATG AATGACGAAGACTACGGCACCATCTATGACACAATCCAAAAT                   GAGAGGACGTATGAGGTTCCAGACCAGCCAGAAGAAAATGAAAGTCCCCATTATGATG                   ATGTCCATGAGTACTTAAGGCCAGAAAATGATTTATATGCCACTCAGCTGAATACCCA                   TGAGTATGATTTTGTGTCAGTCTATACCATTAAGGGTGAAGAGACCAGCTTGGCCTCT                   GTCCAGTCAGAAGACAGAGGCTACCTCCTGCCTGATGAGATATACTCTGAACTCCAGG                   AGGCTCATCCAGGTGAGCCCCAGGAGGACAGGGGCATCTCAATGGAAGGGTTATATTC                   ATCAACCCAGGACCAGCAACTCTGCGCAGCAGAACTCCAGGAGAATGGGAGTGTGATG                   AAGGAAGATCTGCCTTCTCCTTCAAGCTTCACCATTCAGCACAGTAAGGCCTTCTCTA                   CCACCAAGTATTCCTGCTATTCTGATGCTGAAGGTTTGGAAGAAAAGGAGGGAGCTCA                   CATGAACCCTGAGATTTACCTCTTTGTGAAGGTAAGGTCTGCCTCTGACAGGCATACC                   CTGTTCATGCAGATATTATGGCTGCTGTTTTATTTTCCTCTGAATGACCAGGGAAAGA                   TTCATAATGCCATGGTCCTTGGATCTCAATACATATTCAGGAGTCGGAGGGAC TAA   AT                       CAGTCATTAGAGTGTACTCAGCTCTTCACAAAATTAGAGGAATTGGAAGGTGCAT                                           ORF Start: ATG at 72       ORF Stop: TAA at 750           SEQ ID NO:140   226 aa   MW at 26102.2 kD                     NOV44b,   MNDEDYGTIYDTIQNERTYEVPDQPEENESPHYDDVHEYLRPENDLYATQLNTHEYDF       CG59432-02 Protein Sequence           VSVYTIKGEETSLASVQSEDRGYLLPDEIYSELQEAHPGEPQEDRGISMEGLYSSTQD                   QQLCAAELQENGSVNKEDLPSPSSFTIQHSKAFSTTKYSCYSDAEGLEEKEGAHMNPE                   IYLFVKVRSASDRHTLFMQILWLVFYFALNDQGKIHNANVLGSQYIFRSRRD                  
 
     [0556] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 44B.  
               TABLE 44B                          Comparison of NOV44a against NOV44b.                                         Identities/           Protein   NOV44a Residues/   Similarities for           Sequence   Match Residues   the Matched Region                       NOV44b   1 . . . 226   225/226 (99%)               1 . . . 226   225/226 (99%)                      
 
     [0557] Further analysis of the NOV44a protein yielded the following properties shown in Table 44C.  
               TABLE 44C                       Protein Sequence Properties NOV44a                                                PSort   0.6500 probability located in cytoplasm; 0.1000           analysis:   probability located in mitochondrial matrix space;               0.1000 probability located in lysosome (lumen);               0.0000 probability located in endoplasmic reticulum               (membrane)           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0558] A search of the NOV44a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 44D.  
               TABLE 44D                          Geneseq Results for NOV44a                                         NOV44a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value                         No Significant Matches Found                  
 
     [0559] In a BLAST search of public sequence databases, the NOV44a protein was found to have homology to the proteins shown in the BLASTP data in Table 44E.  
               TABLE 44E                          Public BLASTP Results for NOV44a                                         NOV44a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96JT5   CLIC5B- Homo sapiens  (Human),   1 . . . 200   185/202 (91%)    e−104           410 aa.   1 . . . 202   191/202 (93%)       Q9NPY9   DJ447E21.4 (SIMILAR TO   1 . . . 180   180/180 (100%)    e−103           BOVINE CHLORIDE CHANNEL   1 . . . 180   180/180 (100%)           PROTEIN (P64))- Homo sapiens             (Human), 180 aa (fragment).       A47104   chloride channel 64K chain-   1 . . . 197   104/231 (45%)   1e−39           bovine, 437 aa.   1 . . . 229   133/231 (57%)       P35526   Chlorine channel protein p64- Bos     1 . . . 197   103/231 (44%)   1e−38             taurus  (Bovine), 437 aa.   1 . . . 229   131/231 (56%)                  
 
     [0560] PFam analysis predicts that the NOV44a protein contains the domains shown in the Table 44F.  
               TABLE 44F                          Domain Analysis of NOV44a                                             Identities/               Pfam   NOV44a   Similarities for   Expect           Domain   Match Region   the Matched Region   Value                             No Significant Matches Found                  
 
     Example 45  
     [0561] The NOV45 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 45A.  
               TABLE 45A                       NOV45 Sequence Analysis                                                SEQ ID NO:141   877 bp                     NOV45a,   ACTTTGTCCTCTTGGGCTTCACACAGAATCCAAAGGAGCAGAAAGTACTTTTTGTTAT       CS59394-01 DNA Sequence           GTTCTTGCTCTTCTACATTTTGACCATGGTGGGCAACCTGCTCATTGTAGTGACCGTA                   ACTGTCAGTGACACCCTGGGCTCACCAATGTACTTCTTTCTTGCTGGCTTATCATTTA                   TAGATATCATTTATTCTTCATCCATTTCCCCCAGATTGATTTCAGGCTTGTTCTTTGG                   GAATAATTCCATATCCTTCCAATCTTGCATGGCCCAGCTCTTTATCGAGCACATTTTC                   GGTGGGTCAGAGGTCTTTCTCCTGTTGGTQATGGCCTATGACTGCTATGTGGCCATCT                   GTAAGCCCTTGCATTATTTGGTTATCATGAGACAATGGGTGTGTGTTCTGCTGCTGGT                   AGTGTCCTGGGTTGGAGGATTTCTGCACTCAGTATTTCAACTTAGCATTATTTATGGG                   CTCCCATTCTGTGGCCCCAATGTCATTGATCATTTTTTCTGTGACATGTATCCCTTAT                   TGAAACTGGTCTGCACTGACACCCATGCTATTGGCCTCTTAGTGGTOGCCAATGGAGG                   ACTGGCTTGCACTATTGTGTTTCTGCTCTTACTCATCTCTTATGGTGTCATCTTGCAC                   TCTTTAAAGAACCTTAGTCAGAAAGGGAGGCAAAAAGCCCTCTCAACCTGCAGTTCCC                   ACATGACTGTGGTTGTCTTCTTCTTTGTTCCTTGTATTTTTATGTATcCTAGACCTGC                   TAGGACCTTCCCCATTGACAAATCAGTGAGTGTGTTTTATACAGTCATAACCCCAATG                   CTGAACCCCTTAATCTACACTCTGAGAAATTCTGAGATGACAAGTGCTATGAAGAAGC                   TTTAGAG                                         ORF Start: TTT at 3       ORF Stop: TAG at 873           SEQ ID NO:142   290 aa   MW at 32485.7 kD                     NOV45a,   FVLLGFTQNPKEQKVLFVMFLLFYILTMVGNLLIVVTVTVSETLGSPMYFFLAGLSFI       CG59394-01 Protein Sequence           DIIYSSSISPRLISGLFFGNNSISFQSCMAQLFIEHIFGGSEVFLLLVMAYDCYVAIC                   KPLHYLVIMRQWVCVVLLVVSWVGGFLHSVFQLSIIYGLPFCGPNVIDHFFCDMYPLL                   KLVCTDTHAIGLLVVANGGLACTIVFLLLLISYGVILHSLKNLSQKGRQKALSTCSSH                   MTVVVFFFVPCIFMYARPARTFPIDKSVSVFYTVITPMLNPLIYTLRNSEMTSAMKKL                  
 
     [0562] Further analysis of the NOV45a protein yielded the following properties shown in Table 45B.  
               TABLE 45B                       Protein Sequence Properties NOV45a                                        PSort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability           located in endoplasmic reticulum (membrane);           0.1000 probability located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 42 and 43       analysis:                  
 
     [0563] A search of the NOV45a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 45C.  
               TABLE 45C                          Geneseq Results for NOV45a                                         NOV45a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAU24536   Human olfactory receptor    1 . . . 290   273/290 (94%)   e−155           AOLFR21- Homo sapiens , 299 aa.   10 . . . 299   278/290 (95%)           [WO200168805-A2,           20 SEP. 2001]       AAG71950   Human olfactory receptor    1 . . . 290   273/290 (94%)   e−155           polypeptide, SEQ ID NO: 1631-   10 . . . 299   278/290 (95%)             Homo sapiens , 299 aa.           [WO200127158-A2,           19 APR. 2001]       AAG72258   Human olfactory receptor   33 . . . 290   234/258 (90%)   e−131           polypeptide, SEQ ID NO: 1939-    1 . . . 250   240/258 (92%)             Homo sapiens , 262 aa.           [WO200127158-A2,           19 APR. 2001]       AAG72553   Human OR-like polypeptide query    1 . . . 290   198/290 (68%)   e−121           SEQ NO: 2234-   10 . . . 299   242/290 (83%)             Homo sapiens , 327 aa.           [WO200127158-A2,           19 APR. 2001]       AAG71909   Human olfactory receptor    1 . . . 290   198/290 (68%)   e−121           polypeptide, SEQ ID NO: 1590-   10 . . . 299   242/290 (83%)             Homo sapiens , 327 aa.           [WO200127158-A2,           19 APR. 2001]                  
 
     [0564] In a BLAST search of public sequence databases, the NOV45a protein was found to have homology to the proteins shown in the BLASTP data in Table 45D.  
               TABLE 45D                          Public BLASTP Results for NOV45a                                         NOV45a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9QW37   OR18=ODORANT RECEPTOR-    1 . . . 290   192/290 (66%)    e−115           Rattus sp, 307 aa.   10 . . . 299   237/290 (81%)       Q96R66   OLFACTORY RECEPTOR-   57 . . . 269   198/213 (92%)    e−111             Homo sapiens  (Human), 213 aa    1 . . . 213   202/213 (93%)           (fragment).       Q9R0K2   ODORANT RECEPTOR    1 . . . 290   177/290 (61%)    e−105           MOR18- Mus musculus     10 . . . 299   229/290 (78%)           (Mouse), 308 aa.       Q9R0K1   ODORANT RECEPTOR A16-    1 . . . 290   171/290 (58%)    e−102             Mus musculus  (Mouse), 302 aa.   10 . . . 299   226/290 (76%)       CAC88333   SEQUENCE 34 FROM PATENT    1 . . . 290   167/290 (57%)   5e−99           WO0164879- Homo sapiens     10 . . . 299   221/290 (75%)           (Human), 309 aa.                  
 
     [0565] PFam analysis predicts that the NOV45a protein contains the domains shown in the Table 45E.  
               TABLE 45E                          Domain Analysis of NOV45a                                     Identities/           Pfam   NOV45a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               7tm_1: domain 1 of 1   30 . . . 276   50/268 (19%)   4.4e−23               174/268 (65%)                  
 
     Example 46  
     [0566] The NOV46 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 46A.  
               TABLE 46A                       NOV46 Sequence Analysis                                                SEQ ID NO:143   1746 bp                     NOV46a,     ATAATTCAGTTTGAAAACCAGTGGTTTCTCTTTCCTTCCCTATAGGTGTAAAGAATAT         CG59383-01 DNA Sequence             CCAGCTGGTGGCTACAGTTCCCCCTCTGGTTTTGCTGCC   ATG CATCCTGGGCGAACTA                   CTGGTAAAGGGCCCTCTACTCACACTCAGATTGACCAGCAACCTCCACGGCTTCTCAT                   TGTGCACATTGCTCTACCGTCCTGGGCTGACATCTGCACCAACCTCTGTGAGGCTCTG                   CAGAACTTCTTCTCTCTAGCCTGCAGCTTGATGGGCCCCAGCCGCATGTCCCTGTTCA                   GTTTATACATGGTACAAGATCAGCATGAGTGCATCCTCCCTTTTGTGCAAGTGAAAGG                   GAACTTTGCTAGOTTGCAGACCTGCATCTCAGAACTCCGCATGTTACAGAGAGAAGGG                   TGTTTCAGATCACAAGGTGCTTCTCTGCGGCTGGCAGTAGAGGATGGGCTCCAGCAAT                   TCAAACAATACAGCAGACATGTGACCACAAGGGCAGCTCTGACCTATACCTCCCTGGA                   GATTACTATTCTGACTTCTCAGCCTGGAAAAGAGGTGGTCAAACAGTTGGAGGAAGGG                   TTGAAAGATACAGACCTAGCCAGAGTCAGGAGGTTTCAGGTCGTTGAGGTCACAAAGG                   GAATCCTAGAGCACGTGGACTCAGCGTCTCCTGTTGAGGATACCAGCAATGATGAGAG                   TTCTATTCTGGGAACTGACATTGACCTTCAGACTATAGACAATGATATCGTCAGCATG                   GAGATTTTCTTCAAAGCCTGGCTACATAACAGTGGAACAGACCAAGAACAAATCCATC                   TTCTTCTTTCTTCACAGTGTTTCAGCAACATTTCCAGACCCAGAGATAATCCAATGTG                   TCTGAAATGTGATCTCCAAGAGCGACTGCTCTGCCCATCCCTACTCGCTGGCACAGCT                   GACGGCTCCTTGAGAATGGATGACCCTAAAGGAGACTTCATCACACTCTACCAGATGG                   CTTCCCAGTCATCGGCCTCTCATTACAAOCTCCAAGTGATCAAGGCTTTAAAATCTAG                   CGGGCTCTGCGAGTCATTGACATATGGACTCCCGTTCATCCTCAGACCTACAAGCTGT                   TGGCAGCTCGACTGGGATGAGCTGGAGACAAATCAGCAACATTTCCATGCTTTGTGTC                   ACAGCCTGCTGAAAAGGGAATGGCTGCTGTTAGCCAAGGGGGAACCACCGGGCCCAGG                   ACACAGCCAGAGAATTCCTGCCAGCACCTTCTATGTGATCATGCCGTCACACTCCCTC                   ACACTGCTGGTAAAGGCGGTGGCCACGCGGGAACTGATGCTGCCCAGCACCTTCCCCC                   TGCTACCTGAGGACCCACATGATGATAGCCTTAAGAATAGCATGCTGGACAGCCTGGA                   GCTGGAGCCCACCTACAACCCCTTGCATGTTCAAAGCCACCTGTACTCACACCTGAGC                   AGCATCTATGCCAAGCCTCAGGGGCGGCTCCACCCACACTGGGAGAGCCGAGCTCCGA                   GAAAGACTGGGCAGTTGCAGACCAACCGAGCTCGAGCTACTGTGGCCCCCCTGCCTAT                   GACTCCTGTCCCAGGCAGAGCCTCCAAGATGCCAGCAGCCAGCAAATCTTCCTCAGAT                   GCCTTCTTCCTGCCTTCAGAGTGGGAGAAGGATCCCTCAAGGCCC TAA   GTCACCAGCA                       CCAGAGCCCAGCTGCCCAGCTTAACCATATCCATGCTCAGGTTCACATAATGGCTATC                       TGTGGT                                           ORF Start: ATG at 98       ORF Stop: TAA at 1670           SEQ ID NO:144   524 aa   MW AT 58691.3 kD                     NOV46a,   MHPGRTTGKGPSTHTQIDQQPPRLLIVHIALPSWADICTNLCEALQNFFSLACSLMGP       CG59383-01 Protein Sequence           SRMSLFSLYMVQDQHECILPFVQVKGNFARLQTCISELRMLQREGCFRSQGASLRLAV                   EDGLQQEKQYSRHVTTRAALTYTSLEITILTSQPGKEVVKQLEEGLKDTDLARVRRFQ                   VVEVTKGILEHVDSASPVEDTSNDESSILGTDIDLQTIDNDTVSMEIFFKAWLHNSGT                   DQEQIHLLLSSQCFSNISRPRDNPMCLKCDLQERLLCPSLLAGTADGSLRNDDPKGDF                   ITLYQMASQSSASHYKLQVIKALKSSGLCESLTYGLPFILRPTSCWQLDWDELETNQQ                   HFHALCHSLLKREWLLLAKGEPPGPGHSQRIPASTFYVIMPSHSLTLLVKAVATRELM                   LPSTFPLLPEDPHDDSLKNSMLDSLELEPTYNPLHVQSHLYSHLSSIYAKPQGRLHPH                   WESRAPRKTGQLQTNRARATVAPLPMTPVPGRASKNPAASKSSSDAFFLPSEWEKDPS                   RP                                     SEQ ID NO:145   1647 bp                     NOV46b,     AAAGAATATCCAGCTGGTGGCTACAGTTCCCCCTCTGGTTTTGCTGCC   ATG CATCCTG       CG59383-02 DNA Sequence           GGCGAACTACTGGTAAAGGGCCCTCTACTCACACTCAGATTGACCAGCAACCTCCACG                   GCTTCTCATTGTGCACATTGCTCTACCGTCCTGGGCTGACATCTGCACCAACCTCTGT                   GAGGCTCTGCAGAACTTCTTCTCTCTAGCCTGCAGCTTGATGGGCCCCAGCCGCATGT                   CCCTGTTCAGTTTATACATGGTACAAGATCAGCATGAGTGCATCCTCCCTTTTGTGCA                   AGTGAAAOGGAACTTTGCTAGGTTGCAGACCTGCATCTCAGAACTCCGCATGTTACAG                   AGAGAAGGGTGTTTCAGATCACAAGGTGCTTCTCTGCGGCTGGCAGTAGAGGATGGGC                   TCCAGCAATTCAAACAATACAGCAGACATGTGACCACAAGGGCAGCTCTGACCTATAC                   CTCCCTGGAGATTACTATTCTGACTTCTCAGCCTGGAAAAGAGGTGGTCAAACAGTTG                   GAGGAAGGGTTGAAAGATACAGACCTAGCCAGAGTCAGGAGGTTTCAGGTCGTTGAGG                   TCACAAAGGGAATCCTAGAGCACGTGGACTCAGCGTCTCCTGTTGAGGATACCAGCAA                   TGATGAGAGTTCTATTCTGGGAACTGACATTGACCTTCAGACTATAGACAATGATATC                   GTCAGCATGGAGATTTTCTTCAAAGCCTGGCTACATAACAGTGGAACAGACCAGGAAC                   AAATCCATCTTCTTCTTTCTTCACAGTGTTTCAGCAACATTTCCAGACCCAGAGATAA                   TCCAATGTGTCTGAAATGTGATCTCCAAGAGCGACTGCTCTGCCCATCCCTACTCGCT                   GGCACAGCTGACGGCTCCTTGAGAATGGATGACCCTAAAGGAGACTTCATCACACTCC                   ACCAGATGGCTTCCCAGTCATCGGCCTCTCATTACAAGCTCCAAGTGATCAAGGCTTT                   AAAATCTAGCGGGCTCTGCGAGTCATTGACATATGGACTCCCGTTCATCCTCAGACCT                   ACAACCTGTTGGCAGCTGGACTGGGATGAGCTGGAGACAAATCAGCAACATTTCCATG                   CTTTGTGTCACAGCCTGCTGAAAAGGGAATGGCTGCTGTTAGCCAAGGGGGAACCACC                   GGGCCCAGGACACAGCCAGAGAATTCCTGCCAGCACCTTCTATGTGATCATGCCGTCA                   CACTCCCTCACACTGCTGGTAAAGGCGGTGGCCACGCGGCAACTGATGCTGCCCAGCA                   CCTTCCCCCTGCTGCCTGAGGACCCACATGATGATAGCCTTAAGAATGTGGAGAGCAT                   GCTGGACAGCCTGGAGCTGOAGCCCACCTACAACCCCTTGCATGTTCAAAGCCACCTG                   TACTCACACCTGAGCAGCATCTATGCCAAGCCTCAGGGGCGGCTCCACCCACACTGGG                   AGAGCCGAGCTCCGAGAAAGCATCCCTGCAAGACTGGGCAGTTGCAGACCAACCGAGC                   TCGAGCTACTGTGGCCCCCCTGCCTATGACTCCTGTCCCAGGCAGAGCCTCCAAGATG                   CCAGCAGCCAGCAAATCTTCCTCAGATGCCTTCTTCCTGCCTTCAGAGTGGGAGAAGG                   ATCCCTCAAGGCCC TAA   GTCACC                                           ORF Start: ATG at 49       ORF Stop: TAA at 1639           SEQ ID NO:146   530 aa   MW at 59359.1 kD                     NOV46b,   MHPGRTTGKGPSTHTQIDQQPPRLLIVHIALPSWADICTNLCEALQNFFSLACSLMGP       CG59383-02 Protein Sequence           SRMSLFSLYMVQDQHECILPFVQVKGNFARLQTCISELRMLQREGCFRSQGASLRLAV                   EDGLQQFKQYSRHVTTRAALTYTSLEITILTSQPGKEVVKQLEEGLKDTDLARVRRFQ                   VVEVTKGTLEHVDSASPVEDTSNDESSILGTDIDLQTIDNDIVSMEIFFKAWLHNSGT                   DQEQIELLLSSQCFSNISRPRDNPMCLKCDLQERLLCPSLLAGTADGSLRMDDPKGDF                   ITLHQMASQSSASUYKLQVIKALKSSGLCESLTYGLPFILRPTSCWQLDWDELETNQQ                   HFHALCHSLLKREWLLLAKGEPPGPGHSQRIPASTFYVIMPSHSLTLLVKAVATRELM                   LPSTFPLLPEDPHDDSLKNVESMLDSLELEPTYNPLHVQSHLYSHLSSIYAKPQGRLH                   PHWESRAPRKHPCKTGQLQTNRARATVAPLPMTPVPGRASKMPAASKSSSDAPFLPSE                   WEKDPSRP                  
 
     [0567] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 46B.  
               TABLE 46B                          Comparison of NOV46a against NOV46b.                                         Identities/           Protein   NOV44a Residues/   Similarities for           Sequence   Match Residues   the Matched Region                       NOV46b   1 . . . 524   509/530 (96%)               1 . . . 530   510/530 (96%)                      
 
     [0568] Further analysis of the NOV46a protein yielded the following properties shown in Table 46C.  
               TABLE 46C                       Protein Sequence Properties NOV46a                                        PSort   0.4500 probability located in cytoplasm; 0.3000       analysis:   probability located in microbody (peroxisome);           0.1000 probability located in mitochondrial matrix           space; 0.1000 probability located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0569] A search of the NOV46a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 46D.  
               TABLE 46D                          Geneseq Results for NOV46a                                         NOV46a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAM34317   Peptide #8354 encoded by probe for   259 . . . 310   52/52 (100%)   7e−23           measuring placental gene expression-    1 . . . 52   52/52 (100%)             Homo sapiens , 52 aa.           [WO200157272-A2, 9 AUG. 2001]       ABB18624   Protein #623 encoded by probe for   101 . . . 142   42/42 (100%)   2e−16           measuring heart cell gene expression-    1 . . . 42   42/42 (100%)             Homo sapiens , 42 aa.           [WO200157274-A2, 9 AUG. 2001]       AAM66343   Human bone marrow expressed   101 . . . 142   42/42 (100%)   2e−16           probe encoded protein SEQ ID NO:    1 . . . 42   42/42 (100%)           26649- Homo sapiens , 42 aa.           [WO200157276-A2, 9 AUG. 2001]       AAM53955   Human brain expressed single exon   101 . . . 142   42/42 (100%)   2e−16           probe encoded protein SEQ ID NO:    1 . . . 42   42/42 (100%)           26060- Homo sapiens , 42 aa.           [WO200157275-A2, 9 AUG. 2001]       AAM26622   Peptide #659 encoded by probe for   101 . . . 142   42/42 (100%)   2e−16           measuring placental gene expression-    1 . . . 42   42/42 (100%)             Homo sapiens , 42 aa.           [WO200157272-A2, 9 AUG. 2001]                  
 
     [0570] In a BLAST search of public sequence databases, the NOV46a protein was found to have homology to the proteins shown in the BLASTP data in Table 46E.  
               TABLE 46E                          Public BLASTP Results for NOV46a                                         NOV46a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                             Q9Z0E1   D6MM5E PROTEIN -  Mus     1 . . . 524   380/526   (72%)   0.0             musculus  (Mouse), 529 aa.   1 . . . 526   423/526   (80%)       Q96L07   SIMILAR TO DNA SEGMENT,   1 . . . 358   358/358   (100%)   0.0           CHR 6, MIRIAM MEISLER 5,   1 . . . 358   358/358   (100%)           EXPRESSED -  Homo sapiens             (Human), 365 aa.                  
 
     [0571] PFam analysis predicts that the NOV46a protein contains the domains shown in the Table 46F.  
               TABLE 46F                          Domain Analysis of NOV46a                                     Identities/                   Similarities           NOV46a   for the       Pfam Domain   Match Region   Matched Region   Expect Value               RA: domain 1 of 1   124 . . . 214   18/115 (16%)   8.4               65/115 (57%)                  
 
     Example 47  
     [0572] The NOV47 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 47A.  
               TABLE 47A                       NOV47 Sequence Analysis                                                SEQ ID NO:147   960 bp                     NOV47a,     AGGACTAAATAAAATGGCCTAAATTTAAAT   ATG GATTGGGATTTCCATTCTCTTGCAG       CG58526-01 DNA Sequence           ATGCCCAGAACCAAAGAAGAGGTCTGCCTGGTTTTCTTCCTGGAGCTCCAGACCCAGA                   CCAAAGCCTTCCTGCCTCTTCCAATCCAGGGAACCAAGCATGGCAGCTGAGTCTCCCT                   CTGCCAAGCAGTTTCCTGCCAACAGTCAGTCTCCCTCCTGGTCTAGAATATTTAAGCC                   AGTTAGACCTGATAATTATACACCAGCAGGTGGAGCTGCTTGTGATACTTGGTACTGA                   GACCTCCAACAAATATGAGATTAAAAACAGCTTGGGACAAAGAATTTACTTTGCAGTG                   GAGGAAAGCATCTGCTTCAATCGTACTTTCTGTTCCACTCTGCGATCTTGCACCCTGA                   GGATCACAGATAACTCAGGTCGAGAGGTCATTACAGTGAACAGGCCCTTGAGATGTAA                   CAGCTGCTGGTGCCCTTGCTACCTACAAGAGTTAGAAATCCAAGCCCCTCCTGGTACT                   ATAGTTGGTTACGTTACGCAGAAGTGGGACCCCTTTCTGCCTAAATTCACAATCCAAA                   ATGCAAACAAAGAAGATATTTTGAAAATTGTTGGTCCTTGTGTGACATGTGGCTGTTT                   TGGCGATGTGGATTTTGAGAAGGTGAAAACCATTAATGAAAAGCTTACAATTGGGAAG                   ATTTCAAAGTACTGGTCAGGATTTGTAAATGATGTCTTCACAAATGCTGACAATTTCG                   GAATTCATGTTCCTGCAGATCTAGATGTAACAGTCAAAGCAGCAATGATCGGTGCCTG                   TTTTCTCTTTGTAAGTATGGGCTTTGAGAGCCCAGCCCTCCAAGATGAGAAAGAGTCA                   GTGTGGCAATTCAAAAAATCAGAGTGCCCTCTCACCTCCAAACAAGCCCACTTGTTCC                   CCAGCGATGGTTCT TAG   CCAGACTGAAATGAC                                           ORF Start: ATG at 31       ORF Stop: TAG at 943           SEQ ID NO:148   304 aa   MW at 33794.2 kD                     NOV47a,   MDWDFHSLADAQNQRRGLPGFLPGAPDPDQSLPASSNPGNQAWQLSLPLPSSFLPTVS       CG58526-01 Protein Sequence           LPPGLEYLSQLDLIIIHQQVELLVILGTETSNKYEIKNSLGQRIYFAVEESICFNRTF                   CSTLRSCTLRITDNSGREVITVNRPLRCNSCWCPCYLQELEIQAPPGTIVGYVTQKWD                   PFLPKFTIQNANKEDILRIVGPCVTCGCFGDVDFEKVKTINEKLTIGKISKYWSGFVN                   DVFTNADNFGIRVPADLDVTVKAAMIGACFLFVSMGFESPALQDEKESVWQFKKSECP                   LTSKQAHLFPSDGS                  
 
     [0573] Further analysis of the NOV47a protein yielded the following properties shown in Table 47B.  
               TABLE 47B                       Protein Sequence Properties NOV47a                                                PSort   0.8500 probability located in endoplasmic reticulum           analysis:   (membrane); 0.4400 probability located in plasma               membrane; 0.4244 probability located in microbody               (peroxisome); 0.1000 probability located in               mitochondrial inner membrane           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0574] A search of the NOV47a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 47C.  
               TABLE 47C                          Geneseq Results for NOV47a                                         NOV47a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG78341   Human Mm-1 cell line derived   24 . . . 282   152/263 (57%)   5e−84           transplantability-associated gene 1b -   60 . . . 318   187/263 (70%)             Homo sapiens  , 318 aa.           [WO200164894-A2, 7 SEP 2001]       AAB24113   Human phospholipid scramblase   24 . . . 282   152/263 (57%)   5e−84           HPLS protein sequence -  Homo     60 . . . 318   187/263 (70%)             sapiens  , 318 aa. [CN1259574-A,           12 JUL 2000]       AAB24112   Mouse phospholipid scramblase   24 . . . 282   152/263 (57%)   5e−84           MPLS protein sequence - Mus sp,   60 . . . 318   187/263 (70%)           318 aa. [CN1259574-A, 12 JUL           2000]       AAY09309   Human phospholipid scramblase -   24 . . . 282   152/263 (57%)   5e−84             Homo sapiens  , 318 aa.   60 . . . 318   187/263 (70%)           [WO9919352-A2, 22 APR 1999]       AAY29323   Human PL scramblase -  Homo     24 . . . 282   152/263 (57%)   5e−84             sapiens  , 318 aa. [WO9936536-A2,   60 . . . 318   187/263 (70%)           22 JUL 1999]                  
 
     [0575] In a BLAST search of public sequence databases, the NOV47a protein was found to have homology to the proteins shown in the BLASTP data in Table 47D.  
               TABLE 47D                          Public BLASTP Results for NOV47a                                         NOV47a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                         Q9JJ00   Phospholipid scramblase 1 (PL   20 . . . 283   150/267 (56%)   4e−84           scramblase 1) (Transplantability   66 . . . 328   191/267 (71%)           associated protein 1) (TRA1) (NOR1) -             Mus musculus  (Mouse), 328 aa.       Q99M50   PHOSPHOLIPID SCRAMBLASE 1 -   20 . . . 282   150/266 (56%)   6e−84             Mus musculus  (Mouse), 327 aa.   66 . . . 327   191/266 (71%)       O15162   Phospholipid scramblase 1 (PL   24 . . . 282   152/263 (57%)   2e−83           scramblase 1) (Erythrocyte   60 . . . 318   187/263 (70%)           phospholipid scramblase) (Ca2 +           dependent phospholipid scramblase 1)           (MmTRA1b) -  Homo sapiens             (Human), 318 aa.       P58195   Phospholipid scramblase 1 (PL   28 . . . 282   145/256 (56%)   3e−81           scramblase 1) (Ca2 + dependent   84 . . . 335   183/256 (70%)           phospholipid scramblase 1) -  Rattus               norvegicus  (Rat), 335 aa.       Q9NRY7   Phospholipid scramblase 2 (PL   55 . . . 270   135/217 (62%)   le−75           scramblase 2) (Ca2 + dependent    6 . . . 221   164/217 (75%)           phospholipid scramblase 2) -  Homo               sapiens  (Human), 224 aa.                  
 
     [0576] PFam analysis predicts that the NOV47a protein contains the domains shown in the Table 47E.  
               TABLE 47E                          Domain Analysis of NOV47a                                     Identities/           Pfam   NOV47a   Similarities   Expect       Domain   Match Region   for the Matched Region   Value                         No Significant Matches Found                  
 
     Example 48  
     [0577] The NOV48 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 48A.  
               TABLE 48A                       NOV48 Sequence Analysis                                                SEQ ID NO:149   957 bp                     NOV48a,     CCCCTGCTGGTGCCCAAGACCACCGTGGAAGGA   ATG GCTAAAGAGGAGACAAGTGAGT       CG57851-01 DNA Sequence           TAGAATGGGGCTTGTTACCCCCAGAAGAATTTTCCCAAGTGAATGGAATCATTCTTCA                   AAAGAAAATGTGCGATTTCTGGGATAAGATCTGGAACTTCCAAGCCAAGCCTGATGAC                   CTGCTCATTGCTTCTTACCCCAAAGCAGGTACCACTTGGACACAGGAAATTGTAGATC                   TGATACAAAATGATGGCGATATTGAGAAAAGCAGGCGCGCTTCCATTCAACTTCAACA                   CCCTTTCCTGGAGTGGATAAGAATGACACACGCCAGGAAAATTTTTGCAGGGATTGAC                   CAGGCTAACACAATGCCTTCCCCAAGGACCCTGAAAACTCATCTTCCTGTACAACTAC                   TGCCTCCATCCTTCTGGGAGGAAAACTGTAAGATAATCTATGTGGCAAGAAATGCCAA                   GGATAACCTGGTGTCCTACTACCATTTTCAAAGGATGAGCAAAGCACTCCCTGACGTT                   TTGACAGTGGGAGAATACATTATGTGTGGGGAAGTGTTGTGGGGAATATGGGAAGAGA                   TTCGGACTTGGCAACTGCATAGGTTGTTCTGCTGGTTCTTTGATCATGCTTCTGAGAA                   TCCTAGAAAGTTCAAAAGGATAATGGAATTTATGGGGAATAAACTAGATGAAGATCCT                   GTCAAAAGAATTGTTCAGCACACATCTTTTGAAAGTAAGAAGAAAAACCAGATGACCA                   ACTATGTAATGATAACCTGTGACATCATGGACCACTCCATCTCCCCATTTATGAGGAA                   AGGGACCGTTGGAGAGTGGAAGGATTACTTCTCAGCAGCACACAATAAGAGATTTGAT                   GAAGACAGGAAAATGGCTGACTCTTCTCTGACCTTCCACACGGAGCTC TAA   AGAGAGA                       GAGACAAAGTCTATACTACACAGGGGCAC                                           ORF Start: ATG at 34       ORF Stop: TAA at 919           SEQ ID NO:150   295 aa   MW at 34853.7 kD                     NOV48a,   MAKEETSELEWGLLPPEEFSQVNGIILQKKMCDFWDKIWNFQAKPDDLLIASYPKAGT       CG57851-01 Protein Sequence           TWTQEIVDLIQNDGDIEKSRRASIQLQHPFLEWIRMTHARKIFAGIDQANTMPSPRTL                   KTHLPVQLLPPSFWEENCKIIYVARNAKDNLVSYYHFQRMSKALPDVLTVGEYIMCGE                   VLWGIWEEIRTWQLHRLFCWFFDHASENPRKFKRIMEFMGNKLDEDPVKRIVQHTSFE                   SKKKNQMTNYVNITCDIMDESISPFMRKGTVGEWKDYFSAAQNKRFDEDRKMADSSLT                   FHTEL                  
 
     [0578] Further analysis of the NOV48a protein yielded the following properties shown in Table 48B.  
               TABLE 48B                       Protein Sequence Properties NOV48a                                        PSort   0.6400 probability located in microbody (peroxisome);       analysis:   0.4500 probability located in cytoplasm; 0.1000 probability           located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0579] A search of the NOV48a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 48C.  
               TABLE 48C                          Geneseq Results for NOV48a                                         NOV48a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAE12209   Human ST drug-metabolising   16 . . . 295   137/293 (46%)   9e−74           protein 2 encoded by DNA   15 . . . 304   200/293 (67%)           transcript 2 -  Homo sapiens , 304 aa.           [WO200172977-A2, 4 OCT 2001]       AAE12210   Human ST drug-metabolising   16 . . . 295   129/293 (44%)   1e−67           protein 3 encoded by cDNA -  Homo     15 . . . 304   190/293 (64%)             sapiens , 304 aa. [WO200172977-           A2, 4 OCT 2001]       AAE12208   Human ST drug-metabolising   16 . . . 295   128/293 (43%)   6e−67           protein 1 encoded by DNA   15 . . . 304   190/293 (64%)           transcript 1 -  Homo sapiens , 304 aa.           [WO200172977-A2, 4 OCT 2001]       AAE05178   Human drug metabolising enzyme   16 . . . 295   128/293 (43%)   1e−66           (DME-9) protein -  Homo sapiens ,   15 . . . 304   189/293 (63%)           304 aa. [WO200151638-A2,           19 JUL 2001]       AAY67294   Human STP2 (phenol   15 . . . 295   133/292 (45%)   5e−66           sulphotransferase 2) amino acid   10 . . . 295   186/292 (63%)           sequence -  Homo sapiens , 295 aa.           [WO9964630-A1, 16 DEC 1999]                  
 
     [0580] In a BLAST search of public sequence databases, the NOV48a protein was found to have homology to the proteins shown in the BLASTP data in Table 48D.  
               TABLE 48D                          Public BLASTP Results for NOV48a                                         NOV48a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q90WR6   SULFOTRANSFERASE 1C -    3 . . . 295   170/304 (55%)   3e−94             Gallus gallus  (Chicken), 307 aa.    5 . . . 307   218/304 (70%)       P50237   N-hydroxyarylamine    1 . . . 295   172/308 (55%)   3e−92           sulfotransferase (EC 2.8.2.-)    1 . . . 304   222/308 (71%)           (HAST-I) -  Rattus norvegicus             (Rat), 304 aa.       O70262   PHENOL SULFOTRANSFERASE -    18 . . . 295   164/289 (56%)   1e−91             Mus musculus  (Mouse), 304 aa.   19 . . . 304   215/289 (73%)       O75897   Sulfotransferase 1C2 (EC 2.8.2.-)   22 . . . 292   160/282 (56%)   1e−87           (SULT1C) (SULT1C#2) -  Homo     22 . . . 299   203/282 (71%)             sapiens  (Human), 302 aa.       O00338   Sulfotransferase 1C1 (EC 2.8.2.-)   18 . . . 295   149/289 (51%)   1e−80           (SULT1C#1) (ST1C2)   12 . . . 296   201/289 (68%)           (humSULTC2) -  Homo sapiens             (Human), 296 aa.                  
 
     [0581] PFam analysis predicts that the NOV48a protein contains the domains shown in the Table 48E.  
               TABLE 48E                          Domain Analysis of NOV48a                                     Identities/           Pfam   NOV48a   Similarities   Expect       Domain   Match Region   for the Matched Region   Value               Sulfotransfer:   23 . . . 285   116/298 (39%)   6.2e−82       domain 1 of 1       207/298 (69%)                  
 
     Example 49  
     [0582] The NOV49 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 49A.  
               TABLE 49A                       NOV49 Sequence Analysis                                                SEQ ID NO:151   1934 bp                     NOV49a,     CTTGATTACGGAGACTGAACCTTCATAGGGTGCGCACTTACCAAGGACAGGAAGGTTT         CG59377-01 DNA Sequence             CTCTGTTTGAAGGGCTTTAAACTTATAACAAAGAAAATAAAA   ATG ACGACTTCGTCTA                   TCAGACGGCAGATGAAAAACATCGTGAACAATTACTCAGAGGCAGAAATCAAAGTCCG                   GGAAGCCACCTCCAATGACCCGTGGGGCCCGTCCAGTTCTCTGATGACCGAGATTGCC                   GACCTGACCTACAACGTGGTGGCCTTCTCGGAGATCATGAGCATGGTGTGGAAGCGGC                   TGAATGACCATGGCAAGAACTGGCGGCATGTGTACAAGGCGCTGACCCTGCTGGACTA                   CCTCATCAAGACAGGCTCCGAACGTGTGGCCCAGCAGTGCCGGGAGAACATCTTCGCC                   ATCCAGACCCTGAAGGACTTCCAGTACATTGACCOAGATGGCAAGGACCAGGGCATCA                   ATGTGCGTGAGAAGTCAAAGCAACTGGTGGCTCTCCTCAAGGACGAGGAACGGTTGAA                   GGCTGAGAGGGCCCAGGCTCTCAAAACCAAAGAGCGCATGGCCCAGGTTGCCACTGGC                   ATGGGCAGCAACCAGATCACCTTTGGGCGAGGCTCCAGCCAGCCCAACCTCtCCACCA                   GCCACTCGGAGCAGGAGTATGGCAAGGCCGGGGGCTCCCCGGCCTCCTACCATGGCTC                   CACCTCCCCGCGAGTGTCCTCCGAGCTGGAGCAAGCCCGGCCCCAGACTAGTGGAGAA                   GAGGAGCTTCAGCTGCAGCTGGCACTTGCCATGAGCAGAGAAGTGGCTGAGCAGGAAG                   AACGCCTCAGGCGGGGTGATGACCTCAGATTACAGATGGCCCTGGAAGAAAGCCGAAG                   GGACACAGTTAAAATTCCAAAAAAGAAAGAGCAGACTACGCTGTTGGATTTAATGGAT                   GCTCTCCCCAGCTCGGGCCCCGCGGCCCACAAAGCAGAGCCCTGGGGCCCGTCAGCCT                   CCACTAACCAGACCAACCCCTGGGGCGGGCCAGCGGCTCCTGCGAGTACTTCAGACCC                   CTGGCCATCGTTTGGTACCAAGCCAGCTGCCTCCATTGACCCATGGGGGGTGCCCACT                   GGAGCCACCGCACAATCTGTCCCCAAGAACTCGGACCCCTGGGCAGCTTCACAGCAGC                   CTGCCTCCAGTGCTGGGAAAAGAGCTTCTGACGCGTGGGGCGCAGTCTCCACCACCAA                   GCCCGTGTCTGTCTCTGGGTCCTTTGAGCTCTTCAGTAATCTGAATGGTACAATTAAA                   GATGACTTTTCTGAATTTGACAACCTTCGGACTTCAAAAAAAACAGCCGAATCTGTGA                   CCTCTCTGCCATCCCAAAACAATGGAACTACCAGCCCTGACCCCTTTGAGTCTCAACC                   CCTGACTGTCGCCTCAAGCAAGCCCAGCAGTGCCCGGAAAACACCTGAGTCCTTCCTG                   GGCCCCAACGCGGCCCTGGTGAACCTGGACTCACCGGTGACCAGGCCTGCCCCACCAG                   CCCAGTCCCTCAACCCTTTCCTGGCACCAGGTGCTCCCGCCACCTCGGCCCCTGTTAA                   CCCTTTCCAGGTGAACCAGCCCCAGCCGCTGACACTGAACCAGCTTCGGGGGAGCCCA                   GTCCTGGGGACCAGCACATCCTTTGGGCCTGGCCCAGGAGTGGAGTCCATGGCTGTGG                   CCTCGATGACCTCCGCGGCCCCACAGCCAGCTCTGGGGGCCACTGGTTCCTCTCTGAC                   ACCACTGGGCCCTGCAATGATGAACATGGTGGGCAGTGTCGGTATACCCCCATCAGCA                   GCCCAGGCCACTGGCACAACCAACCCTTTCCTTCTC TAG   TGCCTGGGCCTGGGACCCA                       CCCAGAGCACCTGTGCTGGAGGATGCCGAGCAGGCACTCTCGTCTGTGGCACGGGATC                       CAAGAGTTTGGQGATTAGGG                                           ORF Start: ATG at 101       ORF Stop: TAG at 1835           SEQ ID NO:152   578 aa   MW at 61651.2 kD                     NOV49a,   MTTSSIRRQNKNIVNNYSEAEIKVREATSNDPWGPSSSLMTEIADLTYNVVAFSEIMS       CG59377-01 Protein Sequence           MVWKRLNDHGKNWRHVYKALTLLDYLIKTGSERVAQQCRENIFAIQTLKDFQYIDRDG                   KDQGINVREKSKQLVALLKDEERLKAERAQALKTKERMAQVATGMGSNQITFGRGSSQ                   PNLSTSESEQEYGKAGGSPASYHGSTSPRVSSELEQARPQTSGEEELQLQLALAISRE                   VAEQEERLRRGDDLRLQMALEESRRDTVKIPKKKEQTTLLDLMDALPSSGPAAQKAEP                   WGPSASTNQTNPWGGPAAPASTSDPWPSFGTKPAASIDPWGVPTGATAQSVPKNSDPW                   AASQQPASSAGKRASDAWGAVSTTKPVSVSGSFELFSNLNGTIKDDFSEFDNLRTSKK                   TAESVTSLPSQNNGTTSPDPFESQPLTVASSKPSSARKTPESFLGPNAALVNLDSLVT                   RPAPPAQSLNPFLAPGAFATSAPVNPFQVNQPQPLTLNQLRGSPVLGTSTSFGPGPGV                   ESMAVASMTSAAPQPATGATGSSLTPLGPAMMNMVGSVGIPPSAAQATGTTNPFLL                  
 
     [0583] Further analysis of the NOV49a protein yielded the following properties shown in Table 49B.  
               TABLE 49B                       Protein Sequence Properties NOV49a                                        PSort   0.4936 probability located in mitochondrial matrix space;       analysis:   0.3000 probability located in nucleus; 0.2087 probability           located in mitochondrial inner membrane; 0.2087 probability           located in mitochondrial intermembrane space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0584] A search of the NOV49a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologousproteins shown in Table 49C.  
               TABLE 49C                          Geneseq Results for NOV49a                                         NOV49a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues/   Region   Value               AAB93525   Human protein sequence SEQ ID   1 . . . 578   578/584 (98%)   0.0           NO:12872 -  Homo sapiens  , 584 aa.   1 . . . 584   578/584 (98%)           [EP1074617-A2, 7 FEB 2001]       AAB95663   Human protein sequence SEQ ID   40 . . . 403    364/370 (98%)   0.0           NO: 18438 -  Homo sapiens , 370 aa.   1 . . . 370   364/370 (98%)           [EP1074617-A2, 7 FEB 2001]       AAB93011   Human protein sequence SEQ ID   1 . . . 407   385/470 (81%)   0.0           NO:11762 -  Homo sapiens  , 484 aa.   1 . . . 470   390/470 (82%)           [EP1074617-A2, 7 FEB 2001]       AAB42049   Human ORFX ORF1813   1 . . . 578   306/636 (48%)   e−141           polypeptide sequence SEQ ID   1 . . . 551   370/636 (58%)           NO:3626 -  Homo sapiens , 551 aa.           [WO200058473-A2, 5 OCT 2000]       AAB95100   Human protein sequence SEQ ID   1 . . . 578   298/636 (46%)   e−137           NO:17064 -  Homo sapiens , 576 aa.   1 . . . 576   371/636 (57%)           [EP1074617-A2, 7 FEB 2001]                  
 
     [0585] In a BLAST search of public sequence databases, the NOV49a protein was found to have homology to the proteins shown in the BLASTP data in Table 49D.  
               TABLE 49D                          Public BLASTP Results for NOV49a                                             Identities/           Protein       NOV49a   Similarities for       Accession       Residues/Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               O95207   EPSIN 2A -  Homo sapiens     1 . . . 578   576/584 (98%)   0.0           (Human), 584 aa.   1 . . . 584   576/584 (98%)       Q9UPT7   KIAA1065 PROTEIN -  Homo     1 . . . 578   557/641 (86%)   0.0             sapiens  (Human), 641 aa.   1 . . . 641   562/641 (86%)       O95208   EPSIN 2B -  Homo sapiens     1 . . . 578   556/642 (86%)   0.0           (Human), 642 aa.   1 . . . 642   560/642 (86%)       Q9Z1Z3   EH DOMAIN BINDING   1 . . . 578   512/590 (86%)   0.0           PROTEIN EPSIN 2 -  Rattus     1 . . . 583   526/590 (88%)             norvegicus  (Rat), 583 aa.       O70447   INTERSECTIN-EH BINDING   76 . . . 578    438/515 (85%)   0.0           PROTEIN IBP2 -  Mus musculus     2 . . . 509   459/515 (89%)           (Mouse), 509 aa (fragment).                  
 
     [0586] PFam analysis predicts that the NOV49a protein contains the domains shown in the Table 49E.  
               TABLE 49E                          Domain Analysis of NOV49a                                     Identities/           Pfam   NOV49a   Similarities   Expect       Domain   Match Region   for the Matched Region   Value                                         ENTH: domain    17 . . . 140   70/131   (53%)   7.9e−68       1 of 1       117/131   (89%)       VHS: domain 1 of 1    14 . . . 158   33/160   (21%)   3.3               90/160   (56%)       UIM: domain 1 of 2   217 . . . 234   11/18   (61%)   0.043               16/18   (89%)       UIM: domain 2 of 2   242 . . . 259   5/18   (28%)   80               12/18   (67%)                  
 
     Example 50  
     [0587] The NOV50 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 50A.  
               TABLE 50A                       NOV50 Sequence Analysis                                                SEQ ID NO:153   2580 bp                     NOV50a,     ATG CTGCTGGCCCCCTTTTATTGCTGGGTGTGTGCCCATGCTGCTGGCCCCCTTTTAT       CG59258-01 DNA Sequence           TGCTGGGCAGTGACAAACTGTACCATCAGTGGCTCTCCACTGTCCGGAAAGGAAGTGG                   AGCAATTCTGAATACTGTAAAGACCAAAGCAAATCCGGCCATGAAGACTGTCTACAAG                   TTCGACATTGCCGAGAATGGCTGCGCCCCCACCCCAGAAGAGCAGCTGCCAAAGACTG                   CACCGTCCCCACTGGTGGAGGCCAAGGACCCCAAGCTCCGAGAAGACCGGCGGCCAAT                   CACAGTCCACTTTGGACAGGACCAGTCTGAGATGTCTTTCAGCTCAGCACTCACTCAC                   GGCAAAGAGAGTGCCCGGACCCAGCCGGAGAGAGTCGTTGACAGGACTGGCGAGCCCC                   TGAATCCTGAGCGCGCTCTCTCCGGAGATCATCTCTGGCCTGTTACGCACTTGCTCTG                   GGCAACCCTGGGCAAGTCCTTGCTTGCCCTCATCTGTGAAATGGGTAGCAGCCCTCGT                   TCCCTGCAGAGGAGCCTTGCGCTGCTGGGGACACCCCAGCTTATTTGGGAAACTGCAA                   CCACCATGGCCGATGGCCCCACCACGCCCTGTCTAGGAAGCAGAGGCCTCCCCAGCAG                   CGTGTCCACTGTGCCCCTGGCCCTGCGTGAAGTGCCATCAGATGCCCCGCATCCCTGC                   AGCAGGGCCCTCGTGACTGGCGTCACAGATGAGGACACAGAGGCCCAGGGAAGTCACT                   TGCTTGCCAAAGTCACTCAGCAAACCATGTCTGTCTGGCTCTCAGAAAATGGGAAAGA                   AGCCTGGGCATTCAGCCATGAGGGAGCCACGGCTGTAGCCAGTGGAATGACGTACCCT                   CAGTCCAGGATGTGCACCCGGGCAGCCAGGTCCCACAGCCACTACTTTCTTGCCCCCA                   CCACTGCTCCCACAGTTCCCAGAACTCAGTCTCCAGATCTGGGCTCCAGGATGCAGAG                   GCTGTCCTCAGGCCTGGTAAAGCCCTTGCGACACTATGCGGTCTTCCTCTCCGAAGAC                   TCCTCTGATGATGAATGCCAGCGGGAAGAGGGCCCGAGCTCTGGCTTCACCGAGAGCT                   TTTTCTTCTCCGCTCCCTTTGAATGGCCGCAGCCGTATCGGACACTCAGGGAGTCAGA                   CAGCGCGGAAGGCGACGAGGCAGAGAGTCCAGAGCAGCAAGTGCGGAAGTCCACAGGC                   CCTGTCCCAGCTCCCCCTGACCGGGCTGCCAGCATCGACCTTCTGGAAGACGTCTTCA                   GCAACCTGGACATGGAGGCCGCACTGCAGCCACTGGGCCAGGCCAAGAGCTTAGAGGA                   CCTTCGTGCCCCCAAAGACCTGAGGGAGCAGCCAGGGACCTTTGACTATCAGAGGCTG                   GATCTGGGCGGGAGTGAGAGGAGCCGCGGGGTGACAGTGGCCTTGAAGCTTACCCACC                   CGTACAACAAGCTCTGGAGCCTGGGCCAGGACGACATGGCCATCCCCAGCAAGCCCCC                   AGCTGCCTCCCCTGAGAAGCCCTCAGCCCTGCTCGGAAACTCCCTGGCCCTGCCTCGA                   AGGCCCCAGAACCGGGACAGCATCCTGAACCCCAGTGACAAGGAGGAGGTGCCCACCC                   CTACTCTGGGCAGCATCACCATCCCCCGGCCCCAAGGCAGGAAGACCCCAGAGCTGGG                   CATCGTGCCTCCACCGCCCATTCCCCGCCCGGCCAAGCTCCAGGCTGCCGGCGCCGCA                   CTTGGTGACGTCTCAGAGCGGCTGCAGACGGATCGGGACAGGCGAGCTGCCCTGAGTC                   CAGGGCTCCTGCCTGGTGTTGTCCCCCAAGGCCCCACTGAACTGCTCCAGCCGCTCAG                   CCCTGGCCCCGGGGCTGCAGGCACGAGCAGTGACGCCCTGCTCGCCCTCCTGGACCCG                   CTCAGCACAGCCTGGTCAGGCAGCACCCTCCCGTCACGCCCCGCCACCCCGAATGTAG                   CCACCCCATTCACCCCCCAATTCAGCTTCCCCCCTGCAGGGACACCCACCCCATTCCC                   ACAGCCACCACTCAACCCCTTTGTCCCATCCATGCCAGCAGCCCCACCCACCCTGCCC                   CTGGTCTCCACACCAGCCGGGCCTTTCGGGGCCCCTCCAGCTTCCCTGGGGCCGGCTT                   TTGCGTCCGGCCTCCTGCTGTCCAGTGCTGGCTTCTGTGCCCCTCACAGGTCTCAGCC                   CAACCTCTCCGCCCTCTCCATGCCCAACCTCTTTGGCCAGATGCCCATGGGCACCCAC                   ACGAGCCCCCTACAGCCGCTGGGTCCCCCAGCAGTTGCCCCGTCGAGGATCCGAACGT                   TGCCCCTGGCCCGCTCAAGTGCCAGGGCTGCTGAGACCAAGCAGGGGCTCGCCCTGAG                   GCCTGGAGACCCCCCGCTTCTGCCTCCCAGGCCCCCTCAAGGCCTGGAGCCAACACTG                   CAGCCCTCTGCTCCTCAACAGGCCAGAGACCCCTTTGAGGATTTGTTACAGAAAACCA                   AGCAAGACGTGAGCCCGAGTCCGGCCCTGGCCCCGGCCCCAGACTCGGTGGAGCAGCT                   CAGGAAGCAGTGGGAGACCTTCGAG TGA                                           ORF Start: ATG at 1       ORF Stop: TGA at 2578           SEQ ID NO:154   859 aa   MW at 91746.7 kD                     NOV50a,   MLLAPFYCWVCAHAAGPLLLLGSDKLYHQWLSTVRKGSGAILNTVKTKANPAMKTVYK       CG59258-01 Protein Sequence           FDIAENGCAPTPEEQLPKTAPSPLVEAKDPKLREDRRPITVHFCQDQSEMSFSSALTH                   GKESARTQPERVVDRTGEPLNPERALSGDHLWPVTELLWATLGKSLLALICEMGSSPR                   SLQRSLALLGTPQLIWETATTMADGPTTPCLGSRGLPSSVSTVPLALREVPSDAPHPC                   SRALVTGLTDEDTEAQGSHLLAXVTQQTMSVWLSENGKEAWAFSHEGATAVASGMTYP                   QSRMCTRAARSHSHYFLAPTTAPTVPRTQSPDLGSRMQRLSSGLVKPLRHYAVFLSED                   SSDDECQREEGPSSGFTESFFFSAPFEWPQPYRTLRESDSAEGDEAESPEQQVRKSTG                   PVPAPPDRAASIDLLEDVFSNLDMEAALQPLGQAKSLEDLRAPKDLREQPGTFDYQRL                   DLGGSERSRGVTVALKLTHPYNKLWSLGQDDMAIPSKPPAASPEKPSALLGNSLALPR                   RPQNRNSILNPSDKEEVPTPTLGSITIPRPQGRKTPELGIVPPPPIPRPAKLQAAGAA                   LGDVSERLQTDRDRRAALSPGLLPGVVPQGPTELLQPLSPGPGAAGTSSDALLALLDP                   LSTAWSGSTLPSRPATPNVATPPTPQFSFPPAGTPTPFPQPPLNPFVPSMPAAPPTLP                   LVSTPAGPFGAPPASLGPAFASGLLLSSAGFCAPHRSQPNLSALSMPNLFGQMPNGTH                   TSPLQPLGPPAVAPSRIRTLPLARSSARAAETKQGLALRPGDPPLLPPRPPQGLEPTL                   QPSAPQQARDPFEDLLQKTKQDVSPSPALAPAPDSVEQLRKQWETFE                  
 
     [0588] Further analysis of the NOV50a protein yielded the following properties shown in Table 50B.  
               TABLE 50B                       Protein Sequence Properties NOV50a                                        PSort   0.4500 probability located in cytoplasm; 0.3000       analysis:   probability located in microbody (peroxisome);           0.1940 probability located in lysosome (lumen);           0.1000 probability located in mitochondrial matrix space       SignalP   Likely cleavage site between residues 15 and 16       analysis:                  
 
     [0589] A search of the NOV50a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 50C.  
               TABLE 50C                          Geneseq Results for NOV50a                                         NOV50a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAM41501   Human polypeptide SEQ ID NO    22 . . . 103    82/82 (100%)   2e−42           6432- Homo sapiens , 545 aa.    401 . . . 482    82/82 (100%)           [WO200153312-A1,           26 JUL. 2001]       AAM39715   Human polypeptide SEQ ID NO    22 . . . 103    82/101 (81%)   6e−39           2860- Homo sapiens , 559 aa.    396 . . . 496    82/101 (81%)           [WO200153312-A1,           26 JUL. 2001]       AAW31855   Mycobacterium tuberculosis 55    498 . . . 845    96/358 (26%)   8e−12           kDa protein-Mycobacterium    71 . . . 389   125/358 (34%)           tuberculosis, 572 aa.           [WO9741252-A2,           6 NOV. 1997]       AAW31852   Mycobacterium tuberculosis 74    498 . . . 845    96/358 (26%)   8e−12           kDa protein-Mycobacterium    262 . . . 580   125/358 (34%)           tuberculosis, 763 aa.           [WO9741252-A2,           6 NOV. 1997]       AAB50363   Human SRCAP- Homo sapiens ,    501 . . . 845   112/369 (30%)   1e−11           2972 aa. [WO200073467-A1,   1235 . . . 1575   141/369 (37%)           7 DEC. 2000]                  
 
     [0590] In a BLAST search of public sequence databases, the NOV50a protein was found to have homology to the proteins shown in the BLASTP data in Table 50D.  
               TABLE 59D                          Public BLASTP Results for NOV50a                                         NOV50a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9HCG4   KIAA1608 PROTEIN- Homo     309 . . . 859   501/555 (90%)   0.0             sapiens  (Human), 603 aa    62 . . . 603   510/555 (91%)           (fragment).       Q9H796   CDNA: FLJ21129 FIS, CLONE    22 . . . 103    81/101 (80%)   2e−37           CAS06266- Homo sapiens     396 . . . 496    81/101 (80%)           (Human), 559 aa.       AAK44515   HYPOTHETICAL 58.5 KDA   499 . . . 845   104/354 (29%)   8e−14           PROTEIN-Mycobacterium   299 . . . 562   121/354 (33%)           tuberculosis CDC1551, 598 aa.       Q9SN46   EXTENSIN-LIKE PROTEIN-   604 . . . 848    73/249 (29%)   3e−12             Arabidopsis thaliana  (Mouse-ear   407 . . . 626   100/249 (39%)           cress), 839 aa.       Q41805   EXTENSIN-LIKE PROTEIN   492 . . . 848    88/361 (24%)   5e−12           PRECURSOR- Zea mays     415 . . . 749   124/361 (33%)           (Maize), 1188 aa.                  
 
     [0591] PFam analysis predicts that the NOV50a protein contains the domains shown in the Table 50E.  
               TABLE 50E                          Domain Analysis of NOV50a                                             Identities/               Pfam   NOV50a   Similarities for   Expect           Domain   Match Region   the Matched Region   Value                             No Significant Matches Found                  
 
     Example 51  
     [0592] The NOV51 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 51A.  
               TABLE 51A                       NOV51 Sequence Analysis                                                SEQ ID NO:155   1394 bp                     NOV51,     GTGGCCTGCTCCTGCAGCAATCCCAGGACCCCCTGCTC   ATG GGGCTGTTTCCTACTAA       CG59492-01 DNA Sequence           CCCCAAAGAGAAGACCCAGGAGGAACCCCCTGGCCAGAGCAGGGCCCCTGTGTTGACC                   GTGGTGTCCAAGTTCAAGGCCTCACTGGAGCAGCTTCTGCAGGTCCTACACAGCACCA                   CGCCCCACTACATTCGCTGCATCAAGCCCAACAGCCAGGGCCAGGCGCAGACCTTTCT                   CCAAGAGGAGGTCCTGAGCCAGCTGGAGGCCTGTGGCCTCGTGGAGACCATCCATATC                   AGTGCTGCTGGCTTCCCCATCCGGGTCTCTCACCGAAACTTTGTAGAACGATACAAGT                   TACTAAGAAGGCTTCATCCTTGCACATCCTCTGGCCCCGACAGCCCATATCCTGCCAA                   AGGGCTCCCTGAATGGTGTCCACACAGCGAGGAAGCCACGCTTGAACCTCTCATCCAG                   GACATTCTCCACACTCTGCCGGTCCTAACTCAGGCAGCAGCCATAACTGGTGACTCGG                   CTGAGGCCATGCCAGCCCCCATGCACTGTGGCAGGACCAAGGTGTTCATGACTGACTC                   TATGCTGGAGCTTCTGGAATGTGGGCGTGCCCGGGTGCTGGAGCAGTGTGCCCGCTGC                   ATCCAGGGTGGCTGGAGGCGACACCGGCACCGAGAGCAGGAGCGGCAGTGGCGGGCCG                   TCATGCTCATCCAGGCAGCCATTCGTTCCTGGTTAACTCGGAAACACATCCAGAGGCT                   GCATGCAGCTGCCACAGTCATCAAGCGTGCATGGCAGAAGTGGAGAATCAGAATGGCC                   TGCCTTGCTGCTAAAGAGCTGGATGGTGTGGAAGAAAAACACTTCTCTCAAGCTCCCT                   GTTCCCTGAGCACCTCGCCGCTGCAGACCAGGCTCCTGGAGGCAATAATCCGCTTCTG                   GCCCCTGGGACTGGTCCTGGCCAATACGGCTATGGGTGTAGGCAGCTTTCAGAGGAAA                   TTAGTGGTCTGGGCTTGCCTCCAGCTCCCCAGGGGCAGCCCCAGTAGCTACACTGTCC                   AGACAGCACAAGACCAGGCTGGTGTCACGTCCATCCGAGCGCTGCCTCAGGGATCGAT                   AAAGTTTCACTGCAGAAAGTCTCCACTGCGGTATGCTGACATCTGCCCTGAACCTTCA                   CCCTACAGCATTGCAGGCTTTAATCAGATTCTGCTGGAAAGACACAGGCTGATCCACG                   TGACCTCTTCTGCCTTCACTGGGCTGGGG TGA   TCCTTGGTGCCTTTGTTTCCACAAGG                       CCTTTTCCTGCCCCCTGCCTTGCCAAAGACATTTAATCAGCACACAGCTGCCAGACTA                       TTCCCACAGTGCTCCAAATGCACATGAACAACAGTGACGGCTCCAGCCTTCGACCCAG                       AG                                           ORF Start: ATG at 39       ORF Stop: TGA at 1248           SEQ ID NO:156   403 aa   MW at 45142.8 kD                     NOV51a,   MGLFPTNPKEKTQEEPPGQSRAPVLTVVSKFKASLEQLLQVLUSTTPHYIRCIKPNSQ       CG59492-01 Protein Sequence           GQAQTFLQEEVLSQLEACGLVETIHISAAGFPIRVSHRNFVERYKLLRRLHPCTSSGP                   DSPYPAKGLPEWCPHSEEATLEPLIQDILHTLPVLTQAAAITGDSAEAMPAPMHCGRT                   KVFMTDSNLELLECGRARVLEQCARCIQGGWRRHRHREQERQWRAVMLIQAAIRSWLT                   RKHIQRLHAAATVIKRAWQKWRIRMACLAAKELDGVEEKHFSQAPCSLSTSPLQTRLL                   EAIIRFWPLGLVLANTAMGVGSFQRKLVVWACLQLPRGSPSSYTVQTAQDQAGVTSIR                   ALPQGSIKFIICRKSPLRYADICPEPSPYSIAGFNQILLERHRLIHVTSSAFTGLG                  
 
     [0593] Further analysis of the NOV51a protein yielded the following properties shown in Table 51B.  
               TABLE 51B                       Protein Sequence Properties NOV51a                                        PSort   0.3000 probability located in nucleus; 0.2029 probability       analysis:   located in lysosome (lumen); 0.1000 probability located           in mitochondrial matrix space; 00320 probability located           in microbody (peroxisome)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0594] A search of the NOV51a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 51C.  
               TABLE 51C                          Geneseq Results for NOV51a                                         NOV51a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAY94290   Human myosin heavy chain    1 . . . 403   401/403 (99%)   0.0           homologue- Homo sapiens , 612   210 . . . 612   401/403 (99%)           aa. [WO200026372-A1,           11 MAY 2000]       AAU23676   Novel human enzyme polypeptide    17 . . . 403   384/387 (99%)   0.0           #762- Homo sapiens , 387 aa.    1 . . . 387   384/387 (99%)           [WO200155301-A2,           2 AUG. 2001]       ABB10243   Human cDNA SEQ ID NO: 551-    1 . . . 365   365/365 (100%)   0.0             Homo sapiens , 570 aa.   206 . . . 570   365/365 (100%)           [WO200154474-A2,           2 AUG. 2001]       AAU23123   Novel human enzyme polypeptide    1 . . . 365   364/365 (99%)   0.0           #209- Homo sapiens , 567 aa.   203 . . . 567   364/365 (99%)           [WO200155301-A2,           2 AUG. 2001]       AAM23563   Human EST encoded protein SEQ    1 . . . 189   188/189 (99%)   e−108           ID NO: 1088- Homo sapiens , 477   288 . . . 476   188/189 (99%)           aa. [WO200154477-A2,           2 AUG. 2001]                  
 
     [0595] In a BLAST search of public sequence databases, the NOV51a protein was found to have homology to the proteins shown in the BLASTP data in Table 5 ID.  
               TABLE 51D                          Public BLASTP Results for NOV51a                                         NOV51a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96H55   HYPOTHETICAL 86.7 KDA    72 . . . 403   330/332 (99%)   0.0           PROTEIN- Homo sapiens  (Human)   439 . . . 770   330/332 (99%)           770 aa.       Q9D2Z3   1110055A02R1K PROTEIN    3 . . . 394   288/394 (73%)    e−162           RIKEN CDNA 1110055A02    2 . . . 395   320/394 (81%)           GENE)- Mus musculus  (Mouse),           395 aa.       Q948A2   PUTATIVE MYOSIN HEAVY    2 . . . 255    84/258 (32%)   1e−23           CHAIN- Oryza sativa  (Rice), 1601   663 . . . 876   125/258 (47%)           aa.       O74805   HYPOTHETICAL MYOSIN-    20 . . . 347    96/340 (28%)   1e−21           LIKE PROTEIN C2D10.14C IN   615 . . . 903   152/340 (44%)           CHROMOSOME II-             Schizosaccharomyces pombe             (Fission yeast), 1471 aa.       T30148   hypothetical protein E02C12.1-    5 . . . 249    74/248 (29%)   6e−21             Caenorhabditis elegans , 1019 aa.   619 . . . 830   119/248 (47%)                  
 
     [0596] PFam analysis predicts that the NOV51a protein contains the domains shown in the Table 51E.  
               TABLE 51E                          Domain Analysis of NOV51a                                     Identities/           Pfam   NOV51a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               myosin_head: domain 1   26 . . . 105   37/81 (46%)   5.1e−25       of 1       60/81 (74%)                  
 
     Example 52  
     [0597] The NOV52 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 52A.  
               TABLE 52A                       NOV52 Sequence Analysis                                                SEQ ID NO:157   1380 bp                     NOV52a,     TAGAATTCCAGCGGCCGCTGAAATCCTCACTCGGTCAGTTCCTCGGGCGAGTTACGGG         CG59564-01 DNA Sequence             GACGACCTGCGGGAGCACGCGGGCAGTGGCCGGACGCTGAAGCCCAGGAGAGCG   ATG G                   AGACGTATGCGGAGGTTGGGAAGGAGGGCAAGCCTTCCTGTGCATCGGTGGATCTGCA                   GGGAGACAGCTCCTTACAGGTGGAGATTTCTCACGCAGTGAGTGAGCGGGACAAGGTG                   AAATTCACTGTTCAAACAAAGAGCTGCCTCCCTCACTTCGCCCAGACCGAGTTCTCAG                   TCGTGCGGCAGCACGAGGAGTTCATCTGGCTGCATGATGCCTACGTGGAGAATGAGGA                   GTACGCCGGCCTCATCATCCCCCCAGCCCCTCCGAGCCCAGACTTTGAGGCTTCGAGG                   GAAAAGCTACAGAAATTGGGCGAGGGGGACAGCTCTGTCACTCGGGAAGAGTTTGCCA                   AGATGAAGCAGGAGCTGGAAGCGGAGTACCTGGCCATCTTTAAGAAGACAGTTGCGAT                   GCACGAAGTCTTTCTGCAGCGCCTGGCGGCCCACCCCACCCTGCGTCGAGACCACAAC                   TTCTTTGTGTTTTTGCAATATGGACAGGATCTCAGTGTCCGGGGGAAGAACAGGAAGG                   AGCTCCTCGGAGGGTTTCTGAGGAATATTGTGAAGTCCGCGGATGAAGCCCTCATCAC                   GGGCATGTCAGGGCTCAAGGAGGTGGATGACTTCTTTGAGCATGAGAGGACCTTCCTG                   TTGGAGTATCACACCCGTATCCGAGATGCCTGCCTCCGGGCCGACCGCGTCATGCGCG                   CCCACAAGTGCCTGGCAGACGATTATATCCCTATCTCAGCTGCGCTGAGCAGTCTGGG                   AACACAGGAAGTCAACCAGCTAAGGACGAGCTTCCTCAAATTGGCACAGCTCTTTGAC                   CGGCTGAGGAAGCTGGAGGGCCGGGTGGCTTCCGATGAGGACCTGAAGCTGTCAGACA                   TGCTGAGGTACTACATGCGTGACTCACAGGCAGCCAAGGACCTGCTGTACCGGCGGCT                   GCGGGCACTGGCCGACTACGACAATGCCAACAAGGCGCTGCACAAGCCGCGCACCAGG                   AACCGGGAGGTGCGGCCCGCCGAGAGCCACCAGCAGCTGTGCTGCCAACGCTTCGAGC                   GCCTCTCCGACTCCGCCAAGCAAGAGCTCATGGACTTCAAGTCCCGCCGGGTCTCCTC                   TTTTCGAAAGAATCTCATTGAGCTGGCAGAGCTCGAGCTCAAACACGCCAAGGCCAGC                   ACCCTGATTCTCCGGAACACCCTTGTTGCCCTAAAGGGGGAGCCT TAG   AGTAGCCAGA                       GCTCAGCCAGACCCTAATCTGGGATCTCCAGTCACCAGGGTATCCC                                           ORF Start: ATG at 113       ORF Stop: TAG at 1322           SEQ ID NO:158   403 aa   MW at 46384.2 kD                     NOV52a,   METYAEVGKEGKPSCASVDLQGDSSLQVEISDAVSERDKVKFTVQTKSCLPHFAQTEF       CG59564-01 Protein Sequence           SVVRQHEEFIWLHDAYVENEEYAGLIIPPAPPRPDFEASREKLQKLGEGDSSVTREEF                   AKMKQELEAEYLAIFKKTVAMHEVFLQRLAAHPTLRRDHNFFVFLEYGQDLSVRGKNR                   KELLGGFLRNIVKSADEALITGMSGLKEVDDFFFHERTFLLEYHTRTRDACLRADRVN                   RAHKCLADDYIPISAALSSLGTQEVNQLRTSFLKLAELFDRLRKLEGRVASDEDLKLS                   DMLRYYMRDSQAAKDLLYRRLRALADYENANKALDKARTRNREVRPAESEQQLCCQRF                   ERLSDSAKQELMDFKSRRVSSFRKNLIELAELELKHAKASTLILRNTLVALKGEP                  
 
     [0598] Further analysis of the NOV52a protein yielded the following properties shown in Table 52B.  
               TABLE 52B                       Protein Sequence Properties NOV52a                                        PSort   0.6500 probability located in cytoplasm; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0599] A search of the NOV52a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 52C.  
               TABLE 52C                          Geneseq Results for NOV52a                                         NOV52a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAY94209   Human TRAF four associated factor   17 . . . 402   273/386 (70%)    e−160           TFAF2- Homo sapiens , 406 aa.   23 . . . 405   333/386 (85%)           [CA2245340-A1, 19 FEB. 2000]       AAB07856   Amino acid sequence of Smad1   17 . . . 402   273/386 (70%)   1e−160           interactor protein clone S1 + 12-2-   31 . . . 413   333/386 (85%)             Homo sapiens , 414 aa.           [WO200047102-A2, 17 AUG. 2000]       AAB43157   Human ORFX ORF2921   17 . . . 402   273/386 (70%)    e−160           polypeptide sequence SEQ ID   77 . . . 459   333/386 (85%)           NO: 5842- Homo sapiens , 460 aa.           [WO200058473-A2, 5 OCT. 2000]       AAB58368   Lung cancer associated polypeptide   17 . . . 402   273/386 (70%)    e−160           sequence SEQ ID 706- Homo               sapiens , 414 aa. [WO200055180-           A2, 21 SEP. 2000]       AA013507   Human polypeptide SEQ ID NO-   17 . . . 400   242/384 (63%)    e−144           27399- Homo sapiens , 443 aa.   61 . . . 441   317/384 (82%)           [WO200164835-A2, 7 SEP. 2001]                  
 
     [0600] In a BLAST search of public sequence databases, the NOV52a protein was found to have homology to the proteins shown in the BLASTP data in Table 52D.  
               TABLE 52D                          Public BLASTP Results for NOV52a                                         NOV52a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9UNH7   Sorting nexin 6 (TRAF4-associated   17 . . . 402   273/386 (70%)   e−159           factor 2)- Homo sapiens  (Human),   23 . . . 405   333/386 (85%)           406 aa.       Q9CZ03   2810425K19RIK PROTEIN- Mus     17 . . . 402   271/386 (70%)   e−159             musculus  (Mouse), 406 aa.   23 . . . 405   333/386 (86%)       Q9Y5X3   Sorting nexin 5- Homo sapiens     17 . . . 400   242/384 (63%)   e−143           (Human), 404 aa.   22 . . . 402   317/384 (82%)       Q9D8U8   Sorting nexin 5- Mus musculus     17 . . . 400   241/384 (62%)   e−142           (Mouse), 404 aa.   22 . . . 402   314/384 (81%)       Q96NG4   CDNA FLJ30934 FIS, CLONE    1 . . . 237   236/237 (99%)   e−134           FEBRA2007017, MODERATELY    1 . . . 237   236/237 (99%)           SIMILAR TO  HOMO SAPIENS             TRAF4-ASSOCIATED FACTOR 2           MRNA- Homo sapiens  (Human),           277 aa.                  
 
     [0601] PFam analysis predicts that the NOV52a protein contains the domains shown in the Table 52E.  
               TABLE 52E                          Domain Analysis of NOV52a                                     Identities/           Pfam   NOV52a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               PX: domain 1 of 1   23 . . . 164    39/160 (24%)   1.6e−15               103/160 (64%)                  
 
     Example 53  
     [0602] The NOV53 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 53A.  
               TABLE 53A                       NOV53 Sequence Analysis                                                SEQ ID NO:159   3056 bp                     NOV53a,     CTCCTGCGGGGTCAAATACAGAATTTACGCACCCTTCGCTTCCTTGGAGCCTAGCGGC         CG59553-01 DNA Sequence             TCTCCCCGCGTCCAAG   ATG GCGGCAGAAGCAGCTGGTGGGAAATACAGAAGCACAGTC                   AGCAAAAGCAAAGACCCCTCGGCGCTGCTCATCTCTCTGATCAGGACTCTGTCTACTA                   GTGACGATGTCGAAGACAGGGAAAATGAAAAGGGTCGCCTTGAAGAAGCCTACGAGAA                   ATGTGACCGTGACCTGGATGAATTGATTGTACAGCACTACACAGAATTGACGACAGCC                   ATTCGCACATACCAGAGCATCACAGAGCGCATCACTAACTCCCGAAATAAAATAAAGC                   AGGTAAAAGAGAACCTGCTTTCATGCAAGATCCTGCTGCACTGCAAACCGGATGAGCT                   TCGGAAACTGTGCATTGAAGGAATTGAGCATAAGCATGTCCTGAACTTGTTGGATGAA                   ATTGAGAATATCAAGCAAGTGCCTCAAAAGCTGGAACAGTGCATGGCCAGCAAGCACT                   ATCTCAGTGCCACTGACATGTTGGTGTCAGCAGTTGAGTCTTTGGAGGGCCCCCTGCT                   CCACGTCGAAGGACTCAGTGACCTTCGACTACAGCTTCACAGCAAGAAGATGAACCTT                   CACTTGGTTCTCATAGATGAACTACACCGGCACCTGTACATCAAATCGACTAGCCGAG                   TTGTGCAGCGTAACAAGGAAAAAGGGAAAATCAGCTCCCTCGTGAAACATCCTTCTGT                   TCCTCTGATTGATGTTACAAACCTCCCTACTCCTCGAAAATTCCTTGATACCTCTCAC                   TATTCTACTGCTGGAAGCTCAAGTGTGAGGGAGATAAATCTGCAGGACATCAAGGAAG                   ATTTAGAATTGGATCCAGAGGAAAACAGCACCCTGTTTATGGGTATCCTCATTAAGGG                   CTTGGCGAAACTGAAGAAGATCCCAGAAACAGTTAAGGCAATCATAGAGCGCTTGGAG                   CAGGAGTTGAAGCAAATTCTGAAGAGGTCTACAACCCACGTGCCAGACAGTGGCTATC                   AGCGGCGGGAGAACGTTACTGTGGAGAACCAACCAAGGTTGCTTCTAGAACTGCTGGA                   GTTACTGTTTGACAAGTTTAATGCTGTAGCCGCTGCACACTCTGTGGTCCTGGGATAC                   CTGCAGGACACTGTAGTGACTCCACTGACTCAGCAGGAAGATATCAAACTGTATGATA                   TGGCAGATGTATCGGTCAAGATCCAAGATGTTCTACAGATGCTATTAACTCAGTACTT                   GGATATGAAAAATACTCGTACGGCCTCTGAACCATCAGCTCAACTAAGCTATGCCAGC                   ACTGGACGAGAGTTTGCACCCTTTTTTGCCAAGAACAAACCTCAAACGCCAAAAAATT                   CTCTTTTCAAGTTCGAATCGTCCTCCCATGCCATCAGTATGAGCGCCTATCTGCGAGA                   ACAGAGAAGGGAGCTCTATAGTCGGAGTGGACAACTCCAAGGCGGTCCTCATGACAAC                   TTAATTGAAGGTGGAGGAACAAAATTTGTCTGCAAACCTGGAGCCAGAAACATTACCG                   TCATATTCCACCCATTACTAAGATTTATTCAGGAGATTGAGCATGCTCTGCGTCTTGG                   CCCAGCCAAACAGTGTCCTGTTCGAGAGTTTCTCACCGTGTACATCAAAAACATCTTT                   CTCAATCAAGTCTTGCCTGAGATCAACAAGCAGATTGAACGAGTCACTAAAACATCTG                   ACCCTTTGAAGATTCTCGCCAACGCACACACCATGAAGGTGCTGGCACTGCAGCGGCC                   TCTCCTACAGAGCACAATCATTGTGGAGAAGACAGTTCAAGACCTCCTGAACCTGATG                   CATGACTTGAGTGCATATTCAGATCAATTCCTCAACATGGTGTGCGTGAAGCTCCAGG                   AGTACAAGGACACCTGCACTGCAGCTTACAGGGGTATTGTCCAGTCAGAAOAAAAACT                   TGTCATCACTCCATCCTGGGCAAAAGATGATGATATCAGCAGACTCTTGAAATCTCTA                   CCAAACTGGATGAATATGGCTCAACCCAAACAGCTGAGGCCAAAAAGAGAGGAGGAAG                   AAGATTTCATAAGGGCAGCTTTTGGCAAGGAGTCTGAAGTTCTTATTGGGAACCTGGG                   TGATAAATTAATCCCTCCACAAGACATCCTTCCTGACCTCAGTGACCTCAAAGCCTTG                   GCCAACATGCATGAAAGCCTGGAATGCTTGGCAACTCGAACAAAGTCAGCTTTCTCCA                   ATCTTTCTACATCCCAGATGCTTTCTCCTGCTCAAGACAGCCACACGAACACGGATCT                   CCCCCCAGTGTCAGAGCAGATCATGCAGACTCTCAGTGAACTTGCCAAATCGTTCCAG                   GATATGGCTGACCGCTGCTTGCTTGTCTTACATCTCGAAGTGACGGTTCACTGTTTCC                   ACTATCTTATCCCTCTTGCAAAGGAGGGGAACTATGCCATTGTGGCTAATGTGGAAAG                   TATGGATTATGACCCCCTGGTGGTCAAGGTCAACAAAGATATCAGCGCCATTGAAGAG                   GCCATGAGCGCCAGCCTTCAGCAGCACAAGTTCCAGTATATCTTCGAAGGCCTGGGCC                   ACCTGATCTCCTGCATCCTCATTAATGGTGCCCAGTACTTCAGGCGCATCAGTGAGTC                   TGGCATCAAGAAAATGTGTAGGAACATTTTTGTTCTTCAGCAGAATTTGACCAACATC                   ACCATGTCGCCGGAGGCAGACCTGGACTTTGCAAGGCAGTACTACGAGATGCTTTACA                   ACACAGCTGACGAGCTCCTGAACCTGGTGGTGGACCAGGGTGTGAAGTACACGGAGCT                   GGAGTACATCCACGCTCTGACCCTGCTGCACCGCAGCCAGACTGGGGTGGGGGAACTG                   ACCACCCAGAACACGAGCTGCAGAGGAGGCTCAAAGAGATCATCTGCGAGCAGGCTGC                   CATCAAGCAAGCCACCAAGGACAAGAAGA TAA   CTACCGTTTAGCAGGGCGTACTGCGG                       TTGGTGACGGGGGTCCCCTCAGTCACACTCACTTTTTTCC                                           ORF Start: ATG at 75       ORF Stop: TAA at 2988           SEQ ID NO:160   971 aa   MW at 109984.9 kD                     NOV53a,   MAAEAAGGKYRSTVSKSKDPSGLLISVIRTLSTSDDVEDRENEKGRLEEAYEKCDRDL       CG59553-01 Protein Sequence           DELIVQHYTELTTAIRTYQSITERITNSRNKIKQVKENLLSCKMLLHCKRDELRKLWI                   EGIEHKHVLNLLDEIENIKQVPQKLEQCMASKHYLSATDMLVSAVESLEGPLLQVEGL                   SDLRLELHSKKMNLHLVLIDELRRMLYIKSTSRVVQRNKEKGKISSLVRDASVPLIDV                   TNLPTPRKFLDTSHYSTAGSSSVREINLQDIKEDLELDPEENSTLFMGILIKGLAKLK                   KIPETVKAITERLEQELKQIVKRSTTQVADSGYQRGENVTVENQPRLLLELLELLFDK                   FNAVAAAHSVVLGYLQDTVVTPLTQQEDIKLYDMADVWVKIQDVLQMLLTEYLDMKNT                   RTASEPSAQLSYASTGREFAAFFAKKKPQRPKNSLFKEESSSHAISMSAYLREQRREL                   YSRSGELQCCPDDNLTECCGTKFVCKPGAPNTTVTFHPLLRFIQETEHALGLCPAKQC                   PLREFLTVYIKNIFLNQVLAEINKEIEGVTKTSDPLKILANADTMKVLGVQRPLLQST                   IIVEKTVQDLLNLMHDLSAYSDQFLNMVCVKLQEYKDTCTAAYRGIVQSEEKLVISAS                   WAKDDDISRLLKSLPNWMNMAQPKQLRPKREEEEDFIRAAFGKESEVLIGNLGDKLIP                   PQDILRDVSDLKALANMHESLEWLASRTKSAFSNLSTSQMLSPAQDSHTNTDLPPVSE                   QIMQTLSELAFSFQDMADRCLLVLHLEVRVHCFHYLIPLAKEGNYAIVANVESMDYDP                   LVVKLNKDISAIEEAMSASLQQHKFQYIFEGLGHLISCILINGAQYFRRISESGIKKM                   CRNIFVLQQNLTNITMSREADLDFARQYYEMLYNTADELLNLVVDQGVKYTELEYIHA                   LTLLHRSQTGVCELTTQNTSCRCGSKRSSASRLPSSKPPRTRR                  
 
     [0603] Further analysis of the NOV53a protein yielded the following properties shown in Table 53B.  
               TABLE 53B                       Protein Sequence Properties NOV53a                                        PSort   0.5500 probability located in endoplasmic reticulum       analysis:   (membrane); 0.1900 probability located in lysosome           (lumen); 0.1000 probability located in endoplasmic           reticulum (lumen); 0.1000 probability located in outside       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0604] A search of the NOV53a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 53C.  
               TABLE 53C                          Geneseq Results for NOV53a                                         NOV53a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAB93175   Human protein sequence SEQ ID    1 . . . 947   947/947 (100%)   0.0           NO: 12114- Homo sapiens  ,974 aa.    1 . . . 947   947/947 (100%)           [EP1074617-A2, 7 FEB. 2001]       AAW69801   Amino acid sequence of rsec8, a    1 . . . 947   902/948 (95%)   0.0           protein present in SA-17S    1 . . . 948   925/948 (97%)           complex-Rattus sp, 975 aa.           [WO9828419-A2, 2 JUL. 1998]       AAB95143   Human protein sequence SEQ ID   403 . . . 947   545/545 (100%)   0.0           NO: 17163- Homo sapiens , 572 aa.    1 . . . 545   545/545 (100%)           [EP1074617-A2, 7 FEB. 2001]       AAB58175   Lung cancer associated   571 . . . 947   369/377 (97%)   0.0           polypeptide sequence SEQ ID 513-    15 . . . 391   369/377 (97%)             Homo sapiens , 418 aa.           [WO200055180-A2,           21 SEP. 2000]       AAG00950   Human secreted protein, SEQ ID   451 . . . 544    76/94 (80%)   3e−36           NO: 5031- Homo sapiens , 100 aa.    7 . . . 100    79/94 (83%)           [EP1033401-A2, 6 SEP. 2000]                  
 
     [0605] In a BLAST search of public sequence databases, the NOV53a protein was found to have homology to the proteins shown in the BLASTP data in Table 53D.  
               TABLE 53D                          Public BLASTP Results for NOV53a                                         NOV53a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96A65   CDNA FLJ14782 FIS, CLONE    1 . . . 947   947/947 (100%)   0.0           NT2RP4000524, HIGHLY    1 . . . 947   947/947 (100%)           SIMILAR TO  MUS MUSCULUS             SEC8 MRNA (SECRETORY           PROTEIN SEC8)- Homo sapiens             (Human), 974 aa.       Q9C0G4   KIAA1699 PROTEIN- Homo      9 . . . 947   939/939 (100%)   0.0             sapiens  (Human), 966 aa    1 . . . 939   939/939 (100%)           (fragment).       O35382   SEC8- Mus musculus  (Mouse), 971    1 . . . 971   923/972 (94%)   0.0           aa.    1 . . . 971   946/972 (96%)       Q62824   RSEC8- Rattus norvegicus  (Rat),    1 . . . 947   902/948 (95%)   0.0           975 aa (fragment).    1 . . . 948   925/948 (97%)       Q9P102   REC8- Homo sapiens  (Human),   339 . . . 947   609/609 (100%)   0.0           637 aa (fragment).    2 . . . 610   609/609 (100%)                  
 
     [0606] PFam analysis predicts that the NOV53a protein contains the domains shown in the Table 53E.  
               TABLE 53E                          Domain Analysis of NOV53a                                             Identities/               Pfam   NOV53a   Similarities for   Expect           Domain   Match Region   the Matched Region   Value                             No Significant Matches Found                  
 
     Example 54  
     [0607] The NOV54 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 54A.  
               TABLE 54A                       NOV54 Sequence Analysis                                                SEQ ID NO:141   877 bp                     NOV54a,     CAACACGAGGAACA   ATG TCTTCTTTACCCGTGCCATACAAACTGCCTGTGTCTTTGTC       CG59545-01 DNA Sequence           TGTTGGTTCCTGCGTGATAATCAAACCOACACTGATCGACTCTTCTATCAACGAACCA                   CAGCTGCAGGTGGATTTCTACACTGAGATGAATGAGGACTCAGAAATTGCCTTCCATT                   TGCGAGTGCACTTAGGCCGTCGTGTGGTCATGAACAGTCGTGAGTTTGGGATATGGAT                   GTTGGAGGAGAATTTACACTATGTCCCCTTTGAGGATGGCAAACCATTTCACTTGCGC                   ATCTACGTGTGTCTCAATGAGTATGACGTAAAGGTAAATGGTGAATACATTTATGCCT                   TTGTCCATCGAATCCCGCCATCATATGTGAAGATGATTCAAGTCTGGAGAGATCTCTC                   CCTGGACTCAGTGCTTGTCAACAATGGACGGAGA TGA   TCACACTCCTCATTGTTGAGG                       AAACCCTCTTTCTACCTCACCATCGGATTCCTAGAGC                                           ORF Start: ATG at 15       ORF Stop: TGA at 441           SEQ ID NO:162   142 aa   MW at 16511.9 kD                     NOV54a,   MSSLPVPYKLPVSLSVGSCVIIKGTLIDSSINEPQLQVDFYTEMNEDSEIAFHLRVIL       CG59545-01 Protein Sequence           GRRVVMNSREFGIWMLEENLHYVPFEDGKPFDLRIYVCLNEYEVKVNGEYIYAFVHRI                   PPSYVKMTQVWRDVSLDSVLVNNGRR                  
 
     [0608] Further analysis of the NOV54a protein yielded the following properties shown in Table 54B.  
               TABLE 54B                       Protein Sequence Properties NOV54a                                                PSort   0.5500 probability located in endoplasmic reticulum           analysis:   (membrane); 0.1900 probability located in lysosome               (lumen); 0.1000 probability located in endoplasmic               reticulum (lumen); 0.1000 probability located               in outside           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0609] A search of the NOV54a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 54C.  
               TABLE 54C                          Geneseq Results for NOV54a                                         NOV54a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG66741   Human Charcot-Leyden crystal   1 . . . 142   139/142 (97%)   2e−77           protein 5A (CLC5A) -  Homo     1 . . . 142   139/142 (97%)             sapiens , 142 aa. [CN1302875-A,           11 JUL 2001]       AAG66742   Human Charcot-Leyden crystal   6 . . . 142   136/137 (99%)   3e−76           protein 5B (CLC5B) -  Homo     34 . . . 170    136/137 (99%)             sapiens , 170 aa. [CN1302875-A,           11 JUL 2001]       AAM79041   Human protein SEQ ID NO 1703 -   1 . . . 139   107/139 (76%)   2e−56             Homo sapiens , 139 aa.   1 . . . 139   116/139 (82%)           [WO200157190-A2, 09 AUG           2001]       AAY28350   Full Placental Protein 13 amino   1 . . . 139   107/139 (76%)   2e−56           acid sequence -  Homo sapiens , 139   1 . . . 139   116/139 (82%)           aa. [WO9938970-A1, 5 AUG            1999]       AAG78627   Human Charcot-Leyden crystal 4   6 . . . 139   102/134 (76%)   2e−53           CLC4 protein #2 -  Homo sapiens ,   34 . . . 167    111/134 (82%)           167 aa. [CN1302876-A, 11 JUL            2001]                  
 
     [0610] In a BLAST search of public sequence databases, the NOV54a protein was found to have homology to the proteins shown in the BLASTP data in Table 54D.  
               TABLE 54D                          Public BLASTP Results for NOV54a                                         NOV54a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                             Q9UHV8   PLACENTAL PROTEIN 13   1 . . . 139   107/139   (76%)   9e−56           (PLACENTA PROTEIN 13) -  Homo     1 . . . 139   116/139   (82%)             sapiens  (Human), 139 aa.       Q9NR03   PLACENTAL PROTEIN 13-LIKE   1 . . . 139   86/139   (61%)   9e−45           PROTEIN -  Homo sapiens  (Human),   1 . . . 139   107/139   (76%)           139 aa.       A46523   Charcot-Leyden crystal protein -   1 . . . 142   76/142   (53%)   7e−36           human, 142 aa.   1 . . . 142   96/142   (67%)       Q05315   Eosinophil lysophospholipase (EC   2 . . . 142   75/141   (53%)   3e−35           3.1.1.5) (Charcot-Leyden crystal   1 . . . 141   95/141   (67%)           protein) (Lysolecithin acylhydrolase)           (CLC) (Galactin-10) -  Homo sapiens             (Human), 141 aa.       Q96KD6   PLACENTAL PROTEIN 13-LIKE -   1 . . . 104   66/104   (63%)   1e−31             Homo sapiens , (Human), 104 aa   1 . . . 104   79/104   (75%)           (fragment).                  
 
     [0611] PFam analysis predicts that the NOV54a protein contains the domains shown in the Table 54E.  
               TABLE 54E                          Domain Analysis of NOV54a                                     Identities/                   Similarities           NOV54a Match   for the Matched   Expect       Pfam Domain   Region   Region   Value                                         Gal-bind_lectin:   5 . . . 137   37/142   (26%)   3.1e−28       domain 1 of 1       106/142   (75%)                  
 
     Example 55  
     [0612] The NOV55 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 55A.  
               TABLE 55A                       NOV55 Sequence Analysis                                                SEQ ID NO:163   2071 bp                     NOV55a,     AAACTATTTTTAGGCGCACTC   ATG CAGGAAAACCTCAGATTTCCTTCATCAGGAGATG       CG59435-01 DNA Sequence           ATATTAAAATATGGGATGCTTCATCTATCACATTGGTGGATAAATTCAACCCACACAC                   ATCACCACATGGAATCAGCTCAATATGTTCGA~CAGCAATAGTAACTTTTTAGTAACA                   GCATCTTCCAGTGGCGACAAAATAGTTGTCTCAAGTTGCAAATGTAAACCTGTTCCAC                   TTTTAGAGCTTGCTGAAGGGCAAAACCAGACATGTGTCAATTTAAATTCTACATCTAT                   GTATTTGGTAAGCGGAGGCCTAAATAACACTGTTAATATTTGGGATTTAAAATCAAAA                   AGAGTTCATCGATCTCTTAAGGATCATAAAGATCAAGTAACTTGTGTAACATACAATT                   GGAATCATTGCTACATTGCTTCTGGATCTCTTAGTGGTGAAATTATTTTACACAGTGT                   AACCACTAATTTATCTAGTACTCCTTTTGGCCATGGTAGTAACCAGGTTCGGCACTTG                   AAGTACTCCTTGTTTAAGAAATCACTACTGGGCAGTGTTTCGGATAATGGAATAGTAA                   CTCTCTGGGATGTAAATAGTCAGAGTCCATACCATAACTTTGACAGTGTACACAAAGC                   TCCAGCGTCAGGCATCTGTTTTTCTCCTGTCAATGAATTGCTCTTTGTAACCATAGGC                   TTGGATAAAAGAATCATCCTCTAmGACACTTCAAGTAAGAAGCTAGTGAAAACTTTAG                   TGGCTGACACTCCTCTAACTGCGGTAGATTTCATGCCTGATGCAGCCACTTTGGCTAT                   TGGATCTTCCCGGGGGAAAATATATCAATATGATTTAAGAATGTTGAAATCACCAGTT                   AAGACCATCAGTCCTCACAAGACATCTGTGCAGTGTATAGCATTTCAGTACTCCACTG                   TTCTTACTAAGTCAAGTTTAAATAAAGCCTCTTCAAATAACCCCACAACAGTGAACAA                   ACGAAGTGTTAATGTGAATGCTGCTAGTGGAGGAGTTCAGAATTCCGGAATTGTCAGA                   GAAGCACCTGCCACGTCCATTGCCACAGTTCTACCACAACCTATGACATCAGCTATGG                   GGAAAGGAACAGTTGCTGTTCAAGAAAAAGCAGGTTTGCCTCGAAGCATAAACACAGA                   CACTTTATCTAAGGAAACAGACAGTGCAAAAAATCAGGATTTCTCCAGCTTTGATGAT                   ACTGGGAAAAGTAGTTTAGGTGACATGTTCTCACCTATCAGAGATGATGCTGTAGTTA                   ACAAGGGAAGTGATGAGTCCATAGGCAAAGGAGATGGCTTTGACTTTCTACCGCAGTT                   GAACTCAGTGTTTCCTCCAACAAAAAATCCAGTAACTTCAAGTACTTCAGTATTGCAT                   TCTAGTCCTCTTAATGTTTTTATGGGATCTCCAGGGAAAGAGGAAAATCAAAACCGTG                   ATCTAACAGCTGAGTCTAAGAAAATATATATCGGAAAACACGAATCTAAACACTCCTT                   CAAACACTTAGCAAAGTTGGTCACATCTGGTGCTCAAAGTGGAAATCTAAATACCTCT                   CCATCATCTAACCAAACAAGAAATTCTGAGAAATTTGAAAAGCCAGAGAATGAAATTG                   AAGCCCAGTTGATATGTGAACCCCCAATCAATCGATCCTCAACTCCAAATCCAAAGAT                   AGCATCTTCTGTCACTGCTGGAGTTGCCAGTTCACTCTCAGAAAAAATAGCCGACAGC                   ATTCCAAATAACCGGCAAAATGCACCATTGACTTCCATTCAAATTCGTTTTATTCAGA                   ACATCATACAGGAAACGTTGGATGACTTTACAGAAGCATGCCATAGCGACATTGTGAA                   TTTGCAAGTGGAGATGATTAAACAGTTTCATATGCAACTCAATGAAATGCATTCTTTG                   CTGGAAAGATACTCAGTGAATGAAGGTTTAGTGGCTGAAATTGAAAGACTACGAGAAG                   AAAACAAAACATTACGGGCCCACTTT TGA   AATTTCAGTGAATACCTTAATGTTCTGTA                       ATTTGGGAAGTTTCTGGCAACACAGAACTACATAGAATCAT                                           ORF Start: ATG at 22       ORF Stop: TGA at 1999           SEQ ID NO:164   659 aa   MW at 71851.2 kD                     NOV55a,   MQENLRFASSGDDIKTWDASSMTLVDKFNPETSPHGTSSTCWSSNSNFLVTASSSGDK       CG59535-01 Protein Sequence           IVVSSCKCKPVPLLELAEGQKQTCVNLNSTSMYLVSGCLNNTvNTwDLKSKRVERSLK                   DHKDQVTCVTYNWNDCYIASGSLSGEITLHSVTTNLSSTFFGHGSNQVRHLKYSLFKK                   SLLGSVSDNGIVTLWDVNSQSPYHNFDSVHKAPASGICFSPVNELLFVTTGLDKRIIL                   YDTSSKKLVKTLVADTPLTAVDFMPDGATLAIGSSRGKIYQYDLRMLKSPVKTISAHK                   TSVQCIAFQYSTVLTKSSLNKGCSNKPTTVNKRSVNVNAASGGVQNSCIVREAPATSI                   ATVLPQPMTSAMGKGTVAVQEKAGLPRSINTDTLSKETDSGKNQDFSSFDDTGKSSLG                   DMFSPIRDDAVVNKGSDESIGKGDGFDFLPQLNSVFPPRKNPVTSSTSVLHSSPLNVF                   MGSPGKEENENRDLTAESKKIYMGKQESKDSFKQLAKLVTSGAESGNLNTSPSSNQTR                   NSEKFEKPENEIEAQLICEPPINGSSTPNPKIASSVTAGVASSLSEKIADSIGNNRQN                   APLTSIQIRFIQNMIQETLDDFREACHRDIVNLQVEMIKQFHMQLNEMISLLERYSVN                   EGLVAEIERLREENKRLRAHF                                     SEQ ID NO:165   2009 bp                     NOV55b,     AAACTATTTGTAGGCGCAGTC   ATG CAGGAAAACCTCAGATTTGCTTCATCAGGAGATG       CG59435-02 DNA Sequence           ATATTAAAATATGGGATGCTTCATCTATGACATTGGTGGATAAATTCAACCCACACAC                   ATCACCACATGGAATCACCTCAATATGTTGGACCAGCAATAATAACTTTTTAGTAACA                   GCATCTTCCAGTGGCGACAAAATAGTTGTCTCAAGTTGCAAATGTAAACCTGTTCCAC                   TTTTAGAGCTTGCTGAAGGGCAAAAGCAGACATGTGTCAATTTAAATTCTACATCTAT                   GTATTTGGTAAGCGGAGGCCTAAATAACACTGTTAATATTTGCGATTTAAAATCAAAA                   AGAGTTCATCGATCTCTTAACGATCATAAAGATCAACTAACTTGTGTAACATACAATT                   GGAATGATTCCTACATTGCTTCTGGATCTCTTAGTGGTCAAATTATTTTACACAGTGT                   AACCACTAATTTATCTAGTACTCCTTTTGGCCATGGTAGTAACCAGTCTGTTCGGCAC                   TTGAAGTACTCCTTGTTTAAGAAATCACTACTGGGCAGTGTTTCGGATAATGGAATAG                   TAACTCTCTGGGATGTAAATAGTCAGAGTCCATACCATAACTTTGACAGTCTACACAA                   AGCTCCAGCGTCAGGCATCTGTTTTTCTCCTGTCAATGAATTGCTCTTTGTAACCATA                   GCCTTGGATAAAAGAATCATCCTCTATGACACTTCAAGTAAGAAGCTAGTGAAAACTT                   TAGTGGCTGACACTCCTCTAACTGCGGTAGATTTCATGCCTGATGGAGCCACTTTGGC                   TATTGGATCTTCCCGGGGGAAAATATATCAATATGATTTAAGAATGTTGAAATCACCA                   GTTAAGACCATCAGTGCTCACAAGACATCTGTGCAGTGTATAGCATTTCAGTACTCCA                   CTGTTCTTACTAAGTCAAGTTTAAATAAAOGCTCTTCAAATAAGCCCACAACAGTGAA                   CAAACGAAGTGTTAATCTGAATGCTGCTAGTGGAGGAGTTCAGAATTCCGGAATTGTC                   AGAGAAGCACCTGCCACGTCCATTGCCACAGTTCTACCACAACCTATGACATCAGCTA                   TGGGGAAACGAACACTTGCTGTTCAAGAAAAAGCAGGTTTGCCTCGAACCATAAACAC                   AGACACTTTATCTAAGGAAACAGACAGTGGAAAAAATCAGGATTTCTCCAGCTTTGAT                   GATACTGGGAAAAGTAGTTTAGGTGACATGTTCTCACCTATCAGAGATGATGCTGTAG                   TTAACAAGGGAAGTGATGAGTCCATAGGCAAAGGAGATGGCTTTGACTTTCTACCGCA                   GTTGAACTCAGTGTTTCCTCCAAGAAAAAATCCAGTAACTTCAAGTACTTCAGTATTG                   CATTCTAGTCCTCTTAATCTTTTTATGGCATCTCCAGGGAAAGAGGAAAATGAAAACC                   GTGATCTAACAGCTGAGTCTAACAAAATATATATGGGAAAACAGGAATCTAAAGACTC                   CTTCAAACAGTTAGCAAAGTTGGTCACATCTGGTGCTGAAAGTGGAAATCTAAATACC                   TCTCCATCATCTAACCAAACAAGAAATTCTGAGAAATTTGAAAAGCCAGAGAATGAAA                   TTGAAGCCCAGTTGATATGTGAACCCCCAATCAATGGATCCTCAACTCCAAATCCAAA                   GATAGCATCTTCTGTCACTGCTGGAGTTGCCAGTTCACTCTCAGAAAAAATAGCCGAC                   AGCATTGGAAATAACCGGCAAAATGCACCATTGACTTCCATTCAAATTCGTTTTATTC                   AGAACATGATACAGGAAACGTTGCATCACTTTAGAGAAGCATGCCATAGGGACATTGT                   GAATTTGCAAGTGGAGATGATTAAACAGTTTCATATGCAACTGAATGAAATGCATTCT                   TTGCTCGAAAGATACTCAGTGAATGAAGGTTTAGTGGCTGAAATTGAAAGACTACGAG                   AAGAAAACAAAAGATTACGGGCCCACTTT TGA   AATTT                                           ORF Start: ATG at 22       ORF Stop: TGA at 2002           SEQ ID NO:166   600 aa   MW at 71965.3 kD                     NOV55b,   MQENLRFASSGDDIKIWDASSMTLVDKFNPHTSPHGISSICWSSNNNFLVTASSSGDK       CG59435-02 Protein Sequence           IVVSSCKCKPVPLLELAEGQKQTCVNLNSTSMYLVSGGLNNTVNIWDLKSKRVHRSLK                   DHKDQVTCVTYNWNDCYIASGSLSGEIILHSVTTNLSSTPFGHGSNQSVRHLKYSLFK                   KSLLGSVSDNGIVTLWDVNSQSPYHNFDSVHKAPASGICFSPVNELLFVTICLDKRII                   LYDTSSKKLVKTLVADTPLTAVDFMPDGATLAIGSSRGKIYQYDLRMIASPVKTISAH                   KTSVQCIAFQYSTVLTKSSLNXGCSNKPTTVNKRSVNVNAASGGVQNSGIVREAPATS                   IATVLPQPMTSANGKGTVAVQEKAGLPRSINTDTLSKETDSGKNQDFSSFDDTGKSSL                   GDMFSPIRDDAVVNKCSDESTGKGDGFDFLPQLNSVFPPRKNPVTSSTSVLHSSPLNV                   FMGSPGKEENENRDLTAESKKTYMGKQESKDSFKQLAKLVTSGAESGNLNTSPSSNQT                   RNSEKFEKPENEIEAQLICEPPINGSSTPNPKIASSVTAGVASSLSEKIADSIGNNRQ                   NAPLTSIQIRFIQNNIQETLDDFREACHRDIVNLQVEMIKQFHMQLNEMHSLLERYSV                   NEGLVAEIERLREENRRLRAHF                  
 
     [0613] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 55B.  
               TABLE 55B                          Comparison of NOV55a against NOV55b.                                 Identities/           NOV55a Residues/   Similarities for the       Protein Sequence   Match Residues   Matched Region               NOV55b   1 . . . 659   658/660 (99%)           1 . . . 660   659/660 (99%)                  
 
     [0614] Further analysis of the NOV55a protein yielded the following properties shown in Table 55C.  
               TABLE 55C                       Protein Sequence Properties NOV55a                                                PSort   0.4500 probability located in cytoplasm; 0.3000           analysis:   probability located in microbody (peroxisome);               0.1000 probability located in mitochondrial               matrix space; 0.1000 probability located in               lysosome (lumen)           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0615] A search of the NOV55a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 55D.  
               TABLE 55D                          Geneseq Results for NOV55a                                             Identities/                   NOV55a   Similarities       Geneseq   Protein/Organism/Length   Residues/   for the   Expect       Identifier   [Patent #, Date]   Match Residues   Matched Region   Value                                             AAG74568   Human colon cancer antigen protein   256 . . . 659   399/404   (98%)   0.0           SEQ ID NO:5332 -  Homo sapiens ,    1 . . . 404   399/404   (98%)           404 aa. [WO200122920-A2, 5           APR 2001]       AAE10677   Human NEDD1-related protein -   453 . . . 611   145/159   (91%)   4e−75             Homo sapiens , 208 aa.    2 . . . 159   149/159   (93%)           [WO200172955-A2, 4 OCT 2001]       AAM70774   Human bone marrow expressed   240 . . . 306   67/67   (100%)   9e−31           probe encoded protein SEQ ID NO:    1 . . . 67   67/67   (100%)           31080 -  Homo sapiens , 67 aa.           [WO200157276-A2, 9 AUG 2001]       AAM06190   Peptide #4872 encoded by probe for   240 . . . 306   67/67   (100%)   9e−31           measuring breast gene expression -    1 . . . 67   67/67   (100%)             Homo sapiens , 67 aa.           [WO200157270-A2, 9 AUG 2001]       ABB23122   Protein #5121 encoded by probe for   307 . . . 371   65/65   (100%)   3e−29           measuring heart cell gene    1 . . . 65   65/65   (100%)           expression -  Homo sapiens , 65 aa.           [WO200157274-A2, 9 AUG 2001]                  
 
     [0616] In a BLAST search of public sequence databases, the NOV55a protein was found to have homology to the proteins shown in the BLASTP data in Table 55E.  
               TABLE 55E                          Public BLASTP Results for NOV55a                                         NOV55a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                             I60167   regulatory protein Nedd1 - mouse,   1 . . . 659   564/660   (85%)   0.0           660 aa.   1 . . . 660   607/660   (91%)       P33215   NEDD1 protein -  Mus musculus     1 . . . 659   564/660   (85%)   0.0           (Mouse), 675 aa (fragment).   16 . . . 675    607/660   (91%)       Q9CWK2   NEURAL PRECURSOR CELL   1 . . . 659   563/660   (85%)   0.0           EXPRESSED,   1 . . . 660   606/660   (91%)           DEVELOPMENTALLY DOWN-           REGULATED GENE 1 -  Mus               musculus  (Mouse), 660 aa.       Q9FI89   SIMILARITY TO REGULATORY   8 . . . 533   145/550   (26%)   4e−40           PROTEIN NEDD1 -  Arabidopsis     15 . . . 532    246/550   (44%)             thaliana  (Mouse-ear cress), 787 aa.       BAB75165   WD-40 REPEAT PROTEIN -   2 . . . 298   92/307   (29%)   2e−18           Anabaena sp. (strain PCC 7120),   916 . . . 1208    147/307   (46%)           1526 aa.                  
 
     [0617] PFam analysis predicts that the NOV55a protein contains the domains shown in the Table 55F.  
               TABLE 55F                          Domain Analysis of NOV55a                                     Identities/                   Similarities           NOV55a Match   for the Matched   Expect       Pfam Domain   Region   Region   Value                                         WD40: domain 1 of 7   28 . . . 61   6/37   (16%)   57               27/37   (73%)       WD40: domain 2 of 7    70 . . . 105   10/37   (27%)   0.062               27/37   (73%)       WD40: domain 3 of 7   111 . . . 147   9/37   (24%)   20               28/37   (76%)       WD40: domain 4 of 7   153 . . . 190   10/38   (26%)   3.4               29/38   (76%)       WD40: domain 5 of 7   197 . . . 234   7/38   (18%)   19               25/38   (66%)       WD40: domain 6 of 7   240 . . . 275   14/37   (38%)   3.1               28/37   (76%)       WD40: domain 7 of 7   282 . . . 316   8/37   (22%)   1.3e+03               26/37   (70%)                  
 
     Example 56  
     [0618] The NOV56 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 56A.  
               TABLE 56A                       NOV56 Sequence Analysis                                                SEQ ID NO:167   1771 bp                     NOV56a,     GACTGTTTCACC   ATG CAGTGGCTAATGAGGTTCCGGACCCTCTGGGGCATCCACAAAT       CG59439.01 DNA Sequence           CCTTCCACAACATCCACCCTGCCCCTTCACAGCTGCGCTCCCGGTCTTTATCAGAATT                   TGGAGCCCCAAGATGGAATGACTATGAAGTACCGGAGGAATTTAACTTTGCAAGTTAT                   GTACTGGACTACTGCGCTCAAAAGGAGAAGGACGGCAACAGAGGTCCAAATCCAGCTT                   TTTCGTGGGTGAATGGCCAAGGGGATGAAGTAAAGTGGAGCTTCAGAGAGATGGGAGA                   CCTAACCCGCCGTGTAGCCAACCTCTTCACACAGACCTGTGGCCTACAACAGGGACAC                   CATCTGGCCTTOATGCTGCCTCGAGTTCCTGAGTGGTGGCTCGTGGCTGTGGGCTGCA                   TGCGAACAGGGATCATCTTCATTCCTGCGACCATCCTGTTGAAGGCCAAAGACATTCT                   CTATCGACTACAGTTGTCTAAAGCCAAGGGCATTGTGACCATAGATGCCCTTGCCTCA                   GAGGTGGACTCCATAGCTTCTCAGTGCCCCTCTCTGAAAACCAAGCTCCTGGTGTCTG                   ATCACAGCCGTGAAGGGTGGCTGGACTTCCGATCGCTGGTTAAATCAGCATCCCCAGA                   ACACACCTGTGTTAAGTCAAAGACCTTGCACCCAATGGTCATCTTCTTCACCAGTGGG                   ACCACAGGCTTCCCCAAGATGGCAAAACACTCCCATGGGTTGGCCTTACAACCCTCCT                   TCCCAGGAAGTACGAAATTACGCAGCCTGAAGACATCTGATGTCTCCTGGTGCCTGTC                   GGACTCAGGATGGATTGTGGCTACCATTTGGACCCTGGTAGAACCATGGACAGCGGGT                   TGTACAGTCTTTATCCACCATCTGCCACAGTTTGACACCAAGGTCATCATACAGACAT                   TGTTGAAATACCCCATTAACCACTTTTGGGGGGTATCATCTATATATCGAATGATTCT                   GCAGCAGCATTTCACCACCATCAGGTTCCCTGCCCTGGAGCACTGCTATACTGGCCGG                   GAGGTCGTGTTGCCCAAGGATCAGGAGGAGTGGAAAAGACGGACCGGCCTTCTGCTCT                   ACGAGAACTATGGGCAGTCGGAAACGGGACTAATTTGTGCCACCTACTGGGGAATGAA                   GATCAAGCCGGGTTTCATGGGGAAGGCCACTCCACCCTACGACGTCCAGGTCATTGAT                   GACAAGGGCAGCATCCTGCCACCTAACACAGAAGGAAACATTGGCATCAGAATCAAAC                   CTGTCAGGCCTGTGAGCCTCTTCATGTGCTATGAGGGTGACCCAGAGAAGACAGCTAA                   AGTGGAATGTGGGGACTTCTACAACACTGGGGACAGAGGTAAGATGGATGAAGAGGGC                   TACATTTGTTTCCTGGGGAGGAGTCATGACATCATTAATGCCTCTGGGTATCGCATCG                   GGCCTGCAGAGGTTGAAAGCGCTTTGGTGGAGCACCCAGCGGTGGCGGAGTCAGCCGT                   GGTGGGCAGCCCAGACCCGATTCGAGGGGAGGTGGTGAAGGCCTTTATTGTCCTGACC                   CCACACTTCCTGTCCCATGACAAGGATCACCTGACCAAGCAACTGCAGCAGCATGTCA                   AGTCAGTGACAGCCCCATACAAGTACCCAAGGAAGGTGGAGTTTGTCTCAGAGCTGCC                   AAAAACCATCACTGGCAAGATTGAACCGAACGAACTTCCGAAAAACGAGACTGGTCAG                   ATG TAA   TCGGCAGTGAACTCAGAACGCACTG                                           ORF Start: ATG at 13       ORF Stop: TAA at 1744           SEQ ID NO:168   577 aa   MW at 65272.6 kD                     NOV56a,   MQWLMRFRTLWGIHKSFHNIHPAPSQLRCRSLSEFGAPRWNDYEVPEEFNFASYVLDY       CG59439-01 Protein Sequence           WAQKEKEGKRGPNPAFWWVNGQGDEVKWSFREMGDLTRRVANVFTQTCGLQQGDHLAL                   MLPRVPEWWLVAVGCMRTGIIFIPATILLKAKDILYRLQLSKAKGIVTIDALASEVDS                   IASQCPSLKTKLLVSDHSREGWLDFRSLVKSASPEHTCVKSKTLDPMVIFFTSGTTGF                   PKMAKHSHGLALQPSFPGSRKLRSLKTSDVSWCLSDSGWIVATTWTLVEPWTAGCTVF                   IHHLPQFDTKVIIQTLLKYPINHFWGVSSTYRMILQQDFTSIRFPALEHCYTGGEVVL                   PKDQEEWKRRTGLLLYENYGQSETGLICATYWGMKIKPGFMGKATPPYDVQVIDDKGS                   ILPPNTEGNTGIRIKPVRPVSLFMCYEGDPEKTAKVECGDFYNTGDRGKMDEEGYICF                   LGRSDDIINASGYRIGPAEVESALVEHPAVAESAVVGSPDPIRGEVVKAFIVLTPQFL                   SHDKDQLTKELQQHVKSVTAPYKYPRKVEFVSELPKTITGKIERKELRKKETGQM                                     SEQ ID NO:169   1659 bp                     NOV56b,     GTTTCACC   ATG CAGTCGCTAATCACGTTCCGGACCCTCTGGGGCATCCACAAATCCTT       CG59539-02 DNA Sequence           CCACAACATCCACCCTGCCCCTTCACAGCTGCGCTGCCGGTCTTTATCAGAATTTGGA                   GCCCCAACATGGAATGACTATGAAGTACCGGAGGAATTTAACTTTGCAACTTATGTAC                   TGGACTACTGGGCTCAAAAGGAGAAGGAGGGCAAGAGAGGTCCAAATCCAGCTTTTTG                   GTGCGTGAATCCCCAAGGCGATGAAGTAAAGTGCAGCTTCAGAGAGATGGCAGACCTA                   ACCCGCCGTGTAGCCAACGTCTTCACACAGACCTGTGCCCTACAACAGGCAGACCATC                   TGGCCTTGATGCTGCCTCGAGTTCCTGAGTGGTGGCTGGTGGCTGTGGGCTGCATGCG                   AACAGGGATCATCTTCATTCCTGCGACCATCCTGTTGAAGGCCAAAGACATTCTCTAT                   CGACTACAGTTGTCTAAAGCCAAGGCCATTGTGACCATAGATCCCCTTGCCTCAGAGG                   TGGACTCCATAGCTTCTCAGTGCCCCTCTCTGAAAACCAAGCTCCTGGTGTCTGATCA                   CAGCCGVCAAGGGTGGCTGGACTTCCGATCGCTGGTTAAATCAGCATCCCCAGAACAC                   ACCTGTGTTAACTCAAAGACCTTGGACCCAATGGTCATCTTCTTCACCACTGGGACCA                   CAGGCTTCCCCAAGATGGCAAAACACTCCCATGGGTTCGCCTTACAACCCTCCTTCCC                   AGGAAGTAGGAAATTACGGAGCCTCAAAACATCTGATGTCTCCTGGTGCCTGTCGGAC                   TCACGATGCATTGTGGCTACCATTTGGACCCTGGTAGAACCATGGACAGCGGGTTGTA                   CAGTCTTTATCCACCATCTGCCACAGTTTGACACCAAGGTCATCATACAGACATTGTT                   GAAATACCCCATTAACCACTTTTGGGGGGTATCATCTATATATCGAATGATTCTGCAG                   CAGGATTTCACCAGCATCAGGTTCCCTGCCCTGGAGCACTGCTATACTGGCGGGGAGG                   TCGTGTTGCCCAAGGATCACGAGGAGTCGAAAAGACGGACGGGCCTTCTGCTCTACGA                   GAACTATCCCCACTCGGAAACGGGACTAATTTGTGCCACCTACTCGGGAATGAAGATC                   AAGCCGCGTTTCATGGGGAAGGCCACTCCACCCTACGACCTCCAGGGTGACCCAGAGA                   AGACAGCTAAAGTGGAATGTGGCGACTTCTACAACACTGGGGACAGAGGAAAGATGGA                   TGAAGAGGGCTACATTTGTTTCCTGGGGAGGAGTGATCACATCATTAATGCCTCTGGG                   TATCGCATCGGGCCTGCAGAGGTTGAAAGTGCTTTGGTGGAGCACCCAGCGGTCGCGG                   AGTCAGCCGTGGTGGGCAGCCCAGACCCGATTCGAGGGGAGGTGGTGAAGGCCTTTAT                   TGTCCTGACCCCACAGTTCCTGTCCCATGACAAGGATCAGCTGACCAAGGAACTGCAG                   CAGCATCTCAAGTCAGTGACAGCCCCATACAAGTACCCAAGGAAAGTGGAGTTTGTCT                   CAGAGCTGCCAAAAACCATCACTGGCAAGATTGAACGGAAGGAACTTCGGAAAAAGGA                   CACTGGTCAGATG TAA   TCGGCAGTGAACTCAGAAC                                           ORF Start: ATG at 9       ORF Stop: TAA at 1638           SEQ ID NO:170   543 aa   MW at 61518.2 kD                     NOV56b,   MQWLMRFRTLWGIHHSFHNIHPARSQLRCRSLSEFGAPRWNDYEVPEEFNFASYVLDY       CG59439-02 Protein Sequence           WAQKEKEGKRGPNPAFWWVNGQGDEVKWSFREMGDLTRRVANVFTQTCGLQQGDHLAL                   MLPRVPEWWLVAVGCMRTGIIFIPATILLKAKDILYRLQLSKAKGIVTIDALASEVDS                   IASQCPSLKTKLLVSDHSREGWLDFRSLVKSASPEHTCVKSKTLDPMVIFFTSGTTCF                   PKMAKHSHGLALQPSFPGSRKLRSLKTSDVSWCLSDSGWTVATTWTLVEPWTAGCTVF                   IHHLPQFDTKVIIQTLLKYPINHFWGVSSIYRMILQQDFTSIRFPALEHCYTGGEVVL                   PKDQEEWKRRTGLLLYENYGQSETGLICATYWGMKIKPGFMGKATPPYDVQGDPEKTA                   KVECGDFYNTGDRGKMDEEGYICFLGRSDDIINASGYRIGPAEVESALVEHPAVAESA                   VVGSPDPTRGEVVKAFIVLTPQFLSHDKDQLTKELQQHVKSVTAPYKYPRKVEFVSEL                   PKTTTGKIERKELRKKETCQM                  
 
     [0619] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 56B.  
               TABLE 56B                          Comparison of NOV56a against NOV56b.                                 Identities/           NOV56a Residues/   Similarities for the       Protein Sequence   Match Residues   Matched Region               NOV56b   1 . . . 577   543/577 (94%)           1 . . . 543   543/577 (94%)                  
 
     [0620] Further analysis of the NOV56a protein yielded the following properties shown in Table 56C.  
               TABLE 56C                       Protein Sequence Properties NOV56a                                        PSort   0.6400 probability located in microbody (peroxisome);       analysis:   0.4712 probability located in mitochondrial matrix space;           0.1737 probability located in mitochondrial inner membrane;           0.1737 probability located in mitochondrial           intermembrane space       SignalP   Like1y cleavage site between residues 23 and 24       analysis:                  
 
     [0621] A search of the NOV56a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 56D.  
               TABLE 56D                          Geneseq Results for NOV56a                                         NOV56a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the    Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAB43245   Human ORFX ORF3009    46 . . . 573   309/529   (58%)   0.0           polypeptide sequence SEQ ID    1 . . . 527   402/529   (75%)           NO:6018 -  Homo sapiens , 537 aa.           [WO200058473-A2, 5 OCT           2000]       AAM80008   Human protein SEQ ID NO 3654 -   331 . . . 577   247/279   (88%)   e−140             Homo sapiens , 302 aa.    24 . . . 302   247/279   (88%)           [WO200157190-A2, 9 AUG            2001]       AAM80007   Human protein SEQ ID NO 3653 -   331 . . . 577   247/279   (88%)   e−140             Homo sapiens , 302 aa.    24 . . . 302   247/279   (88%)           [WO200157190-A2, 9 AUG            2001]       AAM41894   Human polypeptide SEQ ID NO   257 . . . 573   193/317   (60%)   e−116           6825 -  Homo sapiens , 390 aa.    7 . . . 323   246/317   (76%)           [WO200153312-A1, 26 JUL 2001]       AAM79024   Human protein SEQ ID NO 1686 -   382 . . . 577   196/196   (100%)   e−112             Homo sapiens , 196 aa.    1 . . . 196   196/196   (100%)           [WO200157190-A2, 9 AUG            2001]                  
 
     [0622] In a BLAST search of public sequence databases, the NOV56a protein was found to have homology to the proteins shown in the BLASTP data in Table 56E.  
               TABLE 56E                          Public BLASTP Results for NOV56a                                         NOV56a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96A20   MIDDLE-CHAIN ACYL-COA   1 . . . 577   576/577 (99%)   0.0           SYNTHETASE1 (MEDIUM-   1 . . . 577   576/577 (99%)           CHAIN ACYL-COA           SYNTHETASE) -  Homo sapiens             (Human), 577 aa.       Q9TVB5   XENOBIOTIC/MEDIUM-CHAIN   1 . . . 576   439/576 (76%)   0.0           FATTY ACID:COA LIGASE   1 . . . 576   486/576 (84%)           FORM XL-III PRECURSOR -  Bos               taurus  (Bovine), 577 aa.       Q9BEA2   LIPOATE-ACTIVATING   1 . . . 576   438/576 (76%)   0.0           ENZYME PRECURSOR -  Bos     1 . . . 576   485/576 (84%)             taurus  (Bovine), 577 aa.       Q91VA0   MEDIUM-CHAIN ACYL-COA   1 . . . 577   406/577 (70%)   0.0           SYNTHETASE (EC 6.2.1.2)   1 . . . 573   472/577 (81%)           (HYPOTHETICAL 64.8 KDA           PROTEIN) -  Mus musculus             (Mouse), 573 aa.       O70490   KIDNEY-SPECIFIC PROTEIN -   1 . . . 573   315/580 (54%)   0.0             Rattus norvegicus  (Rat), 572 aa.   1 . . . 567   417/580 (71%)                  
 
     [0623] PFam analysis predicts that the NOV56a protein contains the domains shown in the Table 56F.  
               TABLE 56F                          Domain Analysis of NOV56a                                     Identities/                   Similarities           NOV56a Match   for the Matched   Expect       Pfam Domain   Region   Region   Value               AMP-binding:   87 . . . 499   106/425 (25%)   2.5e−96       domain 1 of 1       299/425 (70%)                  
 
     Example 57  
     [0624] The NOV57 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 57A.  
               TABLE 57A                       NOV57 Sequence Analysis                                                SEQ ID NO:171   2501 bp                     NOV57A,     ACACC   ATG ACCACCCTTCATGATAAGTTCCTGGCGGAGAAACTCCAGTACTACTATAG       CG59354-01 DNA Sequence           CAGCAGTGAGGATGAGGACAGTGACCACCAGGACAAGGACCGAGGCAGATGTGCCCCA                   GCCAGCAGTTCTGTGCCTGCAGAGGCTGACCTGGCAGCCCAAGGCATCTCAGTTAACA                   CAATGACTCTGAAGGAGTTTGCCATAATGAATGAGGACCAAGATGATGAAGAGTTTCT                   GCAGCAGTACCCGAAGCAGCGAATGGAAGAGATGCGGCAGCAGCTTCACAAGGGGCCC                   CAATTCAAGCAAGTTTTTGAGATCTCCAGTGGAGAACGGTTTTTACACATCATTGATA                   AAGAACAGAAAAGCATTGTCATCATCGTTCATATTTATGAGGATGGCATTCCAGGGAC                   CGAACCCATGAATGGTTGCATGATCTGCCTTGCCGCAGAGTACCCAGCTGTCAAGTTC                   TGCAAGGTGAAGACCTCACTTATTGCCGCCAGCAGTCAGTTCACCAGGAATGCCCTTC                   CTGCCCTGCTGATCTATAAGGGGGGTGAATTGATCGGCAATTTTGTTCGTGTTACTGA                   CCAGCTGGGGGATGATTTCTTTGCTGTGCACCTTGAAGCTTTTCTCCAGGAATTTGGA                   TTACTCCCAGAAAAGGAAGTCTTGGTGCTGACATCTGTGCGTAACTCTGCCACGTGTC                   ACAGTGAGGATAGCGACCTGGAAATAGAT TGA   ACTGATAGTCTAGTTGCATAGATTTC                       TCATTGTTTGGGTTGGAATACACGTCATTCTTTATTTTTGTTCCTTTGTCTTCTGGCT                       TTTCAGCTGTTCTTTGTAGTCCCTTTTATTATGCATAAAATAAAGAAATTCTTAGATT                       AAATCAGAATGCTGAATAACCTTGTAGCTAGCAATAAGGTGACTTACAATTGTATAAA                       CAGGAAGCCAGGCTTTTGAACTGTTTACTTAAGATTCTGTGGTGTGACATCTCTGTTA                       TTGTTTCCAGTCAATATTTACAAAGCATCCTAAAGACAGGGTCTTGGAAATTGTCTTC                       AGATGATCTTAGAGGTCTCTGCCAAGTCTGAGAGTATAATTCTGTAGGTATTGTGTTA                       TTTGCAACGTAAATAGTGCATTTTCTTAATCAAATGATTGTAAATTATATTTACTTGT                       AATCAGTTCCATAGCTTTAGACGGTGGTTAGATTTTTTTTTTCCCCACCAGGGTCTTG                       TTTAAAGGGGTCAGCCACCGCACCCAGTCCTGAGGGGTGGCCTCTGCTGCTGGATTTC                       ATGTCTTCCTCCAGCATGACTAACTCTGGAACAGCAGCAAGCGTTGATGCTTACTGAC                       CTGGTGATGTTAGAAGACAAGTAGTTTATGCATTTAAACATTAGAGCTGCAGTGGGGC                       TGGAAATCTTTGTAAAGGAAGTTCTTTCAGTAAGATGCCCCTGCTTGTCTTTGTCTCT                       TTTTTGTTTAACAAGGTAACTTTTTGTTTAACAAGGTAACTTTTTGTTTAACCTAGAT                       TTTTTTTAAAACTTTTTTTTTTTTTCATATTGGAAAAGTAATTCATATTCAGTAGAGG                       AAAACTGACCAAAACAGAAGCAAAAATAAGAAAATTAAAATAATCTCTAATCCTACTA                       CCTAGAATAAAACACTATTAATATTTTGGTCTGTTTCCTGCCAAGGTGTTTTCTGTGT                       ATACATGGATATTTTGTTTGTTTTTAAACAAAACGATGGGATCATTCTGAACATACTG                       TTCTATAGTATGGTCAGCTAATAATATATCAGACCTTTTTTTTATATTATTAAATATT                       CTACAACTTTTTAAAAATGTCTATTAATATTCCATCGTATAGATGTGATATAATTTGC                       TTGATGGTTGTCTCTTAAAAAGAAAGATAGCAAATACTTTTTTTAAATTACAAAAGTG                       ATAGATGTTCATTGTAGAAAATGTAATAAACACTGTTAAGACTTAAAAGCCATATAAT                       TCCACCAACCAAAATTAATCCCTTTTGTCATATTTCTAGTCATTTTTATAGCCTTTTT                       TTTCTATGTATTTATAATAATTATCATTTGCGTTTTTTTCCTTTTTTTAACTTTAAAA                       ATGTATATTCTAGGGTCAGGGGAAATGTAATCTGGAATTAAATATTAGCCTTAAAATT                       CACAATTTTGATTTTCCTGGCTTTTCAGGAATTGACTAACTGTAAAAGAGTCTTGAAA                       GTATTTAGTCAACAAACAGAGTGCATTTTTTTTTTTTTGACTAAGAAAGCTCGTTGTA                       GTAGAAAGGGTGGAATGTATTGAAAATTATTAGAAGCAGGGAAGTATTGTTAGTCTAG                       CTTATTTCCTTTCAGTCTTTTTTCAATATTTTTATAAACATTGAGTACTTACTGAATT                       TAGTTCTGTGCTCTTCCTTATTTAGTGTTGTATCATAAATACTTTGATGTTTCAAACA                       TTCTAATAAATAATTTTCAGTGGCTTCATAATAAAAAAAAAAAAAAAAAAAAAAAAAA                       AAAAAAA                                           ORF Start: ATG at 6       ORF Stop: TGA at 726           SEQ ID NO:172   240 aa   MW at 26866.9 kD                     NOV57a,   MTTLDDKLLGEKLQYYYSSSEDEDSDHEDKDRGRCAPASSSVPAEAELAGEGISVNTM       CG59354-01 Protein Sequence           TLKEFAIMNEDQDDEEFLQQYRKQRMEEMRQQLHKGPQFKQVFEISSGEGFLDMIDKE                   QKSTVTMVHIYEDGIPGTEANNGCMTCLAAEYPAVKFCKVKSSVIGASSQETRNALPA                   LLIYKGGELIGNFVRVTDQLGDDFFAVDLEAFLQEFGLLPEKEVLVLTSVRNSATCHS                   EDSDLEID                                     SEQ ID NO:173   893 bp                     NOV57b,     CACC   ATG ACCACCCTGTATGATAAGTTGCTGGGCCAGAAACTGCAGTACTACTATAGC       CG59354-02 DNA Sequence           AGCAGTGAAGATGAGGACAGTGACCACGAGGACAAGGACCGAGCCATCTCAGTTAACA                   CAGGCCCAAAAGGTGTGATCAATGACTAGCGCCGCTTCAAGCAGTTGGAGACACACCA                   GAGGGAGGAGCAGTGCCGGGAGATGGAAAGGCTGATCAAGAAGCTGTCAATGACTTGC                   AGGTCCCATCTGGATGAAGAGGAGGAGCAACAGAAACAGAAAGACCTCCAGGAGAAGA                   TCAGTGGGAACATGACTCTGAAGGAGTTTGCCATAATGAATGAGGACCAACATGATGA                   AGAGTTTCTGCAGCAGTACCGGAAGCAGCGAATCGAAGAGATGCGGCAGCAGCTTCAC                   AAGCGCCCCCAATTCAAGCAGGTTTTTGAOATCTCCAGTGGAGAAGGGTTTTTAGACA                   TGATTGATAAAGAACAGAAAAGCATTGTCATCATGGTTCATATTTATGAGGATGGCAT                   CAGGGACCGAAGCCATGAATGGTTGCATGATCCCCCTTGCAAGGGGCGTGAATTGATC                   GGCAATTTTGTTCGTGTTACTGACCAGCTGGGOGATGATTTCTTTGCTGTCGACCTTG                   AAGCTTTTCTCCAGGAATTTGGATTACTCCCAGAAAAGGAAGTCTTGGTCCTGACATC                   TGTGCGTAACTCTGCCACGTGTCACAGTGAGGATAGCGACCTGGAAATAGAT TGA   ACT                       GATAGTCTAGTTGCATATAGATTTCTCATTGTTTGGGTTGGAATACACCATTGTTTAT                       TTTTQTTCCTTTGTCTTCTGGCTTTTCAGCTGTTCTTTGTAGTCCCTTTTATTATGCA                       TAAAATAAAAAAATTCTTAGATT                                           ORF Start: ATG at 5       ORF Stop: TGA at 749           SEQ ID NO:174   248 aa   MW at 29227.4 kD                     NOV57b,   MTTLYDKLLGEKLQYYYSSSEDEDSDHEDKDRGISVNTGPKGVINDWRRKFQLETEQR       CG59354-02 Protein Sequence           EEQCREMERLIKKLSMTCRSHLDEEEEQQKQKDLQEKTSGKMTLKEFAIMTEDQDDEE                   FLQQYRKQRNEEMRQQLHKGPQFKQVFEISSGEGFLDMIDKEQKSIVIMVHIYEDGIR                   DRSHEWLHDPPCKGGELIGNFVRVTDQLGDDFFAVDLEAFLQEFGLLPEKEVLVLTSV                   RNSATCHSEDSDLEID                                     SEQ ID NO:175   891 bp                     NOV57c,     CACC   ATG ACCACCCTGTATGATAAGTTGCTGGGGGAGAAACTGCAGTACTACTATAGC       CG59354-02 DNA Sequence           AGCAGTGAAGATGAGGACAGTGACCACGAGGACAAGGACCGAGGCATCTCAGTTAACA                   CAGGCCCAAAAGGTGTGATCAATGACTGGCGCCGCTTCAAGCAGTTGGAGACAGAGCA                   GAGGGAGGAGCAGTGCCGGGAGATGGAAAGGCTCATCAAGAAGCTGTCAATGACTTGC                   AGGTCCCATCTGGATGAAGAGGAGGAGCAACAGAAACAGAAAGACCTCCAGGAGAAGA                   TCAGTGGGAAGATGACTCTGAAGGAGTTTGCCATAATGAATGAGGACCAAGATGATGA                   AGAGTTTCTGCAGCAGTACCGGAAGCAGCGAATGGAAGAGATGCGGCAGCAGCTTCAC                   AAGGGGCCCCAATTCAAGCAGGTTTTTCAGATCTCCAGTGGAGAAGGGTTTTTAGACA                   TGATTGATAAAGAACAGAAAAGCATTGTCATCATGGTTCATATTTATGAGCATGGCAT                   TCCAGGGACCGAAGCCATGAATGGTTGCATGATCCGCCTTGCCGCAGAGTACCCACCT                   GTCAAGTTCTGCAAGGTGAAGAGCTCAGTTATTGGCGCCAGCAGTCAGTTCACCAGGA                   ATGCCCTTCCTGCCCTGCTGATCTATAAGGGGGGTGAATTGATCGGCAATTTTGTTCG                   TGTTACTGACCAGCTGGGGGATGATTTCTTTGCTGTGGACCTTGAAGCTTTTCTCCAG                   GAATTTGGATTACTCCCAGAAAAGGAAGTCTTGGTGCTGACATCTGTGCGTAACTCTG                   CCACGTGTCACAGTGAGGATAGCGACCTGGAAATAGAT TGA   ACTGATAGTCTAGTTGC                       ATAGATTTCTCATTGTTTGGG                                           ORF Start: ATG at 5       ORF Stop: TGA at 851           SEQ ID NO:176   272 aa   MW at 32598.5 kD                     NOV57c,   MTTLYDKLLGEKLQYYYSSSEDEDSDHEDRDRGISVNTGPKGVINDWRRFKQLETEQR       CG59354-03 Protein Sequence           EEQCREMERLIKKLSMTCRSHLDEEEEQQKQKDLQEKISGKMTLKEFAIMNEDQDDEE                   FLQQYRKQRMEEMRQQLEKGPQFKQVFETSSGEGFLDMIDKEQKSIVIMVHIYEDGIP                   GTEAMNGCMIRLAAEYPAVKFCKVKSSVICASSQETRNALPALLIYKGGELIGNFVRV                   TDQLGDDEFAVDLEAFLQEFGLLPEKEVLVLTSVRNSATCHSEDSDLEID                  
 
     [0625] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 57B.  
               TABLE 57B                          Comparison of NOV57a against NOV57b through NOV57c.                                         Identities/               NOV57a Residues/   Similarities for the           Protein Sequence   Match Residues   Matched Region                       NOV57b    58 . . . 240   138/183 (75%)               100 . . . 248   140/183 (76%)           NOV57c    58 . . . 240   182/183 (99%)               100 . . . 282   182/183 (99%)                      
 
     [0626] Further analysis of the NOV57a protein yielded the following properties shown in Table 57C.  
               TABLE 57C                       Protein Sequence Properties NOV57a                                        PSort   0.6500 probability located in cytoplasm; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0627] A search of the NOV57a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 57D.  
               TABLE 57D                          Geneseq Results for NOV57a                                         NOV57a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAE03537   Human secreted    1 . . . 240   226/301 (75%)    e−117           protein variant,    1 . . . 301   230/301 (76%)           SEQ ID NO:           228— Homo               sapiens , 301 aa.           [WO200132675-           A1, May 10,           2001]       AAY99657   Human GTPase    1 . . . 240   226/301 (75%)    e−117           associated    1 . . . 301   230/301 (76%)           protein-8—             Homo sapiens ,           301 aa.           [WO200031263-           A2, Jun. 2, 2000]       AAE02004   Fruitfly viral   55 . . . 214    52/161 (32%)   3e−14            IAP-associated   59 . . . 213    86/161 (53%)           factor (VIAF)—             Drosophila               melanogaster ,           240 aa.           [WO200134798-           A1, May 17,           2001]       AAE02003   Zebrafish viral   21 . . . 236    69/241 (28%)   5e−13            IAP-associated    2 . . . 237   117/241 (47%)           factor (VIAF)—             Brachydanio               rerio , 239 aa.           [WO200134798-           A1, May 17,           2001]       AAE02002   Mouse viral   58 . . . 240    59/195 (30%)   4e−12            IAP-associated   52 . . . 240    99/195 (50%)           factor (VIAF)—             Mus musculus ,           240 aa.           [WO200134798-           A1, May 17,           2001]                  
 
     [0628] In a BLAST search of public sequence databases, the NOV57a protein was found to have homology to the proteins shown in the BLASTP data in Table 57E.  
               TABLE 57E                          Public BLASTP Results for NOV57a                                         NOV57a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q96AF1   HYPOTHETICAL   1 . . . 240   226/301 (75%)   e−117           34.3 KDA   1 . . . 301   230/301 (76%)           PROTEIN— Homo               sapiens  (Human),           301 aa.       Q13371   Phosducin-like   1 . . . 240   225/301 (74%)   e−116           protein (PHLP)—   1 . . . 301   230/301 (75%)             Homo sapiens             (Human), 301 aa.       T17321   hypothetical protein   1 . . . 240   225/301 (74%)   e−116           DKFZp564M1863.1—   1 . . . 301   230/301 (75%)           human, 301 aa.       Q923E8   RIKEN CDNA   1 . . . 240   210/301 (69%)   e−109           1200011E13 GENE—   1 . . . 301   223/301 (73%)             Mus musculus             (Mouse), 301 aa.       Q63737   Phosducin-like protein   1 . . . 240   210/301 (69%)   e−108           (PHLP)— Rattus     1 . . . 301   223/301 (73%)             norvegicus (Rat),             301 aa.                  
 
     [0629] PFam analysis predicts that the NOV57a protein contains the domains shown in the Table 57F.  
               TABLE 57F                          Domain Analysis of NOV57a                                     Identities/               NOV57a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               Phosducin: domain   35 . . . 57    14/23 (61%)   8.7e−08        1 of 2        21/23 (91%)       Phosducin: domain    58 . . . 240   133/183 (73%)   9.7e−148       2 of 2       174/183 (95%)                  
 
     Example 58  
     [0630] The NOV58 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 58A.  
               TABLE 58A                       NOV58 Sequence Analysis                                                SEQ ID NO:177   756 bp                     NOV58a,     G   GAT CCCAATGAAGATACAGAATGGAATGACATTTTAAGAGATTTCCGCATTCTTCCT       CG59319-01 DNA Sequence           CCTAAAGAAGAGTCAAAAGATGAAATTGAAGAAATGGTTTTACGTTTACAGAAAGAAG                   CAATGGTGAAACCATTTGAAAAGATGACTCTTGCACAGCTAAAGGAAGCTGAAGATGA                   ATTCGATGAAGAAGATATGCAGGCTGTTGAAACATATAGAAAGAAGCGGTTACAGGAA                   TGGAAAGCTCTTAAGAAAAAACAAAAATTTGGACAATTAACAGAAATTTCTGGAAATC                   AGTATGTGAATGAAGTCACAAATGCAGAAGAAGATGTGTGGGTTATAATTCATCTATA                   CAGATCAAGCATCCCAATGTGTTTGTTGGTTAACCAGCATCTTAGTCTTCTAGCAAGA                   AAGTTTCCAGAAACTAAATTTGTTAAAGCCATCGTGAATAGCTGTATTCAACACTACC                   ATGACAATTGTTTACCAACAATTTTTGTGTATAAAAATGGTCAGATAGAACCCAAATT                   CATTGGAATTATAGAATGTGCAOGGATAAATCTCAAGCTGOAAGAACTTGAATGGAAG                   CTAGCACAACTTGGAGCAATACAGACTCATTTGCAACAAAACCCCACAAAAGACATGG                   TAGATATGATGGTATCTTCAATTAGAAACACTTCTATTCATGATGACAGTGATAGCTC                   CAACAGTGATAATGATACCAAA TAG   AGAGAAATATTCAATAAATAGCTTTTAGTAAAA                       AA                                   ORF Start: GAT at 2       ORF Stop: TAG at 719           SEQ ID NO:178   239 aa   MW at 27811.3 kD                     NOV58a,   DPNEDTEWNDILRDFGILPPKEESKDEIEEMVLRLQKEAMVKPFEKMTLAQLKEAEDE       CG59319-01 Protein Sequence           FDEEDMQAVETYRKKRLQEWKALKKKQKFGELREISGHQYVNEVTNAEEDVWVIIHLY                   RSSIPMCLLVNQHLSLLARKFPETKFVKATVNSCIQHYHDNCLPTTFVYKNGQIEAKF                   IGIIECGGINLKLEELEWKLAEVGATQTDLEENPRKDMVDMMVSSIRNTSIHDDSDSS                   NSDNDTK                                     SEQ ID NO:179   745 bp                     NOV58b,     GGATCCCAATGAAGATACAGA   ATG GATCCCAATGAAGATACAGAATGGAATGACATTT       CG59319-02 DNA Sequence           TAAGACATTTCGGCATTCTTCCTCCTAAAGAAGAGTCAAAAGATGAAATTGAAGAAAT                   GGTTTTACGTTTACAGAAAGAAGCAATGGTGAAACCATTTGAAAAGATGACTCTTGCA                   CAGCTAAAGGAAGCTGAAGATGAATTTGATGAAGAAGATATGCAGGCTGTTGAAACAT                   ATAGAAAGAAGCGGTTACAGGAATGGAAACCTCTTAACAAAAAACAAAAATTTGGAGA                   ATTAAGAGAAATTTCTCGAAATCAGTATGTGAATGAAGTCACAAATGCAOAAGAAGAT                   GTGTCGGTTATAATTCATCTATACAGATCAAGCATCCCAATGTGTTTGTTGGTTAACC                   AGCATCTTAGTCTTCTAGCAAGAAAGTTTCCAGAAACTAAATTTGTTAAAGCCATCGT                   GAATAGCTGTATTCAACACTACCATGACAATTGTTTACCAACAATTTTTGTGTATAAA                   AATGCTCACATAGAAGCCAAATTCATTGGAATTATAGAATCTGGAGGGATAAATCTCA                   AGCTGGAAGAACTTGAATGGAAGCTAGCAGAAGTTGGAGCAATACAGACTGATTTGGA                   AGAAAACCCCAGAAAACACATCGTAGATATCATGCTATCTTCAATTAGAAACACTTCT                   ATCCATGATGACAGTGATAGCTCCAACAGTGATAATGATACCAAA TAG   A                                           ORF Start: ATG at 22       ORF Stop: TAG at 742           SEQ ID NO:180   240 aa   MW at 27942.5 kD                     NOV58b,   MDPNEDTEWNDILRDFCTLPPKEESKDEIEEMVLRLQKEANVKPBERMTLAQLKEAED       CG59319-02 Protein Sequence           EFDEEDNQAVETYRKKRLQEWKALKKKQKFGELRETSGNQYVNEVTNAEEDVWVIIHL                   YRSSIPMCLLVNQHLSLLARKFPETKFVKAIVNSCIQHYHDNCLPTIFVYKNGQIAEK                   FIGIIECGGINLKLEELEWKLAEVGAIQTDLEENPRKDMVDMMVSSIRNTSIHDDSDS                   SNSDNDTK                  
 
     [0631] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 58B.  
               TABLE 58B                          Comparison of NOV58a against NOV58b.                                 Protein   NOV58a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV58b   1 . . . 239   216/239 (90%)               2 . . . 240   216/239 (90%)                      
 
     [0632] Further analysis of the NOV58a protein yielded the following properties shown in Table 58C.  
               TABLE 58C                       Protein Sequence Properties NOV58a                                        PSort   0.8800 probability located in nucleus; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0633] A search of the NOV58a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 58D.  
               TABLE 58D                          Geneseq Results for NOV58a                                         NOV58a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAE02003   Zebrafish viral   1 . . . 237   133/238 (55%)   3e−75           IAP-associated   3 . . . 239   181/238 (75%)           factor (VIAF)—             Brachydanio rerio ,           239 aa.           [WO200134798-A1,           May 17, 2001]       AAU27979   Mouse contig   1 . . . 231   137/234 (58%)   2e−74           polypeptide   7 . . . 240   176/234 (74%)           sequence #132—             Mus musculus ,           243 aa.           [WO200164834-A2,           Sep. 7, 2001]       AAU27807   Human full-length   1 . . . 231   137/234 (58%)   2e−74           polypeptide   3 . . . 236   176/234 (74%)           sequence #132—             Mus musculus ,           239 aa.           [WO200164834-A2,           Sep. 7, 2001]       AAE02001   Human viral IAP-   1 . . . 231   137/234 (58%)   2e−74           associated factor   3 . . . 236   176/234 (74%)           (VIAF)— Homo               sapiens , 239 aa.           [WO200134798-A1,           May 17, 2001]       AAB68507   Human GTP-   1 . . . 231   137/234 (58%)   2e−74           binding associated   3 . . . 236   176/234 (74%)           protein #7—             Homo sapiens ,           239 aa.           [WO200105970-A2,           Jan. 25, 2001]                  
 
     [0634] In a BLAST search of public sequence databases, the NOV58a protein was found to have homology to the proteins shown in the BLASTP data in Table 58E.  
               TABLE 58E                          Public BLASTP Results for NOV58a                                         NOV58a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9CQU4   1700010B22RIK   1 . . . 239   208/239 (87%)    e−121           PROTEIN— Mus     3 . . . 240   229/239 (95%)             musculus             (Mouse), 240 aa.       Q9WUP3   PDCL2— Mus     1 . . . 239   207/239 (86%)    e−121             musculus     1 . . . 238   228/239 (94%)           (Mouse), 238 aa           (fragment).       Q9DA99   1700016K07RIK   47 . . . 239    165/193 (85%)   3e−94            PROTEIN— Mus     1 . . . 192   183/193 (94%)             musculus             (Mouse), 192 aa.       CAC40345   SEQUENCE 5   1 . . . 237   133/238 (55%)   1e−74            FROM PATENT   3 . . . 239   181/238 (75%)           W00134798—             Brachydanio               rerio  (Zebrafish)           (Zebra danio),           239 aa.       Q9H2J4   HTPHLP   1 . . . 231   137/234 (58%)   8e−74            (UNKNOWN)   3 . . . 236   176/234 (74%)           (PROTEIN FOR           MGC:3062)—             Homo sapiens             (Human), 239 aa.                  
 
     [0635] PFam analysis predicts that the NOV58a protein contains the domains shown in the Table 58F.  
               TABLE 58F                          Domain Analysis of NOV58a                                     Identities/               NOV58a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               Phosducin: domain   60 . . . 175   32/120 (27%)   5.8       1 of 1       55/120 (46%)                  
 
     Example 59  
     [0636] The NOV59 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 59A.  
               TABLE 59A                       NOV59 Sequence Analysis                                                SEQ ID NO:181   981 bp                     NOV59a,     GCC ACCGCGCCCAGCTGGCTTTTGTTTTTTATCCTTCTGCTCCTCATTTACCTATTCA       CG59576-01 DNA Sequence           CCATCATTGGTACTCTTATGCTQTTCTTTGCCATCAAACTGGATTTCTGCCTGCACAG                   CTCCTTCTATTTCTTCATCACTGTCCTCTCCTTCCTAGAGATCTGGTATACCACCATC                   ACCATCCCCAAGATGTTCTTCAACCTACCCAGTGAGCAGAAGACCACCTCCCTGGATG                   GTTGCCTATTGCAGATGTATTTCTTTTACTCCCTCGGCATCACTGAGGTTTGCTTGCT                   CACCACCAGGGCTATGGACACATACCTGGCCATCTGTAATCACCTTTGCTACCCCACA                   GTCACGACACCTCAGCTCTACACTCAGGTGATTCTAGGTTGTTGCATCTGTGGCTTCT                   TCACGCTGCTCCCTGAGATTGCTTGGATATCCACACFGCCATTTTGTGGTCCAAATCA                   AATCCACAACATTTTCTGTGACCTTGATCCTATCCTGAATCTAGCATGTGTAGACACT                   GGCCCAGTTGTTTTAATCAAGGTTGTGGACATTGTACATGCTGTGGAGATCATCACAG                   CTATAATGCTTGTGACTTTGCCTTACCTCCAAATTATTGCAGTGATCCTAAGAAACTG                   CTCTGCTGATCGATGCCAAAAGGCATTTTCTACCTATGCTTTCCACCTTGCTATTTTC                   TTAATCTTTTTTGGAAGTGTAGCCCTGATGTACCTGCTCTTCTCTGCCAAGTACTCCT                   TTTTCTGGGACACAACCATCAGCCTAATGTTTGCAGTGCTGTCACCGACAACAATCAT                   CTGTAGTCTCAGGAATAAAGAGATAAAGGAACCAATAAAAAAGCACATGTCCCAATCA                   ATGATATGCACACATCATGTCAAA TAA   GACCAAATACACACCTCTTAATTACCAAACA                       ATATTTATACAAATATTTACATTAATACGTTCAGTGTGTTTGTTGCTGCTGTG                                           ORF Start: GCC at 1       ORF Stop: TAA at 895           SEQ ID NO:182   298 aa   MW at 33780.0 kD                     NOV59a,   ATAPSWLLFFTLLLLIYLFTIIGSLMVFFAIKLDFCLHSSFYFFTSVLSFLETWYTTI       CG59576-01 Protein Sequence           TIPKMFFNLASEQKTTSLDGCLLQMYFFYSLGITEVCLLTTRAMDRYLAICNHLCYPT                   VTTPQLYTQVTLGCCICGFFTLLPETAWISTLPFCGPNQIHNTFCDLDPILNLACVDT                   GPVVLIKVVDIVHAVEIITAIMLVTLAYVQIIAVILRNCSADGCQKAFSTYAFHLAIF                   LIFFCSVALMYLLFSAKYSFFWDTTTSLMFAVLSPTTITCSLRNKEIKEATKKHMCQS                   MICTHHVK                  
 
     [0637] Further analysis of the NOV59a protein yielded the following properties shown in Table 59B.  
               TABLE 59B                       Protein Sequence Properties NOV59a                                        PSort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability located           in endoplasmic reticulum (membrane); 0.1000 probability           located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 25 and 26       analysis:                  
 
     [0638] A search of the NOV59a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 59C.  
                               TABLE 59C                               NOV59a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value                  AAG72586   Human OR-like    7 . . . 295   286/289 (98%)    e−167           polypeptide query    1 . . . 289   286/289 (98%)           sequence, SEQ           ID NO: 2267—             Homo sapiens ,           289 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG71784   Human olfactory    7 . . . 295   286/289 (98%)    e−167           receptor poly-    1 . . . 289   286/289 (98%)           peptide, SEQ ID           NO: 1465—             Homo sapiens ,           289 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG71785   Human olfactory    5 . . . 292   175/293 (59%)   6e−95            receptor poly-   20 . . . 311   217/293 (73%)           peptide, SEQ ID           NO: 1466—             Homo sapiens ,           318 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAU24721   Human olfactory    7 . . . 283   170/279 (60%)   4e−94            receptor   53 . . . 328   212/279 (75%)           AOLFR220—             Homo sapiens ,           343 aa.           [WO200168805-           A2, Sep. 20,           2001]       AAG71808   Human olfactory    7 . . . 283   170/279 (60%)   4e−94            receptor poly-   29 . . . 304   212/279 (75%)           peptide, SEQ ID           NO: 1489—             Homo sapiens ,           317 aa.           [WO200127158-           A2, Apr. 19,           2001]                  
 
     [0639] In a BLAST search of public sequence databases, the NOV59a protein was found to have homology to the proteins shown in the BLASTP data in Table 59D.  
               TABLE 59D                          Public BLASTP Results for NOV59a                                         NOV59a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q96R35   OLFACTORY   50 . . . 267   107/218 (49%)   7e−55           RECEPTOR—    1 . . . 216   146/218 (66%)             Homo sapiens             (Human), 216 aa           (fragment).       Q9EPG2   M51 OLFACTORY    2 . . . 285   115/289 (39%)   2e−52           RECEPTOR— Mus     19 . . . 303   172/289 (58%)             musculus             (Mouse), 314 aa.       O95007   Olfactory receptor   10 . . . 285   109/279 (39%)   1e−51           6B1 (Olfactory   28 . . . 301   170/279 (60%)           receptor 7-3)           (OR7-3)— Homo               sapiens  (Human),           311 aa.       Q9QWU6   OLFACTORY    1 . . . 289   111/298 (37%)   2e−50           RECEPTOR 17—   20 . . . 314   171/298 (57%)             Mus musculus             (Mouse), 327 aa.       P23270   Olfactory receptor-    1 . . . 289   111/298 (37%)   2e−50           like protein 17—   20 . . . 314   171/298 (57%)             Rattus norvegicus             (Rat), 327 aa.                  
 
     [0640] PFam analysis predicts that the NOV59a protein contains the domains shown in the Table 59E.  
               TABLE 59E                          Domain Analysis of NOV59a                                     Identities/               NOV59a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain   37 . . . 164   30/134 (22%)   5.4e−13       1 of 1       90/134 (67%)                  
 
     Example 60  
     [0641] The NOV60 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 60A.  
               TABLE 60A                       NOV60 Sequence Analysis                                                SEQ ID NO:183   1201 bp                     NOV60a     AGGATAACTTTATATGTTGCAAAATGACTCACATAGTATATTTTATTTAACCAGCCTA         CG59557-1 DNA Sequence             ATTTCAAGGCTGTTTAGTTGCTTGAAAAGAAGGTTTTTATTTGTTCTTTGCATGTACT                       TAGA   ATG CTGACTGTGTTTTATCACCCAACAAGTGAAACCGCTGAAAATATGGATCCA                   GAGAATCAGACAATGGTGACTGAGTTTTATTTCTCTGATTTTCCTCAATCTAAGAATG                   GCAGCCTCTTATTCTTCATTCCTATGCTCTTTATTTATATATTCATTCTTGTTGGAAA                   TTTCATGATTTTCTTTGCTGTCCGACCGCACCCCCATCTCCATAATCCTATGTACACT                   TTTATCAGTGTCTTCTCCTTCCTGGAGATTTGGTACACCACCGTGACTATCCCCAAGA                   TGCTCTCCAACCTTCTCAGTGAACAGAAAACCATCTCTTTCATAGCTTGCCTCCTGCA                   GATGTACTTCTTCCACTCACTCGGGGTCACAGAAGCCCTAGTCCTCACAGTGATGGCC                   ATTGACAGCTGTGTAGCCATCTGCAACCCCCTTCGCTATGCAATCACTATGTCCCCTA                   GACTGTGCATCCAGCTCTCCACTGGCTCTTGCATTTTTGGCTTCCTCATGTTACTGCC                   AGAGATTCTGTGCATTTCCACTCTTCCATTCTGTGGCGCCAACCAAATTCATCAACTC                   TTTTGTGACTTTGAACCTCTGCTGCAGTTAGCCTGCACAGATACGTACATAATTCTGG                   TTGAACATGTGATCCGTGCTATTTCCATTCTGACCTCTGTCTCTGTCATCACCCTTTT                   CTATTTAAGAATCATCACCGTGATCCTGACGATTCCCTCTGGTGAGAGTCGTCACAAG                   GCTTTCTTCACATGTGCAGCCCACATTGCTATTTTCTTCCTGTTTTTTCGCAGTGTGT                   CACTCATGTATCTGCGCTTCTCTGTCACATTCCCACCATTACTGGACAAGGCCATTGC                   ACTGATGTTTGCTGTCCTTGCCCTACTTTTCAACCCAGTAATCTATAGTCTGAGGAAC                   AAAGATATCAAAAACGCCACCAAGAAAATCCTCTGTTCTCAAAAGATCTTCAATGCCT                   CTGGGAGC TAA   TGGAGTTCACACACACCTCTTCAAAGAAATCTCATCATCTCCTTAAG                       TTTAAAATGCTAACAAATCAGTTTTTTTAAATTACCATGCA                                           ORF Start: ATG at 121       ORF Stop: TAA at 1111           SEQ ID NO:184   330 aa   MW at 37439.1 kD                     NOV60a,   MLTVFYEPTSETAENMDPENQTN1VTEFYFSDFPQSKNGSLLFPIPMLFIYIFILVGNF       CG59557-01 Protein Sequence           MIFFAVRPDPHLHNPMYSFISVFSFLEIWYTTVVTIPKMLSNLLSEQKTISFIGCLLQM                   YFFHSLGVTEALVLTVMAIDRCVAICNPLRYAITMSPRLCIQLSTGSCIFGFLMLLPE                   IVCISTLPFCGANQIHQLFCDFEPVLQLACTDTYIILVEDVIRAISILTSVSVITLFY                   LRITTVILRIPSGESRQKAFFTCAAHIAIELLFFGSVSLMYLRFSVTFPPLLDKAIAL                   MFAVLALLFNPVIYSLRNKDMKNATKKILCSQKMFNASGS                  
 
     [0642] Further analysis of the NOV60a protein yielded the following properties shown in Table 60B.  
               TABLE 60B                       Protein Sequence Properties NOV60a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability located           in endoplasmic reticulum (membrane); 0.0300 probability           located in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 67 and 68       analysis:                  
 
     [0643] A search of the NOV60a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 60C.  
               TABLE 60C                          Geneseq Results for NOV60a                                         NOV60a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG71807   Human olfactory   16 . . . 330   313/315 (99%)   e−180           receptor poly-    1 . . . 315   314/315 (99%)           peptide, SEQ ID           NO: 1488—             Homo sapiens ,           319 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG71803   Human olfactory   16 . . . 329   219/314 (69%)   e−129           receptor poly-    1 . . . 314   259/314 (81%)           peptide, SEQ ID           NO: 1484—             Homo sapiens ,           315 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAU246581   Human olfactory    9 . . . 329   218/321 (67%)   e−128           receptor   10 . . . 330   259/321 (79%)           AOLFR156—             Homo sapiens ,           331 aa.           [WO200168805-           A2, Sep. 20,           2001]       AAU24721   Human olfactory   20 . . . 329   196/310 (63%)   e−111           receptor   33 . . . 342   234/310 (75%)           AOLFR220—             Homo sapiens ,           343 aa.           [WO200168805-           A2, Sep. 20,           2001]       AAG71808   Human olfactory   20 . . . 323   195/304 (64%)   e−111           receptor  Homo      9 . . . 312   232/304 (76%)             sapiens , 317 aa.           [WO200127158-           A2, Apr. 19,           2001]                  
 
     [0644] In a BLAST search of public sequence databases, the NOV60a protein was found to have homology to the proteins shown in the BLASTP data in Table 60D.  
               TABLE 60D                          Public BLASTP Results for NOV60a                                         NOV60a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9WU86   ODORANT   15 . . . 324   135/315 (42%)   4e-67           RECEPTOR S1—    8 . . . 320   188/315 (58%)             Mus musculus             (Mouse), 324 aa.       Q9EPG2   M51 OLFACTORY   20 . . . 325   129/307 (42%)   4e−65           RECEPTOR—    5 . . . 311   189/307 (61%)             Mus musculus             (Mouse), 314 aa.       P23270   Olfactory receptor-   24 . . . 319   126/301 (41%)   8e−65           like protein I7—   10 . . . 310   182/301 (59%)             Rattus norvegicus             (Rat), 327 aa.       Q9QWU6   OLFACTORY   16 . . . 319   128/310 (41%)   9e−64           RECEPTOR I7—    1 . . . 310   184/310 (59%)             Mus musculus             (Mouse), 327 aa.       O13036   CHICK   16 . . . 319   122/305 (40%)   1e−63           OLFACTORY    1 . . . 305   187/305 (61%)           RECEPTOR 7—             Gallus gallus             (Chicken), 323 aa.                  
 
     [0645] PFam analysis predicts that the NOV60a protein contains the domains shown in the Table 60E.  
               TABLE 60E                          Domain Analysis of NOV60a                                     Identities/               NOV60a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain   56 . . . 204    45/270 (17%)   2.4e−21       1 of 1       172/270 (64%)                  
 
     Example 61  
     [0646] The NOV61 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 61A.  
               TABLE 61A                       NOV61 Sequence Analysis                                                SEQ ID NO:185   1061 bp                     NOV61a,     CAATCTGCTCCTAAGTCATCTTTTTCTTTTTCACAGGGAA   ATG GGGGAAAATCAGACA       CG59555-01 DNA Sequence           ATGGTCACAGAGTTCCTCCTACTGGGATTTCTCCTGGGCCCAAGGATTCAGATGCTCC                   TCTTTCGGCTCTTCTCCCTGTTCTATATCTTCACCCTGCTGCGGAACGGGGCCATCCT                   GGGGCTCATCTCACTGGACTCCAGACTCCACACCCCCATGTACTTCTTCCTCTCACAC                   CTGGCTGTCGTCGACATCGCCTACACCCGCAACACGGTGCCCCAGATGCTGGCGAACC                   TCCTGCATCCAGCCAAGCCCATCTCCTTTGCTGGCTGCATGACGCAGACCTTTCTCTG                   TTTGAGTTTTGGACACAGCCAATGTCTCCTGCTGGTGCTGATGTCCTACGATCGTTAC                   GTGGCCATCTGCCACCCTCTCCGATACTCCGTCATCATGACCTGGAGAGTCTGCATCA                   CCCTGGCCGTCACTTCCTCCACCTGTGQCTCCCTCCTGGCTCTGGCCCATGTGGTTCT                   CATCCTAAGACTCCCCTTCTCTGGGCCTCATCAAATCAACCACTTCTTCTCTGAAATC                   CTGTCTGTCCTCAGGCTGGCCTGTGCTGACACCTGGCTCAACCAGGTGGTCATCTTTG                   CAGCCTGCGTGTTCTTCCTGGTGGGGCCACCCAGCCTGGTCCTTGTCTCCTACTCGCA                   CATCCTGGCGGCCATCCTGAGGATCCAGTCTGGGGAGGGCCGCAGAAAGGCCTTCTCC                   ACCTGCTCCTCCCACCTCTGCGTGGTGGGACTCTTCTTTGGCAGTGCCATCATCATGT                   ACATGGCCCCCAAGTCCCGCCATCCTGAGGAGCAGCAAAAGGTCTTTTTTCTATTTTA                   CAGTTTTTTCAACCCAACACTTAACCCCCTGATTTACAGCCTGAGGAACGGAGAGGTC                   AAGGGTGCCCTGAGGAGAGCACTGGGCAAGGAAAGTCATTCC TAA   CTGGTCTGACATT                       TGACTCTCCCTCCTCACTCATCTCCTCGAATCTTGGTACCAAATACCACCTAAGTTCA                       CTACTCTCTTTATATCA                                           ORF Start: ATG at 41       ORF Stop: TAA at 971           SEQ ID NO:186   310 aa   MW at 34713.8 kD                     NOV61a   MGENQTMVTEFLLLGFLLGPRIQMLLFGLFSLFYIFTLLGNGAILGLISLDSRLHTPM       CG59555-01 Protein Sequence           YFFLSHLAVVDIAYTRNTVPQMLANLLHPAKPISFAGCMTQTFLCLSFGHSECLLLVL                   MSYDRYVAICHPLRYSVIMTWRVCITLAVTSWTCGSLLALAHVVLILRLPFSGPHEIN                   HFFCEILSVLRLACADTWLNQVVIFAACVFFLVGPPSLVLVSYSHILAAILRIQSGEG                   RRKAFSTCSSHLCVVGLFFGSAIIMYMAPKSRHPEEQQKVFFLFYSFFNPTLNPLIYS                   LRNGEVKGALRRALGKESHS                  
 
     [0647] Further analysis of the NOV61a protein yielded the following properties shown in Table 61B.  
               TABLE 61B                       Protein Sequence Properties NOV61a                                        PSort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability located           in endoplasmic reticulum (membrane); 0.1000 probability           located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 43 and 44       analysis:                  
 
     [0648] A search of the NOV61a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 61C.  
               TABLE 61C                          Geneseq Results for NOV61a                                         NOV61a   Identities/               Protein/   Residues/   Similarities       Geneseq   Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAM29935   Peptide #3972   1 . . . 310   310/310 (100%)   0.0           encoded by probe   2 . . . 311   310/310 (100%)           for measuring           placental gene           expression—             Homo sapiens ,           311 aa.           [WO200157272-           A2, Aug. 9,           2001]       AAM17409   Peptide #3843   1 . . . 310   310/310 (100%)   0.0           encoded by probe   2 . . . 311   310/310 (100%)           for measuring           cervical gene           expression—             Homo sapiens ,           311 aa.           [WO200157278-           A2, Aug. 9,           2001]       AAG72949   Human olfactory   1 . . . 310   310/310 (100%)   0.0           receptor data   2 . . . 311   310/310 (100%)           exploration           sequence, SEQ           ID NO: 2631—             Homo sapiens ,           314 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG72187   Human olfactory   1 . . . 310   310/310 (100%)   0.0           receptor poly-   1 . . . 310   310/310 (100%)           peptide, SEQ ID           NO: 1868—             Homo sapiens ,           310 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAU04577   Human G-protein   1 . . . 310   288/310 (92%)    e−165           coupled receptor   1 . . . 308   294/310 (93%)            like protein,           GPCR #11—             Homo sapiens,             308 aa.           [WO200153454-           A2, Jul. 26, 2001]                  
 
     [0649] In a BLAST search of public sequence databases, the NOV61a protein was found to have homology to the proteins shown in the BLASTP data in Table 61D.  
               TABLE 61D                          Public BLASTP Results for NOV61a                                         NOV61a   Identities/           Protein       Residues/   Similarities       Accession   Protein/   Match   for the   Expect       Number   Organism/Length   Residues   Matched Portion   Value               Q96R46   OLFACTORY   67 . . . 283   217/217 (100%)    e−125           RECEPTOR—    1 . . . 217   217/217 (100%)             Homo sapiens             (Human), 217 aa           (fragment).       O95047   Olfactory    1 . . . 307   217/307 (70%)     e−122           receptor 2A4—    1 . . . 307   250/307 (80%)              Homo sapiens             (Human), 310 aa.       Q9NQN0   DJ1005H11.1   39 . . . 307   187/269 (69%)     e−103           (7 TRANS-    1 . . . 269   216/269 (79%)            MEMBRANE           RECEPTOR           (RHODOPSIN           FAMILY)           (OLFACTORY           RECEPTOR           LIKE)           PROTEIN))—             Homo sapiens             (Human), 272 aa           (fragment).       Q9Z1V2   OLFACTORY   63 . . . 285   172/223 (77%)    9e−98            RECEPTOR    1 . . . 223   190/223 (85%)            B12— Mus               musculus             (Mouse), 223 aa           (fragment).       O43888   OLFACTORY   67 . . . 282   173/217 (79%)    1e−97            RECEPTOR—    1 . . . 217   188/217 (85%)              Homo sapiens             (Human), 217 aa           (fragment).                  
 
     [0650] PFam analysis predicts that the NOV61a protein contains the domains shown in the Table 61E.  
               TABLE 61E                          Domain Analysis of NOV61a                                     Identities/               NOV61a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain   40 . . . 289    65/269 (24%)   1.1e−45       1 of 1       188/269 (70%)                  
 
     Example 62  
     [0651] The NOV62 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 62A.  
               TABLE 62A                       NOV62 Sequence Analysis                                                SEQ ID NO:187   1206 bp                     NOV62a,     AGTTGGTTGTAAATAATTCTGCTTATATTACCTACAGAGTAAACATTATAGCATTATC         CG59551-1 DNA Sequence             ACTCCAGAATCCTTTGTTTCTATGGTTTCCACATCTTTCCAATGTCTAGATGTTCCAG                       CTGCCCATCTCTGACAAATCCACCTGTGTCTCACA   ATG GATGCCACAGCCTGTAATGA                   ATCAGTGGATGGCTCACCCGTCTTCTATCTATTGGGCATCCCCTCTCTGCCAGAGACC                   TTCTTCCTCCCTGTGTTTTTTATTTTCCTCCTCTTCTACCTTCTCATCCTGATGGCTA                   ATGCCCTGATCCTGGTGGCCGTGGTGGCAGAGCCCAGCCTCCACAAGCCCATGTACTT                   CTTTCTGATCAATCTCTCCACCTTCCACATCCTTTTCACCACAACCACTGTCCCCAAG                   ATGCTGTCCTTATTCTTGCTTGCGGACCGCTTCCTCAGCTTTTCTTCCTGCTTACTGC                   AGATGTACCTCTTCCAAACTTTTACATGTTCAGAAGCCTTCATCCTGGTGGTCATGGC                   CTATGACCGCTATGTCGCTATCTGCCACCCACTGCACTACCCTGTCCTCATGAACCCA                   CAGACCAATGCTACCTTGGCAGCCAGTGCCTGGCTAACTGCCCTCCTCCTGCCCATCC                   CAGCACTACTAAGGACCTCCCAGATGGCATATAACAGCATTGCCTACATCTACCACTG                   CTTCTGTCATCATCTGGCTGTGGTCCAGGCCTCCTGCTCTGACACCACCCCCCAGACC                   CTCATGGGCTTCTGCATCGCCATGGTGGTGTCCTTCCTCCCCCTTCTCCTGGTGCTTC                   TCTCCTATGTCCACATCCTGGCCTCAGTGCTTCGCATCAGTTCCCTAGAAGGACGGCC                   AAAAGCCTTCTCCACCTGCAGCTCCCACCTTCTGGTCGTGGGCACCTACTACTCATCT                   ATTGCCATAGCCTACGTGGCCTACACGGCTGACCTGCCCCTTGACTTCCATATCATGG                   GCAATGTGGTATATGCCATTCTCACACCAATTCTCAACCCCCTCATTTACACGCTGAG                   AAACAGCGATGTAAAGGCAGCCATCACCAAAATCATGTCTCAAGACCCACGCTGTGAC                   AGGAGCATT TGA   CCTTTAAATGCAGCTAACTCTGCTTCCAGGACACCAAATAACAGTG                       CTTAGCACAGAGAAAGGACTCAATACATGATAATGAAATAA                                           ORF Start: ATG at 152       ORF Stop: TGA at 1112           SEQ ID NO:188   320 aa   MW at 35502.6 kD                     NOV62a,   MDATACNESVDGSPVFYLLGIPSLPETFFLPVFFIFLLFYLLILMGNALILVAVVAEP       CG59551-1 Protein Sequence           SLHKPMYFFLINLSTLDILFTTTTVPKMLSLFLLGDRFLSFSSCLLQMYLFQSFTCSE                   AFILVVMAYDRYVAICHPLHYPVLMNPQTNATLAASAWLTALLLPIPAVVRTSQMAYN                   SIAYIYHCFCDHLAVVQASCSDTTPQTLMGFCIAMVVSFLPLLLVLLSYVHILASVLR                   ISSLEGRAKAFSTCSSELLVVGTYYSSIAIAYVAYRADLPLDFHIMGNVVYAILTPIL                   NPLIYTLRNRDVKAAITKIMSQDPGCDRSI                  
 
     [0652] Further analysis of the NOV62a protein yielded the following properties shown in Table 62B.  
               TABLE 62B                       Protein Sequence Properties NOV62a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability located           in endoplasmic reticulum (membrane); 0.3000 probability           located in microbody (peroxisome)       SignalP   Likely cleavage site between residues 57 and 58       analysis:                  
 
     [0653] A search of the NOV62a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 62C.  
               TABLE 62C                          Geneseq Results for NOV62a                                         NOV62a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG72119   Human olfactory   35 . . . 290   213/256 (83%)    e−119           receptor poly-    2 . . . 257   228/256 (88%)           peptide, SEQ ID           NO: 1800—             Homo sapiens ,           295 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAU24639   Human olfactory   16 . . . 308   129/293 (44%)   6e−67            receptor   17 . . . 308   186/293 (63%)           AOLFR134—             Homo sapiens ,           325 aa.           [WO200168805-           A2, Sep. 20,           2001]       AAG72479   Human OR-like   16 . . . 308   129/293 (44%)   6e−67            polypeptide query   17 . . . 308   186/293 (63%)           sequence, SEQ           ID NO: 2160—             Homo sapiens ,           324 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG71590   Human olfactory   16 . . . 308   129/293 (44%)   6e−67            receptor poly-   17 . . . 308   186/293 (63%)           peptide, SEQ ID           NO: 1271—             Homo sapiens ,           324 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG71632   Human olfactory   16 . . . 315   126/300 (44%)   3e−64            receptor  Homo     13 . . . 312   179/300 (59%)             sapiens , 316 aa.           [WO200127158-           A2, Apr. 19,           2001]                  
 
     [0654] In a BLAST search of public sequence databases, the NOV62a protein was found to have homology to the proteins shown in the BLASTP data in Table 62D.  
               TABLE 62D                          Public BLASTP Results for NOV62a                                         NOV62a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9Z236   OLFACTORY   70 . . . 289   187/220 (85%)    e−104           RECEPTOR—    2 . . . 221   202/220 (91%)             Rattus norvegicus             (Rat), 221 aa           (fragment).       CAB43131   OLFACTORY   69 . . . 240   136/172 (79%)   1e−73            RECEPTOR—    1 . . . 172   148/172 (85%)             Stenella               coeruleoalba             (Striped dolphin),           172 aa           (fragment).       Q9EPG2   M51   16 . . . 310   131/295 (44%)   2e−67            OLFACTORY   12 . . . 305   191/295 (64%)           RECEPTOR—             Mus musculus             (Mouse), 314 aa.       Q9H208   HP4   16 . . . 312   127/297 (42%)   3e−65            OLFACTORY   12 . . . 308   180/297 (59%)           RECEPTOR—             Homo sapiens             (Human), 317 aa           (fragment).       Q920G5   OLFACTORY   16 . . . 308   126/295 (42%)   1e−62            RECEPTOR   19 . . . 311   180/295 (60%)           P3— Mus               musculus             (Mouse), 324 aa.                  
 
     [0655] PFam analysis predicts that the NOV62a protein contains the domains shown in the Table 62E.  
               TABLE 62E                          Domain Analysis of NOV62a                                     Identities/               NOV62a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain   46 . . . 295    58/268 (22%)   4.6e−38       1 of 1       179/268 (67%)                  
 
     Example 63  
     [0656] The NOV63 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 63A.  
               TABLE 63A                       NOV63 Sequence Analysis                                                SEQ ID NO:189   1042 bp                     NOV63a,     GACCTTTCATCACACTCTGGTCATTTACAAACTGTTATTAAGGA   ATG GGGGACAAGCA       CG59540-01 DNA Sequence           GCCCTGGGTCACAGAATTCATCCTGGTTGGATTCCAGCTCAGTGCAGAGATGGAGATC                   TTTCTCTCTTGCATCTTCTCCCTGTTATATCTCTTCAGTCTACTGAGGAATGGCATGA                   ACATGGGACTCATCTGTCTGGATCCCAGACTACACACCCCCATATACTTCTTCCTGTC                   ACACTTGGCCGTCATTGACATATACTATGCTTCCAACAATTTGCTCAACATGCTCGAA                   AACCTAGTGAAACACAAAAAAACTATCTCGTTCATCTCTTGCATTATGCAGATGGCTT                   TGTATTTGACTTTTGCTGCTGCAGTGTGCATGATTTTGGTGGTGATGTCCTATGACAG                   ATTTGTCGCGATCTGCCATCCCCTGCATTACACTGTCATCATGAACTGGAGAGTGTGC                   ACAGTACTGGCTATTACTTCCTGGGCATCTGCATTTTCCCTGGCCCTCATAAATCTAA                   TTCTCCTTCTAAGGCTGCCCTTCTGTGGGCCCCAGGAGGTGAACCACTTCTTCGGTGA                   AATTCTGTCTGTCCTCAAACTGGCCTGTGCAGACACCTGGATTAATCAAATTTTTGTC                   TTTGCTGGTGGTGTGTTTGTCTTAGTCGGGCCCCTTTCCTTGATGCTGATCTCCTACA                   TGCGCATCCTCTTGGCCATCCTGAAGATCCAGTCAGGCGAGGGCCACAGAAAGCACTT                   CTCTACCTGCTCCTCCCACCTCTGTGTGCTGGCGTTCTTCTTTGCCAACGCCATTGTC                   ATGTACATGGCCCCCAAGTCCCGCCATCCCGAGGAGCAGCAGAAGGTCCTTTCCCTGT                   TTTGCAGCCTTTCGAATCAGGTGCTGAACCCCCCTCTGATCTACAGCTTGACGAATGC                   AGAGGTCAAGAGTGCCCCACAAGAGGGCCAC TGA   AGAAGGAGAGGCTGATGTTACAAT                       CTCAAAGGCACCACGAGGAGAGGGCCTGCTCCGACAAATGGGGAAGTTGGCTTTTT                                           ORF Start: ATG at 45       ORF Stop: TGA at 960           SEQ ID NO:190   305 aa   MW at 345548 kD                     NOV63a,   MGDKQPWVTEFILVGFQLSAEMEIFLSCIFSLLYLFSLLRNGMNMGLICLDPRLHTPI       CG59540-1 Protein Sequence           YFFLSHLAVIDIYYASNNLLNMLENLVKHKKTISFISCIMQMALYLTFAAAVCMILVV                   MSYDRFVAICHPLHYTVIMNWRVCTVLAITSWACGFSLALINLILLLRLPFCGPQEVN                   HFFGEILSVLKLACADTWINEIFVFAGGVFVLVGPLSLMLISYMRTLLAILKIQSGEG                   HRKDFSTCSSHLCVVGFFFANAIVMYMAPKSRHPEEQQKVLSLFCSLWNQVLNPPLIY                   SLRNAEVKSAPQEGH                  
 
     [0657] Further analysis of the NOV63a protein yielded the following properties shown in Table 63B.  
               TABLE 63B                       Protein Sequence Properties NOV63a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability           located in endoplasmic reticulum (membrane); 0.3000           probability located in microbody (peroxisome)       SignalP   Likely cleavage site between residues 43 and 44       analysis:                  
 
     [0658] A search of the NOV63a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 63C.  
               TABLE 63C                          Geneseq Results for NOV63a                                         NOV63a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAU24758   Human olfactory   1 . . . 300   258/300 (86%)   e−146           receptor   1 . . . 299   275/300 (91%)           [WO200168805-A2,           Sep. 20, 2001]       AAG72952   Human olfactory   1 . . . 300   255/300 (85%)   e−144           receptor data   1 . . . 299   272/300 (90%)           exploratorium           sequence, SEQ ID           NO: 2634—             Homo sapiens ,           310 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAG72377   Human OR-like   1 . . . 300   255/300 (85%)   e−144           polypeptide query   1 . . . 299   272/300 (90%)           sequence, SEQ ID           NO: 2058—             Homo sapiens ,           312 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAG72169   Human olfactory   1 . . . 300   255/300 (85%)   e−144           receptor poly-   1 . . . 299   272/300 (90%)           peptide, SEQ ID           NO: 1850—             Homo sapiens ,           312 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAG71994   Human olfactory   1 . . . 300   225/300 (75%)   e−129           receptor poly-   1 . . . 299   256/300 (85%)           peptide, SEQ ID           NO: 1675—             Homo sapiens ,           314 aa.           [WO200127158-A2,           Apr. 19, 2001]                  
 
     [0659] In a BLAST search of public sequence databases, the NOV63a protein was found to have homology to the proteins shown in the BLASTP data in Table 63D.  
               TABLE 63D                          Public BLASTP Results for NOV63a                                         NOV63a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               O95047   Olfactory receptor    1 . . . 299   173/299 (57%)   2e−92           2A4— Homo      1 . . . 298   217/299 (71%)             sapiens  (Human),           310 aa.       O43885   OLFACTORY   67 . . . 281   154/216 (71%)   5e−88           RECEPTOR—    1 . . . 216   182/216 (83%)             Homo sapiens             (Human), 217 aa           (fragment).       O43888   OLFACTORY   67 . . . 281   153/216 (70%)   8e−88           RECEPTOR—    1 . . . 216   182/216 (83%)             Homo sapiens             (Human), 217 aa           (fragment).       Q96R48   OLFACTORY   67 . . . 281   153/216 (70%)   2e−87           RECEPTOR—    1 . . . 216   181/216 (82%)             Homo sapiens             (Human), 217 aa           (fragment).       Q96R47   OLFACTORY   67 . . . 281   149/215 (69%)   3e−84           RECEPTOR—    1 . . . 214   175/215 (81%)             Homo sapiens             (Human), 215 aa           (fragment).                  
 
     [0660] PFam analysis predicts that the NOV63a protein contains the domains shown in the Table 63E.  
               TABLE 63E                          Domain Analysis of NOV63a                                     Identities/               NOV63a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain   47 . . . 290    55/270 (20%)   9.7e−25       1 of 1       174/270 (64%)                  
 
     Example 64  
     [0661] The NOV64 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 64A.  
               TABLE 64A                       NOV64 Sequence Analysis                                                SEQ ID NO:191   973 bp                     NOV64a,     AGGCACTAA   ATG AATATCTGTTTAATTCATAAAGTAACAGAGTTTCTCTTCTCTGGAT       CG59280-01 DNA Sequence           TCCCACAGTTTGAAGATGGTAGCCTCCTCTTCTTCATTCCATTGTTTGTTATCTACAT                   ATTCATTCTCATTGGGAATCTTATTCTATTTTTTCCACTCAGGGTGGATACCCGTCTC                   CACAACCCCATGTATAATTTTATCAGCATTTTCTCATTTCTGGAGATCTGGTACACAA                   CTGCCACAATTCCCAAGATGCTCTCCATCCTCATCAGCAGGCAGAGGACCATCTCCAT                   GGTTGGTTGCCTCTTGCAGATGTACTTCTTCCATTCACTGGGAAATTCAGAGGGGATT                   CAACCATCATGACCCCCGGGCTCTGTGTTCAGCTCTCTGTGGGGTCCTGCATCTTTGG                   CTTTCTTGTGTTGCTCCCAGAGATTGCATGGATTTCCACACTGCCCTTCTGTGGACCC                   AACCAAATCCACCAGATCTTCTGTGATTTTGAACCTGTGCTGCGCTTGGCCTGTACAG                   ACACGTCCATGATTCTGATTGAGGATGTGATCCATGCTGTGGCCATTGTATTCTCTGT                   CCTGATTATTGCCTTTTCTTATATCAGAATCATCACTGTAATCCTGAGGATTCCCTCT                   GTTGAAGGCCGCCAGAAGGCCTTTTCTACCTGTGCCCCCCATCTTACTGTCTTTCTGA                   TGTTCTATGGCAGTGTATCCCTCATGTACCTGCGTTTCTCTGCCACTTTCCCACCGAT                   TTTGCACACAGCTGTTGCACTGATGTTTGCAGTTCTTGCTCCCTTTTTCAACCCTATC                   ATCTATAGCTTTAGAAATAAGGACATGAAGATTCCAATTAAAAAGCTTTTCTGCCCTC                   AGAAGATGGTTAATTTATCTGTAGAT TAA   TGCTAGCTCATAGGCA                                           ORF Start: ATG at 10       ORF Stop: TAA at 955           SEQ ID NO:192   315 aa   MW at 35741.4 kD                     NOV64a,   MNICLIHKVTEFLFSGFPQFEDGSLLFFIPLFVIYIFIVIGNLIVFFAVRVDTRLHNP       CG59280-01 Protein Sequence           MYNFISIFSFLEIWYTTATIPKMLSILISRQRTISMVGCLLQMYFFHSLGNSEGILLT                   TMAIDRYVAICNPLRYPTIMTPGLCVQLSVGSCIFGFLVLLPEIAWISTLPFCGPNQI                   HQIFCDFEPVLRLACTDTSMILTEDVTHAVAIVFSVLIIAFSYIRTTTVTLRTPSVEG                   RQKAFSTCAAHLSVFLMFYGSVSLMYLRFSATFPPILDTAVALMFAVLAPFFNPIIYS                   FRNKDMKTAIKKLFCPQKMVNLSVD                                     SEQ ID NO:193   929 bp                     NOV64b,     TC   TTC TTCATTCCATTGTTTGTTATCTACATATTCATTGTCATTGGGAATCTTATTGT       CG59280-02 DNA Sequence           ATTTTTTGCAGTCAGGGTGGATACCCGTCTCCACAACCCCATGTATAATTTTATCAGC                   ATTTTCTCATTTCTGGAGATCTGGTACACAACTGCCACAATTCCCAAGATGCTCTCCA                   TCCTCATCAGCAGGCAGAGGACCATCTCCATGGTTGGTTGCCTCTTGCAGATGTACTT                   CTTCCATTCACTGGGAAATTCAGAGGGCATTTTGTTGACCACCATGGCCATTGATAGG                   TACGTTGCCATCTGTAACCCTCTCCGCTACCCAACCATCATGACCCCCGGGCTCTGTG                   TTCAGCTCTCTGTGGGGTCCTGCATCTTTGGCTTTCTTGTGTTGCTCCCAGAGATTGC                   ATGGATTTCCACACTGCCCTTCTGTGGACCCAACCAAATCCACCAGATCTTCTGTGAT                   TTTCAACCTGTGCTGCGCTTGGCCTGTACAGACACGTCCATGATTCTGATTGAGGATC                   TGATCCATGCTGTGGCCATTGTATTCTCTGTCCTGATTATTGCCTTTTCTTATATCAG                   AATCATCACTGTAATCCTGAGGATTCCCTCTGTTGAAGGCCGCCAGAAGGCCTTTTCT                   ACCTGTCCCGCCCATCTTACTGTCTTTCTGATGTTCTATGGCAGTGTATCCCTCATGT                   ACCTGCGTTTCTCTCCCACTTTCCCACCGATTTTGGACACAGCTGTTGCACTGATGTT                   TGCAGTTCTTGCTCCCTTTTTCAACCCTATCATCTATAGCTTTACAAATAAGGACATG                   AAGATTCCAATTAAAAAGCTTTTCTGCCCTCAGAAGATCGTTAATTTATCTGTAGAT T                       AA TGCTAGCTCATAGGCACCTTTCACTGTGGATGTTACTCTAACACAATAAACCATAT                         A                                           ORF Start: TTC at 3       ORF Stop: TAA at 870           SEQ ID NO:194   289 aa   MW at 32772.9 kD                     NOV64b,   FFIPLFVIYIFIVIGNLIVFFAVRVDTRLHNPMYNFISIFSFLEIWYTTATIPKMLSI       CG59280-02 Protein Sequence           LISRQRTISMVGCLLQMYFFHSLGNSEGILLTTMAIDRYVAICNPLRYPTIMTPGLCV                   QLSVGSCIFGFLVLLPEIAWISTLPFCGPNQIHQIFCDFEPVLRLACTDTSMILIEDV                   IHAVAIVFSVLIIAFSYTRIITVILRIPSVEGRQKAFSTCAAHLSVFLMFYCSVSLMY                   LRFSATFPPILDTAVALMFAVLAPFFNPIIYSFRNKDMKIAIKKLFCPQKMVNLSVD                  
 
     [0662] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 64B.  
               TABLE 64B                          Comparison of NOV64a against NOV64b.                                 Protein   NOV64a Residues/   Identities/Similarities           Sequence   Match Residues   for the Matched Region                       NOV64b   27 . . . 315   289/289 (100%)                1 . . . 289   289/289 (100%)                      
 
     [0663] Further analysis of the NOV64a protein yielded the following properties shown in Table 64C.  
               TABLE 64C                       Protein Sequence Properties NOV64a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability           located in endoplasmic reticulum (membrane); 0.3000           probability located in microbody (peroxisome)       SignalP   Likely cleavage site between residues 54 and 55       analysis:                  
 
     [0664] A search of the NOV64a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 64D.  
               TABLE 64D                          Geneseq Results for NOV64a                                         NOV64a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG71805   Human olfactory   59 . . . 314   255/256 (99%)   e−145           receptor poly-    1 . . . 256   255/256 (99%)           peptide, SEQ ID           NO: 1486—             Homo sapiens ,           256 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG71803   Human olfactory    9 . . . 311   243/303 (80%)   e−143           receptor SEQ ID    9 . . . 311   267/303 (87%)           NO: 1484—             Homo sapiens ,           315 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAU24658   Human olfactory    9 . . . 311   240/303 (79%)   e−140           receptor   25 . . . 327   264/303 (86%)           AOLFR156—             Homo sapiens ,           331 aa.           [WO200168805-           A2, Sep. 20,           2001]       AAG71807   Human olfactory    9 . . . 313   222/305 (72%)   e−131           receptor poly-    9 . . . 313   259/305 (84%)           peptide, SEQ ID           NO: 1488—             Homo sapiens ,           319 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAU24721   Human olfactory    9 . . . 308   209/300 (69%)   e−119           receptor   37 . . . 336   242/300 (80%)           AOLFR220—             Homo sapiens ,           343 aa.           [WO200168805-           A2, Sep. 20,           2001]                  
 
     [0665] In a BLAST search of public sequence databases, the NOV64a protein was found to have homology to the proteins shown in the BLASTP data in Table 64E.  
               TABLE 64E                          Public BLASTP Results for NOV64a                                         NOV64a   Identities/           Protein       Residues/   Similarities for       Accession   Protein   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9EPG2   M51 OLFACTORY   1 . . . 302   137/303 (45%)   2e−71           RECEPTOR— Mus     4 . . . 303   194/303 (63%)             musculus  (Mouse),           314 aa.       Q9EPV0   M50 OLFACTORY   6 . . . 302   132/298 (44%)   3e−71           RECEPTOR   4 . . . 301   191/298 (63%)           (OLFACTORY           RECEPTOR           M50)— Mus               musculus  (Mouse),           316 aa.       Q9EPG1   M50 OLFACTORY   6 . . . 302   130/298 (43%)   2e−70           RECEPTOR—   4 . . . 301   190/298 (63%)             Mus musculus             (Mouse), 316 aa.       Q9WU86   ODORANT   1 . . . 310   133/313 (42%)   4e−69           RECEPTOR S1—   12 . . . 321    190/313 (60%)             Mus musculus             (Mouse), 324 aa.       Q96KK4   DJ994E9.5   9 . . . 314   137/307 (44%)   9e−68           (OLFACTORY   2 . . . 306   189/307 (60%)           RECEPTOR,           FAMILY 10,           SUBFAMILY C,           MEMBER 1           (HS6M1-17))—             Homo sapiens             (Human), 306 aa.                  
 
     [0666] PFam analysis predicts that the NOV64a protein contains the domains shown in the Table 64F.  
               TABLE 64F                          Domain Analysis of NOV64a                                     Identities/               NOV64a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain   41 . . . 289    51/269 (19%)   2.2e−33       1 of 1       179/269 (67%)                  
 
     Example 65  
     [0667] The NOV65 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 65A.  
               TABLE 65A                       NOV65 Sequence Analysis                                                SEQ ID NO:195   972 bp                     NOV65a,     GC   ATG GTGATCCTGTCCTGGGAAAACCAAACGATGAGAGTGGAATTCGTGCTTCAAGG               CG59568-01 DNA Sequence   ATTCTCTTCCATCAGACAGTTAAATATTTTCCTCTTTATGATAATTTTAGTTTTCTAC                   ATCTTAACTGTTTCTGCAAACATCCTCATTGTCCTTCTAGTTTTAGTCAGACATCATC                   TCCACACCCCTATGTACTTCCTCCTGGTGAACTTGTCCTGTCTGGAGATCTGGTATAC                   CTCTAACATCATCCCCAAAATGTTCCTGATTATCATACCTGAAGAGAAGACTATCTCT                   GTGGCTGGCTGGCTGGCACAATTCTACTTCTTCGGATCCCTGGCTGCCACGGAGTGCC                   TCTTCCTCACTGTGATGTCCTATGATCGCTACCTAGCCATCTGCCAGCCTCTTTGCTA                   CCGTGTCCTCATGACTGGCCCCCTTTGCATCAGGCTAGCTGCTGGCTCTTGCTTCTGC                   TGCTTCCTCCTTACAGCAATCACCATGGTCTTGCTATGTAGACTAACCTTCTGTCGAC                   CCTATGAAACTGATCACTTCTTTTGTGACTTCACCCCTCTGCTTCATCTCTCCTGCAT                   GGATACCTCAGTGACTGAGACCATTGCCTTTGCCACCTCTTCTGCAGTAACTCTGATC                   CCATTTCTCCTCATTGTAGCCTCCTACTCCTCCGTCCTTTCTGCTATCCTAAGAATCC                   CATCTTGCACAGGCCAGAAAAAGGCCTTCTCCACCTGCTCTTCCCACCTCACTGTGGT                   CATACTGTTTTATGGGACACTGATTGCCACATACCTTGTGCCCTCAGCCAACTCATCC                   CAACTCTTGTGCAAAGGGTCCTCTCTGCTCTACATCATCCTGACACCCATGTTTAACC                   CCATCATTTATAGCCTGAGAAATAGAGACATCCATGAAGCTCTGAAGAACTGCTTGAG                   GAAGAAGTCAGGTGTTTGCCTTAGA TAA   TACGAAAAGGAAAAAA                                       ORF Start: ATG at 3   ORF Stop: TAA at 954           SEQ ID NO:196   317 aa MW at 35713.4 kD                     NOV65a,   MVILSWENQTMRVEFVLQGFSSIRQLNIFLFMIILVFYILTVSGNILIVLLVLVRHHL               CG59568-01 Protein Sequence   HTPMYFLLVNLSCLETWYTSNYTPKMLLIIIAEEKTISVAGWLAQFYFFGSLAATECL                   LLTVMSYDRYLATCQPLCYRVLNITGPLCIRLAAGSWFCCFLLTAITMVLLCRLTFCGP                   YETDHFFCDFTPLVHLSCMDTSVTETTAFATSSAVTLTPFLLIVASYSCVLSATLRIP                   SCTGQKKAFSTCSSHLTVVIVFYGTLIATYLVPSANSSQLLCKGSSLLYIILTPMFNP                   IIYSLRDIHEALKKCLRKKSGVCLR                  
 
     [0668] Further analysis of the NOV65a protein yielded the following properties shown in Table 65B.  
               TABLE 65B                       Protein Sequence Properties NOV65a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3888 probability located           in mitochondrial inner membrane; 0.3030 probability located           in mitochondrial intermembrane space       SignalP   Likely cleavage site between residues 45 and 46       analysis:                  
 
     [0669] A search of the NOV65a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 65C.  
               TABLE 65C                          Geneseq Results for NOV65a                                         NOV65a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG72527   Human OR-like   1 . . . 316   315/316 (99%)   0.0           polypeptide query   1 . . . 316   315/316 (99%)           sequence, SEQ ID           NO: 2208—             Homo sapiens ,           316 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG72231   Human olfactory   1 . . . 316   315/316 (99%)   0.0           receptor poly-   1 . . . 316   315/316 (99%)           peptide, SEQ ID           NO: 1912—             Homo sapiens ,           316 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG72084   Human olfactory   1 . . . 316   315/316 (99%)   0.0           receptor poly-   1 . . . 316   315/316 (99%)           peptide, SEQ ID           NO: 1765—             Homo sapiens ,           316 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG72700   Murine OR-like   1 . . . 308   154/308 (50%)   2e−83           polypeptide query   3 . . . 308   208/308 (67%)           sequence, SEQ ID           NO: 2382— Mus               musculus , 314 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG71814   Human olfactory   8 . . . 311   142/304 (46%)   7e−79           receptor poly-   5 . . . 308   208/304 (67%)           peptide, SEQ ID           NO: 1495—             Homo sapiens ,           317 aa.           [WO200127158-           A2, Apr. 19,           2001]                  
 
     [0670] In a BLAST search of public sequence databases, the NOV65a protein was found to have homology to the proteins shown in the BLASTP data in Table 65D.  
               TABLE 65D                          Public BLASTP Results for NOV65a                                         NOV65a   Identities/           Protein       Residues/   Similarities for       Accession   Protein   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9GZK7   Olfactory receptor   1 . . . 308   147/308 (47%)   4e−77           11A1 (Hs6M1-   1 . . . 306   202/308 (64%)           18)— Homo               sapiens  (Human),           315 aa.       O13036   CHICK   7 . . . 311   139/305 (45%)   1e−76           OLFACTORY   4 . . . 308   198/305 (64%)           RECEPTOR 7—             Gallus gallus             (Chicken), 323 aa.       Q9JKA6   OLFACTORY   4 . . . 313   143/311 (45%)   1e−75           RECEPTOR P2—   1 . . . 311   194/311 (61%)             Mus musculus             (Mouse), 315 aa.       Q9WU86   ODORANT   14 . . . 308    144/295 (48%)   2e−75           RECEPTOR S1—   21 . . . 315    189/295 (63%)             Mus musculus             (Mouse), 324 aa.       Q9UGF6   Olfactory receptor   7 . . . 305   138/299 (46%)   5e−75           5V1 (Hs6M1-21)—   4 . . . 302   199/299 (66%)             Homo sapiens             (Human), 321 aa.                  
 
     [0671] PFam analysis predicts that the NOV65a protein contains the domains shown in the Table 65E.  
               TABLE 65E                          Domain Analysis of NOV65a                                     Identities/               NOV65a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               granulin: domain   144 . . . 155     7/13 (54%)   1.7       1 of 1        11/13 (85%)       Trypan_glycop:   218 . . . 241     6/24 (25%)   7.9       domain 1 of 1        21/24 (88%)       7tm_1: domain    44 . . . 293    53/268 (20%)   1.5e−31       1 of 1       172/268 (64%)                  
 
     Example 66  
     [0672] The NOV66 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 66A.  
               TABLE 66A                       NOV66 Sequence Analysis                                                SEQ ID NO:197   987 bp                     NOV66a,     CATCTTCCTATGTGTC   ATG TCTCCTCTTAATGACACAAAAATGGAAGTCCTTAGATTC               CG59224-01 DNA Sequence   CTCCTTATCGGGATCACTGGACTGGAGAAAAGTCGCACCTGGATATCCATTCCTTTCT                   TATCTGTGTACCTTCTTTCTTGGATGCCTAATTTTACCGTCCTCTTTTTTATCAAGAC                   AGACCAAAGCCTCCATGAACCTATGTATTATTTGCTTTCCATGCTCTCCATCTCTGAC                   CTACGGCTGTCTCTGTCTTCCTTACCCATCACTTTGGGACTATTCCTATTTGATGTCC                   ATGAAATTCATGCAGCTCCATGCTTTGCCCAGGAATTTTTTATCCATCTGTTTACACT                   CAGTGAAGCCTCTGTACTGTCTGTAATGGCATTTGACTGGTATGTGGCAATCCACAGT                   CCTTTGAGATACAGCACTATCTTAACTAGTCCCAGAGCCATCAAAACAGGGGTTCTTC                   TGACTTCCAAGAATGTTCTTTTGATCCTTCCACTGCCCTTTCTCTTGCAAAGGCTGAG                   ATATTGTCATCAAAACCTGCTCTCCCACTCCTATTGTCTCCACCAGGATGTCATCAAG                   CTGATGTGTTCTGACAACACAGTCAATGTTGTCTACGGACTCTGTGCAGGACTTTCTA                   CTATGCTGGACTTGGTGTTTATTACCTTCTCCTATATGATTTTAAGGGCTGTACTGGG                   AATTGCTACCCCCAGACAGCAGTTCAAGGCCCTCAACACGTGCATCTCTCACATCTCT                   GGGATGTGTCTCCTATGATCCACGTCCTCATCGCTGATATTTTTCTGCTCGTCCCACC                   GCTGTGCTTATCTTCTATGTGCCCACGCTGAGTGCTGCCATGCTCCACCAGTTTGCCA                   CCTGTTGAATCCCATCGTGTACTGTGTGAAGACCCACCAAATCCGAGAAAAGGTTGTG                   GGCAAACTTTGTCCAAAAGTAAGT TGA   TCAAAGGAATGAGAAAGGGAATGAATGTATA                       A                                       ORF Start: ATG at 17   ORF Stop: TGA at 953           SEQ ID NO:198   312 aa MW at 35250.7 kD                     NOV66a,   MSPLNDTRMEVLRFLLIGITGLEKSRTWISIPFLSVYLLSWMGNFTVLFFIKTEQSLH               CG59224-01 Protein Sequence   EPMYYLLSMLSTSDLGLSLSSLPITLSLFLFDVHETHAAPCFAQEFFIHLFTVSEASV                   LSVMAFDWYVAIHSPLRYSTTLTSPRAIKTGVLLTSKNVLLILPLPFLLQRLRYCHQN                   LLSHSYCLHQDVMKLMCSDNTVNVVYGLCAGLSTMLOLVFITFSYMILRAVLGTATPR                   QQFKALNTCISHICAVLTFYVPTLSAAMLHQFARDVSPMTHVLMADIFLLVPPLLNPI                   VYCVKTHQIREKVVGKLCPKVS                  
 
     [0673] Further analysis of the NOV66a protein yielded the following properties shown in Table 66B.  
               TABLE 66B                       Protein Sequence Properties NOV66a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability located           in endoplasmic reticulum (membrane); 0.2007 probability           located in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 50 and 51       analysis:                  
 
     [0674] A search of the NOV66a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 66C.  
               TABLE 66C                          Geneseq Results for NOV66a                                         NOV66a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG72488   Human OR-like   1 . . . 312   309/313 (98%)   e−176           polypeptide query   1 . . . 313   309/313 (98%)           sequence, SEQ ID           NO: 2169— Homo               sapiens , 319 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAG71557   Human olfactory   1 . . . 312   309/313 (98%)   e−176           receptor poly-   1 . . . 313   309/313 (98%)           peptide, SEQ ID           NO: 1238— Homo               sapiens , 319 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAU24573   Human olfactory   1 . . . 310   186/311 (59%)   e−109           receptor   1 . . . 311   246/311 (78%)           AOLFR63— Homo               sapiens , 313 aa.           [WO200168805-A2,           Sep. 20, 2001]       AAG71558   Human olfactory   1 . . . 310   185/311 (59%)   e−108           receptor  Homo     1 . . . 311   245/311 (78%)             sapiens , 313 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAU24682   Human olfactory   1 . . . 307   188/308 (61%)   e−106           receptor   1 . . . 306   237/308 (76%)           AOLFR181— Homo               sapiens , 312 aa.           [WO200168805-A2,           Sep. 20, 2001]                  
 
     [0675] In a BLAST search of public sequence databases, the NOV66a protein was found to have homology to the proteins shown in the BLASTP data in Table 66D.  
               TABLE 66D                          Public BLASTP Results for NOV66a                                         NOV64a   Identities/           Protein       Residues/   Similarities for       Accession   Protein   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               AAL351091   PROSTATE-   14 . . . 304   141/293 (48%)   2e−77           SPECIFIC G   11 . . . 303   199/293 (67%)           PROTEIN-           COUPLED           RECEPTOR           RA1C— Mus               musculus             (Mouse), 320 aa.       O88628   Olfactory   14 . . . 304   141/293 (48%)   2e−77           receptor 51E2   11 . . . 303   200/293 (68%)           (G-protein           coupled receptor           RA1c)— Rattus               norvegicus             (Rat), 320 aa.       CAC38935   SEQUENCE 9    5 . . . 304   145/302 (48%)   2e−77           FROM PATENT    6 . . . 306   206/302 (68%)           WO0131014—             Homo sapiens             (Human), 318 aa.       CAC37756   SEQUENCE 1    5 . . . 304   145/302 (48%)   3e−77           FROM PATENT    5 . . . 305   206/302 (68%)           WO0125434—             Homo sapiens             (Human), 317 aa.       Q9H255   Olfactory receptor   14 . . . 304   139/293 (47%)   2e−76           51E2 (Prostate   11 . . . 303   198/293 (67%)           specific G-protein           coupled receptor)           (HPRAJ)—             Homo sapiens             (Human), 320 aa.                  
 
     [0676] PFam analysis predicts that the NOV66a protein contains the domains shown in the Table 66E.  
               TABLE 66E                          Domain Analysis of NOV66a                                     Identities/               NOV64a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain   43 . . . 151   30/111 (27%)   6.3e−14       1 of 2       73/111 (66%)       7tm_1: domain   43 . . . 151    16/92 (17%)   0.052       1 of 2        52/92 (57%)                  
 
     Example 67  
     [0677] The NOV67 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 67A.  
               TABLE 67A                       NOV67 Sequence Analysis                                                SEQ ID NO:199   994 bp                     NOV67a,     CACA   ATG TCTGTCTTCAATAGTTCTCCCTTATACCCTCCCTTCCTCCTAACGGGCCTC       CG59222-01 DNA Sequence           TCAGGCCTTGAAAGCAGATATGACTTGATTTCCCTGCCCATCTTCTTGGTTTATGCCA                   CCTCAATTGCCGGGAACATTAGCATCCTCTTCATTATCAGAACTGAGTCTTCCCTCCA                   CCAACCGATGTATTACTTTCTGTCAATGCTGGCATTCACTGACCTGGGCCTATCTAAC                   ACTACCTTACCTACCATGTTCAGTGTCTTCTGGTTCCATGCCCGCGAGATCTCCTTCA                   ATGCTTCTCTGGTCCAAATGTACTTCATTCATCTTTTCTCGATTATTGAGTCAGCTGT                   ACTCCTGGCTATGGCCTTTGACTGCTTTATAGCAATCTGTGAACCCTTGCGCTATGCA                   GCCATCCTAACCAATGATGTAATCATTGGGATTGGGTTGGCAATTGCTGGAAGGGCCT                   TGGCTCTGGTCTTTCCAGCTTCTTTCCTCTTGAAGAGGCTTCAATATCATGATGTCAA                   TATTCTGTCCTACCTCTTCTGCCTGCACCAGGACCTCATAAAGACGACTGTATCCAAC                   TGTCGAGTCAGCAGCATCTATGGCCTCATGGTGGTCATCTGTTCCATGGGACTTGATT                   CAGTCCTTCTCCTCCTCTCCTATGTCCTCATCCTCCCCACACTGTTCAGTATAGCCTC                   CAAGGCAGAGAGAGTGAGAGCCCTCAATACTTGCATCTCCCACATCTGTGCTGTACTC                   ACCTTCTATACACCAATGATTCGCCTATCTATGATCCATCGCTATCCACAGAATCCTT                   CCTCAATTGTCCATGTGCTGATGGCCAATGTCTACTTGCTGGTTCCACCTCTCATGAA                   CCCCGTTGTCTACAGTGTTAAGACCAAGCAGATTCGTGACAGAATCTTCAATAAATTC                   AAGAAACATGAAGTG TAG   ATCACAGAGATTCTCAAACATAACTTTCCCTCCATTCCCC                       ATATATTT                                           ORF Start: ATG at 5       ORF Stop: TAG at 944           SEQ ID NO:200   313 aa   MW at 35044.2 kD                     NOV67a,   MSVFNSSALYPRFLLTGLSGLESRYDLISLPIFLVYATSIAGNISILFIIRTESSLHQ       CG59222-01 Protein Sequence           PMYYFLSMLAFTDLGLSNTTLPTMFSVFWFHAREISFNACLVQMYFIHVFSIIESAVL                   LAMAFDCFIAICEPLRYAAILTNDVIIGIGLAIAGRALALVFPASFLLKRLQYHDVNI                   LSYLFCLHQDLIKTTVSNCRVSSIYGLMVVICSMGLDSVLLLLSYVLILGTVLSIASK                   AERVRALNTCISHICAVLTPYTPMTGLSMIHRYGQNASSIVHVLMANVYLLVPPLMNP                   VVYSVKTKQIRDRIFNKFKKHEV                  
 
     [0678] Further analysis of the NOV67a protein yielded the following properties shown in Table 67B.  
               TABLE 67B                       Protein Sequence Properties NOV67a                                        PSort   0.6000 probability located in plasma membrane; 0.4047       analysis:   probability located in mitochondrial inner membrane; 0.4000           probability located in Golgi body; 0.3480 probability located           in mitochondrial intermembrane space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0679] A search of the NOV67a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 67C.  
               TABLE 67C                          Geneseq Results for NOV67a                                         NOV67a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG72605   Human OR-like   1 . . . 309   295/310 (95%)    e−163           polypeptide query   4 . . . 313   298/310 (95%)           sequence, SEQ ID           NO: 2286— Homo               sapiens , 318 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAG71519   Human olfactory   1 . . . 309   295/310 (95%)    e−163           receptor poly-   4 . . . 313   298/310 (95%)           peptide, SEQ ID           NO: 1200— Homo               sapiens , 318 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAU24683   Human olfactory   5 . . . 308   178/304 (58%)    e−102           receptor   9 . . . 312   235/304 (76%)           AOLFR182— Homo               sapiens , 314 aa.           [WO200168805-A2,           Sep. 20, 2001]       AAG71715   Human olfactory   5 . . . 308   178/304 (58%)    e−102           receptor poly-   9 . . . 312   235/304 (76%)           peptide, SEQ ID           NO: 1396— Homo               sapiens , 314 aa.           [WO200127158-A2,           Apr. 19, 2001]       ABB44526   Human GPCR4a   5 . . . 308   169/304 (55%)   2e−96            polypeptide SEQ ID   6 . . . 309   227/304 (74%)           NO 11— Homo               sapiens , 315 aa.           [WO200174904-A2,           Oct. 11, 2001]                  
 
     [0680] In a BLAST search of public sequence databases, the NOV67a protein was found to have homology to the proteins shown in the BLASTP data in Table 67D.  
               TABLE 67D                          Public BLASTP Results for NOV67a                                         NOV67a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9H344   Olfactory   13 . . . 308   154/296 (52%)   2e−91           receptor 51I2   12 . . . 307   221/296 (74%)           (HOR5′beta12)—             Homo sapiens             (Human), 312 aa.       Q9H2C8   ODORANT    2 . . . 308   160/307 (52%)   5e−89           RECEPTOR   10 . . . 316   216/307 (70%)           HOR3′BETA1—             Homo sapiens             (Human), 321 aa.       Q9H343   Olfactory    5 . . . 312   156/309 (50%)   9e−89           receptor 51I1    5 . . . 313   223/309 (71%)           (HOR5′beta11)—             Homo sapiens             (Human), 314 aa.       AAL35109   PROSTATE-   13 . . . 309   148/297 (49%)   2e−86           SPECIFIC G   11 . . . 307   207/297 (68%)           PROTEIN-           COUPLED           RECEPTOR           RA1C— Mus               musculus             (Mouse), 320 aa.       Q924X8   OLFACTORY    2 . . . 304   150/303 (49%)   1e−85           RECEPTOR    3 . . . 305   221/303 (72%)           S85— Mus               musculus             (Mouse), 314 aa.                  
 
     [0681] PFam analysis predicts that the NOV67a protein contains the domains shown in the Table 67E.  
               TABLE 67E                          Domain Analysis of NOV67a                                     Identities/               NOV67a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain   42 . . . 138   24/99 (24%)   7.8e−14       1 of 1       67/99 (68%)                  
 
     Example 68  
     [0682] The NOV68 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 68A.  
               TABLE 68A                       NOV68 Sequence Analysis                                                SEQ ID NO:201   981 bp                     NOV68a,     GCA   ATG AGAAACCGCAGTGTTGTCCCTGAGTTTGTCCTCCTCGGGCTGTCAGCTGGCC       CG59220-01 DNA Sequence           CCCACACCCACACTCTGCTCTTTGTGCTGTTCGTGGTGATTTGCCTCCTGACTGTGAT                   GGGAAACCTGCTGCTGCTGGTGGTGATTAATGCTGATTCTTGCCTCCACACACCCATG                   TACTTCTTCCTGGGACAATTGTCCTTCTTGGATCTCTGCCATTCCTCTGTCACTGCAC                   CTAAGCTGTTGGAGAACCTCCTGTCTGAGAAGAAAACCATCTCAGTAGAGGGCTGCAT                   GGCTCAGGTCTTCTTTGTGTTTGCCACTGGGGGCACTGAATCCTCCCTGCTTGCTGTG                   ATGGCCTATGACCGCTATGTTGCCATCAGCTCTCCTTTGCTCTATGCCCAACTGATGA                   ACAGACAGCTGTGTTCAGGGCTGGTGGGGGGCTCATGGGGCTTGGCTTTTCTGGATGC                   CCTCATCAATATCCTTGTAGCTCTCAATTTAGACTTCTGTGACGCTCAAAATATCCAC                   CACTTCAGCTGTGAGCTGCCCTCTCTCTATCCTTTGTCTTGCTCTGATGTGTCAGCAA                   GTTTTACCACCCTGCTCTGCTCCAGCTTCCTGCATTTCTTTGGAAATTTTCTCATGAT                   ATTCTTGTCTTATATTTGCATTTTGTCCACCATCCTGAGGATCAGCTCCACTACAGGC                   ACAAGCAAAGCCTTCTCCACCTGCTCCTCCCACCTCACTGCACTGATTTTCTTTTATC                   GCTCCGGATTACTCCGCTATCTCATGCCAAATTCAGGATCCATTCAAGAGCTGATCTT                   CTCCTTGCAGTACAGCGTGATCACTCCCATGCTGAATCTCCTCATTTACAGCCTGAAG                   AACAGGGAGGTGAAGGCAGCTGTGAGAAGAACATTGAGAAAATATTTC TAG   TGTTTCA                       ATAGACTTATGAAATCAGAATGATGAGGGAACTGGATAGAACTGCAACAAGCA                                           ORF Start: ATG at 4       ORF Stop: TAG at 919           SEQ ID NO:202   305 aa   MW at 33732.3 kD                     NOV68a   MRNRSVVPEFVLLGLSAGPQTQTLLFVLFVVICLLTVMGNLLLLVVINADSCLHTPMY       CG59220-01 Protein Sequence           FFLGQLSFLDLCHSSVTAPKLLENLLSEKKTISVEGCMAQVFFVFATGGTESSLLAVM                   AYDRYVAISSPLLYGQVMNRQLCSGLVGGSWGLAFLDALINILVALNLDFCEAQNTGR                   FSCELPSLYPLSCSDVSASFTTLLCSSFLHFFGNFLMTFLSYICTLSTILRISSTTGR                   SKAFSTCSSHLTAVIFFYGSGLLRYLMPNSGSIQELIESLQYSVITPMLNLLTYSLKN                   REVKAAVRRTLRKYF                  
 
     [0683] Further analysis of the NOV68a protein yielded the following properties shown in Table 68B.  
               TABLE 68B                       Protein Sequence Properties NOV68a                                        PSort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability located           in endoplasmic reticulum (membrane); 0.1000 probability           located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 50 and 51       analysis:                  
 
     [0684] A search of the NOV68a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 68C.  
               TABLE 68C                          Geneseq Results for NOV68a                                         NOV68a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value                                         AAU24771   Human olfactory    3 . . . 304   212/302 (70%)    e−120           receptor    5 . . . 306   251/302 (82%)           AOLFR328—             Homo sapiens,             312 aa.           [WO200168805-           A2, Sep. 20,           2001]       AAG98585   Mouse olfactory   66 . . . 279   144/214 (67%)   1e−78            receptor 7—    1 . . . 214   169/214 (78%)             Mus musculus               domesticus ,           214 aa.           [WO200146262-           A2, Jun. 28,            2001]       AAG72680   Murine OR-like    3 . . . 305   148/305 (48%)   3e−74            polypeptide query   20 . . . 324   201/305 (65%)           sequence, SEQ           ID NO: 2362—             Mus musculus ,           337 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG71546   Human olfactory    3 . . . 301   143/302 (47%)   2e−73            receptor poly-    5 . . . 306   201/302 (66%)           peptide, SEQ ID           NO: 1227—             Homo sapiens ,           315 aa.           [WO200127158-           A2, Apr. 19,           2001]       AAG66701   Human GPCR1    3 . . . 301   143/302 (47%)   2e−73            polypeptide—    5 . . . 306   201/302 (66%)             Homo sapiens ,           311 aa.           [WO200160865-           A2, Aug. 23,           2001]                  
 
     [0685] In a BLAST search of public sequence databases, the NOV68a protein was found to have homology to the proteins shown in the BLASTP data in Table 68D.  
               TABLE 68D                          Public BLASTP Results for NOV68a                                         NOV68a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9JM36   OLFACTORY   66 . . . 279    144/214 (67%)   5e−78           RECEPTOR— Mus     1 . . . 214   169/214 (78%)             musculus               domesticus             (western European           house mouse), 214           aa (fragment).       Q9QZ18   OLFACTORY   3 . . . 299   142/299 (47%)   2e−72           RECEPTOR— Mus     5 . . . 303   193/299 (64%)             musculus  (Mouse),           312 aa.       Q9EPG6   B1 OLFACTORY   3 . . . 299   140/299 (46%)   2e−72           RECEPTOR— Mus     5 . . . 303   196/299 (64%)             musculus  (Mouse),           314 aa.       P23266   Olfactory receptor-   3 . . . 305   142/305 (46%)   9e−72           like protein F5—   5 . . . 309   196/305 (63%)             Rattus norvegicus             (Rat), 313 aa.       Q9EQA3   ODORANT   3 . . . 305   143/306 (46%)   2e−71           RECEPTOR K30—   5 . . . 310   202/306 (65%)             Mus musculus             (Mouse), 311 aa.                  
 
     [0686] PFam analysis predicts that the NOV68a protein contains the domains shown in the Table 68E.  
               TABLE 68E                          Domain Analysis of NOV68a                                     Identities/               NOV68a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain   39 . . . 286    54/268 (20%)   1.7e−29       1 of 1       169/268 (63%)                  
 
     Example 69  
     [0687] The NOV69 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 69A.  
               TABLE 69A                       NOV69 Sequence Analysis                                                SEQ ID NO:203   957 bp                     NOV69a,     GTCCACA   ATG GCCAATCAGACTGTGGTGACTGAGTTCTTCCTCCAAGGCCTGACGGAT       CG59218-01 DNA Sequence           ACCAAAGAGCTTCAGGTGGCTGTTTTTCTGCTCCTGCTGCTTGCCTACCTTGTGACTG                   TCTCTGGGAACCTGATCATCATCAGCCTGACCTTGCTGGACACCCGCCTGCAGACATC                   TATGTACTTATTTCTCCAGAATCTGTCCTGCTTAGAAATTTGGTTCCAGACAGTCATC                   GTGCCCAAGATGCTGCTCAACATTGCCATGGGGACCAAGACCGTTAGCTTTGCTGGGT                   GCATTACCCAGGACTTTTTCTTTCCACATCTTCTGGGGGCCACAGAGTTCTTCCTCCT                   CACAGCCATGGCCTATGACCAGTATATTGCCATCTGCAAGCCCCTCCACTACCCCATG                   CTCATAAGTAGTAGAGTCTGCACACAGCTCATCCTCACCTGCTGGCTACTAGGTTTCT                   CCTTCATCATCATGCCTGTCATCCTGACCAGTCAGCTTCCATTCTGTGATACCCACAT                   CAAGCATTTCTTCTGTGACTACACGCCTCTAATGGAGGTGGTCTGCAGTGGGCCAAAG                   GTGCTGGAGATGGTGGATTTTACCCTGGCCTTAGTAGCACTGTTTGGCACCTTGGTAC                   TCATCACCCTGTCCTATGTCCAGATCATCCAGACAATTGTCACAATCCCCGCTGTCCA                   GGAGAGGAAGAAGGCTTTCTCTACCTGTTCCTCTCATGTCATTATGGTTACCATGTGT                   TATGACAGCTCCTTCTTTATGTATGTCAAGCCCTCTCCAGGAAACTGGGTTGATGTCA                   ACAAGGGAGTCTCTCTAATCAATACAATTATTGCCCCACTGTTAAATCCCTTCATCTC                   TACTCTGAGGAACCAACAAGTTAAGCAGGTAATGAAAGACCTAGTCAGAAAAATGACT                   TTGTTCCAAAATAAA TAA   GCGCCCTAAAA                                           ORF Start: ATG at 8       ORF Stop: TAA at 944           SEQ ID NO:204   312 aa   MW at 35358.1 kD                     NOV69a,   MANQTVVTEFFLQGLTDTKELQVAVFLLLLLAYLVTVSGNLIIISLTLLDTRLQTSMY       CG59218-01 Protein Sequence           LFLQNLSCLEIWFQTVIVPKMLLNIAMGTKTVSFAGCITQDFFFPHLLGATEFFLLTA                   MAYDQYIAICRPLHYPMLISSRVCTQLILTCWLLGFSFTIMPVTLTSQLPFCDTHIKH                   FFCDYTPLMEVVCSGPKVLEMVDFTLALVALFGTLVLITLSYVQIIQTIVRIPAVQER                   KKAFSTCSSHVIMVTMCYDSCFFMYVKPSPGKWVDVNKGVSLINTIIAPLLNPFICTL                   RNQQVKQVMKDLVRKNTLFQNK                  
 
     [0688] Further analysis of the NOV69a protein yielded the following properties shown in Table 69B.  
               TABLE 69B                       Protein Sequence Properties NOV69a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability located           in endoplasmic reticulum (membrane); 0.0300 probability           located in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 40 and 41       analysis:                  
 
     [0689] A search of the NOV69a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 69C.  
               TABLE 69C                          Geneseq Results for NOV69a                                         NOV69a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG72538   Human OR-like   1 . . . 312   284/317 (89%)   e−157           polypeptide query   1 . . . 313   293/317 (91%)           sequence, SEQ ID           NO: 2219— Homo               sapiens , 313 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAG72229   Human olfactory   1 . . . 312   284/317 (89%)   e−157           receptor poly-   1 . . . 313   293/317 (91%)           peptide, SEQ ID           NO:1910— Homo               sapiens , 313 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAU24761   Human olfactory   1 . . . 306   173/307 (56%)   2e−96           receptor   1 . . . 306   227/307 (73%)           AOLFR112B—             Homo sapiens ,           309 2001]       AAU24765   Human olfactory   1 . . . 306   166/307 (54%)   2e−94           receptor   1 . . . 306   227/307 (73%)           AOLFR225B—             Homo sapiens ,           309 aa.           [WO200168805-A2,           Sep. 20, 2001]       AAG66353   GPCR partial   1 . . . 309   160/311 (51%)   4e−87           protein sequence—   1 . . . 310   209/311 (66%)           Unidentified,           313 aa.           [WO200155179-A2,           Aug. 2, 2001]                  
 
     [0690] In a BLAST search of public sequence databases, the NOV69a protein was found to have homology to the proteins shown in the BLASTP data in Table 69D.  
               TABLE 69D                          Public BLASTP Results for NOV69a                                         NOV69a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9Z1V0   OLFACTORY    1 . . . 309   160/311 (51%)   2e−86           RECEPTOR    1 . . . 310   209/311 (66%)           C6— Mus               musculus             (Mouse), 313 aa.       CAC88326   SEQUENCE 18    8 . . . 306   142/301 (47%)   4e−78           FROM PATENT   12 . . . 311   200/301 (66%)           WO0164879—             Homo sapiens             (Human), 331 aa.       CAC88328   SEQUENCE 22    8 . . . 306   142/301 (47%)   2e−77           FROM PATENT   12 . . . 311   198/301 (65%)           WO0164879—             Homo sapiens             (Human), 331 aa.       CAC88327   SEQUENCE 20    8 . . . 306   141/301 (46%)   8e−77           FROM PATENT   12 . . . 311   198/301 (64%)           WO0164879—             Homo sapiens             (Human), 331 aa.       O70270   OLFACTORY    3 . . . 308   136/307 (44%)   4e−76           RECEPTOR-   11 . . . 316   208/307 (67%)           LIKE           PROTEIN—             Rattus               norvegicus  (Rat),           327 aa.                  
 
     [0691] PFam analysis predicts that the NOV69a protein contains the domains shown in the Table 69E.  
               TABLE 69E                          Domain Analysis of NOV69a                                     Identities/               NOV69a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain   39 . . . 244    47/214 (22%)   1.9e−25       1 of 1       147/214 (69%)                  
 
     Example 70  
     [0692] The NOV70 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 70A.  
               TABLE 70A                       NOV70 Sequence Analysis                                                SEQ ID NO:205   962 bp                     NOV70a,     CATCTTCCTATGTGTC   ATG TCTCCTCTTAATGACACAAAAATGGAAGTCCTTAGATTC       CG59216-01 DNA Sequence           CTCCTTATCGGGATCACTGGACTGCAGAAAAGTCGCACCTGGATATCCATTCCTTTCT                   TATCTGTGTACCTTCTTTCTTCGATCGGTAATTTTACCGTCCTCTTTTTTATCAAGAC                   AGACCAAAGCCTCCATCAACCTATGTATTATTTGCTTTCCATGCTCTCCATCTCTGAC                   CTAGGGCTGTCTCTGTCTTCCTTACCCATCACTTTGGGACTATTCCTATTTGATGTCC                   ATGAAATTCATGCAGCTCCATGCTTTGCCCAGGAATTTTTTATCCATCTGTTTACAGT                   CAGTGAAGCCTCTGTACTGTCTGTAATGGCATTTGACTGGTATGTGGCAATCCACAGT                   CCTTTGAGATACAGCACTATCTTAACTAGTCCCAGAGCCATCAAAACAGGGGTTCTTC                   TGACTTCCAAGAATGTTCTTTTGATCCTTCCACTGCCCTTTCTCTTGCAAAGGCTGAG                   ATATTGTCATCAAAACCTGCTCTCCCACTCCTATTGTCTCCACCAGGATGTCATGAAG                   CTGATGTGTTCTGACAACACAGTCAATGTTGTCTACGGACTCTGTGCAGGACTTTCTA                   CTATGCTCCACTTGGTGTTTATTACCTTCTCCTATATTATGATTTTAAGGGCTGTACT                   GGGAATTGCTACCCCCAGACAGCAGTTCAAGCCCCTCAACACCTCCATCTCTCACATC                   TGTGCTCTCCTTATCTTCTATGTGCCCACGCTGAGTGCTCCCATGCTCCACCAGTTTC                   CCAGGGATGTGTCTCCTATGATCCACGTCCTCATGGCTGATATTTTTCTGCTGGTGCC                   ACCCCTGTTGAATCCCATCGTGTACTGTGTGAAGACCCACCAAATCCGAGAAAAGGTT                   GTGGGGAAACTTTGTCCAAAAGTAAGT TGA TCAA                                             ORF Start: ATG at 17       ORF Stop: TGA at 956           SEQ ID NO:206   313 aa   MW at 35363.9 kD                     NOV70a,   MSPLNDTKMEVLRFLLIGITGLEKSRTWISIPFLSVYLLSWMGNFTVLFFIKTEQSLH       CG59216-01 Protein Sequence           EPMYYLLSMLSISDLGLSLSSLPITLGLFLFDVHEIHAAPCFAQEFFIHLFTVSEASV                   LSVMAFDWYVAIHSPLRYSTILTSPRAIKTGVLLTSKNVLLILPLPFLLQRLRYCHQN                   LLSHSYCLEQDVMKLMCSDNTVNVVYGLCAGLSTMLDLVFTTFSYTMILRAVLGIATP                   RQQFKALNTCISHICAVLIFYVPTLSAAMLHQFARDVSPMTHVLMADIFLLVPPLLNP                   IVYCVKTHQIREKVVCKLCPKVS                  
 
     [0693] Further analysis of the NOV70a protein yielded the following properties shown in Table 70B.  
               TABLE 70B                       Protein Sequence Properties NOV70a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability located           in endoplasmic reticulum (membrane); 0.2007 probability           located in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 50 and 51       analysis:                  
 
     [0694] A search of the NOV70a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 70C.  
               TABLE 70C                          Geneseq Results for NOV70a                                         NOV70a   Identities/               Protein/   Residues/   Similarities for       Geneseq   Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAG72488   Human OR-like   1 . . . 313   310/313 (99%)   e−178           polypeptide query   1 . . . 313   310/313 (99%)           sequence, SEQ ID           NO: 2169— Homo               sapiens , 319 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAG71557   Human olfactory   1 . . . 313   310/313 (99%)   e−178           receptor poly-   1 . . . 313   310/313 (99%)           peptide, SEQ ID           NO: 1238— Homo               sapiens , 319 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAU24573   Human olfactory   1 . . . 311   186/311 (59%)   e−110           receptor   1 . . . 311   246/311 (78%)           AOLFR63— Homo               sapiens , 313 aa.           [WO200168805-A2,           Sep. 20, 2001]       AAG71558   Human olfactory   1 . . . 311   185/311 (59%)   e−109           receptor poly-   1 . . . 311   245/311 (78%)           peptide, SEQ ID           NO: 1239— Homo               sapiens , 313 aa.           [WO200127158-A2,           Apr. 19, 2001]       AAU24682   Human olfactory   1 . . . 308   188/308 (61%)   e−107           receptor   1 . . . 306   238/308 (77%)           AOLFR181 —             Homo sapiens ,           312 aa.           [WO200168805-A2,           Sep. 20, 2001]                  
 
     [0695] In a BLAST search of public sequence databases, the NOV70a protein was found to have homology to the proteins shown in the BLASTP data in Table 70D.  
               TABLE 70D                          Public BLASTP Results for NOV70a                                         NOV70a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               CAC38935   SEQUENCE 9    5 . . . 305   145/302 (48%)   5e−79           FROM PATENT    6 . . . 306   207/302 (68%)           WO0131014—             Homo sapiens             318 aa.       AAL35109   PROSTATE-   14 . . . 305   141/293 (48%)   7e−79           SPECIFIC G   11 . . . 303   199/293 (67%)           PROTEIN-           COUPLED           RECEPTOR           RA1C— Mus               musculus             (Mouse), 320 aa.       CAC37756   SEQUENCE 1    5 . . . 305   145/302 (48%)   7e−79           FROM PATENT    5 . . . 305   207/302 (68%)           WO0125434—             Homo sapiens             (Human), 317 aa.       O88628   Olfactory receptor   14 . . . 305   141/293 (48%)   7e−79           51E2 (G-protein   11 . . . 303   200/293 (68%)           coupled receptor           RA1c)— Rattus               norvegicus             (Rat), 320 aa.       Q9H255   Olfactory receptor   14 . . . 305   139/293 (47%)   7e−78           51E2 (Prostate   11 . . . 303   198/293 (67%)           specific G-protein           coupled receptor)           (HPRAJ)— Homo               sapiens             (Human), 320 aa.                  
 
     [0696] PFam analysis predicts that the NOV70a protein contains the domains shown in the Table 70E.  
               TABLE 70E                          Domain Analysis of NOV70a                                     Identities/               NOV70a   Similarities for   Expect       Pfam Domain   Match Region   the Matched Region   Value               7tm_1: domain    43 . . . 151   30/111 (27%)   6.3e−14       1 of 2       73/111 (66%)       YCF9: domain   208 . . . 262    10/59 (17%)   7.5         1 of 1        31/59 (53%)       7tm_1: domain   212 . . . 293    18/93 (19%)   0.00034       2 of 2        55/93 (59%)                  
 
     Example 71  
     [0697] The NOV71 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 71A.  
               TABLE 71A                       NOV71 Sequence Analysis                                                SEQ ID NO:207   995 bp                     NOV71a,     GCACA   ATG TCTGTCTTCAATAGTTCTGCCTTATACCCTCGCTTCCTCCTAACGGGCCT       CG59214-01 DNA Sequence           CTCAGGCCTTGAAAGCAGATATGACTTGATTTCCCTGCCCATCTTCTTGGTTTATGCC                   ACCTCAATTGCCGGGAACATTAGCATCCTCTTCATTATCAGAACTGAGTCTTCCCTCC                   ACCAACCGATGTATTACTTTCTGTCAATGCTGGCATTCACTGACCTGGGCCTATCTAA                   CACTACCTTACCTACCATGTTCAGTGTCTTCTGGTTCCATGCCCGGGAGATCTCCTTC                   AATGCTTGTCTGGTCCAAATGTACTTCATTCATGTTTTCTCGATTATTGAGTCAGCTG                   TACTCCTGGCTATCGCCTTTGACTGCTTTATAGCAATCTGTGAACCCTTGCGCTATGC                   AGCCATCCTAACCAATGATGTAATCATTGGGATTGCGTTGGCAATTGCTGGAAGGGCC                   TTGGCTCTGGTCTTTCCAGCTTCTTTCCTCTTGAAGAGGCTTCAATATCATGATGTCA                   ATATTCTGTCCTACCTCTTCTGCCTGCACCAGGACCTCATAAAGACGACTGTATCCAA                   CTGTCGAGTCAGCAGCATCTATGGCCTCATGGTGGTCATCTGTTCCATGGGACTTGAT                   TCAGTGCTTCTCCTCCTCTCCTATGTCCTCATCCTGGGCACAGTGTTGAGTATAGCCT                   CCAAGGCAGAGAGAGTGAGAGCCCTCAATACTTGCATCTCCCACATCTGTGCTGTACT                   TCCTCAATTGTCCATGTGCTGATGGCCAATGTCTACTTGCTGGTTCCACCTCTCATGA                   CACCTTCTATACACCAATGATTGGGCTATCTATGATCCATCGCTATGGACASAATGCT                   ACCCCGTTGTCTACAGTGTTAAGACCAAGCAGATTCGTGACAGAATCTTCAATAAATT                   CAAGAAACATGAAGTG TAG   ATGACAGAGATTCTGAAACATAACTTTCCCTCCATTCCC                       CATATATTT                                           ORF Start: ATG at 6       ORF Stop: TAG at 945           SEQ ID NO:208   313 aa   MW at 35044.2 kD                     NOV71a,   MSVFNSSALYPRFLLTGLSGLESRYDLISLPTELVYATSIAGNTSILFTTRTESSLHQ       CG59214-01 Protein Sequence           PMYYFLSMLAFTDLGLSNTTLPTMFSVFWFHAREISFNACLVQMYFIHVFSIIESAVL                   LAMAFDCFIAICEPLRYAATLTNDVIISTGLAIAGRALALVFPASFLLKRLQYHDVNI                   LSYLFCLHQDLTKTTVSNCRVSSIYGLMVVICSMGLDSVLLLLSYVLILCTVLSTASK                   AERVRALNTCISHICAVLTFYTPMIGLSMTHRYGQNASSTVHVLMANVYLLVPPLMNP                   VVYSVKTKQIRDRIFNKFKKHEV                  
 
     [0698] Further analysis of the NOV71a protein yielded the following properties shown in Table 71B.  
               TABLE 71B                       Protein Sequence Properties NOV71a                                        PSort   0.6000 probability located in plasma membrane; 0.4047       analysis:   probability located in mitochondrial inner membrane;           0.4000 probability located in Golgi body; 0.3480           probability located in mitochondrial intermembrane space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0699] A search of the NOV71a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 71C.  
               TABLE 71C                          Geneseq Results for NOV71a                                             Identities/                   NOV71a   Similarities for       Geneseq   Protein/Organism/Length   Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               AAG72605   Human OR-like polypeptide   1 . . . 309   295/310 (95%)    e−163           query sequence, SEQ ID NO:   4 . . . 313   298/310 (95%)           2286 -  Homo sapiens , 318 aa.           [WO200127158-A2, 19 APR           2001]       AAG71519   Human olfactory receptor   1 . . . 309   295/310 (95%)    e−163           polypeptide, SEQ ID NO: 1200 -   4 . . . 313   298/310 (95%)             Homo sapiens , 318 aa.           [WO200127158-A2, 19 APR           2001]       AAU24683   Human olfactory receptor   5 . . . 308   178/304 (58%)    e−102           aa. [WO200168805-A2, 20 SEP   9 . . . 312   235/304 (76%)           2001]       AAG71715   Human olfactory receptor   5 . . . 308   178/304 (58%)    e−102           polypeptide, SEQ ID NO: 1396 -   9 . . . 312   235/304 (76%)             Homo sapiens , 314 aa.           [WO200127158-A2, 19 APR           2001]       ABB44526   Human GPCR4a polypeptide   5 . . . 308   169/304 (55%)   2e−96           SEQ ID NO 11 -  Homo sapiens ,   6 . . . 309   227/304 (74%)           315 aa. [WO200174904-A2,           11 OCT 2001]                  
 
     [0700] In a BLAST search of public sequence databases, the NOV71a protein was found to have homology to the proteins shown in the BLASTP data in Table 71D.  
               TABLE 71D                          Public BLASTP Results for NOV71a                                         NOV71a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9H344   Olfactory receptor 51I2   13 . . . 308   154/296 (52%)   2e−91           (HOR5′beta12) -  Homo sapiens     12 . . . 307   221/296 (74%)           (Human), 312 aa.       Q9H2C8   ODORANT RECEPTOR    2 . . . 308   160/307 (52%)   5e−89           HOR3′BETA1 -  Homo sapiens     10 . . . 316   216/307 (70%)           Human), 321 aa.       Q9H343   Olfactory receptor 51I1    5 . . . 312   156/309 (50%)   9e−89           (HOR5′beta11) -  Homo sapiens      5 . . . 313   223/309 (71%)           (Human), 314 aa.       AAL35109   PROSTATE-SPECIFIC G   13 . . . 309   148/297 (49%)   2e−86           PROTEIN-COUPLED   11 . . . 307   207/297 (68%)           RECEPTOR RA1C -  Mus               musculus  (Mouse), 320 aa.       Q924X8   OLFACTORY RECEPTOR S85 -    2 . . . 304   150/303 (49%)   1e−85             Mus musculus  (Mouse), 314 aa.    3 . . . 305   221/303 (72%)                  
 
     [0701] PFam analysis predicts that the NOV71a protein contains the domains shown in the Table 71E.  
               TABLE 71E                          Domain Analysis of NOV71a                                     Identities/                   Similarities           NOV71a   for the       Pfam Domain   Match Region   Matched Region   Expect Value               7tm_1:   42 . . . 138   24/99 (24%)   7.8e−14       domain 1 of 1       67/99 (68%)                  
 
     [0702] The NOV72 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 72A.  
               TABLE 72A                       NOV72 Sequence Analysis                                                SEQ ID NO:209   1004 bp                     NOV72a,     CTTCTCATCTTTTCCCTCAAATACTGGG   ATG TCCATTCTCAATACCTCTGAAATGGAA       CG59211-01 DNA Sequence           ATCTCTATTTTCTACTTGGTTGGGATCCCAGGTTTGGAGCATGCCAATATTTGGATCT                   CTATCCCCATATGTCTCATGTACACTGTTGCTATCCTAGGGAATTGTACCATTCTGTT                   TTTCATAAAAACACAGCCTTCTTTGCATGAGCCCATGTACTATTTTCTCTCCATGTTG                   GCTCTCTCTGACCTGGGACTATCCCTCTCCTCTCTCCCTACCATGTTAACGATTTTCC                   TGTTCAATGCTCCAGGAATTTCCCCTGATGCCTGTATTGCTCAAGAGTTTTTCATCCA                   TGGATTCTCAGCTATGGAGTCATCTGTACTTCTTATAATGTCCTTTGATCGCTTTATT                   GCCATCTGCAACCCCCTGAGATACACTTCCATCCTCACCAGTCCCAGAGTCATTCAAA                   TTGGGCTTGCTTTTTCTCTCAAAAATCTTTTGTTCATCCTCCCATTTCCTTTCACTCT                   AAAACATCTAAAATATTGTAAGAAGAACCTCCTGTCCCAATCCTACTGCCTCCATCAA                   GATGTCATGAAACTGGCCTGCACTGACAACAAGGTCAACATCATCTATGGCTTATTTG                   TGGCTCTCACAGGCATCCTAGACTTGACATTTATTTTCATGTCCTACATCTTGATACT                   GAAAGCAGTGTTGAGCATAGCATCAAGAAAGAAAAGGCTCAAGGTCCTCAATACATGT                   GTTTCCCACATCTGTGCTGTGCTCATCTTCTATGTGCCCATTATCTCCCTAGCTGTCA                   TCTACCGGTTTGCCAAACACAGTTTCCCAATCACTAGGATCCTCATAGCTGATGCTTT                   TCTGCTGGTGCCTCCATTGATGAACCCCATTGTATACTGTGTGAAGAGCCAGCAGATA                   AGAAATCTTCTCTTAGAAAAACTGTGCCAGAAGCAAAGC TGA   AGCGGATGCTTAACCA                       CATGATGCTTAACCCAAA                                           ORF Start: ATG at 29       ORF Stop: TGA at 968           SEQ ID NO:210   313 aa   MW at 35313.1 kD                     NOV72a,   MSILNTSEMEISIFYLVGIPGLEHANIWISIPICLMYTVAILGNCTILFFIKTEPSLH       CG59211-01 Protein Sequence           EPMYYFLSMLALSDLGLSLSSLPTMLRIFLFNAPGISPDACIAQEFFIHGFSAMESSV                   LLIMSFDRFIAICNPLRYTSILTSARVIQIGLAFSLKNVLLILPFPFTLKHLKYCKKN                   LLSQSYCLHQDVMKLACTDNKVNIIYGLFVALTGILDLTFTEMSYMLTLKAVLSIASR                   KKRLKVLNTCVSHICAVLTFYVPIISLAVIYRFAKHSFPTTRTLIADAFLLVPPLMNP                   IVYCVKSQQIRNLVLEKLCQKQS                  
 
     [0703] Further analysis of the NOV72a protein yielded the following properties shown in Table 72B.  
               TABLE 72B                       Protein Sequence Properties NOV72a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability located           in endoplasmic reticulum (membrane); 0.0300 probability           located in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 44 and 45       analysis:                  
 
     [0704] A search of the NOV72a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 72C.  
               TABLE 72C                          Geneseq Results for NOV72a                                             Identities/                   NOV72a   Similarities for       Geneseq   Protein/Organism/Length   Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value                                         AAG71564   Human olfactory receptor   1 . . . 313   312/313 (99%)   e−177           polypeptide, SEQ ID NO: 1245 -   5 . . . 317   312/313 (99%)             Homo sapiens , 322 aa.           [WO200127158-A2, 19 APR 2001]       AAU24573   Human olfactory receptor   1 . . . 312   225/312 (72%)   e−131           AOLFR63 -  Homo sapiens , 313 aa.   1 . . . 312   272/312 (87%)           [WO200168805-A2, 20 SEP 2001]       AAG71721   Human olfactory receptor   1 . . . 311   236/312 (75%)   e−131           polypeptide, SEQ ID NO: 1402 -   1 . . . 311   267/312 (84%)             Homo sapiens , 316 aa.           [WO200127158-A2, 19 APR 2001]       AAU24682   Human olfactory receptor   1 . . . 308   224/308 (72%)   e−131           AOLFR181 -  Homo sapiens , 312   1 . . . 306   265/308 (85%)           aa. [WO200168805-A2, 20 SEP            2001]       AAG71701   Human olfactory receptor   1 . . . 308   224/308 (72%)   e−131           polypeptide, SEQ ID NO: 1382 -   1 . . . 306   265/308 (85%)             Homo sapiens , 312 aa.           [WO200127158-A2, 19 APR 2001]                  
 
     [0705] In a BLAST search of public sequence databases, the NOV72a protein was found to have homology to the proteins shown in the BLASTP data in Table 72D.  
               TABLE 72D                          Public BLASTP Results for NOV72a                                         NOV72a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9H344   Olfactory receptor 51I2   12 . . . 304    152/294 (51%)   6e−90           (HOR5′beta12) -  Homo sapiens     10 . . . 303    219/294 (73%)           (Human), 312 aa.       Q9EQQ7   MOR 3′BETA4 -  Mus musculus     1 . . . 309   159/310 (51%)   9e−89           (Mouse), 319 aa.   1 . . . 310   219/310 (70%)       Q9H343   Olfactory receptor 51I1   4 . . . 313   154/311 (49%)   9e−89           (HOR5′beta11) -  Homo sapiens     4 . . . 314   226/311 (72%)           (Human), 314 aa.       CAC38935   SEQUENCE 9 FROM PATENT   5 . . . 305   153/302 (50%)   2e−87           WO0131014 -  Homo sapiens     6 . . . 306   217/302 (71%)           (Human), 318 aa.       CAC37756   SEQUENCE 1 FROM PATENT   5 . . . 305   153/302 (50%)   3e−87           WO0125434 -  Homo sapiens     5 . . . 305   217/302 (71%)           (Human), 317 aa.                  
 
     [0706] PFam analysis predicts that the NOV72a protein contains the domains shown in the Table 72E.  
               TABLE 72E                          Domain Analysis of NOV72a                                     Identities/                   Similarities           NOV72a   for the       Pfam Domain   Match Region   Matched Region   Expect Value                                         DUF40: domain   109 . . . 134   10/26   (38%)   0.38       1 of 1       20/26   (77%)       7tm_1:    43 . . . 144   27/107   (25%)   1.6e−15       domain 1 of 2       71/107   (66%)       7tm_1:   212 . . . 293   16/93   (17%)   4.7       domain 2 of 2       56/93   (60%)       Sina: domain 1 of 1   300 . . . 311   7/12   (58%)   1               10/12   (83%)                  
 
     Example 73  
     [0707] The NOV73 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 73A.  
               TABLE 73A                       NOV73 Sequence Analysis                                                SEQ ID NO:211   1581 bp                     NOV73a,     CTGGTGGGTTGGCGGCTAACGGCCGGAGACAAGAGCGGCCGCCACCATCTCCTCCAAT         CG59276-01 DNA Sequence             GGAAGGGAGACAGGGGCGGGCTTAATGACGGAAGGAGC   ATG GCGTGGAGACACCTGAA                   AAAGCGGGCCCAGGATGCTCTCATCATCCTGGGGGCAGGAGGACTTCTCTTCGCCTCC                   TACCTGATGGCCACGGGAGATGAGCGTTTCTATGCTGAACACCTGATGCCGACTCTGC                   AGGGGCTGCTGGACCCGGAGTCAGCCCACAGACTGGCTGTTCGCTTCACCTCCCTGGG                   GCTCCTTCCACGGGCCAGATTTCAAGACTCTGACATGCTGGAAGTGAGAGTTCTGGGC                   CATAAATTCCGAAATCCAGTAGGAATTGCTGCAGCATTTGACAAGCATGGGGAAGCCG                   TGGACGGACTTTATAAGATGGGCTTTGGTTTTGTTGAGATAGGAAGTGTGACTCCAAA                   ACCTCAGGAAGGAAACCCTAGACCCAGAGTCTTCCGCCTCCCTGAGGACCAAGCTGTC                   ATTAACAGGTATGGATTTAACAGTCACGGGCTTTCAGTGGTGGAACACAGGTTACGGG                   CCAGACAGCAGAAGCAGGCCAAGCTCACAGAAGATGGACTGCCTCTGGGGGTCAACTT                   GGGGAAGAACAAGACCTCAGTGGACGCCGCGGAGGACTACGCAGAAGGGGTGCGCGTA                   CTGGGCCCCCTGGCCGACTACCTGCTGGTGAATGTGTCCAGCCCCAACACTGCCGGGC                   TGCGGAGCCTTCAGGGAAAGGCCGAGCTGCGCCGCCTGCTGACCAAGGTGCTCCAGGA                   GAGGGATGGCTTGCGGAGAGTGCACAGGCCGGCAGTCCTGGTGAAGATCGCTCCTGAC                   CTCACCAGCCAGGATAAGGAGGACATTGCCAGTGTGGTCAAAGAGTTGGGCATCGATG                   GGCTGATTGTTACGAACACCACCGTGAGTCGCCCTGCGGGCCTCCAGGGTGCCCTGCG                   CTCTGAAACAGGAGGGCTGAGTGGGAAGCCCCTCCGGGATTTATCAACTCAAACCATT                   CGGGAGATGTATGCACTCACCCAAGGCAAGGTTTCCCGTCGACTTCCCATAATTGGGG                   TTGGTGGTGTGAGCAGCGGGCAGGACGCGCTGGAGAAGATCCGGGCAGGGGCCTCCCT                   GGTGCAGCTGTACACGGCCCTCACCTTCTGGGGGCCACCCGTTGTGGGCAAAGTCAAG                   CGGGAACTGGAGGCCCTTCTGAAGGAGCAGGGCTTTGGCGGAGTCACAGATGCCATTG                   GAGCAGATCATCGGAGCATGAGGAAACGGGCAGAGAAGCGGCTGATTGTCCAGTCCCC                   CTGCGTGGAGGCTGCTTGGCTGGGCTCCAGCCCAGCGGTGGTGGGTCAGTTGGCACCT                   GGTGGTCTGCTGGTGGTCAGTTTGGGAATTTCCAGGTACGATTGTTTTCAGGCACTGT                   TCTTTGACTTGGTTGCAGAAAAACAGATTTTGCAACACTTTCCAAGGACACAGTGTTA                   CCACTCCCTCACCCTGCCATGGCCTCTTGGTTCTGCTTTTAACTTC TGA   GCCTCAGGG                       AGTCCATCTTGTCTG                                           ORF Start: ATG at 97       ORF Stop: TGA at 1555           SEQ ID NO:212   486 aa   MW at 52982.6 kD                     NOV73a,   MAWRHLKKRAQDAVIILGGGGLLFASYLMATGDERFYAEHLMPTLQGLLDPESAHRLA       CG59276-01 Protein Sequence           VRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVE                   IGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDG                   LPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRL                   LTKVLQERDCLRRVHRPAVLVKIAPDLTSQDKEDTASVVKELGZDCLIVTNTTVSRPA                   GLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGKVSRRVPIIGVGGVSSGQDALEK                   IRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRRMRKRAEK                   RLIVQSPCVEAAWLGSSPAVVGQLGPGGLLVVSLGISRYDCFQALFFDLVAEKQILQH                   FPRTQCYHSLTLPWPLGSAFNF                  
 
     [0708] Further analysis of the NOV73a protein yielded the following properties shown in Table 73B.  
               TABLE 73B                       Protein Sequence Properties NOV73a                                        Psort   0.8110 probability located in plasma membrane; 0.6400       analysis:   probability located in endoplasmic reticulum (membrane);           0.3700 probability located in Golgi body; 0.1839 probability           located in microbody (peroxisome)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0709] A search of the NOV73a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 73C.  
               TABLE 73C                          Geneseq Results for NOV73a                                             Identities/                   NOV73a   Similarities for       Geneseq   Protein/Organism/Length   Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value               AAB70780   Tobacco dihydro-orotase protein -   36 . . . 398   199/383 (51%)    e−101           Nicotiana tabacum, 458 aa.   81 . . . 458   257/383 (66%)           [WO200118190-A2, 15 MAR 2001]       AAG01301   Human secreted protein, SEQ ID    1 . . . 144   143/144 (99%)   3e−79           NO: 5382 -  Homo sapiens , 144 aa.    1 . . . 144   144/144 (99%)           [EP1033401-A2, 6 SEP 2000]       AAG91420   C glutamicum protein fragment SEQ   76 . . . 396   131/328 (39%)   6e−60           ID NO: 5174 - Corynebacterium   60 . . . 366   190/328 (56%)           glutamicum, 371 aa. [EP1108790-           A2, 20 JUN 2001]       AAB46597   C. glutamicum dihydroorotate   76 . . . 396   131/328 (39%)   6e−60           dehydrogenase protein -   10 . . . 316   190/328 (56%)           Corynebacterium glutamicum, 321           aa. [DE19929364-A1, 28 DEC            2000]       AAB80123   Corynebacterium glutamicum MP   76 . . . 396   131/328 (39%)   1e−59           protein sequence SEQ ID NO:980 -   23 . . . 329   190/328 (56%)           Corynebacterium glutamicum, 334           aa. [WO200100843-A2, 4 JAN           2001]                  
 
     [0710] In a BLAST search of public sequence databases, the NOV73a protein was found to have homology to the proteins shown in the BLASTP data in Table 73D.  
               TABLE 73D                          Public BLASTP Results for NOV73a                                         NOV73a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q02127   Dihydroorotate dehydrogenase,   1 . . . 399   392/399 (98%)   0.0           mitochondrial precursor (EC 1.3.3.1)   2 . . . 396   394/399 (98%)           (Dihydroorotate oxidase)           (DHOdehase) -  Homo sapiens             (Human), 396 aa (fragment).       PC1219   dihydroorotate oxidase (EC 1.3.3.1)   1 . . . 399   388/399 (97%)   0.0           precursor - human, 397 aa.   3 . . . 397   393/399 (98%)       Q63707   Dihydroorotate dehydrogenase,   1 . . . 399   350/399 (87%)   0.0           mitochondrial precursor (EC 1.3.3.1)   1 . . . 395   369/399 (91%)           (Dihydroorotate oxidase)           (DHOdehase) -  Rattus norvegicus             (Rat), 395 aa.       O35435   Dihydroorotate dehydrogenase,   1 . . . 399   346/399 (86%)   0.0           mitochondrial precursor (EC 1.3.3.1)   1 . . . 395   366/399 (91%)           (Dihydroorotate oxidase)           (DHOdehase) -  Mus musculus             (Mouse), 395 aa.       Q9FZM9   DIHYDROOROTATE   29 . . . 398    206/394 (52%)   e−101           DEHYDROGENASE -  Oryza sativa     79 . . . 468    261/394 (65%)           (Rice), 468 aa.                  
 
     [0711] PFam analysis predicts that the NOV73a protein contains the domains shown in the Table 73E.  
               TABLE 73E                          Domain Analysis of NOV73a                                     Identities/                   Similarities           NOV73a   for the       Pfam Domain   Match Region   Matched Region   Expect Value               DHOdehase:   77 . . . 381   183/331 (55%)   1.9e−169       domain 1 of 1       282/331 (85%)                  
 
     Example 74  
     [0712] The NOV74 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 74A.  
               TABLE 74A                       NOV74 Sequence Analysis                                                SEQ ID NO:213   1875 bp                     NOV74a,     ATG GCCGCAGCCTCGCCTCTGCGCGACTGCCAGGCCTGGAAGGATGCGAGGCTCCCGC       CG59268-01 DNA Sequence           TCTCCACCACAAGCAACGAAGCCTGCAAGCTGTTCGATGCCACGCTGACCCAGTATGT                   AAAATGGACCAATGACAAGACTCTCGCTGGCATCGAGGGCTGCCTGTCAAAGCTCAAA                   GCAGCAGATCCAACCTTTGTGATGGGCCACGCCATGGCTACTGGCCTTGTGCTGATTG                   GCACTGGAAGCTCCGTGAAGCTGGACAAAGAGCTGGACCTGGCTGTGAAGACAATGGT                   GGAGATTTCAAGAACCCAGCCGCTGACAAGGCGGGAGCAGCTGCACGTGTCTGCAGTA                   GAGACATTTGCCAATGGGAACTTTCCGAAAGCCTGTGAACTATGGGAACAGATTCTCC                   AGGACCACCCGACAGACATGTTGGCCCTGAAATTTTCCCATGATGCTTATTTTTACCT                   GGGCTATCAGGAACAGATGAGAGATTCTGTTGCTCGAATTTACCCCTTCTGCACACCT                   GACATCCCCCTAAGCAGCTATGTGAAAGGCATCTACTCTTTTGGCTTGATGGAAACCA                   ACTTCTACGACCAGGCAGAAAAACTCGCCAAAGAGGCACCAACTCTTTGTCTTCAACA                   CCAGCACCCCACAGACAACTACTGGGCAGGAAAAGCAGGCTGTGATGGGGCCAGGAGT                   GGTAACACATGGGCTCTGTGTCTGCAGCCCCAGGCTGACGCATGGTCCCTGCACACCG                   TCGCTCACATCCACGAGATGAAAGCAGAGATCAAGGATGGGTTGGAATTCATGCAGCA                   CTCAGAGACCTTCTGGAAGGACTCTGATATGTTGGCTTGTCATAACTATTGGCACTGG                   GCTTTATATCTGATTGAGAAGGGTTTAATAACGACAACTTTATTCTTCCAGGGCGAAT                   ATGAGGCCGCGCTGACCATCTACGATACCCACATCCTTCCCAGCCTGCAGGCCAACGA                   TGCAATGCTGGACGTGGTGGACAGCTGCTCCATGCTCTACCGCCTGCAGATGGAAGGA                   GTGTCTGTGGGCCAGCGGTGGCAGGATGTCCTGCCTGTGGCCCGGAAGCACAGCCGAG                   ACCACATCCTGCTGTTCAATGACGCACACTTCCTGATGGCATCCCTGGGTGCACACGA                   CCCCCAGACCACACAGGAGCTGCTGACCACCCTGCGGGACGCCAGCGAGTATGCAGAG                   GGGCCTTCTCGGGGTGGGGGTCCTCACCCTGCCGAGAGGTGCCAGGCCTTTGCCTGTA                   TTATCAGCAATCCTGACGGTTCTGTTAGATTGGCACTGTTATGCCTGCTTACAGATGA                   GCAAACTGAGGCTGGAAGATCCCCAGGGGAGAACTGCCAGCACCTCCTGGCCCGAGAC                   GTGGGGCTGCCCCTGTGCCAGGCCCTGGTGGAGGCTGAGGACGGGAACCCTGACCGCG                   TCCTGGAGCTGCTCCTGCCCATCCGCTACCGGATCGTCCAGCTCGGTGGGAGCAATGC                   CCAGAGAGACGTCTTCAACCAGCTGCTGATTCACGCGGCCTTAAACTGCACCTCCAGC                   GTCCATAAGAACGTAGCCCGGAGCCTTCTGATGGAGCGTGATGCCTTGAAGCCCAACT                   CGCCCCTCACCGAGCGGCTCATCCGCAAGGCAGCTACCGTCCACCTCATGCAGAAGCC                   TTCTACCCGCCAACCCCCACTGCAGGCTGCTCTCTCCATGGAAGGAGGCGGCGGCCGC                   GATGAGCCTTCAGCCTGCCGGGCAGGGGACGTGAACATGGATGACCCTAACAAGGAAG                   TGATTTAATGTTTCCC TGA                                           ORF Start: ATG at 1       ORF Stop: TGA at 1873           SEQ ID NO:214   624 aa   MW at 69393.3 kD                     NOV74a,   MAAASPLRDCQAWKDARLPLSTTSNEACKLFDATLTQYVKWTNDKSLGGTEGCLSKLK       CG59268-01 Protein Sequence           AADPTFVMGHAMATGLVLIGTGSSVKLDKELDLAVKTMVEISRTQPLTRREQLHVSAV                   ETFANGNFPKACELWEQILQDHPTDMLALKFSHDAYFYLGYQEQMRDSVARIYPFWTP                   DIPLSSYVKGTYSEGLMETNFYDQAEKLAKEAPTLCLQHQHPTDNYWAGKAGCDGARS                   GNTWALCLQPQADAWSVHTVAHIHEMKAEIKDGLEFMQHSETFWKDSDMLACHNYWIW                   ALYLIEKGLIRRTLFFQGEYEAALTIYDTHILPSLQANDANLDVVDSCSMLYRLQMEG                   VSVGQRWQDVLPVARKHSRDHILLFNDAHFLMASLGAHDPQTTQELLTTLRDASEYAE                   GPSRGGGPHPAERCQAFACIISNPDGSVRLALLCLLTDEQTEAGRSPGENCQHLLARD                   VGLPLCQALVEAEDGNPDRVLELLLPIRYRIVQLGGSNAQRDVFNQLLIHAALWCTSS                   VHKNVARSLLMERDALKPNSPLTERLTRKAATVHLMQKPSTRQPPLQAALSMEGGGGR                   DEPSACRAGDVNMDDPKKEGKSLLLRRCCCSGCSVEMEGDLMFP                  
 
     [0713] Further analysis of the NOV74a protein yielded the following properties shown in Table 74B.  
               TABLE 74B                       Protein Sequence Properties NOV74a                                        PSort   0.4328 probability located in mitochondrial matrix space;       analysis:   0.3000 probability located in microbody (peroxisome);           0.1137 probability located in mitochondrial inner membrane;           0.1137 probability located in mitochondrial intermembrane           space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0714] A search of the NOV74a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 74C.  
               TABLE 74C                          Geneseq Results for NOV74a                                             Identities/                   NOV74a   Similarities for       Geneseq   Protein/Organism/Length   Residues/   the Matched   Expect       Identifier   [Patent #, Date]   Match Residues   Region   Value                                             AAM41338   Human polypeptide SEQ ID NO   1 . . . 559   463/559   (82%)   0.0           6269 -  Homo sapiens , 478 aa.   10 . . . 478    466/559   (82%)           [WO200153312-A1, 26 JUL           2001]       AAM39552   Human polypeptide SEQ ID NO   1 . . . 529   434/529   (82%)   0.0           2697 -  Homo sapiens , 453 aa.   1 . . . 439   437/529   (82%)           [WO200153312-A1, 26 JUL           2001]       AAG02871   Human secreted protein, SEQ ID   1 . . . 102   102/102   (100%)   1e−52           NO: 6952 -  Homo sapiens , 104 aa.   1 . . . 102   102/102   (100%)           [EP1033401-A2, 6 SEP 2000]       AAM40893   Human polypeptide SEQ ID NO   568 . . . 604    32/37   (86%)   2e−10           5824 -  Homo sapiens , 746 aa.   1 . . . 37    32/37   (86%)           [WO200153312-A1, 26 JUL           2001]       AAM40892   Human polypeptide SEQ ID NO   568 . . . 604    32/37   (86%)   2e−10           5823 -  Homo sapiens , 746 aa.   1 . . . 37    32/37   (86%)           [WO200153312-A1, 26 JUL           2001]                  
 
     [0715] In a BLAST search of public sequence databases, the NOV74a protein was found to have homology to the proteins shown in the BLASTP data in Table 74D.  
               TABLE 74D                          Public BLASTP Results for NOV74a                                         NOV74a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               AAH18918   HYPOTHETICAL 45.7 KDA   66 . . . 559   399/494 (80%)   0.0           PROTEIN -  Homo sapiens      1 . . . 404   402/494 (80%)           (Human), 404 aa.       Q9NWP8   KAIA2372 PROTEIN -  Homo      1 . . . 352   305/352 (86%)    e−172           sapiens (Human), 336 aa.    1 . . . 310   308/352 (86%)   3e−61       Q9XW02   Y54G11A.4 PROTEIN -    4 . . . 556   165/557 (29%)             Caenorhabditis elegans , 497 aa.    6 . . . 458   256/557 (45%)       Q9XW01   Y54G11A.7 PROTEIN -    4 . . . 347   122/347 (35%)   7e−53             Caenorhabditis elegans , 407 aa.    6 . . . 305   177/347 (50%)       Q98CS1   MLR5032 PROTEIN -   60 . . . 553   145/496 (29%)   1e−43             Rhizobium loti  ( Mesorhizobium     46 . . . 435   215/496 (43%)             loti ), 440 aa.                  
 
     [0716] PFam analysis predicts that the NOV74a protein contains the domains shown in the Table 74E.  
               TABLE 74E                          Domain Analysis of NOV74a                                     Identities/           Pfam   NOV74a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               Monooxygenase: domain   225 . . . 410    28/238 (12%)   6.4       1 of 1       121/238 (51%)                  
 
     Example 75  
     [0717] The NOV75 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 75A.  
               TABLE 75A                       NOV75 Sequence Analysis                                                SEQ ID NO:215   1851 bp                     NOV75a,     CAGCTACAGCAAACATCGTTCGAG   ATG TCCCACCAAGAGGGCAGCACAGGTGGCTTAC       CG59549-01 DNA Sequence           CAGACTTAGTGACTGAAAGCCTGTTCAGCAGCCCAGAGGAGCAGTCTGGAGTAGCAGC                   GGTGACGGCGCCCTCCTCACACATTCAAATGGCACCCACAGAGCCATCGACCGGAGAT                   GGTGGTGATACCAGGGATGGTGGTTTCCTGAACGATGCCAGCACAGAAAATCAAAACA                   CAGACTCAGAAAGTTCAAGTGAAGACGTCGAACTTGAAAGCATGGGTGAACGTTTATT                   TGGTTACCCGTTAGTGGGAGAGGAGACAGAAAGGGAGGAGGAAGAAGAAGAGATGGAG                   GAGGAAGGGGAGGAGGAACAACAGCCTCCGATGTGTCCACGATGCGCTGGCACCAACC                   ATGATCAGTGTTTGTTAGACGAGGATCAGGCGTTGGAGGAGTGGATTTCCTCAGAGAC                   ATCTGCCCTGCCCCGATCTCGCTGGCAAGTCCTTACTGCTCTTCGCCAGCGGCAGCTG                   GGTTCAAGTGCCCGCTTTGTATATGAGGCCTGTGGGGCAAGAACCTTTGTGCAGCGTT                   TCCGCCTGCAQTATCTTCTTGGAAGCCATGCCGGTTCTGTCAGTACCATACACTTTAA                   CCAGCGTGGCACCCGACTGGCCAGTAGCGGTGATGACTTAAGGGTGATAGTGTGGGAC                   TGGGTGCGGCAGAAQCCAGTACTGAACTTTGAGAGTGGTCACGATATTAATGTCATCC                   AGGCTAAGTTCTTTCCTAACTGTGGTGATTCCACTCTGGCCATGTGTGGCCATGATGG                   ACAGGTACGGGTAGCAGAACTAATTAATGCATCATATTGCGAGAATACTAAGCGTGTG                   GCCAAGCACAGGGGACCTGCCCACGAGTTGGCTCTGGAGCCAGACTCTCCTTATAAGT                   TCCTCACTTCAGGTGAAGATGCCGTTGTGTTCACCATTGACCTCAGGCAAGACCCGCC                   AGCTTCAAAAGTTGTGCTAACAAGAGAAAATGATAAGAAAGTCGCACTGTATACAATC                   TCTATGAATCCTGCCAATATTTACCAATTTGCAGTGGGTGGACATGATCAGTTTGTAA                   GGATTTATGACCAGAGGAGAATTGATAAGAAAGAAAACAATGGAGTACTCAAGAAATT                   CACTCCTCATCATCTCGTTTATTGTGATTTCCCAACAAACATCACCTCCGTTGTGTAC                   AGCCACGATCGCACAGAGCTCCTGGCCAGCTACAATGATGAAGATATTTACCTCTTCA                   ACTCCTCTCTCAGTGATGGTGCTCAATATGTTAAGAGATATAAGGGGCACAGAAATAA                   TGACACAATCAAATGTGTTAATTTCTATGGCCCCCGGAGTGAGTTTGTCGTGAGCGGT                   AGTGATTGTGGGCACGTCTTCTTCTGGGAGAAATCATCCTCCCAGATCATCCAGTTCA                   TGGAGGGGGACAGAGGATATATAGTAAACTGTCTTGAACCCCACCCTTACCTACCTGT                   GTTGGCGACCAGTGGCCTAGATCAGCATGTCAGCATCTGGACACCCACAGCTAAAACT                   GCCACTGAGCTTACTGGGTTAAAAGATGTGATTAAGAAGAACAAGCAGGAGCGAGATG                   AAGACAACTTGAACTATACGGACTCGTTTGACAACCGCATGCTTCGGTTCTTCGTGCC                   TCACCTGTTACAGAGAGCTCATCAACCCGGCTGGAGAGATCATGGAGCTGAGTTCCCA                   GATGAAGAAGAGTTGGATGAGTCTTCCAGCACCTCAGATACATCCGAGGAGGAGGGCC                   AAGATCGAGTGCAGTGCATACCATCC TGA   AGGCCTCATATCCAGTCCAGCTAG                                           ORF Start: ATG at 25       ORF Stop: TGA at 1825           SEQ ID NO:216   600 aa   MW at 67372.4 kD                     NOV75a,   MSHQEGSTGGLPDLVTESLFSSPEEQSGVAAVTAASSDIEMAATEPSTGDGGDTRDGG       CG59549-01 Protein Sequence           FLNDASTENQNTDSESSSEDVELESMGEGLFGYPLVGEETEREEEEEEMEEEGEEEEQ                   PRMCPRCGGTNHDQCLLDEDQALEEWISSETSALPRSRWQVLTALRQRQLGSSARFVY                   EACGARTFVQRFRLQYLLGSHAGSVSTTHFNQRGTRLASSGDDLRVTVWDWVRQKPVL                   NFESGHDINVIQAKFFPNCGDSTLAMCGHDGQVRVAELINASYCENTKRVAKHRGPAH                   ELALEPDSPYKFLTSGEDAVVFTIDLRQDRPASKVVVTRENDKKVGLYTISMNPANIY                   QFAVGGHDQFVRIYDQRRIDKKENNGVLKKFTPHHLVYCDFPTNITCVVYSHDGTELL                   ASYNDEDTYLFNSSLSDGAQYVKRYKCHRNNDTIKCVNFYGFRSEFVVSGSDCGEVFF                   WEKSSSQIIQFMECDRGDTVNCLEPHPYLPVLATSGLDQHVRIWTPTAKTATELTCLK                   DVIKKNKQERDEDNLNYTDSFDNRNLRFFVRHLLQRAHQPGWRDHGAEFPDEEELDES                   SSTSDTSEEEGQDRVQCIPS                  
 
     [0718] Further analysis of the NOV75a protein yielded the following properties shown in Table 75B.  
               TABLE 75B                       Protein Sequence Properties NOV75a                                        PSort   0.6500 probability located in cytoplasm; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0442 probability located in           microbody (peroxisome)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0719] A search of the NOV75a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 75C.  
               TABLE 75C                          Geneseq Results for NOV75a                                         NOV75a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAR85870   WD-40 domain-contg.  Mus      95 . . . 589   295/495 (59%)    e−179             musculus  protein- Mus musculus ,   333 . . . 815   372/495 (74%)           816 aa. [WO9521252-A2,           10 AUG. 1995]       AAM73935   Human bone marrow expressed    1 . . . 157   157/157 (100%)   2e−87           probe encoded protein SEQ ID NO:    8 . . . 164   157/157 (100%)           34241- Homo sapiens , 164 aa.           [WO200157276-A2, 9 AUG. 2001]       AAM61216   Human brain expressed single exon    1 . . . 157   157/157 (100%)   2e−87           probe encoded protein SEQ ID NO:    8 . . . 164   157/157 (100%)           33321- Homo sapiens , 164 aa.           [WO200157275-A2, 9 AUG. 2001]       AAM34114   Peptide #8151 encoded by probe    1 . . . 157   157/157 (100%)   2e−87           for measuring placental gene    8 . . . 164   157/157 (100%)           expression- Homo sapiens , 164 aa.           [WO200157272-A2, 9 AUG. 2001]       AAB57007   Human prostate cancer antigen   408 . . . 600   144/194 (74%)   2e−80           protein sequence SEQ ID NO: 1585-    22 . . . 214   162/194 (83%)             Homo sapiens , 214 aa.           [WO200055174-A1, 21 SEP. 2000]                  
 
     [0720] In a BLAST search of public sequence databases, the NOV75a protein was found to have homology to the proteins shown in the BLASTP data in Table 75D.  
               TABLE 75D                          Public BLASTP Results for NOV75a                                         NOV75a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q12839   H326 PROTEIN- Homo sapiens      1 . . . 600   408/604 (67%)   0.0           (Human), 597 aa.    1 . . . 597   471/604 (77%)       Q01078   PROTEIN PC326- Mus musculus      95 . . . 589   295/495 (59%)    e−178           (Mouse), 747 aa.   264 . . . 746   372/495 (74%)       Q9W091   CG8001 PROTEIN- Drosophila      68 . . . 587   178/533 (33%)   1e−77             melanogaster  (Fruit fly), 748 aa.   209 . . . 711   280/533 (52%)       Q96E00   UNKNOWN (PROTEIN FOR    1 . . . 246   141/249 (56%)   8e−66           MGC: 9478)- Homo sapiens      1 . . . 243   173/249 (68%)           (Human), 273 aa.       Q9M1E5   HYPOTHETICAL 54.0 KDA   183 . . . 536   136/382 (35%)   2e−62           PROTEIN- Arabidopsis thaliana      42 . . . 419   209/382 (54%)           (Mouse-ear cress), 481 aa.                  
 
     [0721] PFam analysis predicts that the NOV75a protein contains the domains shown in the Table 75E.  
               TABLE 75E                          Domain Analysis of NOV75a                                     Identities/           Pfam   NOV75a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               WD40: domain 1 of 7   188 . . . 224   13/37 (35%)    0.0016               29/37 (78%)       WD40: domain 2 of 7   231 . . . 269   12/39 (31%)   11               26/39 (67%)       WD40: domain 3 of 7   278 . . . 315    9/38 (24%)   2.2e+02               24/38 (63%)       WD40: domain 4 of 7   326 . . . 363    8/38 (21%)    8.8               27/38 (71%)       WD40: domain 5 of 7   382 . . . 418    5/37 (14%)   12               27/37 (73%)       WD40: domain 6 of 7   429 . . . 466    6/38 (16%)   18               26/38 (68%)       WD40: domain 7 of 7   473 . . . 509   11/37 (30%)    0.51               22/37 (59%)                  
 
     Example 76  
     [0722] The NOV76 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 76A.  
               TABLE 76A                       NOV76 Sequence Analysis                                                SEQ ID NO:217   7497 bp                     NOV76a,     ATG GTCTTGCTTCTTTGTCTATCTTGTCTGATTTTCTCCTGTCTGACCTTTTCCTGGT       CG59641-01 DNA Sequence           TAAAAATCTGGGGGAAAATGACGGACTCCAAGCCGATCACCAAGAGTAAATCAGAAGC                   AAACCTCATCCCGAGCCAGGAGCCCTTTCCAGCCTCTGATAACTCAGGGGAGACACCG                   CAGAGAAATGGGGAGGGCCACACTCTGCCCAACACACCCAGCCAGGCCGAGCCAGCCT                   CCCACAAAGGCCCCAAAGATGCCGGTCGGCGGAGAAACTCCCTACCACCCTCCCACCA                   GAAGCCCCCAAGAAACCCCCTTTCTTCCAGTGACGCAGCACCCTCCCCAGAGCTTCAA                   GCCAACGCGACTGGGACACAAGGTCTGGAGGCCACAGATACCAATGGCCTGTCCTCCT                   CAGCCAGGCCCCAGGGCCAGCAAGCTGGCTCCCCCTCCAAAGAAGACAAGAAGCAGGC                   AAACATCAAGAGGCAGCTGATGACCAACTTCATCCTGGGCTCTTTTGATGACTACTCC                   TCCGACGAGGACTCTGTTGCTGGCTCATCTCGTGAGTCTACCCCGAAGGGCAGCCGGC                   CCAGCTTGGGGGCCCTGTCCCTGGAGGCTTATCTGACCACAAGGCCGAGCATGTCGGG                   ACTCCACCTGGTGAAGAGGGGACGGGAACACAAGAAGCTGGACCTGCACAGAGACTTT                   ACCGTGGCTTCTCCCGCTGAGTTTGTCACACGCTTTGGGGGGGATCGGGTCATCGAGA                   AGGTGCTTATTGCCAACAACGGCATTGCCGCCGTGAAGTGCATGCGCTCCATCCGCAG                   GTGGGCCTATGAGATGTTCCGCAACGAGCGGGCCATCCGGTTTGTTGTGATGGTGACC                   CCCGAGGACCTTAAGGCCAACGCAGAGTACATCAAGATGGCGGATCATTACGTCCCCG                   TCCCAGGAGGGCCCAATAACAACAACTATGCCAACGTGGAGCTGATTGTGGACATTGC                   CAAGAGAATCCCCGTGCAGCCGGTGTGGGCTGGCTGGGGCCATGCTTCAGAAAACCCT                   AAACTTCCGGAGCTGCTGTGCAAGAATGGAGTTGCTTTCTTAGGCCCTCCCAGTGAGG                   CCATGTGGGCCTTAGGAGATAAGATCGCCTCCACCGTTGTCGCCCAGACGCTACAGGT                   CCCAACCCTGCCCTGGAGTGGAAGCGGCCTGACAGTGGAGTGGACAGAAGATGATCTG                   CAGCAGGGAAAAAGAATCAGTGTCCCAGAAGATGTTTATGACAAGGGTTGCGTGAAAG                   ACGTAGATGAGGGCTTGGAGGCAGCAGAAACAATTGGTTTTCCATTGATCATCAAAGC                   TTCTGAAGGTGGCGGAGGGAAGGGAATCCGGAAGGCTGAGAGTGCGGAGGACTTCCCG                   ATCCTTTTCAGACAAGTACAGAGTGAGATCCCAGGCTCGCCCATCTTTCTCATGAAGC                   TGGCCCAGCACGCCCGTCACCTGGAAGTTCAGATCCTCGCTGACCAGTATGGGAATGC                   TGTGTCTCTGTTTGGTCGCGACTGCTCCATCCAGCGGCGGCATCAGAAGATCGTTGAG                   GAAGCACCGGCCACCATCGCCCCGCTGGCCATATTCGAGTTCATGGAGCAGTGTGCCA                   TCCGCCTGGCCAAGACCGTGGGCTATGTGAGTGCAGGGACAGTGGAATACCTCTATAG                   TCAGGATGGCAGCTTCCACTTCTTGGAGCTGAATCCTCGCTTGCAGGTGGAACATCCC                   TGCACAGAAATGATTGCTGATGTTAATCTGCCGGCCGCCCAGCTACAGATCGCCATGG                   GCGTGCCACTGCACCGGCTGAAGGATATCCGGCTTCTGTATGGAGAGTCACCATGGGG                   AGTGACTCCCATTTCTTTTGAAACCCCCTCAAACCCTCCCCTCGCCCGAGGCCACGTC                   ATTGCCGCCAGAATCACCAGCGAAAACCCAGACGAGGGTTTTAAGCCGAGCTCCGGGA                   CTGTCCAGGAACTGAATTTCCGGAGCAGCAAGAACGTGTGGGGTTACTTCAGCGTGGC                   CGCTACTGGAGCCCTGCACCAGTTTGCGGATTCCCAATTTGGGCACTGCTTCTCCTGG                   GGAGAGAACCGGGAAGAGGCCATTTCGAACATGGTGGTGGCTTTGAAGGAACTGTCCA                   TCCGAGGCGACTTTAGGACTACCGTGGAATACCTCATTAACCTCCTGGACACCGAGAG                   CTTCCAGAACAACGACATCGACACCGGGTGGTTGGACTACCTCATTGCTGAGAAAGTG                   CAGGCGGAGAAACCGGATATCATGCTTGGGGTGGTATGCGGGGCCTTGAACGTGGCCG                   ATGCGATGTTCAGAACGTGCATGACAGATTTCTTACACTCCCTCCAAAGGCGCCAGGT                   CCTCCCAGCGGATTCACTACTGAACCTCGTAGATGTGGAATTAATTTACGGAGGTGTT                   AAGTACATTCTCAAGGTGGCCCGGCAGTCTCTGACCATGTTCGTTCTCATCATGAATG                   GCTCCCACATCGAGATTGATGCCCACCGCCTGAATGATCCGGGGCTCCTCCTCTCCTA                   CAATGGGAACAGCTACACCACCTACATGAAGGAAGAGGTTGACACTTACCGAATTACC                   ATCGGCAATAAGACGTGTGTGTTTGAGAAGGAGAACGATCCTACAGTCCTGAGATCCC                   CCTCGGCTGGGAAGCTGACACAGTACACAGTGGAGGATGGGGGCCACGTTGAGGCTGG                   GAGCAGCTACGCTGAGATGGAGGTGATGAAGATGATCATGACCCTGAACGTTCAGGAA                   AGAGGCCGGGTGAAGTACATCAAGCGTCCAGGTGCCGTGCTGGAAGCAGGCTGCGTGG                   TGGCCAGGCTGGAGCTCGATGACCCTTCTAAAGTCCACCCGGCTCAACCGTTCACAGG                   AGAACTCCCTGCCCAGCAGACACTGCCCATCCTCGGAGAGAAACTGCACCACGTCTTC                   CACAGCGTCCTGGAAAACCTCACCAACCTCATGAGTCGCTTTTCTCTGCCAGACCCCG                   TTTTTAGCATAAAGCTGAAGGAGTGGGTGCAGAAGCTCATGATGACCCTCCGGCACCC                   GTCACTGCCGCTGCTGGAGCTCCAGGAGATCATGACCAGCGTGGCAGGCCGCATCCCC                   GCCCCTGTGGAGAAGTCTGTCCGCAGGGTGATGGCCCAGTATGCCAGCAACATCACCT                   CGGTGCTGTGCCAGTTCCCCACCCAGCAGATAGCCACCATCCTGGACTGCCATCCAGC                   CACCCTGCAGCGGAAGGCTGATCGAGAGGTCTTCTTCATCAACACCCACAGCATCGTG                   CAGTTGGTCCAGAGATACCGCAGCGCGATCCGCGCCTATATGAAAACAGTGGTGTTGG                   ATCTCCTGAGAAGATACTTGCGTGTTGAGAGCAACGCAAGACATGCTGATGCCAACAC                   CAGTGGGATGGTGGGGGGCGTGAGGAGCCTGAGCTTTACCTCTGTGTGGTGTTTTGTC                   TCCCCCGAATCCCACTACGACAAGTGTGTGATAAACCTCAGGGAGCAGTTCAAGCCAG                   ACATGTCCCAGGTGCTGGACTGCATCTTCTCCCACGCACAGGTGGCCAAGAAGAACCA                   GCTGGTGATCATGTTGATCGATGAGCTGTGTGGCCCAGACCCTTCCCTGTCGGACGAG                   CTGATCTCCATCCTCAACGAGCTCACTCAGCTGAGCAAAAGCGAGCACTGCAAAGTGG                   CCCTCAGAGCCCGGCAGATCCTGATTGCCTCCCACCTCCCCTCCTACGAGCTGCGGCA                   TAACCACGTGGAGTCCATTTTCCTGTCTGCCATTGACATCTACGCCCACCAGTTCTGC                   CCCCACAACCTCAAGAAATTAATACTTTCGGAAACAACCATCTTCGACGTCCTGCCTA                   CTTTCTTCTATCACGCAAACAAAGTCGTGTGCATGGCGTCCTTGGAGCTTTACGTGCC                   GAGGGGCTACATCGCCTATGAGTTAAACAGCCTGCAGCACCGGCAGCTCCCGGACGGC                   ACCTGCGTGGTAGAATTCCAGTTCATCCTGCCGTCCTCCCACCCAAACCGGATGACCG                   TGCCCATCACCATCACCAACCCTGACCTGCTGAGGCACAGCACAGAGCTCTTCATGCA                   CAGCGGCTTCTCCCCACTGTGCCAGCGCATGGGAGCCATGGTAGCCTTCAGGAGATTC                   GAGCACTTCACCAGAAATTTTGATGAAGTCATCTCTTGCTTCGCCAACGTCCCCAAAG                   ACACCCCCCTCTTCACCGAGGCCCGCACCTCCCTATACTCCGAGGATGACTGCAAGAG                   CCTCAGAGAAGAGCCCATCCACATTCTGAATGTGTCCATCCAGTGTGCAGACCACCTG                   GAGGATGAGGCACTGGTGCCGATTTTACGGACATTCGTACAGTCCAAGAAAAATATCC                   TTGTGGATTATCCACTCCGACGAATCACATTCTTGATTGCCCAAGACTTTGCAGAAGA                   TCGCATTTACCGTCACTTCGAACCTGCCCTGGCCTTCCAGCTGGAACTTAACCGGATG                   CGTAACTTCGATCTGACCGCCGTGCCCTGTGCCAACCACAAGATGCACCTTTACCTGG                   GTGCTGCCAAGGTGAAGGAAGGTGTGGAAGTGACGGACCATAGGTTCTTCATCCGCGC                   CATCATCAGGCACTCTGACCTGATCACAAAGGAAGCCTCCTTCGAATACCTGCAGAAC                   GAGGGTGAGCGGCTGCTCCTGGAGGCCATGGACGAGCTGGAGGTGGCGTTCAATAACA                   CCAGCGTGCGCACCGACTGCAACCACATCTTCCTCAACTTCGTGCCCACTGTCATCAT                   GGACCCCTTCAAGATCGAGGAGTCCGTGCGCTACATGGTTATGCGCTACGGCAGCCGG                   CTGTGGAAACTCCGTGTGCTACAGGCTGAGGTCAAGATCAACATCCGCCAGACCACCA                   CCGGCAGTGCCGTTCCCATCCGCCTGTTCATCACCAATGAGTCGGGCTACTACCTGGA                   CATCAGCCTCTACAAAGAAGTGACTGACTCCACATCTGGAAATATCATCTTTCACTCC                   TTCGGCAACAAGCAAGGGCCCCAGCACGGGATGCTGATCAATACTCCCTACGTCACCA                   AGGATCTGCTCCAGGCCAAGCGATTCCACGCCCAGACCCTGGGAACCACCTACATCTA                   TGACTTCCCCGAAATGTTCACCCAGGCAAGTCCGGCGGCTCACACGCGGGTACATGTG                   CACAATGTGCAGCCTCTCTTTAAACTGTGGGGCTCCCCAGACAAGTATCCCAAACACA                   TCCTGACATACACTCAATTAGTGTTGGACTCTCAGGCCCAGCTGGTCCAGATGAACCG                   ACTTCCTGGTGGAAATGAGGTGCCCATGGTGGCCTTCAAAATGAGCTTTAAGACCCAG                   GAGTACCCGGAAGGACGGGATGTGATCGTCATCGGCAATGACATCACCTTTCGCATTG                   GATCCTTTGGCCCTGGAGAGCACCTTCTGTACCTGCCGGCATCCGAGATCCCCCGCGC                   AGAGGGCATTCCCAAAATTTACGTGGCAGCCAACAGTGGCGCCCGTATTCGCATGGCA                   GAGGAGATCAAACACATGTTCCACGTGGCTTGGGTGGACCCAGAAGACCCCCACAAAA                   AAAAAAAAACAGTGGCTTTCAGTGCAGGGAACTGGATTCGTAGCCTCACTAAAGTATT                   TTTTAAGGGATTTAAATACCTGTACCTGACTCCCCAAGACTACACCACAATCAGCTCC                   CTGAACTCCGTCCACTGTAAACACATCGAGGAAGGAGGAGAGTCCAGATACATGATCA                   CGGATATCATCGGGAAGGATGATGGCTTGGGCGTGGAGAATCTGAGGGGCTCAGGCAT                   GATTGCTGGGGAGTCCTCTCTGGCTTACGAAGAGATCGTCACCATTAGCTTGGTGACC                   TGCCGAGCCATTGGGATTGGGGCCTACTTGGTGAGGCTGGGCCAGCGAGTGATCCAGG                   TGGAGAATTCCCACATCATCCTCACAGGAGCAAGTGCTCTCAACAAGGTCCTGGGAAG                   AGAGGTCTACACATCCAACAACCAGCTGGGTGGCGTTCAGATCATGCATTACAATGGT                   GTCTCCCACATCACCGTGCCAGATGACTTTGAGGGGGTTTATACCATCCTGGAGTGGC                   TGTCCTATATGCCAAAGGATAATCACAGCCCTGTCCCTATCATCACACCCACTGACCC                   CATTGACAGAGAAATTGAATTCCTCCCATCCAGAGCTCCCTACGACCCCCGGTGGATG                   CTTGCAGGAAGGCCTCACCCAACTCTGAAGGGAACGTGGCAGAGCGGATTCTTTGACC                   ACGGCAGTTTCAAGGAAATCATGGCACCCTGGGCGCAGACCGTGGTGACAGGACGAGC                   AAGGCTTGGGGGGATTCCCGTGGGAGTGATTGCTGTGGAGACACGGACTGTGGAGGTG                   GCAGTCCCTGCACACCCTGCCAACCTGGATTCTGAGGCCAAGATAATTCAGCAGGCAG                   GACAGGTGTGGTTCCCAGACTCAGCCTACAAAACCGCCCAGGCCCTCAAGGACTTCAA                   CCGGGAGAAGTTCCCCCTGATGATCTTTGCCAACTGGAGGGCGTTCTCCGGTGGCATG                   AAAGACATGTATGACCAGGTGCTGAAGTTTGGAGCCTACATCGTGGACGGCCTTAGAC                   AATACAAACAGCCCATCCTGATCTATATCCCGCCCTATGCGGAGCTCCGGGGAGGCTC                   CTGGGTGGTCATAGATGCCACCATCAACCCGCTGTGCATAGAAATGTATGCAGACAAA                   GAGAGCAGGGGTGGTGTTCTGGAACCAGAGGGGACAGTGGAGATTAAGTTCCGAAAGA                   AAGATCTGATAAAGTCCATGAGAAGGATCGATCCAGCTTACAAGAAGCTCATGGAACA                   GCTAGGGGAACCTGATCTCTCCGACAAGGACCGAAAGGACCTGGAGGGCCGGCTAAAG                   GCTCGCGAGGACCTGCTGCTCCCCATCTACCACCAGGTGGCGGTGCAGTTCGCCGACT                   TCCATGACACACCCGGCCGGATGCTGGAGAAGGGCGTCATATCTGACATCCTGGAGTG                   GAAGACCGCACGCACCTTCCTGTATTGGCGTCTGCGCCGCCTCCTCCTGGAGGACCAG                   GTCAAGCAGGAGATCCTGCAGGCCAGCGGGGAGCTGAGTCACGTGCATATCCAGTCCA                   TGCTGCGTCGCTGGTTCGTGGAGACGGAGGGGGCTGTCAAGGCCTACTTGTGGGACAA                   CAACCAGGTGGTTGTGCAGTGGCTGGAACAGCACTGGCAGGCAGGGGATGGCCCGCGC                   TCCACCATCCGTGAGAACATCACGTACCTGAAGCACGACTCTGTCCTCAAGACCATCC                   GAGGCCTGGTTGAAGAAAACCCCGAGGTGGCCGTGGACTGTGTGATATACCTGAGCCA                   GCACATCAGCCCAGCTGAGCGGGCGCAGGTCGTTCACCTGCTGTCTACCATGGACAGC                   CCGGCCTCCACC TGA                                           ORF Start: ATG at 1       ORF Stop: TGA at 7495           SEQ ID NO:218   2498 aa   MW at 280484.4 kD                     NOV76a,   MVLLLCLSCLIFSCLTFSWLKIWGKMTDSKPITKSKSEANLIPSQEPFPASDNSGETP       CG59641-01 Protein Sequence           QRNGEGHTLPKTPSQAEPASHKGPKDAGRRRNSLPPSHQKPPRNPLSSSDAAPSPELQ                   ANGTGTQGLEATDTNGLSSSARPQGQQAGSPSKEDKKQANIKRQLMTNFILGSFDDYS                   SDEDSVAGSSRESTRKGSRASLGALSLEAYLTTRPSMSGLHLVKRGREHKKLDLHRDF                   TVASPAEFVTRFGGDRVIEKVLIANNGIAAVKCMRSIRRWAYEMFRNERAIRFVVMVT                   PEDLKANAEYIKMADHYVPVPGGPNNNNYANVELIVDIAKRIPVQAVWAGWGHASENP                   KLPELLCKNGVAFLGPPSEAMWALGDKIASTVVAQTLQVPTLPWSGSGLTVEWTEDDL                   QQGKRISVPEDVYDKGCVKDVDEGLEAAERTGFPLMIKASEGGGGKGIRKAESAEDFP                   ILFRQVQSEIPGSPIFLMKLAQHARHLEVQILADQYGNAVSLFGRDCSIQRRHQKIVE                   EAPATIAPLAIFEFMEQCAIRLAKTVGYVSAGTVEYLYSQDGSFHFLELNPRLQVEHP                   CTEMIADVNLPAAQLQIAMGVPLHRLKDIRLLYGESPWGVTPISFETPSNPPLARGBV                   IAARITSENPDEGFKPSSGTVQELNFRSSKNVWGYFSVAATGGLHEFADSQFGHCFSW                   GENREEAISNMVVALKELSIRGDFRTTVEYLINLLETESFQNNDIDTGWLDYLIAEKV                   QAEKPDIMLGVVCGALNVADAMFRTCMTDFLHSLERGQVLPADSLLNLVDVELIYGGV                   KYILKVARQSLTMFVLIMNGCHIEIDAHRLNDGGLLLSYNGNSYTTYMKEEVDSYRIT                   IGNKTCVFEKENDPTVLRSPSAGKLTQYTVEDGGHVEAGSSYAEMEVMKMIMTLNVQE                   RGRVKYIKRPGAVLEAGCVVARLELDDPSKVHPAEPFTGELPAQQTLPILGEKLHQVF                   HSVLENLTNVMSGFCLPEPVFSIKLKEWVQKLMMTLRHPSLPLLELQEIMTSVAGRIP                   APVEKSVRRVMAQYASNITSVLCQFPSQQIATILDCKAATLQRKADREVFFINTQSIV                   QLVQRYRSGIRCYMKTVVLDLLRRYLRVESKARDADANTSGMVGGVRSLSFTSVWCFV                   SPESHYDKCVINLREQFKPDMSQVLDCIFSHAQVAKKNQLVIMLIDELCGPDPSLSDE                   LISILNELTQLSKSEECKVALRARQILIASHLPSYELRHNQVESIFLSAIDMYGHQFC                   PENLKKLILSETTIFDVLPTFFYHANKVVCMASLEVYVRRGYIAYELNSLQHRQLPDG                   TCVVEFQFMLPSSEPNRMTVPISITNPDLLRHSTELFMDSGFSPLCQRNGANVAFRRF                   EDFTRNFDEVISCFANVPKDTPLFSEARTSLYSEDDCKSLREEPIHILNVSIQCADHL                   EDEALVPILRTFVQSKKNILVDYGLRRITFLIAQEFAEDRIYRHLEPALAFQLELNRN                   RNFDLTAVPCANHKMHLYLGAAKVKEGVEVTDHRFFIRAIIRHSDLITKEASFEYLQN                   ECERLLLEAMDELEVAFNNTSVRTDCNBIFLNFVPTVIMDPFKIEESVRYMVMRYGSR                   LWKLRVLQAEVKINIRQTTTGSAVPIRLPITNESGYYLDISLYKEVTDSRSGNIMFHS                   FGNKQGPQHGMLINTPYVTKDLLQAKRFQAQTLGTTYIYDfPEMFRQASPAAQTRVHV                   HNVQALFKLWGSPDKYPKDILTYTELVLDSQGQLVEMNRLPGGNEVGMVAFKMRFKTQ                   EYPEGRDVIVIGNDITFRIGSFGPGEDLLYLRASEMARAEGIPKIYVAANSGARIGMA                   EEIKHMFHVAWVDPEDPHKKKKTVAFSAGNWIRSLTKVPFKGFKYLYLTPQDYTRISS                   LNSVHCKHIEEGGESRYMITDIIGKDDGLGVENLRGSGMIAGESSLAYEEIVTISLVT                   CRAIGIGAYLVRLGQRVIQVENSHIILTGASALNKVLCREVYTSNNQLCGVQIMHYNG                   VSHITVPDDFEGVYTILEWLSYMPKDNESPVPIITPTDPIDREIEFLPSRAPYDPRWM                   LAGRPHPTLKGTWQSGPEDEGSFKEIMAPWAQTVVTGRARLGGIPVGVIAVETRTVEV                   AVPADPANLDSEAKIIQQAGQVWFPDSAYKTAQAVKDFNREKLPLMIFANWRGFSGGM                   KDMYDQVLKPGAYIVDGLRQYKQPILIYIPPYAELRGGSWVVIDATINPLCIEMYADK                   ESRGGVLEPEGTVEIKFRKKDLIKSMRRIDPAYKKLMEQLGEPDLSDKDRKDLEGRLK                   AREDLLLPIYHQVAVQFADFHDTPGRMLEKGVISDILEWKTARTFLYWRLRRLLLEDQ                   VKQEILQASGELSHVHIQSMLRRWFVETEGAVKAYLWDNNQVVVQWLEQHWQAGDGPR                   STIRENITYLKHDSVLKTIRGLVEENPEVAVDCVIYLSQHISPAERAQVVHLLSTMDS                   PAST                  
 
     [0723] Further analysis of the NOV76a protein yielded the following properties shown in Table 76B.  
               TABLE 76B                       Protein Sequence Properties NOV76a                                                PSort   0.6850 probability located in endoplasmic reticulum           analysis:   (membrane); 0.6400 probability located in plasma               membrane; 0.4600 probability located in Golgi               body; 0.1000 probability located in endoplasmic               reticulum (lumen)           SignalP   Likely cleavage site between residues 25 and 26           analysis:                      
 
     [0724] A search of the NOV76a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 76C.  
               TABLE 76C                          Geneseq Results for NOV76a                                         NOV76a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAU32848   Novel human secreted protein    26 . . . 2498   2316/2555 (90%)   0.0           #3339- Homo sapiens , 2486 aa.    1 . . . 2486   2339/2555 (90%)           [WO200179449-A2,           25 OCT. 2001]       AAR05707   Acetyl-CoA-carboxylase-Gallus   163 . . . 2498   1728/2375 (72%)   0.0           sp, 2324 aa. [JP02057179-A,    17 . . . 2324   2003/2375 (83%)           26 FEB. 1990]       AAB86033   Bovine acetyl-coenzyme A   204 . . . 2497   1719/2342 (73%)   0.0           carboxylase−alpha protein    14 . . . 2288   1969/2342 (83%)           fragment- Bos taurus , 2288 aa.           [DE19946173-A1, 5 APR. 2001]       AAR98811     Erysiphe graminis  acetyl   235 . . . 2490   1045/2326 (44%)   0.0           coenzyme A carboxylase-    42 . . . 2271   1432/2326 (60%)             Erysiphe graminis  f.sp.hordei,           2273 aa. [FR2727129-A1,           24 MAY 1996]       AAY24150     Candida albicans  acetyl CoA   239 . . . 2489   1015/2300 (44%)   0.0           carboxylase- Candida albicans,      88 . . . 2269   1396/2300 (60%)           2270 aa. [WO9932635-A1,           1 JUL. 1999]                  
 
     [0725] In a BLAST search of public sequence databases, the NOV76a protein was found to have homology to the proteins shown in the BLASTP data in Table 76D.  
               TABLE 76D                          Public BLASTP Results for NOV76a                                         NOV76a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               O00763   Acetyl-CoA carboxylase 2 (EC    1 . . . 2498   2349/2528 (92%)   0.0           6.4.1.2) (ACC-beta) [Includes:    1 . . . 2483   2384/2528 (93%)           Biotin carboxylase (BC 6.3.4.14)]-             Homo sapiens  (Human), 2483 aa.       O70151   ACETYL-COA CARBOXYLASE-    1 . . . 2497   2068/2524 (81%)   0.0             Rattus norvegicus  (Rat), 2456 aa.    1 . . . 2455   2224/2524 (87%)       CAA48770   ACETYL-COA CARBOXYLASE   163 . . . 2498   1921/2390 (80%)   0.0           (EC 6.4.1.2)- Homo sapiens      17 . . . 2339   2086/2390 (86%)           (Human), 2339 aa.       P11029   Acetyl-CoA carboxylase (EC   163 . . . 2498   1732/2375 (72%)   0.0           6.4.1.2) (ACC) [Includes: Biotin    17 . . . 2324   2004/2375 (83%)           carboxylase (EC 6.3.4.14)]-             Gallus gallus  (Chicken), 2324 aa.       P11497   Acetyl-CoA carboxylase 1 (EC   163 . . . 2497   1736/2396 (72%)   0.0           6.4.1.2) (ACC-alpha) [Includes:    17 . . . 2345   1993/2396 (82%)           Biotin carboxylase (BC 6.3.4.14)]-             Rattus norvegicus  (Rat), 2345 aa.                  
 
     [0726] PFam analysis predicts that the NOV76a protein contains the domains shown in the Table 76E.  
               TABLE 76E                          Domain Analysis of NOV76a                                     Identities/           Pfam   NOV76a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               CPSase_L_chain:    249 . . . 372    49/132 (37%)   2.2e−57       domain 1 of 1       CPSase_L_D2:    374 . . . 619   102/253 (40%)   6.6e−118       domain 1 of 1       218/253 (86%)       Biotin_carb_C:    640 . . . 747    40/118 (34%)   1.9e−53       domain 1 of 1       100/118 (85%)       biotin_lipoyl:    885 . . . 951    22/75 (29%)   6.5e−17       domain 1 of 1        56/75 (75%)       Carboxyl_trans:   1783 . . . 1878    31/100 (31%)   7.4e−34       domain 1 of 2        88/100 (88%)       GTP_cyclohydroI:   2287 . . . 2304    6/18 (33%)   6.6       domain 1 of 1        13/18 (72%)       Carboxyl_trans:   1897 . . . 2374   191/504 (38%)   4.1e−258       domain 2 of 2       447/504 (89%)                  
 
     Example 77  
     [0727] The NOV77 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 77A.  
               TABLE 77A                       NOV77 Sequence Analysis                                                    SEQ ID NO: 219   1624 bp                             NOV77a,     CGCGCGCCGGGG   ATG GAGCCGCAGCCCGGCGGCGCCCGGAGCTGCCGGCGCGGGGCCC           CG59630-01 DNA Sequence           CCGGCGGCGCCTGCGAGCTGGGCCCGGCGGCCGAGGCGGCGCCCATGAGCCTCGCCAT                   CCACAGCACCACGGGCACCCGCTACGACCTGGCCGTGCCGCCCGACGAGACGGTGGAG                   GGGCTGCGCAAGCGGTTGTCCCAGCGCCTCAAAGTGCCCAAGGAGCGCCTGGCTCTTC                   TCCACAAAGACACGCGGCTCAGTTCGGGGAAGCTGCAGGAGTTCGGCGTGGGTGATGG                   CAGCAAGCTGACCTTGGTACCCACCGTGGAAGCGGGCCTCATGTCTCAGGCCTCAAGG                   CCGGAACAGTCCGTGATGCAAGCTCTCGAGAGTCTCACGGAGACGCAGCCCCCAGCGG                   CGCCCGGGCCGGGCCGGGCTGGCGGAGGAGGCTTCCGGAAATACAGATTCATTTTATT                   TAAGCGTCCGTGGCACCGACAGGGACCCCAGAGCCCAGAGAGGGGCGGCGAGAGGCCC                   CAGGTCAGTGACTTCCTGTCGGGCCGTTCGCCACTGACACTGGCCTTGCGTGTGGGCG                   ACCACATGATGTTCGTGCAGCTGCAGCTCGCGGCCCAGCACGCTCCACTGCAACACCG                   CCATGTGCTGGCCGCTGCGGCCGCCGCCGCTGCTGCGCGGGGGGACCCCAGCATAGCC                   TCCCCCGTGTCCTCGCCCTGCCGGCCGGTGTCCAGTGCCGCCCGAGTCCCCCCGGTGC                   CCACCAGCCCGTCCCCTGCATCTCCCTCGCCCATCACAGCCGGCTCCTTCCGGTCCCA                   CGCAGCCTCCACCACCTGCCCGGAGCAGATGGACTGCTCCCCCACGGCCAGCAGCAGT                   GCCAGTCCTGGTGCCAGCACCACGTCTACCCCAGGGGCCAGCCCTGCCCCCCGCTCCC                   GAAAACCCGGCGCCGTCATCGAGAGCTTTGTGAATCACGCCCCGGGGGTCTTCTCAGG                   GACCTTCTCTGGCACGCTACACCCCAACTGCCAAGACAGCAGCGGGCGGCCGCGGCGT                   GACATCGGCACCATCCTGCAGATCCTGAACGACCTCCTGAGCGCCACCCGGCACTACC                   AGGGCATGCCCCCTTCGCTGGCCCAGCTCCGCTGCCACGCCCAGTGCTCCCCGGCCTC                   ACCGGCCCCCGACCTGGCCCCCAGAACTACCTCCTGCGAGAAGCTCACGGCTGCCCCC                   TCAGCCTCCCTGCTGCAGGGCCAGAGCCAGATCCGCATGTGCAAGCCCCCGGGTGACC                   GGCTTCGGCAGACAGAAAACCGCGCCACGCGCTGCAAGGTGGAACGGCTGCAGCTGCT                   TCTGCAGCAGAAACGGCTCCGTAGAAAGGCCCGGCGGGACGCGCGGGGTCCGTACCAC                   TGGTCACCCAGCCGCAAGGCCGGCCGCAGCGACAGCAGTAGCAGCGGGGGCGGCGGCA                   GCCCCAGCGAGGCCTCCGGCTTGGGCCTCGACTTCGAGGACTCCGTGTGGAAGCCAGA                   AGTCAACCCTGACATCAAGTCAGAGTTCGTGGTGGCT TAG   GATCTTCGGATCGGCCAC                       CCTCGCCCCTCGCACCCC   AG CCCAGGGCGGCGGGGACTCCGAGAGCCCCGGAGAGAAC                                         ORF Start: ATG at 13   ORF Stop: TAG at 1546                                     SEQ ID NO: 220   511 aa   MW at 53949.3 kD                                     NOV77a,   MEPQPGGARSCRRGAPGGACELGPAAEAAPMSLAIHSTTGTRYDLAVPPDETVEGLRK           CG59630-01 Protein Sequence           RLSQRLKVPKERLALLHKDTRLSSGKLQEFGVGDGSKLTLVPTVEAGLMSQASRPEQS                   VMQALESLTETQPPAAPGPGRAGGGGFRKYRFILFKRPWHRQGPQSPERGGERPQVSD                   FLSGRSPLTLALRVGDHMMFVQLQLAAQHAPLQHRHVLAAAAAAAAARGDPSIASPVS                   SPCRPVSSAARVPPVPTSPSPASPSPITAGSFRSHAASTTCPEQMDCSPTASSSASPG                   ASTTSTPGASPAPRSRKPGAVIESFVNHAPGVFSGTFSGTLHPNCQDSSGRPRRDIGT                   ILQILNDLLSATRHYQGMPPSLAQLRCHAQCSPASPAPDLAPRTTSCEKLTAAPSASL                   LQGQSQIRMCKPPGDRLRQTENRATRCKVERLQLLLQQKRLRRKARRDARGPYHWSPS                   RKAGRSDSSSSGGGGSPSEASGLGLDFEDSVWKPEVNPDIKSEFVVA                  
 
     [0728] Further analysis of the NOV77a protein yielded the following properties shown in Table 77B.  
               TABLE 77B                       Protein Sequence Properties NOV77a                                        PSort   0.3000 probability located in microbody (peroxisome);       analysis:   0.3000 probability located in nucleus; 0.1526 probability           located in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0729] A search of the NOV77a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 77C.  
               TABLE 77C                          Geneseq Results for NOV77a                                         NOV77a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAB56832   Human prostate cancer antigen   267 . . . 493   189/227 (83%)   e−104           protein sequence SEQ ID NO: 1410-    1 . . . 227   195/227 (85%)             Homo sapiens , 236 aa.           [WO200055174-A1, 21 SEP. 2000]                  
 
     [0730] In a BLAST search of public sequence databases, the NOV77a protein was found to have homology to the proteins shown in the BLASTP data in Table 77D.  
               TABLE 77D                          Public BLASTP Results for NOV77a                                         NOV77a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9JJJ6   MIDNOLIN- Mus musculus      1 . . . 511   475/514 (92%)   0.0           (Mouse), 508 aa.    1 . . . 508   486/514 (94%)       Q96BW8   SIMILAR TO MIDNOLIN-   338 . . . 511   174/174 (100%)   2e−97             Homo sapiens  (Human), 177 aa    4 . . . 177   174/174 (100%)           (fragment).       Q9W2S4   CG9732 PROTEIN- Drosophila     213 . . . 363    58/155 (37%)   6e−18             melanogaster  (Fruit fly), 989 aa.   524 . . . 677    80/155 (51%)       AAL40834   BPLF1-Human herpesvirus 4   200 . . . 406    64/223 (28%)   2e−07           (Epstein-Barr virus), 3179 aa.   320 . . . 530    95/223 (41%)       Q9BKV7   PPG3-Leishmania major, 1325   213 . . . 328    37/121 (30%)   2e−06           aa.   984 . . . 1104    66/121 (53%)                  
 
     [0731] PFam analysis predicts that the NOV77a protein contains the domains shown in the Table 77E.  
               TABLE 77E                          Domain Analysis of NOV77a                                     Identities/           Pfam   NOV77a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               ubiquitin:    31 . . . 99   19/79 (24%)   0.00033       domain 1 of 1       46/79 (58%)       PI3_PI4_kinase:   411 . . . 427    7/18 (39%)   1.5       domain 1 of 1       14/18 (78%)                  
 
     Example 78  
     [0732] The NOV78 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 78A.  
               TABLE 78A                       NOV78 Sequence Analysis                                                    SEQ ID NO: 221   1034 bp                             NOV78a     CCACCGCCACAGCTGCCAGC   ATG TCTGGCCCAGACATCAAGACGCCGACCGCCATCCA           CG59561-01 DNA Sequence           GATCTGCCGGATTATGCGGGACGCTAATGTGGCCCGCAATGTCTACGGCGGGACCATC                   CTGAAGATGATCAAAGAGGCGGGCGCCATCATCAGCACCCGGCATTGCAATCCGCAGA                   ACGGGGATCGCTGTGTGGCCGCTCTGGCTCGGGTCGAGTGCACCCACTTCCTGTGGCC                   CATGTGCATCGGTGAGGTGGCCCACGTCAGCGCGGAGATCACCTACACCTCCAAGCAC                   TCTGTGGAGGTGCAGGTCAACATGATGTCCGAAAACATCCTCACAGGTGCCAAAAAGC                   TGACCAATAAGGCCACCCTCTGGTATGCGCCCCTGTCGCTGACGAACGTGGACAAGGT                   CCTCGAAGAGCCTCCTGTTGTGTATTTCCGGCAGGAGCAGGAGGAGGAGGGCCAGAAG                   CGGTACAAAACCCAGAAGCTGGAGCGCATGGAGACCAACTGGAGGAACGGGGACATCG                   TCCAGCCAGTCCTCAACCCAGAGCCGAACACTGTCAGCTACAGCCAGTCCAGCTTGAT                   CCACCTGGTGGGGCCTTCAGACTGTACCCTGCACAGCTTCGTGCATGAAGGGGTGACC                   ATGAAGGTCATGGACGAGGTCGCCGGGATCTTGGCTGCACGCCACTGCAAGACCAACC                   TCGTCACAGCCTCCATGGAGGCCATTAATTTTGACAACAAGATCAGAAAAGGCTGCAT                   CAAGACCATCTCCGGACGCATGACCTTCACGAGCAATAAGTCCGTAGAGATCGAGGTC                   TTGGTGGATGCCGACTGTGTTGTGGACAGCTCTCAGAAGCGCTACAGGGCCGCCAGTG                   TCTTCACCTATGTGTCGCTGAGCCAGGAAGGCAGGTCGCTGCCCATGCCCCAGCTCGT                   GCCGGAGACCCAGGACGAGAAGGGCTTTGAGGCCTGGCTCGGTGGCTCACGCCTA TAA                       TCCCAGCACTTTAGGATGCTGAGGCAGGCGGATCACTTGACGTCAGGA                                                   ORF Start: ATG at 21   ORF Stop: TAA at 984                                     SEQ ID NO: 222   321 aa   MW at 35738.7 kD                                     NOV78a,   MSGPDIKTPTAIQICRIMRDANVARNVYGGTILKMIKEAGAIISTRHCNPQNGDRCVA           CG59561-01 Protein Sequence           ALARVECTHFLWPMCIGEVAHVSAEITYTSKHSVEVQVNMMSENILTGAKKLTNKATL                   WYAPLSLTNVDKVLEEPPVVYFRQEQEEEGQKRYKTQKLERMETNWRNGDIVQPVLNP                   EPNTVSYSQSSLIHLVGPSDCTLHSFVHEGVTMKVMDEVAGILAARHCKTNLVTASME                   AINFDNKIRKGCIKTISGRMTFTSNKSVEIEVLVDADCVVDSSQKRYRAASVFTYVSL                   SQEGRSLPMPQLVPETQDEKGFEAWLGGSRL                  
 
     [0733] Further analysis of the NOV78a protein yielded the following properties shown in Table 78B.  
               TABLE 78B                       Protein Sequence Properties NOV78a                                        PSort   0.8000 probability located in microbody (peroxisome);       analysis:   0.1000 probability located in mitochondrial matrix space;           0.1000 probability located in lysosome (lumen); 0.0000           probability located in endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0734] A search of the NOV78a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 78C.  
               TABLE 78c                          Geneseq Results for NOV78a                                         NOV78a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAW74896   Human secreted protein encoded by    1 . . . 310   273/313 (87%)    e−154           gene 169 clone HPTTU11- Homo      1 . . . 313   292/313 (93%)             sapiens , 339 aa. [WO9839448-A2,           11 SEP. 1998]       AAY71115   Human Hydrolase protein-13    1 . . . 310   247/313 (78%)    e−133           (HYDRL-13)- Homo sapiens , 375    33 . . . 316   266/313 (84%)           aa. [WO200028045-A2, 18 MAY 2000]       AAY35275     Chlamydia pneumoniae     187 . . . 310    35/124 (28%)   1e−09           transmembrane protein sequence-    16 . . . 138    72/124 (57%)             Chlamydia pneumoniae , 155 aa.           [WO9927105-A2, 3 JUN. 1999]       AAG92590     C glutamicum  protein fragment    24 . . . 309    69/296 (23%)   7e−08           SEQ ID NO: 6344-    35 . . . 307   112/296 (37%)             Corynebacterium glutamicum , 339           aa. [EP1108790-A2, 20 JUN. 2001]       AAB76624     Corynebacterium glutamicum  MCT    24 . . . 309    69/296 (23%)   7e−08           protein SEQ ID NO: 230-    35 . . . 307   112/296 (37%)             Corynebacterium glutamicum , 339           aa. [WO200100805-A2, 4 JAN. 2001]                  
 
     [0735] In a BLAST search of public sequence databases, the NOV78a protein was found to have homology to the proteins shown in the BLASTP data in Table 78D.  
               TABLE 78D                          Public BLASTP Results for NOV78a                                         NOV78a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               O00154   Cytosolic acyl coenzyme A thioester   1 . . . 310   274/313 (87%)   e−154           hydrolase (EC 3.1.2.2) (Long chain   1 . . . 313   293/313 (93%)           acyl-CoA thioester hydrolase) (CTE-           II) (Brain acyl-CoA hydrolase)           (BACH) -  Homo sapiens  (Human),           338 aa.       Q91V12   ACYL-COA HYDROLASE   1 . . . 310   265/313 (84%)   e−150           (HYPOTHETICAL 37.6 KDA   1 . . . 313   287/313 (91%)           PROTEIN) -  Mus musculus  (Mouse),           338 aa.       Q64559   Cytosolic acyl coenzyme A thioester   1 . . . 310   263/313 (84%)   e−149           hydrolase (EC 3.1.2.2) (Long chain   1 . . . 313   286/313 (91%)           acyl-CoA thioester hydrolase) (CTE-           II) (Brain acyl-CoA hydrolase)           (BACH) (ACT) (LACH1) (ACH1) -             Rattus norvegicus  (Rat), 338 aa.       JC5416   palmitoyl-CoA hydrolase (EC   12 . . . 310    251/302 (83%)   e−142           3.1.2.2), hepatic - rat, 343 aa.   17 . . . 318    276/302 (91%)       Q9Y541   DJ202O8.3.1 (HBACH (BRAIN   1 . . . 202   181/204 (88%)   e−100           ACYL-COA HYDROLASE (ACYL   33 . . . 236    190/204 (92%)           COENZYME A THIOESTER           HYDROLASE, EC 3.1.2.2))           (ISOFORM 1)) -  Homo sapiens ,           (Human), 237 aa (fragment).                  
 
     [0736] PFam analysis predicts that the NOV78a protein contains the domains shown in the Table 78E.  
               TABLE 78E                          Domain Analysis of NOV78a                                     Identities/                   Similarities           NOV78a Match   for the Matched   Expect       Pfam Domain   Region   Region   Value                                         Acyl-CoA_hydro:   165 . . . 305   46/147   (31%)   1.1e−47       domain 1 of 1       131/147   (89%)                  
 
     [0737] The NOV79 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 79A.  
               TABLE 79A                       NOV79 Sequence Analysis                                                    SEQ ID NO: 223   4203 bp                             NOV79a     AATGTGATGGGATCACTAGC   ATG TCTGCGGAGAGCGGCCCTGGGACGAGATTGAGAAA           CG59452-01 DNA Sequence           TCTGCCAGTAATGGGGGATGGACTAGAAACTTCCCAAATGTCTACAACACAGGCCCAG                   GCCCAACCCCAGCCAGCCAACGCAGCCAGCACCAACCCCCCGCCCCCAGAGACCTCCA                   ACCCTAACAAGCCCAAGAGGCAGACCAACCAACTGCAATACCTGCTCAGAGTGGTGCT                   CAAGACACTATGGAAACACCAGTTTGCATGGCCTTTCCAGCAGCCTGTGGATGCCGTC                   AAGCTGAACCTCCCTGATTACTATAAGATCATTAAAACGCCTATGGATATGGGAACAA                   TAAAGAAGCGCTTGGAAAACAACTATTACTGGAATGCTCAGGAATGTATCCAGGACTT                   CAACACTATGTTTACAAATTGTTACATCTACAACAAGCCTGGAGATGACATAGTCTTA                   ATGGCAGAAGCTCTGGAAAAGCTCTTCTTGCAAAAAATAAATGAGCTACCCACAGAAG                   AAACCGAGATCATGATAGTCCAGGCAAAAGGAAGAGGACGTGGGAGGAAAGAAACAGG                   TACAGCAAAACCTGGCGTTTCCACGGTACCAAACACAACTCAAGCATCGACTCCTCCG                   CAGACCCAGACCCCTCAGCCGAATCCTCCTCCTGTGCAGGCCACGCCTCACCCCTTCC                   CTGCCGTCACCCCGGACCTCATCGTCCAGACCCCTGTCATGACAGTGGTGCCTCCCCA                   GCCACTGCAGACGCCCCCGCCAGTGCCCCCCCAGCCACAACCCCCACCCGCTCCAGCT                   CCCCAGCCCGTACAGAGCCACCCACCCATCATCGCGGCCACCCCACAGCCTGTGAAGA                   CAAAGAAGGGAGTGAAGAGGAAAGCAGACACCACCACCCCCACCACCATTGACCCCAT                   TCACGAGCCACCCTCGCTGCCCCCGGAGCCCAAGACCACCAAGCTGGGCCAGCGGCGG                   GAGAGCAGCCGGCCTGTGAAACCTCCAAAGAAGGACGTGCCCGACTCTCAGCAGCACC                   CAGCACCAGAGAAGAGCAGCAAGGTCTCGGAGCAGCTCAAGTGCTGCAGCGGCATCCT                   CAAGGAGATGTTTGCCAAGAAGCACGCCGCCTACGCCTGGCCCTTCTACAAGCCTGTG                   GACGTGGAGGCACTGGGCCTACACGACTACTGTGACATCATCAAGCACCCCATGGACA                   TGAGCACAATCAAGTCTAAACTGGAGGCCCGTGAGTACCGTGATGCTCAGGAGTTTGG                   TGCTGACGTCCGATTGATGTTCTCCAACTGCTATAAGTACAACCCTCCTGACCATGAG                   GTGGTGGCCATGGCCCGCAAGCTCCAGGATGTGTTCGAAATGCGCTTTGCCAAGATGC                   CGGACGAGCCTGAGGAGCCAGTGGTGGCCGTGTCCTCCCCGGCAGTGCCCCCTCCCAC                   CAAGGTTGTGGCCCCGCCCTCATCCAGCGACAGCAGCAGCGATAGCTCCTCGGACAGT                   GACAGTTCGACTGATGACTCTGAGGAGGAGCGAGCCCAGCGGCTGGCTGAGCTCCAGG                   AGCAGCTCAAAGCCGTGCACGAGCAGCTTGCAGCCCTCTCTCAGCCCCAGCAGAACAA                   ACCAAAGAAAAAGGAGAAAGACAAGAAGGAAAAGAAAAAAGAAAAGCACAAAAGGAAA                   GAGGAAGTGGAAGAGAATAAAAAAAGCAAAGCCAAGGAACCTCCTCCTAAAAAGACGA                   AGAAAAATAATAGCAGCAACAGCAATGTGAGCAAGAAGGAGCCAGCGCCCATGAAGAG                   CAAGCCCCCTCCCACGTATGAGTCGGAGGAAGAGGACAAGTGCAAGCCTATGTCCTAT                   GAGGAGAAGCGGCAGCTCAGCTTGGACATCAACAAGCTCCCCGGCGAGAAGCTGGGCC                   GCGTGGTGCACATCATCCAGTCACGGGAGCCCTCCCTGAAGAATTCCAACCCCGACGA                   GATTGAAATCGACTTTGAGACCCTGAAGCCGTCCACACTGCGTGAGCTGGAGCGCTAT                   GTCACCTCCTGTTTGCGGAAGAAAAGGAAACCTCAAGCTGAGAAAGTTGATGTGATTG                   CCGGCTCCTCCAAGATGAAGGGCTTCTCGTCCTCAGAGTCGGAGAGCTCCAGTGAGTC                   CAGCTCCTCTGACAGCGAAGACTCCGAAACAGAGATGGCTCCGAAGTCAAAAAAGAAG                   GGGCACCCCGGGAGGGAGCAGAAGCAGCACCATCATCACCACCATCAGCAGATGCAGC                   AGGCCCCGGCTCCTGTGCCCCAGCAGCCGCCCCCGCCTCCCCAGCAGCCCCCACCGCC                   TCCACCTCCGCAGCAGCAACAGCAGCCGCCACCCCCGCCTCCCCCACCCTCCATGCCG                   CAGCAGGCAGCCCCGGCGATGAAGTCCTCGCCCCCACCCTTCATTGCCACCCAGGTGC                   CCGTCCTGGAGCCCCAGCTCCCAGGCAGCGTCTTTGACCCCATCGGCCACTTCACCCA                   GCCCATCCTGCACCTGCCGCAGCCTGAGCTGCCCCCTCACCTGCCCCAGCCGCCTGAG                   CACAGCACTCCACCCCATCTCAACCAGCACGCAGTGGTCTCTCCTCCAGCTTTGCACA                   ACGCACTACCCCAGCAGCCATCACGGCCCAGCAACCGAGCCGCTGCCCTGCCTCCCAA                   GCCCGCCCGGCCCCCAGCCGTGTCACCAGCCTTGACCCAAACACCCCTGCTCCCACAG                   CCCCCCATGGCCCAACCCCCCCAAGTGCTGCTGGAGGATGAAGAGCCACCTGCCCCAC                   CCCTCACCTCCATGCAGATGCAGCTGTACCTGCAGCAGCTGCAGAAGGTGCAGCCCCC                   TACGCCGCTACTCCCTTCCGTGAAGGTGCAGTCCCAGCCCCCACCCCCCCTGCCGCCC                   CCACCCCACCCCTCTGTGCAGCAGCAGCTGCAGCAGCAGCCGCCACCACCCCCACCAC                   CCCAGCCCCAGCCTCCACCCCAGCAGCAGCATCAGCCCCCTCCACGGCCCGTGCACTT                   GCAGCCCATGCAGTTTTCCACCCACATCCAACAGCCCCCGCCACCCCAGGGCCAGCAG                   CCCCCCCATCCGCCCCCAGGCCAGCAGCCACCCCCGCCGCAGCCTGCCAAGCCTCAGC                   AAGTCATCCAGCACCACCATTCACCCCGGCACCACAAGTCGGACCCCTACTCAACCGG                   TCACCTCCGCGAAGCCCCCTCCCCGCTTATGATACATTCCCCCCAGATGTCACAGTTC                   CAGAGCCTGACCCACCAGTCTCCACCCCAGCAAAACGTCCAGCCTAAGAAACAGGTAA                   CTGGCAGGGCTGGGCCAAGTCCTGTGGGCCAGGGCCGGGGGTGCCTGCCCACCTCACC                   GGCCGCTGTGCCTGTGCCATCCCAGGAGCTGCGTGCTGCCTCCGTGGTCCAGCCCCAG                   CCCCTCGTGGTGGTGAAGGAGGAGAAGATCCACTCACCCATCATCCGCAGCGAGCCCT                   TCAGCCCCTCGCTGCGGCCGGAGCCCCCCAAGCACCCGGAGAGCATCAAGGCCCCCGT                   TTATGTTCCAGGGCCGGAAATGAAGCCTGTGGATGTCGGGAGGCCTGTGATCCGGCCC                   CCAGAGCAGAACGCACCGCCACCAGGGGCCCCTGACAAGGACAAACAGAAACAGGAGC                   CGAAGACTCCAGTTGCGCCCAAAAAGGACCTGAAAATCAAGAACATGGGCTCCTGGGC                   CAGCCTAGTGCAGAAGCATCCGACCACCCCCTCCTCCACAGCCAAGTCATCCAGCGAC                   AGCTTCGAGCAGTTCCGCCGCGCCGCTCGGGAGAAAGAGGAGCGTGAGAAGGCCCTGA                   AGGCTCAGGCCGAGCACGCTGAGAAGGAGAAGGAGCGGCTGCGGCAGGAGCGCATGAG                   GAGCCGAGAGGACGAGGATGCGCTGGAGCAGGCCCGGCGGGCCCATGAGGAGGCACGT                   CGGCGCCAGGAGCAGCAGCAGCAGCAGCGCCAGGAGCAACAGCAGCAGCAGCAACAGC                   AAGCAGCTGCGGTGGCTGCCGCCGCCACCCCACAGGCCCAGAGCTCCCAGCCCCAGTC                   CATGCTGGACCAGCAGAGGGAGTTGGCCCGGAAGCGGGAGCAGGAGCGAAGACGCCGG                   GAAGCCATGGCAGCTACCATTGACATGAATTTCCAGAGTGATCTATTGTCAATATTTG                   AAGAAAATCTTTTC TGA   GCGCACCTAG                                           ORF Start: ATG at 21   ORF Stop: TGA at 4191                                     SEQ ID NO: 224   1390 aa   MW at 154728.4 kD                                     NOV79a,   MSAESGPGTRLRNLPVMGDGLETSQMSTTQAQAQPQPANAASTNPPPPETSNPNKPKR           CG59452-01 Protein       Sequences   QTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLEN                   NYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEETEIMIV                   QAKGRGRGRKETGTAKPGVSTVPNTTQASTPPQTQTPQPNPPPVQATPHPFPAVTPDL                   IVQTPVMTVVPPQPLQTPPPVPPQPQPPPAPAPQPVQSHPPIIAATPQPVKTKKGVKR                   KADTTTPTTIDPIHEPPSLPPEPKTTKLGQRRESSRPVKPPKKDVPDSQQHPAPEKSS                   KVSEQLKCCSGILKEMFAKKHAAYAWPFYKPVDVEALGLHDYCDIIKHPMDMSTIKSK                   LEAREYRDAQEFGADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDEPEEP                   VVAVSSPAVPPPTKVVAPPSSSDSSSDSSSDSDSSTDDSEEERAQRLAELQEQLKAVH                   EQLAALSQPQQNKPKKKEKDKKEKKKEKHKRKEEVEENKKSKAKEPPPKKTKKNNSSN                   SNVSKKEPAPMKSKPPPTYESEEEDKCKPMSYEEKRQLSLDINKLPGEKLGRVVHIIQ                   SREPSLKNSNPDEIEIDFETLKPSTLRELERYVTSCLRKKRKPQAEKVDVIAGSSKMK                   GFSSSESESSSESSSSDSEDSETEMAPKSKKKGHPGREQKQHHHHHHQQMQQAPAPVP                   QQPPPPPQQPPPPPPPQQQQQPPPPPPPPSMPQQAAPAMKSSPPPFIATQVPVLEPQL                   PGSVFDPIGHFTQPILHLPQPELPPHLPQPPEHSTPPHLNQHAVVSPPALHNALPQQP                   SRPSNRAAALPPKPARPPAVSPALTQTPLLPQPPMAQPPQVLLEDEEPPAPPLTSMQM                   QLYLQQLQKVQPPTPLLPSVKVQSQPPPPLPPPPHPSVQQQLQQQPPPPPPPQPQPPP                   QQQHQPPPRPVHLQPMQFSTHIQQPPPPQGQQPPHPPPGQQPPPPQPAKPQQVIQHHH                   SPRHHKSDPYSTGHLREAPSPLMIHSPQMSQFQSLTHQSPPQQNVQPKKQVTGRAGPS                   PVGQGRGCLPTSPAAVPVPSQELRAASVVQPQPLVVVKEEKIHSPIIRSEPFSPSLRP                   EPPKHPESIKAPVYVPGPEMKPVDVGRPVIRPPEQNAPPPGAPDKDKQKQEPKTPVAP                   KKDLKIKNMGSWASLVQKHPTTPSSTAKSSSDSFEQFRRAAREKEEREKALKAQAEHA                   EKEKERLRQERMRSREDEDALEQARRAHEEARRRQEQQQQQRQEQQQQQQQQAAAVAA                   AATPQAQSSQPQSMLDQQRELARKREQERRRREAMAATIDMNFQSDLLSIFEENLF                  
 
     [0738] Further analysis of the NOV79a protein yielded the following properties shown in Table 79B.  
               TABLE 79B                       Protein Sequence Properties NOV79a                                        PSort   0.9800 probability located in nucleus; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1000 probability           located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0739] A search of the NOV79a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 79C.  
               TABLE 79C                          Geneseq Results for NOV79a                                         NOV79a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Except       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAY57898   Human transmembrane protein    1 . . . 667   667/667 (100%)   0.0           HTMPN-22 -  Homo sapiens , 688    1 . . . 667   667/667 (100%)           aa. [WO9961471-A2, 2 DEC           1999]       AAY07027   Breast cancer associated antigen   44 . . . 724   407/732 (55%)   0.0           precursor sequence -  Homo     13 . . . 708   487/732 (65%)           sapiens, 754 aa. [WO9904265-A2,           28 JAN 1999]       AAY07114   WO9904265 Seq ID No: 685 -   35 . . . 738   357/761 (46%)    e−170             Homo sapiens , 947 aa.    4 . . . 686   444/761 (57%)           [WO9904265-A2, 28 JAN 1999]       AAW81168   Transcriptional regulatory factor   35 . . . 738   357/761 (46%)    e−170           RING3 -  Homo sapiens , 947 aa.    4 . . . 686   444/761 (57%)           [WO9848015-A1, 29 OCT 1998]       AAU16206   Human novel secreted protein, Seq   51 . . . 255   118/206 (57%)   2e−59           ID 1159 -  Homo sapiens , 235 aa.    1 . . . 203   137/206 (66%)           [WO200155322-A2, 2 AUG           2001]                  
 
     [0740] In a BLAST search of public sequence databases, the NOV79a protein was found to have homology to the proteins shown in the BLASTP data in Table 79D.  
               TABLE 79D                          Public BLASTP Results for NOV79a                                         NOV79a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                             O60885   Bromodomain-containing protein   1 . . . 1390   1357/1391   (97%)   0.0           4 (HUNK1 protein) -  Homo     1 . . . 1362   1360/1391   (97%)             sapiens  (Human), 1362 aa.       Q9ESU6   CELL PROLIFERATION   1 . . . 1390   1318/1400   (94%)   0.0           RELATED PROTEIN CAP -   1 . . . 1400   1338/1400   (95%)             Mus musculus  (Mouse), 1400 aa.       AAL67833   BROMODOMAIN-   1 . . . 1390   1318/1400   (94%)   0.0           CONTAINING PROTEIN BRD4   1 . . . 1400   1338/1400   (95%)           LONG VARIANT -  Mus               musculus  (Mouse), 1400 aa.       O60433   R31546_1 -  Homo sapiens     1 . . . 719    719/719   (100%)   0.0           (Human), 731 aa (fragment).   12 . . . 730    719/719   (100%)       AAL67834   BROMODOMAIN-   1 . . . 719    694/720   (96%)   0.0           CONTAINING PROTEIN BRD4   1 . . . 720    700/720   (96%)           SHORT VARIANT -  Mus               musculus  (Mouse), 723 aa.                  
 
     [0741] PFam analysis predicts that the NOV79a protein contains the domains shown in the Table 79E.  
               TABLE 79E                          Domain Analysis of NOV79a                                     Identities/                   Similarities           NOV79a Match   for the Matched   Expect       Pfam Domain   Region   Region   Value               bromodomain:    63 . . . 152   42/92 (46%)   8.6e−45       domain 1 of 2       82/92 (89%)       bromodomain:   356 . . . 445   40/92 (43%)     3e−40       domain 2 of 2       81/92 (88%)                  
 
     Example 80  
     [0742] The NOV80 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 80A.  
               TABLE 80A                       NOV80 Sequence Analysis                                                    SEQ ID NO: 225   1776 bp                             NOV80a,     TGGTTCGTTTATTCCTGGGGTTGTCATATC   ATG GCTTATAATGACACAGACAGAAACC           CG59572-01 DNA Sequence           AGACTGAGAAGCTCCTAAAAAGAGTACGAGAACTGGAGCAAGAGGTGCAAAGACTTAA                   AAAGGAACAGGCCAAAAATAAGGAGGACTCAAACATTAGAGAAAATTCAGCAGGAGCT                   GGAAAAACTAAGCGTGCATTTGATTTCAGTGCTCATGGCCGAAGACACGTAGCCCTAA                   GAATAGCCTATATGGGCTGGGGATACCAGGGCTTTGCTAGTCAGGAAAACACAAATAA                   TACCATTGAAGAGAAACTGTTTGAAGCTCTAACCAAGACTCGACTAGTAGAAAGCAGA                   CAGACATCCAACTATCACCGATGTGGGAGAACAGATAAAGGAGTTAGTGCCTTTGGAC                   AGGTGATCTCACTTGACCTTCGCTCTCAGTTTCCAAGGGGCAGGGATTCCGAGGACTT                   TAATGTAAAAGAGGAGGCTAATGCTGCTGCTGAAGAGATCCGTTATACCCACATTCTC                   AATCGGGTACTCCCTCCAGACATCCGTATATTGGCCTGGGCCCCTGTAGAACCAAGCT                   TCAGTGCTAGGTTCAGCTGCCTTGAGCGGACTTACCGCTATTTTTTCCCTCGTGCTGA                   TTTAGATATTGTAACCATGGATTATGCAGCTCAGAAGTATGTTGGCACCCATGATTTC                   AGGAACTTGTGTAAAATGGATGTAGCCAACGGTGTGATTAATTTTCAGAGGACTATTC                   TATCTGCTCAAGTACAGCTAGTGGGCCAGAGCCCAGGTGAGGGGAGATGGCAAGAACC                   TTTCCAGTTATGTCAGTTTGAAGTGACTGGCCAGGCATTCCTTTATCATCAAGTCCGA                   TGTATGATGGCTATCCTCTTTCTGATTGGCCAAGGAATGGAGAAGCCAGAGATTATTG                   ATGAGCTGCTGAATATAGAGAAAAATCCCCAAAAGCCTCAATATAGTATGGCTGTAGA                   ATTTCCTCTAGTCTTATATGACTGTAAGTTTGAAAATGTCAAGTGGATCTATGACCAG                   GAGGCTCAGGAGTTCAATATTACCCACCTACAACAACTGTGGGCTAATCATGCTGTCA                   AAACTCACATGTTGTATAGTATGCTACAAGGACTGGACACTGTTCCAGTACCCTGTGG                   AATAGGACCAAAGATGGATGGAATGACAGAATGGGGAAATGTTAAGCCCTCTGTCATA                   AAGCAGACCAGTGCCTTTGTAGAAGGAGTGAAGATGCGCACATATAAGCCCCTCATGG                   ACCGTCCTAAATGCCAAGGACTGGAATCCCGGATCCAGCATTTTGTACGTAGGGGACG                   AATTGAGCACCCACATTTATTCCATGAGGAAGAAACAAAAGCCAAAAGGGACTGTAAT                   GACACACTAGAGGAAGAGAATACTAATTTGGAGACACCAACGAAGAGGGTCTGTGTTG                   ACACAGAAATTAAAAGCATCATT TAA   CCATAGACAATTTGCCAGGATCTAGGAACCAC                       CTAATGGTAGGTGGACAGAAAAGGAAAAAAAAAAAAATTTACTTGCAAGTACTAGGAA                       TTCAGATGATCAGCTCTTAAAAAAAAAAAAAAAGCAAAAAGACTAAAGCCCTATTAAG                       GAAGTTATTGCTTTAATAAGAAATTTCAAATATTCTCTTATCCCGGTCCAAAAGGATT                       AAGCGATTAAAGAACGTAAAATGGAGATGTATTTACATACACCTGGAAACCTGTGCCT                       TGTATTCAAATTCATTAAAGCCTAATCCTGCAAGAA                                                   ORF Start: ATG at 31   ORF Stop: TAA at 1474                                     SEQ ID NO:226   481 aa   MW at 55646.8kD                                     NOV80a,   MAYNDTDRNQTEKLLKRVRELEQEVQRLKKEQAKNKEDSNIRENSAGAGKTKRAFDFS           CG59572-01 Protein Sequence           AHGRRHVALRIAYMGWGYQGFASQENTNNTIEEKLFEALTKTRLVESRQTSNYHRCGR                   TDKGVSAFGQVISLDLRSQFPRGRDSEDFNVKEEANAAAEEIRYTHILNRVLPPDIRI                   LAWAPVEPSFSARFSCLERTYRYFFPRADLDIVTMDYAAQKYVGTHDFRNLCKMDVAN                   GVINFQRTILSAQVQLVGQSPGEGRWQEPFQLCQFEVTGQAFLYHQVRCMMAILFLIG                   QGMEKPEIIDELLNIEKNPQKPQYSMAVEFPLVLYDCKFENVKWIYDQEAQEFNITHL                   QQLWANHAVKTHMLYSMLQGLDTVPVPCGIGPKMDGMTEWGNVKPSVIKQTSAFVEGV                   KMRTYKPLMDRPKCQGLESRIQHFVRRGRIEHPHLFHEEETKAKRDCNDTLEEENTNL                   ETPTKRVCVDTEIKSII                                             SEQ ID NO:227   1508 bp                         NOV80b,     C   ATG GCTTATAATGACACAGACAGAAACCAGACTGAGAAGCTCCTAAAAAGAGTACGA           CG59572-02 DNA Sequence           GAACTGGAGCAAGAGGTGCAAAGACTTAAAAAGGAACAGGCCAAAAATAAGGAGGACT                   CAAACATTAGAGAAAATTCAGCAGGAGCTGGAAAAACTAAGCGTGCATTTGATTTCAG                   TGCTCATGGCCGAAGACACGTAGCCCTAAGAATAGCCTATATGGGCTGGGGATACCAG                   GGCTTTGCTAGTCAGGAAAACACAAATAATACCATTGAAGAGAAACTGTTTGAAGCTC                   TAACCAAGACTCGACTAGTAGAAAGCAGACAGACATCCAACTATCACCGATGTGGGAG                   AACAGATAAAGGAGTTAGTGCCTTTGGACAGGTGATCTCACTTGACCTTCGCTCTCAG                   TTTCCAAGGGGCAGGGATTCCGAGGACTTTAATGTAAAAGAGGAGGCTAATGCTGCTG                   CTGAAGAGATCCGTTATACCCACATTCTCAATCGGGTACTCCCTCCAGACATCCGTAT                   ATTGGCCTGGGCCCCTGTAGAACCAAGCTTCAGTGCTAGGTTCAGCTGCCTTGAGCGG                   ACTTACCGCTATTTTTTCCCTCGTGCTGATTTAGATATTGTAACCATGGATTATGCAG                   CTCAGAAGTATGTTGGCACCCATGATTTCAGGAACTTGTGTAAAATGGATGTAGCCAA                   CGGTGTGATTAATTTTCAGAGGACTATTCTATCTGCTCAAGTACAGCTAGTGGGCCAG                   AGCCCAGGTGAGGGGAGATGGCAAGAACCTTTCCAGTTATGTCAGTTTGAAGTGACTG                   GCCAGGCATTCCTTTATCATCAAGTCCGATGTATGATGGCTATCCTCTTTCTGATTGG                   CCAAGGAATGGAGAAGCCAGAGATTATTGATGAGCTGCTGAATATAGAGAAAAATCCC                   CAAAAGCCTCAATATAGTATGGCTGTAGAATTTCCTCTAGTCTTATATGACTGTAAGT                   TTGAAAATGTCAAGTGGATCTATGACCAGGAGGCTCAGGAGTTCAATATTACCCACCT                   ACAACAACTGTGGGCTAATCATGCTGTCAAAACTCACATGTTGTATAGTATGCTACAA                   GGACTGGACACTGTTCCAGTACCCTGTGGAATAGGACCAAAGATGGATGGAATGACAG                   AATGGGGAAATGTTAAGCCCTCTGTCATAAAGCAGACCAGTGCCTTTGTAGAAGGAGT                   GAAGATGCGCACATATAAGCCCCTCATGGACCGTCCTAAATGCCAAGGACTGGAATCC                   CGGATCCAGCATTTTGTACGTAGGGGACGAATTGAGCACCCACATTTATTCCATGAGG                   AAGAAACAAAAGCCAAAAGGGACTGTAATGACACACTAGAGGAAGAGAATACTAATTT                   GGAGACACCAACGAAGAGGGTCTGTGTTGACACAGAAATTAAAAGTATCATT TAA   CCA                       TAGACAATTTGCCAGGATCTAGGAACCACCTAATGGTAGGTGGACAGAAAAGGAAAAA                                           ORF Start: ATG at 2   ORF Stop: TAA at 1445                                     SEQ ID NO: 228   481 aa   MW at 55646.8 kD                                     NOV80b,   MAYNDTDRNQTEKLLKRVRELEQEVQRLKKEQAKNKEDSNIRENSAGAGKTKRAFDFS           CG59572-02 Protein Sequence           AHGRRHVALRIAYMGWGYQGFASQENTNNTIEEKLFEALTKTRLVESRQTSNYHRCGR                   TDKGVSAFGQVISLDLRSQFPRGRDSEDFNVKEEANAAAEEIRYTHILNRVLPPDIRI                   LAWAPVEPSFSARFSCLERTYRYFFPRADLDIVTMDYAAQKYVGTHDFRNLCKMDVAN                   GVINFQRTILSAQVQLVGQSPGEGRWQEPFQLCQFEVTGQAFLYHQVRCMMAILFLIG                   QGMEKPEIIDELLNIEKNPQKPQYSMAVEFPLVLYDCKFENVKWIYDQEAQEFNITHL                   QQLWANHAVKTHMLYSMLQGLDTVPVPCGIGPKMDGMTEWGNVKPSVIKQTSAFVEGV                   KMRTYKPLMDRPKCQGLESRIQHFVRRGRIEHPHLFHEEETKAKRDCNDTLEEENTNL                   ETPTKRVCVDTEIKSII                  
 
     [0743] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 80B.  
               TABLE 80B                          Comparison of NOV80a against NOV80b.                                 Identities/               Similarities       Protein   NOV80a Residues/   for the       Sequence   Match Residues   Matched Region               NOV80b   1 . . . 481   459/481 (95%)           1 . . . 481   459/481 (95%)                  
 
     [0744] Further analysis of the NOV80a protein yielded the following properties shown in Table 80C.  
               TABLE 80C                       Protein Sequence Properties NOV80a                                        PSort   0.6500 probability located in cytoplasm; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0142 probability located           in microbody (peroxisome)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0745] A search of the NOV80a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 80D.  
               TABLE 80D                          Geneseq Results for NOV80a                                         NOV80a   Identieies/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAM79457   Human protein SEQ ID NO 3103 -   1 . . . 481   478/481   (99%)   0.0             Homo sapiens , 490 aa.   10 . . . 490    480/481   (99%)           [WO200157190-A2, 9 AUG           2001]       AAM78473   Human protein SEQ ID NO 1135 -   1 . . . 481   478/481   (99%)   0.0             Homo sapiens , 481 aa.   1 . . . 481   480/481   (99%)           [WO200157190-A2, 9 AUG           2001]       AAG64907   Human depressed growth rate   209 . . . 431    223/223   (100%)    e−132           protein DEG1 -  Homo sapiens ,   1 . . . 223   223/223   (100%)           248 aa. [CN1296014-A, 23 MAY           2001]       AAG02637   Human secreted protein, SEQ ID   361 . . . 456    96/96   (100%)   5e−53           NO: 6718 -  Homo sapiens , 96 aa.   1 . . . 96    96/96   (100%)           [EP1033401-A2, 6 SEP 2000]       AAB96592   Putative  P. abyssi  pseudourydilate   65 . . . 367    79/305   (25%)   4e−16           synthase I -  Pyrococcus abyssi,     3 . . . 261   140/305   (45%)           263 aa. [FR2792651-A1, 27 OCT           2000]                  
 
     [0746] In a BLAST search of public sequence databases, the NOV80a protein was found to have homology to the proteins shown in the BLASTP data in Table 80E.  
               TABLE 80E                          Public BLASTP Results for NOV80a                                         NOV80a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                             Q9BZE2   FKSG32 -  Homo sapiens  (Human),   1 . . . 481   481/481   (100%)   0.0           481 aa.   1 . . . 481   481/481   (100%)       Q96J23   HYPOTHETICAL 55.6 KDA   1 . . . 481   478/481   (99%)   0.0           PROTEIN -  Homo sapiens  (Human),   1 . . . 481   480/481   (99%)           481 aa.       Q96NB4   CDNA FLJ31140 FIS, CLONE   1 . . . 481   478/481   (99%)   0.0           IMR322001218, HIGHLY   1 . . . 481   479/481   (99%)           SIMILAR TO  MUS MUSCULUS             PSEUDOURIDINE SYNTHASE 3           (PUS3) MRNA -  Homo sapiens             (Human), 481 aa.       Q9JI38   PSEUDOURIDINE SYNTHASE 3 -   5 . . . 480   407/479   (84%)   0.0             Mus musculus  (Mouse), 481 aa.   4 . . . 480   434/479   (89%)       Q9D0F7   2610020J05RIK PROTEIN -  Mus     5 . . . 314   276/312   (88%)   e−158             musculus  (Mouse), 316 aa.   4 . . . 315   291/312   (92%)                  
 
     [0747] PFam analysis predicts that the NOV80a protein contains the domains shown in the Table 80F.  
               TABLE 80F                          Domain Analysis of NOV80a                                     Identities/                   Similarities           NOV80a Match   for the Matched   Expect       Pfam Domain   Region   Region   Value                                         PseudoU_synth_1:   88 . . . 307   70/249   (28%)   4.7e−57       domain 1 of 1       176/249   (71%)                  
 
     Example 81  
     [0748] The NOV81 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 81A.  
               TABLE 81A                       NOV81 Sequence Analysis                                                SEQ ID NO: 229   3080 bp                                     NOV81a,     TTCCAGCCGGCAGG   ATG GAGGACGAGGAAGGCCCTGAGTATGGCAAACCTGACTTTGT           CG59522-01 DNA Sequence           GCTTTTGGACCAAGTGACCATGGAGGACTTCATGAGGAACCTGCAGCTCAGGTTCGAG                   AAGGGCCGCATCTACACCTACATCGGTGAGGTGCTGGTGTCCGTGAACCCCTACCAGG                   AGCTGCCCCTGTATGGGCCTGAGGCCATCGCCAGGTACCAGGGCCGTGAGCTCTATGA                   GCGGCCACCCCATCTCTATGCTGTGGCCAACGCCGCCTACAAGGCAATGAAGCACCGG                   TCCAGGGACACCTGCATCGTCATCTCAGGGGAGAGTGGGGCAGGGAAGACAGAAGCCA                   GTAAGCACATCATGCAGTACATCGCTGCTGTCACCAATCCAAGCCAGAGGGCTGAGGT                   GGAGAGGGTCAAGGACGTGCTGCTCAAGTCCACCTGTGTGCTGGAGGCCTTTGGCAAT                   GCCCGCACCAACCGCAATCACAACTCCAGCCGCTTTGGCAAGTACATGGACATCAACT                   TTGACTTCAAGGGGGACCCGATCGGAGGACACATCCACAGCTACCTACTGGAGAAGTC                   TCGGGTCCTCAAGCAGCACGTGGGTGAAAGAAACTTCCACGCCTTCTACCAATTGCTG                   AGAGGCAGTGAGGACAAGCAGCTGCATGAACTGCACTTGGAGAGAAACCCTGCTGTAT                   ACAATTTCACACACCAGGGAGCAGGACTCAACATGACTGTGAGTGATGAGCAGAGCCA                   CCAGGCAGTGACCGAGGCCATGAGGGTCATCGGCTTCAGTCCTGAAGAGGTGGAGTCT                   GTGCATCGCATCCTGGCTGCCATATTGCACCTGGGAAACATCGAGTTTGTGGAGACGG                   AGGAGGGTGGGCTGCAGAAGGAGGGCCTGGCAGTGGCCGAGGAGGCACTGGTGGACCA                   TGTGGCTGAGCTGACGGCCACACCCCGGGACCTCGTGCTCCGCTCCCTGCTGGCTCGC                   ACAGTTGCCTCGGGAGGCAGGGAACTCATAGAGAAGGGCCACACTGCAGCTGAGGCCA                   GCTATGCCCGGGATGCCTGTGCCAAGGCAGTGTACCAGCGGCTGTTTGAGTGGGTGGT                   GAACAGGATCAACAGTGTCATGGAACCCCGGGGCCGGGATCCTCGGCGTGATGGCAAG                   GACACAGTCATTGGCGTGCTGGACATCTATGGCTTCGAGGTGTTTCCCGTCAACAGTT                   TCGAGCAGTTCTGCATCAACTACTGCAACGAGAAGCTGCAGCAGCTATTCATCCAGCT                   CATCCTGAAGCAGGAACAGGAAGAGTACGAGCGCGAGGGCATCACCTGGCAGAGCGTT                   GAGTATTTCAACAACGCCACCATTGTGGATCTGGTGGAGCGGCCCCACCGTGGCATCC                   TGGCCGTGCTGGACGAGGCCTGCAGCTCTGCTGGCACCATCACTGACCGAATCTTCCT                   GCAGACCCTGGACATGCACCACCGCCATCACCTACACTACACCAGCCGCCAGCTCTGC                   CCCACAGACAAGACCATGGAGTTTGGCCGAGACTTCCGGATCAAGCACTATGCAGGGG                   ACGTCACGTACTCCGTGGAAGGCTTCATCGACAAGAACAGAGATTTCCTCTTCCAGGA                   CTTCAAGCGGCTGCTGTACAACAGCACGGACCCCACTCTACGGGCCATGTGGCCGGAC                   GGGCAGCAGGACATCACAGAGGTGACCAAGCGCCCCCTGACGGCTGGCACACTCTTCA                   AGAACTCCATGGTGGCCCTGGTGGAGAACCTTGCCTCCAAGGAGCCCTTCTACGTCCG                   CTGCATCAAGCCCAATGAGGACAAGGTAGCTGGGAAGCTGGATGAGAACCACTGTCGC                   CACCAGGTCGCATACCTGGGGCTGCTGGAGAATGTGAGGGTCCGCAGGGCTGGCTTCG                   CTTCCCGCCAGCCCTACTCTCGATTCCTGCTCAGGTACAAGATGACCTGTGAATACAC                   ATGGCCCAACCACCTGCTGGGCTCCGACAAGGCAGCCGTGAGCGCTCTCCTGGAGCAG                   CACGGGCTGCAGGGGGACGTGGCCTTTGGCCACAGCAAGCTGTTCATCCGCTCACCCC                   GGACACTGGTCACACTGGAGCAGAGCCGAGCCCGCCTCATCCCCATCATTGTGCTGCT                   ATTGCAGAAGGCATGGCGGGGCACCTTGGCGAGGTGGCGCTGCCGGAGGCTGAGGGCT                   ATCTACACCATCATGCGCTGGTTCCGGAGACACAAGGTGCGGGCTCACCTGGCTGAGC                   TGCAGCGGCGATTCCAGGCTGCAAGGCAGCCGCCACTCTACGGGCGTGACCTTGTGTG                   GCCGCTGCCCCCTGCTGTGCTGCAGCCCTTCCAGGACACCTGCCACGCACTCTTCTGC                   AGGTGGCGGGCCCGGCAGCTGGTGAAGAACATCCCCCCTTCAGACATGCCCCAGATCA                   AGGCCAAGGTGGCCGCCATGGGGGCCCTGCAAGGGCTTCGTCAGGACTGGGGCTGCCG                   ACGGGCCTGGGCCCGAGACTACCTGTCCTCTGCCACTGACAATCCCACAGCATCAAGC                   CTGTTTGCTCAGCGACTAAAGACACTTCAGGACAAAGATGGCTTCGGGGCTGTGCTCT                   TTTCAAGCCATGTCCGCAAGGTGAACCGCTTCCACAAGATCCGGAACCGGGCCCTCCT                   GCTCACAGACCAGCACCTCTACAAGCTGGACCCTGACCGGCAGTACCGGGTGATGCGG                   GCCGTGCCCCTTGAGGCGGTGACGGGGCTGAGCGTGACCAGCGGAGGAGACCAGCTGG                   TGGTGCTGCACGCCCGCGGCCAGGACGACCTCGTGGTGTGCCTGCACCGCTCCCGGCC                   GCCATTGGACAACCGCGTTGGGGAGCTGGTGGGCGTGCTGGCCGCACACTGCCGCAGG                   GAGGGCCGCACCCTGGAGGTTCGCGTCTCCGACTGCATCCCACTAAGCCATCGCGGGG                   TCCGGCGCCTCATCTCCGTGGAGCCCAGGCCGGAGCAGCCAGAGCCCGATTTCCGCTG                   CGCTCGCGGCTCCTTCACCCTGCTCTGGCCCAGCCGC TGA   GCGCCCGCACCCGCCGCA                       CCCCGA                                                   ORF Start: ATG at 15   ORF Stop: TGA at 3054                                     SEQ ID NO: 230   1013 aa   MW at 116044.5kD                                     NOV81a,   MEDEEGPEYGKPDFVLLDQVTMEDFMRNLQLRFEKGRIYTYIGEVLVSVNPYQELPLY           CG59522-01 Protein       Sequence   GPEAIARYQGRELYERPPHLYAVANAAYKAMKHRSRDTCIVISGESGAGKTEASKHIM                   QYIAAVTNPSQRAEVERVKDVLLKSTCVLEAFGNARTNRNHNSSRFGKYMDINFDFKG                   DPIGGHIHSYLLEKSRVLKQHVGERNFHAFYQLLRGSEDKQLHELHLERNPAVYNFTH                   QGAGLNMTVSDEQSHQAVTEAMRVIGFSPEEVESVHRILAAILHLGNIEFVETEEGGL                   QKEGLAVAEEALVDHVAELTATPRDLVLRSLLARTVASGGRELIEKGHTAAEASYARD                   ACAKAVYQRLFEWVVNRINSVMEPRGRDPRRDGKDTVIGVLDIYGFEVFPVNSFEQFC                   INYCNEKLQQLFIQLILKQEQEEYEREGITWQSVEYFNNATIVDLVERPHRGILAVLD                   EACSSAGTITDRIFLQTLDMHHRHHLHYTSRQLCPTDKTMEFGRDFRIKHYAGDVTYS                   VEGFIDKNRDFLFQDFKRLLYNSTDPTLRAMWPDGQQDITEVTKRPLTAGTLFKNSMV                   ALVENLASKEPFYVRCIKPNEDKVAGKLDENHCRHQVAYLGLLENVRVRRAGFASRQP                   YSRFLLRYKMTCEYTWPNHLLGSDKAAVSALLEQHGLQGDVAFGHSKLFIRSPRTLVT                   LEQSRARLIPIIVLLLQKAWRGTLARWRCRRLRAIYTIMRWFRRHKVRAHLAELQRRF                   QAARQPPLYGRDLVWPLPPAVLQPFQDTCHALFCRWRARQLVKNIPPSDMPQIKAKVA                   AMGALQGLRQDWGCRRAWARDYLSSATDNPTASSLFAQRLKTLQDKDGFGAVLFSSHV                   RKVNRFHKIRNRALLLTDQHLYKLDPDRQYRVMRAVPLEAVTGLSVTSGGDQLVVLHA                   RGQDDLVVCLHRSRPPLDNRVGELVGVLAAHCRREGRTLEVRVSDCIPLSHRGVRRLI                   SVEPRPEQPEPDFRCARGSFTLLWPSR                  
 
     [0749] Further analysis of the NOV81a protein yielded the following properties shown in Table 81B.  
               TABLE 81B                       Protein Sequence Properties NOV81a                                        PSort   0.8800 probability located in nucleus; 0.3902 probability       analysis:   located in microbody (peroxisome); 0.2210 probability           located in lysosome (lumen); 0.1000 probability located           in mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0750] A search of the NOV81a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 81C.  
               TABLE 81C                          Geneseq Results for NOV81a                                         NOV81a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAU23125   Novel human enzyme   1 . . . 1013   1009/1018   (99%)   0.0           polypeptide #211- Homo     9 . . . 1026   1011/1018   (99%)             sapiens , 1026 aa.           [WO200155301-A2, 2 AUG           2001]       AAU23128   Novel human enzyme   1 . . . 853   851/858   (99%)   0.0           polypeptide #214 -  Homo     9 . . . 866   851/858   (99%)             sapiens , 909 aa. [WO200155301-           A2, 2 AUG 2001]       AAM80123   Human protein SEQ ID NO 3769 -   243 . . . 1011    438/769   (56%)   0.0             Homo sapiens , 764 aa.   1 . . . 762   570/769   (73%)           [WO200157190-A2, 9 AUG           2001]       AAM79139   Human protein SEQ ID NO 1801 -   254 . . . 1011    434/758   (57%)   0.0             Homo sapiens , 753 aa.   1 . . . 751   564/758   (74%)           [WO200157190-A2, 9 AUG           2001]       AAM39991   Human polypeptide SEQ ID NO   10 . . . 933    410/966   (42%)   0.0           3136 -  Homo sapiens , 1063 aa.   47 . . . 986    556/966   (57%)           [WO200153312-A1, 26 JUL           2001]                  
 
     [0751] In a BLAST search of public sequence databases, the NOV81a protein was found to have homology to the proteins shown in the BLASTP data in Table 81D.  
               TABLE 81D                          Public BLASTP Results for NOV81a                                         NOV81a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                             Q63357   MYOSIN I -  Rattus norvegicus     1 . . . 1011   606/1011   (59%)   0.0           (Rat), 1006 aa.   1 . . . 1004   780/1011   (76%)       A53933   myosin I myr 4 - rat, 1006 aa.   1 . . . 1011   604/1011   (59%)   0.0               1 . . . 1004   778/1011   (76%)       Q96RI6   UNCONVENTIONAL MYOSIN   33 . . . 646    612/619   (98%)   0.0           1G VALINE FORM -  Homo     1 . . . 619    612/619   (98%)             sapiens , (Human), 633 aa           (fragment).       Q96RI5   UNCONVENTIONAL MYOSIN   33 . . . 646    611/619   (98%)   0.0           1G METHONINE FORM -  Homo     1 . . . 619    612/619   (98%)             sapiens , (Human), 633 aa           (fragment).       Q23978   Myosin IA (MIA) (Brush border   8 . . . 1012   503/1017   (49%)   0.0           myosin IA) (BBMIA) -  Drosophila     6 . . . 1007   686/1017   (66%)             melanogaster  (Fruit fly), 1011 aa.                  
 
     [0752] PFam analysis predicts that the NOV81a protein contains the domains shown in the Table 81E.  
               TABLE 81E                          Domain Analysis of NOV81a                                     Identities/                   Similarities           NOV81a Match   for the Matched   Expect       Pfam Domain   Region   Region   Value                                         PRK: domain 1 of 1   97 . . . 109   8/13   (62%)   3.7               10/13   (77%)       Vir_DNA_binding:   575 . . . 592    5/18   (28%)   8.2       domain 1 of 1       14/18   (78%)       myosin_head:   11 . . . 689   305/747   (41%)   8.1e−288       domain 1 of 1       531/747   (71%)                  
 
     Example 82  
     [0753] The NOV82 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 82A.  
               TABLE 82A                       NOV82 Sequence Analysis                                                SEQ ID NO: 231   1066 bp                                     NOV82a,     GAACGA   ATG GGAAACCAGAAATCAGATATTTATGCCCAAGCAAAGCAGGATTTCGTTC           CG59520-01 DNA Sequence           AGCACTACTCCCAGATCGTTAGGGTGCTGACTGAGGATGAGATGGGGCACCCAGAGAC                   AGGAGATGCTACTGCCCGGCTCAAGGAGGTCCTGGAGTACAATGCCATTGGAGGCAAG                   TATCACCGAGGTTTGATGGTGCTAGTAGCGTTCCGGGAGCTGGTGGAGCCGAGGAAAC                   TGGATGCTGATAGTCTCCAGTGGGCACCGACTGTGGGCTGGTATGCGCAACTGCTGCA                   AGCTTTCTTCCTGGTGGCAGATGACATTATGGATTCATCCCTTACCTGCCAGGGACAG                   ATCTCCTGGTATCAGAAGCTGGGCATGGGTTTGGATGCCATCAATGATGCTATCCTTC                   TGGAAGCATGTATCTACTGCCTGCTGAAGCTGTATTGCCGGGAGCAGCCCTATTACCT                   GAACCTGATGGAGCTCTTCCAGCAGAATTCTTATCAGACTGAGATTGGGCAGACCCTC                   GACCTCATCACAACCCCCCAGGGCAATGTGGATCTTCGCAGATGCACCGAAAAAAGGC                   ACAAATCTGTTGTCAAGTACAAGACAGCTTTCTACTCCTTCTACCTTCCTGTAGCTGC                   AGCCATGTACATGTCAAGAATGGATGACAAGAAGGAGCACACCAGTGCCAAGAAGATC                   CTGCTGGAGATTCAAGAGTTCTTTCAGATTCAGGATGATTACCTTGACTTCTCTGGGG                   ACCCCAGTGTGACTGGCAGAGTTGGCAATGACTTCCAGGACAACAAATGCAGCTGGCT                   GGTGGTTCAGTGTCTGCTACAGGCCACTCCAGAACAGTACCAGATCCTGAAGGAAAAT                   TACAGGCAGAAGGAGGCCGAGAAGGTGGCCCGGGTGAAGGCACTATACGAGGAGCTGG                   ATCTGCCAGCCGTGTTCTTGCAGTATGAGAAAGACAGTTACAGCCACGTTATGGGTCT                   CATCGAACAGTACGCAGAGCCCCTGCCCCCAGCCATCTTTCTGGGGCTTGTGCACAAA                   ATCTACAAGTGGAAAAAG TGA   C                                           ORF Start: ATG at 7   ORF Stop: TGA at 1063                                     SEQ ID NO: 232   352 aa    MW at 40740.3 kD                                     NOV82a,   MGNQKSDIYAQAKQDFVQHYSQIVRVLTEDEMGHPETGDATARLKEVLEYNAIGGKYH           CG59520-01 Protein Sequence           RGLMVLVAFRELVEPRKLDADSLQWAPTVGWYAQLLQAFFLVADDIMDSSLTCQGQIS                   WYQKLGMGLDAINDAILLEACIYCLLKLYCREQPYYLNLMELFQQNSYQTEIGQTLDL                   ITTPQGNVDLRRCTEKRHKSVVKYKTAFYSFYLPVAAAMYMSRMDDKKEHTSAKKILL                   EIQEFFQIQDDYLDFSGDPSVTGRVGNDFQDNKCSWLVVQCLLQATPEQYQILKENYR                   QKEAEKVARVKALYEELDLPAVFLQYEKDSYSHVMGLIEQYAEPLPPAIFLGLVHKIY                   KWKK                  
 
     [0754] Further analysis of the NOV82a protein yielded the following properties shown in Table 82B.  
               TABLE 82B                       Protein Sequence Properties NOV82a                                        PSort   0.4066 probability located in microbody (peroxisome); 0.3000       analysis:   probability located in nucleus; 0.1000 probability located in           mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0755] A search of the NOV82a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 82C.  
               TABLE 82C                          Geneseq Results for NOV82a                                         NOV82a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAG29733     Arabidopsis thaliana  protein   10 . . . 352   147/343 (42%)   7e−75           fragment SEQ ID NO: 35427-    2 . . . 342   219/343 (62%)             Arabidopsis thaliana , 342 aa.           [EP1033405-A2, 6 SEP. 2000]       AAG29732     Arabidopsis thaliana  protein   10 . . . 352   147/343 (42%)   7e−75           fragment SEQ ID NO: 35426-    9 . . . 349   219/343 (62%)             Arabidopsis thaliana , 349 aa.           [EP1033405-A2, 6 SEP. 2000]       AAG29734     Arabidopsis thaliana  protein   47 . . . 352   138/306 (45%)   4e−73           fragment SEQ ID NO: 35428-    1 . . . 305   204/306 (66%)             Arabidopsis thaliana , 305 aa.           [EP1033405-A2, 6 SEP. 2000]       AAY43635   Amino acid sequence of the farnesyl   12 . . . 352   145/346 (41%)   4e−69           pyrophosphate synthase enzyme−   11 . . . 355   208/346 (59%)             Phaffia rhodozyma , 355 aa.           [EP955363-A2, 10 NOV. 1999]       AAB48971   Sunflower seedling farnesyl   13 . . . 352   138/343 (40%)   3e−64           pyrophosphate synthase (FPS)-    6 . . . 341   204/343 (59%)             Helianthus annuus , 341 aa.           [EP1063297-A1, 27 DEC. 2000]                  
 
     [0756] In a BLAST search of public sequence databases, the NOV82a protein was found to have homology to the proteins shown in the BLASTP data in Table 82D.  
               TABLE 82D                          Public BLASTP Results for NOV82a                                         NOV82a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96G29   FARNESYL DIPHOSPHATE    2 . . . 352   291/351 (82%)   e−168           SYNTHASE (FARNESYL   69 . . . 419   317/351 (89%)           PYROPHOSPHATE           SYNTHETASE,           DIMETHYLALLYLTRANSTRANSFERASE,           GERANYLTRANSTRANSFERASE)-             Homo sapiens  (Human), 419 aa.       P14324   Farnesyl pyrophosphate synthetase    2 . . . 352   291/351 (82%)   e−168           (FPP synthetase) (FPS) (Farnesyl    3 . . . 353   317/351 (89%)           diphosphate synthetase) [Includes:           Dimethylallyltransferase (EC           2.5.1.1); Geranyltranstransferase           (EC 2.5.1.10)]- Homo sapiens             (Human), 353 aa.       A35726   farnesyl-pyrophosphate synthetase-    2 . . . 352   290/351 (82%)   e−168           human, 353 aa.    3 . . . 353   316/351 (89%)       AAL58886   FARNESYL DIPHOSPHATE    2 . . . 352   270/351 (76%)   e−157           SYNTHASE- Bos taurus  (Bovine),    3 . . . 353   308/351 (86%)           353 aa.       Q14329   FARNESYL PYROPHOSPHATE    6 . . . 352   268/347 (77%)   e−150           SYNTHETASE LIKE-4 PROTEIN-    2 . . . 348   295/347 (84%)             Homo sapiens  (Human), 348 aa.                  
 
     [0757] PFam analysis predicts that the NOV82a protein contains the domains shown in the Table 82E.  
               TABLE 82E                          Domain Analysis of NOV82a                                     Identities/           Pfam   NOV82a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               polyprenyl_synt:   43 . . . 315    82/285 (29%)   6.3e−91       domain 1 of 1       237/285 (83%)                  
 
     Example 83  
     [0758] The NOV83 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 83A.  
               TABLE 83A                       NOV83 Sequence Analysis                                                SEQ ID NO: 233   411 bp                                     NOV83a,     TGCCTACCCCGAGACTGCTGCTGTTCGGAGACCTGCAGGTGAATGCCCCATCACC   ATG             CG59758-01 DNA Sequence           TCTGACCTGGAGGCAAAACCTTCAACTGAGCATTTGGGGGATAAGATAAAAGATGAAG                   ATATTAAACTCAGGGTTATTGGACAGGATAGCAGTGAGATTCATTTCAAAGTGAAAAT                   GACAACACCTCTCAAGAAACTCAAGAAATCGTACTGTCAGAGACAGGGCGTTCCAGTG                   AATTCCCTCAGGTTTCTCTTTGAAGGTCAGAGAATTGCTGATAATCATACTCCAGAAG                   AACTGGGAATGGAGGAAGAAGATGTGATTGAGGTTTATCAGGAACAAATCGGAGGTCA                   TTCAACAGTT TAG   ACATTCTTTTTTTTTTTCCTTTTCCCTCAATCCTTTTTTATTTTT                       TTAAA                                                   ORF Start: ATG at 56   ORF Stop: TAG at 359                                     SEQ ID NO: 234   101 aa   MW at 11526.0 kD                                     NOV83a,   MSDLEAKPSTEHLGDKIKDEDIKLRVIGQDSSEIHFKVKMTTPLKKLKKSYCQRQGVP           CG59758-01 Protein Sequence           VNSLRFLFEGQRIADNHTPEELGMEEEDVIEVYQEQIGGHSTV                                             SEQ ID NO: 235   658 bp                                     NOV83b,     CTACCCCGAGACTGCTGCTGTTCGGAGACCTGCAGGTGAATGCCCCATCACCA   ATG TCT           CG59758-02 DNA Sequence           GACCTGGAGGCAAAACCTTCAACTGAGCATTTGGGGGATAAGATAAAAGATGAAGATA                   TTAAACTCAGGGTTATTGGACAGGATAGCAGTGAGATTCATTTCAAAGTGAAAATGAC                   AACACCTCTCAAGAAACTCAAGAAATCGTACTGTCAGAGACAGGGCGTTCCAGTGAAT                   TCCCTCAGGTTTCTCTTTGAAGGTCAGAGAATTGCTGATAATCATACTCCAGAAGAAC                   TGGGAATGGAGGAAGAAGATGTGATTGAGGTTTATCAGGAACAAATCGGAGGTCATTC                   AACAGTT TAG     ACAATCGGAGGTCATTCAACAGTTTAGACAATCGGAGGTCATTCAACA                         GTTTAGACAATCGGAGGTCATTCAACAGTTTAGACAATCGGAGGTCATTCAACAGTTT                       AGACAATCGGAGGTCATTCAACAGTTTAGACAATCGGAGGTCATTCAACAGTTTAGAC                       AATCGGAGGTCATTCAACAGTTTAGACAATCGGAGGTCATTCAACAGTTTAGACAATC                       GGAGGTCATTCAACAGTTTAGACAATCGGAGGTCATTCAACAGTTTAGACAATCGGAG                       GTCATTCAACAGTTTAGACA                                                   ORF Start: ATG at 53   ORF Stop: TAG at 356                                     SEQ ID NO: 236   101 aa   MW at 11526.0 kD                                     NOV83b,   MSDLEAKPSTEHLGDKIKDEDIKLRVIGQDSSEIHFKVKMTTPLKKLKKSYCQRQGVP           CG59758-02 Protein Sequence           VNSLRFLFEGQRIADNHTPEELGMEEEDVIEVYQEQIGGHSTV                  
 
     [0759] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 83B.  
               TABLE 83B                          Comparison of NOV83a against NOV83b.                                         Identities/           Protein   NOV83a Residues/   Similarities for           Sequence   Match Residues   the Matched Region                       NOV83b   1 . . . 101   101/101 (100%)               1 . . . 101   101/101 (100%)                      
 
     [0760] Further analysis of the NOV83a protein yielded the following properties shown in Table 83C.  
               TABLE 83C                       Protein Sequence Properties NOV83a                                        PSort   0.6500 probability located in cytoplasm; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0761] A search of the NOV83a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 83D.  
               TABLE 83D                          Geneseq Results for NOV83a                                         NOV83a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAM79976   Human protein SEQ ID NO 3622-    1 . . . 101   100/101 (99%)   1e−52             Homo sapiens , 125 aa.   25 . . . 125   100/101 (99%)           [WO200157190-A2, 9 AUG. 2001]       AAM78992   Human protein SEQ ID NO 1654-    1 . . . 101   100/101 (99%)   1e−52             Homo sapiens , 101 aa.    1 . . . 101   100/101 (99%)           [WO200157190-A2, 9 AUG. 2001]       AAY49967   Human sentrin protein sequence-    1 . . . 101    89/101 (88%)   2e−45             Homo sapiens , 101 aa.    1 . . . 101    94/101 (92%)           [U.S. Pat. No. 5985664-A,           16 NOV. 1999]       AAW87984   Ubiquitin-like domain of the    1 . . . 101    89/101 (88%)   2e−45           protein SUMO1-Mammalia, 101    1 . . . 101    94/101 (92%)           aa. [WO9857978-A1, 23 DEC. 1998]       AAW60079     Homo sapiens  sentrin-1    1 . . . 101    89/101 (88%)   2e−45           polypeptide- Homo sapiens , 101    1 . . . 101    94/101 (92%)           aa. [WO9820038-A1, 14 MAY 1998]                  
 
     [0762] In a BLAST search of public sequence databases, the NOV83a protein was found to have homology to the proteins shown in the BLASTP data in Table 83E.  
               TABLE 83E                          Public BLASTP Results for NOV83a                                         NOV83a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q93068   Ubiquitin-like protein SMT3C   1 . . . 101   89/101 (88%)   6e−45           precursor (Ubiquitin-homology domain   1 . . . 101   94/101 (92%)           protein PIC1) (Ubiquitin-like protein           UBL1) (Ubiquitin-related protein           SUMO-1) (GAP modifying protein 1)           (GMP1) (Sentrin)- Homo sapiens             (Human), and, 101 aa.       Q9MZD5   SENTRIN- Cervus nippon  (Sika deer),   1 . . . 101   88/101 (87%)   2e−44           101 aa.   1 . . . 101   93/101 (91%)       O57686   SUMO-1 PROTEIN- Xenopus laevis     1 . . . 100   83/101 (82%)   2e−39           (African clawed frog), 102 aa.   1 . . . 101   90/101 (88%)       Q9PT08   SMALL UBIQUITIN-RELATED   1 . . . 97   72/97 (74%)   9e−35           PROTEIN 1- Oncorhynchus mykiss     1 . . . 97   84/97 (86%)           (Rainbow trout) ( Salmo gairdneri ), 101           aa.       Q9D466   4933411G06RIK PROTEIN- Mus     1 . . . 97   68/97 (70%)   8e−30             musculus  (Mouse), 117 aa.   1 . . . 96   80/97 (82%)                  
 
     [0763] PFam analysis predicts that the NOV83a protein contains the domains shown in the Table 83F.  
               TABLE 83F                          Domain Analysis of NOV83a                                     Identities/           Pfam   NOV83a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               ubiquitin:   20 . . . 95   14/83 (17%)   4.7e−18       domain 1 of 1       66/83 (80%)                  
 
     Example 84  
     [0764] The NOV84 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 84A.  
               TABLE 84A                       NOV84 Sequence Analysis                                                SEQ ID NO: 237   912 bp                                     NOV84a,     ACTCACTA   ATG GGCTCGAGCGGCTGCCTGTGTTTCAGCGGCTCGGGGAAATCCACCGT           CG59586-01 DNA Sequence           GGGCGCCCTGCTGGCATCTGAGCTGGGATGGAAATTCTATGATGCTGATGATTATCAC                   CCGGAGGAAAATCGAAGGAAGATGGGAAAAGGCATACCGCTCAATGACCAGGACCGGA                   TTCCATGGCTCTGTAACTTGCATGACATTTTACTAAGAGATGTAGCCTCGGGACAGCG                   TGTGGTTCTAGCCTGTTCAGCCCTGAAGAAAACGTACAGAGACATATTAACACAAGGA                   AAAGATGGTGTAGCTCTGAAGTGTGAGGAGTCGGGAAAGGAAGCAAAGCAGGCTGAGA                   TGCAGCTCCTGGTGGTCCATCTGAGCGGGTCGTTTGAGGTCATCTCTGGACGCTTACT                   CAAAAGAGAGGGACATTTTATGCCCCCTGAATTATTGCAGTCCCAGTTTGAGACTCTG                   GAGCCCCCAGCAGCTCCAGAAAACTTTATCCAAATAAGTGTGGACAAAAATGTTTCAG                   AGATAATTGCTACAATTATGGAAACCCTAAAAATGAAA TGA   CAATGATTTTGTATCAG                       TGGTCCAAACAGAACTAAGCATAAATCATTGTGCCATCCCAAACCTCGTTCCAGCCGC                       CTTGCCCATACTAGATTCTAAATGTTTCTAAAGGCAAACCCCAATGTGTCAAGACAGA                       CTTGTTTAGGTGTAATTTTAGGAATTATGCTGGTTCATCAGGAAGCAGAGGGGGAGTT                       TTAAAAGTCAAGCTTAAATTGAAGTTTAAATTCATCTATAACCAAATCAAATGATCAG                       AGGAAATTCTGTAATCAATGCTGGAAATCGTTACATTGTTTAGAACATTCTTGCTCAT                       GCCTGTATTTGCACAAATAAATGAAACTTCGCTGTAAAAAAA                                           ORF Start: ATG at 9   ORF Stop: TGA at 561                                     SEQ ID NO: 238   184 aa   MW at 20352.2 kD                                     NOV84a,   MGSSGCLCFSGSGKSTVGALLASELGWKFYDADDYHPEENRRKMGKGIPLNDQDRIPW           CG59586-01 Protein Sequence           LCNLHDILLRDVASGQRVVLACSALKKTYRDILTQGKDGVALKCEESGKEAKQAEMQL                   LVVHLSGSFEVISGRLLKREGHFMPPELLQSQFETLEPPAAPENFIQISVDKNVSEII                   ATIMETLKMK                  
 
     [0765] Further analysis of the NOV84a protein yielded the following properties shown in Table 84B.  
               TABLE 84B                       Protein Sequence Properties NOV84a                                        PSort   0.6500 probability located in cytoplasm; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.1000 probability located in           plasma membrane       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0766] A search of the NOV84a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 84C.  
               TABLE 84C                          Geneseq Results for NOV84a                                         NOV84a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAG73989   Human colon cancer antigen   10 . . . 184   175/175 (100%)   1e−97           protein SEQ ID NO: 4753- Homo     19 . . . 193   175/175 (100%)             sapiens , 193 aa. [WO200122920-           A2, 5 APR. 2001]       AAB58998   Breast and ovarian cancer   10 . . . 184   175/175 (100%)   1e−97           associated antigen protein sequence   19 . . . 193   175/175 (100%)           SEQ ID 706- Homo sapiens , 193           aa. [WO200055173-A1,           21 SEP. 2000]       AAM89100   Human immune/haematopoietic   24 . . . 126    70/103 (67%)   1e−34           antigen SEQ ID NO: 16693- Homo     22 . . . 124    77/103 (73%)             sapiens , 133 aa. [WO200157182-           A2, 9 AUG. 2001]       AAG50675     Arabidopsis thaliana  protein   10 . . . 179    75/173 (43%)   4e−28           fragment SEQ ID NO: 64243-    4 . . . 167   102/173 (58%)             Arabidopsis thaliana , 175 aa.           [EP1033405-A2, 6 SEP. 2000]       AAG50674     Arabidopsis thaliana  protein   10 . . . 179    75/173 (43%)   4e−28           fragment SEQ ID NO: 64242-   16 . . . 179   102/173 (58%)             Arabidopsis thaliana , 187 aa.           [EP1033405-A2, 6 SEP. 2000]                  
 
     [0767] In a BLAST search of public sequence databases, the NOV84a protein was found to have homology to the proteins shown in the BLASTP data in Table 84D.  
               TABLE 84D                          Public BLASTP Results for NOV84a                                         NOV84a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               BAB74785   GLUCONOKINASE-Anabaena   10 . . . 183    72/174 (41%)   1e−30           sp. (strain PCC 7120), 160 aa.    9 . . . 160   101/174 (57%)       Q9RT56   THERMORESISTANT   10 . . . 183    66/174 (37%)   1e−29           GLUCONOKINASE-    4 . . . 159   101/174 (57%)             Deinococcus radiodurans , 172 aa.       CAC93415   PUTATIVE GLUCONOKINASE   10 . . . 174    68/166 (40%)   2e−29           (EC 2.7.1.12)- Yersinia pestis ,   12 . . . 159    95/166 (56%)           167 aa.       Q9CMM6   GLK- Pasteurella multocida , 172   10 . . . 182    68/174 (39%)   2e−29           aa.   15 . . . 169    99/174 (56%)       AAK86014   AGR_C_329P- Agrobacterium     10 . . . 182    74/173 (42%)   6e−29             tumefaciens  str. C58 (Cereon),    5 . . . 159    98/173 (55%)           163 aa.                  
 
     [0768] PFam analysis predicts that the NOV84a protein contains the domains shown in the Table 84E.  
               TABLE 84E                          Domain Analysis of NOV84a                                     Identities/           Pfam   NOV84a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               SKI: domain 1 of 1   9 . . . 182    37/206 (18%)   1.1               114/206 (55%)                  
 
     Example 85  
     [0769] The NOV85 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 85A.  
               TABLE 85A                       NOV85 Sequence Analysis                                                SEQ ID NO: 239   4332 bp                                     NOV85a,     GGCGTATTAACGCGCGGGTGCACACCCCCACGGGCGCGCA   ATG AACAACTATGTGCTT           CG59704-01 DNA Sequence           AATGACGAGATCGGCCAGGGTGCCTTCAGCACTATTTACAAGGGCCGCTATCGCACCA                   CCACCGAGTTCTACGCGATTGCTTCCATCGACAAGAAGCGACGGGAGCGCGTCGTGAA                   CTGCGTTCAGCTGTTACGCTCCATGCACCACTCAAACGTCATAGAGTTCCACAACTGG                   TATGAGACCAACAATCACTTGTGGATCATTACGGAGTACTGCACCGGCGGAGACATGA                   GCACGATCCTCCGCTCGAACATTAATCTCACCACTCAGGCGGTCCAGGCGTTCGGCCG                   TGATGTGGCGATGGGCCTCATGTACATCCACAGTAAGGGTGTCGTGTATAACGACTTG                   CAGACTCGCAATCTGCTGATGGACTCCGCAGCAATGCTGCGCTTCCACGACTTTAGCT                   TGGCCTGTCTCTTCCAAGACGCGGCGACGCGGCCACTGGTGGGGACGCCACTGTACAT                   GGCCCCCGAGTTGTTCATGGCGGATCGCCCGCTGTACTCGATGGCATCAGACCTGTGG                   TCCTTCGGTTGTGTGCTGCACGAGCTGGCGACAGGCAAGCCGCCCTTTGCCGCATCCG                   ACCTCGAGACGCTGCTGGGCGACATACTGACGAGTCCGACGCCAGCGGTGCCTGGTGC                   GCCGGAGTCCTTTCAAACGCTCCTGTGCGGCCTGCTGGAAAAGGACCCGTTGAAGCGC                   TACGCGTGGGTCGATGTTGTCCGCAGCGAGTTCTGGGATGAGCCCTTGCCGCTGCCGA                   GCAACGGCTTTCCATCTCAGGTGGCGTGGGAGGACTACAAGCGTTCGCGTTCTGGACG                   CGGTGCGAGTCAGTATAATTGGACGGACTCCGATGTGCGTGTGGCAGTGGCTCACGCC                   GTGGGGGCAGCGAAATCAAACGCTTCTACGCACAACGTGGAGGAGAGGGAGCGAGCGG                   CTGCGACGTTGAACGTCGCGAAGGAGCTGGACTTCACTGCAAGCGCGGCGATGTTGCT                   GGAACGGTTACCGGAGCGGACACAGGAGCGTGCTGCGCACGCAACAGGCCATGTCGCG                   ACCGCGCACGGCAGCCTGGTGCACGGCTGCCCATCCACGGCCTCAGCGGCGACCTCGC                   CAAGACGTTCAAGGACAAGGCGGCGCTGCTCAAGATTGTGGAAGAGGTCAAAACCGCT                   GTCGAGGGCTTCAAGCCGTGGGTGTCCTTCCACGTCGCTGCGCCACCCGGGCATGAGG                   GAGCGCCACTGGACCGGCTTGTCTCAGAAGCTCGGGATGAAGCTGGTGCCTGGCGACA                   CACTGATGCTTCTGGAGGACTGCGAACCGCTGCTAGCGCACCGCGACACCATTATCAG                   CTACTGCGAGGTGGCCGCGAAGGAGTCGCAGATCGAGATGACGCTCAAGGACATGCGT                   GCCAAGTGGGAGACCAAGTGCTTCATCATCGAGGCATACAAGGAGACAGGCACGTACA                   TCCTCAAGGACACCTCCGAGGTGGTGGAGCTCCTCGACGAGCACCTCAACGTCGTCCA                   GCAGCTGCAGTTCTCTCCATTCAAGGGCTACTTCGAGGAGTCCATCACGGACTGGGAG                   CGCTCCCTCAACCTCATCTCCGACATACTCGAACAATGGCTGGAGTGCCAGCGAGCGT                   GGCGTTATCTGGAGCCGATCCTCAACTCGGAGGACATCGCCATGCAGCTACCGCGACT                   GTCCACGCTGTTCGAGAAGGTGGACCGCACATGGAGACGTGTCATGGGCAACGCGCAC                   GCGCAGCCAAACGCACTCGAGTACTGCATTGGCACAAACAAGCTCTTGGACCACCTGC                   GCGAGGCGAACCGGCTCCTCGAAGTGCTGCAGCACTTGATGGCGCAGAAGGTCAACGT                   TGCCGCTGTTGGTCCGACTGGCACCGGCAAGTCCATCTCACTCGCGCGTCTCGTGCTT                   GGCGGCGGCATGCCGGCCAACTTTCTTGGCCTCAACTTCACCTTCTCGGCGCAGACAA                   AGTGCACAGTGTTGCAGAATTCACTGATGGCCAAGTTCGATAAGCGGCGCTCGCACGT                   CTACGGCGCCCCTGCCGGTAAGCACTTTCTCATCTTCATTGACGACGCGAACCTGCCG                   CAGCCAGAGAAGTACGGCGCGCAGCCCCCGGTGGAGCTTCTGCGGCAGATGCTCGCCC                   AAGGCGGCTTCTACAACTTTACAGGTGGCATCAAGTGGTCCTCCATCATCGACTGCTC                   GCTTGCGCTGGCGATGGGGCCGCCTGGCGGGGGCCGCAGCCGGGTTTCGAACCGCTTT                   ATGCGCTACTTCAATTACCTTGCCTTCCCCGAGATGTCGGACATGTCGAAGCGAACGA                   TCTTGCAGGCCATCCTCGTCGGCGGCCTCGCGCAGAGCGGCCTCGCTGACCGCCTCGC                   GAACGTCGCCTCCGCCGTGGTCGATAGCACGTTGCGGGTGTTTCGCAAGTGCACCCAG                   GTCTTTCTGCCGACCCCGGCGCACGTGCACTACTCCTTCAACATGCGGGATGTGATGC                   GTGTTTTTCCCCTCTTGTACACAGCAGACAAGTCGGTGCTGCAGTCGGAGGAATCCAT                   CGTGCGGCTGTGGATGCACGAGATGCAGCGCGTCTTCTACGATCGCCTCGTCGACGCG                   ACAGACAAGGGTCTGTTCATCGAGTACCTCAATGCCGAGCTGCCGTCCATGGGGGTGG                   ACAAGTCCTACAACGAGGTAGTGAAGGCTGACCGCCTCATCTTTGCCGACGTACTGAG                   CGACAAGGGCGTGTACGAGCAGATTACCGACATGAACGCCCTCACGACACGCATGAAT                   GAGCTGCTGGAGGCGTACAATGACGAGAATGAAGTGAAGATGAACCTCGTGCTCTTCC                   TCGACGCCATCGAGCATGTCTGCCGTATCTCGCGCGTGCTGCGACTGCCGAACGGGCA                   CTGCCTCCTCCTCGGCGTTGGCGGGTCGGGACGCAAGTCACTCACGCGCCTGGCTTGT                   TCTCTGATTGCCGAGATGGAGGTGTTCACGATTGAGCTGTCGAAGAACTTCGGTGTCA                   AGGAATGGCACGAGAGCCTCGCGAAGTTGCTGCTCGAGTGTGGCAAGGACGAGAAGAA                   GCGGACGTTTCTCTTCGCCGACACCCAGCTGGCGCATCCGACGTTTCTGGAGGATGTG                   GCGGGCCTGCTCACATCGGGTGATGTGCCGAACCTCTTTGAGGACCAAGATATCGAGC                   TCATCAACGACAAGTTTCGCGGCGTCTGCCTAAGCGAGAACCTGCCAACGACGAAGGT                   GTCGGTGTACGCGCGCTTTGTGAAGGAGGCGCGAGCCAACCTGCACCTTGTGCTCGCC                   TTCTCTCCCATCGGAGAGGCGTTTCGCAGCCGCCTGCGTATGTTCCCATCGCTCATTG                   CGTGCTGCACAATCGACTGGTTTGCTGAGTGGCCATCCGAGGCGCTACTGTCGGTAGC                   CGCAGTGCAGCTGAACGCCGGCGACGTTACTGACGTCATGGGGGCGGCAAGCCATGCC                   GACTTGCCGGGCTGCTTCCAGGCAGTGCACCGCGCGGCGGCGGAGGTGACGGAGCGCT                   TCTTCACGGAAACGCGTCGTCGCTCGTACGTGACGCCGACGTCCTATCTGTCGCTCCT                   CTCCAACTTCAAAGTGATGGCGGCGGCAAAACGCCGCTTCGTTCGCGAGCAGCGCGGC                   CGCCTCGAGAAGGGGCTGGAGAAGCTGCGGCACACCGAGGTGCAAGTGGCGGAGCTGG                   AGGCCCAGCTCAAGGCGCAGCAGCCGGTTCTGGTGCAGAAAAAGGCAGAGATTCAGTC                   GATGATGGAGCGGCTGACGGTGGACCGAAAGGAGGCGGCGGTGAAGGAGGCGGACGCG                   CGCAGGGAGGCCCAGCTTCCCGGTGGCCGTGCTGCATACGGCGGTGAAGATGACGAA T                       GA   GCCGCCGATGGGGCTGCGGGCGAACGTGATGCGCTCCTACTACGGCTTCACTCCCG                       AGGACCTCGAGCAGGAGGAGAAGCCCGCCGAGTTCAAAAAGATGTTGATGGCATCCGC                       ATGCCTGGTCCCATACCCGAGCACTGAAGAGCAGGGTCTCTGGAGCCTGGCATCGTGG                       GGTGGCCCTCAGCTTCCCCACTCACTGTGGGAAGTTTCCTTAGTGTCTCTGAGCCTGT                       TTCCTCATCCGTTGCCTGAGGATAAACCTGCTTCAGGATTGTTGGTGAAAAGACTTCC                       CTCACCTAGCTTCTGTAACGCCACTGCATGCCACCACTGCTGAGTACTGTTTGTTTGC                       TAGGTTGGTGTCATTCTCATTTTACCAGAAAGTGAAGCTC                                                   ORF Start: ATG at 41   ORF Stop: TGA at 3944                                     SEQ ID NO: 240   1301 aa   MW at 146115.7 kD                                     NOV85a,   MNNYVLNDEIGQGAFSTIYKGRYRTTTEFYAIASIDKKRRERVVNCVQLLRSMHHSNV           CG59704-01 Protein Sequence           IEFHNWYETNNHLWIITEYCTGGDMSTILRSNINLTTQAVQAFGRDVAMGLMYIHSKG                   VVYNDLQTRNLLMDSAAMLRFHDFSLACLFQDAATRPLVGTPLYMAPELFMADRPLYS                   MASDLWSFGCVLHELATGKPPFAASDLETLLGDILTSPTPAVPGAPESFQTLLCGLLE                   KDPLKRYAWVDVVRSEFWDEPLPLPSNGFPSQVAWEDYKRSRSGRGASQYNWTDSDVR                   VAVAHAVGAAKSNASTHNVEERERAAATLNVAKELDFTASAAMLLERLPERTQERAAH                   ATGHVATAHGSLVHGCPSTASAATSPRRSRTRRRCSRLWKRSKPLSRASSRGCPSTSL                   RHPGMRERHWTGLSQKLGMKLVPGDTLMLLEDCEPLLAHRDTIISYCEVAAKESQIEM                   TLKDMRAKWETKCFIIEAYKETGTYILKDTSEVVELLDEHLNVVQQLQFSPFKGYFEE                   SITDWERSLNLISDILEQWLECQRAWRYLEPILNSEDIAMQLPRLSTLFEKVDRTWRR                   VMGNAHAQPNALEYCIGTNKLLDHLREANRLLEVLQHLMAQKVNVAAVGPTGTGKSIS                   LARLVLGGGMPANFLGLNFTFSAQTKCTVLQNSLMAKFDKRRSHVYGAPAGKHFLIFI                   DDANLPQPEKYGAQPPVELLRQMLAQGGFYNFTGGIKWSSIIDCSLALAMGPPGGGRS                   RVSNRFMRYFNYLAFPEMSDMSKRTILQAILVGGLAQSGLADRLANVASAVVDSTLRV                   FRKCTQVFLPTPAHVHYSFNMRDVMRVFPLLYTADKSVLQSEESIVRLWMHEMQRVFY                   DRLVDATDKGLFIEYLNAELPSMGVDKSYNEVVKADRLIFADVLSDKGVYEQITDMNA                   LTTRMNELLEAYNDENEVKMNLVLFLDAIEHVCRISRVLRLPNGHCLLLGVGGSGRKS                   LTRLACSLIAEMEVFTIELSKNFGVKEWHESLAKLLLECGKDEKKRTFLFADTQLAHP                   TFLEDVAGLLTSGDVPNLFEDQDIELINDKFRGVCLSENLPTTKVSVYARFVKEARAN                   LHLVLAFSPIGEAFRSRLRMFPSLIACCTIDWFAEWPSEALLSVAAVQLNAGDVTDVM                   GAASHADLPGCFQAVHRAAAEVTERFFTETRRRSYVTPTSYLSLLSNFKVMAAAKRRF                   VREQRGRLEKGLEKLRHTEVQVAELEAQLKAQQPVLVQKKAEIQSMMERLTVDRKEAA                   VKEADARREAQLPGGRAAYGGEDDE                  
 
     [0770] Further analysis of the NOV85a protein yielded the following properties shown in Table 85B.  
               TABLE 85B                       Protein Sequence Properties NOV85a                                        PSort   0.8800 probability located in nucleus; 0.3562 probability       analysis:   located in microbody (peroxisome); 0.1671 probability located           in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0771] A search of the NOV85a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 85C.  
               TABLE 85C                          Geneseq Results for NOV85a                                         NOV85a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAM79863   Human protein SEQ ID NO 3509-   602 . . . 1287   218/692 (31%)   1e−89             Homo sapiens , 2127 aa.   168 . . . 847   347/692 (49%)           [WO200157190-A2,           9 AUG. 2001]       AAM79862   Human protein SEQ ID NO 3508-   602 . . . 1287   218/692 (31%)   1e−89             Homo sapiens , 2127 aa.   168 . . . 847   347/692 (49%)           [WO200157190-A2,           9 AUG. 2001]       AAM78879   Human protein SEQ ID NO 1541-   602 . . . 1287   218/692 (31%)   1e−89             Homo sapiens , 2143 aa.   108 . . . 787   347/692 (49%)           [WO200157190-A2,           9 AUG. 2001]       AAM78878   Human protein SEQ ID NO 1540-   602 . . . 1287   218/692 (31%)   1e−89             Homo sapiens , 2067 aa.   108 . . . 787   347/692 (49%)           [WO200157190-A2,           9 AUG. 2001]       AAM80293   Human protein SEQ ID NO 3945-   910 . . . 1293   153/393 (38%)   5e−70             Homo sapiens , 1774 aa.    33 . . . 405   227/393 (56%)           [WO200157190-A2,           9 AUG. 2001]                  
 
     [0772] In a BLAST search of public sequence databases, the NOV85a protein was found to have homology to the proteins shown in the BLASTP data in Table 85D.  
               TABLE 85D                          Public BLASTP Results for NOV85a                                         NOV85A   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               AAL37427   CILIARY DYNEIN HEAVY    628 . . . 1293   271/692 (39%)   e−132           CHAIN 7 -  Homo sapiens     1975 . . . 2655   395/692 (56%)           (Human), 4024 aa.       Q27812   DYNEIN HEAVY CHAIN    601 . . . 1247   264/667 (39%)   e−127           ISOTYPE 7B (EC 3.6.1.3) -    654 . . . 1310   389/667 (57%)             Tripneustes gratilla  (Hawaian sea           urchin), 1314 aa (fragment).       Q9MBF8   1 BETA DYNEIN HEAVY    611 . . . 1293   257/693 (37%)   e−117           CHAIN -  Chlamydomonas     2486 . . . 3159   377/693 (54%)             reinhardtii , 4513 aa.       Q9VJC6   DHC36C PROTEIN -  Drosophila      596 . . . 1275   249/699 (35%)   e−116             melanogaster  (Fruit fly), 4010 aa.   1913 . . . 2604   383/699 (54%)       Q9VWZ3   DHC16F PROTEIN -  Drosophila      618 . . . 1301   248/704 (35%)   e−108             melanogaster  (Fruit fly), 4081 aa.   2022 . . . 2709   380/704 (53%)                  
 
     [0773] PFam analysis predicts that the NOV85a protein contains the domains shown in the Table 85E.  
               TABLE 85E                          Domain Analysis of NOV85a                                     Identities/                   Similarities           NOV85a Match   for the   Expect       Pfam Domain   Region   Matched Region   Value                                         pkinase: domain 1 of 1    4 . . . 250   80/286   (28%)   6.8e−62               190/286   (66%)       DEAD: domain 1 of 1   613 . . . 637   7/25   (28%)   0.83               22/25   (88%)       dNK: domain 1 of 1    865 . . . 1020   32/179   (18%)   6.8                101/179   (56%)                  
 
     [0774] The NOV86 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 86A.  
               TABLE 86A                       NOV86 Sequence Analysis                                                SEQ ID NO: 241   1420 bp                                     NOV86a,     GTCCAGCTTTAGCTCTCTGCTCGCCGCCGCCGCTGTCGCCGCCACCTCCTCTGATCTA             CG59628-01 DNA Sequence             CGAAAGTC   ATG TTACCCAACACCGGGAGGCTGGCAGGATGTACAGTTTTTTATCACAGG                   TGCAAGCCGTGGCATTGGCAAAGCTATTGCATTGAAAGCAGCAAAGGATGGAGCAAAT                   ATTGTTATTGCTGCAAAGACCGCCCAGCCACATCCAAAACTTCTAGGCACAATCTATA                   CTGCTGCTGAAGAAATTGAAGCAGTTGGAGGAAAGGCCTTGCCATGTATTGTTGATGT                   GAGAGATGAACAGCAGATCAGTGCTGCAGTGGAGAAAGCCATCAAGAAATTTGGAGGA                   ATTGATATTCTGGTAAATAATGCCAGTGCCATTAGTTTGACCAATACATTGGACACAC                   CTACCAAGAGATTGGATCTGATGATGAACGTGAACACCAGAGGCACCTACCTTGCATC                   TAAAGCATGTATTCCTTATTTGAAAAAGAGCAAAGTTGCTCATATCCTCAATATCAGT                   CCACCACTGAACCTAAATCCAGTTTGGTTCAAACAGCACTGTGCTTATACCATTGCTA                   AGTATGGTATGTCTATGTATGTGCTTGGAATGGCAGAAGAATTTAAAGGTGAAATTGC                   AGTCAATGCATTATGGCCTAAAACAGCCATACACACTGCTGCTATGGATATGCTGGGA                   GGACCTGGTATCGAAAGCCAGTGTAGAAAAGTTGATATCATTGCAGATGCAGCATATT                   CCATTTTCCAAAAGCCAAAAAGTTTTACTGGCAACTTTGTCATTGATGAAAATATCTT                   AAAAGAAGAAGGAATAGAAAATTTTGACGTTTATGCAATTAAACCAGGTCATCCTTTG                   CAACCAGATTTCTTCTTAGATGAATACCCAGAAGCAGTTAGCAAGAAAGTGGAATCAA                   CTGGTGCTGTTCCAGAATTCAAAGAAGAGAAACTGCAGCTGCAACCAAAACCACGTTC                   TGGAGCTGTGGAAGAAACATTTAGAATTGTTAAGGACTCTCTCAGTGATGATGTTGTT                   AAAGCCACTCAAGCAATCTATCTGTTTGAACTCTCCGGTGAAGATGGTGGCACGTGGT                   TTCTTGATCTGAAAAGCAAGGGTGGGAATGTCGGATATGGAGAGCCTTCTGATCAGGC                   AGATGTGGTGATGAGTATGACTACTGATGACTTTGTAAAAATGTTTTCAGGTAAACTA                   AAACCAACAATGGCATTCATGTCAGGGAAATTGAAGATTAAAGGTAACATGGCCCTAG                   CAATCAAATTGGAGAAGCTAATGAATCAGATGAATGCCAGACTG TGA   AGGAAAATATA                       AAAAAAAAGTCGACTGCTATGCTCAAAAAGTAAAAAAAGCTCAACAGTTAAAATCTAA                       TGTTTGTTTTCTTTCCTGTTATATTATA                                                   ORF Start: ATG at 67   ORF Stop: TGA at 1321                                     SEQ ID NO: 242   418 aa   MW at 45394.2 kD                                     NOV86a,   MLPNTGRLAGCTVFITGASRGIGKAIALKAAKDGANIVIAAKTAQPHPKLLGTIYTAA           CG59628-01 Protein Sequence           EEIEAVGGKALPCIVDVRDEQQISAAVEKAIKKFGGIDILVNNASAISLTNTLDTPTK                   RLDLMMNVNTRGTYLASKACIPYLKKSKVAHILNISPPLNLNPVWFKQHCAYTIAKYG                   MSMYVLGMAEEFKGEIAVNALWPKTAIHTAAMDMLGGPGIESQCRKVDIIADAAYSIF                   QKPKSFTGNFVIDENILKEEGIENFDVYAIKPGHPLQPDFFLDEYPEAVSKKVESTGA                   VPEFKEEKLQLQPKPRSGAVEETFRIVKDSLSDDVVKATQAIYLFELSGEDGGTWFLD                   LKSKGGNVGYGEPSDQADVVMSMTTDDFVKMFSGKLKPTMAFMSGKLKIKGNMALAIK                   LEKLMNQMNARL                  
 
     [0775] Further analysis of the NOV86a protein yielded the following properties shown in Table 86B.  
               TABLE 86B                       Protein Sequence Properties NOV86a                                        PSort   0.5500 probability located in endoplasmic reticulum       analysis:   (membrane); 0.5000 probability located in microbody           (peroxisome); 0.1900 probability located in           lysosome (lumen); 0.1000 probability located           in endoplasmic reticulum (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0776] A search of the NOV86a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 86C.  
               TABLE 86C                          Geneseq Results for NOV86a                                         NOV86a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAG81260   Human AFP protein sequence SEQ   1 . . . 418   418/418   (100%)   0.0           ID NO:38 -  Homo sapiens , 418 aa.   1 . . . 418   418/418   (100%)           [WO200129221-A2, 26 APR           2001]       AAB84367   Amino acid sequence of human   1 . . . 418   418/418   (100%)   0.0           alcohol dehydrogenase 21612 -   1 . . . 418   418/418   (100%)             Homo sapiens , 418 aa.           [WO200144446-A2, 21 JUN 2001]       AAG81258   Human AFP protein sequence SEQ   1 . . . 382   382/382   (100%)   0.0           ID NO:34 -  Homo sapiens , 383 aa.   1 . . . 382   382/382   (100%)           [WO200129221-A2, 26 APR           2001]       ABB10251   Human cDNA SEQ ID NO: 559 -   141 . . . 418    271/278   (97%)   e−156             Homo sapiens , 278 aa.   1 . . . 278   274/278   (98%)           [WO200154474-A2, 2 AUG           2001]       AAU23020   Novel human enzyme polypeptide   141 . . . 418    271/278   (97%)   e−156           #106 -  Homo sapiens , 278 aa.   1 . . . 278   274/278   (98%)           [WO200155301-A2, 2 AUG           2001]                  
 
     [0777] In a BLAST search of public sequence databases, the NOV86a protein was found to have homology to the proteins shown in the BLASTP data in Table 86D.  
               TABLE 86D                          Public BLASTP Results for NOV86a                                         NOV86A   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                             CAC38510   SEQUENCE 37 FROM   1 . . . 418   418/418   (100%)   0.0           PATENT WO0129221 -  Homo     1 . . . 418   418/418   (100%)             sapiens  (Human), 418 aa.       CAC38508   SEQUENCE 33 FROM   1 . . . 382   382/382   (100%)   0.0           PATENT WO0129221 -  Homo     1 . . . 382   382/382   (100%)             sapiens  (Human), 383 aa.       Q99LV2   HYPOTHETICAL 54.9 KDA   1 . . . 418   355/496   (71%)   0.0           PROTEIN -  Mus musculus     1 . . . 496   390/496   (78%)           (Mouse), 496 aa.       Q9BT58   SIMILAR TO RIKEN CDNA   163 . . . 418    253/256   (98%)   e−143           2610207116 GENE -  Homo     90 . . . 345    254/256   (98%)             sapiens  (Human), 345 aa.       Q9VB10   CG5590 PROTEIN (GH01709P) -   4 . . . 418   238/422   (56%)   e−128             Drosophila melanogaster  (Fruit   3 . . . 412   300/422   (70%)           fly), 412 aa.                  
 
     [0778] PFam analysis predicts that the NOV86a protein contains the domains shown in the Table 86E.  
               TABLE 86E                          Domain Analysis of NOV86a                                     Identities/                   Similarities           NOV86a Match   for the   Expect       Pfam Domain   Region   Matched Region   Value                                         beta-lactamase:   222 . . . 236   4/15   (27%)   6.5       domain 1 of 1       14/15   (93%)       adh_short:    9 . . . 321   74/339   (22%)   2.4e−29       domain 1 of 1       211/339   (62%)       SCP2: domain 1 of 1   306 . . . 415   41/114   (36%)   1.5e−25               87/114   (76%)                  
 
     Example 87  
     [0779] The NOV87 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 87A.  
               TABLE 87A                       NOV87 Sequence Analysis                                                SEQ ID NO: 243   888 bp                                     NOV87a,   TTCAACAAGGGCCCCTCCTACAGGCTCTTGGCGGACGTCCAGAACAGGCTTCTGTTCA           CG59516-01 DNA Sequence           AATATGACTCCCAGAAGGAGGCAGAGCTCCGCAGCTGGATCAAGGGATTCACTGGCCT                   CTCCATCCGCCCCGACTTCCAGAAGGGCCTGAAGGACGGGATTATTTTATGCACACTC                   GTGAACAAACTGCAGCCGGGCTCAGTCCCCAAGATCAACGGCTTCCGTGTAGAACTGG                   CACCAGCTAGAAAACCTCTCCAACATCCTCAAGGCAATGGTCAGCTACGGCATGATCC                   CGTGGACCTATTTGAGGCCAACGACCTGTTTGAGAGTGGGAACAATATGCAGGTGCGG                   GTGTCTCTTCTCGCCCTGGCAGGGAAGGCCAAGACTAAGGGGCTGCAGAGCGGGGTGG                   ACATCCGTGACAAGTACTCAGAGAAGCAGAACTTCAACGACACCACCATGAAGGCCAG                   GCTGTGCGTCATCCGGCTGCAGATTACCAACAAATGTGCCAGCCAGTCAGGCATGACC                   GCATACGTCACGAGGAGGCATCTCTACGACCCCAAGAACCGCATCCTGCCCCCCATGG                   ACAACTCGACCATCAGCCTCCGGATGGGTACAAACAAGTGCGCCAGCCAGGTGGGCAT                   GACGGCTCCCGGGAACCAGTGGCACATCTATGACACCAAGTTGGGAATCGACAAGTGT                   GAGAACTCCTCCATGTCCCTGAAGATGGGCTACACGCAGGTCGCCAATCACAGCAGAC                   AGGTCTTTGGCCTAGGCCGGCAAATATATGAACCCAAGTACCAGCCGGGTGGCCCAGT                   GGCCCACGGGGCTCCCTCCGCCGGCAACTGCCCAGGGCCAGGGGAGGCCCCT TAG   TAC                       CAGGAGGAGACCAGCTAC                                                   ORF Start: TTC at 1   ORF Stop: TAG at 865                                     SEQ ID NO: 244   288 aa   MW at 31831.2 kD                                     NOV87a,   FNKGPSYRLLADVQNRLLFKYDSQKEAELRSWIKGFTGLSIRPDFQKGLKDGIILCTL           CG59516-01 Protein Sequence           VNKLQPGSVPKINGFRVELAPARKPLQHPQGNGQLRHDPVDLFEANDLFESGNNMQVR                   VSLLALAGKAKTKGLQSGVDIRDKYSEKQNFNDTTMKARLCVIRLQITNKCASQSGMT                   AYVTRRHLYDPKNRILPPMDNSTISLRMGTNKCASQVGMTAPGNQWHIYDTKLGIDKC                   ENSSMSLKMGYTQVANHSRQVFGLGRQIYEPKYQPGGPVAHGAPSAGNCPGPGEAP                                             SEQ ID NO: 245   888 bp                                     NOV87b,   TTCAACAAGGGCCCCTCCTACAGGCTCTTGGCGGACGTCCAGAACAGGCTTCTGTTCA           CG59516-02 DNA Sequence           AATATGACTCCCAGAAGGAGGCAGAGCTCCGCAGCTGGATCAAGGGATTCACTGGCCT                   CTCCATCCGCCCCGACTTCCAGAAGGGCCTGAAGGACGGGATTATTTTATGCACACTC                   GTGAACAAACTGCAGCCGGGCTCAGTCCCCAAGATCAACGGCTTCCGTGTAGAACTGG                   CACCAGCTAGAAAACCTCTCCAACATCCTCAAGGCAATGGTCAGCTACGGCATGATCC                   CGTGGACCTATTTGAGGCCAACGACCTGTTTGAGAGTGGGAACAATATGCAGGTGCGG                   GTGTCTCTTCTCGCCCTGGCAGGGAAGGCCAAGACTAAGGGGCTGCAGAGCGGGGTGG                   ACATCCGTGACAAGTACTCAGAGAAGCAGAACTTCAACGACACCACCATGAAGGCCAG                   GCTGTGCGTCATCCGGCTGCAGATTACCAACAAATGTGCCAGCCAGTCAGGCATGACC                   GCATACGTCACGAGGAGGCATCTCTACGACCCCAAGAACCGCATCCTGCCCCCCATGG                   ACAACTCGACCATCAGCCTCCGGATGGGTACAAACAAGTGCGCCAGCCAGGTGGGCAT                   GACGGCTCCCGGGAACCAGTGGCACATCTATGACACCAAGTTGGGAATCGACAAGTGT                   GAGAACTCCTCCATGTCCCTGAAGATGGGCTACACGCAGGTCGCCAATCACAGCAGAC                   AGGTCTTTGGCCTAGGCCGGCAAATATATGAACCCAAGTACCAGCCGGGTGGCCCAGT                   GGCCCACGGGGCTCCCTCCGCCGGCAACTGCCCAGGGCCAGGGGAGGCCCCT TAG   TAC                       CAGGAGGAGACCAGCTAC                                                   ORF Start: TTC at 1   ORF Stop: TAG at 865                                     SEQ ID NO: 246   288 aa   MW at 31831.2 kD                                     NOV87b,   FNKGPSYRLLADVQNRLLFKYDSQKEAELRSWIKGFTGLSIRPDFQKGLKDGIILCTL           CG59516-02 Protein Sequence           VNKLQPGSVPKINGFRVELAPARKPLQHPQGNGQLRHDPVDLFEANDLFESGNNMQVR                   VSLLALAGKAKTKGLQSGVDIRDKYSEKQNFNDTTMKARLCVIRLQITNKCASQSGMT                   ENSSMSLKMGYTQVANHSRQVFGLGRQIYEPKYQPGGPVAHGAPSAGNCPGPGEAP                  
 
     [0780] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 87B.  
               TABLE 87B                          Comparison of NOV87a against NOV87b.                                 Identities/               Similarities       Protein   NOV87a Residues/   for the       Sequence   Match Residues   Matched Region               NOV87b   1 . . . 288   288/288 (100%)           1 . . . 288   288/288 (100%)                  
 
     [0781] Further analysis of the NOV87a protein yielded the following properties shown in Table 87C.  
               TABLE 87C                       Protein Sequence Properties NOV87a                                        PSort   0.4500 probability located in cytoplasm; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.2110 probability           located in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0782] A search of the NOV87a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 87D.  
               TABLE 87D                          Geneseq Results for NOV87a                                         NOV87a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAR94888   Carponin -  Homo sapiens , 297 aa.   1 . . . 265   136/269   (50%)   7e−63           [JP08073380-A, 19 MAR 1996]   6 . . . 272   176/269   (64%)       AAR72588   Carponin protein -  Homo sapiens ,   1 . . . 265   136/269   (50%)   7e−63           297 aa. [WO9509010-A, 6 APR   6 . . . 272   176/269   (64%)           1995]       AAB43807   Human cancer associated protein   164 . . . 273    67/113   (59%)   6e−30           sequence SEQ ID NO:1252 -  Homo     4 . . . 116   82/113   (72%)             sapiens , 163 aa. [WO200055350-           A1, 21 SEP 2000]       AAM73074   Human bone marrow expressed   157 . . . 225    49/70   (70%)   4e−21           probe encoded protein SEQ ID NO:   2 . . . 71    55/70   (78%)           33380 -  Homo sapiens , 71 aa.           [WO200157276-A2, 09 AUG 2001]       AAM60434   Human brain expressed single exon   157 . . . 225    49/70   (70%)   4e−21           probe encoded protein SEQ ID NO:   2 . . . 71    55/70   (78%)           32539 -  Homo sapiens , 71 aa.           [WO200157275-A2, 9 AUG 2001]                  
 
     [0783] In a BLAST search of public sequence databases, the NOV87a protein was found to have homology to the proteins shown in the BLASTP data in Table 87E.  
               TABLE 87E                          Public BLASTP Results for NOV87a                                         NOV87A   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q08094   Calponin H2, smooth muscle -  Sus     1 . . . 287   219/291 (75%)    e−116             scrofa  (Pig), 296 aa (fragment).   6 . . . 296   237/291 (81%)       Q99439   Calponin H2, smooth muscle   1 . . . 288   218/292 (74%)    e−115           (Neutral calponin) -  Homo sapiens     6 . . . 297   235/292 (79%)           (Human), 309 aa.       Q08093   Calponin H2, smooth muscle -   1 . . . 288   214/291 (73%)    e−112             Mus musculus  (Mouse), 305 aa.   6 . . . 293   231/291 (78%)       O93547   CALPONIN H3 -  Xenopus laevis     1 . . . 269   179/273 (65%)   6e−91           (African clawed frog), 295 aa.   5 . . . 276   208/273 (75%)       Q922F8   UNKNOWN (PROTEIN FOR   59 . . . 288    166/233 (71%)   8e−83           MGC:8135) -  Mus musculus     1 . . . 230   179/233 (76%)           (Mouse), 242 aa.                  
 
     [0784] PFam analysis predicts that the NOV87a protein contains the domains shown in the Table 87F.  
               TABLE 87F                          Domain Analysis of NOV87a                                     Identities/                   Similarities           NOV87a Match   for the   Expect       Pfam Domain   Region   Matched Region   Value                                         CH: domain 1 of 1    23 . . . 123   27/124   (22%)   0.068               65/124   (52%)       calponin:   159 . . . 183   17/26   (65%)   3.8e−07       domain 1 of 2       21/26   (81%)       calponin:   198 . . . 223   15/26   (58%)     3e−08       domain 2 of 2       19/26   (73%)                  
 
     Example 88  
     [0785] The NOV88 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 88A.  
               TABLE 88A                       NOV 88 Sequence Analysis                                                SEQ ID NO: 247   2213 bp                                     NOV88a,     CGTGAGGCACCCACTCTGGGAGCACAGAGAGCTCAGGTAGCCTGCCTAG   ATG GCGGCG           CG59671-02 DNA Sequence           CGCACCCTGGGCCGCGGCGTCGGGAGGCTGCTGGGCAGCCTGCGAGGGCTCTCGGGGC                   AGCCCGCGCGGCCGCCGTGCGGGGTGAGCGCGCCGCGCAGGGCGGCCTCGGGACCCTC                   GGGCAGCGCTCCCGCAGTTGCAGCAGCAGCAGCACAGCCAGGCTCGTATCCCGCGCTG                   AGTGCACAGGCAGCCCGGGAGCCGGCCGCCTTCTGGGGGCCTCTGGCGCGGGACACTC                   TCGTGTGGGACACCCCCTACCACACCGTCTGGGACTGCGACTTCAGCACTGGCAAGAT                   CGGCTGGTTCCTGGGAGGCCAGTTAAATGTCTCTGTCAACTGCTTGGACCAGCATGTT                   CGGAAGTCCCCCGAGAGCGTTGCTTTGATCTGGGAGCGCGATGAGCCTGGAACGGAAG                   TGAGGATCACCTACAGGGAACTACTGGAGACCACGTGCCGCCTGGCCAACACGCTGAA                   GAGGCATGGAGTCCACCGTGGGGACCGTGTTGCCATCTACATGCCCGTGTCCCCATTG                   GCTGTGGCAGCAATGCTGGCCTGTGCCAGGATCGGAGCTGTCCACACAGTCATCTTTG                   CTGGCTTCAGTGCAGAGTCCTTGGCTGGGAGGATCAATGATGCCAAGTGCAAGGTGGT                   TATCACCTTCAACCAAGGACTCCGGGGTGGGCGCGTGGTGGAGCTGAAGAAAATAGTG                   GATGAGGCTGTGAAGCACTGCCCCACCGTGCAGCATGTCCTGGTGGCTCACAGGACAG                   ACAACAAGGTCCACATGGGGGATCTGGACGTCCCGCTGGAGCAGGAAATGGCCAAGGA                   GGACCCTGTTTGCGCCCCAGAGAGCATGGGCAGTGAGGACATGCTCTTCATGCTGTAC                   ACCTCAGGGAGCACCGGAATGCCCAAGGGCATCGTCCATACCCAGGCAGGCTACCTGC                   TCTATGCCGCCCTGACTCACAAGCTTGTGTTTGACCACCAGCCAGGTGACATCTTTGG                   CTGTGTGGCCGACATCGGTTGGATTACAGGACACAGCTACGTGGTGTATGGGCCTCTC                   TGCAATGGTGCCACCAGCGTCCTTTTTGAGAGCACCCCAGTTTATCCCAATGCTGGTC                   GGTACTGGGAGACAGTAGAGAGGTTGAAGATCAATCAGTTCTATGGCGCCCCAACGGC                   TGTCCGGCTGTTGCTGAAATACGGTGATGCCTGGGTGAAGAAGTATGATCGCTCCTCC                   CTGCGGACCCTGGGGTCAGTGGGAGAGCCCATCAACTGTGAGGCCTGGGAGTGGCTTC                   ACAGGGTGGTGGGGGACAGCAGGTGCACGCTGGTGGACACCTGGTGGCAGACAGAAAC                   AGGTGGCATCTGCATCGCACCACGGCCCTCGGAAGAAGGGGCGGAAATCCTCCCTGCC                   ATGGCGATGAGGCCCTTCTTTGGCATCGTCCCCGTCCTCATGGATGAGAAGGGCAGCG                   TCGTGGAGGGCAGCAACGTCTCCGGGGCCCTGTGCATCTCCCAGGCCTGGCCGGGCAT                   GGCCAGGACCATCTATGGCGACCACCAGCGATTTGTGGACGCCTACTTCAAGGCCTAC                   CCAGGCTATTACTTCACTGGAGACGGGGCTTACCGAACTGAGGGCGGCTATTACCAGA                   TCACAGGGCGGATGGATGATGTCATCAACATCAGTGGCCACCGGCTGGGGACCGCAGA                   GATTGAGGACGCCATCGCCGACCACCCTGCAGTACCAGAAAGTGCTGTCATTGGCTAC                   CCCCACGACATCAAAGGAGAAGCTGCCTTTGCCTTCATTGTGGTGAAAGATAGTGCGG                   GTGACTCAGATGTGGTGGTGCAGGAGCTCAAGTCCATGGTGGCCACCAAGATCGCCAA                   ATATGCTGTGCCTGATGAGATCCTGGTGGTGAAACGTCTTCCAAAAACCAGGTCTGGG                   AAGGTCATGCGGCGGCTCCTGAGGAAGATCATCACTAGTGAGGCCCAGGAGCTGGGAG                   ACACTACCACCTTGGAGGACCCCAGCATCATCGCAGAGATCCTGAGTGTCTACCAGAA                   GTGCAAGGACAAGCAGGCTGCTGCTAAG TGA   GCTGGCACCTTGTGGGGCTCTTGGGAT                       GGGCGGGCACCCAAGCCCTGGCTTGTCCTTCCCAGAAGGTACCCCTGAGGTTGGCGTC                       TTCCTACGT                                                   ORF Start: ATG at 50   ORF Stop: TGA at 2117                                     SEQ ID NO: 248   689 aa   MW at 74855.9 kD                                     NOV88a,   MAARTLGRGVGRLLGSLRGLSGQPARPPCGVSAPRRAASGPSGSAPAVAAAAAQPGSY           CG59671-02 Protein Sequence           PALSAQAAREPAAFWGPLARDTLVWDTPYHTVWDCDFSTGKIGWFLGGQLNVSVNCLD                   QHVRKSPESVALIWERDEPGTEVRITYRELLETTCRLANTLKRHGVHRGDRVAIYMPV                   SPLAVAAMLACARIGAVHTVIFAGFSAESLAGRINDAKCKVVITFNQGLRGGRVVELK                   KIVDEAVKHCPTVQHVLVAHRTDNKVHMGDLDVPLEQEMAKEDPVCAPESMGSEDMLF                   MLYTSGSTGMPKGIVHTQAGYLLYAALTHKLVFDHQPGDIFGCVADIGWITGHSYVVY                   GPLCNGATSVLFESTPVYPNAGRYWETVERLKINQFYGAPTAVRLLLKYGDAWVKKYD                   RSSLRTLGSVGEPINCEAWEWLHRVVGDSRCTLVDTWWQTETGGICIAPRPSEEGAEI                   LPAMAMRPFFGIVPVLMDEKGSVVEGSNVSGALCISQAWPGMARTIYGDHQRFVDAYF                   KAYPGYYFTGDGAYRTEGGYYQITGRMDDVINISGHRLGTAEIEDAIADHPAVPESAV                   IGYPHDIKGEAAFAFIVVKDSAGDSVVVQELKSMVATKIAKYAVPDEILVVKKRLPKT                   RSGKVMRRLLRKIITSEAQELGDTTTLEDPSIIAEILSVYQKCKDKQAAAK                  
 
     [0786] Further analysis of the NOV88a protein yielded the following properties shown in Table 88B.  
               TABLE 88B                       Protein Sequence Properties NOV88a                                        PSort   0.6500 probability located in plasma membrane; 0.6000       analysis:   probability located in nucleus; 0.4340 probability           located in mitochondrial inner membrane; 0.3000           probability located in Golgi body       SignalP   Likely cleavage site between residues 23 and 24       analysis:                  
 
     [0787] A search of the NOV88a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 88C.  
               TABLE 88C                          Geneseq Results for NOV88a                                         NOV88a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAU23058   Novel human enzyme polypeptide   26 . . . 689   663/664   (99%)   0.0           #144 -  Homo sapiens , 664 aa.    1 . . . 664   663/664   (99%)           [WO200155301-A2, 2 AUG           2001]       AAB34712   Human secreted protein encoded   172 . . . 689    518/518   (100%)   0.0           by DNA clone vo9 1 -  Homo      1 . . . 518   518/518   (100%)             sapiens , 518 aa. [WO200055375-           A1, 21 SEP 2000]       AAU23050   Novel human enzyme polypeptide   224 . . . 689    459/466   (98%)   0.0           #136 -  Homo sapiens , 479 aa.   18 . . . 479   461/466   (98%)           [WO200155301-A2, 2 AUG           2001]       ABB12253   Human acetate-coA ligase    1 . . . 446   446/446   (100%)   0.0           homologue, SEQ ID NO:2623 -    1 . . . 446   446/446   (100%)             Homo sapiens , 446 aa.           [WO200157188-A2, 9 AUG           2001]       AAR23968   facA gene product - Penicillium   58 . . . 684   305/629   (48%)   e−175           chrysogenum, 669 aa.   45 . . . 669   407/629   (64%)           [WO9207079-A, 30 APR 1992]                  
 
     [0788] In a BLAST search of public sequence databases, the NOV88a protein was found to have homology to the proteins shown in the BLASTP data in Table 88D.  
               TABLE 88D                          Public BLASTP Results for NOV88a                                         NOV88A   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                             Q99NB1   ACETYL-COA SYNTHETASE 2 -   1 . . . 687   599/687   (87%)   0.0             Mus musculus  (Mouse), 682 aa.   1 . . . 680   638/687   (92%)       Q9BEA3   ACETYL-COA SYNTHETASE 2 -   1 . . . 689   575/689   (83%)   0.0             Bos taurus  (Bovine), 675 aa.   1 . . . 675   625/689   (90%)       Q9NUB1   DJ568C11.3 (NOVEL AMP-   212 . . . 689    478/478   (100%)   0.0           BINDING ENZYME SIMILAR TO   1 . . . 478   478/478   (100%)           ACETYL-COENZYME A           LIGASE)) -  Homo sapiens  (Human),           478 aa (fragment).       Q96JI1   KIAA1846 PROTEIN -  Homo     336 . . . 689    354/354   (100%)   0.0             sapiens  (Human), 354 aa (fragment).   1 . . . 354   354/354   (100%)       Q9HV66   ACETYL-COENZYME A   58 . . . 675    326/619   (52%)   0.0           SYNTHETASE -  Pseudomonas     24 . . . 639    433/619   (69%)             aeruginosa , 645 aa.                  
 
     [0789] PFam analysis predicts that the NOV88a protein contains the domains shown in the Table 88E.  
               TABLE 88E                          Domain Analysis of NOV88a                                     Identities/                   Similarities           NOV88a Match   for the   Expect       Pfam Domain   Region   Matched Region   Value               AMP-binding:   142 . . . 580   121/441 (27%)   7.1e−117       domain 1 of 1       341/441 (77%)                  
 
     Example 89  
     [0790] The NOV89 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 89A.  
               TABLE 89A                       NOV89 Sequence Analysis                                                SEQ ID NO: 249   1268 bp                                     NOV89a,     ACTTCTTTCTTTTCTGTTTCAGAGTTACTGATTTATTCTTGAGATTCCTCTACTCTCG             CG56870-01 DNA Sequence             TTATCTGACCTC   ATG GATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCACTTC                   TAAATGATAAGAATGGTACAAGAAACTTCCAGGACTTTGACTGTCAGGAACATGATAT                   AGAAACAACTCATGGTGTGGTCCACGTCACTATAAGAGGCTTACCCAAAGGAAACAGA                   CCAGTTATACTAACATATCATGACATTGGCCTCAACCGTAAATCCTGTTTCAATGCAT                   TCTTTAACTTTGAGGATATGCAAGAGATCACCCAGCACTTTGCTGTCTGTCATGTGGA                   TGCCCCAGGCCAGCAGGAAGGTGCACCCTCTTTCCCAACAGGGTATCAGTACCCCACA                   ATGGATGAGCTGGCTGAAATGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAAGCA                   TCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAACCA                   TCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGCTGG                   ATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTATTT                   TGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAACCTA                   CAGAATGCATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAATTCC                   TACAATGGGCGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATAACA                   AATCAAAAACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGCAGT                   TGAGGCTGTGGTCGAATGCAATTCCCGCCTGAACCCTATAAATACAACTTTGCTAAAG                   ATGGCGGACTGTGGGGGACTGCCCCAGGTAGTTCAGCCTGGGAAGCTCACCGAGGCCT                   TCAAGTACTTTTTGCAGGGAATGGGCTACGTCCCGTCTGCCAGCATGACTCGGCTCGC                   CCGATCACGAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAGTCCCTTCAGC                   CGGTCTGTCACCAGCAATCAGTCAGATGGAACTCAAGAATCCTGTGAGTCCCCTGATG                   TCCTGGACAGACACCAGACCATGGAGGTGTCCTGC TAA   GCAGATGCTCCTCCCCTGGA                       CCATTGCAAGTCCATCCTTCAAATGACCACTCCATAATATAACATTTCAT                                                   ORF Start: ATG at 71   ORF Stop: TAA at 1196                                     SEQ ID NO: 250   375 aa   MW at 41413.3 kD                                     NOV89a,   MDELQDVQLTEIKPLLNDKNGTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVIL           CG56870-01 Protein Sequence           TYHDIGLNRKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDEL                   AEMLPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWA                   ASKLSGLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGR                   RDLEIERPILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADC                   GGLPQVVQPGKLTEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVT                   SNQSDGTQESCESPDVLDRHQTMEVSC                                             SEQ ID NO: 251   1175 bp                                     NOV89b,     TCGTTATCTGACCTC   ATG GATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCAC           CG56870-02 DNA Sequence           TTCTAAATGATAAGAATGGTACAAGAAACTTCCAGGACTTTGACTGTCAGGAACATGA                   TATAGAAACAACTCATGGTGTGGTCCACGTCACTATAAGAGGCTTACCCAAAGGAAAC                   AGACCAGTTATACTAACATATCATGACATTGGCCTCAACCATAAATCCTGTTTCAATG                   CATTCTTTAACTTTGAGGATATGCAAGAGATCACCCAGCACTTTGCTGTCTGTCATGT                   GGATGCCCCAGGCCAGCAGGAAGGTGCACCCTCTTTCCCAACAGGGTATCAGTACCCC                   ACAATGGATGAGCTGGCTGAAGTGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAA                   GCATCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAA                   CCATCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGC                   TGGATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTA                   TTTTGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAAC                   CTACAGAATGCATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAAT                   TCCTACAATGGACGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATA                   ACAAATCAAAAACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGC                   AGTTGAGGCTGTGGTCGAATGCAATTCCCGCCTGAACCCTATAAATACAACTTTGCTA                   AAGATGGCGGACTGTGGGGGACTGCCCCAGGTAGTTCAGCCTGGGAAGCTCACCGAGG                   CCTTCAAGTACTTTTTGCAGGGAATGGGCTACATACCATCTGCCAGCATGACTCGGCT                   CGCCCGATCACGAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAGTCCCTTC                   AGCCGGTCTGTCACCAGCAATCAGTCAGATGGAACTCAAGAATCCTGTGAGTCCCCTG                   ATGTCCTGGACAGACACCAGACCATGGAGGTGTCCTGC TAA   GCAGATGCTCCTCCCCT                       GGACCATTGCAAGTC                                                   ORF Start: ATG at 16   ORF Stop: TAA at 1141                                     SEQ ID NO: 252   375 aa   MW at 41376.2 kD                                     NOV89b,   MDELQDVQLTEIKPLLNDKNGTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVIL           CG56870-02 Protein Sequence           TYHDIGLNHKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDEL                   AEVLPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWA                   ASKLSGLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGR                   RDLEIERPILGQNDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADC                   GGLPQVVQPGKLTEAFKYFLQGMGYIPSASMTRLARSRTHSTSSSLGSGESPFSRSVT                   SNQSDGTQESCESPDVLDRHQTMEVSC                                             SEQ ID NO: 253   1232 bp                                     NOV89c,     ACTTCTTTCTTTTCTGTTTCAGAGTTACTGATTTATTCTTGAGATTCCTCTACTCTCG             CG56870-03 DNA Sequence             TTATCTGACCTC   ATG GATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCACTTC                   TAAATGATAAGGAACATGATATAGAAACAACTCATGGTGTGGTCCACGTCACTATAAG                   AGGCTTACCCAAAGGAAACAGACCAGTTATACTAACATATCATGACATTGGCCTCAAC                   CATAAATCCTGTTTCAATGCATTCTTTAACTTTGAGGATATGCAAGAGATCACCCAGC                   ACTTTGCTGTCTGTCATGTGGATGCCCCAGGCCAGCAGGAAGGTGCACCCTCTTTCCC                   AACAGGGTATCAGTACCCCACAATGGATGAGCTGGCTGAAATGCTGCCTCCTGTTCTT                   ACCCACCTAAGCCTGAAAAGCATCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCC                   TCAGCAGATTTGCACTCAACCATCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGT                   TGACCCTTGCGCTAAAGGCTGGATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACA                   ACCAATGTTGTGGACATTATTTTGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCA                   ACCTGGACCTGATCCAAACCTACAGAATGCATATTGCCCAAGACATCAACCAAGACAA                   CCTGCAGCTCTTCTTGAATTCCTACAATGGGCGCAGAGACCTGGAGATCGAAAGACCC                   ATACTGGGCCAAAATGATAACAAATCAAAAACATTAAAGTGTTCTACTTTACTGGTGG                   TAGGGGACAATTCGCCTGCAGTTGAGGCTGTGGTCGAATGCAATTCCCGCCTGAACCC                   TATAAATACAACTTTGCTAAAGATGGCGGACTGTGGGGGACTGCCCCAGGTAGTTCAG                   CCTGGGAAGCTCACCGAGGCCTTCAAGTACTTTTTGCAGGGAATGGGCTACGTCCCGT                   CTGCCAGCATGACTCGGCTCGCCCGATCACGAACCCACTCAACCTCGAGTAGCCTCGG                   CTCTGGAGAAAGTCCCTTCAGCCGGTCTGTCACCAGCAATCAGTCAGATGGAACTCAA                   GAATCCTGTGAGTCCCCTGATGTCCTGGACAGACACCAGACCATGGAGGTGTCCTGC T                       AA   GCAGATGCTCCTCCCCTGGACCATTGCAAGTCCATCCTTCAAATGACCACTCCATA                       ATATAACATTTCAT                                                   ORF Start: ATG at 71   ORF Stop: TAA at 1160                                     SEQ ID NO: 254   363 aa   MW at 39967.8 kD                                     NOV89c,   MDELQDVQLTEIKPLLNDKEHDIETTHGVVHVTIRGLPKGNRPVILTYHDIGLNHKSC           CG56870-03 Protein Sequence           FNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDELAEMLPPVLTHLS                   LKSEEGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGLTTNVV                   DIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPILGQ                   NDNKSKTLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGKL                   TEAFKYFLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCE                   SPDVLDRHQTMEVSC                                             SEQ ID NO: 255   1220 bp                                     NOV89d,     ACTTCTTTCTTTTCTGTTTCAGAGTTACTGATTTATTCTTGAGATTCCTCTACTCTCG             CG56870-04   DNA Sequence             TTATCTGACCTC   ATG GATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCACTTC                   TAAATGATAAGAATGGTACAAGAAACTTCCAGGACTTTGACTGTCAGGAACATGATAT                   AGAAACAACTCATGGTGTGGTCCACGTCACTATAAGAGGCTTACCCAAAGGAAACAGA                   CCAGTTATACTAACATATCATGACATTGGCCTCAACCGTAAATCCTGTTTCAATGCAT                   TCTTTAACTTTGAGGATATGCAAGAGATCACCCAGCACTTTGCTGTCTGTCATGTGGA                   TGCCCCAGGCCAGCAGGAAGGTGCACCCTCTTTCCCAACAGGGTATCAGTACCCCACA                   ATGGATGAGCTGGCTGAAATGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAAGCA                   TCATTGGAATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAACCA                   TCCAGAGCTTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGCTGG                   ATTGACTGGGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTATTT                   TGGCTCATCACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAACCTA                   CAGAATGCATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAATTCC                   TACAATGGACGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATAACA                   AATCAAAAACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGCAGT                   TGAGGCTGTGATGGCGGACTGTGGGGGACTGCCCCAGGTAGTTCAGCCTGGGAAGTTC                   ACCGAGGCCTTCAAGTACTTTTTGCAGGGAATGGGCTACACACCATCTGCCAGCATGA                   CTCGGCTCGCCCGATCACGAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAG                   TCCCTTCAGCCGGTCTGTCACCAGCAATCAGTCAGATGGAACTCAAGAATCCTGTGAG                   TCCCCTGATGTCCTGGACAGACACCAGACCATGGAGGTGTCCTGC TAA   GCAGATGCTC                       CTCCCCTGGACCATTGCAAGTCCATCCTTCAAATGACCACTCCATAATATAACATTTC                       AT                                                   ORF Start: ATG at 71   ORF Stop: TAA at 1148                                     SEQ ID NO: 256   359 aa   MW at 39652.2 kD                                     NOV89d,   MDELQDVQLTEIKPLLNDKNGTRNFQDFDCQEHDIETTHGVVHVTIRGLPKGNRPVIL           CG56870-04 Protein Sequence           TYHDIGLNRKSCFNAFFNFEDMQEITQHFAVCHVDAPGQQEGAPSFPTGYQYPTMDEL                   AEMLPPVLTHLSLKSIIGIGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWA                   ASKLSGLTTNVVDIILAHHFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGR                   RDLEIERPILGQNDNKSKTLKCSTLLVVGDNSPAVEAVMADCGGLPQVVQPGKFTEAF                   KYFLQGMGYTPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCESPDV                   LDRHQTMEVSC                                             SEQ ID NO: 257   970 bp                                     NOV89e,     ATG GATGAACTTCAGGATGTTCAGCTCACAGAGATCAAACCACTTCTAAATGATAAGA           CG56870-05 DNA Sequence           ATGGTACAAGAAACTTCCAGGACTTTGACTGTCAGTATCAGTACCCCACAATGGATGA                   GCTGGCTGAAATGCTGCCTCCTGTTCTTACCCACCTAAGCCTGAAAAGCATCATTGGA                   ATTGGAGTTGGAGCTGGAGCTTACATCCTCAGCAGATTTGCACTCAACCATCCAGAGC                   TTGTGGAAGGCCTTGTGCTCATTAATGTTGACCCTTGCGCTAAAGGCTGGATTGACTG                   GGCAGCTTCCAAACTCTCTGGCCTGACAACCAATGTTGTGGACATTATTTTGGCTCAT                   CACTTTGGGCAGGAAGAGTTACAGGCCAACCTGGACCTGATCCAAACCTACAGAATGC                   ATATTGCCCAAGACATCAACCAAGACAACCTGCAGCTCTTCTTGAATTCCTACAATGG                   GCGCAGAGACCTGGAGATCGAAAGACCCATACTGGGCCAAAATGATAACAAATCAAAA                   ACATTAAAGTGTTCTACTTTACTGGTGGTAGGGGACAATTCGCCTGCAGTTGAGGCTG                   TGGTCGAATGCAATTCCCGCCTGAACCCTATAAATACAACTTTGCTAAAGATGGCGGA                   CTGTGGGGGACTGCCCCAGGTAGTTCAGCCTGGGAAGCTCACCGAGGCCTTCAAGTAC                   TTTTTGCAGGGAATGGGCTACGTCCCGTCTGCCAGCATGACTCGGCTCGCCCGATCAC                   GAACCCACTCAACCTCGAGTAGCCTCGGCTCTGGAGAAAGTCCCTTCAGCCGGTCTGT                   CACCAGCAATCAGTCAGATGGAACTCAAGAATCCTGTGAGTCCCCTGATGTCCTGGAC                   AGACACCAGACCATGGAGGTGTCCTGC TAA   GCAGATGCTCCTCCCCTGGACCATTGCA                       AGTCCATCCTTCAAATGACCACTCCATAATATAACATTTCAT                                                   ORF Start: ATG at 1   ORF Stop: TAA at 898                                     SEQ ID NO: 258   299 aa   MW at 32956.9 kD                                     NOV89e,   MDELQDVQLTEIKPLLNDKNGTRNFQDFDCQYQYPTMDELAEMLPPVLTHLSLKSIIG           CG56870-05 Protein Sequence           IGVGAGAYILSRFALNHPELVEGLVLINVDPCAKGWIDWAASKLSGLTTNVVDIILAH                   HFGQEELQANLDLIQTYRMHIAQDINQDNLQLFLNSYNGRRDLEIERPILGQNDNKSK                   TLKCSTLLVVGDNSPAVEAVVECNSRLNPINTTLLKMADCGGLPQVVQPGKLTEAFKY                   FLQGMGYVPSASMTRLARSRTHSTSSSLGSGESPFSRSVTSNQSDGTQESCESPDVLD                  
 
     [0791] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 89B.  
               TABLE 89B                          Comparison of NOV89a against NOV89b through NOV89e.                                         Identities/           Protein   NOV89a Residues/   Similarities for           Sequence   Match Residues   the Matched Region                       NOV89b    1 . . . 375   336/375 (89%)                1 . . . 375   338/375 (89%)           NOV89c    1 . . . 375   326/375 (86%)                1 . . . 363   326/375 (86%)           NOV89d    1 . . . 375   321/375 (85%)                1 . . . 359   321/375 (85%)           NOV89e   104 . . . 375   233/272 (85%)                28 . . . 299   233/272 (85%)                      
 
     [0792] Further analysis of the NOV89a protein yielded the following properties shown in Table 89C.  
               TABLE 89C                       Protein Sequence Properties NOV89a                                        PSort   0.4500 probability located in cytoplasm; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1685 probability located           in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0793] A search of the NOV89a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 89D.  
               TABLE 89D                          Geneseq Results for NOV89a                                         NOV89a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAM94019   Human stomach cancer expressed    1 . . . 375   360/375 (96%)   0.0           polypeptide SEQ ID NO 108-    1 . . . 363   361/375 (96%)             Homo sapiens , 363 aa.           [WO200109317-A1, 8 FEB. 2001]       AAG64392   Human reducing agent and    1 . . . 375   360/375 (96%)   0.0           tunicamycin-responsive protein 40-    1 . . . 363   361/375 (96%)             Homo sapiens , 363 aa.           [WO200155375-A1,           2 AUG. 2001]       AAB94494   Human protein sequence SEQ ID    1 . . . 375   360/375 (96%)           NO: 15186- Homo sapiens , 363 aa.    1 . . . 363   361/375 (96%)           [EP1074617-A2, 7 FEB. 2001]       AAU31598   Novel human secreted protein    68 . . . 374   282/323 (87%)   e−154           #2089- Homo sapiens , 395 aa.    1 . . . 307   286/323 (88%)           [WO200179449-A2,           25 OCT. 2001]       AAB95462   Human protein sequence SEQ ID   133 . . . 375   240/243 (98%)   e−138           NO: 17944- Homo sapiens , 286 aa.    44 . . . 286   242/243 (98%)           [EP1074617-A2, 7 FEB. 2001]                  
 
     [0794] In a BLAST search of public sequence databases, the NOV89a protein was found to have homology to the proteins shown in the BLASTP data in Table 89E.  
               TABLE 89E                          Public BLASTP Results for NOV89a                                         NOV89a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Numer   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9UGV2   NDRG3 protein- Homo sapiens     1 . . . 375   373/375 (99%)   0.0           (Human), 375 aa.   1 . . . 375   374/375 (99%)       Q96PL8   NDR1-RELATED   1 . . . 375   372/375 (99%)   0.0           DEVELOPMENT PROTEIN NDR3-   1 . . . 375   373/375 (99%)             Homo sapiens  (Human), 375 aa.       Q9QYF9   NDRG3 protein (Ndr3 protein)-   1 . . . 375   358/375 (95%)   0.0             Mus musculus  (Mouse), 375 aa.   1 . . . 375   368/375 (97%)       AAH18504   SIMILAR TO N-MYC   1 . . . 375   359/388 (92%)   0.0           DOWNSTREAM REGULATED 3-   1 . . . 388   368/388 (94%)             Mus musculus  (Mouse), 388 aa.       Q96SM2   CDNA FLJ14759 FIS, CLONE   1 . . . 375   360/375 (96%)   0.0           NT2RP3003290, MODERATELY   1 . . .363   361/375 (96%)           SIMILAR TO  MUS MUSCULUS             NDR1 RELATED PROTEIN NDR3-             Homo sapiens  (Human), 363 aa.                  
 
     [0795] PFam analysis predicts that the NOV89a protein contains the domains shown in the Table 89F.  
               TABLE 89F                          Domain Analysis of NOV89a                                     Identities/           Pfam   NOV89a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               Orn_Arg_deC_N:   62 . . . 89    7/33 (21%)   1.9       domain 1 of 1        24/33 (73%)       abhydrolase:   87 . . . 310    48/239 (20%)   0.0066       domain 1 of 1       142/239 (59%)       Ndr: domain 1 of 1   22 . . . 346   210/340 (62%)   3.7e−211               311/340 (91%)                  
 
     Example 90  
     [0796] The NOV90 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 90A.  
               TABLE 90A                       NOV90 Sequence Analysis                                                SEQ ID NO: 259   632 bp                                     NOV90a,     GAAACTATAAAGGGTCCGAACCCTCTTTTAAAGGATCCCA   ATG CATTTCTTTGATCCC           CG59764-01 DNA Sequence           TCGCCGGTGCGACGGTACCACCATCCCAGCTGTGAGGCTGCCATCAACACCCACATCA                   GCCTGGAGCTCCACGCATCCTATGTGTACCTGTCCATGGCCTTCTACTTCGACCAGGA                   CGACGCGGCCCTGGAGCACTTTGACCGCTACTTCCTGCGCCAGTCGCAGGAGAAAAGG                   GAGCACGCCCAGGAGCTGATGAGCCTGCAGAACCTGCGCGGTGGCCGCATCTGCCTTC                   ATGACATCAGGAAGCCAGAGGGCCAAGGCTGGGAGAGCGGGCTCAAGGCCATGGAGTG                   CACCTTCCACCTGGAGAAGAACATCAACCAGAGCCTCCTGGAGCTGCACCAGCTGGCC                   AGGGAGAACGGCGACCCCCAGCTCTGCGACTTCCTGGAGAACGACTTCCTGAACCAGC                   AGGCCAAGACCATCAAAGAGCTGGGTGGCTACCTGAGCAACCTGCACAAGATGGGGGC                   CCCGGAAGCAGGCCTGGCAGAGTACCTCTTTAACAAGCTCACCCTGGGCCGCAGCGAA                   CCACTTCCT TGA   ACCAGCAGGCCAAGACCATCAAAGAGATTGGTGGCTACCT                                                   ORF Start: ATG at 41   ORF Stop: TGA at 590                                     SEQ ID NO: 260   183 aa   MW at 21159.6 kD                                     NOV90a,   MHFFDPSPVRRYHHPSCEAAINTHISLELHASYVYLSMAFYFDQDDAALEHFDRYFLR           CG59764-01 Protein Sequence           QSQEKREHAQELMSLQNLRGGRICLHDIRKPEGQGWESGLKAMECTFHLEKNINQSLL                   ELHQLARENGDPQLCDFLENDFLNQQAKTIKELGGYLSNLHKMGAPEAGLAEYLFNKL                   TLGRSEPLP                  
 
     [0797] Further analysis of the NOV90a protein yielded the following properties shown in Table 90B.  
               TABLE 90B                       Protein Sequence Properties NOV90a                                        PSort   0.4500 probability located in cytoplasm; 0.1400 probability       analysis:   located in microbody (peroxisome); 0.1000 probability located           in mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0798] A search of the NOV90a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 90C.  
               TABLE 90C                          Geneseq Results for NOV90a                                         NOV90a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAU07889   Polypeptide sequence for human    7 . . . 180   159/174 (91%)   4e−91           hspG34a- Homo sapiens , 221 aa.   45 . . . 218   164/174 (93%)           [WO200166752-A2,           13 SEP. 2001]       AAU07890   Polypeptide sequence for human    6 . . . 177   125/172 (72%)   6e−70           hspG34b- Homo sapiens , 183 aa.    6 . . . 177   149/172 (85%)           [WO200166752-A2,           13 SEP. 2001]       AAB90804   Human shear stress-response    7 . . . 180   114/174 (65%)   6e−64           protein SEQ ID NO: 108- Homo      7 . . . 180   141/174 (80%)             sapiens , 183 aa. [WO200125427-           A1, 12 APR. 2001]       AAR71567   Human monocyte growth factor-    7 . . . 180   114/174 (65%)   6e−64             Homo sapiens , 183 aa.    7 . . . 180   141/174 (80%)           [JP07031482-A, 3 FEB. 1995]       AAU27741   Mouse full-length polypeptide    6 . . . 180   112/175 (64%)   5e−63           sequence #66- Mus musculus , 182    6 . . . 180   141/175 (80%)           aa. [WO200164834-A2,           7 SEP. 2001]                  
 
     [0799] In a BLAST search of public sequence databases, the NOV90a protein was found to have homology to the proteins shown in the BLASTP data in Table 90D.  
               TABLE 90D                          Public BLASTP Results for NOV90a                                         NOV90a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9BXU8   Ferritin heavy polypeptide-like 17-    6 . . . 177   125/172 (72%)   2e−69             Homo sapiens  (Human), 183 aa.    6 . . . 177   149/172 (85%)       P29389   Ferritin heavy chain (Ferritin H    6 . . . 180   115/175 (65%)   6e−64           subunit)- Cricetulus griseus     10 . . . 184   142/175 (80%)           (Chinese hamster), 185 aa.       A26886   ferritin heavy chain-chicken, 180    6 . . . 180   112/175 (64%)   1e−63           aa.    5 . . . 179   142/175 (81%)       P08267   Ferritin heavy chain (Ferritin H    6 . . . 180   112/175 (64%)   1e−63           subunit)- Gallus gallus  (Chicken),    4 . . . 178   142/175 (81%)           179 aa.       Q95MP7   FERRITIN- Canis familiaris      6 . . . 180   112/175 (64%)   2e−63           (Dog), 183 aa.    6 . . . 180   143/175 (81%)                  
 
     [0800] PFam analysis predicts that the NOV90a protein contains the domains shown in the Table 90E.  
               TABLE 90E                          Domain Analysis of NOV90a                                     Identities/           Pfam   NOV90a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               Bacteriofer:   14 . . . 159    35/172 (20%)   6.7       domain 1 of 1        76/172 (44%)       ferritin:   17 . . . 173    92/161 (57%)   4.7e−87       domain 1 of 1       138/161 (86%)                  
 
     Example 91  
     [0801] The NOV91 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 91A.  
               TABLE 91A                       NOV91 Sequence Analysis                                                SEQ ID NO: 261   487 bp                                     NOV91a,     TGCTGTGCGTTGTCTTTCCTTCTCACTCAAGCCTGTGAAATCTCTCTTTCAGGTTGAC             CG59710-01 DNA Sequence             AGACTA   ATG GAGTTGCATTTTAAATATCTGGGTGCAATGCAGGTGGCGGACAAGAAGA                   TTGAAGGGGAAAAACACGACATGGTCCGGCGAGGAGAGATCATCGACAATGACACCGA                   GGAGGAGTTCTACCTCCGGCGCCTGGATGCGGGGCTCTTTGTTCTCCAGCACATCTGC                   TACATCATGGCCGAGATCTGCAATGCCAATGTCCCCCAGATTCGCCAGAGGGTTCACC                   AGATCCTAAACATGCGAGGAAGCTCCATCAAAATTGTCAGGCATATCATCAAGGAGTA                   TGCAGAGAACATCGGGGACGGCCGGAGCCCGGAGTTCCGGGAGAACGAGCAAAAGCGC                   ATCCTGGGCTTGCTGGAGAACTTC TAG   AGGCACCTTGGCCCTGCGCATCATGGACTCT                       CTCAGCTTCCCTCCCAGGATCAG                                                   ORF Start: ATG at 65   ORF Stop: TAG at 431                                     SEQ ID NO: 262   122 aa   MW at 14385.4 kD                                     NOV91a,   MELHFKYLGAMQVADKKIEGEKHDMVRRGEIIDNDTEEEFYLRRLDAGLFVLQHICYI           CG59710-01 Protein Sequence               MAEICNANVPQIRQRVHQILNMRGSSIKIVRHIIKEYAENIGDGRSPEFRENEQKRIL                   GLLENF                  
 
     [0802] Further analysis of the NOV91a protein yielded the following properties shown in Table 91B.  
               TABLE 91B                       Protein Sequence Properties NOV91a                                        PSort   0.6500 probability located in cytoplasm; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0803] A search of the NOV91a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 91C.  
               TABLE 91C                          Geneseq Results for NOV91a                                         NOV91a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAU28058   Novel human secretory protein,    1 . . . 122   122/122 (100%)   1e−66           Seq ID No 227- Homo sapiens ,   397 . . . 518   122/122 (100%)           518 aa. [WO200166689-A2,           13 SEP. 2001]       AAM93729   Human polypeptide, SEQ ID NO:    1 . . . 122   122/122 (100%)   1e−66           3689- Homo sapiens , 563 aa.   442 . . . 563   122/122 (100%)           [EP1130094-A2, 5 SEP. 2001]       AAB63116   Human secreted protein sequence    1 . . . 119   119/119 (100%)   1e−64           encoded by gene 39 SEQ ID   283 . . . 401   119/119 (100%)           NO: 126 - Homo sapiens , 401 aa.           [WO200061748-A1,           19 OCT. 2000]       AAU28246   Novel human secretory protein,    1 . . . 118   104/120 (86%)   2e−51           Seq ID No 603- Homo sapiens ,   197 . . . 316   106/120 (87%)           360 aa. [WO200166689-A2,           13 SEP. 2001]       ABB21673   Protein #3672 encoded by probe    24 . . . 55    32/32 (100%)   1e−11           for measuring heart cell gene    1 . . . 132    32/32 (100%)           expression- Homo sapiens , 32 aa.           [WO200157274-A2,           9 AUG. 2001]                  
 
     [0804] In a BLAST search of public sequence databases, the NOV91a protein was found to have homology to the proteins shown in the BLASTP data in Table 91D.  
               TABLE 91D                          Public BLASTP Results for NOV91a                                         NOV91a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Numer   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96KD2   TESTES DEVELOPMENT-    1 . . . 122   122/122 (100%)   5e−66           RELATED NYD-SP19- Homo     255 . . . 376   122/122 (100%)             sapiens  (Human), 376 aa.       Q9H7A5   CDNA: FLJ21108 FIS, CLONE    1 . . . 122   121/122 (99%)   5e−65           CAS05257- Homo sapiens     104 . . . 225   121/122 (99%)           (Human), 225 aa.       O62703   P14- Bos taurus  (Bovine), 122 aa.    1 . . . 122   116/122 (95%)   2e−62                1 . . . 122   119/122 (97%)       Q9CWL8   5730471K09RIK PROTEIN- Mus      1 . . . 122   115/122 (94%)   3e−62             musculus  (Mouse), 563 aa.   442 . . . 563   118/122 (96%)       Q9Y3M7   DJ633O20.1 (P14L, SIMILAR TO    1 . . . 93    93/93 (100%)   3e−48             BOS TAURUS  P14)- Homo     192 . . . 284    93/93 (100%)             sapiens  (Human), 284 aa           (fragment).                  
 
     [0805] PFam analysis predicts that the NOV91a protein contains the domains shown in the Table 91E.  
               TABLE 91E                          Domain Analysis of NOV91a                                             Identities/               Pfam   NOV91a   Similarities for   Expect           Domain   Match Region   the Matched Region   Value                             No Significant Matches Found                  
 
     Example 92  
     [0806] The NOV92 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 92A.  
               TABLE 92A                       NOV92 Sequence Analysis                                                SEQ ID NO:263   6527 bp                     NOV92a,     CCACAGAGGGGAAATGCCAGCTTCCCTCTCCCTGGGGCTCCGTGCCCCCTCTGATCCA         CG59754-02 DNA Sequence             GCCCTTCGAATTCCCACCCGCCTCCATCGGCCAGCTGCTCTACATTCCCTGTGTGGTG                       TCCTCGGGGGAC   ATG CCCATCCGTATCACCTGGAGGAAGGACGGACAGGTGATCATCT                   CAGGCTCGGGCGTGACCATCGAGAGCAAGGAATTCATGAGCTCCCTGCAGATCTCTAG                   CGTCTCCCTCAAGCACAACGGCAACTATACATGCATCGCCAGCAACGCAGCCGCCACC                   GTGAGCATTGTGTCTCCAGAACACAGGTTTTTTATTACCTACCACGGCGGGCTGTACA                   TCTCTGACGTACAGAAGGAGGACGCCCTCTCCACCTATCGCTGCATCACCAAGCACAA                   GTATAGCGGGGAGACCCGGCAGAGCAATGGGGCACGCCTCTCTGTGACAGACCCTGCT                   GAGTCGATCCCCACCATCCTGGATGGCTTCCACTCCCAGGAAGTGTGGGCCGGCCACA                   CCGTGGAGCTGCCCTGCACCGCCTCGGGCTACCCTATCCCCGCCATCCGCTGGCTCAA                   GGATGGCCGGCCCCTCCCGGCTGACAGCCGCTGGACCAAGCGCATCACAGGGCTGACC                   ATCAGCGACTTGCGGACCGAGGACAGCGGCACCTACATTTGTGAGGTCACCAACACCT                   TCGGTTCGGCAGAGGCCACAGGCATCCTCATGGTCATTGATCCCCTTCATGTGACCCT                   GACACCAAAGAAGCTGAAGACCGGCATTGGCAGCACGGTCATCCTCTCCTGTGCCCTG                   ACGGGCTCCCCAGAGTTCACCATCCGCTGGTATCGCAACACGGAGCTGGTGCTGCCTG                   ACGAGGCCATCTCCATCCGCGGGCTCAGCAACGAGACGCTGCTCATCACCTCGGCCCA                   GAAGAGCCATTCCGGGGCCTACCAGTGCTTCGCTACCCGCAAGGCCCAGACCGCCCAG                   GACTTTGCCATCATTGCACTTGAGGATGGCACGCCCCGCATCGTCTCGTCCTTCAGCG                   AGAAGGTGGTCAACCCCGGGGAGCAGTTCTCACTGATGTGTGCGGCCAAGGGCGCCCC                   GCCCCCCACGGTCACCTGGGCCCTCGACGATGAGCCCATCGTGCGGGATGGCAGCCAC                   CGCACCAACCAGTACACCATGTCGGACGGCACCACCATCAGCCACATGAACGTCACAG                   GCCCCCAGATCCGCGACGGGGGCGTGTACCGGTGCACAGCGCGGAACTTGGTGGGCAG                   TGCTGAATATCAGGCGCGAATAAACGTAAGAGGCCCACCCAGCATCCGGGCTATGCGG                   AACATCACAGCAGTCGCCGGGCGGGACACCCTTATCAACTGCAGGGTCATCGGCTATC                   CCTACTACTCCATCAAGTGGTACAAGGATGCCTTGCTGCTGCCAGACAACCACCGCCA                   GGTGGTGTTTGAGAATGGGACCCTCAAGCTGACTGACGTGCAGAAGGGCATGGATGAG                   GGGGAGTACCTGTGCAGTGTCCTCATCCAGCCCCAGCTCTCCATCAGCCAGAGCGTTC                   ACGTAGCCGTCAAAGTGCCCCCTCTGATCCAGCCCTTCGAATTCCCACCCGCCTCCAT                   CGGCCAGCTGCTCTACATTCCCTGTGTGGTGTCCTCGGGGGACATGCCCATCCGTATC                   ACCTGGAGGAAGGACGGACAGGTGATCATCTCAGGCTCGGGCGTGACCATCGAGAGCA                   AGGAATTCATGAGCTCCCTGCAGATCTCTAGCGTCTCCCTCAAGCACAACGGCAACTA                   TACATGCATCGCCAGCAACGCAGCCGCCACCGTGAGCCGGGAGCGTCAGCTCATCGTG                   CGTGTGCCCCCTCGATTTGTGGTGCAACCCAACAACCAGGATGGCATCTACGGCAAAG                   CTGGTGTGCTCAACTGCTCGGTGGACGGCTACCCCCCACCCAAGGTCATGTGGAAGCA                   TGCCAAGGGGAGCGGGAACCCCCAGCAGTACCACCCTGTGCCCCTCACTGGCCGCATC                   CAGATCCTGCCCAACAGCTCGCTGCTGATCCGCCACGTCCTAGAAGAGGACATCGGCT                   ACTACCTCTGCCAGGCCAGCAACGGCGTAGGCACCGACATCAGCAAGTCCATGTTCCT                   CACAGTCAAGATCCCGGCCATGATCACTTCCCACCCCAACACCACCATCGCCATCAAG                   GGCCATGCGAAGGAGCTAAACTGCACGGCACGGGGTGAGCGGCCCATCATCATCCGCT                   GGGAGAAGGGGGACACAGTCATCGACCCTGACCGCGTCATGCGGTATGCCATCGCCAC                   CAAGGACAACGGCGACGAGGTCGTCTCCACACTGAAGCTCAAGCCCGCTGACCGTGGG                   GACTCTGTGTTCTTCAGCTGCCATGCCATCAACTCGTATGGGGAGGACCGGGGCTTGA                   TCCAACTCACTGTGCAAGAGCCCCCCGACCCCCCAGAGCTGGAGATCCGGGAGGTGAA                   GGCCCGGAGCATGAACCTGCGCTGGACCCAGCGATTCGACGGGAACAGCATCATCACG                   GGCTTCGACATTGAATACAAGAACAAATCAGATTCCTGGGACTTCAAGCAGTCCACAC                   GCAACATCTCCCCCACCATCAACCAGGCCAACATTGTGGACTTGCACCCGGCATCTGT                   GTACAGCATCCGCATGTACTCTTTCAACAAGATTGGCCGCAGTGAACCAAGCAAGGAG                   CTCACCATCAGCACTGAGGAGGCCGCTCCCGATGGGCCCCCCATGGATGTTACCTTGC                   AGCCAGTGACCTCACAGAGCATCCAGGTGACCTGGAAGGCACCCAAGAAGGAGCTGCA                   GAACGGTGTCATCCGGGGCTACCAGATTGGCTACAGAGAGAACAGCCCCGGCAGCAAC                   GGGCAGTACAGCATCGTGGAGATGAAGGCCACGGGGGACAGCGAGGTCTACACCCTGG                   ACAACCTCAAGAAGTTCGCCCAGTATGGGGTGGTGGTCCAAGCCTTCAATCGGGCTGG                   CACGGGGCCCTCTTCCAGCGAGATCAATGCCACCACTCTGGAGGATGTGCCCAGCCAG                   CCCCCTGAGAACGTCCGGGCCCTGTCCATCACTTCTGACGTGGCCGTCATCTCCTGGT                   CAGAGCCCCCGCGCAGCACCCTCAATGGCGTCCTCAAAGGCTATCGGGTCATCTTCTG                   GTCCCTCTATGTTGATGGGGAGTGGGGCGAGATGCAGAACATCACCACCACGCGGGAG                   CGGGTGGAGCTGCGGGGCATGGAGAAGTTCACCAACTACAGCGTCCAGGTGCTGGCCT                   ACACCCAGGCTGGGGACGGCGTACGCAGCAGTGTGCTCTACATCCAGACCAAGGAGGA                   CGTTCCAGGTCCCCCTGCTGGCATCAAAGCTGTCCCTTCATCAGCTAGCAGTGTGGTT                   GTGTCTTGGCTCCCCCCTACCAAGCCCAACGGGGTGATCCGCAAGTACACCATCTTCT                   GTTCCAGCCCCGGGTCTGGCCAGCCGGCTCCCAGCGAGTACGAGACGAGTCCAGAGCA                   GCTCTTCTACCGGATCGCCCACCTAAACCGCGGTCAGCAGTATCTGCTGTGGGTGGCC                   GCCGTCACCTCTGCCGGCCGGGGCAACAGCAGCGAGAAGGTGACCATCGAGCCTGCTG                   GCAAGGCCCCAGCAAAGATCATCTCCTTTGGGGGCACCGTGACAACACCTTGGATGAA                   AGATGTTCGGCTGCCTTGCAATTCAGTGGGAGATCCAGCCCCTGCTGTGAAGTGGACC                   AAGGACAGTGAAGACTCGGCCATTCCAGTGTCCATGGATGGGCACCGGCTCATCCACA                   CCAATGGCACACTGCTGCTGCGTGCAGTGAAGGCTGAGGACTCTGGCTACTACACGTG                   CACGGCCACCAACACTGGTGGCTTTGACACCATCATCGTCAACCTTCTGGTGCAAGTT                   CCCCCGGACCAGCCCCGCCTCACTGTCTCCAAAACCTCAGCTTCGTCCATCACCCTGA                   CCTGGATTCCAGGTGACAATGGGGGCAGCTCCATCCGAGGCTTCGTGCTACAGTACTC                   GGTGGACAACAGCGAGGAGTGGAAGGATGTGTTCATCAGCTCCAGCGAGCGCTCCTTC                   AAGCTGGACAGCCTCAAGTGTGGCACGTGGTACAAGGTGAAGCTGGCAGCCAAGAACA                   GCGTGGGCTCTGGGCGCATCAGCGAGATCATCGAGGCCAAGACCCACGGGCGGGAGCC                   CTCCTTCAGCAAAGACCAACACCTCTTCACCCACATCAACTCCACGCATGCTCGGCTT                   AACCTGCAGGGCTGGAACAATGGGGGCTGCCCTATCACAGCCATCGTTCTGGAGTACC                   GGCCCAAGGGGACCTGGGCCTGGCAGGGCCTCCGGGCCAACAGCTCCGGGGAGGTGTT                   TCTGACGGAACTGCGAGAGGCCACGTGGTACGAGCTGCGCATGAGGGCTTGCAACAGT                   GCGGGCTGCGGCAATGAAACAGCCCAGTTCGCCACCCTGGACTACGATGGCAGCACCA                   TTCCACCCATCAAGTCTGCTCAAGGTGAAGGGGATGATGTGAAGAAGCTGTTCACCAT                   CGGCTGCCCTGTCATCCTGGCCACACTGGGGGTGGCACTGCTCTTCATCGTACGCAAG                   AAGAGGAAGGAGAAACGGCTGAAGCGACTCCGAGATGCAAAGAGTTTGGCAGAAATGT                   TGATAAGCAAGAACAATAGAAGCTTTGACACCCCTGTGAAAGGGCCACCCCAGGGCCC                   ACGGCTACACATTGACATCCCCAGGGTCCAGCTGCTCATCGAGGACAAAGAAGGCATC                   CTGTCAACCCACAGAGCTTCTGTACTGGCGTCTCCTTGCACCACCCAACCCTCATCCA                   GAGCACAGGACCCCTCATCGACATGTCTGACATCCGGCCAGGAACCAATCCAGTGTCC                   AGGAAGAATGTGAAGTCAGCCCACAGCACCCGGAACCGGTACTCAAGCCAGTGGACCC                   TGACCAAGTGCCAGGCCTCCACACCTGCCCGCACCCTCACCTCCGACTGGCGCACCGT                   GGGCTCCCAGCATGGTGTCACGGTCACTGAGAGTGACAGCTACAGTGCCAGCCTGTCC                   CAGGACACAGACAAAGGAAGGAACAGCATGGTGTCCACTGAGAGTGCCTCTTCCACCT                   ACGAGGAGCTGGCCCGGGCCTATGAGCATGCCAAGCTGGAGGAGCAGCTGCAGCACGC                   CAAGTTTGAGATCACCGAGTGCTTCATCTCTGACAGTTCCTCTGACCAGATGACCACA                   GGCACCAACGAGAACGCCGACAGCATGACATCCATGAGCACACCCTCAGAGCCTGGCA                   TCTGCCGCTTTACCGCCTCACCACCCAAGCCCCAGGATGCGGACCGGGGCAAAAACGT                   GGCTGTGCCCATCCCTCACCGGGCCAACAAGAGTGACTACTGCAACCTGCCCCTGTAT                   GCCAAGTCAGAGGCCTTCTTTCGAAAGGCAGATGGACGTGAGCCCTGCCCCGTGGTCC                   CACCCCGTGAGGCCTCCATCCGGAACCTGGCTCGAACCTACCACACCCAGGCTCGCCA                   CCTGACCCTGGACCCTGCCAGCAAGTCCTTGGGCCTTCCCCACCCAGGGGCCCCCGCT                   GCCGCCTCCACAGCCACCTTACCTCAGAGGACTCTGGCCATGCCAGCCCCCCCAGCCG                   GCACAGCCCCCCCAGCCCCCGGCCCCACCCCTGCTGAGCCACCCACCGCCCCCAGCGC                   TGCCCCTCCGGCCCCCAGCACCGAGCCTCCACGAGCCGGGGGCCCACACACCAAAATG                   GGGGGCTCCAGGGACTCGCTTCTCGAGATGAGCACATCGGGGGTAGGGAGGTCTCAGA                   AGCAGGGGGCCGGGGCCTACTCCAAATCCTACACCCTGGTG TAG   GGCCGGCAGGAAGA                       GCAGCCACGCCTGGGCCGCGCCGCGCCGCAGCCCCACACGCCAGCTCGGCTGTTTTTC                       TGCATTATTTATATTCAACTGACAGACAAAAACCAACCAACGACAAAACAAAAACCCC                       CAATCATGAACGCCTGTACATAGAACTCTTTTGTACAAATGAAACTATTTTCTTCTTC                       TCCATGAAGCCAGGGCACAAAGAATTTGACAGTACAAGTCAAATCCCCCACCCCACAA                       AATATGTGTGGAGATATATATACATATATAGACAGACAGGAACGCCTCCACGAGCTAT                       ATATCTATATATTTCTCTCACCCTATTTTGAGACAGAGGCACAAAGACTCAGCAATTT                       TTTTCCCTCCTCCTCACCTTCCCCCCAGTCTAGGTGGTTTTGACAAAGACCAAAATCC                       CAACTCAGAGACACTGCATGCGATTTTACTGTTCCAAGAAAACCAGGAGTTGCTTCAA                       TTTGCAGATGCTTATGTGTTAATACCTTTTTCTATGAAAAAAGACCCAGCGCCGTGTG                       CAATAAAGGTTATGTTTCCAAAAAAAAGCTT                                           ORF Start: ATG at 129       ORF Stop: TAG at 5958           SEQ ID NO:264   1943 aa   MW at 211904.3 kD                     NOV92a,   MPIRITWRKDGQVIISGSGVTIESKEFMSSLQISSVSLKHNGNYTCIASNAAATVSIV       CG59754-02 Protein       Sequence   SPEHRFFITYHGGLYISDVQKEDALSTYRCITKHKYSGETRQSNGARLSVTDPAESIP                   TILDGFHSQEVWAGHTVELPCTASGYPIPAIRWLKDGRPLPADSRWTKRITGLTISDL                   RTEDSGTYICEVTNTFGSAEATGILMVIDPLHVTLTPKKLKTGIGSTVILSCALTGSP                   EFTIRWYRNTELVLPDEAISIRGLSNETLLITSAQKSHSGAYQCFATRKAQTAQDFAI                   IALEDGTPRIVSSFSEKVVNPGEQFSLMCAAKGAPPPTVTWALDDEPIVRDGSHRTNQ                   YTMSDGTTISHMNVTGPQIRDGGVYRCTARNLVGSAEYQARINVRGPPSIRAMRNITA                   VAGRDTLINCRVIGYPYYSIKWYKDALLLPDNHRQVVFENGTLKLTDVQKGMDEGEYL                   CSVLIQPQLSISQSVHVAVKVPPLIQPFEFPPASIGQLLYIPCVVSSGDMPIRITWRK                   DGQVIISGSGVTIESKEFMSSLQISSVSLKHNGNYTCIASNAAATVSRERQLIVRVPP                   RFVVQPNNQDGIYGKAGVLNCSVDGYPPPKVMWKHAKGSGNPQQYHPVPLTGRIQILP                   NSSLLIRHVLEEDIGYYLCQASNGVGTDISKSMFLTVKIPAMITSHPNTTIAIKGHAK                   ELNCTARGERPIIIRWEKGDTVIDPDRVMRYAIATKDNGDEVVSTLKLKPADRGDSVF                   FSCHAINSYGEDRGLIQLTVQEPPDPPELEIREVKARSMNLRWTQRFDGNSIITGFDI                   EYKNKSDSWDFKQSTRNISPTINQANIVDLHPASVYSIRMYSFNKIGRSEPSKELTIS                   TEEAAPDGPPMDVTLQPVTSQSIQVTWKAPKKELQNGVIRGYQIGYRENSPGSNGQYS                   IVEMKATGDSEVYTLDNLKKFAQYGVVVQAFNRAGTGPSSSEINAEELEDVPSQPPEN                   VRALSITSDVAVISWSEPPRSTLNGVLKGYRVIFWSLYVDGEWGEMQNITTTRERVEL                   RGMEKFTNYSVQVLAYTQAGDGVRSSVLYIQTKEDVPGPPAGIKAVPSSASSVVVSWL                   PPTKPNGVIRKYTIFCSSPGSGQPAPSEYETSPEQLFYRIAHLNRGQQYLLWVAAVTS                   AGRGNSSEKVTIEPAGKAPAKIISFGGTVTTPWMKDVRLPCNSVGDPAPAVKWTKDSE                   DSAIPVSMDGHRLIHTNGTLLLRAVKAEDSGYYTCTATNTGGFDTIIVNLLVQVPPDQ                   PRLTVSKTSASSITLTWIPGDNGGSSIRGFVLQYSVDNSEEWKDVFISSSERSFKLDS                   LKCGTWYKVKLAAKNSVGSGRISEIIEAKTHGREPSFSKDQHLFTHINSTHARLNLQG                   WNNGGCPITAIVLEYRPKGTWAWQGLRANSSGEVFLTELREATWYELRMRACNSAGCG                   NETAQFATLDYDGSTIPPIKSAQGEGDDVKKLFTIGCPVILATLGVALLFIVRKKRKE                   KRLKRLRDAKSLAEMLISKNNRSFDTPVKGPPQGPRLHIDIPRVQLLIEDKEGIKQLG                   DDKATIPVTDAEFSQAVNPQSFCTGVSLHHPTLIQSTGPLIDMSDIRPGTNPVSRKNV                   KSAHSTRNRYSSQWTLTKCQASTPARTLTSDWRTVGSQHGVTVTESDSYSASLSQDTD                   KGRNSMVSTESASSTYEELARAYEHAKLEEQLQHAKFEITECFISDSSSDQMTTGTNE                   NADSMTSMSTPSEPGICRFTASPPKPQDADRGKNVAVPIPHRANKSDYCNLPLYAKSE                   AFFRKADGREPCPVVPPREASIRNLARTYHTQARHLTLDPASKSLGLPHPGAPAAAST                   DSLLEMSTSGVGRSQKQGAGAYSKSYTLV                                     SEQ ID NO:265   6049 bp                     NOV92b,     CCACAGAGGGGAAATGCCAGCTTCCCTCTCCCTGGGGCTCCGTGCCCCCTCTGATCCA         CG59754-01 DNA Sequence             GCCCTTCGAATTCCCACCCGCCTCCATCGGCCAGCTGCTCTACATTCCCTGTGTGGTG                       TCCTCGGGGGAC   ATG CCCATCCGTATCACCTGGAGGAAGGACGGACAGGTGATCATCT                   CAGGCTCGGGCGTGACCATCGAGAGCAAGGAATTCATGAGCTCCCTGCAGATCTCTAG                   CGTCTCCCTCAAGCACAACGGCAACTATACATGCATCGCCAGCAACGCAGCCGCCACC                   GTGAGCATTGTGTCTCCAGAACACAGGTTTTTTATTACCTACCACGGCGGGCTGTACA                   TCTCTGACGTACAGAAGGAGGACGCCCTCTCCACCTATCGCTGCATCACCAAGCACAA                   GTATAGCGGGGAGACCCGGCAGAGCAATGGGGCACGCCTCTCTGTGACAGACCCTGCT                   GAGTCGATCCCCACCATCCTGGATGGCTTCCACTCCCAGGAAGTGTGGGCCGGCCACA                   CCGTGGAGCTGCCCTGCACCGCCTCGGGCTACCCTATCCCCGCCATCCGCTGGCTCAA                   GGATGGCCGGCCCCTCCCGGCTGACAGCCGCTGGACCAAGCGCATCACAGGGCTGACC                   ATCAGCGACTTGCGGACCGAGGACAGCGGCACCTACATTTGTGAGGTCACCAACACCT                   TCGGTTCGGCAGAGGCCACAGGCATCCTCATGGTCATTGATCCCCTTCATGTGACCCT                   GACACCAAAGAAGCTGAAGACCGGCATTGGCAGCACGGTCATCCTCTCCTGTGCCCTG                   ACGGGCTCCCCAGAGTTCACCATCCGCTGGTATCGCAACACGGAGCTGGTGCTGCCTG                   ACGAGGCCATCTCCATCCGCGGGCTCAGCAACGAGACGCTGCTCATCACCTCGGCCCA                   GAAGAGCCATTCCGGGGCCTACCAGTGCTTCGCTACCCGCAAGGCCCAGACCGCCCAG                   GACTTTGCCATCATTGCACTTGAGGATGGCACGCCCCGCATCGTCTCGTCCTTCAGCG                   AGAAGGTGGTCAACCCCGGGGAGCAGTTCTCACTGATGTGTGCGGCCAAGGGCGCCCC                   GCCCCCCACAGTCACCTGGGCCCTCGACGATGAGCCCATCGTGCGGGATGGCAGCCAC                   CGCACCAACCAGTACACCATGTCGGACGGCACCACCATCAGCCACATGAACGTCACAG                   GCCCCCAGATCCGCGACGGGGGCGTGTACCGGTGCACAGCGCGGAACTTGGTGGGCAG                   TGCTGAATATCAGGCGCGAATAAACGTAAGAGGCCCACCCAGCATCCGGGCTATGCGG                   AACATCACAGCAGTCGCCGGGCGGGACACCCTTATCAACTGCAGGGTCATCGGCTATC                   CCTACTACTCCATCAAGTGGTACAAGGATGCCTTGCTGCTGCCAGACAACCACCGCCA                   GGTGGTGTTTGAGAATGGGACCCTCAAGCTGACTGACGTGCAGAAGGGCAGGGATGAG                   GGGGAGTACCTGTGCAGTGTCCTCATCCAGCCCCAGCTCTCCATCAGCCAGAGCGTTC                   ACGTAGCCGTCAAAGTGCCCCCTCTGATCCAGCCCTTCGAATTCCCACCCGCCTCCAT                   CGGCCAGCTGCTCTACATTCCCTGTGTGGTGTCCTCGGGGGACATGCCCATCCGTATC                   ACCTGGAGGAAGGACGGACAGGTGATCATCTCAGGCTCGGGCGTGACCATCGAGAGCA                   AGGAATTCATGAGCTCCCTGCAGATCTCTAGCGTCTCCCTCAAGCACAACGGCAACTA                   TACATGCATCGCCAGCAACGCAGCCGCCACCGTGAGCCGGGAGCGTCAGCTCATCGTG                   CGTGTGCCCCCTCGATTTGTGGTGCAACCCAACAACCAGGATGGCATCTACGGCAAAG                   CTGGTGTGCTCAACTGCTCGGTGGACGGCTACCCCCCACCCAAGGTCATGTGGAAGCA                   TGCCAAGGGTAGCGGGAACCCCCAGCAGTACCACCCTGTGCCCCTCACTGGCCGCATC                   CAGATCCTGCCCAACAGCTCGCTGCTGATCCGCCACGTCCTAGAAGAGGACATCGGCT                   ACTACCTCTGCCAGGCCAGCAACGGCGTAGGCACCGACATCAGCAAGTCCATGTTCCT                   CACAGTCAAGATCCCCACCATCCTGGATGGCTTCCACTCCCAGGAAGTGTGGGCCGGC                   CACACCGTGGAGCTGCCCTGCACCGCCTCGGGCTACCCTATCCCCGCCATCCGCTGGC                   TCAAGGATGGCCGGCCCCTCCCGGCTGACAGCCGCTGGACCAAGCGCATCACAGGGCT                   GACCATCAGCGACTTGCGGACCGAGGACAGCGGCACCTACATTTGTGAGGTCACCAAC                   ACCTTCGGTGAGGCCACAGGCATCCTCATGGTCATTGGTGAGGAGCCCCCCGACCCCC                   CAGAGCTGGAGATCCGGGAGGTGAAGGCCCGGAGCATGAACCTGCGCTGGACCCAGCG                   ATTCGACGGGAACAGCATCATCACGGGCTTCGACATTGAATACAAGAACAAATCAGAT                   TCCTGGGACTTCAAGCAGTCCACACGCAACATCTCCCCCACCATCAACCAGGCCAACA                   TTGTGGACTTGCACCCGGCATCTGTGTACAGCATCCGCATGTACTCTTTCAACAAGAT                   TGGCCGCAGTGAACCAAGCAAGGAGCTCACCATCAGCACTGAGGAGGCCTCAGCTCCC                   GATGGGCCCCCCATGGATGTTACCTTGCAGCCAGTGACCTCACAGAGCATCCAGGTGA                   CCTGGAAGCAGGCACCCAAGAAGGAGCTGCAGAACGGTGTCATCCGGGGCTACCAGAT                   TGGCTACAGAGAGAACAGCCCCGGCAGCAACGGGCAGTACAGCATCGTGGAGATGAAG                   GCCACGGGGGACAGCGAGGTCTACACCCTGGACAACCTCAAGAAGTTCGCCCAGTATG                   GGGTGGTGGTCCAGGCCTTCAATCGGGCTGGCACGGGGCCCTCTTCCAGCGAGATCAA                   TGCCACCACTCTGGAGGATGTGCCCAGCCAGCCCCCTGAGAACGTCCGGGCCCTGTCC                   ATCACTTCTGACGTGGCCGTCATCTCCTGGTCAGAGCCCCCGCGCAGCACCCTCAATG                   GCGTCCTCAAAGGCTATCGGGTCATCTTCTGGTCCCTCTATGTTGATGGGGAGTGGGG                   CGAGATGCAGAACATCACCACCACGCGGGAGCGGGTGGAGCTGCGGGGCATGGAGAAG                   TTCACCAACTACAGCGTCCAGGTGCTGGCCTACACCCAGGCTGGGGACGGCGTACGCA                   GCAGTGTGCTCTACATCCAGACCAAGGAGGACGTTCCAGGTCCCCCTGCTGGCATCAA                   AGCTGTCCCTTCATCAGCTAGCAGTGTGGTTGTGTCTTGGCTCCCCCCTACCAAGCCC                   AACGGGGTGATCCGCAAGTACACCATCTTCTGTTCCAGCCCCGCCCCGCAGGCTCCCA                   GCGAGTACGAGACGAGTCCAGAGCAGCTCTTCTACCGGATCGCCCACCTAAACCGCGG                   TCAGCAGTATCTGCTGTGGGTGGCCGCCGTCACCTCTGCCGGCCGGGGCAACAGCAGC                   GAGAAGGTGACCATCGAGCCTGCTGGCAAGGCCCCAGCAAAGATCATCTCCTTTGGGG                   GCACCGTGACAACACCTTGGATGAAAGATGTTCGGCTGCCTTGCAATTCAGTGGGAGA                   TCCAGCCCCTGCTGTGAAGTGGACCAAGGACAGTGAAGACTCGGCCATTCCAGTGTCC                   ATGGATGGGCACCGGCTCATCCACACCAATGGCACACTGCTGCTGCGTGCAGTGAAGG                   CTGAGGACTCTGGCTACTACACGTGCACGGCCACCAACACTGGTGGCTTTGACACCAT                   CATCGTCAACCTTCTGGTGCAAGTTCCCCCGGACCAGCCCCGCCTCACTGTCTCCAAA                   ACCTCAGCTTCGTCCATCACCCTGACCTGGATTCCAGGTGACAATGGGGGCAGCTCCA                   TCCGAGGTTTTGTGCTACAGTACTCGGTGGACAACAGCGAGGAGTGGAAGGATGTGTT                   CATCAGCTCCAGCGAGCGCTCCTTCAAGCTGGACAGCCTCAAGTGTGGCACGTGGTAC                   AAGGTGAAGCTGGCAGCCAAGAACAGCGTGGGCTCTGGGCGCATCAGCGAGATCATCG                   AGGCCAAGACCCACGGGCGGGAGCCCTCCTTCAGCAAAGACCAACACCTCTTCACCCA                   CATCAACTCCACGCATGCTCGGCTTAACCTGCAGGGCTGGAACAATGGGGGCTGCCCT                   ATCACAGCCATCGTTCTGGAGTACCGGCCCAAGGGGACCTGGGCCTGGCAGGGCCTCC                   GGGCCAACAGCTCCGGGGAGGTGTTTCTGACGGAACTGCGAGAGGCCACGTGGTACGA                   GCTGCGCATGAGGGCTTGCAACAGTGCGGGCTGCGGCAATGAAACAGCCCAGTTCGCC                   ACCCTGGACTACGATGGCAGTACCATTCCACCCATCAAGTCTGCTCAAGGTGAAGGGG                   ATGATGTGAAGAAGCTGTTCACCATCGGCTGCCCTGTCATCCTGGCCACACTGGGGGT                   GGCACTGCTCTTCATCGTACGCAAGAAGAGGAAGGAGAAACGGCTGAAGCGACTCCGA                   GATGCAAAGAGTTTGGCAGAAATGTTGATAAGCAAGAACAATAGAAGCTTTGACACCC                   CTGTGAAAGGGCCACCCCAGGGCCCACGGCTACACATTGACATCCCCAGGGTCCAGCT                   GCTCATCGAGGACAAAGAAGGCATCAAGCAACTGGGTGAGGACAAGGCCACCATCCCT                   GTGACAGATGCTGAGTTCAGCCAAGCTGTCAACCCACAGAGCTTCTGTACTGGCGTCT                   CCTTGCACCACCCAACCCTCATCCAGAGCACAGGACCCCTCATCGACATGTCTGACAT                   CCGGCCAGGAACCGATCCAGTGTCCAGGAAGAATGTGAAGTCAGCCCACAGCACCCGG                   AACCGGTACTCAAGCCAGTGGACCCTGACCAAGTGCCAGGCCTCCACACCTGCCCGCA                   CCCTCACCTCCGACTGGCGCACCGTGGGCTCCCAGCATGGTGTCACGGTCACTGAGAG                   TGACAGCTACAGTGCCAGCCTGTCCCAGGACACAGACAAAGGAAGGAACAGCATGGTG                   TCCACTGAGAGTGCCTCTTCCACCTACGAGGAGCTGGCCCGGGCCTATGAGCATGCCA                   AGCTGGAGGAGCAGCTGCAGCACGCCAAGTTTGAGATCACCGAGTGCTTCATCTCTGA                   CAGTTCCTCTGACCAGATGACCACAGGCACCAACGAGAACGCCGACAGCATGACATCC                   ATGAGCACACCCTCAGAGCCTGGCATCTGCCGCTTTACCGCCTCACCACCCAAGCCCC                   AGGATGCGGACCGGCTGCTGATGCTGGTCCCAGGTGCCCACCTCCCTCCTCAGTCCAT                   CCATGTTGTAGCATATGTCAGAATTTCCTTCTTACTGAACAAGGGTGGGGGAGACCTG                   GCTTCTGATCTTAGCTCCGGCAGAGCTTGCAGTGAGCCGAGATCACGCGGCACCCGGC                   CACCAACACTGGTGGCTTTGACACCATCATCGTCAACCTGTGAGGCAGGTGACCCCAG                   GTGGGGACAGGGATGGAGAAAGGGTAGGGATTCCATCATGCGAGAGGGTCATCGAATG                   GAAGAAGCCAAACCAAGGGAGAGACAGACCTCTGGAGAAACAGAGGTGCACATGGAAG                   GGGAGGCAGGAGAGCTGGGGAGTGGGAGTGGGAGTGAGGGTGTGGGAGAGCCAGCACC                   TTCCCGTCACGGGGGGACTCCCCACACCCCATCACAGGGTCCGCCCTTGTGC TAA   GGG                       GTGGTGGCTTTCCCCTCACAGTTCCCCCGGACCAGCCCCGCCTCACTGTCTCCAAAAC                       CTCAGCTTCGTCCATCACCCTGACCTGGATTCCAGGTGACAATGGGGGCAGCTCCATC                       CGAGGTGAGGAGGGGTCTGGATGCGGGGGAAGATAGGGGAAGGAATTCTGGGCCCGGG                       GCAGGGAAGGGGCTTCA                                           ORF Start: ATG at 129       ORF Stop: TAA at 5853           SEQ ID NO:266   1908 aa   MW at 208575.3 kD                     NOV92b,   MPIRITWRKDGQVIISGSGVTIESKEFMSSLQISSVSLKHNGNYTCIASNAAATVSIV       CG59754-01 Protein       Sequence   SPEHRFFITYHGGLYISDVQKEDALSTYRCITKHKYSGETRQSNGARLSVTDPAESIP                   TILDGFHSQEVWAGHTVELPCTASGYPIPAIRWLKDGRPLPADSRWTKRITGLTISDL                   RTEDSGTYICEVTNTFGSAEATGILMVIDPLHVTLTPKKLKTGIGSTVILSCALTGSP                   EFTIRWYRNTELVLPDEAISIRGLSNETLLITSAQKSHSGAYQCFATRKAQTAQDFAI                   IALEDGTPRIVSSFSEKVVNPGEQFSLMCAAKGAPPPTVTWALDDEPIVRDGSHRTNQ                   YTMSDGTTISHMNVTGPQIRDGGVYRCTARNLVGSAEYQARINVRGPPSIRAMRNITA                   VAGRDTLINCRVIGYPYYSIKWYKDALLLPDNHRQVVFENGTLKLTDVQKGMDEGEYL                   CSVLIQPQLSISQSVHVAVKVPPLIQPFEFPPASIGQLLYIPCVVSSGDMPIRITWRK                   DGQVIISGSGVTIESKEFMSSLQISSVSLKHNGNYTCIASNAAATVSRERQLIVRVPP                   RFVVQPNNQDGIYGKAGVLNCSVDGYPPPKVMWKHAKGSGNPQQYHPVPLTGRIQILP                   NSSLLIRHVLEEDIGYYLCQASNGVGTDISKSMFLTVKIPTILDGFHSQEVWAGHTVE                   LPCTASGYPIPAIRWLKDGRPLPADSRWTKRITGLTISDLRTEDSGTYICEVTNTFGE                   ATGILMVIGEEPPDPPELEIREVKARSMNLRWTQRFDGNSIITGFDIEYKNKSDSWDF                   KQSTRNISPTINQANIVDLHPASVYSIRMYSFNKIGRSEPSKELTISTEEASAPDGPP                   MDVTLQPVTSQSIQVTWKQAPKKELQNGVIRGYQIGYRENSPGSNGQYSIVEMKATGD                   SEVYTLDNLKKFAQYGVVVQAFNRAGTGPSSSEINATTLEDVPSQPPENVRALSITSD                   VAVISWSEPPRSTLNGVLKGYRVIFWSLYVDGEWGEMQNITTTRERVELRGMEKFTNY                   SVQVLAYTQAGDGVRSSVLYIQTKEDVPGPPAGIKAVPSSASSVVVSWLPPTKPNGVI                   RKYTIFCSSPAPQAPSEYETSPEQLFYRIAHLNRGQQYLLWVAAVTSAGRGNSSEKVT                   IEPAGKAPAKIISFGGTFTTPWMKDVRLPCNSVGDPAPAVKWTKDSEDSAIPVSMDGH                   RLIHTNGTLLLRAVKAEDSGYYTCTATNTGGFDTIIVNLLVQVPPDQPRLTVSKTSAS                   SITLTWIPGDNGGSSIRGFVLQYSVDNSEEWKDVFISSSERSFKLDSLKCGTWYKVKL                   AAKNSVGSGRISEIIEAKTHGREPSFSKDQHLFTHINSTHARLNLQGWNNGGCPITAI                   VLEYRPKGTWAWQGLRANSSGEVFLTELREATWYELRMRACNSAGCGNETAQFATLDY                   DGSTIPPIKSAQGEGDDVKKLFTIGCPVILATLGVALLFIVRKKRKEKRLKRLRDAKS                   LAEMLISKNNRSFDTPVKGPPQGPRLHIDIPRVQLLIEDKEGIKQLGEDKATIPVTDA                   EFSQAVNPQSFCTGVSLHHPTLIQSTGPLIDMSDIRPGTDPVSRKNVKSAHSTRNRYS                   SQWTLTKCQASTPARTLTSDWRTVGSQHGVTVTESDSYSASLSQDTDKGRNSMVSTES                   ASSTYEELARAYEHAKLEEQLQHAKFEITECFISDSSSDQMTTGTNENADSMTSMSTP                   SEPGICRFTASPPKPQDADRLLMLVPGAHLPPQSIHVVAYVRISFLLNKGGGDLASDL                   SSGRACSEPRSRGTRPPTLVALTPSSSTCEAGDPRWGQGWRKGRDSIMREGHRMEEAK                   PRERQTSGETEVHMEGEAGELGSGSGSEGVGEPAPSRHGGTPHTPSQGPPLC                  
 
     [0807] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 92B.  
               TABLE 92B                          Comparison of NOV92a against NOV92b.                                         Identities/           Protein   NOV92a Residues/   Similarities for           Sequence   Match Residues   the Matched Region                       NOV92b   1 . . . 1771   1663/1773 (93%)               1 . . . 1760   1681/1773 (94%)                      
 
     [0808] Further analysis of the NOV92a protein yielded the following properties shown in Table 92C.  
               TABLE 92C                       Protein Sequence Properties NOV92a                                        PSort   0.7000 probability located in plasma membrane; 0.3000       analysis:   probability located in microbody (peroxisome); 0.3000           probability located in nucleus; 0.2000 probability located           in endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0809] A search of the NOV92a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 92D.  
               TABLE 92D                          Geneseq Results for NOV92a                                         NOV92a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAU28091   Novel human secretory protein,   200 . . . 1943   1744/1744 (100%)   0.0           Seq ID No 260- Homo sapiens ,    1 . . . 1744   1744/1744 (100%)           1744 aa. [WO200166689-A2,           13 SEP. 2001]       AAM78713   Human protein SEQ ID NO 1375-   200 . . . 1943   1744/1744 (100%)   0.0             Homo sapiens , 1744 aa.    1 . . . 1744   1744/1744 (100%)           [WO200157190-A2,           9 AUG. 2001]       AAM39040   Human polypeptide SEQ ID NO   200 . . . 1943   1744/1744 (100%)   0.0           2185- Homo sapiens , 1744 aa.    1 . . . 1744   1744/1744 (100%)           [WO200153312-A1,           26 JUL. 2001]       AAW42086   Human Down syndrome-cell    44 . . . 1778   1085/1745 (62%)   0.0           adhesion molecule DS-CAM1-   154 . . . 1890   1357/1745 (77%)           [WO9817795-A1, 30 APR. 1998]       AAW42087   Human Down syndrome-cell    44 . . . 1457    890/1416 (62%)   0.0           adhesion molecule DS-CAM2-   154 . . . 1564   1109/1416 (77%)             Homo sapiens , 1571 aa.           [WO9817795-A1, 30 APR. 1998]                  
 
     [0810] In a BLAST search of public sequence databases, the NOV92a protein was found to have homology to the proteins shown in the BLASTP data in Table 92E.  
               TABLE 92E                          Public BLASTP Results for NOV92a                                         NOV92a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               AAL57166   DOWN SYNDROME CELL    44 . . . 1943   1889/1900 (99%)   0.0           ADHESION MOLECULE   155 . . . 2053   1892/1900 (99%)           DSCAML1- Homo sapiens             (Human), 2053 aa.       Q9ULT7   KIAA1132 PROTEIN- Homo     122 . . . 1943   1822/1822 (100%)   0.0             sapiens  (Human), 1822 aa    1 . . . 1822   1822/1822 (100%)           (fragment).           O60469   Down syndrome cell adhesion    44 . . . 1943   1123/1920 (58%)   0.0           molecule precursor (CHD2)-   154 . . . 2012   1410/1920 (72%)             Homo sapiens  (Human),           2012 aa.       Q9ERC8   DOWN SYNDROME CELL    44 . . . 1943   1119/1921 (58%)   0.0           ADHESION MOLECULE-   154 . . . 2013   1405/1921 (72%)             Mus musculus  (Mouse),           2013 aa.       AAL57167   DOWN SYNDROME CELL    44 . . . 1943   1119/1921 (58%)   0.0           ADHESION MOLECULE   154 . . . 2013   1405/1921 (72%)           DSCAM- Rattus norvegicus             (Rat), 2013 aa.                  
 
     [0811] PFam analysis predicts that the NOV92a protein contains the domains shown in the Table 92F.  
               TABLE 92F                          Domain Analysis of NOV92a                                     Identities/           Pfam   NOV92a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               ig: domain 1 of 10     1 . . . 48   12/49 (24%)   2.7e−05               38/49 (78%)       ig: domain 2 of 10    72 . . . 90    8/19 (42%)   85               14/19 (74%)       ig: domain 3 of 10    130 . . . 186   22/60 (37%)   2.1e−14               46/60 (77%)       ig: domain 4 of 10    219 . . . 278   16/63 (25%)   4.9e−09               44/63 (70%)       ig: domain 5 of 10    312 . . . 377   14/69 (20%)   1.5e−07               50/69 (72%)       ig: domain 6 of 10    409 . . . 467   12/61 (20%)   4.8e−05               41/61 (67%)       ig: domain 7 of 10    500 . . . 561   17/64 (27%)   3.2e−11               49/64 (77%)       ig: domain 8 of 10    594 . . . 659   19/69 (28%)   9.4e−07               47/69 (68%)       ig: domain 9 of 10    693 . . . 759    9/70 (13%)   7.9e−06               47/70 (67%)       fn3: domain 1 of 6    777 . . . 864   22/89 (25%)    3e−16               65/89 (73%)       fn3: domain 2 of 6    876 . . . 968   33/93 (35%)   3.1e−16               68/93 (73%)       fn3: domain 3 of 6    980 . . . 1069   26/93 (28%)   2.9e−16               69/93 (74%)       fn3: domain 4 of 6   1081 . . . 1167   24/88 (27%)   3.7e−17               64/88 (73%)       ig: domain 10 of 10   1194 . . . 1255   17/65 (26%)   4.3e−09               46/65 (71%)       fn3: domain 5 of 6   1274 . . . 1357   30/86 (35%)   1.2e−18               67/86 (78%)       fn3: domain 6 of 6   1371 . . . 1453   27/86 (31%)    0.045               53/86 (62%)                  
 
     Example 93  
     [0812] The NOV93 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 93A.  
               TABLE 93A                       NOV93 Sequence Analysis                                                SEQ ID NO:267   1272 bp                     NOV93a,     A   GAG CCTGGTATGCAGGAGGTGCTCTGTAAATACCTGCCCCATACATACCCGCCCCAT       CG59800-01 DNA Sequence           ACATACCCACCCCATACATACCCACCCCATACATACCTGCCCTGTCCATACCTCCCCC                   CTACATACCTGCCCCGTCCATACCTGCCCCCTACATACCTGCCCCGTCCATACCTGCC                   CCCTACATACCTGCTCTGTCTATACCTGTGGCTAGGACTGTGGCCTTCCTTCTTAGCC                   GCTCAGAGCCTGCCTCCTCCTCTGCAGAGTGGCGGTGGTAGCAGGGCTTCCCGCGCGC                   CGATGCTGCTCGTGGCCCTGGTGCTCGGCGCCTACTGCCTCTGCGCCCTCCCCGGCCG                   CTGCCCGCCCGCCGCCCCCGCCCCCGCGCCCGCCCCCGCGCCCTCCGAGCCGTCCAGC                   TCCGTCCACCGCCCGGGACCACCCGGCCTGCCTTTGGCCACCGGTCCCGGCCGCCGGC                   CCTTCCCGCAACCGCTCATCGTTGGCGTGAAGAAGGGCGGCACGCGCGCCCTGCTGGA                   GTTTCTCCGGCTGCACCCCGACCTCCGCGCGCTCGCCTCTGAGCCCCACTTCTTCGAC                   AGGTGCCCCGACCGCGGCCTCCCCTGGTCCCGCAGTCTGATGCCCCGAACCCTCCATG                   GGCAGATCACCATGGAGACGACCCCGGGCTACTTCGTGACGCGAGAGGCCCCCCGCCG                   CATCCACGCCATGTCCCCGGACACGAAGCTGATCGTGGTGGTGCGGAACCCCGTCACC                   CGGGCCATCTCCGACTAGGCCCACACGCTCTCCAAGACCCCGGGCCTGCCCAGCTTCC                   GCGCCCTGGCCTTCCGCCACGGCCTGGGCCCCGTGGACACAGCCTGGAGCGCCGTCCG                   CATCCGCCTGTACGCCCACCACCTGGACCACTGGCTGCGCTACTTCCCCCTGTCCCAC                   TTCCTGTTCGTCAGCGGGGAGCGTCTGGTCAGCGACCCGGCCGGAGAGCTCGGCCGCG                   TGCAGGACTTCCTGGGCCTGAAACGGGTCGTCACGGACAAGCACTTCTACTTCAACGC                   CACCAAGGGCTTCCCCTGCCTCAAGAAGGCCCAGGGCGGCAGCCCTCCCCCCTGCCTG                   GGCAAGTCCAAGGGCCGGCCACACCCACCCGTGCCCCAGGCCGTGGTCCGGCGCCTGC                   AGGAGTTCTACCCGCCCTTCAACCGCAGGTTCTACCAGATCACGGGCCAGGACTTCGG                   C TGGGGCTGAGCGGCACCCTGGGCATGCTCAGCACCTTGATTGACACCCGCTCG                                           ORF Start: GAG at 2       ORF Stop: GGC at 1217           SEQ ID NO:268   405 aa   MW at 43994.8 kD                     NOV93a   MQEVLCKYLPHTYPPHTYPPHTYPPHTYLPCPYLPPTYLPRPYLPPTYLPRPYLPPTY       CG59800-01 Protein Sequence           LLCLYLWLGLWFCFIQSLFPPLQSGGGSRASRAPMLLVALVLGAYCLCALPGRCPF                   AARAPAPAPAPSEPSSSVERPGAPGLPLASGPGRRRFPQALIVGVKKGGTRALLEFLR                   LHPDXRALGSEXEFFDRCXXXCLXWXRSLMPRTLDGQTTMEXTPXYFVTREAPRRIHA                   MSPDTKLIVVVRNPVTRAISDXXQTLSKTPGLPSFRALAFRHGLGPVDTAWSAVRIGL                   YAQHLDEWLRYFPLSEELFVSGERLVSDPAGEVGRVQDFLGLKRVVTDKHFYFNATKG                   FPCLKKAQGGSRPRCLGKSKGRPHPRVPQAXVRRLQEFYRPFNRRFYQMTGQDFGWG                  
 
     [0813] Further analysis of the NOV93a protein yielded the following properties shown in Table 93B.  
               TABLE 93B                       Protein Sequence Properties NOV93a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability           located in endoplasmic reticulum (membrane); 0.1000           probability located in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 7 and 8       analysis:                  
 
     [0814] A search of the NOV93a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 93C.  
               TABLE 93C                          Geneseq Results for NOV93a                                         NOV93a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAB95507   Human protein sequence SEQ ID   31 . . . 253   121/229 (52%)   4e−55           NO: 18067- Homo sapiens , 390 aa.   11 . . . 237   146/229 (62%)           [EP1074617-A2, 7 FEB. 2001]       AAY17066   Human 3-OST-3B protein- Homo     31 . . . 253   121/229 (52%)   4e−55             sapiens , 390 aa. [WO9922005-A2,   11 . . . 237   146/229 (62%)           6 MAY 1999]       AAB70115   Human 3-OST-3B- Homo sapiens ,   31 . . . 253   121/230 (52%)   9e−54           391 aa. [WO200113910-A2,   11 . . . 238   146/230 (62%)           1 MAR. 2001]       AAB70114   Murine 3-OST-3B-Mus sp, 391   31 . . . 253   119/231 (51%)   2e−51           aa. [WO200113910-A2,   11 . . . 238   147/231 (63%)           1 MAR. 2001]       AAU12275   Human PRO5004 polypeptide   86 . . . 253   102/170 (60%)   9e−48           sequence- Homo sapiens , 367 aa.   45 . . . 214   117/170 (68%)           [WO200140466-A2, 7 JUN. 2001]                  
 
     [0815] In a BLAST search of public sequence databases, the NOV93a protein was found to have homology to the proteins shown in the BLASTP data in Table 93D.  
               TABLE 93D                          Public BLASTP Results for NOV93a                                         NOV93a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96QI5   C439A6.1 (NOVEL PROTEIN   85 . . . 253   160/169 (94%)   2e−89           SIMILAR TO HEPARAN   61 . . . 229   162/169 (95%)           SULFATE (GLUCOSAMINE) 3-O-           SULFOTRANSFERASES)- Homo               sapiens  (Human), 381 aa (fragment).       Q96RX7   HEPARAN SULPHATE D-   95 . . . 253   153/159 (96%)   1e−85           GLUCOSAMINYL 3-O-    1 . . . 159   155/159 (97%)           SULFOTRANSFERASE-3B LIKE-             Homo sapiens  (Human), 311 aa.       Q9Y662   HEPARAN SULFATE D-   31 . . . 253   121/229 (52%)   1e−54           GLUCOSAMINYL 3-O-   11 . . . 237   146/229 (62%)           2.8.2.23)- Homo sapiens  (Human),           390 aa.       Q9QZS6   D-GLYCOSAMINYL 3-O-   31 . . . 253   119/230 (51%)   3e−52           SULFOTRANSFERASE-3B- Mus     11 . . . 237   147/230 (63%)             musculus  (Mouse), 390 aa.       Q9Y278   HEPARAN SULFATE D-   86 . . . 253   102/170 (60%)   3e−47           GLUCOSAMINYL 3-O-   45 . . . 214   117/170 (68%)           SULFOTRANSFERASE-2 (EC           2.8.2.23)- Homo sapiens  (Human),           367 aa.                  
 
     [0816] PFam analysis predicts that the NOV93a protein contains the domains shown in the Table 93E.  
               TABLE 93E                          Domain Analysis of NOV93a                                             Identities/               Pfam   NOV93a   Similarities for   Expect           Domain   Match Region   the Matched Region   Value                             No Significant Matches Found                  
 
     [0817] The NOV94 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 94A.  
               TABLE 94A                       NOV94 Sequence Analysis                                                SEQ ID NO:269   2949 bp                     NOV94a,     GTCCGCCTCCCGGCCGCCGAGCCGCAGCCGCCGAGATGCGCGCCGCCCCGGGCCGCGC         CG59761-01 DNA Sequence             CCCCGCCGGGTCCCGCCCGCCCCGCTGCCGCTGAGCGC   ATG GGCCCGGACCGCGCCGC                   GCCGCTCCGGGAGCCGGGCCCGCGGTCCCGCCACCACCCCGCGCGGGACAGATTCATT                   CACTTTGGAGCTGTAAGTACTGATGTATTAGGGTGCAGCCCTCATTGTTCATTGACGC                   ACAGTCCCAAAATGAATATCCAAGAGCAGGGTTTCCCCTTCGACCTCGGAGCAAGTTT                   CACCGAAGATGCTCCCCGACCCCCAGTCCCTCGTGAGGAGCGAGAACTCGTGTCCACA                   GACCCGAGGCCCGCCAGCTACAGTTTCTGCTCCGGGAAAGGTGTTGGCATTAAAGGTG                   AGACTTCGACGGCCACTCCGAGGCGCTCGGATCTCGACCTGGGGTATGAGCCTGAGGG                   CAGTCCCTCCCCCACCCCACCATACTTGAAGTGGGCTGAGTCACTGCATTCCCTGCTG                   GATGACCAAGATGGGATAAGCCTGTTCAGGACTTTCCTGAAGCAGGAGGGCTGTGCCG                   ACTTGCTGCACTTCTGGTTTGCCTGCACTGCCTTCAGCAACCTGGAGCCCTGTCACTC                   GAACGAGGAGAAGAGGCTGAAGCTGGCGAGAGCCATCTACCCAAAGTACATTCTTGAT                   AACAATGGCATCGTGTCCCGGCAGACCAAGCCAGCCACCAAGAGCTTCATAAAGGGCT                   GCATCATGAAGCAGCTGATCGATCCTCCCATGTTTGACCAGGCCCAGACCGAAATCCA                   GGCCACTATGGAGGAAAACACCTATCCCTCCTTCCTTAAGTCTCATATTTATTTGGAA                   TATACGAGGACAGGCTCGGAGAGCCCCAAAGTCTGTAGTGACCAGACCTCTGCGTCAG                   GGACAGGGAAGGGCATATCTGGATACCTGCCGACCTTAAATGAAGATGAGGAATGGAA                   GTGTGACCAGGACATGGATCACGACGATGGCAGAGACGCTGCTCCCCCCGGAAGACTC                   CCTCAGAAGCTGCTCCTGGAGACAGCTGCCCCGAGGGTCTCCTCCAGTAGACGGTACA                   GCGAAGGCAGAGAGTTCAGGTATGGATCCTGGCGGGAGCCAGTCAACCCCTATTATGT                   CAATGCCGGCTATGCCCTGGCCCCAGCCACCAGTGCCAACCACAGCGAGCAGCAGAGC                   CTGTCCAGCGATGCAGACACCCTGTCCCTCACGGACAGCAGCGTGGATGGGATCCCCC                   CATACAGGATCCGTAAGCAGCACCGCAGGGAGATGCAGGAGAGCGTGCAGGTCAATGG                   GCGGGTGCCCCTACCTCACATTCCCCGCACGTACCGGGTGCCGAAGGAGGTCCGCGTG                   GAGCCTCAGAAGTTCGCGGAGGACCTCATCCACCGCCTGGAGGCTGTGCAGCGCACGC                   CGGAGGCCGAGGAGAAGCTGGAGGAGCGGCTGAAGCGCGTGCGCATGGAGGAGGAAGG                   TGAGGACGGCGATCCATCATCAGGGCCCCCAGGGCCGTGTCACAAGCTGCCTCCCGCC                   CCCGCTTGGCACCACTTCCCGCCCCGCCTGTGTTGGACATGGGCTTGTGCCGGGCTCC                   GGGATGCACACGAGGAGAACCCTGAGAGCATCCTGGACGAGCACGTACAGCGTGTGCT                   GACGACACCTGGCCGCCAGTCGCCTGGGCCTGGCCATCGCTCCCCGGACAGTGGGCAC                   GTGGCCAAGATGCCAGTGGCACTGGGGGGTGCCGCCTCGGGGCACGGGAAGCACGTAC                   CCAAGTCAGGGGCGAAGCTGGACGCGGCCGGCCTGCACCACCACCGACACGTCCACCA                   CCACGTCCACCACAGCACAGCCCGGCCCAAGGAGCAGGTGGAGGCCGAGGCCACCCGC                   AGGGCCCAGAGCACCTTCGCCTCGGGCCTGGAACCACACAGCCATGGCGCAAGGTCCC                   GAGCCTACTCAGAGAGTGTTCGCGCTGCCCCCAACGCCAGTGATGGCCTCGCCCACAC                   TGGGAAGGTGGGCGTGGCGTGCAAAAGAAATGCCAAGAAGGCCGAGTCGGGGAAGAGC                   GCCAGCACCCAGGTGCCAGGTGCCTCGGAGGATGCGGAGAAGAACCAGAAAATCATGC                   AGTGGATCATTGAGGGGGAAAAGGAGATCAGCAGCCACCGCACCACCGCCCACGGGTC                   TTCGGGGACCAGGAAGCCACAGCCCCATGAGAACTCCAGACCCTTGTCCCTTGAGCAC                   CCCTGCCCCGGCCCTCAGCTCCGGACCTCCGTGCAGCCCTCCCACCTCTTCATCCAAG                   ACCCCACCATGCCACCCCACCCAGCTCCCAACCCCCTAACCCAGCTGGAGGAGGCGCG                   CCGACGTCTCGAGGAGCAAGAAAACAGAGCCAGCCGAGCACCCTCCAAGCAGACGTAT                   CTCCAGCAGGTTATGCCGCGCGGACGCGCCTCCGTCAGGCCAGCGTCCGCGCCGGTCC                   TGCACGTGGTACCAGCCGTGTCGGACATGGAGCTCTCCGAGACAGAGACAAGATCGCA                   GAGGAAGGTCCGCGGCGGGAGTGCCCAGCCGTGTGACAGCATCGTTGTGGCCTACTAC                   TTCTGCGGGGAACCCATCCCCTACCGCACCCTGGTGAGGGGCCGCGCTGTCACCCTGG                   GCCAGTTCAAGGAGCTGCTGACCAAAAAGGGCAGCTACAGATACTACTTCAAGAAAGT                   GAGCGACGAGTTTGACTGTGCGGTGGTGTTTGAGGAGGTTCGAGAGGACGAGGCCGTC                   CTGCCCGTCTTTGAGGAGAACATCATCGGCAAAGTGGAGAAGGTGGAC TGA   TAGGCTG                       GTGGGCTGGCCCCTGTGCCAGGCGACCCCCTTGGCGGGCACGGGTGTCACGGCCAGGC                       AGATCACCTCGTACTCAGGAGCCCGATGGGGAACAGTGTTGCCTGTACC                                           ORF Start: ATG at 97       ORF Stop: TGA at 2833           SEQ ID NO:270   912 aa   MW at 101118.1 kD                     NOV94a,   MGPDRAAPLREPGPGSRHHRARDRLIHFGAVSTDVLGCSAHCSLTQSPKMNIQEQGFP       CG59761-01 Protein Sequence           LDLGASFTEDAPRPPVPGEEGELVSTDPRPASYSFCSGKGVGIKGETSTATPRRSDLD                   LGYEPEGSASPTPPYLKWAESLHSLLDDQDGISLFRTFLKQEGCADLLDFWFACTGFR                   KLEPCDSNEEKRLKLARAIYRKYILDNNGIVSRQTKPATKSFIKGCIMKQLIDPAMFD                   QAQTEIQATMEENTYPSFLKSDIYLEYTRTGSESPKVCSDQSSGSGTGKGISGYLPTL                   NEDEEWKCDQDMDEDDGRDAAPPGRLPQKLLLETAAPRVSSSRRYSEGREFRYGSWRE                   PVNPYYVNAGYALAPATSANDSEQQSLSSDADTLSLTDSSVDGIPPYRIRKQHRREMQ                   ESVQVNGRVPLPHIPRTYRVPKEVRVEPQKFAEELIHRLEAVQRTREAEEKLEERLKR                   VRMEEEGEDGDPSSGPPGPCHKLPPAPAWHHFPPRLCWTWACAGLRDAHEENPESILD                   EHVQRVLRTPGRQSPGPGHRSPDSGHVAKMPVALGGAASGHGKHVPKSGAKLDAAGLH                   HHRHVHHHVHHSTARPKEQVEAEATRRAQSSFAWGLEPHSHGARSRGYSESVGAAPNA                   SDGLAHSGKVGVACKRNAKKAESGKSASTEVPGASEDAEKNQKIMQWIIEGEKEISRH                   RRTGHGSSGTRKPQPHENSRPLSLEHPWAGPQLRTSVQPSHLFIQDPTMPPHPAPNPL                   TQLEEARRRLEEEEKRASRAPSKQRYVQEVMRRGRACVRPACAPVLHVVPAVSDMELS                   ETETRSQRKVGGGSAQPCDSIVVAYYFCGEPIPYRTLVRGRAVTLGQFKELLTKKGSY                   RYYFKKVSDEFDCGVVFEEFREDEAVLPVFEEKIIGKVEKVD                  
 
     [0818] Further analysis of the NOV94a protein yielded the following properties shown in Table 94B.  
               TABLE 94B                       Protein Sequence Properties NOV94a                                        PSort   0.6000 probability located in nucleus; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1000 probability located           in mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0819] A search of the NOV94a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 94C.  
               TABLE 94C                          Geneseq Results for NOV94a                                         NOV94a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAG68175   Wnt signaling protein SEQ ID   13 . . . 912   898/900 (99%)   0.0           NO: 91- Homo sapiens , 900 aa.    1 . . . 900   898/900 (99%)           [WO200177327-A1,           18 OCT. 2001]       AAW96264   Human axin- Homo sapiens , 900   13 . . . 912   898/900 (99%)   0.0           aa. [WO9902179-A1,    1 . . . 900   898/900 (99%)           21 JAN. 1999]       AAW96265   Murine axin- Mus musculus , 992    6 . . . 912   781/914 (85%)   0.0           aa. [WO9902179-A1,   84 . . . 992   820/914 (89%)           21 JAN. 1999]       AAW93569   Human conductin protein- Homo     60 . . . 912   378/892 (42%)   e−171             sapiens , 840 aa. [WO9911780-A2,   12 . . . 840   506/892 (56%)           11 MAR. 1999]       AAW93570   Human conductin protein- Homo     60 . . . 912   378/892 (42%)   e−171             sapiens , 840 aa. [WO9911780-A2,   12 . . . 840   506/892 (56%)           11 MAR. 1999]                  
 
     [0820] In a BLAST search of public sequence databases, the NOV94a protein was found to have homology to the proteins shown in the BLASTP data in Table 94D.  
               TABLE 94D                          Public BLASTP Results for NOV94a                                         NOV94a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               O15169   Axin 1 (Axis inhibition protein 1)   13 . . . 912   898/900 (99%)   0.0           (hAxin)- Homo sapiens  (Human),    1 . . . 900   898/900 (99%)           900 aa (fragment).       Q96S28   AXIN- Homo sapiens  (Human),   50 . . . 912   858/863 (99%)   0.0           862 aa.    1 . . . 862   858/863 (99%)       O35625   Axin 1 (Axis inhibition protein 1)    6 . . . 912   781/914 (85%)   0.0           (Fused protein)- Mus musculus     84 . . . 992   820/914 (89%)           (Mouse), 992 aa (fragment).       O70239   Axin 1 protein (Axis inhibition    6 . . . 912   756/914 (82%)   0.0           protein 1) (rAxin)- Rattus     21 . . . 893   793/914 (86%)             norvegicus  (Rat), 893 aa           (fragment).       T08422   negative regualtor axin [imported]-   46 . . . 912   726/872 (83%)   0.0           rat, 832 aa.    2 . . . 832   760/872 (86%)                  
 
     [0821] PFam analysis predicts that the NOV94a protein contains the domains shown in the Table 94E.  
               TABLE 94E                          Domain Analysis of NOV94a                                     Identities/           Pfam   NOV94a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               RGS: domain 1 of 2   137 . . . 198   23/75 (31%)   5.6e−06               44/75 (59%)       RGS: domain 2 of 2   231 . . . 260   13/30 (43%)   0.12               21/30 (70%)       TP2: domain 1 of 1   585 . . . 709   33/147 (22%)   9.6               52/147 (35%)       DIX: domain 1 of 1   830 . . . 912   40/86 (47%)   5.6e−44               83/86 (97%)                  
 
     Example 95  
     [0822] The NOV95 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 95A.  
               TABLE 95A                       NOV95 Sequence Analysis                                                SEQ ID NO:271   2223 bp                     NOV95a,     TTGCAGGCATCACCCACGCCCTCTGCACCCACGCTGGAGGACGGGGAGGTTGTCAGGG         CG59756-01 DNA Sequence             GCTATGATGAG   ATG AGTCGGGGCCGCTTCGACTTTGATGATGGAGGGGCGTACTGCGG                   GGGCTGGGAGGGGGGAAAGGCCCATGGGCATGGACTGTGCACAGGCCCCAAGGGCCAG                   GGCGAATACTCTCGCTCCTGGAACTTTGGCTTTGAGGTGGCAGGTGTCTACACCTCGC                   CCAGCGGAAACACCTTTGAGGGATACTGGAGCCAGGGCAAACGGCATGGGCTGGGCAT                   AGAGACCAAGGGGCGCTGGCTCTACAAGGCCGAGTGGACACATGGCTTCAAGGGACGC                   GCCTGCAAGACGGCTATGGCACCGAGACCTATGCTGATGGAGGGACGTACCAAGGCCA                   GTTCACCAACGGCATGCGCCATGGCTACGGAGTACGCCAGAGCGTGCCCTACGGGATG                   GCAACCGCACGGTGGCCCCGGACTCTCCCGCCTCGCCGGCCTCCGACGGCCCCGCGCT                   GCCCTCGCCCGCCATCCCGCGTGGCGGCTTCGCGCTCAGCCTCCTGGCCAATGCCGAG                   GCGGCCGCGCGGGCGCCCAAGGGCGGCGGCCTCTTCCAGCGGGCCGCGCTGCTGGGCA                   ACCTGCGGCGCGCAGAGTCGCGCACGTCCGTGGGTAGCCAGCGCAGCCGTGTCAGCTT                   CCTTAAGAGCGACCTCAGCTCGGGCGCCAGCGACGCCGCGTCCACCGCCAGCCTGCGA                   GAGGCCGCCGAGGGCGCCGACGAGGCCGCACCCTTCGAGGCCGATATCGACGCCACCA                   CCACCGAGACCTACATGGGCGAGTGGAAGAACGACAAACGCTCGGGCTTCGGCGTGAC                   CGAACGCTCCAGTGGCCTCCGCTACGAGGGCGAGTGGCTGGACAACCTGCGCCACGGC                   TATGGCTCCACCACGCTGCCCGACGGCCACCCCGAGGAGGGCAAGTACCGCCACAACG                   TGCTGGTCAAGGACACCAAGCGCCGCATGCTGCAGCTCAAGAGCAACAAGGTCCGCCA                   GAAAGTGGAGCACAGTGTGGAGGGTGCCCAGCGCGCCGCTGCTATCGCGCCCCAGAAG                   GCCGAGATTGCCGCCTCCAGGACAAGCCACGCCAAGGCCAAAGCTGAGGCAGCGGAAC                   AGGCCGCCCTGGCTGCCAACCAGGACTCCAACATTGCTCGCACTTTGGCCAGGGAGCT                   GGCTCCGGACTTCTACCAGCCAGGTCCGGAATATCAGAAGCGCCGGCTGCTGCAGGAG                   ATCCTGGAGAACTCGGAGAGCCTGCTGGAGCCCCCCGACCGGGGCGCCGGCGCAGCGG                   GCCTCCGACAGCCGCCCCGCGAGAGCCCGCAGCTGCACGAGCGTGAGACCCCTCGGCC                   CGAGGGTCCCTCCCCGTCACCGGCCGGGACGCCCCCGCAGCCCAAGCGGCCCAGGCCC                   GGGGTGTCCAAGGACCGCCTGCTGAGCCCAGGCGCCTGGAACGGCGAGCCCAGCGGTG                   AGGGCAGCCGGTCAGTCACTCCGTCCGAGGGCGCGGGCCGCCGCAGCCCCGCGCGTCC                   AGCCACCGAGCGCATGGCCATCGAGGCTCTGCAGGCACCGCCTGCGCCGTCGCGGGAG                   CCGGAGGTGGCGCTTTACCAGGGCTACCACACCTATGCTGTGCGCACCACCCCGCCCG                   AGCCCCCACCCTTTGACGACCAGCCCGACCCCGACGTCTCCGGGTCCGAGTCCGCGCC                   CTCGTCCCCCGCCACCGCCCCCCTGCAGGCCCCCACCCTCCGAGGCCCCGAGCCTGCA                   CGCGAGACCCCCGCCAAGCTGGAGCCCAAGCCCATCATCCCCAAAGCCGAGCCCAGGG                   CCAAGGCCCGCAAGACTGAGGCTCCAGGGCTGACCAAGGCGGGGGCCAAGAAGAAGGC                   GCGGAAGGAGGCCGCACTGGCGGCAGAGGCGGAGGTGGAGGTGGAAGAGGTCCCCAAC                   ACCATCCTCATCTGCATGGTGATCCTGCTGAACATCGGCCTGGCCATCCTCTTTGTTC                   ACCTCCTGACC TGA   CCGTCGCTTACCAGGTGCAGCCAGCTGGCTGCAGGAGGGGTTGG                       GGGGCAGGAGCCCCTGGGG                                           ORF Start: ATG at 70       ORF Stop: TGA at 2158           SEQ ID NO:272   696 aa   MW at 74220.7 kD                     NOV95a,   MSGGRFDFDDQCAYCGGWEGGKAEGHQLCTGPKCQGEYSGSFGFEVAGVYTWPSGN       CG59756-01 Protein Sequence           TFEGYWSQGKRHGLGIETKGRWLYKGEWTHGFKGRYGIRQSSSSGAKYEGTWNNGLQD                   GYGTETYADGGTYQGQFTNGMRHGYCVRQSVPYGMAVVVRSPLRTSLSSLRSEHSNGT                   VAPDSPASPASDCPALPSPAIPRGGFALSLLANAEAAAPAPKGGGLFQRGAILGRLRR                   AESRTSVGSQRSRVSFLKSDLSSGASDAASTASLGEAAEGADEAAPFEADTDATTTET                   YMGEWKNDKRSGFGVSERSSGLRYEGEWLDNLRHGYGCTTLPDGHREEGKYRHNVLVK                   DTKRRMLQLKSNKVRQKVEHSVEGAQRAAAIARQKAEIAASRTSHAKAKAEAAEQAAL                   AANQESNIARTLARELAPDFYQPGPEYQKRRLLQEILENSESLLEPPDRGAGAAGLPQ                   PPRESPQLHERETPRPEGGSPSPAGTPPQPKRPRPGVSKDGLLSPGAWNGEPSGEGSR                   SVTPSEGAGRRSPARPATERMAIEAIQAPPAPSREPEVALYQGYHSYAVRTTPPEPPP                   FEDQPEPEVSGSESAPSSPATAPLQAFTLRGPEPARETPAKLEPKPIIPKAEPRAKAR                   KTEARCLTKACAKKKARKEAALAAEAEVEVEEVPNTILICMVILLNICLAILFVHLLT                  
 
     [0823] Further analysis of the NOV95a protein yielded the following properties shown in Table 95B.  
               TABLE 95B                       Protein Sequence Properties NOV95a                                        PSort   0.8000 probability located in nucleus; 0.7000 probability       analysis:   located in plasma membrane; 0.3133 probability located in           microbody (peroxisome); 0.2000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0824] A search of the NOV95a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 95C.  
               TABLE 95C                          Geneseq Results for NOV95a                                         NOV95a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAM79123   Human protein SEQ ID NO 1785-    3 . . . 696   293/704 (41%)    e−127             Homo sapiens , 628 aa.    4 . . . 628   377/704 (52%)           [WO200157190-A2, 9 AUG. 2001]       AAM80107   Human protein SEQ ID NO 3753-   283 . . . 696   146/421 (34%)   2e−43             Homo sapiens , 378 aa.    24 . . . 378   194/421 (45%)           [WO200157190-A2, 9 AUG. 2001]       ABB21683   Protein #3682 encoded by probe for   257 . . . 389    78/133 (58%)   7e−42           measuring heart cell gene expression-    6 . . . 135   104/133 (77%)             Homo sapiens , 135 aa.           [WO200157274-A2, 9 AUG. 2001]       AAM57089   Human brain expressed single exon   257 . . . 389    78/133 (58%)   7e−42           probe encoded protein SEQ ID NO:    6 . . . 135   104/133 (77%)           29194- Homo sapiens , 135 aa.           [WO200157275-A2, 9 AUG. 2001]       AAM17323   Peptide #3757 encoded by probe for   257 . . . 389    78/133 (58%)   7e−42           measuring cervical gene expression-    6 . . . 135   104/133 (77%)             Homo sapiens , 135 aa.           [WO200157278-A2, 9 AUG. 2001]                  
 
     [0825] In a BLAST search of public sequence databases, the NOV95a protein was found to have homology to the proteins shown in the BLASTP data in Table 95D.  
               TABLE 95D                          Public BLASTP Results for NOV95a                                         NOV95a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9GKY7   JUNCTOPHILIN TYPE 2-    1 . . . 696   644/701 (91%)   0.0             Oryctolagus cuniculus  (Rabbit), 694 aa.    1 . . . 694   662/701 (93%)       Q9ET79   JUNCTOPHILIN TYPE 2- Mus      1 . . . 696   608/706 (86%)   0.0             musculus  (Mouse), 696 aa.    1 . . . 696   644/706 (91%)       Q9BR39   DJ1108D11.1 (NOVEL PROTEIN   128 . . . 672   544/545 (99%)   0.0           SIMILAR TO  C. ELEGANS  T22C1.7)-    1 . . . 545   544/545 (99%)             Homo sapiens  (Human), 552 aa           (fragment).       Q9GKY8   MITSUGUMIN72/JUNCTOPHILIN    1 . . . 696   364/704 (51%)   0.0           TYPE1- Oryctolagus cuniculus      1 . . . 662   468/704 (65%)           (Rabbit), 662 aa.       Q9ET80   JUNCTOPHILTN TYPE 1- Mus      1 . . . 696   371/707 (52%)   0.0           musculus (Mouse), 660 aa.    1 . . . 660   469/707 (65%)                  
 
     [0826] PFam analysis predicts that the NOV95a protein contains the domains shown in the Table 95E.  
               TABLE 95E                          Domain Analysis of NOV95a                                     Identities/           Pfam   NOV95a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               MORN: domain 1 of 7    14 . . . 36   10/23 (43%)   1.1               13/23 (57%)        MORN: domain 2 of 7    38 . . . 59    9/23 (39%)   0.31               15/23 (65%)       MORN: domain 3 of 7    60 . . . 77    8/23 (35%)   3               15/23 (65%)       MORN: domain 4 of 7   106 . . . 128   11/23 (48%)   3.7e−06               20/23 (87%)       MORN: domain 5 of 7   129 . . . 151    8/23 (35%)   0.027               15/23 (65%)       MORN: domain 6 of 7   291 . . . 313   12/23 (52%)   0.00056               19/23 (83%)       MORN: domain 7 of 7   314 . . . 336   11/23 (48%)   0.00022               19/23 (83%)                  
 
     Example 96  
     [0827] The NOV96 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 96A.  
               TABLE 96A                       NOV96 Sequence Analysis                                                SEQ ID NO:273   3257 bp                     NOV96a,     CGTAGGCGCTTCGGCC   ATG ACTGCGGAGCTGCAGCAGGACGACGCGGCCGGCGCGGCA       CG59708-01 DNA Sequence           GACGGCCACGGCTCGAGCTGCCAAATGCTGTTAAATCAACTGAGAGAAATCACAGGCA                   TTCAGGACCCTTCCTTTCTCCATGAAGCTCTGAAGGCCAGTAATCGTCACATTACTCA                   GGCAGTCAGCCTTCTCACTGATGAGAGAGTTAAGGAGCCCAGTCAAGACACTGTTGCT                   ACAGAACCATCTGAACTAGAGGCGACTGCTGCCAACAAGGAAGTATTAGCAAAAGTTA                   TAGACCTTACTCATGATAACAAAGATGATCTTCAGGCTGCCATTGCTTTGAGTCTACT                   GGAGTCTCCCAAAATTCAAGCTGATGGAAGAGATCTTAACAGGATGCATGAAGCAACC                   TCTGCAGAAACTAAACGCTCAAAGAGAAAACGCTGTGAAGTCTGGGGAGAAAACCCCA                   ATCCCAATGACTGGAGGAGAGTTGATGGTTGGCCAGTTGGGCTGTAAAATGTTGGCAA                   TACATGTTGGTTTAGTGCTGTTATTCAGTCTCTCTTTCAATTGCCTCAATTTCGAAGA                   CTTGTTCTCAGTTATAGTCTGCCACAAAATGTACTTGAAAATTGTCGAAGTCATACAG                   AAAAGAGAAATATCATGTTTATGCAAGAGCTTCAGTATTTGTTTGCTCTAATGATGGG                   ATCAAATAGAAAATTTGTAGACCCCTCTGCAGCCCTGGATCTATTAAAGGGAGCATTC                   CGATCATCTGAGGAACAGCAGCAAGATGTGAGTGAATTCACACACAACCTCCTGGATT                   GGCTAGACCACGCATTCCAGCTACCTGTTAATGTTAACAGTCCCAGGAACAAATCTGA                   AAATCCAATGGTGCAGCTGTTCTATGGTACTTTCCTGACTGAAGGGCTTCGTGAAGGA                   AAACCCTTTTGTAACAATGAGACCTTCGGCCAGTATCCTCTTCAGCTAAACGGTTATC                   GCAACTTACACGAGTGTTTGCAAGGGGCCATGGTGCAGGGTGATGTTCAGCTTCTTCC                   CTCCGATCACTCGGTGAAGTATGGACAAGAGCGTTGGTTTACAAAGCTACCTCCAGTG                   TTCACCTTTGAACTCTCAAGATTTGAGTTTAATCACTCCCTTGGGCAGCCAGAGAAAA                   TTCACAATAAGCTGGAATTTCCTCAGATTATTTATATGGACACCTACATGTACACGAG                   CAAGGAGCTTATTCGAAATAAGAGAGAGTGTATTCGAAAGTTGAAGGAGGAAATAAAA                   ATTCTGCAGCAAAAATTGGAAAGGTATGTGAAATATCGCTCAGGCCCAGCTCGCTTCC                   CGCTCCCGGACATGCTGAAATATGTTATTGAATTTGCTAGTACAAAACCTGCCTCAGA                   AAGCTGTCCACCTGAAAGTGACACACATATGACATTACCACTTTCTTCAGTGCACTGC                   TCGGTTTCTGACCAGACATCCAAGGAAAGTACAAGTACAGAAAGCTCTTCTCAGGATG                   TTGAAAGTACCTTTTCTTCTCCTGAAGATTCTTTACCCAAGTCTAAACCACTGACATC                   TTCTCGGTCTTCCATGGAAATGCCTTCACAGCCAGCTCCACGAACAGTCACAGATGAG                   GAGATAAATTTTGTTAAGACCTCTCTTCAGAGATGGAGGACTGAGATTGAACAAGATA                   TACAAGATTTAAAGACTTGTATTGCAAGTACTACTCAGACTATTGAACAGATGTACTG                   CGATCCTCTCCTTCGTCAGGTGCCTTATCGCTTGCATGCAGTTCTTGTTCATGAAGGA                   CAAGCAAATCCTGGACACTATTGGGCCTATATCTATAATCAACCCCGACAGAGCTGGC                   TCAAGTACAATGACATCTCTGTTACTGAATCTTCCTGGGAAGAAGTTGAAAGAGATTC                   CTATGGAGGCCTGAGAAATGTTAGTCCTTACTGTCTGATGTACATTAATGCCAAACTA                   CCCTACTTCAATCCAGAGGCAGCCCCAACTGAATCAGATCAAATGTCAGAAGTGGAAG                   CCCTATCTGTGGAACTCAAGCATTACATTCAGGAGGATAACTGGCGGTTTGAGCAGGA                   AGTAGAGGAGTGGGAAGAAGAGCAGTCTTGCAAAATCCCTCAAATGGAGTCCTCCCCC                   AACTCCTCATCACAGGGCTACTCTACATCACAAGAGCCTTCAGTAGCCTCTTCTCATG                   GGGTTCGCTGCTTGTCATCTGAGCATGCTGTGATTGTAAAGGAGCAAACTGCCCAGGC                   TATTGCAAACACAGCCCGTGCCTATGAGAAGAGCGGTGTAGAAGCGGCACTGAGTGAG                   GCATTCCATGAAGAATACTCCAGGCTCTATCAGCTTGCCAAAGAGACCCCCACCTCTC                   ACAGTGATCCTCGACTTCAGCATGTCCTTGTCTACTTTTTCCAAAATGAAGCACCCAA                   AAGGGTAGTAGAACGAACGCTTCTGGAACAGTTTGCAGATAAAAATCTTAGCTATGAT                   GAAAGATCAATCAGCATTATGAAGGTGGCTCAAGCGAAACTGAAGGAAATTGGTCCAG                   ATGAGATGAATATGGAAGAGTACAAGAGGTGGCATGAAGATTATAGTTTGTTCCGAAA                   AGTGTCTGTGTATCTCCTAACAGCCCTACAACTCTATCAAAAAGGAAAGTACCAAGAC                   GCACTTTCCTACCTGGTATATGCCTACCAGAGCAATGCTGCCCTGCTGATGAAGGGGC                   GGCATTAATGTGATGAATGAACTGATCATCCCCTGCATTCACCTTATCATTAATAATG                   ACATTTCCAAGGATGATCTGGATGCCATTGAGGTCATGAGAAACCATTGGTGCTCTTA                   CCTTGGGCAAGATATTGCAGAAAATCTGCAGCTGTGCCTAGGCGAGTTTCTACCCAGA                   CTTCTAGATCCTTCTGCAGAAATCATCGTCTTGAAAGAGCCTCCAACTATTCGACCCA                   ATTCTCCCTATGACCTATGTAGCCGATTTGCAGCTGTCATGGAGTCAATTCAGGGAGT                   TTCAACTGTGACAGTGAAA TAA   GCTCCCACATGTTCAAGGCCCATTCTGGTTCCTGGC                       TGCCTGCCTCTTGCACACAAGTTCGTTGTCATAGTCCTCACCTTGGGAAAAGGATTAG                       GTGGGCACA                                           ORF Start: ATG at 17       ORF Stop: TAA at 3152           SEQ ID NO:274   1045 aa   MW at 119041.7 kD                     NOV96a,   MTAELQQDDAAGAADGHGSSCQMLLNQLREITGIQDPSFLHEALKASNGDITQAVSLL       CG59708-01 Protein       Sequence   TDERVKBPSQDTVATEPSEVEGSAANKEVLAKVTDLTHDNKDDLQAAIALSLLESPKI                   QADGRDLNRMHEATSAETKRSKRKRCEVWGENPNPNDWRRVDGWPVGLKNVGNTCWFS                   AVIQSLFQLPEFRRLVLSYSLPQNVLENCRSHTEKRNIMFMQELQYLFALMMGSNRKF                   VDPSAALDLLKGAFRSSEEQQQDVSEFTHKLLDWLEDAFQLAVNVNSPRNKSENPMVQ                   LFYGTFLTEGVREGKPFCNNETFGQYPLQVNGYRNLDECLEGAMVEGDVELLPSDHSV                   KYGQERWFTKLPPVLTFELSRFEFNQSLGQPEKIHNKLEFPQIIYMDRYMYRSKELIR                   NKRECIRKLKEEIKILQQKLERYVKYGSGPARFPLPDMLKYVIEFASTKPASESCPPE                   SDTHMTLPLSSVHCSVSDQTSKESTSTESSSQDVESTFSSPEDSLPKSKPLTSSRSSM                   EMPSQPAPRTVTDEEINFVKTCLQRWRSEIEQDIQDLKTCIASTTQTIEQMYCDPLLR                   QVPYRLHAVLVHEGQANAGHYWAYIYNQPRQSWLKYNDISVTESSWEEVERDSYGGLR                   NVSAYCLMYINAKLPYFNAEAAPTESDQMSEVEALSVELKHYIQEDNWRFEQEVEEWE                   EEQSCKIPQMESSPNSSSQGYSTSQEPSVASSHGVRCLSSEHAVIVKEQTAQAIANTA                   RAYEKSGVEAALSEAFHEEYSRLYQLAKETPTSHSDPRLQHVLVYFFQNEAPKRVVER                   TLLEQFADKNLSYDERSISIMKVAQAKLKEIGPDDMNMEEYKRWHEDYSLFRKVSVYL                   LTGLELYQKGKYQEALSYLVYAYQSNAALLMKGPRRGVKESVIALYRRKCLLELNAKA                   ASLFETNDDHSVTEGINVMNELIIPCIHLIINNDISKDDLDAIEVMRNHWCSYLGQDI                   AENLQLCLGEFLPRLLDPSAEIIVLKEPPTIRPNSPYDLCSRFAAVMESIQGVSTVTVK                                     SEQ ID NO:275   3044 bp                     NOV96b,     CGTAGGCGCTTCGGCC   ATG ACTGCGGAGCTGCAGCAGGACGACGCGGCCGGCGCGGCA       CG59708-02 DNA Sequence           GACGGCCACGGCTCGAGCTGCCAAATGCTGTTAAATCAACTGAGAGAAATCACAGGCA                   TTCAGGACCCTTCCTTTCTCCATGAAGCTCTGAAGGCCAGTAATGGTGACATTACTCA                   GGCAGTCAGCCTTCTCACTGATGAGAGAGTTAAGGAGCCCAGTCAAGACACTGTTGCT                   ACAGAACCATCTGAAGTAGAGGGGAGTGCTGCCAACAAGGAAGTATTAGCAAAAGTTA                   TAGACCTTACTCATGATAACAAAGATGATCTTCAGGCTGCCATTGCTTTGAGTCTACT                   GGAGTCTCCCAAAATTCAAGCTGATGGAAGAGATCTTAACAGGATGCATGAAGCAACC                   TCTGCAGAAACTAAACGCTCAAAGAGAAATATCATGTTTATGCAAGAGCTTCAGTATT                   TGTTTGCTCTAATGATGGGATCAAATAGAAAATTTGTAGACCCGTCTGCAGCCCTGGA                   TCTATTAAAGGGAGCATTCCGATCATCTGAGGAACAGCAGCAAGATGTGAGTGAATTC                   ACACACAAGCTCCTGGATTGGCTAGAGGACGCATTCCAGCTAGCTGTTAATGTTAACA                   GTCCCAGGAACAAATCTGAAAATCCAATGGTGCAGCTGTTCTATGGTACTTTCCTGAC                   TGAAGGGGTTCGTGAAGGAAAACCCTTTTGTAACAATGAGACCTTCGGCCAGTATCCT                   CTTCAGGTAAACGGTTATCGCAACTTAGACGAGTGTTTGGAAGGGGCCATGGTGGAGG                   GTGATGTTGAGCTTCTTCCCTCCGATCACTCGGTGAAGTATGGACAAGAGCGTTGGTT                   TACAAAGCTACCTCCAGTGTTGACCTTTGAACTCTCAAGATTTGAGTTTAATCAGTCC                   CTTGGGCAGCCAGAGAAAATTCACAATAAGCTGGAATTTCCTCAGATTATTTATATGG                   ACAGGTACATGTACAGGAGCAAGGAGCTTATTCGAAATAAGAGAGAGTGTATTCGAAA                   GTTGAAGGAGGAAATAAAAATTCTGCAGCAAAAATTGGAAAGGTATGTGAAATATGGC                   TCAGGCCCAGCTCCGTTCCCGCTCCCGGACATGCTGAAATATGTTATTGAATTTGCTA                   GTACAAAACCTGCCTCAGAAAGCTGTCCACCTGAAAGTGACACACATATGACATTACC                   ACTTTCTTCAGTGCACTGCTCGGTTTCTGACCAGACATCCAAGGAAACTACAAGTACA                   GAAACCTCTTCTCAGGATGTTGAAAGTACCTTTTCTTCTCCTGAAGATTCTTTACCCA                   AGTCTAAACCACTGACATCTTCTCGGTCTTCCATGGAAATGCCTTCACAGCCAGCTCC                   ACGAACAGTCACAGATGAGCAGATAAATTTTGTTAAGACCTGTCTTCAGACATGGAGG                   AGTGAGATTGAACAAGATATACAAGATTTAAAGACTTGTATTGCAAGTACTACTCAGA                   CTATTGAACAGATGTACTGCGATCCTCTCCTTCGTCAGGTGCCTTATCGCTTGCATGC                   AGTTCTTGTTCATGAACGACAAGCAAATGCTGGACACTATTCGGCCTATATCTATAAT                   CAACCCCGACAGAGCTGGCTCAAGTACAATGACATCTCTGTTACTGAATCTTCCTGGG                   AACAAGTTCAAAGAGATTCCTATGGAGGCCTGAGAAATGTTACTGCTTACTGTCTCAT                   CTACATTAATCCCAAACTACCCTACTTCAATGCAGAGGCAGCCCCAACTGAATCAGAT                   CAAATGTCAGAACTGGAAGCCCTATCTCTGGAACTCAAGCATTACATTCACGAGGATA                   ACTGGCGGTTTGAGCAGGAAGTAGAGGAGTGGGAAGAAGAGCAGTCTTGCAAAATCCC                   TCAAATCGAGTCCTCCCCCAACTCCTCATCACAGGCCTACTCTACATCACAAGAGCCT                   TCAGTAGCCTCTTCTCATGGGGTTCGCTGCTTGTCATCTGAGCATGCTGTGATTGTAA                   AGGAGCAAACTGCCCAGGCTATTGCAAACACAGCCCGTGCCTATGAGAAGAGCGGTGT                   AGAAGCGGCACTGAGTGAGGCATTCCATGAAGAATACTCCAGGCTCTATCAGCTTGCC                   AAAGAGACCCCCACCTCTCACAGTGATCCTCGACTTCAGCATGTCCTTGTCTACTTTT                   TAAAAATCTTAGCTATGATCAAAGATCAATCAGCATTATGAAGGTGGCTCAAGCGAAA                   CTGAAGGAAATTGGTCCAGATGACATGAATATGGAAGAGTACAAGAGGTGGCATGAAG                   ATTATAGTTTGTTCCGAAAAGTGTCTGTGTATCTCCTAACAGGCCTAGAACTCTATCA                   AAAAGGAAAGTACCAAGAGGCACTTTCCTACCTGGTATATCCCTACCAGAGCAATGCT                   GCCCTGCTGATGAACCGGCCCCGCCGGCGGCTCAAAGAATCCGTCATTGCTTTATACC                   GAAGAAAATGCCTTCTCGAGCTGAATGCCAAAGCAGCTTCTCTTTTTGAAACAAATGA                   CACCTTATCATTAATAATGACATTTCCAAGGATGATCTGGATGCCATTGAGGTCATGA                   GAAACCATTGGTCCTCTTACCTTGGGCAAGATATTGCAGAAAATCTGCAGCTGTGCCT                   AGGGGAGTTTCTACCCAGACTTCTAGATCCTTCTCCAGAAATCATCGTCTTGAAAGAG                   CCTCCAACTATTCGACCCAATTCTCCCTATGACCTATGTAGCCGATTTGCAGCTGTCA                   TCGAGTCAATTCAGGGAGTTTCAACTGTCACAGTGAAA TAA   GCTCCCACATGTTCAAG                       GCCCATTCTGGTTCCTGGCTGCCTCCCTCTTGCACAGAAGTTCCTTGTCATACTGCTC                       ACCTTGGGAAAAGGATTAGGTGGGCACA                                           ORF Start: ATG at 17       ORF Stop: TAA at 2939           SEQ ID NO:276   974 aa   MW at 110687.3 kD                     NOV96b,   MTAELQQDDAAGAADGHGSSCQMLLNQLREITGIQDPSFLHEALKASNGDITQAVSLL       CG59708-02 Protein       Sequence   TDERVKBPSQDTVATEPSEVEGSAANKEVLAKVTDLTHDNKDDLQAAIALSLLESPKI                   QADGRDLNRMHEATSAETKRSKRNIMFMQELQYLFALMMGSNRKFVDPSAALDLLKGA                   FRSSEEQQQDVSEFTHKLLDWLEDAFQLAVNVNSPRNKSENPMVQLFYGTFLTEGVRE                   GKPFCNNETFGQYPLQVNGYRNLDECLEGAMVEGDVELLPSDHSVKYGQERWFTKLPP                   VLTFELSRFEFNQSLGQPEKIHNKLEFPQIIYMDRYMYRSKELIRNKRECIRKLKEEI                   KILQQKLERYVKYGSGPARFPLPDMLKYVIEFASTKPASESCPPESDTHMTLPLSSVH                   CSVSDQTSKESTSTESSSQDVESTFSSPEDSLPKSKPLTSSRSSMEMPSQPAPRTVTD                   EEINFVKTCLQRWRSEIEQDIQDLKTCIASTTQTIEQMYCDPLLRQVPYRLHAVLVHE                   GQANAGHYWAYIYNQPRQSWLKYNDISVTESSWEEVERDSYGGLRNVSAYCLMYINAK                   LPYFNAEAAPTESDQMSEVEALSVELKHYIQEDNWRFEQEVEEWEEEQSCKIPQMESS                   PNSSSQGYSTSQEPSVASSHGVRCLSSEHAVIVKEQTAQAIANTARAYEKSGVEAALS                   EAFHEEYSRLYQLAKETPTSHSDPRLQHVLVYFFQNEAPKRVVERTLLEQFADKNLSY                   DERSISIMKVAQAKLKEIGPDDMNMEEYKRWHEDYSLFRKVSVYLLTGLELYQKGKYQ                   EALSYLVYAYQSNAALLMKGPRRGVKESVIALYRRKCLLELNAKAASLFETNDDHSVT                   EGINVMNELIIPCIHLIINNDISKDDLDAIEVMRNHWCSYLGQDIAENLQLCLGEFLP                   RLLDPSAEIIVLKEPPTIRPNSPYDLCSRFAAVMESIQGVSTVTVK                                     SEQ ID NO:277   3231 bp                     NOV96c,     GCGCTTCGGCC   ATG ACTGCGGAGCTGCAGCAGGACGACGCGGCCGGCGCGGCAGACGG       CG59708-03 DNA Sequence           CCACGGCTCGAGCTGCCAAATGCTGTTAAATCAACTGAGAGAAATCACAGGCATTCAG                   GACCCTTCCTTTCTCCATGAAGCTCTGAGGGCCAGTAATGGTGACATTACTCAGGCAG                   TCAGCCTTCTCACTGATGAGAGAGTTAAGGAGCCCAGTCAAGACACTGTTGCTACAGA                   ACCATCTGAAGTAGAGGGGAGTGCTGCCAACAAGGAAGTATTAGCAAAAGTTATAGAC                   ACCATCTGAAGTAGAGGGGAGTGCTGCCAACAAGGAAGTATTAGCAAAAGTTATAGAC                   CTTACTCATGATAACAAAGATGATCTTCAGGCTGCCATTGCTTTGAGTCTACTGGAGT                   CTCCCAAAATTCAAGCTGATGGAAGAGATCTTAACAGGATGCATGAAGCAACCTCTGC                   AGAAACTAAACGCTCAAAGAGAAAACGCTGTGAAGTCTGGGGAGAAAACCCCAATCCC                   AATGACTGGAGGAGAGTTGATGGTTGGCCAGTTGGGCTGAAAAATGTTGGCAATACAT                   GTTGGTTTAGTGCTGTTATTCAGTCTCTCTTTCAATTGCCTGAATTTCGAAGACTTGT                   TCTCAGTTATAGTCTGCCACAAAATGTACTTGAAAATTGTCGAAGTCATACAGAAAAG                   AGAAATATCATGTTTATGCAAGAGCTTCAGTATTTGTTTGCTCTAATGATGGGATCAA                   ATAGAAAATTTGTAGACCCGTCTGCAGCCCTGGATCTATTAAAGGGAGCATTCCGATC                   ATCTGAGGAACAGCAGCAAGATGTGAGTGAATTCACACACAAGCTCCTGGATTGGCTA                   GAGGACGCATTCCAGCTAGCTGTTAATGTTAACAGTCCCAGGAACAAATTTGAAAATC                   CAATGGTGCAGCTGTTCTATGGTACTTTCCTGACTGAAGGGGTTCGTGAAGGAAAACC                   CTTTTGTAACAATGAGACCTTCGCCCAGTATCCTCTTCAGCTAAACGGTTATCCCAAC                   TTAGACGAGTGTTTCGAAGGGGCCATGGTGGAGGCTGATGTTGAGCTTCTTCCCTCCG                   ATCACTCGGTGAAGTATGGACAAGAGCGTTGGTTTACAAAGCTACCTCCAGTGTTGAC                   CTTTGAACTCTCAACATTTGAGTTTAATCAGTCCCTTGGGCAGCCAGAGAAAATTCAC                   AATAAGCTGGAATTTCCTCAGATTATTThTATGGACAQGTACATGTACAGGAGCAAGG                   GCAGCAAAAATTGGAAGGGTATGTGAAATATGGCTCAGGCCCAGCTCGGTTCCCGCTC                   CCGGACATGCTCAAATATCTTATTGAATTTCCTAGTACAAAACCTGCCTCAGAAAGCT                   GTCCACCTGAAACTGACACACATATGACATTACCACTTTCTTCAGTGCACTGCTCGCT                   AGTACCTTTTCTTCTCCTGAAGATTCTTTACCCAAGTCTAAACCACTGACATCTTCTC                   GGTCTTCCATGGAAATGCCTTCACAGCCAGCTCCACGAACACTCACAGATGAGGAGAT                   AAATTTTGTTAAGACCTGTCTTCAGAGATGCAGCAGTGAGATTCAACAAGATATACAA                   GATTTAAAGACTTGTATTGCAAGTACTACTCAGACTATTCAACAGATGTACTGCGATC                   CTCTCCTTCGTCAGGTGCCTTATCGCTTGCATGCAGTTCTTGTTCATCAAGGACAAGC                   AAATGCTGGACACTATTGGGCCTATATCTATAATCAACCCCGACAGAGCTGCCTCAAG                   TACAATGACATCTCTCTTACTGAATCTTCCTGGGAACAAGTTGAAAGAGATTCCTATG                   CACCCCTGAGAAATGTTACTGCTTACTGTCTGATGTACATTAACGACAAACTACCCTA                   CTCATCACAGGACTACTCTACATCACAAGAGCCTTCAGTACCCTCTTCTCATGGGCTT                   CGCTGCTTCTCATCTGAGCATGCTGTGATTGTAAAGGAGCAAACTGCCCAGGCTATTG                   CAAACACAGCCCGTGCCTATGAGAAGAGCCGTGTACAAGCGGCACTCAGTGAGGCATT                   CCATGAACAATACTCCAGGCTCTATCAGCTTGCCAAAGAGACCCCCACCTCTCACAGT                   GATCCTCGACTTCAGCATGTCCTTGTCTACTTTTTCCAAAATGAAGCACCCAAAAGGG                   TAGTAGAACGAACCCTTCTGGAACAGTTTGCAGATAAAAATCTTAGCTATGATGAAAG                   ATGAATATGGAAGAGTACAAGAAGTGGCATGAAGATTATAGTTTGTTCCGAAAAGTGT                   CTGTGTATCTCCTAACAGGCCTAGAACTCTATCAAAAAGGAAAGTACCAAGAGGCACT                   TTCCTACCTGGTATATGCCTACCAGAGCAATGCTGCCCTGCTGATGAAGGGGCCCCCC                   CGGGGGGTCAAACAATCCGTGATTGCTTTATACCGAAGAAAATGCCTTCTGCAGCTGA                   ATGCCAAAGCAGCTTCTCTTTTTGAAACAAATGATGATCACTCCGTAACTGAGGGCAT                   TAATGTGATGAATGAACTGATCATCCCCTGCATTCACCTTATCATTAATAATGACATT                   GGCAAGATATTGCAGAAAATCTGCAGCTGTGCCTAGGGGAGTTTCTACCCAGACTTCT                   AGATCCTTCTGCAGAAATCATCCTCTTGAAAGAGCCTCCAACTATTCGACCCAATTCT                   CCCTATGACCTATGTAGCCGATTTCCAGCTGTCATGGAGTCAATTCAGGGAGTTTCAA                   CTGTGACACTGAAATAAGCTCCCACATGTTCAAGCCCCATTCTGGTTCCTGGCTGCCT                   GCCTCTTGCACAGAACTTCCTTGTCATAGTGCTCACCTTGG                                         ORF Start: ATG at 12       ORF Stop: TAA at 3147           SEQ ID NO:278   1045 aa   MW at 119107.7 kD                     NOV96c,   MTAELQQDDAAGAADGHGSSCQMLLNQLREITGIQDPSFLHEALKASNGDITQAVSLL       CG59708-03 Protein       Sequence   TDERVKBPSQDTVATEPSEVEGSAANKEVLAKVTDLTHDNKDDLQAAIALSLLESPKI                   QADGRDLNRMHEATSAETKRSKRKRCEVWGENPNPNDWRRVDGWPVGLKNVGNTCWFS                   AVIQSLFQLPEFRRLVLSYSLPQNVLENCRSHTEKRNIMFMQELQYLFALMMGSNRKF                   VDPSAALDLLKGAFRSSEEQQQDVSEFTHKLLDWLEDAFQLAVNVNSPRNKSENPMVQ                   LFYGTFLTEGVREGKPFCNNETFGQYPLQVNGYRNLDECLEGAMVEGDVELLPSDHSV                   KYGQERWFTKLPPVLTFELSRFEFNQSLGQPEKIHNKLEFPQIIYMDRYMYRSKELIR                   NKRECIRKLKEEIKILQQKLERYVKYGSGPARFPLPDMLKYVIEFASTKPASESCPPE                   SDTHMTLPLSSVHCSVSDQTSKESTSTESSSQDVESTFSSPEDSLPKSKPLTSSRSSM                   EMPSQPAPRTVTDEEINFVKTCLQRWRSEIEQDIQDLKTCIASTTQTIEQMYCDPLLR                   QVPYRLHAVLVHEGQANAGHYWAYIYNQPRQSWLKYNDISVTESSWEEVERDSYGGLR                   NVSAYCLMYINAKLPYFNAEAAPTESDQMSEVEALSVELKHYIQEDNWRFEQEVEEWE                   EEQSCKIPQMESSPNSSSQGYSTSQEPSVASSHGVRCLSSEHAVIVKEQTAQAIANTA                   RAYEKSGVEAALSEAFHEEYSRLYQLAKETPTSHSDPRLQHVLVYFFQNEAPKRVVER                   TLLEQFADKNLSYDERSISIMKVAQAKLKEIGPDDMNMEEYKRWHEDYSLFRKVSVYL                   LTGLELYQKGKYQEALSYLVYAYQSNAALLMKGPRRGVKESVIALYRRKCLLELNAKA                   ASLFETNDDHSVTEGINVMNELIIPCIHLIINNDISKDDLDAIEVMRNHWCSYLGQDI                   AENLQLCLGEFLPRLLDPSAEIIVLKEPPTIRPNSPYDLCSRFAAVMESIQGVSTVTVK                  
 
     [0828] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 96B.  
               TABLE 96B                          Comparison of NOV96a against NOV96b through NOV96c.                                         Identities/           Protein   NOV96a Residues/   Similarities for           Sequence   Match Residues   the Matched Region                       NOV96b   209 . . . 1045   805/837 (96%)               138 . . . 974   805/837 (96%)           NOV96c    1 . . . 1045   979/1045 (93%)                1 . . . 1045   981/1045 (93%)                      
 
     [0829] Further analysis of the NOV96a protein yielded the following properties shown in Table 96C.  
               TABLE 96C                       Protein Sequence Properties NOV96a                                        PSort   0.8800 probability located in nucleus; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1000 probability located           in mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0830] A search of the NOV96a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 96D.  
               TABLE 96D                          Geneseq Results for NOV96a                                         NOV96a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAE04874   Human protease protein-1 (PRTS-   22 . . . 1036   524/1035 (50%)   0.0           1)  Homo sapiens , 1055 aa.   18 . . . 1047   713/1035 (68%)           [WO200146443-A2,           28 JUN. 2001]       AAB31552   A human ubiquitin specific   22 . . . 1036   524/1035 (50%)   0.0           protease 25 (USP25)- Homo     18 . . . 1047   713/1035 (68%)             sapiens , 1055 aa. [WO200079267-           A2, 28 DEC. 2000]       AAB31546   A human ubiquitin specific   22 . . . 1036   524/1035 (50%)   0.0           protease 25 (USP25)- Homo     18 . . . 1047   713/1035 (68%)             sapiens , 1055 aa. [WO200078934-           A2, 28 DEC. 2000]       AAB74491   Human SYK kinase binding   22 . . . 1036   522/1035 (50%)   0.0           protein  sapiens , 1055 aa.   18 . . . 1047   710/1035 (68%)           [WO200121654-A2,           29 MAR. 2001]       AAB31556   A human ubiquitin specific   22 . . . 1036   525/1067 (49%)   0.0           protease (USP)- Homo sapiens ,   18 . . . 1079   717/1067 (66%)           1087 aa. [WO200079267-A2,           28 DEC. 2000]                  
 
     [0831] In a BLAST search of public sequence databases, the NOV96a protein was found to have homology to the proteins shown in the BLASTP data in Table 96E.  
               TABLE 96E                          Public BLASTP Results for NOV96a                                         NOV96a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96RU2   UBIQUITIN SPECIFIC PROTEASE-    1 . . . 1045   1041/1077 (96%)   0.0             Homo sapiens  (Human), 1077 aa.    1 . . . 1077   1042/1077 (96%)       Q9P213   KIAA1515 PROTEIN- Homo     304 . . . 1045    738/742 (99%)   0.0           sapiens (Human), 757 aa (fragment).    16 . . . 757    739/742 (99%)       P57080   Ubiquitin carboxyl-terminal    22 . . . 1036    527/1033 (51%)   0.0           hydrolase 25 (EC 3.1.2.15)    18 . . . 1047    710/1033 (68%)           (Ubiquitin thiolesterase 25)           (Ubiquitin-specific processing           protease 25) (Deubiquitinating           enzyme 25) (mUSP25)- Mus               musculus  (Mouse), 1055 aa.       Q9UHP3   Ubiquitin carboxyl-terminal    22 . . . 1036    525/1067 (49%)   0.0           hydrolase 25 (EC 3.1.2.15)    18 . . . 1079    717/1067 (66%)           (Ubiquitin thiolesterase 25)           (Ubiquitin-specific processing           protease 25) (Deubiquitinating           enzyme 25) (USP on chromosome           21)- Homo sapiens  (Human), 1087           aa.       Q9H9W1   CDNA FLJ12512 FIS, CLONE   313 . . . 1036   363/733 (49%)   0.0           NT2RM2001730, WEAKLY    2 . . . 729   510/733 (69%)           SIMILAR TO PROBABLE           UBIQUITIN CARBOXYL-           TERMINAL HYDROLASE           K02C4.3 (EC 3.1.2.15)- Homo               sapiens  (Human), 737 aa.                  
 
     [0832] PFam analysis predicts that the NOV96a protein contains the domains shown in the Table 96F.  
               TABLE 96F                          Domain Analysis of NOV96a                                     Identities/           Pfam   NOV96a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               UIM: domain 1 of 1    96 . . . 113    9/18 (50%)   8.4               14/18 (78%)       UCH-1: domain 1 of 1   162 . . . 193   14/32 (44%)   2.6e−11               28/32 (88%)       UCH-2: domain 1 of 1   580 . . . 649   26/72 (36%)   1.5e−19               56/72 (78%)                  
 
     Example 97  
     [0833] The NOV97 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 97A.  
               TABLE 97A                       NOV97 Sequence Analysis                                                SEQ ID NO:279   1601 bp                     NOV97a,     AGGGCAGAGGCCACAGCGCCATCCCCTTCCCCATGGTCTCCCTACCCCCAACCTGCAC         CG59559-01 DNA Sequence             TGGGCGCTCCGCCCAGAGGTGAGTCCCTCCCAGCCCTTCTCTCCTTCTGTCCTAGCCA                       TCCGCAGAGCCATCCTCTGCAAAGGAAGGAGCTAGGCTGTGCGCCCTGGGCCTC   ATG A                   GGGGGACTCTGTGCATAGGGCAGTATACAAGGACCTGGTGCTTCTGCTGCAGAAGGAC                   CGCCTGCTCACTCCCGGGCAGCTTAGAGCAAGGGGGCAGCTGAACTTCGAACAAGATG                   AGCTGGTGGACGGAGGCCAGCGGGGCCACATGCACAACGGCCTTAACTACCGTGAGGT                   CCGCGAGTTCCGCTCCGACCACCATCTGCTACGTTTTTACTTCCTCACCCGCGTGTAC                   TCCCATTACCTCCAGACCATCTTGAAAGAGCTGCAGTCGGGCGAGCACGCCCCCGACC                   TGGTCATCATGAATTCCTGCCTCTGGGACATCTCCAGGTATGGTCCGAACTCCTGGAG                   AAGCTACCTCGAGAACCTGGAGAACCTGTTCCAGTCCCTGGGCCAGGTGCTGCCCGAG                   TCTTGCCTCCTGGTGTGGAACACGGCCATGCCTGTGGGCGAGGAAGTCACCGGGGGTT                   TTCTTCCGCCCAAGCTCCGGCGGCACAAGGCCACCTTCCTGAAAAACGAAGTGGTCAA                   AGCCAACTTCCACAGCGCCACCGACGCACGTAAACATAACTTCGATGTACTGGACTTG                   CATTTCCACTTCCCCCACGCGAGGGAGAACCTGCACTGGGACGGGGTGCACTGGAATG                   GACGTGTGCACCGCTGCCTCTCCCAGCTGCTGCTGGCCCACGTGGCCGACGCCTGGGG                   TGTGGACCTGCCCCACCGCCACCCCGTGGGCGAGTGGATCAAGAAGAAAAAACCTGGC                   CCGAGAGTCGAAGGGCCGCCCCAGGCCAACAGAAATCACCCGGCCTTACCTCTGTCCC                   CACCCTTACCTTCCCCCACATACCGCCCCCTGCTTGGGTTCCCACCCCAGCGCTTGCC                   GCTGCTCCCGCTCCTGTCCCCACAGCCTCCTCCTCCCATTCTCCATCACCAGGGAATG                   CCCCGGTTCCCACACGGTCCCCCAGATGCCTGTTTTTCCTCAGACCATACTTTCCAGT                   CGCATCAATTCTATTGCCATTCAGATGTCCCCTCATCAGCCCATGCAGGTTTCTTCGT                   CGAAGACAATTTTATGGTTGGTCCTCAGCTGCCTATGCCCTTCTTCCCCACACCCCGT                   TATCAGCGGCCTGCCCCAGTGGTACATAGGGGTTTTGGCAGGTATCGTCCCCGTGGCC                   CCTATACGCCCTGGGGACAGCGGCCTCGACCTTCAAAGAGAAGGGCCCCAGCCAATCC                   TGAGCCAAGGCCTCAA TAG   ACGGACCTAGGCCTTATTTCCTCTTTATGAACATGGATT                       GGACAGATCTGACACTTCCTTTCCATTGCTTCGCCTGAACAGACTGACCTTGTTAACT                       TAAGCCTCCAGTCCATGCCTCGTCTTCCTTTTGTT                                           ORF Start: ATG at 171       ORF Stop: TAG at 1467           SEQ ID NO:280   432 aa   MW at 49726.6 kD                     NOV97a,   MILLRASEVRQLLHNKFVVILGDSVHRAVYKDLVLLLQKDRLLTPGQLRARGELNFEQ       CG59559-01 Protein Sequence           DELVDGGQRGHMHNGLNYREVREFRSDHHLVRFYFLTRVYSDYLQTILKELQSGEHAP                   DLVIMNSCLWDISRYGPNSWRSYLENLENLFQCLGQVLPESCLLVWNTAMPVGEEVTG                   GFLPPKLRRQKATFLKNEVVKANFHSATEARKHNFDVLDLHFHFRHARENLHWDGVHW                   NGRVHRCLSQLLLAHVADAWGVELPHRHPVGEWIKKKKPGPRVEGPPQANRNHPALPL                   SPPLPSPTYRPLLGFPPQRLPLLPLLSPQPPPPILHHQGMPRFPQGPPDACFSSDHTF                   QSDQFYCHSDVPSSAHAGFFVEDNFMVGPQLPMPFFPTPRYQRPAPVVHRGFGRYRPR                   GPYTPWGQRPRPSKRRAPANPEPRPQ                  
 
     [0834] Further analysis of the NOV97a protein yielded the following properties shown in Table 97B.  
               TABLE 97B                       Protein Sequence Properties NOV97a                                        PSort   0.5937 probability located in mitochondrial matrix space;       analysis:   0.5103 probability located in microbody (peroxisome); 0.4900           probability located in nucleus; 0.3252 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0835] A search of the NOV97a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 97C.  
               TABLE 97C                          Geneseq Results for NOV97a                                         NOV97a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAG74241   Human colon cancer antigen protein   34 . . . 294   162/268 (60%)   1e−82           SEQ ID NO: 5005- Homo sapiens ,    1 . . . 266   191/268 (70%)           281 aa. [WO200122920-A2,           5 APR. 2001]       AAE03639   Human extracellular matrix and cell    1 . . . 421   197/435 (45%)   2e−82           adhesion molecule-3 (XMAD-3)-    1 . . . 366   231/435 (52%)             Homo sapiens , 386 aa.           [WO200142285-A2, 14 JUN. 2001]                  
 
     [0836] In a BLAST search of public sequence databases, the NOV97a protein was found to have homology to the proteins shown in the BLASTP data in Table 97D.  
               TABLE 97D                          Public BLASTP Results for NOV97a                                         NOV97a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96HM7   SIMILAR TO HYPOTHETICAL    1 . . . 432   432/432 (100%)   0.0           PROTEIN FLJ22376- Homo sapiens      1 . . . 432   432/432 (100%)           (Human), 432 aa.       Q96B20   HYPOTHETICAL 31.4 KDA   121 . . . 310   190/190 (100%)    e−116           PROTEIN- Homo sapiens  (Human),    1 . . . 190   190/190 (100%)           279 aa.       Q9H1Q7   BA12M19.1.3 (NOVEL PROTEIN)    1 . . . 421   234/437 (53%)    e−111           (CDNA FLJ31791 FIS, CLONE    18 . . . 434   273/437 (61%)           NT2RI2008749, WEAKLY           SIMILAR TO SPLICEOSOME           ASSOCIATED PROTEIN 49)-             Homo sapiens  (Human), 454 aa.       Q9H1Q6   BA12M19.1.1 (NOVEL PROTEIN)-    1 . . . 421   197/435 (45%)   7e−82             Homo sapiens  (Human), 403 aa.    18 . . . 383   231/435 (52%)       Q9H6D1   CDNA: FLJ22376 FIS, CLONE    1 . . . 421   196/435 (45%)   1e−81           HRC07327- Homo sapiens      18 . . . 383   231/435 (53%)           (Human), 403 aa.                  
 
     [0837] PFam analysis predicts that the NOV97a protein contains the domains shown in the Table 97E.  
               TABLE 97E                          Domain Analysis of NOV97a                                             Identities/               Pfam   NOV97a   Similarities for   Expect           Domain   Match Region   the Matched Region   Value                             No Significant Matches Found                  
 
     [0838] The NOV98 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 98A.  
               TABLE 98A                       NOV98 Sequence Analysis                                                SEQ ID NO:281   981 bp                     NOV98a,     GCGCCGGGTCCCAGAATCTAGTCCTACGCCACGGTTTTGACCACGCGTGACCCGCTGC         CG59669-01 DNA Sequence             CCAGCCGGCCCGGCCATCAGGTGGTCCGTGTGTCCCTCTGAC   ATG TCGTCCTGCAGCC                   GCGTGGCCCTGGTAACTGGGGCTAACAAAGGCATCGGCTTTGCGATCACGCGTGACCT                   GTGTCGGAAATTCTCCGGGGACGTGGTGCTCACGGCGCGGGACGAGGCGCGGGGCCGC                   GCGGCGGTGCAGCAGCTGCAGGCGGAGGGCCTGAGCCCACGCTTCCACCAGCTGGACA                   TCGACGACCCGCAGAGCATCCGTGCGCTGCGCGACTTTCTGCGCAAGGAGTACGGGGG                   ACTTAACGTGCTGGTCAACAACGCGGGCATCGCCTTTAGAAGTACTGATCTCACCCAC                   TTTCACATTCTAAGAGAAGCTGCAATGAAAACTAACTTTTTTGGTACCCAGGCCGTCT                   GCACAGAGCTACTCCCTCTAATAAAAACCCAAGGTAGAGTGGTGAATATATCAAGCCT                   AATAAGTCTAGAGGCCCTGAAAAACTGCAGCCTGGAGCTACAGCAGAAGTTTCGAAGT                   GAGACCATCACAGAGGAGGAGCTGGTGGGGCTCATGAACAAGTTTGTGGAGGATACAA                   AGAAAGGAGTCCATGCAAAAGAAGGCTGGCCTAATAGTGCATACGGGGTGTCTAAGAT                   TGGAGTGACAGTCCTGTCCAGAATCCTTGCCAGGAAACTCAATGAGCAGAGGAGAGGG                   GACAAGATCCTTCTGAATGCCTGCTGCCCTGGCTGGGTCAGAACCGACATGGCAGGAC                   CACAAGCCACCAAAAGCCCAGAAGAAGGAGCAGAGACCCCTGTGTACTTGGCCCTTTT                   GCCTCCAGATGCAGAGGGACCTCATGGGCAGTTTGTTCAAGATAAAAAAGTGGAACAA                   TGG TGA   ACTCAGCTCTTTGTACAGCTCCCATCTGTAGCCTGTCCTAAAGGGGA                                           ORF Start: ATG at 101       ORF Stop: TGA at 932           SEQ ID NO:282   277 aa   MW at 30547.7 kD                     NOV98a,   MSSCSRVALVTGANKGIGFAITRDLCRKFSGDVVLTARDEARGRAAVQQLQAEGLSPR       CG59669-01 Protein Sequence           FHQLDIDDPQSIRALRDFLRKEYGGLNVLVNNAGIAFRSTDLTHFHILREAAMKTNFF                   GTQAVCTELLPLIKTQGRVVNISSLISLEALKNCSLELQQKFRSETITEEELVGLMNK                   FVEDTKKGVHAKEGWPNSAYGVSKIGVTVLSRILARKLNEQRRGDKILLNACCPGWVR                   TDMAGPQATKSPEEGAETPVYLALLPPDAEGPHGQFVQDKKVEQW                  
 
     [0839] Further analysis of the NOV98a protein yielded the following properties shown in Table 98B.  
               TABLE 98B                       Protein Sequence Properties NOV98a                                        PSort   0.4766 probability located in mitochondrial matrix space;       analysis:   0.4500 probability located in cytoplasm; 0.1822 probability           located in mitochondrial inner membrane; 0.1822 probability           located in mitochondrial intermembrane space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0840] A search of the NOV98a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 98C.  
               TABLE 98C                          Geneseq Results for NOV98a                                         NOV98a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAW51011   Human liver carbonyl reductase-    1 . . . 277   236/277 (85%)    e−134             Homo sapiens , 277 aa.    1 . . . 277   252/277 (90%)           [U.S. Pat. No. 5756299-A,           26 MAY 1998]       AAU33100   Novel human secreted protein   142 . . . 277   119/136 (87%)   2e−66           #3591- Homo sapiens , 175 aa.    39 . . . 174   128/136 (93%)           [WO200179449-A2, 25 Oct. 2001]       AAM73641   Human bone marrow expressed    1 . . . 97    86/97 (88%)   7e−43           probe encoded protein SEQ ID NO:    1 . . . 97    92/97 (94%)           33947- Homo sapiens , 123 aa.           [WO200157276-A2, 9 AUG. 2001]       AAM60948   Human brain expressed single exon    1 . . . 97    86/97 (88%)   7e−43           probe encoded protein SEQ ID NO:    1 . . . 97    92/97 (94%)           33053- Homo sapiens , 123 aa.           [WO200157275-A2, 9 AUG. 2001]       AAM33832   Peptide #7869 encoded by probe for    1 . . . 97    86/97 (88%)   7e−43           measuring placental gene expression-    1 . . . 97    92/97 (94%)             Homo sapiens , 123 aa.           [WO200157272-A2, 9 AUG. 2001]                  
 
     [0841] In a BLAST search of public sequence databases, the NOV98a protein was found to have homology to the proteins shown in the BLASTP data in Table 98D.  
               TABLE 98D                          Public BLASTP Results for NOV98a                                         NOV98a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q924V2   CARBONYL REDUCTASE 2-   1 . . . 277   243/277 (87%)   e−139             Cricetulus griseus  (Chinese   1 . . . 277   260/277 (93%)           hamster), 277 aa.       Q91X28   SIMILAR TO CARBONYL   1 . . . 277   244/277 (88%)   e−139           REDUCTASE 1- Mus musculus     1 . . . 277   256/277 (92%)           (Mouse), 277 aa.       Q924V3   CARBONYL REDUCTASE 1-   1 . . . 277   241/277 (87%)   e−137             Cricetulus griseus  (Chinese   1 . . . 277   256/277 (92%)           hamster), 277 aa.       P48758   Carbonyl reductase [NADPH] 1 (EC   2 . . . 277   240/276 (86%)   e−136           1.1.1.184) (NADPH-dependent   1 . . . 276   253/276 (90%)           carbonyl reductase 1)- Mus               musculus  (Mouse), 276 aa.       JC5284   carbonyl reductase (NADPH) (EC   1 . . . 277   236/277 (85%)   e−134           1.1.1.184), inducible-rat, 277 aa.   1 . . . 277   249/277 (89%)                  
 
     [0842] PFam analysis predicts that the NOV98a protein contains the domains shown in the Table 98E.  
               TABLE 98E                          Domain Analysis of NOV98a                                     Identities/           Pfam   NOV98a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               adh_short: domain 1   4 . . . 274    67/286 (23%)   1.6e−38       of 1       185/286 (65%)                  
 
     Example 99.  
     [0843] The NOV99 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 99A.  
               TABLE 99A                       NOV99 Sequence Analysis                                                SEQ ID NO:283   1001 bp                     NOV99a,     CTTGGTATAAGTAAGTGCTCGTCAATGTTGGCTACTCTCA   ATG TCAGAGCCGCAGCCG       CG58624-01 DNA Sequence           CGGGGCGCAGAGCGCGATCTCTACCGGGACACGTGGGTGCGATACCTGGGCTATGCCA                   ATGAGGTGGGCGAGGCTTTCCGCTCTCTTGTGCCAGCGGCGGTGGTGTGGCTGAGCTA                   TGGCGTGGCCAGCTCCTACGTGCTGGCGGATGCCATTGACAAAGGCAAGAAGGCTGGA                   GAGGTGCCCAGCCCTGAAGCAGGCCGCAGCGCCAGGGTGACTGTGGCTGTGGTGGACA                   CCTTTGTATGGCAGGCTCTAGCCTCTGTGGCCATTCCGGGCTTCACCATCAACCGCGT                   GTGTGCTGCCTCTCTCTATGTCCTGGGCACTGCCACCCGCTGGCCCCTGGCTGTCCGC                   AAGTGGACCACCACCGCGCTTGGGCTGTTGACCATCCCCATCATTATCCACCCCATTG                   ACAGGGATCATCCACTCTCCAGTGATGAGAGTGGATCATCCAGTCTCCAGCACGAAGG                   GCCAGGGGTCCCACAGGTGAGTGGAGCCCCAGCAGCCCCCTCAGCTCTGCGTGCCCAT                   GTACTGGTCTTCTCCCTGGCTCTATACTCAGTGTTCAAGGGGTTGGACGGGGCTTGGG                   CCGCGGAGCTGCGCCTGGCTTTGCTGCTCCACAAGGGCACCGTGGCTGTCAGCCTGTC                   CCTGCAACTGCTGCAGAGCCACGTAGGGTTACAGGTGGTGGCTGGCTGTGGGATCCAC                   TTCTTGTGCATGACACTTCTAGGCATCCGGCTGGGTGCGGCTCTGGCACAGTCAGCAG                   GGCCTCTGCACCAGCTGGCCCAGTCTGTGCTAGAGGGCATGGTGGCTGGCACCTTCCT                   GTATACCACCTTTCTGGAAATCTTTCCACAGGAGCTGGCGACTTCTGAGCAAAGGATC                   CTCAAGGTCATTCTGCTCCTAGAAGGGTGTGCCCTGCTCACTGGCCTGCTCTTCATCC                   ATATC TAG   GGGGCTT                                           ORF Start: ATG at 41       ORF Stop: TAG at 992           SEQ ID NO:284   317aa   MW at 33737.8 kD                     NOV99a,   MSEPQPRGAERDLYRDTWVRYLGYANEVGEAFRSLVPAAVVWLSYGVASSYVLADAID       CG58624-01 Protein Sequence           KGKKAGEVPSPEAGRSARVTVAVVDTFVWQALASVAIPGFTINRVCAASLYVLGTATR                   WPLAVRKWTTTALGLLTIPIIIHPIDRDHPLSSDESGSSSLQHEGPGVPQVSGAPAAP                   SALRAHVLVFSLALYSVFKGLDGAWAAELRLALLLHKGTVAVSLSLQLLQSHVGLQVV                   AGCGIHFLCMTLLGIRLGAALAQSAGPLHQLAQSVLEGMVAGTFLYTTFLEIFPQELA                   TSEQRILKVILLLEGCALLTGLLFIHI                  
 
     [0844] Further analysis of the NOV99a protein yielded the following properties shown in Table 99B.  
               TABLE 99B                       Protein Sequence Properties NOV99a                                        PSort   0.6000 probability located in plasma membrane;       analysis:   0.4000 probability located in Golgi body; 0.3000           probability located in endoplasmic reticulum (membrane);           0.1000 probability located in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 55 and 56       analysis:                  
 
     [0845] A search of the NOV99a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 99C.  
               TABLE 99C                          Geneseq Results for NOV99a                                         NOV99a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAM93835   Human polypeptide, SEQ ID NO:   140 . . . 317   134/184 (72%)   3e−63           3905- Homo sapiens , 324 aa.   141 . . . 324   145/184 (77%)           [EP1130094-A2, 5 SEP. 2001]       AAY52394   Human transmembrane protein   140 . . . 317   134/184 (72%)   3e−63           HP10528- Homo sapiens , 324 aa.   141 . . . 324   145/184 (77%)           [WO9955862-A2, 4 NOV. 1999]       AAY84895   A human proliferation and   140 . . . 317   134/184 (72%)   3e−63           apoptosis related protein- Homo     141 . . . 324   145/184 (77%)             sapiens , 324 aa. [WO200023589-           A2, 27 APR. 2000]       AAB43291   Human ORFX ORF3055   140 . . . 317   134/184 (72%)   3e−63           polypeptide sequence SEQ ID   140 . . . 323   145/184 (77%)           NO: 6110- Homo sapiens , 323 aa.           [WO200058473-A2, 5 OCT. 2000]       AAM93650   Human polypeptide, SEQ ID NO:   140 . . . 317   133/184 (72%)   2e−62           3514- Homo sapiens , 324 aa.   141 . . . 324   144/184 (77%)           [EP1130094-A2, 5 SEP. 2001]                  
 
     [0846] In a BLAST search of public sequence databases, the NOV99a protein was found to have homology to the proteins shown in the BLASTP data in Table 99D.  
               TABLE 99D                          Public BLASTP Results for NOV99a                                         NOV99a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q9UDX5   WUGSC:H_DJ0539M06.2 PROTEIN -    1 . . . 152   145/152 (95%)   6e−78             Homo sapiens  (Human), 166 aa.    1 . . . 152   145/152 (95%)       Q9CRB8   2610507A21RIK PROTEIN    1 . . . 168   133/168 (79%)   8e−69           (1700020C11RIK PROTEIN) -  Mus      1 . . . 164   143/168 (84%)             musculus  (Mouse), 166 aa.       Q9CZX4   2610507A21RIK PROTEIN -  Mus      1 . . . 143   125/143 (87%)   2e−68             musculus  (Mouse), 166 aa.    1 . . . 143   133/143 (92%)       Q9NY26   IRT1 PROTEIN (SIMILAR TO   140 . . . 317   134/184 (72%)   1e−62           ZINC/IRON REGULATED   141 . . . 324   145/184 (77%)           TRANSPORTER-LIKE)           (HYPOTHETICAL 34.2 KDA           PROTEIN) (UNKNOWN) (PROTEIN           FOR MGC:14180) -  Homo sapiens             (Human), 324 aa.       Q9Y380   CGI-71 PROTEIN -  Homo sapiens     140 . . . 317   134/184 (72%)   1e−62           (Human), 324 aa.   141 . . . 324   145/184 (77%)                  
 
     [0847] PFam analysis predicts that the NOV99a protein contains the domains shown in the Table 99E.  
               TABLE 99E                          Domain Analysis of NOV99a                                     Identities/                   Similarities           NOV99a Match   for the   Expect       Pfam Domain   Region   Matched Region   Value                                         Syndecan: domain 1 of 1   235 . . . 255   9/21   (43%)   6.9               16/21   (76%)       Zip: domain 1 of 1   174 . . . 313   52/178   (29%)   2.3e−15               108/178   (61%)                  
 
     Example 100  
     [0848] The NOV100 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 100A.  
               TABLE 100A                       NOV100 Sequence Analysis                                                SEQ ID NO:285   987 bp                     NOV100a,     AGACGCTCACACAGACAACCTCAAGTCCAGCAACATCTTAGTAGCCCAAAATCGACTG         CG59679-01 DNA Sequence             CTTTAGTTCTTCTGGTGGGTGCCTCTCACTGTCCACTCGGCT   ATG CCATCCTGCAGTC                   GCATTGCACTGGTGACTGGAGCTAATAAGGGCATTGGCTTTGCGATCACTCGTGACCT                   GTGTCAGCAATTCTCAGGGGATGTGGTGCTCACTGCACGGGACGAGGCACGGGGCCTT                   GCGGCAGTGCAGAAGCTGCAGGCTGAGGGCCTGATTCCTCGCTTCCACCAGCTGGACA                   TCAATGACCCTCAGAGCATCCATGCACTTCGCAACTTTCTGCTCAAGGAGTACGGAGG                   CCTGGATGTGCTGGTCAACAACGCGGGCATTGGCGTGCTTTTCAAAGTGGATGACCCA                   ACACCCTTCGACATTCAAGCTGAGGTGACACTGAAGACGAACTTTTTTGCCACTAGAA                   ATGTCTGCACTGAGTTACTGCCTATAATGAAACCACATGGTAGAGTGGTGAACATCAG                   CAGTCTGCAGGGGTTAAAAGCCCTTGAGAACTGCAGGGAAGATCTTCAGGAAAAGTTC                   CGATGTGACACACTTACCGAGGTGGACCTGGTCGACCTCATGAAAAAGTTTGTGGAGG                   ATACAAAAAATGAAGTCCATGAGAGGGAAGGTTGGCCAGACTCGGCTTACGGGGTGTC                   GAAGCTGGGGGTGACAGTCCTTACGAGGATCCTGGCCCGGCAGCTGGATGAAAAGAGG                   AAAGCGGACAGGATTCTGCTCAATGCCTGCTGCCCGGGATGGGTGAAGACCGACATGG                   CGAGGGACCAGGGCTCCCGGACCGTGGAAGAGGGGGCCGAAACCCCCGTTTACTTGGC                   TCTCCTGCCTCCAGATGCCACTGAACCTCACGGCCAGCTAGTCCGTGACAAAGTTGTG                   CAAACTTGG TGA   ACGTCTGCTCTGGGGCTTAATTGTTTGATAAACGTTAGCGGGAGAGA                                           ORF Start: ATG at 101       ORF Stop: TGA at 938           SEQ ID NO:286   279 aa   MW at 31007.2 kD                     NOV100a,   MPSCSRIALVTGANKGIGFAITRDLCQQFSGDVVLTARDEARGLAAVQKLQAEGLIPR       CG59679-01 Protein Sequence           FHQLDINDPQSIHALRNFLLKEYGGLDVLVNNAGIGVLFKVDDPTPFDIQAEVTLKTN                   FFATRNVCTELLPIMKPHGRVVNISSLQGLKALENCREDLQEKFRCDTLTEVDLVDLM                   KKFVEDTKNEVHEREGWPDSAYGVSKLGVTVLTRILARQLDEKRKADRILLNACCPGW                   VKTDMARDQGSRTVEEGAETPVYLALLPPDATEPHGQLVRDKVVQTW                  
 
     [0849] Further analysis of the NOV100a protein yielded the following properties shown in Table 100B.  
               TABLE 100B                       Protein Sequence Properties NOV100a                                        PSort   0.3600 probability located in mitochondrial matrix space;       analysis:   0.3000 probability located in microbody (peroxisome); 0.1808           probability located in lysosome (lumen); 0.0000 probability           located in endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0850] A search of the NOV100a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 100C.  
               TABLE 100C                          Geneseq Results for NOV100a                                         NOV100a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAW51011   Human liver carbonyl reductase -    1 . . . 279   198/279   (70%)    e−112             Homo sapiens , 277 aa.    1 . . . 277   233/279   (82%)           [US5756299-A, 26 MAY 1998]       AAU33100   Novel human secreted protein   145 . . . 279   88/135   (65%)   2e−48           #3591 -  Homo sapiens , 175 aa.    40 . . . 174   110/135   (81%)           [WO200179449-A2, 25 OCT           2001]       AAG46601     Arabidopsis thaliana  protein    3 . . . 259   106/268   (39%)   6e−43           fragment SEQ ID NO: 58644 -    20 . . . 283   157/268   (58%)             Arabidopsis thaliana , 302 aa.           [EP1033405-A2, 6 SEP 2000]       AAG46600     Arabidopsis thaliana  protein    3 . . . 259   106/268   (39%)   6e−43           fragment SEQ ID NO: 58643 -    34 . . . 297   157/268   (58%)             Arabidopsis thaliana , 316 aa.           [EP1033405-A2, 6 SEP 2000]       AAG46599     Arabidopsis thaliana  protein    3 . . . 259   106/268   (39%)           fragment SEQ ID NO: 58642 -    45 . . . 308   157/268   (58%)             Arabidopsis thaliana , 327 aa.           [EP1033405-A2, 6 SEP 2000]                  
 
     [0851] In a BLAST search of public sequence databases, the NOV100a protein was found to have homology to the proteins shown in the BLASTP data in Table 100D.  
               TABLE 100D                          Public BLASTP Results for NOV100a                                         NOV100a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q9JJN7   CARBONYL REDUCTASE (EC   1 . . . 279   246/279 (88%)   e−140           1.1.1.184) (CARBONYL   1 . . . 277   262/279 (93%)           REDUCTASE 3) -  Cricetulus               griseus  (Chinese hamster), 277 aa.       AAH02812   CARBONYL REDUCTASE 3 -   1 . . . 279   227/279 (81%)   e−126             Homo sapiens  (Human), 277 aa.   1 . . . 277   246/279 (87%)       O75828   Carbonyl reductase [NADPH] 3   3 . . . 279   226/277 (81%)   e−126           (EC 1.1.1.184) (NADPH-   2 . . . 276   245/277 (87%)           dependent carbonyl reductase 3) -             Homo sapiens  (Human), 276 aa.       Q924V2   CARBONYL REDUCTASE 2 -   1 . . . 279   206/279 (73%)   e−119             Cricetulus griseus  (Chinese   1 . . . 277   244/279 (86%)           hamster), 277 aa.       Q91X28   SIMILAR TO CARBONYL   1 . . . 279   204/279 (73%)   e−116           REDUCTASE 1 -  Mus musculus     1 . . . 277   240/279 (85%)           (Mouse), 277 aa.                  
 
     [0852] PFam analysis predicts that the NOV100a protein contains the domains shown in the Table 100E.  
               TABLE 100E                          Domain Analysis of NOV100a                                     Identities/                   Similarities           NOV100a Match   for the   Expect       Pfam Domain   Region   Matched Region   Value                                         adh_short:   4 . . . 277   77/316   (24%)   5.2e−31       domain 1 of 1       186/316   (59%)                  
 
     Example 101  
     [0853] The NOV101 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 101A.  
               TABLE 101A                          NOV101 Sequence Analysis                                     SEQ ID NO:287   1011 bp                     NOV101a,     CTCCTCGGGGGGGCGGCGGCGGCG   ATG TTCTCGGTCCTCTCGTACGGGCGGCTGGTGG       CG59644-01 DNA Sequence           CCCGCGCCGTGCTCGGCGGCCTCTCGCAGACCGACCCCAGGGCCGGCGGCGGCGGCGG                   CGGCGCCGTGCTCGGCGGCCTCTCGCAGACCGACCCCAGGGCCGGCGGCGGCGGCGGC                   GGCGACTACGGACTGGTGACGGCCGGCTGCGGCTTCGGGAAGGACTTCCGTAAGGGCC                   TCCTCAAGAAGGGCGCGTGCTACGGGGACGACGCGTGCTTCGTGGCCCGGCACCGTTC                   CGCGGACGTGCTCGGTGTTGCAGATGGTGTAGGAGGCTGGAGAGACTATGGAGTTGAT                   CCATCTCAATTCTCAGGGACTTTAATGCGGACGTGTGAACGTTTAGTAAAAGAAGGAC                   GGTTCGTACCTAGTAATCCCATTGGAATTCTCACCACAAGCTACTGTGAGTTGCTGCA                   AAATAAAGTCCCTTTGCTCGGTAGCAGCACCGCCTGCATTGTGGTGCTGGACAGAACC                   AGCCACCGCTTACACACAGCAAACCTGGGCGATTCAGGCTTCCTGGTTGTCAGGGGTG                   GTGAAGTCGTGCACCGATCAGATGAGCAGCAGCATTACTTCAACACTCCATTCCAGCT                   CTCAATCGCTCCCCCTGAAGCCGAGGGAGTCGTCTTGAGCGACAGTCCGGATGCTGCT                   GATAGCACGTCTTTCGATGTCCAGCTAGGAGACATTATCCTGACGGCAACAGATGGAC                   TCTTTGACAACATGCCTGATTATATGATTCTTCAGGAGCTAAAAAAGTTAAAGAATTC                   AAATTATGAGAGTATACAACAGACTGCCAGAAGCATTGCTGAGCAAGCTCATGAGCTG                   GCCTATGACCCAAATTATATGTCACCTTTTGCACAGTTTGCATGTGACAATGGATTGA                   ATGTGAGAGGTGGTGGAAAGCCAGATGACATCACCGTCCTTCTTTCAATAGTGGCTGA                   GTATACAGAC TAG   CTGAGGTGTCAA                                           ORF Start: ATG at 25       ORF Stop: TAG at 997           SEQ ID NO:288   324 aa   MW at 34311.1 kD                     NOV101a,   MFSVLSYGRLVARAVLGGLSQTDPRAGGGGGGAVLGGLSQTDPRAGGGGGGDYGLVTA       CG59644-01 Protein Sequence           GCGFGKDFRKGLLKKGACYGDDACFVARHRSADVLGVADGVGGWRDYGVDPSQFSGTL                   MRTCERLVKEGRFVPSNPIGILTTSYCELLQNKVPLLGSSTACIVVLDRTSHRLHTAN                   LGDSGFLVVRGGEVVHRSDEQQHYFNTPFQLSIAPPEAEGVVLSDSPDAADSTSFDVQ                   LGDIILTATDGLFDNMPDYMILQELKKLKNSNYESIQQTARSIAEQAHELAYDPNYMS                   PFAQFACDNGLNVRGGGKPDDITVLLSIVAEYTD                  
 
     [0854] Further analysis of the NOV101a protein yielded the following properties shown in Table 101B.  
               TABLE 101B                       Protein Sequence Properties NOV101a                                        PSort   0.5708 probability located in mitochondrial matrix space;       analysis:   0.4996 probability located in mitochondrial intermembrane           space; 0.2852 probability located in mitochondrial inner           membrane; 0.2852 probability located in mitochondrial           outer membrane       SignalP   Likely cleavage site between residues 23 and 24       analysis:                  
 
     [0855] A search of the NOV101a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 101C.  
               TABLE 101C                          Geneseq Results for NOV101a                                         NOV101a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAB85357   Human phosphatase (PP) (clone ID    1 . . . 324   304/324 (93%)    e−173           3402521CD1) -  Homo sapiens , 304    1 . . . 304   304/324 (93%)           aa. [WO200153469-A2, 26 JUL           2001]       AAU32112   Novel human secreted protein    25 . . . 324   272/300 (90%)    e−156           #2603 -  Homo sapiens , 304 aa.    6 . . . 304   274/300 (90%)           [WO200179449-A2, 25 OCT           2001]       AAG52267     Arabidopsis thaliana  protein    71 . . . 320   101/261 (38%)   4e−33           fragment SEQ ID NO: 66421 -    99 . . . 340   133/261 (50%)             Arabidopsis thaliana , 348 aa.           [EP1033405-A2, 6 SEP 2000]       AAG52266     Arabidopsis thaliana  protein    71 . . . 320   101/261 (38%)   4e−33           fragment SEQ ID NO: 66420 -   125 . . . 366   133/261 (50%)             Arabidopsis thaliana , 374 aa.           [EP1033405-A2, 6 SEP 2000]       AAG52265     Arabidopsis thaliana  protein    71 . . . 320   101/261 (38%)   4e−33           fragment SEQ ID NO: 66419 -   218 . . . 459   133/261 (50%)             Arabidopsis thaliana , 467 aa.           [EP1033405-A2, 6 SEP 2000]                  
 
     [0856] In a BLAST search of public sequence databases, the NOV101a protein was found to have homology to the proteins shown in the BLASTP data in Table 101D.  
               TABLE 101D                          Public BLASTP Results for NOV101a                                         NOV101a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q9W0E2   CG12091 PROTETN -  Drosophila      1 . . . 320   163/322 (50%)   1e−83             melanogaster  (Fruit fly), 321 aa.    1 . . . 320   218/322 (67%)       Q9W3R1   CG15035 PROTEIN -  Drosophila      55 . . . 319   127/266 (47%)   1e−64             melanogaster  (Fruit fly), 374 aa.   109 . . . 373   178/266 (66%)       O18183   W09D10.4 PROTEIN -    4 . . . 320   136/331 (41%)   2e−60             Caenorhabditis elegans , 330 aa.    7 . . . 330   198/331 (59%)       Q9VAH4   CG7615 PROTEIN -  Drosophila      35 . . . 319   122/285 (42%)   2e−56             melanogaster  (Fruit fly), 314 aa.    26 . . . 309   168/285 (58%)       Q9SUK9   HYPOTHETICAL 36.2 KDA    71 . . . 320   101/261 (38%)   1e−32           PROTEIN -  Arabidopsis thaliana      86 . . . 327   133/261 (50%)           (Mouse-ear cress), 335 aa.                  
 
     [0857] PFam analysis predicts that the NOV101a protein contains the domains shown in the Table 110E.  
               TABLE 101E                          Domain Analysis of NOV101a                                     Identities/                   Similarities           NOV101a Match   for the   Expect       Pfam Domain   Region   Matched Region   Value               PP2C: domain 1 of 1   147 . . . 191   13/48 (27%)   0.26               36/48 (75%)                  
 
     Example 102  
     [0858] The NOV1102 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 102A.  
               TABLE 102A                       NOV 102 Sequence Analysis                                                SEQ ID NO:289   523 bp                     NOV102a,     AGTCCCAGTACTATCAGCC   ATG GTCAACCACACCATGTTCTTCGACGTTGCTGTCGAC       CG59662-01 DNA Sequence           AGTGAGCCCTTGGACCACGTCTCCTTTGAGCTGTTTGCAGAAAAGTTTCCAAAGACAG                   CAGAAAACGTTCGTGCTCTGAGCACTGAAGAGAAAGGATTTGGTTATAAGGGTCCCTG                   CTTTCACAGAATTATACCAGCATTTATGTGTCAGGGTGGTGACTTCACGCACCATAAT                   GGCACTGGTGGCAAGTCCATCTACGGGGAGAAATTTGAAGATGAGAAATTTATCCTAA                   AGCGTACAGGTCCTGGCATCTTGTCCATGGCAAATTCTGGACCCAACACAAACTGTTC                   CGTTTTTTTCATCTGCACTGCCAAGACGGGGTGGTTGGATGGCAAGCATGTAGTCTTT                   GGCAAGGTGAAAGAAGGCATGAATATTTTGGAGGCCATAGAGCAATTTGGGTCCAGGA                   ATGGCAAGACCAGCAAGAAGACCACCATTGCTGACTGTGGACAGCTCTGG TAA   GTTTGA                                           ORF Start: ATG at 20       ORF Stop: TAA at 515           SEQ ID NO:290   165 aa   MW at 18237.7 kD                     NOV102a,   MVNHTMFFDVAVDSEPLDHVSFELFAEKFPKTAENVRALSTEEKGFGYKGPCFHRIIP       CG59662-01 DNA Sequence           AFMCQGGDFTHHNGTGGKSIYGEKFEDEKFILKRTGPGILSMANSGPNTNCSVFFICT                   AKTGWLDGKHVVFGKVKEGMNILEAIEQFGSRNGKTSKKTTIADCGQLW                  
 
     [0859] Further analysis of the NOV102a protein yielded the following properties shown in Table 102B.  
               TABLE 102B                       Protein Sequence Properties NOV102a                                        PSort   0.6400 probability located in microbody (peroxisome);       analysis:   0.4500 probability located in cytoplasm; 0.1000           probability located in mitochondrial matrix space;           0.1000 probability located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0860] A search of the NOV102a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 102C.  
               TABLE 102C                          Geneseq Results for NOV102a                                         NOV102a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAU01195   Human cyclophilin A protein -   1 . . . 164   141/164 (85%)   1e−80             Homo sapiens , 165 aa.   1 . . . 164   148/164 (89%)           [WO200132876-A2, 10 MAY           2001]       AAW56028   Calcineurin protein - Mammalia,   1 . . . 164   141/164 (85%)   1e−80           165 aa. [WO9808956-A2,   1 . . . 164   148/164 (89%)           5 MAR 1998]       AAG65275   Haematopoietic stem cell   2 . . . 164   140/163 (85%)   5e−80           proliferation agent related human   1 . . . 163   147/163 (89%)           protein #2 -  Homo sapiens , 164 aa.           [JP2001163798-A, 19 JUN 2001]       AAP90431   Cyclophulin -  Homo sapiens     2 . . . 164   140/163 (85%)   5e−80           (human), 164 aa. [EP326067-A,   1 . . . 163   147/163 (89%)           2 AUG 1989]       AAG03831   Human secreted protein, SEQ ID   1 . . . 164   140/164 (85%)   8e−80           NO: 7912 -  Homo sapiens , 165 aa.   1 . . . 164   147/164 (89%)           [EP1033401-A2, 6 SEP 2000]                  
 
     [0861] In a BLAST search of public sequence databases, the NOV102a protein was found to have homology to the proteins shown in the BLASTP data in Table 102D.  
               TABLE 102D                          Public BLASTP Results for NOV102a                                         NOV102a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               CAC39529   SEQUENCE 26 FROM PATENT   1 . . . 164   141/164 (85%)   4e−80           (Human), 165 aa.   1 . . . 164   148/164 (89%)       Q9BRU4   PEPTIDYLPROLYL ISOMERASE   1 . . . 164   140/164 (85%)   2e−79           A (CYCLOPHILIN A) -  Homo     1 . . . 164   147/164 (89%)             sapiens  (Human), 165 aa.       P05092   Peptidyl-prolyl cis-trans isomerase   2 . . . 164   140/163 (85%)   2e−79           A (EC 5.2.1.8) (PPIase) (Rotamase)   1 . . . 163   147/163 (89%)           (Cyclophilin A) (Cyclosporin A-           binding protein) -  Homo sapiens             (Human),, 164 aa.       Q961X3   PEPTIDYLPROLYL ISOMERASE   1 . . . 164   140/164 (85%)   5e−79           A (CYCLOPHILIN A) -  Homo     1 . . . 164   147/164 (89%)             sapiens  (Human), 165 aa.       P04374   Peptidyl-prolyl cis-trans isomerase   2 . . . 164   138/163 (84%)   7e−79           A (EC 5.2.1.8) (PPIase) (Rotamase)   1 . . . 163   147/163 (89%)           (Cyclophilin A) (Cyclosporin A-           binding protein) -  Bos taurus             (Bovine), and, 163 aa.                  
 
     [0862] PFam analysis predicts that the NOV102a protein contains the domains shown in the Table 102E.  
               TABLE 102E                          Domain Analysis of NOV102a                                     Identities/                   Similarities           NOV102a Match   for the   Expect       Pfam Domain   Region   Matched Region   Value               pro_isomerase:   5 . . . 165   105/180 (58%)   4.2e−91       domain 1 of 1       141/180 (78%)                  
 
     Example 103  
     [0863] The NOV103 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 103A.  
               TABLE 103A                       NOV103 Sequence Analysis                                                SEQ ID NO:291   8860 bp                     NOV103a,     GGATCCTTGAGGGCACTGGTGCGACTTTCAGGTGAGGTCTTAGCAGATGAAAGCGGCT         CG59773-01 DNA Sequence             GGCTGTGGCCCGCGCCAGTAGTGCTTTCTGCTCCGCACTCGCCGTGAGCCAGGTGTGC                       AACCGGATTTGGGGCGAGGGTCGCGCTGGCTACCTCGCATGCGCAGAGCCGGAAGCCC                       GCTGACCGGACTACAGCTCCCAGAAGAGCCTTGTGGAGGCCGCAGACGCGAAGCCGCT                       GGCGCCATCTTGAAATCTGATCCTCCATCCCCGAGGCTTTGCGTCTGCGCGGCCGGCC                       GCTGCTGCTCCGGGAGCCCAGTCTGCTAAAAGGGGAGGACGTTGAGGACGCGGCGGCT                       GGCGGGAGAGACAGCTGGGGAGAGACATGGCAGGGTCGGAGCGCGGCCTGCGCCTCTG                       TCACTCAGCATCCTCTTAGGCGTTTCCACGCCCGCCCCCTGCCCGAGGGGCGGGGCTG                       ACGGCTCTGGTACCCGGAGTCGGCGCGCGGGGCAGGGGCGCGCCCCTGCAGAGTGGGG                       ACCCCACTGGGCTGTGCCATGCTGACCGGAGACCACCGAGGCGGGAGACAGAGCGCGG                       CGAAGAGCCATTGAGTGGTCACCCAGTAGCCGCCGCCGCCGCCGCCTCGGGAAGCTTG                       CCACCCGCTAGGAGGGAAG   ATG AAGGAGATTTGCAGGATCTGTGCCCGAGAGCTGTGT                   GGAAACCAGCGGCGCTGGATCTTCCACACGGCGTCCAAGCTCAATCTCCAGGTTCTGC                   TTTCGCACGTCTTGGGCAAGGATGTCCCCCGCGATGGCAAAGCCGAGTTCGCTTGCAG                   CAAGTGTGCTTTCATGCTTGATCGAATCTATCGATTCGACACAGTTATTGCCCGGATT                   GAAGCGCTTTCTATTGAGCGCTTGCAAAAGCTGCTACTGGAGAAGGATCGCCTCAAGT                   TCTGCATTGCCAGTATGTATCGGAAGAATAACGATGACTCTGGCGCGGAGATCAAGGC                   GGGGAATGGGACGGTTGACATGTCCGTCTTACCCGATGCGAGATACTCTGCACTGCTC                   CAGGAGGACTTCGCCTATTCAGGGTTTGAGTGCTGGGTGGAGAATGAGGATCAGATCC                   AGGAGCCACACAGCTGCCATGGTTCAGAAGGCCCTGGAAACCGACCCAGGAGATGCCG                   TGGTTGTGCCGCTTTGCGGGTTGCTGATTCTGACTATGAAGCCATTTGTAAGGTACCT                   CGAAAGGTGGCCAGAAGTATCTCCTGCGGCCCTTCTAGCAGGTGGTCGACCAGCATTT                   GCACTGAAGAACCAGCGTTGTCTGAGGTTGGGCCACCCGACTTAGCAAGCACAAAGGT                   ACCCCCAGATGGAGAAAGCATGGAGGAAGAGACGCCTGGTTCCTCTGTGGAATCTTTG                   GATGCAAGCGTCCAGGCTAGCCCTCCACAACAGAAAGATGAGGAGACTGAGAGAAGTG                   CAAAGGAACTTGGAAAGTGTGACTGTTGTTCAGATGATCAGGCTCCGCAGCATGGGTG                   TAATCACAAGCTGGAATTAGCTCTTAGCATGATTAAAGGTCTTGATTATAAGCCCATC                   CAGAGCCCCCGAGGGAGCAGGCTTCCGATTCCAGTGAAATCCAGCCTACCTGGAGCCA                   AGCCTGGCCCTAGCATGACAGATGGAGTTAGTTCCGGTTTCCTTAACAGGTCTTTGAA                   ACCCCTTTACAAGACACCTGTGAGTTATCCCTTGGAGCTTTCAGACCTGCAGGAGCTG                   TGGGATGATCTCTGTGAAGATTATTTGCCGCTCCGGGTCCAGCCCATGACTGAAGAGT                   TGCTGAAACAACAAAAGCTGAATTCACATGAGACCACTATAACTCAGCAGTCTGTATC                   TGATTCCCACTTGGCAGAACTCCAGGAAAAAATCCAGCAAACAGAGGCCACCAACAAG                   ATTCTTCAAGAGAAACTTAATGAAATGAGCTATGAACTAAAGTGTGCTCAGGAGTCGT                   CTCAAAAGCAAGATGGTACAATTCAGAACCTCAAGGAAACTCTGAAAAGCAGGGAACG                   TGAGACTGAGGAGTTGTACCAGGTAATTGAAGGTCAAAATGACACAATGGCAAAGCTT                   CGAGAAATGCTGCACCAAAGCCAGCTTGGACAACTTCACAGCTCAGAGGGTACTTCTC                   CAGCTCAGCAACAGGTAGCTCTGCTTGATCTTCAGAGTGCTTTATTCTGCAGCCAACT                   TGAAATACAGAAGCTCCAGAGGGTGGTACGACAGAAAGAGCGCCAACTGGCTGATGCC                   AAACAATGTGTGCAATTTGTAGAGGCTGCAGCACACGAGAGTGAACAGCAGAAAGAGG                   CTTCTTGGAAACATAACCAGGAATTGCGAAAAGCCTTGCAGCAGCTACAAGAAGAATT                   GCAGAATAAGAGCCAACAGCTTCGTGCCTGGGAGGCTGAAAAATACAATGAGATTCGA                   ACCCAGGAACAAAACATCCAGCACCTAAACCATAGTCTGAGTCACAAGGAGCAGTTGC                   TTCAGGAATTTCGGGAGCTCCTACAGTATCGAGATAACTCAGACAAAACCCTTGAAGC                   AAATGAAATGTTGCTTGAGAAACTTCGCCAGCGAATACATGATAAAGCTGTTGCTCTG                   GAGCGGGCTATAGATGAAAAATTCTCTGCTCTAGAAGAGAAAGAAAAAGAACTGCGCC                   AGCTTCGTCTTGCTGTGAGAGAGCGAGATCATGACTTAGAGAGACTGCGCGATGTCCT                   CTCCTCCAATGAAGCTACTATGCAAAGTATGGAGAGTCTCCTGAGGGCCAAAGGCCTG                   GAAGTGGAACAGTTATCTACTACCTGTCAAAACCTCCAGTGGCTGAAAGAAGAAATGG                   AAACCAAATTTAGCCGTTGGCAGAAGGAACAAGAGAGTATCATTCAGCAGTTACAGAC                   GTCTCTTCATGATAGGAACAAAGAAGTGGAGGATCTTAGTGCAACACTGCTCTGCAAA                   CTTGGACCAGGGCAGAGTGAGATAGCAGAGGAGCTGTGCCAGCGTCTACAGCGAAAGG                   AAAGGATGCTGCAGGACCTTCTAAGTGATCGAAATAAACAAGTGCTGGAACATGAAAT                   GGAGATTCAAGGCCTGCTTCAGTCTGTGAGCACCAGGGAGCAGGAAAGCCAAGCTGCT                   GCAGAGAAGTTGGTGCAAGCCTTAATGGAAAGAAATTCAGAATTACAGGCCCTGCGCC                   AATATTTAGGAGGGAGAGACTCCCTGATGTCCCAAGCACCCATCTCTAACCAACAAGC                   TGAAGTTACCCCCACTGGCCGTCTTGGAAAACAGACTGATCAAGGTTCAATGCAGATA                   CCTTCCAGAGATGATAGCACTTCATTGACTGCCAAAGAGGATGTCAGCATACCCAGAT                   CCACATTAGGAGACTTGGACACAGTTGCAGGGCTGGAAAAAGAACTGAGTAATGCCAA                   AGAGGAACTTGAACTCATGGCTAAAAAAGAAAGAGAAAGTCAGATGGAACTTTCTGCT                   CTACAGTCCATGATGGCTGTGCAGGAAGAAGAGCTGCAGGTGCAGGCTGCTGATATGG                   AGTCTCTGACCAGGAACATACAGATTAAAGAAGATCTCATAAAGGACCTGCAAATGCA                   ACTGGTTGATCCTGAAGACATACCAGCTATGGAACGCCTGACCCAGGAAGTCTTACTT                   CTTCGGGAAAAAGTTGCTTCAGTAGAATCCCAGGGTCAAGAAATTTCAGGAAACCGAA                   GACAACAGTTGCTGCTGATGCTAGAAGGACTAGTAGATGAACGGAGTCGGCTCAATGA                   GGCCTTACAAGCAGAGAGACAGCTCTATAGCAGTCTGGTGAAGTTCCATGCCCATCCA                   GAGAGCTCTGAGAGAGACCGAACTCTGCAGGTGGAACTGGAAGGGGCTCAGGTGTTAC                   GCAGTCGGCTAGAAGAAGTTCTTGGAAGAAGCTTGGAGCGCTTAAACAGGCTGGAGAC                   CCTGGCCGCCATTGGAGGTGCAGCTGCAGGGGATGACACCGAAGATACAAGCACTGAG                   TTCACTGACAGTATTGAGGAGGAGGCTGCACACCATAGTCACCAGCAACTTGTCAAGG                   TGGCTTTGGAGAAAAGTCTGGCAACTGTGGAGACCCAGAACCCATCTTTTTCCCCTCC                   TTCTCCGATGGGAGGGGACAGTAACAGGTGTCTTCAGGAAGAAATGCTCCACCTGAGG                   GCTGAGTTCCACCAGCACTTAGAAGAGAAGAGGAAAGCTGAGGAGGAACTGAAGGAGC                   TAAAGGCTCAAATTGAGGAAGCAGGATTCTCCTCAGTGTCCCACATCAGGAACACCAT                   GCTGAGCCTTTGCCTTGAGAATGCGGAGCTGAAAGAGCAGATGGGAGAAGCAATGTCT                   GATGGATGGGAGATCGAGGAAGACAAGGAGAAGGGCGAGGTGATGGTTGAGACTGTGG                   TAACCAAAGAGGGTCTGAGTGAGAGTAGCCTTCAGGCTGAGTTCAGAAAGCTCCAGGG                   AAAACTGAAGAATGCCCACAATATCATCAACCTCCTCAAAGAACAACTTGTGCTGAGT                   AGCAAGGAAGGGAATAGTAAACTTACTCCAGAGCTCCTTGTGCATCTGACCAGCACCA                   TTGAAAGAATAAACACAGAACTGGTTGGTTCCCCTGGGAAGCACCAACACCAAGAGGA                   GGGGAATGTGACTGTGAGGCCTTTCCCCAGACCCCAGAGCCTTGACCTTGGGGCTACC                   TTCACAGTGGATGCCCACCAATTGGATAACCAGTCCCAGCCTCGTGACCCTGGGCCTC                   AGTCAGCGTTTAGCCTACCAGGGTCCACCCAGCACCTGCGCTCCCAGCTGTCACAATG                   CAAACAACGCTATCAAGATCTCCAGGAGAAGCTGCTGCTATCAGAAGCCACTGTCTTT                   GCTCAGGCTAACGAGCTGGAGAAATACAGAGTTATGCTTACAGGTGAATCCTTGGTGA                   AGCAGGACAGCCAGCAGATCCAGGTGGACCTCCAGGACCTGGGCTATGAGACTTGTGG                   CCGAAGCGAGAATGAGGCTGAACGGGAGGAAACCACCAGTCCTGAGTGTGAGGAGCAC                   AACAGCCTCAAGGAAATGGTCCTGATGGAGGGGCTGTGCTCTGAGCAGGGACGCCGGG                   GCTCAACACTGGCTAGTTCCTCTGAGAGGAAGCCCTTGGAGAACCAGCTAGGGAAGCA                   GGAAGAGTTCCGGGTATATGGAAAGTCAGAAAACATCTTGGTCCTACGAAAGGACATC                   AAAGATCTGAAGGCCCAGCTGCAGAATGCCAACAAGGTCATTCAAAACCTCAAGAGCC                   GGGTCCGGTCCCTCTCAGTTACAAGTGATTATTCGTCTAGTCTGGAAAGACCCCGGAA                   GCTGAGAGCTGTTGGCACCTTGGAGGGGTCTTCACCTCATAGTGTCCCTGATGAGGAT                   GAGGGGTGGCTGTCTGATGGCACTGGGGCTTTCTACTCTCCAGGGCTTCAGGCCAAAA                   AGGACCTGGAGAGTCTCATCCAGAGAGTATCCCAGCTGGAGGCCCAGCTCCCAAAAAA                   TGGACTAGAAGAGAAGCTGGCTGAGGAGCTGAGATCAGCCTCGTGGCCTGGGAAATAT                   GATTCCCTGATTCAGGATCAGGCCCGGGAACTGTCTTACCTACGGCAAAAAATACGAG                   TGAGGATCTCCTAAGGAGCAATGACATTGACTACTACCTGGGACAGAGCTTCCGGGAG                   TGAGGATCTCCTAAGGAGCAATGACATTGACTACTACCTGGGACAGAGCTTCCGGGAG                   CAACTCGCCCAGGGAAGCCAGCTGACAGAGAGGCTCACCAGCAAACTCAGCACCAAGG                   ATCATAAAAGTGAGAAAGATCAAGCTGGACTTGAGCCACTGGCCCTCAGGCTCAGCAG                   GGAGCTGCAGGAGAAGGAGAAAGTGATTGAAGTCCTGCAGGCCAAGCTGGATGCTCGG                   TCCCTCACACCCTCCAGCAGCCATGCCTTGTCTGACTCCCACCGCTCTCCCAGCAGCA                   CCTCTTTCCTGTCTGATGAACTGGAAGCCTGCTCTGACATGGACATAGTCAGCGAGTA                   CACACACTATGAAGAGAAGAAAGCTTCTCCCAGTCACTCAGATTCCATCCATCATTCG                   AGTCATTCTGCTGTGTTGTCTTCTAAACCATCATCAACCAGTGCATCTCAGGGGGCTA                   AGGCCGAATCCAACAGCAACCCCATCAGCTTGCCAACTCCCCAGAATACCCCCAAGGA                   GGCCAACCAGGCCCATTCAGGCTTTCATTTTCACTCCATACCCAAGCTGGCTAGCCTT                   CCTCAGGCACCATTGCCCTCAGCTCCATCCAGCTTCCTGCCTTTCAGCCCCACTGGCC                   CTCTCCTCCTTGGCTGCTGTGAGACACCAGTGGTCTCCTTGGCTGAGGCTCAGCAGGA                   GCTACAGATGCTGCAGAAGCAGTTGGGAGAAAGTGCCAGCACTGTTCCTCCTGCTTCC                   ACAGCTACATTGCTGAGCAACGACTTGGAAGCCGACTCTTCCTACTACCTCAACTCTG                   CCCAGCCTCACTCTCCTCCAAGGGGCACCATAGAACTGGGAAGAATCCTAGAGCCTGG                   GTACCTGGGCAGCAGTGGCAAGTGGGATGTGATGAGGCCTCAGAAAGGGAGTGTATCT                   GGGGACCTATCCTCAGGCTCCTCTGTGTACCAGCTTAACTCCAAACCCACAGGGGCTG                   ACCTGCTGGAAGAGCATCTTGGTGAAATCCGGAACCTGCGCCAGCGCCTGGAGGAGTC                   CATCTGCATCAATGACCGCCTACGGGAGCAACTGGAACACCGGCTGACCTCTACTGCT                   CGTGGAAGGGGATCCACTTCTAACTTCTACAGTCAGGGCCTGGAGTCCATACCTCAGC                   TCTGCAATGAGAACAGAGTCCTCAGGGAAGACAATCGAAGACTTCAGGCTCAACTGAG                   TCATGTTTCCAGAGAGCACTCCCAGGAAACAGAAAGCCTGAGGGAGGCTCTGCTGTCC                   TCTCGATCCCACCTTCAAGAGCTGGAAAAGGAGCTGGAGCACCAGAAGGTGGAAAGGC                   AGCAGCTTTTGGAAGACTTGAGGGAGAAGCAGCAAGAGGTCTTGCATTTCAGGGAGGA                   ACGTCTTTCCCTCCAGGAAAACGACTCCAGACTGCAGCACAAGCTGGTTCTCCTGCAG                   CAACAGTGTGAAGAGAAACAGCAGCTCTTTGAGTCCCTCCAGTCAGAGCTACAAATCT                   ACGAGGCACTTTATGGCAATTCCAAGAAGGGGCTGAAAGGCTTGGGTTTGGATACTTC                   TCCAGTAATGAAGACCCCTCCCAAGCTAGAGGGTGATGCTACTGATGGCTCCTTTGCC                   AATAAGCATGGCCGCCATGTCATTGGCCACATTGATGACTACAGTGCCCTAAGACAGC                   AGATTGCGGAGGGCAAGCTGCTGGTCAAAAAGATAGTGTCTCTTGTGAGATCAGCGTG                   CAGCTTCCCTGGCCTTGAAGCCCAAGGCACAGAGGTGCTAGGCAGCAAAGGTATTCAT                   GAGCTTCGGAGCAGCACCAGTGCCCTGCACCATGCCCTAGAGGAGTCGGCTTCCCTCC                   TCACCATGTTCTGGAGAGCAGCCCTGCCAAGCACCCACATCCCTGTGCTGCCTGGCAA                   AGTGGGAGAATCAACAGAAAGGGAACTTCTGGAACTGAGAACCAAAGTATCCAAACAG                   GAGCGGCTCCTTCAGAGCACAACTGAGCATCTGAAGAACGCCAACCAGCAGAAGGAGA                   GCATGGAGCAGTTCATCGTCAGCCAGCTAACCAGAACACATGATGTTTTAAAGAAGGC                   AAGGACTAACTTAGAGGTGAAATCCCTAAGGGCTCTGCCATGTACTCCAGCCTTG TGA                       CCCTTGCCTTCCAGGAACCATGCAAGAAGCGCAGCCACCAGAAGTCCTTAAAACAGCA                       GGAAAGGTGGGCCTGTCCCCCTTTTGTGCAGCTACCTATCTGCTGAGGAGCATCTGGG                       CCTCATTCCTCCAAGTCCACGGGAGGGTCCAGAAGAGGGAGTCAGAGATGTATCCTGG                       TGGAGCTGGGAGAAAGGCAGAAAGCCTTTCTGACAGCTATGGAATACGATTAGCCAAG                       GTCCACTTGGCCCAGCACTAAGAAAAAGATGCGTAGTTTGCACAGAAGGTTTTGTGAT                       CCTGCCTCTCAACAGCCCCAGCAGCTTGGGAACTAGCAAGAGCACATTTCTTGCCTCA                       TCAGCTGTCCTGAGATGGAAAACTCAGTGGATATAGGACCCTGATTCCGATGAAAGGG                       GCACGTGGTCCCAATGCTGGAGCTCCTCTGGCAGGTTCTAAAAGCACACTACTGAGCA                       GCGGTGCCCTGCCGGACACTGCTGGCGGGGGCTCAGTGAGCACTACTCACAGATCCAC                       ACCTGACCCTGTTGGGTCGAGTCAGGCTGGGCCTTGGTCTGCACTGTAGCACCTGTGT                       TCTTTGAGTTCACATCATGAATGTGGTGACTTCCCAGATACCATCTCAGGCTTAACCT                       AGCACATCCTATTTCTTTTCTTCTATGATATCCAAATTGGACTGACCTCACTTCAAAG                       TTGCTGTCCCATTTTGTCACCCTATCTTATCTCGGGGAAATTGCAGACTGATGGCCAG                       ACCAACTCTGTTGAAATTCTTGCATAGAGCAAACCTGTGCTCATTTTTAAGTGGCATG                       GGAGAGGCCCCCAGCCTAGTAAAGCCTAGTCTGTGTCTTCACAGTGCTGGTAGAATGT                       GTTTGTGTGTATAAATATATGATATAGATTTATATATGTTGCTAACGCCATATATTGA                       AGGCCAACATAACTGGTGGACAGGGTGGGTGACAGAAAATGAAAGCCTTTTTGGTGAT                       TGTTAAAGCAAGATGTGTATAAAGAAATAAATAGTTTTTCTTTC                                           ORF Start: ATG at 658       ORF Stop: TGA at 7828           SEQ ID NO:292   2390 aa   MW at 268843.7 kD                     NOV103a,   MKEICRICARELCGNQRRWIFHTASKLNLQVLLSHVLGKDVPRDGKAEFACSKCAFML       CG59773-01 Protein       Sequence   DRIYRFDTVIARIEALSIERLQKLLLEKDRLKFCIASMYRKNNDDSGAEIKAGNGTVD                   MSVLPDARYSALLQEDFAYSGFECWVENEDQIQEPHSCHGSEGPGNRPRRCRGCAALR                   VADSDYEAICKVPRKVARSISCGPSSRWSTSICTEEPALSEVGPPDLASTKVPPDGES                   MEEETPGSSVESLDASVQASPPQQKDEETERSAKELGKCDCCSDDQAPQHGCNHKLEL                   ALSMIKGLDYKPIQSPRGSRLPIPVKSSLPGAKPGPSMTDGVSSGFLNRSLKPLYKTP                   VSYPLELSDLQELWDDLCEDYLPLRVQPMTEELLKQQKLNSHETTITQQSVSDSHLAE                   LQEKIQQTEATNKILQEKLNEMSYELKCAQESSQKQDGTIQNLKETLKSRERETEELY                   QVIEGQNDTMAKLREMLHQSQLGQLHSSEGTSPAQQQVALLDLQSALFCSQLEIQKLQ                   RVVRQKERQLADAKQCVQFVEAAAHESEQQKEASWKHNQELRKALQQLQEELQNKSQQ                   LRAWEAEKYNEIRTQEQNIQHLNHSLSHKEQLLQEFRELLQYRDNSDKTLEANEMLLE                   KLRQRIHDKAVALERAIDEKFSALEEKEKELRQLRLAVRERDHDLERLRDVLSSNEAT                   MQSMESLLRAKGLEVEQLSTTCQNLQWLKEEMETKFSRWQKEQESIIQQLQTSLHDRN                   KEVEDLSATLLCKLGPGQSEIAEELCQRLQRKERMLQDLLSDRNKQVLEHEMEIQGLL                   QSVSTREQESQAAAEKLVQALMERNSELQALRQYLGGRDSLMSQAPISNQQAEVTPTG                   RLGKQTDQGSMQIPSRDDSTSLTAKEDVSIPRSTLGDLDTVAGLEKELSNAKEELELM                   AKKERESQMELSALQSMMAVQEEELQVQAADMESLTRNIQIKEDLIKDLQMQLVDPED                   IPAMERLTQEVLLLREKVASVESQGQEISGNRRQQLLLMLEGLVDERSRLNEALQAER                   QLYSSLVKFHAHPESSERDRTLQVELEGAQVLRSRLEEVLGRSLERLNRLETLAAIGG                   AAAGDDTEDTSTEFTDSIEEEAAHHSHQQLVKVALEKSLATVETQNPSFSPPSPMGGD                   SNRCLQEEMLHLRAEFHQHLEEKRKAEEELKELKAQIEEAGFSSVSHIRNTMLSLCLE                   NAELKEQMGEAMSDGWEIEEDKEKGEVMVETVVTKEGLSESSLQAEFRKLQGKLKNAH                   NIINLLKEQLVLSSKEGNSKLTPELLVHLTSTIERINTELVGSPGKHQHQEEGNVTVR                   PFPRPQSLDLGATFTVDAHQLDNQSQPRDPGPQSAFSLPGSTQHLRSQLSQCKQRYQD                   LQEKLLLSEATVFAQANELEKYRVMLTGESLVKQDSKQIQVDLQDLGYETCGRSENEA                   EREETTSPECEEHNSLKEMVLMEGLCSEQGRRGSTLASSSERKPLENQLGKQEEFRVY                   GKSENILVLRKDIKDLKAQLQNANKVIQNLKSRVRSLSVTSDYSSSLERPRKLRAVGT                   LEGSSPHSVPDEDEGWLSDGTGAFYSPGLQADDKLESLIQRVSQLEAQLPKNGLEEKL                   AEELRSASWPGKYDSLIQDQARELSYLRQKIREGRGICYLITRHAKDTVKSFEDLLRS                   NDIDYYLGQSFREQLAQGSQLTERLTSKLSTKDHKSEKDQAGLEPLALRLSRELQEKE                   KVIEVLQAKLDARSLTPSSSHALSDSHRSPSSTSFLSDELEACSDMDIVSEYTHYEEK                   KASPSHSDSIHHSSHSAVLSSKPSSTSASQGAKAESNSNPISLPTPQNTPKEANQAHS                   GFHFHSIPKLASLPQAPLPSAPSSFLPFSPTGPLLLGCCETPVVSLAEAQQELQMLQK                   QLGESASTVPPASTATLLSNDLEADSSYYLNSAQPHSPPRGTIELGRILEPGYLGSSG                   KWDVMRPQKGSVSGDLSSGSSVYQLNSKPTGADLLEEHLGEIRNLRQRLEESICINDR                   LREQLEHRLTSTARGRGSTSNFYSQGLESIPQLCNENRVLREDNRRLQAQLSHVSREH                   SQETESLREALLSSRSHLQELEKELEHQKVERQQLLEDLREKQQEVLHFREERLSLQE                   NDSRLQHKLVLLQQQCEEKQQLFESLQSELQIYEALYGNSKKGLKGLGLDTSPVMKTP                   PKLEGDATDGSFANKHGRHVIGHIDDYSALRQQIAEGKLLVKKIVSLVRSACSFPGLE                   AQGTEVLGSKGIHELRSSTSALHHALEESASLLTMFWRAALPSTHIPVLPGKVGESTE                   RELLELRTKVSKQERLLQSTTEHLKNANQQKESMEQFIVSQLTRTHDVLKKARTNLEV                   KSLRALPCTPAL                                     SEQ ID NO:293   7161 bp                     NOV103b,     GTTGAGGGGGCAATCGGGCACGCTCCTCCCCATGGGTTGCCCATC   ATG TCTAATGGAT       CG59773-02 DNA Sequence           ATCGCACTCTGTCCCAGCACCTCAATGACCTGAAGAAGGAGAACTTCAGCCTCAAGCT                   GCGCATCTACTTCCTGGAGGAGCGCATGCAACAGAAGTATGAGGCCAGCCGGGAGGAC                   ATCTACAAGCGGAACATTGAGCTGAAGGTTGAAGTGGAGAGCTTGAAACGAGAACTCC                   AGGACAAGAAACAGCATCTGGATAAAACATGGGCTGATGTGGAGAATCTCAACAGTCA                   GAATGAAGCTGAGCTCCGACGCCAGTTTGAGGAGCGACAGCAGGAGACGGAGCATGTT                   TATGAGCTCTTGGAGAATAAGATCCAGCTTCTGCAGGAGGAATCCAGGCTAGCAAAGA                   ATGAAGCTGCGCGGATGGCAGCTCTGGTGGAAGCAGAGAAGGAGTGTAACCTGGAGCT                   CTCAGAGAAACTGAAGGGAGTCACCAAAAACTGGGAAGATGTACCAGGAGACCAGGTC                   AAGCCCGACCAATACACTGAGGCCCTGGCCCAGAGGGACAGGAGAATTGAAGAACTGA                   ATCAGAGCCTGGCTGCCCAGGAGAGGCTTGTAGAACAGCTATCTCGGGAGAAACAACA                   ACTGCTACATCTGTTGGAGGAGCCAACTAGCATGGAAGTGCAGCCCATGACTGAAGAG                   TTGCTGAAACAACAAAAGCTGAATTCACATGAGACCACTATAACTCAGCAGTCTGTAT                   CTGATTCCCACTTGGCAGAACTCCAGGAAAAAATCCAGCAAACAGAGGCCACCAACAA                   GATTCTTCAAGAGAAACTTAATGAAATGAGCTATGAACTAAAGTGTGCTCAGGAGTCG                   TCTCAAAAGCAAGATGGTACAATTCAGAACCTCAAGGAAACTCTGAAAAGCAGGGAAC                   GTGAGACTGAGGAGTTGTACCAGGTAATTGAAGGTCAAAATGACACAATGGCAAAGCT                   TCGAGAAATGCTGCACCAAAGCCAGCTTGGACAACTTCAGAGCTCAGAGGGTACTTCT                   CCAGCTCAGCAACAGGTAGCTCTGCTTGATCTTCAGAGTGCTTTATTCTGCAGCCAAC                   TTGAAATACAGAAGCTCCAGAGGGTGGTACGACAGAAAGAGCGCCAACTGGCTGATGC                   CAAACAATGTGTGCAATTTGTAGAGGCTGCAGCACACGAGAGTGAACAGCAGAAAGAG                   GCTTCTTGGAAACATAACCAGGAATTGCGAAAAGCCTTGCAGCAGCTACAAGAAGAAT                   TGCAGAATAAGAGCCAACAGCTTCGTGCCTGGGAGGCTGAAAAATACAATGAGATTCG                   AACCCAGGAACAAAACATCCAGCACCTAAACCATAGTCTGAGTCACAAGGAGCAGTTG                   CTTCAGGAATTTCGGGAGCTCCTACAGTATCGAGATAACTCAGACAAAACCCTTGAAG                   CAAATGAAATGTTGCTTGAGAAACTTCGCCAGCGAATACATGATAAAGCTGTTGCTCT                   GGAGCGGGCTATAGATGAAAAATTCTCTGCTCTAGAAGAGAAAGAAAAAGAACTGCGC                   CAGCTTCGTCTTGCTGTGAGAGAGCGAGATCATGACTTAGAGAGACTGCGCGATGTCC                   TCTCCTCCAATGAAGCTACTATGCAAAGTATGGAGAGTCTCCTGAGGGCCAAAGGCCT                   GGAAGTGGAACAGTTATCTACTACCTGTCAAAACCTCCAGTGGCTGAAAGAAGAAATG                   GAAACCAAATTTAGCCGTTGGCAGAAGGAACAAGAGAGTATCATTCAGCAGTTACAGA                   CGTCTCTTCATGATAGGAACAAAGAAGTGGAGGATCTTAGTGCAACACTGCTCTGCAA                   ACTTGGACCAGGGCAGAGTGAGATAGCAGAGGAGCTGTGCCAGCGTCTACAGCGAAAG                   GAAAGGATGCTGCAGGACCTTCTAAGTGATCGAAATAAACAAGTGCTGGAACATGAAA                   TGGAGATTCAAGGCCTGCCTCAGTCTGTGAGCACCAGGGAGCAGGAAAGCCAAGCTGC                   TGCAGAGAAGTTGGTGCAAGCCTTAATGGAAAGAAATTCAGAATTACAGGCCCTGCGC                   CAATATTTAGGAGGGAGAGACTCCCTGATGTCCCAAGCACCCATCTCTAACCAACAAG                   CTGAAGTTACCCCCACTGGCCGTCTTGGAAAACAGACTGATCAAGGTTCAATGCAGAT                   ACCTTCCAGAGATGATAGCACTTCATTGACTGCCAAAGAGGATGTCAGCATACCCAGA                   TCCACATTAGGAGATTTGGACACAGTTGCAGGGCTGGAAAAAGAACTGAGTAATGCCA                   AAGAGGAACTTGAACTCATGGCTAAAAAAGAAAGAGAATCACAGATGGAACTTTCTGC                   TCTACAGTCCATGATGGCTGTGCAGGAAGAAGAGCTGCAGGTGCAGGCTGCTGATATG                   GAGTCTCTGACCAGGAACATACAGATTAAAGAAGATCTCATAAAGGACCTGCAAATGC                   AACTGGTTGATCCTGAAGACATACCAGCTATGGAACGCCTGACCCAGGAAGTCTTACT                   TCTTCGGGAAAAAGTTGCTTCAGTAGAATCCCAGGGTCAAGAAATTTCAGGAAACCGA                   AGACAACAGCAGTTGCTGCTGATGCTAGAAGGACTAGTAGATGAACGGAGTCGGCTCA                   ATGAGGCCTTACAAGCAGAGAGACAGCTCTATAGCAGTCTGGTGAAGTTCCATGCCCA                   TCCAGAGAGCTCTGAGAGAGACCGAACTCTGCAGGTGGAACTGGAAGGGGCTCAGGTG                   TTACGCAGTCGGCTAGAAGAAGTTCTTGGAAGAAGCTTGGAGCGCTTAAACAGGCTGG                   AGACCCTGGCCGCCATTGGAGGTGCAGCTGCAGGGGATGACACCGAAGATACAAGCAC                   TGAGTTCACTGACAGTATTGAGGAGGAGGCTGCACACCATAGTCACCAGCAACTTGTC                   AAGGTGGCTTTGGAGAAAAGTCTGGCAACTGTGGAGACCCAGAACCCATCTTTTTCCC                   CTCCTTCTCCGATGGGAGGGGACAGTAACAGGTGTCTTCAGGAAGAAATGCTCCACCT                   GAGGGCTGAGATCCACCAGCACTTAGAAGAGAAGAGGAAAGCTGAGGAGGAACTGAAG                   GAGCTAAAGGCTCAAATTGAGGAAGCAGGATTCTCCTCAGTGTCCCACATCAGGAACA                   CCATGCTGAGCCTTTGCCTTGAGAATGCGGAGCTGAAAGAGCAGATGGGAGAAACAAT                   GTCTGATGGATGGGAGATCGAGGAAGACAAGGAGAAGGGCGAGGTGATGGTTGAGACT                   GTGGTAACCAAAGAGGGTCTGAGTGAGAGTAGCCTTCAGGCTGAGTTCAGAAAGCTCC                   AGGGAAAACTGAAGAATGCCCACAATATCATCAACCTCCTCAAAGAACAACTTGTGCT                   GAGTAGCAAGGAAGGGAATAGTAAACTTACTCCAGAGCTCCTTGTGCATCTGACCAGC                   ACCATCGAAAGAATAAACACAGAACTGGTTGGTTCCCCTGGGAAGCACCAACACCAAG                   AGGAGGGGAATGTGACTGTGAGGCCTTTCCCCAGACCCCAGAGCCTTGACCTTGGGGC                   TACCTTCACAGTGGATGCCCACCAACAGTTGGATAACCAGTCCCAGCCTCGTGACCCT                   GGGCCTCAGCCAGCGTTTAGCCTACCAGGGTCCACCCAGCACCTGCGCTCCCAGCTGT                   CACAATGCAAACAACGCTATCAAGATCTCCAGGAGAAGCTGCTGCTATCAGAAGCCAC                   TGTCTTTGCTCAGGCTAACGAGCTGGAGAAATACAGAGTTATGCTTAGTGAATCCTTG                   GTGAAGCAGGACAGCAAGCAGATCCAGGTGGACTTCCAGGACCTGGGCTATGAGACTT                   GTGGCCGAAGCGAGAATGAGGCTGAACGGGAGGAAACCACCAGTCCTGAGTGTGAGGA                   GCACAACAGCCTCAAGGAAATGGTCCTGATGGAGGGGCTGTGCTCTGAGCAGGGACGC                   CGGGGCTCAACACTGGCTAGTTCCTCTGAGAGGAAGCCCTTGGAGAACCAGCTAGGGA                   AGCAGGAAGAGTTCCGGGTATATGGAAAGTCAGAAAACATCTTGGTCCTACGAAAGGA                   CATCGAAGATCTGAAGGCCCAGCTGCAGAATGCCAACAAGGTCATTCAAAACCTCAAG                   AGCCGGGTCCGGTCCCTCTCAGTTACAAGTGATTATTCGTCTAGTCTGGAAAGACCCC                   GGAAGCTGAGAGCTGTTGGCACCTTGGAGGGGTCTTCACCTCATAGTGTCCCTGATGA                   GGATGAGGGGTGGCTGTCTGATGGCACTGGGGCTTTCTACTCTCCAGGGCTTCAGGCC                   AAAAAGGACCTGGAGAGTCTCATCCAGAGAGTATCCCAGCTGGAGGCCCAGCTCCCAG                   AAAATGGACTAGAAGAGAAGCTGGCTGAGGAGCTGAGATCAGCCTCGTGGCCTGGGAA                   ATATGATTCCCTGATTCAGGATCAGGCCCGGGAACTGTCTTACCTACGGCAAAAAATA                   CGAGAAGGGAGAGGTATTTGTTATCTTATCACCCAGCATGCAAAAGATACAGTAAAAT                   CTTTTGAGGATCTCCTAAGGAGCAATGACATTGACTACTACCTGGGACAGAGCTTCCG                   GGAGCAACTCGCCCAGGGAAGCCAGCTGACAGAGAGGCTCACCAGCAAACTCAGCACA                   GAGGATCATAAAAGTGAGAAAGATCAAGCTGGACTTGAGCCACTGGCCCTCAGGCTCA                   GCAGGGAGCTGCAGGAGAAGGAGAAAGTGATTGAAGTCCTGCAGGCCAAGCTGGATGC                   TCGGTCCCTCACACCCTCCAGCAGCCGTGCCTTGTCTGACTCCCACCGCTCTCCCAGC                   AGCACCTCTTTCCTGTCTGATGATCTGGAAGCCTGCTCTGACATGGACATAGTCAGCG                   AGTACACACACTATGAAGAGAAGAAAGCTTCTCCCAGTCACTCAGGTAGCAGTGCATC                   TCAGGGGGCTAAGGCCGAATCCAACAGCAACCCCATCAGCTTGCCAACTCCCCAGAAT                   ACCCCCAAGGAGGCCAACCAAGCCCATTCAGGCTTTCATTTTCACTCCATACCCAAGC                   TGGCTAGCCTTCCTCAGGCACCATTGCCCTCAGCTCCATCCAGCTTCCTGCCTTTCAG                   CCCCACTGGCCCTCCCCTCCTTGGCTGCTGTGAGACACCAGAGGTCTCCTTGGCTGAG                   TCTCAGCAGGAGCTACAGATGCTGCAGAAGCAGTTGGGAGAAAGTAGCACTGTTCCTC                   CTGCTTCCACAGCTACATTGCTGAGCAACGACTTGGAAGCCGACTCTTCCTACTACCT                   CAACTCTGCCCAGCCTCACTCTCCTCCAAGGGGCACCATAGAACTGGGAAGAATCCTA                   GAGCCTGGGTACCTGGGCAGCAGTGGCAAGTGGGATGTGATGAGGCCTCAGAAAGGGA                   GTGTATCTGGGGACCTATCCTCAGGCTCCTCTGTGTACCAGCTTAACTCCAAACCCAC                   AGGGGCTGACCTGCTGGAAGAGCATCTTGGTGAAATCTGGAACCTGCGCCAGCGCCTG                   GAGGAGTCCATCTGCATCAATGACTGCCTACGGGAGCAACTGGAACACCGGCTGACCT                   CTACTGCTCGTGGAAGGGGATCCACTTCTAACTTCTACAGTCAGGGCCTGGAGTCCAT                   ACCTCAGCTCTGCAATGAGAACAGAGTCCTCAGGGAAGAAAATCGAAGACTTCAGGCT                   CAACTGAGTCATGTTTCCAGAGGTCACTCCCAGGAAACAGAAAGCCTGAGGGAGGCTC                   TGCTGTCCTCTCGATCCCACCTTCAAGAGCTGGAAAAGGAGCTGGAGCACCAGAAGGT                   GGAAAGGCAGCAGCTTTTGGAAGACTTGAGGGAGAAGCAGCAAGAGGTCTTGCATTTC                   AGGGAGGAACGTCTTTCCCTCCAGGAAAACGACTCCAGACTGCAGCACAAGCTGGTTC                   TCCTGCAGCAACAGTGTGAAGAGAAACAGCAGCTCTTTGAGTCCCTCCAGTCAGAGCT                   ACAAATCTACGAGGCACTTTATGGCAATTCCAAGAAGGGGCTGAAAGCTTACAGCCTG                   GATGCCTGTCACCAAATCCCTTTGAGCAGTGACCTGAGCCACCTGGTGGCAGAGGTAC                   AAGCTCTGAGAGGGCAGCTGGAGCAGAGCATTCAGGGGAACAATTGTCTGCGACTGCA                   GCTGCAACAGCAGCTGGAGAGCGGTGCTGGCAAAGCCAGCCTCAGCCCCTCCTCCATT                   AACCAGAACTTCCCAGCCAGCACTGACCCTGGAAACAAGCAGCTGCTCCTCCAAGGTT                   CAGCTGTGTCCCCTCCAGTCCGGGATGTTGGTATGAATTCCCCAGCTCTGGTCTTCCC                   CAGCTCTGCTTCCTCTACTCCTGGCTCAGATTCAGTTGTGTTGTCATTTTCTTTTTCA                   GGCTTGGGTTTGGATACTTCTCCAGTAATGAAGACCCCTCCCAAGCTAGAGGGTGATG                   CTACTGATGGCTCCTTTGCCAATAAGCATGGCCGCCATGTCATTGGCCACATTGATGA                   CTACAGTGCCCTAAGACAGCAGATTGCGGAGGGCAAGCTGCTGGTCAAAAAGATAGTG                   TCTCTTGTGAGATCAGCGTGCAGCTTCCCTGGCCTTGAAGCCCAAGGCACAGAGGGCA                   GCAAAGGCATTCATGAGCTTCGGAGCAGCACCAGTGCCCTGCACCATGCCCTAGAGGA                   GTCGGCTTCCCTCCTCACCATGTTCTGGAGAGCGGCCCTGCCAAGCACCCACATCCCT                   GTGCTGCCTGGCAAACAGGGAGAATCAACAGAAAGGGAACTTCTGGAACTGAGAACCA                   AAGTATCCAAACAGGAGCAGCTCCTTCAGAGCACAACTGAGCATCTGAAGAACGCCAA                   CCAGCAGAAGGAGAGCATGGAACAGTTCATTGTCAGCGTAACCAGAACACATGATGTT                   TTAAAGAAGGCAAGGACTAACTTAGAGGTGAAATCCCTAAGGGCTCTGCCGTGTACTC                   CAGCCTTG TGA   CCCTTGCCTTCCAGGAACCATGCAAGAAGCGCAGCCACCAGAAGTCC                       TTAAAACAGCAGGAAGGTGAGCCTGTCCCCCTTTTGTGCAGCTACCTATCTGCTGAG                       GAGCATCTGGGCCTCATTCCTCCAAGT                                           ORF Start: ATG at 46       ORF Stop: TGA at 7027           SEQ ID NO:294   2327 aa   MW at 263034.6 kD                     NOV103b,   MSNGYRTLSQHLNDLKKENFSLKLRIYFLEERMQQKYEASREDIYKRNIELKVEVESL       CG59773-02 Protein       Sequence   KRELQDKKQHLDKTWADVENLNSQNEAELRRQFEERQQETEHVYELLENKIQLLQEES                   RLAKNEAARMAALVEAEKECNLELSEKLKGVTKNWEDVPGDQVKPDQYTEALAQRDRR                   IEELNQSLAAQERLVEQLSREKQQLLHLLEEPTSMEVQPMTEELLKQQKLNSHETTIT                   QQSVSDSHLAELQEKIQQTEATNKILQEKLNEMSYELKCAQESSQKQDGTIQNLKETL                   KSRERETEELYQVIEGQNDTMAKLREMLHQSQLGQLQSSEGTSPAQQQVALLDLQSAL                   FCSQLEIQKLQRVVRQKERQLADAKQCVQFVEAAAHESEQQKEASWKHNQELRKALQQ                   LQEELQNKSQQLRAWEAEKYNEIRTQEQNIQHLNHSLSHKEQLLQEFRELLQYRDNSD                   KTLEANEMLLEKLRQRIHDKAVALERAIDEKFSALEEKEKELRQLRLAVRERDHDLER                   LRDVLSSNEATMQSMESLLRAKGLEVEQLSTTCQNLQWLKEEMETKFSRWQKEQESII                   QQLQTSLHDRNKEVEDLSATLLCKLGPGQSEIAEELCQRLQRKERMLQDLLSDRNKQV                   LEHEMEIQGLLQSVSTREQESQAAAEKLVQALMERNSELQALRQYLGGRDSLMSQAPI                   SNQQAEVTPTGRLGKQTDQGSMQIPSRDDSTSLTAKEDVSIPRSTLGDLDTVAGLEKE                   LSNAKEELELMAKKERESQMELSALQSMMAVQEEELQVQAADMESLTRNIQIKEDLIK                   DLQMQLVDPEDIPAMERLTQEVLLLREKVASVESQGQEISGNRRQQQLLLMLEGLVDE                   RSRLNEALQAERQLYSSLVKFHAHPESSERDRTLQVELEGAQVLRSRLEEVLGRSLER                   LNRLETLAAIGGAAAGDDTEDTSTEFTDSIEEEAAHHSHQQLVKVALEKSLATVETQN                   PSFSPPSPMGGDSNRCLQEEMLHLRAEIHQHLEEKRKAEEELKELKAQIEEAGFSSVS                   HIRNTMLSLCLENAELKEQMGETMSDGWEIEEDKEKGEVMVETVVTKEGLSESSLQAE                   FRKLQGKLKNAHNIINLLKEQLVLSSKEGNSKLTPELLVHLTSTIERINTELVGSPGK                   HQHQEEGNVTVRPFPRPQSLDLGATFTVDAHQQLDNQSQPRDPGPQPAFSLPGSTQHL                   RSQLSQCKQRYQDLQEKLLLSEATVFAQANELEKYRVMLSESLVKQDSKQIQVDFQDL                   GYETCGRSENEAEREETTSPECEEHNSLKEMVLMEGLCSEQGRRGSTLASSSERKPLE                   NQLGKQEEFRVYGKSENILVLRKDIEDLKAQLQNANKVIQNLKSRVRSLSVTSDYSSS                   LERPRKLRAVGTLEGSSPHSVPDEDEGWLSDGTGAFYSPGLQAKKDLESLIQRVSQLE                   AQLPENGLEEKLAEELRSASWPGKYDSLIQDQARELSYLRQKIREGRGICYLITQHAK                   DTVKSFEDLLRSNDIDYYLGQSFREQLAQGSQLTERLTSKLSTEDHKSEKDQAGLEPL                   ALRLSRELQEKEKVIEVLQAKLDARSLTPSSSRALSDSHRSPSSTSFLSDELEACSDM                   DIVSEYTHYEEKKASPSHSGSSASQGAKAESNSNPISLPTPQNTPKEANQAHSGFHFH                   SIPKLASLPQAPLPSAPSSFLPFSPTGPPLLGCCETPEVSLAESQQELQMLQKQLGES                   STVPPASTATLLSNDLEADSSYYLNSAQPHSPPRGTIELGRILEPGYLGSSGKWDVMR                   PQKGSVSGDLSSGSSVYQLNSKPTGADLLEEHLGEIWNLRQRLEESICINDCLREQLE                   HRLTSTARGRGSTSNFYSQGLESIPQLCNENRVLREENRRLQAQLSHVSRGHSQETES                   LREALLSSRSHLQELEKELEHQKVERQQLLEDLREDQQEVLHFREERLSLQENDSRLQ                   HKLVLLQQQCEEKQQLFESLQSELQIYEALYGNSKKGLKAYSLDACHQIPLSSDLSHL                   VAEVQALRGQLEQSIQGNNCLRLQLQQQLESGAGKASLSPSSINQNFPASTDPGNKQL                   LLQGSAVSPPVRDVGMNSPALVFPSSASSTPGSDSVVLSFSFSGLGLDTSPVMKTPPK                   LEGDATDGSFANKHGRHVIGHIDDYSALRQQIAEGKLLVKKIVSLVRSACSFPGLEAQ                   GTEGSKGIHELRSSTSALHHALEESASLLTMFWRAALPSTHIPVLPGKQGESTERELL                   ELRTKVSKQEQLLQSTTEHLKNANQQKESMEQFIVSVTRTHDVLKKARTNLEVKSLRA                   LPCTPAL                                     SEQ ID NO:295   7084 bp                     NOV103c,     GTTGAGGGGGCAATCGGGCACGCTCCTCCCCATGGGTTGCCCATCATGTCTAATGGAT         CG59773-03 DNA Sequence             ATCGCACTCTGTCCCAGCACCTCAATGACCTGAAGAAGGAGAACTTCAGCCTCAAGCT                       GCTCATCTACTTCCTGGAGGAGCGCATGCAACAGAAGT   ATG AGGCCAGCCGGGAGGAC                   ATCTACAAGCGGGGGTGATGTGGAGAATCTCAACAGTCAGAATGAAGCTGAGCTCCGA                   CGCCAGTTTGAGGAGCGACAGCAGGAGACGGAGCATGTTTATGAGCTCTTGGAGAATA                   AGATCCAGCTTCTGCAGGAGGAATCCAGGCTAGCAAAGAATGAAGCTGCGCGGATGGC                   AGCTCTGGTGGAAGCAGAGAAGGAGTGTAACCTGGAGCTCTCAGAGAAACTGAAGGGA                   GTCACCAAAAACTGGGAAGATGTACCAGGAGACCAGGTCAAGCCCGACCAATACACTG                   AGACCCTGGCCCAGAGGGACAAGAGAATTGAAGAACTGAATCAGAGCCTGGCTGCCCA                   GGAGAGGCTTGTAGAACAGCTATCTCGGGAGAAACAACAACTGCTACATCTGTTGGAG                   GAGCCAACTAGCATGGAAGTGCAGCCCATGACTGAAGAGTTGCTGAAACAACAAAAGC                   TGAATTCACATGAGACCACTATAACTCAGCAGTCTGTATCTGATTCCCACTTGGCAGA                   ACTCCAGGAAAAAATCCAGCAAACAGAGGCCACCAACAAGATTCTTCAAGAGAAACTT                   AATGAAATGAGCTATGAACTAAAGTGTGCTCAGGAGTCGTCTCAAAAGCAAGATGGTA                   CAATTCAGAACCTCAAGGAAACTCTGAAAAGCAGGGAACGTGAGACTGAGGAGTTGTA                   CCAGGTAATTGAAGGTCAAAATGACACAATGGCAAAGCTTCGAGAAATGCTGCACCAA                   AGCCAGCTTGGACAACTTCAGAGCTCAGAGGGTACTTCTCCAGCTCAGCAACAGGTAG                   CTCTGCTTGATCTTCAGAGTGCTTTATTCTGCAGCCAACTTGAAATACAGAAGCTCCA                   GAGGGTGGTACGACAGAAAGAGCGCCAACTGGCTGATGCCAAACAATGTGTGCAATTT                   GTAGAGGCTGCAGCACACGAGAGTGAACAGCAGAAAGAGGCTTCTTGGAAACATAACC                   AGGAATTGCGAAAAGCCTTGCAGCAGCTACAAGAAGAATTGCAGAATAAGAGCCAACA                   GCTTCGTGCCTGGGAGGCTGAAAAATACAATGAGATTCGAACCCAGGAACAAAACATC                   CAGCACCTAAACCATAGTCTGAGTCACAAGGAGCAGTTGCTTCAGGAATTTCGGGAGC                   TCCTACAGTATCGAGATAACTCAGACAAAACCCTTGAAGCAAATGAAATGTTGCTTGA                   GAAACTTCGCCAGCGAATACATGATAAAGCTGTTGCTCTGGAGCGGGCTATAGATGAA                   AAATTCTCTGCTCTAGAAGAGAAAGAAAAAGAACTGCGCCAGCTTCGTCTTGCTGTGA                   GAGAGCGAGATCATGACTTAGAGAGACTGCGCGATGTCCTCTCCTCCAATGAAGCTAC                   TATGCAAAGTATGGAGAGTCTCCTGAGGGCCAAAGGCCTGGAAGTGGAACAGTTATCT                   ACTACCTGTCAAAACCTCCAGTGGCTGAAAGAAGAAATGGAAACCAAATTTAGCCGTT                   GGCAGAAGGAACAAGAGAGTATCATTCAGCAGTTACAGACGTCTCTTCATGATAGGAA                   CAAAGAAGTGGAGGATCTTAGTGCAACACTGCTCTGCAAACTTGGACCAGGGCAGAGT                   GAGATAGCAGAGGAGCTGTGCCAGCGTCTACAGCGAAAGGAAAGGATGCTGCAGGACC                   TTCTAAGTGATCGAAATAAACAAGTGCTGGAACATGAAATGGAGATTCAAGGCCTGCT                   TCAGTCTGTGAGCACCAGGGAGCAGGAAAGCCAAGCTGCTGCAGAGAAGTTGGTGCAA                   GCCTTAATGGAAAGAAATTCAGAATTACAGGCCCTGCGCCAATATTTAGGAGGGAGAG                   ACTCCCTGATGTCCCAAGCACCCATCTCTAACCAACAAGCTGAAGTTACCCCCACTGG                   CCGTCTTGGAAAACAGACTGATCAAGGTTCAATGCAGATACCTTCCAGAGATGATAGC                   ACTTCATTGACTGCCAAAGAGGATGTCAGCATACCCAGATCCACATTAGGAGATTTGG                   ACACAGTTGCAGGGCTGGAAAAAGAACTGAGTAATGCCAAAGAGGAACTTGAACTCAT                   GGCTAAAAAAGAAAGAGAATCACAGATGGAACTTTCTGCTCTACAGTCCATGATGGCT                   GTGCAGGAAGAAGAGCTGCAGGTGCAGGCTGCTGATATGGAGTCTCTGACCAGGAACA                   TACAGATTAAAGAAGATCTCATAAAGGACCTGCAAATGCAACTGGTTGATCCTGAAGA                   CATACCAGCTATGGAACGCCTGACCCAGGAAGTCTTACTTCTTCGGGAAAAAGTTGCT                   TCAGTAGAATCCCAGGGTCAAGAAATTTCAGGAAACCGAAGACAACAGCAGTTGCTGC                   TGATGCTAGAAGGACTAGTAGATGAACGGAGTCGGCTCAATGAGGCCTTACAAGCAGA                   GAGACAGCTCTATAGCAGTCTGGTGAAGTTCCATGCCCATCCAGAGAGCTCTGAGAGA                   GACCGAACTCTGCAGGTGGAACTGGAAGGGGCTCAGGTGTTACGCAGTCGGCTAGAAG                   AACTTCTTGGAAGAAGCTTGGAGCGCTTAAACAGGCTGGAGACCCTGGCCGCCATTGG                   AGGTGCAGCTGCAGGGGATGACACCGAAGATACAAGCACTGAGTTCACTGACAGTATT                   GAGGAGGAGGCTGCACACCATAGTCACCAGCAACTTGTCAAGGTGGCTTTGGAGAAAA                   GTCTGGCAACTGTGGAGACCCAGAACCCATCTTTTTCCCCTCCTTCTCCGATGGGAGG                   GGACAGTAACAGGTGTCTTCAGGAAGAAATGCTCCACCTGAGGGCTGAGATCCACCAG                   CACTTAGAAGAGAAGAGGAAAGCTGAGGAGGAACTGAAGGAGCTAAAGGCTCAAATTG                   AGGAAGCAGGATTCTCCTCAGTGTCCCACATCAGGAACACCATGCTGAGCCTTTGCCT                   TGAGAATGCGGAGCTGAAAGAGCAGATGGGAGAAACAATGTCTGATGGATGGGAGATC                   GAGGAAGACAAGGAGAAGGGCGAGGTGATGGTTGAGACTGTGGTAACCAAAGAGGGTC                   TGAGTGAGAGTAGCCTTCAGGCTGAGTTCAGAAAGCTCCAGGGAAAACTGAAGAATGC                   CCACAATATCATCAACCTCCTCAAAGAACAACTTGTGCTGAGTAGCAAGGAAGGGAAT                   AGTAAACTTACTCCAGAGCTCCTTGTGCATCTGACCAGCACCATCGAAAGAATAAACA                   CAGAACTGGTTGGTTCCCCTGGGAAGCACCAACACCAAGAGGAGGGGAATGTGACTGT                   GAGGCCTTTCCCCAGACCCCAGAGCCTTGACCTTGGGGCTACCTTCACAGTGGATGCC                   CACCAACAGTTGGATAACCAGTCCCAGCCTCGTGACCCTGGGCCTCAGCCAGCGTTTA                   GCCTACCAGGGTCCACCCAGCACCTGCGCTCCCAGCTGTCACAATGCAAACAACGCTA                   TCAAGATCTCCAGGAGAAGCTGCTGCTATCAGAAGCCACTGTCTTTGCTCAGGCTAAC                   GAGCTGGAGAAATACAGAGTTATGCTTAGTGAATCCTTGGTGAAGCAGGACAGCAAGC                   AGATCCAGGTGGACTTCCAGGACCTGGGCTATGAGACTTGTGGCCGAAGCGAGAATGA                   GGCTGAACGGGAGGAAACCACCAGTCCTGAGTGTGAGGAGCACAACAGCCTCAAGGAA                   ATGGTCCTGATGGAGGGGCTGTGCTCTGAGCAGGGACGCCGGGGCTCAACACTGGCTA                   GTTCCTCTGAGAGGAAGCCCTTGGAGAACCAGCTAGGGAAGCAGGAAGAGTTCCGGGT                   ATATGGAAAGTCAGAAAACATCTTGGTCCTACGAAAGGACATCGAAGATCTGAAGGCC                   CAGCTGCAGAATGCCAACAAGGTCATTCAAAACCTCAAGAGCCGGGTCCGGTCCCTCT                   CAGTTACAAGTGATTATTCGTCTAGTCTGGAAAGACCCCGGAAGCTGAGAGCTGTTGG                   CACCTTGGAGGGGTCTTCACCTCATAGTGTCCCTGATGAGGATGAGGGGTGGCTGTCT                   GATGGCACTGGGGCTTTCTACTCTCCAGGGCTTCAGGCCAAAAAGGACCTGGAGAGTC                   TCATCCAGAGAGTATCCCAGCTGGAGGCCCAGCTCCCAGAAAATGGACTAGAAGAGAA                   GCTGGCTGAGGAGCTGAGATCAGCCTCGTGGCCTGGGAAATATGATTCCCTGATTCAG                   GATCAGGCCCGGGAACTGTCTTACCTACGGCAAAAAATACGAGAAGGGAGAGGTATTT                   GTTATCTTATCACCCAGCATGCAAAAGATACAGTAAAATCTTTTGAGGATCTCCTAAG                   GAGCAATGACATTGACTACTACCTGGGACAGAGCTTCCGGGAGCAACTCGCCCAGGGA                   AGCCAGCTGACAGAGAGGCTCACCAGCAAACTCAGCACAGAGGATCATAAAAGTGAGA                   AAGATCAAGCTGGACTTGAGCCACTGGCCCTCAGGCTCAGCAGGGAGCTGCAGGAGAA                   GGAGAAAGTGATTGAAGTCCTGCAGGCCAAGCTGGATGCTCGGTCCCTCACACCCTCC                   AGCAGCCGTGCCTTGTCTGACTCCCACCGCTCTCCCAGCAGCACCTCTTTCCTGTCTG                   ATGAGCTGGAAGCCTGCTCTGACATGGACATAGTCAGCGAGTACACACACTATGAAGA                   GAAGAAAGCTTCTCCCAGTCACTCAGGTAGCAGTGCATCTCAGGGGGCTAAGGCCGAA                   TCCAACAGCAACCCCATCAGCTTGCCAACTCCCCAGAATACCCCCAAGGAGGCCAACC                   AAGCCCATTCAGGCTTTCATTTTCACTCCATACCCAAGCTGGCTAGCCTTCCTCAGGC                   ACCATTGCCCTCAGCTCCATCCAGCTTCCTGCCTTTCAGCCCCACTGGCCCTCCCCTC                   CTTGGCTGCTGTGAGACACCAGAGGTCTCCTTGGCTGAGTCTCAGCAGGAGCTACAGA                   TGCTGCAGAAGCAGTTGGGAGAAAGTAGCACTGTTCCTCCTGCTTCCACAGCTACATT                   GCTGAGCAACGACTTGGAAGCCGACTCTTCCTACTACCTCAACTCTGCCCAGCCTCAC                   TCTCCTCCAAGGGGCACCATAGAACTGGGAAGAATCCTAGAGCCTGGGTACCTGGGCA                   GCAGTGGCAAGTGGGATGTGATGAGGCCTCAGAAAGGGAGTGTATCTGGGGACCTATC                   CTCAGGCTCCTCTGTGTACCAGCTTAACTCCAAACCCACAGGGGCTGACCTGCTGGAA                   GAGCATCTTGGTGAAATCTGGAACCTGCGCCAGCGCCTGGAGGAGTCCATCTGCATCA                   ATGACTGCCTACGGGAGCAACTGGAACACCGGCTGACCTCTACTGCTCGTGGAAGGGG                   ATCCACTTCTAACTTCTACAGTCAGGGCCTGGAGTCCATACCTCAGCTCTGCAATGAG                   AACAGAGTCCTCAGGGAAGAAAATCGAAGACTTCAGGCTCAACTGAGTCATGTTTCCA                   GAGGTCACTCCCAGGAAACAGAAAGCCTGAGGGAGGCTCTGCTGTCCTCTCGATCCCA                   CCTTCAAGAGCTGGAAAAGGAGCTGGAGCACCAGAAGGTGGAAAGGCAGCAGCTTTTG                   GAAGACTTGAGGGAGAAGCAGCAAGAGGTCTTGCATTTCAGGGAGGAACGTCTTTCCC                   TCCAGGAAAACGACTCCAGACTGCAGCACAAGCTGGTTCTCCTGCAGCAACAGTGTGA                   AGAGAAACAGCAGCTCTTTGAGTCCCTCCAGTCAGAGCTACAAATCTACGAGGCACTT                   TATGGCAATTCCAAGAAGGGGCTGAAAGCTTACAGCCTGGATGCCTGTCACCAAATCC                   CTTTGAGCAGTGACCTGAGCCACCTGGTGGCAGAGGTACAAGCTCTGAGAGGGCAGCT                   GGAGCAGAGCATTCAGGGGAACAATTGTCTGCGACTGCAGCTGCAACAGCAGCTGGAG                   AGCGGTGCTGGCAAAGCCAGCCTCAGCCCCTCCTCCATTAACCAGAACTTCCCAGCCA                   GCACTGACCCTGGAAACAAGCAGCTGCTCCTCCAAGGTTCAGCTGTGTCCCCTCCAGT                   CCGGGATGTTGGTATGAATTCCCCAGCTCTGGTCTTCCCCAGCTCTGCTTCCTCTACT                   CCTGGCTCAGATTCAGTTGTGTTGTCATTTTCTTTTTCAGGCTTGGGTTTGGATACTT                   CTCCAGTAATGAAGACCCCTCCCAAGCTAGAGGGTGATGCTACTGATGGCTCCTTTGC                   CAATAAGCATGGCCGCCATGTCATTGGCCACATTGATGACTACAGTGCCCTAAGACAG                   CAGATTGCGGAGGGCAAGCTGCTGGTCAAAAAGATAGTGTCTCTTGTGAGATCAGCGT                   GCAGCTTCCCTGGCCTTGAAGCCCAAGGCACAGAGGGCAGCAAAGGCATTCATGAGCT                   TCGGAGCAGCACCAGTGCCCTGCACCATGCCCTAGAGGAGTCGGCTTCCCTCCTCACC                   ATGTTCTGGAGAGCGGCCCTGCCAAGCACCCACATCCCTGTGCTGCCTGGCAAACAGG                   GAGAATCAACAGAAAGGGAACTTCTGGAACTGAGAACCAAAGTATCCAAACAGGAGCA                   GCTCCTTCAGAGCACAACTGAGCATCTGAAGAACGCCAACCAGCAGAAGGAGAGCATG                   GAACAGTTCATTGTCAGCGTAACCAGAACACATGATGTTTTAAAGAAGGCAAGGACTA                   ACTTAGAGGTGAAATCCCTAAGGGCTCTGCCGTGTACTCCAGCCTTG TGA   CCCTTGCC                       TTCCAGGAACCATGCAAGAAGCGCAGCCACCAGAAGTCCTTAAAACAGCAGGAAAGGT                       GAGCCTGTCCCCCTTTTGTGCAGCTACCTATCTGCTGAGGAGCATCTGGGCCTCATTC                       CTCCAAGT                                           ORF Start: ATG at 155       ORF Stop: TGA at 6950           SEQ ID NO:296   2265 aa   MW at 255081.5 kD                     NOV103c,   MRPAGRTSTSGGDVENLNSQNEAELRRQFEERQQETEHVYELLENKIQLLQEESRLAK       CG59773-03 Protein       Sequence   NEAARMAALVEAEKECNLELSEKLKGVTKNWEDVPGDQVKPDQYTETLAQRDKRIEEL                   NQSLAAQERLVEQLSREKQQLLHLLEEPTSMEVQPMTEELLKQQKLNSHEETTITQQSV                   SDSHLAELQEKIQQTEATNKILQEKLNEMSYELKCAQESSQKQDGTIQNLKETLKSRE                   RETEELYQVIEGQNDTMAKLREMLHQSQLGQLHSSEGTSPAQQQVALLDLQSALFCSQ                   LEIQKLQRVVRQKERQLADAKQCVQFVEAAAHESEQQKEASWKHNQELRKALQQLQEE                   LQNKSQQLRAWEAEKYNEIRTQEQNIQHLNHSLSHKEQLLQEFRELLQYRDNSDKTLE                   ANEMLLEKLRQRIHDKAVALERAIDEKFSALEEKEKELRQLRLAVRERDHDLERLRDV                   LSSNEATMQSMESLLRAKGLEVEQLSTTCQNLQWLKEEMETKFSRWQKEQESIIQQLQ                   TSLHDRNKEVEDLSATLLCKLGPGQSEIAEELCQRLQRKERMLQDLLSDRNKQVLEHE                   MEIQGLLQSVSTREQESQAAAEKLVQALMERNSELQALRQYLGGRDSLMSQAPISNQQ                   AEVTPTGRLGKQTDQGSMQIPSRDDSTSLTAKEDVSIPRSTLGDLDTVAGLEKELSNA                   KEELELMAKKERESQMELSALQSMMAVQEEELQVQAADMESLTRNIQIKEDLIKDLQM                   QLVDPEDIPAMERLTQEVLLLREKVASVESQGQEISGNRRQQQLLLMLEGLVDERSRL                   NEALQAERQLYSSLVKFHAHPESSERDRTLQVELEGAQVLRSRLEEVLGRSLERLNRL                   ETLAAIGGAAAGDDTEDTSTEFTDSIEEEAAHHSHQQLVKVALEKSLATVETQNPSFS                   PPSPMGGDSNRCLQEEMLHLRAEFHQHLEEKRKAEEELKELKAQIEEAGFSSVSHIRN                   TMLSLCLENAELKEQMGEAMSDGWEIEEDKEKGEVMVETVVTKEGLSESSLQAEFRKL                   QGKLKNAHNIINLLKEQLVLSSKEGNSKLTPELLVHLTSTIERINTELVGSPGKHQHQ                   EEGNVTVRPFPRPQSLDLGATFTVDAHQQLDNQSQPRDPGPQSAFSLPGSTQHLRSQL                   SQCKQRYQDLQEKLLLSEATVFAQANELEKYRVMLSESLVKQDSKQIQVDFQDLGYET                   CGRSENEAEREETTSPECEEHNSLKEMVLMEGLCSEQGRRGSTLASSSERKPLENQLG                   KQEEFRVYGKSENILVLRKDIEDLKAQLQNANKVIQNLKSRVRSLSVTSDYSSSLERP                   RKLRAVGTLEGSSPHSVPDEDEGWLSDGTGAFYSPGLQAKKDLESLIQRVSQLEAQLP                   ENGLEEKLAEELRSASWPGKYDSLIQDQARELSYLRQKIREGRGICYLITQHAKDTVK                   SFEDLLRSNDIDYYLGQSFREQLAQGSQLTERLTSKLSTEDHKSEKDQAGLEPLALRL                   SRELQEKEKVIEVLQAKLDARSLTPSSSRALSDSHRSPSSTSFLSDELEACSDMDIVS                   EYTHYEEKKASPSHSGSSASQGAKAESNSNPISLPTPQNTPKEANQAHSGFHFHSIPK                   LASLPQAPLPSAPSSFLPFSPTGPPLLGCCETPEVSLAESQQELQMLQKQLGESSTVP                   PASTATLLSNDLEADSSYYLNSAQPHSPPRGTIELGRILEPGYLGSSGKWDVMRPQKG                   SVSGDLSSGSSVYQLNSKPTGADLLEEHLGEIWNLRQRLEESICINDCLREQLEHRLT                   STARGRGSTSNFYSQGLESIPQLCNENRVLREENRRLQAQLSHVSRGHSQETESLREA                   LLSSRSHLQELEKELEHQKVERQQLLEDLREKQQEVLHFREERLSLQENDSRLQHKLV                   LLQQQCEEKQQLFESLQSELQIYEALYGNSKKGLKAYSLDACHQIPLSSDLSHLVAEV                   QALRGQLEQSIQGNNCLRLQLQQQLESGAGKASLSPSSINQNFPASTDPGNKQLLLQG                   SAVSPPVRDVGMNSPALVFPSSASSTPGSDSVVLSFSFSGLGLDTSPVKMTPPKLEGD                   ATDGSFANKHGRHVIGHIDDYSALRQQIAEGKLLVKKIVSLVRSACSFPGLEAQGTEG                   SKGIHELRSSTSALHHALEESASLLTMFWRAALPSTHIPVLPGKQGESTERELLELRT                   KVSKQEQLLQSTTEHLKNANQQKESMEQFIVSVTRTHDVLKKARTNLEVKSLRARPCT                   PAL                  
 
     [0864] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 103B.  
               TABLE 103B                          Comparison of NOV103a against NOV103b through NOV103c.                                 Identities/               Similarities       Protein   NOV103a Residues/   for the       Sequence   Match Residues   Matched Region               NOV103b   365 . . . 2196   1510/1834 (82%)           202 . . . 2016   1518/1834 (82%)       NOV103c   365 . . . 2196   1510/1834 (82%)           140 . . . 1954   1518/1834 (82%)                  
 
     [0865] Further analysis of the NOV103a protein yielded the following properties shown in Table 103C.  
               TABLE 103C                       Protein Sequence Properties NOV103a                                        PSort   0.5855 probability located in mitochondrial matrix space;       analysis:   0.4200 probability located in nucleus; 0.3000 probability           located in microbody (peroxisome); 0.2957 probability located           in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 39 and 40       analysis:                  
 
     [0866] A search of the NOV103a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 103D.  
               TABLE 103D                          Geneseq Results for NOV103a                                         NOV103a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAY71159   Human phosphodiesterase    1 . . . 2196   2193/2204 (99%)   0.0           interacting protein, myomegalin-    1 . . . 2204   2193/2204 (99%)             Homo sapiens , 2517 aa.           [WO200027861-A1,           18 MAY 2000]       AAM40183   Human polypeptide SEQ ID NO   635 . . . 2196   1557/1570 (99%)   0.0           3328- Homo sapiens , 1883 aa.    1 . . . 1570   1559/1570 (99%)           [WO200153312-A1,           26 JUL. 2001]       AAY71158   phosphodiesterase interacting   365 . . . 2197   1433/1837 (78%)   0.0           protein, myomegalin-Rattus sp,   202 . . . 2017   1572/1837 (85%)           2326 aa. [WO200027861-A1,           18 MAY 2000]       AAY67600   Human adipose tissue protein #3-    1 . . . 934   925/934 (99%)   0.0             Homo sapiens , 944 aa.    1 . . . 934   927/934 (99%)           [JP2000037190-A, 8 FEB. 2000]       AAU01768   Human secreted protein #47-   365 . . . 1102   730/738 (98%)   0.0             Homo sapiens , 934 aa.   197 . . . 934   733/738 (98%)           [WO200123546-A1, 5 APR. 2001]                  
 
     [0867] In a BLAST search of public sequence databases, the NOV103a protein was found to have homology to the proteins shown in the BLASTP data in Table 103E.  
               TABLE 103E                          Public BLASTP Results for NOV103a                                         NOV103a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               O75042   KIAA0454 PROTEIN- Homo     636 . . . 2196   1558/1569 (99%)   0.0             sapiens  (Human), 1882 aa    1 . . . 1569   1558/1569 (99%)           (fragment).       Q9WUJ3   MYOMEGALIN- Rattus     365 . . . 2197   1444/1838 (78%)   0.0             norvegicus  (Rat), 2324 aa.   202 . . . 2015   1581/1838 (85%)       O75065   KIAA0477 PROTEIN- Homo      1 . . . 1132   1132/1132 (100%)   0.0             sapiens  (Human), 1132 aa.    1 . . . 1132   1132/1132 (100%)       Q25893   LIVER STAGE ANTIGEN-   356 . . . 1459    243/1129 (21%)   4e−35             Plasmodium falciparum  (isolate   605 . . . 1651    488/1129 (42%)           NF54), 1909 aa.       Q13439   Golgi autoantigen, golgin   229 . . . 1749    349/1638 (21%)   4e−34           subfamily A 4 (Trans-Golgi p230)   267 . . . 1814    679/1638 (41%)           (256 kDa golgin) (Golgin-245)           (72.1 protein)- Homo sapiens             (Human), 2230 aa.                  
 
     [0868] PFam analysis predicts that the NOV103a protein contains the domains shown in the Table 103F.  
               TABLE 103F                          Domain Analysis of NOV103a                                     Identities/           Pfam   NOV103a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               Somatomedin_B:    150 . . . 189    14/47 (30%)   7.6       domain 1 of 1        25/47 (53%)       necA: domain 1 of 1    621 . . . 650    8/30 (27%)   8.1                22/30 (73%)       Ribosomal_L10:    604 . . . 695    20/109 (18%)   9.9       domain 1 of 1        59/109 (54%)       Dishevelled:    844 . . . 914    19/74 (26%)   2.7       domain 1 of 1        37/74 (50%)       Transposase_22:   1135 . . . 1416    71/376 (19%)   4.6       domain 1 of 1       127/376 (34%)       Phe_tRNA-synt_N:   2079 . . . 2152    13/79 (16%)   4.9       domain 1 of 1        49/79 (62%)                  
 
     Example 104  
     [0869] The NOV104 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 104A.  
               TABLE 104A                       NOV104 Sequence Analysis                                                SEQ ID NO:297   736 bp                     NOV104a,     AAAGCACCCGAG   ATG ACCCCGGCTCCTCCACCAGGAGCGCGGCCGGGCGCGGCGTCCC       CG57460-01 DNA Sequence           TAGCGGGCTTCGCCGGGGTGGCGTCTCTGGGGCCTGGGGACCCCCGCCGCGCCGCTGA                   CCCGCGCCCTCTGCCCCCAGCGCTGTGCTTCGCCGTGAGCCGCTCGCTGCTGCTGACG                   TGCCTGGTGCCGGCCGCGCTGCTGGGCCTGCGCTACTACTACAGCCGCAAGGTGATCC                   GCGCCTACCTGGAGTGCGCGCTGCACACGGACATGGCGGACATCGAGCAGTACTACAT                   GAAGCCGCCCGGTGTGTCCCTGACCGCCCTATCCCCTGCAGGCTCCTGCTTCTGGGTG                   GCCGTGCTGGATGGCAACGTGGTGGGCATTGTGGCTGCACGGGCCCACGAGGAGGACA                   ACACGGTGGAGCTGCTGCGGATGTCTGTGGACTCACGTTTCCGAGGCAAGGGCATCGC                   CAAGGCGCTGGGCCGGAAGGTGCTGGAGTTCGCCGTGGTGCACAACTACTCCGCGGTG                   GTGCTGGGCACGACGGCCGTCAAGGTGGCCGCCCACAAGCTCTACGAGTCGCTGGGCT                   TCAGACACATGGGCGCCAGTGACCACTACGTGCTGCCGGGCATGACCCTCTCGCTGGC                   TGAGCGCCTCTTCTTCCAGGTCCGCTACCACCGCTACCGCCTGCAGCTGCGCGAGGAG                     TGA   CCGCCGCCGCTCGCCCGCCCGCCCCCCCGGCCGCCCT                                           ORF Start: ATG at 13       ORF Stop: TGA at 697           SEQ ID NO:298   228 aa   MW at 24767.5 kD                     NOV104a,   MTPAPPPGARPGAASLAGFAGVASLGPGDPRRAADPRPLPPALCFAVSRSLLLTCLVP       CG57460-01 Protein Sequence           AALLGLRYYYSRKVIRAYLECALHTDMADIEQYYMKPPGVSLTALSPAGSCFWVAVLD                   GNVVGIVAARAHEEDNTVELLRMSVDSRFRGKGIAKALGRKVLEFAVVHNYSAVVLGT                   TAVKVAAHKLYESLGFRHMGASDHYVLPGMTLSLAERLFFQVRYHRYRLQLREE                  
 
     [0870] Further analysis of the NOV104a protein yielded the following properties shown in Table 104B.  
               TABLE 104B                       Protein Sequence Properties NOV104a                                        PSort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability           located in endoplasmic reticulum (membrane); 0.1000           probability located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 64 and 65       analysis:                  
 
     [0871] A search of the NOV104a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 104C.  
               TABLE 104C                          Geneseq Results for NOV104a                                         NOV104a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAB19986   Human camello 3 (Hcml3) protein   42 . . . 195   144/154 (93%)   7e−76           (partial)- Homo sapiens , 144 aa.    1 . . . 144   144/154 (93%)           [WO200077024-A1,           21 DEC. 2000]       AAB19985   Human camello 2 (Hcml2) protein-   47 . . . 200    63/158 (39%)   1e−21             Homo sapiens , 227 aa.   56 . . . 203    92/158 (57%)           [WO200077024-A1,           21 DEC. 2000]       AAB19984   Human camello 1 (Hcml1) protein-   41 . . . 196    60/160 (37%)   7e−20             Homo sapiens , 227 aa.   50 . . . 199    88/160 (54%)           [WO200077024-A1,           21 DEC. 2000]       AAY57959   Human TSC501 protein SEQ ID   41 . . . 196    59/160 (36%)   4e−19           NO: 1- Homo sapiens , 227 aa.   50 . . . 199    87/160 (53%)           [JP11332579-A, 7 DEC. 1999]       AAB19987   Mouse camello 1 (Mcml1)   41 . . . 194    63/158 (39%)   1e−18           protein-Mus sp, 222 aa.   50 . . . 197    87/158 (54%)           [WO200077024-A1,           21 DEC. 2000]                  
 
     [0872] In a BLAST search of public sequence databases, the NOV104a protein was found to have homology to the proteins shown in the BLASTP data in Table 104D.  
               TABLE 104D                          Public BLASTP Results for NOV104a                                         NOV104a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9UHF3   PUTATIVE N-   47 . . . 200   63/158 (39%)   5e−21           ACETYLTRANSFERASE   56 . . . 203   92/158 (57%)           CAMELLO 2- Homo sapiens             (Human), 227 aa.       Q9UHE5   PUTATIVE N-   41 . . . 196   60/160 (37%)   3e−19           ACETYLTRANSFERASE CML1-   50 . . . 199   88/160 (54%)             Homo sapiens  (Human), 227 aa.       Q9UQ17   GLA PROTEIN- Homo sapiens     41 . . . 196   60/160 (37%)   3e−19           (Human), 227 aa.   50 . . . 199   88/160 (54%)       Q96QI8   KIDNEY-AND LIVER-SPECIFIC   41 . . . 196   59/160 (36%)   1e−18           GENE - Homo sapiens  (Human),   50 . . . 199   87/160 (53%)           227 aa.       O75839   TSC501 PROTEIN- Homo     41 . . . 196   59/160 (36%)   1e−18             sapiens  (Human), 227 aa.   50 . . . 199   87/160 (53%)                  
 
     [0873] PFam analysis predicts that the NOV104a protein contains the domains shown in the Table 104E.  
               TABLE 104E                          Domain Analysis of NOV104a                                     Identities/           Pfam   NOV104a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               Acetyltransf: domain 1   111 . . . 191   28/82 (34%)   2.2e−17       of 1       64/82 (78%)                  
 
     Example 105  
     [0874] The NOV105 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 105A.  
               TABLE 105A                       NOV105 Sequence Analysis                                                SEQ ID NO:299   1230 bp                     NOV105a,     CTTCCCGGCGGCTGCGCG   ATG GACAGCCCCGAGGTGACCTTCACTCTCGCCTATCTGG       CG57464-01 DNA Sequence           TGTTCGCCGTGTGCTTCGTGTTCACGCCCAACGAGTTCCACGCGGCGGGGCTCACGGT                   GCAGAACCTGCTGTCGGGCTGGCTGGGCAGCGAGGACGCCGCCTTCGTGCCCTTCCAC                   TTGCGCCGCACGGCCGCCACGCTGTTGTGCCACTCGCTGCTGCCGCTCGGTGAGGCTG                   CTCGGGCCGGCCGGCCGCATCCTCTCCTGCGCAGGGCTTGCTGGGAGGTCAGGAGGAG                   GCCTCCGCCAGCTCCCCGAGGCCCCGAAAGCGCCTGGGCGCAGCTGGGGAGAGGCGCC                   GGTCCTCATCCAGAGGGACCGCGGCGTGGGCTGAGCGCGCTTAGGGGTGCCGCCGGCC                   TGGCCTGGCGGCTCTTCCTGCTGCTGGCCGTGACCCTCCCCTCCATCGCCTGCATCCT                   GATCTACTACTGGTCCCGTGACCGGTGGGCCTGCCACCCACTGGCGCGCACCCTGGCC                   CTCTACGCCCTCCCACAGTCTGGCTGGCAGGCTGTTGCCTCCTCTGTCAACACTGAGT                   TCCGGCGGATTGACAAGTTTGCCACCGGTGCACCAGGTGCCCGTGTGATTGTGACAGA                   CACGTGGGTGATGAAGGTAACCACCTACCGAGTGCACGTGGCCCAGCAGCAGGACGTG                   CACCTGACTGTGACGGAGTCTCGGCAGCATGAGCTCTCGCCAGACTCGAACTTGCCCG                   TGCAGCTCCTCACCATCCGTGTGGCCAGCACCAACCCTGCTGTGCAGGCCTTTGACAT                   CAGGCTGAACTCCACTGAGTACGGGGAGCTCTGCGAGAAGCTCCGGGCACCCATCCGC                   AGGGCAGCCCATGTGGTCATCCACCAGAGCCTGGGCGACCTGTTCCTGGAGACATTTG                   CCTCCCTGGTAGAGGTCAACCCGGCCTACTCAGTGCCCAGCAGCCAGGTGGGGGGCCT                   GGAGGCCTGCATAGGCTGCATGCAGACACGTGCCAGCGTGAAGCTGGTGAAGACCTGC                   CAGGAGGCAGCCACAGGCGAGTGCCAGCAGTGTTACTGCCGCCCCATGTGGTGCCTCA                   CCTGCATGGGCAAGTGGTTCGCCAGCCGCCAGGACCCCCTGCGCCCTGACACCTGGCT                   GGCCAGCCGCGTGCCCTGCCCCACCTGCCGCGCACGCTTCTGCATCCTGGATGTGTGC                   ACCGTGCGC TGA                                           ORF Start: ATG at 19       ORF Stop: TGA at 1228           SEQ ID NO:300   403 aa   MW at 44585.0 kD                     NOV105a,   MDSPEVTFTLAYLVFAVCFVFTPNEFHAAGLTVQNLLSGWLGSEDAAFVPFHLRRTAA       CG57464-01 Protein Sequence           TLLCHSLLPLGEAARAGRPHPLLRRACWEVRRRPPPAPRGPESAWAQLGRGAGPHPEG                   PRRGLSALRGAAGLAWRLFLLLAVTLPSIACILIYYWSRDRWACHPLARTLALYALPQ                   SGWQAVASSVNTEFRRIDKFATGAPGARVIVTDTWVMKVTTYRVHVAQQQDVHLTVTE                   SRQHELSPDSNLPVQLLTIRVASTNPAVQAFDIRLNSTEYGELCEKLRAPIRRAAHVV                   IHQSLGDLFLETFASLVEVNPAYSVPSSQVGGLEACIGCMQTRASVKLVKTCQEAATG                   ECQQCYCRPMWCLTCMGKWFASRQDPLRPDTWLASRVPCPTCRARFCILDVCTVR                  
 
     [0875] Further analysis of the NOV105a protein yielded the following properties shown in Table 105B.  
               TABLE 105B                       Protein Sequence Properties NOV105a                                        PSort   0.6760 probability located in plasma membrane; 0.1000       analysis:   probability located in endoplasmic reticulum (membrane);           0.1000 probability located in endoplasmic reticulum (lumen);           0.1000 probability located in outside       SignalP   Likely cleavage site between residues 29 and 30       analysis:                  
 
     [0876] A search of the NOV105a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 105C.  
               TABLE 105C                          Geneseq Results for NOV105a                                         NOV105a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAG81377   Human AFP protein sequence SEQ   1 . . . 403   344/409 (84%)   0.0           ID NO: 272- Homo sapiens , 362   1 . . . 362   345/409 (84%)           aa. [WO200129221-A2,           26 APR. 2001]                  
 
     [0877] In a BLAST search of public sequence databases, the NOV105a protein was found to have homology to the proteins shown in the BLASTP data in Table 105D.  
               TABLE 105D                          Public BLASTP Results for NOV105a                                         NOV105a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               CAC38627   SEQUENCE 271 FROM    1 . . . 403   345/409 (84%)   0.0           PATENT WO0129221- Homo      1 . . . 362   346/409 (84%)             sapiens  (Human), 362 aa.       Q9DCF3   0610039G24RIK PROTEIN-    1 . . . 403   311/403 (77%)    e−176             Mus musculus  (Mouse), 362 aa.    1 . . . 362   328/403 (81%)       Q96GP5   SIMILAR TO RIKEN CDNA    1 . . . 265   211/271 (77%)    e−109           0610039G24 GENE- Homo      1 . . . 226   212/271 (77%)             sapiens  (Human), 232 aa.       Q9VN16   CG14646 PROTEIN- Drosophila      1 . . . 399   123/409 (30%)   1e−55             melanogaster  (Fruit fly), 409 aa.    1 . . . 383   202/409 (49%)       Q95TM4   LD39811P- Drosophila     20 . . . 399   117/390 (30%)   1e−51             melanogaster  (Fruit fly), 393 aa.    4 . . . 367   192/390 (49%)                  
 
     [0878] PFam analysis predicts that the NOV105a protein contains the domains shown in the Table 105E.  
               TABLE 105E                          Domain Analysis of NOV105a                                             Identities/               Pfam   NOV105a   Similarities for   Expect           Domain   Match Region   the Matched Region   Value                             No Significant Matches Found                  
 
     Example 106  
     [0879] The NOV106 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 106A.  
               TABLE 106A                       NOV106 Sequence Analysis                                                SEQ ID NO:301   1136 bp                     NOV106a,     TTTCTGCA   ATG GGAGCCTCCGCCACCCACCCTGGAGCCACAGAAGGCCCAGAAGCCAA       CG57466-01 DNA Sequence           ATGGACAGCTGGTGAACCCCAACAACTTCTGGAAGAACCCGAAAGATGTGTGCGCCCA                   CGCCCATGGCCTCTCAGGGCCCAGGCCTGGGACGTGACCACCACTAACTGCTCAGCCA                   ATATCAACTTGACCCACCAGCCCTGGTTCCAGGTCCTGGAGCCGCAGTTCCGGCAGTT                   TCTCTTCTACCGCCACTGCCGCTACTTCCCCATGCTGCTGAACCACCCGGAGAAGTGC                   AGGGGCGATGTCTACCTGCTGGTGGTTGTCAAGTCGGTCATCACGCAGCACGACCGCC                   GCGAGGCCATCCGCCAGACCTGGGCGCGAGCGGCAGTCCGCGGGTGGGGGCCGAGCGC                   CGTGCGCACCCTCTTCCTGCTGGGCACGGCCTCCAAGCAGGAGGAGCGCACGCACTAC                   CAGCAGCTGCTGGCCTACGAAGACGCCCTCTACGGCGACATCCTGCAGTGGGGCTTTC                   TCGACACCTTCTTCAACCTGACCCTCAAGGAGATCCACTTCCTCAAGTGGCTGGACAT                   CTACTGCCCCCACGTCCCCTTCATTTTCAAAGGCGACGATGACGTCTTCGTCAACCCC                   ACCAACCTGCTAGAATTTCTGGCTGACCGGCAGCCACAGGAAAACCTGTTCGTGGGCG                   ATGTCCTGCAGCACGCTCGGCCCATTCGCAGGAAAGACAACAAATACTACATCCCGGG                   GGCCCTGTACGGCAAGGCCAGCTATCCGCCGTATGCAGGCGGCGGTGGCTTCCTCATG                   GCCGGCAGCCTGGCCCGGCGCCTGCACCATGCCTGCGACACCCTGGAGCTCTACCCGA                   TCGACGACGTCTTTCTGGGCATGTGCCTGGAGGTGCTGGGCGTGCAGCCCACGGCCCA                   CGAGGGCTTCAAGACTTTCGGCATCTCCCGGAACCGCAACAGCCGCATGAACAAGGAG                   CCGTGCTTTTTCCGCGCCATGCTCGTGGTGCACAAGCTGCTGCCCCCTGAGCTGCTCG                   CCATGTGGGGGCTGGTGCACAGCAATCTCACCTGCTCCCGCAAGCTCCAGGTGCTC TG                       A   CCCCAGCCGGGCTACTAGGACAGGCCAGGGCAC                                           ORF Start: ATG at 9       ORF Stop: TGA at 1101           SEQ ID NO:302   364 aa   MW at 41853.8 kD                     NOV106a,   MGASATHPGATEGPEAKWTAGEPQQLLEEPERCVRPRPWPLRAQAWDVTTTNCSANIN       CG57466-01 Protein Sequence           LTHQPWFQVLEPQFRQFLFYRHCRYFPDMLLNHPEKCRGDVYLLVVVKSVITQHDRREA                   IRQTWARAAVRGWGPSAVRTLFLLGTASKQEERTHYQQLLAYEDALYGDILQWGFLDT                   FFNLTLKEIHFLKWLDIYCPHVPFIFKGDDDVFVNPTNLLEFLADRQPQENLFVGDVL                   QHARPIRRKDNKYYIPGALYGKASYPPYAGGGGFLMAGSLARRLHHACDTLELYPIDD                   VFLGMCLEVLGVQPTAHEGFKTFGISRNRNSRMNKEPCFFRAMLVVHKLLPPELLAMW                   GLVHSNLTCSRKLQVL                  
 
     [0880] Further analysis of the NOV106a protein yielded the following properties shown in Table 106B.  
               TABLE 106B                       Protein Sequence Properties NOV106a                                        PSort   0.6400 probability located in microbody (peroxisome); 0.4500       analysis:   probability located in cytoplasm; 0.3122 probability located           in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0881] A search of the NOV106a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 106C.  
               TABLE 106C                          Geneseq Results for NOV106a                                         NOV106a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAB24035   Human PRO4397 protein sequence   72 . . . 352   149/300 (49%)   4e−76           SEQ ID NO: 42- Homo sapiens ,   84 . . . 380   191/300 (63%)           402 aa. [WO200053750-A1,           14 SEP. 2000]       AAU29167   Human PRO polypeptide sequence   26 . . . 363   149/348 (42%)   9e−76           #144- Homo sapiens , 372 aa.   27 . . . 371   207/348 (58%)           [WO200168848-A2,           20 SEP. 2001]       AAB88404   Human membrane or secretory   26 . . . 363   149/348 (42%)   9e−76           protein clone PSEC0159- Homo     27 . . . 371   207/348 (58%)             sapiens , 372 aa. [EP1067182-A2,           10 JAN. 2001]       AAB49750   Human beta 1,3-N-   26 . . . 363   149/348 (42%)   9e−76           acetylglucosamine transferase   27 . . . 371   207/348 (58%)           protein G4- Homo sapiens , 372 aa.           [WO200100848-A1, 4 JAN. 2001]       AAB49749   Human beta 1,3-N-   26 . . . 363   149/348 (42%)   9e−76           acetylglucosamine transferase   27 . . . 371   207/348 (58%)           protein G4- Homo sapiens , 372 aa.           [WO200100848-A1, 4 JAN. 2001]                  
 
     [0882] In a BLAST search of public sequence databases, the NOV106a protein was found to have homology to the proteins shown in the BLASTP data in Table 106D.  
               TABLE 106D                          Public BLASTP Results for NOV106a                                         NOV106a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               AAL32295   BETA-3-GALACTOSYLTRANSFERASE-    46 . . . 364   199/319 (62%)    e−121             Brachydanio rerio  (Zebrafish) (Zebra danjo),   101 . . . 417   249/319 (77%)           418 aa.       AAL32297   BETA-3-GALACTOSYLTRANSFERASE-    29 . . . 360   180/337 (53%)    e−104             Brachydanio rerio  (Zebrafish) ( Zebra danio ),    82 . . . 409   244/337 (71%)           412 aa.       Q96EK0   UNKNOWN (PROTEIN FOR MGC: 20513)-    60 . . . 352   152/313 (48%)   9e−76             Homo sapiens  (Human), 377 aa.    46 . . . 355   198/313 (62%)       CAC39768   SEQUENCE 175 FROM PATENT    26 . . . 363   149/348 (42%)   3e−75           EP1067182- Homo sapiens  (Human), 372 aa.    27 . . . 371   207/348 (58%)       Q9C0J2   BETA-1,3-N-    26 . . . 363   149/348 (42%)   3e−75           ACETYLGLUCOSAMINYLTRANSFERASE    27 . . . 371   207/348 (58%)           BGNT-3- Homo sapiens  (Human), 372 aa.                  
 
     [0883] PFam analysis predicts that the NOV106a protein contains the domains shown in the Table 106E.  
               TABLE 106E                          Domain Analysis of NOV106a                                     Identities/           Pfam   NOV106a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               P13_P14_kinase:   195 . . . 205    8/12 (67%)   8.5       domain 1 of 1        10/12 (83%)       Galactosyl_T:   112 . . . 308    69/212 (33%)   7.7e−45       domain 1 of 1       148/212 (70%)                  
 
     Example 107  
     [0884] The NOV107 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 107A.  
               TABLE 107A                       NOV107 Sequence Analysis                                                SEQ ID NO:303   4091 bp                     NOV 107a,     AAGCAAGAGGCTGAG   ATG GATCTTGAGGCGGCAAAGAACGGAACAGCCTGGCGCCCCA       CG57468-01 DNA Sequence           CGAGCGCGGAGGGCGACTTTGAACTGGGCATCAGCAGCAAACAAAAAAGGAAAAAAAC                   GAAGACAGTGAAAATGATTGGAGTATTAACATTGTTTCGATACTCCGATTGGCAGGAT                   AAATTGTTTATGTCGCTGGGTACCATCATGGCCATAGCTCACGGATCAGGTCTCCCCC                   TCATGATGATAGTATTTGGAGAGATGACTGACAAATTTGTTGATACTGCAGGAAACTT                   CTCCTTTCCAGTGAACTTTTCCTTGTCGCTGCTAAATCCAGGCAAAATTCTGGAAGAA                   GAAATGACTAGATATGCATATTACTACTCAGGATTGGGTGCTGGAGTTCTTGTTGCTG                   CCTATATACAAGTTTCATTTTGGACTTTGGCAGCTGGTCGACAGATCAGGAAAATTAG                   GCAGAAGTTTTTTCATGCTATTCTACGACAGGAAATAGGATGGTTTGACATCAATGAC                   ACCACTGAACTCAATACGCGGCTAACAGATGACATCTCCAAAATCAGTGAAGGAATTG                   GTGACAAGGTTGGAATGTTCTTTCAAGCAGTAGCCACGTTTTTTGCAGGATTCATAGT                   GGGATTCATCAGAGGATGGAAGCTCACCCTTGTGATAATGGCCATCAGCCCTATTCTA                   GGACTCTCTGCAGCCGTTTGGGCAAAGATACTCTCGGCATTTAGTGACAAAGAACTAG                   CTGCTTATGCAAAAGCAGGCGCCGTGGCAGAAGAGGCTCTGGGGGCCATCAGGACTGT                   GATAGCTTTCGGGGGCCAGAACAAAGAGCTGGAAAGGTATCAGAAACATTTAGAAAAT                   GCCAAAGAGATTGGAATTAAAAAAGCTATTTCAGCAAACATTTCCATGGGTATTGCCT                   TCCTGTTAATATATGCATCATATGCACTGGCCTTCTGGTATGGATCCACTCTAGTCAT                   ATCAAAAGAATATACTATTGGAAATGCAATGACAGTTTTTTTTTCAATCCTAATTGGA                   GCTATGGCCATCGGAGAAACGCTCGTTTTGGCTCCTGAATATTCCAAAGCCAAATCGG                   GGGCTGCGCATCTGTTTGCCTTGTTGGAAAAGAAACCAAATATAGACAGCCGCAGTCA                   AGAAGGGAAAAAGCCAGTAAGCGACACATGTGAAGGGAATTTAGAGTTTCGAGAAGTC                   TCTTTCTTCTATCCATGTCGCCCAGATGTTTTCATCCTCCGTGGCTTATCCCTCAGTA                   TTGAGCGAGGAAAGACAGTAGCATTTGTGGGGAGCAGCGGCTGTGGGAAAAGCACTTC                   TGTTCAACTTCTGCAGAGACTTTATGACCCCGTGCAAGGACAAGTGGATGGTGTGGAT                   GCAAAAGAATTGAATGTACAGTGGCTCCGTTCCCAAATAGCAATCGTTCCTCAAGAGC                   CTGTGCTCTTCAACTGCAGCATTGCTGAGAACATCGCCTATGGTGACAACAGCCGTGT                   GGTGCCATTAGATGAGATCAAAGAAGCCGCAAATGCAGCAAATATCCATTCTTTTATT                   GAAGGTCTCCCTGAGAAATACAACACACAAGTTGGACTGAAAGGAGCACAGCTTTCTG                   GCGGCCAGAAACAAAGACTAGCTATTGCAAGGGCTCTTCTCCAAAAACCCAAAATTTT                   ATTGTTGGATGAGGCCACTTCAGCCCTCGATAATGACAGTGAGTGGCAGGTGGTTCAG                   CATGCCCTTGATAAAGCCAGGACGGGAAGGACATGCCTAGTGGTCACTCACAGGCTCT                   CTGCAATTCAGAACGCAGATTTGATAGTGGTTCTGCACAATGGAAAGATAAAGGAACA                   AGGAACTCATCAAGAGCTCCTGAGAAATCGAGACATATATTTTAAGTTAGTGAATGCA                   CAGTCAGCGAGCAAAGGTCGGACTACAATCGTGGTAGCACACCGACTTTCTACTATTC                   GAAGTGCAGATTTGATTGTGACCCTAAAGGATGGAATGCTGGCGGAGAAAGGAGCACA                   TGCTGAACTAATGGCAAAACGAGGTCTATATTATTCACTTGTGATGTCACAGGTAATG                   CTTATGGGGACTCTTTCAGACTGTGGTAATAGTCTTCCTGAAGTCTCTCTATTAAAAA                   TTTTAAAGTTAAACAAGCCTGAATGGCCTTTTGTGGTTCTGGGGACATTGGCTTCTGT                   TCTAAATGGAACTGTTCATCCAGTATTTTCCATCATCTTTGCAAAAATTATAACCGTA                   ATGTTTGGAAATAATGATCTTTTGTTTTTCCTCAAAATTTTTTTATATTCATTCCTTT                   TGTTTTTCCTCAAACAAGGTTTCAGCGTAGATTTTTGTTTGTTTGCTTTTCAGGGATT                   ATTTTACGGCAGAGCAGGGGAAATTTTAACGATGAGATTAAGACACTTGGCCTTCAAA                   GCCATGTTATATCAGGATATTGCCTGGTTTGATGAAAAGGAAAACAGCACAGGAGGCT                   TGACAACAATATTAGCCATAGATATAGCACAAATTCAAGGAGCAACAGGTTCCAGGAT                   TGGCGTCTTAACACAAAATGCAACTAACATGGGACTTTCAGTTATCATTTCCTTTATA                   TATGGATGGGAGATGACATTCCTGATTCTGAGTATTGCTCCAGTACTTGCCGTGACAG                   GAATGATTGAAACCGCAGCAATGACTGGATTTGCCAACAAAGATAAGCAAGAACTTAA                   GCATGCTGGAAAGGTAAAGATAGCAACTGAAGCTTTGGAGAATATACGTACTATAGTG                   TCATTAACAAGGGAAAAAGCCTTCGAGCAAATGTATGAAGAGATGCTTCAGACTCAAC                   ACAGGAGAAATACCTCGAAGAAAGCACAGATTATTGGAAGCTGTTATGCATTCAGCCA                   TGCCTTTATATATTTTGCCTATGCGGCAGGGTTTCGATTTGGAGCCTATTTAATTCAA                   GCTGGACGAATGTCAAATGCTTTATCTTTTGATAGAGTTTTTACTGCAATTGCATATG                   GAGCTATGGCCATCGGAGAAACGCTCGTTTTGGCTCCTGAATATTCCAAAGCCAAATC                   GGGGGCTGCGCATCTGTTTGCCTTGTTGGAAAAGAAACCAAATATAGACAGCCGCAGT                   CAAGAAGGGAAAAAGCCACTTTCACAGGACACATGTGAAGGGAATTTAGAGTTTCGAG                   AAGTCTCTTTCTTCTATCCATGTCGCCCAGATGTTTTCATCCTCCGTGGCTTATCCCT                   CAGTATTGAGCGAGGAAAGACAGTAGCATTTGTGGGGAGCAGCGGCTGTGGGAAAAGC                   ACTTCTGTTCAACTTCTGCAGAGACTTTATGACCCCGTGCAAGGACAACAGCTGTTTG                   ATGGTGTGGATGCAAAAGAATTGAATGTACAGTGGCTCCGTTCCCAAATAGCAATCGT                   TCCTCAAGAGCCTGTGCTCTTCAACTGCAGCATTGCTGAGAACATCGCCTATGGTGAC                   AACAGCCGTGTGGTGCCATTAGATGAGATCAAAGAAGCCGCAAATGCAGCAAATATCC                   ATTCTTTTATTGAAGGTCTCCCTAAATACAACACACAAGTTGGACTGAAAGGAGCACA                   GCTTTCTGGCGGCCAGAAACAAAGACTAGCTATTGCAAGGGCTCTTCTCCAAAAACCC                   AAAATTTTATTGTTGGATGAGGCCACTTCAGCCCTCGATAATGACAGTGAGAAGGTAC                   AGGTGGTTCAGCATGCCCTTGATAAAGCCAGGACGGGAAGGACATGCCTAGTGGTCAC                   TCACAGGCTCTCTGCAATTCAGAACGCAGATTTGATAGTGGTTCTGCACAATGGAAAG                   ATAAAGGAACAAGGAACTCATCAAGAGCTCCTGAGAAATCGAGACATATATTTTAAGT                   TAGTGAATGCACAGTCAGCGAGCAAAGGTCGGACTACAATCGTGGTAGCACACCGACT                   TTCTACTATTCGAAGTGCAGATTTGATTGTGACCCTAAAGGATGGAATGCTGGCGGAG                   AAAGGAGCACATGCTGAACTAATGGCAAAACGAGGTCTATATTATTCACTTGTGATGT                   CACAGGTAATGCTTATG TGA   CATAATGCTAT                                           ORF Start: ATG at 16       ORF Stop: TGA at 4078           SEQ ID NO:304   1354 aa   MW at 149167.3 kD                     NOV107a,   MDLEAAKNGTAWRPTSAEGDFELGISSKQKRKKTKTVKMIGVLTLFRYSDWQDKLFMS       CG57468-01 Protein       Sequence   LGTIMAIAHGSGLPLMMIVFGEMTDKFVDTAGNFSFPVNFSLSLLNPGKILEEEMTRY                   AYYYSGLGAGVLVAAYIQVSFWTLAAGRQIRKIRQKFFHAILRQEIGWFDINDTTELN                   TRLTDDISKISEGIGDKVGMFFQAVATFFAGFIVGFIRGWKLTLVIMAISPILGLSAA                   VWAKILSAFSDKELAAYAKAGAVAEEALGAIRTVIAFGGQNKELERYQKHLENAKEIG                   IKKAISANISMGIAFLLIYASYALAFWYGSTLVISKEYTIGNAMTVFFSILIGAMAIG                   ETLVLAPEYSKAKSGAAHLFALLEKKPNIDSRSQEGKKPVSDTCEGNLEFREVSFFYP                   CRPDVFILRGLSLSIERGKTVAFVGSSGCGKSTSVQLLQRLYDPVQGQVDGVDAKELN                   VQWLRSQIAIVPQEPVLFNCSIAENIAYGDNSRVVPLDEIKEAANAANIHSFIEGLPE                   KYNTQVGLKGAQLSGGQKQRLAIARALLQKPKILLLDEATSALDNDSEWQVVQHALDK                   ARTGRTCLVVTHRLSAIQNADLIVVLHNGKIKEQGTHQELLRNRDIYFKLVNAQSASK                   GRTTIVVAHRLSTIRSADLIVTLKDGMLAEKGAHAELMAKRGLYYSLVMSQVMLMGTL                   SDCGNSLPEVSLLKILKLNKPEWPFVVLGTLASVLNGTVHPVFSIIFAKIITVMFGNN                   DLLFFLKIFLYSFLLFFLKQGFSVDFCLFAFQGLFYGRAGEILTMRLRHLAFKAMLYQ                   DIAWFDEKENSTGGLTTILAIDIAQIQGATGSRIGVLTQNATNMGLSVIISFIYGWEM                   TFLILSIAPVLAVTGMIETAAMTGFANKDKQELKHAGKVKIATEALENIRTIVSLTRE                   KAFEQMYEEMLQTQHRRNTSKKAQIIGSCYAFSHAFIYFAYAAGFRFGAYLIQAGRMS                   NALSFDRVFTAIAYGAMAIGETLVLAPEYSKAKSGAAHLFALLEKKPNIDSRSQEGKK                   PLSQDTCEGNLEFREVSFFYPCRPDVFILRGLSLSIERGKTVAFVGSSGCGKSTSVQL                   LQRLYDPVQGQQLFDGVDAKELNVQWLRSQIAIVPQEPVLFNCSIAENIAYGDNSRVV                   PLDEIKEAANAANIHSFIEGLPKYNTQVGLKGAQLSGGQKQRLAIARALLQKPKILLL                   DEATSALDNDSEKVQVVQHALDKARTGRTCLVVTHRLSAIQNADLIVVLHNGKIKEQG                   THQELLRNRDIYFKLVNAQSASKGRTTIVVAHRLSTIRSADLIVTLKDGMLAEKGAHA                   ELMAKRGLYYSLVMSQVMLM                  
 
     [0885] Further analysis of the NOV107a protein yielded the following properties shown in Table 107B.  
               TABLE 107B                       Protein Sequence Properties NOV107a                                        PSort   0.6000 probability located in plasma membrane; 0.4000       analysis:   probability located in Golgi body; 0.3000 probability           located in endoplasmic reticulum (membrane); 0.3000           probability located in microbody (peroxisome)       SignalP   No Known Signal Sequence Predicted       analysis.                  
 
     [0886] A search of the NOV107a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 107C.  
               TABLE 107C                          Geneseq Results for NOV107a                                         NOV107a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAB81064   Cynomologous monkey P-   1 . . . 1299   750/1312 (57%)   0.0           glycoprotein variant 1- Macaca     1 . . . 1278   964/1312 (73%)             fascicularis , 1280 aa.           [WO200123565-A1, 5 APR. 2001]       AAB81065   Cynomologous monkey P-   1 . . . 1299   749/1312 (57%)   0.0           glycoprotein variant 2- Macaca     1 . . . 1281   967/1312 (73%)             fascicularis , 1283 aa.           [WO200123565-A1, 5 APR. 2001]           AAB81959   Human MDR1- Homo sapiens ,   1 . . . 1299   749/1324 (56%)   0.0           1280 aa. [WO200121762-A2,   1 . . . 1278   967/1324 (72%)           29 MAR. 2001]       AAY58186   Human wild-type multidrug   1 . . . 1299   749/1324 (56%)   0.0           resistance-1 (MDR-1) protein-   1 . . . 1278   967/1324 (72%)             Homo sapiens , 1280 aa.           [WO9961589-A2, 2 DEC. 1999]       AAW44073   Human multidrug resistance P-   1 . . . 1299   749/1324 (56%)   0.0           glycoprotein MDR1- Homo     1 . . . 1278   967/1324 (72%)             sapiens , 1280 aa. [WO9740160-           A1, 30 OCT. 1997]                  
 
     [0887] In a BLAST search of public sequence databases, the NOV107a protein was found to have homology to the proteins shown in the BLASTP data in Table 107D.  
               TABLE 107D                          Public BLASTP Results for NOV107a                                         NOV107a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               P23174   Multidrug resistance protein 3 (P-   1 . . . 1299   818/1303 (62%)   0.0           glycoprotein 3)- Cricetulus     1 . . . 1279   999/1303 (75%)             griseus  (Chinese hamster), 1281           aa.       P21440   Multidrug resistance protein 2 (P-   1 . . . 1299   823/1306 (63%)   0.0           glycoprotein 2)- Mus musculus     1 . . . 1274   998/1306 (76%)           (Mouse), 1276 aa.       Q08201   Multidrug resistance protein 2 (P-   1 . . . 1299   823/1309 (62%)   0.0           glycoprotein 2)- Rattus     1 . . . 1276   999/1309 (75%)             norvegicus  (Rat), 1278 aa.       CAC37764   SEQUENCE 1 FROM PATENT   1 . . . 1299   750/1312 (57%)   0.0           WO0123565- Macaca fascicularis     1 . . . 1278   964/1312 (73%)           (Crab eating macaque)           (Cynomolgus monkey), 1280 aa.       CAC37765   SEQUENCE 3 FROM PATENT   1 . . . 1299   749/1312 (57%)   0.0           WO0123565- Macaca fascicularis     1 . . . 1281   967/1312 (73%)           (Crab eating macaque)           (Cynomolgus monkey), 1283 aa.                  
 
     [0888] PFam analysis predicts that the NOV107a protein contains the domains shown in the Table 107E.  
               TABLE 107E                          Domain Analysis of NOV107a                                     Identities/           Pfam   NOV107a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               ABC_membrane:    57 . . . 350   115/301 (38%)   3.3e−83       domain 1 of 2       252/301 (84%)       MVIN:    57 . . . 447    70/531 (13%)   5.8       domain 1 of 1       263/531 (50%)       SAA_proteins:    518 . . . 524    6/7 (86%)   3       domain 1 of 1        7/7 (100%)       ABC_tran:    424 . . . 609    76/199 (38%)   3.1e−56       domain 1 of 2       150/199 (75%)       DsbD:    722 . . . 926    39/249 (16%)   9.6       domain 1 of 1       126/249 (51%)       ABC_membrane:    722 . . . 1008    80/297 (27%)   2.2e−43       domain 1 of 2       222/297 (75%)       ABC_tran:   1083 . . . 1270    77/202 (38%)   7.1e−54       domain 2 of 2       154/202 (76%)       GidB:   1170 . . . 1312    29/202 (14%)   6.6       domain 1 of 1        97/202 (48%)                  
 
     Example 108  
     [0889] The NOV108 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 108A.  
               TABLE 108A                       NOV108 Sequence Analysis                                                SEQ ID NO:305   520 bp                     NOV 108a,     CCCCGTTCTATCAGCC   ATG GTCAACCCCACCAGGTTCTTAGACATCATCGTGGATGGT       CG59609-01 DNA Sequence           GAGCTCTTGGGACGTGTCTCCTTTGAGCTGTTTGCAGACAAGATTCCAAAGACAGCAG                   AAAATTTTTGTGCTCTAATCATTGGAGAGAAAGGATTTGGTTATAAAGGTTCCTACTT                   TCACAGAATTGTTCCTGGGTTTATGTGTCAGGGTGGTGACTTCACACAGCATAATGGC                   ACTGGTGGCAAGTCCATCTACGGGAAGAAATTTGATGATGAGAACTTCGTCCTAAATT                   ATACAGGTCCTGGCATCTTGTCCGTGGAGAATGCTGGACCCAACACAAATGGTTCCCA                   GTTTTTCATCTGCACTGCCATGTCTGAGTGGTTGGATGGCATGCAGGTGGTCTTTGGC                   AAGGGAAGGAAGGTGAGTATTGTGGAAGCCATGGAGTGCTTTGGGTCCACAAATGGCA                   AGACCAGCAAGAAGATCACCATTGCTGACTGTGGACAACTC TAA   TAGGTTTGACTT                                           ORF Start: ATG at 17       ORF Stop: TAA at 506           SEQ ID NO:306   163 aa   MW at 17734.1 kD                     NOV 108a,   MVNPTRFLDIIVDGELLGRVSFELFADKIPKTAENFCALIIGEKGFGYKGSYFHRIVP       CG59609-01 Protein Sequence           GFMCQGGDFTQHNGTGGKSIYGKKFDDENFVLNYTGPGILSVENAGPNTNGSQFFICT                   AMSEWLDCMQVVGKCRKVGIVEAMECFGSTNCKTSKKITIADCGQL                  
 
     [0890] Further analysis of the NOV108a protein yielded the following properties shown in Table 108B.  
               TABLE 108B                       Protein Sequence Properties NOV108a                                        PSort   0.6400 probability located in microbody (peroxisome);       analysis:   0.6000 probability located in plasma membrane; 0.4500           probability located in cytoplasm; 0.1000 probability           located in mitochondrial matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0891] A search of the NOV108a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 108C.  
               TABLE 108C                          Geneseq Results for NOV108a                                         NOV108a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAU01195   Human cyclophilin A protein-   1 . . . 163   134/164 (81%)   2e−75             Homo sapiens , 165 aa.   1 . . . 164   147/164 (88%)           [WO200132876-A2, 10 MAY 2001]       AAW56028   Calcineurin protein-Mammalia,   1 . . . 163   134/164 (81%)   2e−75           165 aa. [WO9808956-A2,   1 . . . 164   147/164 (88%)           5 MAR 1998]           AAR13726   Bovine cyclophilin- Bos taurus ,   2 . . . 163   133/163 (81%)   5e−75           163 aa. [U.S. Pat. No. 5047512-A,   1 . . . 163   146/163 (88%)           10 SEP. 1991]       AAG65275   Haematopoietic stem cell   2 . . . 163   133/163 (81%)   9e−75           proliferation agent related human   1 . . . 163   146/163 (88%)           protein #2- Homo sapiens , 164 aa.           [JP2001163798-A, 19 JUN. 2001]       AAP90431   Cyclophilin- Homo sapiens     2 . . . 163   133/163 (81%)   9e−75           (human), 164 aa. [EP326067-A,   1 . . . 163   146/163 (88%)           2 AUG. 1989]                  
 
     [0892] In a BLAST search of public sequence databases, the NOV108a protein was found to have homology to the proteins shown in the BLASTP data in Table 108D.  
               TABLE 108D                          Public BLASTP Results for NOV108a                                         NOV108a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               CAC39529   SEQUENCE 26 FROM PATENT   1 . . . 163   134/164 (81%)   8e−75           WO0132876- Homo sapiens     1 . . . 164   147/164 (88%)           (Human), 165 aa.       Q9BRU4   PEPTIDYLPROLYL ISOMERASE   1 . . . 163   134/164 (81%)   2e−74           A (CYCLOPHILIN A)- Homo     1 . . . 164   146/164 (88%)             sapiens  (Human), 165 aa.       P04374   Peptidyl-prolyl cis-trans isomerase   2 . . . 163   133/163 (81%)   2e−74           A (EC 5.2.1.8) (PPIase) (Rotamase)   1 . . . 163   146/163 (88%)           (Cyclophilin A) (Cyclosporin A-           binding protein)- Bos taurus             (Bovine), and, 163 aa.       P05092   Peptidyl-prolyl cis-trans isomerase   2 . . . 163   133/163 (81%)   3e−74           A (EC 5.2.1.8) (PPIase) (Rotamase)   1 . . . 163   146/163 (88%)           (Cyclophilin A) (Cyclosporin A-           binding protein)- Homo sapiens             (Human),, 164 aa.       Q9TTC6   CYCLOPHILIN 18- Oryctolagus     1 . . . 163   133/164 (81%)   5e−74             cuniculus  (Rabbit), 164 aa.   1 . . . 164   147/164 (89%)                  
 
     [0893] PFam analysis predicts that the NOV108a protein contains the domains shown in the Table 108E.  
               TABLE 108E                          Domain Analysis of NOV108a                                     Identities/           Pfam   NOV108a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               pro_isomerase:   5 . . . 163   101/181 (56%)   5.2e−79       domain 1 of 1       137/181 (76%)                  
 
     Example 109  
     [0894] The NOV109 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 109A.  
               TABLE 109A                       NOV109 Sequence Analysis                                                SEQ ID NO:307   887 bp                     NOV109a,     GATATCATTTTTT   ATG GCAGCCATTGTTAAGCCTCCAGAACCTATACCTTTAAAATGG       CG59613-01 DNA Sequence           TTAACAGATAAGCCAGTTTGGATAGAACAATGGCCACTGAGTAAAGAGAAACTGGAGG                   CTTTAGAGGATTTGGTTACTGAACAATTCTCAATAATCATTTTCCAAAAAGTGAACCT                   ACACAGCATGAAAGTATCACACATTTCCTTAGTGCAGCTAACCCTGTGTGACCAGGGC                   TTCAACACATACCACTGTGACCACAACCTAGCCATGAGCATGAGCCTCACCAGCATGT                   CCAAAATGCTAAAATACAACAATGGCAGTGAAGACATCACTACATGGAGGGCTGAAGG                   TACTATGGATCTCTTGGTGCTAGAATTTGAAGCACTAAATCAAGAGAACTTTGTGGAC                   TGTGAATTGAAGTTAATGACTCTAGATGTTGAGCAACTTGAAATTCCAGAACAAGAGT                   ACAGCTGTGTAATAAAGATGCATTCTAGTGAATTTGTTCATATATGCCAAGATCTCAG                   TCATATTGGAGAGTCTGCTATAATTTCTTGTGCAAAAGATGGAGTGAATTTTTCTGCA                   AATGGAGAACTTGGACATGGAAACATTGCCACAATTGCCCAAACAAGTAATTACAATA                   AAGAAGAGGAGGCTGTTGCCATAATGATGAATGGGCCAGTTCAGCTAACTTTTGCACT                   AAGTTACTTAAATTTCTTTATAACAGGCACTCCACTCTCTCAGATGCACCCCTTGCTG                   GAGAGTATAAGATTGCCGGATATGGAACATTTAAAGTATTATTTGGCTCCCAAAATTG                   AGGATGAAAAAGGATTT TAG   AAATTCTTAGAATCCAAGAAAATAAAACTAAGCTCTTT                       GAAAATTGCTTCTGAGA                                           ORF Start: ATG at 14       ORF Stop: TAG at 830           SEQ ID NO:308   272 aa   MW at 30831.1 kD                     NOV109a,   MAAIVKPPEPIPLKWLTDKPVWIEQWPLSKEKLEALEDLVTEQFSIIIFQKVNLHSMK               CG59613-01 Protein Sequence   VSHISLVQLTLCDQGFNTYHCDHNLAMSMSLTSMSKMLKYNNGSEDITTWRAEGTMDL                   LVLEFEALNQENFVDCELKLMTLDVEQLEIPEQEYSCVIKMHSSEFVHICQDLSHIGE                   SAIISCAKDGVNFSANGELGHGNIATIAQTSNYNKEEEAVAIMMNGPVQLTFALSYLN                   FFITGTPLSQMHIPLLESIRLPDMEHLKYYLAPKIEDEKGF                  
 
     [0895] Further analysis of the NOV109a protein yielded the following properties shown in Table 109B.  
               TABLE 109B                       Protein Sequence Properties NOV109a                                        PSort   0.6500 probability located in cytoplasm; 0.1000 probability       analysis:   located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen); 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   Likely cleavage site between residues 19 and 20       analysis:                  
 
     [0896] A search of the NOV109a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 109C.  
               TABLE 109C                          Geneseq Results for NOV109a                                         NOV109a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAY51639   Human PCNA protein fragment-   25 . . . 271   158/255 (61%)   8e−78             Homo sapiens , 261 aa.    8 . . . 260   184/255 (71%)           [WO200008164-A2, 17 FEB. 2000]       AAY52010   Human PCNA protein- Homo     25 . . . 271   158/255 (61%)   8e−78             sapiens , 261 aa. [DE19840771-A1,    8 . . . 260   184/255 (71%)           10 FEB. 2000]       AAB43712   Human cancer associated protein   25 . . . 271   158/255 (61%)   8e−78           sequence SEQ ID NO: 1157- Homo     16 . . . 268   184/255 (71%)             sapiens , 269 aa. [WO200055350-           A1, 21 SEP. 2000]       AAG75139   Human colon cancer antigen   25 . . . 269   157/253 (62%)   5e−77           protein SEQ ID NO: 5903- Homo     16 . . . 266   182/253 (71%)             sapiens , 268 aa. [WO200122920-           A2, 5 APR. 2001]       AAW90758   Human PCNA protein fragment #2-   39 . . . 268   149/238 (62%)   7e−73             Homo sapiens , 236 aa.    1 . . . 236   171/238 (71%)           [DE19840771-A1, 10 FEB. 2000]                  
 
     [0897] In a BLAST search of public sequence databases, the NOV109a protein was found to have homology to the proteins shown in the BLASTP data in Table 109D.  
               TABLE 109D                          Public BLASTP Results for NOV109a                                         NOV109a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               P12004   Proliferating cell nuclear antigen   25 . . . 271   158/255 (61%)   3e−77           (PCNA) (Cyclin)- Homo sapiens      8 . . . 260   184/255 (71%)           (Human), 261 aa.       P04961   Proliferating cell nuclear antigen   25 . . . 271   158/255 (61%)   5e−77           (PCNA) (Cyclin)- Rattus norvegicus      8 . . . 260   185/255 (71%)           (Rat), 261 aa.       P57761   Proliferating cell nuclear antigen   25 . . . 271   158/255 (61%)   7e−77           (PCNA)- Cricetulus griseus      8 . . . 260   184/255 (71%)           (Chinese hamster), 261 aa.       Q91ZH2   11 DAYS EMBRYO CDNA,   25 . . . 272   156/256 (60%)   1e−75           RIKEN FULL-LENGTH    8 . . . 261   183/256 (70%)           ENRICHED LIBRARY,           CLONE: 2700095L20, FULL           INSERT SEQUENCE- Mus               musculus  (Mouse), 261 aa.       P17918   Proliferating cell nuclear antigen   25 . . . 270   155/254 (61%)   5e−75           (PCNA) (Cyclin)- Mus musculus      8 . . . 259   182/254 (71%)           (Mouse), 261 aa.                  
 
     [0898] PFam analysis predicts that the NOV109a protein contains the domains shown in the Table 109E.  
               TABLE 109E                          Domain Analysis of NOV109a                                     Identities/           Pfam   NOV109a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               PCNA:    23 . . . 143   46/128 (36%)   2.3e−20       domain 1 of 1       83/128 (65%)       PCNA_C:   145 . . . 265   59/131 (45%)   1.6e−45       domain 1 of 1       98/131 (75%)                  
 
     Example 110  
     [0899] The NOV110 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 110A.  
               TABLE 110A                       NOV110 Sequence Analysis                                                SEQ ID NO:309   1233 bp                     NOV110a,     TGGCA   ATG GAAGAAGAGATCCCCGCGCTCTTCATTGACAATGGCTCCGGCATGTGGAA       CG59619-01 DNA Sequence           AGCAGCTTTGCTGGGAGACAATGCCCTCCGAGCCATATTCCCCTCCATCATCGGGCAC                   CCCCGGCACCAGGGCGTGATGGTGGGCATGGGCCAGAAGGACTCCTACGTGGGCGACC                   AGGCCCAGAGCAAGTGCGGCATCCTGACCCTGAAGTACCCCATCAAGCATGGCATCGT                   CACAAACTGGGACGACATGGAGAAGATCTGGCACCATGTTTTCTACAACGAGCTGTGC                   GTGGCCCTGGAGGAGCAGGTGGTGCTGCTGACCGAGGCCCCGCTAAACCCCAGGGCCA                   ATAGGGAGAAGATGACTCAGATCATGTTTAAGACCTTCAACACCCAGGCCATGTACGT                   GGCCATTCAGGCCGTGCTGACCCTCCACAGCTCTGGTTGCACCACTGGCATTGTCATG                   GACTCTGGAGATGGGGTCACCCACACAGTGCCCATCTACGAGCGCCACACCCTCCCTC                   ACACCATCTTGCATCTGGACCTGGCTGGCCAGGACCTTACTGACTACCTCATGAAGAT                   CCCTACCTACCGCAGCTATAGCTTCAACACCATGGCCAAGTGGAAAATCGTGCGCAAC                   ATCAAGGAGAAGCTATGCTATGTCGCTCTGGACTTCGAGGAGGAGATGGCCACTGCTG                   CATCCTCCTCCTCCCTGGAGAAGAGCTACGAGCTGCCTGACAGCCAGGCCATCATTAT                   TAGCAATGAGCGGTTCCGGTGTCCGGAGGCACTGTTCCAGCCTTCCTTCCTGGGCATG                   GAATCCTGTGGCATCCATGAAAGTACCTTCAACTCCATCATGAAGTGTGATATGGACA                   TCCCCAAAGACCTGTACGCCAACACAGTGCTGTCTGGCGTCACCACCATGTACCCTGG                   CATCCCCAATAGGATGCAGAAGGAGATCACTGCCCTGGCATCCAGCACCATGAAGATC                   AAGATATCGTGCCCCATCGTGCCCCCAGAGTGCAAGTACTTTGTGTGGATCGGTGGCT                   CCATCCTGGCCTCACTGTCCACCTTCCAGCAGATGTGGATTAGCAAGCAGGAGTACAA                   CGAGTCGGGCCCCTCCATCATCCACCGCAAATGGACTGCGAGCAGATGCATAGCATTT                   GCTGCATGGGTTAATTCAGAAGTA TAA   ATTTGCCCCTGGCAAATGCATATACCTCATG                       CTAGCCTCACGATAC                                           ORF Start: ATG at 6       ORF Stop: TAA at 1185           SEQ ID NO:310   393 aa   MW at 44147.5 kD                     NOV110A,   MEEEIPALFIDNGSGMWKAALLGDNALRAIFPSIIGHPRHQGVMVGMGQKDSYVGDQA       CG59619-01 Protein Sequence           QSKCGILTLKYPIKHGIVTNWDDMEKIWHHVFYNELCVALEEQVVLLTEAPLNPRANR                   EKMTQIMFKTFNTQAMYVAIQAVLTLHSSGCTTGIVMDSGDGVTHTVPIYERHTLPHT                   ILHLDLAGQDLTDYLMKIPTYRSYSFNTMAKWKIVRNIKEKLCYVALDFEEEMATAAS                   SSSLEKSYELPDSQAIIISNERFRCPEALFQPSFLGMESCGIHESTFNSIMKCDMDIP                   KDLYANTVLSGVTTMYPGIPNRMQKEITALASSTMKIKISCPIVPPECKYFVWIGGSI                   LASLSTFQQMWISKQEYNESGPSIIHRKWTASRCTAFAAWVNSEV                  
 
     [0900] Further analysis of the NOV110a protein yielded the following properties shown in Table 110B.  
               TABLE 110B                       Protein Sequence Properties NOV110a                                        PSort   0.4500 probability located in cytoplasm; 0.1547 probability       analysis:   located in microbody (peroxisome); 0.1000 probability located           in mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0901] A search of the NOV110a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 110C.  
               TABLE 110C                          Geneseq Results for NOV110a                                         NOV110A   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length [Patent   Match   the Matched   Expect       Identifier   +190, Date]   Residues   Region   Value                                     AAU32060   Novel human secreted protein   1..3764 315/376 (83%)   e−180           #2551 -  Homo sapiens,  399 aa.   25..397    336/376 (88%)           [WO200179449-A2, 25 OCT. 2001]               AAB43991   Human cancer associated protein   1..376   311/376 (82%)   e−179           sequence SEQ ID NO:1436 -  Homo.     39..411    336/376 (88%)             sapiens,  413 aa. [WO200055350-           A1, 21 SEP. 2000]               AAP61532   Sequence of beta-actin -  Homo     1..376   311/376 (82%)   e−179             sapiens,  375 aa. [EP174608-A, 19   1..373   335/376 (88%)           MAR. 1986]               AAB12985   Human beta-actin protein sequence   2..376   310/375 (82%)   e−178           -  Homo sapiens,  374 aa.   1..372   334/375 (88%)           [US6087398-A, 11 JUL. 2000]               AAR50328   Drug resistant structural protein -   1..376   309/376 (82%)   e−178             Homo sapiens,  375 aa.   1..373   335/376 (88%)           [JP06038773-A, 15 FEB. 1994]                  
 
     [0902] In a BLAST search of public sequence databases, the NOV110a protein was found to have homology to the proteins shown in the BLASTP data in Table 110D.  
               TABLE 110D                          Public BLASTP Results for NOV110a                                         NOV110a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               P02571   Actin, cytoplasmic 2 (Gamma-actin)-   1 . . . 376   315/376 (83%)   e−179             Homo sapiens  (Human),, 375 aa.   1 . . . 373   336/376 (88%)       ATBOG   actin gamma (tentative sequence)-   2 . . . 376   314/375 (83%)   e−179           bovine, 374 aa.   1 . . . 372   335/375 (88%)       P53505   Actin, cytoplasmic type 5- Xenopus     2 . . . 376   313/375 (83%)   e−178             laevis  (African clawed frog), 376 aa.   3 . . . 374   335/375 (88%)       P29751   Actin, cytoplasmic 1 (Beta-actin)-   1 . . . 376   311/376 (82%)   e−178             Oryctolagus cuniculus  (Rabbit), 375   1 . . . 373   337/376 (88%)           aa.       O93400   ACTIN, CYTOPLASMIC 1   1 . . . 376   311/376 (82%)   e−178           (BETA-ACTIN) (CYTOPLASMIC   1 . . . 373   336/376 (88%)           BETA ACTIN)- Xenopus laevis             (African clawed frog), 375 aa.                  
 
     [0903] PFam analysis predicts that the NOV110a protein contains the domains shown in the Table 110E.  
               TABLE 110E                          Domain Analysis of NOV110a                                     Identities/                   Similarities           NOV110a   for the   Expect       Pfam Domain   Match Region   Matched Region   Value               actin: domain 1 of 1   1 . . . 378   284/382 (74%)   2.2e−227               336/382 (88%)                  
 
     Example 111.  
     [0904] The NOV111 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 111A.  
               TABLE 111A                       NOV111 Sequence Analysis                                                SEQ ID NO:311   1197 bp                     NOV111a,     AACC   ATG TCTAAGCGGGAGTCCTTTAACCTGGAAAGTTATGAATTGGACAAAAGCTTC       CG59621-01 DNA Sequence           TGGCTAACCAGATTCACTGAACTGAAGGGCACAGGTTGCAAAGTGCCCCAAGATGTCT                   TGCAAAAATTGCTGGAATCTTTACAGGAGAACCACTTCCAAGAAGATGAGCAGTTTCT                   GGGAGCCGTTATGCCAAGGCTTCGCATTGGAATGGATACTTGTGCCATTTCTTTGAGG                   CATGGTGGGCTTTCCTTGGTTCAAACCACAGATTACATTTACCCGATCGTAGACGACC                   CTTACATGATGGGCAGGATAGCATGTGCCAATGTCCTCAGTGACCTCTATGCAATGGG                   GGTCACAGAATGTGACAATATGCTGATGCTCCTTGGAGTCAGTAATAAAATGACCGAC                   AGGGAAAGGGATAAAGTGATGCCTCTGATTATCCAAAGTTTTAAAGATGCAGCTGAGG                   AAGCAGGAATGTCTGTAATGGTCAGCCAAACAGTACTAAATCCCTGGATTGTCCTGGG                   AGGAGTCACTACCACTGTCTTCCAGCCCAATGAATTTATCATGCCAGACAATGCAGTG                   CCAGGGGACGTGCTGGTGTTGACAAAACCCCTGGGGACACAGGTGGCAGTGGCTGTGC                   ACCAGTGGCTGGATATTCCTTTGAAATGGAATAAGATTAAGCTAGTGGTCACCGAAGA                   TGTAGAGCTGGCCAACCAGGAGGCGATGATGAACATGGTGAGGCTCAACAGGACAGCT                   GCAGGACTCATGCACACGTTCAATGCCCACATGGCCACTGACATCACGGGCTTCGGGA                   TTTTGGGCCACGTGCAGAACCTAGCCAAGCAGCAGAGGAACGAGGTGTCGTTTGTAAT                   TCACAACCTCCTGGTGCTGGCCAAGATGGCTGCGGTGAGCAAGGCCTGCGGAAACATG                   TTCAGCCTCATGCATGGGACCTGCCCGGAGACCTCAGGCGGCCTTCTGATCTGTTTAC                   CATGTCAGCAAGCAGCTCGGTTCTGTGCAGAGATAAAGTCCCCCAAATATAGTGAAGG                   CCACCAAGCATGGATTATTGGGATTGTAGAGAAGGGCAACCACACAGCCAGAATCATA                   GACAAACCCCAGATCATCAAGGTTGCACCACAAGTGGCCACTCAAAATGTGAATCTCA                   CACCCGGGGCCACATCT TAA   TCTAGACAGAAATAGCT                                           ORF Start: ATG at 5       ORF Stop: TAA at 1178           SEQ ID NO:312   391 aa   MW at 43193.9 kD                     NOV111a,   MSKRESFNLESYELDKSFWLTRFTELKGTGCKVPQDVLQKLLESLQENHFQEDEQFLG       CG59621-01 Protein Sequence           AVMPRLRIGMDTCAISLRHGGLSLVQTTDYIYPIVDDPYMMGRIACANVLSDLYAMGV                   TECDNMLMLLGVSNKMTDRERDKVMPLIIQSFKDAAEEAGMSVMVSQTVLNPWIVLGG                   VTTTVFQPNEFIMPDNAVPGDVLVLTKPLGTQVAVAVHQWLDIPLKWNKIKLVVTEDV                   ELANQEAMMNMVRLNRTAAGLMHTFNAHMATDITGFGILGHVQNLAKQQRNEVSFVIH                   NLLVLAKMAAVSKACGNMFSLMHGTCPETSGGLLICLPCQQAARFCAEIKSPKYSEGH                   QAWIIGIVEKGNHTARIIDKPQIIKVAPQVATQNVNLTPGATS                  
 
     [0905] Further analysis of the NOV111a protein yielded the following properties shown in Table 111B.  
               TABLE 111B                       Protein Sequence Properties NOV111a                                        PSort   0.8500 probability located in endoplasmic reticulum       analysis:   (membrane); 0.4400 probability located in plasma membrane;           0.1000 probability located in mitochondrial inner membrane;           0.1000 probability located in Golgi body       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0906] A search of the NOV111a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 111C.  
               TABLE 111C                          Geneseq Results for NOV111a                                         NOV111a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAB58174   Lung cancer associated polypeptide   166 . . . 391   168/227   (74%)   2e−88           sequence SEQ ID 512 -  Homo      20 . . . 243   189/227   (83%)             sapiens , 250 aa. [WO200055180-           A2, 21 SEP 2000]       AAO01161   Human polypeptide SEQ ID NO   147 . . . 264   81/119   (68%)   2e−36           15053 -  Homo sapiens , 122 aa.    1 . . . 118   92/119   (77%)           [WO200164835-A2, 7 SEP 2001]       AAB53700   Human colon cancer antigen protein   42 . . . 99   53/58   (91%)   1e−24           sequence SEQ ID NO:1240 -  Homo      1 . . . 58   54/58   (92%)             sapiens , 106 aa. [WO200055351-           A1, 21 SEP 2000]                  
 
     [0907] In a BLAST search of public sequence databases, the NOV111a protein was found to have homology to the proteins shown in the BLASTP data in Table 111D.  
               TABLE 111D                          Public BLASTP Results for NOV111a                                         NOV111a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q9BVT4   SELENOPHOSPHATE   1 . . . 391   364/392 (92%)   0.0           SYNTHETASE, HUMAN   1 . . . 392   367/392 (92%)           SELENIUM DONOR PROTEIN -             Homo sapiens  (Human), 392 aa.       P49903   Selenide,water dikinase 1 (EC   1 . . . 375   348/376 (92%)   0.0           2.7.9.3) (Selenophosphate   1 . . . 376   351/376 (92%)           synthetase 1) (Selenium donor           protein 1) -  Homo sapiens             (Human), 383 aa.       AAC50958   SELENOPHOSPHATE   2 . . . 391   272/411 (66%)   e−147           SYNTHETASE 2-  Homo sapiens     33 . . . 441    313/411 (75%)           (Human), 448 aa.       Q99611   Selenide,water dikinase 2 (EC   2 . . . 391   272/411 (66%)   e−147           2.7.9.3) (Selenophosphate   33 . . . 441    313/411 (75%)           synthetase 2) (Selenium donor           protein 2) -  Homo sapiens             (Human), 448 aa.       AAC53024   SELENOPHOSPHATE   2 . . . 387   267/407 (65%)   e−146           SYNTHETASE 2 -  Mus musculus     36 . . . 441    307/407 (74%)           (Mouse), 452 aa.                  
 
     [0908] PFam analysis predicts that the NOV111a protein contains the domains shown in the Table 111E.  
               TABLE 111E                          Domain Analysis of NOV111a                                     Identities/                   Similarities           NOV111a   for the   Expect       Pfam Domain   Match Region   Matched Region   Value                                         AIRS: domain 1 of 1    32 . . . 188   29/180   (16%)     3e−18               113/180   (63%)       AIRS_C:   191 . . . 367   34/197   (17%)   1.1e−20       domain 1 of 1       125/197   (63%)                  
 
     Example 112.  
     [0909] The NOV112 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 112A.  
               TABLE 112A                       NOV112 Sequence Analysis                                                SEQ ID NO:313   544 bp                     NOV112a,     CG   ATG GGACACAGACAGGTCACCCCAGCTCTGATCTTTGCCATCACAGTTGCTACAAT       CG59625-01 DNA Sequence           CGGCTCTTTCCAGTTTGGCTACAACACTGGGGTCATCAATGCTCCTGAGACGGTGCAG                   ATCATAAAGGAATTTATCAATAAAACTTTGACGGACAAGGCAAATGCCCCTCCCTCTG                   AGGTGCTGCTCACGAATCTCTGGTCCTTGTCTGTGGCCATATTTTCCGTCGGGGGTAT                   GATCGGCTCCTTTTCCGTCGGACTCTTTGTTAACCGCTTTGGCAGGAGGCGCAATTCA                   ATGCTGATTGTCAACCTGTTGGCTGCCACTGGTGGCTGCCTTATGGGACTGTGTAAAA                   TAGCTGAGTCAGTTGAAATGCTGATCCTGGGCCGCTTGGTTATTGGCCTCTTCTGCGG                   ACTCTGCACAGGTTTTGTGCCCATGTACATTGGAGAGATCTCGCCTACTGCCCTGAGG                   GGTGCCTTTGGCACTCTCAACCAGCTGGGCATAGTTATTGGAATTCTGGTGGCCCAGG                   TAATCTTTGGTCTGGAACTCATCCTTGGGTCTGAAGAGCTATGGCCGGTGCTATTAGG                   CTTTACCATCCTTCCAGCTATCCTGCAAAGTGCAGCCCTTCCATGTTGCCCTGAAAGT                   CCCAGATTTTTGCTCATTAACAGAAAAAAAGAGGAGAATGCTACGCGGGTCCTCCAGC                   GGTTGTGGGGCACCCAGGATGTATCCCAAGACATCCAGGAGATGAAAGATGAGAGTGC                   AAGGATGTCACAAGAAAAGCAAGTCACCGTGCTGGAGCTCTTTAGAGTGTCCAGCTAC                   CGACAGCCCATCATCATTTCCATTGTGCTCCAGCTCTCTCAGCAGCTCTCTGGGATCA                   ATGCTGTGGTGTTCTATTACTCAACAGGAATCTTCAAGGATGCAGGTGTTCAACAGCC                   CATCTATGCCACCATCAGCGCGGGTGTGGTTAATACTATCTTCACTTTACTTTCTGTA                   GTAGCTCAGATGCTGTTTTCATGGAAAGGAAAACTGAAGTTTCATGTCATAACTGTTT                   CTTTGTTATTAAAGCTGGGTTACACTGTCTTTAAATTTAATCTTCTGTGTTCCTTCCT                   CTTACAGAATCACTATAATGGGATGAGCTTTGTCTGTATTGGGGCTATCTTGGTCTTT                   GTGGCCTGTTTTGAAATTGGACCAGGCCCCATTCCCTGGTTTATTGTGGCCGAACTCT                   TCAGCCAGGGCCCCCGCCCAGCTGCGATGGCAGTGGCCGGCTGCTCCAACTGGACCTC                   CAACTTCCTAGTCGGATTGCTCTTCCCCTCTGCTGCTTACTATTTAGGAGCCTACGTT                   TTTATTATCTTCACCGGCTTCCTCATTACCTTCTTGGCCTTTACCTTCTTCAAAGTCC                   CTGAGACCCGTGGCAGGACTTTTGAGGATATCACACGGGCCTTTGAAGGGCAGGCACA                   CGGTGCAGATAGATCTGGGAAGGACGGCGTCATGGGGATGAACAGCATCGAGCCTGCT                   AAGGAGACCACCACCAATGTC TAA   GTCATGCCTCCT                                           ORF Start: ATG at 3       ORF Stop: TAA at 1530           SEQ ID NO:314   509 aa   MW at 55571.7 kD                     NOV112a,   MGHRQVTPALIFAITVATIGSFQFGYNTGVINAPETVQIIKEFINKTLTDKANAPPSE       CG59625-01 Protein Sequence           VLLTNLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRRNSMLIVNLLAATGGCLMGLCKI                   AESVEMLILGRLVIGLFCGLCTGFVPMYIGEISPTALRGAFGTLNQLGIVIGILVAQV                   IFGLELILGSEELWPVLLGFTILPAILQSAALPCCPESPRFLLINRKKEENATRVLQR                   LWGTQDVSQDIQEMKDESARMSQEKQVTVLELFRVSSYRQPIIISIVLQLSQQLSGIN                   AVVFYYSTGIFKDAGVQQPIYATISAGVVNTIFTLLSVVAQMLFSWKGKLKFHVITVS                   LLLKLGYTVFKFNLLCSFLLQNHYNGMSFVCIGAILVFVACFEIGPGPIPWFIVAELF                   SQGPRPAAMAVAGCSNWTSNFLVGLLFPSAAYYLGAYVFIIFTGFLITFLAFTFFKVP                   ETRGRTFEDITRAFEGQAHGADRSGKDGVMGMNSIEPAKETTTNV                  
 
     [0910] Further analysis of the NOV112a protein yielded the following properties shown in Table 112B.  
               TABLE 112B                       Protein Sequence Properties NOV112a                                        Psort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability           located in endoplasmic reticulum (membrane); 0.1000           probability located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 22 and 23       analysis:                  
 
     [0911] A search of the NOV112a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 112C.  
               TABLE 112C                          Geneseq Results for NOV112a                                         NOV112a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAY27289   Glucose transporter protein   1 . . . 505   389/505 (77%)   0.0           GLUT3 -  Homo sapiens , 494 aa.   1 . . . 492   431/505 (85%)           [US5942398-A, 24 AUG 1999]       AAR11360   Glucose Transporter Protein from   4 . . . 491   289/489 (59%)   e−156           CHO cells - Cricetulus sp, 492 aa.   6 . . . 481   364/489 (74%)           [WO9103554-A, 21 MAR 1991]       AAW17835   Human glucose transporter GLUT-   4 . . . 491   287/489 (58%)   e−155           1 -  Homo sapiens , 492 aa.   6 . . . 481   362/489 (73%)           [WO9715668-A2, 1 MAY 1997]       AAW93000   Human GLUT1 protein -  Homo     4 . . . 491   284/489 (58%)   e−153             sapiens , 492 aa. [WO9618957-A1,   6 . . . 481   360/489 (73%)           20 JUN 1996]       AAB30522   Amino acid sequence of a   6 . . . 501   289/496 (58%)   e−151           consensus GLUT polypeptide -   10 . . . 490    357/496 (71%)           Synthetic, 493 aa. [US6136547-A,           24 OCT 2000]                  
 
     [0912] In a BLAST search of public sequence databases, the NOV112a protein was found to have homology to the proteins shown in the BLASTP data in Table 112D.  
               TABLE 112D                          Public BLASTP Results for NOV112a                                         NOV112a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               P11169   Solute carrier family 2, facilitated   1 . . . 509   446/510 (87%)   0.0           glucose transporter, member 3   1 . . . 496   468/510 (91%)           (Glucose transporter type 3, brain) -             Homo sapiens  (Human), 496 aa.       P47842   Solute carrier family 2, facilitated   1 . . . 507   400/507 (78%)   0.0           glucose transporter, member 3   1 . . . 494   446/507 (87%)           (Glucose transporter type 3, brain) -             Canis familiaris  (Dog), 495 aa.       P47843   Solute carrier family 2, facilitated   1 . . . 505   389/505 (77%)   0.0           glucose transporter, member 3   1 . . . 492   431/505 (85%)           (Glucose transporter type 3, brain) -             Ovis aries  (Sheep), 494 aa.       P58352   Solute carrier family 2, facilitated   1 . . . 505   390/505 (77%)   0.0           glucose transporter, member 3   1 . . . 492   431/505 (85%)           (Glucose transporter type 3, brain) -             Bos taurus  (Bovine), 494 aa.       Q07647   Solute carrier family 2, facilitated   1 . . . 508   380/508 (74%)   0.0           glucose transporter, member 3   1 . . . 492   422/508 (82%)           (Glucose transporter type 3, brain) -             Rattus norvegicus  (Rat), 493 aa.                  
 
     [0913] PFam analysis predicts that the NOV112a protein contains the domains shown in the Table 112E.  
               TABLE 112E                          Domain Analysis of NOV112a                                     Identities/                   Similarities           NOV112a   for the   Expect       Pfam Domain   Match Region   Matched Region   Value                                         Herpes_glycop:    1 . . . 249   40/417   (10%)   7.2       domain 1 of 1       171/417   (41%)       GntP_permease:   65 . . . 329   70/478   (15%)   2.5       domain 1 of 1       185/478   (39%)       sugar_tr:   12 . . . 478   188/503   (37%)   2.2e−158       domain 1 of 1       410/503   (82%)                  
 
     Example 113  
     [0914] The NOV113 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 113A.  
               TABLE 113A                       NOV113 Sequence Analysis                                                SEQ ID NO:315   1731 bp                     NOV113a,     ACTACTTCGCCGACACTCGCCAGCCTCGGCTACGAGCAAAAA   ATG CACCGCACCATGA       CG59887-01 DNA Sequence           GCTCGTTCACCTCGTTTGCCCTGGCCTTTTCCATGGTCTCGATCAACACCGGCGTGGT                   CACGCTGTTCGCCGACCCGTTCAACCGCGTCGGGGGCATCGGCATCCTCCTGTGGCTG                   TTGGTGATCCCGCTGGTGTGCTGCATCGTCATGGTCTACTGCCACCTGGCCGGGCGCA                   TTCCGCTCACCGGCTACGCCTACCAATGGTCCAGCCGATTGGCGGGCAATCACTTCGG                   CTGGTTTACCGGCTGGGTGGCGTTCACCTCGTTTGTCGCCGGTACAGCCGCCACCTCG                   GCGGCCATCGGTACGGTGTTCGCACCGGAGATCTGGGCCAACCCGACACAGGGTCAGA                   TCCAGGGCCTGAGCATCGGCGCCACGCTGGTGGTGGGCTTGCTGAATATCTGCGGGAT                   TCGCCTGGCCACCCGGATCAACGACATCGGCGCGATCATCGAAATCATCGGCACGGTA                   CTGCTGGCGATTGCGTTGTTCTTCGGGGTGTTTTTCTTCTTTGAGCACACCCAGGGCG                   TGGCGATCCTGACCTCCGCGCAACCAGTGAGCGGCGGCACGCTCAGCTTCACCACCAT                   CGCCCTCGCCACCTTGCTGCCGGTCTCGGTGCTGCTGGGTTGGGAAGGCGCCGCCGAC                   CTGTCCGAGGAAACCAAGGACCCACGCCGCGCCGCGCCCCGGGCGATGATTCGTGCGG                   TGCTGGTGTCCAGCGTATTGGGCTTCGTGGTGTTCGCCTTGCTGAGCATCGCGATCCC                   GGGCTCGGTCAGCGAACTGCTCAGCCACAGCGAAAACCCGGTGATCAATATCGTGCGC                   CTGCAACTGGGCAATGCCGCCGGCGTGGGCATGATCGTGATCGCTTTCGCCTCGATCC                   TCGCCTGCCTGATCGCCAACATGGCGGTGGCCACGCGCATGACCTTCGCCCTGTCCCG                   GGACAACATGCTGCCGGGCTCCAAGGTGCTGGCGAAGATCAACCCGCACTTCGGCACG                   CCGGTCGCCGCCATCGTGCTGATCACCGCCATCGCCGTGCTGCTGAACCTGGCGAGTG                   GCGGGTTTGTCACGGCGATCTACTCGATGGTCGGCCTGACCTACTACTGCACTTACCT                   GCTGACGCTGATTGCCGCGTACCTGGCCTATAAAAACGGCCGGATGCCGGGGGCGCCT                   GCGGGCGTGTTCAGCCTGGGCCGCTGGTTGCTGCCGATGATTATCCTCGGCGGCCTGT                   GGGCCATCGCGGTGATCCTGACCCTGAGCGTGCCGGAAGAAAGCCACACTGGCGCTAT                   CACCACCGGGGTTACACTCGGCGTGGGCGTGTTGTGGTGGTTGTTTTCACTGCGCACG                   CGCCTTAACAATGGCACCGCCGGGCCGAGCGGCAAATTGCTCGACCAC TAG   CCGCTGA                       TTGCAGCCAAAAGACAAAACCCCGAACACCGGGGTTTTGTCTTGTCACCTCCAAGGAG                       CTTCCCGATGTTTGAACAGGCCAGCTGGCTCAATCAACCCCAGCATTGGCGCCGAGAA                       GGCGAGCGACTCAAGGTCCGCACCGATGCCAGTACCGATTTCTGGCGTGAAACCCACT                       ATGGTTTTGTACGCGACAACGGGCATTTCCTGTTTGTTGAAACCGACGGCGACTTTAC                       CGCCCAAGTCAAAATCCACAGTGAGTTTACCCACCTGTATGACCTTCGC                                           ORF Start: ATG at 43       ORF Stop: TAG at 1441           SEQ ID NO:316   466 aa   MW at 49070.4 kD                     NOV113a,   MHRTMSSFTSFALAFSMVSINTGVVTLFADPFNRVGGIGILLWLLVIPLVCCIVMVYC       CG59887-01 Protein Sequence           HLAGRIPLTGYAYQWSSRLAGNHFGWFTGWVAFTSFVAGTAATSAAIGTVFAPEIWAN                   PTQGQIQGLSIGATLVVGLLNICGIRLATRINDIGAIIEIIGTVLLAIALFFGVFFFF                   EHTQGVAILTSAQPVSGGTLSFTTIALATLLPVSVLLGWEGAADLSEETKDPRRAAPR                   AMIRAVLVSSVLGFVVFALLSIAIPGSVSELLSHSENPVINIVRLQLGNAAGVGMIVI                   AFASILACLIANMAVATRMTFALSRDNMLPGSKVLAKINPHFGTPVAAIVLITAIAVL                   LNLASGGFVTAIYSMVGLTYYCTYLLTLIAAYLAYKNGRMPGAPAGVFSLGRWLLPMI                   ILGGLWAIAVILTLSVPEESHTGAITTGVTLGVGVLWWLFSLRTRLNNGTAGPSGKLL                   DH                                     SEQ ID NO:317   1433 bp                     NOV113b,     AAAA   ATG CACCGCACCATGAGCTCGTTCACCTCGTTTGCCCTGGCCTTTTCCATGGTC       CG59887-02 DNA Sequence           TCGATCAACACCGGCGTGGTCACGCTGTTCGCCGACCCGTTCAACCGCGTCGGGGGCA                   TCGGCATCCTCCTGTGGCTGTTGGTGATCCCGCTGGTGTGCTGCATCGTCATGGTCTA                   CTGCCACCTGGCCGGGCGCATTCCGCTCACCGGCTACGCCTACCAATGGTCCAGCCGA                   TTGGCGGGCAATCACTTCGGCTGGTTTACCGGCTGGGTGGCGTTCACCTCGTTTGTCG                   CCGGTACAGCCGCCACCTCGGCGGCCATCGGTACGGTGTTCGCACCGGAGATCTGGGC                   CAACCCGACACAGGGTCAGATCCAGGGCCTGAGCATCGGCGCCACGCTGGTGGTGGGC                   TTGCTGAATATCTGCGGGATTCGCCTGGCCACCCGGATCAACGACATCGGCGCGATCA                   TCGAAATCATCGGCACGGTACTGCTGGCGATTGCGTTGTTCTTCGGGGTGTTTTTCTT                   CTTTGAGCACACCCAGGGCGTGGCGATCCTGACCTCCGCGCAACCAGTGAGCGGCGGC                   ACGCTCAGCTTCACCACCATCGCCCTCGCCACCTTGCTGCCGGTCTCGGTGCTGCTGG                   GTTGGGAAGGCGCCGCCGACCTGTCCGAGGAAACCAAGGACCCACGCCGCGCCGCGCC                   CCGGGCGATGATTCGTGCGGTGCTGGTGTCCAGCGTATTGGGCTTCGTGGTGTTCGCC                   TTGCTGAGCATCGCGATCCCGGGCTCGGTCAGCGAACTGCTCAGCCGCAGCGAAAACC                   CGGTGATCAATATCGTGCGCCTGCAACTGGGCAATGCCGCCGGCGTGGGCATGGTCGT                   GATCGCTTTCGCCTCGATCCTCGCCTGCCTGATCGCCAACATGGCGGTGGCCACGCGC                   ATGACCTTCGCCCTGTCCCGGGACAACATGCTGCCGGGCTCCAAGGTGCTGGCGAAGA                   TCAACCCGCACTTCGGCACGCCGGTCGCCGCCATCGTGCTGATCACCGCCATCGCCGT                   GCTGCTGAACCTGGCGAGTGGCGGGTTTGTCACGGCGATCTACTCGATGGTCGGCCTG                   ACCTACTACTGCACTTACCTGCTGACGCTGATTGCCGCGTACCTGGCCTATAAAAACG                   GCCGGATGCCGGGGGCGCCTGCGGGCGTGTTCAGCCTGGGCCGCTGGTTGCTGCCGAT                   GATTATCCTCGGCGGCCTGTGGGCCATCGCGGTGATCCTGACCCTGAGCGTGCCGGAA                   GAAAGCCACACTGGCGCTATCACCACCGGGGTTACACTCGGCGTGGGCGTGTTGTGGT                   GGTTGTTTTCACTGCGCACGCGCCTTAACAATGGCACCGCCGGGCCGAGCGGCAAATT                   GCTCGACCAC TAG   CCGCTGATTGCAGCCAAAAGACAAAACC                                                   ORF Start: ATG at 5       ORF Stop: TAG at 1403           SEQ ID NO:318   466 aa   MW at 49075.4 kD                     NOV113b,   MHRTMSSFTSFALAFSMVSINTGVVTLFADPFNRVGGIGILLWLLVIPLVCCIVMVYC       CG59887-02 Protein Sequence           HLAGRIPLTGYAYQWSSRLAGNHFGWFTGWVAFTSFVAGTAATSAAIGTVFAPEIWAN                   PTQGQIQGLSIGATLVVGLLNICGIRLATRINDIGAIIEIIGTVLLAIALFFGVFFFF                   EHTQGVAILTSAQPVSGGTLSFTTIALATLLPVSVLLGWEGAADLSEETKDPRRAAPR                   AMIRAVLVSSVLGFVVFALLSIAIPGSVSELLSRSENPVINIVRLQLGNAAGVGMVVI                   AFASILACLIANMAVATRMTFALSRDNMLPGSKVLAKINPHFGTPVAAIVLITAIAVL                   LNLASGGFVTAIYSMVGLTYYCTYLLTLIAAYLAYKNGRMPGAPAGVFSLGRWLLPMI                   ILGGLWAIAVILTLSVPEESHTGAITTGVTLGVGVLWWLFSLRTRLNNGTAGPSGKLL                   DH                  
 
     [0915] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 113B.  
               TABLE 113B                          Comparison of NOV113a against NOV113b.                                 Identities/               Similarities       Protein   NOV113a Residues/   for the       Sequence   Match Residues   Matched Region               NOV113b   1 . . . 466   343/466 (73%)           1 . . . 466   344/466 (73%)                  
 
     [0916] Further analysis of the NOV113a protein yielded the following properties shown in Table 113C.  
               TABLE 113C                       Protein Sequence Properties NOV113a                                        PSort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability           located in endoplasmic reticulum (membrane); 0.1000           probability located in endoplasmic reticulum (lumen)       SignalP   Likely cleavage site between residues 59 and 60       analysis:                  
 
     [0917] A search of the NOV113a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 113D.  
               TABLE 113D                          Geneseq Results for NOV113a                                         NOV113a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAG49885     Arabidopsis thaliana  protein    1 . . . 449   122/486 (25%)   3e−31           fragment SEQ ID NO: 63155 -   17 . . . 492   217/486 (44%)             Arabidopsis thaliana , 504 aa.           [EP1033405-A2, 6 SEP 2000]       AAG49884     Arabidopsis thaliana  protein    1 . . . 449   122/486 (25%)   3e−31           fragment SEQ ID NO: 63154 -   29 . . . 504   217/486 (44%)             Arabidopsis thaliana , 516 aa.           [EP1033405-A2, 6 SEP 2000]       AAG20282     Arabidopsis thaliana  protein    1 . . . 449   122/486 (25%)   3e−31           fragment SEQ ID NO: 22407 -   17 . . . 492   217/486 (44%)             Arabidopsis thaliana , 504 aa.           [EP1033405-A2, 6 SEP 2000]       AAG20281     Arabidopsis thaliana  protein    1 . . . 449   122/486 (25%)   3e−31           fragment SEQ ID NO: 22406 -   29 . . . 504   217/486 (44%)             Arabidopsis thaliana , 516 aa.           [EP1033405-A2, 6 SEP 2000]       AAG20280     Arabidopsis thaliana  protein    1 . . . 449   122/486 (25%)   3e−31           fragment SEQ ID NO: 22405 -   41 . . . 516   217/486 (44%)             Arabidopsis thaliana , 528 aa.           [EP1033405-A2, 6 SEP 2000]                  
 
     [0918] In a BLAST search of public sequence databases, the NOV113a protein was found to have homology to the proteins shown in the BLASTP data in Table 113E.  
               TABLE 113E                          Public BLASTP Results for NOV113a                                         NOV113a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q9KZF1   PROBABLE AMINO    3 . . . 450   139/469 (29%)   2e−41           ACID/METABOLITE   27 . . . 481   214/469 (44%)           PERMEASE - Streptomyces           coelicolor, 504 aa.       Q98H14   AMINO ACID/METABOLITE    1 . . . 446   118/466 (25%)   1e−36           PERMEASE -  Rhizobium loti     27 . . . 485   209/466 (44%)           ( Mesorhizobium loti ), 518 aa.       Q92NI8   PUTATIVE AMINO-ACID    1 . . . 449   122/475 (25%)   1e−32           PERMEASE PROTEIN -   25 . . . 487   204/475 (42%)             Rhizobium meliloti  ( Sinorhizobium               meliloti ), 515 aa.       O22509   PUTATIVE AMINO ACID OR    1 . . . 449   122/486 (25%)   1e−30           GABA PERMEASE -  Arabidopsis     29 . . . 504   217/486 (44%)             thaliana  (Mouse-ear cress), 516 aa.       Q9ZU50   PUTATIVE AMINO ACID    1 . . . 449   120/487 (24%)   2e−28           PERMEASE -  Arabidopsis thaliana     29 . . . 505   216/487 (43%)           (Mouse-ear cress), 517 aa.                  
 
     [0919] PFam analysis predicts that the NOV113a protein contains the domains shown in the Table 113F.  
               TABLE 113F                          Domain Analysis of NOV113a                                     Identities/                   Similarities           NOV113a   for the   Expect       Pfam Domain   Match Region   Matched Region   Value                                         oxidored_q3:   162 . . . 307   28/182   (15%)   3.7       domain 1 of 1       91/182   (50%)       ISK_Channel:   196 . . . 326   32/136   (24%)   8.8       domain 1 of 1       55/136   (40%)       ABC2_membrane:   122 . . . 377   46/273   (17%)   8.3       domain 1 of 1       154/273   (56%)       SSF: domain 1 of 1    7 . . . 394   77/470   (16%)   7.8               222/470   (47%)       Aa_trans:    29 . . . 417   67/483   (14%)   9.7       domain 1 of 1       236/483   (49%)       aa_permeases:    1 . . . 451   86/516   (17%)   1.1e−05       domain 1 of 1       287/516   (56%)                  
 
     [0920] The NOV114 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 114A.  
               TABLE 114A                       NOV114 Sequence Analysis                                                SEQ ID NO:319   876 bp                     NOV114a,     AACTTGCTTTTGGGAGCCAGCGGT   ATG GCGTCGGGCTGCAAGATTGGCCCGTCCATCC       CG59861-01 DNA Sequence           TCAACAGCGACCTGGCCAATTTAGGGGCCGAGTGCTCCCGGATGCTAGACTCTGGGGC                   CGATTATCTGCACCTGGACGTAATGGACGGGCATTTTGTTCCCAACATCACCTTTGGT                   CACCCTGTGGTGGAAAGCCTTCGAAAGCAGCTAGGCCAGGACCCTTTCTTTGACATGC                   ACATGATGGTGTCCAAGCCAGAACAGTGGGTAAAGCCAATGGCTGTAGCAGGAGCCAA                   TCAGTACACCTTTCATCTCGAGGCTACTGAGAACCCAGGGGCTTTGATTAAAGACATT                   CGGGAGAATGGGATGAAGGTTGGCCTTGCCATCAAACCAGGAACCTCAGTTGAGTATT                   TGGCACCATGGGCTAATCAGATAGATATGGCCTTGGTTATGACAGTGGAACCGGGGTT                   TGGAGGGCAGAAATTCATGGAAGATATGATGCCAAAGGTTCACTGGTTGAGGACCCAG                   TTCCCATCTTTGGATATAGAGGTCGATGGTGGAGTAGGTCCTGACACTGTCCATAAAT                   GTGCAGAGGCAGGAGCTAACATGATTGTGTCTGGCAGTGCTATTATGAGGAGTGAAGA                   CCCCAGATCTGTGATCAATCTATTAAGAAATGTTTGCTCAGAAGCTGCTCAGAAACGT                   TCTCTTGATCGG TGA   AACCATAAGGAGCCCAGTGTTCCTGTTCATGAAATCTCCCTTT                       TACTGGAAAACAGGAATATTGACTACCAAATCACAATGCAATTGAAGCCGTACTGCTT                       TTTTGAGCAGTTATTCATTCCAGTGATTAAAACTGATTGTGCAGAATAAAAAAAAAAA                       AAAAAA                                           ORF Start: ATG at 25       ORF Stop: TGA at 709           SEQ ID NO:320   228 aa   MW at 24901.4 kD                     NOV114a,   MASGCKIGPSILNSDLANLGAECSRMLDSGADYLHLDVMDGHFVPNITFGHPVVESLR       CG59861-01 Protein Sequence           KQLGQDPFFDMHMMVSKPEQWVKPMAVAGANQYTFHLEATENPGALIKDIRENGMKVG                   LAIKPGTSVEYLAPWANQIDMALVMTVEPGFGGQKFMEDMMPKVHWLRTQFPSLDIEV                   DGGVGPDTVHKCAEAGANMIVSGSAIMRSEDPRSVINLLRNVCSEAAQKRSLDR                                     SEQ ID NO:321   730 bp                     NOV114b,     AACTTGCTTTTGGGAGCCAGCGGT   ATG GCGTCGGGCTGCAAGATTGGCCCGTCCATCC       CG59861-02 DNA Sequence           TCAACAGCGACCTGGCCAATTTAGGGGCCGAGTGCCTCCGGATGCTAGACTCTGGGGC                   CGATTATCTGCACCTGGACGTAATGGACGGGCATTTTGTTCCCAACATCACCTTTGGT                   CACCCTGTGGTAGAAAGCCTTCGAAAGCAGCTAGGCCAGGACCCTTTCTTTGACATGC                   ACATGATGGTGTCCAAGCCAGAACAGTGGGTAAAGCCAATGGCTGTAGCAGGAGCCAA                   TCAGTACACCTTTCATCTCGAGGCTACTGAGAACCCAGGGGCTTTGATTAAAGACATT                   CGGGAGAATGGGATGAAGGTTGGCCTTGCCATCAAACCAGGAACCTCAGTTGAGTATT                   TGGCACCATGGGCTAATCAGATAGATATGGCCTTGGTTATGACAGTGGAACCGGGGTT                   TGGAGGGCAGAAATTCATGGAAGATATGATGCCAAAGGTTCACTGGTTGAGGACCCAG                   TTCCCATCTTTGGATATAGAGGTCGATGGTGGAGTAGGTCCTGACACTGTCCATAAAT                   GTGCAGAGGCAGGAGCTAACATGATTGTGTCTGGCAGTGCTATTATGAGGAGTGAAGA                   CCCCAGATCTGTGATCAATCTATTAAGAAATGTTTGCTCAGAAGCTGCTCAGAAACGT                   TCTCTTGATCGG TGA   AACCATAAGGAGCCCAGTG                                           ORF Start: ATG at 25       ORF Stop: TGA at 709           SEQ ID NO:322   228 aa   MW at 24927.5 kD                     NOV114b,   MASGCKIGPSILNSDLANLGAECLRMLDSGADYLHLDVMDGHFVPNITFGHPVVESLR       CG59861-02 Protein Sequence           KQLGQDPFFDMHMMVSKPEQWVKPMAVAGANQYTFHLEATENPGALIKDIRENGMKVG                   LAIKPGTSVEYLAPWANQIDMALVMTVEPGFGGQKFMEDMMPKVHWLRTQFPSLDIEV                   DGGVGPDTVHKCAEAGANMIVSGSAIMRSEDPRSVINLLRNVCSEAAQKRSLDR                  
 
     [0921] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 114B.  
               TABLE 114B                          Comparison of NOV114a against NOV114b.                                 Identities/               Similarities       Protein   NOV114a Residues/   for the       Sequence   Match Residues   Matched Region               NOV114b   1 . . . 228   227/228 (99%)           1 . . . 228   227/228 (99%)                  
 
     [0922] Further analysis of the NOV114a protein yielded the following properties shown in Table 114C.  
               TABLE 114C                       Protein Sequence Properties NOV114a                                        PSort   0.6500 probability located in cytoplasm; 0.1753 probability       analysis:   located in lysosome (lumen); 0.1000 probability located in           mitochondrial matrix space; 0.0000 probability located in           endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0923] A search of the NOV114a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 114D.  
               TABLE 114D                          Geneseq Results for NOV114a                                     Protein/Organism/Length   NOV114a   Identities/               [Patent #,   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAM41358   Human polypeptide SEQ ID NO   1 . . . 228   227/228   (99%)   e−132           6289 -  Homo sapiens , 247 aa.   20 . . . 247    227/228   (99%)           [WO200153312-A1, 26 JUL           2001]       AAM41357   Human polypeptide SEQ ID NO   1 . . . 228   227/228   (99%)   e−132           6288 -  Homo sapiens , 247 aa.   20 . . . 247    227/228   (99%)           [WO200153312-A1, 26 JUL           2001]       AAM39571   Human polypeptide SEQ ID NO   1 . . . 228   227/228   (99%)   e−132           2716 -  Homo sapiens , 228 aa.   1 . . . 228   227/228   (99%)           [WO200153312-A1, 26 JUL           2001]       AAB71912   Human ISOM-4 -  Homo sapiens ,   1 . . . 228   227/228   (99%)   e−132           228 aa. [WO200112790-A2, 22   1 . . . 228   227/228   (99%)           FEB 2001]       AAM39572   Human polypeptide SEQ ID NO   1 . . . 228   227/246   (92%)   e−129           2717 -  Homo sapiens , 246 aa.   1 . . . 246   227/246   (92%)           [WO200153312-A1, 26 JUL           2001]                  
 
     [0924] In a BLAST search of public sequence databases, the NOV114a protein was found to have homology to the proteins shown in the BLASTP data in Table 114E.  
               TABLE 114E                          Public BLASTP Results for NOV114a                                         NOV114a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                             Q96AT9   HYPOTHETICAL 24.9 KDA   1 . . . 228   227/228   (99%)    e−131           PROTEIN -  Homo sapiens     1 . . . 228   227/228   (99%)           (Human), 228 aa.       Q9BSB5   HYPOTHETICAL 25.3 KDA   1 . . . 228   227/228   (99%)    e−131           PROTEIN-  Homo sapiens     5 . . . 232   227/228   (99%)           (Human), 232 aa (fragment).       AAH19126   HYPOTHETICAL 24.9 KDA   1 . . . 228   221/228   (96%)    e−129           PROTEIN -  Mus musculus     1 . . . 228   226/228   (98%)           (Mouse), 228 aa.       O43767   RIBULOSE-5-PHOSPHATE-   55 . . . 228    174/174   (100%)   2e−98           EPIMERASE -  Homo sapiens     1 . . . 174   174/174   (100%)           (Human), 174 aa (fragment).       Q96N34   CDNA FLJ31466 FIS, CLONE   69 . . . 228    160/178   (89%)   2e−86           NT2NE2001372, HIGHLY   1 . . . 178   160/178   (89%)           SIMILAR TO HOMO SAPIENS           PUTATIVE RIBULOSE-5-           PHOSPHATE-EPIMERASE -             Homo sapiens  (Human), 178 aa.                  
 
     [0925] PFam analysis predicts that the NOV114a protein contains the domains shown in the Table 114F.  
               TABLE 114F                          Domain Analysis of NOV114a                                     Identities/                   Similarities       Pfam   NOV114a   for the   Expect       Domain   Match Region   Matched Region   Value                                         Ribul_P_3_epim:    6 . . . 204   95/209   (45%)   1.9e−105       domain 1 of 1       174/209   (83%)       IGPS: domain 1 of 1   179 . . . 213   15/35   (43%)   0.02               27/35   (77%)       trp_syntA:    34 . . . 222   45/273   (16%)   2.9        domain 1 of 1       124/273   (45%)                  
 
     [0926] The NOV115 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 115A.  
               TABLE 115A                       NOV115 Sequence Analysis                                                SEQ ID NO:323   1761 bp                     NOV115a,     AGTGTGGTACCTATCTGTCCCCCCTCTGGAGGGGTTGACAAGGGAAAGGGCACCGGGG         CG59857-01 DNA Sequence             GGCACAGAG   ATG CAGGACAGATTGCACATCCTGGAGGACCTGAATATGCTCTACATTC                   GGCAGATGGCACTCAGCCTGGAGGACACGGAGTTGCAGAGGAAGCTAGACCATGAGAT                   CCGGATGAGGGAAGGGGCCTGTAAGCTGCTGGCAGCCTGCTCCCAGCGAGAGCAGGCT                   CTGGAGGCCACCAAGAGCCTGCTAGTGTGCAACAGCCGCATCCTCAGCTACATGGGCG                   AGCTGCAGCGGCGCAAGGAGGCGCAGGTGCTGGGGAAGACAAGCCGGCGGCCTTCTGA                   CAGTGGCCCGCCCGCTGAGCGCTCCCCCTGCCGCGGCCGGGTCTGCATCTCTGACCTC                   CGGATTCCACTCATGTGGAAGGACACAGAATATTTCAAGAACAAAGACTTGCACCGCT                   GGGCTGTGTTCCTGCTGCTGCAGCTGGGGGAACACATCCAGGACACAGAGATGATCCT                   AGTGGACAGGACCCTCACAGACATCTCCTTTCAGAGCAATGTGCTCTTCGCTGAGGCG                   GGGCCAGACTTTGAACTGCGGTTAGAGCTGTATGGGGCCTGTGTGGAAGAAGAGGGGG                   CCCTGACTGGCGGCCCCAAGAGGCTTGCCACCAAACTCAGCAGCTCCCTGGGCCGCTC                   CTCAGGGAGGCGTGTCCGGGCATCGCTGGACAGTGCTGGGGGTTCAGGGAGCAGTCCC                   ATCTTGCTCCCCACCCCAGTTGTTGGTGGTCCTCGTTACCACCTCTTGGCTCACACCA                   CACTCACCCTGGCAGCAGTGCAAGATGGATTCCGCACACATGACCTCACCCTTGCCAG                   TCATGAGGAGAACCCTGCCTGGCTGCCCCTTTATGGTAGCGTGTGTTGCCGTCTGGCA                   GCTCAGCCTCTCTGCATGACTCAGCCCACTGCAAGTGGTACCCTCAGGGTGCAGCAAG                   CTGGGGAGATGCAGAACTGGGCACAAGTGCATGGAGTTCTGAAAGGCACAAACCTCTT                   CTGTTACCGGCAACCTGAGGATGCAGACACTGGGGAAGAGCCGCTGCTTACTATTGCT                   GTCAACAAGGAGACTCGAGTCCGGGCAGGGGAGCTGGACCAGGCTCTAGGACGGCCCT                   TCACCCTAAGCATCAGTAACCAGTATGGGGATGATGAGGTGACACACACCCTTCAGAC                   AGAAAGTCGGGAAGCACTGCAGAGCTGGATGGAGGCTCTGTGGCAGCTTTTCTTTGAC                   ATGAGCCAATGGAAGCAGTGCTGTGATGAAATCATGAAAATTGAAACTCCTGCTCCCC                   GGAAACCACCCCAAGCACTGGCAAAGCAGGGGTCCTTGTACCATGAGATGGCTATTGA                   GCCGCTGGATGACATCGCAGCGGTGACAGACATCCTGACCCAGCGGGAGGGCGCAAGG                   CTGGAGACACCCCCACCCTGGCTGGCAATGTTTACAGACCAGCCTGCCCTGCCTAACC                   CCTGCTCGCCTGCCTCAGTGGCCCCAGCCCCAGACTGGACCCACCCCCTGCCCTGGGG                   GAGACCCCGAACCTTTTCCCTGGATGCTGTCCCCCCAGACCACTCCCCTAGGGCTCGC                   TCGGTTGCCCCCCTCCCACCTCAGCGATCCCCACGGACCAGAGGCCTCTGCAGCAAAG                   GCCAACCTCGCACTTGGCTCCAGTCACCAGTG TGA   GAGAGAAAGGTGCTGGCATAGGA                       TCTGCCCAGAAGAGAAAATGA                                           ORF Start: ATG at 68       ORF Stop: TGA at 1715           SEQ ID NO:324   549 aa   MW at 61171.0 kD                     NOV115a,   MQDRLHILEDLNMLYIRQMALSLEDTELQRKLDHEIRMREGACKLLAACSQREQALEA       CG5987-01 Protein Sequence           TKSLLVCNSRILSYMGELQRRKEAQVLGKTSRRPSDSGPPAERSPCRGRVCISDLRIP                   LMWKDTEYFKNKDLHRWAVFLLLQLGEHIQDTEMILVDRTLTDISFQSNVLFAEAGPD                   FELRLELYGACVEEEGALTGGPKRLATKLSSSLGRSSGRRVRASLDSAGGSGSSPILL                   PTPVVGGPRYHLLAHTTLTLAAVQDGFRTHDLTLASHEENPAWLPLYGSVCCRLAAQP                   LCMTQPTASGTLRVQQAGEMQNWAQVHGVLKGTNLFCYRQPEDADTGEEPLLTIAVNK                   ETRVRAGELDQALGRPFTLSISNQYGDDEVTHTLQTESREALQSWMEALWQLFFDMSQ                   WKQCCDEIMKIETPAPRKPPQALAKQGSLYHEMAIEPLDDIAAVTDILTQREGARLET                   PPPWLAMFTDQPALPNPCSPASVAPAPDWTHPLPWGRPRTFSLDAVPPDHSPRARSVA                   PLPPQRSPRTRGLCSKGQPRTWLQSPV                  
 
     [0927] Further analysis of the NOV115a protein yielded the following properties shown in Table 115B.  
               TABLE 115B                       Protein Sequence Properties NOV115a                                                PSort   0.4500 probability located in cytoplasm; 0.3000           analysis:   probability located in microbody (peroxisome);               0.1707 probability located in lysosome (lumen);               0.1000 probability located in mitochondrial               matrix space           SignalP   No Known Signal Sequence Predicted           analysis:                      
 
     [0928] A search of the NOV115a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 115C.  
               TABLE 115C                          Geneseq Results for NOV115a                                         NOV115a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAB35241   Human rhotekin -  Homo sapiens ,   24 . . . 549   526/527 (99%)   0.0           563 aa. [US6183990-B1, 6 FEB   37 . . . 563   526/527 (99%)           2001]       AAY44559   Human Rhotekin protein -  Homo     24 . . . 549   526/527 (99%)   0.0             sapiens , 563 aa. [WO9958667-A1,   37 . . . 563   526/527 (99%)           18 NOV 1999]       AAB35242   Human rhotekin EST-derived   24 . . . 549   522/527 (99%)   0.0           protein -  Homo sapiens , 527 aa.    1 . . . 527   523/527 (99%)           [US6183990-B1, 6 FEB 2001]       AAY44560   Human Rhotekin variant protein -   24 . . . 549   522/527 (99%)   0.0             Homo sapiens , 527 aa.    1 . . . 527   523/527 (99%)           [WO9958667-A1, 18 NOV 1999]       AAB26790   Human Ras correlative GTP   24 . . . 549   518/527 (98%)   0.0           binding kinase protein sequence -   18 . . . 544   519/527 (98%)             Homo sapiens , 544 aa.           [CN1257924-A, 28 JUN 2000]                  
 
     [0929] In a BLAST search of public sequence databases, the NOV115a protein was found to have homology to the proteins shown in the BLASTP data in Table 115D.  
               TABLE 115D                          Public BLASTP Results for NOV115a                                         NOV115a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               AAH17727   SIMILAR TO RHOTEKIN -    1 . . . 549   549/550 (99%)   0.0             Homo sapiens  (Human), 550 aa.    1 . . . 550   549/550 (99%)       Q9BST9   SIMILAR TO RHOTEKIN -   24 . . . 549   526/527 (99%)   0.0             Homo sapiens  (Human), 587 aa   61 . . . 587   526/527 (99%)           (fragment).       Q96PT6   RTKN -  Homo sapiens  (Human),   24 . . . 549   518/527 (98%)   0.0           544 aa.   18 . . . 544   519/527 (98%)       Q9HB05   RHOTEKIN -  Homo sapiens     24 . . . 549   505/527 (95%)   0.0           (Human), 567 aa (fragment).   41 . . . 567   513/527 (96%)       Q61192   RHOTEKIN -  Mus musculus      1 . . . 549   477/551 (86%)   0.0           (Mouse), 551 aa.    1 . . . 551   500/551 (90%)                  
 
     [0930] PFam analysis predicts that the NOV115a protein contains the domains shown in the Table 115E.  
               TABLE 115E                          Domain Analysis of NOV115a                                     Identities/                   Similarities       Pfam   NOV115a   for the   Expect       Domain   Match Region   Matched Region   Value                                         HR1: domain 1 of 1   23 . . . 95   17/87   (20%)   0.27               54/87   (62%)       PH: domain 1 of 1   296 . . . 397   19/102   (19%)   1e−06               72/102   (71%)                  
 
     Example 116  
     [0931] The NOV116 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 116A.  
               TABLE 116A                       NOV116 Sequence Analysis                                                SEQ ID NO:325   450 bp                     NOV116a,     CTGGGAGACTGAAAAA   ATG CAGACCACCGGGGTATTACTCATTTCTCCAGCTCTGATC       CG59855-01 DNA Sequence           TGCTGTTGTACCAGGGGTCTAATCAGGCCTGTGTCTGCCTTCTCCTTGAATAGCCCAG                   AGAATTCATCTAAACAGCCTTCCTACAGCAGCTCCCCACTCCAGGTGGCCAGACGGGA                   GTTCCAGACCAGTGTTGTCTCCCGGGACACTGACACAGCCGCCAAGTTTATTGGTGCT                   GGGTCAGCCACAGTTGGTGTGGCTGATTCAGGGGCTGGCATTGGAGCGGTGTTTGGCA                   GCTTGATTATTGTCTATGCCAGGAAGCTGTCTCTCAAGCAGCAACTCCTCTTCTATGC                   CATTCTGGGCTTTGCCCTGTCTGAGGCCATGGGGCTCTTCTGTTTGATGATCTCCTTC                   TTCATCCTGTTCGCCATG TGA   GGCTCCGTGAGGGTCACCTGCCT                                           ORF Start: ATG at 17       ORF Stop: TGA at 425           SEQ ID NO:326   136 aa   MW at 14384.6 kD                     NOV116a,   MQTTGVLLISPALICCCTRGLIRPVSAFSLNSPENSSKQPSYSSSPLQVARREFQTSV       CG59855-01 Protein Sequence           VSRDTDTAAKFIGAGSATVGVADSGAGIGAVFGSLIIVYARKLSLKQQLLFYAILGFA                   LSEAMGLFCLMISFFILFAM                                     SEQ ID NO:327   434 bp                     NOV116b,     ATG CAGACCACCGGGGTATTACTCATTTCTCCAGCTCTGATCTGCTGTTGTACCAGGG       CG59855-02 DNA Sequence           GTCTAATCAGGCCTGTGTCTGCCTTCTCCTTGAATAGCCCAGAGAATTCATCTAAACA                   GCCTTCCTACAGCAGCTCCCCACTCCAGGTGGCCAGACGGGAGTTCCAGACCAGTGTT                   GTCTCCCGGGACACTGACACAGCCGCCAAGTTTATTGGTGCTGGGTCAGCCACAGTTG                   GTGTGGCTGATTCAGAGGCTGGCATTGGAGCGGTGTTTGGCAGCTTGATTATTGTCTA                   TGCCAGGAAGCTGTCTCTCAAGCAGCAACTCCTCTTCTATGCCATTCTGGGCTTTGCC                   CTGTCTGAGGCCATGGGGCTCTTCTGTTTGATGATCTCCTTCTTCATCCTGTTCGCCA                   TG TGA   GGCTCCGTGAGGGTCACCTGCCT                                           ORF Start: ATG AT 1       ORF Stop: TGA at 409           SEQ ID NO:328   136 aa   MW at 14456.7 kD                     NOV116b,   MQTTGVLLISPALICCCTRGLIRPVSAFSLNSPENSSKQPSYSSSPLQVARREFQTSV       CG59855-02 Protein Sequence           VSRDTDTAAKFIGAGSATVGVADSEAGIGAVFGSLIIVYARKLSLKQQLLFYAILGFA                   LSEAMGLFCLMISFFILFAM                  
 
     [0932] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 116B.  
               TABLE 116B                          Comparison of NOV116a against NOV116b.                                 Identities/               Similarities       Protein   NOV116a Residues/   for the       Sequence   Match Residues   Matched Region               NOV116b   1 . . . 136   120/136 (88%)           1 . . . 136   120/136 (88%)                  
 
     [0933] Further analysis of the NOV116a protein yielded the following properties shown in Table 116C.  
               TABLE 116C                       Protein Sequence Properties NOV116a                                        PSort   0.9190 probability located in plasma membrane; 0.3000       analysis:   probability located in lysosome (membrane); 0.1888           probability located in microbody (peroxisome); 0.1000           probability located in endoplasmic reticulum (membrane)       SignalP   Likely cleavage site between residues 28 and 29       analysis:                  
 
     [0934] A search of the NOV116a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 116D.  
               TABLE 116D                          Geneseq Results for NOV116a                                         NOV116a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAG75142   Human colon cancer antigen protein   1 . . . 136   115/136   (84%)   2e−57           SEQ ID NO:5906 -  Homo sapiens ,   7 . . . 142   119/136   (86%)           142 aa. [WO200122920-A2,           5 APR 2001]       AAB43866   Human cancer associated protein   1 . . . 136   115/136   (84%)   2e−57           sequence SEQ ID NO:1311 -  Homo     7 . . . 142   119/136   (86%)             sapiens , 142 aa. [WO200055350-           Al, 21 SEP 2000]       AAU69713   Cell death protective sequence CNI-   7 . . . 136   85/136   (62%)   2e−36           00730, protein #1 -  Homo sapiens ,   7 . . . 142   98/136   (71%)           142 aa. [WO200176532-A2,           18 OCT 2001]       ABB12016   Human ATP synthase subunit   7 . . . 136   85/136   (62%)   2e−36           homologue, SEQ ID NO:2386 -   52 . . . 187    98/136   (71%)             Homo sapiens , 187 aa.           [WO200157188-A2, 9 AUG           2001]       AAB53428   Human colon cancer antigen protein   7 . . . 136   85/136   (62%)   2e−36           sequence SEQ ID NO:968 -  Homo     77 . . . 212    98/136   (71%)             sapiens , 212 aa. [WO200055351 -           A1, 21 SEP 2000]                  
 
     [0935] In a BLAST search of public sequence databases, the NOV116a protein was found to have homology to the proteins shown in the BLASTP data in Table 116E.  
               TABLE 116E                          Public BLASTP Results for NOV116a                                         NOV115a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               P05496   ATP synthase lipid-binding protein,   1 . . . 136   115/136 (84%)   9e−57           mitochondrial precursor (EC   1 . . . 136   119/136 (86%)           3.6.1.34) (ATP synthase proteolipid           P1) (ATPase protein 9) (ATPase           subunit C) -  Homo sapiens  (Human),           136 aa.       P32876   ATP synthase lipid-binding protein,   1 . . . 136   113/136 (83%)   1e−54           mitochondrial precursor (EC   1 . . . 136   117/136 (85%)           3.6.1.34) (ATP synthase proteolipid           P1) (ATPase protein 9) (ATPase           subunit C) -  Bos taurus  (Bovine), 136           aa.       P17605   ATP synthase lipid-binding protein,   1 . . . 136   113/136 (83%)   2e−54           mitochondrial precursor (EC   1 . . . 136   117/136 (85%)           3.6.1.34) (ATP synthase proteolipid           P1) (ATPase protein 9) (ATPase           subunit C) -  Ovis aries  (Sheep), 136           aa.       Q9CR84   ATP SYNTHASE C CHAIN   1 . . . 136   112/136 (82%)   1e−53           ISOFORM 1 (EC 3.6.1.34) (LIPID-   1 . . . 136   117/136 (85%)           BINDING PROTEIN) (SUBUNIT C) -              Mus musculus  (Mouse), 136 aa.       P48202   ATP synthase lipid-binding protein,   1 . . . 136   112/136 (82%)   1e−53           mitochondrial precursor (EC   1 . . . 136   117/136 (85%)           3.6.1.34) (ATP synthase proteolipid           P1) (ATPase protein 9) (ATPase           subunit C) -  Mus musculus  (Mouse),           136 aa.                  
 
     [0936] PFam analysis predicts that the NOV116a protein contains the domains shown in the Table 116F.  
               TABLE 116F                          Domain Analysis of NOV116a                                     Identities/                   Similarities       Pfam   NOV116a   for the   Expect       Domain   Match Region   Matched Region   Value               ATP-synt_C:   67 . . . 135   31/70 (44%)   2.3e−18       domain 1 of 1       57/70 (81%)                  
 
     [0937] The NOV117 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 117A.  
               TABLE 117A                       NOV117 Sequence Analysis                                                SEQ ID NO:329   1769 bp                     NOV117a,     GAGGTG   ATG CTGGAGACCTGCGGACTTCTCATGTCTCTGGGCTGTCCTTTGTTCAAAC       CG59807-01 DNA Sequence           CAGAGCTGATCTACCAGTTGGATCACAGACAGGAGCTATGGATGGCTACAAAAGACCT                   CTCCCAAAGCTCCTATCCAGGTGACAACACAAAACCCAAGACCACAGAGCCTACCTTT                   TCTCACCTGGCCTTGCCTGAGGAAGTCTTACTCCAGGAACAACTGACACAAGGAGCCT                   CAAAGAACTCCCAATTAGGGCAATCCAAGGATCAGGATGGGCCATCTGAAATGCAAGA                   AGTCCACTTGAAAATAGGGATAGGCCCCCAGCGGGGGAAGCTGCTGGAGAAAATGAGT                   TCTGAACGTGATGGTTTGGGGTCAGATGATGGTGTATGTACAAAGATTACACAGAAAC                   AAGTTTCAACAGAAGGTGATCTCTATGAATGTGATTCACATGGACCAGTTACAGATGC                   CTTGATTCGCGAAGAGAAAAATTCCTATAAATGTGAGGAATGCGGGAAAGTGTTTAAA                   AAGAATGCCCTCCTTGTTCAGCATGAACGGATTCACACTCAAGTGAAGCCCTATGAAT                   GCACAGAGTGTGGGAAAACCTTTAGCAAGAGCACTCATCTTCTTCAGCACCTCATCAT                   CCACACTGGGGAGAACCCCTATAAGTGCATGGAGTGTGGGAAGGCTTTTAACCGCAGG                   TCACACCTCACACGGCACCAGCGGATTCACAGTGGAGAGAAGCCTTATAAGTGCAGTG                   AATGTGGAAAGGCCTTCACCCACCGCTCCACTTTTGTCTTGCATCACAGGAGCCACAC                   TGGAGAAAAACCCTTTGTGTGCAAAGAGTGTGGCAAAGCCTTTCGAGATAGGCCAGGT                   TTCATTCGACACTACATCATCCACACGGGAGAGAAGCCCTATGAGTGCATTGAGTGTG                   GGAAGGCCTTCAACCGCCGGTCATACCTCACGTGGCACCAACAGATTCACACTGGAGT                   GAAACCCTTTGAATGCAACGAGTGTGGAAAAGCTTTTTGCGAGAGTGCAGACCTCATT                   CAACACTACATTATCCACACTGGGGAGAAGCCCTATAAGTGCATGGAGTGTGGGAAGG                   CGTTCAACCGTAGGTCACACCTCAAGCAGCATCAACGGATTCACACTGGGGAGAAGCC                   TTATGAATGCAGTGAATGTGGAAAGGCCTTCACCCACTGCTCCACTTTTGTCTTGCAT                   AAAAGGACCCACACAGGAGAAAAACCCTATGAATGCAAAGAATGTGGAAAAGCCTTTA                   GTGATAGGGCAGACCTCATTCGCCACTTCAGCATCCACACTGGAGAGAAACCCTATGA                   GTGCGTGGAGTGTGGAAAGGCCTTCAACCGCAGCTCACACCTCACGAGGCACCAACAG                   ATTCACACTGGAGAGAAACCCTATGAATGCATCCAGTGTGGGAAAGCCTTTTGCCGGA                   GCGCAAACCTTATTCGACACTCCATCATTCACACTGGAGAGAAGCCGTATGAATGCAG                   TGAGTGTGGAAAGGCTTTTAATCGCGGCTCATCCCTCACACATCATCAAAGGATTCAT                   ACTGGGAGAAACCCTACCATTGTAACAGATGTGGGAAGACCTTTTATGACTGCACAGA                   CTTCAGTCAACATCCAGGAACTTTTATTAGGGAAAGAGTTTTTGAATATCACCACTGA                   AGAAAATCTGTGG TGA   AAGGGAACATCTTACCATCTGGCCATTCACACTGAAGAGAAA                       CTTCATAAGCATCCTCTCTTTGAGAAAAC                                           ORF Start: ATG at 7       ORF Stop: TGA at 1696           SEQ ID NO:330   563 aa   MW at 64300.6 kD                     NOV117a,   MLETCGLLMSLGCPLFKPELIYQLDHRQELWMATKDLSQSSYPGDNTKPKTTEPTFSH       CG59807-01 Protein Sequence           LALPEEVLLQEQLTQGASKNSQLGQSKDQDGPSEMQEVHLKIGIGPQRGKLLEKMSSE                   RDGLGSDDGVCTKITQKQVSTEGDLYECDSHGPVTDALIREEKNSYKCEECQKVFKKN                   ALLVQHERTHTQVKPYECTECGKTFSKSTHLLQHLITHTGEKPYKCMECGKAFNRRSH                   LTRHQRTHSGEKPYKCSECGKAFTHRSTFVLHHRSHTGEKPFVCKECGKAFRDRPGFI                   RHYIIHTGEKPYECIECGKAFNRRSYLTWHQQIHTGVKPFECNECGKAFCESADLIQH                   YIIHTGEKPYKCMECGKAFNRRSHLKQHQRIHTGEKPYECSECGKAFTHCSTFVLHKR                   THTGEKPYECKECGKAFSDRADLIRHFSIHTGEKPYECVECGKAFNRSSHLTRHQQIH                   TGEKPYECIQCGKAFCRSANLIRHSIIHTGEKPYECSECGKAFNRGSSLTHHQRIHTG                   RNPTIVTDVGRPFMTAQTSVNIQELLLGKEFLNITTEENLW                  
 
     [0938] Further analysis of the NOV117a protein yielded the following properties shown in Table 117B.  
               TABLE 117B                       Protein Sequence Properties NOV117a                                        Psort   0.4500 probability located in cytoplasm; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1000 probability           located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen)       SignalP   Likely cleavage site between residues 19 and 20       analysis:                  
 
     [0939] A search of the NOV117a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 117C.  
               TABLE 117C                          Geneseq Results for NOV117a                                         NOV117a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAM79549   Human protein SEQ ID NO 3195 -    1 . . . 563   563/566 (99%)   0.0             Homo sapiens , 603 aa.   38 . . . 603   563/566 (99%)           [WO200157190-A2, 9 AUG 2001]       AAM78565   Human protein SEQ ID NO 1227 -    1 . . . 563   563/566 (99%)   0.0             Homo sapiens , 603 aa.   38 . . . 603   563/566 (99%)           [WO200157190-A2, 9 AUG           2001]       ABB21767   Protein #3766 encoded by probe for   44 . . . 562   375/519 (72%)   0.0           measuring heart cell gene   10 . . . 527   437/519 (83%)           expression -  Homo sapiens , 551 aa.           [WO200157274-A2, 9 AUG           2001]       AAM69575   Human bone marrow expressed   44 . . . 562   375/519 (72%)   0.0           probe encoded protein SEQ ID NO:   10 . . . 527   437/519 (83%)           29881 -  Homo sapiens , 551 aa.           [WO200157276-A2, 9 AUG 2001]       AAM57172   Human brain expressed single exon   44 . . . 562   375/519 (72%)   0.0           probe encoded protein SEQ ID NO:   10 . . . 527   437/519 (83%)           29277 -  Homo sapiens , 551 aa.           [WO200157275-A2, 9 AUG 2001]                  
 
     [0940] In a BLAST search of public sequence databases, the NOV117a protein was found to have homology to the proteins shown in the BLASTP data in Table 117D.  
               TABLE 117D                          Public BLASTP Results for NOV117a                                         NOV117a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               O43296   Zinc finger    1 . . . 562   401/562 (71%)   0.0           protein 264 -  Homo      43 . . . 603   468/562 (82%)             sapiens  (Human),           627 aa.       Q96NL3   CDNA FLJ30663    1 . . . 535   299/535 (55%)   0.0           FIS, CLONE    38 . . . 572   369/535 (68%)           SIMILAR TO ZINC           FINGER PROTEIN           84 -  Homo sapiens             (Human), 588 aa.       Q99676   Zinc finger    2 . . . 535   261/542 (48%)   e−151           protein 184 -  Homo      58 . . . 595   355/542 (65%)             sapiens  (Human),           751 aa.       Q96SE7   ZINC FINGER   151 . . . 541   233/391 (59%)   e−148           1111 -  Homo     306 . . . 694   281/391 (71%)             sapiens  (Human),           839 aa.       Q03923   Zinc finger protein    1 . . . 535   266/544 (48%)   e−148           85 (Zinc finger    33 . . . 547   328/544 (59%)           protein HPF4)           (HTF1) -  Homo               sapiens  (Human),           595 aa.                  
 
     [0941] PFam analysis predicts that the NOV117a protein contains the domains shown in the Table 117E.  
               TABLE 117E                          Domain Analysis of NOV117a                                     Identities/               NOV117a   Similarities           Match   for the Matched   Expect       Pfam Domain   Region   Region   Value               KRAB: domain 1 of 1    1 . . . 34   14/66 (21%)   0.15               24/66 (36%)       zf-C2H2: domain 1 of 13   162 . . . 184   11/24 (46%)   3.6e−06               19/24 (79%)       zf-C2H2: domain 2 of 13   190 . . . 212   11/24 (46%)   7.1e−06               19/24 (79%)       zf-C2H2: domain 3 of 13   218 . . . 240   14/24 (58%)   2.3e−07               22/24 (92%)       zf-BED: domain 1 of 3   203 . . . 241   13/52 (25%)   2               25/52 (48%)       zf-C2H2: domain 4 of 13   246 . . . 268   11/24 (46%)   4.6e−05               20/24 (83%)       LIM: domain 1 of 1   220 . . . 284   16/72 (22%)   0.69               50/72 (69%)       zf-C2H2: domain 5 of 13   274 . . . 296    8/24 (33%)   7.6e−05               18/24 (75%)       zf-C2H2: domain 6 of 13   302 . . . 324   11/24 (46%)   8.4e−05               20/24 (83%)       Zn_carbOpept: domain 1   312 . . . 330    5/19 (26%)   1.2       of 1       17/19 (89%)       zf-C2H2: domain 7 of 13   330 . . . 352    8/24 (33%)   9.7e−05               19/24 (79%)       zf-C2H2: domain 8 of 13   358 . . . 380   14/24 (58%)   5.3e−07               22/24 (92%)       zf-BED: domain 2 of 3   343 . . . 381   12/52 (23%)   1.3               26/52 (50%)       zf-C2H2: domain 9 of 13   386 . . . 408   11/24 (46%)   9.4e−05               20/24 (83%)       zf-C2H2: domain 10 of 13   414 . . . 436   11/24 (46%)   5e−06               20/24 (83%)       zf-C2H2: domain 11 of 13   442 . . . 464   12/24 (50%)   3e−07               22/24 (92%)       zf-BED: domain 3 of 3   427 . . . 465   14/52 (27%)   0.38               27/52 (52%)       zf-C2H2: domain 12 of 13   470 . . . 492   12/24 (50%)   0.00044               19/24 (79%)       zf-C2H2: domain 13 of 13   498 . . . 520   12/24 (50%)   9.8e−07               22/24 (92%)                  
 
     Example 118  
     [0942] The NOV118 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 118A.  
               TABLE 118A                       NOV118 Sequence Analysis                                                SEQ ID NO:331   1899 bp                     NOV118a,     CAAACTCTACTACCTCTAT   ATG ACATTTCAGGTGTCTGTGACCTTTGATGATGTGGCT       CG59805-01 DNA Sequence           GTGACTTTCACCCAGGAGGAGTGGGGCCAGCTGGACCTAGCTCAGCGGACCCTGTACC                   AGGAGGTGATGCTGGAAAACTGTGGGCTCCTGGTATCTCTGGGTGGGTGTCCTGTTCC                   CAGACCTGAGCTGATCTACCACCTAGAGCATGGGCAGGAGCCATGGACCAGGAAGGAA                   GACCTCTCCCAAGGCACCTGTCCAGGTGACAAAGGAAAACCCAAGAGCACAGAACCTA                   CCACCTGTGAGCTAGCCTTGTCTGAAGGAATCTCTTTTTGGGGACAACTAACACAAGG                   AGCTTCAGGGGACTCCCAGTTGGGGCAACCCAAGGATCAGGATGGGTTTTCAGAAATG                   CAGGGAGAACGCTTGAGACCAGGGTTAGATTCCCAAAAGGAGAAGCTTCCTGGAAAAA                   TGAGCCCCAAACATGATGGTTTAGGGACAGCTGATAGTGTGTGTTCAAGGATTATACA                   GGATCGAGTCTCCTTAGGAGATGATGTCCATGACTGTGACTCACATGGATCAGGTAAA                   AATCCAGTTATTCAGGAAGAGGAAAATATCTTTAAATGCAATGAATGTGAAAAAGTGT                   TTAACAAGAAACGCCTGCTTGCTCGGCATGAGAGGATTCACTCTGGAGTGAAGCCCTA                   TGAATGCACAGAGTGTCGAAAAACCTTTAGCAAGAGTACATACCTCCTGCAGCACCAC                   ATGGTCCACACTGGGGAGAAGCCCTATAAGTGCATGGAGTGTGGGAAGGCTTTTAATC                   GGAAGTCACACCTTACCCAGCACCAGCGGATTCACAGTGGAGAGAAGCCTTATAAGTG                   CAGTGAATGTGGAAAGGCCTTCACCCACCGCTCCACTTTTGTCTTGCATAACAGGAGC                   CACACTGGAGAAAAACCCTTTGTGTGCAAAGAGTGTGGCAAAGCCTTTCGAGATAGGC                   CAGGTTTCATTCGACACTACATCATCCACAGTGGTGAGAATCCCTACGAGTGCTTCGA                   ATGTGGCAAGGTCTTCAAACACAGATCATACCTCATGTGGCACCAGCAGACTCATACC                   GGGGAGAAGCCCTATGAGTGCAGTGAATGTGGGAAGGCCTTCTGTGAGAGCGCAGCGC                   TGATTCACCACTATGTCATCCACACTGGAGAGAAGCCCTTTGAGTGCCTCGAGTGTGG                   GAAGGCTTTCAACCACCGATCCTACCTCAAAAGGCACCAGCGGATTCACACTGGGGAG                   AAGCCATATGTGTGTAGTGAATGCGGAAAGGCCTTCACCCACTGCTCTACTTTCATCT                   TGCATAAAAGGGCCCACACTGGAGAAAAACCTTTCGAGTGCAAAGAGTGTGGGAAAGC                   CTTTAGCAATAGGGCAGACCTCATTCGCCACTTCAGCATCCACACTGGAGAGAAGCCC                   TATGAGTGCATGGAGTGTGGAAAGGCCTTCAACCGCAGGTCAGGCCTCACAAGGCACC                   AGCGGATTCATAGTGGAGAGAAGCCCTATGAATGCATCGAGTGTGGGAAAACATTTTG                   CTGGAGCACAAACCTCATTCGACACTCTATCATCCACACTGGAGAGAAGCCGTATGAG                   TGCAGTGAATGTGGAAAGGCCTTCAGTCGCAGCTCGTCCCTCACTCAGCATCAAAGGA                   TGCATACTGGGAGAAATCCTATCAGTGTAACAGATGTGGGAAGACCTTTTACAAGTGG                   GCAGACCTCAGTCAACATCCAAGAACTTTTATTGGGGAAAAACTTTTTGAATGTCACC                   ACTGAGGAAAATCTTTTGCAAGAGGAAGCATCTTACATGGCATCTGATCGTACATACC                   AAAGAGAAACCCCACAAGTGTCTTCACTG TGA   GAAAACCTTCT                                           ORF Start: ATG at 20       ORF Stop: TGA at 1886           SEQ ID NO:332   622 aa   MW at 70677.2 kD                     NOV118a,   MTFQVSVTFDDVAVTFTQEEWGQLDLAQRTLYQEVMLENCGLLVSLGGCPVPRPELIY       CG59805-01 Protein Sequence           HLEHGQEPWTRKEDLSQGTCPGDKGKPKSTEPTTCELALSEGISFWGQLTQGASGDSQ                   LGQPKDQDGFSEMQGERLRPGLDSQKEKLPGKMSPKHDGLGTADSVCSRIIQDRVSLG                   DDVHDCDSHGSGKNPVIQEEENIFKCNECEKVFNKKRLLARHERIHSGVKPYECTECG                   KTFSKSTYLLQHHMVHTGEKPYKCMECGKAFNRKSHLTQHQRIHSGEKPYKCSECGKA                   FTHRSTFVLHNRSHTGEKPFVCKECGKAFRDRPGFIRHYIIHSGENPYECFECGKVFK                   HRSYLMWHQQTHTGEKPYECSECGKAFCESAALIHHYVIHTGEKPFECLECCKAFNHR                   SYLKRHQRIHTGEKPYVCSECGKAFTHCSTFILHKRAHTGEKPFECKECGKAFSNRAD                   LIRHFSIHTGEKPYECMECGKAFNRRSGLTRHQRIHSGEKPYECIECGKTFCWSTNLI                   RHSIIHTGEKPYECSECGKAFSRSSSLTQHQRMHTGRNPISVTDVGRPFTSGQTSVNI                   QELLLGKNFLNVTTEENLLQEEASYMASDRTYQRETPQVSSL                  
 
     [0943] Further analysis of the NOV118a protein yielded the following properties shown in Table 118B.  
               TABLE 118B                       Protein Sequence Properties NOV118a                                        PSort   0.4500 probability located in cytoplasm; 0.3796 probability       analysis:   located in microbody (peroxisome); 0.1000 probability located           in mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0944] A search of the NOV118a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 118C.  
               TABLE 118C                          Geneseq Results for NOV118a                                             Identities/                   NOV118a   Similarities           Protein/Organism/   Residues/   for       Geneseq   Length   Match   the Matched   Expect       Number   [Patent #, Date]   Residues   Portion   Value               ABB22693   Protein #4692   81 . . . 548   468/468   0.0           encoded by probe    1 . . . 468   (100%)           for measuring heart       468/468           cell gene       (100%)           expression -             Homo sapiens ,           468 aa.           [WO200157274-A2,           09 AUG. 2001]       AAM70526   Human bone   81 . . . 548   468/468   0.0           marrow expressed    1 . . . 468   (100%)           probe encoded       468/468           protein SEQ       (100%)           ID NO:           30832 -  Homo               sapiens , 468 aa.           [WO200157276-A2,           09 AUG. 2001]       AAM58080   Human brain   81 . . . 548   468/468   0.0           expressed single    1 . . . 468   (100%)           exon probe encoded       468/468           protein SEQ ID NO:       (100%)           30185 -  Homo               sapiens , 468 aa.           [WO200157275-A2,           09 AUG. 2001]       AAM30843   Peptide #4880   81 . . . 548   468/468   0.0           encoded by probe    1 . . . 468   (100%)           for measuring       468/468           placental gene       (100%)           expression -  Homo               sapiens , 468 aa.           [WO200157272-A2,           09 AUG. 2001]       AAM18364   Peptide #4798   81 . . . 548   468/468   0.0           encoded by probe    1 . . . 468   (100%)           for measuring       468/468           cervical gene       (100%)           expression -  Homo               sapiens , 468 aa.           [WO200157278-A2,           09 AUG. 2001]                  
 
     [0945] In a BLAST search of public sequence databases, the NOV118a protein was found to have homology to the proteins shown in the BLASTP data in Table 118D.  
               TABLE 118D                          Public BLASTP Results for NOV118a                                         NOV118a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               O43296   Zinc finger    4 . . . 622   530/619 (85%)   0.0             sapiens     11 . . . 627   567/619 (90%)           (Human), 627 aa.       Q96NL3   CDNA FLJ30663    7 . . . 572   334/566 (59%)   0.0           FIS, CLONE    9 . . . 573   403/566 (71%)           FCBBF1000598,           MODERATELY           SIMILAR TO           ZINC FINGER           PROTEIN 84 -             Homo sapiens             (Human), 588 aa.       Q99676   Zinc finger    2 . . . 571   280/604 (46%)   e−160           protein 184 -  Homo     23 . . . 623   377/604 (62%)             sapiens  (Human),           751 aa.       P51523   Zinc finger    4 . . . 617   286/637 (44%)   e−157           protein 84 (Zinc    5 . . . 626   368/637 (56%)           finger protein           HPF2) -  Homo               sapiens (Human),             738 aa.       Q9BX82   EZFIT-RELATED    7 . . . 617   278/621 (44%)   e−156           PROTEIN 1 -   14 . . . 626   364/621 (57%)             Homo sapiens             (Human), 626 aa.                  
 
     [0946] PFam analysis predicts that the NOV118a protein contains the domains shown in the Table 118E.  
               TABLE 118E                          Domain Analysis of NOV118a                                     Identities/               NOV118a   Similarities           Match   for the Matched   Expect       Pfam Domain   Region   Region   Value               KRAB: domain 1 of 1    7 . . . 70   41/66 (62%)   2.2e−33               54/66 (82%)       zf-C2H2: domain 1 of 13   198 . . . 220   11/24 (46%)   3.9e−05               17/24 (71%)       BolA: domain 1 of 1   161 . . . 238   14/88 (16%)   3.4               49/88 (56%)       zf-C2H2: domain 2 of 13   226 . . . 248   10/24 (42%)   6.2e−05               18/24 (75%)       zf-C2H2: domain 3 of 13   254 . . . 276   14/24 (58%)     5e−07               22/24 (92%)       TFIIS: domain 1 of 1   257 . . . 292   12/39 (31%)   5.7               21/39 (54%)       zf-C2H2: domain 4 of 13   282 . . . 304   11/24 (46%)   3.7e−05               20/24 (83%)       LIM: domain 1 of 1   256 . . . 320   14/71 (20%)   0.38               48/71 (68%)       zf-C2H2: domain 5 of 13   310 . . . 332    8/24 (33%)   7.6e−05               18/24 (75%)       zf-C2H2: domain 6 of 13   338 . . . 360   11/24 (46%)   1.1e−05               19/24 (79%)       zf-C2H2: domain 7 of 13   366 . . . 388    9/24 (38%)   0.00027               18/24 (75%)       zf-C2H2: domain 8 of 13   394 . . . 416   12/24 (50%)   7.9e−07               21/24 (88%)       zf-C2H2: domain 9 of 13   422 . . . 444   10/24 (42%)   0.00014               19/24 (79%)       zf-C2H2: domain 10 of 13   450 . . . 472   10/24 (42%)   8.3e−06               20/24 (83%)       zf-C2H2: domain 11 of 13   478 . . . 500   13/24 (54%)     3e−07               21/24 (88%)       zf-BED: domain 1 of 1   463 . . . 501   14/52 (27%)   0.1               29/52 (56%)       zf-C2H2: domain 12 of 13   506 . . . 528   11/24 (46%)   0.0016               17/24 (71%)       zf-C2H2: domain 13 of 13   534 . . . 556   13/24 (54%)   7.2e−08               23/24 (96%)                  
 
     Example 119  
     [0947] The NOV119 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 119A.  
               TABLE 119A                       NOV119 Sequence Analysis                                                SEQ ID NO:333   1546 bp                     NOV119a,     GCTCAGTAGGCGTCGGGCTGTGATGCCCCAACTGCTCCAGCGTCTGCAGGCGCGCGCG         CG59928-01 DNA Sequence             GGCGCGGTAGGCGTACTCGCTGGCCGGATAGCGCGTGATGATGAACTGGTAGGTCTGC                       GCCGCATCGACGAACAGGCTCTCGCGCTCCAGGCATTGACCGCGCAGCAGGGAAATCT                       CCGGCTGCAGGTAATTGCGTGAGCGGCTCTTGCGCTCGGCCTGCGACAGCTCCAGCGC                       GACACGGGCGCAATCGCCTTCGTTGTAGGCGCGATAGGCGTTGTTCAGATGATGGTCG                       AGCGAGACACGGGTGCAACCCGCAGCAACCAGGGCCACGGCCAGAATGATCAGGTTAC                       GCATGGGCAATTCCTCCAATGAGCAGTGTATCGACAGCCCAGGCAAAAACTGAACAGC                       GGCAAGCCGACGACGGTTTTTCTGGCGGCGCCTTGGCATGACGCCACTGCCTCTCATT                       TTATCAACGCCAGCGCCACGACCGCTCGTCCTCTCGAACCAGCGCTAAATCCCCTTCT                       GCGCTGACCCATATCAATGCCGTTCAGCGCAACAGGGTGTGTAATGTAGGTACAGACT                       CCAGGCGAGGACGCTGCC   ATG AAACTGCAACGACTGTTGGTCGTCATCGACGCCGAAC                   ACCAGCAACAACCCGCCCTGCAACGCGCAGCCGATGTGGCACGCAAGACCGGCGCCGA                   ATTGCACCTGTTGCAGATCGAATACCACCCAAGCCTGGAAAGCGGCCTGCTGGACAGC                   CATCTGCTCAACCGCGCCCGTGAAACCATCCTGCGACAGAGCCACGAGGCCCTGCGTG                   CCAGCGTCGCTCACCTGAGCGATGAAGGATTCAAGATCGCAGTGGACGTGCGCTGGGG                   CAAACGTCGTCATGAAGAAATCCTCGCCCGCGTCGCGGTGTTGCAACCGGACATCCTG                   TTCAAGTCGACTCATCCCAGCAGTGCGCTGCGCCGCCTGTTGTTCAGTGATACCAGTT                   GGCAGCTGATTCGCCGCAGCCCGGTGCCGCTGTGGCTGGTACACGACGCCGAGCCCCA                   TGGTCAGAGCCTGTGCGCTGCGCTCGACCCGCTGCACAGCGCGGACAAACCTGCCGCC                   CTCGATCATCAGTTGATTGATGCCAGCCAGACCCTGCAGGCCGAGCTCGGCTTACAGG                   CCCAATACCTGCATGCACAGGCGCCTCTGCCGCGGTCGCTGCTGTTCGACGCCGAGGT                   AGCGCAGGAATATGAAGACTACGTGACCCAGTGCAGCCGCGAGCACCGCGAAGCCTTC                   GACAAGCTGATCGCCCAGCACGCCATCGATAGAGCACAGGCCCACCTGTTGGACGGTT                   TTGCCGAGGAAGTCATCCCGCGTTTCGTGCGTGAGCACAATATAGGCCTGCTGGTGAT                   GGGCGCCATCGCCCGCGGCCATCTGGACAGCCTGCTGATCGGCCACACCGCAGAACGG                   GTGCTGGAACGTGTCGAGTGCGATCTGCTGGTGATCAAATCGCACGGCAAAGGG TAG   T                       GCACAGGAACAATGACTACAGCCCGACGCCTACTGAGC                                           ORF Start: ATG at 599       ORF Stop: TAG at 1505           SEQ ID NO:334   302 aa   MW at 33922.3 kD                     NOV119a,   MKLQRLLVVIDAEHQQQPALQRAADVARKTGAELHLLQIEYHPSLESGLLDSHLLNRA       CG59928-01 Protein Sequence           RETILRQSHEALRASVAHLSDEGFKIAVDVRWGKRRHEEILARVAVLQPDILFKSTHP                   SSALRRLLFSDTSWQLIRRSPVPLWLVHDAEPHGQSLCAALDPLHSADKPAALDHQLI                   DASQTLQAELGLQAQYLHAQAPLPRSLLFDAEVAQEYEDYVTQCSREEREAFDKLIAQ                   HAIDRAQAHLLDGFAEEVIPRFVREHNIGLLVMGAIARGHLDSLLIGHTAERVLERVE                   CDLLVIKSHGKG                  
 
     [0948] Further analysis of the NOV119a protein yielded the following properties shown in Table 119B.  
               TABLE 119B                       Protein Sequence Properties NOV119a                                        PSort   0.3000 probability located in microbody (peroxisome); 0.3000       analysis:   probability located in nucleus; 0.2014 probability located in           lysosome (lumen); 0.1000 probability located in mitochondrial           matrix space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0949] A search of the NOV119a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 119C.  
               TABLE 119C                          Geneseq Results for NOV119a                                             Identities/                   NOV119a   Similarities           Protein/Organism/   Residues/   for       Geneseq   Length   Match   the Matched   Expect       Number   [Patent #, Date]   Residues   Portion   Value                         No Significant Matches Found                  
 
     [0950] In a BLAST search of public sequence databases, the NOV119a protein was found to have homology to the proteins shown in the BLASTP data in Table 119D.  
               TABLE 119D                          Public BLASTP Results for NOV119a                                         NOV119a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q9HW73   HYPOTHETICAL   1 . . . 297   156/299 (52%)   1e−79           PROTEIN PA4328 -   1 . . . 299   200/299 (66%)             Pseudomonas               aeruginosa , 304 aa.       Q9KS28   HYPOTHETICAL   5 . . . 300    78/302 (25%)   4e−29           PROTEIN   6 . . . 304   147/302 (47%)           VC1433 -             Vibrio cholerae ,           315 aa.       CAC91106   PUTATIVE   2 . . . 300    93/310 (30%)   2e−28           STRESS   3 . . . 303   137/310 (44%)           PROTEIN -             Yersinia pestis ,           318 aa.       AAL20579   PUTATIVE   4 . . . 297    91/305 (29%)   2e−28           UNIVERSAL   5 . . . 300   139/305 (44%)           STRESS           PROTEIN -             Salmonella               typhimurium  LT2,           315 aa.       CAD01669   CONSERVED   4 . . . 297    91/305 (29%)   3e−28           HYPOTHETICAL   5 . . . 300   139/305 (44%)           PROTEIN -             Salmonella enterica             subsp.  enterica               serovar Typhi ,           315 aa.                  
 
     [0951] PFam analysis predicts that the NOV119a protein contains the domains shown in the Table 119E.  
               TABLE 119E                          Domain Analysis of NOVL19a                                     Identities/               NOV119a   Similarities   Expect       Pfam Domain   Match Region   for the Matched Region   Value                                     Usp: domain 1 of 2    2 . . . 144   28/153 (18%)   0.0014               92/153 (60%)       Usp: domain 2 of 2   160 . . . 297   28/153 (18%)   0.013               88/153 (58%)                  
 
     Example 120  
     [0952] The NOV120 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 120A.  
               TABLE 120A                       NOV120 Sequence Analysis                                                SEQ ID NO:335   2202 bp                     NOV120a,     CACCCTCCCGCCCCGCCCCCCGTCCA   ATG CTGAGCTCAGTCTGCGTCTCGTCCTTCCG       CG59947-01 DNA Sequence           CGGGCGCCAGGGGGCCAGCAAGCAGCAGCCGGCGCCACCGCCGCAGCCGCCCGAGGTC                   CCCGGTGGCGACAGCGGCAAGATCGTGATCAACGTGGGCGGCGTGCGCCATGAGACGT                   ACCGCTCGACGCTGCGCACCCTGCCGGGGACGCGGCTGGCCGGCCTGACGGAGCCCGA                   GGCGGCGGCACGCTTCGACTACGACCCGGGCGCCGACGAGTTCTTCTTTGACCGGCAC                   CCGGGAGTCTTCGCGTACGTGCTCAACTACTACCGCACCGGCAAGCTGCACTGCCCAG                   CCGACGTGTGCGGGCCCCTGTTTGAGGAGGAGCTCGGCTTCTGGGGCATCGACGAGAC                   CGACGTGGAGGCCTGCTGCTGGATGACCTACCGGCAGCATCGCGACGCTGAGGAGGCG                   CTCGACTCCTTCGAGGCGCCCGACCCCGCGGGCGCCGCCAACGCCGCCAACGCCGCAG                   GCGCCCACGACGGAGGCCTGGACGACGAGGCGGGCGCGGGCGGCGGCGGCCTGGACGG                   AGCGGGCGGCGAGCTCAAGCGCCTCTGCTTCCAGGACGCGGGCGGCGGCGCCGGGGGG                   CCGCCAGGGGGCGCGGGCGGCGCGGGCGGCACATGGTGGCGCCGCTGGCAGCCCCGCG                   TGTGGGCGCTCTTCGAGGACCCCTACTCGTCGCGGGCTGCCAGGTATGTGGCCTTCGC                   CTCCCTCTTCTTCATCCTCATCTCCATCACCACCTTCTGCCTGGAAACCCATGAGGGC                   TTCATCCATATTAGCAACAAGACGGTGACCCAGGCCTCCCCGATCCCCGGGGCACCTC                   CGGAGAACATCACCAACGTGGAGGTGGAGACGGAGCCCTTCCTGACCTACGTGGAGGG                   GGTGTGCGTGGTCTGGTTCACCTTCGAGTTCCTCATGCGCATCACCTTCTGCCCAGAC                   AAGGTGGAGTTTCTTAAAAGCAGCCTCAACATCATCGACTGTGTGGCCATCCTGCCCT                   TCTATCTCGAGGTGGGCCTCTCGGGCCTCAGCTCCAAGGCCGCCAAAGACGTGCTGGG                   CTTCCTGCGGGTGGTCCGCTTCGTCCGCATCCTGCGCATCTTCAAGCTGACCCGGCAC                   TTCGTGGGGCTGCGCGTGCTGGGACACACGCTCCGCGCCAGCACCAACGAGTTCCTGC                   TGCTCATCATCTTCCTGGCCCTGGGGGTGCTCATCTTCGCCACCATGATTTACTACGC                   TGAGCGCATTGGCGCCGACCCCGATGACATCCTGGGCTCCAACCACACCTACTTCAAG                   AACATCCCCATTGGCTTCTGGTGGGCTGTGGTCACCATGACGACCCTGGGCTATGGAG                   ACATGTACCCCAAGACGTGGTCGGGGATGCTGGTCGGGGCGCTGTGTGCCCTGGCGGG                   GGTGCTGACCATCGCCATGCCTGTGCCCGTCATTGTCAACAACTTTGGCATGTACTAT                   TCGCTGGCCATGGCCAAGCAGAAGCTGCCCAAGAAGAAGAACAAACACATCCCCCGGC                   CCCCGCAACCGGGCTCGCCCAACTACTGCAAGCCTGACCCACCCCCGCCACCCCCGCC                   CCACCCGCACCACGGCAGCGGGGGCATCAGCCCGCCGCCACCCATCACCCCACCCTCC                   ATGGGGGTGACTGTGGCCGGGGCCTACCCAGCGGGGCCCCACACGCACCCCGGGCTGC                   TCAGGGGGGGAGCGGGTGGGCTGGGGATCATGGGGCTGCCTCCTCTGCCAGCCCCCGG                   CGAGCCTTGCCCGTTGGCTCAGGAGGAGGTGATTGAGATCAACCGGGCAGATCCTCGC                   CCCAATGGGGATCCGGCAGCAGCTGCGCTTGCCCACGAGGACTGCCCAGCCATTGACC                   AGCCTGCCATGTCCCCGGAAGACAAGAGCCCCATCACGCCTGGAAGCCGTGGCCGCTA                   TAGCCGGGACCGAGCCTGCTTCCTCCTCACCGACTATGCCCCTTCCCCTGATGGCTCC                   ATCCGAAAAGCCACTGGTGCTCCCCCACTGCCCCCCCAAGACTGGCGTAAGCCAGGCC                   CCCCAAGCTTCTTGCCCGACCTCAACGCCAACGCCGCGGCCTGGATATCCCCC TAG   TG                       GACGAACCCCCTCCCCCCGGGCTCTTGTCACCGCCTGAGACCTCGCGAGACTTTCG                                           ORF Start: ATG at 27       ORF Stop: TAG at 2142           SEQ ID NO:336   705 aa   MW at 75590.5 kD                     NOV120a,   MLSSVCVSSFRGRQGASKQQPAPPPQPPEVPGGDSGKIVINVGGVRHETYRSTLRTLP       CG59947-01 Protein Sequence           GTRLAGLTEPEAAARFDYDPGADEFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFE                   EELGFWGIDETDVEACCWMTYRQHRDAEEALDSFEAPDPAGAANAANAAGAHDGGLDD                   EAGAGGGGLDGAGGELKRLCFQDAGGGAGGPPGGAGGAGGTWWRRWQPRVWALFEDPY                   SSRAARYVAFASLFFILISITTFCLETHEGFIHISNKTVTQASPIPGAPPENITNVEV                   ETEPFLTYVEGVCVVWFTFEFLMRITFCPDKVEFLKSSLNIIDCVAILPFYLEVGLSG                   LSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALG                   VLIFATMIYYAERIGADPDDILGSNHTYFKNIPIGFWWAVVTMTTLGYGDMYPKTWSG                   MLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPKKKNKHIPRPPQPGSPNY                   CKPDPPPPPPPHPHHGSGGISPPPPITPPSMGVTVAGAYPAGPHTHPGLLRGGAGGLG                   IMGLPPLPAPGEPCPLAQEEVIEINRADPRPNGDPAAAALAHEDCPAIDQPAMSPEDK                   SPITPGSRGRYSRDRACFLLTDYAPSPDGSIRKATGAPPLPPQDWRKPGPPSFLPDLN                   ANAAAWISP                  
 
     [0953] Further analysis of the NOV120a protein yielded the following properties shown in Table 120B.  
               TABLE 120B                       Protein Sequence Properties NOV120a                                        PSort   0.6000 probability located in plasma membrane; 0.5071       analysis:   probability located in mitochondrial inner membrane;           0.4000 probability located in Golgi body; 0.3000 probability           located in endoplasmic reticulum (membrane)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0954] A search of the NOV120a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 120C.  
               TABLE 120C                          Geneseq Results for NOV120a                                             Identities/                   NOV120a   Similarities           Protein/Organism/   Residues/   for       Geneseq   Length   Match   the Matched   Expect       Number   [Patent #, Date]   Residues   Region   Value               AAY34120   human potassium   32 . . . 526   371/510   0.0           channel K +    4 . . . 476   (72%)           Hnov4 -  Homo         399/510             sapiens , 601 aa.       (77%)           [WO9943696-A1,           02 SEP. 1999]       AAY32016     Caenorhabditis     33 . . . 512   217/486    e−113             elegans  cation   27 . . . 465   (44%)           channel protein -       300/486             Caenorhabditis         (61%)             elegans , 556 aa.           [WO9947923-A2,           23 SEP. 1999]       AAB86319   Human Kv4.2   16 . . . 521   173/511   5e−69           protein -  Homo     22 . . . 441   (33%)             sapiens , 629 aa.       256/511           [DE19963612-A1,       (49%)           12 JUL. 2001]       AAY13523   Amino acid   16 . . . 521   173/511   8e−68           sequence of   23 . . . 442   (33%)           KV4.2FL ion       257/511           channel protein -       (49%)           Mammalia, 630 aa.           [WO9923880-A1,           20 MAY 1999]       AAW42996   Putative mature   17 . . . 510   171/503   2e−66           potassium    4 . . . 425   (33%)           channel 2       240/503           protein -  Homo         (46%)             sapiens , 494 aa.           [U.S. Pat.           No. 5710019-A,           20 JAN. 1998]                  
 
     [0955] In a BLAST search of public sequence databases, the NOV120a protein was found to have homology to the proteins shown in the BLASTP data in Table 120D.  
               TABLE 120D                          Public BLASTP Results for NOV120a                                         NOV120a   Identities/           Protein       Residues/   Similarities for       Accession   Protein/   Match   the Matched   Expect       Number   Organism/Length   Residues   Portion   Value               Q14003   Voltage-gated    1 . . . 705   704/757 (92%)   0.0           potassium channel    1 . . . 757   704/757 (92%)           protein Kv3.3           (KSHIIID) -             Homo sapiens             (Human), 757 aa.       Q01956   Voltage-gated    1 . . . 693   663/757 (87%)   0.0           potassium channel    1 . . . 756   668/757 (87%)           protein Kv3.3           (KSHIIID) -  Rattus               norvegicus  (Rat),           889 aa.       Q63959   Voltage−gated    1 . . . 671   650/725 (89%)   0.0           potassium channel    1 . . . 724   653/725 (89%)           protein Kv3.3           (KSHIIID) -  Mus               musculus  (Mouse),           769 aa.       A42073   potassium channel   32 . . . 607   557/576 (96%)   0.0           protein Kv3.3 -           mouse, 679 aa.       Q9PVD1   KV3.1   34 . . . 671   441/640 (68%)   0.0           POTASSIUM    6 . . . 547   479/640 (73%)           CHANNEL -             Xenopus               laevis  (African           clawed frog),           592 aa.                  
 
     [0956] PFam analysis predicts that the NOV120a protein contains the domains shown in the Table 120E.  
               TABLE 120E                          Domain Analysis of NOV120a                                     Identities/               NOV120a   Similarities           Match   for the Matched   Expect       Pfam Domain   Region   Region   Value               K_tetra: domain 1 of 1    36 . . . 137    50/112 (45%)   1.6e−47                86/112 (77%)       thaumatin: domain 1 of 1   314 . . . 319    4/6 (67%)   0.7                6/6 (100%)       ion trans: domain 1 of 1   295 . . . 486    51/231 (22%)   2.1e−29               155/231 (67%)                  
 
     Example 121  
     [0957] The NOV121 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 121A.  
               TABLE 121A                       NOV121 Sequence Analysis                                                SEQ ID NO:337   1943 bp                     NOV121a,     AGATCCACGTGATCTCCAAAGACCCCTGTTGTCTTGTGTTGGGAGGTGGATCCTGAAT         CG59938-01 DNA Sequence             CCACCCAGAGAAGCCTGATACCAATAAAATCCCTGCTTGCTTTCCAGGAGACCCTTGG                       TCTTC   ATG TCTTTGGTGTGTGCACTCTTGAACACATGCCAGGCACACAGGGTGCATGA                   CGACAAGCCTAATATTGTCCTAATCATGGTTGATGACCTGGGTATTGGAGATCTGGGC                   TGCTACGGCAATGACACCATGAGGACGCCTCACATCGACCGCCTTGCCAGGGAAGGCG                   TGCGACTGACTCAGCACATCTCTGCCCCCTCCCTCTGCAGCCCAAGCCGGTCCGCGTT                   CTTGACGGGAAGATACCCCATCCGATCAGGTATGGTTTCTAGTGGTAATAGACGTGTC                   ATCCAAAATCTTGCAGTCCCCGCACGCCTCCCTCTTAATGAGACAACACTTGCAGCCT                   TGCTAAAGAAGCAAGGATACAGCACCGGGCTTATAGGTAACTTAGGCAAATGGCACCT                   GGGTTTGAGCTGCGCCTCTCGGAATGATCACTGTTACCACCCGCTCAACCATGGTTTT                   CACTACTTTTACGGGGTGCCTTTTGGACTTTTAAGCGACTGCCAGGCATCCAAGACAC                   CAGAACTGCACCGCTGGCTCAGGATCAAACTGTGGATCTCCACGGTAGCCCTTGCCCT                   GGTTCCTTTTCTGCTTCTCATTCCCAAGTTCGCCCGCTGGTTCTCAGTGCCATGGAAG                   GTCATCTTTGTCTTTGCTCTCCTCGCCTTTCTGTTTTTCACTTCCTGGTACTCTAGTT                   ATGGATTTACTCGACGTTGGAATTGCATCCTTATGAGGAACCATGAAATTATCCAGCA                   GCCAATGAAACACGAGAAAGTAGCTTCCCTCATGCTGAAGCAGGCACTTGCTTTCATT                   GAAAGGTACAAAAGGGAACCTTTTCTCCTCTTTTTTTCCTTCCTGCACGTACATACTC                   CACTCATCTCCAAAAAGAAGTTTGTTGGGCGCAGTAAATATGGCAGGTATGCCGACAA                   TGTAGAAGAAATGGATTGGATGGTGGGTGGTAAAATCCTGGATGCCCTGGACCAGGAG                   CGCCTGGCCAACCACACCTTGGTGTACTTCACCTCTGACAACGGGGGCCACCTGGAGC                   CCCTCCACGGGGCTGTTCAGCTGGGTGGCTGGAACGGGATCTACAAAGGTGGCAAAGG                   AATGGGAGGATGGGAAGGAGGTATCCGTCTGCCAGGGATATTCCGGTGGCCGTCAGTC                   TTGGACGCTGGGAGAGTGATCAATCAGCCCACCAGCTTAATCGACATCTATCCGACGC                   TGTCTTATATAGGCGGAGGGATCTTGTCCCAGGACAGAGTGATTGACGGCCAGAACCT                   AATGCCCCTGCTGGAACGAAGGGCGTCCCACTCCGACCACGAGTTCCTCTTCCACTAC                   TGTGGGGTCTATCTGCACACGGTCAGGTGGCATCAGAAGGACACTGTGTGGAAAGCTC                   ATTATGTGACTCCTAAATTCTACCCTGAAGGAACAGGTGCCTGCTATGGGAGTGGAAT                   ATGTTCATGTTCGGGCCATGTAACCTACCACCACCCACCACTCCTCTTTGACATCTCA                   AGAGACCCTTCAGAAGCCCTTCCACTGAACCCTGACAATGAGCCATTATTTGACTCCG                   TGATCAAAAAGATGGAGGCAGCCATAAGAGAGCATCGTAGGACACTAACACCTGTCCC                   ACAGCAGTTCTCTCTGTTCAACACAATTTGGAAACCATGGCTGCAGCCTTGCTCTGCG                   ACCTTCCCCTTCTGTGGGTGTGACAAGGAAGATGACATCCTTCCCATGGCTCCC TGA   G                       ACCATGCGGACCACGTGTTACCCACCACAAACTTACTGTTACAATGGTCATAGGAGCA                       GAGCTCACCTGACTGATTCATTCCATTTG                                           ORF Start: ATG at 122       ORF Stop: TGA at 1853           SEQ ID NO:338   577 aa   MW at 65099.5 kD                     NOV121a,   MSLVCALLNTCQAHRVHDDKPNIVLTMVDDLGIGDLGCYGNDTMRTPHIDRLARECVR       CG59938-01 Protein Sequence           LTQHISAASLCSPSRSAFLTGRYFIRSGMVSSGNRRVIQNLAVPAGLPLNETTLAALL                   KKQGYSTGLIGKLGKWHLGLSCASRNDHCYHPLNHGFHYFYGVPFGLLSDCQASKTPE                   LHRWLRIKLWISTVALALVPFLLLIPKFARWFSVPWKVIEVFALLAFLFFTSWYSSYG                   FTRRWNCILMRNHEIIQQPMKEEKVASLMLKEALAFIERYKREPFLLFFSFLHVHTPL                   ISKKKFVGRSKYGRYGDNVEEMDWMVGGKILDALDQERLANHTLVYFTSDNGGHLEPL                   DGAVQLGGWNGIYKGGKGMGGWEGGIRVPGIFRWPSVLEAGRVINEPTSLMDIYPTLS                   YIGGGILSQDRVIDGQNLMPLLEGRASHSDHEFLFHYCGVYLHTVRWHQKDTVWKAHY                   VTPKFYPEGTGACYGSGICSCSGDVTYHDPPLLFDISRDPSEALPLNPDNEPLFDSVI                   KKMEAAIREHRRTLTPVPQQFSVFNTIWKPWLQPCCGTFPFCGCDKEDDILPMAP                  
 
     [0958] Further analysis of the NOV121a protein yielded the following properties shown in Table 121B.  
               TABLE 121B                       Protein Sequence Properties NOV121a                                        PSort   0.6400 probability located in plasma membrane; 0.4600       analysis:   probability located in Golgi body; 0.3700 probability located           in endoplasmic reticulum (membrane); 0.1000 probability           located in endoplasmic reticulum (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0959] A search of the NOV121a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 121C.  
               TABLE 121C                          Geneseq Results for NOV121a                                         NOV121a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAM78688   Human protein SEQ ID NO 1350-    1 . . . 572   388/576 (67%)   0.0             Homo sapiens , 590 aa.   10 . . . 580   449/576 (77%)           [WO200157190-A2, 9 AUG. 2001]       AAM39343   Human polypeptide SEQ ID NO   20 . . . 571   331/555 (59%)   0.0           2488- Homo sapiens , 589 aa.   37 . . . 587   404/555 (72%)           [WO200153312-A1, 26 JUL. 2001]       AAM41129   Human polypeptide SEQ ID NO   20 . . . 571   331/555 (59%)   0.0           6060- Homo sapiens , 646 aa.   94 . . . 644   404/555 (72%)           [WO200153312-A1, 26 JUL. 2001]           AAY39920   Human steroid sulphatase protein   20 . . . 569   295/559 (52%)   e−166           sequence- Homo sapiens , 583 aa.   26 . . . 575   374/559 (66%)           [WO9950453-A1, 7 OCT. 1999]       AAB51185   Human sulfatase protein C SEQ ID   20 . . . 569   294/559 (52%)   e−165           NO: 14- Homo sapiens , 583 aa.   26 . . . 575   372/559 (65%)           [U.S. Pat. No. 6153188-A,           28 NOV. 2000]                  
 
     [0960] In a BLAST search of public sequence databases, the NOV121a protein was found to have homology to the proteins shown in the BLASTP data in Table 121D.  
               TABLE 121D                          Public BLASTP Results for NOV121a                                         NOV121a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               P54793   Arylsulfatase F precursor (EC    1 . . . 572   379/577 (65%)   0.0           3.1.6.-) (ASF)- Homo sapiens     10 . . . 581   441/577 (75%)           (Human), 591 aa.       AAH20229   HYPOTHETICAL 64.9 KDA    4 . . . 574   358/574 (62%)   0.0           PROTEIN- Homo sapiens     24 . . . 593   440/574 (76%)           (Human), 593 aa.       P51689   Arylsulfatase D precursor (EC    4 . . . 574   349/574 (60%)   0.0           3.1.6.-) (ASD)- Homo sapiens     24 . . . 593   429/574 (73%)           (Human), 593 aa.       P51690   Arylsulfatase E precursor (EC   20 . . . 571   334/555 (60%)   0.0           3.1.6.-) (ASE)- Homo sapiens     37 . . . 587   405/555 (72%)           (Human), 589 aa.       P08842   Steryl-sulfatase precursor (EC   20 . . . 569   295/559 (52%)   e−166           3.1.6.2) (Steroid sulfatase) (Steryl-   26 . . . 575   374/559 (66%)           sulfate sulfohydrolase)           (Arylsulfatase C) (ASC)- Homo               sapiens  (Human), 583 aa.                  
 
     [0961] PFam analysis predicts that the NOV121a protein contains the domains shown in the Table 121E.  
               TABLE 121E                          Domain Analysis of NOV121a                                     Identities/           Pfam   NOV121a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               Sulfatase:   21 . . . 504   231/530 (44%)   1e−187       domain 1 of 1       410/530 (77%)                  
 
     Example 122  
     [0962] The NOV122 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 122A.  
               TABLE 122A                       NOV122 Sequence Analysis                                                SEQ ID NO:339   3005 bp                     NOV122a,     ATTTCTTTGGTGTTGTCTTCACAGCTGAACTTGCAAAACAGATTGGAACTTCAAGATT         CG59746-01 DNA Sequence             ATCAATAATCGGAGATACGTATATTTTATTTGTAAAGAAAAC   ATG GCTGCCCTATTCC                   TACGTGGTTTTGTCCAAATAGGGAACTGCAAGACTGGGATATCTAAGTCAAAAGAAGC                   ATTCATTGAAGCAGTGGAAAGAAAGAAGAAAGATAGACTGGTGCTGTATTTCAAAAGT                   GGAAAATATAGCACTTTTCCGCTAAGTGATAATATTCAAAATGTAGTCCTTAAATCCT                   ATAGAGGAAACCAAAATCACCTGCATTTAACTTTACAAAATAATAATGCCTTGTTTAT                   TGAAGGATTATCCTCCACAGATGCTGAACAATTGAAGATATTCTTGGACAGAGTTCAT                   CAAAACGAGGTTCAGCCACCTGTGAGACCTGGTAAGGGTGGGAGTGTCTTTTCTAGCA                   CAACACAGAAGGAAATCAACAAAACTTCATTCCAGAAAGTTGATGAGAAATCAAGTAG                   CAAATCTTTTGAGATAGCAAAAGGAAGTGGGACAGGTGTCCTTCAGAGGATGCCTTTG                   CTTACATCAAAATTGACACTTACTTGCGGAGAGTTATCAGAAAATCAGCACAAGAAGA                   GGAAAAGAATGCTCTCATCTAGCTCAGACATCAATGAGGAATTCTTGAAAGAAAATAA                   TTCTGTAGAATACAAGAAATCCAACGCAGATTGTTCGAGGTGTGTAAGCTATAATCGA                   GAGAAACAATTGAAGTTAAAAGAGTTAGAAGAGAATAAGAAATTGGAATGTGAATCTT                   CATGCATCATGAACGCCACTGGAAATCCTTACCTACATGACATTGGTCTTCTCCAAGC                   TCTCACTGAGAAAATGGTTTTGGTATTTCTGTTACAACAAGGGTATAGTGACGGTTAC                   ACAAAGTGGGATAAATTAAAACTATTTTTTGAATTATTTCCAGAGAAAATATGCCACG                   GCCTCCCCAATTTGGGAAACACCTGTTATATGAATGCAGTGTTACAGTCTCTACTTTC                   AATCCCATCGTTTGCTGATGATTTACTTAATCAGAGTTTCCCATGGGGTAAAATTCCC                   CTTAATGCTCTTACCATGTGCTTGGCACGGCTACTTTTTTTTAAACATACCTATAATA                   TAGAAATCAAGGAGATGTTACTCTTGAATCTTAAAAAGGCCATTTCAGCAGCTGCAGA                   GATATTCCATGGCAATGCACAGAACGATGCTCATGAGTTTTTAGCTCACTGTTTAGAT                   GGGAAGATAATTTTCCTAAACAGGTTTTTGCTGATGATCCTGACACCAGTGGGTTTTC                   TTGCCCTGTCATTACTAATTTTGAGTTAGAGTTGTTGCACTCCATTGCTTGTAAAGCT                   TGTGGTCAGGTTATTCTCAAGACAGAACTGAATAATTACCTCTCCATCAACCTTCCCC                   AAAGAATAAAACCACATCCTTCATCTATTCAGTCTACTTTTGATCTTTTTTTTCCAGC                   AGAAGAGCTTGAGTATAAATCTCCAAAATGTGAGCACAAGACTTCCGTTGCAGTGCAC                   TCATTCAGTAGGCTACCTACAATCCTTATTCTTCACCTCAAACGCTATACCTTGAATC                   AGTTTTGTGCATTAAACAAGAATGACCAGCAAGTCATCATTTCCAAATATTTAAACGT                   GTCTTCTCATTGCAATCAACGCACCAGACCACCTCTTCCCTTGAGTGAGGATGGAGAA                   ATTACAGATTTCCAATTATTAAAACTTATTCGAAAGATGACTTCTCCAAACATCACTG                   TATCATGGCCTGCAACAAAGGAATCCAAAGATATCCTGGCTCCACACATTCGATCAGA                   TAAGCAGTCTGAACAAAAAAAAGGCCAGACAGTCTTTAAAGGGGCAAGCAGAAGACAG                   CAGCAAAAGTACCTTGGAAAAAATTCTAAACCAAATGAGCTAGAATCTGTATACTCAG                   GAGATCGAGCATTCATTGAAAAACAACCGTTAGCTCACTTAATGACGTATCTGGAAGA                   TACCTCACTTTGTCAGTTCCACAAAGCTGGAGGTAAACCTCCCAGCAGCCCAGGCACA                   CCTCTCTCAAAAGTTCACTTTCAAACACTGCCCCAAAATCCAAAACCAAAGAAATATG                   TGAAAACCACTAAGTTTGTACCTTTTGATAGGATTATCAATCCTACTAAAGATTTGTA                   TGAAGATAAAAATATCAGAATTCCAGAAAGATTCCAAAAAGTGTCTGAACAGACTCAG                   CAGTGTGACGGTATGAGAATCTGTGAACAAGCCCCTCAGCAGGCACTGCCTCAAAGCT                   TTCCAAAGCCAGGCACCCACGCCCACACAAAGAACCTCCTAACACCTACAAAATTAAA                   TCTACAGAAGTCTAACAGGAATTCCCTACTTGCACTGGGTTCCAATAAGAATCCAAGA                   AACAAAGACATTTTAGATAAGATAAAATCTAAAGCCAAGGAAACAAAAAGAAATGATG                   ATAAGGGAGATCATACCTACCGGCTCATTAGTGTTGTCAGCCATCTTGGGAACACTCT                   AAACTCACCCCATTATATCTGTGATCCCTATCACTTTCACAAACACATCTCCTTCACT                   TACGATGATATCCCGGTGTTACCTATCCAGGAGGCCCAGATGCAGGAGGATAGGCCTT                   GCACTGGGTACATCTTCTTTTACATGCATAATGAGATCTTTGAAGAGATGTTGAAAAG                   AGAAGAGAATGCCCAGCTTAATAGCAAGGAGGTAGAGGAGACCCTTCAGAAGGAA TAA                       GAGGAACGTACTCCTCCTTGTACAGATCTCCCTGACTGTCTCACTCGATACCACTTCC                       TCCATGGAAGGAAAACTGTGAACTTTATCCAGAGATGAAAATGCAATTAGTCTAGGAC                       CAAAGGTCAAACAGAAACACTTAATGGGGAGATCTGCATTCTAATCC                                           ORF Start: ATG at 101       ORF Stop: TAA at 2840           SEQ ID NO:340   913 aa   MW at 104046.0 kD                     NOV122a,   MAALFLRGFVQIGNCKTGISKSKEAFIEAVERKKKDRLVLYFKSGKYSTFRLSDNIQN       CG59746-01 Protein       Sequence   VVLKSYRGNQNHLHLTLQNNNGLFIEGLSSTDAEQLKIFLDRVHQNEVQPPVRPGKGG                   SVFSSTTQKEINKTSFHKVDEKSSSKSFEIAKGSGTGVLQRMPLLTSKLTLTCGELSE                   NQHKKRKRMLSSSSEMNEEFLKENNSVEYKKSKADCSRCVSYNREKQLKLKELEENKK                   LECESSCIMNATGNPYLDDIGLLQALTEKMVLVFLLQQGYSDGYTKWDKLKLFFELFP                   EKICHGLPNLGNTCYMNAVLQSLLSIPSFADDLLNQSFPWGKIPLNALTMCLARLLFF                   KDTYNIEIKEMLLLNLKKAISAAAEIFHGNAQNDAHEFLAHCLDQLKDNMEKLNTIWK                   PKSEFGEDNFPKQVFADDPDTSGFSCPVITNFELELLHSIACKACGQVILKTELNNYL                   SINLPQRIKAHPSSIQSTFDLFFGAEELEYKCAKCEHKTSVGVHSFSRLPRILIVHLK                   RYSLNEFCALKKNDQEVIISKYLKVSSHCNEGTRPPLPLSEDGEITDFQLLKVIRKMT                   SGNISVSWPATKESKDILAPHIGSDKESEQKKGQTVFKGASRRQQQKYLGKNSKPNEL                   ESVYSGDRAFIEKEPLAHLMTYLEDTSLCQFHKAGGKPASSPGTPLSKVDFQTVPENP                   KRKKYVKTSKFVAFDRIINPTKDLYEDKNIRIPERFQKVSEQTQQCDGMRICEQAPQQ                   ALPQSFPKPGTQGHTKNLLRPTKLNLQKSNRNSLLALGSNKNPRNKDILDKIKSKAKE                   TKRNDDKGDHTYRLISVVSHLGKTLKSGHYICDAYDFEKQIWFTYDDMRVLGIQEAQM                   QEDRRCTGYIFFYMHNEIFEEMLKREENAQLNSKEVEETLQKE                  
 
     [0963] Further analysis of the NOV122a protein yielded the following properties shown in Table 122B.  
               TABLE 122B                       Protein Sequence Properties NOV122a                                        PSort   0.7000 probability located in nucleus; 0.4270 probability       analysis:   located in mitochondrial matrix space; 0.3000 probability           located in microbody (peroxisome); 0.1047 probability located           in mitochondrial inner membrane       SignalP   Likely cleavage site between residues 16 and 17       analysis:                  
 
     [0964] A search of the NOV122a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 122C.  
               TABLE 122C                          Geneseq Results for NOV122a                                         NOV122a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAU07888   Polypeptide sequence for human    1 . . . 913   913/913 (100%)   0.0           hspG25- Homo sapiens , 913 aa.    1 . . . 913   913/913 (100%)           [WO200166752-A2, 13 SEP. 2001]       AAB75607   Human cancer associated antigen    1 . . . 905   429/920 (46%)   0.0           precursor HOM-TES-84/6 SEQ ID    1 . . . 904   566/920 (60%)           NO: 6- Homo sapiens , 912 aa.           [WO200100874-A2, 4 JAN. 2001]       AAU07869   Polypeptide sequence for    1 . . . 904   335/921 (36%)    e−147           mammalian Spg25-Mammalia,    1 . . . 834   504/921 (54%)           835 aa. [WO200166752-A2,           13 SEP. 2001]       AAG75460   Human colon cancer antigen   810 . . . 912    61/105 (58%)   3e−28           protein SEQ ID NO: 6224- Homo      3 . . . 107    79/105 (75%)             sapiens , 109 aa. [WO200122920-           A2, 5 APR. 2001]       AAB39364   Gene 8 human secreted protein   810 . . . 871    39/64 (60%)   5e−15           homologous amino acid sequence    1 . . . 64    48/64 (74%)           #113- Bos taurus , 64 aa.           [WO200057903-A2, 5 OCT. 2000]                  
 
     [0965] In a BLAST search of public sequence databases, the NOV122a protein was found to have homology to the proteins shown in the BLASTP data in Table 122D.  
               TABLE 122D                          Public BLASTP Results for NOV122a                                         NOV122a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q9BXU7   Ubquitin carboxyl-terminal    1 . . . 913   913/913 (100%)   0.0           hydrolase 26 (EC 3.1.2.15)    1 . . . 913   913/913 (100%)           (Ubiquitin thiolesterase 26)           (Ubiquitin-specific processing           protease 26) (Deubiquitinating           enzyme 26)- Homo sapiens             (Human), 913 aa.       Q9HBJ7   UBIQUITIN-SPECIFIC    1 . . . 905   429/920 (46%)   0.0           PROCESSING PROTEASE- Homo      1 . . . 904   566/920 (60%)             sapiens  (Human), 922 aa.       Q9HCH8   KIAA1594 PROTEIN- Homo     50 . . . 912   393/932 (42%)   e−171             sapiens  (Human), 931 aa (fragment).    3 . . . 929   535/932 (57%)       Q99MX1   Ubiquitin carboxyl-terminal    1 . . . 904   335/921 (36%)   e−147           hydrolase 26 (EC 3.1.2.15)    1 . . . 834   504/921 (54%)           (Ubiquitin thiolesterase 26)           (Ubiquitin-specific processing           protease 26) (Deubiquitinating           enzyme 26)- Mus musculus             (Mouse), 835 aa.       Q9ES63   UBIQUITIN-SPECIFIC    1 . . . 908   341/933 (36%)   e−131           PROCESSING PROTEASE- Mus      1 . . . 848   480/933 (50%)             musculus  (Mouse), 869 aa.                  
 
     [0966] PFam analysis predicts that the NOV122a protein contains the domains shown in the Table 122E.  
               TABLE 122E                          Domain Analysis of NOV122a                                     Identities/           Pfam   NOV122a   Similarities for   Expect       Domain   Match Region   the Matched Region   Value               UCH-1:   295 . . . 326   21/32 (66%)   8.8e−12       domain 1 of 1       29/32 (91%)       UCH-2:   820 . . . 885   20/72 (28%)   2.2e−11       domain 1 of 1       47/72 (65%)                  
 
     Example 123  
     [0967] The NOV123 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 123A.  
               TABLE 123A                       NOV123 Sequence Analysis                                                SEQ ID NO:341   2146 bp                      NOV123a,     GAAGGAGCGGGC   ATG AGGCGCTGCCCGTGCCGTGGGAGCCTGAACGAGGCGGAGGCCG       CG88613-01 DNA Sequence           GGGCGCTGCCCGCGGCGGCCCGCATGGGACTGGAGGCGCCGCGAGGAGGGCGCCGGCG                   GCAGCCGGGACAGCAGCGACCTGGGCCCGGCGCAGGGGCCCCGGCGGGGCGGCCGGAG                   GGGGGCGGGCCCTGGGCCCGGACACAGGGGTCCAGCCTCCACAGCGAGCCTGAGAGGG                   CCGGCCTCGGGCCTGCGCCGGGGACAGAGAGTCCGCAGGCAGAATTCTGGACAGACGG                   ACAGACTGAGCCCGCGGCAGCTGGCCTTGGAGTAGAGACCGAGAGGCCCAAGCAAAAG                   ACGGAGCCAGACAGGTCCAGCCTCCGGACGCATCTAGAATGGAGCTGGTCAGAGCTGG                   AGACGACTTGTCTTTGGACGGAGACCGGGACAGATGGCCTTTGGACTGATCCCCACAC                   GTCCGACCTCCAGTTTCAGCCCGAGGAGGCCAGCCCCTGGACACAGCCAGGGGTTCAT                   GGGCCCTGGACAGAGCTGGAAACGCATGCCTCACAGACTCAGCCAGAGAGGGTCAAGT                   CCTGGGCTGATAACCTCTGGACCCACCAGAACAGTTCCAGCCTCCAGACTCACCCAGA                   AGGAGCCTGTCCCTCAAAAGAGCCAAGTGCTGATGGCTCCTGGAAAGAATTGTATACT                   GATGGCTCCAGGACACAACAGGATATTGAAGGTCCCTGGACAGACCCATATACTGATG                   GCTCCCAGAAAAAACAGGATACTGAAGCAGCCAGGAAACAGCCTGGCACTGGTGGTTT                   CCAAATACAACAGGATACTGATGGCTCCTGGACACAACCTAGCACTGACGGTTCCCAG                   ACAGCACCTCGGACAGACTGCCTCTTCGGAGAGCCTCAGGATGGCCCATTAGAGGAAC                   CAGAGCCTGGAGAATTCCTCACTCACCTGTACTCTCACCTGAAGTGTAGCCCCCTGTG                   CCCTGTGCCCCGCCTCATCATTACCCCTGAGACCCCTCAGCCTGAGGCCCAGCCAGTG                   GGACCCCCCTCCCGGGTTGAGGGGGGCAGCGGCGGCTTCTCCTCTGCCTCTTCTTTCG                   ACGAGTCTGAGGATGACGTGGTCGCCGGGGGCGGAGGTGCCAGCGATCCCGAGGACAG                   GTCTGGGAGCAAACCCTGGAAGAAGCTGAAGACAGTTCTGAAGTATTCACCCTTTGTG                   GTCTCCTTCCGAAAACACTACCCTTGCGTCCAGCTTTCTGGACATGCTGGGAACTTCC                   AGGCAGGAGAGGATGGTCGCATTCTGAAACCTTTCTGTCAGTGTGACCAGCGCAGCCT                   GGAGCAGCTGATGAAAGACCCGCTGCGACCTTTCGTGCCTGCCTACTATGGCATGGTG                   CTGCAGGATGGCCAGACCTTCAACCAGATGGAAGACCTCCTGCCTGACTTTGAGGGCC                   CCTCCATTATGGACTGCAACATGGGCAGCAGCACCTATCTGGAAGAGGAGCTAGTGAA                   GGCACGGCAACGTCCCCGTCCCCGGAAGGACATCTATGAGAAGATGGTGGCTGTGGAC                   CCTGGGGCCCCTACCCCTGAGGAGCATGCCCAGCGTGCAGTCACCAAGCCCCGCTACA                   TGCAGTGGAGGGAAACCATGAGCTCCACCTCTACCCTGGGCTTCCGGATCGAGGGCAT                   CAAGAAGCCAGATGGGACCTGTAACACCAACTTCAAGAAGACGCAGGCACTGGAGCAG                   GTGACAAAAGTGCTGGAGGACTTCGTGGATGGAGACCACGTCATCCTGCAAAAGTACG                   TGGCATGCCTAGAAGAACTTCGTGAAGCTCTGCAGATCTCCCCCTTCTTCAAGACCCA                   CGAGGTGGTAGGCAGCTCCCTCCTCTTCGTGCACGACCACACCGGCCTGGCCAAGGTC                   TGGATGATAGACTTCGGCAAGACGGTGGCCTTGCCCGACCACCAGACGCTCAGCCACA                   GGCTGCCCTGGGCTGAGGGCAACCGTGAGGACGGCTACCTCTGGGGCCTGGACAACAT                   GATCTGCCTCCTGCAGGGGCTGGCACAGAGC TGA   GCTGCTCAGCCACCATCAGGTTAA                       TTGGATGGCGCCAGTCTGGCTGGAGGAGCCCTGAGATGCCATGGGAGGCCTGAGGTTG                                           ORF Start: ATG at 13       ORF Stop: TGA at 2062           SEQ ID NO:342   683 aa   MW at 75206.8 kD                     NOV123a,   MRRCPCRGSLNEAEAGALPAAARMGLEAPRGGRRRQPGQQRPGPGAGAPAGRPEGGGP       CG88613-01 Protein Sequence           WARTEGSSLHSEPERAGLGPAPGTESPQAEFWTDGQTEPAAAGLGVETERPKQKTEPD                   RSSLRTHLEWSWSELETTCLWTETGTDGLWTDPHRSDLQFQPEEASPWTQPGVHGPWT                   ELETHGSQTQPERVKSWADNLWTHQNSSSLQTHPEGACPSKEPSADGSWKELYTDGSR                   TQQDIEGPWTEPYTDGSQKKQDTEAARKQPGTGGFQIQQDTDGSWTQPSTDGSQTAPG                   TDCLLGEPEDGPLEEPEPGELLTHLYSHLKCSPLCPVPRLIITPETPEPEAQPVGPPS                   RVEGGSGGFSSASSFDESEDDVVAGGGGASDPEDRSGSKPWKKLKTVLKYSPFVVSFR                   KHYPWVQLSGHAGNFQAGEDGRILKRFCQCEQRSLEQLMKDPLRPFVPAYYGMVLQDG                   QTFNQMEDLLADFEGPSIMDCKMGSRTYLEEELVKARERPRPRKDMYEKMVAVDPGAP                   TPEEHAQGAVTKPRYMQWRETMSSTSTLGFRIEGIKKADGTCNTNFKKTQALEQVTKV                   LEDFVDGDHVILQKYVACLEELREALEISPFFKTHEVVGSSLLFVHDHTGLAKVWMID                   FGKTVALPDHQTLSHRLPWAEGNREDGYLWGLDNMICLLQGLAQS                  
 
     [0968] Further analysis of the NOV123a protein yielded the following properties shown in Table 123B.  
               TABLE 123B                       Protein Sequence Properties NOV123a                                        PSort   0.5663 probability located in microbody (peroxisome); 0.3000       analysis:   probability located in nucleus; 0.1000 probability located in           mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0969] A search of the NOV123a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 123C.  
               TABLE 123C                          Geneseq Results for NOV123a                                         NOV123a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAM41393   Human polypeptide SEQ ID NO    1 . . . 683   682/683 (99%)   0.0           6324- Homo sapiens , 687 aa.    5 . . . 687   682/683 (99%)           [WO200153312-A1, 26 JUL. 2001]       AAM39607   Human polypeptide SEQ ID NO    12 . . . 683   642/680 (94%)   0.0           2752- Homo sapiens , 711 aa.    36 . . . 711   643/680 (94%)           [WO200153312-A1, 26 JUL. 2001]       AAE04364   Human kinase (PKIN)-5- Homo     273 . . . 682   219/432 (50%)   e−117             sapiens , 798 aa. [WO200146397-   380 . . . 793   285/432 (65%)           A2, 28 JUN. 2001]                  
 
     [0970] In a BLAST search of public sequence databases, the NOV123a protein was found to have homology to the proteins shown in the BLASTP data in Table 123D.  
               TABLE 123D                          Public BLASTP Results for NOV123a                                         NOV121a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               Q96DU7   INOSITOL 1,4,5-    1 . . . 683   683/683 (100%)   0.0           TRISPHOSPHATE 3-KINASE C-    1 . . . 683   683/683 (100%)             Homo sapiens  (Human), 683 aa.       Q9Y475   INOSITOL 1,4,5-    83 . . . 683   601/601 (100%)   0.0           TRISPHOSPHATE 3-KINASE    4 . . . 604   601/601 (100%)           ISOENZYME (EC 2.7.1.127)-             Homo sapiens  (Human), 604 aa           (fragment).       S17682   1D-myo-inositol-trisphosphate 3-   273 . . . 682   219/432 (50%)   e−117           kinase (EC 2.7.1.127) B-human,    54 . . . 467   285/432 (65%)           472 aa.       CAB65055   INOSITOL 1,4,5-   273 . . . 682   219/432 (50%)   e−117           TRISPHOSPHATE 3-KINASE B-   528 . . . 941   285/432 (65%)             Homo sapiens  (Human), 946 aa.       Q96JS1   INOSITOL 1,4,5-   273 . . . 682   219/432 (50%)   e−117           TRISPHOSPHATE 3-KINASE,   528 . . . 941   285/432 (65%)           ISOFORM B (EC 2.7.1.127)-             Homo sapiens  (Human), 946 aa.                  
 
     [0971] PFam analysis predicts that the NOV123a protein contains the domains shown in the Table 123E.  
               TABLE 123E                          Domain Analysis of NOV123a                                             Identities/               Pfam   NOV123a   Similarities for   Expect           Domain   Match Region   the Matched Region   Value                             No Significant Matches Found                  
 
     Example 124  
     [0972] The NOV124 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 124A.  
               TABLE 124A                       NOV124 Sequence Analysis                                                SEQ ID NO:343   1395 bp                     NOV124a,     GGTAAGACGACCTCTGGATGCTCACCCTGCCCTCTTCACCTCTCGTCCCCAGCTGTTT         CG59993-01 DNA Sequence             CCTCTGCCACC   ATG AGGAACATTTTCAAGAGGAACCAGGAGCCTATTGTGCCTCCTGC                   CACCACCACCGCCACGATGCCCATTGGACCCGTCGACAACTCCACTGAGAGTGCCGCT                   TAAACAAGATTCCCTTACCACCCTGGGCACTGATCGCCATTGCTCTGGTTGCTGGGCT                   CCTGCTTCTCACCTGCTGCTTCTGCATCTGCAAGAAATGCTGCTGCAAGAAGAAGAAG                   AACAAGAAGGAGAAGGCCAAAGGCATGAAGAATGCCATGAACATGAAGGACATGAAAG                   GGGGTCAGGATGACGACGACGCAGAGACACGCCTCACTGAGGGGGAAGGTGAAGGGGA                   GGAGGAGAAAGAGCCAGAGAACCTGGGCAAACTGCAGTTTTCCCTGGACTATGATTTT                   CAGGCTAATCAGCTTACTGTGGGCGTTCTGCAGGCTGCTGAACTGCCTGCCCTGGACA                   TGGGAGGCACCTCAGACCCTTATGTCAAGGTCTTCCTCCTTCCTGACAAGAAGAAGAA                   ATATGAGACCAAACTCCATCGGAAGACACTGAACCCTGCCTTCAATGAAACCTTCACC                   TTCAAGGTGCCATACCAGGAGCTTGGGGGCAAAACTCTGGTGATGGCCATCTATGACT                   TTGACCGCTTCTCCAAACATGACATCATTGCAGAGGTAAAGGTGCCTATCAACACAGT                   GGACCTCGGCCAGCCCATTGAGGAGTGGAGAGACCTGCAAGGCGGGGAAAAGCAGGAG                   CCGGAGAAGCTCGGCGACATCTGCACCTCCCTGCGCTATGTGCCCACGGCCGGGAAGC                   TCACTGTCTGCATCCTGGAGGCTAAGAACCTCAAGAAGATGGACGTGGGCGGCCTTTC                   AGACCCGTACGTGAAGATCCACCTGATGCAGAATGGCAAGAGGCTCAAGAAGAAGAAG                   ACAACCGTGAAGAAGAAGACCCTGAACCCATACTTCAACGAGTCCTTCAGCTTTGAGA                   TCCCCTTCGAGCAGATTCACAAAGTCCAGGTAGTCGTCACCGTGCTGGACTATGACAA                   GCTGCGCAAGAACGAAGCCATACGCAAGATCTTCGTGGGCAGCAATGCCACGGGCACA                   GAGCTGCGGCACTGGTCCGAGATGCTGGCCAACCCCCGGAGGCCCATCGCCCAGTGGC                   ACTCGCTCAAGCCTGAGGACGAGGTGCATGCACTCCTGGGCAACAACAAG TAG   ACAGC                       AGCGGCTGGGACCCCACACCTTTCACGGACACTGACAAGATCCAGAGCTATCAATACC                       TCA                                           ORF Start: ATG at 70       ORF Stop: TAG at 1327           SEQ ID NO:344   419 aa   MW at 46871.8 kD                     NOV124a,   MRNIFKRNQEPIVAPATTTATMPIGPVDNSTESGGAGESQEDMFAKLKEKLFNEINKI       CG59993-01 Protein Sequence           PLPPWALIAIAVVAGLLLLTCCFCICKKCCCKKKKNKKEKGKGMKNAMNMKDMKGGQD                   DDDAETGLTEGEGEGEEEKEPENLGKLQFSLDYDFQANQLTVGVLQAAELPALDMGGT                   SDPYVKVFLLPDKKKKYETKVHRKTLNPAFNETFTFKVPYQELGGKTLVMAIYDFDRF                   SKHDIIGEVKVPMNTVDLGQPIEEWRDLQGGEKEEPEKLGDICTSLRYVPTAGKLTVC                   ILEAKNLKKMDVGGLSDPYVKIHLMQNGKRLKKKKTTVKKKTLNPYFNESFSFEIPFE                   QIQKVQVVVTVLDYDKLGKNEAIGKIFVGSNATGTELRHWSDMLANPRRPIAQWHSLK                   PEEEVDALLGKNK                                     SEQ ID NO:345   1338 bp                     NOV124b,     CCACC   ATG AGGAACATTTTCAAGACGAACCAGGAGCCTATTGTGGCTCCTCCCACCAC       CG59993-02 DNA Sequence           CACCGCCACGATGCCCATTGGACCCGTGGACAACTCCACTGAGAGTGGGGGTGCTGGG                   GAGAGTCAGGAGGACATCTTTGCCAAACTGAACGAGAAGTTATTCAATGAGATAAACA                   AGATTCCCTTACCACCCTGGGCACTGATCGCCATTGCTGTGGTTGCTGGGCTCCTGCT                   TCTCACCTGCTGCTTCTGCATCTGCAAGAAATGCTGCTGCAAGAAGAAGAAGAACAAG                   AAGGAGAAGGGCAAAGGTATGAAGAATGCCATGAACATGAAGGACATGAAAGGGGGTC                   AGGATGACGACGACGCAGAGACAGGCCTCACTGAGGGGGAAGGTGAAGGGGAGGAGGA                   AATCAGCTTACTGTGGGCCTTCTGCAGGCTGCTGAACTGCCTGCCCTGCACATGGGAG                   GCACCTCACACCCTTATGTCAAGGTCTTCCTCCTTCCTGACAAGAAGAAGAAATATGA                   GACCAAAGTCCATCGGAAGACACTGAACCCTGCCTTCAATGAAACCTTCACCTTCAAG                   GTCCCATACCAGGAGCTTGGGGGCAAAACTCTGGTCATGGCCATCTATGACTTTGACC                   GCTTCTCCAAACATGACATCATTGCAGAGGTAAAGGTGCCTATGAACACAGTGGACCT                   CGGCCAGCCCATTGAGGAGTGGAGAGACCTGCAAGGCGGCGAAAAGGAGGAGCCGGAG                   AAGCTGGGCGACATCTGCACCTCCCTGCGCTATGTGCCCACGGCCGGGAAGCTCACTG                   TCTGCATCCTGGAGGCTAAGAACCTCAAGAAGATGGACCTGGGCGGCCTTTCAGACCC                   ATGAACAAGAAGACCCTGAACCCATACTTCAACGAGTCCTTCAGCTTTGACATCCCCT                   TCCAGCAGATTCAGAAACTCCAGGTAGTGGTCACCGTGCTGGACTATGACAAGCTGGG                   CAAGAACGAAGCCATAGGCAAGATCTTCGTGGGCAGCAATGCCACGGGCACACAGCTG                   CGGCACTGGTCCGACATGCTGGCCAACCCCCGGAGGCCCATCGCCCAGTGGCACTCGC                   TCAAGCCTGAGGAGGAGGTGGGTGCACTCCTGGGCAAGAACAAG TAG   ACAGCAGCGGC                       TGGGACCCCACACCTTTCACGGACACTGACAAGATCCAGAGCTATCAATAAGGTGTAG                       GCGG                                           ORF Start: ATG at 6       ORF Stop: TAG at 1263           SEQ ID NO:346   419 aa   MW at 46845.9 kD                     NOV124b,   MRNIFKRNQEPIVAPATTTATMPIGPVDNSTESGGAGESQEDMFAKLKEKLFNEINKI       CG59993-02 Protein Sequence           PLPPWALIAIAVVAGLLLLTCCFCICKKCCCKKKKNKKEKGKGMKNAMNMKDMKGGQD                   DDDAETGLTEGEGEGEEEKEPENLGKLQFSLDYDFQANQLTVGVLQAAELPALDMGGT                   SDPYVKVFLLPDKKKKYETKVHRKTLNPAFNETFTFKVPYQELGGKTLVMAIYDFDRF                   SKHDIIGEVKVPMNTVDLGQPIEEWRDLQGGEKEEPEKLGDICTSLRYVPTAGKLTVC                   ILEAKNLKKMDVGGLSDPYVKIHLMQNGKRLKKKKTTVKKKTLNPYFNESFSFEIPFE                   QIQKVQVVVTVLDYDKLGKNEAIGKIFVGSNATGTELRHWSDMLANPRRPIAQWHSLK                   PEEEVDALLGKNK                  
 
     [0973] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 124B.  
               TABLE 124B                          Comparison of NOV124a against NOV124b.                                         Identities/           Protein   NOV124a Residues/   Similarities for           Sequence   Match Residues   the Matched Region                       NOV124b   1 . . . 419   335/419 (79%)               1 . . . 419   335/419 (79%)                      
 
     [0974] Further analysis of the NOV124a protein yielded the following properties shown in Table 124C.  
               TABLE 124C                       Protein Sequence Properties NOV124a                                        PSort   0.8202 probability located in mitochondrial inner       analysis:   membrane; 0.6000 probability located in endoplasmic           reticulum (membrane); 0.3500 probability located in           nucleus; 0.3034 probability located in mitochondrial           intermembrane space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0975] A search of the NOV124a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 124D.  
               TABLE 124D                          Geneseq Results for NOV124a                                         NOV124a                   Protein/Organism/   Residues/   Identities/       Geneseq   Length [Patent #,   Match   Similarities for   Expect       Identifier   Date]   Residues   the Matched Region   Value               AAR97722   Mouse inositol polyphosphate    1 . . . 419   412/422 (97%)   0.0           binding protein IP4-BP- Mus      1 . . . 422   414/422 (97%)             musculus , 422 aa. [JP08092290-A,           9 APR. 1996]       AAU19715   Human novel extracellular matrix   128 . . . 405   141/280 (50%)   2e−80           protein, Seq ID No 365- Homo     169 . . . 447   201/280 (71%)             sapiens , 461 aa. [WO200155368-           A1, 2 AUG. 2001]       AAU19714   Human novel extracellular matrix   141 . . . 409   140/273 (51%)   3e−74           protein, Seq ID No 364- Homo      11 . . . 281   193/273 (70%)             sapiens , 295 aa. [WO200155368-           A1, 2 AUG. 2001]       AAW87702   A human membrane fusion protein    59 . . . 407   146/352 (41%)   4e−73           designated SYTAX2- Homo      31 . . . 364   220/352 (62%)             sapiens , 375 aa. [WO9856813-A2,           17 DEC. 1998]       AAO05534   Human polypeptide SEQ ID NO    33 . . . 164   127/135 (94%)   5e−70           19426- Homo sapiens , 149 aa.    15 . . . 149   131/135 (96%)           [WO200164835-A2, 7 SEP. 2001]                  
 
     [0976] In a BLAST search of public sequence databases, the NOV124a protein was found to have homology to the proteins shown in the BLASTP data in Table 124E.  
               TABLE 124E                          Public BLASTP Results for NOV124a                                         NOV124a               Protein       Residues/   Identities/       Accession       Match   Similarities for   Expect       Number   Protein/Organism/Length   Residues   the Matched Portion   Value               P29101   Synaptotagmin II (SytII)- Rattus      1 . . . 419   411/422 (97%)   0.0             norvegicus  (Rat), 422 aa.    1 . . . 422   414/422 (97%)       A55417   synaptotagmin II-mouse, 422 aa.    1 . . . 419   412/422 (97%)   0.0                1 . . . 422   414/422 (97%)       P46097   Synaptotagmin II (SytII)- Mus      1 . . . 419   411/422 (97%)   0.0             musculus  (Mouse), 422 aa.    1 . . . 422   413/422 (97%)       P24506   Synaptotagmin B (Synaptic vesicle,   10 . . . 419   341/413 (82%)   0.0           protein O-P65-B)- Discopyge     27 . . . 439   366/413 (88%)             ommata  (Electric ray), 439 aa.       P46096   Synaptotagmin I (SytI) (p65)-   10 . . . 419   323/418 (77%)   0.0             Mus musculus  (Mouse), 421 aa.    8 . . . 421   353/418 (84%)                  
 
     [0977] PFam analysis predicts that the NOV124a protein contains the domains shown in the Table 124F.  
               TABLE 124F                          Domain Analysis of NOV124a                                     Identities/                   Similarities       Pfam   NOV124a   for the   Expect       Domain   Match Region   Matched Region   Value               Adeno_E3_CR2:    62 . . . 108   16/50 (32%)   6.5       domain 1 of 1       26/50 (52%)       C2: domain 1 of 2   156 . . . 242   54/97 (56%)   1.8e−42               81/97 (84%)       C2: domain 2 of 2   287 . . . 375   44/97 (45%)   2.9e−39               80/97 (82%)                  
 
     Example 125  
     [0978] The NOV125 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 125A.  
               TABLE 125A                       NOV125 Sequence Analysis                                                SEQ ID NO:347   3226 bp                     NOV125a,     GGACCACTTCTGATGCATCTCTGGGTCCCAACACTATCCACTGCAAGGCCTCGAAACA         CG59991-01 DNA Sequence             GGGGGGCCAG   ATG GCACCCCCATTTAGCACAAGAGACACGTCCACACTCTGTGAGCCC                   AAAGGGAGAAGGCTCAGGCCACGGCAGAGACGGAACCAGGAAAACGTCACGAAAAACA                   GCCTCAAGTTGCCAGGTCCCTTGCAGGAACAGACAGGCCTGGGGCCGCCCCACCTGGG                   CTCAGAGCTTGCGCTGCATCCAGGTGACACATGGGACTACAACAGTCACGTGATGACC                   AAATTCGCTGAGGAGGAGGATGTACGTCGTAGTTTTGAAAACACTGCTGCTGACTGGC                   CGGAAATGCAAACGTTCGCTGGTCCTTTTGATTCAGACCGGTGGGCCTTCCGGCCTCG                   CACGGTGGTTCTGCACGGAAAGTCAGGAATTGGGAAATCGGCTCTAGCCAGAAGGATC                   GTGCTGTGCTGGGCGCAAGGTGGACTCTACCAGGGAATGTTCTCCTACGTCTTCTTCC                   TCCCCGTTAGAGAGATGCAGCGGAAGAACGAGAGCAGTGTCACAGAGTTCATCTCCAG                   GGAGTGGCCAGACTCCCAGGCTCCGGTGACGGAGATCATGTCCCGACCAGAAAGGCTG                   TTGTTCATCATTGACGGTTTCGATGACCTGGGCTCTGTCCTCAACAATGACACAAAGC                   TCTGCAAAGACTGGGCTGAGAACCAGCCTCCGTTCACCCTCATACGCAGTCTGCTGAG                   GAAGGTCCTGCTCCCTGAGTCCTTCCTGATCGTCACCGTCAGAGACGTGGGCACAGAG                   CTTGCGTGCGATCATCAACAACCGTGAGCTCCTCCACCAGTGCCAGCTGCCCGCCGTC                   TGCCGTATGGCTGTGGAGGGAGTGTGGAATAGCAAGTCAGTGTTTGACGGTGACGACC                   TCATCGTTCAAGGACTCGCCGAGTCTGAGCTCCGTCCTCTCTTTCACATGAACATCCT                   TCTCCCAGACAGCCACTGTGAGGAGTACTACACCTTCTTCCACCTCAGTCTCCAGGAC                   TTCTGTGCCGCCTTGTACTACGTGTTAGAGGGCCTGGAAATCGAGCCAGCTCTCTGCC                   CTCTCTACGTTGAGAAGACAAAGAGGTCCATGGAGCTTAAACAGGCAGGCTTCCATAT                   CCACTCCCTTTGGATGAAGCCTTTCTTGTTTGGCCTCGTCACCGAAGACGTAAGGAGG                   CCACTGGAGGTCCTGCTGGGCTGTCCCGTTCCCCTGGGGGTGAAGCAGAAGCTTCTGC                   ACTGGGTCTCTCTGTTGGGTCAGCAGCCTAATGCCACCACCCCAGGAGACACCCTGGA                   CGCCTTCCACTGTCTTTTCCAGACTCAAGACAAAGAGTTTGTTCGCTTGGCATTAAAC                   AGCTTCCAACAACTGTGGCTTCCGATTAACCAGAACCTGGACTTGATAGCATCTTCCT                   TCTGCCTCCAGCACTGTCCGTATTTGCGGAAAATTCGGGTGGATGTCAAAGGCATCTT                   CCCAAGAGATGAGTCCCCTCAGGCATGTCCTCTGGTCCCTCTATGGATGCCGGATAAG                   ACCCTCATTGAGGAGCACTCCCAAGATTTCTGCTCCATGCTTGGCACCCACCCACACC                   TGCCAAGCTGAGGCATCCCACCTCCAACATACAGACCCTGATGTTTAGAAATGCACAG                   ATTACCCGTGCTGTCCAGCACCTCTGCAGAATCCTCATCGCCAACCGTAACCTAAGAT                   CCCTCAACTTCGGAGGCACCCACCTCAACGAAGAGGATGTAAGGATGCCCTGTGAACC                   CTTAAAACACCCAAAATGTTTGTTGGAGTCTTTGAGGCTGGATTCCTGTGGATTGACC                   CATGCCTGTTACCTGAACATCTCCCAAATCCTTACGACCTCCCCCAGCCTCAAATCTC                   TGAGCCTGGCACGAAACAAGGTGACACACCACGGAGTAATGCCTCTCAGTCATGCCTT                   GACACTCTCCCAGTGCGCCCTCCACAAGCTGATACTGGAGCACTCTGGCATCACACCC                   ACGGGTTGCCAGAGTCTCGCCTCAGCCCTCGTCAGCAACCGGAGCTTGACACACCTGT                   CCCTATCCAACAACACCCTGCCGAACGAAGGTGTAAATCTACTCTCTCGATCCATGAG                   GCTTCCCCACTGTAGTCTGCACAGGCTGATGCTGAATCAGTGCCACCTGGACACGGCT                   GGCTGTGCTTTTCTTGCACTTCCCCTTATGGGTAACTCATGCCTCACGCACCTGAGCC                   TTAGCATGAACCCTCTGGAAGACAATGGCCTCAACCTTCTGTGCCAGCTCATGAGAGA                   ACCATCTTGTCATCTCCACCACCTCCACTTGGTAAAGTCTCATCTCACCGCCCCGTGC                   CGGACAATGCCCTGGGTGACCCTCGCGTTCCTGCACTGTGCCAGCCACTGAAGCAAAA                   CAACACTGTTCTGACCACACTCGGGTTGAAGCCATGTCCACTGACTTCTCATTGCTGT                   GAGGCACTCTCCTTCCCCCTTTCCTCCAACCGGCATCTGACCAGTCTAAACCTGCTGC                   AGAATAACTTCACTCCCAAAGGAATGATCAAGCTCTGTTCGGCCTTTCCCTGTCCCAC                   GTCTAACTTACACATAATTCGCCTGTGGAAATGGCAGTACCCTGTCCAAATAACCAAG                   CTGCTCCACCAAGTGCAGCTACTCAACCCCCGAGTCGTAATTCACGGTAGTTCGCATT                   CTTTTCATCAACATGACCGGTACTGGTGGAAAAAC TGA   ACATACCCAAACCTGCCCCA                       CTCACACCCATCTGATGGAGGAACTTTAAACCCTGT                                           ORF Start: ATG at 69       ORF Stop: TGA at 3168           SEQ ID NO:348   1033 aa   MW at 116310.7 kD                     NOV125a,   MGPPFSTRETSTLCEPKGRRLRPRQRRNQENVTKNSLKLPGPLQEQTGLGPPHLGSEL       CG59991-01 Protein       Sequence   GLHGGDTWDYKSHVMTKFAEEEDVRRSFENTAADWPEMQTLAGAFDSDRWGFRPRTVV                   LHGKSGIGKSALARRIVLCWAQGGLYQGMFSYVFFLPVREMQRKKESSVTEFISREWP                   DSQAPVTEIMSRPERLLFIIDGFDDLGSVLNNDTKLCKDWAEKQPPFTLIRSLLRKVL                   LPESFLIVTVRDVGTEKLKSEVVSPRYLLVRGISGEQRIHLLLERGIGEHQKTQGLRA                   IMNNRELLDQCQVPAVGSLICVALQLQDVVGESVAPFNQTLTGLHAAFVFHQLTPRGV                   VRRCLNLEERVVLKRFCRMAVEGVWNRKSVFDGDDLMVQGLGESELRALFHMNILLPD                   SHCEEYYTFFHLSLQDFCAALYYVLEGLEIEPALCPLYVEKTKRSMELKQAGFHIHSL                   WMKRFLFGLVSEDVRRPLEVLLGCPVPLGVKQKLLHWVSLLGQQPNATTPGDTLDAFH                   CLFETQDKEFVRLALNSFQEVWLPINQNLDLIASSFCLQHCPYLRKIRVDVKGIFPRD                   ESAEACPVVPLWMRDKTLIEEQWEDFCSMLGTHPHLRQLDLGSSILTERAMKTLCAKL                   RHPTCKIQTLMFRNAQITPGVQHLWRIVMANRNLRSLNLGGTHLKEEDVRMACEALKH                   PKCLLESLRLDCCFLTHACYLKISQILTTSPSLKSLSLAGNKVTDQGVMPLSDALRVS                   QCALQKLILEDCGITATGCQSLASALVSNRSLTHLCLSNNSLGNEGVNLLCRSMRLPH                   CSLQRLMLNQCHLDTAGCGFLALALMGNSWLTHLSLSMNPVEDNGVKLLCEVMREPSC                   HLQDLELVKCHLTAACCESLSCVISRSRHLKSLDLTDNALGDGGVAALCEGLKQKNSV                   LTRLGLKACGLTSDCCEALSLALSCNRHLTSLNLVQNNFSPKGMMKLCSAFACPTSNL                   QIIGLWKWQYPVQIRKLLEEVQLLKPRVVIDGSWHSFDEDDRYWWKN                  
 
     [0979] Further analysis of the NOV125a protein yielded the following properties shown in Table 125B.  
               TABLE 125B                       Protein Sequence Properties NOV125a                                        PSort   0.7600 probability located in nucleus; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1000 probability           located in mitochondrial matrix space; 0.1000 probability           located in lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0980] A search of the NOV125a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 125C.  
               TABLE 125C                          Geneseq Results for NOV125a                                         NOV125a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               AAE07514   Human PYRIN-1 protein -  Homo     103 . . . 934   276/843 (32%)    e−126             sapiens , 1034 aa. [WO200161005-    207 . . . 1003   445/843 (52%)           A2, 23 AUG 2001]       AAE07513   Human nucleotide binding site 1   114 . . . 935   281/839 (33%)    e−120           (NBS-1) protein -  Homo sapiens ,   180 . . . 990   431/839 (50%)           1033 aa. [WO200161005-A2,           23 AUG 2001]       AAU07878   Polypeptide sequence for   207 . . . 963   218/766 (28%)   7e−95           mammalian Spg65 - Mammalia,    9 . . . 748   380/766 (49%)           748 aa. [WO200166752-A2,           13 SEP 2001]       AAE06758   Human G-protein coupled receptor-    21 . . . 764   235/772 (30%)   3e−88           8 (GCREC-8) protein -  Homo     219 . . . 959   380/772 (48%)             sapiens , 1473 aa. [WO200157085-           A2, 9 AUG 2001]       AAB62571   Human CARD-7 polypeptide -    21 . . . 764   235/772 (30%)   3e−88           [WO200130813-A1, 3 MAY    219 . . . 959   380/772 (48%)           2001]                  
 
     [0981] In a BLAST search of public sequence databases, the NOV125a protein was found to have homology to the proteins shown in the BLASTP data in Table 125D.  
               TABLE 125D                          Public BLASTP Results for NOV125a                                             Identities/           Protein       NOV125a   Similarities       Accession       Residues/   for the   Expect       Number   Protein/Organism/Length   Match Residues   Matched Portion   Value                                             Q9JLR2   MATERNAL-ANTIGEN-THAT-    24 . . . 1033   548/1019   (53%)   0.0           EMBRYOS-REQUIRE PROTEIN -    104 . . . 1111   716/1019   (69%)             Mus musculus  (Mouse), 1111 aa.       Q9R1M5   MATER PROTEIN -  Mus musculus      24 . . . 1033   547/1019   (53%)   0.0           (Mouse), 1111 aa.    104 . . . 1111   716/1019   (69%)       AAL35293   NALP4 -  Homo sapiens  (Human),    63 . . . 958   291/907   (32%)   e−133           994 aa.    94 . . . 981   473/907   (52%)       Q96MN2   CDNA FLJ32126 FIS, CLONE    63 . . . 958   291/907   (32%)   e−133           PEBLM2000112, WEAKLY    19 . . . 906   473/907   (52%)           SIMILAR TO  HOMO SAPIENS             NUCLEOTIDE-BINDING SITE           PROTEIN 1 MRNA -  Homo               sapiens  (Human), 919 aa.       AAL12497   CRYOPYRIN -  Homo sapiens     103 . . . 934   276/843   (32%)   e−125           (Human), 1034 aa.    207 . . . 1003   445/843   (52%)                  
 
     [0982] PFam analysis predicts that the NOV125a protein contains the domains shown in the Table 125E.  
               TABLE 125E                          Domain Analysis of NOV125a                                     Identities/               NOV125a   Similarities           Match   for the       Pfam Domain   Region   Matched Region   Expect Value               LRR: domain 1 of 6   671 . . . 695    6/25 (24%)   1.6e+02               16/25 (64%)       LRR: domain 2 of 6   728 . . . 752    7/27 (26%)   2.3e+02               17/27 (63%)       LRR: domain 3 of 6   785 . . . 809    7/26 (27%)   1.6e+02               19/26 (73%)       LRR: domain 4 of 6   814 . . . 836    6/25 (24%)   4.3e+02               14/25 (56%)       LRR: domain 5 of 6   899 . . . 923    8/26 (31%)   27               20/26 (77%)       LRR: domain 6 of 6   956 . . . 977    7/25 (28%)   2.9e+02               16/25 (64%)                  
 
     [0983] The NOV126 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 126A.  
               TABLE 126A                       NOV126 Sequence Analysis                                                SEQ ID NO:349   2310 bp                     NOV126a,     CCGCGCCTCAGTCCGCCGTCCGCCCTCCGCGCCCGCGCCGCTAGC   ATG ACCGACGCGC       CG59987-01 DNA Sequence           TGTTGCCCGCGGCCCCCCAGCCGCTGGAGAAGGAGAACGACGGCTACTTTCGGAAGGG                   CTGTAATCCCCTTGCACAAACCGGCCGGAGTAAATTCCAGAATCAAAGAGCTGCTTTG                   AATCAGCAGATCCTGAAAGCCGTGCGGATGAGGACCGGAGCGGAAAACCTTCTGTTTG                   TGGCCACAAACTCAAAGGTGCGGGAGCAAGTGCGGCTGGAGCTGAGCTTCGTCAACTC                   AGACCTGCAGATGCTCAAGGAAGAGCTGGAGGGGCTGAACATCTCGGTGGGCGTCTAT                   CAGAACACAGAGGAGGCATTTACCATTCCCCTGATTCCTCTTGGCCTGAAGGAAACGA                   AAGACGTCGACTTTGCAGTCGTCCTCAAGGATTTTATCCTGGAACATTACAGTGAAGA                   TGGCTATTTATATCAAGATGAAATTGCACATCTTATGGATCTGACACAAGCTTGTCGG                   ACGCCTAGCCGGGATGAGGCCGGGGTGGAACTGCTGATGACATACTTCATCCAGCTGG                   GCTTTGTCGAGAGTCCATTCTTCCCCCCCACACGGCAGATGGGACTCCTGTTCACCTG                   GTATGACTCTCTCACCGGGGTTCCGGTCAGCCAGCAGAACCTGCTGCTGGAGAAGGCC                   AGTGTCCTGTTCAACACTGGGGCCCTCTACACCCAGATTGGGACCCGGTGTGATCGGC                   AGACGCAGGCTGGCCTGGAGAGTGCCATAGATGCCTTTCAGAGAGCCGCAGGGGTTTT                   AAATTACCTGAAAGACACATTTACCCATACTCCAAGTTACGACATGACCCCTGCCATG                   CTCAGCGTGCTCGTCAAAATGATGCTTCCACAAGCCCAAGAAAGCGTGTTTGAGAAAA                   TCAGCCTTCCTGCGATCCGGAATGAATTCTTCATGCTGGTGAAGGTGGCTCAGGAGGC                   AAAGAGAACATCCCCTACTCCTGGGCCAGCTTAGCCTGCGTGAAGGCCCACCACTACG                   CGGCCCTGCCCCACTACTTCACTGCCATCCTCCTCATCCACCACCAGGTGAAGCCAGG                   CACGGATCTGGACCACCAGGAGAAGTGCCTGTCCCAGCTCTACGACCACATGCCAGAG                   GGGCTGACACCCTTGGCCACACTGAAGAATGATCACCACCGCCGACAGCTGGGGAAGT                   CCCACTTGCGCAGAGCCATGGCTCATCACGAGGAGTCGGTGCCGGAGGCCAGCCTCTG                   CAAGAAGCTGCCGAGCATTGAGGTGCTACAGAAGGTGCTGTGTGCCGCACAGGAACGC                   TCCCGGCTCACGTACGCCCACCACCAGGAGGAGGATCACCTGCTGAACCTGATCGACC                   CCCCCAGAGTGTTGTTGCTAAAACTGAGCAAGAGGTTGACATTATATTGCCCCAGTTC                   TCCAGCTGACAGTCACGGACTTCTTCCAGAAGCTGGGCCCTTATCTGTGCTGTCGGCT                   AACAAGCGGTGGACGCCTCCTCGAAGCATCCGCTTCACTGCAGAACAAGGGGACTTGG                   CGTTCACCTTGAGAGGGAACGCCCCCGTTCACCTTCACTTCCTGGATCCTTACTGCTC                   TGCCTCGGTGGCAGCAGCCCGGGAAGGAGATTATATTGTCTCCATTCAGCTTGTGGAT                   TGTAAGTGGCTGACGCTGAGTGAGGTTATGAAGCTGCTGAAGAGCTTTGGCGAGGACG                   AGATCGAAATGAAAGTCGTGAGCCTCCTGGACTCCACATCATCCATGCATAATAAGAG                   TGCCACATACTCCGTGGGAATGCACAAAACGTACTCCATGATCTGCTTAGCCATTCAT                   GATGACGACAAAACTGATAAAACCAAGAAAATCTCCAAGAAGCTTTCCTTCCTGAGTT                   GGCTGCACGGCCTCACGTCAAGAAGAAGCTGCCCTCCCCTTTCAGCCTTCTCAACTCA                   GACACTTCTTGGTAC TAA   TGTGAGGAAACAAACATGTTCAGGCCCCCAACATTTCCGG                       TGCTGACTCGGCCTTAAACGTTTGTGCCATAATGGAAAATATCTATCTATCTGTTCTC                       AAATCCTGTTTTTCTCATAGTGTAAACTCACATTTGATGTGTTTTTATGAAGGAAAGT                       AACCAAGAAACCTCTAGGAATTAGTGAAAAAAGAACTTTTTTGAGGTG                                           ORF Start: ATG at 46       ORF Stop: TAA at 2104           SEQ ID NO:350   686 aa   MW at 76812.3 kD                     NOV126a,   MTDALLPAAPQPLEKENDGYFRKGCNPLAQTGRSKLQNQRAALNQQILKAVRMRTGAE       CG59987-01 Protein Sequence           NLLKVATNSKVREQVRLELSFVNSDLQMLKEELEGLNISVGVYQNTEEAFTIPLIPLG                   LKETKDVDFAVVLKDFILEHYSEDGYLYEDEIADLMDLRQACRTPSRDEAGVELLMTY                   FIQLGFVESRFFPPTRQMGLLFTWYDSLTGVPVSQQNLLLEKASVLFNTGALYTQIGT                   RCDRQTQAGLESAIDAFQRAAGVLNYLKDTFTHTPSYDMSPAMLSVLVKMMLAQAQES                   VFEKISLPGIRNEFFMLVKVAQEAAKVGEVYQQLHAAMSQAPVKENIPYSWASLACVK                   AHHYAALAHYFTAILLIDHQVKPGTDLDHQEKCLSQLYDHMPEGLTPLATLKNDQQRR                   QLGKSELRRAMAHHEESVREASLCKKLRSIEVLQKVLCAAQERSRLTYAQHQEEDDLL                   NLIDAPRVLLLKLSKRLTLYCPSSPADSHGLLPEAGPLSVLSANKRWTPPRSIRFTAE                   EGDLGFTLRGNAPVQVHFLDPYCSASVAGAREGDYIVSIQLVDCKWLTLSEVMKLLKS                   FGEDEIEMKVVSLLDSTSSMHNKSATYSVGMQKTYSMICLAIDDDDKTDKTKKISKKL                   SFLSWGTNKNRQKSASTLCLPSVGAARPQVKKKLPSPFSLLNSDSSWY                                     SEQ ID NO:351   2109 bp                     NOV126b,     CGCCGCTAGC   ATG ACCGACGCGCTGTTGCCCGCGGCCCCCCAGCCGCTGGAGAAGGAG       CG59987-02 DNA Sequence           AACGACGGCTACTTTCGGAAGGGCTGTAATCCCCTTGCACAAACCGGCCGGAGTAAAT                   TGCAGAATCAAAGAGCTGCTTTGAATCAGCAGATCCTGAAAGCCGTGCGGATGAGGAC                   CGGAGCGGAAAACCTTCTGAAAGTGGCCACAAACTCAAAGGTGCGGGAGCAAGTGCGG                   CTGGAGCTGAGCTTCGTCAACTCAGACCTGCAGATCCTCAAGGAAGAGCTGGAGGGGC                   TGAACATCTCGCTGCGCGTCTATCACAACACAGACGAGGCATTTACGATTCCCCTGAT                   TCCTCTTGGCCTGAACGAAACCAAAGACGTCCACTTTGCACTCCTCCTCAACGATTTT                   ATCCTCGAACATTACAGTGAAGATGGCTATTTATATGAAGATGAAATTGCAGATCTTA                   TGGATCTGAGACAAGCTTGTCCGACGCCTAGCCGGGATGACGCCGGGGTGGAACTGCT                   GATGACATACTTCATCCAGCTGGGCTTTGTCCACAGTCGATTCTTCCCGCCCACACGG                   CAGATGGGACTCCTGTTCACCTGGTATGACTCTCTCACCGCGGTTCCGGTCACCCAGC                   AGAACCTGCTGCTGGAGAAGGCCAGTGTCCTGTTCAACACTGGGGCCCTCTACACCCA                   GATTCGGACCCGGTGCGATCGGCAGACGCAGGCTGCGCTGGAGACTGCCATAGATGCC                   TTTCAGAGAGCCGCACGGGTTTTAAATTACCTGAAAGACACATTTACCCATACTCCAA                   GTTACGACATGAGCCCTGCCATGCTCAGCGTGCTCGTCAAAATGATGCTTCCACAAGC                   CCAAGAAACCGTGTTTGAGAAAATCAGCCTTCCTCCGATCCCGAATGAATTCTTCATG                   CTGGTGAAGGTGGCTCAGGAGGCTGCTAAGGTGGGAGACGTCTACCAACAGCTACACC                   CTGCGTGAAGGCCCACCACTACGCGGCCCTGGCCCACTACTTCACTGCCATCCTCCTC                   CAGCCATCAGCCAGGCCCCCGTGAAAGACAACATCCCCTACTCCTGGGCCAGCTTAGC                   ATCGACCACCAGGTGAAGCCAGGCACGGATCTGGACCACCAGGACAAGTGCCTGTCCC                   GCAGCGCCGACAGCTCGGGAAGTCCCACTTGCGCACACCCATCGCTCATCACGAGCAG                   TCGGTGCGGGAGGCAAGCCTCTGCAAGAAGCTGCGGAGCATTGACGTGCTACAGAAGG                   TGCTGTGTGCCGCACAGGAACGCTCCCGGCTCACGTACGCCCAGCACCAGGAGGAGGA                   TGACCTGCTGAACCTGATCGACGCCCCCAGTGTTGTTGCTAAAACTGAGCAAGAGGTT                   GACATTATATTGCCCCAGTTCTCCAAGCTGACAGTCACGGACTTCTTCCAGAACCTCG                   GCCCCTTATCTGTGTTTTCGGCTAACAAGCGGTGGACGCCTCCTCGAAGCATCCGCTT                   CACTGCAGAAGAAGGGGACTTGGGGTTCACCTTGAGAGGGAACGCCCCCGTTCAGGTT                   CACTTCCTCGATCCTTACTCCTCTGCCTCCCTGCCAGGAGCCCGCGAAGGACATTATA                   TTGTCTCCATTCAGCTTCTGGATTGTAAGTCGCTGACGCTGAGTGAGGTTATGAAGCT                   GCTGAAGAGCTTTGGCGAGGACGAGATCGAGATCAAAGTCGIGAGCCTCCTGGACTCC                   ACATCATCCATGCATAATAAGAGTGCCACATACTCCCTGGGAATG TAG   AAAACGTACT                       CCATGATCTCCTTAGCCATTCATGATGACGACAAAACTGATAAAACCAAGAAAATCTC                       CAAGAAGCTTTCCTTCCTGAGTTGGGGCACCAACAACAACAGACACAAGTCAGCCAGC                       ACCTTGTGCCTCCCATCGGTCGGGGCTGCACGGCCTCAGGTCAAGAAGAAGCTGCCCT                       CCCCTTTCACCCTTCTCAACTCACACACTTCTTGGTACTAATGTGAGCAAACAAACAT                       GTTCAGGCCCCGAACATTTCC                                           ORF Start: ATG at 11       ORF Stop: TAG at 1844           SEQ ID NO:352   611 aa   MW at 68613.9 kD                     NOV126b,   MTDALLPAAPQPLEKENDGYFRKGCNPLAQTGRSKLQNQRAALNQQILKAVRMRTGAE       CG59987-02 Protein Sequence           NLLKVATNSKVREQVRLELSFVNSDLQMLKEELEGLNISVGVYQNTEEAFTIPLIPLG                   LKETKDVDFAVVLKDFILEHYSEDGYLYEDEIADLMDLRQACRTPSRDEAGVELLMTY                   FIQLGFVESRFFPPTRQMGLLFTWYDSLTGVPVSQQNLLLEKASVLFNTGALYTQIGT                   RCDRQTQAGLESAIDAFQRAAGVLNYLKDTFTHTPSYDMSPAMLSVLVKMMLAQAQES                   VFEKISLPGIRNEFFMLVKVAQEAAKVGEVYQQLHAAMSQAPVKENIPYSWASLACVK                   AHHYAALAHYFTAILLIDHQVKPGTDLDHQEKCLSQLYDHMPEGLTPLATLKNDQQRR                   QLGKSELRRAMAHHEESVREASLCKKLRSIEVLQKVLCAAQERSRLTYAQHQEEDDLL                   NLIDAPRVLLLKLSKRLTLYCPSSPADSHGLLPEAGPLSVLSANKRWTPPRSIRFTAE                   EGDLGFTLRGNAPVQVHFLDPYCSASVAGAREGDYIVSIQLVDCKWLTLSEVMKLLKS                   FGEDEIEMKVVSLLDSTSSMHNKSATYSVGM                  
 
     [0984] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 126B.  
               TABLE 126B                          Comparison of NOV126a against NOV126b.                                         Identities/                   Similarities           Protein   NOV126a Residues/   for the           Sequence   Match Residues   Matched Region                       NOV126b   1 . . . 611   585/612 (95%)               1 . . . 611   590/612 (95%)                      
 
     [0985] Further analysis of the NOV126a protein yielded the following properties shown in Table 126C.  
               TABLE 126C                       Protein Sequence Properties NOV126a                                        PSort   0.4500 probability located in cytoplasm; 0.3000 probability       analysis:   located in microbody (peroxisome); 0.1000 probability located           in mitochondrial matrix space; 0.1000 probability located in           lysosome (lumen)       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0986] A search of the NOV126a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 126D.  
               TABLE 126D                          Geneseq Results for NOV126a                                         NOV126a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAU10192   Human prostate specific protein   1 . . . 686   660/687   (96%)   0.0           PSL22 -  Homo sapiens , 686 aa.   1 . . . 686   665/687   (96%)           [WO200172962-A2, 4 OCT 2001]       AAB68561   Human GTP-binding associated   27 . . . 686    626/661   (94%)   0.0           protein #61 -  Homo sapiens , 666 aa.   7 . . . 666   633/661   (95%)           [WO200105970-A2, 25 JAN 2001]       AAG64579   Human transcription termination   201 . . . 686    458/487   (94%)   0.0           factor binding protein 54 -  Homo     3 . . . 488   464/487   (95%)             sapiens , 488 aa. [CN1297918-A,           6 JUN 2001]       AAB29661   Human histidine domain-protein   110 . . . 357    82/252   (32%)   3e−28           tyrosine phosphatase, SEQ ID NO:2   7 . . . 253   135/252   (53%)           [WO200063392-A1, 26 OCT 2000]       AAU00869   Human cancer related protein 5 -   409 . . . 597    70/189   (37%)   2e−27             Homo sapiens , 257 aa.   8 . . . 196   102/189   (53%)           [WO200118014-A1, 15 MAR           2001]                  
 
     [0987] In a BLAST search of public sequence databases, the NOV126a protein was found to have homology to the proteins shown in the BLASTP data in Table 126E.  
               TABLE 126E                          Public BLASTP Results for NOV126a                                         NOV126a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value               Q96RU1   RHOPHILIN-LIKE PROTEIN -    1 . . . 686   627/688 (91%)   0.0             Homo sapiens  (Human), 685 aa.    1 . . . 685   640/688 (92%)       Q9DBN2   1300002E07RIK PROTEIN -    1 . . . 686   573/687 (83%)   0.0             Mus musculus  (Mouse), 686 aa.    1 . . . 686   616/687 (89%)       Q61085   GTP-RHO binding protein 1   16 . . . 596   273/583 (46%)    e−135           (Rhophilin) -  Mus musculus     20 . . . 580   361/583 (61%)           (Mouse), 643 aa.       Q9XYY9   RHOPHILIN -  Drosophila     21 . . . 615   248/654 (37%)    e−110             melanogaster  (Fruit fly), 718 aa.   31 . . . 674   363/654 (54%)       Q96PV9   KIAA1929 PROTEIN -  Homo     23 . . . 366   178/346 (51%)   1e−93             sapiens  (Human), 410 aa   17 . . . 362   241/346 (69%)           (fragment).                  
 
     [0988] PFam analysis predicts that the NOV126a protein contains the domains shown in the Table 126F.  
               TABLE 126F                          Domain Analysis of NOV126a                                     Identities/                   Similarities       Pfam   NOV126a   for the   Expect       Domain   Match Region   Matched Region   Value                                         HR1: domain 1 of 1    38 . . . 110   19/87   (22%)   1.2e−05               53/87   (61%)       BRO1: domain 1 of 1   111 . . . 263   60/172   (35%)   3.8e−56               125/172   (73%)       PDZ: domain 1 of 1   516 . . . 593   20/84   (24%)   0.46               53/84   (63%)                  
 
     Example 127  
     [0989] The NOV127 clone was analyzed, and the nucleotide and predicted polypeptide sequences are shown in Table 127A.  
               TABLE 127A                       NOV127 Sequence Analysis                                                SEQ ID NO:353   3351 bp                     NOV127a,   CGTCCCGTGGCCATGACGACCGCTCAGAGGGACTCCCTGTTGTGGAAGCTCGCGGGGT       CG59971-01 DNA Sequence           TGCTGCGCGAGTCCCGTCATGTGGTCCTGTCTGGCTGTAGCACCCTGAGCCTGCTGAC                   TCCCACACTGCAACAGCTGAACCACGTATTTGAGCTGCACCTGGGGCCATGGGGCCCT                   GGCCAGACAGGCTTTGTGGCTCTGCCCTCCCATCCTGCCGACTCCCCTGTTATTCTTC                   AGCTTCAGTTTCTCTTCGATGTGCTGCAGAAAACACTTTCACTCAAGCTGGTCCATGT                   TGCTGGTCCTGGCCCCACAGGGCCCATCAAGATTTTCCCCTTCAAATCCCTTCGGCAC                   CTGGAGCTCCCAGGTGTTCCCCTCCACTGTCTCCATGGCCTCCCAGGCATCTACTCCC                   AGCTACAATGCACTGACCGCCTTAGACAGCTCCCTGCGCCTCTTGTCAGCTCTGCGTT                   TCTTGAACCTAAGCCACAATCAAGTCCAGGACTGTCAGGGATTCCTGATGGATTTGTG                   TGAGCTCCACCATCTGGACATCTCCTATAATCGCCTGCATTTGGTGCCAAGAATGGGA                   CCCTCAGGGGCTGCTCTGGGGGTCCTGATACTGCGAGGCAATGAGCTTCGGAGCCTGC                   CAGGCCTAGAGCAGCTGAGGAATCTGCGGCACCTGGATTTGGCATACAACCTGCTGGA                   AGGACACCGGGAGCTGTCACCACTGTGGCTGCTGGCTGAGCTCCGCAAGCTCTACCTG                   GAGGGGAACCCTCTTTGGTTCCACCCTGAGCACCGAGCAGCCACTGCCCAGTACTTGT                   CACCCCGGGCCACCCATGCTGCTACTGGCTTCCTTCTCGATGGCAAGGTCTTGTCACT                   GACAGATTTTCAGCAGACTCACACATCCTTGCGGCTCAGCCCCATGGGCCCACCTTTG                   CCCTGGCCAGTGGGGAGTACTCCTGAAACCTCAGGTCGCCCTGACCTGAGTGACAGCC                   TCTCCTCAGGGGGTGTTGTGACCCAGCCCCTGCTTCATAAGGTTAAGAGCCGAGTCCG                   TGTGAGGCGGGCAAGCATCTCTGAACCCAGTGATACGGACCCGGAGCCCCGAACTCTG                   AACCCCTCTCCGGCTGGTTGGTTCGTGCAGCAGCACCCGGAGCTGGAGCTCATGAGCA                   GCTTCCGGGAACGGTTCGGCCGCAACTGGCTGCAGTACAGGAGTCACCTGGAGCCCTC                   CGGAAACCCTCTGCCGGCCACCCCCACTACTTCTGCACCCAGTGCACCTCCAGCCAGC                   TCCCAGGGCCCCGACACTGCACCCAGACCTTCACCCCCGCAGCAGGAAGCCAGAGGCC                   CCCAGGAGTCACCACAGAAAATGTCAGAGGAGGTCAGGGCGGAGCCACAGGAGGAGGA                   AGAGGAGAAGGAGGGGAAGGAGGAGAAGGAGGAGGGGGAGATGGTGGAACAGGGAGAA                   GAGGAGGCAGGAGAGGAGGAAGAAGAGGAGCAGGACCAGAAGGAAGTGGAAGCGGAAC                   TCTGTCGCCCCTTGTTGGTGTGTCCCCTGGAGGGGCCTGAGGGCGTACGGGGCAGGGA                   ATGCTTTCTCAGGGTCACTTCTGCCCACCTGTTTGAGGTGGAACTCCAAGCAGCTCGC                   ACCTTGGAGCGACTGGAGCTCCAGAGTCTGGAGGCAGCTGAGATAGAGCCGGAGGCCC                   AGGCCCAGGGTCCCCCTCTTGCTCCGCAGGGCTCAGATCTGCTCCCTGGAGCCCCCAT                   CCTCAGTCTGCGCTTCTCCTACATCTGCCCTGACCGGCAGTTGCGTCGCTATTTGGTG                   CTGGAGCCTGATGCCCACGCAGCTGTCCACCAGCTGCTTGCCGTGTTGACCCCAGTCA                   CCAATGTGGCTCGGGAACAGCTTGGGGAGGCCAGGGACCTCCTGCTGGGTAGATTCCA                   GTCTCTACGCTGTGGCCATGAGTTCAAGCCAGAGGAGCCCAGCATCGGATTAGACAGT                   GAGGAAGGCTGGAGGCCTCTGTTCCAAAAGACAGAATCTCCTGCTGTGTGTCCTAACT                   AGTCGCATAGAGCTGGGCCTGGCAGCCCAGAGCCTGCGGCTAGAGTGGGCAGCTGGGG                   CGGGCCGCTGTGTGCTGCTGCCCCGACATGCCAGGCATTGCCGGGCCTTCCTAGAGCA                   GCTCCTTGGTGTCTTGCAGTCTCTCCCCCCTGCCTGGAGGAACTCTGTCAGTGCCACA                   GAGGAGGAGGTCACCCCCCAGCACCGGCTCTGGCCATTGCTGGAAAAAGACTCATCCT                   GCAGCTGATGCTTCCCTCCACCTGCCTCGTATCCCTGTTGCTGACTCCCTCCACCCTG                   TTCCTGTTAGATGAGGATGCTGCAGGGTCCCCGGCAGAGCCCTCTCCTCCAGCACCAT                   CTGCCGAAGCCTCTGAGAAGGTGCCTCCCTCGGCGCCGCGCCCTGCTGTCCGTGTCAG                   GGAGCAGCAGCCACTCAGCAGCCTGAGCTCCGTGCTGCTCTACCGCTCAGCCCCTGAG                   GACTTGCGGCTGCTCTTCTACCATGAGGTGTCCCGGCTGGAGAGCTTTTCGGCACTCC                   GGAGCTGTTTTCCATCCGACTCCGCACACTCATCCAAGAGGCGCTCGCCCTTCACCGA                     TGA   GGGTCCCACGCTGACCTTGGCCCTGACCTCAGGAGCCACGCT                                           ORF start: ATG at 13       ORF Stop: TGA at 3307           SEQ ID NO:354   1098 aa   MW at 121004.1 kD                     NOV127a,   MTTAQRDSLLWKLAGLLRESGDVVLSGCSTLSLLTPTLQQLNHVFELHLGPWGPGQTG       CG59971-01 Protein       Sequence   FVALPSHPADSPVILQLQFLFDVLQKTLSLKLVHVAGPGPTGPIKIFPFKSLRHLELR                   GVPLHCLHGLRGIYSQLETLICSRSLQALEELLSACGGDFCSALPWLALLSANFSYNA                   LTALDSSLRLLSALRFLNLSHNQVQDCQGFLMDLCELHHLDISYNRLHLVPRMGPSGA                   ALGVLILRGNELRSLPGLEQLRNLRHLDLAYNLLEGHRELSPLWLLAELRKLYLEGNP                   LWFHPEHRAATAQYLSPRARDAATGFLLDGKVLSLTDFQQTHTSLGLSPMGPPLPWPV                   GSTPETSGGPDLSDSLSSGGVVTQPLLHKVKSRVRVRRASISEPSDTDPEPRTLNPSP                   AGWFVQQHPELELMSSFRERFGRNWLQYRSHLEPSGNPLPATPTTSAPSAPPASSQGP                   DTAPRPSPPQEEARGPQESPQKMSEEVRAEPQEEEEEKEGKEEKEEGEMVEQGEEEAG                   EEEEEEQDQKEVEAELCRPLLVCPLEGPEGVRGRECFLRVTSAHLFEVELQAARTLER                   LELQSLEAAEIEPEAQAQGPPLATGSDLLPGAPILSLRFSYICPDRQLRRYLVLEPDA                   AHAAVQELLAVLTPVTNVAREQLGEARDLLLGRFQCLRCGHEFKPEEPRMGLDSEEGW                   RPLFQKTESPAVCPNCGSDHVVLLAVSRGTPNRERKQGEQSLAPSPSASPVCHPPGHG                   DHLDRAKNSPPQAPSTRDHGSWSLSPAPERCGLRSVDHRLRLFLDVEVFSDAQEEFQC                   CLKVPVALAGHTGEFMCLVVVSDRRLYLLKVTGEMSEPPASWLQLTLAVPLQDLSGIE                   LGLAGQSLRLEWAAGAGRCVLLPRDARHCRAFLEELLGVLQSLPPAWRNCVSATEEEV                   TPQHRLWPLLEKDSSLEARQFFYLRAFLVEGEASVQLMLPSTCLVSLLLTPSTLFLLD                   EDAAGSPAEPSPPAASGEASEKVPPSGPGPAVRVREQQPLSSLSSVLLYRSAPEDLRL                   LFYDEVSRLESFWALRVVCQEQLTALLAWIREPWEELFSIGLRTVIQEALALDR                                     SEQ ID NO:355   3348 bp                     NOV127b,     CGTCCCGTGGCC   ATG ACGACCGCTCAGAGGGACTCCCTGTTGTGGAAGCTCGCGGGGT       CG59971-02 DNA Sequence DNA Sequence           TGCTGCGGGAGTCCGGTGATGTGGTCCTGTCTGGCTGTAGCACCCTGAGCCTGCTGAC                   TCCCACACTGCAACAGCTGAACCACGTATTTGAGCTGCACCTGGGGCCATGGGGCCCT                   GGCCAGACAGGCTTTGTGGCTCTGCCCTCCCATCCTGCCGACTCCCCTGTTATTCTTC                   AGCTTCAGTTTCTCTTCGATGTGCTGCAGAAAACACTTTCACTCAAGCTGGTCCATGT                   TGCTGGTCCTGGCCCCACAGGGCCCATCAAGATTTTCCCCTTCAAATCCCTTCGGCAC                   CTGGAGCTCCGAGGTGTTCCCCTCCACTGTCTGCATGGCCTCCGAGGCATCTACTCCC                   AGCTGGAGACCCTGATTTGCAGCAGGAGCCTCCAGGCATTAGACGAGCTCCTCTCAGC                   CTGCGGCGGCGACTTCTGCTCTGCCCTCCCTTGGCTGGCTCTGCTTTCTGCCAACTTC                   AGCTACAATGCACTGACCGCCTTAGACAGCTCCCTGCGCCTCTTGTCAGCTCTGCGTT                   TCTTGAACCTAAGCCACAATCAAGTCCAGGACTGTCAGGGATTCCTGATGGATTTCTG                   TGAGCTCCACCATCTGGACATCTCCTATAATCGCCTGCATTTGGTGCCAAGAATGGGA                   CCCTCAGGGCCTGCTCTGGGGCTCCTGATACTGCGAGGCAATGAGCTTCGGAGCCTGC                   CAGGCCTAGAGCAGCTGAGGAATCTGCGGCACCTGGATTTGGCATACAACCTGCTGGA                   AGGACACCGGGAGCTGTCACCACTGTGGCTGCTGGCTGAGCTCCGCAAGCTCTACCTG                   GAGGGCAACCCTCTTTGGTTCCACCCTGAGCACCGAGCAGCCACTGCCCAGTACTTGT                   CACCCCGGGCCAGGGATGCTGCTACTGGCTTCCTTCTCGATGGCAAGGTCTTGTCACT                   GACAGATTTTCAGCAGACTCACACATCCTTGGGGCTCAGCCCCATGGGCCCACCTTTG                   AACCCCTCTCCGCCTCGTTGGTTCGTGCAGCAGCACCCGGAGCTGGAGCTCATGAGCA                   GCTTCCGGGAACGGTTCGGCCGCAACTGGCTGCAGTACAGGAGTCACCTGGAGCCCTC                   CGGAAACCCTCTGCCGGCCACCCCCACTACTTCTGCACCCAGTGCACCTCCAGCCAGC                   TCCCAGGGCCCCGACACTGCACCCAGACCTTCACCCCCGCAGGAGGAAGCCAGAGGCC                   CCCAGGAGTCACCACAGAAAATGTCAGAGGAGCTCAGGGCGGAGCCACAGGAGGAGGA                   AGACGAGAAGGAGGGGAAGGAGGAGAAGGAGGAGGGGGAGATGGTGGAACAGGGAGAA                   GAGGACGCAGGAGAGGAGGAAGAAGAGCAGCAGGACCAGAACGAAGTGGAACCGGAAC                   TCTGTCGCCCCTTGTTGGTCTGTCCCCTGGAGGGGCCTGAGGGCGTACGGGGCAGGGA                   ATGCTTTCTCAGGGTCACTTCTGCCCACCTGTTTGAGGTGGPACTCCAAGCAGCTCGC                   ACCTTGGAGCGACTGGAGCTCCAGAGTCTGGAGGCACCTGAGATAGAGCCGGAGGCCC                   ACGCCCAGAGGTCGCCCAGGCCCACGGGCTCAGATCTGCTCCCTGGAGCCCCCATGCT                   CAGTCTGCGCTTCTCCTACATCTGCCCTGACCGGCAGTTGCGTCGCTATTTGGTGCTG                   GAGCCTGATGCCCACGCAGCTCTCCAGGAGCTGCTTGCCGTGTTGACCCCAGTCACCA                   ATCTGGCTCGGCAACAGCTTGCCGACCCCAGGGACCTCCTGCTGGGTAGATTCCAGTG                   TCTACGCTCTGCCCATGACTTCAAGCCAGAGGAGCCCAGGATGGGATTAGACAGTGAG                   GAAGGCTCGAGGCCTCTGTTCCAAAAGACAGAATCTCCTGCTGTGTGTCCTAACTGTG                   CTAGTCACCACGTGCTTCTCCTCCCTCTCTCTCGGGGAACCCCCAACAGCGACCCGAA                   ACAGGCACAGCAGTCTCTGGCTCCTTCTCCGTCTGCCACCCCTCTCTGCCACCCTCCT                   GGCCATGCTCACCACCTTCACAGGGCCAACAACAGCCCACCTCACGCACCGACCACCC                   CTGACCATGGTAGTTGGAGCCTCAGTCCCGCCCGTGAGCGCTGTGGCCTCCGCTCTGT                   GGACCACCGACTCCGGCTCTTCCTGGATGTTGAGGTGTTCAGCGATGCCCACGAGGAG                   TTCCAGTGCTGCCTCAAGGTCCCACTCCCATTGGCAGGCCACACTGGGGAGTTCATGT                   GCCTTCTGCTTGTGTCTGACCGCAGCCTCTACCTGTTGAAGGTGACTGGGGAGATGAC                   TGACCCTCCAGCTACCTGGCTGCAGCTGACCCTGGCTCTTCCCCTCCAGGATCTGAGT                   GGCATACAGCTGGGCCTGGCAGGCCACAGCCTGCGGCTAGAGTGGGCAGCTCGGGCGG                   GCCGCTGTGTGCTCCTGCCCCGACATCCCAGCCATTGCCGGGCCTTCCTAGACGACCT                   CCTTGGTGTCTTGCAGTCTCTGCCCCCTCCCTGCAGGAACTGTGTCACTGCCACAGAG                   GAGGAGGTCACCCCCCACCACCGGCTCTGGCCATTCCTGGAAAAACACTCATCCTTGC                   AGGCTCCCCAGTTCTTCTACCTTCCGGCGTTCCTGGTTGAACCTGAAGCCTCTCTCCA                   GCTGATGCTTCCCTCCACCTGCCTCGTATCCCTGTTGCTGACTCCGTCCACCCTGTTC                   CTGTTAGATGAGGATGCTGCAGGGTCCCCGGCACAGCCCTCTCCTCCAGCAGCATCTG                   GCGAACCCTCTGAGAAGGTGCCTCCCTCGGGGCCCCGCCCTGCTGTGCGTGTCAGCCA                   GCAGCACCCACTCAGCAGCCTGAGCTCCGTGCTGCTCTACCGCTCAGCCCCTGAGGAC                   TTGCGGCTGCTCTTCTACGATGAGGTGTCCCGGCTGGAGAGCTTTTGGGCACTCCGTG                   TGGTGTGTCAGGAGCAGCTGACAGCCCTGCTTGCCTGGATCCGGGAACCATGGGAGGA                   GCTGTTTTCCATCGGACTCCGGACAGTGATCCAAGAGGCGCTGGCCCTTGACCGA TGA                       GGGTCCCACGCTGACCTTGGCCCTGACCTCAGGAGCCACGCT                                           ORF Start: ATG at 13       ORF Stop: TGA at 3304           SEQ ID NO:356   1097 aa   MW at 121064.1 kD                     NOV127b,   MTTAQRDSLLWKLAGLLRESGDVVLSGCSTLSLLTPTLQQLNHVFELHLGPWGPGQTG       CG59971-02 Protein       Sequence   FVALPSHPADSPVILQLQFLFDVLQKTLSLKLVHVAGPGPTGPIKIFPFKSLRHLELR                   GVPLHCLHGLRGIYSQLETLICSRSLQALEELLSACGGDFCSALPWLALLSANFSYNA                   LTALDSSLRLLSALRFLNLSHNQVQDCQGFLMDLCELHHLDISYNRLHLVPRMGPSGA                   ALGVLILRGNELRSLPGLEQLRNLRHLDLAYNLLEGHRELSPLWLLAELRKLYLEGNP                   LWFHPEHRAATAQYLSPRARDAATGFLLDGKVLSLTDFQQTHTSLGLSPMGPPLPWPV                   GSTPETSGGPDLSDSLSSGGVVTQPLLHKVKSRVRVRRASISEPSDTDPEPRTLNPSP                   AGWFVQQHPELELMSSFRERFGRNWLQYRSHLEPSGNPLPATPTTSAPSAPPASSQGP                   DTAPRPSPPQEEARGPQESPQKMSEEVRAEPQEEEEEKEGKEEKEEGEMVEQGEEEAG                   EEEEEEQDQKEVEAELCRPLLVCPLEGPEGVRGRECFLRVTSAHLFEVELQAARTLER                   LELQSLEAAEIEPEAQAQGPPLATGSDLLPGAPILSLRFSYICPDRQLRRYLVLEPDA                   HAAVQELLAVLTPVTNVAREQLGEARDLLLGRFQCLRCGHEFKPEEPRMGLDSEEGWR                   PLFQKTESPAVCPNCGSDHVVLLAVSRGTPNRERKQGEQSLAPSPSASPVCHPPGHGD                   HLDRAKNSPPQAPSTRDHGSWSLSPAPERCGLRSVDHRLRLFLDVEVFSDAQEEFQCC                   LKVPVALAGHTGEFMCLVVVSDRRLYLLKVTGEMSEPPASWLQLTLAVPLQDLSGIEL                   GLAGQSLRLEWAAGAGRCVLLPRDARHCRAFLEELLGVLQSLPPAWRNCVSATEEEVT                   PQHRLWPLLEKDSSLEARQFFYLRAFLVEGEASVQLMLPSTCLVSLLLTPSTLFLLDE                   DAAGSPAEPSPPAASGEASEKVPPSGPGPAVRVREQQPLSSLSSVLLYRSAPEDLRLL                   FYDEVSRLESFWALRVVCQEQLTALLAWIREPWEELFSIGLRTVIQEALALDR                  
 
     [0990] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 127B.  
               TABLE 127B                          Comparison of NOV127a against NOV127b.                                         Identities/                   Similarities           Protein   NOV127a Residues/   for the           Sequence   Match Residues   Matched Region                       NOV127b   1 . . . 1098   891/1098 (81%)               1 . . . 1097   891/1098 (81%)                      
 
     [0991] Further analysis of the NOV127a protein yielded the following properties shown in Table 127C.  
               TABLE 127C                       Protein Sequence Properties NOV127a                                        PSort   0.5163 probability located in mitochondrial matrix space;       analysis:   0.3000 probability located in microbody (peroxisome); 0.2442           probability located in mitochondrial inner membrane; 0.2442           probability located in mitochondrial intermembrane space       SignalP   No Known Signal Sequence Predicted       analysis:                  
 
     [0992] A search of the NOV127a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 127D.  
               TABLE 127D                          Geneseq Results for NOV127a                                         NOV127a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value                                             AAM39827   Human polypeptide SEQ ID NO   375 . . . 528   140/154   (90%)   3e−78           2972 -  Homo sapiens , 169 aa.    14 . . . 167   145/154   (93%)           [WO200153312-A1, 26 JUL 2001]       AAM41613   Human polypeptide SEQ ID NO   375 . . . 528   140/154   (90%)   4e−78           6544 -  Homo sapiens , 184 aa.    29 . . . 182   145/154   (93%)           [WO200153312-A1, 26 JUL 2001]       AAU19764   Human novel extracellular matrix   444 . . . 647   157/207   (75%)   2e−75           protein, Seq ID No 414 -  Homo      13 . . . 209   160/207   (76%)             sapiens , 211 aa. [WO200155368-           A1, 2 AUG 2001]       ABB19833   Protein #1832 encoded by probe   409 . . . 535   127/127   (100%)   2e−70           for measuring heart cell gene    1 . . . 127   127/127   (100%)           expression -  Homo sapiens , 127 aa.           [WO200157274-A2, 9 AUG           2001]       AAM67606   Human bone marrow expressed   409 . . . 535   127/127   (100%)   2e−70           probe encoded protein SEQ ID    1 . . . 127   127/127   (100%)           NO: 27912 -  Homo sapiens , 127           aa. [WO200157276-A2, 9 AUG           2001]                  
 
     [0993] In a BLAST search of public sequence databases, the NOV127a protein was found to have homology to the proteins shown in the BLASTP data in Table 127E.  
               TABLE 127E                          Public BLASTP Results for NOV127a                                         NOV127a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the   Expect       Number   Protein/Organism/Length   Residues   Matched Portion   Value                                             AAL49726   LKB1-INTERACTING     1 . . . 1098   1077/1098   (98%)   0.0           PROTEIN 1 -  Homo sapiens      12 . . . 1099   1078/1098   (98%)           (Human), 1099 aa.       Q96PY9   KIAA1898 PROTEIN -  Homo      76 . . . 1098   1003/1023   (98%)   0.0             sapiens  (Human), 1013 aa     1 . . . 1013   1003/1023   (98%)           (fragment).       Q96CN3   SIMILAR TO RIKEN CDNA    288 . . . 1098   793/811   (97%)   0.0           1200014D22 GENE -  Homo      4 . . . 804   793/811   (97%)             sapiens  (Human), 804 aa           (fragment).       Q9DBT7   1200014D22RIK PROTEIN -      1 . . . 1098   816/1098   (74%)   0.0             Mus musculus  (Mouse), 1072 aa.     1 . . . 1072   895/1098   (81%)       Q9VMK9   CG9044 PROTEIN -  Drosophila      12 . . . 433   139/459   (30%)   6e−38             melanogaster  (Fruit fly), 1289 aa.    8 . . . 463   220/459   (47%)                  
 
     [0994] PFam analysis predicts that the NOV127a protein contains the domains shown in the Table 127F.  
               TABLE 127F                          Domain Analysis of NOV127a                                     Identities/                   Similarities       Pfam   NOV127a   for the   Expect       Domain   Match Region   Matched Region   Value                                         LRR: domain 1 of 5   164 . . . 186   7/25   (28%)   2.5e+02               15/25   (60%)       LRR: domain 2 of 5   187 . . . 209   6/25   (24%)   2.5e+02               16/25   (64%)       LRR: domain 3 of 5   210 . . . 231   8/25   (32%)   83               13/25   (52%)       LRR: domain 4 of 5   233 . . . 254   9/25   (36%)   16               17/25   (68%)       LRR: domain 5 of 5   255 . . . 279   10/27   (37%)   22               19/27   (70%)       Pkinase_C:   620 . . . 629   5/11   (45%)   8.9       domain 1 of 1       9/11   (82%)       rubredoxin:   669 . . . 686   5/18   (28%)   4.6       domain 1 of 2       13/18   (72%)       rubredoxin:   708 . . . 713   5/6   (83%)   1.2e+03       domain 2 of 2       6/6   (100%)                  
 
     Example B  
     Sequencing Methodology and Identofication of NOVX Clones  
     [0995] 1. GeneCalling™ Technology: This is a proprietary method of performing differential gene expression profiling between two or more samples developed at CuraGen and described by Shimkets, et al., “Gene expression analysis by transcript profiling coupled to a gene database query” Nature Biotechnology 17:198-803 (1999). cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then digested with up to as many as 120 pairs of restriction enzymes and pairs of linker-adaptors specific for each pair of restriction enzymes were ligated to the appropriate end. The restriction digestion generates a mixture of unique cDNA gene fragments. Limited PCR amplification is performed with primers homologous to the linker adapter sequence where one primer is biotinylated and the other is fluorescently labeled. The doubly labeled material is isolated and the fluorescently labeled single strand is resolved by capillary gel electrophoresis. A computer algorithm compares the electropherograms from an experimental and control group for each of the restriction digestions. This and additional sequence-derived information is used to predict the identity of each differentially expressed gene fragment using a variety of genetic databases. The identity of the gene fragment is confirmed by additional, gene-specific competitive PCR or by isolation and sequencing of the gene fragment.  
     [0996] 2. SeqCalling™ Technology: cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then sequenced using CuraGen&#39;s proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation&#39;s database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.  
     [0997] 3. PathCalling™ Technology:  
     [0998] The NOVX nucleic acid sequences are derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, are sequenced. In silico prediction was based on sequences available in CuraGen Corporation&#39;s proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.  
     [0999] The laboratory screening was performed using the methods summarized below:  
     [1000] cDNA libraries were derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then directionally cloned into the appropriate two-hybrid vector (Gal4-activation domain (Gal4-AD) fusion). Such cDNA libraries as well as commercially available cDNA libraries from Clontech (Palo Alto, Calif.) were then transferred from  E. coli  into a CuraGen Corporation proprietary yeast strain (disclosed in U.S. Pat. Nos. 6,057,101 and 6,083,693, incorporated herein by reference in their entireties).  
     [1001] Gal4-binding domain (Gal4-BD) fusions of a CuraGen Corportion proprietary library of human sequences was used to screen multiple Gal4-AD fusion cDNA libraries resulting in the selection of yeast hybrid diploids in each of which the Gal4-AD fusion contains an individual cDNA. Each sample was amplified using the polymerase chain reaction (PCR) using non-specific primers at the cDNA insert boundaries. Such PCR product was sequenced; sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation&#39;s database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.  
     [1002] Physical clone: the cDNA fragment derived by the screening procedure, covering the entire open reading frame is, as a recombinant DNA, cloned into pACT2 plasmid (Clontech) used to make the cDNA library. The recombinant plasmid is inserted into the host and selected by the yeast hybrid diploid generated during the screening procedure by the mating of both CuraGen Corporation proprietary yeast strains N106′ and YULH (U.S. Pat. Nos. 6,057,101 and 6,083,693).  
     [1003] 4. RACE: Techniques based on the polymerase chain reaction such as rapid amplification of cDNA ends (RACE), were used to isolate or complete the predicted sequence of the cDNA of the invention. Usually multiple clones were sequenced from one or more human samples to derive the sequences for fragments. Various human tissue samples from different donors were used for the RACE reaction. The sequences derived from these procedures were included in the SeqCalling Assembly process described in preceding paragraphs.  
     [1004] 5. Exon Linking: The NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. Table B1 shows the sequences of the PCR primers used for obtaining different clones. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain—amygdala, brain—cerebellum, brain—hippocampus, brain—substantia nigra, brain—thalamus, brain—whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma—Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation&#39;s database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.  
     [1005] 6. Physical Clone:  
     [1006] Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.  
     [1007] The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clones used for expression and screening purposes.  
     Example C  
     Quantitative Expression Analysis of Clones in Various Cells and Tissues  
     [1008] The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoimmune diseases), Panel CNSD.01 (containing central nervous system samples from normal and diseased brains) and CNS_neurodegeneration_panel (containing samples from normal and Alzheimer&#39;s diseased brains).  
     [1009] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.  
     [1010] First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β-actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer&#39;s instructions.  
     [1011] In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer&#39;s instructions. Reactions containing up to 10 μg of total RNA were performed in a volume of 20 μl and incubated for 60 minutes at 42° C. This reaction can be scaled up to 50 μg of total RNA in a final volume of 100 μl. sscDNA samples are then normalized to reference nucleic acids as described previously, using 1×TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer&#39;s instructions.  
     [1012] Probes and primers were designed for each assay according to Applied Biosystems Primer Express Software package (version I for Apple Computer&#39;s Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration=250 nM, primer melting temperature (Tm) range=58°-60° C., primer optimal Tm=59° C., maximum primer difference=2° C., probe does not have 5′G, probe Tm must be 10° C. greater than primer Tm, amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, Tex., USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5′ and 3′ ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200 nM.  
     [1013] PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer&#39;s instructions. Reverse transcription was performed at 48° C. for 30 minutes followed by amplification/PCR cycles as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.  
     [1014] When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1×TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer&#39;s instructions. PCR amplification was performed as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were analyzed and processed as described previously.  
     [1015] Panels 1, 1.1, 1.2, and 1.3D  
     [1016] The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.  
     [1017] In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:  
     [1018] ca.=carcinoma,  
     [1019] *=established from metastasis,  
     [1020] met=metastasis,  
     [1021] s cell var=small cell variant,  
     [1022] non-s=non-sm=non-small,  
     [1023] squam=squamous,  
     [1024] pl. eff=pl effusion=pleural effusion,  
     [1025] glio=glioma,  
     [1026] astro=astrocytoma, and  
     [1027] neuro=neuroblastoma.  
     [1028] General_screening_panel_v0.4  
     [1029] The plates for Panel 1.4 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panel 1.4 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panel 1.4 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panel 1.4 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.31).  
     [1030] Panels 2D and 2.2  
     [1031] The plates for Panels 2D and 2.2 generally include 2 control wells and 94 test samples; composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute&#39;s Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have “matched margins” obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted “NAT” in the results below. The tumor tissue and the “matched margins” are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, Calif.), Research Genetics, and Invitrogen.  
     [1032] Panel 3D  
     [1033] The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature.  
     [1034] Panels 4D, 4R, and 4.1D  
     [1035] Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, Calif.) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, Calif.). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn&#39;s disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, Pa.).  
     [1036] Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, Md.) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.  
     [1037] Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco/Life Technologies, Rockville, Md.), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 μg/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco) with PEA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μg/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×10 6 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10 −5 M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1-7 days for RNA preparation.  
     [1038] Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer&#39;s instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, Utah), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSFs and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μg/ml for 6 and 12-14 hours.  
     [1039] CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection column!; and a Vario Magnet according to the manufacturer&#39;s instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMBM 5% FCS (Hyclone), 100AM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco) and plated at 10 6 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 ug/ml anti-CD28 (Pharmingen) and 3 ug/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 5 M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.  
     [1040] To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resupended at 10 6 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μg/ml or anti-CD40 (Pharmingen) at approximately 10 μg/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.  
     [1041] To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 101 g/ml anti-CD28 (Pharmingen) and 2 μg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, Md.) were cultured at 10 5 -10 6 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 μg/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μg/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 1001M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (11 g/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.  
     [1042] The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×10 5 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×10 5 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5 M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.  
     [1043] For these cell lines and blood cells, RNA was prepared by lysing approximately 10 7 cells/ml using Trizol (Gibco BRL). Briefly, {fraction (1/10)} volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at −20° C. overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μl of RNAse-free water and 35 μl buffer (Promega) 5 μl DTT, 7 μl RNAsin and 8 μl DNAse were added. The tube was incubated at 37° C. for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with {fraction (1/10)} volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNAse free water. RNA was stored at −80° C.  
     [1044] AI_comprehensive panel_v1.0  
     [1045] The plates for AI_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, Md.). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.  
     [1046] Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.  
     [1047] Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn&#39;s patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebvid and two were on phenobarbital.  
     [1048] Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-i anti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.  
     [1049] In the labels employed to identify tissues in the AI_comprehensive panel_v1.0 panel, the following abbreviations are used:  
     [1050] AI=Autoimmunity  
     [1051] Syn=Synovial  
     [1052] Normal=No apparent disease  
     [1053] Rep22/Rep20=individual patients  
     [1054] RA=Rheumatoid arthritis  
     [1055] Backus=From Backus Hospital  
     [1056] IDA=Osteoarthritis  
     [1057] (SS) (BA) (MF)=Individual patients  
     [1058] Adj=Adjacent tissue  
     [1059] Match control=adjacent tissues  
     [1060] -M=Male  
     [1061] -F=Female  
     [1062] COPD=Chronic obstructive pulmonary disease  
     [1063] Panels: 5D and 5I  
     [1064] The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.  
     [1065] In the Gestational Diabetes study subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (&lt;1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:  
                                                      Patient 2   Diabetic Hispanic, overweight, not on insulin           Patient 7-9   Nondiabetic Caucasian and obese (BMI &gt; 30)           Patient 10   Diabetic Hispanic, overweight, on insulin           Patient 11   Nondiabetic African American and overweight           Patient 12   Diabetic Hispanic on insulin                      
 
     [1066] Adipocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr. 2, 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:  
     [1067] Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose  
     [1068] Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated  
     [1069] Donor 2 and 3 AD: Adipose, Adipose Differentiated  
     [1070] Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.  
     [1071] Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.  
     [1072] In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:  
     [1073] GO Adipose=Greater Omentum Adipose  
     [1074] SK=Skeletal Muscle  
     [1075] UT=Uterus  
     [1076] PL=Placenta  
     [1077] AD=Adipose Differentiated  
     [1078] AM=Adipose Midway Differentiated  
     [1079] U=Undifferentiated Stem Cells  
     [1080] Panel CNSD.01  
     [1081] The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.  
     [1082] Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer&#39;s disease, Parkinson&#39;s disease, Huntington&#39;s disease, Progressive Supernuclear Palsy, Depression, and “Normal controls”. Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington&#39;s disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington&#39;s cases. Likewise Parkinson&#39;s disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.  
     [1083] In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:  
     [1084] PSP=Progressive supranuclear palsy  
     [1085] Sub Nigra=Substantia nigra  
     [1086] Glob Palladus=Globus palladus  
     [1087] Temp Pole=Temporal pole  
     [1088] Cing Gyr=Cingulate gyrus  
     [1089] BA4=Brodman Area 4  
     [1090] Panel CNS_Neurodegeneration_V1.0  
     [1091] The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.  
     [1092] Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer&#39;s disease (AD) patients, and eight brains from “Normal controls” who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer&#39;s like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer&#39;s like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0=no evidence of plaques, 3=severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a “control” region within AD patients. Not all brain regions are represented in all cases.  
     [1093] In the labels employed to identify tissues in the CNS_Neurodeeneration_V1.0 panel, the following abbreviations are used:  
     [1094] AD=Alzheimer&#39;s disease brain; patient was demented and showed AD-like pathology upon autopsy  
     [1095] Control=Control brains; patient not demented, showing no neuropathology  
     [1096] Control (Path)=Control brains; pateint not demented but showing sever AD-like pathology  
     [1097] SupTemporal Ctx=Superior Temporal Cortex  
     [1098] Inf Temporal Ctx=Inferior Temporal Cortex  
     [1099] A. CG58522-01: Human Platelet-Activating Factor Acetylhydrolase Ib Beta  
     [1100] Expression of gene CG58522-01 was assessed using the primer-probe set Ag3365, described in Table AA. Results of the RTQ-PCR runs are shown in Table AB.  
     [1101] Table AA. Probe Name Ag3365 
               TABLE AA                          Probe Name Ag3365                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cagaatgaaccaaggagactca-3′   22   3   357               Probe   TET-5′-ctactccgcatgcggcagaagacatt-3′-TAMRA   26   35   358               Reverse   5′-cacatccatctgtcatctcctt-3′   22   62   359                  
 
     [1102]               TABLE AB                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3365,       (%) Ag3365,           Run       Run       Tissue Name   216709759   Tissue Name   216709759                                     Adipose   0.0   Renal ca. TK-10   0.0       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.0       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   10.7   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   4.9   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   0.0       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   7.9   Stomach Pool   0.0       IGROV-1       Ovarian ca.   26.8   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   1.7   Lymph Node Pool   16.5       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   0.0       Breast Pool   0.0   Thymus Pool   0.0       Trachea   0.0   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   0.0   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   3.3   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   4.5   CNS cancer (glio)   6.2               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   25.7               295       Lung ca. A549   0.0   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   100.0   Brain (fetal)   0.0       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   4.8               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   0.0   Brain (Substantia   1.8               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   3.6       Fetal Liver   0.0   Brain (whole)   6.9       Liver ca. HepG2   0.0   Spinal Cord Pool   0.0       Kidney Pool   0.0   Adrenal Gland   0.0       Fetal Kidney   0.0   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.0                    
     [1103] CNS_neurodegeneration_v1.0 Summary: Ag3365—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1104] General_screening_panel_v1.4 Summary: Ag3365—Significant expression of this gene is seen only in the lung cancer cell line NCI-H23 (CT=33.1). Therefore, expression of this gene may be used to distinguish this sample from the other samples on this panel.  
     [1105] Panel 4D Summary: Ag3365—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1106] B. CG58520-01: Gamma-Aminobutyric-Acid Receptor Gamma-1  
     [1107] Expression of gene CG58520-01 was assessed using the primer-probe set Ag3364, described in Table BA.  
     [1108] Table BA. Probe Name Ag3364 
               TABLE BA                          Probe Name Ag3364                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ttcttctgcggagtcaaagtag-3′   22   43   360               Probe   TET-5′-ttggtcttcttgttactgaccctgca-3′-TAMRA   26   75   361               Reverse   5′-tcatctgccttatcaacgtttc-3′   22   106   362                  
 
     [1109] CNS_neurodegeneration_v1.0 Summary: Ag3364—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1110] General_screening_panel_v1.4 Summary: Ag3364—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1111] Panel 4D Summary: Ag3364—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1112] Panel CNS — 1 Summary: Ag3364—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1113] C. CG58520-03: Gamma-Aminobutyric-Acid Receptor Gamma-1 Subunit Precursor (Gaba(A) Receptor)  
     [1114] Expression of gene CG58520-03 was assessed using the primer-probe set Ag5092, described in Table CA.  
     [1115] Table CA. Probe Name Ag5092 
               TABLE CA                          Probe Name Ag5092                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gaacattcctgtccactgga-3′   20   625   363               Probe   TET-5′-attttcaagcgatggataccctaaaa-3′-TAMRA   26   645   364               Reverse   5′-cacttctacggagggctttt-3′   20   692   365                  
 
     [1116] CNS_neurodegeneration_v1.0 Summary: Ag5092—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1117] General_screening_panel_v1.5 Summary: Ag5092—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1118] Panel 4.1D Summary: Ag5092—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1119] D. CG58518-01: Gamma-Aminobutyric-Acid Receptor RHO-3  
     [1120] Expression of gene CG58518-01 was assessed using the primer-probe sets Ag3363, Ag1130, Ag1198, Ag1253 and Ag1603, described in Tables DA, DB, DC, DD and DE. Results of the RTQ-PCR runs are shown in Tables DF, DG and DH.  
     [1121] Table DA. Probe Name Ag3363 
               TABLE DA                          Probe Name Ag3363                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tggctttccagttagtctcctt-3′   22   14   366               Probe   TET-5′-cacctacatctggatcatattgaaacca-3′-TAMRA   28   36   367               Reverse   5′-ttgatgttagaagcagcacaaa-3′   22   68   368                  
 
     [1122] Table DB. Probe Name Ag1130 
               TABLE DB                          Probe Name Ag1130                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gtcctggctttccagttagtct-3′   22   10   369               Probe   TET-5′-tcacctacatctggatcatattgaaacca-3′-TAMRA   29   35   370               Reverse   5′-ttgatgttagaagcagcacaaa-3′   22   68   371                  
 
     [1123] Table DC. Probe Name Ag1198 
               TABLE DC                          Probe Name Ag1198                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gtcctggctttccagttagtct-3′   22   10   372               Probe   TET-5′-tcacctacatctggatcatattgaaacca-3′-TAMRA   29   35   373               Reverse   5′-ttgatgttagaagcagcacaaa-3′   22   68   374                  
 
     [1124] Table DD. Probe Name Ag1253 
               TABLE DD                          Probe Name Ag1253                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atctgggtgcctgatatctttt-3′   22   466   375               Probe   TET-5′-tgtccactctaaaagatccttcatccatga-3′-TAMRA   30   489   376               Reverse   5′-cgcagcatgatattctccatag-3′   22   524   377                  
 
     [1125] Table DE. Probe Name Ag1603 
               TABLE DE                          Probe Name Ag1603                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gtcctggctttccagttagtct-3′   22   10   378               Probe   TET-5′-tcacctacatctggatcatattgaaacca-3′-TAMRA   29   35   379               Reverse   5′-ttgatgttagaagcagcacaaa-3′   22   68   380                  
 
     [1126]               TABLE DF                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3363,       (%) Ag3363,           Run       Run       Tissue Name   216709559   Tissue Name   216709559                                     Adipose   0.0   Renal ca. TK-10   0.0       Melanoma*   0.0   Bladder   6.6       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.0       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   16.7   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   0.0       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   0.0   Lymph Node Pool   6.8       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   0.0       Breast ca. T47D   6.4   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   8.5       Breast Pool   0.0   Thymus Pool   0.0       Trachea   0.0   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   10.9               (glio/astro) U-118-MG       Fetal Lung   0.0   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   77.9   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   100.0   CNS cancer (glio) SF-   11.4               295       Lung ca. A549   10.1   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   34.4   Brain (fetal)   0.0       Lung ca. NCI-H460   30.6   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   0.0   Brain (Substantia   0.0               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   5.1       Fetal Liver   0.0   Brain (whole)   50.0       Liver ca. HepG2   0.0   Spinal Cord Pool   0.0       Kidney Pool   3.0   Adrenal Gland   0.0       Fetal Kidney   8.4   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.0                    
     [1127]               TABLE DG                          Panel 1.2                                                 Rel.   Rel.   Rel.       Rel.   Rel.   Rel.           Exp. (%)   Exp. (%)   Exp. (%)       Exp. (%)   Exp. (%)   Exp. (%)           Ag1130,   Ag1130,   Ag1198,       Ag1130,   Ag1130,   Ag1198,       Tissue   Run   Run   Run   Tissue   Run   Run   Run       Name   125117140   126566764   129140506   Name   125117140   126566764   129140506                                                     Endothelial   0.0   0.0   0.0   Renal ca.   0.0   0.0   0.0       cells               786-0       Heart   0.0   0.0   0.0   Renal ca.   7.3   4.7   0.0       (Fetal)               A498       Pancreas   0.0   0.0   0.0   Renal ca.   0.0   0.0   0.0                       RXF 393       Pancreatic   9.0   0.0   0.0   Renal ca.   0.0   0.0   0.0       ca. CAPAN 2               ACHN       Adrenal   0.0   2.6   0.0   Renal ca.   3.9   0.0   0.0       Gland               UO-31       Thyroid   0.0   0.0   0.0   Renal ca.   0.0   0.0   0.0                       TK-10       Salivary   0.0   0.0   0.0   Liver   26.6   0.0   0.0       gland       Pituitary   0.0   0.0   0.0   Liver   25.3   0.0   0.0       gland               (fetal)       Brain   0.0   0.0   0.0   Liver ca.   0.0   0.0   0.0       (fetal)               (hepatoblast)                       HepG2       Brain   2.6   20.0   0.0   Lung   0.0   0.0   0.0       (whole)       Brain   1.3   32.1   0.0   Lung   0.0   0.0   0.0       (amygdala)               (fetal)       Brain   1.5   3.8   0.0   Lung ca.   3.4   0.0   0.0       (cerebellum)               (small                       cell) LX-1       Brain   0.0   27.0   0.0   Lung ca.   28.5   74.2   0.0       (hippocampus)               (small                       cell) NCI-                       H69       Brain   9.9   22.5   9.8   Lung ca.   3.8   9.7   0.0       (thalamus)               (s.cell                       var.)                       SHP-77       Cerebral   0.0   0.0   0.0   Lung ca.   8.8   4.1   5.3       Cortex               (large                       cell)NCI-                       H460       Spinal cord   4.4   0.0   0.0   Lung ca.   51.4   9.5   7.2                       (non-sm.                       cell) A549       glio/astro   0.0   0.0   0.0   Lung ca.   0.0   0.0   0.0       U87-MG               (non-                       s.cell)                       NCI-H23       glio/astro   0.0   0.0   0.0   Lung ca.   8.4   2.7   9.6       U-118-MG               (non-                       s.cell)                       HOP-62       astrocytoma   2.9   0.0   0.0   Lung ca.   0.0   0.0   0.0       SW1783               (non-s.cl)                       NCI-                       H522       neuro*; met   0.0   0.0   0.0   Lung ca.   3.2   8.7   0.0       SK-N-AS               (squam.)                       SW 900       astrocytoma   5.1   0.0   0.0   Lung ca.   2.3   15.9   0.0       SF-539               (squam.)                       NCI-                       H596       astrocytoma   2.3   0.0   0.0   Mammary   0.0   0.0   0.0       SNB-75               gland       glioma   6.3   20.7   9.0   Breast   0.0   0.0   0.0       SNB-19               ca.*                       (pl.ef)                       MCF-7       glioma   1.4   0.0   1.8   Breast   0.0   0.0   0.0       U251               ca.*                       (pl.ef)                       MDA-                       MB-231       glioma SF-   0.0   0.0   0.0   Breast   14.1   37.4   0.0       295               ca.* (pl.                       ef) T47D       Heart   0.0   0.0   0.0   Breast ca.   12.5   21.0   12.3                       BT-549       Skeletal   2.3   0.0   0.0   Breast ca.   0.0   0.0   0.0       Muscle               MDA-N       Bone   0.0   0.0   0.0   Ovary   0.0   0.0   0.0       marrow       Thymus   0.0   0.0   0.0   Ovarian   0.0   0.0   0.0                       ca.                       OVCAR-3       Spleen   2.2   0.0   0.0   Ovarian   0.0   0.0   0.0                       ca.                       OVCAR-4       Lymph   0.0   0.0   0.0   Ovarian   66.9   35.4   4.4       node               ca.                       OVCAR-5       Colorectal   11.3   27.7   21.8   Ovarian   2.7   0.0   0.0       Tissue               ca.                       OVCAR-8       Stomach   0.0   0.0   0.0   Ovarian   6.0   0.0   0.0                       ca.                       IGROV-1       Small   5.4   0.0   0.0   Ovarian   30.8   0.0   0.0       intestine               ca.                       (ascites)                       SK-OV-3       Colon ca.   3.2   0.0   0.0   Uterus   0.0   0.0   0.0       SW480       Colon ca.*   0.0   0.0   0.0   Placenta   0.0   0.0   0.0       SW620       (SW480       met)       Colon ca.   1.9   14.4   0.0   Prostate   6.9   0.0   0.0       HT29       Colon ca.   0.0   0.0   0.0   Prostate   100.0   0.0   0.0       HCT-116               ca.* (bone                       met) PC-3       Colon ca.   0.0   0.0   0.0   Testis   54.7   100.0   36.9       CaCo-2       Colon ca.   72.2   75.8   100.0   Melanoma   4.2   0.0   0.0       Tissue               Hs688(A).T       (ODO3866)       Colon ca.   5.3   4.8   0.0   Melanoma*   2.7   34.2   13.3       HCC-2998               (met)                       Hs688(B).T       Gastric ca.*   50.3   0.0   0.0   Melanoma   0.0   0.0   0.0       (liver met)               UACC-       NCI-N87               62       Bladder   6.0   22.1   0.0   Melanoma   31.4   36.3   20.2                       M14       Trachea   0.0   0.0   0.0   Melanoma   0.0   0.0   0.0                       LOX                       IMVI       Kidney   2.0   0.0   0.0   Melanoma*   2.4   0.0   0.0                       (met)                       SK-MEL-5       Kidney   1.1   2.5   0.0       (fetal)                    
     [1128]               TABLE DH                          Panel 4R                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag1198, Run       Ag1198, Run       Tissue Name   142014937   Tissue Name   142014937                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   2.5   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   16.4       LAK cells IL-2 + IL-12   0.0   Lupus kidney   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 1   100.0       CD40       Monocytes rest   0.0   IBD Colitis 2   0.0       Monocytes LPS   0.0   IBD Crohn&#39;s   0.0       Macrophages rest   0.0   Colon   0.0       Macrophages LPS   0.0   Lung   0.0       HUVEC none   0.0   Thymus   0.0       HUVEC starved   0.0   Kidney   0.0                    
     [1129] CNS_neurodegeneration_v1.0 Summary: Ag3363—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1130] General_screening_panel_v1.4 Summary: Ag3363—Significant expression is seen in lung cancer cell line NCI-H1146 (CT=34.5) and lung cancer cell line SHP-77 (CT=34.2). Therefore, expression of this can be used to distinguish these samples from the rest of the samples on this panel.  
     [1131] Panel 1.2 Summary: Ag1130/Ag1198—Three different runs using the same primer sequences yield similar results. Significant expression of this gene is seen in testis and a colon cancer sample. Therefore, expression of this gene can be used to differentiate these samples from other samples on these panels. Results from a third experiment using the probe and primer set Ag1253 show low/undetectable levels of expression in all the samples on this panel.  
     [1132] Panel 1.3D Summary: Ag1253—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1133] Panel 2D Summary: Ag1603—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown)  
     [1134] Panel 4D Summary: Ag1130/Ag1198/Ag1253/Ag3363—Two experiments showed possible experimental difficulties, while the other three runs showed expression of this gene as low/undetectable (CTs&gt;35) across all of the samples on the panel.  
     [1135] Panel 4R Summary: Ag1198—Significant expression of this gene is seen only in the IBD colitis 1 sample (CT=34.2). Therefore, expression of this gene can be used to differentiate this sample from others on the panel.  
     [1136] Panel CNS 1 Summary: Ag1253/Ag1603—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1137] E. CG58516-01: G-Protein Beta WD-40 Repeats  
     [1138] Expression of gene CG58516-01 was assessed using the primer-probe set Ag3362, described in Table EA. Results of the RTQ-PCR runs are shown in Tables EB and EC.  
     [1139] Table EA. Probe Name Ag3362 
               TABLE EA                          Probe Name Ag3362                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gtcgggcaggacctttact-3′   19   1474   381               Probe   TET-5′-tcctacagctaattctgcagggcaca-3′-TAMRA   26   1498   382               Reverse   5′-tacgctttactcccgtaagtca-3′   22   1543   383                  
 
     [1140]               TABLE EB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3362,           Ag3362, Run       Run       Tissue Name   210153738   Tissue Name   210153738                                     AD 1 Hippo   9.9   Control (Path) 3   0.0               Temporal Ctx       AD 2 Hippo   33.2   Control (Path) 4   24.3               Temporal Ctx       AD 3 Hippo   4.3   AD 1 Occipital   2.0               Ctx       AD 4 Hippo   16.5   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   96.6   AD 3 Occipital   5.4               Ctx       AD 6 Hippo   43.2   AD 4 Occipital   24.7               Ctx       Control 2 Hippo   29.1   AD 5 Occipital   24.5               Ctx       Control 4 Hippo   16.6   AD 6 Occipital   31.9               Ctx       Control (Path) 3   3.8   Control 1 Occipital   0.9       Hippo       Ctx       AD 1 Temporal Ctx   7.1   Control 2 Occipital   89.5               Ctx       AD 2 Temporal Ctx   23.2   Control 3 Occipital   12.6               Ctx       AD 3 Temporal Ctx   5.6   Control 4 Occipital   6.3               Ctx       AD 4 Temporal Ctx   20.0   Control (Path) 1   65.1               Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   15.8       Ctx       Occipital Ctx       AD 5 SupTemporal   43.8   Control (Path) 3   2.0       Ctx       Occipital Ctx       AD 6 Inf Temporal   30.8   Control (Path) 4   11.6       Ctx       Occipital Ctx       AD 6 Sup Temporal   69.7   Control 1 Parietal   2.8       Ctx       Ctx       Control 1 Temporal   9.0   Control 2 Parietal   39.2       Ctx       Ctx       Control 2 Temporal   59.0   Control 3 Parietal   23.5       Ctx       Ctx       Control 3 Temporal   11.7   Control (Path) 1   69.7       Ctx       Parietal Ctx       Control 4 Temporal   8.2   Control (Path) 2   14.9       Ctx       Parietal Ctx       Control (Path) 1   56.3   Control (Path) 3   0.9       Temporal Ctx       Parietal Ctx       Control (Path) 2   34.2   Control (Path) 4   38.7       Temporal Ctx       Parietal Ctx                    
     [1141]               TABLE EC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3362,       (%) Ag3362,           Run       Run       Tissue Name   216523482   Tissue Name   216523482                                     Adipose   6.3   Renal ca. TK-10   44.1       Melanoma*   17.6   Bladder   9.4       Hs688(A).T       Melanoma*   18.3   Gastric ca. (liver met.)   21.6       Hs688(B).T       NCI-N87       Melanoma* M14   17.1   Gastric ca. KATO III   17.6       Melanoma*   13.6   Colon ca. SW-948   5.8       LOXIMVI       Melanoma* SK-   19.6   Colon ca. SW480   34.6       MEL-5       Squamous cell   14.6   Colon ca.* (SW480   14.2       carcinoma SCC-4       met) SW620       Testis Pool   4.0   Colon ca. HT29   7.2       Prostate ca.* (bone   90.8   Colon ca. HCT-116   14.3       met) PC-3       Prostate Pool   4.0   Colon ca. CaCo-2   19.8       Placenta   11.4   Colon cancer tissue   3.6       Uterus Pool   2.1   Colon ca. SW1116   9.4       Ovarian ca.   17.4   Colon ca. Colo-205   8.8       OVCAR-3       Ovarian ca. SK-   47.0   Colon ca. SW-48   13.2       OV-3       Ovarian ca.   14.7   Colon Pool   5.7       OVCAR-4       Ovarian ca.   31.6   Small Intestine Pool   10.2       OVCAR-5       Ovarian ca.   12.9   Stomach Pool   6.2       IGROV-1       Ovarian ca.   6.7   Bone Marrow Pool   1.3       OVCAR-8       Ovary   12.5   Fetal Heart   1.1       Breast ca. MCF-7   75.8   Heart Pool   3.4       Breast ca. MDA-   30.4   Lymph Node Pool   8.7       MB-231       Breast ca. BT 549   65.5   Fetal Skeletal Muscle   2.3       Breast ca. T47D   100.0   Skeletal Muscle Pool   9.4       Breast ca. MDA-N   33.4   Spleen Pool   4.6       Breast Pool   4.6   Thymus Pool   7.3       Trachea   7.7   CNS cancer   33.9               (glio/astro) U87-MG       Lung   4.9   CNS cancer   27.2               (glio/astro) U-118-MG       Fetal Lung   7.1   CNS cancer   16.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   9.3   CNS cancer (astro)   14.3               SF-539       Lung ca. LX-1   15.8   CNS cancer (astro)   60.7               SNB-75       Lung ca. NCI-H146   4.9   CNS cancer (glio)   13.8               SNB-19       Lung ca. SHP-77   16.5   CNS cancer (glio) SF-   28.5               295       Lung ca. A549   27.2   Brain (Amygdala)   5.3               Pool       Lung ca. NCI-H526   4.1   Brain (cerebellum)   5.0       Lung ca. NCI-H23   15.0   Brain (fetal)   16.4       Lung ca. NCI-H460   9.5   Brain (Hippocampus)   5.5               Pool       Lung ca. HOP-62   7.6   Cerebral Cortex Pool   8.7       Lung ca. NCI-H522   18.2   Brain (Substantia   8.3               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   6.3       Fetal Liver   7.3   Brain (whole)   7.0       Liver ca. HepG2   29.5   Spinal Cord Pool   5.6       Kidney Pool   17.7   Adrenal Gland   6.3       Fetal Kidney   4.6   Pituitary gland Pool   0.8       Renal ca. 786-0   17.2   Salivary Gland   5.6       Renal ca. A498   5.1   Thyroid (female)   9.7       Renal ca. ACHN   17.3   Pancreatic ca.   11.7               CAPAN2       Renal ca. UO-31   11.1   Pancreas Pool   9.2                    
     [1142] CNS_neurodegeneration_v1.0 Summary: Ag3362 Highest expression of the CG58516-01 gene is seen in the occipital cortex of a control patient and the temporal cortex of an Alzheimer&#39;s patient. While the CG58516-01 gene does not appear to be preferentially expressed in Alzheimer&#39;s disease, this panel confirms expression of the CG58516-01 gene at moderate/high levels in the brain in an additional set of individuals. Please see Panel 1.4 for discussion of potential utility of this gene in the central nervous system.  
     [1143] General_screening_panel_v1.4 Summary: Ag3362 The CG58516-01 gene is widely expressed in this panel, with highest expression in the breast cancer cell line T47D (CT=29). Significant expression is also seen in cell lines derived from prostate, breast and ovarian cancers. In general, expression of the CG58516-0l gene appears to be greater in the cancer cell lines than in normal tissue. Thus, the expression of this gene could be used to distinguish these cell line types from others in the panel.  
     [1144] Among tissues involved in central nervous system function, this gene is expressed at low but significant levels in all brain regions examined. This gene encodes a protein with a putativie zinc-finger motif. Since these proteins are known to interact with nucleic acids, this suggests that this gene product may play a potential role in transcription. Thus, therapeutic modulation of the CG58516-01 gene product may be used to regulate the transcription of disease-related proteins such as ataxin, huntingtin, or various apoptosis cascade proteins.  
     [1145] Among tissues with metabolic function, this gene is expressed at low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, skeletal muscle, heart, and fetal liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     REFERENCES  
     [1146] 1. Zhu W, Chan E K, Li J, Hemmerich P, Tan E M. (2001) Transcription activating property of autoantigen SG2NA and modulating effect of WD-40 repeats. Exp Cell Res. 269(2):312-21  
     [1147] Panel 4D Summary: Ag3362 Results from one experiment with the CG58516-01 gene are not included because the amp plot corresponding to the run indicates that there were problems with the experiment.  
     [1148] F. CG58473-01: Protein Kinase  
     [1149] Expression of gene CG58473-01 was assessed using the primer-probe set Ag3357, described in Table FA. Results of the RTQ-PCR runs are shown in Tables FB and FC.  
     [1150] Table FA. Probe Name Ag3357 
               TABLE FA                          Probe Name Ag3357                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gtcaaggtggccctaaaattc-3′   21   853   384               Probe   TET-5′-ccaggacctcatctccaagctgctta-3′-TAMRA   26   897   385               Reverse   5′-agccgttctgaggggttat-3′   19   926   386                  
 
     [1151]               TABLE FB                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3357,       (%) Ag3357,           Run       Run       Tissue Name   216523477   Tissue Name   216523477                                     Adipose   0.0   Renal ca. TK-10   13.2       Melanoma*   0.0   Bladder   7.2       Hs688(A).T       Melanoma*   1.1   Gastric ca. (liver met.)   5.4       Hs688(B).T       NCI-N87       Melanoma* M14   50.0   Gastric ca. KATO III   49.0       Melanoma*   33.0   Colon ca. SW-948   14.9       LOXIMVI       Melanoma* SK-   24.7   Colon ca. SW480   95.9       MEL-5       Squamous cell   11.6   Colon ca.* (SW480   53.6       carcinoma SCC-4       met) SW620       Testis Pool   8.2   Colon ca. HT29   10.3       Prostate ca.* (bone   3.2   Colon ca. HCT-116   76.3       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   14.1       Placenta   2.4   Colon cancer tissue   6.3       Uterus Pool   0.0   Colon ca. SW1116   18.6       Ovarian ca.   51.1   Colon ca. Colo-205   24.3       OVCAR-3       Ovarian ca. SK-   53.2   Colon ca. SW-48   26.1       OV-3       Ovarian ca.   10.4   Colon Pool   4.6       OVCAR-4       Ovarian ca.   12.3   Small Intestine Pool   1.7       OVCAR-5       Ovarian ca.   10.1   Stomach Pool   1.2       IGROV-1       Ovarian ca.   13.4   Bone Marrow Pool   1.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   20.3   Heart Pool   0.0       Breast ca. MDA-   65.1   Lymph Node Pool   1.4       MB-231       Breast ca. BT 549   100.0   Fetal Skeletal Muscle   0.0       Breast ca. T47D   34.2   Skeletal Muscle Pool   1.6       Breast ca. MDA-N   36.3   Spleen Pool   3.4       Breast Pool   1.3   Thymus pool   4.7       Trachea   0.0   CNS cancer   7.8               (glio/astro) U87-MG       Lung   0.0   CNS cancer   54.0               (glio/astro) U-118-MG       Fetal Lung   5.0   CNS cancer   7.9               (neuro; met) SK-N-AS       Lung ca. NCI-N417   17.9   CNS cancer (astro)   22.4               SF-539       Lung ca. LX-1   28.5   CNS cancer (astro)   19.2               SNB-75       Lung ca. NCI-H146   74.7   CNS cancer (glio)   14.6               SNB-19       Lung ca. SHP-77   40.6   CNS cancer (glio) SF-   3.0               295       Lung ca. A549   64.6   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   23.8   Brain (cerebellum)   0.0       Lung ca. NCI-H23   63.7   Brain (fetal)   0.0       Lung ca. NCI-H460   0.8   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   2.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   34.4   Brain (Substantia   2.6               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   9.3       Fetal Liver   0.0   Brain (whole)   2.5       Liver ca. HepG2   11.4   Spinal Cord Pool   0.0       Kidney Pool   0.0   Adrenal Gland   0.0       Fetal Kidney   3.1   Pituitary gland Pool   1.4       Renal ca. 786-0   20.0   Salivary Gland   0.0       Renal ca. A498   3.6   Thyroid (female)   0.0       Renal ca. ACHN   18.9   Pancreatic ca.   20.4               CAPAN2       Renal ca. UO-31   10.4   Pancreas Pool   1.3                    
     [1152]               TABLE FC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3357, Run       Ag3357, Run       Tissue Name   165231196   Tissue Name   165231196                                     Secondary Th1 act   9.0   HUVEC IL-1beta   9.5       Secondary Th2 act   43.2   HUVEC IFN gamma   6.3       Secondary Tr1 act   46.0   HUVEC TNF alpha +   7.3               IFN gamma       Secondary Th1 rest   6.7   HUVEC TNF alpha +   25.3               IL4       Secondary Th2 rest   12.2   HUVEC IL-11   13.1       Secondary Tr1 rest   1.9   Lung Microvascular EC   3.3               none       Primary Th1 act   6.1   Lung Microvascular EC   7.1               TNF alpha + IL-1beta       Primary Th2 act   21.8   Microvascular Dermal   10.9               EC none       Primary Tr1 act   33.0   Microsvasular Dermal   7.3               EC TNF alpha + IL-1beta       Primary Th1 rest   28.1   Bronchial epithelium   1.9               TNF alpha + IL1beta       Primary Th2 rest   12.1   Small airway epithelium   3.6               none       Primary Tr1 rest   29.7   Small airway epithelium   36.3               TNF alpha + IL-1beta       CD45RA CD4   28.5   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   39.8   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   18.6   Astrocytes rest   1.4       Secondary CD8   26.8   Astrocytes TNF alpha +   1.2       lymphocyte rest       IL-1beta       Secondary CD8   19.2   KU-812 (Basophil) rest   18.2       lymphocyte act       CD4 lymphocyte none   10.6   KU-812 (Basophil)   30.4               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   15.6   CCD1106   18.3       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   7.7               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   42.6   Liver cirrhosis   25.7       LAK cells IL-2 + IL-12   24.0   Lupus kidney   0.0       LAK cells IL-2 + IFN   24.8   NCI-H292 none   7.8       gamma       LAK cells IL-2 + IL-18   40.3   NCI-H292 IL-4   26.4       LAK cells   0.0   NCI-H292 IL-9   29.7       PMA/ionomycin       NK Cells IL-2 rest   23.5   NCI-H292 IL-13   20.7       Two Way MLR 3 day   13.7   NCI-H292 IFN gamma   27.9       Two Way MLR 5 day   13.2   HPAEC none   8.6       Two Way MLR 7 day   11.7   HPAEC TNF alpha + IL-   2.4               1beta       PBMC rest   0.0   Lung fibroblast none   5.5       PBMC PWM   52.1   Lung fibroblast TNF   2.2               alpha + IL-1beta       PBMC PHA-L   14.6   Lung fibroblast IL-4   0.0       Ramos (B cell) none   16.5   Lung fibroblast IL-9   0.0       Ramos (B cell)   14.7   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   100.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   10.4   Dermal fibroblast   40.1       and IL-4       CCD1070 rest       EOL-1 dbcAMP   9.9   Dermal fibroblast   43.8               CCD1070 TNF alpha       EOL-1 dbcAMP   13.2   Dermal fibroblast   23.5       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   4.7   Dermal fibroblast IFN   3.7               gamma       Dendritic cells LPS   1.1   Dermal fibroblast IL-4   4.6       Dendritic cells anti-   0.0   IBD Colitis 2   0.0       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   0.0   Colon   28.1       Macrophages rest   4.3   Lung   59.0       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   28.3   Kidney   10.0       HUVEC starved   25.3                    
     [1153] CNS_neurodegeneration_v1.0 Summary: Ag3357—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1154] General_screening_panel_v1.4 Summary: Ag3357 This gene is primarily expressed in cancer cell lines, with highest expression in a breast cancer cell line BT 549(CT=32.8). This gene is expressed in the following cell lines but not the corresponding healthy tissue: gastric, brain, colon, lung, breast, ovarian cancer and melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition using antibodies or small molecule drugs might be of use in the treatment of these cancers.  
     [1155] Panel 4D Summary: Ag3357 Highest expression of the CG58473-01 gene is seen in pokeweed mitogen-activated purified peripheral blood B lymphocytes (CT=33.2). In addition, no expression of the transcript is seen in PBMC that contain normal B cells, but the transcript is induced when PBMC are treated with the B cell selective pokeweed mitogen. The transcript is not seen in the B cell lymphoma cell line Ramos regardless of stimulation. Thus, the putative protein encoded by this gene could potentially be used diagnostically to identify activated B cells. Therefore, therapeutics that antagonize the function of this gene product may be useful as therapeutic drugs to reduce or eliminate the symptoms in patients with autoimmune and inflammatory diseases in which B cells play a part in the intiation or progression of the disease process, such as lupus erythematosus, Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.  
     [1156] G. CG58470-01: UDP-N-Acetylhexosamine Pyrophosphorylase  
     [1157] Expression of gene CG58470-01 was assessed using the primer-probe set Ag5940, described in Table GA.  
     [1158] Table GA. Probe Name Ag5940 
               TABLE GA                          Probe Name Ag5940                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atatcctgaagctacaacagttagct-3′   26   422   387               Probe   TET-5′-tggcaacaaatgcattattccatattacg-3′-TAMRA   29   459   388               Reverse   5′-gagtgaactcgctggtcatg-3′   20   489   389                  
 
     [1159] General_screening_panel_v1.5 Summary: Ag5940—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1160] Panel 5 Islet Summary: Ag5940—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1161] H. CG58593-01: Ubiquitin-52  
     [1162] Expression of gene CG58593-01 was assessed using the primer-probe set Ag3421, described in Table HA.  
     [1163] Table HA. Probe Name Ag3421 
               TABLE HA                          Probe Name Ag3421                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atctgctgcaagtgctatgc-3′   20   291   390               Probe   TET-5′-cggtgctatcaactgccacaagaaga-3′-TAMRA   26   323   391               Reverse   5′-tgaccttcttcctggggtac-3′   20   371   392                  
 
     [1164] CNS_neurodegeneration_v1.0 Summary: Ag3421—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1165] General_screening_panel_v1.4 Summary: Ag3421—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1166] Panel 4D Summary: Ag3421—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1167] I. CG57871-01: Tousled-Like Kinase  
     [1168] Expression of gene CG57871-01 was assessed using the primer-probe set Ag3351, described in Table IA. Results of the RTQ-PCR runs are shown in Tables IB and IC.  
     [1169] Table IA. Probe Name Ag3351 
               TABLE IA                          Probe Name Ag3351                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gatcctcactgcaacattcttt-3′   22   346   393               Probe   TET-5′-aatcccttaccgcgacgagtagaaca-3′-TAMRA   26   372   394               Revers   5′-gcactgccatctaaaccataga-3′   22   403   395                  
 
     [1170]               TABLE IB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.                   (%) Ag3351,       Rel. Exp.(%)           Run       Ag3351, Run       Tissue Name   210141594   Tissue Name   210141594                                     AD 1 Hippo   10.4   Control (Path) 3   3.0               Temporal Ctx       AD 2 Hippo   33.4   Control (Path) 4   65.1               Temporal Ctx       AD 3 Hippo   5.5   AD 1 Occipital   20.2               Ctx       AD 4 Hippo   8.4   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   100.0   AD 3 Occipital   3.8               Ctx       AD 6 Hippo   33.4   AD 4 Occipital   45.1               Ctx       Control 2 Hippo   29.9   AD 5 Occipital   15.2               Ctx       Control 4 Hippo   6.7   AD 6 Occipital   46.7               Ctx       Control (Path) 3   3.7   Control 1 Occipital   2.7       Hippo       Ctx       AD 1 Temporal Ctx   16.8   Control 2 Occipital   52.5               Ctx       AD 2 Temporal Ctx   45.1   Control 3 Occipital   45.4               Ctx       AD 3 Temporal Ctx   6.9   Control 4 Occipital   6.3               Ctx       AD 4 Temporal Ctx   54.0   Control (Path) 1   79.0               Occipital Ctx       AD 5 Inf Temporal   92.0   Control (Path) 2   34.4       Ctx       Occipital Ctx       AD 5 SupTemporal   13.0   Control (Path) 3   0.8       Ctx       Occipital Ctx       AD 6 Inf Temporal   48.6   Control (Path) 4   40.6       Ctx       Occipital Ctx       AD 6 Sup Temporal   56.6   Control 1 Parietal   6.9       Ctx       Ctx       Control 1 Temporal   6.2   Control 2 Parietal   48.0       Ctx       Ctx       Control 2 Temporal   29.3   Control 3 Parietal   26.1       Ctx       Ctx       Control 3 Temporal   32.8   Control (Path) 1   73.7       Ctx       Parietal Ctx       Control 4 Temporal   13.9   Control (Path) 2   57.4       Ctx       Parietal Ctx       Control (Path) 1   79.6   Control (Path) 3   3.4       Temporal Ctx       Parietal Ctx       Control (Path) 2   97.3   Control (Path) 4   78.5       Temporal Ctx       Parietal Ctx                    
     [1171]               TABLE IC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3351, Run       Ag3351, Run       Tissue Name   165222896   Tissue Name   165222896                                     Secondary Th1 act   16.5   HUVEC IL-1beta   15.4       Secondary Th2 act   26.4   HUVEC IFN gamma   13.5       Secondary Tr1 act   23.3   HUVEC TNF alpha +   17.0               IFN gamma       Secondary Th1 rest   6.0   HUVEC TNF alpha +   11.0               IL4       Secondary Th2 rest   10.7   HUVEC IL-11   5.4       Secondary Tr1 rest   2.1   Lung Microvascular EC   12.4               none       Primary Th1 act   19.2   Lung Microvascular EC   9.6               TNF alpha + IL-1beta       Primary Th2 act   17.6   Microvascular Dermal   14.7               EC none       Primary Tr1 act   36.1   Microsvasular Dermal   14.8               EC TNF alpha + IL-1beta       Primary Th1 rest   55.5   Bronchial epithelium   14.1               TNF alpha + IL1beta       Primary Th2 rest   43.8   Small airway epithelium   7.7               none       Primary Tr1 rest   15.9   Small airway epithelium   50.3               TNF alpha + IL-1beta       CD45RA CD4   13.0   Coronery artery SMC rest   15.6       lymphocyte act       CD45RO CD4   21.0   Coronery artery SMC   6.1       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   12.9   Astrocytes rest   11.5       Secondary CD8   14.9   Astrocytes TNF alpha +   11.8       lymphocyte rest       IL-1beta       Secondary CD8   14.8   KU-812 (Basophil) rest   19.2       lymphocyte act       CD4 lymphocyte none   10.7   KU-812 (Basophil)   54.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   12.7   CCD1106   12.2       CD95 CH11       (Keratinocytes) none       LAK cells rest   17.2   CCD1106   9.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   22.4   Liver cirrhosis   7.4       LAK cells IL-2 + IL-12   20.4   Lupus kidney   3.4       LAK cells IL-2 + IFN   37.9   NCI-H292 none   47.6       gamma       LAK cells IL-2 + IL-18   18.6   NCI-H292 IL-4   42.3       LAK cells   10.5   NCI-H292 IL-9   30.4       PMA/ionomycin       NK Cells IL-2 rest   17.8   NCI-H292 IL-13   15.7       Two Way MLR 3 day   33.2   NCI-H292 IFN gamma   25.5       Two Way MLR 5 day   10.6   HPAEC none   13.5       Two Way MLR 7 day   9.9   HPAEC TNF alpha + IL-   17.7               1beta       PBMC rest   12.8   Lung fibroblast none   11.5       PBMC PWM   63.3   Lung fibroblast TNF   12.4               alpha + IL-1beta       PBMC PHA-L   18.0   Lung fibroblast IL-4   31.2       Ramos (B cell) none   14.0   Lung fibroblast IL-9   22.2       Ramos (B cell)   77.9   Lung fibroblast IL-13   27.4       ionomycin       B lymphocytes PWM   100.0   Lung fibroblast IFN   44.8               gamma       B lymphocytes CD40L   30.8   Dermal fibroblast   33.7       and IL-4       CCD1070 rest       EOL-1 dbcAMP   11.3   Dermal fibroblast   50.0               CCD1070 TNF alpha       EOL-1 dbcAMP   13.7   Dermal fibroblast   13.4       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   14.7   Dermal fibroblast IFN   14.3               gamma       Dendritic cells LPS   19.8   Dermal fibroblast IL-4   25.7       Dendritic cells anti-   14.2   IBD Colitis 2   2.0       CD40       Monocytes rest   22.5   IBD Crohn&#39;s   3.2       Monocytes LPS   32.8   Colon   26.8       Macrophages rest   31.0   Lung   14.6       Macrophages LPS   30.8   Thymus   28.7       HUVEC none   18.3   Kidney   45.4       HUVEC starved   45.7                    
     [1172] CNS_neurodegeneration_v1.0 Summary: Ag3351—This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. While no differential expression of this gene is detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls, the widespread expression of this gene in the brain suggests that therapeutic modulation of the expression or function of this gene may be effective in the treatment of neurologic disorders such as Parkinson&#39;s disease, epilepsy, stroke and multiple sclerosis.  
     [1173] General_screening_panel_v1.4 Summary: Ag3351—Results from one experiment are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [1174] Panel 4D Summary: Ag3351 The CG57871-01 gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1175] J. CG58590-01 and CG58590-02: PALS Guanylate Kinase  
     [1176] Expression of gene CG58590-01 and CG58590-02 was assessed using the primer-probe set Ag3380, described in Table JA. Results of the RTQ-PCR runs are shown in Tables JB, JC and JD. Please note that CG58590-02 represents a full-length physical clone of the CG58590-01 gene, validating the prediction of the gene sequence.  
     [1177] Table JA. Probe Name Ag3380 
               TABLE JA                          Probe Name Ag3380                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tttgatacggcaattgtgaatt-3′   22   1931   396               Probe   TET-5′-ccgatcttgataaagcctatcaggaa-3′-TAMRA   26   1953   397               Reverse   5′-cccactgaggttcagtatcaag-3′   22   2000   398                  
 
     [1178]               TABLE JB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3380,           Ag3380, Run       Run       Tissue Name   210153753   Tissue Name   210153753                                     AD 1 Hippo   12.9   Control (Path) 3   4.7               Temporal Ctx       AD 2 Hippo   27.7   Control (Path) 4   24.3               Temporal Ctx       AD 3 Hippo   4.8   AD 1 Occipital   15.6               Ctx       AD 4 Hippo   7.7   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   100.0   AD 3 Occipital   7.5               Ctx       AD 6 Hippo   64.2   AD 4 Occipital   19.1               Ctx       Control 2 Hippo   25.5   AD 5 Occipital   29.5               Ctx       Control 4 Hippo   9.9   AD 6 Occipital   40.1               Ctx       Control (Path) 3   8.4   Control 1 Occipital   4.2       Hippo       Ctx       AD 1 Temporal Ctx   17.6   Control 2 Occipital   65.5               Ctx       AD 2 Temporal Ctx   25.3   Control 3 Occipital   13.4               Ctx       AD 3 Temporal Ctx   4.9   Control 4 Occipital   6.4               Ctx       AD 4 Temporal Ctx   17.4   Control (Path) 1   78.5               Occipital Ctx       AD 5 Inf Temporal   81.8   Control (Path) 2   9.4       Ctx       Occipital Ctx       AD 5 SupTemporal   42.9   Control (Path) 3   3.2       Ctx       Occipital Ctx       AD 6 Inf Temporal   48.6   Control (Path) 4   9.9       Ctx       Occipital Ctx       AD 6 Sup Temporal   53.6   Control 1 Parietal   6.0       Ctx       Ctx       Control 1 Temporal   5.7   Control 2 Parietal   37.1       Ctx       Ctx       Control 2 Temporal   34.6   Control 3 Parietal   16.5       Ctx       Ctx       Control 3 Temporal   10.2   Control (Path) 1   67.4       Ctx       Parietal Ctx       Control 4 Temporal   7.1   Control (Path) 2   18.7       Ctx       Parietal Ctx       Control (Path) 1   41.5   Control (Path) 3   3.3       Temporal Ctx       Parietal Ctx       Control (Path) 2   29.5   Control (Path) 4   34.4       Temporal Ctx       Parietal Ctx                    
     [1179]               TABLE JC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3380,       (%) Ag3380,           Run       Run       Tissue Name   217043276   Tissue Name   217043276                                     Adipose   9.0   Renal ca. TK-10   25.5       Melanoma*   18.9   Bladder   15.9       Hs688(A).T       Melanoma*   16.8   Gastric ca. (liver met.)   52.5       Hs688(B).T       NCI-N87       Melanoma* M14   14.9   Gastric ca. KATO III   34.6       Melanoma*   21.6   Colon ca. SW-948   4.9       LOXIMVI       Melanoma* SK-   27.0   Colon ca. SW480   82.4       MEL-5       Squamous cell   28.7   Colon ca.* (SW480   20.6       carcinoma SCC-4       met) SW620       Testis Pool   5.1   Colon ca. HT29   9.2       Prostate ca.* (bone   59.9   Colon ca. HCT-116   20.6       met) PC-3       Prostate Pool   8.6   Colon ca. CaCo-2   22.8       Placenta   3.9   Colon cancer tissue   10.1       Uterus Pool   1.9   Colon ca. SW1116   6.2       Ovarian ca.   32.5   Colon ca. Colo-205   4.9       OVCAR-3       Ovarian ca. SK-   57.4   Colon ca. SW-48   4.2       OV-3       Ovarian ca.   14.7   Colon Pool   11.4       OVCAR-4       Ovarian ca.   59.5   Small Intestine Pool   9.8       OVCAR-5       Ovarian ca.   13.1   Stomach Pool   7.4       IGROV-1       Ovarian ca.   19.2   Bone Marrow Pool   4.2       OVCAR-8       Ovary   5.9   Fetal Heart   6.3       Breast ca. MCF-7   35.1   Heart Pool   4.9       Breast ca. MDA-   58.2   Lymph Node Pool   11.4       MB-231       Breast ca. BT 549   26.8   Fetal Skeletal Muscle   3.3       Breast ca. T47D   100.0   Skeletal Muscle Pool   8.1       Breast ca. MDA-N   8.7   Spleen Pool   5.6       Breast Pool   10.4   Thymus Pool   6.3       Trachea   5.5   CNS cancer   39.2               (glio/astro) U87-MG       Lung   3.8   CNS cancer   54.7               (glio/astro) U-118-MG       Fetal Lung   11.8   CNS cancer   19.6               (neuro; met) SK-N-AS       Lung ca. NCI-N417   3.2   CNS cancer (astro)   12.2               SF-539       Lung ca. LX-1   20.7   CNS cancer (astro)   29.7               SNB-75       Lung ca. NCI-H146   3.8   CNS cancer (glio)   13.4               SNB-19       Lung ca. SHP-77   17.9   CNS cancer (glio) SF-   28.9               295       Lung ca. A549   30.6   Brain (Amygdala)   11.8               Pool       Lung ca. NCI-H526   3.6   Brain (cerebellum)   6.0       Lung ca. NCI-H23   29.3   Brain (fetal)   8.4       Lung ca. NCI-H460   14.8   Brain (Hippocampus)   14.5               Pool       Lung ca. HOP-62   19.5   Cerebral Cortex Pool   16.2       Lung ca. NCI-H522   28.7   Brain (Substantia   16.0               nigra) Pool       Liver   0.4   Brain (Thalamus) Pool   22.7       Fetal Liver   11.9   Brain (whole)   5.9       Liver ca. HepG2   12.9   Spinal Cord Pool   16.0       Kidney Pool   18.4   Adrenal Gland   5.1       Fetal Kidney   22.8   Pituitary gland Pool   3.8       Renal ca. 786-0   28.5   Salivary Gland   2.1       Renal ca. A498   5.0   Thyroid (female)   8.2       Renal ca. ACHN   22.4   Pancreatic ca.   51.4               CAPAN 2       Renal ca. UO-31   36.9   Pancreas Pool   12.3                    
     [1180]               TABLE JD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3380, Run       Ag3380, Run       Tissue Name   165296532   Tissue Name   165296532                                     Secondary Th1 act   13.1   HUVEC IL-1beta   15.0       Secondary Th2 act   14.6   HUVEC IFN gamma   19.6       Secondary Tr1 act   15.2   HUVEC TNF alpha +   28.3               IFN gamma       Secondary Th1 rest   4.6   HUVEC TNF alpha +   26.1               IL4       Secondary Th2 rest   4.7   HUVEC IL-11   7.8       Secondary Tr1 rest   8.0   Lung Microvascular EC   25.5               none       Primary Th1 act   14.9   Lung Microvascular EC   19.5               TNF alpha + IL-1beta       Primary Th2 act   13.2   Microvascular Dermal   37.9               EC none       Primary Tr1 act   20.7   Microsvasular Dermal   24.8               EC TNF alpha + IL-1beta       Primary Th1 rest   35.6   Bronchial epithelium   37.1               TNF alpha + IL1beta       Primary Th2 rest   24.0   Small airway epithelium   15.0               none       Primary Tr1 rest   16.2   Small airway epithelium   100.0               TNF alpha + IL-1beta       CD45RA CD4   23.3   Coronery artery SMC rest   30.1       lymphocyte act       CD45RO CD4   18.2   Coronery artery SMC   13.6       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   7.4   Astrocytes rest   22.5       Secondary CD8   13.4   Astrocytes TNF alpha +   21.2       lymphocyte rest       IL-1beta       Secondary CD8   4.4   KU-812 (Basophil) rest   17.9       lymphocyte act       CD4 lymphocyte none   8.0   KU-812 (Basophil)   68.3               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   10.7   CCD1106   22.1       CD95 CH11       (Keratinocytes) none       LAK cells rest   13.5   CCD1106   9.2               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   12.9   Liver cirrhosis   3.1       LAK cells IL-2 + IL-12   13.2   Lupus kidney   2.9       LAK cells IL-2 + IFN   15.6   NCI-H292 none   48.6       gamma       LAK cells IL-2 + IL-18   17.0   NCI-H292 IL-4   66.9       LAK cells   9.5   NCI-H292 IL-9   59.5       PMA/ionomycin       NK Cells IL-2 rest   7.0   NCI-H292 IL-13   36.6       Two Way MLR 3 day   15.2   NCI-H292 IFN gamma   42.6       Two Way MLR 5 day   7.0   HPAEC none   14.3       Two Way MLR 7 day   9.6   HPAEC TNF alpha + IL-   25.9               1beta       PBMC rest   6.4   Lung fibroblast none   12.5       PBMC PWM   60.7   Lung fibroblast TNF   11.0               alpha + IL-1beta       PBMC PHA-L   18.8   Lung fibroblast IL-4   25.9       Ramos (B cell) none   31.9   Lung fibroblast IL-9   20.6       Ramos (B cell)   94.0   Lung fibroblast IL-13   18.8       ionomycin       B lymphocytes PWM   42.9   Lung fibroblast IFN   23.3               gamma       B lymphocytes CD40L   24.7   Dermal fibroblast   59.5       and IL-4       CCD1070 rest       EOL-1 dbcAMP   12.9   Dermal fibroblast   64.2               CCD1070 TNF alpha       EOL-1 dbcAMP   10.4   Dermal fibroblast   32.8       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   19.6   Dermal fibroblast IFN   10.7               gamma       Dendritic cells LPS   10.7   Dermal fibroblast IL-4   21.6       Dendritic cells anti-   18.8   IBD Colitis 2   2.0       CD40       Monocytes rest   15.0   IBD Crohn&#39;s   3.6       Monocytes LPS   13.8   Colon   36.9       Macrophages rest   25.3   Lung   19.3       Macrophages LPS   8.1   Thymus   72.2       HUVEC none   19.9   Kidney   24.5       HUVEC starved   35.8                    
     [1181] CNS_neurodegeneration_v1.0 Summary: Ag3380 This panel does not show differential expression of the CG58590-01 gene in Alzheimer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.  
     [1182] General_screening_panel_v1.4 Summary: Ag3380—This gene is expressed at low to moderate levels in all samples on this pattern. The highest level of expression is seen in breast cancer cell line T47D (CT=27.8). Based on expression in this panel, this gene may be involved in brain, colon, renal, lung, ovarian and prostate cancer as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition using antibodies or small molecule drugs might be of use in the treatment of these cancers.  
     [1183] This gene product is also expressed in adipose, pancreas, adrenal, thyroid, pituitary, skeletal muscle, heart, and fetal liver. This widespread expression in tissues with metabolic function suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes;. Furthermore, this gene is more highly expressed in fetal (CT=30.9) liver when compared to expression in the adult (CT&gt;35) and may be useful for the differentiation of the fetal and adult sources of this tissue.  
     [1184] In addition, this gene is expressed at moderate levels in the all regions of the CNS examined. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1185] Panel 4D Summary: Ag3380—This gene is expressed from moderate to low levels across all of the samples on this panel. The highest expression is seen in small airway epithelium treated with TNFalpha and IL-1beta (CT=28.7). Interestingly, expression is much lower in untreated small airway epithelium (CT=31.5). There is also a significant difference between mononuclear cells treated with PWM (CT=29.5) and untreated cells (CT=32.7). Therefore, expression of this gene can be used to differentiate treated and untreated samples.  
     [1186] Expression of this gene is detected at a moderate level (CT=30.2) in normal colon (similar levels for colon are seen on panel 1.4 (CT=30.9), but is significantly lower in the IBD Colitis 2 (CT=34.4) and IBD Crohn&#39;s (CT=33.5) samples. Therefore, therapies designed with the protein encoded for by this gene may potentially modulate colon function and play a role in the identification and treatment of inflammatory or autoimmune diseases, which effect the colon including Crohn&#39;s disease and ulcerative colitis.  
     [1187] K. CG58572-01 and CG58572-02: Glucosamine-Phosphate N-Acetyltransferase  
     [1188] Expression of gene CG58572-01 and full length clone CG58572-02 was assessed using the primer-probe set Ag3375, described in Table KA. Results of the RTQ-PCR runs are shown in Tables KB, KC and KD.  
     [1189] Table KA. Probe Name Ag3375 
               TABLE KA                          Probe Name Ag3375                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-aagaagtggactggagtcagaa-3′   22   58   399               Probe   TET-5′-tacattttctccagccatttccccaa-3′-TAMRA   26   86   400               Reverse   5′-agcagtacaaagaggcctcaa-3′   21   135   401                  
 
     [1190]               TABLE KB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.                   (%) Ag3375,       Rel. Exp. (%)           Run       Ag3375, Run       Tissue Name   210154239   Tissue Name   210154239                                     AD 1 Hippo   17.1   Control (Path) 3   4.8               Temporal Ctx       AD 2 Hippo   19.3   Control (Path) 4   27.5               Temporal Ctx       AD 3 Hippo   7.4   AD 1 Occipital Ctx   11.5       AD 4 Hippo   4.5   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   72.2   AD 3 Occipital Ctx   5.9       AD 6 Hippo   53.6   AD 4 Occipital Ctx   12.7       Control 2 Hippo   20.3   AD 5 Occipital Ctx   26.6       Control 4 Hippo   6.8   AD 6 Occipital Ctx   19.8       Control (Path) 3   5.5   Control 1 Occipital   3.2       Hippo       Ctx       AD 1 Temporal   11.6   Control 2 Occipital   36.1       Ctx       Ctx       AD 2 Temporal   23.8   Control 3 Occipital   7.4       Ctx       Ctx       AD 3 Temporal   5.5   Control 4 Occipital   4.1       Ctx       Ctx       AD 4 Temporal   16.5   Control (Path) 1   66.0       Ctx       Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   8.2       Ctx       Occipital Ctx       AD 5 Sup   55.9   Control (Path) 3   1.9       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   37.9   Control (Path) 4   12.2       Ctx       Occipital Ctx       AD 6 Sup   59.5   Control 1 Parietal   2.4       Temporal Ctx       Ctx       Control 1   3.5   Control 2 Parietal   31.6       Temporal Ctx       Ctx       Control 2   25.3   Control 3 Parietal   11.7       Temporal Ctx       Ctx       Control 3   8.2   Control (Path) 1   49.7       Temporal Ctx       Parietal Ctx       Control 3   4.0   Control (Path) 2   15.4       Temporal Ctx       Parietal Ctx       Control (Path) 1   52.9   Control (Path) 3   4.2       Temporal Ctx       Parietal Ctx       Control (Path) 2   26.6   Control (Path) 4   32.5       Temporal Ctx       Parietal Ctx                    
     [1191]               TABLE KC                          Panel 1.3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3375,       Ag3375,       Tissue Name   Run 165674233   Tissue Name   Run 165674233                                     Liver adenocarcinoma   51.8   Kidney (fetal)   9.7       Pancreas   9.3   Renal ca. 786-0   19.6       Pancreatic ca. CAPAN 2   52.1   Renal ca. A498   26.2       Adrenal gland   8.9   Renal ca. RXF 393   15.7       Thyroid   6.3   Renal ca. ACHN   8.2       Salivary gland   18.3   Renal ca. UO-31   35.4       Pituitary gland   15.1   Renal ca. TK-10   9.8       Brain (fetal)   15.5   Liver   20.4       Brain (whole)   34.6   Liver (fetal)   16.5       Brain (amygdala)   16.0   Liver ca.   49.0               (hepatoblast) HepG2       Brain (cerebellum)   34.2   Lung   4.5       Brain (hippocampus)   12.1   Lung (fetal)   5.4       Brain (substantia nigra)   12.8   Lung ca. (small cell)   32.3               LX-1       Brain (thalamus)   17.9   Lung ca. (small cell)   17.3               NCI-H69       Cerebral Cortex   10.4   Lung ca. (s.cell var.)   30.1               SHP-77       Spinal cord   13.3   Lung ca. (large   66.4               cell)NCI-H460       glio/astro U87-MG   14.8   Lung ca. (non-sm.   19.1               cell) A549       glio/astro U-118-MG   95.3   Lung ca. (non-s.cell)   13.8               NCI-H23       Astrocytoma SW1783   42.0   Lung ca. (non-s.cell)   18.7               HOP-62       neuro*; met SK-N-AS   47.0   Lung ca. (non-s.cl)   19.5               NCI-H522       Astrocytoma SF-539   11.4   Lung ca. (squam.)   9.9               SW 900       Astrocytoma SNB-75   15.6   Lung ca. (squam.)   19.6               NCI-H596       glioma SNB-19   11.8   Mammary gland   14.6       glioma U251   40.9   Breast ca.* (pl.ef)   81.2               MCF-7       glioma SF-295   10.1   Breast ca.* (pl.ef)   91.4               MDA-MB-231       Heart (fetal)   1.3   Breast ca.* (pl.ef)   35.4               T47D       Heart   4.7   Breast ca. BT-549   97.9       Skeletal muscle (fetal)   1.2   Breast ca. MDA-N   14.8       Skeletal muscle   38.7   Ovary   1.6       Bone marrow   4.6   Ovarian ca.   39.2               OVCAR-3       Thymus   2.7   Ovarian ca.   23.0               OVCAR-4       Spleen   7.9   Ovarian ca.   13.8               OVCAR-5       Lymph node   13.0   Ovarian ca.   8.5               OVCAR-8       Colorectal   3.3   Ovarian ca. IGROV-1   5.6       Stomach   27.7   Ovarian ca.*   44.8               (ascites) SK-OV-3       Small intestine   19.3   Uterus   19.5       Colon ca. SW480   16.5   Placenta   2.6       Colon ca.*    29.1   Prostate   15.6       SW620(SW480 met)       Colon ca. HT29   13.8   Prostate ca.* (bone   56.6               met)PC-3       Colon ca. HCT-116   27.7   Testis   40.6       Colon ca. CaCo-2   17.4   Melanoma   5.5               Hs688(A).T       Colon ca.   26.4   Melanoma* (met)   8.9       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   32.1   Melanoma UACC-   17.8               62       Gastric ca.* (liver met)   100.0   Melanoma M14   27.7       NCI-N87       Bladder   28.7   Melanoma LOX   6.6               IMVI       Trachea   9.4   Melanoma* (met)   13.0               SK-MEL-5       Kidney   9.0   Adipose   8.0                    
     [1192]               TABLE KD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3375, Run       Ag3375, Run       Tissue Name   165296547   Tissue Name   165296547                                     Secondary Th1 act   14.6   HUVEC IL-1beta   24.5       Secondary Th2 act   13.0   HUVEC IFN gamma   24.5       Secondary Tr1 act   17.3   HUVEC TNF alpha +   24.0               IFN gamma       Secondary Th1 rest   0.9   HUVEC TNF alpha +   23.2               IL4       Secondary Th2 rest   1.5   HUVEC IL-11   12.1       Secondary Tr1 rest   2.9   Lung Microvascular EC   21.3               none       Primary Th1 act   16.0   Lung Microvascular EC   24.1               TNF alpha + IL-1beta       Primary Th2 act   12.1   Microvascular Dermal   27.4               EC none       Primary Tr1 act   25.0   Microsvasular Dermal   24.0               EC TNF alpha + IL-1beta       Primary Th1 rest   10.4   Bronchial epithelium   20.3               TNF alpha + IL1beta       Primary Th2 rest   6.1   Small airway epithelium   11.3               none       Primary Tr1 rest   9.0   Small airway epithelium   54.0               TNF alpha + IL-1beta       CD45RA CD4   14.6   Coronery artery SMC rest   23.5       lymphocyte act       CD45RO CD4   13.6   Coronery artery SMC   12.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   14.2   Astrocytes rest   5.3       Secondary CD8   14.4   Astrocytes TNF alpha +   5.4       lymphocyte rest       IL-1beta       Secondary CD8   5.8   KU-812 (Basophil) rest   19.5       lymphocyte act       CD4 lymphocyte none   2.4   KU-812 (Basophil)   56.3               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   2.6   CCD1106   26.6       CD95 CH11       (Keratinocytes) none       LAK cells rest   5.1   CCD1106   7.8               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   10.7   Liver cirrhosis   2.6       LAK cells IL-2 + IL-12   12.5   Lupus kidney   0.8       LAK cells IL-2 + IFN   20.2   NCI-H292 none   28.7       gamma       LAK cells IL-2 + IL-18   16.6   NCI-H292 IL-4   54.7       LAK cells   12.5   NCI-H292 IL-9   45.7       PMA/ionomycin       NK Cells IL-2 rest   7.1   NCI-H292 IL-13   24.3       Two Way MLR 3 day   6.8   NCI-H292 IFN gamma   33.2       Two Way MLR 5 day   8.9   HPAEC none   17.8       Two Way MLR 7 day   6.0   HPAEC TNF alpha + IL-   30.1               1beta       PBMC rest   0.8   Lung fibroblast none   10.2       PBMC PWM   42.3   Lung fibroblast TNF   6.3               alpha + IL-1beta       PBMC PHA-L   11.6   Lung fibroblast IL-4   27.2       Ramos (B cell) none   30.6   Lung fibroblast IL-9   26.8       Ramos (B cell)   100.0   Lung fibroblast IL-13   21.8       ionomycin       B lymphocytes PWM   77.4   Lung fibroblast IFN   29.5               gamma       B lymphocytes CD40L   12.2   Dermal fibroblast   42.3       and IL-4       CCD1070 rest       EOL-1 dbcAMP   13.0   Dermal fibroblast   51.4               CCD1070 TNF alpha       EOL-1 dbcAMP   6.9   Dermal fibroblast   22.5       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   4.5   Dermal fibroblast IFN   11.1               gamma       Dendritic cells LPS   3.8   Dermal fibroblast IL-4   19.5       Dendritic cells anti-   2.9   IBD Colitis 2   0.7       CD40       Monocytes rest   2.2   IBD Crohn&#39;s   0.9       Monocytes LPS   1.3   Colon   7.6       Macrophages rest   6.6   Lung   6.2       Macrophages LPS   2.7   Thymus   9.4       HUVEC none   17.4   Kidney   4.2       HUVEC starved   37.4                    
     [1193] CNS_neurodegeneration_v1.0 Summary: Ag3375 This panel does not show differential expression of the CG58572-01 gene in Alzheimer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.  
     [1194] Panel 1.3D Summary: Ag3375—This gene is expressed at moderate to low levels in all samples on this panel, with the highest expression in gastric cancer cell line NCI-N87 (CT=28.8). Based on expression in this panel, this gene may be involved in gastric, pancreatic, brain, colon, renal, lung, breast, ovarian and prostate cancer as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene might be of use in the treatment of these cancers.  
     [1195] This gene product is also expressed in adipose, pancreas, adrenal, thyroid, pituitary, skeletal muscle, heart, and liver. This widespread expression in tissues with metabolic function suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes.  
     [1196] In addition, this gene is expressed at moderate levels in the CNS. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1197] Panel 4D Summary: Ag3375 The CG58572-01 gene is ubiquitously expressed on this panel, with highest expression in the B cell line Ramos treated with ionomycin (CT=26.2). Significant levels of expression are also seen in pokeweed mitogen-activated B lymphocytes. Therefore, therapies that antagonize the function of this gene product may be useful as therapeutic drugs to reduce or eliminate the symptoms in patients with autoimmune and inflammatory diseases in which B cells play a part in the initiation or progression of the disease process, such as lupus erythematosus, Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.  
     [1198] Interestingly, there is a difference between the levels of expression in resting and activated secondary T cells. The level in activated secondary T cells (CT=28.7-29.2) appears to be higher than in resting T cells (CT=31.3-33.1). Therefore, therapeutics designed with the protein encoded by this transcript could be important in the regulation of T cell function.  
     [1199] L. CG58564-01 and CG58564-02: Protein Tyrosine Phosphatase  
     [1200] Expression of gene CG58564-01 and full length clone CG58564-02 was assessed using the primer-probe sets Ag3023 and Ag3373, described in Tables LA and LB. Results of the RTQ-PCR runs are shown in Tables LC, LD, LE and LF.  
     [1201] Table LA. Probe Name Ag3023 
               TABLE LA                          Probe Name Ag3023                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ctaatgctggatttgtccatca-3′   22   492   402               Probe   TET-5′-tcaggaatatgaagccatctacctagca-3′-TAMRA   28   517   403               Reverse   5′-tggagtggtgacatcatctgta-3′   22   555   404                  
 
     [1202] Table LB. Probe Name Ag3373 
               TABLE LB                          Probe Name Ag3373                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atttgtccatcaacttcaggaa-3′   22   502   405               Probe   TET-5′-tgaagccatctacctagcaaaattaaca-3′-TAMRA   28   526   406               Reverse   5′-tggagtggtgacatcatctgta-3′   22   555   407                  
 
     [1203]               TABLE LC                          CNS_neurodegeneration_v1.0                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3023, Run   Ag3373, Run   Tissue   Ag3023, Run   Ag3373, Run       Tissue Name   209821074   210154071   Name   209821074   210154071                                             AD 1 Hippo   10.9   16.8   Control   9.1   8.0                   (Path) 3                   Temporal                   Ctx       AD 2 Hippo   34.2   37.6   Control   40.6   65.5                   (Path) 4                   Temporal                   Ctx       AD 3 Hippo   12.0   15.8   AD 1   24.7   29.1                   Occipital                   Ctx       AD 4 Hippo   13.8   10.3   AD 2   0.0   0.0                   Occipital                   Ctx                   (Missing)       AD 5 hippo   60.7   57.8   AD 3   14.7   15.0                   Occipital                   Ctx       AD 6 Hippo   80.7   72.2   AD 4   35.4   22.4                   Occipital                   Ctx       Control 2   35.8   38.4   AD 5   3.9   30.4       Hippo           Occipital                   Ctx       Control 4   16.5   11.7   AD 6   46.0   37.4       Hippo           Occipital                   Ctx       Control (Path)   13.1   15.4   Control 1   9.9   10.7       3 Hippo           Occipital                   Ctx       AD 1 Temporal   39.0   31.4   Control 2   39.0   38.4       Ctx           Occipital                   Ctx       AD 2 Temporal   38.7   73.2   Control 3   23.0   20.6       Ctx           Occipital                   Ctx       AD 3 Temporal   9.5   13.2   Control 4   13.3   13.3       Ctx           Occipital                   Ctx       AD 4 Temporal   27.9   34.9   Control   80.1   76.3       Ctx           (Path) 1                   Occipital                   Ctx       AD 5 Inf   59.0   100.0   Control   17.3   20.0       Temporal Ctx           (Path) 2                   Occipital                   Ctx       AD 5   33.2   44.1   Control   8.4   8.7       SupTemporal           (Path) 3       Ctx           Occipital                   Ctx       AD 6 Inf   100.0   73.2   Control   21.2   20.6       Temporal Ctx           (Path) 4                   Occipital                   Ctx       AD 6 Sup   79.6   80.1   Control 1   12.1   16.3       Temporal Ctx           Parietal Ctx       Control 1   10.2   13.7   Control 2   48.0   40.9       Temporal Ctx           Parietal Ctx       Control 2   41.2   31.9   Control 3   17.9   16.3       Temporal Ctx           Parietal Ctx       Control 3   20.3   20.0   Control   74.7   64.2       Temporal Ctx           (Path) 1                   Parietal Ctx       Control 4   9.7   9.9   Control   28.9   59.9       Temporal Ctx           (Path) 2                   Parietal Ctx       Control (Path)   59.9   68.3   Control   10.2   9.0       1 Temporal Ctx           (Path) 3                   Parietal Ctx       Control (Path)   40.3   41.2   Control   44.8   43.8       2 Temporal Ctx           (Path) 4                   Parietal Ctx                    
     [1204]               TABLE LD                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3373,       Ag3373,           Run       Run       Tissue Name   217043119   Tissue Name   217043119                                     Adipose   12.0   Renal ca. TK-10   20.3       Melanoma*   30.8   Bladder   23.2       Hs688(A).T       Melanoma*   69.3   Gastric ca. (liver met.)   25.3       Hs688(B).T       NCI-N87       Melanoma* M14   15.0   Gastric ca. KATO III   30.8       Melanoma*   26.6   Colon ca. SW-948   9.7       LOXIMVI       Melanoma* SK-   21.5   Colon ca. SW480   35.1       MEL-5       Squamous cell   33.0   Colon ca.* (SW480   13.9       carcinoma SCC-4       met) SW620       Testis Pool   19.8   Colon ca. HT29   8.5       Prostate ca.* (bone   100.0   Colon ca. HCT-116   36.9       met) PC-3       Prostate Pool   9.2   Colon ca. CaCo-2   42.9       Placenta   3.8   Colon cancer tissue   9.0       Uterus Pool   7.4   Colon ca. SW1116   5.8       Ovarian ca.   28.5   Colon ca. Colo-205   4.3       OVCAR-3       Ovarian ca. SK-   40.3   Colon ca. SW-48   4.2       OV-3       Ovarian ca.   20.0   Colon Pool   20.7       OVCAR-4       Ovarian ca.   35.1   Small Intestine Pool   12.2       OVCAR-5       Ovarian ca.   10.9   Stomach Pool   9.9       IGROV-1       Ovarian ca.   9.2   Bone Marrow Pool   11.6       OVCAR-8       Ovary   9.7   Fetal Heart   20.7       Breast ca. MCF-7   37.6   Heart Pool   10.6       Breast ca. MDA-   37.1   Lymph Node Pool   17.9       MB-231       Breast ca. BT 549   62.4   Fetal Skeletal Muscle   12.3       Breast ca. T47D   61.1   Skeletal Muscle Pool   16.0       Breast ca. MDA-N   10.0   Spleen Pool   11.6       Breast Pool   17.3   Thymus Pool   12.2       Trachea   12.0   CNS cancer   29.1               (glio/astro) U87-MG       Lung   6.7   CNS cancer   69.3               (glio/astro) U-118-MG       Fetal Lung   34.2   CNS cancer   34.9               (neuro; met) SK-N-AS       Lung ca. NCI-N417   5.4   CNS cancer (astro)   19.1               SF-539       Lung ca. LX-1   17.2   CNS cancer (astro)   35.8               SNB-75       Lung ca. NCI-H146   3.0   CNS cancer (glio)   11.3               SNB-19       Lung ca. SHP-77   18.6   CNS cancer (glio) SF-   26.4               295       Lung ca. A549   29.1   Brain (Amygdala)   4.5               Pool       Lung ca. NCI-H526   4.6   Brain (cerebellum)   8.1       Lung ca. NCI-H23   31.6   Brain (fetal)   13.2       Lung ca. NCI-H460   18.2   Brain (Hippocampus)   5.3               Pool       Lung ca. HOP-62   14.1   Cerebral Cortex Pool   5.4       Lung ca. NCI-H522   31.6   Brain (Substantia   4.8               nigra) Pool       Liver   1.2   Brain (Thalamus) Pool   8.0       Fetal Liver   32.3   Brain (whole)   6.2       Liver ca. HepG2   14.6   Spinal Cord Pool   6.6       Kidney Pool   22.1   Adrenal Gland   8.1       Fetal Kidney   26.1   Pituitary gland Pool   3.0       Renal ca. 786-0   28.7   Salivary Gland   4.7       Renal ca. A498   11.3   Thyroid (female)   4.4       Renal ca. ACHN   12.2   Pancreatic ca.   17.3               CAPAN2       Renal ca. UO-31   24.1   Pancreas Pool   17.1                    
     [1205]               TABLE LE                          Panel 1.3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3023, Run       Ag3023, Run       Tissue Name   167966931   Tissue Name   167966931                                     Liver adenocarcinoma   51.1   Kidney (fetal)   26.2       Pancreas   6.1   Renal ca. 786-0   34.2       Pancreatic ca. CAPAN 2   17.7   Renal ca. A498   17.6       Adrenal gland   3.8   Renal ca. RXF 393   17.2       Thyroid   3.0   Renal ca. ACHN   13.5       Salivary gland   3.9   Renal ca. UO-31   0.0       Pituitary gland   3.6   Renal ca. TK-10   23.0       Brain (fetal)   8.1   Liver   11.7       Brain (whole)   8.5   Liver (fetal)   8.0       Brain (amygdala)   6.7   Liver ca.   26.2               (hepatoblast) HepG2       Brain (cerebellum)   15.2   Lung   3.1       Brain (hippocampus)   5.4   Lung (fetal)   11.0       Brain (substantia nigra)   9.0   Lung ca. (small cell)   12.9               LX-1       Brain (thalamus)   4.2   Lung ca. (small cell)   9.9               NCI-H69       Cerebral Cortex   2.0   Lung ca. (s.cell var.)   67.8               SHP-77       Spinal cord   6.9   Lung ca. (large   3.4               cell)NCI-H460       glio/astro U87-MG   28.5   Lung ca. (non-sm.   45.1               cell) A549       glio/astro U-118-MG   46.7   Lung ca. (non-s.cell)   22.7               NCI-H23       astrocytoma SW1783   40.6   Lung ca. (non-s.cell)   25.7               HOP-62       neuro*; met SK-N-AS   27.2   Lung ca. (non-s.cl)   38.2               NCI-H522       astrocytoma SF-539   29.7   Lung ca. (squam.)   27.4               SW 900       astrocytoma SNB-75   35.1   Lung ca. (squam.)   29.9               NCI-H596       glioma SNB-19   15.6   Mammary gland   5.1       glioma U251   37.9   Breast ca.* (pl.ef)   47.0               MCF-7       glioma SF-295   18.4   Breast ca.* (pl.ef)   22.7               MDA-MB-231       Heart (fetal)   2.9   Breast ca.* (pl.ef)   86.5               T47D       Heart   12.9   Breast ca. BT-549   15.9       Skeletal muscle (fetal)   3.4   Breast ca. MDA-N   10.4       Skeletal muscle   36.3   Ovary   2.9       Bone marrow   4.5   Ovarian ca.   26.1               OVCAR-3       Thymus   14.3   Ovarian ca.   16.3               OVCAR-4       Spleen   8.7   Ovarian ca.   83.5               OVCAR-5       Lymph node   11.8   Ovarian ca.   9.3               OVCAR-8       Colorectal   10.4   Ovarian ca. IGROV-1   12.0       Stomach   7.8   Ovarian ca.*   100.0               (ascites) SK-OV-3       Small intestine   5.1   Uterus   4.9       Colon ca. SW480   19.3   Placenta   1.3       Colon ca.*   42.9   Prostate   3.9       SW620(SW480 met)       Colon ca. HT29   9.9   Prostate ca.* (bone   78.5               met)PC-3       Colon ca. HCT-116   26.2   Testis   9.7       Colon ca. CaCo-2   41.5   Melanoma   5.9               Hs688(A).T       Colon ca.   6.3   Melanoma* (met)   14.2       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   16.0   Melanoma UACC-   14.0               62       Gastric ca.* (liver met)   18.8   Melanoma M14   5.7       NCI-N87       Bladder   30.6   Melanoma LOX   8.8               IMVI       Trachea   3.2   Melanoma* (met)   14.7               SK-MEL-5       Kidney   9.6   Adipose   18.9                    
     [1206]               TABLE LF                          Panel 4D                                         Rel.   Rel.       Rel.   Rel.           Exp. (%)   Exp. (%)       Exp. (%)   Exp. (%)           Ag3023,   Ag3373,       Ag3023,   Ag3373,           Run   Run       Run   Run       Tissue Name   164516146   165296617   Tissue Name   164516146   165296617                                             Secondary Th1 act   18.6   17.9   HUVEC IL-1beta   20.3   18.6       Secondary Th2 act   24.3   28.5   HUVEC IFN   25.3   22.7                   gamma       Secondary Tr1 act   22.8   21.8   HUVEC TNF   16.3   18.0                   alpha + IFN                   gamma       Secondary Th1 rest   7.5   6.8   HUVEC TNF   18.2   13.4                   alpha + IL4       Secondary Th2 rest   11.6   9.5   HUVEC IL-11   13.7   9.9       Secondary Tr1 rest   12.1   10.7   Lung   25.7   21.6                   Microvascular EC                   none       Primary Th1 act   20.7   16.5   Lung   26.2   18.3                   Microvascular EC                   TNF alpha + IL-                   1beta       Primary Th2 act   20.2   19.3   Microvascular   27.5   21.3                   Dermal EC none       Primary Tr1 act   23.3   27.7   Microsvasular   20.7   19.9                   Dermal EC                   TNF alpha + IL-                   1beta       Primary Th1 rest   51.1   51.4   Bronchial   13.0   16.3                   epithelium                   TNF alpha +                   IL1beta       Primary Th2 rest   26.2   29.5   Small airway   8.1   8.5                   epithelium none       Primary Tr1 rest   23.7   26.1   Small airway   50.3   39.8                   epithelium                   TNF alpha + IL-                   1beta       CD45RA CD4   14.6   11.0   Coronery artery   20.2   18.9       lymphocyte act           SMC rest       CD45RO CD4   25.2   22.4   Coronery artery   12.0   9.8       lymphocyte act           SMC TNF alpha +                   IL-1beta       CD8 lymphocyte   20.4   15.8   Astrocytes rest   10.4   11.1       act       Secondary CD8   16.5   19.9   Astrocytes   11.7   9.8       lymphocyte rest           TNF alpha + IL-                   1beta       Secondary CD8   13.2   9.3   KU-812   47.6   38.2       lymphocyte act           (Basophil) rest       CD4 lymphocyte   17.1   11.6   KU-812   94.0   92.0       none           (Basophil)                   PMA/ionomycin       2ry   18.3   16.6   CCD1106   19.9   13.2       Th1/Th2/Tr1_anti-           (Keratinocytes)       CD95 CH11           none       LAK cells rest   25.5   16.0   CCD1106   6.0   4.8                   (Keratinocytes)                   TNF alpha + IL-                   1beta       LAK cells IL-2   27.2   22.5   Liver cirrhosis   3.1   2.7       LAK cells IL-   27.2   19.3   Lupus kidney   2.1   1.7       2 + IL-12       LAK cells IL-   36.3   34.4   NCI-H292 none   30.1   18.9       2 + IFN gamma       LAK cells IL-2 +   35.1   29.7   NCI-H292 IL-4   33.9   34.6       IL-18       LAK cells   12.4   11.0   NCI-H292 IL-9   40.1   29.1       PMA/ionomycin       NK Cells IL-2 rest   20.0   15.0   NCI-H292 IL-13   16.2   14.2       Two Way MLR 3   24.0   16.7   NCI-H292 IFN   16.6   18.4       day           gamma       Two Way MLR 5   12.9   10.1   HPAEC none   13.6   13.5       day       Two Way MLR 7   11.4   9.5   HPAEC TNF   25.3   25.3       day           alpha + IL-1beta       PBMC rest   13.7   10.5   Lung fibroblast   11.4   14.2                   none       PBMC PWM   69.3   66.4   Lung fibroblast   6.1   7.2                   TNF alpha + IL-                   1beta       PBMC PHA-L   22.8   17.7   Lung fibroblast   28.5   29.1                   IL-4       Ramos (B cell)   24.1   19.3   Lung fibroblast   23.0   23.3       none           IL-9       Ramos (B cell)   100.0   100.0   Lung fibroblast   20.6   18.9       ionomycin           IL-13       B lymphocytes   71.7   74.2   Lung fibroblast   39.0   32.5       PWM           IFN gamma       B lymphocytes   29.1   28.7   Dermal fibroblast   33.9   31.0       CD40L and IL-4           CCD1070 rest       EOL-1 dbcAMP   12.1   10.5   Dermal fibroblast   76.8   62.0                   CCD1070 TNF                   alpha       EOL-1 dbcAMP   14.5   10.9   Dermal fibroblast   20.3   13.9       PMA/ionomycin           CCD1070 IL-                   1beta       Dendritic cells   13.2   14.8   Dermal fibroblast   14.2   9.5       none           IFN gamma       Dendritic cells LPS   11.7   8.3   Dermal fibroblast   26.4   20.4                   IL-4       Dendritic cells   17.7   12.7   IBD Colitis 2   2.6   2.2       anti-CD40       Monocytes rest   16.7   17.6   IBD Crohn&#39;s   2.0   1.9       Monocytes LPS   6.4   5.0   Colon   11.9   10.5       Macrophages rest   23.5   22.8   Lung   13.3   11.2       Macrophages LPS   9.9   7.1   Thymus   14.4   12.9       HUVEC none   20.6   17.9   Kidney   27.5   19.6       HUVEC starved   43.5   38.4                    
     [1207] CNS_neurodegeneration_v1.0 Summary: Ag3023/Ag3373 This panel does not show differential expression of the CG58564-01 gene in Alzheimer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.  
     [1208] General_screening_panel_v1.4 Summary: Ag3373 Highest expression of the CG58564-01 gene is seen in a prostate cancer cell line (CT=27). Overall, this gene is expressed at moderate levels in the cancer cell lines in this panel. A higher level of expression is observed in clusters of cell lines derived from prostate, brain, melanoma, colon, lung, breast and ovarian cancer when compared to expression in normal prostate, brain, colon, lung, breast and ovary. Thus, this gene could potentially be used as a diagnostic marker of cancer in these tissues. Furthermore, inhibition of the activity of this gene product using small molecule drugs may be effective in the treatment of cancer in these tissues.  
     [1209] Among tissues with metabolic function, this gene product has moderate levels of expression in adipose, heart, skeletal muscle, adrenal, pituitary, thyroid and pancreas. Thus, this gene product may be a small molecule target for the treatment of endocrine and metabolic diseases, including obesity and Types 1 and 2 diabetes.  
     [1210] In addition, this gene appears to be differentially expressed in fetal (CT value=29) vs adult liver (CT value=33) and may be useful for differentiation between the two sources of this tissue.  
     [1211] This gene is also expressed at moderate levels in all central nervous system samples present on this panel. Please see Panel 10.3D for discussion of utility of this gene in the central nervous system.  
     [1212] Panel 1.3D Summary: Ag3023 The CG58564-01 gene is ubiquitously expressed among the samples on this panel, with highest expression in an ovarian cancer cell line (CT=28.8). Overall, the expression of this gene shows good agreement with panel 1.4. A higher level of expression is observed in prostate, brain, melanoma, colon, lung, pancreatic, breast and ovarian cancer cell lines than the normal prostate, brain, colon, lung, pancreas, breast and ovary. Thus, expression of this gene could be used as a diagnostic marker of cancer in these tissues. Furthermore, inhibition of the activity of this gene product using small molecule drugs may be effective in the treatment of cancer in these tissues.  
     [1213] Among tissues with metabolic function, expression of this gene is widespread, as in the previous panel. Please see Panel 1.4 for discussion of utility of this gene in metabolic disease.  
     [1214] This gene represents a phosphatase that is also expressed at low to moderate levels across the CNS. Some phosphatases comprise a family of MAP kinase regulating enzymes, members of which are upregulated in brains subjected to insults such as ischemia and seizure activity. MAP kinases are kown to regulate neurotrophic and neurotoxic pathways. Consequently, agents that modulate the activity of this gene may have utility in attenuating the apoptotic and neurodegenerative processes following brain insults.  
     REFERENCES  
     [1215] 1. Wiessner C. The dual specificity phosphatase PAC-1 is transcriptionally induced in the rat brain following transient forebrain ischemia. Brain Res Mol Brain Res February 1995;28(2):353-6  
     [1216] 2. Boschert U, Muda M, Camps M, Dickinson R, Arkinstall S. Induction of the dual specificity phosphatase PAC1 in rat brain following seizure activity. Neuroreport Sep. 29, 1997;8(14):3077-80  
     [1217] Panel 4D Summary: Ag3023/Ag3373 The CG585864-01 gene is expressed at high to moderate levels in a wide range of cell types and tissues of significance in the immune response in health and disease. Highest expression of this gene is seen in ionomycin treated Ramos B cells (CT=26.83). Therefore, targeting of this gene product with a small molecule drug or antibody therapeutic may modulate the functions of cells of the immune system as well as resident tissue cells and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, and arthritis, including osteoarthritis and rheumatoid arthritis.  
     [1218] M. CG58564-03: Dual Specificity Phosphatase  
     [1219] Expression of gene CG58564-03 was assessed using the primer-probe sets Ag3023, Ag3373 and Ag5847, described in Tables MA, MB and MC. Results of the RTQ-PCR runs are shown in Tables MD, ME, MF, MG and NM.  
     [1220] Table MA. Probe Name Ag3023 
               TABLE MA                          Probe Name Ag3023                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ctaatgctggatttgtccatca-3′   22   261   408               Probe   TET-5′-tcaggaatatgaagccatctacctagca-3′-TAMRA   28   230   409               Reverse   5′-tggagtggtgacatcatctgta-3′   22   198   410                  
 
     [1221] Table MB. Probe Name Ag3373 
               TABLE MB                          Probe Name Ag3373                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atttgtccatcaacttcaggaa-3′   22   251   411               Probe   TET-5′-tgaagccatctacctagcaaaattaaca-3′-TAMRA   28   221   412               Reverse   5′-tggagtggtgacatcatctgta-3′   22   198   413                  
 
     [1222] Table MC. Probe Name Ag5847 
               TABLE MC                          Probe Name Ag5847                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cattccaaatgtttctgtagt-3′   21   335   414               Probe   TET-5′-ttcatagcagatgaatatgggcctaagaac-3′-TAMRA   30   371   415               Reverse   5′-ccacagtgcaaggaagac-3′   18   457   416                  
 
     [1223]               TABLE MD                          CNS_neurodegeneration_v1.0                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3023, Run   Ag3373, Run   Tissue   Ag3023, Run   Ag3373, Run       Tissue Name   209821074   210154071   Name   209821074   210154071                                             AD 1 Hippo   10.9   16.8   Control   9.1   8.0                   (Path) 3                   Temporal                   Ctx       AD 2 Hippo   34.2   37.6   Control   40.6   65.5                   (Path) 4                   Temporal                   Ctx       AD 3 Hippo   12.0   15.8   AD 1   24.7   29.1                   Occipital                   Ctx       AD 4 Hippo   13.8   10.3   AD 2   0.0   0.0                   Occipital                   Ctx                   (Missing)       AD 5 hippo   60.7   57.8   AD 3   14.7   15.0                   Occipital                   Ctx       AD 6 Hippo   80.7   72.2   AD 4   35.4   22.4                   Occipital                   Ctx       Control 2   35.8   38.4   AD 5   3.9   30.4       Hippo           Occipital                   Ctx       Control 4   16.5   11.7   AD 6   46.0   37.4       Hippo           Occipital                   Ctx       Control (Path)   13.1   15.4   Control 1   9.9   10.7       3 Hippo           Occipital                   Ctx       AD 1 Temporal   39.0   31.4   Control 2   39.0   38.4       Ctx           Occipital                   Ctx       AD 2 Temporal   38.7   73.2   Control 3   23.0   20.6       Ctx           Occipital                   Ctx       AD 3 Temporal   9.5   13.2   Control 4   13.3   13.3       Ctx           Occipital                   Ctx       AD 4 Temporal   27.9   34.9   Control   80.1   76.3       Ctx           (Path) 1                   Occipital                   Ctx       AD 5 Inf   59.0   100.0   Control   17.3   20.0       Temporal Ctx           (Path) 2                   Occipital                   Ctx       AD 5   33.2   44.1   Control   8.4   8.7       SupTemporal           (Path) 3       Ctx           Occipital                   Ctx       AD 6 Inf   100.0   73.2   Control   21.2   20.6       Temporal Ctx           (Path) 4                   Occipital                   Ctx       AD 6 Sup   79.6   80.1   Control 1   12.1   16.3       Temporal Ctx           Parietal Ctx       Control 1   10.2   13.7   Control 2   48.0   40.9       Temporal Ctx           Parietal Ctx       Control 2   41.2   31.9   Control 3   17.9   16.3       Temporal Ctx           Parietal Ctx       Control 3   20.3   20.0   Control   74.7   64.2       Temporal Ctx           (Path) 1                   Parietal Ctx       Control 4   9.7   9.9   Control   28.9   59.9       Temporal Ctx           (Path) 2                   Parietal Ctx       Control (Path)   59.9   68.3   Control   10.2   9.0       1 Temporal Ctx           (Path) 3                   Parietal Ctx       Control (Path)   40.3   41.2   Control   44.8   43.8       2 Temporal Ctx           (Path) 4                   Parietal Ctx                    
     [1224]               TABLE ME                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3373, Run       Ag3373, Run       Tissue Name   217043119   Tissue Name   217043119                                     Adipose   12.0   Renal ca. TK-10   20.3       Melanoma*   30.8   Bladder   23.2       Hs688(A).T       Melanoma*   69.3   Gastric ca. (liver met.)   25.3       Hs688(B).T       NCI-N87       Melanoma* M14   15.0   Gastric ca. KATO III   30.8       Melanoma*   26.6   Colon ca. SW-948   9.7       LOXIMVI       Melanoma* SK-   21.5   Colon ca. SW480   35.1       MEL-5       Squamous cell   33.0   Colon ca.* (SW480   13.9       carcinoma SCC-4       met) SW620       Testis Pool   19.8   Colon ca. HT29   8.5       Prostate ca.* (bone   100.0   Colon ca. HCT-116   36.9       met) PC-3       Prostate Pool   9.2   Colon ca. CaCo-2   42.9       Placenta   3.8   Colon cancer tissue   9.0       Uterus Pool   7.4   Colon ca. SW1116   5.8       Ovarian ca.   28.5   Colon ca. Colo-205   4.3       OVCAR-3       Ovarian ca. SK-   40.3   Colon ca. SW-48   4.2       OV-3       Ovarian ca.   20.0   Colon Pool   20.7       OVCAR-4       Ovarian ca.   35.1   Small Intestine Pool   12.2       OVCAR-5       Ovarian ca.   10.9   Stomach Pool   9.9       IGROV-1       Ovarian ca.   9.2   Bone Marrow Pool   11.6       OVCAR-8       Ovary   9.7   Fetal Heart   20.7       Breast ca. MCF-7   37.6   Heart Pool   10.6       Breast ca. MDA-   37.1   Lymph Node Pool   17.9       MB-231       Breast ca. BT 549   62.4   Fetal Skeletal Muscle   12.3       Breast ca. T47D   61.1   Skeletal Muscle Pool   16.0       Breast ca. MDA-N   10.0   Spleen Pool   11.6       Breast Pool   17.3   Thymus Pool   12.2       Trachea   12.0   CNS cancer   29.1               (glio/astro) U87-MG       Lung   6.7   CNS cancer   69.3               (glio/astro) U-118-MG       Fetal Lung   34.2   CNS cancer   34.9               (neuro; met) SK-N-AS       Lung ca. NCI-N417   5.4   CNS cancer (astro) SF-   19.1               539       Lung ca. LX-1   17.2   CNS cancer (astro)   35.8               SNB-75       Lung ca. NCI-H146   3.0   CNS cancer (glio)   11.3               SNB-19       Lung ca. SHP-77   18.6   CNS cancer (glio) SF-   26.4               295       Lung ca. A549   29.1   Brain (Amygdala) Pool   4.5       Lung ca. NCI-H526   4.6   Brain (cerebellum)   8.1       Lung ca. NCI-H23   31.6   Brain (fetal)   13.2       Lung ca. NCI-H460   18.2   Brain (Hippocampus)   5.3               Pool       Lung ca. HOP-62   14.1   Cerebral Cortex Pool   5.4       Lung ca. NCI-H522   31.6   Brain (Substantia   4.8               nigra) Pool       Liver   1.2   Brain (Thalamus) Pool   8.0       Fetal Liver   32.3   Brain (whole)   6.2       Liver ca. HepG2   14.6   Spinal Cord Pool   6.6       Kidney Pool   22.1   Adrenal Gland   8.1       Fetal Kidney   26.1   Pituitary gland Pool   3.0       Renal ca. 786-0   28.7   Salivary Gland   4.7       Renal ca. A498   11.3   Thyroid (female)   4.4       Renal ca. ACHN   12.2   Pancreatic ca.   17.3               CAPAN2       Renal ca. UO-31   24.1   Pancreas Pool   17.1                    
     [1225]               TABLE MF                          General_screening_panel_v1.5                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag5847, Run       Ag5847, Run       Tissue Name   247590257   Tissue Name   247590257                                     Adipose   0.1   Renal ca. TK-10   0.2       Melanoma*   0.1   Bladder   0.1       Hs688(A).T       Melanoma*   0.1   Gastric ca. (liver met.)   0.2       Hs688(B).T       NCI-N87       Melanoma* M14   0.1   Gastric ca. KATO III   0.1       Melanoma*   0.1   Colon ca. SW-948   0.1       LOXIMVI       Melanoma* SK-   0.1   Colon ca. SW480   0.2       MEL-5       Squamous cell   0.2   Colon ca.* (SW480   1.8       carcinoma SCC-4       met) SW620       Testis Pool   0.1   Colon ca. HT29   0.0       Prostate ca.* (bone   0.6   Colon ca. HCT-116   0.2       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.2   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.1   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.1   Colon Pool   0.1       OVCAR-4       Ovarian ca.   0.2   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.1   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.1   Fetal Heart   0.1       Breast ca. MCF-7   0.3   Heart Pool   0.0       Breast ca. MDA-   0.2   Lymph Node Pool   0.1       MB-231       Breast ca. BT 549   0.2   Fetal Skeletal Muscle   0.1       Breast ca. T47D   0.2   Skeletal Muscle Pool   0.1       Breast ca. MDA-N   0.1   Spleen Pool   0.1       Breast Pool   0.0   Thymus Pool   0.1       Trachea   0.1   CNS cancer   0.2               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.5               (glio/astro) U-118-MG       Fetal Lung   0.2   CNS cancer   0.2               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.1               539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.2               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.1               SNB-19       Lung ca. SHP-77   0.1   CNS cancer (glio) SF-   0.2               295       Lung ca. A549   0.2   Brain (Amygdala) Pool   0.0       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   0.1   Brain (fetal)   0.1       Lung ca. NCI-H460   0.1   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   0.1   Brain (Substantia   0.0               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   0.0       Fetal Liver   0.1   Brain (whole)   0.0       Liver ca. HepG2   0.1   Spinal Cord Pool   0.0       Kidney Pool   0.1   Adrenal Gland   0.0       Fetal Kidney   0.1   Pituitary gland Pool   0.0       Renal ca. 786-0   0.2   Salivary Gland   100.0       Renal ca. A498   0.1   Thyroid (female)   0.0       Renal ca. ACHN   0.1   Pancreatic ca.   0.1               CAPAN2       Renal ca. UO-31   0.1   Pancreas Pool   0.0                    
     [1226]               TABLE MG                          Panel 1.3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3023, Run       Ag3023, Run       Tissue Name   167966931   Tissue Name   167966931                                     Liver adenocarcinoma   51.1   Kidney (fetal)   26.2       Pancreas   6.1   Renal ca. 786-0   34.2       Pancreatic ca. CAPAN 2   17.7   Renal ca. A498   17.6       Adrenal gland   3.8   Renal ca. RXF 393   17.2       Thyroid   3.0   Renal ca. ACHN   13.5       Salivary gland   3.9   Renal ca. UO-31   0.0       Pituitary gland   3.6   Renal ca. TK-10   23.0       Brain (fetal)   8.1   Liver   11.7       Brain (whole)   8.5   Liver (fetal)   8.0       Brain (amygdala)   6.7   Liver ca.   26.2               (hepatoblast) HepG2       Brain (cerebellum)   15.2   Lung   3.1       Brain (hippocampus)   5.4   Lung (fetal)   11.0       Brain (substantia nigra)   9.0   Lung ca. (small cell)   12.9               LX-1       Brain (thalamus)   4.2   Lung ca. (small cell)   9.9               NCI-H69       Cerebral Cortex   2.0   Lung ca. (s.cell var.)   67.8               SHP-77       Spinal cord   6.9   Lung ca. (large   3.4               cell)NCI-H460       Glio/astro U87-MG   28.5   Lung ca. (non-sm.   45.1               cell) A549       Glio/astro U-118-MG   46.7   Lung ca. (non-s.cell)   22.7               NCI-H23       astrocytoma SW1783   40.6   Lung ca. (non-s.cell)   25.7               HOP-62       neuro*; met SK-N-AS   27.2   Lung ca. (non-s.cl)   38.2               NCI-H522       astrocytoma SF-539   29.7   Lung ca. (squam.)   27.4               SW 900       astrocytoma SNB-75   35.1   Lung ca. (squam.)   29.9               NCI-H596       glioma SNB-19   15.6   Mammary gland   5.1       glioma U251   37.9   Breast ca.* (pl.ef)   47.0               MCF-7       glioma SF-295   18.4   Breast ca.* (pl.ef)   22.7               MDA-MB-231       Heart (fetal)   2.9   Breast ca.* (pl.ef)   86.5               T47D       Heart   12.9   Breast ca. BT-549   15.9       Skeletal muscle (fetal)   3.4   Breast ca. MDA-N   10.4       Skeletal muscle   36.3   Ovary   2.9       Bone marrow   4.5   Ovarian ca.   26.1               OVCAR-3       Thymus   14.3   Ovarian ca.   16.3               OVCAR-4       Spleen   8.7   Ovarian ca.   83.5               OVCAR-5       Lymph node   11.8   Ovarian ca.   9.3               OVCAR-8       Colorectal   10.4   Ovarian ca. IGROV-1   12.0       Stomach   7.8   Ovarian ca.*   100.0               (ascites) SK-OV-3       Small intestine   5.1   Uterus   4.9       Colon ca. SW480   19.3   Placenta   1.3       Colon ca.*   42.9   Prostate   3.9       SW620(SW480 met)       Colon ca. HT29   9.9   Prostate ca.* (bone   78.5               met)PC-3       Colon ca. HCT-116   26.2   Testis   9.7       Colon ca. CaCo-2   41.5   Melanoma   5.9               Hs688(A).T       Colon ca.   6.3   Melanoma* (met)   14.2       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   16.0   Melanoma UACC-   14.0               62       Gastric ca.* (liver met)   18.8   Melanoma M14   5.7       NCI-N87       Bladder   30.6   Melanoma LOX   8.8               IMVI       Trachea   3.2   Melanoma* (met)   14.7               SK-MEL-5       Kidney   9.6   Adipose   18.9                    
     [1227]               TABLE MH                          Panel 4D                                         Rel.   Rel.       Rel.   Rel.           Exp. (%)   Exp. (%)       Exp. (%)   Exp. (%)           Ag3023,   Ag3373,       Ag3023,   Ag3373,           Run   Run       Run   Run       Tissue Name   164516146   165296617   Tissue Name   164516146   165296617                                             Secondary Th1 act   18.6   17.9   HUVEC IL-1beta   20.3   18.6       Secondary Th2 act   24.3   28.5   HUVEC IFN   25.3   22.7                   gamma       Secondary Tr1 act   22.8   21.8   HUVEC TNF   16.3   18.0                   alpha + IFN                   gamma       Secondary Th1 rest   7.5   6.8   HUVEC TNF   18.2   13.4                   alpha + IL4       Secondary Th2 rest   11.6   9.5   HUVEC IL-11   13.7   9.9       Secondary Tr1 rest   12.1   10.7   Lung   25.7   21.6                   Microvascular EC                   none       Primary Th1 act   20.7   16.5   Lung   26.2   18.3                   Microvascular EC                   TNF alpha + IL-                   1beta       Primary Th2 act   20.2   19.3   Microvascular   27.5   21.3                   Dermal EC none       Primary Tr1 act   23.3   27.7   Microsvasular   20.7   19.9                   Dermal EC                   TNF alpha + IL-                   1beta       Primary Th1 rest   51.1   51.4   Bronchial   13.0   16.3                   epithelium                   TNF alpha +                   IL1beta       Primary Th2 rest   26.2   29.5   Small airway   8.1   8.5                   epithelium none       Primary Tr1 rest   23.7   26.1   Small airway   50.3   39.8                   epithelium                   TNF alpha + IL-                   1beta       CD45RA CD4   14.6   11.0   Coronery artery   20.2   18.9       lymphocyte act           SMC rest       CD45RO CD4   25.2   22.4   Coronery artery   12.0   9.8       lymphocyte act           SMC TNF alpha +                   IL-1beta       CD8 lymphocyte   20.4   15.8   Astrocytes rest   10.4   11.1       act       Secondary CD8   16.5   19.9   Astrocytes   11.7   9.8       lymphocyte rest           TNF alpha + IL-                   1beta       Secondary CD8   13.2   9.3   KU-812   47.6   38.2       lymphocyte act           (Basophil) rest       CD4 lymphocyte   17.1   11.6   KU-812   94.0   92.0       none           (Basophil)                   PMA/ionomycin       2ry   18.3   16.6   CCD1106   19.9   13.2       Th1/Th2/Tr1_anti-           (Keratinocytes)       CD95 CH11           none       LAK cells rest   25.5   16.0   CCD1106   6.0   4.8                   (Keratinocytes)                   TNF alpha + IL-                   1beta       LAK cells IL-2   27.2   22.5   Liver cirrhosis   3.1   2.7       LAK cells IL-   27.2   19.3   Lupus kidney   2.1   1.7       2 + IL-12       LAK cells IL-   36.3   34.4   NCI-H292 none   30.1   18.9       2 + IFN gamma       LAK cells IL-2 +   35.1   29.7   NCI-H292 IL-4   33.9   34.6       IL-18       LAK cells   12.4   11.0   NCI-H292 IL-9   40.1   29.1       PMA/ionomycin       NK Cells IL-2 rest   20.0   15.0   NCI-H292 IL-13   16.2   14.2       Two Way MLR 3   24.0   16.7   NCI-H292 IFN   16.6   18.4       day           gamma       Two Way MLR 5   12.9   10.1   HPAEC none   13.6   13.5       day       Two Way MLR 7   11.4   9.5   HPAEC TNF   25.3   25.3       day           alpha + IL-1beta       PBMC rest   13.7   10.5   Lung fibroblast   11.4   14.2                   none       PBMC PWM   69.3   66.4   Lung fibroblast   6.1   7.2                   TNF alpha + IL-                   1beta       PBMC PHA-L   22.8   17.7   Lung fibroblast   28.5   29.1                   IL-4       Ramos (B cell)   24.1   19.3   Lung fibroblast   23.0   23.3       none           IL-9       Ramos (B cell)   100.0   100.0   Lung fibroblast   20.6   18.9       ionomycin           IL-13       B lymphocytes   71.7   74.2   Lung fibroblast   39.0   32.5       PWM           IFN gamma       B lymphocytes   29.1   28.7   Dermal fibroblast   33.9   31.0       CD40L and IL-4           CCD1070 rest       EOL-1 dbcAMP   12.1   10.5   Dermal fibroblast   76.8   62.0                   CCD1070 TNF                   alpha       EOL-1 dbcAMP   14.5   10.9   Dermal fibroblast   20.3   13.9       PMA/ionomycin           CCD1070 IL-                   1beta       Dendritic cells   13.2   14.8   Dermal fibroblast   14.2   9.5       none           IFN gamma       Dendritic cells LPS   11.7   8.3   Dermal fibroblast   26.4   20.4                   IL-4       Dendritic cells   17.7   12.7   IBD Colitis 2   2.6   2.2       anti-CD40       Monocytes rest   16.7   17.6   IBD Crohn&#39;s   2.0   1.9       Monocytes LPS   6.4   5.0   Colon   11.9   10.5       Macrophages rest   23.5   22.8   Lung   13.3   11.2       Macrophages LPS   9.9   7.1   Thymus   14.4   12.9       HUVEC none   20.6   17.9   Kidney   27.5   19.6       HUVEC starved   43.5   38.4                    
     [1228] CNS_neurodegeneration_v1.0 Summary: Ag3023/Ag3373 This panel does not show differential expression of the CG56804-03 gene, a splice variant of CG56804-01, in Alzheimrer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system. Ag5847—This primer pair recognizes only the splice variant CG58564-03. Expression of this variant is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1229] General_screening_panel_v1.4 Summary: Ag3373 Highest expression of the CG56804-03 gene is seen in a prostate cancer cell line (CT=27). Overall, this gene is expressed at moderate levels in the cancer cell lines in this panel. A higher level of expression is observed in clusters of cell lines derived from prostate, brain, melanoma, colon, lung, breast and ovarian cancer when compared to expression in normal prostate, brain, colon, lung, breast and ovary. Thus, this gene could potentially be used as a diagnostic marker of cancer in these tissues. Furthermore, inhibition of the activity of this gene product using small molecule drugs may be effective in the treatment of cancer in these tissues.  
     [1230] Among tissues with metabolic function, this gene product has moderate levels of expression in adipose, heart, skeletal muscle, adrenal, pituitary, thyroid and pancreas. Thus, this gene product may be a small molecule target for the treatment of endocrine and metabolic diseases, including obesity and Types 1 and 2 diabetes.  
     [1231] In addition, this gene appears to be differentially expressed in fetal (CT value=29) vs adult liver (CT value=33) and may be useful for differentiation between the two sources of this tissue.  
     [1232] This gene is also expressed at moderate levels in all central nervous system samples present on this panel. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.  
     [1233] General_screening_panel_v1.5 Summary: Ag5847—This primer pair, specific to this splice variant, CG58564-03. Expression of this variant is highest in salivary gland (CT=28.6). Therefore, expression of this gene can be used to differentiate this sample from others on the panel.  
     [1234] Panel 1.3D Summary: Ag3023 The CG56804-03 gene is ubiquitously expressed among the samples on this panel, with highest expression in an ovarian cancer cell line (CT=28.8). Overall, the expression of this gene shows good agreement with panel 1.4. A higher level of expression is observed in prostate, brain, melanoma, colon, lung, pancreatic, breast and ovarian cancer cell lines than the normal prostate, brain, colon, lung, pancreas, breast and ovary. Thus, expression of this gene could be used as a diagnostic marker of cancer in these tissues. Furthermore, inhibition of the activity of this gene product using small molecule drugs may be effective in the treatment of cancer in these tissues.  
     [1235] Among tissues with metabolic function, expression of this gene is widespread, as in the previous panel. Please see Panel 1.4 for discussion of utility of this gene in metabolic disease.  
     [1236] This gene represents a dual specificity phosphatase that is also expressed at low to moderate levels across the CNS. Dual-specificity phosphatases comprise a family of MAP kinase regulating enzymes, members of which are upregulated in brains subjected to insults such as ischemia and seizure activity. MAP kinases are kown to regulate neurotrophic and neurotoxic pathways. Consequently, agents that modulate the activity of this gene may have utility in attenuating the apoptotic and neurodegenerative processes following brain insults.  
     [1237] Panel 4.1D Summary: Ag5847—This primer pair recognizes a splice variant of CG58564-03. Expression of this variant is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1238] Panel 4D Summary: Ag3023/Ag3373 The CG56804-03 gene is expressed at high to moderate levels in a wide range of cell types and tissues of significance in the immune response in health and disease. Highest expression of this gene is seen in ionomycin treated Ramos 13 cells (CT=26.83). Therefore, targeting of this gene product with a small molecule drug or antibody therapeutic may modulate the functions of cells of the immune system as well as resident tissue cells and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, and arthritis, including osteoarthritis and rheumatoid arthritis.  
     [1239] N. CG58564-04: Dual Specificity Phosphatase  
     [1240] Expression of gene CG58564-04, a splice variant of CG58564-01, was assessed using the primer-probe sets Ag3023, Ag3373 and Ag5844, described in Tables NA, NB and NC. Results of the RTQ-PCR runs are shown in Tables ND, NE, NF and NG.  
     [1241] Table NA. Probe Name Ag3023 
               TABLE NA                          Probe Name Ag3023                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ctaatgctggatttgtccatca-3′   22   190   417               Probe   TET-5′-tcaggaatatgaagccatctacctagca-3′-TAMRA   28   159   418               Reverse   5′-tggagtggtgacatcatctgta-3′   22   127   419                  
 
     [1242] Table NB. Probe Name Ag3373 
               TABLE NB                          Probe Name Ag3373                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atttgtccatcaacttcaggaa-3′   22   180   420               Probe   TET-5′-tgaagccatctacctagcaaaattaaca-3′-TAMRA   28   150   421               Reverse   5′-tggagtggtgacatcatctgta-3′   22   127   422                  
 
     [1243] Table NC. Probe Name Ag5844 
               TABLE NC                          Probe Name Ag5844                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ccttagtctaaataactgctg-3′   21   377   423               Probe   TET-5′-agtttgcttcaatattttgtcgtatgcata-3′-TAMRA   30   415   424               Reverse   5′-aggagtggacctaccctat-3′   19   552   425                  
 
     [1244]               TABLE ND                          CNS_neurodegeneration_v1.0                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3023, Run   Ag3373, Run   Tissue   Ag3023, Run   Ag3373, Run       Tissue Name   209821074   210154071   Name   209821074   210154071                                             AD 1 Hippo   10.9   16.8   Control   9.1   8.0                   (Path) 3                   Temporal                   Ctx       AD 2 Hippo   34.2   37.6   Control   40.6   65.5                   (Path) 4                   Temporal                   Ctx       AD 3 Hippo   12.0   15.8   AD 1   24.7   29.1                   Occipital                   Ctx       AD 4 Hippo   13.8   10.3   AD 2   0.0   0.0                   Occipital                   Ctx                   (Missing)       AD 5 hippo   60.7   57.8   AD 3   14.7   15.0                   Occipital                   Ctx       AD 6 Hippo   80.7   72.2   AD 4   35.4   22.4                   Occipital                   Ctx       Control 2   35.8   38.4   AD 5   3.9   30.4       Hippo           Occipital                   Ctx       Control 4   16.5   11.7   AD 6   46.0   37.4       Hippo           Occipital                   Ctx       Control (Path)   13.1   15.4   Control 1   9.9   10.7       3 Hippo           Occipital                   Ctx       AD 1 Temporal   39.0   31.4   Control 2   39.0   38.4       Ctx           Occipital                   Ctx       AD 2 Temporal   38.7   73.2   Control 3   23.0   20.6       Ctx           Occipital                   Ctx       AD 3 Temporal   9.5   13.2   Control 4   13.3   13.3       Ctx           Occipital                   Ctx       AD 4 Temporal   27.9   34.9   Control   80.1   76.3       Ctx           (Path) 1                   Occipital                   Ctx       AD 5 Inf   59.0   100.0   Control   17.3   20.0       Temporal Ctx           (Path) 2                   Occipital                   Ctx       AD 5   33.2   44.1   Control   8.4   8.7       SupTemporal           (Path) 3       Ctx           Occipital                   Ctx       AD 6 Inf   100.0   73.2   Control   21.2   20.6       Temporal Ctx           (Path) 4                   Occipital                   Ctx       AD 6 Sup   79.6   80.1   Control 1   12.1   16.3       Temporal Ctx           Parietal Ctx       Control 1   10.2   13.7   Control 2   48.0   40.9       Temporal Ctx           Parietal Ctx       Control 2   41.2   31.9   Control 3   17.9   16.3       Temporal Ctx           Parietal Ctx       Control 3   20.3   20.0   Control   74.7   64.2       Temporal Ctx           (Path) 1                   Parietal Ctx       Control 4   9.7   9.9   Control   28.9   59.9       Temporal Ctx           (Path) 2                   Parietal Ctx       Control (Path)   59.9   68.3   Control   10.2   9.0       1 Temporal Ctx           (Path) 3                   Parietal Ctx       Control (Path)   40.3   41.2   Control   44.8   43.8       2 Temporal Ctx           (Path) 4                   Parietal Ctx                    
     [1245]               TABLE NE                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3373, Run       Ag3373, Run       Tissue Name   217043119   Tissue Name   217043119                                     Adipose   12.0   Renal ca. TK-10   20.3       Melanoma*   30.8   Bladder   23.2       Hs688(A).T       Melanoma*   69.3   Gastric ca. (liver met.)   25.3       Hs688(B).T       NCI-N87       Melanoma* M14   15.0   Gastric ca. KATO III   30.8       Melanoma*   26.6   Colon ca. SW-948   9.7       LOXIMVI       Melanoma* SK-   21.5   Colon ca. SW480   35.1       MEL-5       Squamous cell   33.0   Colon ca.* (SW480   13.9       carcinoma SCC-4       met) SW620       Testis Pool   19.8   Colon ca. HT29   8.5       Prostate ca.* (bone   100.0   Colon ca. HCT-116   36.9       met) PC-3       Prostate Pool   9.2   Colon ca. CaCo-2   42.9       Placenta   3.8   Colon cancer tissue   9.0       Uterus Pool   7.4   Colon ca. SW1116   5.8       Ovarian ca.   28.5   Colon ca. Colo-205   4.3       OVCAR-3       Ovarian ca. SK-   40.3   Colon ca. SW-48   4.2       OV-3       Ovarian ca.   20.0   Colon Pool   20.7       OVCAR-4       Ovarian ca.   35.1   Small Intestine Pool   12.2       OVCAR-5       Ovarian ca.   10.9   Stomach Pool   9.9       IGROV-1       Ovarian ca.   9.2   Bone Marrow Pool   11.6       OVCAR-8       Ovary   9.7   Fetal Heart   20.7       Breast ca. MCF-7   37.6   Heart Pool   10.6       Breast ca. MDA-   37.1   Lymph Node Pool   17.9       MB-231       Breast ca. BT 549   62.4   Fetal Skeletal Muscle   12.3       Breast ca. T47D   61.1   Skeletal Muscle Pool   16.0       Breast ca. MDA-N   10.0   Spleen Pool   11.6       Breast Pool   17.3   Thymus Pool   12.2       Trachea   12.0   CNS cancer   29.1               (glio/astro) U87-MG       Lung   6.7   CNS cancer   69.3               (glio/astro) U-118-MG       Fetal Lung   34.2   CNS cancer   34.9               (neuro; met) SK-N-AS       Lung ca. NCI-N417   5.4   CNS cancer (astro) SF-   19.1               539       Lung ca. LX-1   17.2   CNS cancer (astro)   35.8               SNB-75       Lung ca. NCI-H146   3.0   CNS cancer (glio)   11.3               SNB-19       Lung ca. SHP-77   18.6   CNS cancer (glio) SF-   26.4               295       Lung ca. A549   29.1   Brain (Amygdala) Pool   4.5       Lung ca. NCI-H526   4.6   Brain (cerebellum)   8.1       Lung ca. NCI-H23   31.6   Brain (fetal)   13.2       Lung ca. NCI-H460   18.2   Brain (Hippocampus)   5.3               Pool       Lung ca. HOP-62   14.1   Cerebral Cortex Pool   5.4       Lung ca. NCI-H522   31.6   Brain (Substantia   4.8               nigra) Pool       Liver   1.2   Brain (Thalamus) Pool   8.0       Fetal Liver   32.3   Brain (whole)   6.2       Liver ca. HepG2   14.6   Spinal Cord Pool   6.6       Kidney Pool   22.1   Adrenal Gland   8.1       Fetal Kidney   26.1   Pituitary gland Pool   3.0       Renal ca. 786-0   28.7   Salivary Gland   4.7       Renal ca. A498   11.3   Thyroid (female)   4.4       Renal ca. ACHN   12.2   Pancreatic ca.   17.3               CAPAN2       Renal ca. UO-31   24.1   Pancreas Pool   17.1                    
     [1246]               TABLE NF                          Panel 1.3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3023, Run       Ag3023, Run       Tissue Name   167966931   Tissue Name   167966931                                     Liver adenocarcinoma   51.1   Kidney (fetal)   26.2       Pancreas   6.1   Renal ca. 786-0   34.2       Pancreatic ca. CAPAN 2   17.7   Renal ca. A498   17.6       Adrenal gland   3.8   Renal ca. RXF 393   17.2       Thyroid   3.0   Renal ca. ACHN   13.5       Salivary gland   3.9   Renal ca. UO-31   0.0       Pituitary gland   3.6   Renal ca. TK-10   23.0       Brain (fetal)   8.1   Liver   11.7       Brain (whole)   8.5   Liver (fetal)   8.0       Brain (amygdala)   6.7   Liver ca.   26.2               (hepatoblast) HepG2       Brain (cerebellum)   15.2   Lung   3.1       Brain (hippocampus)   5.4   Lung (fetal)   11.0       Brain (substantia nigra)   9.0   Lung ca. (small cell)   12.9               LX-1       Brain (thalamus)   4.2   Lung ca. (small cell)   9.9               NCI-H69       Cerebral Cortex   2.0   Lung ca. (s.cell var.)   67.8               SHP-77       Spinal cord   6.9   Lung ca. (large   3.4               cell)NCI-H460       Glio/astro U87-MG   28.5   Lung ca. (non-sm.   45.1               cell) A549       Glio/astro U-118-MG   46.7   Lung ca. (non-s.cell)   22.7               NCI-H23       astrocytoma SW1783   40.6   Lung ca. (non-s.cell)   25.7               HOP-62       neuro*; met SK-N-AS   27.2   Lung ca. (non-s.cl)   38.2               NCI-H522       astrocytoma SF-539   29.7   Lung ca. (squam.)   27.4               SW 900       astrocytoma SNB-75   35.1   Lung ca. (squam.)   29.9               NCI-H596       glioma SNB-19   15.6   Mammary gland   5.1       glioma U251   37.9   Breast ca.* (pl.ef)   47.0               MCF-7       glioma SF-295   18.4   Breast ca.* (pl.ef)   22.7               MDA-MB-231       Heart (fetal)   2.9   Breast ca.* (pl.ef)   86.5               T47D       Heart   12.9   Breast ca. BT-549   15.9       Skeletal muscle (fetal)   3.4   Breast ca. MDA-N   10.4       Skeletal muscle   36.3   Ovary   2.9       Bone marrow   4.5   Ovarian ca.   26.1               OVCAR-3       Thymus   14.3   Ovarian ca.   16.3               OVCAR-4       Spleen   8.7   Ovarian ca.   83.5               OVCAR-5       Lymph node   11.8   Ovarian ca.   9.3               OVCAR-8       Colorectal   10.4   Ovarian ca. IGROV-1   12.0       Stomach   7.8   Ovarian ca.*   100.0               (ascites) SK-OV-3       Small intestine   5.1   Uterus   4.9       Colon ca. SW480   19.3   Placenta   1.3       Colon ca.*   42.9   Prostate   3.9       SW620(SW480 met)       Colon ca. HT29   9.9   Prostate ca.* (bone   78.5               met)PC-3       Colon ca. HCT-116   26.2   Testis   9.7       Colon ca. CaCo-2   41.5   Melanoma   5.9               Hs688(A).T       Colon ca.   6.3   Melanoma* (met)   14.2       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   16.0   Melanoma UACC-   14.0               62       Gastric ca.* (liver met)   18.8   Melanoma M14   5.7       NCI-N87       Bladder   30.6   Melanoma LOX   8.8               IMVI       Trachea   3.2   Melanoma* (met)   14.7               SK-MEL-5       Kidney   9.6   Adipose   18.9                    
     [1247]               TABLE NG                          Panel 4D                                         Rel.   Rel.       Rel.   Rel.           Exp. (%)   Exp. (%)       Exp. (%)   Exp. (%)           Ag3023,   Ag3373,       Ag3023,   Ag3373,           Run   Run       Run   Run       Tissue Name   164516146   165296617   Tissue Name   164516146   165296617                                             Secondary Th1 act   18.6   17.9   HUVEC IL-1beta   20.3   18.6       Secondary Th2 act   24.3   28.5   HUVEC IFN   25.3   22.7                   gamma       Secondary Tr1 act   22.8   21.8   HUVEC TNF   16.3   18.0                   alpha + IFN                   gamma       Secondary Th1 rest   7.5   6.8   HUVEC TNF   18.2   13.4                   alpha + IL4       Secondary Th2 rest   11.6   9.5   HUVEC IL-11   13.7   9.9       Secondary Tr1 rest   12.1   10.7   Lung   25.7   21.6                   Microvascular EC                   none       Primary Th1 act   20.7   16.5   Lung   26.2   18.3                   Microvascular EC                   TNF alpha + IL-                   1beta       Primary Th2 act   20.2   19.3   Microvascular   27.5   21.3                   Dermal EC none       Primary Tr1 act   23.3   27.7   Microsvasular   20.7   19.9                   Dermal EC                   TNF alpha + IL-                   1beta       Primary Th1 rest   51.1   51.4   Bronchial   13.0   16.3                   epithelium                   TNF alpha +                   IL1beta       Primary Th2 rest   26.2   29.5   Small airway   8.1   8.5                   epithelium none       Primary Tr1 rest   23.7   26.1   Small airway   50.3   39.8                   epithelium                   TNF alpha + IL-                   1beta       CD45RA CD4   14.6   11.0   Coronery artery   20.2   18.9       lymphocyte act           SMC rest       CD45RO CD4   25.2   22.4   Coronery artery   12.0   9.8       lymphocyte act           SMC TNF alpha +                   IL-1beta       CD8 lymphocyte   20.4   15.8   Astrocytes rest   10.4   11.1       act       Secondary CD8   16.5   19.9   Astrocytes   11.7   9.8       lymphocyte rest           TNF alpha + IL-                   1beta       Secondary CD8   13.2   9.3   KU-812   47.6   38.2       lymphocyte act           (Basophil) rest       CD4 lymphocyte   17.1   11.6   KU-812   94.0   92.0       none           (Basophil)                   PMA/ionomycin       2ry   18.3   16.6   CCD1106   19.9   13.2       Th1/Th2/Tr1_anti-           (Keratinocytes)       CD95 CH11           none       LAK cells rest   25.5   16.0   CCD1106   6.0   4.8                   (Keratinocytes)                   TNF alpha + IL-                   1beta       LAK cells IL-2   27.2   22.5   Liver cirrhosis   3.1   2.7       LAK cells IL-   27.2   19.3   Lupus kidney   2.1   1.7       2 + IL-12       LAK cells IL-   36.3   34.4   NCI-H292 none   30.1   18.9       2 + IFN gamma       LAK cells IL-2 +   35.1   29.7   NCI-H292 IL-4   33.9   34.6       IL-18       LAK cells   12.4   11.0   NCI-H292 IL-9   40.1   29.1       PMA/ionomycin       NK Cells IL-2 rest   20.0   15.0   NCI-H292 IL-13   16.2   14.2       Two Way MLR 3   24.0   16.7   NCI-H292 IFN   16.6   18.4       day           gamma       Two Way MLR 5   12.9   10.1   HPAEC none   13.6   13.5       day       Two Way MLR 7   11.4   9.5   HPAEC TNF   25.3   25.3       day           alpha + IL-1beta       PBMC rest   13.7   10.5   Lung fibroblast   11.4   14.2                   none       PBMC PWM   69.3   66.4   Lung fibroblast   6.1   7.2                   TNF alpha + IL-                   1beta       PBMC PHA-L   22.8   17.7   Lung fibroblast   28.5   29.1                   IL-4       Ramos (B cell)   24.1   19.3   Lung fibroblast   23.0   23.3       none           IL-9       Ramos (B cell)   100.0   100.0   Lung fibroblast   20.6   18.9       ionomycin           IL-13       B lymphocytes   71.7   74.2   Lung fibroblast   39.0   32.5       PWM           IFN gamma       B lymphocytes   29.1   28.7   Dermal fibroblast   33.9   31.0       CD40L and IL-4           CCD1070 rest       EOL-1 dbcAMP   12.1   10.5   Dermal fibroblast   76.8   62.0                   CCD1070 TNF                   alpha       EOL-1 dbcAMP   14.5   10.9   Dermal fibroblast   20.3   13.9       PMA/ionomycin           CCD1070 IL-                   1beta       Dendritic cells   13.2   14.8   Dermal fibroblast   14.2   9.5       none           IFN gamma       Dendritic cells LPS   11.7   8.3   Dermal fibroblast   26.4   20.4                   IL-4       Dendritic cells   17.7   12.7   IBD Colitis 2   2.6   2.2       anti-CD40       Monocytes rest   16.7   17.6   IBD Crohn&#39;s   2.0   1.9       Monocytes LPS   6.4   5.0   Colon   11.9   10.5       Macrophages rest   23.5   22.8   Lung   13.3   11.2       Macrophages LPS   9.9   7.1   Thymus   14.4   12.9       HUVEC none   20.6   17.9   Kidney   27.5   19.6       HUVEC starved   43.5   38.4                    
     [1248] CNS_neurodegeneration_v1.0 Summary: Ag3023/Ag3373 This panel does not show differential expression of the CG56804-04 gene in Alzheimer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system. Ag5847—This primer pair recognizes a splice variant of CG58564-01 designated CG58564-04. Expression of this variant is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1249] General_screening_panel_v1.4 Summary: Ag3373 Highest expression of the CG56804-04 gene is seen in a prostate cancer cell line (CT=27). Overall, this gene is expressed at moderate levels in the cancer cell lines in this panel. A higher level of expression is observed in clusters of cell lines derived from prostate, brain, melanoma, colon, lung, breast and ovarian cancer when compared to expression in normal prostate, brain, colon, lung, breast and ovary. Thus, this gene could potentially be used as a diagnostic marker of cancer in these tissues. Furthermore, inhibition of the activity of this gene product using small molecule drugs may be effective in the treatment of cancer in these tissues.  
     [1250] Among tissues with metabolic function, this gene product has moderate levels of expression in adipose, heart, skeletal muscle, adrenal, pituitary, thyroid and pancreas. Thus, this gene product may be a small molecule target for the treatment of endocrine and metabolic diseases, including obesity and Types 1 and 2 diabetes.  
     [1251] In addition, this gene appears to be differentially expressed in fetal (CT value=29) vs adult liver (CT value=33) and may be useful for differentiation between the two sources of this tissue.  
     [1252] This gene is also expressed at moderate levels in all central nervous system samples present on this panel. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.  
     [1253] General_screening_panel_v1.5 Summary: Ag5844—This primer pair recognizes a splice variant of CG58564-01. Expression of this variant is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1254] Panel 1.3D Summary: Ag3023 The CG56804-04 gene is ubiquitously expressed among the samples on this panel, with highest expression in an ovarian cancer cell line (CT=28.8). Overall, the expression of this gene shows good agreement with panel 1.4. A higher level of expression is observed in prostate, brain, melanoma, colon, lung, pancreatic, breast and ovarian cancer cell lines than the normal prostate, brain, colon, lung, pancreas, breast and ovary. Thus, expression of this gene could be used as a diagnostic marker of cancer in these tissues. Furthermore, inhibition of the activity of this gene product using small molecule drugs may be effective in the treatment of cancer in these tissues.  
     [1255] Among tissues with metabolic function, expression of this gene is widespread, as in the previous panel. Please see Panel 1.4 for discussion of utility of this gene in metabolic disease.  
     [1256] This gene represents a dual specificity phosphatase that is also expressed at low to moderate levels across the CNS. Dual-specificity phosphatases comprise a family of MAP kinase regulating enzymes, members of which are upregulated in brains subjected to insults such as ischemia and seizure activity. MAP kinases are known to regulate neurotrophic and neurotoxic pathways. Consequently, agents that modulate the activity of this gene may have utility in attenuating the apoptotic and neurodegenerative processes following brain insults.  
     [1257] Panel 41.1D Summary: Ag5844—This primer pair recognizes a splice variant of CG58564-01. Expression of this variant is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1258] Panel 4D Summary: Ag3023/Ag3373 The CG56804-04 gene is expressed at high to moderate levels in a wide range of cell types and tissues of significance in the immune response in health and disease. Highest expression of this gene is seen in ionomycin treated Ramos cells (CT=26.83). Therefore, targeting of ghis gene product with a small molecule drug or antibody therapeutic may modulate the functions of cells of the immune system as well as resident tissue cells and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, and arthritis, including osteoarthritis and rheumatoid arthritis.  
     [1259] O. CG57819-01: RPGR-Interacting Protein-1  
     [1260] Expression of gene CG57819-01 was assessed using the primer-probe set Ag3338, described in Table OA. Results of the RTQ-PCR runs are shown in Tables OB and OC.  
     [1261] Table OA. Probe Name Ag3338 
               TABLE OA                          Probe Name Ag3338                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cccattcagcactgaaacag-3′   20   3021   426               Probe   TET-5′-tcctgtaaatgacaaagaatcctctgaaca-3′-TAMRA   30   3055   427               Reverse   5′-tgcttcactgacttcagaacct-3′   22   3085   428                  
 
     [1262]               TABLE OB                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3338, Run       Ag3338, Run       Tissue Name   215773746   Tissue Name   215773746                                     Adipose   1.1   Renal ca. TK-10   0.8       Melanoma*   0.0   Bladder   1.1       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.2   Colon ca. SW480   0.4       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   100.0   Colon ca. HT29   0.5       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.2       met) PC-3       Prostate Pool   1.0   Colon ca. CaCo-2   1.0       Placenta   0.0   Colon cancer tissue   0.9       Uterus Pool   0.0   Colon ca. SW1116   0.2       Ovarian ca.   0.9   Colon ca. Colo-205   0.2       OVCAR-3       Ovarian ca. SK-   0.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   1.2   Colon Pool   0.5       OVCAR-4       Ovarian ca.   3.5   Small Intestine Pool   0.3       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.2       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.9   Fetal Heart   0.8       Breast ca. MCF-7   1.9   Heart Pool   1.1       Breast ca. MDA-   1.2   Lymph Node Pool   1.4       MB-231       Breast ca. BT 549   0.2   Fetal Skeletal Muscle   0.2       Breast ca. T47D   6.7   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   1.4       Breast Pool   0.5   Thymus Pool   0.0       Trachea   0.9   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.2   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   0.4   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.0               539       Lung ca. LX-1   0.8   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   0.5   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.1   CNS cancer (glio) SF-   0.2               295       Lung ca. A549   1.5   Brain (Amygdala) Pool   0.7       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.6       Lung ca. NCI-H23   1.5   Brain (fetal)   0.9       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   0.7               Pool       Lung ca. HOP-62   3.0   Cerebral Cortex Pool   0.2       Lung ca. NCI-H522   0.0   Brain (Substantia   0.7               nigra) Pool       Liver   0.4   Brain (Thalamus) Pool   1.3       Fetal Liver   0.5   Brain (whole)   0.0       Liver ca. HepG2   0.2   Spinal Cord Pool   0.9       Kidney Pool   0.9   Adrenal Gland   0.0       Fetal Kidney   0.6   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   3.4               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.8                    
     [1263]               TABLE OC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3338, Run       Ag3338, Run       Tissue Name   165221737   Tissue Name   165221737                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   6.9       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   2.6               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   1.9               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   4.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   4.6   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   0.0       LAK cells IL-2 + IL-12   0.0   Lupus kidney   2.4       LAK cells IL-2 + IFN   0.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   4.5       LAK cells   3.1   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   14.0   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   3.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   4.7   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   13.9   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   6.0   IBD Colitis 2   0.0       CD40       Monocytes rest   100.0   IBD Crohn&#39;s   0.0       Monocytes LPS   0.0   Colon   15.2       Macrophages rest   1.3   Lung   4.0       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   0.0   Kidney   3.1       HUVEC starved   0.0                    
     [1264] CNS_neurodegeneration_v1.0 Summary: Ag3338—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1265] General_screening_panel_v1.4 Summary: Ag3338—Expression of this gene is highest in testis (CT=29.4). Therefore, expression of this gene could be used to distinguish this sample from others on the panel.  
     [1266] There is also low expression in pancreatic cancer cell line CAPAN2, lung cancer cell line HOP-62, breast cancer cell line T47D, and ovarian cancer cell line OVCAR-5. Thus, expression of this gene could be used to differentiate these samples from other samples on this panel.  
     [1267] Panel 4D Summary: Ag3338—Significant expression of this gene is seen only in resting monocytes (CT=32.3) Therefore, expression of this gene can be used to differentiate between this sample and others on this panel.  
     [1268] P. CG57789-01 and CG57789-02: RAS-Like Protein RRP22-like  
     [1269] Expression of gene CG57789-01 and variant CG57789-02 was assessed using the primer-probe set Ag3333, described in Table PA. Results of the RTQ-PCR runs are shown in Tables PB, PC and PD.  
     [1270] Table PA. Probe Name Ag3333 
               TABLE PA                          Probe Name Ag3333                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tcgactttccacccatcag-3′   19   181   429               Probe   TET-5′-cttccctgtcaatacgctccaggagt-3′-TAMRA   26   203   430               Reverse   5′-aggatgtaggcgtggacact-3′   20   258   431                  
 
     [1271]               TABLE PB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%) Ag3333,       Rel. Exp. (%) Ag3333,       Tissue Name   Run 210146459   Tissue Name   Run 210146459                                     AD 1 Hippo   22.2   Control (Path) 3   7.5               Temporal Ctx       AD 2 Hippo   18.8   Control (Path) 4   21.6               Temporal Ctx       AD 3 Hippo   17.9   AD 1 Occipital Ctx   29.7       AD 4 Hippo   8.7   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   100.0   AD 3 Occipital Ctx   15.8       AD 6 Hippo   42.9   AD 4 Occipital Ctx   24.7       Control 2 Hippo   25.9   AD 5 Occipital Ctx   90.1       Control 4 Hippo   12.1   AD 6 Occipital Ctx   16.3       Control (Path) 3   13.4   Control 1 Occipital   4.2       Hippo       Ctx       AD 1 Temporal   21.3   Control 2 Occipital   74.7       Ctx       Ctx       AD 2 Temporal   29.1   Control 3 Occipital   14.5       Ctx       Ctx       AD 3 Temporal   13.3   Control 4 Occipital   4.5       Ctx       Ctx       AD 4 Temporal   15.8   Control (Path) 1   47.3       Ctx       Occipital Ctx       AD 5 Inf Temporal   92.0   Control (Path) 2   13.5       Ctx       Occipital Ctx       AD 5 Sup   43.2   Control (Path) 3   4.1       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   26.4   Control (Path) 4   14.6       Ctx       Occipital Ctx       AD 6 Sup   31.6   Control 1 Parietal   7.6       Temporal Ctx       Ctx       Control 1   5.8   Control 2 Parietal   39.2       Temporal Ctx       Ctx       Control 2   51.8   Control 3 Parietal   21.9       Temporal Ctx       Ctx       Control 3   14.5   Control (Path) 1   56.3       Temporal Ctx       Parietal Ctx       Control 3   8.1   Control (Path) 2   20.2       Temporal Ctx       Parietal Ctx       Control (Path) 1   39.2   Control (Path) 3   6.2       Temporal Ctx       Parietal Ctx       Control (Path) 2   40.9   Control (Path) 4   24.5       Temporal Ctx       Parietal Ctx                    
     [1272]               TABLE PC                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3333, Run       Ag3333, Run       Tissue Name   216516940   Tissue Name   216516940                                     Adipose   4.4   Renal ca. TK-10   40.1       Melanoma*   0.9   Bladder   5.0       Hs688(A).T       Melanoma*   1.8   Gastric ca. (liver met.)   4.5       Hs688(B).T       NCI-N87       Melanoma* M14   2.7   Gastric ca. KATO III   20.0       Melanoma*   0.3   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.9   Colon ca. SW480   100.0       MEL-5       Squamous cell   0.1   Colon ca.* (SW480   33.0       carcinoma SCC-4       met) SW620       Testis Pool   2.1   Colon ca. HT29   5.0       Prostate ca.* (bone   2.4   Colon ca. HCT-116   0.1       met) PC-3       Prostate Pool   0.5   Colon ca. CaCo-2   37.1       Placenta   5.7   Colon cancer tissue   2.3       Uterus Pool   0.3   Colon ca. SW1116   16.2       Ovarian ca.   52.9   Colon ca. Colo-205   0.2       OVCAR-3       Ovarian ca. SK-   0.6   Colon ca. SW-48   0.2       OV-3       Ovarian ca.   17.9   Colon Pool   2.2       OVCAR-4       Ovarian ca.   4.5   Small Intestine Pool   1.0       OVCAR-5       Ovarian ca.   0.9   Stomach Pool   0.9       IGROV-1       Ovarian ca.   15.4   Bone Marrow Pool   1.8       OVCAR-8       Ovary   4.2   Fetal Heart   10.9       Breast ca. MCF-7   0.7   Heart Pool   2.8       Breast ca. MDA-   0.4   Lymph Node Pool   4.4       MB-231       Breast ca. BT 549   42.0   Fetal Skeletal Muscle   1.1       Breast ca. T47D   13.0   Skeletal Muscle Pool   46.7       Breast ca. MDA-N   0.1   Spleen Pool   0.0       Breast Pool   2.4   Thymus Pool   2.3       Trachea   2.4   CNS cancer   0.9               (glio/astro) U87-MG       Lung   0.2   CNS cancer   0.3               (glio/astro) U-118-MG       Fetal Lung   0.9   CNS cancer   69.7               (neuro; met) SK-N-AS       Lung ca. NCI-N417   17.1   CNS cancer (astro) SF-   2.2               539       Lung ca. LX-1   1.1   CNS cancer (astro)   15.9               SNB-75       Lung ca. NCI-H146   14.5   CNS cancer (glio)   0.6               SNB-19       Lung ca. SHP-77   37.6   CNS cancer (glio) SF-   6.0               295       Lung ca. A549   0.4   Brain (Amygdala) Pool   28.5       Lung ca. NCI-H526   23.5   Brain (cerebellum)   29.1       Lung ca. NCI-H23   8.2   Brain (fetal)   21.3       Lung ca. NCI-H460   14.3   Brain (Hippocampus)   27.7               Pool       Lung ca. HOP-62   1.7   Cerebral Cortex Pool   36.1       Lung ca. NCI-H522   86.5   Brain (Substantia   40.1               nigra) Pool       Liver   1.6   Brain (Thalamus) Pool   37.6       Fetal Liver   0.7   Brain (whole)   59.5       Liver ca. HepG2   6.2   Spinal Cord Pool   12.3       Kidney Pool   3.8   Adrenal Gland   4.7       Fetal Kidney   7.4   Pituitary gland Pool   3.7       Renal ca. 786-0   0.2   Salivary Gland   48.0       Renal ca. A498   20.9   Thyroid (female)   1.1       Renal ca. ACHN   8.5   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   3.0   Pancreas Pool   4.0                    
     [1273]               TABLE PD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3333, Run       Ag3333, Run       Tissue Name   165084139   Tissue Name   165084139                                     Secondary Th1 act   0.8   HUVEC IL-1beta   0.0       Secondary Th2 act   3.0   HUVEC IFN gamma   0.5       Secondary Tr1 act   0.6   HUVEC TNF alpha +   0.8               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.5   HUVEC IL-11   0.3       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.6               none       Primary Th1 act   5.7   Lung Microvascular EC   0.4               TNF alpha + IL-1beta       Primary Th2 act   9.8   Microvascular Dermal   0.0               EC none       Primary Tr1 act   3.8   Microsvasular Dermal   0.4               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   1.1               TNF alpha + IL1beta       Primary Th2 rest   0.4   Small airway epithelium   1.9               none       Primary Tr1 rest   0.6   Small airway epithelium   1.4               TNF alpha + IL-1beta       CD45RA CD4   4.1   Coronery artery SMC rest   1.7       lymphocyte act       CD45RO CD4   1.7   Coronery artery SMC   1.2       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   1.4   Astrocytes rest   100.0       Secondary CD8   7.4   Astrocytes TNF alpha +   59.9       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   2.0       lymphocyte act       CD4 lymphocyte none   0.8   KU-812 (Basophil)   4.1               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.5   CCD1106   12.5       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.5   CCD1106   6.2               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.3   Liver cirrhosis   0.9       LAK cells IL-2 + IL-12   0.5   Lupus kidney   3.9       LAK cells IL-2 + IFN   0.0   NCI-H292 none   29.3       gamma       LAK cells IL-2 + IL-18   0.6   NCI-H292 IL-4   39.5       LAK cells   0.3   NCI-H292 IL-9   23.3       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   21.9       Two Way MLR 3 day   0.8   NCI-H292 IFN gamma   14.5       Two Way MLR 5 day   0.9   HPAEC none   0.5       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   4.5       PBMC PWM   8.1   Lung fibroblast TNF   2.2               alpha + IL-1beta       PBMC PHA-L   11.6   Lung fibroblast IL-4   12.9       Ramos (B cell) none   0.0   Lung fibroblast IL-9   9.2       Ramos (B cell)   0.0   Lung fibroblast IL-13   8.5       ionomycin       B lymphocytes PWM   15.4   Lung fibroblast IFN   8.4               gamma       B lymphocytes CD40L   2.1   Dermal fibroblast   40.6       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   20.9               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   19.3       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   1.8               gamma       Dendritic cells LPS   0.5   Dermal fibroblast IL-4   3.8       Dendritic cells anti-   0.0   IBD Colitis 2   0.0       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   2.5       Monocytes LPS   0.0   Colon   4.2       Macrophages rest   0.0   Lung   9.1       Macrophages LPS   0.0   Thymus   11.3       HUVEC none   0.4   Kidney   2.6       HUVEC starved   0.6                    
     [1274] CNS_neurodegeneration_v1.0 Summary: This panel confirms the expression of this gene in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1275] General_screening_panel_v1.4 Summary: Ag3333 This gene is expressed at moderate to low levels in many of the samples on this panel, with the highest expression in colon cancer cell line SW480 (CT=27.8). Expression is significantly lower in SW680, a cell line derived from a metastasis of the primary tumor represented by SW480. Thus, expression of this gene could be used to differentiate between these two cell lines and potentially between primary colon cancer and its metastases.  
     [1276] Based on expression in this panel, this gene may be involved in gastric, brain, colon, renal, lung, breast, ovarian and prostate cancer as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition using antibodies or small molecule drugs might be of use in the treatment of these cancers.  
     [1277] This gene product is also expressed in adipose, pancreas, adrenal, thyroid, pituitary, skeletal muscle, heart, and liver. This widespread expression in tissues with metabolic function suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes  
     [1278] This gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1279] Panel 4D Summary: Ag3333 The CG57789-01 gene is expressed at moderate to low levels in several samples on this panel, with the highest expression in resting astrocytes (CT=28.4). Moderate expression of this gene is seen in treated and untreated dermal and lung fibroblasts and the airway epithelial tumor line NCI-H292 cells. Thus, the transcript or the protein it encodes may be involved in pathological and inflammatory skin and lung conditions, including psoriasis, asthma, allergy, emphysema, and COPD.  
     [1280] Q. CG57758-01 and CG57758-02: Sodium/Lithium-Dependent Dicarboxylate Transporter  
     [1281] Expression of gene CG57758-01, a splice variant of CG57758-02, and CG57758-02 was assessed using the primer-probe sets Ag3326 and Ag3692, described in Tables QA and QB. Results of the RTQ-PCR runs are shown in Tables QC, QD, QE and QF.  
     [1282] Table QA. Probe Name Ag3326 
               TABLE QA                          Probe Name Ag3326                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ccatttactggtgcacagaagt-3′   22   149   432               Probe   TET-5′-atccctctggctgtcacctctctcat-3′-TAMRA   26   172   433               Reverse   5′-ggagtccagaatctggaagagt-3′   22   216   434                  
 
     [1283] Table QB. Probe Name Ag3692 
               TABLE QB                          Probe Name Ag3692                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ccatttactggtgcacagaagt-3′   22   149   435               Probe   TET-5′-atccctctggctgtcacctctctcat-3′-TAMRA   26   172   436               Reverse   5′-ggagtccagaatctggaagagt-3′   22   216   437                  
 
     [1284]                                                               Rel.   Rel.   Rel.       Rel.   Rel.   Rel.           Exp. (%)   Exp. (%)   Exp. (%)       Exp. (%)   Exp. (%)   Exp. (%)           Ag3326,   Ag3692,   Ag3692,       Ag3326,   Ag3692,   Ag3692,       Tissue   Run   Run   Run   Tissue   Run   Run   Run       Name   210144197   211145262   224337942   Name   210144197   211145262   224337942                                                                AD 1   2.1   4.3   1.0   Control   8.5   15.3   12.0       Hippo               (Path) 3                       Temporal                       Ctx       AD 2   20.9   28.3   25.0   Control   31.2   36.6   52.1       Hippo               (Path) 4                       Temporal                       Ctx       AD 3   0.0   0.9   0.6   AD 1   2.7   3.0   0.0       Hippo               Occipital                       Ctx       AD 4   2.1   7.1   2.6   AD 2   0.0   0.0   0.0       Hippo               Occipital                       Ctx                       (Missing)       AD 5   72.7   97.9   85.3   AD 3   1.5   7.2   1.3       hippo               Occipital                       Ctx       AD 6   13.7   18.3   5.5   AD 4   71.7   35.6   30.6       Hippo               Occipital                       Ctx       Control 2   14.5   20.2   15.2   AD 5   25.3   31.9   12.4       Hippo               Occipital                       Ctx       Control 4   11.7   7.4   5.1   AD 6   17.2   19.1   11.2       Hippo               Occipital                       Ctx       Control   6.7   4.4   4.5   Control 1   7.0   9.0   8.1       (Path) 3               Occipital       Hippo               Ctx       AD 1   4.0   1.7   2.8   Control 2   33.2   44.8   26.1       Temporal               Occipital       Ctx               Ctx       AD 2   80.7   50.7   37.4   Control 3   30.1   37.6   21.9       Temporal               Occipital       Ctx               Ctx       AD 3   3.6   0.0   1.1   Control 4   16.3   12.6   8.2       Temporal               Occipital       Ctx               Ctx       AD 4   19.5   30.6   15.2   Control   42.0   55.9   52.9       Temporal               (Path) 1       Ctx               Occipital                       Ctx       AD 5 Inf   100.0   100.0   99.3   Control   6.7   13.0   7.7       Temporal               (Path) 2       Ctx               Occipital                       Ctx       AD 5   32.8   29.1   33.2   Control   8.7   6.6   5.4       SupTemporal               (Path) 3       Ctx               Occipital                       Ctx       AD 6 Inf   27.7   21.3   26.6   Control   8.1   9.0   7.4       Temporal               (Path) 4       Ctx               Occipital                       Ctx       AD 6 Sup   41.8   53.6   17.0   Control 1   21.2   23.0   15.3       Temporal               Parietal       Ctx               Ctx       Control 1   12.0   33.9   18.3   Control 2   48.6   38.2   22.1       Temporal               Parietal       Ctx               Ctx       Control 2   30.1   49.3   44.4   Control 3   28.3   34.4   32.8       Temporal               Parietal       Ctx               Ctx       Control 3   38.7   39.5   33.4   Control   78.5   97.3   100.0       Temporal               (Path) 1       Ctx               Parietal                       Ctx       Control 4   17.6   25.2   24.1   Control   50.7   50.7   37.9       Temporal               (Path) 2       Ctx               Parietal                       Ctx       Control   69.7   70.7   49.7   Control   10.7   10.1   9.6       (Path) 1               (Path) 3       Temporal               Parietal       Ctx               Ctx       Control   35.4   50.7   33.4   Control   30.6   24.5   40.9       (Path) 2               (Path) 4       Temporal               Parietal       Ctx               Ctx                    
     [1285]               TABLE QD                          General_screening_panel_v1.4                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3326, Run   Ag3692, Run       Ag3326, Run   Ag3692, Run       Tissue Name   215678613   217131191   Tissue Name   215678613   217131191                                             Adipose   0.0   0.0   Renal ca. TK-10   11.4   12.0       Melanoma*   0.0   0.0   Bladder   0.0   0.1       Hs688(A).T       Melanoma*   0.1   0.0   Gastric ca. (liver   0.0   0.0       Hs688(B).T           met.) NCI-N87       Melanoma*   0.0   0.0   Gastric ca.   0.0   0.0       M14           KATO III       Melanoma*   0.0   0.0   Colon ca. SW-   0.0   0.0       LOXIMVI           948       Melanoma*   0.0   0.0   Colon ca.   0.0   0.0       SK-MEL-5           SW480       Squamous   0.9   0.7   Colon ca.*   0.0   0.0       cell           (SW480 met)       carcinoma           SW620       SCC-4       Testis Pool   0.1   0.2   Colon ca. HT29   0.0   0.0       Prostate ca.*   0.0   0.0   Colon ca. HCT-   0.0   0.0       (bone met)           116       PC-3       Prostate Pool   0.0   0.0   Colon ca. CaCo-2   0.0   0.0       Placenta   0.0   0.0   Colon cancer   0.1   0.0                   tissue       Uterus Pool   0.0   0.0   Colon ca.   0.0   0.0                   SW1116       Ovarian ca.   0.0   0.0   Colon ca. Colo-   0.0   0.0       OVCAR-3           205       Ovarian ca.   0.0   0.0   Colon ca. SW-48   0.0   0.0       SK-OV-3       Ovarian ca.   0.1   0.0   Colon Pool   0.6   0.0       OVCAR-4       Ovarian ca.   0.0   0.0   Small Intestine   0.1   0.0       OVCAR-5           Pool       Ovarian ca.   0.0   0.0   Stomach Pool   0.0   0.0       IGROV-1       Ovarian ca.   2.8   2.2   Bone Marrow   0.0   0.1       OVCAR-8           Pool       Ovary   0.7   0.6   Fetal Heart   0.0   0.0       Breast ca.   0.0   0.0   Heart Pool   0.0   0.0       MCF-7       Breast ca.   0.0   0.0   Lymph Node   0.1   0.0       MDA-MB-           Pool       231       Breast ca. BT   0.6   0.8   Fetal Skeletal   0.0   0.0       549           Muscle       Breast ca.   0.0   0.0   Skeletal Muscle   0.0   0.0       T47D           Pool       Breast ca.   0.0   0.0   Spleen Pool   0.4   0.2       MDA-N       Breast Pool   0.0   0.1   Thymus Pool   0.0   0.0       Trachea   0.2   0.1   CNS cancer   0.0   0.0                   (glio/astro) U87-                   MG       Lung   0.0   0.0   CNS cancer   0.0   0.0                   (glio/astro) U-                   118-MG       Fetal Lung   0.2   0.1   CNS cancer   0.0   0.0                   (neuro; met) SK-                   N-AS       Lung ca.   0.0   0.0   CNS cancer   0.0   0.0       NCI-N417           (astro) SF-539       Lung ca. LX-1   0.0   0.0   CNS cancer   0.0   0.0                   (astro) SNB-75       Lung ca.   0.0   0.0   CNS cancer   0.0   0.0       NCI-H146           (glio) SNB-19       Lung ca.   0.0   0.0   CNS cancer   0.1   0.1       SHP-77           (glio) SF-295       Lung ca.   0.0   0.1   Brain   0.4   0.4       A549           (Amygdala) Pool       Lung ca.   2.0   0.0   Brain   1.4   1.0       NCI-H526           (cerebellum)       Lung ca.   0.7   0.6   Brain (fetal)   0.7   0.4       NCI-H23       Lung ca.   0.0   0.0   Brain   0.5   0.7       NCI-H460           (Hippocampus)                   Pool       Lung ca.   0.1   0.2   Cerebral Cortex   1.4   1.5       HOP-62           Pool       Lung ca.   0.0   0.0   Brain (Substantia   1.4   1.4       NCI-H522           nigra) Pool       Liver   28.7   24.1   Brain   1.1   0.9                   (Thalamus) Pool       Fetal Liver   100.0   100.0   Brain (whole)   4.1   3.7       Liver ca.   29.5   26.2   Spinal Cord Pool   0.1   0.2       HepG2       Kidney Pool   0.0   0.0   Adrenal Gland   2.6   1.9       Fetal Kidney   0.1   0.1   Pituitary gland   0.0   0.2                   Pool       Renal ca.   0.0   0.0   Salivary Gland   40.9   35.1       786-0       Renal ca.   0.0   0.0   Thyroid (female)   0.0   0.0       A498       Renal ca.   0.0   0.0   Pancreatic ca.   0.5   0.8       ACHN           CAPAN2       Renal ca.   0.0   0.0   Pancreas Pool   0.0   0.0       UO-31                    
     [1286]               TABLE QE                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3692, Run       Ag3692, Run       Tissue Name   169987356   Tissue Name   169987356                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   11.3               EC none       Primary Tr1 act   4.2   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   28.5               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   5.7               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   3.9   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   3.6       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   4.3               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   10.7       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   94.0       LAK cells IL-2 + IL-12   0.0   NCI-H292 none   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 IL-4   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-9   0.0       LAK cells   0.0   NCI-H292 IL-13   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 3 day   0.0   HPAEC none   0.0       Two Way MLR 5 day   3.2   HPAEC TNF alpha + IL-   0.0               1beta       Two Way MLR 7 day   0.0   Lung fibroblast none   0.0       PBMC rest   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PWM   0.0   Lung fibroblast IL-4   0.0       PBMC PHA-L   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-13   0.0       Ramos (B cell)   0.0   Lung fibroblast IFN   0.0       ionomycin       gamma       B lymphocytes PWM   0.0   Dermal fibroblast   0.0               CCD1070 rest       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 IL-1beta       EOL-1 dbcAMP   0.0   Dermal fibroblast IFN   0.0       PMA/ionomycin       gamma       Dendritic cells none   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells LPS   0.0   Dermal Fibroblasts rest   0.0       Dendritic cells anti-   0.0   Neutrophils TNFa + LPS   0.0       CD40       Monocytes rest   0.0   Neutrophils rest   0.0       Monocytes LPS   0.0   Colon   0.0       Macrophages rest   0.0   Lung   0.0       Macrophages LPS   0.0   Thymus   2.4       HUVEC none   0.0   Kidney   100.0       HUVEC starved   0.0                    
     [1287]               TABLE QF                          Panel 5 Islet                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3326, Run       Ag3326, Run       Tissue Name   242385365   Tissue Name   242385365                                     97457_Patient-   0.0   94709_Donor 2 AM - A_adipose   0.2       02go_adipose       97476_Patient-   0.0   94710_Donor 2 AM - B_adipose   0.0       07sk_skeletal muscle       97477_Patient-   0.0   94711_Donor 2 AM - C_adipose   0.0       07ut_uterus       97478_Patient-   0.0   94712_Donor 2 AD - A_adipose   0.0       07pl_placenta       99167_Bayer Patient 1   0.3   94713_Donor 2 AD - B_adipose   0.0       97482_Patient-   0.0   94714_Donor 2 AD - C_adipose   0.0       08ut_uterus       97483_Patient-   0.0   94742_Donor 3 U -   0.0       08pl_placenta       A_Mesenchymal Stem Cells       97486_Patient-   0.0   94743_Donor 3 U -   0.0       09sk_skeletal muscle       B_Mesenchymal Stem Cells       97487_Patient-   0.0   94730_Donor 3 AM - A_adipose   0.0       09ut_uterus       97488_Patient-   0.0   94731_Donor 3 AM - B_adipose   0.0       09pl_placenta       97492_Patient-   0.0   94732_Donor 3 AM - C_adipose   0.0       10ut_uterus       97493_Patient-   0.0   94733_Donor 3 AD - A_adipose   0.0       10pl_placenta       97495_Patient-   0.0   94734_Donor 3 AD - B_adipose   0.0       11go_adipose       97496_Patient-   0.0   94735_Donor 3 AD - C_adipose   0.0       11sk_skeletal muscle       97497_Patient-   0.0   77138_Liver_HepG2untreated   100.0       11ut_uterus       97498_Patient-   0.0   73556_Heart_Cardiac stromal   0.0       11pl_placenta       cells (primary)       97500_Patient-   0.1   81735_Small Intestine   39.5       12go_adipose       97501_Patient-   0.3   72409_Kidney_Proximal   0.0       12sk_skeletal muscle       Convoluted Tubule       97502_Patient-   0.0   82685_Small   0.0       12ut_uterus       intestine_Duodenum       97503_Patient-   0.0   90650_Adrenal_Adrenocortical   0.0       12pl_placenta       adenoma       94721_Donor 2 U -   0.0   72410_Kidney_HRCE   0.0       A_Mesenchymal       Stem Cells       94722_Donor 2 U -   0.0   72411_Kidney_HRE   0.0       B_Mesenchymal       Stem Cells       94723_Donor 2 U -   0.0   73139_Uterus_Uterine smooth   0.0       C_Mesenchymal       muscle cells       Stem Cells                    
     [1288] CNS_neurodegeneration_v1.0 Summary: Ag3326/Ag3692—Three experiments done with two primer pairs (same sequence) are in excellent agreement. This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1289] General_screening_panel_v1.4 Summary: Ag3326/Ag3692 Two experiments with the smae probe and primer set produce results that are in excellent agreement. This gene is highly expressed in fetal liver (CT=26.5-27.0) and moderately expressed in adult liver (CT=28.5-28.8) and liver cancer cell line HepG2 (CT=28.4-28.8). This result agrees with the results seen in Panel 5 (expression in HepG2 (CT=29.2). These results are in agreement with published data that show a novel sodium dicarboxylate transporter in brain, choroid plexus kidney, intestine and liver. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker for liver derived tissue.  
     [1290] This gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, and cerebral cortex. Therefore, this gene may play a role in central nervous system disorders such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1291] Low but significant levels of expression are also seen in the adrenal gland. Thus, this gene product may also be involved in metabolic disorders of this gland, including adrenoleukodystrophy and congenital adrenal hyperplasia.  
     REFERENCES  
     [1292] 1. Pajor A M, Gangula R, Yao X. Cloning and functional characterization of a high-affinity Na(+)/dicarboxylate cotransporter from mouse brain. Am J Physiol Cell Physiol May 2001;280(5):C1215-23.  
     [1293] 2. Chen X Z, Shayakul C, Berger UV, Tian W, Hediger M A. Characterization of a rat Na+-dicarboxylate cotransporter. J Biol Chem Aug. 14, 1998;273(33):20972-81.  
     [1294] Panel 4.1D Summary: Ag3692 Significant expression of this gene is seen only in kidney and a liver cirrhosis sample (CTs=34.0). These results confirm that this gene is expressed in liver derived samples. The presence in the kidney is also in agreement with published results. Please see Panel 1.4. This gene product may be involved in maintaining or restoring normal function to the kidney during inflammation.  
     [1295] Panel 4D Summary: Ag3326 Results from one experiment are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [1296] Panel 5 Islet Summary: Ag3326—The highest expression of this gene is in liver cancer cell line HepG2 (CT=29.2). There is also moderate expression in the small intestine (CT=30.5). These results compare well with previously published reports of sodium dicarboxylate transporter expression in mouse and rat (see discussion Panel 1.4).  
     [1297] R. CG57758-04 and CG57758-05: Sodium:Sulfate Symporter  
     [1298] Expression of gene CG57758-04 and CG57758-05, both splice variants of CG577584-01, was assessed using the primer-probe sets Ag3326, Ag3692 and Ag5818, described in Tables RA, RB and RC. Results of the RTQ-PCR runs are shown in Tables RD, RE, RF, RG and RH.  
     [1299] Table RA. Probe Name Ag3326 
               TABLE RA                          Probe Name Ag3326                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ccatttactggtgcacagaagt-3′   22   138   438               Probe   TET-5′-atccctctggctgtcacctctctcat-3′-TAMRA   26   161   439               Reverse   5′-ggagtccagaatctggaagagt-3′   22   205   440                  
 
     [1300] Table RB. Probe Name Ag3692 
               TABLE RB                          Probe Name Ag3692                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ccatttactggtgcacagaagt-3′   22   138   441               Probe   TET-5′-atccctctggctgtcacctctctcat-3′-TAMRA   26   161   442               Reverse   5′-ggagtccagaatctggaagagt-3′   22   205   443                  
 
     [1301] Table RC. Probe Name Ag5818 
               TABLE RC                          Probe Name Ag5818                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ccatcaccttgatcttgtcc-3′   20   1341   444               Probe   TET-5′-ttatgactcctgttttcaccatggaggca-3′-TAMRA   29   1429   445               Reverse   5′-cagaagactccaattatgttca-3′   22   1458   446                  
 
     [1302]               TABLE RD                          CNS_neurodegeneration_v1.0                                                 Rel.   Rel.   Rel.       Rel.   Rel.   Rel.           Exp. (%)   Exp. (%)   Exp. (%)       Exp. (%)   Exp. (%)   Exp. (%)           Ag3326,   Ag3692,   Ag3692,       Ag3326,   Ag3692,   Ag3692,       Tissue   Run   Run   Run   Tissue   Run   Run   Run       Name   210144197   211145262   224337942   Name   210144197   211145262   224337942                                                     AD 1   2.1   4.3   1.0   Control   8.5   15.3   12.0       Hippo               (Path) 3                       Temporal                       Ctx       AD 2   20.9   28.3   25.0   Control   31.2   36.6   52.1       Hippo               (Path) 4                       Temporal                       Ctx       AD 3   0.0   0.9   0.6   AD 1   2.7   3.0   0.0       Hippo               Occipital                       Ctx       AD 4   2.1   7.1   2.6   AD 2   0.0   0.0   0.0       Hippo               Occipital                       Ctx                       (Missing)       AD 5   72.7   97.9   85.3   AD 3   1.5   7.2   1.3       hippo               Occipital                       Ctx       AD 6   13.7   18.3   5.5   AD 4   71.7   35.6   30.6       Hippo               Occipital                       Ctx       Control 2   14.5   20.2   15.2   AD 5   25.3   31.9   12.4       Hippo               Occipital                       Ctx       Control 4   11.7   7.4   5.1   AD 6   17.2   19.1   11.2       Hippo               Occipital                       Ctx       Control   6.7   4.4   4.5   Control 1   7.0   9.0   8.1       (Path) 3               Occipital       Hippo               Ctx       AD 1   4.0   1.7   2.8   Control 2   33.2   44.8   26.1       Temporal               Occipital       Ctx               Ctx       AD 2   80.7   50.7   37.4   Control 3   30.1   37.6   21.9       Temporal               Occipital       Ctx               Ctx       AD 3   3.6   0.0   1.1   Control 4   16.3   12.6   8.2       Temporal               Occipital       Ctx               Ctx       AD 4   19.5   30.6   15.2   Control   42.0   55.9   52.9       Temporal               (Path) 1       Ctx               Occipital                       Ctx       AD 5 Inf   100.0   100.0   99.3   Control   6.7   13.0   7.7       Temporal               (Path) 2       Ctx               Occipital                       Ctx       AD 5   32.8   29.1   33.2   Control   8.7   6.6   5.4       SupTemporal               (Path) 3       Ctx               Occipital                       Ctx       AD 6 Inf   27.7   21.3   26.6   Control   8.1   9.0   7.4       Temporal               (Path) 4       Ctx               Occipital                       Ctx       AD 6 Sup   41.8   53.6   17.0   Control 1   21.2   23.0   15.3       Temporal               Parietal       Ctx               Ctx       Control 1   12.0   33.9   18.3   Control 2   48.6   38.2   22.1       Temporal               Parietal       Ctx               Ctx       Control 2   30.1   49.3   44.4   Control 3   28.3   34.4   32.8       Temporal               Parietal       Ctx               Ctx       Control 3   38.7   39.5   33.4   Control   78.5   97.3   100.0       Temporal               (Path) 1       Ctx               Parietal                       Ctx       Control 4   17.6   25.2   24.1   Control   50.7   50.7   37.9       Temporal               (Path) 2       Ctx               Parietal                       Ctx       Control   69.7   70.7   49.7   Control   10.7   10.1   9.6       (Path) 1               (Path) 3       Temporal               Parietal       Ctx               Ctx       Control   35.4   50.7   33.4   Control   30.6   24.5   40.9       (Path) 2               (Path) 4       Temporal               Parietal       Ctx               Ctx                    
     [1303]               TABLE RE                          General_screening_panel_v1.4                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3326, Run   Ag3692, Run       Ag3326, Run   Ag3692, Run       Tissue Name   215678613   217131191   Tissue Name   215678613   217131191                                             Adipose   0.0   0.0   Renal ca. TK-10   11.4   12.0       Melanoma*   0.0   0.0   Bladder   0.0   0.1       Hs688(A).T       Melanoma*   0.1   0.0   Gastric ca. (liver   0.0   0.0       Hs688(B).T           met.) NCI-N87       Melanoma*   0.0   0.0   Gastric ca.   0.0   0.0       M14           KATO III       Melanoma*   0.0   0.0   Colon ca. SW-   0.0   0.0       LOXIMVI           948       Melanoma*   0.0   0.0   Colon ca.   0.0   0.0       SK-MEL-5           SW480       Squamous   0.9   0.7   Colon ca.*   0.0   0.0       cell           (SW480 met)       carcinoma           SW620       SCC-4       Testis Pool   0.1   0.2   Colon ca. HT29   0.0   0.0       Prostate ca.*   0.0   0.0   Colon ca. HCT-   0.0   0.0       (bone met)           116       PC-3       Prostate Pool   0.0   0.0   Colon ca. CaCo-2   0.0   0.0       Placenta   0.0   0.0   Colon cancer   0.1   0.0                   tissue       Uterus Pool   0.0   0.0   Colon ca.   0.0   0.0                   SW1116       Ovarian ca.   0.0   0.0   Colon ca. Colo-   0.0   0.0       OVCAR-3           205       Ovarian ca.   0.0   0.0   Colon ca. SW-48   0.0   0.0       SK-OV-3       Ovarian ca.   0.1   0.0   Colon Pool   0.6   0.0       OVCAR-4       Ovarian ca.   0.0   0.0   Small Intestine   0.1   0.0       OVCAR-5           Pool       Ovarian ca.   0.0   0.0   Stomach Pool   0.0   0.0       IGROV-1       Ovarian ca.   2.8   2.2   Bone Marrow   0.0   0.1       OVCAR-8           Pool       Ovary   0.7   0.6   Fetal Heart   0.0   0.0       Breast ca.   0.0   0.0   Heart Pool   0.0   0.0       MCF-7       Breast ca.   0.0   0.0   Lymph Node   0.1   0.0       MDA-MB-           Pool       231       Breast ca. BT   0.6   0.8   Fetal Skeletal   0.0   0.0       549           Muscle       Breast ca.   0.0   0.0   Skeletal Muscle   0.0   0.0       T47D           Pool       Breast ca.   0.0   0.0   Spleen Pool   0.4   0.2       MDA-N       Breast Pool   0.0   0.1   Thymus pool   0.0   0.0       Trachea   0.2   0.1   CNS cancer   0.0   0.0                   (glio/astro) U87-                   MG       Lung   0.0   0.0   CNS cancer   0.0   0.0                   (glio/astro) U-                   118-MG       Fetal Lung   0.2   0.1   CNS cancer   0.0   0.0                   (neuro; met) SK-                   N-AS       Lung ca.   0.0   0.0   CNS cancer   0.0   0.0       NCI-N417           (astro) SF-539       Lung ca. LX-1   0.0   0.0   CNS cancer   0.0   0.0                   (astro) SNB-75       Lung ca.   0.0   0.0   CNS cancer   0.0   0.0       NCI-H146           (glio) SNB-19       Lung ca.   0.0   0.0   CNS cancer   0.1   0.1       SHP-77           (glio) SF-295       Lung ca.   0.0   0.1   Brain   0.4   0.4       A549           (Amygdala) Pool       Lung ca.   2.0   0.0   Brain   1.4   1.0       NCI-H526           (cerebellum)       Lung ca.   0.7   0.6   Brain (fetal)   0.7   0.4       NCI-H23       Lung ca.   0.0   0.0   Brain   0.5   0.7       NCI-H460           (Hippocampus)                   Pool       Lung ca.   0.1   0.2   Cerebral Cortex   1.4   1.5       HOP-62           Pool       Lung ca.   0.0   0.0   Brain (Substantia   1.4   1.4       NCI-H522           nigra) Pool       Liver   28.7   24.1   Brain   1.1   0.9                   (Thalamus) Pool       Fetal Liver   100.0   100.0   Brain (whole)   4.1   3.7       Liver ca.   29.5   26.2   Spinal Cord Pool   0.1   0.2       HepG2       Kidney Pool   0.0   0.0   Adrenal Gland   2.6   1.9       Fetal Kidney   0.1   0.1   Pituitary gland   0.0   0.2                   Pool       Renal ca.   0.0   0.0   Salivary Gland   40.9   35.1       786-0       Renal ca.   0.0   0.0   Thyroid (female)   0.0   0.0       A498       Renal ca.   0.0   0.0   Pancreatic ca.   0.5   0.8       ACHN           CAPAN2       Renal ca.   0.0   0.0   Pancreas Pool   0.0   0.0       UO-31                    
     [1304]               TABLE RF                          General_screening_panel_v1.5                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag5818, Run       Ag5818, Run       Tissue Name   245382899   Tissue Name   245382899                                     Adipose   0.0   Renal ca. TK-10   13.4       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.0       MEL-5       Squamous cell   1.4   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   0.5   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.4       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.1   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   0.0       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   1.9   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.3   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   0.0   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   0.4   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   0.7       Breast Pool   0.0   Thymus Pool   0.0       Trachea   0.2   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   0.2   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.0               539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.2   Brain (Amygdala) Pool   0.7       Lung ca. NCI-H526   0.0   Brain (cerebellum)   1.1       Lung ca. NCI-H23   1.5   Brain (fetal)   0.8       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   0.6               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   1.7       Lung ca. NCI-H522   0.0   Brain (Substantia   1.2               nigra) Pool       Liver   40.3   Brain (Thalamus) Pool   1.3       Fetal Liver   100.0   Brain (whole)   5.6       Liver ca. HepG2   33.2   Spinal Cord Pool   0.3       Kidney Pool   0.0   Adrenal Gland   6.0       Fetal Kidney   0.0   Pituitary gland Pool   0.2       Renal ca. 786-0   0.0   Salivary Gland   67.4       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.7               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.0                    
     [1305]               TABLE RG                          Panel 4.1D                                         Rel.   Rel.       Rel.   Rel.           Exp. (%)   Exp. (%)       Exp. (%)   Exp. (%)           Ag3692,   Ag5818,       Ag3692,   Ag5818,           Run   Run       Run   Run       Tissue Name   169987356   246920287   Tissue Name   169987356   246920287                                             Secondary Th1 act   0.0   0.0   HUVEC IL-1beta   0.0   0.0       Secondary Th2 act   0.0   0.0   HUVEC IFN   0.0   0.0                   gamma       Secondary Tr1 act   0.0   0.0   HUVEC TNF   0.0   0.0                   alpha + IFN                   gamma       Secondary Th1 rest   0.0   0.0   HUVEC TNF   0.0   0.0                   alpha + IL4       Secondary Th2 rest   0.0   0.0   HUVEC IL-11   0.0   0.0       Secondary Tr1 rest   0.0   0.0   Lung   0.0   0.0                   Microvascular EC                   none       Primary Th1 act   0.0   0.0   Lung   0.0   0.0                   Microvascular EC                   TNF alpha + IL-                   1beta       Primary Th2 act   0.0   0.0   Microvascular   11.3   0.0                   Dermal EC none       Primary Tr1 act   4.2   0.0   Microsvasular   0.0   0.0                   Dermal EC                   TNF alpha + IL-                   1beta       Primary Th1 rest   0.0   0.0   Bronchial   28.5   0.0                   epithelium                   TNF alpha +                   IL1beta       Primary Th2 rest   0.0   0.0   Small airway   5.7   0.0                   epithelium none       Primary Tr1 rest   0.0   0.0   Small airway   0.0   0.0                   epithelium                   TNF alpha + IL-                   1beta       CD45RA CD4   3.9   0.0   Coronery artery   0.0   0.0       lymphocyte act           SMC rest       CD45RO CD4   0.0   0.0   Coronery artery   0.0   0.0       lymphocyte act           SMC TNF alpha +                   IL-1beta       CD8 lymphocyte   0.0   0.0   Astrocytes rest   0.0   0.0       act       Secondary CD8   0.0   0.0   Astrocytes   0.0   0.0       lymphocyte rest           TNF alpha + IL-                   1beta       Secondary CD8   0.0   0.0   KU-812   3.6   24.3       lymphocyte act           (Basophil) rest       CD4 lymphocyte   0.0   0.0   KU-812   4.3   0.0       none           (Basophil)                   PMA/ionomycin       2ry   0.0   0.0   CCD1106   10.7   0.0       Th1/Th2/Tr1_anti-           (Keratinocytes)       CD95 CH11           none       LAK cells rest   0.0   0.0   CCD1106   0.0   0.0                   (Keratinocytes)                   TNF alpha + IL-                   1beta       LAK cells IL-2   0.0   0.0   Liver cirrhosis   94.0   27.5       LAK cells IL-   0.0   0.0   NCI-H292 none   0.0   0.0       2 + IL-12       LAK cells IL-   0.0   0.0   NCI-H292 IL-4   0.0   0.0       2 + IFN gamma       LAK cells IL-2 +   0.0   0.0   NCI-H292 IL-9   0.0   0.0       IL-18       LAK cells   0.0   0.0   NCI-H292 IL-13   0.0   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   0.0   NCI-H292 IFN   0.0   0.0                   gamma       Two Way MLR 3   0.0   0.0   HPAEC none   0.0   0.0       day       Two Way MLR 5   3.2   0.0   HPAEC TNF   0.0   0.0       day           alpha + IL-1beta       Two Way MLR 7   0.0   0.0   Lung fibroblast   0.0   0.0       day           none       PBMC rest   0.0   0.0   Lung fibroblast   0.0   0.0                   TNF alpha + IL-                   1beta       PBMC PWM   0.0   0.0   Lung fibroblast   0.0   0.0                   IL-4       PBMC PHA-L   0.0   0.0   Lung fibroblast   0.0   0.0                   IL-9       Ramos (B cell)   0.0   0.0   Lung fibroblast   0.0   0.0       none           IL-13       Ramos (B cell)   0.0   0.0   Lung fibroblast   0.0   0.0       ionomycin           IFN gamma       B lymphocytes   0.0   0.0   Dermal fibroblast   0.0   0.0       PWM           CCD1070 rest       B lymphocytes   0.0   0.0   Dermal fibroblast   0.0   0.0       CD40L and IL-4           CCD1070 TNF                   alpha       EOL-1 dbcAMP   0.0   0.0   Dermal fibroblast   0.0   0.0                   CCD1070 IL-                   1beta       EOL-1 dbcAMP   0.0   0.0   Dermal fibroblast   0.0   0.0       PMA/ionomycin           IFN gamma       Dendritic cells   0.0   0.0   Dermal fibroblast   0.0   0.0       none           IL-4       Dendritic cells LPS   0.0   0.0   Dermal   0.0   0.0                   Fibroblasts rest       Dendritic cells   0.0   0.0   Neutrophils   0.0   0.0       anti-CD40           TNFa + LPS       Monocytes rest   0.0   0.0   Neutrophils rest   0.0   0.0       Monocytes LPS   0.0   0.0   Colon   0.0   0.0       Macrophages rest   0.0   0.0   Lung   0.0   0.0       Macrophages LPS   0.0   0.0   Thymus   2.4   0.0       HUVEC none   0.0   0.0   Kidney   100.0   100.0       HUVEC starved   0.0   0.0                    
     [1306]               TABLE RH                          Panel 5 Islet                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3326, Run       Ag3326, Run       Tissue Name   242385365   Tissue Name   242385365                                     97457_Patient-   0.0   94709_Donor 2 AM - A_adipose   0.2       02go_adipose       97476_Patient-   0.0   94710_Donor 2 AM - B_adipose   0.0       07sk_skeletal muscle       97477_Patient-   0.0   94711_Donor 2 AM - C_adipose   0.0       07ut_uterus       97478_Patient-   0.0   94712_Donor 2 AD - A_adipose   0.0       07pl_placenta       99167_Bayer Patient   0.3   94713_Donor 2 AD - B_adipose   0.0       1       97482_Patient-   0.0   94714_Donor 2 AD - C_adipose   0.0       08ut_uterus       97483_Patient-   0.0   94742_Donor 3 U -   0.0       08pl_placenta       A_Mesenchymal Stem Cells       97486_Patient-   0.0   94743_Donor 3 U -   0.0       09sk_skeletal muscle       B_Mesenchymal Stem Cells       97487_Patient-   0.0   94730_Donor 3 AM - A_adipose   0.0       09ut_uterus       97488_Patient-   0.0   94731_Donor 3 AM - B_adipose   0.0       09pl_placenta       97492_Patient-   0.0   94732_Donor 3 AM - C_adipose   0.0       10ut_uterus       97493_Patient-   0.0   94733_Donor 3 AD - A_adipose   0.0       10pl_placenta       97495_Patient-   0.0   94734_Donor 3 AD - B_adipose   0.0       11go_adipose       97496_Patient-   0.0   94735_Donor 3 AD - C_adipose   0.0       11sk_skeletal muscle       97497_Patient-   0.0   77138_Liver_HepG2untreated   100.0       11ut_uterus       97498_Patient-   0.0   73556_Heart_Cardiac stromal   0.0       11pl_placenta       cells (primary)       97500_Patient-   0.1   81735_Small Intestine   39.5       12go_adipose       97501_Patient-   0.3   72409_Kidney_Proximal   0.0       12sk_skeletal muscle       Convoluted Tubule       97502_Patient-   0.0   82685_Small   0.0       12ut_uterus       intestine_Duodenum       97503_Patient-   0.0   90650_Adrenal_Adrenocortical   0.0       12pl_placenta       adenoma       94721_Donor 2 U -   0.0   72410_Kidney_HRCE   0.0       A_Mesenchymal       Stem Cells       94722_Donor 2 U -   0.0   72411_Kidney_HRE   0.0       B_Mesenchymal       Stem Cells       94723_Donor 2 U -   0.0   73139_Uterus_Uterine smooth   0.0       C_Mesenchymal       muscle cells       Stem Cells                    
     [1307] CNS_neurodegeneration_v1.0 Summary: Ag3326/Ag3692—Three experiments done with two primer pairs (same sequence) are in excellent agreement. This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders. Ag5818 Results from one experiment are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [1308] General_screening_panel_v1.4 Summary: Ag3326/Ag3692 Two experiments with the same probe and primer set produce results that are in excellent agreement. This gene is highly expressed in fetal liver (CT=26.5-27.0) and moderately expressed in adult liver (CT=28.5-28.8) and liver cancer cell line HepG2 (CT=28.4-28.8). This result agrees with In the results seen in Panel 5 (expression in HepG2 (CT=29.2). These results are in agreement with published data that show a novel sodium dicarboxylate transporter in brain, choroid plexus kidney, intestine and liver. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker for liver derived tissue.  
     [1309] This gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, and cerebral cortex. Therefore, this gene may play a role in central nervous system disorders such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1310] Low but significant levels of expression are also seen in the adrenal gland. Thus, this gene product may also be involved in metabolic disorders of this gland, including adrenoleukodystrophy and congenital adrenal hyperplasia.  
     REFERENCES  
     [1311] 1. Pajor A M, Gangula R, Yao X. Cloning and functional characterization of a high-affinity Na(+)/dicarboxylate cotransporter from mouse brain. Am J Physiol Cell Physiol May 2001;280(5):C1215-23.  
     [1312] 2. Chen X Z, Shayakul C, Berger UV, Tian W, Hediger M A. Characterization of a rat Na+-dicarboxylate cotransporter. J Biol Chem Aug. 14, 1998;273(33):20972-81.  
     [1313] General_screening_panel_v1.5 Summary: Ag5818 Results using this primer pair are in excellent agreement with the results seen in panel 1.4. See Panel 1.4 for discussion. Panel 4.1D Summary: Ag3692 Significant expression of this gene is seen only in kidney and a liver cirrhosis sample (CTs=34.0). These results confirm that this gene is expressed in liver derived samples. The presence in the kidney is also in agreement with published results. Please see Panel 1.4. This gene product may be involved in maintaining or restoring normal function to the kidney during inflammation.  
     [1314] Panel 4D Summary: Ag3326 Results from one experiment are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [1315] Panel 5 Islet Summary: Ag3326 The highest expression of this gene is in liver cancer cell line HepG2 (CT=29.2). There is also moderate expression in the small intestine (CT=30.5). These results compare well with previously published reports of sodium dicarboxylate transporter expression in mouse and rat (see discussion Panel 1.4).  
     [1316] S. CG57732-01 and CG57732-02 and CG57732-03: CA2+/Calmodulin-Dependent Protein Kinase IV Kinase  
     [1317] Expression of gene CG57732-01 and full length clones CG57732-02 and CG57732-03, was assessed using the primer-probe set Ag3317, described in Table SA. Results of the RTQ-PCR runs are shown in Tables SB, SC and SD. Please note CG57732-03 represents a splice variant of CG57732-01.  
     [1318] Table SA. Probe Name Ag3317 
               TABLE SA                          Probe Name Ag3317                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ggcctacaacgaaagtgaaga-3′   21   451   447               Probe   TET-5′-cagacactatgcaatgaaagtcctttcca-3′-TAMRA   29   472   448               Reverse   5′-ggaaagccatactgcttcagta-3′   22   510   449                  
 
     [1319]               TABLE SB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3317,           Ag3317, Run       Run       Tissue Name   210144081   Tissue Name   210144081                                     AD 1 Hippo   10.7   Control (Path) 3   4.1               Temporal Ctx       AD 2 Hippo   23.7   Control (Path) 4   42.6               Temporal Ctx       AD 3 Hippo   4.5   AD 1 Occipital   12.5               Ctx       AD 4 Hippo   7.5   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   97.9   AD 3 Occipital   5.4               Ctx       AD 6 Hippo   25.7   AD 4 Occipital   18.4               Ctx       Control 2 Hippo   24.8   AD 5 Occipital   21.8               Ctx       Control 4 Hippo   4.3   AD 6 Occipital   58.6               Ctx       Control (Path) 3   2.8   Control 1 Occipital   1.5       Hippo       Ctx       AD 1 Temporal Ctx   10.4   Control 2 Occipital   94.0               Ctx       AD 2 Temporal Ctx   35.8   Control 3 Occipital   21.5               Ctx       AD 3 Temporal Ctx   5.8   Control 4 Occipital   2.6               Ctx       AD 4 Temporal Ctx   23.2   Control (Path) 1   100.0               Occipital Ctx       AD 5 Inf Temporal   88.9   Control (Path) 2   13.8       Ctx       Occipital Ctx       AD 5 Sup Temporal   26.6   Control (Path) 3   0.9       Ctx       Occipital Ctx       AD 6 Inf Temporal   39.5   Control (Path) 4   19.6       Ctx       Occipital Ctx       AD 6 Sup Temporal   47.3   Control 1 Parietal   4.9       Ctx       Ctx       Control 1 Temporal   4.4   Control 2 Parietal   33.0       Ctx       Ctx       Control 2 Temporal   63.3   Control 3 Parietal   27.4       Ctx       Ctx       Control 3 Temporal   20.4   Control (Path) 1   95.9       Ctx       Parietal Ctx       Control 4 Temporal   8.7   Control (Path) 2   24.5       Ctx       Parietal Ctx       Control (Path) 1   77.4   Control (Path) 3   2.0       Temporal Ctx       Parietal Ctx       Control (Path) 2   38.7   Control (Path) 4   51.8       Temporal Ctx       Parietal Ctx                    
     [1320]               TABLE SC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3317,       (%) Ag3317,           Run       Run       Tissue Name   215678602   Tissue Name   215678602                                     Adipose   2.4   Renal ca. TK-10   14.2       Melanoma*   6.2   Bladder   10.5       Hs688(A).T       Melanoma*   7.9   Gastric ca. (liver met)   22.2       Hs688(B).T       NCI-N87       Melanoma* M14   18.2   Gastric ca. KATO   23.0               III       Melanoma*   9.4   Colon ca. SW-948   11.1       LOXIMVI       Melanoma* SK-   9.8   Colon ca. SW480   20.9       MEL-5       Squamous cell   1.6   Colon ca.* (SW   21.6       carcinoma SCC-4       480 met) SW620       Testis Pool   13.1   Colon ca. HT29   11.3       Prostate ca.* (bone   6.4   Colon ca. HCT-116   27.0       met) PC-3       Prostate Pool   3.1   Colon ca. CaCo-2   1.6       Placenta   1.8   Colon cancer tissue   11.3       Uterus Pool   3.9   Colon ca. SW1116   9.7       Ovarian ca.   11.6   Colon ca. Colo-205   1.7       OVCAR-3       Ovarian ca. SK-   18.7   Colon ca. SW-48   8.8       OV-3       Ovarian ca.   3.4   Colon Pool   17.1       OVCAR-4       Ovarian ca.   17.2   Small Intestine Pool   21.2       OVCAR-5       Ovarian ca.   6.2   Stomach Pool   5.3       IGROV-1       Ovarian ca.   4.7   Bone Marrow Pool   5.1       OVCAR-8       Ovary   2.9   Fetal Heart   6.8       Breast ca. MCF-7   6.1   Heart Pool   5.4       Breast ca. MDA-   20.3   Lymph Node Pool   13.4       MB-231       Breast ca. BT 549   7.4   Fetal Skeletal Muscle   2.6       Breast ca. T47D   37.9   Skeletal Muscle Pool   2.3       Breast ca. MDA-N   9.0   Spleen Pool   2.8       Breast Pool   12.0   Thymus Pool   9.0       Trachea   17.2   CNS cancer   66.4               (glio/astro) U87-MG       Lung   0.7   CNS cancer   53.2               (glio/astro) U-118-MG       Fetal Lung   6.0   CNS cancer   4.6               (neuro; met) SK-N-AS       Lung ca. NCI-N417   16.5   CNS cancer (astro)   17.2               SF-539       Lung ca. LX-1   20.9   CNS cancer (astro)   21.5               SNB-75       Lung ca. NCI-H146   7.0   CNS cancer (glio)   5.1               SNB-19       Lung ca. SHP-77   23.0   CNS cancer (glio)   12.2               SF-295       Lung ca. A549   23.7   Brain (Amygdala)   46.3               Pool       Lung ca. NCI-H526   4.4   Brain (Cerebellum)   92.7       Lung ca. NCI-H23   5.8   Brain (fetal)   25.7       Lung ca. NCI-H460   10.3   Brain (Hippocampus)   42.9               Pool       Lung ca. HOP-62   7.0   Cerebral Cortex Pool   100.0       Lung ca. NCI-H522   2.9   Brain (Substantia   76.3               nigra) Pool       Liver   0.1   Brain (Thalamus) Pool   63.7       Fetal Liver   1.3   Brain (whole)   56.6       Liver ca. HepG2   1.4   Spinal Cord Pool   9.3       Kidney Pool   26.2   Adrenal Gland   16.2       Fetal Kidney   3.5   Pituitary gland Pool   16.4       Renal ca. 786-0   26.4   Salivary Gland   13.4       Renal ca. A498   14.2   Thyroid (female)   6.3       Renal ca. ACHN   33.2   Pancreatic ca.   2.6               CAPAN2       Renal ca. UO-31   4.3   Pancreas Pool   19.6                    
     [1321]               TABLE SD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3317, Run       Ag3317, Run       Tissue Name   164683049   Tissue Name   164683049                                     Secondary Th1 act   21.6   HUVEC IL-1beta   3.8       Secondary Th2 act   23.2   HUVEC IFN gamma   12.5       Secondary Tr1 act   22.8   HUVEC TNF alpha +   2.9               IFN gamma       Secondary Th1 rest   12.7   HUVEC TNF alpha +   9.0               IL4       Secondary Th2 rest   9.3   HUVEC IL-11   4.0       Secondary Tr1 rest   33.7   Lung Microvascular EC   24.3               none       Primary Th1 act   44.1   Lung Microvascular EC   11.3               TNF alpha + IL-1beta       Primary Th2 act   49.3   Microvascular Dermal   41.5               none       Primary Tr1 act   74.2   Microsvasular Dermal EC   17.2               TNF alpha + IL-1beta       Primary Th1 rest   38.2   Bronchial epithelium   31.2               TNF alpha + IL1beta       Primary Th2 rest   44.4   Small airway epithelium   8.0               none       Primary Tr1 rest   50.0   Small airway epithelium   11.1               TNF alpha + IL-1beta       CD45RA CD4   41.2   Coronery artery SMC rest   20.6       lymphocyte act       CD45RO CD4   25.0   Coronery artery SMC   19.6       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   17.8   Astrocytes rest   14.7       Secondary CD8   21.8   Astrocytes TNF alpha +   11.0       lymphocyte rest       IL-1beta       Secondary CD8   7.4   KU-812 (Basophil) rest   2.1       lymphocyte act       CD4 lymphocyte none   21.8   KU-812 (Basophil)   12.9               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   5.8   CCD1106   30.6       CD95 CH11       (Keratinocytes) none       LAK cells rest   51.1   CCD1106   23.7               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   7.0   Liver cirrhosis   0.8       LAK cells IL-2 + IL-12   25.5   Lupus kidney   2.2       LAK cells IL-2 + IFN   35.4   NCI-H292 none   33.7       gamma       LAK cells IL-2 + IL-18   28.7   NCI-H292 IL-4   43.5       LAK cells   20.6   NCI-H292 IL-9   36.3       PMA/ionomycin       NK Cells IL-2 rest   13.5   NCI-H292 IL-13   35.6       Two Way MLR 3 day   33.0   NCI-H292 IFN gamma   24.3       Two Way MLR 5 day   9.6   HPAEC none   22.8       Two Way MLR 7 day   10.0   HPAEC TNF alpha + IL-   8.3               1beta       PBMC rest   12.0   Lung fibroblast none   11.8       PBMC PWM   24.7   Lung fibroblast TNF   1.2               alpha + IL-1beta       PBMC PHA-L   32.5   Lung fibroblast IL-4   19.2       Ramos (B cell) none   1.5   Lung fibroblast IL-9   12.1       Ramos (B cell)   0.0   Lung fibroblast IL-13   14.8       ionomycin       B lymphocytes PWM   41.2   Lung fibroblast IFN   17.2               gamma       B lymphocytes CD40L   14.5   Dermal fibroblast   100.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   20.0   Dermal fibroblast   57.8               CCD1070 TNF alpha       EOL-1 dbcAMP   60.3   Dermal fibroblast   14.2       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   55.5   Dermal fibroblast IFN   24.1               gamma       Dendritic cells LPS   26.1   Dermal fibroblast IL-4   39.0       Dendritic cells anti-   74.7   IBD Colitis 2   1.6       CD40       Monocytes rest   48.0   IBD Crohn&#39;s   2.7       Monocytes LPS   15.4   Colon   19.1       Macrophages rest   98.6   Lung   14.4       Macrophages LPS   5.6   Thymus   10.5       HUVEC none   27.9   Kidney   100.0       HUVEC starved   27.0                    
     [1322] CNS_neurodegeneration_v1.0 Summary: Ag3317—This panel does not show differential expression of this gene in Alzheimer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.  
     [1323] General_screening_panel_v1.4 Summary: Ag3317—There is low to moderate expression this gene across all samples on this panel. This gene is expressed at moderate levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, and cerebral cortex. Highest expression is observed in the cerebral cortex (CT=29.0). This gene encodes a calmodulin-dependent protein kinase IV homolog, which is known to play a role in. Ca2+ signaling in the CNS that controls neuronal growth, differentiation, and plasticity. Mice deficient in calmodulin-dependent protein kinase IV were found to have cerebellar defects. Therefore, this gene may play a role in central nervous system disorders such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1324] This gene product is also expressed in adipose, pancreas, adrenal, thyroid, pituitary, skeletal muscle, heart, and liver. This widespread expression in tissues with metabolic function suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes.  
     [1325] Based on expression in this panel, this gene may be also be involved in gastric, pancreatic, brain, colon, renal, lung, breast, ovarian and prostate cancer as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition using antibodies or small molecule drugs might be of use in the treatment of these cancers.  
     REFERENCES  
     [1326] 1. Okuno S, Kitani T, Fujisawa H. Evidence for the existence of Ca2+/calmodulin-dependent protein kinase IV kinase isoforms in rat brain. J Biochem (Tokyo) June 1996;119(6):1176-81.  
     [1327] 2. Ribar T J, Rodriguiz R M, Khiroug L, Wetsel W C, Augustine G J, Means A R. Cerebellar defects in Ca2+/calmodulin kinase IV-deficient mice. J Neurosci Nov. 15, 2000;20(2C2):RC 107.  
     [1328] Panel 4D Summary: Ag3317—This gene was found to have low expression across almost all the samples on this panel, with the highest level of expression seen in kidney and resting dermal Fibroblasts (CTs=32). Expression of Ca2+/calmodulin-dependent kinase type IV in thymocytes has been found in mice, where it plays a role in Ca2+-dependent gene transcription.  
     [1329] REFERENCE  
     [1330] 1. Raman V, Blaeser F, Ho N, Engle D L, Williams C B, Chatila T A. Requirement for Ca2+/calmodulin-dependent kinase type IV/Gr in setting the thymocyte selection threshold. J Immunol Dec. 1, 2001;167(11):6270-8.  
     [1331] T. CG57709-01: Novel Mitochondrial Protein  
     [1332] Expression of gene CG57709-01 was assessed using the primer-probe set Ag3323, described in Table TA. Results of the RTQ-PCR runs are shown in Tables TB, TC and TD.  
     [1333] Table TA. Probe Name Ag3323 
               TABLE TA                          Probe Name Ag3323                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atgtgcagaggatacgcatg-3′   20   589   450               Probe   TET-5′-tgcaaaacaggaagacaaaggaaggg-3′-TAMRA   26   626   451               Reverse   5′-tggttctggcattctagacg-3′   20   665   452                  
 
     [1334]               TABLE TB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.       Rel. Exp.           (%) Ag3323,       (%) Ag3323,           Run       Run       Tissue Name   210144152   Tissue Name   210144152                                     AD 1 Hippo   22.5   Control (Path) 3   5.2               Temporal Ctx       AD 2 Hippo   29.5   Control (Path) 4   32.5               Temporal Ctx       AD 3 Hippo   6.9   AD 1 Occipital   18.6               Ctx       AD 4 Hippo   7.4   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   82.4   AD 3 Occipital   7.6               Ctx       AD 6 Hippo   66.4   AD 4 Occipital   17.8               Ctx       Control 2 Hippo   27.5   AD 5 Occipital   30.8               Ctx       Control 4 Hippo   11.9   AD 6 Occipital   48.6               Ctx       Control (Path) 3   8.4   Control 1 Occipital   4.0       Hippo       Ctx       AD 1 Temporal Ctx   18.6   Control 2 Occipital   58.2               Ctx       AD 2 Temporal Ctx   30.6   Control 3 Occipital   14.2               Ctx       AD 3 Temporal Ctx   7.6   Control 4 Occipital   6.6               Ctx       AD 4 Temporal Ctx   21.5   Control (Path) 1   70.7               Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   12.6       Ctx       Occipital Ctx       AD 5 Sup Temporal   42.6   Control (Path) 3   2.4       Ctx       Occipital Ctx       AD 6 Inf Temporal   48.6   Control (Path) 4   14.6       Ctx       Occipital Ctx       AD 6 Sup Temporal   42.0   Control 1 Parietal   6.5       Ctx       Ctx       Control 1 Temporal   6.3   Control 2 Parietal   48.0       Ctx       Ctx       Control 2 Temporal   39.0   Control 3 Parietal   19.6       Ctx       Ctx       Control 3 Temporal   13.1   Control (Path) 1   61.1       Ctx       Parietal Ctx       Control 4 Temporal   8.9   Control (Path) 2   19.3       Ctx       Parietal Ctx       Control (Path) 1   53.6   Control (Path) 3   3.8       Temporal Ctx       Parietal Ctx       Control (Path) 2   34.2   Control (Path) 4   42.6       Temporal Ctx       Parietal Ctx                    
     [1335]               TABLE TC                          Panel 1.3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3323,       Ag3323,       Tissue Name   Run 165678151   Tissue Name   Run 165678151                                     Liver adenocarcinoma   25.0   Kidney (fetal)   6.5       Pancreas   12.8   Renal ca. 786-0   14.3       Pancreatic ca. CAPAN 2   24.5   Renal ca. A498   34.2       Adrenal gland   12.2   Renal ca. RXF 393   14.2       Thyroid   6.9   Renal ca. ACHN   12.9       Salivary gland   14.0   Renal ca. UO-31   48.6       Pituitary gland   10.1   Renal ca. TK-10   7.2       Brain (fetal)   13.7   Liver   20.2       Brain (whole)   29.7   Liver (fetal)   22.1       Brain (amygdala)   21.3   Liver ca.   21.3               (hepatoblast) HepG2       Brain (cerebellum)   24.7   Lung   6.7       Brain (hippocampus)   25.7   Lung (fetal)   14.8       Brain (substantia nigra)   20.0   Lung ca. (small cell)   39.8               LX-1       Brain (thalamus)   27.2   Lung ca. (small cell)   25.0               NCI-H69       Cerebral Cortex   33.0   Lung ca. (s.cell var.)   42.3               SHP-77       Spinal cord   16.5   Lung ca. (large   25.7               cell)NCI-H460       glio/astro U87-MG   8.9   Lung ca. (non-sm.   12.0               cell) A549       glio/astro U-118-MG   100.0   Lung ca. (non-s.cell)   9.1               NCI-H23       astrocytoma SW1783   14.6   Lung ca. (non-s.cell)   9.5               HOP-62       neuro*; met SK-N-AS   43.2   Lung ca. (non-s.cl)   10.7               NCI-H522       astrocytoma SF-539   13.9   Lung ca. (squam.)   12.4               SW 900       astrocytoma SNB-75   29.7   Lung ca. (squam.)   59.0               NCI-H596       glioma SNB-19   13.5   Mammary gland   10.6       glioma U251   43.8   Breast ca.* (pl.ef)   46.3               MCF-7       glioma SF-295   17.7   Breast ca.* (pl.ef)   31.6               MDA-MB-231       Heart (fetal)   22.7   Breast ca.* (pl.ef)   15.1               T47D       Heart   14.5   Breast ca. BT-549   54.0       Skeletal muscle (fetal)   6.8   Breast ca. MDA-N   11.5       Skeletal muscle   55.5   Ovary   8.7       Bone marrow   10.7   Ovarian ca.   26.2               OVCAR-3       Thymus   5.5   Ovarian ca.   21.6               OVCAR-4       Spleen   13.3   Ovarian ca.   20.9               OVCAR-5       Lymph node   24.8   Ovarian ca.   12.6               OVCAR-8       Colorectal   8.8   Ovarian ca. IGROV-1   4.4       Stomach   15.1   Ovarian ca.*   23.5               (ascites) SK-OV-3       Small intestine   28.3   Uterus   14.3       Colon ca. SW480   27.5   Placenta   6.9       Colon ca.*   17.6   Prostate   9.5       SW620(SW480 met)       Colon ca. HT29   14.6   Prostate ca.* (bone   17.7               met)PC-3       Colon ca. HCT-116   43.2   Testis   10.1       Colon ca. CaCo-2   12.7   Melanoma   7.6               Hs688(A).T       Colon ca.   22.5   Melanoma* (met)   6.6       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   25.2   Melanoma UACC-   19.6               62       Gastric ca.* (liver met)   29.5   Melanoma M14   39.2       NCI-N87       Bladder   6.1   Melanoma LOX   13.4               IMVI       Trachea   13.2   Melanoma* (met)   21.2               SK-MEL-5       Kidney   15.6   Adipose   6.5                    
     [1336]               TABLE TD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3323, Run       Ag3323, Run       Tissue Name   165296416   Tissue Name   165296416                                     Secondary Th1 act   32.3   HUVEC IL-1beta   3.8       Secondary Th2 act   22.8   HUVEC IFN gamma   12.0       Secondary Tr1 act   29.9   HUVEC TNF alpha +   8.1               IFN gamma       Secondary Th1 rest   3.8   HUVEC TNF alpha +   11.1               IL4       Secondary Th2 rest   4.3   HUVEC IL-11   8.4       Secondary Tr1 rest   6.0   Lung Microvascular EC   7.6               none       Primary Th1 act   33.0   Lung Microvascular EC   6.9               TNF alpha + IL-1beta       Primary Th2 act   25.0   Microvascular Dermal   14.7               EC none       Primary Tr1 act   40.1   Microsvasular Dermal   7.6               EC TNF alpha + IL-1beta       Primary Th1 rest   17.8   Bronchial epithelium   17.3               TNF alpha + IL1beta       Primary Th2 rest   11.6   Small airway epithelium   6.6               none       Primary Tr1 rest   15.0   Small airway epithelium   18.4               TNF alpha + IL-1beta       CD45RA CD4   15.0   Coronery artery SMC rest   9.9       lymphocyte act       CD45RO CD4   24.7   Coronery artery SMC   6.5       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   19.3   Astrocytes rest   5.1       Secondary CD8   22.7   Astrocytes TNF alpha +   3.9       lymphocyte rest       IL-1beta       Secondary CD8   12.9   KU-812 (Basophil) rest   14.0       lymphocyte act       CD4 lymphocyte none   2.9   KU-812 (Basophil)   22.1               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   5.4   CCD1106   16.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   7.2   CCD1106   8.1               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   17.2   Liver cirrhosis   1.7       LAK cells IL-2 + IL-12   15.1   Lupus kidney   1.0       LAK cells IL-2 + IFN   27.9   NCI-H292 none   30.1       gamma       LAK cells IL-2 + IL-18   17.7   NCI-H292 IL-4   49.0       LAK cells   1.9   NCI-H292 IL-9   33.2       PMA/ionomycin       NK Cells IL-2 rest   8.4   NCI-H292 IL-13   26.2       Two Way MLR 3 day   9.9   NCI-H292 IFN gamma   26.6       Two Way MLR 5 day   18.4   HPAEC none   11.7       Two Way MLR 7 day   8.9   HPAEC TNF alpha + IL-   7.5               1beta       PBMC rest   3.8   Lung fibroblast none   8.0       PBMC PWM   50.3   Lung fibroblast TNF   5.5               alpha + IL-1beta       PBMC PHA-L   29.3   Lung fibroblast IL-4   19.1       Ramos (B cell) none   33.9   Lung fibroblast IL-9   15.3       Ramos (B cell)   83.5   Lung fibroblast IL-13   11.4       ionomycin       B lymphocytes PWM   100.0   Lung fibroblast IFN   16.5               gamma       B lymphocytes CD40L   22.4   Dermal fibroblast   28.9       and IL-4       CCD1070 rest       EOL-1 dbcAMP   10.5   Dermal fibroblast   31.2               CCD1070 TNF alpha       EOL-1 dbcAMP   3.7   Dermal fibroblast   11.3       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   9.9   Dermal fibroblast IFN   5.2               gamma       Dendritic cells LPS   6.3   Dermal fibroblast IL-4   12.3       Dendritic cells anti-   7.3   IBD Colitis 2   0.7       CD40       Monocytes rest   7.0   IBD Crohn&#39;s   1.0       Monocytes LPS   1.4   Colon   8.8       Macrophages rest   13.5   Lung   5.8       Macrophages LPS   3.5   Thymus   17.3       HUVEC none   11.9   Kidney   12.3       HUVEC starved   24.8                    
     [1337] CNS_neurodegeneration_v1.0 Summary: Ag3323 This panel does not show differential expression of the CG57709-01 gene in Alzheimer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.  
     [1338] Panel 1.3D Summary: Ag3323—This gene is expressed at moderate levels in all samples on this panel, with highest expression in a brain cancer cell line. Expression is also seen in all the cancer cell lines on this panel. Thus, expression of this gene could be used to differentiate between this brain cancer cell line sample and other samples on this panel and as a marker for brain cancer.  
     [1339] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [1340] This molecule is also expressed at moderate to low levels in the CNS and may be a small molecule target for the treatment of neurologic diseases such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, schizophrenia, stroke and multiple sclerosis.  
     [1341] Panel 4D Summary: Ag3323—This gene is expressed at high to moderate levels in all samples on this panel, with highest expression in B lymphocytes stimulated with polkweed mitoger (CT=24.5). In addition, this gene is expressed at higher levels in ionomycin-activated Ramos B lymphocytes. The high levels of expression in activated B lymphocytes suggests that therapies that antagonize the function of this gene product may reduce or eliminate the symptoms in patients with autoimmune and inflammatory diseases in which B cells play a part in the initiation or progression of the disease process, such as lupus erythemratosus, Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.  
     [1342] U. CG57700-01: Hydroxyacylglutathione Hydrolase (Glyoxalase II)  
     [1343] Expression of gene CG57700-01 was assessed using the primer-probe set Ag3311, described in Table UA. Results of the RTQ-PCR runs are shown in Table UB.  
     [1344] Table UA. Probe Name Ag3311 
               TABLE UA                          Probe Name Ag3311                                             Start           Primers   Sequences   Length   Position   SEQ ID NO:                                         Forward   5′-acgcttagcaacctggagtt-3′   20   536   453               Probe   TET-5′-accacgtgagagccaagctgtcct-3′-TAMRA   24   582   454               Reverse   5′-gtcatcctcatccctcttctg-3′   21   611   456                  
 
     [1345]               TABLE UB                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3311, Run       Ag3311, Run       Tissue Name   164682845   Tissue Name   164682845                                     Secondary Th1 act   10.2   HUVEC IL-1beta   0.0       Secondary Th2 act   3.8   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   1.6   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   5.1               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   4.2       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   2.7               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   0.0       LAK cells IL-2 + IL-12   0.0   Lupus kidney   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   4.5   NCI-H292 IFN gamma   1.9       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   3.7   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   14.1       Ramos (B cell)   0.0   Lung fibroblast IL-13   4.3       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   1.6   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   2.1   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   3.0       Dendritic cells anti-   2.5   IBD Colitis 2   0.0       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   0.0   Colon   100.0       Macrophages rest   0.0   Lung   29.3       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   0.0   Kidney   2.4       HUVEC starved   0.0                    
     [1346] AI_comprehensive panel_v1.0 Summary: Ag3311—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1347] CNS_neurodegeneration_v1.0 Summary: Ag3311—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1348] General_screening_panel_v1.4 Summary: Ag3311—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1349] Panel 4D Summary: Ag3311—Significant expression of this gene is seen only in colon (CT=33.9). Therefore, expression of this gene can be used to distinguish between this sample and the others on the panel and between healthy and inflammed bowel. Since expression is not detectable in samples derived from Crohn&#39;s and colitis patients, therapeutic modulation of the expression or function of this gene may be useful in the treatment of inflammatory bowel disease.  
     [1350] V. CG58553-01: Vasolpressin Receptor  
     [1351] Expression of gene CG58553-01 was assessed using the primer-probe set Ag3372, described in Table VA. Results of the RTQ-PCR runs are shown in Tables VB and VC.  
     [1352] Table VA. Probe Name Ag3372 
               TABLE VA                          Probe Name Ag3372                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cggatctggtcatcacaca-3′   19   1983   457               Probe   TET-5′-ccacccacaacctcccaaggaact-3′-TAMRA   24   2017   458               Reverse   5′-agcctcagaaggtcgagatg-3′   20   2041   459                  
 
     [1353]               TABLE VB                          Panel 1.3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3372,       Ag3372,       Tissue Name   Run 165524269   Tissue Name   Run 165524269                                     Liver adenocarcinoma   0.7   Kidney (fetal)   0.0       Pancreas   0.2   Renal ca. 786-0   0.0       Pancreatic ca. CAPAN 2   0.0   Renal ca. A498   0.1       Adrenal gland   0.0   Renal ca. RXF 393   0.0       Thyroid   0.1   Renal ca. ACHN   0.0       Salivary gland   0.1   Renal ca. UO-31   0.0       Pituitary gland   0.2   Renal ca. TK-10   0.0       Brain (fetal)   0.0   Liver   2.1       Brain (whole)   0.3   Liver (fetal)   0.0       Brain (amygdala)   0.0   Liver ca.   0.2               (hepatoblast) HepG2       Brain (cerebellum)   0.1   Lung   2.4       Brain (hippocampus)   0.5   Lung (fetal)   0.2       Brain (substantia nigra)   0.2   Lung ca. (small cell)   0.0               LX-1       Brain (thalamus)   0.0   Lung ca. (small cell)   0.0               NCI-H69       Cerebral Cortex   0.0   Lung ca. (s.cell var.)   0.1               SHP-77       Spinal cord   1.0   Lung ca. (large   0.0               cell)NCI-H460       glio/astro U87-MG   0.0   Lung ca. (non-sm.   0.1               cell) A549       glio/astro U-118-MG   0.0   Lung ca. (non-s.cell)   0.6               NCI-H23       astrocytoma SW1783   0.0   Lung ca. (non-s.cell)   0.1               HOP-62       neuro*; met SK-N-AS   0.0   Lung ca. (non-s.cl)   0.0               NCI-H522       astrocytoma SF-539   0.0   Lung ca. (squam.)   0.0               SW 900       astrocytoma SNB-75   0.1   Lung ca. (squam.)   0.0               NCI-H596       glioma SNB-19   0.4   Mammary gland   0.7       glioma U251   0.2   Breast ca.* (pl.ef)   0.0               MCF-7       glioma SF-295   0.0   Breast ca.* (pl.ef)   0.0               MDA-MB-231       Heart (fetal)   0.0   Breast ca.* (pl.ef)   0.1               T47D       Heart   0.0   Breast ca. BT-549   0.0       Skeletal muscle (fetal)   0.0   Breast ca. MDA-N   0.0       Skeletal muscle   0.0   Ovary   0.0       Bone marrow   1.6   Ovarian ca.   0.2               OVCAR-3       Thymus   1.7   Ovarian ca.   0.0               OVCAR-4       Spleen   2.8   Ovarian ca.   0.2               OVCAR-5       Lymph node   5.5   Ovarian ca.   0.2               OVCAR-8       Colorectal   0.2   Ovarian ca. IGROV-1   0.0       Stomach   1.2   Ovarian ca.*   0.0               (ascites) SK-OV-3       Small intestine   100.0   Uterus   0.0       Colon ca. SW480   0.0   Placenta   0.8       Colon ca.*    0.0   Prostate   0.1       SW620(SW480 met)       Colon ca. HT29   0.0   Prostate ca.* (bone   0.0               met)PC-3       Colon ca. HCT-116   0.0   Testis   1.4       Colon ca. CaCo-2   0.3   Melanoma   0.0               Hs688(A).T       Colon ca.   0.7   Melanoma* (met)   0.0       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   3.8   Melanoma UACC-   0.0               62       Gastric ca.* (liver met)   1.0   Melanoma M14   0.2       NCI-N87       Bladder   0.0   Melanoma LOX   0.2               IMVI       Trachea   0.1   Melanoma* (met)   0.4               SK-MEL-5       Kidney   0.6   Adipose   1.3                    
     [1354]               TABLE VC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3372, Run       Ag3372, Run       Tissue Name   165296616   Tissue Name   165296616                                     Secondary Th1 act   1.4   HUVEC IL-1beta   0.0       Secondary Th2 act   1.4   HUVEC IFN gamma   0.0       Secondary Tr1 act   2.9   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   5.4   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   6.4   HUVEC IL-11   0.0       Secondary Tr1 rest   12.0   Lung Microvascular EC   0.0               none       Primary Th1 act   11.4   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   18.9   Microvascular Dermal   0.0               EC none       Primary Tr1 act   27.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   27.5   Bronchial epithelium   0.1               TNF alpha + IL1beta       Primary Th2 rest   13.6   Small airway epithelium   0.0               none       Primary Tr1 rest   32.8   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   3.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   8.5   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   5.8   Astrocytes rest   0.0       Secondary CD8   3.1   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   2.9   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   4.7   KU-812 (Basophil)   0.1               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   7.5   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   1.8   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   5.8   Liver cirrhosis   1.5       LAK cells IL-2 + IL-12   2.3   Lupus kidney   0.6       LAK cells IL-2 + IFN   5.5   NCI-H292 none   2.5       gamma       LAK cells IL-2 + IL-18   5.5   NCI-H292 IL-4   1.8       LAK cells   2.7   NCI-H292 IL-9   5.9       PMA/ionomycin       NK Cells IL-2 rest   6.0   NCI-H292 IL-13   2.3       Two Way MLR 3 day   2.1   NCI-H292 IFN gamma   3.0       Two Way MLR 5 day   0.9   HPAEC none   0.0       Two Way MLR 7 day   1.8   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   1.5   Lung fibroblast none   0.0       PBMC PWM   5.6   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.9   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.2   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   2.2   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   3.7   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   1.0   Dermal fibroblast   5.2               CCD1070 TNF alpha       EOL-1 dbcAMP   0.4   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.2   Dermal fibroblast IFN   0.1               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   0.4       CD40       Monocytes rest   0.3   IBD Crohn&#39;s   8.4       Monocytes LPS   0.2   Colon   100.0       Macrophages rest   0.7   Lung   0.9       Macrophages LPS   0.0   Thymus   8.1       HUVEC none   0.0   Kidney   6.8       HUVEC starved   0.0                    
     [1355] Panel 1.3D Summary: Ag3372 Highest expression of the CG58553-01 gene is seen in the small intestine sample (CT=26.8). This gene encodes a novel vasopressin gene that plays a role in regulating electrolyte transport in the colon. Therefore, regulation of the transcript or the protein it encodes could be important in maintaining normal cellular homeostasis and in the treatment of Crohn&#39;s disease and ulcerative colitis.  
     [1356] Among tissues with metabolic function, this gene is expressed in liver and adipose. Thus, this gene product may be involved in disorders that affect these tissues, such as obesity and type II diabetes.  
     [1357] Low, but significant expression is also seen in the hippocampus. The hippocampus is critical for learning and memory. Thus, this gene product may have utility treating CNS disorders involving memory deficits, including Alzheimer&#39;s disease and aging.  
     REFERENCES  
     [1358] 1. Sato Y, Hanai H, Nogaki A, Hirasawa K, Kaneko E, Hayashi H, Suzuki Y. Role of the vasopressin V(1) receptor in regulating the epithelial functions of the guinea pig distal colon. Am J Physiol October 1999;277(4 Pt 1):G819-28.  
     [1359] Panel 4D Summary: Ag3372 In agreement with the results seen in panel 1.4, the highest level of expression of this gene is in the colon sample (CT=27.5). Interestingly, the expression is significantly lower in the IBD colitis 2 (CTh35) and IBD Crohn&#39;s (CT=30.9) samples. Therefore, alterations in the expression of this gene may be used in the treatment of Crohn&#39;s disease and ulcerative colitis.  
     [1360] In addition, the expression of the CG58553-01 gene in several preparations of T lymphocytes suggests that small molecule antagonists, therapeutic antibodies specific for this molecule, or the extracellular domain of this protein, may be useful to reduce or eliminate the symptoms of Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, or psoriasis.  
     [1361] W. CG58626-01: Phospholipase  
     [1362] Expression of gene CG58626-01 was assessed using the primer-probe set Ag3386, described in Table WA. Results of the RTQ-PCR runs are shown in Tables WB, WC and WD.  
     [1363] Table WA. Probe Name Ag3386 
               TABLE WA                          Probe Name Ag3386                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-agtggcggtcaaaacttactct-3′   22   1386   460               Probe   TET-5′-tggagacactgttgattccattactcctg-3′-TAMRA   29   1411   461               Reverse   5′-ctgctgttcagcatatccctta-3′   22   1455   462                  
 
     [1364]               TABLE WB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3386,           Ag3386, Run       Run       Tissue Name   210154893   Tissue Name   210154893                                     AD 1 Hippo   6.4   Control (Path) 3   4.2               Temporal Ctx       AD 2 Hippo   21.5   Control (Path) 4   25.0               Temporal Ctx       AD 3 Hippo   5.0   AD 1 Occipital   14.4               Ctx       AD 4 Hippo   5.3   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   95.3   AD 3 Occipital   3.3               Ctx       AD 6 Hippo   51.1   AD 4 Occipital   18.7               Ctx       Control 2 Hippo   26.4   AD 5 Occipital   28.7               Ctx       Control 4 Hippo   4.5   AD 6 Occipital   52.5               Ctx       Control (Path) 3   4.0   Control 1 Occipital   2.4       Hippo       Ctx       AD 1 Temporal Ctx   13.5   Control 2 Occipital   56.3               Ctx       AD 2 Temporal Ctx   24.5   Control 3 Occipital   11.0               Ctx       AD 3 Temporal Ctx   3.8   Control 4 Occipital   4.3               Ctx       AD 4 Temporal Ctx   18.9   Control (Path) 1   100.0               Occipital Ctx       AD 5 Inf Temporal   95.9   Control (Path) 2   8.8       Ctx       Occipital Ctx       AD 5 Sup Temporal   37.6   Control (Path) 3   1.7       Ctx       Occipital Ctx       AD 6 Inf Temporal   52.5   Control (Path) 4   12.3       Ctx       Occipital Ctx       AD 6 Sup Temporal   63.7   Control 1 Parietal   5.4       Ctx       Ctx       Control 1 Temporal   4.9   Control 2 Parietal   39.5       Ctx       Ctx       Control 2 Temporal   38.4   Control 3 Parietal   11.3       Ctx       Ctx       Control 3 Temporal   12.2   Control (Path) 1   77.4       Ctx       Parietal Ctx       Control 4 Temporal   5.0   Control (Path) 2   20.7       Ctx       Parietal Ctx       Control (Path) 1   76.8   Control (Path) 3   2.7       Temporal Ctx       Parietal Ctx       Control (Path) 2   37.6   Control (Path) 4   45.4       Temporal Ctx       Parietal Ctx                    
     [1365]               TABLE WC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3386,       (%) Ag3386,           Run       Run       Tissue Name   217043839   Tissue Name   217043839                                     Adipose   12.2   Renal ca. TK-10   10.7       Melanoma*   26.4   Bladder   18.4       Hs688(A).T       Melanoma*   30.4   Gastric ca. (liver met.)   26.6       Hs688(B).T       NCI-N87       Melanoma* M14   13.1   Gastric ca. KATO III   0.0       Melanoma*   22.8   Colon ca. SW-948   10.8       LOXIMVI       Melanoma* SK-   22.7   Colon ca. SW480   40.9       MEL-5       Squamous cell   11.2   Colon ca.* (SW480   20.4       carcinoma SCC-4       met) SW620       Testis Pool   47.0   Colon ca. HT29   5.2       Prostate ca.* (bone   80.1   Colon ca. HCT-116   100.0       met) PC-3       Prostate Pool   7.1   Colon ca. CaCo-2   13.8       Placenta   3.2   Colon cancer tissue   13.6       Uterus Pool   6.4   Colon ca. SW1116   10.2       Ovarian ca.   22.8   Colon ca. Colo-205   1.8       OVCAR-3       Ovarian ca. SK-   94.0   Colon ca. SW-48   2.4       OV-3       Ovarian ca.   4.7   Colon Pool   27.7       OVCAR-4       Ovarian ca.   29.3   Small Intestine Pool   14.6       OVCAR-5       Ovarian ca.   12.7   Stomach Pool   12.2       IGROV-1       Ovarian ca.   11.1   Bone Marrow Pool   6.9       OVCAR-8       Ovary   11.6   Fetal Heart   8.1       Breast ca. MCF-7   36.9   Heart Pool   6.3       Breast ca. MDA-   39.5   Lymph Node Pool   13.9       MB-231       Breast ca. BT 549   28.5   Fetal Skeletal Muscle   3.6       Breast ca. T47D   52.9   Skeletal Muscle Pool   6.7       Breast ca. MDA-N   11.3   Spleen Pool   17.1       Breast Pool   28.1   Thymus Pool   26.1       Trachea   11.0   CNS cancer   33.2               (glio/astro) U87-MG       Lung   6.0   CNS cancer   44.1               (glio/astro) U-118-MG       Fetal Lung   39.2   CNS cancer   44.4               (neuro; met) SK-N-AS       Lung ca. NCI-N417   6.3   CNS cancer (astro)   10.4               SF-539       Lung ca. LX-1   33.9   CNS cancer (astro)   27.7               SNB-75       Lung ca. NCI-H146   14.3   CNS cancer (glio)   10.2               SNB-19       Lung ca. SHP-77   73.2   CNS cancer (glio) SF-   28.7               295       Lung ca. A549   25.3   Brain (Amygdala)   23.2               Pool       Lung ca. NCI-H526   5.8   Brain (cerebellum)   19.8       Lung ca. NCI-H23   30.1   Brain (fetal)   35.6       Lung ca. NCI-H460   20.2   Brain (Hippocampus)   25.2               Pool       Lung ca. HOP-62   11.9   Cerebral Cortex Pool   39.2       Lung ca. NCI-H522   20.7   Brain (Substantia   23.0               nigra) Pool       Liver   0.7   Brain (Thalamus) Pool   45.7       Fetal Liver   29.5   Brain (whole)   24.0       Liver ca. HepG2   10.1   Spinal Cord Pool   22.5       Kidney Pool   21.3   Adrenal Gland   8.5       Fetal Kidney   19.5   Pituitary gland Pool   7.0       Renal ca. 786-0   15.9   Salivary Gland   1.9       Renal ca. A498   3.5   Thyroid (female)   3.2       Renal ca. ACHN   8.0   Pancreatic ca.   3.7               CAPAN2       Renal ca. UO-31   12.2   Pancreas Pool   18.2                    
     [1366]               TABLE WD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3386, Run       Ag3386, Run       Tissue Name   165296474   Tissue Name   165296474                                     Secondary Th1 act   30.4   HUVEC IL-1beta   2.0       Secondary Th2 act   35.6   HUVEC IFN gamma   3.3       Secondary Tr1 act   27.9   HUVEC TNF alpha +   3.8               IFN gamma       Secondary Th1 rest   8.9   HUVEC TNF alpha +   3.3               IL4       Secondary Th2 rest   8.0   HUVEC IL-11   1.5       Secondary Tr1 rest   11.3   Lung Microvascular EC   5.5               none       Primary Th1 act   57.4   Lung Microvascular EC   4.8               TNF alpha + IL-1beta       Primary Th2 act   36.9   Microvascular Dermal   3.7               EC none       Primary Tr1 act   51.1   Microsvasular Dermal   3.3               EC TNF alpha + IL-1beta       Primary Th1 rest   54.0   Bronchial epithelium   5.5               TNF alpha + IL1beta       Primary Th2 rest   18.8   Small airway epithelium   2.1               none       Primary Tr1 rest   24.7   Small airway epithelium   6.1               TNF alpha + IL-1beta       CD45RA CD4   12.4   Coronery artery SMC rest   4.6       lymphocyte act       CD45RO CD4   33.9   Coronery artery SMC   2.4       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   29.3   Astrocytes rest   3.0       Secondary CD8   26.1   Astrocytes TNF alpha +   3.0       lymphocyte rest       IL-1beta       Secondary CD8   20.7   KU-812 (Basophil) rest   12.1       lymphocyte act       CD4 lymphocyte none   1.1   KU-812 (Basophil)   27.7               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   12.8   CCD1106   2.7       CD95 CH11       (Keratinocytes) none       LAK cells rest   12.0   CCD1106   0.8               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   24.3   Liver cirrhosis   0.3       LAK cells IL-2 + IL-12   28.7   Lupus kidney   0.7       LAK cells IL-2 + IFN   42.0   NCI-H292 none   8.1       gamma       LAK cells IL-2 + IL-18   45.1   NCI-H292 IL-4   9.5       LAK cells   8.8   NCI-H292 IL-9   8.5       PMA/ionomycin       NK Cells IL-2 rest   21.8   NCI-H292 IL-13   4.5       Two Way MLR 3 day   18.7   NCI-H292 IFN gamma   3.6       Two Way MLR 5 day   11.0   HPAEC none   2.5       Two Way MLR 7 day   10.9   HPAEC TNF alpha + IL-   3.0               1beta       PBMC rest   4.5   Lung fibroblast none   4.6       PBMC PWM   66.0   Lung fibroblast TNF   3.3               alpha + IL-1beta       PBMC PHA-L   17.9   Lung fibroblast IL-4   12.1       Ramos (B cell) none   26.1   Lung fibroblast IL-9   12.3       Ramos (B cell)   100.0   Lung fibroblast IL-13   6.7       ionomycin       B lymphocytes PWM   88.9   Lung fibroblast IFN   16.6               gamma       B lymphocytes CD40L   49.3   Dermal fibroblast   8.2       and IL-4       CCD1070 rest       EOL-1 dbcAMP   13.0   Dermal fibroblast   37.1               CCD1070 TNF alpha       EOL-1 dbcAMP   9.5   Dermal fibroblast   4.4       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   8.9   Dermal fibroblast IFN   6.0               gamma       Dendritic cells LPS   5.4   Dermal fibroblast IL-4   12.1       Dendritic cells anti-   4.3   IBD Colitis 2   0.7       CD40       Monocytes rest   4.7   IBD Crohn&#39;s   0.5       Monocytes LPS   2.6   Colon   3.4       Macrophages rest   8.8   Lung   4.9       Macrophages LPS   2.8   Thymus   4.1       HUVEC none   2.8   Kidney   13.0       HUVEC starved   6.4                    
     [1367] CNS_neurodegeneration_v1.0 Summary: Ag3386 This panel confirms the expression of this gene at moderate to low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1368] General_screening_panel_v1.4 Summary: Ag3386 This gene is moderately expressed in most of the samples on this panel. Based on expression in this panel, this gene may be involved in gastric, pancreatic, brain, colon, renal, lung, breast, ovarian and prostate cancer as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition using antibodies or small molecule drugs might be of use in the treatment of these cancers.  
     [1369] This gene product is also expressed in adipose, pancreas, adrenal, thyroid, pituitary, skeletal muscle, heart, and liver. This widespread expression in tissues with metabolic function suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes.  
     [1370] In addition, this gene is expressed at moderate levels in the CNS. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1371] Panel 4D Summary: Ag3386 The CG58626-01 transcript is expressed ubiquitously in this panel. Highest expression of this transcript is seen in activated Ramos cells and activated B cells (CTs=27). The expression of this transcript in activated lymphoid cells when compared to non activated cells suggests that the CG58626-01 gene may be important for the diagnosis or pathogenesis of immune mediated diseases. Therefore, modulation of the expression and/or activity of this gene product might important for the treatment of autoimmune diseases, allergy, and delayed type hypersensitivity.  
     [1372] X. CG57597-01: Hypothetical Protein  
     [1373] Expression of gene CG57597-01 was assessed using the primer-probe set Ag3293, described in Table XA.  
     [1374] Table XA. Probe Name Ag3293 
               TABLE XA                          Probe Name Ag3293                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cagaaacctgtgaactctgcat-3′   22   40   463               Probe   TET-5′-atgcaccaccactcctggctaatttt-3′-TAMRA   26   69   464               Reverse   5′-ataaaaggtttgagccggatt-3′   21   115   465                  
 
     [1375] CNS_neurodegeneration_v1.0 Summary: Ag3293—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1376] General_screening_panel_v1.4 Summary: Ag3293—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1377] Panel 4D Summary: Ag3293—Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1378] Y. CG57804-01: talin  
     [1379] Expression of gene CG57804-01 was assessed using the primer-probe set Ag3337, described in Table YA. Results of the RTQ-PCR runs are shown in Tables YB, YC and YD.  
     [1380] Table YA. Probe Name Ag3337 
               TABLE YA                          Probe Name Ag3337                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ggatttcaagcccagatacaat-3′   22   781   466               Probe   TET-5′-tggacctcatgtggaacataaacaca-3′-TAMRA   26   804   467               Reverse   5′-ggcaggaattccttcagatc-3′   20   844   468                  
 
     [1381]               TABLE YB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3337,           Ag3337, Run       Run       Tissue Name   210138775   Tissue Name   210138775                                     AD 1 Hippo   6.8   Control (Path) 3   3.6               Temporal Ctx       AD 2 Hippo   25.3   Control (Path) 4   22.4               Temporal Ctx       AD 3 Hippo   3.6   AD 1 Occipital Ctx   5.6       AD 4 Hippo   5.7   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   78.5   AD 3 Occipital Ctx   2.2       AD 6 Hippo   27.5   AD 4 Occipital Ctx   14.7       Control 2 Hippo   27.4   AD 5 Occipital Ctx   44.1       Control 4 Hippo   8.1   AD 6 Occipital Ctx   16.6       Control (Path) 3   4.3   Control 1 Occipital   1.6       Hippo       Ctx       AD 1 Temporal   7.6   Control 2 Occipital   67.8       Ctx       Ctx       AD 2 Temporal   24.5   Control 3 Occipital   11.9       Ctx       Ctx       AD 3 Temporal   3.3   Control 4 Occipital   3.0       Ctx       Ctx       AD 4 Temporal   15.3   Control (Path) 1   89.5       Ctx       Occipital Ctx       AD 5 Inf Temporal   89.5   Control (Path) 2   8.2       Ctx       Occipital Ctx       AD 5 Sup Temporal   35.8   Control (Path) 3   0.6       Ctx       Occipital Ctx       AD 6 Inf Temporal   27.4   Control (Path) 4   10.3       Ctx       Occipital Ctx       AD 6 Sup   32.8   Control 1 Parietal   3.6       Temporal Ctx       Ctx       Control 1   3.4   Control 2 Parietal   23.7       Temporal Ctx       Ctx       Control 2   47.6   Control 3 Parietal   14.1       Temporal Ctx       Ctx       Control 3   12.4   Control (Path) 1   100.0       Temporal Ctx       Parietal Ctx       Control 3   5.8   Control (Path) 2   21.9       Temporal Ctx       Parietal Ctx       Control (Path) 1   64.2   Control (Path) 3   2.0       Temporal Ctx       Parietal Ctx       Control (Path) 2   42.0   Control (Path) 4   39.2       Temporal Ctx       Parietal Ctx                    
     [1382]               TABLE YC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3337,       (%) Ag3337,           Run       Run       Tissue Name   215773748   Tissue Name   215773748                                     Adipose   20.2   Renal ca. TK-10   22.1       Melanoma*   58.6   Bladder   14.2       Hs688(A).T       Melanoma*   22.8   Gastric ca. (liver met.)   16.2       Hs688(B).T       NCI-N87       Melanoma* M14   5.7   Gastric ca. KATO   100.0               III       Melanoma*   5.5   Colon ca. SW-   16.3       LOXIMVI       948       Melanoma* SK-   3.4   Colon ca. SW480   4.2       MEL-5       Squamous cell   4.4   Colon ca.* (SW480   2.6       carcinoma SCC-4       met) SW620       Testis Pool   5.1   Colon ca. HT29   0.7       Prostate ca.* (bone   6.4   Colon ca. HCT-116   7.6       met) PC-3           Prostate Pool   3.4   Colon ca. CaCo-2   81.8       Placenta   1.6   Colon cancer tissue   1.7       Uterus Pool   2.1   Colon ca. SW1116   1.6       Ovarian ca.   8.9   Colon ca. Colo-205   0.1       OVCAR-3       Ovarian ca. SK-   32.1   Colon ca. SW-48   3.2       OV-3       Ovarian ca.   7.2   Colon Pool   8.0       OVCAR-4       Ovarian ca.   21.0   Small Intestine Pool   7.9       OVCAR-5       Ovarian ca.   23.5   Stomach Pool   5.7       IGROV-1       Ovarian ca.   5.4   Bone Marrow Pool   3.8       OVCAR-8       Ovary   11.7   Fetal Heart   24.8       Breast ca. MCF-7   5.1   Heart Pool   10.2       Breast ca. MDA-   19.5   Lymph Node Pool   10.6       MB-231       Breast ca. BT 549   11.7   Fetal Skeletal Muscle   30.1       Breast ca. T47D   30.8   Skeletal Muscle Pool   24.8       Breast ca. MDA-N   5.0   Spleen Pool   2.9       Breast Pool   6.9   Thymus Pool   0.0       Trachea   10.3   CNS cancer   10.7               (glio/astro) U87-MG       Lung   2.2   CNS cancer   68.3               (glio/astro) U-118-MG       Fetal Lung   10.8   CNS cancer   23.5               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.8   CNS cancer (astro)   21.5               SF-539       Lung ca. LX-1   1.7   CNS cancer (astro)   40.3               SNB-75       Lung ca. NCI-H146   0.4   CNS cancer (glio)   27.7               SNB-19       Lung ca. SHP-77   11.9   CNS cancer (glio) SF-   38.2               295       Lung ca. A549   13.6   Brain (Amygdala)   28.7               Pool       Lung ca. NCI-H526   7.6   Brain (cerebellum)   38.7       Lung ca. NCI-H23   10.2   Brain (fetal)   58.6       Lung ca. NCI-H460   5.1   Brain (Hippocampus)   25.7               Pool       Lung ca. HOP-62   3.8   Cerebral Cortex Pool   59.0       Lung ca. NCI-H522   10.1   Brain (Substantia   39.2               nigra) Pool       Liver   0.3   Brain (Thalamus) Pool   51.4       Fetal Liver   15.3   Brain (whole)   58.2       Liver ca. HepG2   53.2   Spinal Cord Pool   18.6       Kidney Pool   18.4   Adrenal Gland   11.1       Fetal Kidney   11.4   Pituitary gland Pool   4.7       Renal ca. 786-0   31.0   Salivary Gland   14.0       Renal ca. A498   0.7   Thyroid (female)   4.9       Renal ca. ACHN   20.3   Pancreatic ca.   7.5               CAPAN2       Renal ca. UO-31   8.1   Pancreas Pool   9.4                    
     [1383]               TABLE YD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3337, Run       Ag3337, Run       Tissue Name   165725932   Tissue Name   165725932                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.7       Secondary Th2 act   0.0   HUVEC IFN gamma   3.9       Secondary Tr1 act   0.4   HUVEC TNF alpha +   0.3               IFN gamma       Secondary Th1 rest   0.4   HUVEC TNF alpha +   0.6               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.3       Secondary Tr1 rest   0.3   Lung Microvascular EC   2.1               none       Primary Th1 act   0.3   Lung Microvascular EC   5.1               TNF alpha + IL-1beta       Primary Th2 act   1.3   Microvascular Dermal   16.4               EC none       Primary Tr1 act   0.6   Microsvasular Dermal   9.8               EC TNF alpha + IL-1beta       Primary Th1 rest   1.3   Bronchial epithelium   1.2               TNF alpha + IL1beta       Primary Th2 rest   0.6   Small airway epithelium   1.3               none       Primary Tr1 rest   0.3   Small airway epithelium   2.1               TNF alpha + IL-1beta       CD45RA CD4   18.7   Coronery artery SMC rest   9.9       lymphocyte act       CD45RO CD4   0.6   Coronery artery SMC   3.5       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   1.2   Astrocytes rest   100.0       Secondary CD8   0.9   Astrocytes TNF alpha +   65.5       lymphocyte rest       IL-1beta       Secondary CD8   0.2   KU-812 (Basophil) rest   11.7       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   8.5               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.3   CCD1106   2.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   4.0   CCD1106   2.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   1.2   Liver cirrhosis   3.6       LAK cells IL-2 + IL-12   0.4   Lupus Kidney   13.6       LAK cells IL-2 + IFN   2.1   NCI-H292 none   11.0       gamma       LAK cells IL-2 + IL-18   1.2   NCI-H292 IL-4   25.0       LAK cells   2.0   NCI-H292 IL-9   15.6       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   12.5       Two Way MLR 3 day   5.2   NCI-H292 IFN gamma   4.6       Two Way MLR 5 day   2.7   HPAEC none   1.5       Two Way MLR 7 day   1.8   HPAEC TNF alpha + IL-   2.5               1beta       PBMC rest   0.2   Lung fibroblast none   80.1       PBMC PWM   1.9   Lung fibroblast TNF   22.7               alpha + IL-1beta       PBMC PHA-L   0.3   Lung fibroblast IL-4   97.3       Ramos (B cell) none   2.4   Lung fibroblast IL-9   47.6       Ramos (B cell)   2.1   Lung fibroblast IL-13   81.8       ionomycin       B lymphocytes PWM   0.7   Lung fibroblast IFN   50.7               gamma       B lymphocytes CD40L   0.6   Dermal fibroblast   94.6       and IL-4       CCD1070 rest       EOL-1 dbcAMP   4.9   Dermal fibroblast   43.2               CCD1070 TNF alpha       EOL-1 dbcAMP   1.2   Dermal fibroblast   31.2       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   12.8   Dermal fibroblast IFN   14.2               gamma       Dendritic cells LPS   1.3   Dermal fibroblast IL-4   95.9       Dendritic cells anti-   11.4   IBD Colitis 2   1.2       CD40       Monocytes rest   0.5   IBD Crohn&#39;s   9.1       Monocytes LPS   1.3   Colon   60.7       Macrophages rest   13.6   Lung   8.0       Macrophages LPS   2.8   Thymus   39.2       HUVEC none   1.0   Kidney   10.4       HUVEC starved   1.6                    
     [1384] CNS_neurodegeneration_v1.0 Summary: Ag3337—This panel confirms the expression of this gene at low to moderate levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders  
     [1385] General_screening_panel_v1.4 Summary: Ag3337—This gene is expressed in almost all samples on this panel. This gene is expressed at moderate levels in the CNS. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1386] In addition, this gene is also expressed in adipose, pancreas, adrenal, thyroid, pituitary, skeletal muscle, heart, and liver. This widespread expression in tissues with metabolic function suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes.  
     [1387] Panel 4D Summary: Ag3337 This gene is most highly expressed in resting astrocytes (CT=28.9). In addition, this gene is highly expressed in a cluster of treated and untreated samples derived from lung and dermal fibroblasts. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pathological and inflammatory lung and skin diseases, such as psoriasis, asthma, emphysema, and allergies.  
     [1388] Z. CG57551-01: NAC-1 Like Gene  
     [1389] Expression of gene CG57551-01 was assessed using the primer-probe set Ag3282, described in Table ZA. Results of the RTQ-PCR runs are shown in Tables ZB, ZC and ZD.  
     [1390] Table ZA. Probe Name Ag3282 
               TABLE ZA                          Probe Name Ag3282                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cagatcctcagcttctgctaca-3′   22   269   469               Probe   TET-5′-accagttcctgctcatgtacacggct-3′-TAMRA   26   318   470               Reverse   5′-atctcctggatctgcaggaa-3′   20   347   471                  
 
     [1391]               TABLE ZB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%) Ag3282,       Rel. Exp. (%) Ag3282,       Tissue Name   Run 210060482   Tissue Name   Run 210060482                                     AD 1 Hippo   22.8   Control (Path) 3   9.7               Temporal Ctx       AD 2 Hippo   49.0   Control (Path) 4   24.3               Temporal Ctx       AD 3 Hippo   11.5   AD 1 Occipital   16.5               Ctx       AD 4 Hippo   12.3   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   66.9   AD 3 Occipital   10.2               Ctx       AD 6 Hippo   59.9   AD 4 Occipital   18.2               Ctx       Control 2 Hippo   49.3   AD 5 Occipital   9.5               Ctx       Control 4 Hippo   18.7   AD 6 Occipital   41.5               Ctx       Control (Path) 3   6.3   Control 1 Occipital   6.8       Hippo       Ctx       AD 1 Temporal Ctx   19.2   Control 2 Occipital   91.4               Ctx       AD 2 Temporal Ctx   40.3   Control 3 Occipital   16.3               Ctx       AD 3 Temporal Ctx   14.3   Control 4 Occipital   12.2               Ctx       AD 4 Temporal Ctx   18.3   Control (Path) 1   100.0               Occipital Ctx       AD 5 Inf Temporal   66.0   Control (Path) 2   9.2       Ctx       Occipital Ctx       AD 5 SupTemporal   37.4   Control (Path) 3   5.3       Ctx       Occipital Ctx       AD 6 Inf Temporal   36.1   Control (Path) 4   15.8       Ctx       Occipital Ctx       AD 6 Sup Temporal   34.4   Control 1 Parietal   11.7       Ctx       Ctx       Control 1 Temporal   10.0   Control 2 Parietal   34.2       Ctx       Ctx       Control 2 Temporal   74.7   Control 3 Parietal   23.3       Ctx       Ctx       Control 3 Temporal   15.0   Control (Path) 1   72.7       Ctx       Parietal Ctx       Control 4 Temporal   15.5   Control (Path) 2   21.6       Ctx       Parietal Ctx       Control (Path) 1   74.2   Control (Path) 3   5.5       Temporal Ctx       Parietal Ctx       Control (Path) 2   31.2   Control (Path) 4   35.8       Temporal Ctx       Parietal Ctx                    
     [1392]               TABLE ZC                          General_screening_panel_v1.4                                 Rel. Exp. (%) Ag3282, Run       Rel. Exp. (%) Ag3282, Run       Tissue Name   216512995   Tissue Name   216512995                                     Adipose   1.8   Renal ca. TK-10   22.7       Melanoma*   16.3   Bladder   6.3       Hs688(A).T       Melanoma*   25.0   Gastric ca. (liver met.)   47.0       Hs688(B).T       NCI-N87       Melanoma* M14   25.3   Gastric ca. KATO III   45.7       Melanoma*   21.6   Colon ca. SW-948   19.3       LOXIMVI       Melanoma* SK-   17.0   Colon ca. SW480   50.3       MEL-5       Squamous cell   24.7   Colon ca.* (SW480   25.9       carcinoma SCC-4       met) SW620       Testis Pool   6.1   Colon ca. HT29   17.7       Prostate ca.* (bone   67.8   Colon ca. HCT-116   100.0       met) PC-3       Prostate Pool   3.5   Colon ca. CaCo-2   29.1       Placenta   9.6   Colon cancer tissue   14.0       Uterus Pool   0.6   Colon ca. SW1116   12.7       Ovarian ca.   41.2   Colon ca. Colo-205   7.6       OVCAR-3       Ovarian ca. SK-   65.5   Colon ca. SW-48   5.8       OV-3       Ovarian ca.   35.8   Colon Pool   4.9       OVCAR-4       Ovarian ca.   37.6   Small Intestine Pool   2.4       OVCAR-5       Ovarian ca.   28.9   Stomach Pool   3.3       IGROV-1       Ovarian ca.   14.2   Bone Marrow Pool   1.5       OVCAR-8       Ovary   3.9   Fetal Heart   3.0       Breast ca. MCF-7   42.3   Heart Pool   2.2       Breast ca. MDA-   69.7   Lymph Node Pool   5.6       MB-231       Breast ca. BT 549   51.4   Fetal Skeletal Muscle   1.5       Breast ca. T47D   86.5   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   26.4   Spleen Pool   2.8       Breast Pool   4.6   Thymus Pool   3.8       Trachea   8.7   CNS cancer   60.3               (glio/astro) U87-MG       Lung   0.2   CNS cancer   100.0               (glio/astro) U-118-MG       Fetal Lung   6.3   CNS cancer   47.3               (neuro; met) SK-N-AS       Lung ca. NCI-N417   8.4   CNS cancer (astro) SF-   22.8               539       Lung ca. LX-1   17.3   CNS cancer (astro)   47.3               SNB-75       Lung ca. NCI-H146   15.3   CNS cancer (glio)   29.3               SNB-19       Lung ca. SHP-77   16.5   CNS cancer (glio) SF-   49.3               295       Lung ca. A549   27.2   Brain (Amygdala) Pool   6.9       Lung ca. NCI-H526   6.1   Brain (cerebellum)   15.1       Lung ca. NCI-H23   25.9   Brain (fetal)   9.2       Lung ca. NCI-H460   8.0   Brain (Hippocampus)   8.9               Pool       Lung ca. HOP-62   11.9   Cerebral Cortex Pool   13.4       Lung ca. NCI-H522   21.9   Brain (Substantia   15.3               nigra) Pool       Liver   1.7   Brain (Thalamus) Pool   11.5       Fetal Liver   9.8   Brain (whole)   12.6       Liver ca. HepG2   18.2   Spinal Cord Pool   7.1       Kidney Pool   5.0   Adrenal Gland   5.3       Fetal Kidney   3.4   Pituitary gland Pool   1.9       Renal ca. 786-0   42.0   Salivary Gland   4.0       Renal ca. A498   16.7   Thyroid (female)   3.6       Renal ca. ACHN   13.9   Pancreatic ca.   15.5               CAPAN2       Real ca. UO-31   17.4   Pancreas Pool   6.6                    
     [1393]               TABLE ZD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3282, Run       Ag3282, Run       Tissue Name   164634321   Tissue Name   164634321                                     Secondary Th1 act   52.9   HUVEC IL-1beta   13.6       Secondary Th2 act   67.8   HUVEC IFN gamma   42.9       Secondary Tr1 act   75.3   HUVEC TNF alpha +   37.1               IFN gamma       Secondary Th1 rest   8.4   HUVEC TNF alpha +   42.6               IL4       Secondary Th2 rest   11.4   HUVEC IL-11   25.9       Secondary Tr1 rest   12.2   Lung Microvascular EC   41.2               none       Primary Th1 act   53.6   Lung Microvascular EC   36.3               TNF alpha + IL-1beta       Primary Th2 act   44.4   Microvascular Dermal   50.3               EC none       Primary Tr1 act   60.7   Microsvasular Dermal   33.0               EC TNF alpha + IL-1beta       Primary Th1 rest   37.6   Bronchial epithelium   51.4               TNF alpha + IL1beta       Primary Th2 rest   15.8   Small airway epithelium   23.3               none       Primary Tr1 rest   18.3   Small airway epithelium   71.7               TNF alpha + IL-1beta       CD45RA CD4   33.0   Coronery artery SMC rest   43.5       lymphocyte act       CD45RO CD4   54.7   Coronery artery SMC   31.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   42.9   Astrocytes rest   38.4       Secondary CD8   50.3   Astrocytes TNF alpha +   37.1       lymphocyte rest       IL-1beta       Secondary CD8   32.5   KU-812 (Basophil) rest   36.1       lymphocyte act       CD4 lymphocyte none   2.4   KU-812 (Basophil)   90.8               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   11.7   CCD1106   64.2       CD95 CH11       (Keratinocytes) none       LAK cells rest   18.9   CCD1106   34.4               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   41.2   Liver cirrhosis   2.9       LAK cells IL-2 + IL-12   29.5   Lupus kidney   2.2       LAK cells IL-2 + IFN   36.3   NCI-H292 none   38.4       gamma       LAK cells IL-2 + IL-18   34.2   NCI-H292 IL-4   66.9       LAK cells   11.8   NCI-H292 IL-9   62.4       PMA/ionomycin       NK Cells IL-2 rest   29.3   NCI-H292 IL-13   65.1       Two Way MLR 3 day   21.9   NCI-H292 IFN gamma   48.3       Two Way MLR 5 day   27.7   HPAEC none   31.2       Two Way MLR 7 day   27.0   HPAEC TNF alpha + IL-   37.6               1beta       PBMC rest   6.5   Lung fibroblast none   35.6       PBMC PWM   89.5   Lung fibroblast TNF   20.7               alpha + IL-1beta       PBMC PHA-L   53.6   Lung fibroblast IL-4   63.3       Ramos (B cell) none   40.6   Lung fibroblast IL-9   55.5       Ramos (B cell)   56.3   Lung fibroblast IL-13   44.8       ionomycin       B lymphocytes PWM   100.0   Lung fibroblast IFN   71.2               gamma       B lymphocytes CD40L   41.2   Dermal fibroblast   78.5       and IL-4       CCD1070 rest       EOL-1 dbcAMP   50.0   Dermal fibroblast   88.9               CCD1070 TNF alpha       EOL-1 dbcAMP   46.3   Dermal fibroblast   49.7       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   33.2   Dermal fibroblast IFN   21.5               gamma       Dendritic cells LPS   26.1   Dermal fibroblast IL-4   43.8       Dendritic cells anti-   29.9   IBD Colitis 2   1.2       CD40       Monocytes rest   17.1   IBD Crohn&#39;s   1.8       Monocytes LPS   14.0   Colon   15.4       Macrophages rest   59.0   Lung   16.6       Macrophages LPS   29.1   Thymus   15.6       HUVEC none   35.1   Kidney   18.9       HUVEC starved   62.0                    
     [1394] CNS_neurodegeneration_v1.0 Summary: Ag3282—This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1395] General_screening_panel_v1.4 Summary: Ag3282 Highest expression of this gene is seen in a brain cancer cell line (CT=24.3). This gene appears to be expressed more highly in the cancer cell lines than in the normal tissue samples on this panel and may be involved in cellular growth and proliferation. Based on this expression profile, this gene may be involved in gastric, pancreatic, brain, colon, renal, lung, breast, ovarian and prostate cancer as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition using antibodies or small molecule drugs might be of use in the treatment of these cancers.  
     [1396] This gene is also expressed at high levels in all regions of the CNS examined. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1397] In addition, this gene product is expressed in adipose, pancreas, adrenal, thyroid, pituitary, fetal skeletal muscle, heart, and liver. This widespread expression in tissues with metabolic function suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes.  
     [1398] Furthermore, this gene is more highly expressed in fetal skeletal muscle (CT=30.4) and liver (CT=27) when compared to expression in the adult skeletal muscle (CT&gt;35) and liver (CT=30) may be useful for the differentiation of the fetal and adult sources of this tissue.  
     [1399] Panel 4D Summary: Ag3282 This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. Highest expression is seen in polkweed mitogen stimulated B lymphocytes (CT=25.7). In addition, expression is seen in members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in Panel 1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1400] AA. CG57411-01: Kelch-Like Protein KLHL3C  
     [1401] Expression of gene CG57411-01 was assessed using the primer-probe set Ag3229, described in Table AAA. Results of the RTQ-PCR runs are shown in Tables AAB, AAC, AAD and AAE.  
     [1402] Table AAA. Probe Name Ag3229 
               TABLE AAA                          Probe Name Ag3229                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gcagcgagctctaccacat-3′   19   287   472               Probe   TET-5′-aaggccttcgcgctgcagatctt-3′-TAMRA   23   310   473               Reverse   5′-aagtcgtccttggagatgct-3′   20   364   474                  
 
     [1403]               TABLE AAB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%) Ag3229,       Rel. Exp. (%) Ag3229,       Tissue Name   Run 209862301   Tissue Name   Run 209862301                                     AD 1 Hippo   16.3   Control (Path) 3   8.0               Temporal Ctx       AD 2 Hippo   34.6   Control (Path) 4   35.8               Temporal Ctx       AD 3 Hippo   15.9   AD 1 Occipital Ctx   18.6       AD 4 Hippo   6.9   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   100.0   AD 3 Occipital Ctx   11.7       AD 6 Hippo   35.4   AD 4 Occipital Ctx   17.7       Control 2 Hippo   31.2   AD 5 Occipital Ctx   49.7       Control 4 Hippo   12.1   AD 6 Occipital Ctx   14.2       Control (Path) 3   6.2   Control 1 Occipital   3.3       Hippo       Ctx       AD 1 Temporal   21.6   Control 2 Occipital   69.3       Ctx       Ctx       AD 2 Temporal   33.0   Control 3 Occipital   26.6       Ctx       Ctx       AD 3 Temporal   14.1   Control 4 Occipital   7.5       Ctx       Ctx       AD 4 Temporal   16.8   Control (Path) 1   72.2       Ctx       Occipital Ctx       AD 5 Inf Temporal   71.7   Control (Path) 2   13.7       Ctx       Occipital Ctx       AD 5 Sup   32.3   Control (Path) 3   6.3       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   30.6   Control (Path) 4   16.8       Ctx       Occipital Ctx       AD 6 Sup   33.9   Control 1 Parietal   8.6       Temporal Ctx       Ctx       Control 1   4.4   Control 2 Parietal   39.8       Temporal Ctx       Ctx       Control 2   56.6   Control 3 Parietal   21.5       Temporal Ctx       Ctx       Control 3   19.6   Control (Path) 1   66.4       Temporal Ctx       Parietal Ctx       Control 3   14.2   Control (Path) 2   26.8       Temporal Ctx       Parietal Ctx       Control (Path) 1   62.0   Control (Path) 3   5.2       Temporal Ctx       Parietal Ctx       Control (Path) 2   36.1   Control (Path) 4   54.3       Temporal Ctx       Parietal Ctx                    
     [1404]               TABLE AAC                          General_screening_panel_v1.4                                                     Rel. Exp. (%) Ag3229, Run       Rel. Exp. (%) Ag3229, Run       Tissue Name   214439727   Tissue Name   214439727                                     Adipose   6.0   Renal ca. TK-10   20.4       Melanoma*   8.1   Bladder   6.7       Hs688(A).T       Melanoma*   13.5   Gastric ca. (liver met.)   11.2       Hs688(B).T       NCI-N87       Melanoma* M14   2.1   Gastric ca. KATO III   59.5       Melanoma*   24.8   Colon ca. SW-948   0.6       LOXIMVI       Melanoma* SK-   20.7   Colon ca. SW480   31.6       MEL-5       Squamous cell   6.7   Colon ca.* (SW480   4.7       carcinoma SCC-4       met) SW620       Testis Pool   3.0   Colon ca. HT29   2.7       Prostate ca.* (bone   17.8   Colon ca. HCT-116   35.1       met) PC-3       Prostate Pool   8.5   Colon ca. CaCo-2   2.5       Placenta   14.2   Colon cancer tissue   6.2       Uterus Pool   5.8   Colon ca. SW1116   3.3       Ovarian ca.   40.9   Colon ca. Colo-205   5.4       OVCAR-3       Ovarian ca. SK-   17.7   Colon ca. SW-48   3.3       OV-3       Ovarian ca.   11.9   Colon Pool   25.0       OVCAR-4       Ovarian ca.   84.1   Small Intestine Pool   14.9       OVCAR-5       Ovarian ca.   2.0   Stomach Pool   6.4       IGROV-1       Ovarian ca.   8.1   Bone Marrow Pool   9.7       OVCAR-8       Ovary   8.7   Fetal Heart   1.7       Breast ca. MCF-7   0.9   Heart Pool   10.7       Breast ca. MDA-   30.1   Lymph Node Pool   21.8       MB-231       Breast ca. BT 549   8.1   Fetal Skeletal Muscle   4.2       Breast ca. T47D   100.0   Skeletal Muscle Pool   8.7       Breast ca. MDA-N   0.0   Spleen Pool   10.4       Breast Pool   22.4   Thymus pool   11.2       Trachea   10.4   CNS cancer   55.5               (glio/astro) U87-MG       Lung   1.7   CNS cancer   44.8               (glio/astro) U-118-MG       Fetal Lung   6.7   CNS cancer   5.8               (neuro; met) SK-N-AS       Lung ca. NCI-N417   11.7   CNS cancer (astro) SF-   0.4               539       Lung ca. LX-1   37.1   CNS cancer (astro)   5.0               SNB-75       Lung ca. NCI-H146   6.2   CNS cancer (glio)   2.9               SNB-19       Lung ca. SHP-77   61.1   CNS cancer (glio) SF-   39.0               295       Lung ca. A549   6.3   Brain (Amygdala) Pool   8.4       Lung ca. NCI-H526   8.7   Brain (cerebellum)   22.2       Lung ca. NCI-H23   6.3   Brain (fetal)   48.6       Lung ca. NCI-H460   2.9   Brain (Hippocampus)   8.5               Pool       Lung ca. HOP-62   8.1   Cerebral Cortex Pool   20.7       Lung ca. NCI-H522   0.5   Brain (Substantia   14.7               nigra) Pool       Liver   0.3   Brain (Thalamus) Pool   13.8       Fetal Liver   1.8   Brain (whole)   11.5       Liver ca. HepG2   0.2   Spinal Cord Pool   3.3       Kidney Pool   26.8   Adrenal Gland   29.9       Fetal Kidney   10.2   Pituitary gland Pool   10.7       Renal ca. 786-0   7.5   Salivary Gland   4.1       Renal ca. A498   4.0   Thyroid (female)   1.1       Renal ca. ACHN   11.9   Pancreatic ca.   1.0               CAPAN2       Renal ca. UO-31   15.3   Pancreas Pool   28.7                    
     [1405]               TABLE AAD                          Panel 2.2                                 Rel. Exp. (%) Ag3229, Run       Rel. Exp. (%) Ag3229, Run       Tissue Name   174442765   Tissue Name   174442765                                     Normal Colon   15.5   Kidney Margin   100.0               (OD04348)       Colon cancer   31.9   Kidney malignant   10.7       (OD06064)       cancer (OD06204B)       Colon Margin   20.6   Kidney normal   11.6       (OD06064)       adjacent tissue               (OD06204E)       Colon cancer   6.0   Kidney Cancer   38.4       (OD06159)       (OD04450-01)       Colon Margin   12.7   Kidney Margin   17.4       (OD06159)       (OD04450-03)       Colon cancer   3.7   Kidney Cancer   0.0       (OD06297-04)       8120613       Colon Margin   22.4   Kidney Margin   6.0       (OD06297-05)       8120614       CC Gr.2 ascend colon   6.5   Kidney Cancer   12.0       (ODO3921)       9010320       CC Margin (ODO3921)   10.5   Kidney Margin   9.9               9010321       Colon cancer metastasis   8.6   Kidney Cancer   47.3       (OD06104)       8120607       Lung Margin   6.2   Kidney Margin   5.6       (OD06104)       8120608       Colon mets to lung   31.0   Normal Uterus   48.3       (OD04451-01)       Lung Margin   39.5   Uterine Cancer 064011   14.9       (OD04451-02)       Normal Prostate   41.2   Normal Thyroid   2.6       Prostate Cancer   8.1   Thyroid Cancer   4.3       (OD04410)       064010       Prostate Margin   10.6   Thyroid Cancer   15.3       (OD04410)       A302152       Normal Ovary   23.2   Thyroid Margin   2.7               A302153       Ovarian cancer   7.2   Normal Breast   46.0       (OD06283-03)       Ovarian Margin   17.8   Breast Cancer   5.9       (OD06283-07)       (OD04566)       Ovarian Cancer 064008   22.2   Breast Cancer 1024   27.4       Ovarian cancer   9.0   Breast Cancer   19.5       (OD06145)       (OD04590-01)       Ovarian Margin   13.4   Breast Cancer Mets   13.5       (OD06145)       (OD04590-03)       Ovarian cancer   6.3   Breast Cancer   12.2       (OD06455-03)       Metastasis (OD04655-               05)       Ovarian Margin   12.9   Breast Cancer 064006   8.1       (OD06455-07)       Normal Lung   14.5   Breast Cancer 9100266   3.0       Invasive poor diff. lung   5.0   Breast Margin   3.4       adeno (ODO4945-01)       9100265       Lung Margin   37.4   Breast Cancer   11.2       (ODO4945-03)       A209073       Lung Malignant Cancer   9.6   Breast Margin   61.1       (OD03126)       A2090734       Lung Margin   14.2   Breast cancer   4.7       (OD03126)       (OD06083)       Lung Cancer   4.9   Breast cancer node   12.7       (OD05014A)       metastasis (OD06083)       Lung Margin   39.0   Normal Liver   2.8       (OD05014B)       Lung cancer   17.4   Liver Cancer 1026   13.6       (OD06081)       Lung Margin   32.3   Liver Cancer 1025   12.9       (OD06081)       Lung Cancer   4.2   Liver Cancer 6004-T   13.2       (OD04237-01)       Lung Margin   24.7   Liver Tissue 6004-N   1.3       (OD04237-02)       Ocular Melanoma   12.9   Liver Cancer 6005-T   43.2       Metastasis       Ocular Melanoma   10.7   Liver Tissue 6005-N   4.8       Margin (Liver)       Melanoma Metastasis   52.9   Liver Cancer 064003   39.5       Melanoma Margin   21.0   Normal Bladder   9.3       (Lung)       Normal Kidney   4.7   Bladder Cancer 1023   5.8       Kidney Ca, Nuclear   40.3   Bladder Cancer   4.2       grade 2 (OD04338)       A302173       Kidney Margin   7.5   Normal Stomach   31.4       (OD04338)       Kidney Ca Nuclear   82.4   Gastric Cancer   1.2       grade 1/2 (OD04339)       9060397       Kidney Margin   13.2   Stomach Margin   7.1       (OD04339)       9060396       Kidney Ca, Clear cell   8.3   Gastric Cancer   7.4       type (OD04340)       9060395       Kidney Margin   24.7   Stomach Margin   10.9       (OD04340)       9060394       Kidney Ca, Nuclear   13.1   Gastric Cancer 064005   10.4       grade 3 (OD04348)                    
     [1406]               TABLE AAE                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3229, Run       Ag3229, Run       Tissue Name   164389704   Tissue Name   164389704                                     Secondary Th1 act   3.4   HUVEC IL-1beta   20.0       Secondary Th2 act   4.8   HUVEC IFN gamma   32.5       Secondary Tr1 act   2.1   HUVEC TNF alpha +   26.6               IFN gamma       Secondary Th1 rest   1.2   HUVEC TNF alpha +   35.1               IL4       Secondary Th2 rest   2.0   HUVEC IL-11   17.6       Secondary Tr1 rest   4.5   Lung Microvascular EC   34.2               none       Primary Th1 act   17.7   Lung Microvascular EC   49.0               TNF alpha + IL-1beta       Primary Th2 act   5.3   Microvascular Dermal   30.6               EC none       Primary Tr1 act   25.9   Microsvasular Dermal   38.7               EC TNF alpha + IL-1beta       Primary Th1 rest   14.0   Bronchial epithelium   46.7               TNF alpha + IL1beta       Primary Th2 rest   6.5   Small airway epithelium   22.1               none       Primary Tr1 rest   22.1   Small airway epithelium   97.9               TNF alpha + IL-1beta       CD45RA CD4   12.7   Coronery artery SMC rest   31.2       lymphocyte act       CD45RO CD4   6.6   Coronery artery SMC   10.5       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   2.4   Astrocytes rest   7.5       Secondary CD8   4.2   Astrocytes TNF alpha +   8.6       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.8       lymphocyte act       CD4 lymphocyte none   5.6   KU-812 (Basophil)   2.9               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   3.7   CCD1106   6.2       CD95 CH11       (Keratinocytes) none       LAK cells rest   5.9   CCD1106   6.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   3.0   Liver cirrhosis   15.5       LAK cells IL-2 + IL-12   6.2   Lupus kidney   12.2       LAK cells IL-2 + IFN   10.7   NCI-H292 none   30.8       gamma       LAK cells IL-2 + IL-18   5.0   NCI-H292 IL-4   49.7       LAK cells   4.0   NCI-H292 IL-9   43.5       PMA/ionomycin       NK Cells IL-2 rest   1.9   NCI-H292 IL-13   31.6       Two Way MLR 3 day   9.0   NCI-H292 IFN gamma   17.7       Two Way MLR 5 day   3.3   HPAEC none   18.0       Two Way MLR 7 day   1.2   HPAEC TNF alpha + IL-   58.2               1beta       PBMC rest   0.8   Lung fibroblast none   40.6       PBMC PWM   10.7   Lung fibroblast TNF   11.0               alpha + IL-1beta       PBMC PHA-L   10.2   Lung fibroblast IL-4   100.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   55.1       Ramos (B cell)   0.0   Lung fibroblast IL-13   78.5       ionomycin       B lymphocytes PWM   23.3   Lung fibroblast IFN   82.4               gamma       B lymphocytes CD40L   18.6   Dermal fibroblast   45.4       and IL-4       CCD1070 rest       EOL-1 dbcAMP   1.8   Dermal fibroblast   36.3               CCD1070 TNF alpha       EOL-1 dbcAMP   2.0   Dermal fibroblast   23.8       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   5.9   Dermal fibroblast IFN   4.6               gamma       Dendritic cells LPS   8.0   Dermal fibroblast IL-4   16.6       Dendritic cells anti-   3.3   IBD Colitis 2   6.2       CD40       Monocytes rest   4.2   IBD Crohn&#39;s   3.6       Monocytes LPS   0.9   Colon   30.1       Macrophages rest   3.1   Lung   19.9       Macrophages LPS   1.4   Thymus   20.6       HUVEC none   35.1   Kidney   20.9       HUVEC starved   58.2                    
     [1407] CNS_neurodegeneration_v1.0 Summary: A3229—This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1408] General_screening_panel_v1.4 Summary: Ag3229—Highest levels of expression of this gene are seen in breast cancer cell line T47D (CT=28.5). Based on expression in this panel, this gene may be involved in gastric, brain, colon, renal, lung, breast, ovarian and prostate cancer as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition using antibodies or small molecule drugs might be of use in the treatment of these cancers.  
     [1409] This gene product is also expressed in adipose, pancreas, adrenal, thyroid, pituitary, skeletal muscle, and heart. This widespread expression in tissues with metabolic function suggests, that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes.  
     [1410] In addition, this gene is expressed at low to moderate levels in all regions of the CNS examined. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1411] Panel 2.2 Summary: Ag3229 Highest expression of the CG57411-01 gene is seen in the kidney (CT=32.2). In addition, significant levels of expression are seen in samples derived from normal lung and breast. Expression in these normal tissues is also higher than in the corresponding malignant tissue. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of lung, breast and kidney cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung, breast and kidney cancer.  
     [1412] Panel 4D Summary: Ag3229 Highest expression of the CG57411-01 gene is seen in IL-4 treated lung fibroblasts (CT=31.3). Significant levels of expression are seen in activated-NCI-H292 mucoepidermoid cells as well as untreated NCI-H292 cells. Moderate expression is also detected in IL-9, IL-13 and IFN gamma activated lung fibroblasts, human pulmonary aortic endothelial cells (treated and untreated), small airway epithelium (treated and untreated), treated bronchial epithelium and lung microvascular endothelial cells (treated and untreated). The expression of this gene in cells derived from or within the lung suggests that this gene may be involved in normal conditions as well as pathological and inflammatory lung disorders that include chronic obstructive pulmonary disease, asthma, allergy and emphysema. Moderate/low expression of this gene is also detected in treated and untreated HUVECs (endothelial cells) and coronary artery smooth muscle cells (treated and untreated) and normal tissues that include lung, colon, thymus and kidney. Expression in the various immune cell types and tissue samples suggests that therapeutic modulation of this gene product may ameliorate symptoms associated with infectious conditions as well as inflammatory and autoimmune disorders that include psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.  
     [1413] AB. CG57399-01 and CG57399-03: Phospholipase ADRAB-B Precursor  
     [1414] Expression of gene CG57399-01 and variant CG57399-03 was assessed using the primer-probe sets Ag3952 and Ag3226, described in Tables ABA and ABB. Results of the RTQ-PCR runs are shown in Tables ABC and ABD.  
               TABLE ABA                          Probe Name Ag3952                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ctgtgtccctgtgtcctgaa-3′   20   1633   475               Probe   TET-5′-tcaacagaacttgctaccctcatcga-3′-TAMRA   26   1666   476               Reverse   5′-gtgggtcttctcctgaaacttc-3′   22   1701   477                  
 
     [1415]               TABLE ABB                          Probe Name Ag3226                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gatgatcctcaggtcactgtgt-3′   22   1617   478               Probe   TET-5′-ccctgtgtcctgaagtttgatgataactca-3′-TAMRA   30   1639   479               Reverse   5′-tcgatgagggtagcaagttct-3′   21   1671   480                    
     [1416]               TABLE ABC                          General_screening_panel_v1.4                                 Rel. Exp. (%) Ag3952, Run       Rel. Exp. (%) Ag3952, Run       Tissue Name   213856126   Tissue Name   213856126                                     Adipose   9.0   Renal ca. TK-10   15.0       Melanoma*   3.0   Bladder   22.7       Hs688(A).T       Melanoma*   3.4   Gastric ca. (liver met.)   13.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.9   Gastric ca. KATO III   75.3       Melanoma*   11.7   Colon ca. SW-948   4.3       LOXIMVI       Melanoma* SK-   1.5   Colon ca. SW480   97.3       MEL-5       Squamous cell   8.7   Colon ca.* (SW480   4.4       carcinoma SCC-4       met) SW620       Testis Pool   12.8   Colon ca. HT29   0.4       Prostate ca.* (bone   10.5   Colon ca. HCT-116   1.2       met) PC-3       Prostate Pool   12.9   Colon ca. CaCo-2   60.7       Placenta   5.1   Colon cancer tissue   28.7       Uterus Pool   6.5   Colon ca. SW1116   0.0       Ovarian ca.   7.3   Colon ca. Colo-205   0.9       OVCAR-3       Ovarian ca. SK-   26.4   Colon ca. SW-48   26.1       OV-3       Ovarian ca.   1.9   Colon Pool   18.8       OVCAR-4       Ovarian ca.   6.7   Small Intestine Pool   5.3       OVCAR-5       Ovarian ca.   9.2   Stomach Pool   7.9       IGROV-1       Ovarian ca.   4.2   Bone Marrow Pool   8.4       OVCAR-8       Ovary   10.0   Fetal Heart   1.2       Breast ca. MCF-7   0.4   Heart Pool   5.7       Breast ca. MDA-   92.0   Lymph Node Pool   32.1       MB-231       Breast ca. BT 549   5.5   Fetal Skeletal Muscle   1.2       Breast ca. T47D   2.5   Skeletal Muscle Pool   4.7       Breast ca. MDA-N   1.6   Spleen Pool   18.2       Breast Pool   19.6   Thymus Pool   19.3       Trachea   10.3   CNS cancer   38.2               (glio/astro) U87-MG       Lung   1.2   CNS cancer   12.2               (glio/astro) U-118-MG       Fetal Lung   8.3   CNS cancer   0.9               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.9   CNS cancer (astro) SF-   7.6               539       Lung ca. LX-1   27.2   CNS cancer (astro)   17.1               SNB-75       Lung ca. NCI-H146   10.7   CNS cancer (glio)   6.8               SNB-19       Lung ca. SHP-77   47.3   CNS cancer (glio) SF-   5.7               295       Lung ca. A549   5.1   Brain (Amygdala) Pool   7.0       Lung ca. NCI-H526   0.0   Brain (cerebellum)   3.2       Lung ca. NCI-H23   4.1   Brain (fetal)   19.3       Lung ca. NCI-H460   0.5   Brain (Hippocampus)   13.1               Pool       Lung ca. HOP-62   2.7   Cerebral Cortex Pool   14.8       Lung ca. NCI-H522   1.3   Brain (Substantia   6.3               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   15.2       Fetal Liver   1.7   Brain (whole)   10.4       Liver ca. HepG2   0.5   Spinal Cord Pool   5.3       Kidney Pool   21.2   Adrenal Gland   100.0       Fetal Kidney   1.6   Pituitary gland Pool   4.3       Renal ca. 786-0   1.7   Salivary Gland   3.4       Renal ca. A498   1.3   Thyroid (female)   14.5       Renal ca. ACHN   4.3   Pancreatic ca.   1.7               CAPAN2       Renal ca. UO-31   17.4   Pancreas Pool   24.5                    
     [1417]               TABLE ABD                          Panel 1.3D                                 Rel. Exp. (%) Ag3226, Run       Rel. Exp. (%) Ag3226, Run       Tissue Name   167994701   Tissue Name   167994701                                     Liver adenocarcinoma   2.5   Kidney (fetal)   16.3       Pancreas   0.0   Renal ca. 786-0   0.9       Pancreatic ca. CAPAN2   0.0   Renal ca. A498   1.4       Adrenal gland   19.6   Renal ca. RXF 393   3.4       Thyroid   16.3   Renal ca. ACHN   1.4       Salivary gland   0.0   Renal ca. UO-31   2.8       Pituitary gland   1.9   Renal ca. TK-10   4.4       Brain (fetal)   25.5   Liver   0.0       Brain (whole)   4.6   Liver (fetal)   1.1       Brain (amygdala)   6.7   Liver ca.   0.0               (hepatoblast) HepG2       Brain (cerebellum)   1.6   Lung   8.8       Brain (hippocampus)   22.2   Lung (fetal)   1.7       Brain (substantia nigra)   3.1   Lung ca. (small cell)   18.6               LX-1       Brain (thalamus)   3.2   Lung ca. (small cell)   4.2               NCI-H69       Cerebral Cortex   26.2   Lung ca. (s.cell var.)   100.0               SHP-77       Spinal cord   3.1   Lung ca. (large   0.0               cell)NCI-H460       glio/astro U87-MG   7.5   Lung ca. (non-sm.   6.7               cell) A549       glio/astro U-118-MG   4.2   Lung ca. (non-s.cell)   5.7               NCI-H23       astrocytoma SW1783   1.2   Lung ca. (non-s.cell)   0.0               HOP-62       neuro*; met SK-N-AS   0.0   Lung ca. (non-s.cl)   0.0               NCI-H522       astrocytoma SF-539   0.0   Lung ca. (squam.)   0.9               SW 900       astrocytoma SNB-75   4.3   Lung ca. (squam.)   3.7               NCI-H596       glioma SNB-19   6.0   Mammary gland   6.3       glioma U251   14.1   Breast ca.* (pl.ef)   0.0               MCF-7       glioma SF-295   0.0   Breast ca.* (pl.ef)   45.4               MDA-MB-231       Heart (fetal)   1.4   Breast ca.* (pl.ef)   4.3               T47D       Heart   1.0   Breast ca. BT-549   7.1       Skeletal muscle (fetal)   0.7   Breast ca. MDA-N   0.0       Skeletal muscle   3.2   Ovary   10.9       Bone marrow   3.1   Ovarian ca.   0.0               OVCAR-3       Thymus   5.7   Ovarian ca.   2.4               OVCAR-4       Spleen   7.2   Ovarian ca.   5.2               OVCAR-5       Lymph node   0.0   Ovarian ca.   0.0               OVCAR-8       Colorectal   4.8   Ovarian ca. IGROV-1   0.0       Stomach   5.1   Ovarian ca.*   3.0               (ascites) SK-OV-3       Small intestine   1.5   Uterus   5.8       Colon ca. SW480   33.2   Placenta   0.0       Colon ca.*   8.8   Prostate   1.6       SW620(SW480 met)       Colon ca. HT29   0.0   Prostate ca.* (bone   2.6               met)PC-3       Colon ca. HCT-116   0.0   Testis   7.4       Colon ca. CaCo-2   35.4   Melanoma   0.0               Hs688(A).T       Colon ca.   24.5   Melanoma* (met)   0.0       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   15.7   Melanoma UACC-   0.0               62       Gastric ca.* (liver met)   6.4   Melanoma M14   0.0       NCI-N87       Bladder   14.6   Melanoma LOX   0.0               IMVI       Trachea   4.4   Melanoma* (met)   0.0               SK-MEL-5       Kidney   2.4   Adipose   17.3                    
     [1418] General_screening_panel_v1.4 Summary: Ag3952 Highest expression of this gene is seen in the adrenal gland (CT=29). Thus, this gene product may be a treatment for Addison&#39;s disease and other adrenalopathies. This gene also has low levels of expression in adipose, heart, skeletal muscle, pituitary, thyroid, and pancreas. Therapeutic modulation of this gene product may be important for the diagnosis or treatment of endocrine or metabolic disease, including Types 1 and 2 diabetes, obesity and pancreatitis.  
     [1419] Expression of this gene is also seen in sample derived from colon, gastric, lung and breast cancers. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon, gastric, lung and breast cancers.  
     [1420] Low but significant levels of expression are also seen for all regions of the CNS examined. Thus, this gene product may be useful for treatment of CNS disorders such as Alzheimner&#39;s disease, Parkinson&#39;s disease, stroke, epilepsy, schizophrenia and multiple sclerosis.  
     [1421] Panel 1.3D Summary: Ag3952 Highest expression of the CG57399-01 gene is seen in a lung cancer cell line (CT=32.5). Low but significant expression is also seen in cell lines derived from breast and colon cancers. Overall, expression is consistent with expression seen in Panel 1.4. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon, gastric, lung and breast cancers.  
     [1422] Among metabolic tissues, significant levels of expression are seen in adipose and the adrenal gland. Thus, this gene product may be useful for treatment of obesity, Addisonl&#39;s disease and other adrenalopathies.  
     [1423] In addition, this gene is expressed in the hippocampus, and cerebral cortex. Both these regions of the brain undergo degeneration in Alzheimer&#39;s disease. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of this disease or any other neurodegenerative disorders.  
     [1424] AC. CG57399-02: Phospholipase Adrab-B Precursor  
     [1425] Expression of gene CG57399-02 was assessed using the primer-probe set Ag3952, described in Table ACA. Results of the RTQ-PCR runs are shown in Table ACB. Please note that this gene represents a variant of CG57399-01. This sequence however, only corresponds to probe and primer set Ag3952.  
               TABLE ACA                          Probe Name Ag3952                                                 SEQ ID       Primers   Sequences   Length   Start Position   NO:                                         Forward   5′-ctgtgtccctgtgtcctgaa-3′   20   578   481               Probe   TET-5′-tcaacagaacttgctaccctcatcga-3′-TAMRA   26   611   482               Reverse   5′-gtgggtcttctcctgaaacttc-3′   22   646   483                  
 
     [1426]               TABLE ACB                          General_screening_panel_v1.4                                 Rel. Exp. (%) Ag3952, Run       Rel. Exp. (%) Ag3952, Run       Tissue Name   213856126   Tissue Name   213856126                                     Adipose   9.0   Renal ca. TK-10   15.0       Melanoma*   3.0   Bladder   22.7       Hs688(A).T       Melanoma*   3.4   Gastric ca. (liver met.)   13.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.9   Gastric ca. KATO III   75.3       Melanoma*   11.7   Colon ca. SW-948   4.3       LOXIMVI       Melanoma* SK-   1.5   Colon ca. SW480   97.3       MEL-5       Squamous cell   8.7   Colon ca.* (SW480   4.4       carcinoma SCC-4       met) SW620       Testis Pool   12.8   Colon ca. HT29   0.4       Prostate ca.* (bone   10.5   Colon ca. HCT-116   1.2       met) PC-3       Prostate Pool   12.9   Colon ca. CaCo-2   60.7       Placenta   5.1   Colon cancer tissue   28.7       Uterus Pool   6.5   Colon ca. SW1116   0.0       Ovarian ca.   7.3   Colon ca. Colo-205   0.9       OVCAR-3       Ovarian ca. SK-   26.4   Colon ca. SW-48   26.1       OV-3       Ovarian ca.   1.9   Colon Pool   18.8       OVCAR-4       Ovarian ca.   6.7   Small Intestine Pool   5.3       OVCAR-5       Ovarian ca.   9.2   Stomach Pool   7.9       IGROV-1       Ovarian ca.   4.2   Bone Marrow Pool   8.4       OVCAR-8       Ovary   10.0   Fetal Heart   1.2       Breast ca. MCF-7   0.4   Heart Pool   5.7       Breast ca. MDA-   92.0   Lymph Node Pool   32.1       MB-231       Breast ca. BT 549   5.5   Fetal Skeletal Muscle   1.2       Breast ca. T47D   2.5   Skeletal Muscle Pool   4.7       Breast ca. MDA-N   1.6   Spleen Pool   18.2       Breast Pool   19.6   Thymus Pool   19.3       Trachea   10.3   CNS cancer   38.2               (glio/astro) U87-MG       Lung   1.2   CNS cancer   12.2               (glio/astro) U-118-MG       Fetal Lung   8.3   CNS cancer   0.9               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.9   CNS cancer (astro) SF-   7.6               539       Lung ca. LX-1   27.2   CNS cancer (astro)   17.1               SNB-75       Lung ca. NCI-H146   10.7   CNS cancer (glio)   6.8               SNB-19       Lung ca. SHP-77   47.3   CNS cancer (glio) SF-   5.7               295       Lung ca. A549   5.1   Brain (Amygdala) Pool   7.0       Lung ca. NCI-H526   0.0   Brain (cerebellum)   3.2       Lung ca. NCI-H23   4.1   Brain (fetal)   19.3       Lung ca. NCI-H460   0.5   Brain (Hippocampus)   13.1               Pool       Lung ca. HOP-62   2.7   Cerebral Cortex Pool   14.8       Lung ca. NCI-H522   1.3   Brain (Substantia   6.3               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   15.2       Fetal Liver   1.7   Brain (whole)   10.4       Liver ca. HepG2   0.5   Spinal Cord Pool   5.3       Kidney Pool   21.2   Adrenal Gland   100.0       Fetal Kidney   1.6   Pituitary gland Pool   4.3       Renal ca. 786-0   1.7   Salivary Gland   3.4       Renal ca. A498   1.3   Thyroid (female)   14.5       Renal ca. ACHN   4.3   Pancreatic ca.   1.7               CAPAN2       Renal ca. UO-31   17.4   Pancreas Pool   24.5                    
     [1427] General_screening_panel_v1.4 Summary: Ag3952 Highest expression of this gene is seen in the adrenal gland (CT=29). Thus, this gene product may be a treatment for Addison&#39;s disease and other adrenalopathies. This gene also has low levels of expression in adipose., heart, skeletal muscle, pituitary, thyroid, and pancreas. Therapeutic modulation of this gene product may be important for the diagnosis or treatment of endocrine or metabolic disease, including Types 1 and 2 diabetes, obesity and pancreatitis.  
     [1428] Expression of this gene is also seen in cell line samples derived from colon, gastric, lung and breast cancers. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon, gastric, lung and breast cancers.  
     [1429] Low but significant levels of expression are also seen for all regions of the CNS examined. Thus, this gene product may be useful for treatment of CNS disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, stroke, epilepsy, schizophrenia and multiple sclerosis.  
     [1430] AD. CG59311-01: ACYL-Coenzyme a Thioester Hydrolase bp.  
     [1431] Expression of gene CG59311-01, splice variant CG59311-02, and full length clone CG59311-03, was assessed using the primer-probe set Ag3541, described in Table ADA. Results of the RTQ-PCR runs are shown in Tables ADB and ADC.  
     [1432] Table ADA. Probe Name Ag3541 
               TABLE ADA                          Probe Name Ag3541                                             Start   SEQ ID       Primer   Sequences   Length   Position   NO:                                         Forward   5′-ctcactcaaaggcacaggtaga-3′   22   1199   484               Probe   TET-5′-tggcagcaaattcaaactttcttcca-3′-TAMRA   26   1225   485               Reverse   5′-tttgctgtgcttgacagatttt-3′   22   1269   486                  
 
     [1433]               TABLE ADB                          General_screening_panel_v1.4                                 Rel. Exp. (%) Ag3541, Run       Rel. Exp. (%) Ag3541, Run       Tissue Name   217049294   Tissue Name   217049294                                     Adipose   0.0   Renal ca. TK-10   6.0       Melanoma*   0.7   Bladder   3.7       Hs688(A).T       Melanoma*   1.6   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   2.7       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   5.4       carcinoma SCC-4       met) SW620       Testis Pool   3.1   Colon ca. HT29   0.0       Prostate ca.* (bone   1.4   Colon ca. HCT-116   0.6       met) PC-3       Prostate Pool   2.3   Colon ca. CaCo-2   0.6       Placenta   0.5   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   2.9   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.9   Colon Pool   4.6       OVCAR-4       Ovarian ca.   27.0   Small Intestine Pool   6.6       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   3.1       IGROV-1       Ovarian ca.   1.8   Bone Marrow Pool   1.4       OVCAR-8       Ovary   2.5   Fetal Heart   9.2       Breast ca. MCF-7   2.4   Heart Pool   3.4       Breast ca. MDA-   8.0   Lymph Node Pool   3.9       MB-231       Breast ca. BT 549   4.9   Fetal Skeletal Muscle   4.9       Breast ca. T47D   52.9   Skeletal Muscle Pool   13.5       Breast ca. MDA-N   0.0   Spleen Pool   0.0       Breast Pool   6.7   Thymus pool   4.7       Trachea   0.9   CNS cancer   0.9               (glio/astro) U87-MG       Lung   1.7   CNS cancer   12.1               (glio/astro) U-118-MG       Fetal Lung   2.2   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.0               539       Lung ca. LX-1   4.2   CNS cancer (astro)   5.2               SNB-75       Lung ca. NCI-H146   2.1   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   6.7   CNS cancer (glio) SF-   0.7               295       Lung ca. A549   0.0   Brain (Amygdala) Pool   4.2       Lung ca. NCI-H526   0.0   Brain (cerebellum)   100.0       Lung ca. NCI-H23   10.2   Brain (fetal)   14.7       Lung ca. NCI-H460   3.4   Brain (Hippocampus)   9.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   9.7       Lung ca. NCI-H522   8.5   Brain (Substantia   3.5               nigra) Pool       Liver   0.5   Brain (Thalamus) Pool   10.5       Fetal Liver   1.5   Brain (whole)   12.9       Liver ca. HepG2   0.5   Spinal Cord Pool   7.6       Kidney Pool   9.8   Adrenal Gland   10.2       Fetal Kidney   7.9   Pituitary gland Pool   3.1       Renal ca. 786-0   0.0   Salivary Gland   1.7       Renal ca. A498   0.0   Thyroid (female)   0.9       Renal ca. ACHN   0.0   Pancreatic ca.   2.8               CAPAN2       Renal ca. UO-31   3.3   Pancreas Pool   6.6                    
     [1434]               TABLE ADC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3541, Run       Ag3541, Run       Tissue Name   166447041   Tissue Name   166447041                                     Secondary Th1 act   2.7   HUVEC IL-1beta   0.0       Secondary Th2 act   4.1   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   2.1       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   2.7   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   2.3       lymphocyte act       CD45RO CD4   1.7   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   1.8       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   4.2       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   1.4               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   2.8   CCD1106   9.8               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   22.2       LAK cells IL-2 + IL-12   0.0   Lupus kidney   18.4       LAK cells IL-2 + IFN   0.0   NCI-H292 none   10.4       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   7.2       LAK cells   0.0   NCI-H292 IL-9   15.2       PMA/ionomycin       NK Cells IL-2 rest   1.7   NCI-H292 IL-13   3.1       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   7.3       Two Way MLR 5 day   5.3   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   1.7       PBMC PWM   0.0   Lung fibroblast TNF   5.7               alpha + IL-1beta       PBMC PHA-L   2.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   2.2   Lung fibroblast IL-13   3.2       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   2.9       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   2.9               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   3.5   Dermal fibroblast IL-4   1.5       Dendritic cells anti-   0.0   IBD Colitis 2   5.4       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   0.0   Colon   14.1       Macrophages rest   4.5   Lung   0.0       Macrophages LPS   2.1   Thymus   100.0       HUVEC none   0.0   Kidney   2.3       HUVEC starved   2.5                    
     [1435] CNS_neurodegeneration_v1.0 Summary: Ag3541—Expression of this gene is low/undetectable (CTs&gt;34.5) across all of the samples on this panel (data not shown).  
     [1436] General_screening_panel_v1.4 Summary: Ag3541 Significant expression of this gene is seen only in cerebellum, fetal brain, the breast cancer cell line T47D, and ovarian cancer cell line OVCAR-5 (CTs=32-35). Therefore, expression of this gene can be used to differentiate between these samples and others on this panel.  
     [1437] Panel 4D Summary: Ag3541—There is significant expression of this gene only in thymus (CT=33.8). Therefore, expression of this gene may be used to identify thymic tissue. Furthermore, drugs that inhibit the function of this protein may regulate T cell development in the thymus and reduce or eliminate the symptoms of T cell mediated autoimmune or inflammatory diseases, including asthma, allergies, inflammatory bowel disease, lupus erythematosus, or rheumatoid arthritis. Additionally, therapeutics designed against this putative protein may disrupt T cell development in the thymus and function as an immunosuppresant for tissue transplant.  
     [1438] AE. CG59309-01: Acyl-Coenzyme a Thioester Hydrolase  
     [1439] Expression of gene CG59309-01 was assessed using the primer-probe set Ag3540, described in Table AEA. Results of the RTQ-PCR runs are shown in Tables AEB, AEC, AED and AEE.  
     [1440] Table AEA. Probe Name Ag3540 
               TABLE AEA                          Probe Name Ag3540                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ccacgttggctctagcttatta-3′   22   649   487               Probe   TET-5′-tgaagatctccccaataacatggaca-3′-TAMRA   26   677   488               Reverse   5′-ttcgaagtactccagggatatg-3′   22   704   489                  
 
     [1441]               TABLE AEB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%) Ag3540,       Rel. Exp. (%) Ag3540,       Tissue Name   Run 210638385   Tissue Name   Run 210638385                                     AD 1 Hippo   13.7   Control (Path) 3   8.2               Temporal Ctx       AD 2 Hippo   26.2   Control (Path) 4   34.2               Temporal Ctx       AD 3 Hippo   13.1   AD 1 Occipital   23.2               Ctx       AD 4 Hippo   3.4   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   30.4   AD 3 Occipital   7.8               Ctx       AD 6 Hippo   55.9   AD 4 Occipital   15.0               Ctx       Control 2 Hippo   24.0   AD 5 Occipital   8.1               Ctx       Control 4 Hippo   4.5   AD 6 Occipital   76.3               Ctx       Control (Path) 3   6.2   Control 1 Occipital   3.6       Hippo       Ctx       AD 1 Temporal Ctx   11.0   Control 2 Occipital   96.6               Ctx       AD 2 Temporal Ctx   19.5   Control 3 Occipital   36.3               Ctx       AD 3 Temporal Ctx   4.8   Control 4 Occipital   3.9               Ctx       AD 4 Temporal Ctx   15.6   Control (Path) 1   100.0               Occipital Ctx       AD 5 Inf Temporal   36.9   Control (Path) 2   7.6       Ctx       Occipital Ctx       AD 5 SupTemporal   27.4   Control (Path) 3   1.6       Ctx       Occipital Ctx       AD 6 Inf Temporal   47.3   Control (Path) 4   16.6       Ctx       Occipital Ctx       AD 6 Sup Temporal   64.2   Control 1 Parietal   8.7       Ctx       Ctx       Control 1 Temporal   7.0   Control 2 Parietal   20.7       Ctx       Ctx       Control 2 Temporal   53.2   Control 3 Parietal   27.2       Ctx       Ctx       Control 3 Temporal   19.9   Control (Path) 1   88.9       Ctx       Parietal Ctx       Control 4 Temporal   10.5   Control (Path) 2   10.8       Ctx       Parietal Ctx       Control (Path) 1   68.3   Control (Path) 3   10.1       Temporal Ctx       Parietal Ctx       Control (Path) 2   25.3   Control (Path) 4   47.6       Temporal Ctx       Parietal Ctx                    
     [1442]               TABLE AEC                          General_screening_panel_v1.4                                 Rel. Exp. (%) Ag3540, Run       Rel. Exp. (%) Ag3540, Run       Tissue Name   217049291   Tissue Name   217049291                                     Adipose   1.3   Renal ca. TK-10   0.1       Melanoma*   0.7   Bladder   1.1       Hs688(A).T       Melanoma*   0.5   Gastric ca. (liver met.)   5.6       Hs688(B).T       NCI-N87       Melanoma* M14   0.2   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   10.3       MEL-5       Squamous cell   0.3   Colon ca.* (SW480   2.8       carcinoma SCC-4       met) SW620       Testis Pool   0.3   Colon ca. HT29   0.8       Prostate ca.* (bone   0.8   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.3   Colon ca. CaCo-2   3.5       Placenta   1.4   Colon cancer tissue   1.4       Uterus Pool   0.1   Colon ca. SW1116   0.0       Ovarian ca.   1.6   Colon ca. Colo-205   3.3       OVCAR-3       Ovarian ca. SK-   3.6   Colon ca. SW-48   1.7       OV-3       Ovarian ca.   0.4   Colon Pool   0.2       OVCAR-4       Ovarian ca.   23.7   Small Intestine Pool   0.3       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.1       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.2       OVCAR-8       Ovary   0.1   Fetal Heart   0.4       Breast ca. MCF-7   0.0   Heart Pool   0.2       Breast ca. MDA-   2.5   Lymph Node Pool   0.3       MB-231       Breast ca. BT 549   3.0   Fetal Skeletal Muscle   0.1       Breast ca. T47D   100.0   Skeletal Muscle Pool   0.4       Breast ca. MDA-N   0.0   Spleen Pool   0.2       Breast Pool   0.3   Thymus Pool   0.3       Trachea   0.4   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.3               (glio/astro) U-118-MG       Fetal Lung   0.2   CNS cancer   1.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.6               539       Lung ca. LX-1   3.5   CNS cancer (astro)   3.1               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.1   CNS cancer (glio) SF-   0.2               295       Lung ca. A549   1.4   Brain (Amygdala) Pool   0.7       Lung ca. NCI-H526   0.7   Brain (cerebellum)   2.1       Lung ca. NCI-H23   1.3   Brain (fetal)   0.5       Lung ca. NCI-H460   0.8   Brain (Hippocampus)   1.0               Pool       Lung ca. HOP-62   1.2   Cerebral Cortex Pool   0.9       Lung ca. NCI-H522   0.0   Brain (Substantia   1.3               nigra) Pool       Liver   2.6   Brain (Thalamus) Pool   1.1       Fetal Liver   0.8   Brain (whole)   1.4       Liver ca. HepG2   0.1   Spinal Cord Pool   0.5       Kidney Pool   0.7   Adrenal Gland   0.8       Fetal Kidney   0.6   Pituitary gland Pool   0.1       Renal ca. 786-0   0.0   Salivary Gland   0.2       Renal ca. A498   0.0   Thyroid (female)   0.7       Renal ca. ACHN   0.0   Pancreatic ca.   9.4               CAPAN2       Renal ca. UO-31   1.1   Pancreas Pool   0.9                    
     [1443]               TABLE AED                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3540, Run       Ag3540, Run       Tissue Name   166447040   Tissue Name   166447040                                     Secondary Th1 act   4.8   HUVEC IL-1beta   1.7       Secondary Th2 act   10.2   HUVEC IFN gamma   0.9       Secondary Tr1 act   12.9   HUVEC TNF alpha +   1.5               IFN gamma       Secondary Th1 rest   2.1   HUVEC TNF alpha +   0.8               IL4       Secondary Th2 rest   1.4   HUVEC IL-11   1.5       Secondary Tr1 rest   1.6   Lung Microvascular EC   0.6               none       Primary Th1 act   4.7   Lung Microvascular EC   0.8               TNF alpha + IL-1beta       Primary Th2 act   6.8   Microvascular Dermal   1.5               EC none       Primary Tr1 act   7.3   Microsvasular Dermal   0.8               EC TNF alpha + IL-1beta       Primary Th1 rest   6.6   Bronchial epithelium   1.3       7       TNF alpha + IL1beta       Primary Th2 rest   2.6   Small airway epithelium   0.6               none       Primary Tr1 rest   4.2   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   4.1   Coronery artery SMC rest   0.9       lymphocyte act       CD45RO CD4   10.9   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   6.6   Astrocytes rest   2.6       Secondary CD8   17.0   Astrocytes TNF alpha +   2.1       lymphocyte rest       IL-1beta       Secondary CD8   6.0   KU-812 (Basophil) rest   2.2       lymphocyte act       CD4 lymphocyte none   2.0   KU-812 (Basophil)   10.2               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   2.4   CCD1106   6.8       CD95 CH11       (Keratinocytes) none       LAK cells rest   2.0   CCD1106   25.7               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   16.2   Liver cirrhosis   12.0       LAK cells IL-2 + IL-12   12.8   Lupus kidney   5.1       LAK cells IL-2 + IFN   15.6   NCI-H292 none   44.8       gamma       LAK cells IL-2 + IL-18   7.4   NCI-H292 IL-4   37.6       LAK cells   3.4   NCI-H292 IL-9   41.2       PMA/ionomycin       NK Cells IL-2 rest   9.0   NCI-H292 IL-13   19.8       Two Way MLR 3 day   10.5   NCI-H292 IFN gamma   30.1       Two Way MLR 5 day   7.2   HPAEC none   1.2       Two Way MLR 7 day   8.9   HPAEC TNF alpha + IL-   3.3               1beta       PBMC rest   0.5   Lung fibroblast none   0.9       PBMC PWM   3.8   Lung fibroblast TNF   0.7               alpha + IL-1beta       PBMC PHA-L   1.0   Lung fibroblast IL-4   0.5       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.9       ionomycin       B lymphocytes PWM   10.3   Lung fibroblast IFN   1.2               gamma       B lymphocytes CD40L   3.8   Dermal fibroblast   1.1       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   18.9               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   1.9       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   14.9   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   8.9   Dermal fibroblast IL-4   1.5       Dendritic cells anti-   7.9   IBD Colitis 2   2.9       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   1.9       Monocytes LPS   0.6   Colon   82.9       Macrophages rest   40.3   Lung   9.7       Macrophages LPS   6.1   Thymus   100.0       HUVEC none   1.1   Kidney   1.8       HUVEC starved   1.4                    
     [1444]               TABLE AEE                          Panel 5 Islet                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3540, Run       Ag3540, Run       Tissue Name   242386396   Tissue Name   242386396                                     97457_Patient-   3.3   94709_Donor 2 AM - A_adipose   9.1       02go_adipose       97476_Patient-   0.8   94710_Donor 2 AM - B_adipose   1.6       07sk_skeletal muscle       97477_Patient-   0.0   94711_Donor 2 AM - C_adipose   1.4       07ut_uterus       97478_Patient-   12.9   94712_Donor 2 AD - A_adipose   2.8       07pl_placenta       99167_Bayer Patient 1   15.5   94713_Donor 2 AD - B_adipose   5.8       97482_Patient-   3.4   94714_Donor 2 AD - C_adipose   4.2       08ut_uterus       97483_Patient-   3.4   94742_Donor 3 U -   3.0       08pl_placenta       A_Mesenchymal Stem Cells       97486_Patient-   100.0   94743_Donor 3 U -   1.1       09sk_skeletal muscle       B_Mesenchymal Stem Cells       97487_Patient-   1.6   94730_Donor 3 AM - A_adipose   4.3       09ut_uterus       97488_Patient-   2.6   94731_Donor 3 AM - B_adipose   2.0       09pl_placenta       97492_Patient-   3.1   94732_Donor 3 AM - C_adipose   2.0       10ut_uterus       97493_Patient-   23.2   94733_Donor 3 AD - A_adipose   10.7       10pl_placenta       97495_Patient-   0.8   94734_Donor 3 AD - B_adipose   3.0       11go_adipose       97496_Patient-   0.0   94735_Donor 3 AD - C_adipose   4.0       11sk_skeletal muscle       97497_Patient-   2.5   77138_Liver_HepG2untreated   0.7       11ut_uterus       97498_Patient-   6.7   73556_Heart_Cardiac stromal   0.0       11pl_placenta       cells (primary)       97500_Patient-   6.5   81735_Small Intestine   4.8       12go_adipose       97501_Patient-   4.5   72409_Kidney_Proximal   0.7       12sk_skeletal muscle       Convoluted Tubule       97502_Patient-   6.7   82685_Small   3.6       12ut_uterus       intestine_Duodenum       97503_Patient-   2.4   90650_Adrenal_Adrenocortical   0.6       12pl_placenta       adenoma       94721_Donor 2 U -   2.2   72410_Kidney_HRCE   8.0       A_Mesenchymal       Stem Cells       94722_Donor 2 U -   0.6   72411_Kidney_HRE   8.5       B_Mesenchymal       Stem Cells       94723_Donor 2 U -   3.1   73139_Uterus_Uterine smooth   0.0       C_Mesenchymal       muscle cells       Stem Cells                    
     [1445] CNS_neurodegeneration_v1.0 Summary: Ag3540—This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment.  
     [1446] General_screening_panel_v1.4 Summary: Ag3540 This gene is most highly expressed in a breast cancer cell line (CT=27.1). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of breast cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of breast cancer.  
     [1447] Among metabolic tissues, this gene, an acyl coA thioesterase homolog, has a low level of expression in adipose, adult and fetal liver, adrenal, thyroid and pancreas. Acyl CoA thioesterases have multiple roles in lipid homeostasis. Therefore, therapeutic modulation of this gene product may be a treatment for endocrine and metabolic disease, including Types 1 and 2 diabetes and obesity.  
     [1448] In addition, this gene is expressed in all CNS regions examined. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of neurologic disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, stroke, schizophrenia and multiple sclerosis.  
     REFERENCES  
     [1449] 1. Hunt M C, Alexson S E. The role Acyl-CoA thioesterases play in mediating intracellular lipid metabolism. Prog Lipid Res. March 2002;41(2):99-130.  
     [1450] 2. Hunt M C, Nousiainen S E, Huttunen M K, Orii K E, Svensson L T, Alexson S E. Peroxisome proliferator-induced long chain acyl-CoA thioesterases comprise a highly conserved novel multi-gene family involved in lipid metabolism. J. Biol. Chem. Nov. 26, 1999;274(48):34317-26.  
     [1451] Panel 4D Summary: Ag3540 Highest expression of the CG59309-01 gene is seen in the thymus and colon (CTs=31.5). Significant levels of expression are also seen in a cluter of treated and untreated samples derived from the NCI-H292 mucoepidermoid cell line. Thus, expression of this gene could be used as a marker for thymus and colon. Furthermore, therapeutic modulation of the expression or function of this gene may regulate T cell development in the thymus and reduce or eliminate the symptoms of T cell mediated autoimmune or inflammatory diseases, including asthma, allergies, inflammatory bowel disease, lupus erythematosus, or rheumatoid arthritis. Additionally, small molecule or antibody therapeutics designed against this putative protein may disrupt T cell development in the thymus and function as an immunosuppresant for tissue transplant.  
     [1452] Panel 5 Islet Summary: Ag3540 This gene has moderate expression in skeletal muscle, (highest expression CT=30.5). Acyl CoA thioesterases function in peroxisomal fatty acid oxidation. Therefore, therapeutic modulation of this homolog may increase fatty acid oxidation in muscle and be a treatment for Type 2 diabetes and obesity.  
     [1453] REFERENCES  
     [1454] 1. Hunt M C, Solaas K, Kase B F, Alexson S E. Characterization of an acyl-coA thioesteirase that functions as a major regulator of peroxisomal lipid metabolism. J. Biol. Chem. Jan. 11, 2002;277(2):1128-38.  
     [1455] AF. CG57364-01: CG6896  
     [1456] Expression of gene CG57364-01 was assessed using the primer-probe sets Ag3218 and Ag3378, described in Tables AFA and AFB. Results of the RTQ-PCR runs are shown in Tables AFC, AFD, AFE and AFF.  
     [1457] Table AFA. Probe Name Ag3218 
               TABLE AFA                          Probe Name Ag3218                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ctcctgaagcaggtcctctt-3′   20   249   490               Probe   TET-5′-cctcccagtgttgtccttctggagg-3′-TAMRA   25   270   491               Reverse   5′-gacttcttccaggtcatttcg-3′   21   303   492                  
 
     [1458] Table AFB. Probe Name Ag3378 
               TABLE AFB                          Probe Name Ag3378                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ctcctgaagcaggtcctctt-3′   20   249   493               Probe   TET-5′-cctcccagtgttgtccttctggagg-3′-TAMRA   25   270   494               Reverse   5′-gacttcttccaggtcatttcg-3′   21   303   495                  
 
     [1459]               TABLE AFC                          CNS_neurodegeneration_v1.z0                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3218, Run   Ag3378, Run   Tissue   Ag3218, Run   Ag3378, Run       Tissue Name   209861784   210154573   Name   209861784   210154573                                             AD 1 Hippo   37.6   30.4   Control   17.6   16.7                   (Path) 3                   Temporal                   Ctx       AD 2 Hippo   31.0   37.6   Control   37.6   31.2                   (Path) 4                   Temporal                   Ctx       AD 3 Hippo   34.2   21.5   AD 1   56.3   40.3                   Occipital                   Ctx       AD 4 Hippo   40.6   25.3   AD 2   0.0   0.0                   Occipital                   Ctx                   (Missing)       AD 5 hippo   100.0   69.3   AD 3   43.2   24.1                   Occipital                   Ctx       AD 6 Hippo   62.9   55.9   AD 4   80.1   24.3                   Occipital                   Ctx       Control 2   55.1   52.9   AD 5   17.9   25.2       Hippo           Occipital                   Ctx       Control 4   35.4   39.5   AD 6   66.9   55.5       Hippo           Occipital                   Ctx       Control (Path)   22.8   26.8   Control 1   27.9   17.4       3 Hippo           Occipital                   Ctx       AD 1 Temporal   40.3   28.3   Control 2   94.0   64.6       Ctx           Occipital                   Ctx       AD 2 Temporal   83.5   94.6   Control 3   43.5   40.6       Ctx           Occipital                   Ctx       AD 3 Temporal   30.8   24.5   Control 4   20.3   22.5       Ctx           Occipital                   Ctx       AD 4 Temporal   61.1   26.8   Control   79.6   51.4       Ctx           (Path) 1                   Occipital                   Ctx       AD 5 Inf   84.7   100.0   Control   34.4   24.7       Temporal Ctx           (Path) 2                   Occipital                   Ctx       AD 5   55.9   39.8   Control   25.2   16.2       SupTemporal           (Path) 3       Ctx           Occipital                   Ctx       AD 6 Inf   47.0   46.0   Control   76.3   45.1       Temporal Ctx           (Path) 4                   Occipital                   Ctx       AD 6 Sup   63.7   41.2   Control 1   31.0   21.9       Temporal Ctx           Parietal Ctx       Control 1   32.8   18.0   Control 2   67.4   45.1       Temporal Ctx           Parietal Ctx       Control 2   52.1   39.2   Control 3   31.4   29.3       Temporal Ctx           Parietal Ctx       Control 3   34.9   28.1   Control   48.6   58.6       Temporal Ctx           (Path) 1                   Parietal Ctx       Control 4   62.9   36.3   Control   46.3   27.0       Temporal Ctx           (Path) 2                   Parietal Ctx       Control (Path)   75.8   50.0   Control   26.1   23.8       1 Temporal Ctx           (Path) 3                   Parietal Ctx       Control (Path)   56.6   41.8   Control   48.0   54.3       2 Temporal Ctx           (Path) 4                   Parietal Ctx                    
     [1460]               TABLE AFD                          Panel 1.3D                                         Rel.   Rel.       Rel.   Rel.           Exp. (%)   Exp. (%)       Exp. (%)   Exp. (%)           Ag3218,   Ag3378,       Ag3218,   Ag3378,           Run   Run       Run   Run       Tissue Name   168013878   165674263   Tissue Name   168013878   165674263                                             Liver   10.7   20.2   Kidney (fetal)   48.3   13.9       adenocarcinoma       Pancreas   10.8   13.1   Renal ca. 786-0   15.6   10.4       Pancreatic ca.   9.6   5.4   Renal ca.   19.2   14.9       CAPAN 2           A498       Adrenal gland   5.1   18.4   Renal ca. RXF   39.0   33.2                   393       Thyroid   12.3   33.2   Renal ca.   12.1   11.3                   ACHN       Salivary gland   5.1   5.5   Renal ca. UO-   18.9   17.8                   31       Pituitary gland   21.5   74.7   Renal ca. TK-   20.0   10.1                   10       Brain (fetal)   19.5   36.1   Liver   18.0   8.7       Brain (whole)   22.1   29.9   Liver (fetal)   5.5   25.3       Brain (amygdala)   57.4   46.7   Liver ca.   14.2   14.1                   (hepatoblast)                   HepG2       Brain (cerebellum)   25.2   23.5   Lung   14.1   18.7       Brain   28.1   85.9   Lung (fetal)   17.2   4.0       (hippocampus)       Brain (substantia   11.5   16.7   Lung ca.   6.5   14.8       nigra)           (small cell)                   LX-1       Brain (thalamus)   57.0   67.4   Lung ca.   20.6   4.8                   (small cell)                   NCI-H69       Cerebral Cortex   75.8   36.9   Lung ca.   100.0   39.8                   (s.cell var.)                   SHP-77       Spinal cord   9.7   13.2   Lung ca.   5.0   37.1                   (large                   cell)NCI-                   H460       glio/astro U87-   22.8   13.6   Lung ca. (non-   27.7   13.6       MG           sm. cell) A549       glio/astro U-118-   37.4   79.6   Lung ca. (non-   61.1   44.1       MG           s.cell) NCI-                   H23       astrocytoma   29.9   14.9   Lung ca. (non-   29.9   13.7       SW1783           s.cell) HOP-                   62       neuro*; met SK-   17.1   52.5   Lung ca. (non-   11.3   3.1       N-AS           s.cl) NCI-                   H522       astrocytoma SF-   15.5   16.0   Lung ca.   23.2   13.5       539           (squam.) SW                   900       astrocytoma SNB-   43.8   50.0   Lung ca.   41.5   10.2       75           (squam.) NCI-                   H596       glioma SNB-19   17.9   26.2   Mammary   14.8   35.1                   gland       glioma U251   47.6   39.0   Breast ca.*   48.6   39.0                   (pl.ef) MCF-7       glioma SF-295   12.3   10.7   Breast ca.*   25.9   60.7                   (pl.ef) MDA-                   MB-231       Heart (fetal)   38.4   8.0   Breast ca.*   77.4   21.2                   (pl.ef) T47D       Heart   3.5   5.0   Breast ca. BT-   47.0   95.9                   549       Skeletal muscle   17.0   10.0   Breast ca.   16.6   7.3       (fetal)           MDA-N       Skeletal muscle   4.4   7.2   Ovary   10.1   4.7       Bone marrow   1.3   14.7   Ovarian ca.   36.3   31.2                   OVCAR-3       Thymus   13.9   12.3   Ovarian ca.   33.0   20.7                   OVCAR-4       Spleen   2.6   12.9   Ovarian ca.   42.6   15.7                   OVCAR-5       Lymph node   1.7   15.9   Ovarian ca.   8.7   5.2                   OVCAR-8       Colorectal   18.2   11.8   Ovarian ca.   11.3   15.1                   IGROV-1       Stomach   14.8   33.7   Ovarian ca.*   43.5   17.0                   (ascites) SK-                   OV-3       Small intestine   18.3   66.0   Uterus   10.5   21.8       Colon ca. SW480   12.9   14.2   Placenta   2.6   15.0       Colon ca.*   17.0   14.2   Prostate   11.7   30.6       SW620 (SW480       met)       Colon ca. HT29   17.2   18.8   Prostate ca.*   35.4   40.3                   (bone met) PC-3       Colon ca. HCT-   16.5   18.2   Testis   23.3   100.0       116       Colon ca. CaCo-2   20.9   7.4   Melanoma   5.0   1.4                   Hs688(A).T       Colon ca.   14.7   21.9   Melanoma*   6.0   3.5       tissue (ODO3866)           (met)                   Hs688(B).T       Colon ca. HCC-   22.1   13.1   Melanoma   14.3   12.2       2998           UACC-62       Gastric ca.* (liver   48.6   82.4   Melanoma   3.1   8.2       met) NCI-N87           M14       Bladder   6.2   4.7   Melanoma   30.1   8.4                   LOX IMVI       Trachea   12.8   49.3   Melanoma*   21.8   13.1                   (met) SK-                   MEL-5       Kidney   43.5   35.4   Adipose   9.2   3.0                    
     [1461]               TABLE AFE                          Panel 2.2                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3218, Run       Ag3218, Run       Tissue Name   174416494   Tissue Name   174416494                                     Normal Colon   5.9   Kidney Margin   70.2               (OD04348)       Colon cancer   5.6   Kidney malignant   3.9       (OD06064)       cancer (OD06204B)       Colon Margin   3.6   Kidney normal   6.7       (OD06064)       adjacent tissue               (OD06204E)       Colon cancer   6.3   Kidney Cancer   15.1       (OD06159)       (OD04450-01)       Colon Margin   7.0   Kidney Margin   3.1       (OD06159)       (OD04450-03)       Colon cancer   2.6   Kidney Cancer   2.5       (OD06297-04)       8120613       Colon Margin   5.6   Kidney Margin   18.2       (OD06297-05)       8120614       CC Gr.2 ascend colon   20.0   Kidney Cancer   2.4       (ODO3921)       9010320       CC Margin (ODO3921)   13.7   Kidney Margin   4.4               9010321       Colon cancer metastasis   0.0   Kidney Cancer   23.0       (OD06104)       8120607       Lung Margin   11.0   Kidney Margin   15.1       (OD06104)       8120608       Colon mets to lung   29.9   Normal Uterus   2.3       (OD04451-01)       Lung Margin   0.3   Uterine Cancer 064011   6.1       (OD04451-02)       Normal Prostate   5.6   Normal Thyroid   6.6       Prostate Cancer   3.9   Thyroid Cancer   6.8       (OD04410)       064010       Prostate Margin   6.1   Thyroid Cancer   11.9       (OD04410)       A302152       Normal Ovary   7.0   Thyroid Margin   7.7               A302153       Ovarian cancer   1.3   Normal Breast   3.4       (OD06283-03)       Ovarian Margin   0.0   Breast Cancer   9.9       (OD06283-07)       (OD04566)       Ovarian Cancer 064008   31.2   Breast Cancer 1024   16.8       Ovarian cancer   3.5   Breast Cancer   100.0       (OD06145)       (OD04590-01)       Ovarian Margin   8.4   Breast Cancer Mets   26.2       (OD06145)       (OD04590-03)       Ovarian cancer   13.7   Breast Cancer   36.3       (OD06455-03)       Metastasis (OD04655-               05)       Ovarian Margin   1.1   Breast Cancer 064006   5.4       (OD06455-07)       Normal Lung   5.4   Breast Cancer 9100266   12.8       Invasive poor diff. lung   14.5   Breast Margin   1.0       adeno (ODO4945-01)       9100265       Lung Margin   2.7   Breast Cancer   3.3       (ODO4945-03)       A209073       Lung Malignant Cancer   1.8   Breast Margin   11.7       (OD03126)       A2090734       Lung Margin   5.1   Breast cancer   6.9       (OD03126)       (OD06083)       Lung Cancer   12.8   Breast cancer node   10.7       (OD05014A)       metastasis (OD06083)       Lung Margin   3.3   Normal Liver   9.4       (OD05014B)       Lung cancer   6.3   Liver Cancer 1026   2.6       (OD06081)       Lung Margin   2.7   Liver Cancer 1025   9.7       (OD06081)       Lung Cancer   12.9   Liver Cancer 6004-T   10.4       (OD04237-01)       Lung Margin   6.4   Liver Tissue 6004-N   5.3       (OD04237-02)       Ocular Melanoma   4.6   Liver Cancer 6005-T   4.2       Metastasis       Ocular Melanoma   0.1   Liver Tissue 6005-N   11.5       Margin (Liver)       Melanoma Metastasis   1.6   Liver Cancer 064003   22.5       Melanoma Margin   4.6   Normal Bladder   6.1       (Lung)       Normal Kidney   10.4   Bladder Cancer 1023   10.8       Kidney Ca, Nuclear   14.6   Bladder Cancer   15.1       grade 2 (OD04338)       A302173       Kidney Margin   10.5   Normal Stomach   15.0       (OD04338)       Kidney Ca Nuclear   44.8   Gastric Cancer   7.1       grade 1/2 (OD04339)       9060397       Kidney Margin   17.7   Stomach Margin   10.4       (OD04339)       9060396       Kidney Ca, Clear cell   5.3   Gastric Cancer   8.4       type (OD04340)       9060395       Kidney Margin   25.3   Stomach Margin   10.4       (OD04340)       9060394       Kidney Ca, Nuclear   7.5   Gastric Cancer 064005   7.7       grade 3 (OD04348)                    
     [1462]               TABLE AFF                          Panel 4D                                         Rel.   Rel.       Rel.   Rel.           Exp. (%)   Exp. (%)       Exp. (%)   Exp. (%)           Ag3218,   Ag3378,       Ag3218,   Ag3378,           Run   Run       Run   Run       Tissue Name   164682519   165296553   Tissue Name   164682519   165296553                                             Secondary Th1 act   18.2   25.7   HUVEC IL-1beta   14.5   12.9       Secondary Th2 act   39.0   26.6   HUVEC IFN   47.0   25.3                   gamma       Secondary Tr1 act   33.2   19.1   HUVEC TNF   43.5   45.1                   alpha + IFN                   gamma       Secondary Th1 rest   9.5   12.2   HUVEC TNF   37.1   48.0                   alpha + IL4       Secondary Th2 rest   11.2   5.1   HUVEC IL-11   43.5   18.0       Secondary Tr1 rest   22.7   8.0   Lung   16.8   61.6                   Microvascular EC                   none       Primary Th1 act   43.2   27.9   Lung   18.6   14.7                   Microvascular EC                   TNF alpha + IL-                   1beta       Primary Th2 act   30.1   12.0   Microvascular   31.2   23.8                   Dermal EC none       Primary Tr1 act   24.7   14.4   Microsvasular   66.4   22.1                   Dermal EC                   TNF alpha + IL-                   1beta       Primary Th1 rest   25.2   17.4   Bronchial   30.6   29.3                   epithelium                   TNF alpha +                   IL-1beta       Primary Th2 rest   15.5   7.5   Small airway   36.1   24.3                   epithelium none       Primary Tr1 rest   21.3   6.7   Small airway   76.3   62.9                   epithelium                   TNF alpha + IL-                   1beta       CD45RA CD4   35.4   16.6   Coronery artery   49.7   28.1       lymphocyte act           SMC rest       CD45RO CD4   27.9   25.9   Coronery artery   25.3   23.7       lymphocyte act           SMC TNF                   alpha + IL-1beta       CD8 lymphocyte   21.0   14.8   Astrocytes rest   22.2   31.2       act       Secondary CD8   39.2   17.8   Astrocytes   26.1   25.0       lymphocyte rest           TNF alpha + IL-                   1beta       Secondary CD8   20.9   7.4   KU-812   90.8   85.3       lymphocyte act           (Basophil) rest       CD4 lymphocyte   4.5   11.8   KU-812   87.1   72.2       none           (Basophil)                   PMA/ionomycin       2ry   2.6   10.0   CCD1106   36.6   36.9       Th1/Th2/Tr1_anti-           (Keratinocytes)       CD95 CH11           none       LAK cells rest   11.7   12.3   CCD1106   33.4   20.4                   (Keratinocytes)                   TNF alpha + IL-                   1beta       LAK cells IL-2   6.8   27.5   Liver cirrhosis   25.5   19.9       LAK cells IL-   37.1   11.6   Lupus kidney   44.4   15.7       2 + IL-12       LAK cells IL-   20.7   19.1   NCI-H292 none   79.6   64.6       2 + IFN gamma       LAK cells IL-2 +   21.9   14.7   NCI-H292 IL-4   85.3   96.6       IL-18       LAK cells   4.7   3.3   NCI-H292 IL-9   100.0   98.6       PMA/ionomycin       NK Cells IL-2 rest   11.9   11.3   NCI-H292 IL-13   68.8   50.7       Two Way MLR 3   23.7   11.0   NCI-H292 IFN   80.1   56.6       day           gamma       Two Way MLR 5   12.5   6.1   HPAEC none   38.4   27.2       day       Two Way MLR 7   12.3   8.7   HPAEC TNF   42.6   43.2       day           alpha + IL-1beta       PBMC rest   6.0   5.7   Lung fibroblast   31.2   21.3                   none       PBMC PWM   40.3   27.7   Lung fibroblast   14.7   24.5                   TNF alpha + IL-                   1beta       PBMC PHA-L   37.9   17.7   Lung fibroblast   47.0   42.6                   IL-4       Ramos (B cell)   11.7   14.9   Lung fibroblast   49.3   30.6       none           IL-9       Ramos (B cell)   33.9   26.8   Lung fibroblast   36.6   42.6       ionomycin           IL-13       B lymphocytes   33.7   40.9   Lung fibroblast   44.8   22.5       PWM           IFN gamma       B lymphocytes   34.4   18.3   Dermal fibroblast   33.7   47.3       CD40L and IL-4           CCD1070 rest       EOL-1 dbcAMP   50.0   28.1   Dermal fibroblast   47.3   33.2                   CCD1070 TNF                   alpha       EOL-1 dbcAMP   44.1   32.1   Dermal fibroblast   50.0   34.6       PMA/ionomycin           CCD1070 IL-                   1beta       Dendritic cells   33.9   19.6   Dermal fibroblast   24.0   34.4       none           IFN gamma       Dendritic cells LPS   21.9   10.2   Dermal fibroblast   24.3   32.8                   IL-4       Dendritic cells   49.7   33.9   IBD Colitis 2   6.0   11.7       anti-CD40       Monocytes rest   10.7   10.3   IBD Crohn&#39;s   25.3   26.1       Monocytes LPS   30.6   9.3   Colon   70.7   100.0       Macrophages rest   41.2   33.7   Lung   64.6   17.7       Macrophages LPS   20.0   7.5   Thymus   80.7   56.3       HUVEC none   26.8   29.5   Kidney   26.4   41.5       HUVEC starved   26.2   37.6                    
     [1463] CNS_neurodegeneration_v1.0 Summary: Ag3218/Ag3378—Two different experiments using probe/primer sets with the same sequence are in very good agreement. This panel confirms the expression of this gene at low levels to moderate levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected, between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.3D for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1464] Panel 1.3D Summary: Ag3218/Ag3378—Two different experiments using probe/primer sets with the same sequence are in good agreement. Highest expression is seen in testis and a lung cancer cell line (CTs=30-31). This panel confirms the expression of this gene at low levels in the brain. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1465] This gene product is also expressed in adipose, pancreas, thyroid, pituitary, heart, and liver. This widespread expression in tissues with metabolic function suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes.  
     [1466] Based on expression in this panel, this gene may be involved in gastric, pancreatic, brain, colon, renal, lung, breast, ovarian and prostate cancer as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition using antibodies or small molecule drugs might be of use in the treatment of these cancers.  
     [1467] Panel 2.2 Summary: Ag3218—This gene is expressed at low to moderate levels in many samples on this panel, with the highest levels of expression in breast cancer sample OD04590-01 (CT=30.3). This gene is expressed in a cluster of breast cancer samples with no expression in normal breast (CTh35). Similarly, this gene is expressed in ovarian cancer samples at higher levels than the matched margin samples.  
     [1468] Interestingly, this gene is expressed at higher levels in kidney cancer margin samples than in the matched cancer samples.  
     [1469] This gene is homologous to a mouse myosin phosphatase targeting subunit (MYPT) which have been found to play a role in cell division. MYPT undergoes mitosis-specific phosphorylation which is reversed during cytokinesis.  
     REFERENCES  
     [1470] 1. Totsukawa G, Yamakita Y, Yamashiro S, Hosoya H, Hartshorne D J, Matsumura F. Activation of myosin phosphatase targeting subunit by mitosis-specific phosphorylation. J Cell Biol Feb. 22, 1999;144(4):735-44.  
     [1471] Panel 4D Summary: Ag3218/Ag3378—Two different experiments using probe/primer sets with the same sequence are in very good agreement. Highest expression is seen in the colon and a mucoepidermoid cell line (CTs=30-32). This gene is expressed at low to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1472] AG. CG59241-01: Amiloride-Sensitive Sodium Channel  
     [1473] Expression of gene CG59241-01 was assessed using the primer-probe set Ag3407, described in Table AGA. Results of the RTQ-PCR runs are shown in Tables AGB, AGC and AGD.  
     [1474] Table AGA. Probe Name Ag3407 
               TABLE AGA                          Probe Name Ag3407                                             Start   SEQ ID       Primers   Sequences   Length   Postion   NO:                                         Forward   5′-gtcaccctctgcaacactaatg-3′   22   268   496               Probe   TET-5′-ctgtcccagctcagctaccctgactt-3′-TAMRA   26   298   497               Reverse   5′-tttcatccagtcccagcat-3′   19   340   498                  
 
     [1475]               TABLE AGB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%) Ag3407,       Rel. Exp. (%) Ag3407,       Tissue Name   Run 210349883   Tissue Name   Run 210349883                                     AD 1 Hippo   18.4   Control (Path) 3   4.1               Temporal Ctx       AD 2 Hippo   29.7   Control (Path) 4   40.3               Temporal Ctx       AD 3 Hippo   18.3   AD 1 Occipital   36.9               Ctx       AD 4 Hippo   5.4   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   91.4   AD 3 Occipital   19.1               Ctx       AD 6 Hippo   80.7   AD 4 Occipital   18.8               Ctx       Control 2 Hippo   9.3   AD 5 Occipital   18.3               Ctx       Control 4 Hippo   19.9   AD 6 Occipital   28.9               Ctx       Control (Path) 3   8.8   Control 1 Occipital   4.3       Hippo       Ctx       AD 1 Temporal Ctx   28.5   Control 2 Occipital   80.1               Ctx       AD 2 Temporal Ctx   41.8   Control 3 Occipital   20.2               Ctx       AD 3 Temporal Ctx   32.5   Control 4 Occipital   6.0               Ctx       AD 4 Temporal Ctx   36.3   Control (Path) 1   92.7               Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   25.3       Ctx       Occipital Ctx       AD 5 SupTemporal   56.6   Control (Path) 3   3.0       Ctx       Occipital Ctx       AD 6 Inf Temporal   82.4   Control (Path) 4   41.2       Ctx       Occipital Ctx       AD 6 Sup Temporal   44.1   Control 1 Parietal   21.9       Ctx       Ctx       Control 1 Temporal   15.3   Control 2 Parietal   79.0       Ctx       Ctx       Control 2 Temporal   24.1   Control 3 Parietal   22.2       Ctx       Ctx       Control 3 Temporal   34.6   Control (Path) 1   77.9       Ctx       Parietal Ctx       Control 4 Temporal   12.0   Control (Path) 2   47.6       Ctx       Parietal Ctx       Control (Path) 1   53.6   Control (Path) 3   6.2       Temporal Ctx       Parietal Ctx       Control (Path) 2   56.6   Control (Path) 4   67.4       Temporal Ctx       Parietal Ctx                    
     [1476]               TABLE AGC                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3407, Run       Ag3407, Run       Tissue Name   216821458   Tissue Name   216821458                                     Adipose   0.2   Renal ca. TK-10   16.6       Melanoma*   2.3   Bladder   0.3       Hs688(A).T       Melanoma*   0.4   Gastric ca. (liver met.)   8.8       Hs688(B).T       NCI-N87       Melanoma* M14   2.0   Gastric ca. KATO III   0.7       Melanoma*   2.5   Colon ca. SW-948   3.7       LOXIMVI       Melanoma* SK-   8.7   Colon ca. SW480   14.1       MEL-5       Squamous cell   1.2   Colon ca.* (SW480   21.2       carcinoma SCC-4       met) SW620       Testis Pool   0.4   Colon ca. HT29   10.7       Prostate ca.* (bone   4.4   Colon ca. HCT-116   64.2       met) PC-3       Prostate Pool   2.3   Colon ca. CaCo-2   32.3       Placenta   0.5   Colon cancer tissue   13.2       Uterus Pool   0.0   Colon ca. SW1116   12.5       Ovarian ca.   8.4   Colon ca. Colo-205   0.3       OVCAR-3       Ovarian ca. SK-   9.7   Colon ca. SW-48   0.6       OV-3       Ovarian ca.   1.6   Colon Pool   2.8       OVCAR-4       Ovarian ca.   18.9   Small Intestine Pool   4.5       OVCAR-5       Ovarian ca.   4.9   Stomach Pool   1.4       IGROV-1       Ovarian ca.   5.9   Bone Marrow Pool   1.8       OVCAR-8       Ovary   2.0   Fetal Heart   2.4       Breast ca. MCF-7   16.7   Heart Pool   0.3       Breast ca. MDA-   12.1   Lymph Node Pool   3.5       MB-231       Breast ca. BT 549   22.7   Fetal Skeletal Muscle   1.9       Breast ca. T47D   27.4   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   4.5   Spleen Pool   0.0       Breast Pool   2.9   Thymus Pool   2.1       Trachea   9.0   CNS cancer   0.9               (glio/astro) U87-MG       Lung   0.0   CNS cancer   11.7               (glio/astro) U-118-MG       Fetal Lung   10.8   CNS cancer   58.6               (neuro; met) SK-N-AS       Lung ca. NCI-N417   1.3   CNS cancer (astro) SF-   28.1               539       Lung ca. LX-1   21.8   CNS cancer (astro)   24.7               SNB-75       Lung ca. NCI-H146   5.4   CNS cancer (glio)   7.3               SNB-19       Lung ca. SHP-77   11.7   CNS cancer (glio) SF-   4.8               295       Lung ca. A549   8.0   Brain (Amygdala) Pool   3.9       Lung ca. NCI-H526   0.0   Brain (cerebellum)   36.1       Lung ca. NCI-H23   7.4   Brain (fetal)   100.0       Lung ca. NCI-H460   5.4   Brain (Hippocampus)   5.6               Pool       Lung ca. HOP-62   2.9   Cerebral Cortex Pool   5.6       Lung ca. NCI-H522   8.5   Brain (Substantia   7.1               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   11.3       Fetal Liver   0.0   Brain (whole)   13.4       Liver ca. HepG2   0.8   Spinal Cord Pool   12.7       Kidney Pool   2.1   Adrenal Gland   0.0       Fetal Kidney   3.7   Pituitary gland Pool   0.0       Renal ca. 786-0   1.7   Salivary Gland   0.9       Renal ca. A498   0.7   Thyroid (female)   0.0       Renal ca. ACHN   1.9   Pancreatic ca.   2.3               CAPAN2       Renal ca. UO-31   0.2   Pancreas Pool   2.6                    
     [1477]               TABLE AGD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3407, Run       Ag3407, Run       Tissue Name   165296462   Tissue Name   165296462                                     Secondary Th1 act   7.9   HUVEC IL-1beta   0.0       Secondary Th2 act   17.1   HUVEC IFN gamma   0.0       Secondary Tr1 act   40.1   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   4.4   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   7.0   HUVEC IL-11   0.0       Secondary Tr1 rest   11.7   Lung Microvascular EC   0.0               none       Primary Th1 act   61.1   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   69.3   Microvascular Dermal   0.0               EC none       Primary Tr1 act   90.8   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   20.0   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   42.6   Small airway epithelium   3.0               none       Primary Tr1 rest   52.5   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   2.8   Coronery artery SMC rest   3.6       lymphocyte act       CD45RO CD4   14.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   5.8   Astrocytes rest   11.6       Secondary CD8   18.9   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   22.2   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   4.5   CCD1106   2.7       CD95 CH11       (Keratinocytes) none       LAK cells rest   3.3   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   4.0   Liver cirrhosis   13.5       LAK cells IL-2 + IL-12   5.7   Lupus kidney   4.1       LAK cells IL-2 + IFN   21.3   NCI-H292 none   9.0       gamma       LAK cells IL-2 + IL-18   6.7   NCI-H292 IL-4   14.8       LAK cells   0.0   NCI-H292 IL-9   3.5       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   5.0   NCI-H292 IFN gamma   5.5       Two Way MLR 5 day   2.3   HPAEC none   0.0       Two Way MLR 7 day   8.2   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   2.8       PBMC PWM   21.3   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   20.4   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   2.8   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   100.0   Lung fibroblast IFN   1.4               gamma       B lymphocytes CD40L   19.8   Dermal fibroblast   34.4       and IL-4       CCD1070 rest       EOL-1 dbcAMP   2.6   Dermal fibroblast   68.8               CCD1070 TNF alpha       EOL-1 dbcAMP   6.2   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   14.1       Dendritic cells anti-   6.0   IBD Colitis 2   0.0       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   6.5   Colon   42.3       Macrophages rest   0.0   Lung   35.8       Macrophages LPS   0.0   Thymus   45.4       HUVEC none   0.0   Kidney   55.1       HUVEC starved   0.0                    
     [1478] CNS_neurodegeneration_v1.0 Summary: Ag3407 This panel confirms the expression of this gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1479] General_screening_panel_v1.4 Summary: Ag3407 Highest expression of the CG59241-01 gene is seen in fetal brain (CT=31.3). Furthermore, low to moderate levels of expression is also observed in CNS cancer cell lines (CTs=32-34). The CG59241-01 gene codes for a putative amiloride-sensitive sodium channel. A similar amiloride-sensitive sodium channel was shown to be highly expressed in malignant glioblastoma multiforme tumors and to be a charachteristic feature of malignant brain tumor cells (Ref. 1). Therefore, therapeutic modulation of the activity of the protein encoded by this gene may be beneficial in the treatment of CNS cancer. Significant expression is also seen in a cluster of cell lines derived from brain, colon, breast, and ovarian cancers. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.  
     [1480] In addition, this gene is expressed at low levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     REFERENCES  
     [1481] 1. Bubien J K, Keeton D A, Fuller C M, Gillespie G Y, Reddy A T, Mapstone T B, Benos D J. (1999) Malignant human gliomas express an amiloride-sensitive Na+ conductance. Am J Physiol 276(6 Pt 1):C1405-10  
     [1482] Panel 4D Summary: Ag3407 Highest expression Of the CG59241-01 gene is detected in PWM treated B lymphocytes (CT=32). Similar expression is also detected in primary activated Th1, Th2 and Tr1 cells, as well as TNF alpha treated dermal fibroblast CCD1070 cells (CTs=32). Therefore, expression of this gene can be used to distinguish these samples from other samples in the panel. Furthermore, this gene is expressed in activated lymphocytes. Likewise, no expression of this gene is seen in PBMC that contain normal B cells (CTr=40), but it is induced when PBMC are treated with the pokeweed mitogen or PHA-L (CTs=34). In addition, the transcript is not seen in the B cell lymphoma Ramos regardless of stimulation. Therefore, the gene product could potentially be used therapeutically in the treatment of Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, psoriasis and in other diseases in which T cells and B cells are activated.  
     [1483] In addition, low expression of this gene is also observed in normal colon, lung, thymus and kidney tissues. The CG59241-01 gene encodes an amiloride-sensitive sodium channel, A similar channel, the amiloride-sensitive epithelial sodium channel (ENaC) constitutes the limiting step for sodium reabsorption in epithelial cells that line the distal nephron, distal colon, ducts of several exocrine glands and lung airways and plays an important role in pathophysiological and clinical conditions such as hypertension or lung edema. ENaC has been implicated in two genetic diseases, Liddle&#39;s syndrome and pseudoeiypoaldosteronism (PHA-1) (Ref. 1). Therefore, antibody or small molecule therapies designed with the protein encoded for by CG59241-01 gene could modulate kidney/colon/lung function and be important in the treatment of inflammatory or autoimmune diseases of these tissues in addition to hypertension, lung edema, Liddle&#39;s syndrom and PHA-1.  
     REFERENCE  
     [1484] 1. Hummler E. (11998) Reversal of convention: from man to experimental animal in elucidating the function of the renal amiloride-sensitive sodium channel. Exp Nephrol July-August 1998;6(4):265-71  
     [1485] AH. CG58602-01: FAD Binding Domain Containing Protein  
     [1486] Expression of gene CG58602-01 was assessed using the primer-probe set Ag3385, described in Table AHA. Results of the RTQ-PCR runs are shown in Tables AHB, AHC and AHD.  
     [1487] Table AHA. Probe Name Ag3385 
               TABLE AHA                          Probe Name Ag3385                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tcatgaatccaggcaaagtg-3′   20   1427   499               Probe   TET-5′-ttagcccacaagttccctgactacgg-3′-TAMRA   26   1468   500               Reverse   5′-tggcatgaagaaaagttcca-3′   20   1503   501                  
 
     [1488]               TABLE AHB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%) Ag3385,       Rel. Exp. (%) Ag3385,       Tissue Name   Run 210154892   Tissue Name   Run 210154892                                     AD 1 Hippo   34.6   Control (Path) 3   21.2               Temporal Ctx       AD 2 Hippo   47.6   Control (Path) 4   36.1               Temporal Ctx       AD 3 Hippo   11.9   AD 1 Occipital Ctx   28.1       AD 4 Hippo   24.3   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   56.3   AD 3 Occipital Ctx   15.0       AD 6 Hippo   63.3   AD 4 Occipital Ctx   34.9       Control 2 Hippo   42.6   AD 5 Occipital Ctx   52.1       Control 4 Hippo   24.7   AD 6 Occipital Ctx   25.3       Control (Path) 3   23.3   Control 1 Occipital   14.3       Hippo       Ctx       AD 1 Temporal   23.8   Control 2 Occipital   69.3       Ctx       Ctx       AD 2 Temporal   73.7   Control 3 Occipital   29.5       Ctx       Ctx       AD 3 Temporal   7.3   Control 4 Occipital   14.9       Ctx       Ctx       AD 4 Temporal   39.0   Control (Path) 1   68.3       Ctx       Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   11.0       Ctx       Occipital Ctx       AD 5 Sup   55.5   Control (Path) 3   8.9       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   64.2   Control (Path) 4   17.3       Ctx       Occipital Ctx       AD 6 Sup   54.0   Control 1 Parietal   32.8       Temporal Ctx       Ctx       Control 1   23.8   Control 2 Parietal   62.0       Temporal Ctx       Ctx       Control 2   50.3   Control 3 Parietal   33.4       Temporal Ctx       Ctx       Control 3   38.4   Control (Path) 1   70.7       Temporal Ctx       Parietal Ctx       Control 3   19.2   Control (Path) 2   31.4       Temporal Ctx       Parietal Ctx       Control (Path) 1   56.6   Control (Path) 3   20.9       Temporal Ctx       Parietal Ctx       Control (Path) 2   47.6   Control (Path) 4   43.2       Temporal Ctx       Parietal Ctx                    
     [1489]               TABLE AHC                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3385, Run       Ag3385, Run       Tissue Name   217043538   Tissue Name   217043538                                     Adipose   2.4   Renal ca. TK-10   3.5       Melanoma*   0.7   Bladder   6.6       Hs688(A).T       Melanoma*   1.1   Gastric ca. (liver met.)   2.1       Hs688(B).T       NCI-N87       Melanoma* M14   0.9   Gastric ca. KATO III   0.9       Melanoma*   1.3   Colon ca. SW-948   4.5       LOXIMVI       Melanoma* SK-   2.2   Colon ca. SW480   0.8       MEL-5       Squamous cell   0.1   Colon ca.* (SW480   1.3       carcinoma SCC-4       met) SW620       Testis Pool   1.3   Colon ca. HT29   0.6       Prostate ca.* (bone   5.8   Colon ca. HCT-116   1.9       met) PC-3       Prostate Pool   4.0   Colon ca. CaCo-2   28.5       Placenta   2.5   Colon cancer tissue   2.0       Uterus Pool   0.5   Colon ca. SW1116   0.9       Ovarian ca.   1.1   Colon ca. Colo-205   3.5       OVCAR-3       Ovarian ca. SK-   3.7   Colon ca. SW-48   4.2       OV-3       Ovarian ca.   0.2   Colon Pool   3.0       OVCAR-4       Ovarian ca.   42.0   Small Intestine Pool   3.5       OVCAR-5       Ovarian ca.   8.0   Stomach Pool   1.8       IGROV-1       Ovarian ca.   2.7   Bone Marrow Pool   0.9       OVCAR-8       Ovary   3.3   Fetal Heart   12.9       Breast ca. MCF-7   10.3   Heart Pool   8.3       Breast ca. MDA-   3.0   Lymph Node Pool   3.5       MB-231       Breast ca. BT 549   1.3   Fetal Skeletal Muscle   2.6       Breast ca. T47D   100.0   Skeletal Muscle Pool   25.5       Breast ca. MDA-N   0.4   Spleen Pool   0.2       Breast Pool   3.1   Thymus Pool   2.7       Trachea   3.2   CNS cancer   4.0               (glio/astro) U87-MG       Lung   2.9   CNS cancer   1.3               (glio/astro) U-118-MG       Fetal Lung   3.0   CNS cancer   1.8               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.2   CNS cancer (astro) SF-   1.3               539       Lung ca. LX-1   1.1   CNS cancer (astro)   0.9               SNB-75       Lung ca. NCI-H146   0.4   CNS cancer (glio)   5.0               SNB-19       Lung ca. SHP-77   3.1   CNS cancer (glio) SF-   5.5               295       Lung ca. A549   4.3   Brain (Amygdala) Pool   5.5       Lung ca. NCI-H526   0.4   Brain (cerebellum)   13.5       Lung ca. NCI-H23   6.8   Brain (fetal)   5.6       Lung ca. NCI-H460   1.5   Brain Hippocampus)   5.2               Pool       Lung ca. HOP-62   0.1   Cerebral Cortex Pool   7.1       Lung ca. NCI-H522   3.6   Brain (Substantia   11.5               nigra) Pool       Liver   13.6   Brain (Thalamus) Pool   7.2       Fetal Liver   12.0   Brain (whole)   7.2       Liver ca. HepG2   2.7   Spinal Cord Pool   4.8       Kidney Pool   6.2   Adrenal Gland   6.0       Fetal Kidney   4.0   Pituitary gland Pool   1.7       Renal ca. 786-0   0.2   Salivary Gland   6.6       Renal ca. A498   1.4   Thyroid (female)   5.2       Renal ca. ACHN   0.8   Pancreatic ca.   3.5               CAPAN2       Renal ca. UO-31   0.9   Pancreas Pool   4.4                    
     [1490]               TABLE AHD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3385, Run       Ag3385, Run       Tissue Name   165296471   Tissue Name   165296471                                     Secondary Th1 act   1.2   HUVEC IL-1beta   0.0       Secondary Th2 act   3.6   HUVEC IFN gamma   3.7       Secondary Tr1 act   2.6   HUVEC TNF alpha +   0.7               IFN gamma       Secondary Th1 rest   0.4   HUVEC TNF alpha +   2.2               IL4       Secondary Th2 rest   0.9   HUVEC IL-11   1.3       Secondary Tr1 rest   0.4   Lung Microvascular EC   3.2               none       Primary Th1 act   1.1   Lung Microvascular EC   1.5               TNF alpha + IL-1beta       Primary Th2 act   0.7   Microvascular Dermal   3.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   1.1   Bronchial epithelium   0.6               TNF alpha + IL-1beta       Primary Th2 rest   0.5   Small airway epithelium   0.7               none       Primary Tr1 rest   0.6   Small airway epithelium   0.8               TNF alpha + IL-1beta       CD45RA CD4   2.0   Coronery artery SMC rest   0.5       lymphocyte act       CD45RO CD4   3.7   Coronery artery SMC   2.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.9   Astrocytes rest   1.5       Secondary CD8   2.7   Astrocytes TNF alpha +   2.6       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   3.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   8.2               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   3.3       CD95 CH11       (Keratinocytes) none       LAK cells rest   9.4   CCD1106   0.3               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.8   Liver cirrhosis   7.9       LAK cells IL-2 + IL-12   1.5   Lupus kidney   2.3       LAK cells IL-2 + IFN   3.7   NCI-H292 none   3.3       gamma       LAK cells IL-2 + IL-18   2.5   NCI-H292 IL-4   8.4       LAK cells   2.0   NCI-H292 IL-9   2.6       PMA/ionomycin       NK Cells IL-2 rest   0.7   NCI-H292 IL-13   2.9       Two Way MLR 3 day   4.6   NCI-H292 IFN gamma   1.8       Two Way MLR 5 day   2.8   HPAEC none   2.3       Two Way MLR 7 day   1.8   HPAEC TNF alpha + IL-   1.9               1beta       PBMC rest   0.6   Lung fibroblast none   1.5       PBMC PWM   11.0   Lung fibroblast TNF   0.7               alpha + IL-1beta       PBMC PHA-L   2.3   Lung fibroblast IL-4   1.6       Ramos (B cell) none   0.0   Lung fibroblast IL-9   2.0       Ramos (B cell)   0.9   Lung fibroblast IL-13   0.9       ionomycin       B lymphocytes PWM   3.5   Lung fibroblast IFN   0.7               gamma       B lymphocytes CD40L   5.4   Dermal fibroblast   1.6       and IL-4       CCD1070 rest       EOL-1 dbcAMP   5.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   1.2   Dermal fibroblast   2.3       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   15.5   Dermal fibroblast IFN   0.5               gamma       Dendritic cells LPS   4.5   Dermal fibroblast IL-4   0.4       Dendritic cells anti-   11.7   IBD Colitis 2   0.3       CD40       Monocytes rest   8.7   IBD Crohn&#39;s   0.0       Monocytes LPS   0.6   Colon   5.1       Macrophages rest   13.5   Lung   6.7       Macrophages LPS   1.6   Thymus   100.0       HUVEC none   0.6   Kidney   11.3       HUVEC starved   1.7                    
     [1491] CNS_neurodegeneration_v1.0 Summary: Ag3385 This panel confirms the expression of CG58602-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1492] General_screening_panel_v1.4 Summary: Ag3385 Highest expression of the CG58602-01 gene is seen in a breast cancer cell line (CT=26.3). Significant expression is also seen in an ovarian cancer cell line. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of breast and ovarian cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of breast and ovarian cancers.  
     [1493] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [1494] Expression of this gene is higher in fetal skeletal muscle (CT=28.3) when compared to expression in adult skeletal muscle (CT=31.5). Thus, expression of this gene could be used to distinguish fetal from adult skeletal muscle.  
     [1495] In addition, this gene is expressed at high levels (CTs=29-30.4) in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1496] Panel 4D Summary: Ag3385 Highest expression of the CG58602-01 gene is seen in the thymus (CT=28). Thus, the putative protein encoded for by this gene could therefore play an important role in T cell development. Therefore, small molecule therapeutics designed against the proetin encoded by this gene could be utilized to modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitiution.  
     [1497] AI. CG58468-01: Serum Amyloid P Component  
     [1498] Expression of gene CG58468-01 was assessed using the primer-probe set Ag3356, described in Table AIA. Results of the RTQ-PCR runs are shown in Table AIB.  
     [1499] Table AIA. Probe Name Ag3356 
               TABLE AIA                          Probe Name Ag3356                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-aggcatttattttccctcaaga-3′   22   106   502               Probe   TET-5′-agtctatgtgtccctgatccccaagg-3′-TAMRA   26   137   503               Reverse   5′-gttttcaggcaaagcttgaagt-3′   22   181   504                  
 
     [1500]               TABLE AIB                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3356, Run       Ag3356, Run       Tissue Name   216523476   Tissue Name   216523476                                     Adipose   2.2   Renal ca. TK-10   0.0       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.0       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   1.7   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   100.0       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   5.6       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   10.7       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   2.6       Breast ca. MDA-   0.0   Lymph Node Pool   25.9       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   2.1       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   0.0       Breast Pool   19.6   Thymus Pool   0.0       Trachea   1.5   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   5.0   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.0               539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.0   Brain (Amygdala) Pool   0.0       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   38.7   Brain (fetal)   2.6       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   0.0   Brain (Substantia   0.0               nigra) Pool       Liver   2.3   Brain (Thalamus) Pool   0.0       Fetal Liver   0.0   Brain (whole)   0.0       Liver ca. HepG2   0.0   Spinal Cord Pool   2.1       Kidney Pool   19.1   Adrenal Gland   0.0       Fetal Kidney   0.0   Pituitary gland Pool   2.1       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   7.2                    
     [1501] CNS_neurodegeneration_v1.0 Summary: Ag3356 Expression of the CG58468-01 gene is low/undetectable in all the samples on this panel. (CTs&gt;35). (Data not shown.)  
     [1502] General_screening_panel_v1.4 Summary: Ag3356 Expression of the CG58468-01 gene is restricted to the colon (CT=34). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel.  
     [1503] Panel 4D Summary: Ag3356 Results from one experiment with the CG56003-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [1504] AJ. CG58183-01: N-Methyl-D-Aspartate Receptor  
     [1505] Expression of gene CG58183-01 was assessed using the primer-probe set Ag3355, described in Table AJA. Results of the RTQ-PCR runs are shown in Tables AJB, AJC and AJD.  
     [1506] Table AJA. Probe Name Ag3355 
               TABLE AJA                          Probe Name Ag3355                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gctggccaactctgtctagac-3′   21   1617   505               Probe   TET-5′-tgactcttccacattggacagccttt-3′-TAMRA   26   1649   506               Reverse   5′-ttactgctatggaggctgctaa-3′   22   1675   507                  
 
     [1507]               TABLE AJB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%) Ag3355,       Rel. Exp. (%) Ag3355,       Tissue Name   Run 210142850   Tissue Name   Run 210142850                                     AD 1 Hippo   17.7   Control (Path) 3   7.3               Temporal Ctx       AD 2 Hippo   27.4   Control (Path) 4   47.6               Temporal Ctx       AD 3 Hippo   8.8   AD 1 Occipital Ctx   18.8       AD 4 Hippo   16.2   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   53.6   AD 3 Occipital Ctx   3.0       AD 6 Hippo   51.4   AD 4 Occipital Ctx   27.2       Control 2 Hippo   41.8   AD 5 Occipital Ctx   55.1       Control 4 Hippo   10.4   AD 6 Occipital Ctx   6.3       Control (Path) 3   4.5   Control 1 Occipital   2.8       Hippo       Ctx       AD 1 Temporal   18.3   Control 2 Occipital   39.0       Ctx       Ctx       AD 2 Temporal   48.0   Control 3 Occipital   18.2       Ctx       Ctx       AD 3 Temporal   5.7   Control 4 Occipital   3.4       Ctx       Ctx       AD 4 Temporal   15.2   Control (Path) 1   81.8       Ctx       Occipital Ctx       AD 5 Inf   61.6   Control (Path) 2   9.0       Temporal Ctx       Occipital Ctx       AD 5 Sup   69.3   Control (Path) 3   0.0       Temporal Ctx       Occipital Ctx       AD 6 Inf   66.9   Control (Path) 4   13.3       Temporal Ctx       Occipital Ctx       AD 6 Sup   62.9   Control 1 Parietal   6.6       Temporal Ctx       Ctx       Control 1   8.5   Control 2 Parietal   74.7       Temporal Ctx       Ctx       Control 2   66.9   Control 3 Parietal   21.0       Temporal Ctx       Ctx       Control 3   34.9   Control (Path) 1   100.0       Temporal Ctx       Parietal Ctx       Control 3   7.0   Control (Path) 2   21.9       Temporal Ctx       Parietal Ctx       Control (Path) 1   90.1   Control (Path) 3   6.0       Temporal Ctx       Parietal Ctx       Control (Path) 2   74.7   Control (Path) 4   50.7       Temporal Ctx       Parietal Ctx                    
     [1508]               TABLE AJC                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3355, Run       Ag3355, Run       Tissue Name   216523475   Tissue Name   216523475                                     Adipose   0.0   Renal ca. TK-10   0.0       Melanoma*   0.9   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.2       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   2.4   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   2.1   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.4   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.3   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   2.2       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   3.4       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   2.4       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   1.5       OVCAR-8       Ovary   4.4   Fetal Heart   1.9       Breast ca. MCF-7   0.0   Heart Pool   3.6       Breast ca. MDA-   0.0   Lymph Node Pool   2.9       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   1.8       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   4.3       Breast Pool   5.7   Thymus Pool   4.7       Trachea   1.7   CNS cancer   0.0               (glio/astro) U87-MG       Lung   1.6   CNS cancer   0.1               (glio/astro) U-118-MG       Fetal Lung   0.0   CNS cancer   3.2               (neuro; met) SK-N-AS       Lung ca. NCI-N417   17.8   CNS cancer (astro) SF-   14.8               539       Lung ca. LX-1   0.0   CNS cancer (astro)   17.6               SNB-75       Lung ca. NCI-H146   4.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   11.7   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.0   Brain (Amygdala) Pool   27.7       Lung ca. NCI-H526   0.3   Brain (cerebellum)   0.7       Lung ca. NCI-H23   1.9   Brain (fetal)   100.0       Lung ca. NCI-H460   0.3   Brain (Hippocampus)   33.0               Pool       Lung ca. HOP-62   0.3   Cerebral Cortex Pool   42.3       Lung ca. NCI-H522   0.0   Brain (Substantia   43.8               nigra) Pool       Liver   0.2   Brain (Thalamus) Pool   50.7       Fetal Liver   0.4   Brain (whole)   71.2       Liver ca. HepG2   0.0   Spinal Cord Pool   15.0       Kidney Pool   1.4   Adrenal Gland   0.0       Fetal Kidney   7.2   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.1       Renal ca. A498   0.0   Thyroid (female)   0.1       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   2.7                    
     [1509]               TABLE AJD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3355, Run       Ag3355, Run       Tissue Name   165241988   Tissue Name   165241988                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   11.8   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   57.8       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   67.4               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   39.8       LAK cells IL-2 + IL-12   0.0   Lupus kidney   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   0.0       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   0.0   Colon   12.7       Macrophages rest   0.0   Lung   15.2       Macrophages LPS   0.0   Thymus   100.0       HUVEC none   0.0   Kidney   73.2       HUVEC starved   0.0                    
     [1510] CNS_neurodegeneration_v1.0 Summary: Ag3355 This panel confirms the expression of CG58183-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1511] General_screening_panel_v1.4 Summary: Ag3355 Highest expression of CG58183-01 gene is detected in fetal brain (Ct=29.2). In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord (CTs=29-32). Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1512] This gene codes for N-methyl-D-aspartate (NMDA) receptor 3A protein. In cats and rhodent models competitive NMDA receptor antagonists, such as D-(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid, which act at the neurotransmitter recognition site were shown to be effective in reducing ischaemic brain damage when administered prior to the onset of an ischaemic episode (Ref. 1). Therefore, therapeutic modulation of the activity of the protein encoded by this gene may be beneficial in the treatment of ischaemic brain.  
     [1513] Among tissues with metabolic or endocrine function, this gene is expressed at low levels in pancreas, heart, and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [1514] Furthermore, low to moderate expression of this gene is detected in lung cancer, and CNS3 cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of lung cancer or CNS cancer.  
     REFERENCES  
     [1515] 1. McCulloch J. (1991) Ischaemic brain damage—prevention with competitive and non-comnpetitive antagonists of N-methyl-D-aspartate receptors. Arzneimittelforschung 41(3A):319-24.  
     [1516] Panel 4D Summary: Ag3355 Expression of the CG58183-01 gene is limited to a few samples, with highest expression in the thymus (CT=33.5). Thus, expression of this gene may be useful as a marker of thymic tissue. Low, but significant levels of expression are also seen in the kidney, in TNF-alpha and IL-1 beta treated astrocytes and in the PMA/ionomycin treated basophil cell line KU-812. Thus, this gene product may be involved in the normal homeostasis of this tissue. Therefore, agonistic antibodies or protein therapeutics may be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis. In addition, the expression of this transcript in astrocytes treated with TNF-a and IL-1 indicates that therapeutics designed against the protein encoded by this gene may be useful for the treatment of inflammatory CNS diseases such as multiple sclerosis.  
     [1517] AK. CG59315-01: connexin  
     [1518] Expression of gene CG59315-01 was assessed using the primer-probe set Ag3542, described in Table AKA. Results of the RTQ-PCR runs are shown in Tables AKB and AKC.  
     [1519] Table AKA. Probe Name Ag3542 
               TABLE AKA                          Probe Name Ag3542                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ggacacctcccaacctagatc-3′   21   1024   508               Probe   TET-5′-tacctgtcttccttccttgaggctgg-3′-TAMRA   26   1046   509               Reverse   5′-ttgcattcttgtgtccatgag-3′   21   1081   510                  
 
     [1520]               TABLE AKB                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3542, Run       Ag3542, Run       Tissue Name   217049297   Tissue Name   217049297                                     Adipose   17.3   Renal ca. TK-10   6.8       Melanoma*   0.4   Bladder   2.5       Hs688(A).T       Melanoma*   1.0   Gastric ca. (liver met.)   13.1       Hs688(B).T       NCI-N87       Melanoma* M14   12.2   Gastric ca. KATO III   12.2       Melanoma*   0.0   Colon ca. SW-948   3.8       LOXIMVI       Melanoma* SK-   0.7   Colon ca. SW480   39.0       MEL-5       Squamous cell   2.0   Colon ca.* (SW480   6.7       carcinoma SCC-4       met) SW620       Testis Pool   0.3   Colon ca. HT29   2.3       Prostate ca.* (bone   0.0   Colon ca. HCT-116   17.7       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   2.8       Placenta   1.2   Colon cancer tissue   1.6       Uterus Pool   0.0   Colon ca. SW1116   0.3       Ovarian ca.   6.3   Colon ca. Colo-205   0.3       OVCAR-3       Ovarian ca. SK-   2.5   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   1.7       OVCAR-4       Ovarian ca.   25.0   Small Intestine Pool   6.3       OVCAR-5       Ovarian ca.   6.4   Stomach Pool   5.4       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   3.1       OVCAR-8       Ovary   0.6   Fetal Heart   1.7       Breast ca. MCF-7   12.9   Heart Pool   1.5       Breast ca. MDA-   5.0   Lymph Node Pool   3.6       MB-231       Breast ca. BT 549   8.7   Fetal Skeletal Muscle   0.0       Breast ca. T47D   100.0   Skeletal Muscle Pool   6.1       Breast ca. MDA-N   2.7   Spleen Pool   5.8       Breast Pool   4.9   Thymus Pool   3.0       Trachea   9.3   CNS cancer   1.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   13.7               (glio/astro) U-118-MG       Fetal Lung   3.2   CNS cancer   35.4               (neuro; met) SK-N-AS       Lung ca. NCI-N417   1.2   CNS cancer (astro) SF-   4.9               539       Lung ca. LX-1   11.7   CNS cancer (astro)   2.7               SNB-75       Lung ca. NCI-H146   2.9   CNS cancer (glio)   1.4               SNB-19       Lung ca. SHP-77   8.1   CNS cancer (glio) SF-   12.5               295       Lung ca. A549   10.8   Brain (Amygdala) Pool   0.4       Lung ca. NCI-H526   2.1   Brain (cerebellum)   13.6       Lung ca. NCI-H23   8.1   Brain (fetal)   6.9       Lung ca. NCI-H460   0.8   Brain (Hippocampus)   1.5               Pool       Lung ca. HOP-62   10.2   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   4.9   Brain (Substantia   0.2               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   1.2       Fetal Liver   1.2   Brain (whole)   0.0       Liver ca. HepG2   0.0   Spinal Cord Pool   0.4       Kidney Pool   3.1   Adrenal Gland   2.0       Fetal Kidney   0.0   Pituitary gland Pool   1.8       Renal ca. 786-0   6.3   Salivary Gland   3.2       Renal ca. A498   0.0   Thyroid (female)   3.8       Renal ca. ACHN   12.1   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   3.2   Pancreas Pool   4.2                    
     [1521]               TABLE AKC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3542, Run       Ag3542, Run       Tissue Name   166453844   Tissue Name   166453844                                     Secondary Th1 act   3.9   HUVEC IL-1beta   0.0       Secondary Th2 act   5.4   HUVEC IFN gamma   2.4       Secondary Tr1 act   3.8   HUVEC TNF alpha +   0.4               IFN gamma       Secondary Th1 rest   33.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   5.3   HUVEC IL-11   1.4       Secondary Tr1 rest   14.8   Lung Microvascular EC   3.1               none       Primary Th1 act   6.1   Lung Microvascular EC   1.9               TNF alpha + IL-1beta       Primary Th2 act   0.6   Microvascular Dermal   1.9               EC none       Primary Tr1 act   5.5   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   84.7   Bronchial epithelium   2.7               CCD1070 TNF alpha       EOL-1 dbcAMP   11.7   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   6.3   Dermal fibroblast IFN   0.3               gamma       Dendritic cells LPS   1.4   Dermal fibroblast IL-4   1.4       Dendritic cells anti-   2.3   IBD Colitis 2   4.0       CD40       Monocytes rest   53.2   IBD Crohn&#39;s   3.2       Monocytes LPS   19.2   Colon   100.0       Macrophages rest   0.6   Lung   11.1       Macrophages LPS   0.0   Thymus   2.7       HUVEC none   5.4   Kidney   7.7       HUVEC starved   4.3                    
     [1522] CNS_neurodegeneration_v1.0 Summary: Ag3542 Expression of the CG59315-01 gene is low/undetectable in all the samples on this panel. (CTs&gt;35). (Data not shown.)  
     [1523] General_screening_panel_v1.4 Summary: Ag3542 Expression of the CG59315-01 gene is highest in a breast cancer cell line (CT=31.3). Furthermore, there is significant expression in a cluster of cell lines derived from brain cancer, colon cancer and ovarian cancer. Therefore, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of colon, brain, ovarian, and breast cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon, brain, ovarian, and breast cancers.  
     [1524] Low but significant levels of expression are also seen in the cerebellum. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [1525] Among metabolic tissues, this gene is expressed at low levels in adipose. Therefore, this gene product may be useful in the treatment of obesity.  
     [1526] Panel 4D Summary: Ag3542 Expression of the CG59315-01 gene is highest in the normal colon (CT=30). Furthermore, expression is undetectable in colon samples from Crohn&#39;s and colitis patients. Thus, expression of this gene could be used to differentiate between normal and inflammed colon. This gene encodes a connexin homolog, a gap junction protein involved in intercellular communication.  
     [1527] The expression of this connexin-like protein in several of the resting and activated T lymphocyte preparations and in resting monocytes suggests that small molecule antagonists or therapeutic antibodies that block its function may also be useful in the treatment of a number of inflammatory and autoimmune diseases in which T cells and monocytes play a pivotal role. These include, but are not limited to, Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, or psoriasis.  
     REFERENCES  
     [1528] 1. Kwak B R, Mulhaupt F, Veillard N, Gros D B, Mach F. Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol Feb. 1, 2002;22(2):225-30  
     [1529] AL. CG59203-01: Lysozyme C-Like Protein  
     [1530] Expression of gene CG59203-01 was assessed using the primer-probe set Ag3392, described in Table ALA. Results of the RTQ-PCR runs are shown in Tables ALB and ALC.  
     [1531] Table ALA. Probe Name Ag3392 
               TABLE ALA                          Probe Name Ag3392                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tgtgaggtttcctaaactggaa-3′   22   540   511               Probe   TET-5′-ctttgcagcaacgccctagggttt-3′-TAMRA   24   576   512               Reverse   5′-tgacacaggcatttggacat-3′   20   607   513                  
 
     [1532]               TABLE ALB                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3392, Run       Ag3392, Run       Tissue Name   216821373   Tissue Name   216821373                                     Adipose   0.0   Renal ca. TK-10   2.7       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.7       Hs688(B).T       NCI-N87       Melanoma* M14   1.2   Gastric ca. KATO III   0.4       Melanoma*   0.0   Colon ca. SW-948   0.6       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   2.0       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   4.7       carcinoma SCC-4       met) SW620       Testis Pool   100.0   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   1.2       Placenta   0.7   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.4   Colon ca. Colo-205   11.6       OVCAR-3       Ovarian ca. SK-   1.0   Colon ca. SW-48   2.2       OV-3       Ovarian ca.   0.0   Colon Pool   1.1       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.4       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   1.3       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   15.2   Heart Pool   1.1       Breast ca. MDA-   0.0   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   1.7   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.5       Breast ca. MDA-N   0.0   Spleen Pool   0.0       Breast Pool   0.0   Thymus Pool   0.9       Trachea   1.1   CNS cancer   1.4               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.5               (glio/astro) U-118-MG       Fetal Lung   0.8   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.0               539       Lung ca. LX-1   5.4   CNS cancer (astro)   6.1               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   3.1   Brain (Amygdala) Pool   0.0       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   0.9   Brain (fetal)   0.0       Lung ca. NCI-H460   1.1   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.5       Lung ca. NCI-H522   0.0   Brain (Substantia   0.0               nigra) Pool       Liver   1.5   Brain (Thalamus) Pool   0.9       Fetal Liver   1.2   Brain (whole)   0.0       Liver ca. HepG2   18.3   Spinal Cord Pool   0.0       Kidney Pool   1.6   Adrenal Gland   0.0       Fetal Kidney   0.0   Pituitary gland Pool   0.0       Renal ca. 786-0   0.3   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.0                    
     [1533]               TABLE ALC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3392, Run       Ag3392, Run       Tissue Name   165296470   Tissue Name   165296470                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   36.9   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL-1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   100.0       LAK cells IL-2 + IL-12   0.0   Lupus kidney   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   16.8   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   11.1   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   26.8   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   0.0       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   0.0   Colon   0.0       Macropages rest   0.0   Lung   0.0       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   0.0   Kidney   0.0       HUVEC starved   0.0                    
     [1534] CNS_neurodegeneration_v1.0 Summary: Ag3392 Expression of the CG59203-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1535] General_screening_panel_v1.4 Summary: Ag3392 Highest expression of the CG59203-01 gene is seen in the testis. Thus, expression of this gene could be used as a marker of testicular tissue. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in treating infertility or hypogonadism.  
     [1536] Panel 4D Summary: Ag3392 Significant expression of this gene is detected in a liver cirrhosis sample (CT=33.8). Furthermore, expression of this gene is not detected in normal liver in Panel 1.3D, suggesting that its expression is unique to liver cirrhosis. Therefore, therapeutic modulation of the expression or function of this gene may reduce or inhibit fibrosis that occurs in liver cirrhosis. In addition, expression of this gene could also be used for the diagnosis of liver cirrhosis.  
     [1537] AM. CG58662-01: Cytoplasmic Protein  
     [1538] Expression of gene CG58662-01 was assessed using the primer-probe set Ag3387, described in Table AMA. Results of the RTQ-PCR runs are shown in Tables AMB, AMC and AMD.  
     [1539] Table AMA. Probe Name Ag3387 
               TABLE AMA                          Probe Name Ag3387                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-aacctgcactcctccatga-3′   19   504   514               Probe   TET-5′-agaccccagcagggtatcctctgag-3′-TAMRA   25   532   515               Reverse   5′-ctctgtcagtgcccacatct-3′   20   564   516                  
 
     [1540]               TABLE AMB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.                   (%)           Rel. Exp. (%)       Ag3387,           Ag3387, Run       Run       Tissue Name   210155038   Tissue Name   210155038                                     AD 1 Hippo   15.7   Control (Path) 3   7.3               Temporal Ctx       AD 2 Hippo   34.6   Control (Path) 4   42.0               Temporal Ctx       AD 3 Hippo   5.5   AD 1 Occipital Ctx   17.9       AD 4 Hippo   9.7   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   95.3   AD 3 Occipital Ctx   5.4       AD 6 Hippo   33.9   AD 4 Occipital Ctx   19.6       Control 2 Hippo   41.5   AD 5 Occipital Ctx   61.1       Control 4 Hippo   9.0   AD 6 Occipital Ctx   19.5       Control (Path) 3   6.7   Control 1 Occipital   5.8       Hippo       Ctx       AD 1 Temporal   11.2   Control 2 Occipital   83.5       Ctx       Ctx       AD 2 Temporal   37.6   Control 3 Occipital   19.3       Ctx       Ctx       AD 3 Temporal   4.0   Control 4 Occipital   5.0       Ctx       Ctx       AD 4 Temporal   21.5   Control (Path) 1   88.9       Ctx       Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   13.4       Ctx       Occipital Ctx       AD 5 Sup   37.9   Control (Path) 3   5.8       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   35.6   Control (Path) 4   24.3       Ctx       Occipital Ctx       AD 6 Sup   39.2   Control 1 Parietal   9.4       Temporal Ctx       Ctx       Control 1   6.7   Control 2 Parietal   44.4       Temporal Ctx       Ctx       Control 2   65.5   Control 3 Parietal   28.5       Temporal Ctx       Ctx       Control 3   19.3   Control (Path) 1   90.8       Temporal Ctx       Parietal Ctx       Control 3   11.4   Control (Path) 2   25.7       Temporal Ctx       Parietal Ctx       Control (Path) 1   83.5   Control (Path) 3   5.6       Temporal Ctx       Parietal Ctx       Control (Path) 2   56.6   Control (Path) 4   56.6       Temporal Ctx       Parietal Ctx                    
     [1541]               TABLE AMC                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3387,       Ag3387,       Tissue Name   Run 217043912   Tissue Name   Run 217043912                                     Adipose   8.2   Renal ca. TK-10   66.4       Melanoma* Hs688(A).T   30.6   Bladder   11.2       Melanoma*   34.6   Gastric ca. (liver met.)   15.3       Hs688(B).T       NCI-N87       Melanoma* M14   27.0   Gastric ca. KATO III   20.6       Melanoma* LOXIMVI   17.6   Colon ca. SW-948   1.1       Melanoma* SK-   25.3   Colon ca. SW480   33.0       MEL-5       Squamous cell   5.7   Colon ca.* (SW480   29.9       carcinoma SCC-4       met) SW620       Testis Pool   17.8   Colon ca. HT29   8.8       Prostate ca.* (bone   27.7   Colon ca. HCT-116   15.4       met) PC-3       Prostate Pool   16.0   Colon ca. CaCo-2   13.1       Placenta   11.0   Colon cancer tissue   13.8       Uterus Pool   1.7   Colon ca. SW1116   7.9       Ovarian ca.   17.0   Colon ca. Colo-205   4.4       OVCAR-3       Ovarian ca. SK-   11.3   Colon ca. SW-48   9.3       OV-3       Ovarian ca.   7.1   Colon Pool   20.4       OVCAR-4       Ovarian ca.   37.4   Small Intestine Pool   12.5       OVCAR-5       Ovarian ca.   23.7   Stomach Pool   12.1       IGROV-1       Ovarian ca.   16.8   Bone Marrow Pool   4.3       OVCAR-8       Ovary   20.0   Fetal Heart   18.7       Breast ca. MCF-7   5.6   Heart Pool   12.3       Breast ca. MDA-   41.5   Lymph Node Pool   18.9       MB-231       Breast ca. BT 549   55.1   Fetal Skeletal Muscle   8.9       Breast ca. T47D   63.3   Skeletal Muscle Pool   23.2       Breast ca. MDA-N   23.5   Spleen Pool   10.8       Breast Pool   25.5   Thymus Pool   18.0       Trachea   13.6   CNS cancer   62.4               (glio/astro) U87-MG       Lung   5.3   CNS cancer   12.5               (glio/astro) U-118-MG       Fetal Lung   32.5   CNS cancer   8.1               (neuro; met) SK-N-AS       Lung ca. NCI-N417   6.2   CNS cancer (astro) SF-   17.3               539       Lung ca. LX-1   33.7   CNS cancer (astro)   27.2               SNB-75       Lung ca. NCI-H146   10.0   CNS cancer (glio)   25.9               SNB-19       Lung ca. SHP-77   39.2   CNS cancer (glio) SF-   54.0               295       Lung ca. A549   43.8   Brain (Amygdala) Pool   47.6       Lung ca. NCI-H526   6.5   Brain (cerebellum)   90.1       Lung ca. NCI-H23   44.8   Brain (fetal)   56.6       Lung ca. NCI-H460   23.8   Brain (Hippocampus) Pool   45.7       Lung ca. HOP-62   53.6   Cerebral Cortex Pool   60.3       Lung ca. NCI-H522   100.0   Brain (Substantia   61.6               nigra) Pool       Liver   4.4   Brain (Thalamus) Pool   75.8       Fetal Liver   17.0   Brain (whole)   63.3       Liver ca. HepG2   33.9   Spinal Cord Pool   24.1       Kidney Pool   37.1   Adrenal Gland   23.5       Fetal Kidney   16.4   Pituitary gland Pool   3.9       Renal ca. 786-0   14.8   Salivary Gland   9.9       Renal ca. A498   7.5   Thyroid (female)   29.1       Renal ca. ACHN   26.2   Pancreatic ca.   39.8               CAPAN2       Renal ca. UO-31   81.8   Pancreas Pool   49.3                    
     [1542]               TABLE AMD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3387, Run       Ag3387, Run       Tissue Name   165296475   Tissue Name   165296475                                     Secondary Th1 act   24.1   HUVEC IL-1beta   12.1       Secondary Th2 act   29.9   HUVEC IFN gamma   27.0       Secondary Tr1 act   26.2   HUVEC TNF alpha +   19.1               IFN gamma       Secondary Th1 rest   18.9   HUVEC TNF alpha +   16.0               IL4       Secondary Th2 rest   22.8   HUVEC IL-11   16.4       Secondary Tr1 rest   28.1   Lung Microvascular EC   36.6               none       Primary Th1 act   12.4   Lung Microvascular EC   27.2               TNF alpha + IL-1beta       Primary Th2 act   20.9   Microvascular Dermal   43.5               EC none       Primary Tr1 act   25.7   Microsvasular Dermal   23.2               EC TNF alpha + IL-1beta       Primary Th1 rest   46.0   Bronchial epithelium   18.0               TNF alpha + IL1beta       Primary Th2 rest   36.1   Small airway epithelium   3.9               none       Primary Tr1 rest   37.6   Small airway epithelium   33.2               TNF alpha + IL-1beta       CD45RA CD4   5.7   Coronery artery SMC rest   19.6       lymphocyte act       CD45RO CD4   19.9   Coronery artery SMC   12.7       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   16.2   Astrocytes rest   27.9       Secondary CD8   11.3   Astrocytes TNF alpha +   21.8       lymphocyte rest       IL-1beta       Secondary CD8   12.3   KU-812 (Basophil) rest   7.6       lymphocyte act       CD4 lymphocyte none   5.7   KU-812 (Basophil)   22.1               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   12.2   CCD1106   12.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   19.2   CCD1106   19.3               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   25.9   Liver cirrhosis   9.4       LAK cells IL-2 + IL-12   10.2   Lupus kidney   3.2       LAK cells IL-2 + IFN   26.4   NCI-H292 none   62.0       gamma       LAK cells IL-2 + IL-18   21.2   NCI-H292 IL-4   71.2       LAK cells   4.2   NCI-H292 IL-9   52.5       PMA/ionomycin       NK Cells IL-2 rest   21.2   NCI-H292 IL-13   24.8       Two Way MLR 3 day   30.6   NCI-H292 IFN gamma   33.7       Two Way MLR 5 day   26.2   HPAEC none   27.7       Two Way MLR 7 day   16.8   HPAEC TNF alpha + IL-   12.6               1beta       PBMC rest   10.7   Lung fibroblast none   25.3       PBMC PWM   21.3   Lung fibroblast TNF   12.1               alpha + IL-1beta       PBMC PHA-L   25.5   Lung fibroblast IL-4   48.0       Ramos (B cell) none   18.4   Lung fibroblast IL-9   34.6       Ramos (B cell)   68.3   Lung fibroblast IL-13   51.1       ionomycin       B lymphocytes PWM   54.0   Lung fibroblast IFN   63.3               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   20.4       and IL-4       CCD1070 rest       EOL-1 dbcAMP   18.4   Dermal fibroblast   74.2               CCD1070 TNF alpha       EOL-1 dbcAMP   3.1   Dermal fibroblast   4.6       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   28.1   Dermal fibroblast IFN   10.1               gamma       Dendritic cells LPS   29.7   Dermal fibroblast IL-4   23.8       Dendritic cells anti-   19.6   IBD Colitis 2   1.4       CD40       Monocytes rest   17.2   IBD Crohn&#39;s   2.4       Monocytes LPS   1.6   Colon   21.8       Macrophages rest   30.8   Lung   16.6       Macrophages LPS   17.4   Thymus   100.0       HUVEC none   22.8   Kidney   48.0       HUVEC starved   28.5                    
     [1543] CNS_neurodegeneration_v1.0 Summary: Ag3387 This panel does not show differential expression of the CG58662-01 gene in Alzheimer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.  
     [1544] General_screening_panel_v1.4 Summary: Ag3387 Expression of the CG58662-01 gene is ubiquitous in this panel, with highest expression in a lung cancer cell line (CT=29.5). In addition, this gene is expressed at higher levels in kidney cancer cell lines when compared to normal kidney expression. Thus, expression of this gene could be used to differentiate these samples from other samples and as a marker for these cancers. Furthermore, therapeutic modulation of the expression of function of this gene may be effective in the treatment of lung and kidney cancer.  
     [1545] Among metabolic tissues this gene is expressed at moderate to low levels in adipose, adrenal gland, pancreas, pituitary, and adult and fetal skeletal muscle, heart and liver. This widespread expression among these tissues suggests that this gene plays a role in normal metabolic and neuroendocrine function and that disregulated expression of this gene may contribute to neuroendocrine diseases or metabolic disorders, such as obesity and diabetes.  
     [1546] In addition, this gene is expressed at moderate to low levels in all CNS regions examinded and may be a small molecule target for the treatment of neurologic diseases, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [1547] Panel 4D Summary: Ag3387 The CG58662-01 gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease, with highest expression in the thymus (CT=31). In addition, expression is seen in members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1548] AN. CG59371-01: Novel Cytoplasmic Protein  
     [1549] Expression of gene CG59371-01 was assessed using the primer-probe set Ag3558, described in Table ANA. Results of the RTQ-PCR runs are shown in Tables ANB, ANC, AND and ANE.  
     [1550] Table ANA. Probe Name Ag3558 
               TABLE ANA                          Probe Name Ag3558                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cttgaggctgagaaggagaag-3′   21   208   517               Probe   TET-5′-tgcttatcaactcacagagaaggaca-3′-TAMRA   26   231   518               Reverse   5′-gttggtctctcagtcgctgta-3′   21   263   519                  
 
     [1551]               TABLE ANB                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3558, Run       Ag3558, Run       Tissue Name   213391281   Tissue Name   213391281                                     Adipose   0.4   Renal ca. TK-10   14.3       Melanoma* Hs688(A).T   1.9   Bladder   5.7       Melanoma*   2.2   Gastric ca. (liver met.)   6.4       Hs688(B).T       NCI-N87       Melanoma* M14   41.5   Gastric ca. KATO III   82.9       Melanoma* LOXIMVI   30.1   Colon ca. SW-948   14.8       Melanoma* SK-MEL-5   23.8   Colon ca. SW480   81.2       Squamous cell   34.6   Colon ca.* (SW480   24.0       carcinoma SCC-4       met) SW620       Testis Pool   7.6   Colon ca. HT29   20.6       Prostate ca.* (bone met) PC-3   9.7   Colon ca. HCT-116   61.6       Prostate Pool   0.1   Colon ca. CaCo-2   17.7       Placenta   0.3   Colon cancer tissue   7.7       Uterus Pool   0.1   Colon ca. SW1116   6.9       Ovarian ca.   15.3   Colon ca. Colo-205   3.2       OVCAR-3       Ovarian ca. SK-OV-3   62.0   Colon ca. SW-48   9.3       Ovarian ca. OVCAR-4   27.5   Colon Pool   0.3       Ovarian ca.   14.4   Small Intestine Pool   0.1       OVCAR-5       Ovarian ca.   5.8   Stomach Pool   2.0       IGROV-1       Ovarian ca.   2.5   Bone Marrow Pool   0.3       OVCAR-8       Ovary   0.2   Fetal Heart   3.3       Breast ca. MCF-7   15.5   Heart Pool   0.0       Breast ca. MDA-   100.0   Lymph Node Pool   0.5       MB-231       Breast ca. BT 549   72.7   Fetal Skeletal Muscle   0.7       Breast ca. T47D   17.1   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   13.5   Spleen Pool   0.8       Breast Pool   0.2   Thymus Pool   7.2       Trachea   0.4   CNS cancer   17.6               (glio/astro) U87-MG       Lung   0.0   CNS cancer   61.6               (glio/astro) U-118-MG       Fetal Lung   2.5   CNS cancer   14.9               (neuro; met) SK-N-AS       Lung ca. NCI-N417   5.4   CNS cancer (astro) SF-   21.6               539       Lung ca. LX-1   27.2   CNS cancer (astro)   30.4               SNB-75       Lung ca. NCI-H146   15.2   CNS cancer (glio)   4.6               SNB-19       Lung ca. SHP-77   42.0   CNS cancer (glio) SF-   0.8               295       Lung ca. A549   28.5   Brain (Amygdala) Pool   0.1       Lung ca. NCI-H526   6.4   Brain (cerebellum)   0.0       Lung ca. NCI-H23   21.3   Brain (fetal)   1.1       Lung ca. NCI-H460   0.7   Brain (Hippocampus) Pool   0.2       Lung ca. HOP-62   4.7   Cerebral Cortex Pool   0.1       Lung ca. NCI-H522   23.8   Brain (Substantia   0.1               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   0.0       Fetal Liver   0.8   Brain (whole)   0.0       Liver ca. HepG2   7.7   Spinal Cord Pool   0.1       Kidney Pool   0.1   Adrenal Gland   0.2       Fetal Kidney   4.1   Pituitary gland Pool   0.0       Renal ca. 786-0   52.5   Salivary Gland   0.0       Renal ca. A498   6.5   Thyroid (female)   0.2       Renal ca. ACHN   14.0   Pancreatic ca. CAPAN2   43.2       Renal ca. UO-31   20.2   Pancreas Pool   0.9                    
     [1552]               TABLE ANC                          General_screening_panel_v.1.5                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3558, Run       Ag3558, Run       Tissue Name   248592792   Tissue Name   248592792                                     Adipose   0.4   Renal ca. TK-10   16.6       Melanoma* Hs688(A).T   2.0   Bladder   3.3       Melanoma*   3.1   Gastric ca. (liver met.)   6.7       Hs688(B).T       NCI-N87       Melanoma* M14   34.9   Gastric ca. KATO III   93.3       Melanoma* LOXIMVI   26.4   Colon ca. SW-948   13.0       Melanoma* SK-MEL-5   29.5   Colon ca. SW480   76.3       Squamous cell   33.0   Colon ca.* (SW480   25.5       carcinoma SCC-4       met) SW620       Testis Pool   7.2   Colon ca. HT29   18.8       Prostate ca.* (bone met) PC-3   10.3   Colon ca. HCT-116   55.5       Prostate Pool   0.1   Colon ca. CaCo-2   23.5       Placenta   0.1   Colon cancer tissue   5.0       Uterus Pool   0.2   Colon ca. SW1116   4.6       Ovarian ca.   29.5   Colon ca. Colo-205   5.6       OVCAR-3       Ovarian ca. SK-   40.6   Colon ca. SW-48   6.8       OV-3       Ovarian ca.   29.5   Colon Pool   0.2       OVCAR-4       Ovarian ca.   11.7   Small Intestine Pool   0.2       OVCAR-5       Ovarian ca.   4.6   Stomach Pool   0.2       IGROV-1       Ovarian ca.   5.2   Bone Marrow Pool   0.2       OVCAR-8       Ovary   0.2   Fetal Heart   2.0       Breast ca. MCF-7   18.0   Heart Pool   0.0       Breast ca. MDA-   85.3   Lymph Node Pool   0.5       MB-231       Breast ca. BT 549   100.0   Fetal Skeletal Muscle   0.8       Breast ca. T47D   23.3   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   20.2   Spleen Pool   1.0       Breast Pool   0.3   Thymus Pool   3.7       Trachea   0.4   CNS cancer   15.4               (glio/astro) U87-MG       Lung   0.0   CNS cancer   64.6               (glio/astro) U-118-MG       Fetal Lung   3.5   CNS cancer   24.7               (neuro; met) SK-N-AS       Lung ca. NCI-N417   5.0   CNS cancer (astro) SF-   21.6               539       Lung ca. LX-1   32.1   CNS cancer (astro)   30.4               SNB-75       Lung ca. NCI-H146   13.6   CNS cancer (glio)   4.8               SNB-19       Lung ca. SHP-77   34.9   CNS cancer (glio) SF-   3.3               295       Lung ca. A549   35.4   Brain (Amygdala) Pool   0.0       Lung ca. NCI-H526   3.4   Brain (cerebellum)   0.0       Lung ca. NCI-H23   15.9   Brain (fetal)   0.7       Lung ca. NCI-H460   0.4   Brain (Hippocampus) Pool   0.0       Lung ca. HOP-62   4.5   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   25.5   Brain (Substantia   0.0               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   0.0       Fetal Liver   1.3   Brain (whole)   0.0       Liver ca. HepG2   6.6   Spinal Cord Pool   0.0       Kidney Pool   0.1   Adrenal Gland   0.1       Fetal Kidney   4.6   Pituitary gland Pool   0.0       Renal ca. 786-0   44.1   Salivary Gland   0.0       Renal ca. A498   4.2   Thyroid (female)   0.1       Renal ca. ACHN   15.2   Pancreatic ca.   48.3               CAPAN2       Renal ca. UO-31   20.4   Pancreas Pool   0.5                    
     [1553]               TABLE AND                          Panel 2.2                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3558, Run   Ag3558, Run       Ag3558, Run   Ag3558, Run       Tissue Name   173762113   174924057   Tissue Name   173762113   174924057                                             Normal Colon   12.5   5.6   Kidney Margin   3.3   1.1                   (OD04348)       Colon cancer   100.0   100.0   Kidney   5.6   8.9       (OD06064)           malignant                   cancer                   (OD06204B)       Colon Margin   27.5   17.7   Kidney normal   0.6   0.3       (OD06064)           adjacent tissue                   (OD06204E)       Colon cancer   3.1   4.8   Kidney Cancer   6.3   2.8       (OD06159)           (OD04450-01)       Colon Margin   5.6   7.3   Kidney Margin   0.6   0.0       (OD06159)           (OD04450-03)       Colon cancer   11.5   16.6   Kidney Cancer   0.0   0.0       (OD06297-04)           8120613       Colon Margin   12.5   7.8   Kidney Margin   0.3   0.3       (OD06297-05)           8120614       CC Gr.2 ascend   6.9   5.7   Kidney Cancer   0.2   1.9       colon           9010320       (ODO3921)       CC Margin   6.8   6.4   Kidney Margin   2.1   2.3       (ODO3921)           9010321       Colon cancer   6.8   4.9   Kidney Cancer   0.8   1.7       metastasis           8120607       (OD06104)       Lung Margin   17.9   12.6   Kidney Margin   0.3   0.0       (OD06104)           8120608       Colon mets to   15.1   23.3   Normal Uterus   1.6   0.5       lung       (OD04451-01)       Lung Margin   2.5   1.6   Uterine Cancer   3.5   3.6       (OD04451-02)           064011       Normal Prostate   2.1   0.0   Normal   0.3   0.0                   Thyroid       Prostate Cancer   0.0   0.2   Thyroid Cancer   1.1   0.7       (OD04410)           064010       Prostate Margin   0.4   0.3   Thyroid Cancer   1.2   1.0       (OD04410)           A302152       Normal Ovary   2.7   0.4   Thyroid Margin   0.3   0.3                   A302153       Ovarian cancer   30.1   32.8   Normal Breast   2.7   1.9       (OD06283-03)       Ovarian Margin   1.4   1.3   Breast Cancer   7.4   8.5       (OD06283-07)           (OD04566)       Ovarian Cancer   7.0   1.9   Breast Cancer   4.3   6.5       064008           1024       Ovarian cancer   1.2   1.9   Breast Cancer   11.8   13.9       (OD06145)           (OD04590-01)       Ovarian Margin   0.9   0.6   Breast Cancer   8.0   6.8       (OD06145)           Mets                   (OD04590-03)       Ovarian cancer   28.1   30.4   Breast Cancer   7.9   11.0       (OD06455-03)           Metastasis                   (OD04655-05)       Ovarian Margin   0.7   0.6   Breast Cancer   5.7   5.8       (OD06455-07)           064006       Normal Lung   1.4   1.3   Breast Cancer   0.7   0.3                   9100266       Invasive poor   25.0   20.3   Breast Margin   1.8   1.1       diff. lung adeno           9100265       (ODO4945-01       Lung Margin   1.0   1.7   Breast Cancer   2.5   1.2       (ODO4945-03)           A209073       Lung Malignant   6.3   6.4   Breast Margin   3.0   1.2       Cancer           A2090734       (OD03126)       Lung Margin   1.3   1.0   Breast cancer   15.7   24.7       (OD03126)           (OD06083)       Lung Cancer   13.5   10.3   Breast cancer   16.5   15.0       (OD05014A)           node metastasis                   (OD06083)       Lung Margin   3.1   4.8   Normal Liver   0.0   0.0       (OD05014B)       Lung cancer   38.4   28.7   Liver Cancer   1.2   0.0       (OD06081)           1026       Lung Margin   1.2   1.1   Liver Cancer   4.1   1.3       (OD06081)           1025       Lung Cancer   7.4   3.8   Liver Cancer   0.9   0.9       (OD04237-01)           6004-T       Lung Margin   0.8   1.9   Liver Tissue   2.2   1.4       (OD04237-02)           6004-N       Ocular   0.2   0.6   Liver Cancer   0.8   1.0       Melanoma           6005-T       Metastasis       Ocular   0.0   0.0   Liver Tissue   1.3   0.3       Melanoma           6005-N       Margin (Liver)       Melanoma   13.2   12.5   Liver Cancer   1.6   2.0       Metastasis           064003       Melanoma   1.6   1.1   Normal   4.4   4.4       Margin (Lung)           Bladder       Normal Kidney   0.3   0.0   Bladder Cancer   4.6   1.9                   1023       Kidney Ca,   0.0   1.0   Bladder Cancer   23.0   15.4       Nuclear grade 2           A302173       (OD04338)       Kidney Margin   0.8   0.3   Normal   6.5   9.5       (OD04338)           Stomach       Kidney Ca   0.6   2.6   Gastric Cancer   2.9   3.2       Nuclear grade           9060397       1/2 (OD04339)       Kidney Margin   0.8   0.6   Stomach   4.9   1.0       (OD04339)           Margin                   9060396       Kidney Ca,   0.6   1.2   Gastric Cancer   6.3   4.6       Clear cell type           9060395       (OD04340)       Kidney Margin   0.7   1.4   Stomach   3.5   3.0       (OD04340)           Margin                   9060394       Kidney Ca,   36.9   31.0   Gastric Cancer   22.1   20.0       Nuclear grade 3           064005       (OD04348)                    
     [1554]               TABLE ANE                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3558, Run       Ag3558, Run       Tissue Name   166488678   Tissue Name   166488678                                     Secondary Th1 act   17.9   HUVEC IL-1beta   10.3       Secondary Th2 act   12.4   HUVEC IFN gamma   12.2       Secondary Tr1 act   12.3   HUVEC TNF alpha +   12.8               IFN gamma       Secondary Th1 rest   1.7   HUVEC TNF alpha +   14.9               IL4       Secondary Th2 rest   2.6   HUVEC IL-11   8.6       Secondary Tr1 rest   2.5   Lung Microvascular EC   5.2               none       Primary Th1 act   9.1   Lung Microvascular EC   4.8               TNF alpha + IL-1beta       Primary Th2 act   11.6   Microvascular Dermal   19.5               EC none       Primary Tr1 act   11.4   Microsvasular Dermal   8.5               EC TNF alpha + IL-1beta       Primary Th1 rest   32.8   Bronchial epithelium   1.0               TNF alpha + IL1beta       Primary Th2 rest   10.4   Small airway epithelium   0.5               none       Primary Tr1 rest   13.4   Small airway epithelium   5.8               TNF alpha + IL-1beta       CD45RA CD4   10.7   Coronery artery SMC rest   2.3       lymphocyte act       CD45RO CD4   17.2   Coronery artery SMC   1.3       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   12.2   Astrocytes rest   1.4       Secondary CD8   11.7   Astrocytes TNF alpha +   0.7       lymphocyte rest       IL-1beta       Secondary CD8   10.4   KU-812 (Basophil) rest   3.1       lymphocyte act       CD4 lymphocyte none   0.1   KU-812 (Basophil)   6.6               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   6.0   CCD1106   11.3       CD95 CH11       (Keratinocytes) none       LAK cells rest   1.8   CCD1106   2.6               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   16.3   Liver cirrhosis   0.3       LAK cells IL-2 + IL-12   9.7   Lupus Kidney   0.0       LAK cells IL-2 + IFN   19.9   NCI-H292 none   12.2       gamma       LAK cells IL-2 + IL-18   16.4   NCI-H292 IL-4   29.7       LAK cells   0.7   NCI-H292 IL-9   24.3       PMA/ionomycin       NK Cells IL-2 rest   9.9   NCI-H292 IL-13   16.4       Two Way MLR 3 day   1.5   NCI-H292 IFN gamma   16.0       Two Way MLR 5 day   7.4   HPAEC none   8.9       Two Way MLR 7 day   6.1   HPAEC TNF alpha + IL-   5.5               1beta       PBMC rest   0.1   Lung fibroblast none   2.2       PBMC PWM   44.4   Lung fibroblast TNF   2.3               alpha + IL-1beta       PBMC PHA-L   23.3   Lung fibroblast IL-4   0.8       Ramos (B cell) none   13.4   Lung fibroblast IL-9   2.3       Ramos (B cell)   47.0   Lung fibroblast IL-13   0.5       ionomycin       B lymphocytes PWM   79.0   Lung fibroblast IFN   0.5               gamma       B lymphocytes CD40L   16.2   Dermal fibroblast   48.6       and IL-4       CCD1070 rest       EOL-1 dbcAMP   6.3   Dermal fibroblast   100.0               CCD1070 TNF alpha       EOL-1 dbcAMP   4.5   Dermal fibroblast   25.5       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   1.1   Dermal fibroblast IFN   14.0               gamma       Dendritic cells LPS   0.1   Dermal fibroblast IL-4   14.9       Dendritic cells anti-   0.1   IBD Colitis 2   0.5       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.2       Monocytes LPS   0.0   Colon   1.7       Macropages rest   3.0   Lung   1.2       Macrophages LPS   0.4   Thymus   0.0       HUVEC none   18.7   Kidney   11.4       HUVEC starved   0.0                    
     [1555] CNS_neurodegeneration_v1.0 Summary: Ag3558 Expression of the CG59371-0l gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1556] General_screening_panel_v1.4 Summary: Ag3558 Highest expression of the CG59371-01 gene is seen in a breast cancer cell line (CT=23.4). Overall, expression of this gene is significantly higher in cancer cell lines and fetal derived tissues than in samples derived from normal adult tissues. There are significant levels of expression in clusters of cell lines derived from pancreatic, brain, colon, gastric, renal, lung, ovarian, breast and melanoma cancers. Thus, expression of this gene in could be used to differentiate between the cancer derived samples and fetal tissues from other samples on this panel and as a marker to detect the presence of cancer. Furthermore, the much higher levels of expression in proliferative tissue suggest that this gene may be involved in cell proliferation. Therefore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.  
     [1557] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [1558] This molecule is a novel protein phosphatase expressed at moderate to low levels in all regions of the CNS examined. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [1559] General_screening_panel_v1.5 Summary: Ag3558 Results from this experiment are in excellent agreement with results from Panel 1.4. Please see that panel for discussion of utility of this gene in cancer, metabolic disorders and the central nervous system.  
     [1560] Panel 2.2 Summary: Ag3558 Two experiments with the same probe and primer produce results that are in excellent agreement, with highest expression of the CG59371-01 gene in colon cancer (CTs=30). Furthermore, expression is higher in kidney, lung, ovary and colon cancers when compared to normal adjacent tissue. In addition, significant expression is also seen in gastric, breast, and bladder cancer. Thus, expression of this gene in could be used to differentiate between the cancer derived samples and other samples on this panel and as a marker to detect the presence of cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.  
     [1561] Panel 4D Summary: Ag3558 The CG59371-01 gene is widely expressed among the samples on this panel, with highest expression in dermal fibroblasts treated with TNF-alpha. Significant levels of expression are also seen in treated and untreated samples from skin, lung, T-cells and B-cells. Therefore, modulation of the expression or activity of the protein encoded by this transcript through the application of antibodies or peptides therapeutics may be beneficial for the treatment of lung inflammatory diseases such as asthma, and chronic obstructive pulmonary diseases, inflammatory skin diseases such as psoriasis, atopic dermatitis, ulcerative dermatitis, and ulcerative colitis, autoimmune diseases such as Crohn&#39;s disease, lupus erythematosus, rheumatoid arthritis and osteoarthritis and in other diseases in which T cells and B cells are activated.  
     [1562] AO. CG59346-01: Cortactin-Binding Protein 1  
     [1563] Expression of gene CG59346-01 was assessed using the primer-probe set Ag3550, described in Table AOA. Results of the RTQ-PCR runs are shown in Tables AOB, AOC and AOD.  
     [1564] Table AOA. Probe Name Ag3550 
               TABLE AOA                          Probe Name Ag3550                                                 SEQ ID       Primers   Sequence   Length   Start Position   NO:                                         Forward   5′-gccaacagagatgaacaaagag-3′   22   3459   520               Probe   TET-5′-accgcctctccttctcccgctct-3′-TAMRA   23   3508   521               Reverse   5′-ttggaaggctaaagacatctga-3′   22   3532   522                  
 
     [1565]               TABLE AOB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.                   (%)           Rel. Exp. (%)       Ag3550,           Ag3550, Run       Run       Tissue Name   210641081   Tissue Name   210641081                                     AD 1 Hippo   12.8   Control (Path) 3   5.1               Temporal Ctx       AD 2 Hippo   38.7   Control (Path) 4   40.3               Temporal Ctx       AD 3 Hippo   10.4   AD 1 Occipital Ctx   18.8       AD 4 Hippo   15.8   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   79.6   AD 3 Occipital Ctx   7.2       AD 6 Hippo   49.3   AD 4 Occipital Ctx   25.9       Control 2 Hippo   37.4   AD 5 Occipital Ctx   37.6       Control 4 Hippo   10.3   AD 6 Occipital Ctx   19.6       Control (Path) 3   9.6   Control 1 Occipital   2.1       Hippo       Ctx       AD 1 Temporal   15.7   Control 2 Occipital   56.6       Ctx       Ctx       AD 2 Temporal   37.1   Control 3 Occipital   26.8       Ctx       Ctx       AD 3 Temporal   8.6   Control 4 Occipital   5.0       Ctx       Ctx       AD 4 Temporal   30.6   Control (Path) 1   93.3       Ctx       Occipital Ctx       AD 5 Inf Temporal   66.9   Control (Path) 2   14.6       Ctx       Occipital Ctx       AD 5 Sup   38.7   Control (Path) 3   2.6       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   45.4   Control (Path) 4   23.8       Ctx       Occipital Ctx       AD 6 Sup   53.2   Control 1 Parietal   8.7       Temporal Ctx       Ctx       Control 1   7.3   Control 2 Parietal   48.0       Temporal Ctx       Ctx       Control 2   36.6   Control 3 Parietal   17.2       Temporal Ctx       Ctx       Control 3   29.7   Control (Path) 1   84.1       Temporal Ctx       Parietal Ctx       Control 3   14.6   Control (Path) 2   28.5       Temporal Ctx       Parietal Ctx       Control (Path) 1   100.0   Control (Path) 3   4.6       Temporal Ctx       Parietal Ctx       Control (Path) 2   65.5   Control (Path) 4   56.6       Temporal Ctx       Parietal Ctx                    
     [1566]               TABLE AOC                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3550, Run       Ag3550, Run       Tissue Name   217048931   Tissue Name   217048931                                     Adipose   0.5   Renal ca. TK-10   27.7       Melanoma* Hs688(A).T   1.4   Bladder   13.7       Melanoma*   1.6   Gastric ca. (liver met.)   25.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   24.5       Melanoma*   0.0   Colon ca. SW-948   1.4       LOXIMVI       Melanoma* SK-MEL-5   0.8   Colon ca. SW480   8.8       Squamous cell   2.1   Colon ca.* (SW480   7.4       carcinoma SCC-4       met) SW620       Testis Pool   2.0   Colon ca. HT29   2.0       Prostate ca.* (bone   15.2   Colon ca. HCT-116   7.1       met) PC-3       Prostate Pool   6.7   Colon ca. CaCo-2   92.0       Placenta   18.9   Colon cancer tissue   6.0       Uterus Pool   0.0   Colon ca. SW1116   1.8       Ovarian ca.   7.6   Colon ca. Colo-205   3.0       OVCAR-3       Ovarian ca. SK-   14.9   Colon ca. SW-48   3.1       OV-3       Ovarian ca.   3.4   Colon Pool   2.2       OVCAR-4       Ovarian ca.   24.5   Small Intestine Pool   5.0       OVCAR-5       Ovarian ca.   2.1   Stomach Pool   6.9       IGROV-1       Ovarian ca.   2.4   Bone Marrow Pool   0.2       OVCAR-8       Ovary   1.4   Fetal Heart   0.1       Breast ca. MCF-7   34.6   Heart Pool   0.1       Breast ca. MDA-   8.2   Lymph Node Pool   2.8       MB-231       Breast ca. BT 549   0.2   Fetal Skeletal Muscle   0.2       Breast ca. T47D   57.4   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   1.8       Breast Pool   4.6   Thymus Pool   7.2       Trachea   14.1   CNS cancer   0.1               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.1               (glio/astro) U118-MG       Fetal Lung   19.5   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   1.5   CNS cancer (astro) SF-   0.0               539       Lung ca. LX-1   24.7   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   7.4   CNS cancer (glio)   2.1               SNB-19       Lung ca. SHP-77   0.2   CNS cancer (glio) SF-   0.1               295       Lung ca. A549   26.1   Brain (Amygdala) Pool   22.1       Lung ca. NCI-H526   13.9   Brain (cerebellum)   63.3       Lung ca. NCI-H23   6.6   Brain (fetal)   100.0       Lung ca. NCI-H460   11.1   Brain (Hippocampus) Pool   28.1       Lung ca. HOP-62   0.2   Cerebral Cortex Pool   34.2       Lung ca. NCI-H522   0.5   Brain (Substantia   26.2               nigra) Pool       Liver   3.6   Brain (Thalamus) Pool   37.9       Fetal Liver   19.1   Brain (whole)   57.8       Liver ca. HepG2   26.4   Spinal Cord Pool   2.8       Kidney Pool   0.3   Adrenal Gland   2.6       Fetal Kidney   11.7   Pituitary gland Pool   3.6       Renal ca. 786-0   23.3   Salivary Gland   25.5       Renal ca. A498   11.0   Thyroid (female)   6.9       Renal ca. ACHN   27.7   Pancreatic ca.   15.3               CAPAN2       Renal ca. UO-31   12.7   Pancreas Pool   12.9                    
     [1567]               TABLE AOD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3550, Run       Ag3550, Run       Tissue Name   166453850   Tissue Name   166453850                                     Secondary Th1 act   0.2   HUVEC IL-1beta   0.0       Secondary Th2 act   0.1   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   9.5               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   8.1               none       Primary Tr1 rest   0.0   Small airway epithelium   27.2               TNF alpha + IL-1beta       CD45RA CD4   1.4   Coronery artery SMC rest   0.7       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   1.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   5.2       Secondary CD8   0.0   Astrocytes TNF alpha +   5.9       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.1               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   10.5       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   23.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   22.8       LAK cells IL-2 + IL-12   0.1   Lupus kidney   22.5       LAK cells IL-2 + IFN   0.0   NCI-H292 none   66.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   81.8       LAK cells   0.0   NCI-H292 IL-9   69.7       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   58.6       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   61.1       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   57.4       PBMC PWM   0.0   Lung fibroblast TNF   45.7               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   36.6       Ramos (B cell) none   0.0   Lung fibroblast IL-9   33.9       Ramos (B cell)   0.0   Lung fibroblast IL-13   17.2       ionomycin       B lymphocytes PWM   2.4   Lung fibroblast IFN   34.9               gamma       B lymphocytes CD40L   11.3   Dermal fibroblast   28.5       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   11.3               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   4.8       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.3               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.3   IBD Colitis 2   6.9       CD40       Monocytes rest   36.3   IBD Crohn&#39;s   2.0       Monocytes LPS   0.0   Colon   36.6       Macrophages rest   0.0   Lung   14.3       Macrophages LPS   0.0   Thymus   100.0       HUVEC none   0.0   Kidney   0.1       HUVEC starved   0.0                    
     [1568] CNS_neurodegeneration_v1.0 Summary: Ag3550 This panel does not show differential expression of the CG59346-01 gene in Alzheimer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.  
     [1569] General_screening_panel_v1.4 Summary: Ag3550 Highest expression of the CG59346-01 gene is seen in the brain. Expression of this gene is seen at high levels in the cerebellum, cerebral cortex, and thalamus and at moderate levels in the amygdala, hippocampus, and thalamus. This CG59346-01 gene encodes a homologue of Proline-rich synapse-associated protein-1/cortactin binding protein 1 (ProSAP1/CortBP1). ProSAP1 is PDZ-domain protein highly enriched in the postsynaptic density (PSD) and involved in in the assembly of the PSD during neuronal differentiation that may function with contactin, in the recruitment and activation of neural intracellular signaling pathways. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1570] In addition, moderate levels of expression are seen in colon, gastric, renal, pancreatic, lung, ovarian, breast and prostate cancer cell lines. Thus, expression of this gene could be used to detect the presence of cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.  
     [1571] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [1572] In addition, this gene is expressed at higher levels in fetal lung and kidney (CTs=29) when compared to expression in adult lung and kidney (CTs=35-40). Thus, expression of this gene could be used to differentiate between the two sources of lung and kidney tissue.  
     REFERENCES  
     [1573] 1. Peles E, Nativ M, Lustig M, Grumet M, Schilling J, Martinez R, Plowman G D, Schlessinger J. Identification of a novel contactin-associated transmembrane receptor with multiple domains implicated in protein-protein interactions. EMBO J. Mar. 3, 1997;16(5):978-88.  
     [1574] 2. Boeckers T M, Kreutz M R, Winter C, Zuschratter W, Smalla K H, Sanmarti-Vila L, Wex H, Langnaese K, Bockmann J, Garner C C, Gundelfinger E D. (1999) Proline-rich synapse-associated protein-1/cortactin binding protein 1 (ProSAP1/CortBP1) is a PDZ-domain protein highly enriched in the postsynaptic density. J Neurosci Aug. 1, 1999;19(15):6506-18.  
     [1575] Panel 4D Summary: Ag3550 Highest expression of the CG59346-01 gene is seen in thymus (CT=27). In addition, significant levels of expression are seen in IL-4, IL-9, IL-13 and IFN gamma activated-NCI-H292 mucoepidermoid cells as well as untreated NCI-H292 cells. Moderate/low expression is also detected in IL-4, IL-9, IL-13 and IFN gamma activated lung fibroblasts, small airway epithelium (treated and untreated), and treated bronchial epithelium. The expression of this gene in cells derived from or within the lung suggests, that this gene may be involved in normal conditions as well as pathological and inflammatory lung disorders that include chronic obstructive pulmonary disease, asthma, allergy and emphysema.  
     [1576] In addition, significant levels of expression are seen in treated and untreated dermal fibroblasts and keratinocytes, suggesting that modulation of the expression or function of this gene may also reduce symtptoms in inflammatory skin diseases such as psoriasis, atopic dermatitis, and ulcerative dermatitis.  
     [1577] AP. CG57814-01 and CG57814-02: Basic I 19 Protein  
     [1578] Expression of gene CG57814-01 and varian CG57814-02 was assessed using the primer-p robe set Ag791, described in Table APA.  
     [1579] Table APA. Probe Name Ag791 
               TABLE APA                          Probe Name Ag791                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-aaatgtgatgaccaaggttctg-3′   22   1290   523               Probe   TET-5′-agcacacattatccagcgaaagcatg-3′-TAMRA   26   1319   524               Reverse   5′-tgtcaaagaaacccttgttgtc-3′   22   1368   525                  
 
     [1580] Panel 1.2 Summary: Ag791 Expression of the CG57814-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1581] AQ. CG59327-01: Monocarboxylate Transporter 1 Like Protein  
     [1582] Expression of gene CG59327-01 was assessed using the primer-probe set Ag3548, described in Table AQA. Results of the RTQ-PCR runs are shown in Tables AQB and AQC.  
     [1583] Table AOA. Probe Name Ag3548 
               TABLE AQA                          Probe Name Ag3548                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atttgcatacagcagctttgtc-3′   22   517   526               Probe   TET-5′-ttcatctcccagaaatcgtcaatttg-3′-TAMRA   26   549   527               Reverse   5′-accttcgtttgctccaataagt-3′   22   579   528                  
 
     [1584]                                               Rel. Exp. (%)       Rel. Exp. (%)           Ag3548, Run       Ag3548, Run       Tissue Name   217048438   Tissue Name   217048428                                                Adipose   0.0   Renal ca. TK-10   3.6       Melanoma* Hs688(A).T   0.0   Bladder   0.0       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-MEL-5   0.0   Colon ca. SW480   1.3       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   0.0   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   1.2   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-OV-3   0.0   Colon ca. SW-48   0.0       Ovarian ca.   0.0   Colon Pool   2.2       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   0.0   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   1.9   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   0.0       Breast Pool   0.0   Thymus Pool   0.0       Trachea   0.0   CNS cancer   0.0               (glio/astro) U87-MG       Lung   2.4   CNS cancer   6.5               (glio/astro) U-118-MG       Fetal Lung   0.0   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.0               539       Lung ca. LX-1   0.0   CNS cancer (astro)   6.4               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.0   Brain (Amygdala) Pool   0.0       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   0.0   Brain (fetal)   0.0       Lung ca. NCI-H460   0.0   Brain (Hippocampus) Pool   0.0       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   3.1   Brain (Substantia   0.0               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   0.0       Fetal Liver   0.0   Brain (whole)   0.0       Liver ca. HepG2   0.0   Spinal Cord Pool   0.0       Kidney Pool   0.0   Adrenal Gland   0.0       Fetal Kidney   3.4   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   100.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.0                    
     [1585]               TABLE AQC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3548, Run       Ag3548, Run       Tissue Name   166453848   Tissue Name   166453848                                     SecondaryTh1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.5       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       PrimaryTh1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   100.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.2               TNF alpha + IL-1beta       Primary Th2 rest   0.0   Small airway epithelium   1.2               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.3       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.3               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   6.5       LAK cells IL-2 + IL-12   0.0   Lupus kidney   0.7       LAK cells IL-2 + IFN   0.0   NCI-H292 none   1.8       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   1.7       LAK cells   0.0   NCI-H292 IL-9   0.2       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.5       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   2.0       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   3.5       Monocytes LPS   0.0   Colon   1.0       Macrophages rest   0.0   Lung   2.3       Macrophages LPS   0.0   Thymus   0.7       HUVEC none   0.0   Kidney   0.0       HUVEC starved   0.4                    
     [1586] CNS_neurodegeneration_v1.0 Summary: Ag3548 Expression of the CG59327-01 gene is low/undetectable in all the samples on the panel (CTs&gt;35). (Data not shown.)  
     [1587] General_screening_panel_v1.4 Summary: Ag3548 Significant expression of the CG59327-01 gene is restricted to a sample derived from a kidney cancer cell line (CT=33.34). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of kidney cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of kidney cancer.  
     [1588] Panel 4D Summary: Ag3548 Significant expression of the CG59327-01 gene is restricted to a samples derived from untreated microvascular dermal endothelial cells (CT=30.3). Thus, expression of this gene could be used as a marker of these cells.  
     [1589] AR. CG59494-01: Myelin P2  
     [1590] Expression of gene CG59494-01, which represents a full length physical clone, was assessed using the primer-probe set Ag3206, described in Table ARA. Results of the RTQ-PCR runs are shown in Tables ARB and ARC.  
     [1591] Table ARA. Probe Name Ag3206 
               TABLE ARA                          Probe Name Ag3206                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-agtgttgatgggaaaatgatga-3′   22   160   455               Probe   TET-5′-ccataagaacagaaagttctttccaggaca-3′-TAMRA   30   182   758               Reverse   5′-ccccagcttgaaggagatc-3′   19   216   759                  
 
     [1592]               TABLE ARB                          Panel 1.3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3206, Run       Ag3206, Run       Tissue Name   165527079   Tissue Name   165527079                                     Liver adenocarcinoma   0.0   Kidney (fetal)   10.5       Pancreas   0.0   Renal ca. 786-0   0.0       Pancreatic ca. CAPAN 2   17.8   Renal ca. A498   15.6       Adrenal gland   0.0   Renal ca. RXF 393   0.0       Thyroid   0.0   Renal ca. ACHN   14.8       Salivary gland   0.0   Renal ca. UO-31   0.0       Pituitary gland   0.0   Renal ca. TK-10   0.0       Brain (fetal)   0.0   Liver   0.0       Brain (whole)   9.9   Liver (fetal)   0.0       Brain (amygdala)   0.0   Liver ca.   0.0               (hepatoblast) HepG2       Brain (cerebellum)   0.0   Lung   0.0       Brain (hippocampus)   0.0   Lung (fetal)   0.0       Brain (substantia nigra)   0.0   Lung ca. (small cell) LX-1   4.5       Brain (thalamus)   0.0   Lung ca. (small cell)   0.0               NCI-H69       Cerebral Cortex   0.0   Lung ca. (s.cell var.)   18.0               SHP-77       Spinal cord   33.4   Lung ca. (large   41.2               cell)NCI-H460       glio/astro U87-MG   0.0   Lung ca. (non-sm.   0.0               cell) A549       glio/astro U-118-MG   0.0   Lung ca. (non-s.cell)   0.0               NCI-H23       astrocytoma SW1783   0.0   Lung ca. (non-s.cell)   0.0               HOP-62       neuro*; met SK-N-AS   0.0   Lung ca. (non-s.cl)   0.0               NCI-H522       astrocytoma SF-539   0.0   Lung ca. (squam.)   0.0               SW 900       astrocytoma SNB-75   11.7   Lung ca. (squam.)   0.0               NCI-H596       glioma SNB-19   0.0   Mammary gland   14.4       glioma U251   0.0   Breast ca.* (pl.ef)   0.0               MCF-7       glioma SF-295   0.0   Breast ca.* (pl.ef)   0.0               MDA-MB-231       Heart (fetal)   0.0   Breast ca.* (pl.ef)   0.0               T47D       Heart   15.5   Breast ca. BT-549   0.0       Skeletal muscle (fetal)   0.0   Breast ca. MDA-N   0.0       Skeletal muscle   0.0   Ovary   0.0       Bone marrow   0.0   Ovarian ca.   14.0               OVCAR-3       Thymus   0.0   Ovarian ca.   0.0               OVCAR-4       Spleen   0.0   Ovarian ca.   0.0               OVCAR-5       Lymph node   0.0   Ovarian ca.   0.0               OVCAR-8       Colorectal   0.0   Ovarian ca. IGROV-1   11.6       Stomach   0.0   Ovarian ca.*   0.0               (ascites) SK-OV-3       Small intestine   0.0   Uterus   0.0       Colon ca. SW480   0.0   Placenta   0.0       Colon ca.*   0.0   Prostate   0.0       SW620(SW480 met)       Colon ca. HT29   0.0   Prostate ca.* (bone   100.0               met)PC-3       Colon ca. HCT-116   0.0   Testis   27.5       Colon ca. CaCo-2   42.0   Melanoma   0.0               Hs688(A).T       Colon ca.   0.0   Melanoma* (met)   0.0       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   0.0   Melanoma UACC-62   0.0       Gastric ca.* (liver met)   0.0   Melanoma M14   0.0       NCI-N87       Bladder   0.0   Melanoma LOX   0.0               IMVI       Trachea   0.0   Melanoma* (met)   0.0               SK-MEL-5       Kidney   0.0   Adipose   0.0                    
     [1593]               TABLE ARC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3206, Run       Ag3206, Run       Tissue Name   164531735   Tissue Name   164531735                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   11.9   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   12.6               IFN gamma       Secondary Th1 rest   11.9   HUVEC TNF alpha +   15.9               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   75.8               none       Primary Th1 act   0.0   Lung Microvascular EC   100.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   72.2               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   29.7       LAK cells IL-2 + IL-12   0.0   Lupus kidney   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 none   97.3       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   43.8       PMA/ionomycin       NK Cells IL-2 rest   7.8   NCI-H292 IL-13   24.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   12.7       Two Way MLR 5 day   0.0   HPAEC none   14.3       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   33.2               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   16.2       Ramos (B cell)   0.0   Lung fibroblast IL-13   15.9       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   15.0       Dendritic cells anti-   0.0   IBD Colitis 2   27.4       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   0.0   Colon   6.7       Macrophages rest   0.0   Lung   0.0       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   27.7   Kidney   0.0       HUVEC starved   20.0                    
     [1594] Panel 1.3D Summary: Ag3206 Expression of the CG59494-01 gene is restricted to a sample derived from a prostate cancer cell line (CT=34.9). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of prostate cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of prostate cancer.  
     [1595] Panel 4D Summary: Ag3206 Expression of the CG59494-01 gene is primarily restricted to a cluster of samples derived from microvasculature of the lung and the dermis suggesting a role for this gene in the maintenance of the integrity of the microvasculature. Therefore, therapeutics designed for this putative protein could be beneficial for the treatment of diseases associated with damaged microvasculature including heart diseases or inflammatory diseases, such as psoriasis, asthma, and chronic obstructive pulmonary diseases.  
     [1596] AS. CG59432-01 and CG59432-02: Chloride Channel  
     [1597] Expression of gene CG59432-01 and CG59432-02 was assessed using the primer-110 probe set Ag5938, described in Table ASA. Results of the RTQ-PCR runs are shown in Tables ASB and ASC. Please note that CG59432-02 represents a full-length physical clone of CG59432-01 gene, validating the prediction of the gene sequence.  
     [1598] Table ASA. Probe Name Ag5938 
               TABLE ASA                          Probe Name Ag5938                                                 SEQ ID       Primers   Sequences   Length   Start Position   NO:                                         Forward   5′-ttgtgtcagtctataccattaa-3′   22   626   529               Probe   TET-5′-accagcttggcctctgtccagt-3′-TAMRA   22   658   530               Reverse   5′-tcctggagttcagagtatatct-3′   22   710   531                  
 
     [1599]               TABLE ASB                          General_screening_panel_v1.5                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag5938, Run       Ag5938, Run       Tissue Name   248102142   Tissue Name   248102142                                     Adipose   6.3   Renal ca. TK-10   2.7       Melanoma* Hs688(A).T   0.0   Bladder   17.6       Melanoma*   0.0   Gastric ca. (liver met.)   100.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   8.2       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-MEL-5   0.0   Colon ca. SW480   7.5       Squamous cell   21.5   Colon ca.* (SW480   0.6       carcinoma SCC-4       met) SW620       Testis Pool   21.0   Colon ca. HT29   7.1       Prostate ca.* (bone   0.0   Colon ca. HCT-116   11.0       met) PC-3       Prostate Pool   6.9   Colon ca. CaCo-2   25.2       Placenta   0.0   Colon cancer tissue   4.7       Uterus Pool   1.5   Colon ca. SW1116   2.7       Ovarian ca.   20.2   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-OV-3   0.0   Colon ca. SW-48   0.0       Ovarian ca.   0.0   Colon Pool   5.7       OVCAR-4       Ovarian ca.   24.7   Small Intestine Pool   7.6       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   3.2       IGROV-1       Ovarian ca.   2.8   Bone Marrow Pool   6.6       OVCAR-8       Ovary   0.0   Fetal Heart   1.0       Breast ca. MCF-7   4.2   Heart Pool   4.3       Breast ca. MDA-   0.0   Lymph Node Pool   3.8       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   59.9       Breast ca. T47D   0.0   Skeletal Muscle Pool   93.3       Breast ca. MDA-N   0.0   Spleen Pool   3.2       Breast Pool   10.4   Thymus Pool   3.6       Trachea   15.1   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.6   CNS cancer   3.1               (glio/astro) U-118-MG       Fetal Lung   31.6   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.0               539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   3.2   CNS cancer (glio)   3.6               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.0   Brain (Amygdala) Pool   47.3       Lung ca. NCI-H526   32.8   Brain (cerebellum)   15.3       Lung ca. NCI-H23   0.0   Brain (fetal)   1.8       Lung ca. NCI-H460   0.0   Brain (Hippocampus) Pool   15.8       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   27.0       Lung ca. NCI-H522   0.0   Brain (Substantia   25.2               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   29.1       Fetal Liver   7.0   Brain (whole)   9.5       Liver ca. HepG2   0.0   Spinal Cord Pool   11.0       Kidney Pool   6.8   Adrenal Gland   8.4       Fetal Kidney   17.1   Pituitary gland Pool   6.3       Renal ca. 786-0   0.0   Salivary Gland   4.8       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   1.4               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   4.5                    
     [1600]               TABLE ASC                          Panel 5 Islet                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag5938, Run       Ag5938, Run       Tissue Name   248045753   Tissue Name   248045753                                     97457_Patient-   0.0   94709_Donor 2 AM - A_adipose   0.0       02go_adipose       97476_Patient-   0.0   94710_Donor 2 AM - B_adipose   0.0       07sk_skeletal muscle       97477_Patient-   0.0   94711_Donor 2 AM - C_adipose   0.0       07ut_uterus       97478_Patient-   1.1   94712_Donor 2 AD - A_adipose   0.0       07pl_placenta       99167_Bayer Patient 1   0.0   94713_Donor 2 AD - B_adipose   0.0       97482_Patient-   0.0   94714_Donor 2 AD - C_adipose   0.0       08ut_uterus       97483_Patient-   0.0   94742_Donor 3 U -   0.0       08pl_placenta       A_Mesenchymal Stem Cells       97486_Patient-   0.0   94743_Donor 3 U -   0.0       09sk_skeletal muscle       B_Mesenchymal Stem Cells       97487_Patient-   0.0   94730_Donor 3 AM - A_adipose   0.7       09ut_uterus       97488_Patient-   0.5   94731_Donor 3 AM - B_adipose   0.0       09pl_placenta       97492_Patient-   0.0   94732_Donor 3 AM - C_adipose   0.0       10ut_uterus       97493_Patient-   0.4   94733_Donor 3 AD - A_adipose   0.0       10pl_placenta       97495_Patient-   1.0   94734_Donor 3 AD - B_adipose   0.0       11go_adipose       97496_Patient-   2.4   94735_Donor 3 AD - C_adipose   0.0       11sk_skeletal muscle       97497_Patient-   0.0   77138_Liver_HepG2untreated   0.0       11ut_uterus       97498_Patient-   0.0   73556_Heart_Cardiac stromal   0.0       11pl_placenta       cells (primary)       97500_Patient-   0.7   81735_Small Intestine   100.0       12go_adipose       97501_Patient-   6.8   72409_Kidney_Proximal   0.0       12sk_skeletal muscle       Convoluted Tubule       97502_Patient-   0.0   82685_Small   4.6       12ut_uterus       intestine_Duodenum       97503_Patient-   0.0   90650_Adrenal_Adrenocortical   0.0       12pl_placenta       adenoma       94721_Donor 2 U -   0.0   72410_Kidney_HRCE   0.0       A_Mesenchymal       Stem Cells       94722_Donor 2 U -   0.0   72411_Kidney_HRE   0.0       B_Mesenchymal       Stem Cells       94723_Donor 2 U -   6.5   73139_Uterus_Uterine smooth   0.0       C_Mesenchymal       muscle cells       Stem Cells                    
     [1601] General_screening_panel_v1.5 Summary: Ag5938 Highest expression of the CG59432-01 gene is seen in a gastric cancer cell line (CT=32.5). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel. In addition, low expression of this gene is seen in colon cancer CaCo-2, lung cancer NCI-H526, ovarian cancer OVCAR-5, and squamous cell carcinoma SCC-4 cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.  
     [1602] Significant expression is also detected in fetal skeletal muscle and adult skeletal muscle (CT=32.5). At least 50 disease-causing mutations in the skeletal muscle voltage-gated chloride channel gene (CLCN1), almost all of which originate from Caucasian families, have been identified. Therefore, therapeutic modulation of this gene product, a chloride channel homolog, may be a treatment for myotonia congenita and other muscle channelopathies.  
     [1603] In addition, this gene is expressed at low levels in most regions of the central nervous system examined, including amygdala, substantia nigra, thalamus, and cerebral cortex. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     REFERENCES  
     [1604] 1. Sasaki R, Ito N, Shimamura M, Murakami T, Kuzuhara S, Uchino M, Uyama E. A novel CLCN1 mutation: P480T in a Japanese family with Thomsen&#39;s myotonia congenita. Muscle Nerve. March 2001;24(3):357-63.  
     [1605] Panel 5 Islet Summary: Ag5938 Expression of the CG59432-01 is restricted to a sample from small intestine (CT=31.6). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker for this tissue.  
     [1606] AT. CG59383-01: D6MM5E  
     [1607] Expression of gene CG59383-01 was assessed using the primer-probe set Ag3427, described in Table ATA. Results of the RTQ-PCR runs are shown in Tables ATB, ATC and ATD.  
     [1608] Table AJTA. Probe Name Ag3427 
               TABLE ATA                          Probe Name Ag3427                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cagtggaacagaccaagaaca-3′   21   784   532               Probe   TET-5′-tctttcttcacagtgtttcagcaaca-3′-TAMRA   26   817   533               Reverse   5′-ggattatctctgggtctggaa-3′   21   844   534                  
 
     [1609]               TABLE ATB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3427, Run       Ag3427, Run       Tissue Name   210351187   Tissue Name   210351187                                     AD 1 Hippo   11.4   Control (Path) 3   2.0               Temporal Ctx       AD 2 Hippo   50.3   Control (Path) 4   23.3               Temporal Ctx       AD 3 Hippo   10.2   AD 1 Occipital Ctx   9.8       AD 4 Hippo   17.6   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   59.5   AD 3 Occipital Ctx   0.0       AD 6 Hippo   42.9   AD 4 Occipital Ctx   17.0       Control 2 Hippo   21.2   AD 5 Occipital Ctx   25.3       Control 4 Hippo   6.1   AD 6 Occipital Ctx   29.9       Control (Path) 3   15.1   Control 1 Occipital   3.0       Hippo       Ctx       AD 1 Temporal   22.7   Control 2 Occipital   32.3       Ctx       Ctx       AD 2 Temporal   45.1   Control 3 Occipital   26.2       Ctx       Ctx       AD 3 Temporal   6.0   Control 4 Occipital   8.4       Ctx       Ctx       AD 4 Temporal   39.0   Control (Path) 1   84.1       Ctx       Occipital Ctx       AD 5 Inf   100.0   Control (Path) 2   11.7       Temporal Ctx       Occipital Ctx       AD 5 Sup   53.6   Control (Path) 3   0.9       Temporal Ctx       Occipital Ctx       AD 6 Inf   57.0   Control (Path) 4   10.3       Temporal Ctx       Occipital Ctx       AD 6 Sup   58.2   Control 1 Parietal   6.4       Temporal Ctx       Ctx       Control 1   18.8   Control 2 Parietal   48.6       Temporal Ctx       Ctx       Control 2   51.1   Control 3 Parietal   38.7       Temporal Ctx       Ctx       Control 3   16.5   Control (Path) 1   54.7       Temporal Ctx       Parietal Ctx       Control 3   5.5   Control (Path) 2   8.4       Temporal Ctx       Parietal Ctx       Control (Path) 1   82.9   Control (Path) 3   1.4       Temporal Ctx       Parietal Ctx       Control (Path) 2   33.0   Control (Path) 4   16.2       Temporal Ctx       Parietal Ctx                    
     [1610]               TABLE ATC                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3427, Run       Ag3427, Run       Tissue Name   216821480   Tissue Name   216821480                                     Adipose   0.5   Renal ca. TK-10   8.4       Melanoma* Hs688(A).T   0.0   Bladder   1.7       Melanoma*   0.1   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.2   Gastric ca. KATO III   0.3       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.2   Colon ca. SW480   0.4       MEL-5       Squamous cell   14.5   Colon ca.* (SW480   0.1       carcinoma SCC-4       met) SW620       Testis Pool   10.7   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   100.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.1       Placenta   0.2   Colon cancer tissue   1.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   2.9   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-OV-3   50.7   Colon ca. SW-48   0.0       Ovarian ca.   2.1   Colon Pool   0.4       OVCAR-4       Ovarian ca.   1.1   Small Intestine Pool   0.3       OVCAR-5       Ovarian ca.   9.7   Stomach Pool   0.9       IGROV-1       Ovarian ca.   13.7   Bone Marrow Pool   0.4       OVCAR-8       Ovary   0.2   Fetal Heart   0.0       Breast ca. MCF-7   0.1   Heart Pool   0.0       Breast ca. MDA-   0.0   Lymph Node Pool   0.4       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   0.2       Breast ca. T47D   2.1   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   0.2       Breast Pool   1.7   Thymus Pool   1.4       Trachea   1.7   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.4               (glio/astro) U-118-MG       Fetal Lung   0.4   CNS cancer   0.1               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.0               539       Lung ca. LX-1   0.3   CNS cancer (astro)   0.8               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   13.9               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.0   Brain (Amygdala) Pool   1.7       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.9       Lung ca. NCI-H23   0.2   Brain (fetal)   0.1       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   2.2               Pool       Lung ca. HOP-62   0.5   Cerebral Cortex Pool   1.7       Lung ca. NCI-H522   0.1   Brain (Substantia nigra) Pool   1.0       Liver   0.0   Brain (Thalamus) Pool   2.9       Fetal Liver   0.1   Brain (whole)   1.7       Liver ca. HepG2   0.0   Spinal Cord Pool   0.2       Kidney Pool   0.2   Adrenal Gland   0.4       Fetal Kidney   0.8   Pituitary gland Pool   1.3       Renal ca. 786-0   0.1   Salivary Gland   0.6       Renal ca. A498   0.1   Thyroid (female)   1.9       Renal ca. ACHN   0.0   Pancreatic ca.   0.1               CAPAN2       Renal ca. UO-31   0.5   Pancreas Pool   2.3                    
     [1611]               TABLE ATD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3427, Run       Ag3427, Run       Tissue Name   166396769   Tissue Name   166396769                                     Secondary Th1 act   1.4   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.8   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   1.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   2.9   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   4.9   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   2.5   Bronchial epithelium   7.9               TNF alpha + IL-1beta       Primary Th2 rest   2.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.6   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.9   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   5.0       Secondary CD8   1.0   Astrocytes TNF alpha +   2.4       lymphocyte rest       IL-1beta       Secondary CD8   0.8   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   2.0   CCD1106   28.5       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   100.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   23.8       LAK cells IL-2 + IL-12   1.6   Lupus kidney   3.4       LAK cells IL-2 + IFN   3.7   NCI-H292 none   1.8       gamma       LAK cells IL-2 + IL-18   0.9   NCI-H292 IL-4   3.8       LAK cells   0.0   NCI-H292 IL-9   2.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   4.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   1.1       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.9   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   0.7   Lung fibroblast TNF   0.8               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.7       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   3.4   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   4.0   Dermal fibroblast   0.9       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   5.6               CCD1070 TNF alpha       EOL-1 dbcAMP   1.1   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   1.6       Dendritic cells anti-   0.0   IBD Colitis 2   5.9       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   2.4       Monocytes LPS   0.0   Colon   4.1       Macrophages rest   0.0   Lung   1.7       Macrophages LPS   0.0   Thymus   12.4       HUVEC none   0.0   Kidney   10.2       HUVEC starved   0.0                    
     [1612] CNS_neurodegeneration_v1.0 Summary: Ag3427 This panel confirms the expression of CG59383-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1613] General_screening_panel_v1.4 Summary: Ag3427 Highest expression of the CG59383-01 gene is seen in a colon cancer cell line (CT=27.2). Significant expression is also seen in a cluster of samples derived from ovarian cancer cell lines. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker for the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of ovarian or colon cancers.  
     [1614] This molecule is also expressed at low levels in all regions of the CNS examined. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [1615] Among tissues with metabolic function, this gene is expressed at low levels in adipose and pancreas. This expression suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes  
     [1616] Panel 4D Summary: Ag3427 Highest expression of the CG59383-01 gene is seen in keratinocytes treated with the inflammatory cytokines TNF-alpha and IL-1 beta (CT=30.3). Therefore, modulation of the expression or activity of the protein encoded by this transcript through the application of small molecule therapeutics may be useful in the treatment of asthma, COPD, emphysema, psoriasis and wound healing.  
     [1617] AU. CG58526-01: Scramblase  
     [1618] Expression of gene CG358526-01 was assessed using the primer-probe set Ag3366, described in Table AUA. Results of the RTQ-PCR runs are shown in Table AUB.  
     [1619] Table AUA. Probe Name Ag3366 
               TABLE AUA                          Probe Name Ag3366                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tgtcttcacaaatgctgacaat-3′   22   729   535               Probe   TET-5′-ttcggaattcatgttcctgcagatct-3′-TAMRA   26   751   536               Reverse   5′-gatcattgctgctttgactgtt-3′   22   783   537                  
 
     [1620]               TABLE AUB                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3366, Run       Ag3366, Run       Tissue Name   217042585   Tissue Name   217042585                                     Adipose   0.0   Renal ca. TK-10   0.0       Melanoma* Hs688(A).T   0.0   Bladder   0.0       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-MEL-5   0.0   Colon ca. SW480   0.0       Squamous cell   0.0   Colon ca.* (SW480   100.0       carcinoma SCC-4       met) SW620       Testis Pool   69.3   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   25.2       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   43.2       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   0.0       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   49.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   0.0   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   3.9       Breast Pool   0.0   Thymus Pool   0.0       Trachea   0.0   CNS cancer   3.5               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   0.0   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro) SF-   0.0               539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.0   Brain (Amygdala) Pool   12.5       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   0.0   Brain (fetal)   13.8       Lung ca. NCI-H460   0.0   Brain (Hippocampus) Pool   15.0       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   2.6       Lung ca. NCI-H522   0.0   Brain (Substantia   7.5               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   15.7       Fetal Liver   0.0   Brain (whole)   15.2       Liver ca. HepG2   0.0   Spinal Cord Pool   7.5       Kidney Pool   0.0   Adrenal Gland   0.0       Fetal Kidney   0.0   Pituitary gland Pool   22.8       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.0                    
     [1621] CNS_neurodegeneration_v1.0 Summary: Ag3366 Expression of the CG58526-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.) General_screening_panel_v1.4 Summary: Ag3366 Expression of the CG58526-01 gene is restricted to a sample derived from a colon cancer cell line (CT=34.5) and the testis. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of colon cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon cancer.  
     [1622] Panel 4D Summary: Ag3366 Results from one experiment with the CG58526-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [1623] AV. CG57851-01: Sulfotransferase  
     [1624] Expression of gene CG57851-01 was assessed using the primer-probe set Ag3349, described in Table AVA. Results of the RTQ-PCR runs are shown in Tables AVB, AVC and AVD.  
     [1625] Table AVA. Probe Name Ag3349 
               TABLE AVA                          Probe Name Ag3349                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-acaaaatgatggcgatattgag-3′   22   237   538               Probe   TET-5′-cgcttccattcaacttcaacaccct-3′-TAMRA   25   270   539               Reverse   5′-tcattcttatccactccaggaa-3′   22   295   540                  
 
     [1626]               TABLE AVB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3349, Run       Ag3349, Run       Tissue Name   210141483   Tissue Name   210141483                                     AD 1 Hippo   32.8   Control (Path) 3   0.0               Temporal Ctx       AD 2 Hippo   61.6   Control (Path) 4   48.6               Temporal Ctx       AD 3 Hippo   18.0   AD 1 Occipital   10.5               Ctx       AD 4 Hippo   8.9   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   18.0   AD 3 Occipital   0.0               Ctx       AD 6 Hippo   11.7   AD 4 Occipital   0.0               Ctx       Control 2 Hippo   27.4   AD 5 Occipital   8.6               Ctx       Control 4 Hippo   17.9   AD 6 Occipital   0.0               Ctx       Control (Path) 3   12.7   Control 1   0.0       Hippo       Occipital Ctx       AD 1 Temporal Ctx   14.8   Control 2   0.0               Occipital Ctx       AD 2 Temporal Ctx   8.7   Control 3   51.4               Occipital Ctx       AD 3 Temporal Ctx   8.2   Control 4   5.6               Occipital Ctx       AD 4 Temporal Ctx   10.4   Control (Path) 1   100.0               Occipital Ctx       AD 5 Inf Temporal   7.2   Control (Path) 2   17.8       Ctx       Occipital Ctx       AD 5 Sup Temporal   7.4   Control (Path) 3   0.0       Ctx       Occipital Ctx       AD 6 Inf Temporal   9.1   Control (Path) 4   41.2       Ctx       Occipital Ctx       AD 6 Sup Temporal   27.9   Control 1 Parietal   3.3       Ctx       Ctx       Control 1 Temporal   9.2   Control 2 Parietal   70.7       Ctx       Ctx       Control 2 Temporal   25.9   Control 3 Parietal   14.3       Ctx       Ctx       Control 3 Temporal   13.4   Control (Path) 1   35.8       Ctx       Parietal Ctx       Control 4 Temporal   3.7   Control (Path) 2   17.7       Ctx       Parietal Ctx       Control (Path) 1   53.2   Control (Path) 3   0.0       Temporal Ctx       Parietal Ctx       Control (Path) 2   51.1   Control (Path) 4   52.1       Temporal Ctx       Parietal Ctx                    
     [1627]               TABLE AVC                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3349, Run       Ag3349, Run       Tissue Name   215620671   Tissue Name   215620671                                     Adipose   3.6   Renal ca. TK-10   1.9       Melanoma* Hs688(A).T   4.5   Bladder   35.4       Melanoma*   0.3   Gastric ca. (liver met.)   0.4       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.7       Melanoma*   0.5   Colon ca. SW-948   2.8       LOXIMVI       Melanoma* SK-MEL-5   8.0   Colon ca. SW480   10.2       Squamous cell   0.0   Colon ca.* (SW480   13.5       carcinoma SCC-4       met) SW620       Testis Pool   5.4   Colon ca. HT29   0.0       Prostate ca.* (bone   0.8   Colon ca. HCT-116   0.7       met) PC-3       Prostate Pool   15.1   Colon ca. CaCo-2   3.0       Placenta   0.0   Colon cancer tissue   7.0       Uterus Pool   0.4   Colon ca. SW1116   0.2       Ovarian ca.   0.9   Colon ca. Colo-205   0.8       OVCAR-3       Ovarian ca. SK-   18.4   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   5.3       OVCAR-4       Ovarian ca.   10.4   Small Intestine Pool   2.7       OVCAR-5       Ovarian ca.   0.3   Stomach Pool   5.8       IGROV-1       Ovarian ca.   1.3   Bone Marrow Pool   1.7       OVCAR-8       Ovary   5.0   Fetal Heart   2.0       Breast ca. MCF-7   1.0   Heart Pool   2.4       Breast ca. MDA-   1.3   Lymph Node Pool   8.9       MB-231       Breast ca. BT 549   0.4   Fetal Skeletal Muscle   2.7       Breast ca. T47D   9.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   1.6   Spleen Pool   0.4       Breast Pool   10.5   Thymus Pool   10.5       Trachea   1.2   CNS cancer   11.4               (glio/astro) U87-MG       Lung   1.3   CNS cancer   2.4               (glio/astro) U-118-MG       Fetal Lung   7.6   CNS cancer   0.1               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.3   CNS cancer (astro) SF-   0.2               539       Lung ca. LX-1   100.0   CNS cancer (astro)   4.6               SNB-75       Lung ca. NCI-H146   0.8   CNS cancer (glio)   3.1               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   5.3               295       Lung ca. A549   0.8   Brain (Amygdala) Pool   0.4       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.9       Lung ca. NCI-H23   7.1   Brain (fetal)   1.6       Lung ca. NCI-H460   0.8   Brain (Hippocampus) Pool   0.8       Lung ca. HOP-62   2.6   Cerebral Cortex Pool   2.3       Lung ca. NCI-H522   0.4   Brain (Substantia   2.2               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   2.8       Fetal Liver   10.5   Brain (whole)   3.1       Liver ca. HepG2   0.8   Spinal Cord Pool   4.1       Kidney Pool   7.9   Adrenal Gland   2.4       Fetal Kidney   47.3   Pituitary gland Pool   1.4       Renal ca. 786-0   2.6   Salivary Gland   1.4       Renal ca. A498   0.9   Thyroid (female)   0.9       Renal ca. ACHN   1.3   Pancreatic ca.   3.7               CAPAN2       Renal ca. UO-31   2.8   Pancreas Pool   9.3                    
     [1628]               TABLE AVD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3349, Run       Ag3349, Run       Tissue Name   165222879   Tissue Name   165222879                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.8   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   2.3               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   2.3               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.6               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL-1beta       Primary Th2 rest   0.7   Small airway epithelium   0.4               none       Primary Tr1 rest   0.0   Small airway epithelium   2.1               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.6       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   1.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.6       CD95 CH11       (Keratinocytes) none       LAK cells rest   1.4   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   3.3       LAK cells IL-2 + IL-12   0.0   Lupus kidney   5.8       LAK cells IL-2 + IFN   1.0   NCI-H292 none   0.6       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   1.3   NCI-H292 IL-9   1.5       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.8       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.3       Two Way MLR 5 day   0.0   HPAEC none   0.7       Two Way MLR 7 day   1.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   0.6               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.9       Ramos (B cell)   0.6   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.6       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.8               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   7.4   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   2.1   Dermal fibroblast IL-4   0.7       Dendritic cells anti-   2.9   IBD Colitis 2   0.0       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   1.3   Colon   0.6       Macrophages rest   0.9   Lung   0.7       Macrophages LPS   0.2   Thymus   100.0       HUVEC none   0.0   Kidney   1.7       HUVEC starved   0.0                    
     [1629] CNS_neurodegeneration_v1.0 Summary: Ag3349 This panel confirms the expression of CG57851-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. The expression of this gene in the brain suggests that therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [1630] General_screening_panel_v1.4 Summary: Ag3349 Highest expression of the CG57851-01 gene is seen in a lung cancer cell line (CT=30). Thus, expression of this gene may be used to differentiate between this sample and other samples on this panel and as a marker for lung cancer. This gene encodes a sulfotransferase homolog. Sulfotransferases are involved in the metabolism of drugs and endogenous compounds in the body and also synthesize the complex glycoproteins found on the cell surface of cancer cells. Therefore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung cancer.  
     [1631] Among tissues with metabolic function, this gene is expressed at moderate to low levels in adipose and pancreas. This expression among these tissues suggests that this gene product may play a role in normal metabolic function and that disregulated expression of this gene may contribute to metabolic diseases, such as obesity and diabetes.  
     [1632] Panel 4D Summary: Ag3349 Highest expression of the CG57851-01 gene is seen in the thymus (CT=29.7). The putative protein encoded by this gene could therefore play an important role in T cell development. Small molecule therapeutics designed against the protein encoded by this gene could be utilized to modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitution.  
     [1633] Panel 5 Islet Summary: Ag3349 Expression of the CG57851-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1634] AW. CG59258-01: KIAA1608 Protein  
     [1635] Expression of gene CG59258-01 was assessed using the primer-probe set Ag3520, described in Table AWA.  
     [1636] Table AWA. Probe Name Ag3520 
               TABLE AWA                          Probe Name Ag3520                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cctcacagatgaggacacaga-3′   21   717   541               Probe   TET-5′acttgcttgccaaagtcactcagcaa-3′-TAMRA   26   752   542               Reverse   5′-tttctgagagccagacagacat-3′   22   781   543                  
 
     [1637] CNS_neurodegeneration_v1.0 Summary: Ag3520 Expression of the CG59258-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1638] General_screening_panel_v1.4 Summary: Ag3520 Expression of the CG59258-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1639] Panel 4D Summary: Ag3520 Expression of the CG59258-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1640] AX. CG59564-01: Sorting Nexin 6  
     [1641] Expression of gene CG59564-01 was assessed using the primer-probe set Ag3471, described in Table AXA. Results of the RTQ-PCR runs are shown in Tables AXB, AXC and AXD.  
     [1642] Table AXA. Probe Name Ag3471 
               TABLE AXA                          Probe Name Ag3471                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gtgcctggcagacgattata-3′   20   820   544               Probe   TET-5′-ctatctcagctgcgctgagcagtctg-3′-TAMRA   26   843   545               Reverse   5′-gtccttagctggttgacttcct-3′   22   876   546                  
 
     [1643]               TABLE AXB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3471, Run       Ag3471, Run       Tissue Name   210376963   Tissue Name   210376963                                     AD 1 Hippo   10.8   Control (Path) 3   2.4               Temporal Ctx       AD 2 Hippo   27.0   Control (Path) 4   28.5               Temporal Ctx       AD 3 Hippo   5.9   AD 1 Occipital Ctx   10.3       AD 4 Hippo   10.8   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   64.6   AD 3 Occipital Ctx   3.6       AD 6 Hippo   43.8   AD 4 Occipital Ctx   30.4       Control 2 Hippo   56.3   AD 5 Occipital Ctx   100.0       Control 4 Hippo   4.0   AD 6 Occipital Ctx   14.5       Control (Path) 3   2.3   Control 1 Occipital   1.1       Hippo       Ctx       AD 1 Temporal   11.5   Control 2 Occipital   82.9       Ctx       Ctx       AD 2 Temporal   36.3   Control 3 Occipital   13.3       Ctx       Ctx       AD 3 Temporal   4.7   Control 4 Occipital   5.4       Ctx       Ctx       AD 4 Temporal   27.9   Control (Path) 1   87.7       Ctx       Occipital Ctx       AD 5 Inf   85.9   Control (Path) 2   10.3       Temporal Ctx       Occipital Ctx       AD 5 Sup   37.1   Control (Path) 3   1.5       Temporal Ctx       Occipital Ctx       AD 6 Inf   46.3   Control (Path) 4   12.2       Temporal Ctx       Occipital Ctx       AD 6 Sup   52.1   Control 1 Parietal   3.1       Temporal Ctx       Ctx       Control 1   3.6   Control 2 Parietal   38.4       Temporal Ctx       Ctx       Control 2   81.2   Control 3 Parietal   17.4       Temporal Ctx       Ctx       Control 3   19.1   Control (Path) 1   88.9       Temporal Ctx       Parietal Ctx       Control 3   8.0   Control (Path) 2   22.2       Temporal Ctx       Parietal Ctx       Control (Path) 1   88.9   Control (Path) 3   1.7       Temporal Ctx       Parietal Ctx       Control (Path) 2   48.0   Control (Path) 4   38.7       Temporal Ctx       Parietal Ctx                    
     [1644]               TABLE AXC                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3471, Run       Ag3471, Run       Tissue Name   222691297   Tissue Name   222691297                                     Adipose   2.3   Renal ca. TK-10   2.7       Melanoma* Hs688(A).T   3.1   Bladder   4.2       Melanoma*   4.2   Gastric ca. (liver met.)   6.3       Hs688(B).T       NCI-N87       Melanoma* M14   13.0   Gastric ca. KATO III   4.1       Melanoma*   0.7   Colon ca. SW-948   0.7       LOXIMVI       Melanoma* SK-MEL-5   0.8   Colon ca. SW480   2.6       Squamous cell   1.5   Colon ca.* (SW480   4.5       carcinoma SCC-4       met) SW620       Testis Pool   6.2   Colon ca. HT29   2.2       Prostate ca.* (bone   3.8   Colon ca. HCT-116   3.9       met) PC-3       Prostate Pool   0.7   Colon ca. CaCo-2   3.5       Placenta   2.3   Colon cancer tissue   1.0       Uterus Pool   0.7   Colon ca. SW1116   1.9       Ovarian ca.   5.3   Colon ca. Colo-205   0.6       OVCAR-3       Ovarian ca. SK-   2.1   Colon ca. SW-48   2.3       OV-3       Ovarian ca.   2.8   Colon Pool   7.0       OVCAR-4       Ovarian ca.   5.8   Small Intestine Pool   5.8       OVCAR-5       Ovarian ca.   5.3   Stomach Pool   5.5       IGROV-1       Ovarian ca.   3.0   Bone Marrow Pool   3.5       OVCAR-8       Ovary   7.1   Fetal Heart   1.7       Breast ca. MCF-7   2.2   Heart Pool   3.1       Breast ca. MDA-   2.4   Lymph Node Pool   9.5       MB-231       Breast ca. BT 549   98.6   Fetal Skeletal Muscle   1.4       Breast ca. T47D   8.4   Skeletal Muscle Pool   4.2       Breast ca. MDA-N   4.5   Spleen Pool   1.8       Breast Pool   7.5   Thymus Pool   6.2       Trachea   2.7   CNS cancer   7.0               (glio/astro) U87-MG       Lung   1.9   CNS cancer   4.9               (glio/astro) U-118-MG       Fetal Lung   13.4   CNS cancer   11.3               (neuro; met) SK-N-AS       Lung ca. NCI-N417   2.2   CNS cancer (astro) SF-   1.9               539       Lung ca. LX-1   2.2   CNS cancer (astro)   23.8               SNB-75       Lung ca. NCI-H146   2.1   CNS cancer (glio)   3.6               SNB-19       Lung ca. SHP-77   3.7   CNS cancer (glio) SF-   11.3               295       Lung ca. A549   3.7   Brain (Amygdala) Pool   22.1       Lung ca. NCI-H526   2.5   Brain (cerebellum)   42.9       Lung ca. NCI-H23   17.6   Brain (fetal)   100.0       Lung ca. NCI-H460   1.8   Brain (Hippocampus) Pool   26.6       Lung ca. HOP-62   3.6   Cerebral Cortex Pool   33.0       Lung ca. NCI-H522   5.7   Brain (Substantia   29.3               nigra) Pool       Liver   0.1   Brain (Thalamus) Pool   37.4       Fetal Liver   1.3   Brain (whole)   55.1       Liver ca. HepG2   1.3   Spinal Cord Pool   7.7       Kidney Pool   10.6   Adrenal Gland   1.5       Fetal Kidney   6.7   Pituitary gland Pool   0.6       Renal ca. 786-0   0.9   Salivary Gland   0.8       Renal ca. A498   0.8   Thyroid (female)   0.8       Renal ca. ACHN   2.1   Pancreatic ca.   3.0               CAPAN2       Renal ca. UO-31   3.4   Pancreas Pool   7.4                    
     [1645]               TABLE AXD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3471, Run       Ag3471, Run       Tissue Name   166417126   Tissue Name   166417126                                     Secondary Th1 act   10.2   HUVEC IL-1beta   2.3       Secondary Th2 act   11.2   HUVEC IFN gamma   7.8       Secondary Tr1 act   19.2   HUVEC TNF alpha +   4.7               IFN gamma       Secondary Th1 rest   28.7   HUVEC TNF alpha +   6.3               IL4       Secondary Th2 rest   18.4   HUVEC IL-11   6.2       Secondary Tr1 rest   24.5   Lung Microvascular EC   6.4               none       Primary Th1 act   8.7   Lung Microvascular EC   7.1               TNF alpha + IL-1beta       Primary Th2 act   20.4   Microvascular Dermal   6.9               EC none       Primary Tr1 act   31.0   Microsvasular Dermal   2.5               EC TNF alpha + IL-1beta       Primary Th1 rest   45.7   Bronchial epithelium   2.6               TNF alpha + IL1beta       Primary Th2 rest   23.3   Small airway epithelium   3.1               none       Primary Tr1 rest   25.3   Small airway epithelium   3.3               TNF alpha + IL-1beta       CD45RA CD4   9.7   Coronery artery SMC rest   3.9       lymphocyte act       CD45RO CD4   23.2   Coronery artery SMC   4.6       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   9.0   Astrocytes rest   12.7       Secondary CD8   24.8   Astrocytes TNF alpha +   18.9       lymphocyte rest       IL-1beta       Secondary CD8   19.9   KU-812 (Basophil) rest   26.2       lymphocyte act       CD4 lymphocyte none   10.6   KU-812 (Basophil)   50.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   22.7   CCD1106   6.9       CD95 CH11       (Keratinocytes) none       LAK cells rest   6.4   CCD1106   10.9               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   27.5   Liver cirrhosis   15.3       LAK cells IL-2 + IL-12   21.3   Lupus Kidney   4.2       LAK cells IL-2 + IFN   27.4   NCI-H292 none   5.8       gamma       LAK cells IL-2 + IL-18   22.7   NCI-H292 IL-4   7.2       LAK cells   8.2   NCI-H292 IL-9   3.6       PMA/ionomycin       NK Cells IL-2 rest   13.6   NCI-H292 IL-13   3.7       Two Way MLR 3 day   23.7   NCI-H292 IFN gamma   3.2       Two Way MLR 5 day   5.6   HPAEC none   3.7       Two Way MLR 7 day   7.7   HPAEC TNF alpha + IL-   2.3               1beta       PBMC rest   6.1   Lung fibroblast none   18.3       PBMC PWM   7.3   Lung fibroblast TNF   20.6               alpha + IL-1beta       PBMC PHA-L   7.1   Lung fibroblast IL-4   16.6       Ramos (B cell) none   6.3   Lung fibroblast IL-9   9.2       Ramos (B cell)   3.2   Lung fibroblast IL-13   7.9       ionomycin       B lymphocytes PWM   12.2   Lung fibroblast IFN   6.2               gamma       B lymphocytes CD40L   11.1   Dermal fibroblast   11.4       and IL-4       CCD1070 rest       EOL-1 dbcAMP   7.4   Dermal fibroblast   28.5               CCD1070 TNF alpha       EOL-1 dbcAMP   12.5   Dermal fibroblast   7.2       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   13.4   Dermal fibroblast IFN   6.9               gamma       Dendritic cells LPS   14.0   Dermal Fibroblasts IL-4   12.8       Dendritic cells anti-   15.9   IBD Colitis 2   1.7       CD40       Monocytes rest   21.3   IBD Crohn&#39;s   4.8       Monocytes LPS   11.4   Colon   100.0       Macrophages rest   23.5   Lung   12.6       Macrophages LPS   3.7   Thymus   8.9       HUVEC none   6.7   Kidney   34.4       HUVEC starved   11.0                    
     [1646] CNS_neurodegeneration_v1.0 Summary: Ag3471 This panel does not show differential expression of the CG59564-01 gene in Alzheimer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.  
     [1647] General_screening_panel_v1.4 Summary: Ag3471 The CG59564-01 gene, a sorting nexin homolog, shows highly brain preferential expression. Moderate levels of expression are seen in all brain regions examined, with highest expression in the fetal brain (CT=28.5). Thus, this gene would be useful for distinguishing brain tissue from non-neural tissue, and may be beneficial as a drug target in neurologic disease, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [1648] Among tissues with metabolic function, this gene is expressed at low levels in pituitary, adipose, adrenal gland, pancreas, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [1649] In addition, this gene is expressed at significant levels in a breast cancer cell line (CT=28.6). Thus, expression of this gene could be used to differentiate this sample from other samples on this panel and as a marker for breast cancer.  
     [1650] Panel 4D Summary: Ag3471 The CG59564-01 gene, a sorting nexin homolog, is most highly expressed in normal colon (CT=30). In addition, this gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1651] AY. CG59553-01: Secretory Protein SEC8  
     [1652] Expression of gene CG59553-01 was assessed using the primer-probe set Ag3465, described in Table AYA. Results of the RTQ-PCR runs are shown in Tables AYB, AYC and AYD.  
     [1653] Table AYA. Probe Name Ag3465 
               TABLE AYA                          Probe Name Ag3465                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ttcacagcaagaagatgaacct-3′   22   616   547               Probe   TET-5′-tcatagatgaactacaccggcacctg-3′-TAMRA   26   649   548               Reverse   5′-ctcggctagtcgatttgatgt-3′   21   676   549                  
 
     [1654]               TABLE AYB                          CNS_neurodegeneration_v1.0                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3465, Run       Ag3465, Run       Tissue Name   210376516   Tissue Name   210376516                                     AD 1 Hippo   21.3   Control (Path) 3   8.2               Temporal Ctx       AD 2 Hippo   33.0   Control (Path) 4   40.9               Temporal Ctx       AD 3 Hippo   11.0   AD 1 Occipital Ctx   20.7       AD 4 Hippo   11.6   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   87.7   AD 3 Occipital Ctx   10.3       AD 6 Hippo   46.7   AD 4 Occipital Ctx   24.8       Control 2 Hippo   29.7   AD 5 Occipital Ctx   40.6       Control 4 Hippo   20.4   AD 6 Occipital Ctx   25.3       Control (Path) 3   14.2   Control 1 Occipital   6.7       Hippo       Ctx       AD 1 Temporal   21.3   Control 2 Occipital   59.9       Ctx       Ctx       AD 2 Temporal   38.7   Control 3 Occipital   21.8       Ctx       Ctx       AD 3 Temporal   8.2   Control 4 Occipital   11.8       Ctx       Ctx       AD 4 Temporal   30.8   Control (Path) 1   79.6       Ctx       Occipital Ctx       AD 5 Inf    100.0   Control (Path) 2   18.8       Temporal Ctx       Occipital Ctx       AD 5 Sup   58.2   Control (Path) 3   4.0       Temporal Ctx       Occipital Ctx       AD 6 Inf    47.6   Control (Path) 4   25.7       Temporal Ctx       Occipital Ctx       AD 6 Sup   52.1   Control 1 Parietal   14.2       Temporal Ctx       Ctx       Control 1   11.8   Control 2 Parietal   56.6       Temporal Ctx       Ctx       Control 2   42.0   Control 3 Parietal   23.8       Temporal Ctx       Ctx       Control 3   22.8   Control (Path) 1   75.3       Temporal Ctx       Parietal Ctx       Control 3   14.0   Control (Path) 2   29.7       Temporal Ctx       Parietal Ctx       Control (Path) 1   64.6   Control (Path) 3   8.5       Temporal Ctx       Parietal Ctx       Control (Path) 2   47.0   Control (Path) 4   52.9       Temporal Ctx       Parietal Ctx                    
     [1655]               TABLE AYC                          General_screening_panel_v1.4                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3465, Run       Ag3465, Run       Tissue Name   217118990   Tissue Name   217118990                                     Adipose   13.1   Renal ca. TK-10   60.7       Melanoma* Hs688(A).T   22.5   Bladder   37.9       Melanoma*   30.1   Gastric ca. (liver met.)   42.9       Hs688(B).T       NCI-N87       Melanoma* M14   54.7   Gastric ca. KATO III   48.0       Melanoma*   15.5   Colon ca. SW-948   5.5       LOXIMVI       Melanoma* SK-MEL-5   42.0   Colon ca. SW480   57.4       Squamous cell   8.7   Colon ca.* (SW480   37.4       carcinoma SCC-4       met) SW620       Testis Pool   12.8   Colon ca. HT29   25.0       Prostate ca.* (bone   63.7   Colon ca. HCT-116   28.3       met) PC-3       Prostate Pool   13.0   Colon ca. CaCo-2   46.7       Placenta   7.1   Colon cancer tissue   26.4       Uterus Pool   12.0   Colon ca. SW1116   8.6       Ovarian ca.   37.4   Colon ca. Colo-205   6.9       OVCAR-3       Ovarian ca. SK-   21.5   Colon ca. SW-48   7.5       OV-3       Ovarian ca.   26.1   Colon Pool   21.8       OVCAR-4       Ovarian ca.   42.0   Small Intestine Pool   25.5       OVCAR-5       Ovarian ca.   23.5   Stomach Pool   15.4       IGROV-1       Ovarian ca.   24.7   Bone Marrow Pool   9.4       OVCAR-8       Ovary   14.0   Fetal Heart   6.9       Breast ca. MCF-7   38.4   Heart Pool   11.1       Breast ca. MDA-   49.0   Lymph Node Pool   23.8       MB-231       Breast ca. BT 549   45.4   Fetal Skeletal Muscle   11.9       Breast ca. T47D   74.7   Skeletal Muscle Pool   26.2       Breast ca. MDA-N   20.4   Spleen Pool   39.2       Breast Pool   22.8   Thymus Pool   39.8       Trachea   15.4   CNS cancer   100.0               (glio/astro) U87-MG       Lung   6.8   CNS cancer   54.7               (glio/astro) U-118-MG       Fetal Lung   41.5   CNS cancer   50.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   12.2   CNS cancer (astro) SF-   19.3               539       Lung ca. LX-1   26.1   CNS cancer (astro)   75.3               SNB-75       Lung ca. NCI-H146   12.6   CNS cancer (glio)   23.8               SNB-19       Lung ca. SHP-77   33.9   CNS cancer (glio) SF-   95.3               295       Lung ca. A549   43.8   Brain (Amygdala) Pool   11.6       Lung ca. NCI-H526   7.6   Brain (cerebellum)   12.2       Lung ca. NCI-H23   78.5   Brain (fetal)   32.5       Lung ca. NCI-H460   25.0   Brain (Hippocampus) Pool   12.7       Lung ca. HOP-62   28.5   Cerebral Cortex Pool   15.8       Lung ca. NCI-H522   25.0   Brain (Substantia   11.7               nigra) Pool       Liver   2.0   Brain (Thalamus) Pool   17.7       Fetal Liver   18.7   Brain (whole)   15.6       Liver ca. HepG2   15.5   Spinal Cord Pool   12.5       Kidney Pool   36.6   Adrenal Gland   17.7       Fetal Kidney   26.8   Pituitary gland Pool   6.0       Renal ca. 786-0   55.5   Salivary Gland   7.0       Renal ca. A498   19.8   Thyroid (female)   6.6       Renal ca. ACHN   31.0   Pancreatic ca.   40.3               CAPAN2       Renal ca. UO-31   48.0   Pancreas Pool   28.7                    
     [1656]               TABLE AYD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3465, Run       Ag3465, Run       Tissue Name   166417102   Tissue Name   166417102                                     Secondary Th1 act   22.1   HUVEC IL-1beta   14.6       Secondary Th2 act   33.9   HUVEC IFN gamma   17.8       Secondary Tr1 act   44.4   HUVEC TNF alpha +   10.6               IFN gamma       Secondary Th1 rest   33.4   HUVEC TNF alpha +   8.3               IL4       Secondary Th2 rest   25.0   HUVEC IL-11   8.2       Secondary Tr1 rest   29.7   Lung Microvascular EC   12.3               none       Primary Th1 act   14.3   Lung Microvascular EC   14.8               TNF alpha + IL-1beta       Primary Th2 act   41.2   Microvascular Dermal   15.5               EC none       Primary Tr1 act   46.7   Microsvasular Dermal   14.7               EC TNF alpha + IL-1beta       Primary Th1 rest   88.9   Bronchial epithelium   15.5               TNF alpha + IL1beta       Primary Th2 rest   39.2   Small airway epithelium   14.0               none       Primary Tr1 rest   31.0   Small airway epithelium   65.5               TNF alpha + IL-1beta       CD45RA CD4   20.6   Coronery artery SMC rest   18.3       lymphocyte act       CD45RO CD4   29.9   Coronery artery SMC   12.5       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   23.0   Astrocytes rest   28.7       Secondary CD8   24.1   Astrocytes TNF alpha +   31.6       lymphocyte rest       IL-1beta       Secondary CD8   18.7   KU-812 (Basophil) rest   19.8       lymphocyte act       CD4 lymphocyte none   19.5   KU-812 (Basophil)   42.6               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   37.4   CCD1106   21.8       CD95 CH11       (Keratinocytes) none       LAK cells rest   17.1   CCD1106   100.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   35.8   Liver cirrhosis   16.5       LAK cells IL-2 + IL-12   32.3   Lupus kidney   23.5       LAK cells IL-2 + IFN   38.4   NCI-H292 none   48.6       gamma       LAK cells IL-2 + IL-18   32.5   NCI-H292 IL-4   45.1       LAK cells   12.0   NCI-H292 IL-9   49.7       PMA/ionomycin       NK Cells IL-2 rest   24.7   NCI-H292 IL-13   26.4       Two Way MLR 3 day   31.4   NCI-H292 IFN gamma   25.3       Two Way MLR 5 day   19.6   HPAEC none   17.9       Two Way MLR 7 day   14.9   HPAEC TNF alpha + IL-   20.2               1beta       PBMC rest   18.4   Lung fibroblast none   39.2       PBMC PWM   18.7   Lung fibroblast TNF   32.8               alpha + IL-1beta       PBMC PHA-L   10.2   Lung fibroblast IL-4   28.3       Ramos (B cell) none   61.6   Lung fibroblast IL-9   20.4       Ramos (B cell)   46.7   Lung fibroblast IL-13   19.5       ionomycin       B lymphocytes PWM   28.1   Lung fibroblast IFN   26.6               gamma       B lymphocytes CD40L   44.8   Dermal fibroblast   26.8       and IL-4       CCD1070 rest       EOL-1 dbcAMP   33.2   Dermal fibroblast   50.7               CCD1070 TNF alpha       EOL-1 dbcAMP   25.5   Dermal fibroblast   18.4       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   30.1   Dermal fibroblast IFN   19.2               gamma       Dendritic cells LPS   19.1   Dermal fibroblast IL-4   34.6       Dendritic cells anti-   33.7   IBD Colitis 2   9.0       CD40       Monocytes rest   25.0   IBD Crohn&#39;s   12.4       Monocytes LPS   16.3   Colon   56.3       Macrophages rest   44.4   Lung   16.4       Macrophages LPS   14.4   Thymys   49.3       HUVEC none   20.4   Kidney   52.1       HUVEC starved   37.1                    
     [1657] CNS_neurodegeneration_v1.0 Summary: Ag3465 This panel does not show differential expression of the CG59553-01 gene in Alzheimer&#39;s disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.  
     [1658] General_screening_panel_v1.4 Summary: Ag3465 Highest expression of the CG59553-01 gene is seen in a brain cancer cell line (CTs=24). Expression of this gene is ubiquitous throughout this panel, with significant levels of expression in clusters of cell lines derived from brain, renal, colon, lung, breast, ovarian, and melanoma cancers. These high levels of expression in all the samples on this panel suggest a role for this gene in cell growth and proliferation.  
     [1659] This molecule is also expressed at high levels in all regions of the CNS examined. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [1660] Among tissues with metabolic function, this gene is expressed at high to moderate levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [1661] Panel 4D Summary: Ag3465 The CG59553-01 gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1662] AZ. CG59435-01 and CG59435-02: Human Nedd1  
     [1663] Expression of gene CG59435-01 and CG59435-02 was assessed using the primer-probe set Ag3437, described in Table AZA. Results of the RTQ-PCR runs are shown in Tables AZB, AZC and AZD. Please note that CG59435-02 represents a full-length physical clone of the CG59435-01 gene, validating the prediction of the gene sequence.  
     [1664] Table AZA. Probe Name Ag3437 
               TABLE AZA                          Probe Name Ag3437                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tggtgctgaaagtggaaatc-3′   20   1536   550               Probe   TET-5′-cctctccatcatctaaccaaacaaga-3′-TAMRA   26   1562   1551               Reverse   5′-tgggcttcaatttcattctct-3′   21   1611   552                  
 
     [1665]               TABLE AZB                          CNS_neurodegeneration_v1.0                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3437,       Ag3437,           Run       Run       Tissue Name   210374394   Tissue Name   210374394                                     AD 1 Hippo   8.9   Control (Path) 3   6.9               Temporal Ctx       AD 2 Hippo   25.7   Control (Path) 4   27.9               Temporal Ctx       AD 3 Hippo   18.2   AD 1 Occipital   26.6               Ctx       AD 4 Hippo   13.2   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   52.9   AD 3 Occipital   7.6               Ctx       AD 6 Hippo   100.0   AD 4 Occipital   26.6               Ctx       Control 2 Hippo   26.1   AD 5 Occipital   26.8               Ctx       Control 4 Hippo   26.2   AD 6 Occipital   21.8               Ctx       Control (Path) 3   14.7   Control 1   9.0       Hippo       Occipital Ctx       AD 1 Temporal Ctx   35.8   Control 2   23.5               Occipital Ctx       AD 2 Temporal Ctx   27.7   Control 3   17.8               Occipital Ctx       AD 3 Temporal Ctx   14.6   Control 4   14.6               Occipital Ctx       AD 4 Temporal Ctx   23.3   Control (Path) 1   70.2               Occipital Ctx       AD 5 Inf Temporal   65.5   Control (Path) 2   12.9       Ctx       Occipital Ctx       AD 5 SupTemporal   47.0   Control (Path) 3   4.9       Ctx       Occipital Ctx       AD 6 Inf Temporal   78.5   Control (Path) 4   22.2       Ctx       Occipital Ctx       AD 6 Sup Temporal   92.0   Control 1 Parietal   13.3       Ctx       Ctx       Control 1 Temporal   10.9   Control 2 Parietal   50.0       Ctx       Ctx       Control 2 Temporal   23.5   Control 3 Parietal   13.1       Ctx       Ctx       Control 3 Temporal   17.9   Control (Path) 1   35.4       Ctx       Parietal Ctx       Control 4 Temporal   12.8   Control (Path) 2   26.6       Ctx       Parietal Ctx       Control (Path) 1   37.4   Control (Path) 3   5.4       Temporal Ctx       Parietal Ctx       Control (Path) 2   44.4   Control (Path) 4   29.3       Temporal Ctx       Parietal Ctx                    
     [1666]               TABLE AZC                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3437,       Ag3437,           Run       Run       Tissue Name   217066730   Tissue Name   217066730                                     Adipose   10.0   Renal ca. TK-10   24.0       Melanoma*   25.7   Bladder   18.6       Hs688(A).T       Melanoma*   27.5   Gastric ca. (liver met.)   100.0       Hs688(B).T       NCI-N87       Melanoma* M14   34.9   Gastric ca. KATO III   60.3       Melanoma*   31.9   Colon ca. SW-948   9.7       LOXIMVI       Melanoma* SK-   8.7   Colon ca. SW480   61.6       MEL-5       Squamous cell   24.8   Colon ca.* (SW480   46.3       carcinoma SCC-4       met) SW620       Testis Pool   25.9   Colon ca. HT29   22.7       Prostate ca.* (bone   84.1   Colon ca. HCT-116   72.2       met) PC-3       Prostate Pool   12.3   Colon ca. CaCo-2   32.8       Placenta   0.3   Colon cancer tissue   38.2       Uterus Pool   11.4   Colon ca. SW1116   7.5       Ovarian ca.   33.2   Colon ca. Colo-205   6.7       OVCAR-3       Ovarian ca. SK-   92.7   Colon ca. SW-48   7.1       OV-3       Ovarian ca.   9.7   Colon Pool   27.2       OVCAR-4       Ovarian ca.   26.4   Small Intestine Pool   22.8       OVCAR-5       Ovarian ca.   16.5   Stomach Pool   12.3       IGROV-1       Ovarian ca.   6.5   Bone Marrow Pool   13.5       OVCAR-8       Ovary   7.6   Fetal Heart   21.9       Breast ca. MCF-7   24.3   Heart Pool   11.7       Breast ca. MDA-   84.1   Lymph Node Pool   30.4       MB-231       Breast ca. BT 549   68.3   Fetal Skeletal Muscle   15.2       Breast ca. T47D   52.1   Skeletal Muscle Pool   28.5       Breast ca. MDA-N   18.9   Spleen Pool   15.8       Breast Pool   26.6   Thymus Pool   21.2       Trachea   9.2   CNS cancer   14.0               (glio/astro) U87-MG       Lung   4.9   CNS cancer   91.4               (glio/astro) U-118-MG       Fetal Lung   49.0   CNS cancer   55.5               (neuro; met) SK-N-AS       Lung ca. NCI-N417   4.9   CNS cancer (astro)   14.5               SF-539       Lung ca. LX-1   37.4   CNS cancer (astro)   33.0               SNB-75       Lung ca. NCI-H146   6.8   CNS cancer (glio)   12.5               SNB-19       Lung ca. SHP-77   51.4   CNS cancer (glio)   51.4               SF-295       Lung ca. A549   33.9   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   8.4   Brain (cerebellum)   1.5       Lung ca. NCI-H23   34.4   Brain (fetal)   6.2       Lung ca. NCI-H460   98.6   Brain (Hippocampus)   3.0               Pool       Lung ca. HOP-62   15.2   Cerebral Cortex Pool   3.0       Lung ca. NCI-H522   37.9   Brain (Substantia   3.6               nigra) Pool       Liver   0.4   Brain (Thalamus) Pool   3.9       Fetal Liver   26.8   Brain (whole)   1.1       Liver ca. HepG2   11.3   Spinal Cord Pool   5.0       Kidney Pool   23.2   Adrenal Gland   3.3       Fetal Kidney   42.9   Pituitary gland Pool   4.5       Renal ca. 786-0   41.5   Salivary Gland   0.9       Renal ca. A498   12.9   Thyroid (female)   4.2       Renal ca. ACHN   20.2   Pancreatic ca.   20.7               CAPAN2       Renal ca. UO-31   29.7   Pancreas Pool   19.8                    
     [1667]               TABLE AZD                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3437, Run       Ag3437, Run       Tissue Name   169839068   Tissue Name   169839068                                     Secondary Th1 act   44.8   HUVEC IL-1beta   23.2       Secondary Th2 act   57.8   HUVEC IFN gamma   26.2       Secondary Tr1 act   60.7   HUVEC TNF alpha +   18.6               IFN gamma       Secondary Th1 rest   10.2   HUVEC TNF alpha +   16.7               IL4       Secondary Th2 rest   14.3   HUVEC IL-11   10.9       Secondary Tr1 rest   13.9   Lung Microvascular EC   28.1               none       Primary Th1 act   37.4   Lung Microvascular EC   25.3               TNF alpha + IL-1beta       Primary Th2 act   34.9   Microvascular Dermal   19.9               EC none       Primary Tr1 act   39.0   Microsvasular Dermal   17.3               EC TNF alpha + IL-1beta       Primary Th1 rest   17.8   Bronchial epithelium   20.9               TNF alpha + IL1beta       Primary Th2 rest   14.7   Small airway epithelium   4.9               none       Primary Tr1 rest   23.2   Small airway epithelium   20.4               TNF alpha + IL-1beta       CD45RA CD4   39.0   Coronery artery SMC rest   10.7       lymphocyte act       CD45RO CD4   37.4   Coronery artery SMC   10.7       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   31.9   Astrocytes rest   9.2       Secondary CD8   33.7   Astrocytes TNF alpha +   6.4       lymphocyte rest       IL-1beta       Secondary CD8   21.8   KU-812 (Basophil) rest   36.6       lymphocyte act       CD4 lymphocyte none   10.4   KU-812 (Basophil)   100.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   15.7   CCD1106   21.9       CD95 CH11       (Keratinocytes) none       LAK cells rest   21.8   CCD1106   29.9               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   24.1   Liver cirrhosis   6.0       LAK cells IL-2 + IL-12   33.2   NCI-H292 none   13.0       LAK cells IL-2 + IFN   38.4   NCI-H292 IL-4   25.2       gamma       LAK cells IL-2 + IL-18   33.9   NCI-H292 IL-9   32.8       LAK cells   9.3   NCI-H292 IL-13   26.2       PMA/ionomycin       NK Cells IL-2 rest   27.9   NCI-H292 IFN gamma   37.9       Two Way MLR 3 day   23.2   HPAEC none   13.7       Two Way MLR 5 day   25.3   HPAEC TNF alpha + IL-   30.8               1beta       Two Way MLR 7 day   23.8   Lung fibroblast none   12.1       PBMC rest   9.1   Lung fibroblast TNF   9.5               alpha + IL-1beta       PBMC PWM   25.9   Lung fibroblast IL-4   11.7       PBMC PHA-L   27.7   Lung fibroblast IL-9   19.3       Ramos (B cell) none   23.5   Lung fibroblast IL-13   11.2       Ramos (B cell)   23.0   Lung fibroblast IFN   19.5       ionomycin       gamma       B lymphocytes PWM   36.3   Dermal fibroblast   66.9               CCD1070 rest       B lymphocytes CD40L   21.5   Dermal fibroblast   70.2       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   21.0   Dermal fibroblast   46.3               CCD1070 IL-1beta       EOL-1 dbcAMP   19.8   Dermal fibroblast IFN   17.1       PMA/ionomycin       gamma       Dendritic cells none   10.2   Dermal fibroblast IL-4   21.5       Dendritic cells LPS   10.8   Dermal Fibroblasts rest   8.9       Dendritic cells anti-   9.1   Neutrophils TNFa + LPS   0.5       CD40       Monocytes rest   10.1   Neutrophils rest   5.7       Monocytes LPS   11.6   Colon   5.5       Macrophages rest   13.9   Lung   10.7       Macrophages LPS   15.7   Thymus   39.2       HUVEC none   11.8   Kidney   8.8       HUVEC starved   18.7                    
     [1668] CNS_neurodegeneration_v1.0 Summary: Ag3437 This panel confirms the expression of CG59435-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1669] General_screening_panel_v1.4 Summary: Ag3437 The CG59435-01 is gene is ubiquitously expressed in this panel, with highest expression in a gastric cancer cell line (CT=26.5). In addition, significant levels of expression are evident in cell lines from brain cancer, colon cancer, ovarian cancer, breast cancer, prostate cancer and lung cancer. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.  
     [1670] In addition, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among metabolic tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [1671] In addition, the CG59435-01 gene encodes a homologue of mouse NEDD1 protein. Nedd is an acronym of “neural precursor cell expressed developmentally and down-regulated” (Ref 1) The developmentally regulated mouse gene Nedd1 encodes a protein with similarities to the beta subunit of heterotrimeric GTP-binding proteins that has growth suppressing activity when overexpressed in various cultured cell types. Neddl mRNA is shown to be strongly expressed in early embryonic brain and may play a role in the differentiation-coupled growth arrest in neuronal cells (Ref. 2). The moderate to low levels (CT=30-0.33) in all regions of the central nervous system examined suggest that this gene product may also play a role in the differentiation-coupled growth arrest in neuronal cells. Furthermore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     REFERENCES  
     [1672] 1. Kumar S, Tomooka Y, Noda M. (1992) Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun 185(3):1155-61  
     [1673] 2. Kumar S, Matsuzaki T, Yoshida Y, Noda M. (1994) Molecular cloning and biological activity of a novel developmentally regulated gene encoding a protein with beta-transducin-like structure. J Biol Chem 269(15):11318-26.  
     [1674] Panel 4.1D Summary: Ag3437 The CG59435-01 is gene is ubiquitously expressed in this panel, with highest expression in the basophil cell line KU-812 treated with PMA/ionomycin (CT=27.9). This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1675] BA. CG59439-01 and CG59439-02: Xenobiotic/Medium-Chain Fatty acid:CoA Ligase Form XL-III  
     [1676] Expression of gene CG59439-01 was assessed using the primer-probe set Ag3438, described in Table BAA. Results of the RTQ-PCR runs are shown in Table BAB. Please note that CG59439-02 represents a full-length physical clone of the CG59439-01 gene, validating the prediction of the gene sequence.  
     [1677] Table BAA. Probe Name Ag3438 
               TABLE BAA                          Probe Name Ag3438                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-accccattaaccacttttgg-3′   20   938   553               Probe   TET-5′-tcatctatatatcgaatgattctgcagca-3′-TAMRA   29   964   554               Reverse   5′-gaacctgatgctggtgaaatc-3′   21   994   555                  
 
     [1678]               TABLE BAB                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3438, Run       Ag3438, Run       Tissue Name   198383568   Tissue Name   198383568                                     Secondary Th1 act   4.0   HUVEC IL-1beta   0.0       Secondary Th2 act   100.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   25.9   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   9.4               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   7.0               none       Primary Tr1 rest   0.0   Small airway epithelium   13.8               TNF alpha + IL-1beta       CD45RA CD4   16.3   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   25.9       lymphocyte act       CD4 lymphocyte none   12.9   KU-812 (Basophil)   10.5               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   6.9   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   6.1   Liver cirrhosis   20.4       LAK cells IL-2 + IL-12   7.7   NCI-H292 none   0.0       LAK cells IL-2 + IFN   13.6   NCI-H292 IL-4   6.7       gamma       LAK cells IL-2 + IL-18   14.2   NCI-H292 IL-9   11.7       LAK cells   0.0   NCI-H292 IL-13   25.9       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IFN gamma   17.2       Two Way MLR 3 day   14.9   HPAEC none   0.0       Two Way MLR 5 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       Two Way MLR 7 day   0.0   Lung fibroblast none   0.0       PBMC rest   4.4   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PWM   2.7   Lung fibroblast IL-4   0.0       PBMC PHA-L   21.2   Lung fibroblast IL-9   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-13   0.0       Ramos (B cell)   0.0   Lung fibroblast IFN   0.0       ionomycin       gamma       B lymphocytes PWM   0.0   Dermal fibroblast   0.0               CCD1070 rest       B lymphocytes CD40L   11.1   Dermal fibroblast   0.0       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   12.2   Dermal fibroblast   0.0               CCD1070 IL-1beta       EOL-1 dbcAMP   0.0   Dermal fibroblast IFN   0.0       PMA/ionomycin       gamma       Dendritic cells none   6.9   Dermal fibroblast IL-4   0.0       Dendritic cells LPS   0.0   Dermal Fibroblasts rest   0.0       Dendritic cells anti-   0.0   Neutrophils TNFa + LPS   0.0       CD40       Monocytes rest   6.4   Neutrophils rest   4.8       Monocytes LPS   0.0   Colon   5.5       Macrophages rest   7.0   Lung   0.0       Macrophages LPS   0.0   Thymus   3.6       HUVEC none   0.0   Kidney   22.4       HUVEC starved   0.0                    
     [1679] CNS_neurodegeneration_v1.0 Summary: Ag3438 Expression of the CG59439-02 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1680] General_screening_panel_v1.4 Summary: Ag3438 Results from one experiment with the CG5;9439-02 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [1681] Panel 4.1D Summary: Ag3438 Expression of the CG59439-02 gene is restricted to a sample derived from chronically activated Th2 cells (CT=33).  
     [1682] Panel 41D Summary: Ag3438 Results from one experiment with the CG59439-02 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [1683] BB. CG59354-01 and CG59354-02 and CG59354-03: Phosducin-Like Protein  
     [1684] Expression of gene CG59354-01 and variant CG59354-02 was assessed using the primer-probe set Ag3553, described in Table BBA. Results of the RTQ-PCR runs are shown in Tables BBB, BBC and BBD. Please note that CG59354-03 represents a full-length physical clone of the CG59354-01 gene, validating the prediction of the gene sequence.  
               TABLE BBA                          Probe Name Ag3553                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tctatttccaggtcgctatcct-3′   22   1778   556               Probe   TET-5′-acgcacagatgtcagcaccaagactt-3′-TAMRA   26   1822   557               Reverse   5′-ggaatttggattactcccagaa-3′   22   1852   558                  
 
     [1685]               TABLE BBB                          CNS_neurodegeneration_v1.0                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3553,       Ag3553,           Run       Run       Tissue Name   210641082   Tissue Name   210641082                                     AD 1 Hippo   11.3   Control (Path) 3   3.7               Temporal Ctx       AD 2 Hippo   17.8   Control (Path) 4   19.6               Temporal Ctx       AD 3 Hippo   4.8   AD 1 Occipital   15.6               Ctx       AD 4 Hippo   4.6   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   70.2   AD 3 Occipital   4.5               Ctx       AD 6 Hippo   55.5   AD 4 Occipital   12.5               Ctx       Control 2 Hippo   20.3   AD 5 Occipital   28.7               Ctx       Control 4 Hippo   14.5   AD 6 Occipital   32.1               Ctx       Control (Path) 3   7.0   Control 1 Occipital   3.5       Hippo       Ctx       AD 1 Temporal Ctx   15.1   Control 2 Occipital   51.1               Ctx       AD 2 Temporal Ctx   18.8   Control 3 Occipital   14.4               Ctx       AD 3 Temporal Ctx   3.4   Control 4 Occipital   4.7               Ctx       AD 4 Temporal Ctx   11.7   Control (Path) 1   64.6               Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   8.0       Ctx       Occipital Ctx       AD 5 SupTemporal   50.7   Control (Path) 3   3.9       Ctx       Occipital Ctx       AD 6 Inf Temporal   69.7   Control (Path) 4   11.8       Ctx       Occipital Ctx       AD 6 Sup Temporal   66.9   Control 1 Parietal   7.0       Ctx       Ctx       Control 1 Temporal   4.8   Control 2 Parietal   41.2       Ctx       Ctx       Control 2 Temporal   26.6   Control 3 Parietal   12.0       Ctx       Ctx       Control 3 Temporal   9.1   Control (Path) 1   62.0       Ctx       Parietal Ctx       Control 4 Temporal   7.5   Control (Path) 2   21.6       Ctx       Parietal Ctx       Control (Path) 1   44.8   Control (Path) 3   3.5       Temporal Ctx       Parietal Ctx       Control (Path) 2   24.8   Control (Path) 4   41.8       Temporal Ctx       Parietal Ctx                    
     [1686]               TABLE BBC                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3553,       Ag3553,           Run       Run       Tissue Name   217049381   Tissue Name   217049381                                     Adipose   5.2   Renal ca. TK-10   40.6       Melanoma*   40.3   Bladder   29.9       Hs688(A).T       Melanoma*   31.9   Gastric ca. (liver met.)   39.5       Hs688(B).T       NCI-N87       Melanoma* M14   41.5   Gastric ca. KATO III   55.9       Melanoma*   37.1   Colon ca. SW-948   9.0       LOXIMVI       Melanoma* SK-   25.9   Colon ca. SW480   68.3       MEL-5       Squamous cell   17.9   Colon ca.* (SW480   23.5       carcinoma SCC-4       met) SW620       Testis Pool   5.4   Colon ca. HT29   20.0       Prostate ca.* (bone   31.4   Colon ca. HCT-116   66.0       met) PC-3       Prostate Pool   9.0   Colon ca. CaCo-2   32.8       Placenta   4.0   Colon cancer tissue   17.4       Uterus Pool   5.5   Colon ca. SW1116   4.0       Ovarian ca.   40.1   Colon ca. Colo-205   11.3       OVCAR-3       Ovarian ca. SK-   47.3   Colon ca. SW-48   9.9       OV-3       Ovarian ca.   11.4   Colon Pool   18.4       OVCAR-4       Ovarian ca.   37.9   Small Intestine Pool   11.7       OVCAR-5       Ovarian ca.   25.0   Stomach Pool   14.9       IGROV-1       Ovarian ca.   16.6   Bone Marrow Pool   6.9       OVCAR-8       Ovary   10.2   Fetal Heart   4.6       Breast ca. MCF-7   42.6   Heart Pool   6.6       Breast ca. MDA-   50.7   Lymph Node Pool   21.3       MB-231       Breast ca. BT 549   81.8   Fetal Skeletal Muscle   3.8       Breast ca. T47D   85.9   Skeletal Muscle Pool   6.0       Breast ca. MDA-N   33.0   Spleen Pool   13.9       Breast Pool   17.3   Thymus Pool   11.1       Trachea   16.4   CNS cancer   44.4               (glio/astro) U87-MG       Lung   5.3   CNS cancer   45.4               (glio/astro) U-118-MG       Fetal Lung   33.7   CNS cancer   44.8               (neuro; met) SK-N-AS       Lung ca. NCI-N417   5.8   CNS cancer (astro)   31.0               SF-539       Lung ca. LX-1   22.7   CNS cancer (astro)   100.0               SNB-75       Lung ca. NCI-H146   16.7   CNS cancer (glio)   27.4               SNB-19       Lung ca. SHP-77   59.5   CNS cancer (glio)   59.5               SF-295       Lung ca. A549   41.5   Brain (Amygdala)   8.3               Pool       Lung ca. NCI-H526   5.4   Brain (cerebellum)   8.0       Lung ca. NCI-H23   31.0   Brain (fetal)   23.8       Lung ca. NCI-H460   33.4   Brain (Hippocampus)   10.7               Pool       Lung ca. HOP-62   21.9   Cerebral Cortex Pool   15.1       Lung ca. NCI-H522   17.8   Brain (Substantia   11.0               nigra) Pool       Liver   0.5   Brain (Thalamus) Pool   16.6       Fetal Liver   18.3   Brain (whole)   11.8       Liver ca. HepG2   9.2   Spinal Cord Pool   11.7       Kidney Pool   29.5   Adrenal Gland   6.5       Fetal Kidney   16.2   Pituitary gland Pool   4.7       Renal ca. 786-0   57.0   Salivary Gland   9.2       Renal ca. A498   7.9   Thyroid (female)   8.3       Renal ca. ACHN   20.9   Pancreatic ca.   30.4               CAPAN2       Renal ca. UO-31   29.1   Pancreas Pool   21.3                    
     [1687]               TABLE BBD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3553, Run       Ag3553, Run       Tissue Name   166487505   Tissue Name   166487505                                     Secondary Th1 act   45.4   HUVEC IL-1beta   17.0       Secondary Th2 act   42.9   HUVEC IFN gamma   39.2       Secondary Tr1 act   58.6   HUVEC TNF alpha +   27.4               IFN gamma       Secondary Th1 rest   6.7   HUVEC TNF alpha +   31.4               IL4       Secondary Th2 rest   14.5   HUVEC IL-11   23.7       Secondary Tr1 rest   15.0   Lung Microvascular EC   41.2               none       Primary Th1 act   38.4   Lung Microvascular EC   28.3               TNF alpha + IL-1beta       Primary Th2 act   24.5   Microvascular Dermal   59.0               EC none       Primary Tr1 act   32.8   Microsvasular Dermal   23.5               EC TNF alpha + IL-1beta       Primary Th1 rest   57.0   Bronchial epithelium   21.5               TNF alpha + IL1beta       Primary Th2 rest   43.2   Small airway epithelium   5.8               none       Primary Tr1 rest   39.0   Small airway epithelium   52.5               TNF alpha + IL-1beta       CD45RA CD4   25.5   Coronery artery SMC rest   14.3       lymphocyte act       CD45RO CD4   34.6   Coronery artery SMC   12.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   28.1   Astrocytes rest   18.2       Secondary CD8   30.8   Astrocytes TNF alpha +   11.3       lymphocyte rest       IL-1beta       Secondary CD8   21.9   KU-812 (Basophil) rest   19.6       lymphocyte act       CD4 lymphocyte none   6.0   KU-812 (Basophil)   71.2               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   21.9   CCD1106   31.6       CD95 CH11       (Keratinocytes) none       LAK cells rest   24.8   CCD1106   9.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   32.8   Liver cirrhosis   4.1       LAK cells IL-2 + IL-12   24.0   Lupus kidney   4.0       LAK cells IL-2 + IFN   37.6   NCI-H292 none   35.1       gamma       LAK cells IL-2 + IL-18   27.2   NCI-H292 IL-4   39.2       LAK cells   16.8   NCI-H292 IL-9   49.0       PMA/ionomycin       NK Cells IL-2 rest   23.5   NCI-H292 IL-13   28.7       Two Way MLR 3 day   21.5   NCI-H292 IFN gamma   29.5       Two Way MLR 5 day   16.3   HPAEC none   38.2       Two Way MLR 7 day   17.6   HPAEC TNF alpha + IL-   27.2               1beta       PBMC rest   8.0   Lung fibroblast none   9.4       PBMC PWM   91.4   Lung fibroblast TNF   11.1               alpha + IL-1beta       PBMC PHA-L   33.9   Lung fibroblast IL-4   34.6       Ramos (B cell) none   29.5   Lung fibroblast IL-9   21.3       Ramos (B cell)   85.3   Lung fibroblast IL-13   15.8       ionomycin       B lymphocytes PWM   100.0   Lung fibroblast IFN   39.2               gamma       B lymphocytes CD40L   33.0   Dermal fibroblast   45.1       and IL-4       CCD1070 rest       EOL-1 dbcAMP   35.8   Dermal fibroblast   75.3               CCD1070 TNF alpha       EOL-1 dbcAMP   46.7   Dermal fibroblast   37.4       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   14.3   Dermal fibroblast IFN   15.7               gamma       Dendritic cells LPS   15.2   Dermal fibroblast IL-4   25.9       Dendritic cells anti-   22.2   IBD Colitis 2   1.4       CD40       Monocytes rest   10.4   IBD Crohn&#39;s   1.5       Monocytes LPS   16.7   Colon   16.7       Macrophages rest   27.9   Lung   12.2       Macrophages LPS   5.7   Thymus   28.7       HUVEC none   29.5   Kidney   28.5       HUVEC starved   67.4                    
     [1688] CNS_neurodegeneration_v1.0 Summary: Ag3553 This panel confirms the expression of CG59354-03 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1689] General_screening_panel_v1.4 Summary: Ag3553 The CG59354-03 gene is ubiquitously expressed in this panel, with highest expression in a brain cancer cell line (CT=25.9). In addition, significant levels of expression are seen in cell lines derived from colon, breast, ovarian, renal, lung, prostate, and melanoma cancers. Furthermore, higher levels of expression are seen in fetal liver and lung (CTs=27-28) when compared to expression in the adult tissues (CTs=30-33). The high levels of expression in fetal tissue and cancer cell lines, both of which are highly proliferative, suggests that this gene product may be involved in cell growth and differentiation. Therefore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of cancer.  
     [1690] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases;, such as obesity and diabetes.  
     [1691] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. The CG59354-03 gene encodes a splice variant of phosphoducin-like protein (PHLP). PDCL is a putative modulator of heterotrimeric G proteins. It was initially isolated as the product of an ethanol-responsive gene in neural cell cultures (Ref. 1). PDCL shares extensive amino acid sequence homology with phosducin (PDC), a phosphoprotein expressed in retina and pineal gland that inhibits several G protein-coupled signaling pathways by binding to the beta-gamma subunits, of G proteins. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     REFERENCES  
     [1692] 1. Miles M F, Barhite S, Sganga M, Elliott M. (1993) Phosducin-like protein: an ethanol.-responsive potential modulator of guanine nucleotide-binding protein function. Proc Natl Acad Sci USA 90(22):10831-5  
     [1693] Panel 4D Summary: Ag3553 The CG59354-03 gene is ubiquitously expressed in this panel, with highest expression in B cells treated with polk-weed mitogen (CT=27.2). In addition, this gene is expressd at is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1694] BC. CG59319-01 and CG59319-02: Phosducin-Like Protein  
     [1695] Expression of gene CG59319-01 was assessed using the primer-probe set Ag3544, described in Table BCA. Results of the RTQ-PCR runs are shown in Tables BCB and BCC. Please note that CG59319-02 represents a full-length physical clone of the CG59319-01 gene, validating the prediction of the gene sequence.  
     [1696] Table BCA. Probe Name Ag3544 
               TABLE BCA                          Probe Name Ag3544                                             Start           Primers   Sequences   Length   Position   SEQ ID NO:                                         Forward   5′-tacagatcaagcatcccaatgt-3′   22   347   559               Probe   TET-5′-tggttaaccagcatcttagtcttctagca-3′-TAMRA   29   375   560               Reverse   5′-ttcacgatggctttaacaaatt-3′   22   423   561                  
 
     [1697]               TABLE BCB                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3544,       Ag3544,           Run       Run       Tissue Name   217048127   Tissue Name   217048127                                     Adipose   0.0   Renal ca. TK-10   0.0       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.7       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.2       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.0       MEL-5       Squamous cell   1.4   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   100.0   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.3       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   1.2   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.9   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   0.0       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   0.2   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   0.2   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.3   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   0.0       Breast Pool   0.0   Thymus Pool   0.0       Trachea   0.5   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   0.0   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.3               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio)   0.2               SF-295       Lung ca. A549   0.0   Brain (Amygdala)   0.2               Pool       Lung ca. NCI-H526   1.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   0.0   Brain (fetal)   0.6       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.2       Lung ca. NCI-H522   0.0   Brain (Substantia   0.0               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   0.0       Fetal Liver   0.0   Brain (whole)   0.0       Liver ca. HepG2   0.0   Spinal Cord Pool   0.0       Kidney Pool   0.0   Adrenal Gland   0.0       Fetal Kidney   0.0   Pituitary gland Pool   0.0       Renal ca. 786-0   1.6   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.2       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.0                    
     [1698]               TABLE BCC                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3544, Run       Ag3544, Run       Tissue Name   169850546   Tissue Name   169850546                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   2.6   Bronchial epithelium   0.0               TNF alpha + IL-1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   100.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   61.1               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   0.0       LAK cells IL-2 + IL-12   0.0   NCI-H292 none   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 IL-4   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-9   0.0       LAK cells   0.0   NCI-H292 IL-13   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 3 day   0.0   HPAEC none   0.0       Two Way MLR 5 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       Two Way MLR 7 day   0.0   Lung fibroblast none   0.0       PBMC rest   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PWM   0.0   Lung fibroblast IL-4   0.0       PBMC PHA-L   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-13   0.0       Ramos (B cell)   0.0   Lung fibroblast IFN   0.0       ionomycin       gamma       B lymphocytes PWM   0.0   Dermal fibroblast   0.0               CCD1070 rest       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 IL-1beta       EOL-1 dbcAMP   0.0   Dermal fibroblast IFN   0.0       PMA/ionomycin       gamma       Dendritic cells none   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells LPS   0.0   Dermal fibroblasts rest   0.0       Dendritic cells anti-   0.0   Neutrophils TNFa + LPS   0.0       CD40       Monocytes rest   0.0   Neutrophils rest   0.0       Monocytes LPS   0.0   Colon   0.0       Macrophages rest   0.0   Lung   0.0       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   0.0   Kidney   0.0       HUVEC starved   0.0                    
     [1699] CNS_neurodegeneration_v1.0 Summary: Ag3544 Expression of the CG59319-02 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1700] General_screening_panel_v1.4 Summary: Ag3544 Expression of the CG59319-02 gene is restricted to a sample derived from the testis (CT=29.8). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker of testicular tissue. Furthermore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of male infertility or hypogonadism.  
     [1701] Panel 4.1D Summary: Ag3544 Expression of the CG59319-02 gene is restricted to samples derived from the basophil cell line KU-812 (CTs=32). Thus, expression of this gene could be used as a marker of this cell type. Furthermore, the specific pattern of expression of this gene suggests that therapeutic modulation of the expression or function of the protein encoded by this gene may block or inhibit inflammation or tissue damage due to basophil activation in response to asthma, allergies, hypersensitivity reactions, psoriasis, and viral infections.  
     [1702] BD. CG59576-01: Olfactory Receptor  
     [1703] Expression of gene CG59576-01 was assessed using the primer-probe set Ag3478, described in Table BDA. Results of the RTQ-PCR runs are shown in Table BDB.  
     [1704] Table BDA. Probe Name Ag3478 
               TABLE BDA                          Probe Name Ag3478                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tggaagtgtagccctgatgtac-3′   22   708   562               Probe   TET-5′-tgctcttctctgccaagtactccttt-3′-TAMRA   26   731   563               Reverse   5′-aaacattaggctgatggttgtg-3′   22   765   564                  
 
     [1705]               TABLE BDB                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3478, Run       Ag3478, Run       Tissue Name   166441540   Tissue Name   166441540                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   9.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL-1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   4.6               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   2.6   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   100.0       LAK cells IL-2 + IL-12   0.0   Lupus kidney   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   25.7       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   24.3       Monocytes LPS   0.0   Colon   5.9       Macrophages rest   0.0   Lung   5.8       Macrophages LPS   0.0   Thymus   5.9       HUVEC none   0.0   Kidney   10.2       HUVEC starved   0.0                    
     [1706] CNS_neurodegeneration_v1.0 Summary: Ag3478 Expression of the CG59576-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1707] General_screening_panel_v1.4 Summary: Ag3478 Expression of the CG59576-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1708] General_screening_panel_v1.5 Summary: Ag3478 Expression of the CG59576-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1709] Panel 4D Summary: Ag3478 Expression of the CG59576-01 gene is restricted to a sample derived from liver cirrhosis (CT=32.3). Furthermore, expression of this gene is not detected in normal liver in Panel 1.4, suggesting that its expression is unique to liver cirrhosis. This gene encodes a putative GPCR; therefore, antibodies or small molecule therapeutics could reduce or inhibit fibrosis that occurs in liver cirrhosis. In addition, antibodies to this putative GPCR could also be used for the diagnosis of liver cirrhosis.  
     [1710] Panel 5 Islet Summary: Ag3478 Expression of the CG59576-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1711] BE. CG59557-01: Olfactory Receptor  
     [1712] Expression of gene CG59557-01 was assessed using the primer-probe set Ag3470, described in Table BEA. Results of the RTQ-PCR runs are shown in Table BEB.  
     [1713] Table BEA. Probe Name Ag3470 
               TABLE BEA                          Probe Name Ag3470                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ccaaccttctcagtgaacagaa-3′   22   413   565               Probe   TET-5′-tctctttcataggttgcctcctgca-3′-TAMRA   27   440   566               Reverse   5′-ccgagtgagtggaagaagtaca-3′   22   467   567                  
 
     [1714]               TABLE BEB                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3470, Run       Ag3470, Run       Tissue Name   166417125   Tissue Name   166417125                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   3.2   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   3.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   2.8   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   2.9   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   100.0       LAK cells IL-2 + IL-12   0.0   Lupus kidney   2.2       LAK cells IL-2 + IFN   0.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   3.2   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   5.8   Lung fibroblast none   0.0       PBMC PWM   2.7   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   6.5   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   2.2   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   3.2   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   20.9   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   19.6       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   4.9       Monocytes LPS   6.3   Colon   13.9       Macrophages rest   21.6   Lung   14.8       Macrophages LPS   0.0   Thymus   2.2       HUVEC none   0.0   Kidney   0.0       HUVEC starved   0.0                    
     [1715] CNS_neurodegeneration_v1.0 Summary: Ag3470 Expression of the CG59557-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1716] General_screening_panel_v1.4 Summary: Ag3470 Expression of the CG59557-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [1717] Panel 4D Summary: Ag3470 Expression of the CG59557-01 gene is detected in a liver cirrhosis sample (CT=32.2). Furthermore, expression of this gene is not detected in normal liver in Panel 1.4, suggesting that its expression is unique to liver cirrhosis. This gene encodes a putative GPCR; therefore, antibodies or small molecule therapeutics could reduce or inhibit fibrosis that occurs in liver cirrhosis. In addition, antibodies to this putative GPCR could also be used for the diagnosis of liver cirrhosis.  
     [1718] BF. CG59555-01: Olfactory Receptor  
     [1719] Expression of gene CG59555-01 was assessed using the primer-probe set Ag3467, described in Table BFA. Results of the RTQ-PCR runs are shown in Tables BFB, BFC and BFD.  
     [1720] Table BFA. Probe Name Ag3467 
               TABLE BFA                          Probe Name Ag3467                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ggcaaggaaagtcattcctaa-3′   21   953   568               Probe   TET-5′-tggtgtgacatttgactctccctcct-3′-TAMRA   26   975   569               Reverse   5′-tggtaccaagattccaggagat-3′   22   1006   570                  
 
     [1721]               TABLE BFB                          CNS_neurodegeneration_v1.0                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3467,       Ag3467,           Run       Run       Tissue Name   210376517   Tissue Name   210376517                                     AD 1 Hippo   4.6   Control (Path) 3   14.8               Temporal Ctx       AD 2 Hippo   29.7   Control (Path) 4   15.2               Temporal Ctx       AD 3 Hippo   10.7   AD 1 Occipital   14.5               Ctx       AD 4 Hippo   28.9   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   21.6   AD 3 Occipital   14.5               Ctx       AD 6 Hippo   100.0   AD 4 Occipital   14.8               Ctx       Control 2 Hippo   8.8   AD 5 Occipital   13.7               Ctx       Control 4 Hippo   35.6   AD 6 Occipital   10.3               Ctx       Control (Path) 3   21.9   Control 1 Occipital   18.3       Hippo       Ctx       AD 1 Temporal Ctx   28.3   Control 2 Occipital   7.9               Ctx       AD 2 Temporal Ctx   37.4   Control 3 Occipital   16.2               Ctx       AD 3 Temporal Ctx   7.4   Control 4 Occipital   24.0               Ctx       AD 4 Temporal Ctx   28.3   Control (Path) 1   28.3               Occipital Ctx       AD 5 Inf Temporal   19.3   Control (Path) 2   10.1       Ctx       Occipital Ctx       AD 5 Sup Temporal   33.4   Control (Path) 3   12.6       Ctx       Occipital Ctx       AD 6 Inf Temporal   39.8   Control (Path) 4   14.3       Ctx       Occipital Ctx       AD 6 Sup Temporal   83.5   Control 1 Parietal   8.7       Ctx       Ctx       Control 1 Temporal   14.4   Control 2 Parietal   22.2       Ctx       Ctx       Control 2 Temporal   13.6   Control 3 Parietal   9.8       Ctx       Ctx       Control 3 Temporal   11.8   Control (Path) 1   33.2       Ctx       Parietal Ctx       Control 4 Temporal   16.0   Control (Path) 2   12.4       Ctx       Parietal Ctx       Control (Path) 1   24.3   Control (Path) 3   19.6       Temporal Ctx       Parietal Ctx       Control (Path) 2   6.1   Control (Path) 4   12.9       Temporal Ctx       Parietal Ctx                    
     [1722]               TABLE BFC                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3467,       Ag3467,           Run       Run       Tissue Name   217119371   Tissue Name   217119371                                     Adipose   11.6   Renal ca. TK-10   14.6       Melanoma*   27.0   Bladder   14.1       Hs688(A).T       Melanoma*   27.9   Gastric ca. (liver met.)   3.2       Hs688(B).T       NCI-N87       Melanoma* M14   11.2   Gastric ca. KATO III   2.1       Melanoma*   0.0   Colon ca. SW-948   0.4       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   12.7       MEL-5       Squamous cell   1.8   Colon ca.* (SW480   10.4       carcinoma SCC-4       met) SW620       Testis Pool   7.0   Colon ca. HT29   1.7       Prostate ca.* (bone   15.2   Colon ca. HCT-116   7.9       met) PC-3       Prostate Pool   9.7   Colon ca. CaCo-2   5.3       Placenta   1.7   Colon cancer tissue   3.6       Uterus Pool   5.1   Colon ca. SW1116   0.4       Ovarian ca.   4.1   Colon ca. Colo-205   0.2       OVCAR-3       Ovarian ca. SK-   16.2   Colon ca. SW-48   0.5       OV-3       Ovarian ca.   5.2   Colon Pool   20.6       OVCAR-4       Ovarian ca.   13.9   Small Intestine Pool   26.8       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   19.5       IGROV-1       Ovarian ca.   9.5   Bone Marrow Pool   16.7       OVCAR-8       Ovary   8.4   Fetal Heart   23.5       Breast ca. MCF-7   0.8   Heart Pool   11.2       Breast ca. MDA-   26.2   Lymph Node Pool   31.9       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   7.1       Breast ca. T47D   18.2   Skeletal Muscle Pool   1.8       Breast ca. MDA-N   10.9   Spleen Pool   22.4       Breast Pool   26.6   Thymus Pool   25.9       Trachea   9.5   CNS cancer   0.4               (glio/astro) U87-MG       Lung   12.4   CNS cancer   0.2               (glio/astro) U-118-MG       Fetal Lung   100.0   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   11.6   CNS cancer (astro)   1.5               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   1.1               SNB-19       Lung ca. SHP-77   0.1   CNS cancer (glio)   20.0               SF-295       Lung ca. A549   3.0   Brain (Amygdala)   1.9               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   1.0       Lung ca. NCI-H23   13.9   Brain (fetal)   2.5       Lung ca. NCI-H460   5.4   Brain (Hippocampus)   0.2               Pool       Lung ca. HOP-62   6.7   Cerebral Cortex Pool   1.3       Lung ca. NCI-H522   0.0   Brain (Substantia   1.6               nigra) Pool       Liver   0.1   Brain (Thalamus) Pool   2.5       Fetal Liver   6.6   Brain (whole)   1.1       Liver ca. HepG2   1.4   Spinal Cord Pool   4.5       Kidney Pool   34.4   Adrenal Gland   6.3       Fetal Kidney   76.3   Pituitary gland Pool   4.5       Renal ca. 786-0   28.1   Salivary Gland   1.8       Renal ca. A498   12.1   Thyroid (female)   13.4       Renal ca. ACHN   23.0   Pancreatic ca.   1.0               CAPAN2       Renal ca. UO-31   25.0   Pancreas Pool   27.2                    
     [1723]               TABLE BFD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3467, Run       Ag3467, Run       Tissue Name   166417105   Tissue Name   166417105                                     Secondary Th1 act   2.4   HUVEC IL-1beta   1.5       Secondary Th2 act   5.1   HUVEC IFN gamma   18.2       Secondary Tr1 act   7.2   HUVEC TNF alpha +   6.2               IFN gamma       Secondary Th1 rest   18.2   HUVEC TNF alpha +   1.7               IL4       Secondary Th2 rest   14.6   HUVEC IL-11   1.8       Secondary Tr1 rest   22.1   Lung Microvascular EC   0.6               none       Primary Th1 act   1.3   Lung Microvascular EC   0.3               TNF alpha + IL-1beta       Primary Th2 act   9.0   Microvascular Dermal   0.1               EC none       Primary Tr1 act   7.2   Microsvasular Dermal   0.5               EC TNF alpha + IL-1beta       Primary Th1 rest   100.0   Bronchial epithelium   1.5               TNF alpha + IL1beta       Primary Th2 rest   38.7   Small airway epithelium   1.6               none       Primary Tr1 rest   28.1   Small airway epithelium   6.6               TNF alpha + IL-1beta       CD45RA CD4   1.9   Coronery artery SMC rest   4.5       lymphocyte act       CD45RO CD4   8.7   Coronery artery SMC   5.1       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   4.0   Astrocytes rest   0.4       Secondary CD8   7.5   Astrocytes TNF alpha +   1.7       lymphocyte rest       IL-1beta       Secondary CD8   4.7   KU-812 (Basophil) rest   0.7       lymphocyte act       CD4 lymphocyte none   9.3   KU-812 (Basophil)   3.2               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   52.5   CCD1106   1.5       CD95 CH11       (Keratinocytes) none       LAK cells rest   4.6   CCD1106   16.4               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   15.1   Liver cirrhosis   14.6       LAK cells IL-2 + IL-12   6.5   Lupus kidney   37.6       LAK cells IL-2 + IFN   10.9   NCI-H292 none   4.6       gamma       LAK cells IL-2 + IL-18   6.9   NCI-H292 IL-4   5.2       LAK cells   1.1   NCI-H292 IL-9   5.6       PMA/ionomycin       NK Cells IL-2 rest   3.1   NCI-H292 IL-13   2.3       Two Way MLR 3 day   11.0   NCI-H292 IFN gamma   1.5       Two Way MLR 5 day   6.0   HPAEC none   3.6       Two Way MLR 7 day   6.7   HPAEC TNF alpha + IL-   10.5               1beta       PBMC rest   2.6   Lung fibroblast none   15.3       PBMC PWM   4.2   Lung fibroblast TNF   5.9               alpha + IL-1beta       PBMC PHA-L   3.1   Lung fibroblast IL-4   5.6       Ramos (B cell) none   0.0   Lung fibroblast IL-9   5.6       Ramos (B cell)   0.1   Lung fibroblast IL-13   5.1       ionomycin       B lymphocytes PWM   6.0   Lung fibroblast IFN   7.9               gamma       B lymphocytes CD40L   6.5   Dermal fibroblast   4.5       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   21.6               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   2.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.4   Dermal fibroblast IFN   3.5               gamma       Dendritic cells LPS   0.1   Dermal fibroblast IL-4   6.9       Dendritic cells anti-   0.1   IBD Colitis 2   10.6       CD40       Monocytes rest   1.6   IBD Crohn&#39;s   1.8       Monocytes LPS   1.7   Colon   34.9       Macrophages rest   8.4   Lung   6.7       Macrophages LPS   1.2   Thymus   26.8       HUVEC none   2.6   Kidney   11.3       HUVEC starved   2.8                    
     [1724] CNS_neurodegeneration_v1.0 Summary: Ag3467 The CG59555-01 gene encodes a putative GPCR. It is expressed at low to moderate levels in most of the samples used in this panel. This panel confirms the expression of CG59555-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 10.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1725] General_screening_panel_v1.4 Summary: Ag3467 The CG59555-01 gene encodes a putative GPCR. It is expressed at low to moderate levels in large number of the samples used in this panel. Highest expression of this gene is detected in fetal lung (CT=28). Interestingly, this gene is expressed at much higher levels in fetal (CT=28) when compared to adult lung (CT=31). Therefore, expression of this gene can be used to distinguish fetal lung from adult lung and from other samples used in this panel. In addition, this gene is also expressed at much higher levels in fetal fetal liver (CT=32) as compared to adult liver (CT=38). Thus, expression of this gene can be used to distinguish fetal liver from adult liver.  
     [1726] Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases;, such as obesity and diabetes.  
     [1727] This gene is also expressed at low levels in all regions of the central nervous system examined, including amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Several neurotransmitter receptors are GPCRs, including the dopamine receptor family, the serotonin receptor family, the GABAB receptor, muscarinic acetylcholine receptors, and others; thus this GPCR may represent a novel neurotransmitter receptor. Targeting various neurotransmitter receptors (dopamine, serotonin) has proven to be an effective therapy in psychiatric illnesses such as schizophrenia, bipolar disorder, and depression. Furthermore, the cerebral cortex and hippocampus are regions of the brain that are known to be involved in Alzheimer&#39;s disease, seizure disorders, and in the normal process of memory formation. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1728] Panel 4D Summary: Ag3467 The CG59555-01 gene encodes a putative GPCR. Highest expression of this gene is detected in resting primary Th1 cells (CT=27). This gene is expressed at moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests; that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1729] BG. CG59551-01: Olfactory Receptor  
     [1730] Expression of gene CG59551-01 was assessed using the primer-probe set Ag3463, described in Table BGA. Results of the RTQ-PCR runs are shown in Tables BGB and BGC.  
     [1731] Table BGA. Probe Name Ag3463 
               TABLE BGA                          Probe Name Ag3463                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ctatggtttccagatgtttcca-3′   22   78   571               Probe   5′-tagatgttccagctgcccatctctga-3′-TAMRA   26   105   572               Reverse   5′-attqtqaqacacaqctqqattt-3′   22   132   573                  
 
     [1732]               TABLE BGB                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3463,       Ag3463,           Run       Run       Tissue Name   217067349   Tissue Name   217067349                                     Adipose   0.0   Renal ca. TK-10   9.0       Melanoma*   0.0   Bladder   11.2       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   13.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   43.8   Colon ca. SW480   11.6       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   85.9   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   10.7       met) PC-3       Prostate Pool   7.2   Colon ca. CaCo-2   12.8       Placenta   12.8   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   100.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   11.9   Colon Pool   12.5       OVCAR-4       Ovarian ca.   11.3   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   26.1   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   0.0   Lymph Node Pool   23.2       MB-231       Breast ca. BT 549   20.3   Fetal Skeletal Muscle   82.9       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   31.9   Spleen Pool   0.0       Breast Pool   12.5   Thymus Pool   0.0       Trachea   20.9   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   24.0               (glio/astro) U-118-MG       Fetal Lung   23.7   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   38.2               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   8.8   CNS cancer (glio)   33.2               SF-295       Lung ca. A549   0.0   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   57.4   Brain (fetal)   48.6       Lung ca. NCI-H460   31.2   Brain (Hippocampus)   21.3               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   35.6       Lung ca. NCI-H522   14.4   Brain (Substantia   15.5               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   14.1       Fetal Liver   0.0   Brain (whole)   0.0       Liver ca. HepG2   5.0   Spinal Cord Pool   29.5       Kidney Pool   37.9   Adrenal Gland   14.8       Fetal Kidney   0.0   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   12.2                    
     [1733]               TABLE BGC                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3463, Run       Ag3463, Run       Tissue Name   169839351   Tissue Name   169839351                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   1.3   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   2.6   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   1.4               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.6               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   7.2       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   100.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   1.1               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   1.2       LAK cells IL-2 + IL-12   0.0   NCI-H292 none   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 IL-4   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-9   0.0       LAK cells   0.0   NCI-H292 IL-13   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 3 day   1.3   HPAEC none   1.2       Two Way MLR 5 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       Two Way MLR 7 day   0.0   Lung fibroblast none   1.0       PBMC rest   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PWM   0.0   Lung fibroblast IL-4   0.0       PBMC PHA-L   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell) none   1.3   Lung fibroblast IL-13   0.0       Ramos (B cell)   0.0   Lung fibroblast IFN   0.0       ionomycin       gamma       B lymphocytes PWM   0.0   Dermal fibroblast   0.0               CCD1070 rest       B lymphocytes CD40L   1.2   Dermal fibroblast   0.0       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 IL-1beta       EOL-1 dbcAMP   0.0   Dermal fibroblast IFN   0.0       PMA/ionomycin       gamma       Dendritic cells none   6.1   Dermal fibroblast IL-4   0.0       Dendritic cells LPS   0.0   Dermal Fibroblast rest   0.0       Dendritic cells anti-   1.2   Neutrophils TNFa + LPS   0.0       CD40       Monocytes rest   0.0   Neutrophils rest   0.0       Monocytes LPS   0.0   Colon   0.5       Macrophages rest   4.1   Lung   0.0       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   0.0   Kidney   2.3       HUVEC starved   0.0                    
     [1734] CNS_neurodegeneration_v1.0 Summary: Ag3463  
     [1735] Expression of the CG59551-01 gene is low/undetectable in all the samples on this panel. (Data not shown.)  
     [1736] General_screening_panel_v1.4 Summary: Ag3463 The CG59551-01 gene encodes a putative GPCR. Highest expression of this gene is detected in an ovarian cancer cell line SK-OV-3 (CT=34). In addition, low expression of this gene is also observed in fetal skeletal muscle (CT=34.4), one of the lung cancer cell line (CT=34.9), and testis (CT=34.3). Thus, expression of this gene can be used to distinguish these sample from other samples used in this panel. In addition, therapeutic modulation of the activity of the GPCR encoded by this gene may be useful in the treatment of ovarian and lung cancer, fertility, hypogonadism, and muscle related diseases.  
     [1737] Panel 4.1D Summary: Ag3463 The CG59551-01 gene encodes a putative GPCR. Highest expression of this gene is seen in KU-812 cells treated with PMA/ionomycin (CT=30.86). Thus, expression of this gene can be used to distinguish this sample from other samples used in this panel. In addition, expression of this gene is high in KU-812 (basophils) cells treated with PMA/ionomycin (CT=30.86) as compared to resting KU-812 cells (CT=34.66). Therefore, expression of this gene can be used to distinguish resting from PMA/ionomycin treated-basophils. It is known that GPCR-type receptors are important in multiple physiological responses mediated by basophils (ref. 1). Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene could block or inhibit inflammation or tissue damage due to basophil activation in response to asthma, allergies, hypersensitivity reactions, psoriasis, and viral infections.  
     REFERENCES  
     [1738] 1. Heinemann A., Hartnell A., Stubbs V. E., Murakami K., Soler D., LaRosa G., Askenase P. W., Williams T. J., Sabroe I. (2000) Basophil responses to chemokines are regulated by both sequential and cooperative receptor signaling. J. Immunol. 165: 7224-7233.  
     [1739] BH. CG759540-01: Olfactory Receptor  
     [1740] Expression of gene CG59540-01 was assessed using the primer-probe sets A03460 and Ag 1519, described in Tables BHA and BHB. Results of the RTQ-PCR runs are shown in Tables BHC, BHD and BHE.  
     [1741] Table BHA. Probe Name Ag3460 
               TABLE BHA                          Probe Name Ag3460                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tcagtgcagagatggagatctt-3′   22   97   574               Probe   TET-5′-tgcatcttctccctgttatatctcttca-3′-TAMRA   28   126   575               Reverse   5′-gacagatgagtcccatgttcat-3′   22   171   576                  
 
     [1742] Table BHB. Probe Name Ag1519 
               TABLE BHB                          Probe Name Ag1519                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cctggccctcataaatctaatt-3′   22   503   577               Probe   TET-5′-ctccttctaaggctgcccttctgtgg-3′-TAMRA   26   525   578               Reverse   5′-acagacagaatttcaccgaaga-3′   22   571   579                  
 
     [1743]               TABLE BHC                          Panel 1.2                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag1519,       Ag1519,           Run       Run       Tissue Name   142098791   Tissue Name   142098791                                     Endothelial cells   0.0   Renal ca. 786-0   32.1       Heart (Fetal)   1.3   Renal ca. A498   10.7       Pancreas   1.5   Renal ca. RXF 393   7.5       Pancreatic ca.   3.6   Renal ca. ACHN   10.2       CAPAN 2       Adrenal Gland   4.7   Renal ca. UO-31   26.8       Thyroid   0.4   Renal ca. TK-10   14.0       Salivary gland   27.7   Liver   7.2       Pituitary gland   0.0   Liver (fetal)   3.5       Brain (fetal)   0.0   Liver ca.   0.9               (hepatoblast) HepG2       Brain (whole)   0.0   Lung   0.0       Brain (amygdala)   0.0   Lung (fetal)   1.3       Brain (cerebellum)   0.0   Lung ca. (small cell)   22.8               LX-1       Brain   0.3   Lung ca. (small cell)   11.5       (hippocampus)       NCI-H69       Brain (thalamus)   0.2   Lung ca. (s. cell var.)   0.0               SHP-77       Cerebral Cortex   0.3   Lung ca. (large   2.3               cell)NCI-H460       Spinal cord   0.0   Lung ca. (non-sm.   5.1               cell) A549       glio/astro U87-MG   0.4   Lung ca. (non-s. cell)   7.7               NCI-H23       glio/astro   0.9   Lung ca. (non-s. cell)   6.8       U-118-MG       HOP-62       astrocytoma   0.0   Lung ca. (non-s. cl)   0.9       SW1783       NCI-H522       neuro*; met SK-N-   0.0   Lung ca. (squam.)   52.1       AS       SW 900       astrocytoma SF-539   0.0   Lung ca. (squam.)   4.1               NCI-H596       astrocytoma   0.0   Mammary gland   11.8       SNB-75       glioma SNB-19   4.0   Breast ca.* (pl. ef)   11.3               MCF-7       glioma U251   0.0   Breast ca.* (pl. ef)   1.4               MDA-MB-231       glioma SF-295   2.8   Breast ca.* (pl. ef)   6.3               T47D       Heart   13.9   Breast ca. BT-549   0.0       Skeletal Muscle   0.2   Breast ca. MDA-N   12.5       Bone marrow   0.7   Ovary   1.5       Thymus   0.0   Ovarian ca.   12.4               OVCAR-3       Spleen   0.7   Ovarian ca.   23.8               OVCAR-4       Lymph node   0.0   Ovarian ca.   38.2               OVCAR-5       Colorectal Tissue   4.5   Ovarian ca.   35.6               OVCAR-8       Stomach   2.6   Ovarian ca. IGROV-1   2.4       Small intestine   2.6   Ovarian ca. (ascites)   11.2               SK-OV-3       Colon ca. SW480   3.1   Uterus   1.7       Colon ca.* SW620   12.3   Placenta   0.8       (SW480 met)       Colon ca. HT29   12.3   Prostate   14.2       Colon ca. HCT-116   14.3   Prostate ca.* (bone   12.6               met) PC-3       Colon ca. CaCo-2   11.5   Testis   0.4       Colon ca. Tissue   5.7   Melanoma   6.5       (ODO3866)       Hs688(A).T       Colon ca.   100.0   Melanoma* (met)   12.2       HCC-2998       Hs688(B).T       Gastric ca.* (liver   15.7   Melanoma UACC-   0.0       met) NCI-N87       62       Bladder   95.3   Melanoma M14   10.3       Trachea   1.0   Melanoma LOX   0.0               IMVI       Kidney   55.9   Melanoma* (met)   0.0               SK-MEL-5       Kidney (fetal)   7.7                    
     [1744]               TABLE BHD                          Panel 1.3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag1519,       Ag1519,       Tissue Name   Run 165529518   Tissue Name   Run 165529518                                     Liver adenocarcinoma   0.0   Kidney (fetal)   0.0       Pancreas   38.7   Renal ca. 786-0   8.1       Pancreatic ca. CAPAN 2   7.9   Renal ca. A498   0.0       Adrenal gland   29.9   Renal ca. RXF 393   29.7       Thyroid   26.6   Renal ca. ACHN   13.4       Salivary gland   0.0   Renal ca. UO-31   0.0       Pituitary gland   17.2   Renal ca. TK-10   16.8       Brain (fetal)   0.0   Liver   0.0       Brain (whole)   0.0   Liver (fetal)   27.4       Brain (amygdala)   0.0   Liver ca.   0.0               (hepatoblast) HepG2       Brain (cerebellum)   0.0   Lung   0.0       Brain (hippocampus)   0.0   Lung (fetal)   15.6       Brain (substantia nigra)   0.0   Lung ca. (small cell)   50.7               LX-1       Brain (thalamus)   0.0   Lung ca. (small cell)   0.0               NCI-H69       Cerebral Cortex   0.0   Lung ca. (s. cell var.)   25.0               SHP-77       Spinal cord   0.0   Lung ca. (large   26.1               cell)NCI-H460       glio/astro U87-MG   0.0   Lung ca. (non-sm.   0.0               cell) A549       glio/astro U-118-MG   0.0   Lung ca. (non-s. cell)   0.0               NCI-H23       astrocytoma SW1783   0.0   Lung ca. (non-s. cell)   27.4               HOP-62       neuro*; met SK-N-AS   0.0   Lung ca. (non-s. cl)   0.0               NCI-H522       astrocytoma SF-539   0.0   Lung ca. (squam.)   18.0               SW 900       astrocytoma SNB-75   0.0   Lung ca. (squam.)   0.0               NCI-H596       glioma SNB-19   0.0   Mammary gland   27.0       glioma U251   18.8   Breast ca.* (pl. ef)   27.0               MCF-7       glioma SF-295   0.0   Breast ca.* (pl. ef)   45.7               MDA-MB-231       Heart (fetal)   16.4   Breast ca.* (pl. ef)   13.7               T47D       Heart   0.0   Breast ca. BT-549   0.0       Skeletal muscle (fetal)   0.0   Breast ca. MDA-N   13.8       Skeletal muscle   18.8   Ovary   0.0       Bone marrow   0.0   Ovarian ca.   0.0               OVCAR-3       Thymus   0.0   Ovarian ca.   11.4               OVCAR-4       Spleen   0.0   Ovarian ca.   2.6               OVCAR-5       Lymph node   34.4   Ovarian ca.   12.3               OVCAR-8       Colorectal   100.0   Ovarian ca. IGROV-1   0.0       Stomach   0.0   Ovarian ca.*   33.7               (ascites) SK-OV-3       Small intestine   0.0   Uterus   0.0       Colon ca. SW480   22.8   Placenta   17.6       Colon ca.*   10.0   Prostate   0.0       SW620(SW480 met)       Colon ca. HT29   16.7   Prostate ca.* (bone   0.0               met)PC-3       Colon ca. HCT-116   16.8   Testis   0.0       Colon ca. CaCo-2   15.6   Melanoma   15.1               Hs688(A).T       Colon ca.   28.9   Melanoma* (met)   9.0       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   31.0   Melanoma UACC-   0.0               62       Gastric ca.* (liver met)   36.6   Melanoma M14   26.2       NCI-N87       Bladder   51.4   Melanoma LOX   0.0               IMVI       Trachea   0.0   Melanoma* (met)   14.1               SK-MEL-5       Kidney   56.3   Adipose   0.0                    
     [1745]               TABLE BHE                          Panel 2D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag1519,       Ag1519,       Tissue Name   Run 145158010   Tissue Name   Run 145158010                                     Normal Colon   81.8   Kidney Margin   5.0               8120608       CC Well to Mod Diff   6.0   Kidney Cancer   0.0       (ODO3866)       8120613       CC Margin (ODO3866)   7.3   Kidney Margin   1.9               8120614       CC Gr.2 rectosigmoid   5.8   Kidney Cancer   7.6       (ODO3868)       9010320       CC Margin (ODO3868)   0.0   Kidney Margin   5.8               9010321       CC Mod Diff   18.6   Normal Uterus   4.2       (ODO3920)       CC Margin (ODO3920)   10.6   Uterus Cancer   47.3               064011       CC Gr.2 ascend colon   8.2   Normal Thyroid   21.6       (ODO3921)       CC Margin (ODO3921)   4.8   Thyroid Cancer   42.3               064010       CC from Partial   47.6   Thyroid Cancer   20.9       Hepatectomy       A302152       (ODO4309) Mets       Liver Margin   10.4   Thyroid Margin   59.5       (ODO4309)       A302153       Colon mets to lung   12.2   Normal Breast   71.2       (OD04451-01)       Lung Margin (OD04451-   6.5   Breast Cancer   15.7       02)       (OD04566)       Normal Prostate 6546-1   11.6   Breast Cancer   19.9               (OD04590-01)       Prostate Cancer   31.6   Breast Cancer Mets   41.5       (OD04410)       (OD04590-03)       Prostate Margin   25.5   Breast Cancer   33.7       (OD04410)       Metastasis               (OD04655-05)       Prostate Cancer   27.2   Breast Cancer   27.0       (OD04720-01)       064006       Prostate Margin   31.4   Breast Cancer 1024   48.0       (OD04720-02)       Normal Lung 061010   25.2   Breast Cancer   3.3               9100266       Lung Met to Muscle   6.2   Breast Margin   7.8       (ODO4286)       9100265       Muscle Margin   0.0   Breast Cancer   24.8       (ODO4286)       A209073       Lung Malignant Cancer   39.0   Breast Margin   32.3       (OD03126)       A209073       Lung Margin (OD03126)   12.0   Normal Liver   3.5       Lung Cancer (OD04404)   4.9   Liver Cancer 064003   56.6       Lung Margin (OD04404)   27.9   Liver Cancer 1025   7.2       Lung Cancer (OD04565)   11.9   Liver Cancer 1026   1.8       Lung Margin (OD04565)   1.4   Liver Cancer 6004-T   6.0       Lung Cancer (OD04237-   52.5   Liver Tissue 6004-N   0.0       01)       Lung Margin (OD04237-   20.7   Liver Cancer 6005-T   5.6       02)       Ocular Mel Met to Liver   5.6   Liver Tissue 6005-N   0.0       (ODO4310)       Liver Margin   2.2   Normal Bladder   24.0       (ODO4310)       Melanoma Mets to Lung   0.0   Bladder Cancer 1023   3.3       (OD04321)       Lung Margin (OD04321)   24.7   Bladder Cancer   5.7               A302173       Normal Kidney   100.0   Bladder Cancer   2.9               (OD04718-01)       Kidney Ca, Nuclear   34.4   Bladder Normal   0.0       grade 2 (OD04338)       Adjacent (OD04718-               03)       Kidney Margin   54.7   Normal Ovary   3.9       (OD04338)       Kidney Ca Nuclear   81.8   Ovarian Cancer   7.2       grade 1/2 (OD04339)       064008       Kidney Margin   48.3   Ovarian Cancer   38.4       (OD04339)       (OD04768-07)       Kidney Ca, Clear cell   11.0   Ovary Margin   5.1       type (OD04340)       (OD04768-08)       Kidney Margin   56.6   Normal Stomach   11.4       (OD04340)       Kidney Ca, Nuclear   3.4   Gastric Cancer   6.5       grade 3 (OD04348)       9060358       Kidney Margin   43.2   Stomach Margin   0.0       (OD04348)       9060359       Kidney Cancer   11.5   Gastric Cancer   6.7       (OD04622-01)       9060395       Kidney Margin   3.5   Stomach Margin   4.5       (OD04622-03)       9060394       Kidney Cancer   17.8   Gastric Cancer   0.0       (OD04450-01)       9060397       Kidney Margin   42.0   Stomach Margin   6.7       (OD04450-03)       9060396       Kidney Cancer 8120607   0.0   Gastric Cancer   16.6               064005                    
     [1746] CNS_neurodegeneration_v1.0 Summary: Ag3460 Expression of the CG59540-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel.  
     [1747] General_screening_panel_v1.4 Summary: Ag3460 Expression of the CG59540-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel.  
     [1748] Panel 1.2 Summary: Ag1519 The expression of the CG59540-01 gene appears to be highest in a sample derived from a colon cancer cell line (HCC-2998) (CT=28.2). In addition, there is substantial expression associated with normal kidney and bladder. Thus, the expression of this gene could be used to distinguish these tissues from other tissues in the panel. In addition there was noted expression clustered in ovarian, renal and colon cancer cell lines. Therefore, therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics might be of use in the treatment of colon cancer, renal cancer or ovarian cancer.  
     [1749] Among tissues with metabolic function, there is moderate expression in fetal and adult heart, adrenal, and pancreas. This expression suggests that therapeutic modulation of the expression or function of the protein encoded by this gene may be useful in the treatment of diseases that involve these tissues, including obesity and diabetes.  
     [1750] In addition, there appears to be higher levels of expression in adult heart (CT=31) when compared to expression in fetal heart (CT=34.4). Thus, expression of this gene could be used to differentiate between adult and fetal heart tissue. Conversely, expression of this gene is higher in fetal lung (CT=34.5) than in adult lung (CT=40). Thus, expression of this gene could also be used to differentiate between adult and fetal lung.  
     [1751] Panel 1.3D Summary: Ag1519 Significant expression the CG59540-01 gene is limited to a sample derived from colorectal tissue (CT=34.3). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel, and between coloreclal tissue and other normal or malignant tissues.  
     [1752] Panel 2D Summary: Ag1519 The expression of the CG59540-01 gene in panel 2 appears to be highest in a samples derived from normal kidney tissue (CT=32). In addition there appears to be substantial difference in expression between normal kidney adjacent to cancer tissue and the cancer tissue itself. Thus, the expression of this gene could be used to distinguish normal kidney tissue from other samples in the panel. In addition, the expression of this gene could be used to distinguish normal kidney from malignant tissue. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics might be of use in the treatment of kidney cancer.  
     [1753] Panel 4D Summary: Ag3460 Expression of the CG59540-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel.  
     [1754] BI. CG59280-01 and CG59280-02: Olfactory Receptor  
     [1755] Expression of gene CG59280-01 and CG59280-02 was assessed using the primer-probe set Ag3527, described in Table BIA. Results of the RTQ-PCR runs are shown in Table BIB. Please note that CG59280-02 represents a full-length physical clone of the CG59280-01 gene, validating the prediction of the gene sequence.  
     [1756] Table BIA. Probe Name Ag3527 
               TABLE BIA                          Probe Name Ag3527                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atggccattgataggtacgtt-3′   21   361   580               Probe   TET-5′-catctgtaaccctctccgctacccaa-3′-TAMRA   26   384   581               Reverse   5′-ccacagagagctgaacacaga-3′   21   428   582                  
 
     [1757]               TABLE BIB                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3527, Run       Ag3527, Run       Tissue Name   166446354   Tissue Name   166446354                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   2.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   4.2               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   4.2               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   4.4   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   100.0       LAK cells IL-2 + IL-12   0.0   Lupus kidney   0.0       LAK cells IL-2 + IFN   5.1   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   4.5       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   3.1   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   4.5   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   5.3   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   9.9   IBD Colitis 2   10.8       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   8.9       Monocytes LPS   27.0   Colon   0.0       Macrophages rest   9.5   Lung   4.6       Macrophages LPS   4.0   Thymus   0.0       HUVEC none   0.0   Kidney   0.0       HUVEC starved   0.0                    
     [1758] CNS_neurodegeneration_v1.0 Summary: Ag3527 Expression of the CG59280-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel. (Data not shown.)  
     [1759] General_screening_panel_v1.4 Summary: Ag3527 Expression of the CG59280-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel. (Data not shown.) This gene encodes a G protein-coupled receptor (GPCR), a type of cell surface receptor involved in signal transduction. It is most similar to members of the odorant receptor subfamily of GPCRs. Based on analogy to other odorant receptor genes, we predict that expression of this gene may be highest in nasal epithelium, a sample not represented on this panel.  
     [1760] Panel 4D Summary: Ag3527 Highest expression of the CG59280-01 gene is seen in the liver cirrhosis sample (CT=31.81). Thus, expression of this gene could be used to differentiate between this sample from the other samples on this panel and as a marker to detect the presence of liver cirrhosis. Furthermore, expression of this gene is not detected in normal liver in Panel 1.4, suggesting that its expression is unique to liver cirrhosis. This gene encodes a putative GPCR; therefore, antibodies or small molecule therapeutics could reduce or inhibit fibrosis that occurs in liver cirrhosis. In addition, antibodies to this putative GPCR could also be used for the diagnosis of liver cirrhosis.  
     [1761] BJ. CG59568-01: GPCR  
     [1762] Expression of gene CG59568-01 was assessed using the primer-probe set Ag3474, described in Table BJA. Results of the RTQ-PCR runs are shown in Table BJB.  
     [1763] Table BJA. Probe Name Ag3474 
               TABLE BJA                          Probe Name Ag3474                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ttacagcaatcaccatggtctt-3′   22   475   760               Probe   TET-5′-accttctgtggaccctatgaaactg-3′-TAMRA   26   510   761               Reverse   5′-gggtgaagtcacaaaagaagtg-3′   22   537   762                  
 
     [1764]               TABLE BJB                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3474, Run       Ag3474, Run       Tissue Name   166417193   Tissue Name   166417193                                     Secondary Th1 act   7.1   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   4.2   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   2.2   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   3.3   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   5.9   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.3               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   1.7   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   3.1               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.5               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   100.0       LAK cells IL-2 + IL-12   3.6   Lupus kidney   0.0       LAK cells IL-2 + IFN   3.9   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   2.4   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   6.2               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.3       ionomycin       B lymphocytes PWM   8.4   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   1.6               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   1.5   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   11.9       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   5.8   Colon   1.5       Macrophages rest   3.4   Lung   0.0       Macrophages LPS   0.0   Thymus   3.8       HUVEC none   0.0   Kidney   6.7       HUVEC starved   0.0                    
     [1765] CNS_neurodegeneration_v1.0 Summary: Ag3474 Expression of the CG59568-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel. (Data not shown.)  
     [1766] General_screening_panel_v1.4 Summary: Ag3474 Expression of the CG59568-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel. (Data not shown.) This gene encodes a G protein-coupled receptor (GPCR), a type of cell surface receptor involved in signal transduction. It is most similar to members of the odorant receptor subfamily of GPCRs. Based on analogy to other odorant receptor genes, we predict that expression of this gene may be highest in nasal epithelium, a sample not represented on this panel.  
     [1767] Panel 4D Summary: Ag3474 Highest expression of the CG59280-01 gene is seen in the liver cirrhosis sample (CT=31.37). Thus, expression of this gene could be used to differentiate between this sample from the other samples on this panel and as a marker to detect the presence of liver cirrhosis. Furthermore, expression of this gene is not detected in normal liver in Panel 1.4, suggesting that its expression is unique to liver cirrhosis. This gene encodes a putative GPCR; therefore, antibodies or small molecule therapeutics could reduce or inhibit fibrosis that occurs in liver cirrhosis. In addition, antibodies to this putative GPCR could also be used for the diagnosis of liver cirrhosis.  
     REFERENCES  
     [1768] 1. Mark M. D., Wittemann S., Herlitze S. (2000) G protein modulation of recombinant P/Q-type calcium channels by regulators of G protein signalling proteins. J. Physiol 528 Pt 1: 65-77.  
     [1769] BK. CG59224-01 and CG59216-01: GPCR  
     [1770] Expression of gene CG59224-01 and variant CG59216-01 was assessed using the primer-probe sets Ag3400 and Ag3405, described in Tables BKA and BKB. Results of the RTQ-PCR runs are shown in Table BKC.  
     [1771] Table BKA. Probe Name Ag3400 
               TABLE BKA                          Probe Name Ag3400                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tctctgacctagggctgtctct-3′   22   225   584               Probe   TET-5′-tcttccttacccatcactttgggact-3′-TAMRA   26   248   585               Reverse   5′-catgaatttcatggacatcaaa-3′   22   281   586                  
 
     [1772] Table BKB. Probe Name Ag3405 
               TABLE BKB                          Probe Name Ag3405                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cacatctgtgctgtgcttatct-3′   22   746   587               Probe   TET-5′-agtgctgccatgctccaccagttt-3′-TAMRA   24   785   588               Reverse   5′-acgtggatcataggagacacat-3′   22   816   589                  
 
     [1773]               TABLE BKC                          General_screening_panel_v1.4                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3400, Run   Ag3405, Run       Ag3400, Run   Ag3405, Run       Tissue Name   216822602   216838741   Tissue Name   216822602   216838741                                             Adipose   0.0   0.0   Renal ca. TK-10   0.0   0.0       Melanoma*   0.0   0.0   Bladder   1.2   0.0       Hs688(A).T       Melanoma*   0.0   0.0   Gastric ca. (liver   0.0   0.0       Hs688(B).T           met.) NCI-N87       Melanoma*   0.0   0.0   Gastric ca.   0.0   0.0       M14           KATO III       Melanoma*   0.0   0.0   Colon ca. SW-   0.0   0.0       LOXIMVI           948       Melanoma*   0.0   0.0   Colon ca.   0.0   0.0       SK-MEL-5           SW480       Squamous   0.0   0.0   Colon ca.*   0.0   0.0       cell           (SW480 met)       carcinoma           SW620       SCC-4       Testis Pool   0.0   0.0   Colon ca. HT29   0.0   0.0       Prostate ca.*   0.0   0.0   Colon ca. HCT-   0.0   0.0       (bone met)           116       PC-3       Prostate Pool   3.2   1.8   Colon ca. CaCo-2   0.0   0.0       Placenta   0.0   0.0   Colon cancer   0.0   0.0                   tissue       Uterus Pool   0.0   0.0   Colon ca.   0.0   0.0                   SW1116       Ovarian ca.   0.0   0.0   Colon ca. Colo-   0.0   0.0       OVCAR-3           205       Ovarian ca.   1.0   0.0   Colon ca. SW-48   0.0   0.0       SK-OV-3       Ovarian ca.   0.0   0.0   Colon Pool   0.0   0.0       OVCAR-4       Ovarian ca.   0.0   0.0   Small Intestine   0.0   0.0       OVCAR-5           Pool       Ovarian ca.   0.0   0.0   Stomach Pool   0.0   0.0       IGROV-1       Ovarian ca.   0.0   0.0   Bone Marrow   0.0   0.0       OVCAR-8           Pool       Ovary   0.0   0.0   Fetal Heart   0.0   0.0       Breast ca.   0.0   0.0   Heart Pool   1.7   1.3       MCF-7       Breast ca.   0.0   0.0   Lymph Node   0.0   0.0       MDA-MB-           Pool       231       Breast ca. BT   0.0   0.0   Fetal Skeletal   0.0   0.0       549           Muscle       Breast ca.   0.0   0.0   Skeletal Muscle   0.0   0.0       T47D           Pool       Breast ca.   0.0   0.5   Spleen Pool   0.0   0.0       MDA-N       Breast Pool   0.0   0.5   Thymus Pool   0.0   0.5       Trachea   0.0   0.0   CNS cancer   0.0   0.0                   (glio/astro) U87-                   MG       Lung   0.0   0.0   CNS cancer   0.0   0.0                   (glio/astro) U-                   118-MG       Fetal Lung   0.0   0.0   CNS cancer   0.0   0.0                   (neuro; met) SK-                   N-AS       Lung ca.   0.0   0.0   CNS cancer   0.0   0.0       NCI-N417           (astro) SF-539       Lung ca. LX-1   0.0   0.0   CNS cancer   0.0   0.0                   (astro) SNB-75       Lung ca.   2.5   3.3   CNS cancer   0.0   0.0       NCI-H146           (glio) SNB-19       Lung ca.   100.0   100.0   CNS cancer   0.0   0.0       SHP-77           (glio) SF-295       Lung ca.   0.0   0.0   Brain   0.0   0.0       A549           (Amygdala) Pool       Lung ca.   0.0   0.0   Brain   0.0   0.0       NCI-H526           (cerebellum)       Lung ca.   0.0   0.0   Brain (fetal)   0.0   0.0       NCI-H23       Lung ca.   0.0   0.0   Brain   0.0   0.0       NCI-H460           (Hippocampus)                   Pool       Lung ca.   0.0   0.0   Cerebral Cortex   0.0   0.6       HOP-62       Lung ca.   0.0   0.0   Brain (Substantia   0.0   0.0       NCI-H522           nigra) Pool       Liver   0.0   0.0   Brain   0.0   0.0                   (Thalamus) Pool       Fetal Liver   0.0   0.0   Brain (whole)   0.0   0.0       Liver ca.   0.0   0.0   Spinal Cord Pool   0.0   0.0       HepG2       Kidney Pool   0.0   0.4   Adrenal Gland   0.0   0.0       Fetal Kidney   10.8   2.6   Pituitary gland   0.0   0.0                   Pool       Renal ca.   0.0   0.0   Salivary Gland   0.0   0.0       786-0       Renal ca.   0.0   0.0   Thyroid (female)   0.0   0.0       A498       Renal ca.   0.0   0.0   Pancreatic ca.   0.0   0.0       ACHN           CAPAN2       Renal ca.   0.0   0.0   Pancreas Pool   0.0   1.2       UO-31                    
     [1774] CNS_neurodegeneration_v1.0 Summary: Ag3400/Ag3405 Expression of the CG59224-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel. (Data not shown.)  
     [1775] General_screening_panel_v1.4 Summary: Ag3400/Ag3405 Two experiments with two different probe and primer sets produce results that are in excellent agreement, with significant expression of the CG59224-01 gene exclusively in a lung cancer cell line sample (CTs=30-33). Therefore, expression of this gene may be used to distinguish this sample from other samples on this panel and as a marker for lung cancer. Furthermore, therapeutic modulation of the activity of the GPCR encoded by this gene may be beneficial in the treatment of lung cancer.  
     [1776] Panel 4D Summary: Ag3400/Ag3405 Expression of the CG59224-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel. (Data not shown.) This gene encodes a G protein-coupled receptor (GPCR), a type of cell surface receptor involved in signal transduction. It is most similar to members of the odorant receptor subfamily of GPCRs. Based on analogy to other odorant receptor genes, we predict that expression of this gene may be highest in nasal epithelium, a sample not represented on this panel.  
     [1777] BL. CG59214-01 and CG59214-01: GPCR  
     [1778] Expression of gene CG59214-01 and CG59214-01 was assessed using the primer-probe sets Ag3398 and Ag3404, described in Tables BLA and BLB. Results of the RTQ-PCR runs are shown in Tables BLC and BLD.  
     [1779] Table BLA. Probe Name Ag3398 
               TABLE BLA                          Probe Name Ag3398                                             Start   SEQ       Primers   Sequences   Length   Position   ID NO:                                         Forward   5′-atacttgcatctcccacatctg-3′   22   724   590               Probe   TET-5′-caccaatgattgggctatctatgatcca-3′-TAMRA   28   766   591               Reverse   5′-tgaggaagcattctgtccatag-3′   22   797   592                  
 
     [1780] Table BLB. Probe Name Ag3404 
               TABLE BLB                          Probe Name Ag3404                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atacttgcatctcccacatctg-3′   22   724   593               Probe   TET-5′-caccaatgattgggctatctatgatcca-3′-TAMRA   28   766   594               Reverse   5′-tgaggaagcattctgtccatag-3′   22   797   595                  
 
     [1781]               TABLE BLC                          General_screening_panel_v1.4                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3398, Run   Ag3404, Run       Ag3398, Run   Ag3404, Run       Tissue Name   216822567   216838380   Tissue Name   216822567   216838380                                             Adipose   0.0   0.0   Renal ca. TK-10   0.0   0.0       Melanoma*   0.0   0.0   Bladder   0.0   0.0       Hs688(A).T       Melanoma*   0.0   0.0   Gastric ca. (liver   0.0   0.0       Hs688(B).T           met.) NCI-N87       Melanoma*   0.0   0.0   Gastric ca.   0.0   0.0       M14           KATO III       Melanoma*   0.0   0.0   Colon ca. SW-   0.0   0.0       LOXIMVI           948       Melanoma*   0.0   88.9   Colon ca.   0.0   0.0       SK-MEL-5           SW480       Squamous   0.0   0.0   Colon ca.*   0.0   0.0       cell           (SW480 met)       carcinoma           SW620       SCC-4       Testis Pool   0.0   0.0   Colon ca. HT29   0.0   0.0       Prostate ca.*   0.0   0.0   Colon ca. HCT-   0.0   0.0       (bone met)           116       PC-3       Prostate Pool   0.0   0.0   Colon ca. CaCo-2   0.0   0.0       Placenta   0.0   0.0   Colon cancer   0.0   0.0                   tissue       Uterus Pool   0.0   0.0   Colon ca.   0.0   0.0                   SW1116       Ovarian ca.   0.0   0.0   Colon ca. Colo-   0.0   0.0       OVCAR-3           205       Ovarian ca.   0.0   0.0   Colon ca. SW-48   0.0   0.0       SK-OV-3       Ovarian ca.   0.0   0.0   Colon Pool   0.0   0.0       OVCAR-4       Ovarian ca.   0.0   0.0   Small Intestine   0.0   8.9       OVCAR-5           Pool       Ovarian ca.   0.0   0.0   Stomach Pool   0.0   15.6       IGROV-1       Ovarian ca.   0.0   0.0   Bone Marrow   0.0   0.0       OVCAR-8           Pool       Ovary   0.0   7.5   Fetal Heart   0.0   0.0       Breast ca.   0.0   0.0   Heart Pool   0.0   0.0       MCF-7       Breast ca.   0.0   0.0   Lymph Node   0.0   0.0       MDA-MB-           Pool       231       Breast ca. BT   0.0   0.0   Fetal Skeletal   0.0   0.0       549           Muscle       Breast ca.   0.0   0.0   Skeletal Muscle   0.0   0.0       T47D           Pool       Breast ca.   6.9   0.0   Spleen Pool   0.0   0.0       MDA-N       Breast Pool   0.0   0.0   Thymus Pool   0.0   0.0       Trachea   0.0   0.0   CNS cancer   0.0   0.0                   (glio/astro) U87-                   MG       Lung   0.0   0.0   CNS cancer   0.0   12.5                   (glio/astro) U-                   118-MG       Fetal Lung   0.0   0.0   CNS cancer   0.0   0.0                   (neuro; met) SK-                   N-AS       Lung ca.   0.0   0.0   CNS cancer   0.0   0.0       NCI-N417           (astro) SF-539       Lung ca. LX-1   0.0   0.0   CNS cancer   0.0   0.0                   (astro) SNB-75       Lung ca.   0.0   0.0   CNS cancer   0.0   0.0       NCI-H146           (glio) SNB-19       Lung ca.   100.0   100.0   CNS cancer   0.0   0.0       SHP-77           (glio) SF-295       Lung ca.   0.0   0.0   Brain   0.0   0.0       A549           (Amygdala) Pool       Lung ca.   0.0   0.0   Brain   0.0   0.0       NCI-H526           (cerebellum)       Lung ca.   0.0   0.0   Brain (fetal)   0.0   0.0       NCI-H23       Lung ca.   0.0   0.0   Brain   0.0   0.0       NCI-H460           (Hippocampus)                   Pool       Lung ca.   0.0   0.0   Cerebral Cortex   0.0   0.0       HOP-62           Pool       Lung ca.   0.0   0.0   Brain (Substantia   0.0   0.0       NCI-H522           nigra) Pool       Liver   0.0   0.0   Brain   4.3   0.0                   (Thalamus) Pool       Fetal Liver   0.0   0.0   Brain (whole)   0.0   0.0       Liver ca.   0.0   0.0   Spinal Cord Pool   0.0   0.0       HepG2       Kidney Pool   0.0   0.0   Adrenal Gland   0.0   0.0       Fetal Kidney   11.1   8.5   Pituitary gland   0.0   0.0                   Pool       Renal ca.   0.0   0.0   Salivary Gland   0.0   0.0       786-0       Renal ca.   0.0   0.0   Thyroid (female)   0.0   0.0       A498       Renal ca.   0.0   0.0   Pancreatic ca.   0.0   0.0       ACHN           CAPAN2       Renal ca.   0.0   0.0   Pancreas Pool   0.0   0.0       UO-31                    
     [1782]               TABLE BLD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3404, Run       Ag3404, Run       Tissue Name   165825947   Tissue Name   165825947                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   5.8               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   8.9   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   100.0       LAK cells IL-2 + IL-12   0.0   Lupus kidney   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   3.9       Dendritic cells anti-   0.0   IBD Colitis 2   7.2       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   4.0       Monocytes LPS   0.0   Colon   5.5       Macrophages rest   0.0   Lung   3.1       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   0.0   Kidney   0.0       HUVEC starved   0.0                    
     [1783] CNS_neurodegeneration_v1.0 Summary: Ag3398/Ag3404 Expression of the CG59222-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel. (Data not shown.)  
     [1784] General_screening_panel_v1.4 Summary: Ag3398/Ag3404 Two experiments with two different probe and primer sets produce results that are in excellent agreement, with significant expression of the CG59222-01 gene exclusively in a lung cancer cell line sample (CT=33.8). Therefore, expression of this gene may be used to this sample from other samples on this panel and as a marker for lung cancer. Furthermore, therapeutic modulation of the activity of the GPCR encoded by this gene may be beneficial in the treatment of lung cancer.  
     [1785] Panel 4D Summary: Ag3404 Highest expression of the CG59222-01 gene is seen in the liver cirrhosis sample (CT=32.65). Thus, expression of this gene could be used to differentiate between this sample from the other samples on this panel and as a marker to detect the presence of liver cirrhosis. Furthermore, expression of this gene is not detected in normal liver in Panel 1.4, suggesting that its expression is unique to liver cirrhosis. This gene encodes a putative GPCR; therefore, antibodies or small molecule therapeutics could reduce or inhibit fibrosis that occurs in liver cirrhosis. In addition, antibodies to this putative GPCR could also be used for the diagnosis of liver cirrhosis. Ag3398 Expression of CG59222-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (Data not shown).  
     [1786] BM. CG159220-01: GPCR  
     [1787] Expression of gene CG59220-01 was assessed using the primer-probe set Ag3402, described in Table BMA. Results of the RTQ-PCR runs are shown in Tables BMB, BMC and BMD.  
     [1788] Table BMA. Probe Name Ag3402 
               TABLE BMA                          Probe Name Ag3402                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ctccacacacccatgtacttct-3′   22   160   596               Probe   TET-5′-cttggatctctgccattcctctgtca-3′-TAMRA   26   201   597               Reverse   5′-aggaggttctccaacagcttag-3′   22   233   598                  
 
     [1789]               TABLE BMB                          CNS_neurodegeneration_v1.0                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3402,       Ag3402,           Run       Run       Tissue Name   210349784   Tissue Name   210349784                                     AD 1 Hippo   9.0   Control (Path) 3   18.6               Temporal Ctx       AD 2 Hippo   46.3   Control (Path) 4   56.6               Temporal Ctx       AD 3 Hippo   8.8   AD 1 Occipital Ctx   21.6       AD 4 Hippo   24.1   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   52.9   AD 3 Occipital Ctx   15.0       AD 6 Hippo   39.2   AD 4 Occipital Ctx   48.0       Control 2 Hippo   41.8   AD 5 Occipital Ctx   56.3       Control 4 Hippo   18.2   AD 6 Occipital Ctx   31.4       Control (Path) 3   13.7   Control 1 Occipital   14.4       Hippo       Ctx       AD 1 Temporal   27.4   Control 2 Occipital   55.5       Ctx       Ctx       AD 2 Temporal   57.0   Control 3 Occipital   42.3       Ctx       Ctx       AD 3 Temporal   10.2   Control 4 Occipital   21.2       Ctx       Ctx       AD 4 Temporal   54.3   Control (Path) 1   100.0       Ctx       Occipital Ctx       AD 5 Inf Temporal   42.9   Control (Path) 2   27.7       Ctx       Occipital Ctx       AD 5 Sup   28.7   Control (Path) 3   9.0       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   41.8   Control (Path) 4   34.2       Ctx       Occipital Ctx       AD 6 Sup   51.4   Control 1 Parietal   23.5       Temporal Ctx       Ctx       Control 1   18.2   Control 2 Parietal   28.5       Temporal Ctx       Ctx       Control 2   43.2   Control 3 Parietal   29.5       Temporal Ctx       Ctx       Control 3   32.8   Control (Path) 1   99.3       Temporal Ctx       Parietal Ctx       Control 3   20.0   Control (Path) 2   46.7       Temporal Ctx       Parietal Ctx       Control (Path) 1   87.1   Control (Path) 3   12.0       Temporal Ctx       Parietal Ctx       Control (Path) 2   60.3   Control (Path) 4   82.4       Temporal Ctx       Parietal Ctx                    
     [1790]               TABLE BMC                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3402,       Ag3402,           Run       Run       Tissue Name   216823314   Tissue Name   216823314                                     Adipose   14.7   Renal ca. TK-10   2.5       Melanoma*   10.1   Bladder   28.7       Hs688(A).T       Melanoma*   1.4   Gastric ca. (liver met.)   17.9       Hs688(B).T       NCI-N87       Melanoma* M14   0.9   Gastric ca. KATO III   0.7       Melanoma*   0.8   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   2.1   Colon ca. SW480   1.7       MEL-5       Squamous cell   2.9   Colon ca.* (SW480   1.8       carcinoma SCC-4       met) SW620       Testis Pool   25.9   Colon ca. HT29   1.3       Prostate ca.* (bone   1.2   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   16.0   Colon ca. CaCo-2   0.7       Placenta   1.3   Colon cancer tissue   7.4       Uterus Pool   15.6   Colon ca. SW1116   0.0       Ovarian ca.   3.1   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   6.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.6   Colon Pool   49.7       OVCAR-4       Ovarian ca.   2.9   Small Intestine Pool   53.6       OVCAR-5       Ovarian ca.   1.6   Stomach Pool   15.8       IGROV-1       Ovarian ca.   1.6   Bone Marrow Pool   14.5       OVCAR-8       Ovary   48.3   Fetal Heart   9.1       Breast ca. MCF-7   0.6   Heart Pool   39.5       Breast ca. MDA-   0.0   Lymph Node Pool   39.2       MB-231       Breast ca. BT 549   2.4   Fetal Skeletal Muscle   5.8       Breast ca. T47D   1.3   Skeletal Muscle Pool   47.6       Breast ca. MDA-N   0.4   Spleen Pool   22.2       Breast Pool   31.6   Thymus Pool   12.9       Trachea   5.9   CNS cancer   0.8               (glio/astro) U87-MG       Lung   16.6   CNS cancer   3.4               (glio/astro) U-118-MG       Fetal Lung   30.8   CNS cancer   1.5               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   9.7   CNS cancer (astro)   1.1               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   1.1               SNB-19       Lung ca. SHP-77   0.6   CNS cancer (glio) SF-   4.1               295       Lung ca. A549   0.6   Brain (Amygdala)   28.1               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   35.1       Lung ca. NCI-H23   5.9   Brain (fetal)   12.3       Lung ca. NCI-H460   0.9   Brain (Hippocampus)   39.8               Pool       Lung ca. HOP-62   1.6   Cerebral Cortex Pool   88.9       Lung ca. NCI-H522   7.1   Brain (Substantia   43.2               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   74.2       Fetal Liver   2.5   Brain (whole)   26.1       Liver ca. HepG2   0.7   Spinal Cord Pool   100.0       Kidney Pool   51.8   Adrenal Gland   24.1       Fetal Kidney   16.7   Pituitary gland Pool   8.6       Renal ca. 786-0   0.8   Salivary Gland   3.2       Renal ca. A498   0.0   Thyroid (female)   8.9       Renal ca. ACHN   1.4   Pancreatic ca.   0.8               CAPAN2       Renal ca. UO-31   1.5   Pancreas Pool   24.8                    
     [1791]               TABLE BMD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3402, Run       Ag3402, Run       Tissue Name   165825209   Tissue Name   165825209                                     Secondary Th1 act   0.0   HUVEC IL-1beta   3.5       Secondary Th2 act   0.0   HUVEC IFN gamma   6.5       Secondary Tr1 act   3.3   HUVEC TNF alpha +   15.4               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   2.9               IL4       Secondary Th2 rest   5.2   HUVEC IL-11   9.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   2.7               none       Primary Th1 act   5.4   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   3.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   10.7               EC TNF alpha + IL-1beta       Primary Th1 rest   3.3   Bronchial epithelium   18.0               TNF alpha + IL1beta       Primary Th2 rest   5.1   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   79.0               TNF alpha + IL-1beta       CD45RA CD4   2.7   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   2.5       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   11.3       Secondary CD8   3.0   Astrocytes TNF alpha +   75.3       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   2.6       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   6.8               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   1.6   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   27.9               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   5.1   Liver cirrhosis   90.8       LAK cells IL-2 + IL-12   3.0   Lupus kidney   51.8       LAK cells IL-2 + IFN   4.5   NCI-H292 none   28.1       gamma       LAK cells IL-2 + IL-18   23.2   NCI-H292 IL-4   10.6       LAK cells   0.0   NCI-H292 IL-9   23.5       PMA/ionomycin       NK Cells IL-2 rest   6.2   NCI-H292 IL-13   4.8       Two Way MLR 3 day   12.1   NCI-H292 IFN gamma   10.3       Two Way MLR 5 day   3.1   HPAEC none   5.8       Two Way MLR 7 day   5.8   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   3.7       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   6.4       Ramos (B cell)   0.0   Lung fibroblast IL-13   3.2       ionomycin       B lymphocytes PWM   2.6   Lung fibroblast IFN   10.5               gamma       B lymphocytes CD40L   1.8   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   13.7               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   6.5   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   4.7   Dermal fibroblast IL-4   6.3       Dendritic cells anti-   0.0   IBD Colitis 2   27.0       CD40       Monocytes rest   24.8   IBD Crohn&#39;s   9.3       Monocytes LPS   3.1   Colon   100.0       Macrophages rest   4.0   Lung   24.7       Macrophages LPS   0.0   Thymus   59.5       HUVEC none   6.5   Kidney   27.0       HUVEC starved   41.2                    
     [1792] CNS_neurodegeneration_v1.0 Summary: Ag3402 The CG59220-01 gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. The GPCR family of receptors contains a large number of neurotransmitter receptors, including the dopamine, serotonin, a and b-adrenerlyic, acetylcholine muscarinic, histamine, peptide, and metabotropic glutamate receptors. GPCRs are excellent drug targets in various neurologic and psychiatric diseases. All antipsychotics have been shown to act at the dopamine D2 receptor; similarly novel antipsychotics also act at the serotonergic receptor, and often the muscarinic and adrenergic receptors as well. While the majority of antidepressants can be classified as selective serotonin reuptake inhibitors, blockade of the 5-HT1A and a2 adrenergic receptors increases the effects of these drugs. The GPCRs are also of use as drug targets in the treatment of stroke. Blockade of the glutamate receptors may decrease the neuronal death resulting from excitotoxicity; further more the purinergic receptors have also been implicated as drug targets in the treatment of cerebral ischemia. The b-adrenergic receptors have been implicated in the treatment of ADHD with Ritalin, while the a-adrenergic receptors have been implicated in memory. Therefore this gene may be of use as a small molecule target for the treatment of any of the described diseases.  
     [1793] General_screening_panel_v1.4 Summary: Ag3402 The CG59220-01 gene represents a novel G-protein coupled receptor (GPCR) with highest expression in spinal cord sample (CT=31.12) and moderate expression in other samples from brain. Please see Panel CNS_neurodegeneration_v1.0 for discussion of utility of this gene in the central nervous system.  
     [1794] Low levels of expression of the CG59220-01 gene are also observed in areas outside of the central nervous system such as the, adipose tissue, fetal and adult heart, skeletal muscle, adrenal gland, pituitary gland, and thyroid suggesting the possibility of a wider role in intercellular signaling. Therapeutic modulation of the expression or function of this gene may therefore be useful in the treatment of metabolic disorders, including obesity and diabetes.  
     [1795] Panel 4D Summary: Ag3402 The CG59220-01 gene represents a novel G-protein coupled receptor (GPCR) with highest expression in colon (CT=33.12). Thus expression of this gene can be used to distinguish these samples from other samples used in this panel. In addition, expression of this gene is low/undetectable (CT values&gt;35) in samples derived from IBD colitis and IBS Crohn&#39;s. Therefore, expression of this gene can be used to distinguish normal colon sample from the IBD colitis and IBD Crohn&#39;s sample used in this panel.  
     [1796] BN. CG59218-01: GPCR  
     [1797] Expression of gene CG59218-01 was assessed using the primer-probe set Ag3401, described in Table BNA. Results of the RTQ-PCR runs are shown in Tables BNB.  
     [1798] Table BNA. Probe Name Ag3401 
               TABLE BNA                          Probe Name Ag3401                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gctggctactaggtttctcctt-3′   22   447   599               Probe   TET-5′-atcatcatgcctgtcatcctgaccag-3′-TAMRA   26   470   600               Reverse   5′-ttgatgtgggtatcacagaatg-3′   22   504   601                  
 
     [1799]               TABLE BNB                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3401, Run       Ag3401, Run       Tissue Name   165825154   Tissue Name   165825154                                     Secondary Th1 act   2.4   HUVEC IL-1beta   0.0       Secondary Th2 act   3.4   HUVEC IFN gamma   0.0       Secondary Tr1 act   8.4   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   3.1   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   3.1   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   8.1   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   3.3   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   8.1   Astrocytes rest   5.7       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   1.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   5.7   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   3.1   Liver cirrhosis   100.0       LAK cells IL-2 + IL-12   3.2   Lupus kidney   0.0       LAK cells IL-2 + IFN   8.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   4.3   NCI-H292 IL-4   0.0       LAK cells   2.1   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   3.3   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   3.4   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   2.5       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   14.8               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   6.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   17.1       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   6.1   Colon   0.0       Macrophages rest   0.0   Lung   0.0       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   0.0   Kidney   3.2       HUVEC starved   0.0                    
     [1800] CNS_neurodegeneration_v1.0 Summary: Ag3401 Expression of the CG59218-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1801] General_screening_panel_v1.4 Summary: Ag3401 Expression of the CG59218-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown). This gene product is most similar to members of the odorant receptor subfamily of GPCRs. Based on analogy to other odorant receptor genes, we predict that expression of this gene may be highest in nasal epithelium, a sample not represented on this panel.  
     [1802] Panel 4D Summary: Ag3401 Highest expression of the CG59218-01 gene is seen in the liver cirrhosis sample (CT=33.03). Thus, expression of this gene could be used to differentiate between this sample from the other samples on this panel and as a marker to detect the presence of liver cirrhosis. Furthermore, expression of this gene is not detected in normal liver in Panel 1.4, suggesting that its expression is unique to liver cirrhosis. This gene encodes a putative GPCR; therefore, antibodies or small molecule therapeutics could reduce or inhibit fibrosis that occurs in liver cirrhosis. In addition, antibodies to this putative GPCR could also be used for the diagnosis of liver cirrhosis.  
     [1803] BO. CG59211-01: GPCR  
     [1804] Expression of gene CG59211-01 was assessed using the primer-probe set Ag3397, described in Table BOA. Results of the RTQ-PCR runs are shown in Table BOB.  
                   TABLE BOA                          Probe Name A3397                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-tcacaggcatcctagacttgac-3′   22   645   602                   Probe   TET-5′-tcatgtcctacatgttgatactgaaagca-3′-TAMRA   29   675   603               Reverse   5′-tttcttgatgctatgctcaaca-3′   22   705   604                  
 
     [1805]               TABLE BOB                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3397,       Ag3397,           Run       Run       Tissue Name   216822307   Tissue Name   216822307                                     Adipose   0.0   Renal ca. TK-10   0.0       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.0       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.7       carcinoma SCC-4       met) SW620       Testis Pool   0.0   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   0.6       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.5       Breast ca. MCF-7   0.0   Heart Pool   0.5       Breast ca. MDA-   0.0   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   0.0       Breast Pool   0.6   Thymus Pool   0.0       Trachea   0.0   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   0.0   CNS cancer   0.8               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   2.6   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   100.0   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.0   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   0.0   Brain (fetal)   0.0       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   0.0   Brain (Substantia   0.0               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   0.0       Fetal Liver   0.0   Brain (whole)   0.9       Liver ca. HepG2   0.0   Spinal Cord Pool   0.0       Kidney Pool   0.9   Adrenal Gland   0.0       Fetal Kidney   3.3   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.0                    
     [1806] CNS_neurodegeneration_v1.0 Summary: Ag3397 Expression of the CG59211-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel. (Data not shown.) This gene encodes a G protein-coupled receptor (GPCR), a type of cell surface receptor involved in signal transduction. It is most similar to members of the odorant receptor subfamily of GPCRs. Based on analogy to other odorant receptor genes, we predict that expression of this gene may be highest in nasal epithelium, a sample not represented on this panel.  
     [1807] General_screening_panel_v1.4 Summary: Ag3397 Significant expression of the CG59211-01 gene is seen exclusively in one of the lung cancer sample (CT=32.29). Therefore, expression of this gene may be used to distinguish this sample from other samples on this panel and as a marker for lung cancer. There is an increasing awareness that some GPCRs can regulate proliferative signaling pathways and that chronic stimulation or mutational activation of receptors can lead to oncogenic transformation. Activating mutations in GPCRs are associated with several types of human tumors and some receptors exhibit potent oncogenic activity due to agonist overexpression (Whitehead et al., 2001). Therefore, therapeutic modulation of the activity of the GPCR encoded by this gene may be beneficial in the treatment of lung cancer.  
     REFERENCES  
     [1808] 1. Whitehead I P, Zohn I E, Der C J. (2001) Rho GTPase-dependent transformation by G protein-coupled receptors. Oncogene Mar. 26, 2001;20(13):1547-55  
     [1809] Panel 4D Summary: Ag3397 Expression of the CG59211-01 gene is low/undetectable (CT values&gt;35) across the samples in this panel. (Data not shown.)  
     [1810] BP. CG59276-01: Dihydroorotate Dehydrogenase  
     [1811] Expression of gene CG59276-01 was assessed using the primer-probe set Ag3524, described in Table BPA. Results of the RTQ-PCR runs are shown in Tables BPB, BPC, BPD, BPE and BPF.  
                   TABLE BPA                          Probe Name Ag3524                                         Start   SEQ ID                       Primers   Sequences   Length   Position   NO:               Forward   5′-ttcaggcactgttctttgactt-3′   22   1439   605                   Probe   TET-5′-aacagattttgcaacactttccaagg-3′-TAMRA   26   1472   606               Reverse   5′-tgagggagtggtaacactgtgt-3′   22   1498   607                  
 
     [1812]               TABLE BPB                          CNS_neurodegeneration_v1.0                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3524,       Ag3524,           Run       Run       Tissue Name   206915926   Tissue Name   206915926                                     AD 1 Hippo   26.8   Control (Path) 3   18.9               Temporal Ctx       AD 2 Hippo   30.8   Control (Path) 4   51.4               Temporal Ctx       AD 3 Hippo   25.3   AD 1 Occipital Ctx   37.1       AD 4 Hippo   38.2   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   77.4   AD 3 Occipital Ctx   16.5       AD 6 Hippo   83.5   AD 4 Occipital Ctx   40.9       Control 2 Hippo   43.8   AD 5 Occipital Ctx   33.9       Control 4 Hippo   20.6   AD 6 Occipital Ctx   17.0       Control (Path) 3   17.6   Control 1 Occipital   6.3       Hippo       Ctx       AD 1 Temporal   37.1   Control 2 Occipital   74.7       Ctx       Ctx       AD 2 Temporal   31.2   Control 3 Occipital   22.1       Ctx       Ctx       AD 3 Temporal   6.5   Control 4 Occipital   25.7       Ctx       Ctx       AD 4 Temporal   79.6   Control (Path) 1   89.5       Ctx       Occipital Ctx       AD 5 Inf Temporal   97.9   Control (Path) 2   18.4       Ctx       Occipital Ctx       AD 5 Sup   56.3   Control (Path) 3   11.2       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   100.0   Control (Path) 4   24.8       Ctx       Occipital Ctx       AD 6 Sup   66.9   Control 1 Parietal   26.8       Temporal Ctx       Ctx       Control 1   10.6   Control 2 Parietal   68.3       Temporal Ctx       Ctx       Control 2   13.4   Control 3 Parietal   28.1       Temporal Ctx       Ctx       Control 3   25.9   Control (Path) 1   58.6       Temporal Ctx       Parietal Ctx       Control 3   36.6   Control (Path) 2   51.4       Temporal Ctx       Parietal Ctx       Control (Path) 1   80.7   Control (Path) 3   6.9       Temporal Ctx       Parietal Ctx       Control (Path) 2   76.8   Control (Path) 4   54.7       Temporal Ctx       Parietal Ctx                    
     [1813]               TABLE BPC                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3524,       Ag3524,           Run       Run       Tissue Name   213390931   Tissue Name   213390931                                     Adipose   6.2   Renal ca. TK-10   9.3       Melanoma*   3.1   Bladder   22.1       Hs688(A).T       Melanoma*   9.2   Gastric ca. (liver met.)   24.8       Hs688(B).T       NCI-N87       Melanoma* M14   0.9   Gastric ca. KATO III   0.0       Melanoma*   0.4   Colon ca. SW-948   1.2       LOXIMVI       Melanoma* SK-   0.7   Colon ca. SW480   4.2       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   10.5       carcinoma SCC-4       met) SW620       Testis Pool   11.3   Colon ca. HT29   1.1       Prostate ca.* (bone   3.1   Colon ca. HCT-116   5.3       met) PC-3       Prostate Pool   8.7   Colon ca. CaCo-2   8.5       Placenta   1.3   Colon cancer tissue   7.2       Uterus Pool   2.9   Colon ca. SW1116   1.4       Ovarian ca.   6.9   Colon ca. Colo-205   1.6       OVCAR-3       Ovarian ca. SK-   11.7   Colon ca. SW-48   1.7       OV-3       Ovarian ca.   0.2   Colon Pool   12.6       OVCAR-4       Ovarian ca.   8.5   Small Intestine Pool   20.9       OVCAR-5       Ovarian ca.   2.5   Stomach Pool   13.2       IGROV-1       Ovarian ca.   4.1   Bone Marrow Pool   8.7       OVCAR-8       Ovary   15.3   Fetal Heart   9.5       Breast ca. MCF-7   3.4   Heart Pool   11.3       Breast ca. MDA-   3.1   Lymph Node Pool   27.2       MB-231       Breast ca. BT 549   23.5   Fetal Skeletal Muscle   9.1       Breast ca. T47D   19.5   Skeletal Muscle Pool   6.7       Breast ca. MDA-N   0.3   Spleen Pool   8.9       Breast Pool   25.2   Thymus Pool   18.2       Trachea   12.6   CNS cancer   8.7               (glio/astro) U87-MG       Lung   13.3   CNS cancer   7.5               (glio/astro) U-118-MG       Fetal Lung   41.8   CNS cancer   21.3               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   2.4               SF-539       Lung ca. LX-1   32.1   CNS cancer (astro)   97.9               SNB-75       Lung ca. NCI-H146   1.4   CNS cancer (glio)   3.0               SNB-19       Lung ca. SHP-77   2.3   CNS cancer (glio) SF-   26.1               295       Lung ca. A549   5.4   Brain (Amygdala)   4.1               Pool       Lung ca. NCI-H526   0.4   Brain (cerebellum)   33.0       Lung ca. NCI-H23   100.0   Brain (fetal)   25.5       Lung ca. NCI-H460   7.9   Brain (Hippocampus)   7.5               Pool       Lung ca. HOP-62   4.2   Cerebral Cortex Pool   7.7       Lung ca. NCI-H522   1.4   Brain (Substantia   5.8               nigra) Pool       Liver   1.4   Brain (Thalamus) Pool   11.7       Fetal Liver   9.3   Brain (whole)   9.5       Liver ca. HepG2   5.2   Spinal Cord Pool   10.5       Kidney Pool   40.3   Adrenal Gland   9.1       Fetal Kidney   40.1   Pituitary gland Pool   2.0       Renal ca. 786-0   12.9   Salivary Gland   8.3       Renal ca. A498   3.4   Thyroid (female)   2.5       Renal ca. ACHN   5.4   Pancreatic ca.   9.3               CAPAN2       Renal ca. UO-31   7.2   Pancreas Pool   20.9                    
     [1814]               TABLE BPD                          Panel 2D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3524,       Ag3524,       Tissue Name   Run 169590472   Tissue Name   Run 169590472                                     Normal Colon   28.1   Kidney Margin   1.8               8120608       CC Well to Mod Diff   2.4   Kidney Cancer   2.7       (ODO3866)       8120613       CC Margin (ODO3866)   1.4   Kidney Margin   8.0               8120614       CC Gr.2 rectosigmoid   3.5   Kidney Cancer   6.0       (ODO3868)       9010320       CC Margin (ODO3868)   1.1   Kidney Margin   11.7               9010321       CC Mod Diff   9.9   Normal Uterus   4.8       (ODO3920)       CC Margin (ODO3920)   6.0   Uterus Cancer   2.3               064011       CC Gr.2 ascend colon   12.3   Normal Thyroid   6.6       (ODO3921)       CC Margin (ODO3921)   3.1   Thyroid Cancer   0.5               064010       CC from Partial   12.8   Thyroid Cancer   2.1       Hepatectomy       A302152       (ODO4309) Mets       Liver Margin   34.6   Thyroid Margin   9.2       (ODO4309)       A302153       Colon mets to lung   12.2   Normal Breast   13.6       (OD04451-01)       Lung Margin (OD04451-   2.9   Breast Cancer   6.4       02)       (OD04566)       Normal Prostate 6546-1   9.9   Breast Cancer   9.8               (OD04590-01)       Prostate Cancer   16.6   Breast Cancer Mets   14.0       (OD04410)       (OD04590-03)       Prostate Margin   15.4   Breast Cancer   5.3       (OD04410)       Metastasis               (OD04655-05)       Prostate Cancer   20.6   Breast Cancer   11.2       (OD04720-01)       064006       Prostate Margin   16.6   Breast Cancer 1024   31.6       (OD04720-02)       Normal Lung 061010   27.2   Breast Cancer   8.0               9100266       Lung Met to Muscle   3.5   Breast Margin   4.6       (ODO4286)       9100265       Muscle Margin   6.7   Breast Cancer   4.1       (ODO4286)       A209073       Lung Malignant Cancer   3.7   Breast Margin   8.4       (OD03126)       A209073       Lung Margin (OD03126)   10.8   Normal Liver   100.0       Lung Cancer (OD04404)   4.1   Liver Cancer 064003   44.4       Lung Margin (OD04404)   4.3   Liver Cancer 1025   47.0       Lung Cancer (OD04565)   0.9   Liver Cancer 1026   0.9       Lung Margin (OD04565)   8.5   Liver Cancer 6004-T   59.5       Lung Cancer (OD04237-   13.2   Liver Tissue 6004-N   6.6       01)       Lung Margin (OD04237-   4.5   Liver Cancer 6005-T   1.5       02)       Ocular Mel Met to Liver   6.7   Liver Tissue 6005-N   0.5       (ODO4310)       Liver Margin   6.7   Normal Bladder   21.5       (ODO4310)       Melanoma Mets to Lung   3.9   Bladder Cancer 1023   0.9       (OD04321)       Lung Margin (OD04321)   4.7   Bladder Cancer   5.9               A302173       Normal Kidney   35.8   Bladder Cancer   5.5               (OD04718-01)       Kidney Ca, Nuclear   18.0   Bladder Normal   6.5       grade 2 (OD04338)       Adjacent (OD04718-               03)       Kidney Margin   14.1   Normal Ovary   4.5       (OD04338)       Kidney Ca Nuclear   13.7   Ovarian Cancer   3.7       grade 1/2 (OD04339)       064008       Kidney Margin   9.9   Ovarian Cancer   11.0       (OD04339)       (OD04768-07)       Kidney Ca, Clear cell   10.8   Ovary Margin   1.1       type (OD04340)       (OD04768-08)       Kidney Margin   12.7   Normal Stomach   7.6       (OD04340)       Kidney Ca, Nuclear   0.5   Gastric Cancer   3.3       grade 3 (OD04348)       9060358       Kidney Margin   10.6   Stomach Margin   4.0       (OD04348)       9060359       Kidney Cancer   0.9   Gastric Cancer   8.2       (OD04622-01)       9060395       Kidney Margin   1.6   Stomach Margin   5.5       (OD04622-03)       9060394       Kidney Cancer   4.2   Gastric Cancer   3.8       (OD04450-01)       9060397       Kidney Margin   5.4   Stomach Margin   0.9       (OD04450-03)       9060396       Kidney Cancer 8120607   1.0   Gastric Cancer   14.5               064005                    
     [1815]               TABLE BPE                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3524, Run       Ag3524, Run       Tissue Name   166445583   Tissue Name   166445583                                     Secondary Th1 act   13.9   HUVEC IL-1beta   2.4       Secondary Th2 act   17.1   HUVEC IFN gamma   16.4       Secondary Tr1 act   15.4   HUVEC TNF alpha +   4.8               IFN gamma       Secondary Th1 rest   36.6   HUVEC TNF alpha +   3.8               IL4       Secondary Th2 rest   19.1   HUVEC IL-11   6.1       Secondary Tr1 rest   28.7   Lung Microvascular EC   9.2               none       Primary Th1 act   10.2   Lung Microvascular EC   5.0               TNF alpha + IL-1beta       Primary Th2 act   18.2   Microvascular Dermal   14.5               EC none       Primary Tr1 act   28.5   Microsvasular Dermal   10.4               EC TNF alpha + IL-1beta       Primary Th1 rest   100.0   Bronchial epithelium   6.1               TNF alpha + IL-1beta       Primary Th2 rest   42.3   Small airway epithelium   3.3               none       Primary Tr1 rest   35.8   Small airway epithelium   29.3               TNF alpha + IL-1beta       CD45RA CD4   14.6   Coronery artery SMC rest   5.6       lymphocyte act       CD45RO CD4   28.7   Coronery artery SMC   3.4       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   17.7   Astrocytes rest   12.1       Secondary CD8   23.7   Astrocytes TNF alpha +   11.5       lymphocyte rest       IL-1beta       Secondary CD8   12.7   KU-812 (Basophil) rest   23.2       lymphocyte act       CD4 lymphocyte none   22.2   KU-812 (Basophil)   37.1               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   39.5   CCD1106   5.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   17.9   CCD1106   41.5               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   41.2   Liver cirrhosis   37.9       LAK cells IL-2 + IL-12   31.0   Lupus kidney   21.8       LAK cells IL-2 + IFN   47.0   NCI-H292 none   25.0       gamma       LAK cells IL-2 + IL-18   44.8   NCI-H292 IL-4   21.3       LAK cells   5.3   NCI-H292 IL-9   21.6       PMA/ionomycin       NK Cells IL-2 rest   17.8   NCI-H292 IL-13   9.2       Two Way MLR 3 day   47.6   NCI-H292 IFN gamma   10.6       Two Way MLR 5 day   13.0   HPAEC none   16.5       Two Way MLR 7 day   18.8   HPAEC TNF alpha + IL-   4.0               1beta       PBMC rest   7.6   Lung fibroblast none   30.4       PBMC PWM   24.7   Lung fibroblast TNF   24.3               alpha + IL-1beta       PBMC PHA-L   4.9   Lung fibroblast IL-4   23.8       Ramos (B cell) none   19.5   Lung fibroblast IL-9   14.6       Ramos (B cell)   10.7   Lung fibroblast IL-13   17.1       ionomycin       B lymphocytes PWM   22.8   Lung fibroblast IFN   24.1               gamma       B lymphocytes CD40L   40.1   Dermal fibroblast   20.3       and IL-4       CCD1070 rest       EOL-1 dbcAMP   15.9   Dermal fibroblast   22.4               CCD1070 TNF alpha       EOL-1 dbcAMP   11.7   Dermal fibroblast   0.6       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   22.2   Dermal fibroblast IFN   10.6               gamma       Dendritic cells LPS   14.5   Dermal fibroblast IL-4   11.8       Dendritic cells anti-   23.5   IBD Colitis 2   7.3       CD40       Monocytes rest   37.9   IBD Crohn&#39;s   8.0       Monocytes LPS   15.8   Colon   54.0       Macrophages rest   10.2   Lung   9.7       Macrophages LPS   5.0   Thymus   39.5       HUVEC none   17.3   Kidney   63.7       HUVEC starved   11.8                    
     [1816]               TABLE BPF                          Panel 5 Islet                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3524, Run       Ag3524, Run       Tissue Name   242386392   Tissue Name   242386392                                     97457_Patient-   66.0   94709_Donor 2 AM - A_adipose   9.0       02go_adipose       97476_Patient-   10.7   94710_Donor 2 AM - B_adipose   9.8       07sk_skeletal muscle       97477_Patient-   9.4   94711_Donor 2 AM - C_adipose   8.1       07ut_uterus       97478_Patient-   7.8   94712_Donor 2 AD - A_adipose   17.8       07pl_placenta       99167_Bayer Patient   10.2   94713_Donor 2 AD - B_adipose   27.0       1       97482_Patient-   0.0   94714_Donor 2 AD - C_adipose   43.5       08ut_uterus       97483_Patient-   0.0   94742_Donor 3 U -   0.0       08pl_placenta       A_Mesenchymal Stem Cells       97486_Patient-   0.0   94743_Donor 3 U -   0.0       09sk_skeletal muscle       B_Mesenchymal Stem Cells       97487_Patient-   0.0   94730_Donor 3 AM - A_adipose   16.8       09ut_uterus       97488_Patient-   17.0   94731_Donor 3 AM - B_adipose   7.8       09pl_placenta       97492_Patient-   28.1   94732_Donor 3 AM - C_adipose   18.0       10ut_uterus       97493_Patient-   25.3   94733_Donor 3 AD - A_adipose   0.0       10pl_placenta       97495_Patient-   61.6   94734_Donor 3 AD - B_adipose   0.0       11go_adipose       97496_Patient-   28.5   94735_Donor 3 AD - C_adipose   18.9       11sk_skeletal muscle       97497_Patient-   16.2   77138_Liver_HepG2untreated   15.8       11ut_uterus       97498_Patient-   5.0   73556_Heart_Cardiac stromal   9.7       11pl_placenta       cells (primary)       97500_Patient-   100.0   81735_Small Intestine   62.9       12go_adipose       97501_Patient-   42.6   72409_Kidney_Proximal   24.0       12sk_skeletal muscle       Convoluted Tubule       97502_Patient-   41.8   82685_Small   32.8       12ut_uterus       intestine_Duodenum       97503_Patient-   0.0   90650_Adrenal_Adrenocortical   0.0       12pl_placenta       adenoma       94721_Donor 2 U -   0.0   72410_Kidney_HRCE   39.8       A_Mesenchymal       Stem Cells       94722_Donor 2 U -   0.0   72411_Kidney_HRE   21.8       B_Mesenchymal       Stem Cells       94723_Donor 2 U -   0.0   73139_Uterus_Uterine smooth   8.1       C_Mesenchymal       muscle cells       Stem Cells                    
     [1817] CNS_neurodegeneration_v1.0 Summary: Ag3524 No differential expression of the CG59276-01 gene is detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. However, as observed in panel 1.4 this gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1818] General_screening_panel_v1.4 Summary: Ag3524 Expression of the CG59276-01 gene is highest in a sample derived from a brain and lung cancer cell lines (CTs=29). Thus, the expression of this gene could be used to distinguish these samples from the other samples in the panel. The CG59276-01 gene encodes a dihydroorotate dehydrogenase (DHODH) homolog. DHODH is an enzyme involved in the pathway for pyrimidine production. Drugs known to inhibit DHODH activity, such as brequinar sodium (Dup-785), have been shown to have anti-tumor activities (ref. 1). Therefore, therapeutic modulation of the activity of this gene encoded by this gene may be beneficial in the treatment of CNS and lung cancer. In addition, low to moderate expression of this gene is seen in all of the samples on this panel. Therefore, this gene may be playing an important role in cellular function.  
     [1819] This gene is expressed at low to moderate levels in a number of tissues with metabolic or endocrine function, including adipose, adrenal gland, gastrointestinal tract, pancreas, and skeletal muscle. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [1820] Recently, it has been demonstrated that down regulation of DHODH mRNA using RNA interference (RNAi) may inhibit growth of  Plasmodium falciparum  (ref 2). REFERENCES  
     [1821] 1. Braakhuis B J, van Dongen G A, Peters G J, van Walsum M, Snow G B (1990) Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts. Cancer Lett 49(2):133-7.  
     [1822] 2. McRobert L, McConkey G A.(2002) RNA interference (RNAi) inhibits growth of  Plasmodium falciparum . Mol Biochem Parasitol 119(2):273-8  
     [1823] Panel 2D Summary: Ag3524 The expression of this gene appears to be highest in a sample derived from a normal liver tissue (CT=30.3). In addition, there appears to be substantial expression in other samples derived from liver cancers and breast cancers. Thus, the expression of this gene could be used to distinguish normal liver tissue from other samples in the panel. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, protein therapeutics or antibodies could be of benefit in the treatment of liver or breast cancer.  
     [1824] Panel 4D Summary: Ag3524 Highest expression of the CG59276-01 gene is detected in resting primary Th1 cells (CT=30.03). In addition, the expression of this gene is significantly reduced in activated primary Th1 cells, suggesting a regulatory role for this gene in T-cell activation. The CG59276-01 encodes a dihydroorotate dehydrogenase, an enzyme involved in the pathway for pyrimidine production. Recently, an inhibitor of this enzyme, leflunomide has been shown to be an effective treatment for rheumatoid arthritis (ref 1). Therefore, therapeutics designed with the protein encoded for by this transcript could be important in regulating T cell function and treating T cell mediated diseases such as asthma, rheumatoid arthritis, psoriasis, IBD, and systemic lupus erythematosus.  
     [1825] Overall, this gene is expressed at low to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation.  
     [1826] Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     REFERENCES  
     [1827] 1. Schattenkirchner M. (2000) The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review. Immunopharmacology 47(2-3):291-3  
     [1828] Panel 5 Islet Summary: Ag3524 This gene has a low level of expression in adipose tissue (CTs=33-35). Thus, this gene product may be a small molecule drug for the treatment of obesity and obesity-related diseases, including Type 2 diabetes.  
     [1829] BQ. CG59268-01: K1AA2372  
     [1830] Expression of gene CG59268-01 was assessed using the primer-probe set Ag3523, described in Table BQA. Results of the RTQ-PCR runs are shown in Tables BQB and BQC.  
                   TABLE BQA                          Probe Name Ag3523                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-tactcttttggcttgatggaaa-3′   22   556   608           Probe   TET-5′-ccaacttctacgaccaggcagaaaa-3′-TAMRA   25   578   609       Reverse   5′-gacaaagagttggtgcctcttt-3′   22   610   610                  
 
     [1831]               TABLE BQB                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3523,       (%) Ag3523,           Run       Run       Tissue Name   216874716   Tissue Name   216874716                                     Adipose   47.6   Renal ca. TK-10   62.9       Melanoma*   4.0   Bladder   25.2       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   40.1       Hs688(B).T       NCI-N87       Melanoma* M14   15.4   Gastric ca. KATO III   0.0       Melanoma*   0.8   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   39.5   Colon ca. SW480   9.7       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   10.2       carcinoma SCC-4       met) SW620       Testis Pool   35.8   Colon ca. HT29   27.2       Prostate ca.* (bone   8.5   Colon ca. HCT-116   52.5       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   31.2       Placenta   0.0   Colon cancer tissue   14.1       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   12.2       OVCAR-3       Ovarian ca. SK-   16.3   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   10.3   Colon Pool   0.0       OVCAR-4       Ovarian ca.   47.6   Small Intestine Pool   3.9       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   4.3       IGROV-1       Ovarian ca.   1.5   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   4.2       Breast ca. MCF-7   6.0   Heart Pool   4.2       Breast ca. MDA-   8.8   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   33.4   Fetal Skeletal Muscle   0.0       Breast ca. T47D   62.9   Skeletal Muscle Pool   5.1       Breast ca. MDA-N   8.8   Spleen Pool   0.0       Breast Pool   0.0   Thymus Pool   0.0       Trachea   0.0   CNS cancer   9.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   33.2               (glio/astro) U-118-MG       Fetal Lung   15.1   CNS cancer   23.5               (neuro; met) SK-N-AS       Lung ca. NCI-N417   3.5   CNS cancer (astro)   11.0               SF-539       Lung ca. LX-1   3.7   CNS cancer (astro)   13.8               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   20.7               SNB-19       Lung ca. SHP-77   11.0   CNS cancer (glio) SF-   30.1               295       Lung ca. A549   6.3   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   3.8   Brain (fetal)   4.5       Lung ca. NCI-H460   13.5   Brain (Hippocampus)   4.6               Pool       Lung ca. HOP-62   4.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   9.2   Brain (Substantia   4.4               nigra) Pool       Liver   4.5   Brain (Thalamus) Pool   0.0       Fetal Liver   0.0   Brain (whole)   0.0       Liver ca. HepG2   100.0   Spinal Cord Pool   0.0       Kidney Pool   6.5   Adrenal Gland   8.3       Fetal Kidney   17.9   Pituitary gland Pool   6.6       Renal ca. 786-0   38.7   Salivary Gland   16.3       Renal ca. A498   3.2   Thyroid (female)   0.0       Renal ca. ACHN   9.0   Pancreatic ca.   16.5               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   11.3                    
     [1832]               TABLE BQC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3523, Run       Ag3523, Run       Tissue Name   166407138   Tissue Name   166407138                                     Secondary Th1 act   11.3   HUVEC IL-1beta   1.5       Secondary Th2 act   2.7   HUVEC IFN gamma   0.0       Secondary Tr1 act   9.5   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   1.3   HUVEC IL-11   5.1       Secondary Tr1 rest   1.7   Lung Microvascular EC   0.0               none       Primary Th1 act   13.1   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   10.8   Microvascular Dermal   1.0               EC none       Primary Tr1 act   7.5   Microsvasular Dermal   1.6               EC TNF alpha + IL-1beta       Primary Th1 rest   1.4   Bronchial epithelium   0.0               TNF alpha + IL-1beta       Primary Th2 rest   0.0   Small airway epithelium   1.0               none       Primary Tr1 rest   2.6   Small airway epithelium   4.4               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   8.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   1.5   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   3.1   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   1.0   KU-812 (Basophil)   8.1               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   3.7   CCD1106   4.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   7.2   CCD1106   2.2               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   15.3       LAK cells IL-2 + IL-12   8.9   Lupus kidney   5.0       LAK cells IL-2 + IFN   12.2   NCI-H292 none   1.0       gamma       LAK cells IL-2 + IL-18   4.7   NCI-H292 IL-4   0.6       LAK cells   1.4   NCI-H292 IL-9   1.6       PMA/ionomycin       NK Cells IL-2 rest   7.9   NCI-H292 IL-13   1.5       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   1.2       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   5.5   Lung fibroblast none   0.0       PBMC PWM   2.6   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   3.9       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   8.2   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   1.5   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   4.5   Dermal fibroblast   13.9               CCD1070 TNF alpha       EOL-1 dbcAMP   10.8   Dermal fibroblast   0.4       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   0.0       CD40       Monocytes rest   11.5   IBD Crohn&#39;s   66.0       Monocytes LPS   6.4   Colon   100.0       Macrophages rest   4.5   Lung   0.0       Macrophages LPS   1.4   Thymus   38.4       HUVEC none   1.9   Kidney   0.0       HUVEC starved   1.6                    
     [1833] CNS_neurodegeneration_v1.0 Summary: Ag3523 Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1834] General_screening_panel_v1.4 Summary: Ag3523 Expression of the CG59268-01 gene is highest in sample derived from liver cancer cell line (CT=32.55). Therefore, expression of this gene may be used to distinguish liver cancers from the other samples on this panel. In addition, low levels of expression of this gene are also observed in one of the ovarian cancer, 2 of the breast cancer, 2 of the renal cancer, bladder, gastric cancer, 3 of the colon cancer, and 4 of the CNS cancer samples. Therefore, therapeutic modulation of the activity of this gene product may be beneficial in the treatment of these cancers.  
     [1835] Among the tissues with metabolic or endocrine function, this gene is expressed at low levels in adipose tissue sample. Adipose tissue has several crucial roles including (i) mobilization from stores of fatty acids as an energy source, (ii) catabolism of lipoproteins such as very-low-density lipoprotein and (iii) synthesis and release of hormonal signals such as leptin and interleukin-6 (Coppack et al., 2001). Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity, hyperlipidemia, and insulin resistance.  
     REFERENCES  
     [1836] 1. Coppack S W, Patel J N, Lawrence V J. (2001) Nutritional regulation of lipid metabolism in human adipose tissue. Exp Clin Endocrinol Diabetes; 109(Suppl 2):S202-S214  
     [1837] Panel 4D Summary: Ag3523 Expression of the CG59268-01 gene is highest in sample derived from colon (CT=31.56). Therefore, expression of this gene may be used to distinguish colon sample from the other samples on this panel. In addition, significant expression of this gene is also observed in IBD Crohn&#39;s sample (CT=32.16). Thus, expression of this gene in colon and Crohn&#39;s sample can be used to distinguish these two samples from IBD Colitis 2 sample. In addition, therapeutic modulation of the activity of this gene product may be beneficial in the treatment of IBD Crohn&#39;s disease.  
     [1838] BR. CG59549-01: H326 Like  
     [1839] Expression of gene CG59549-01 was assessed using the primer-probe set Ag3464, described in Table BRA. Results of the RTQ-PCR runs are shown in Tables BRB and BRC.  
                   TABLE BRA                          Probe Name Ag3464                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-gtgcgtcacctgttacagaga-3′   21   1678   611                   Probe   TET-5′-ctcatcaacccggctggagagatcat-3′-TAMRA   26   1700   612               Reverse   5′-ctcttcttcatctgggaactca-3′   22   1731   613                  
 
     [1840]               TABLE BRB                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3464,       (%) Ag3464,           Run       Run       Tissue Name   217067408   Tissue Name   217067408                                     Adipose   0.0   Renal ca. TK-10   0.0       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   1.6       Hs688(B).T       NCI-N87       Melanoma* M14   1.0   Gastric ca. KATO III   2.1       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   23.8   Colon ca. SW480   2.6       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   22.8   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.3       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   1.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   3.3       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.9       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   4.8   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   0.0   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   0.0       Breast ca. T47D   4.9   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   1.1   Spleen Pool   0.0       Breast Pool   2.2   Thymus Pool   0.7       Trachea   0.0   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   20.4               (glio/astro) U-118-MG       Fetal Lung   0.0   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   2.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.7   CNS cancer (glio) SF-   100.0               295       Lung ca. A549   0.6   Brain (Amygdala)   1.1               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   0.0   Brain (fetal)   0.0       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   2.6   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   0.0   Brain (Substantia   0.8               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   1.1       Fetal Liver   0.0   Brain (whole)   0.0       Liver ca. HepG2   0.0   Spinal Cord Pool   0.8       Kidney Pool   0.0   Adrenal Gland   2.0       Fetal Kidney   3.2   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   1.8                    
     [1841]               TABLE BRC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3464, Run       Ag3464, Run       Tissue Name   166417099   Tissue Name   166417099                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   2.5   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL-1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   12.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   5.9   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   100.0       LAK cells IL-2 + IL-12   0.0   Lupus kidney   0.0       LAK cells IL-2 + IFN   0.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   10.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   3.2       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   7.0       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   0.0       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   6.3       Monocytes LPS   0.0   Colon   27.4       Macrophages rest   0.0   Lung   3.8       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   0.0   Kidney   0.0       HUVEC starved   0.0                    
     [1842] CNS_neurodegeneration_v1.0 Summary: Ag3464 Expression of the CG59549-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1843] General_screening_panel_v1.4 Summary: Ag3464 Expression of the CG59549-01 gene is highest in a CNS cancer (glio) SF-295 sample (CT=31.15). Thus, the expression of this gene could be used to distinguish this sample from the other samples in the panel. In addition, low to moderate expression of this gene is detected in a melanoma and a CNS cancer sample. Therefore, therapeutic modulation of this gene or its protein product may be beneficial in the treatment of melanoma and CNS cancer.  
     [1844] Panel 4D Summary: Ag3464 Low but significant expression of the CG59549-01 gene is detected exclusively in liver cirrhosis sample (CT=33.4). Therefore, expression of this gene may be used to distinguish liver cirrhosis from the other samples on this panel. Furthermore, expression of this gene is not detected in normal liver in Panel 1.3D, suggesting that its expression is unique to liver cirrhosis. Therefore, antibodies or small molecule therapeutics could reduce or inhibit fibrosis that occurs in liver cirrhosis. In addition, antibodies to this gene product could also be used for the diagnosis of liver cirrhosis.  
     [1845] BS. CG59641-01: Acetyl-Coa Carboxylase 2  
     [1846] Expression of gene CG59641-01 was assessed using the primer-probe set Ag3502, described in Table BSA. Results of the RTQ-PCR runs are shown in Table BSB.  
                   TABLE BSA                          Probe Name Ag3502                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-ctccctacgtcaccaaggat-3′   20   5090   614                   Probe   TET-5′-aagcgattccaggcccagaccct-3′-TAMRA   23   5122   615               Reverse   5′-ccgggaagtcatagatgtaggt-3′-   22   5152   616                  
 
     [1847]               TABLE BSB                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3502,       (%) Ag3502,           Run       Run       Tissue Name   217131537   Tissue Name   217131537                                     Adipose   100.0   Renal ca. TK-10   6.6       Melanoma*   1.5   Bladder   14.2       Hs688(A).T       Melanoma*   1.4   Gastric ca. (liver met.)   11.6       Hs688(B).T       NCI-N87       Melanoma* M14   7.2   Gastric ca. KATO III   4.2       Melanoma*   0.0   Colon ca. SW-948   0.5       LOXIMVI       Melanoma* SK-   14.8   Colon ca. SW480   7.8       MEL-5       Squamous cell   0.2   Colon ca.* (SW480   5.8       carcinoma SCC-4       met) SW620       Testis Pool   10.0   Colon ca. HT29   1.0       Prostate ca.* (bone   19.9   Colon ca. HCT-116   5.8       met) PC-3       Prostate Pool   12.9   Colon ca. CaCo-2   8.2       Placenta   1.9   Colon cancer tissue   7.6       Uterus Pool   9.2   Colon ca. SW1116   2.0       Ovarian ca.   6.6   Colon ca. Colo-205   9.0       OVCAR-3       Ovarian ca. SK-   12.2   Colon ca. SW-48   1.7       OV-3       Ovarian ca.   1.9   Colon Pool   20.7       OVCAR-4       Ovarian ca.   8.5   Small Intestine Pool   27.9       OVCAR-5       Ovarian ca.   1.2   Stomach Pool   28.7       IGROV-1       Ovarian ca.   1.7   Bone Marrow Pool   8.0       OVCAR-8       Ovary   12.1   Fetal Heart   30.6       Breast ca. MCF-7   63.7   Heart Pool   16.7       Breast ca. MDA-   4.5   Lymph Node Pool   18.8       MB-231       Breast ca. BT 549   1.8   Fetal Skeletal Muscle   5.4       Breast ca. T47D   10.8   Skeletal Muscle Pool   66.0       Breast ca. MDA-N   2.3   Spleen Pool   14.9       Breast Pool   39.0   Thymus Pool   16.4       Trachea   15.3   CNS cancer   5.8               (glio/astro) U87-MG       Lung   5.6   CNS cancer   9.1               (glio/astro) U-118-MG       Fetal Lung   13.6   CNS cancer   5.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   2.3   CNS cancer (astro)   3.1               SF-539       Lung ca. LX-1   6.4   CNS cancer (astro)   3.7               SNB-75       Lung ca. NCI-H146   2.2   CNS cancer (glio)   1.3               SNB-19       Lung ca. SHP-77   2.8   CNS cancer (glio)   8.1               SF-295       Lung ca. A549   10.0   Brain (Amygdala)   6.2               Pool       Lung ca. NCI-H526   0.9   Brain (cerebellum)   13.0       Lung ca. NCI-H23   26.6   Brain (fetal)   4.2       Lung ca. NCI-H460   3.9   Brain (Hippocampus)   7.5               Pool       Lung ca. HOP-62   1.4   Cerebral Cortex Pool   8.4       Lung ca. NCI-H522   13.5   Brain (Substantia   7.0               nigra) Pool       Liver   23.2   Brain (Thalamus) Pool   10.2       Fetal Liver   11.7   Brain (whole)   8.8       Liver ca. HepG2   6.6   Spinal Cord Pool   9.1       Kidney Pool   38.7   Adrenal Gland   50.0       Fetal Kidney   10.4   Pituitary gland Pool   7.4       Renal ca. 786-0   1.5   Salivary Gland   11.3       Renal ca. A498   1.4   Thyroid (female)   5.1       Renal ca. ACHN   3.0   Pancreatic ca.   1.7               CAPAN2       Renal ca. UO-31   2.5   Pancreas Pool   17.0                    
     [1848] General_screening_panel_v1.4 Summary: Ag3502 The CG59641-01 encodes an acetyl-CoA carboxylase 2 (ACC2) protein. Expression of this gene is highest in adipose tissue (CT=25.5). High levels of expression of this gene are also detected in other tissues with metabolic or endocrine function such as pancreas, adrenal gland, gastrointestinal tract, heart, skeletal muscle, and thyroid. Acetyl-coenzyme A (acetyl-CoA) carboxylase (ACC) catalyzes the synthesis of malonyl-CoA, a metabolite that plays a pivotal role in the synthesis and oxidation of fatty. Hence, ACC links fatty acid and carbohydrate metabolism through the shared intermediate acetyl-CoA, the product of pyruvate dehydrogenase. It has been shown recently that mutations in ACC2 gene lead to loss of body fat in a normal caloric intake in mouse (Abu-Elheiga et al., 2001). Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [1849] Low to moderate expression of this gene is also detected in most of the samples used in this panel suggesting the possibility of a wider role in intercellular signaling for this molecule.  
     [1850] Among tissues that originate in the central nervous system, this gene is expressed in all regions represented on this panel. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [1851] In addition, significantly higher levels of expression are seen in a breast cancer cell line. Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of breast cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of breast cancer.  
     REFERENCES  
     [1852] 1. Abu-Elheiga L, Matzuk M M, Abo-Hashema K A, Wakil S J. (2001) Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science Mar. 30, 2001;291(5513):2613-6  
     [1853] BT. CG59630-01: Midnolin  
     [1854] Expression of gene CG59630-01 was assessed using the primer-probe set Ag3425, described in Table BTA. Results of the RTQ-PCR runs are shown in Tables BTB, BTC and BTD.  
                   TABLE BTA                          Probe Name Ag3425                                                         SEQ ID           Primers   Sequences   Length   Start Position   NO:               Forward   5′-aagctgaccttggtacccac-3′   20   295   617                   Probe   TET-5′-ctcatgtctcaggcctcaaggcc-3′-TAMRA   23   328   618               Reverse   5′-ctctcgagagcttgcatcac-3′   20   361   619                  
 
     [1855]               TABLE BTB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.       Rel. Exp.           (%) Ag3425,       (%) Ag3425,           Run       Run       Tissue Name   210350911   Tissue Name   210350911                                     AD 1 Hippo   18.6   Control (Path) 3   14.0               Temporal Ctx       AD 2 Hippo   44.1   Control (Path) 4   25.0               Temporal Ctx       AD 3 Hippo   11.3   AD 1 Occipital Ctx   13.6       AD 4 Hippo   19.3   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   53.2   AD 3 Occipital Ctx   11.5       AD 6 Hippo   100.0   AD 4 Occipital Ctx   24.7       Control 2 Hippo   47.0   AD 5 Occipital Ctx   53.2       Control 4 Hippo   38.2   AD 6 Occipital Ctx   80.7       Control (Path) 3   10.5   Control 1 Occipital   19.9       Hippo       Ctx       AD 1 Temporal   17.3   Control 2 Occipital   49.3       Ctx       Ctx       AD 2 Temporal   33.7   Control 3 Occipital   31.2       Ctx       Ctx       AD 3 Temporal   10.4   Control 4 Occipital   13.9       Ctx       Ctx       AD 4 Temporal   19.1   Control (Path) 1   81.2       Ctx       Occipital Ctx       AD 5 Inf Temporal   49.3   Control (Path) 2   11.0       Ctx       Occipital Ctx       AD 5 Sup   45.4   Control (Path) 3   8.4       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   97.3   Control (Path) 4   19.6       Ctx       Occipital Ctx       AD 6 Sup   85.9   Control 1 Parietal   18.8       Temporal Ctx       Ctx       Control 1   20.3   Control 2 Parietal   29.9       Temporal Ctx       Ctx       Control 2   59.9   Control 3 Parietal   32.3       Temporal Ctx       Ctx       Control 3   32.3   Control (Path) 1   91.4       Temporal Ctx       Parietal Ctx       Control 3   17.4   Control (Path) 2   32.3       Temporal Ctx       Parietal Ctx       Control (Path) 1   70.7   Control (Path) 3   7.7       Temporal Ctx       Parietal Ctx       Control (Path) 2   27.5   Control (Path) 4   45.1       Temporal Ctx       Parietal Ctx                    
     [1856]               TABLE BTC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3425,       (%) Ag3425,           Run       Run       Tissue Name   217049295   Tissue Name   217049295                                     Adipose   17.8   Renal ca. TK-10   26.4       Melanoma*   15.5   Bladder   16.0       Hs688(A).T       Melanoma*   19.5   Gastric ca. (liver met.)   26.6       Hs688(B).T       NCI-N87       Melanoma* M14   10.5   Gastric ca. KATO III   23.0       Melanoma*   15.7   Colon ca. SW-948   11.6       LOXIMVI       Melanoma* SK-   8.0   Colon ca. SW480   27.5       MEL-5       Squamous cell   27.2   Colon ca.* (SW480   15.3       carcinoma SCC-4       met) SW620       Testis Pool   5.6   Colon ca. HT29   15.2       Prostate ca.* (bone   18.7   Colon ca. HCT-116   40.6       met) PC-3       Prostate Pool   3.3   Colon ca. CaCo-2   41.8       Placenta   16.8   Colon cancer tissue   19.6       Uterus Pool   2.6   Colon ca. SW1116   9.5       Ovarian ca.   27.7   Colon ca. Colo-205   41.5       OVCAR-3       Ovarian ca. SK-   58.2   Colon ca. SW-48   6.8       OV-3       Ovarian ca.   4.0   Colon Pool   5.9       OVCAR-4       Ovarian ca.   27.2   Small Intestine Pool   6.6       OVCAR-5       Ovarian ca.   30.1   Stomach Pool   42.9       IGROV-1       Ovarian ca.   19.3   Bone Marrow Pool   2.7       OVCAR-8       Ovary   7.6   Fetal Heart   9.0       Breast ca. MCF-7   37.1   Heart Pool   5.7       Breast ca. MDA-   15.3   Lymph Node Pool   6.5       MB-231       Breast ca. BT 549   51.1   Fetal Skeletal Muscle   6.6       Breast ca. T47D   100.0   Skeletal Muscle Pool   17.4       Breast ca. MDA-N   8.3   Spleen Pool   11.2       Breast Pool   41.8   Thymus Pool   8.0       Trachea   15.9   CNS cancer   46.3               (glio/astro) U87-MG       Lung   2.6   CNS cancer   20.7               (glio/astro) U-118-MG       Fetal Lung   55.5   CNS cancer   29.1               (neuro; met) SK-N-AS       Lung ca. NCI-N417   43.5   CNS cancer (astro)   13.8               SF-539       Lung ca. LX-1   23.5   CNS cancer (astro)   36.9               SNB-75       Lung ca. NCI-H146   5.8   CNS cancer (glio)   29.1               SNB-19       Lung ca. SHP-77   11.7   CNS cancer (glio)   73.7               SF-295       Lung ca. A549   21.5   Brain (Amygdala)   5.3               Pool       Lung ca. NCI-H526   15.7   Brain (cerebellum)   14.6       Lung ca. NCI-H23   12.9   Brain (fetal)   20.6       Lung ca. NCI-H460   49.3   Brain (Hippocampus)   4.6               Pool       Lung ca. HOP-62   10.1   Cerebral Cortex Pool   4.9       Lung ca. NCI-H522   16.2   Brain (Substantia   10.4               nigra) Pool       Liver   1.3   Brain (Thalamus) Pool   6.1       Fetal Liver   9.3   Brain (whole)   45.1       Liver ca. HepG2   29.7   Spinal Cord Pool   5.8       Kidney Pool   8.0   Adrenal Gland   13.6       Fetal Kidney   11.3   Pituitary gland Pool   6.8       Renal ca. 786-0   23.0   Salivary Gland   4.6       Renal ca. A498   18.2   Thyroid (female)   13.9       Renal ca. ACHN   13.6   Pancreatic ca.   7.6               CAPAN2       Renal ca. UO-31   28.5   Pancreas Pool   14.0                    
     [1857]               TABLE BTD                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3425, Run       Ag3425, Run       Tissue Name   169839020   Tissue Name   169839020                                     Secondary Th1 act   20.6   HUVEC IL-1beta   46.7       Secondary Th2 act   30.6   HUVEC IFN gamma   23.3       Secondary Tr1 act   32.1   HUVEC TNF alpha +   13.3               IFN gamma       Secondary Th1 rest   18.2   HUVEC TNF alpha +   22.8               IL4       Secondary Th2 rest   23.8   HUVEC IL-11   22.5       Secondary Tr1 rest   12.6   Lung Microvascular EC   37.9               none       Primary Th1 act   2.8   Lung Microvascular EC   22.2               TNF alpha + IL-1beta       Primary Th2 act   24.7   Microvascular Dermal   24.1               EC none       Primary Tr1 act   20.0   Microsvasular Dermal   21.2               EC TNF alpha + IL-1beta       Primary Th1 rest   18.6   Bronchial epithelium   26.6               TNF alpha + IL-1beta       Primary Th2 rest   19.5   Small airway epithelium   23.5               none       Primary Tr1 rest   22.4   Small airway epithelium   27.2               TNF alpha + IL-1beta       CD45RA CD4   17.7   Coronery artery SMC rest   22.1       lymphocyte act       CD45RO CD4   19.8   Coronery artery SMC   20.2       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   14.1   Astrocytes rest   24.7       Secondary CD8   23.8   Astrocytes TNF alpha +   17.8       lymphocyte rest       IL-1beta       Secondary CD8   12.2   KU-812 (Basophil) rest   16.5       lymphocyte act       CD4 lymphocyte none   6.5   KU-812 (Basophil)   36.6               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   15.2   CCD1106   40.1       CD95 CH11       (Keratinocytes) none       LAK cells rest   34.2   CCD1106   41.8               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   24.5   Liver cirrhosis   20.0       LAK cells IL-2 + IL-12   21.6   NCI-H292 none   41.2       LAK cells IL-2 + IFN   23.2   NCI-H292 IL-4   58.6       gamma       LAK cells IL-2 + IL-18   22.2   NCI-H292 IL-9   61.6       LAK cells   97.3   NCI-H292 IL-13   47.6       PMA/ionomycin       NK Cells IL-2 rest   28.7   NCI-H292 IFN gamma   54.0       Two Way MLR 3 day   32.5   HPAEC none   16.6       Two Way MLR 5 day   30.1   HPAEC TNF alpha + IL-   20.7               1beta       Two Way MLR 7 day   18.7   Lung fibroblast none   46.0       PBMC rest   27.9   Lung fibroblast TNF   20.2               alpha + IL-1beta       PBMC PWM   25.3   Lung fibroblast IL-4   47.0       PBMC PHA-L   22.7   Lung fibroblast IL-9   52.1       Ramos (B cell) none   25.5   Lung fibroblast IL-13   45.1       Ramos (B cell)   23.5   Lung fibroblast IFN   50.0       ionomycin       gamma       B lymphocytes PWM   17.8   Dermal fibroblast   28.3               CCD1070 rest       B lymphocytes CD40L   23.8   Dermal fibroblast   37.1       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   34.4   Dermal fibroblast   13.3               CCD1070 IL-1beta       EOL-1 dbcAMP   87.7   Dermal fibroblast IFN   28.5       PMA/ionomycin       gamma       Dendritic cells none   32.3   Dermal fibroblast IL-4   26.2       Dendritic cells LPS   21.5   Dermal Fibroblasts rest   26.6       Dendritic cells anti-   32.8   Neutrophils TNFa + LPS   33.7       CD40       Monocytes rest   54.3   Neutrophils rest   100.0       Monocytes LPS   93.3   Colon   18.4       Macrophages rest   23.8   Lung   28.7       Macrophages LPS   36.1   Thymus   28.1       HUVEC none   24.7   Kidney   14.0       HUVEC starved   38.4                    
     [1858] CNS_neurodegeneration_v1.0 Summary: Ag3425 This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1859] General_screening_panel_v1.4 Summary: Ag3425 The CG59630-01 gene is a homologue of mouse midnoline (midbrain nucleolar protein). Its expression is moderate to high across all of the samples on this panel, with highest expression in a breast cancer cell line (CT=25.3). The widespread expression suggests that this gene may play an important role in cellular function. In mouse, the expression of this gene is developmentally regulated: it is strongly expressed at the mesencephalon (midbrain) of the embryo and is involved in regulation of genes related to neurogenesis in the nucleolus (Tsukahara et al., 2000). Based on the gene&#39;s expression in all CNS regions examined, this gene may therefore play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1860] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     REFERENCE  
     [1861] 1. Tsukahara M, Suemori H, Noguchi S, Ji Z S, Tsunoo H. (2000) Novel nucleolar protein, midnolin, is expressed in the mesencephalon during mouse development. Gene Aug. 22, 2000;254(1-2):45-55  
     [1862] Panel 4.1D Summary: Ag3425 The CG59630-01 gene is a homologue of mouse midnoline (midbrain nucleolar protein). Its expression is moderate to high across all of the samples on this panel, with highest expression in resting neutrophils (CT=29.1). In addition, this gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [1863] BU. CG59561-01: Cytosolic Acyl Coenzyme a Thioester Hydrolase  
     [1864] Expression of gene CG59561-01 was assessed using the primer-probe set Ag3424, described in Table BUA. Results of the RTQ-PCR runs are shown in Tables BUB, BUC and BUD.  
                   TABLE BUA                          Probe Name Ag3424                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-aagctgaccaataaggccac-3′   20   345   620                   Probe   TET-5′-gtggacaaggtcctcgaagagcctc-3′-TAMRA   25   396   621               Reverse   5′-ctgccggaaatacacaacag-3′   20   421   622                  
 
     [1865]               TABLE BUB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.       Rel. Exp. (%)           (%) Ag3424       (%) Ag3424           Run       Run       Tissue Name   210350585   Tissue Name   210350585                                     AD 1 Hippo   8.8   Control (Path) 3   1.5               Temporal Ctx       AD 2 Hippo   16.7   Control (Path) 4   25.5               Temporal Ctx       AD 3 Hippo   2.7   AD 1 Occipital   3.7               Ctx       AD 4 Hippo   4.7   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   100.0   AD 3 Occipital   2.0               Ctx       AD 6 Hippo   34.6   AD 4 Occipital   8.5               Ctx       Control 2 Hippo   44.8   AD 5 Occipital   11.7               Ctx       Control 4 Hippo   2.2   AD 6 Occipital   90.8               Ctx       Control (Path) 3   2.0   Control 1 Occipital   0.8       Hippo       Ctx       AD 1 Temporal Ctx   2.4   Control 2 Occipital   84.1               Ctx       AD 2 Temporal Ctx   16.6   Control 3 Occipital   5.1               Ctx       AD 3 Temporal Ctx   2.1   Control 4 Occipital   1.3               Ctx       AD 4 Temporal Ctx   8.6   Control (Path) 1   96.6               Occipital Ctx       AD 5 Inf Temporal   62.9   Control (Path) 2   5.7       Ctx       Occipital Ctx       AD 5 SupTemporal   28.3   Control (Path) 3   0.5       Ctx       Occipital Ctx       AD 6 Inf Temporal   26.6   Control (Path) 4   8.8       Ctx       Occipital Ctx       AD 6 Sup Temporal   22.1   Control 1 Parietal   2.0       Ctx       Ctx       Control 1 Temporal   1.2   Control 2 Parietal   22.1       Ctx       Ctx       Control 2 Temporal   65.1   Control 3 Parietal   19.9       Ctx       Ctx       Control 3 Temporal   8.7   Control (Path) 1   94.0       Ctx       Parietal Ctx       Control 4 Temporal   2.4   Control (Path) 2   14.0       Ctx       Parietal Ctx       Control (Path) 1   61.1   Control (Path) 3   0.9       Temporal Ctx       Parietal Ctx       Control (Path) 2   28.3   Control (Path) 4   39.0       Temporal Ctx       Parietal Ctx                    
     [1866]               TABLE BUC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3424, Run       Ag3424, Run       Tissue Name   166385382   Tissue Name   166385382                                     Secondary Th1 act   62.9   HUVEC IL-1beta   4.0       Secondary Th2 act   37.9   HUVEC IFN gamma   10.7       Secondary Tr1 act   68.8   HUVEC TNF alpha +   18.6               IFN gamma       Secondary Th1 rest   4.2   HUVEC TNF alpha +   15.5               IL4       Secondary Th2 rest   12.1   HUVEC IL-11   10.2       Secondary Tr1 rest   4.4   Lung Microvascular EC   28.7               none       Primary Th1 act   66.9   Lung Microvascular EC   25.7               TNF alpha + IL-1beta       Primary Th2 act   61.1   Microvascular Dermal   36.3               EC none       Primary Tr1 act   43.2   Microsvasular Dermal   20.3               EC TNF alpha + IL-1beta       Primary Th1 rest   30.1   Bronchial epithelium   25.5               TNF alpha + IL-1beta       Primary Th2 rest   17.4   Small airway epithelium   19.5               none       Primary Tr1 rest   15.9   Small airway epithelium   52.1               TNF alpha + IL-1beta       CD45RA CD4   14.8   Coronery artery SMC rest   14.8       lymphocyte act       CD45RO CD4   37.6   Coronery artery SMC   8.3       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   43.8   Astrocytes rest   13.9       Secondary CD8   49.7   Astrocytes TNF alpha +   13.3       lymphocyte rest       IL-1beta       Secondary CD8   24.1   KU-812 (Basophil) rest   23.8       lymphocyte act       CD4 lymphocyte none   0.9   KU-812 (Basophil)   51.4               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   9.0   CCD1106   62.4       CD95 CH11       (Keratinocytes) none       LAK cells rest   33.0   CCD1106   37.1               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   27.7   Liver cirrhosis   3.5       LAK cells IL-2 + IL-12   25.5   Lupus kidney   1.0       LAK cells IL-2 + IFN   35.6   NCI-H292 none   16.2       gamma       LAK cells IL-2 + IL-18   21.9   NCI-H292 IL-4   23.5       LAK cells   3.6   NCI-H292 IL-9   29.5       PMA/ionomycin       NK Cells IL-2 rest   15.1   NCI-H292 IL-13   13.4       Two Way MLR 3 day   9.4   NCI-H292 IFN gamma   20.6       Two Way MLR 5 day   17.4   HPAEC none   17.4       Two Way MLR 7 day   13.1   HPAEC TNF alpha + IL-   20.9               1beta       PBMC rest   0.8   Lung fibroblast none   37.9       PBMC PWM   88.9   Lung fibroblast TNF   34.9               alpha + IL-1beta       PBMC PHA-L   52.5   Lung fibroblast IL-4   69.7       Ramos (B cell) none   17.2   Lung fibroblast IL-9   49.7       Ramos (B cell)   31.9   Lung fibroblast IL-13   45.4       ionomycin       B lymphocytes PWM   75.8   Lung fibroblast IFN   90.8               gamma       B lymphocytes CD40L   9.9   Dermal fibroblast   54.3       and IL-4       CCD1070 rest       EOL-1 dbcAMP   11.0   Dermal fibroblast   84.1               CCD1070 TNF alpha       EOL-1 dbcAMP   8.1   Dermal fibroblast   30.6       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   38.2   Dermal fibroblast IFN   31.4               gamma       Dendritic cells LPS   31.9   Dermal fibroblast IL-4   45.4       Dendritic cells anti-   37.1   IBD Colitis 2   2.5       CD40       Monocytes rest   0.4   IBD Crohn&#39;s   4.7       Monocytes LPS   0.6   Colon   45.4       Macrophages rest   12.6   Lung   16.6       Macrophages LPS   5.8   Thymus   100.0       HUVEC none   16.0   Kidney   20.6       HUVEC starved   27.4                    
     [1867]               TABLE BUD                          Panel 5 Islet                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3424, Run       Ag3424, Run       Tissue Name   242385366   Tissue Name   242385366                                     97457_Patient-   8.2   94709_Donor 2 AM - A_adipose   6.7       02go_adipose       97476_Patient-   3.9   94710_Donor 2 AM - B_adipose   8.7       07sk_skeletal muscle       97477_Patient-   7.4   94711_Donor 2 AM - C_adipose   5.9       07ut_uterus       97478_Patient-   7.9   94712_Donor 2 AD - A -   8.3       07pl_placenta       adipose       99167_Bayer Patient   4.8   94713_Donor 2 AD - B_adipose   5.4       1       97482_Patient-   4.1   94714_Donor 2 AD - C_adipose   7.7       08ut_uterus       97483_Patient-   2.4   94742_Donor 3 U -   3.0       08pl_placenta       A_Mesenchymal Stem Cells       97486_Patient-   0.0   94743_Donor 3 U -   9.9       09sk_skeletal muscle       B_Mesenchymal Stem Cells       97487_Patient-   5.3   94730_Donor 3 AM - A_adipose   22.5       09ut_uterus       97488_Patient-   2.3   94731_Donor 3 AM - B_adipose   15.1       09pl_placenta       97492_Patient-   4.8   94732_Donor 3 AM - C_adipose   10.2       10ut_uterus       97493_Patient-   6.6   94733_Donor 3 AD - A_adipose   29.7       10pl_placenta       97495_Patient-   0.9   94734_Donor 3 AD - B_adipose   6.4       11go_adipose       97496_Patient-   0.3   94735_Donor 3 AD - C_adipose   34.9       11sk_skeletal muscle       97497_Patient-   9.8   77138_Liver_HepG2untreated   57.8       11ut_uterus       97498_Patient-   3.0   73556_Heart_Cardiac stromal   10.3       11pl_placenta       cells (primary)       97500_Patient-   1.7   81735_Small Intestine   23.7       12go_adipose       97501_Patient-   1.4   72409_Kidney_Proximal   4.5       12sk_skeletal muscle       Convoluted Tubule       97502_Patient-   10.2   82685_Small   1.2       12ut_uterus       intestine_Duodenum       97503_Patient-   3.2   90650_Adrenal_Adrenocortical   1.4       12pl_placenta       adenoma       94721_Donor 2 U -   6.8   72410_Kidney_HRCE   100.0       A_Mesenchymal       Stem Cells       94722_Donor 2 U -   2.8   72411_Kidney_HRE   69.7       B_Mesenchymal       Stem Cells       94723_Donor 2 U -   5.1   73139_Uterus_Uterine smooth   22.4       C_Mesenchymal       muscle cells       Stem Cells                    
     [1868] CNS_neurodegeneration_v1.0 Summary: Ag3424 This panel confirms the expression of the CG59561-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. This expression profile suggests that this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1869] General_screening_panel_v1.4 Summary: Ag3424 Results from one experiment with the CG59561-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run. (Data not shown.)  
     [1870] Panel 4D Summary: Ag3424 The CG59561-01 gene encodes a protein homologous to cytosolic acyl coenzyme A thioester hydrolase (Brain acyl-CoA hydrolase, BACH). Among the tissue samples used in this panel, highest expression of this gene is detected in thymus (CT=29.6). In addition, expression of this gene is stimulated in activated primary and secondary—Th1, Th2 and Tr1 cells. Therefore, this gene product may play an important role in T cell development. Thus, therapeutics designed with the protein encoded for by this transcript could be important in regulating T cell function and treating T cell mediated diseases such as emphysema, asthma, arthritis, psoriasis, IBD, and systemic lupus erythematosus.  
     [1871] Interestingly, expression of this gene is also seen in activated PBMCs (CTs=30) as compared to resting PBMCs (CT=36) suggesting a role for this gene product in B-cell and T-cell proliferation. Therefore, small molecules that antagonize the function of this gene product may be useful as therapeutic drugs to reduce or eliminate the symptoms in patients with autoimmune and inflammatory diseases in which B cells play a part in the initiation or progression of the disease process, such as systemic lupus erythematosus, Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.  
     [1872] Panel 5 Islet Summary: Ag3424 The CG59561-01 gene is expressed at low levels in adipose and placenta, with highest expression in the kidney (CT=30.8). As an enzyme involved in lipid homeostasis, therapeutic modulation of this gene product may be a treatment for obesity and obesity-related diseases, including Type 2 diabetes.  
     [1873] BV. CG59452-01: Cell Proliferation Related Protein Cap  
     [1874] Expression of gene CG59452-01 was assessed using the primer-probe set Ag3443, described in Table BVA. Results of the RTQ-PCR runs are shown in Tables BVB and BVC.  
                   TABLE BVA                          Probe Name Ag3443                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-caggaatgtatccaggacttca-3′   22   387   623                   Probe   TET-5′-catctacaacaagcctggagatgaca-3′-TAMRA   26   431   624               Reverse   5′-tttccagagcttctgccatt-3′   20   464   625                  
 
     [1875]               TABLE BVB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.       Rel. Exp.           (%) Ag3443,       (%) Ag3443,           Run       Run       Tissue Name   210374885   Tissue Name   210374885                                     AD 1 Hippo   10.2   Control (Path) 3   6.2               Temporal Ctx       AD 2 Hippo   28.3   Control (Path) 4   27.0               Temporal Ctx       AD 3 Hippo   8.0   AD 1 Occipital Ctx   13.6       AD 4 Hippo   4.8   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   84.1   AD 3 Occipital Ctx   6.0       AD 6 Hippo   71.7   AD 4 Occipital Ctx   17.9       Control 2 Hippo   31.4   AD 5 Occipital Ctx   54.3       Control 4 Hippo   6.1   AD 6 Occipital Ctx   22.7       Control (Path) 3   3.3   Control 1 Occipital   4.0       Hippo       Ctx       AD 1 Temporal   21.9   Control 2 Occipital   73.7       Ctx       Ctx       AD 2 Temporal   33.4   Control 3 Occipital   13.7       Ctx       Ctx       AD 3 Temporal   7.4   Control 4 Occipital   7.7       Ctx       Ctx       AD 4 Temporal   16.8   Control (Path) 1   100.0       Ctx       Occipital Ctx       AD 5 Inf Temporal   74.7   Control (Path) 2   11.0       Ctx       Occipital Ctx       AD 5 Sup   36.1   Control (Path) 3   1.3       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   79.0   Control (Path) 4   15.3       Ctx       Occipital Ctx       AD 6 Sup   85.9   Control 1 Parietal   6.1       Temporal Ctx       Ctx       Control 1   8.6   Control 2 Parietal   35.8       Temporal Ctx       Ctx       Control 2   48.3   Control 3 Parietal   12.9       Temporal Ctx       Ctx       Control 3   11.4   Control (Path) 1   59.5       Temporal Ctx       Parietal Ctx       Control 3   6.5   Control (Path) 2   25.5       Temporal Ctx       Parietal Ctx       Control (Path) 1   93.3   Control (Path) 3   2.4       Temporal Ctx       Parietal Ctx       Control (Path) 2   23.8   Control (Path) 4   23.2       Temporal Ctx       Parietal Ctx                    
     [1876]               TABLE BVC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3443, Run       Ag3443, Run       Tissue Name   166397102   Tissue Name   166397102                                     Secondary Th1 act   22.7   HUVEC IL-1beta   18.2       Secondary Th2 act   25.7   HUVEC IFN gamma   18.6       Secondary Tr1 act   37.9   HUVEC TNF alpha +   16.6               IFN gamma       Secondary Th1 rest   15.7   HUVEC TNF alpha +   17.0               IL4       Secondary Th2 rest   11.2   HUVEC IL-11   9.3       Secondary Tr1 rest   11.5   Lung Microvascular EC   14.2               none       Primary Th1 act   16.6   Lung Microvascular EC   12.9               TNF alpha + IL-1beta       Primary Th2 act   29.9   Microvascular Dermal   17.7               EC none       Primary Tr1 act   44.1   Microsvasular Dermal   17.1               EC TNF alpha + IL-1beta       Primary Th1 rest   69.7   Bronchial epithelium   6.8               TNF alpha + IL-1beta       Primary Th2 rest   40.9   Small airway epithelium   8.5               none       Primary Tr1 rest   24.5   Small airway epithelium   40.9               TNF alpha + IL-1beta       CD45RA CD4   15.6   Coronery artery SMC rest   9.4       lymphocyte act       CD45RO CD4   30.4   Coronery artery SMC   8.5       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   19.3   Astrocytes rest   16.3       Secondary CD8   27.7   Astrocytes TNF alpha +   30.4       lymphocyte rest       IL-1beta       Secondary CD8   16.3   KU-812 (Basophil) rest   26.8       lymphocyte act       CD4 lymphocyte none   12.4   KU-812 (Basophil)   80.7               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   17.3   CCD1106   13.6       CD95 CH11       (Keratinocytes) none       LAK cells rest   10.7   CCD1106   100.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   30.4   Liver cirrhosis   10.4       LAK cells IL-2 + IL-12   24.5   Lupus kidney   16.5       LAK cells IL-2 + IFN   34.2   NCI-H292 none   22.4       gamma       LAK cells IL-2 + IL-18   20.9   NCI-H292 IL-4   36.9       LAK cells   13.3   NCI-H292 IL-9   27.5       PMA/ionomycin       NK Cells IL-2 rest   15.6   NCI-H292 IL-13   15.9       Two Way MLR 3 day   19.5   NCI-H292 IFN gamma   15.9       Two Way MLR 5 day   16.2   HPAEC none   9.3       Two Way MLR 7 day   15.1   HPAEC TNF alpha + IL-   18.9               1beta       PBMC rest   13.1   Lung fibroblast none   20.4       PBMC PWM   26.6   Lung fibroblast TNF   20.9               alpha + IL-1beta       PBMC PHA-L   9.6   Lung fibroblast IL-4   19.5       Ramos (B cell) none   39.2   Lung fibroblast IL-9   12.2       Ramos (B cell)   37.9   Lung fibroblast IL-13   10.5       ionomycin       B lymphocytes PWM   31.4   Lung fibroblast IFN   29.1               gamma       B lymphocytes CD40L   32.3   Dermal fibroblast   26.8       and IL-4       CCD1070 rest       EOL-1 dbcAMP   18.7   Dermal fibroblast   46.3               CCD1070 TNF alpha       EOL-1 dbcAMP   45.7   Dermal fibroblast   16.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   12.8   Dermal fibroblast IFN   7.5               gamma       Dendritic cells LPS   9.6   Dermal fibroblast IL-4   17.1       Dendritic cells anti-   14.6   IBD Colitis 2   4.2       CD40       Monocytes rest   20.6   IBD Crohn&#39;s   2.9       Monocytes LPS   20.9   Colon   49.0       Macrophages rest   15.8   Lung   11.1       Macrophages LPS   12.9   Thymus   20.2       HUVEC none   24.3   Kidney   33.2       HUVEC starved   33.7                    
     [1877] CNS_neurodegeneration_v1.0 Summary: Ag3443 This panel confirms the expression of the CG59452-01 gene at significant levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Expression of this gene in the brain suggests that it may play a role in central nervous system disorders other than Alzheimer&#39;s disease, such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1878] General_screening_panel_v1.4 Summary: Ag3443 The amp plot indicates that there were experimental difficulties with this run. (Data not shown).  
     [1879] Panel 4D Summary: Ag3443 Highest expression of the CG59452-01 gene is detected in TNFalpha+IL-1 beta treated keratinocytes and PMA/ionomycin treated KU-812 basophil cells (CTs=24.5). Thus, antibody or small molecule therapies designed with the protein encoded for by this gene could block or inhibit inflammation or tissue damage due to basophil activation in response to asthma, allergies, hypersensitivity reactions, psoriasis, and viral infections.  
     [1880] BW. CG59572-01 and CG59572-02: Pseudouridine Synthase 3  
     [1881] Expression of gene CG59572-01 and CG59572-02 was assessed using the primer-probe set Ag3476, described in Table BWA. Results of the RTQ-PCR runs are shown in Tables BWB, BWC and BWD. Please note that CG59572-02 represents a full-length physical clone of the CG59572-01 gene, validating the prediction of the gene sequence.  
                   TABLE BWA                          Probe Name Ag3476                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-acctacaacaactgtgggctaa-3′   22   1070   626                   Probe   TET-5′-tcatgctgtcaaaactcacatgttgt-3′-TAMRA   26   1092   627               Reverse   5′-ggaacagtgtccagtccttgta-3′   22   1127   628                  
 
     [1882]               TABLE BWB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.                   (%) Ag3476,       Rel. Exp. (%)           Run       Ag3476, Run       Tissue Name   210377171   Tissue Name   210377171                                     AD 1 Hippo   16.7   Control (Path) 3   4.5               Temporal Ctx       AD 2 Hippo   23.8   Control (Path) 4   31.6               Temporal Ctx       AD 3 Hippo   10.3   AD 1 Occipital   28.5               Ctx       AD 4 Hippo   8.5   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   88.3   AD 3 Occipital   7.9               Ctx       AD 6 Hippo   77.4   AD 4 Occipital   20.6               Ctx       Control 2 Hippo   37.4   AD 5 Occipital   35.4               Ctx       Control 4 Hippo   9.6   AD 6 Occipital   54.7               Ctx       Control (Path) 3   8.4   Control 1 Occipital   4.7       Hippo       Ctx       AD 1 Temporal Ctx   18.6   Control 2 Occipital   67.8               Ctx       AD 2 Temporal Ctx   32.3   Control 3 Occipital   15.6               Ctx       AD 3 Temporal Ctx   8.0   Control 4 Occipital   5.6               Ctx       AD 4 Temporal Ctx   21.6   Control (Path) 1   100.0               Occipital Ctx       AD 5 Inf Temporal   84.1   Control (Path) 2   7.8       Ctx       Occipital Ctx       AD 5 SupTemporal   41.5   Control (Path) 3   5.9       Ctx       Occipital Ctx       AD 6 Inf Temporal   77.4   Control (Path) 4   18.0       Ctx       Occipital Ctx       AD 6 Sup Temporal   88.3   Control 1 Parietal   8.1       Ctx       Ctx       Control 1 Temporal   5.4   Control 2 Parietal   47.0       Ctx       Ctx       Control 2 Temporal   40.1   Control 3 Parietal   18.2       Ctx       Ctx       Control 3 Temporal   22.1   Control (Path) 1   71.7       Ctx       Parietal Ctx       Control 4 Temporal   5.1   Control (Path) 2   20.6       Ctx       Parietal Ctx       Control (Path) 1   55.1   Control (Path) 3   5.3       Temporal Ctx       Parietal Ctx       Control (Path) 2   31.6   Control (Path) 4   46.3       Temporal Ctx       Parietal Ctx                    
     [1883]               TABLE BWC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3476,       (%) Ag3476,           Run       Run       Tissue Name   217119004   Tissue Name   217119004                                     Adipose   5.7   Renal ca. TK-10   13.9       Melanoma*   13.4   Bladder   16.3       Hs688(A).T       Melanoma*   14.6   Gastric ca. (liver met.)   42.9       Hs688(B).T       NCI-N87       Melanoma* M14   18.6   Gastric ca. KATO III   92.0       Melanoma*   38.7   Colon ca. SW-948   7.3       LOXIMVI       Melanoma* SK-   27.0   Colon ca. SW480   40.9       MEL-5       Squamous cell   9.9   Colon ca.* (SW480   27.5       carcinoma SCC-4       met) SW620       Testis Pool   5.9   Colon ca. HT29   24.0       Prostate ca.* (bone   34.4   Colon ca. HCT-116   32.5       met) PC-3       Prostate Pool   5.6   Colon ca. CaCo-2   52.1       Placenta   1.1   Colon cancer tissue   10.4       Uterus Pool   3.8   Colon ca. SW1116   3.9       Ovarian ca.   15.4   Colon ca. Colo-205   6.1       OVCAR-3       Ovarian ca. SK-   20.7   Colon ca. SW-48   9.0       OV-3       Ovarian ca.   14.5   Colon Pool   13.6       OVCAR-4       Ovarian ca.   44.8   Small Intestine Pool   8.4       OVCAR-5       Ovarian ca.   18.4   Stomach Pool   7.0       IGROV-1       Ovarian ca.   10.3   Bone Marrow Pool   4.0       OVCAR-8       Ovary   7.0   Fetal Heart   6.3       Breast ca. MCF-7   16.8   Heart Pool   5.4       Breast ca. MDA-   31.0   Lymph Node Pool   14.5       MB-231       Breast ca. BT 549   51.1   Fetal Skeletal Muscle   4.2       Breast ca. T47D   100.0   Skeletal Muscle Pool   10.7       Breast ca. MDA-N   28.7   Spleen Pool   5.4       Breast Pool   11.0   Thymus Pool   8.2       Trachea   6.2   CNS cancer   11.9               (glio/astro) U87-MG       Lung   2.0   CNS cancer   44.1               (glio/astro) U-118-MG       Fetal Lung   15.5   CNS cancer   29.9               (neuro; met) SK-N-AS       Lung ca. NCI-N417   14.5   CNS cancer (astro)   13.6               SF-539       Lung ca. LX-1   31.0   CNS cancer (astro)   43.8               SNB-75       Lung ca. NCI-H146   9.3   CNS cancer (glio)   16.0               SNB-19       Lung ca. SHP-77   36.6   CNS cancer (glio) SF-   44.8               295       Lung ca. A549   14.4   Brain (Amygdala)   3.6               Pool       Lung ca. NCI-H526   21.6   Brain (cerebellum)   7.8       Lung ca. NCI-H23   23.0   Brain (fetal)   7.6       Lung ca. NCI-H460   13.9   Brain (Hippocampus)   4.5               Pool       Lung ca. HOP-62   14.9   Cerebral Cortex Pool   6.3       Lung ca. NCI-H522   38.7   Brain (Substantia   3.4               nigra) Pool       Liver   1.9   Brain (Thalamus) Pool   6.9       Fetal Liver   17.2   Brain (whole)   3.8       Liver ca. HepG2   18.4   Spinal Cord Pool   3.6       Kidney Pool   12.9   Adrenal Gland   3.8       Fetal Kidney   15.3   Pituitary gland Pool   3.2       Renal ca. 786-0   13.4   Salivary Gland   1.8       Renal ca. A498   7.1   Thyroid (female)   4.4       Renal ca. ACHN   10.4   Pancreatic ca.   27.7               CAPAN2       Renal ca. UO-31   22.1   Pancreas Pool   14.7                    
     [1884]               TABLE BWD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3476, Run       Ag3476, Run       Tissue Name   166420471   Tissue Name   166420471                                     Secondary Th1 act   31.4   HUVEC IL-1beta   27.5       Secondary Th2 act   30.6   HUVEC IFN gamma   23.7       Secondary Tr1 act   40.3   HUVEC TNF alpha +   15.4               IFN gamma       Secondary Th1 rest   11.6   HUVEC TNF alpha +   16.2               IL4       Secondary Th2 rest   9.3   HUVEC IL-11   13.4       Secondary Tr1 rest   9.2   Lung Microvascular EC   12.3               none       Primary Th1 act   23.5   Lung Microvascular EC   11.0               TNF alpha + IL-1beta       Primary Th2 act   44.8   Microvascular Dermal   20.3               EC none       Primary Tr1 act   55.5   Microsvasular Dermal   13.6               EC TNF alpha + IL-1beta       Primary Th1 rest   48.6   Bronchial epithelium   7.8               TNF alpha + IL1beta       Primary Th2 rest   24.7   Small airway epithelium   9.5               none       Primary Tr1 rest   22.8   Small airway epithelium   48.0               TNF alpha + IL-1beta       CD45RA CD4   15.9   Coronery artery SMC rest   14.1       lymphocyte act       CD45RO CD4   45.1   Coronery artery SMC   9.8       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   26.2   Astrocytes rest   13.9       Secondary CD8   46.3   Astrocytes TNF alpha +   14.2       lymphocyte rest       IL-1beta       Secondary CD8   23.0   KU-812 (Basophil) rest   29.5       lymphocyte act       CD4 lymphocyte none   6.3   KU-812 (Basophil)   55.1               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   15.8   CCD1106   18.7       CD95 CH11       (Keratinocytes) none       LAK cells rest   8.4   CCD1106   100.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   29.1   Liver cirrhosis   12.8       LAK cells IL-2 + IL-12   35.8   Lupus kidney   7.9       LAK cells IL-2 + IFN   42.6   NCI-H292 none   44.4       gamma       LAK cells IL-2 + IL-18   28.7   NCI-H292 IL-4   52.5       LAK cells   14.0   NCI-H292 IL-9   55.5       PMA/ionomycin       NK Cells IL-2 rest   19.9   NCI-H292 IL-13   29.3       Two Way MLR 3 day   23.0   NCI-H292 IFN gamma   30.1       Two Way MLR 5 day   31.0   HPAEC none   10.7       Two Way MLR 7 day   18.0   HPAEC TNF alpha + IL-   13.1               1beta       PBMC rest   4.8   Lung fibroblast none   23.3       PBMC PWM   39.5   Lung fibroblast TNF   16.0               alpha + IL-1beta       PBMC PHA-L   11.4   Lung fibroblast IL-4   27.7       Ramos (B cell) none   18.2   Lung fibroblast IL-9   22.5       Ramos (B cell)   16.2   Lung fibroblast IL-13   19.6       ionomycin       B lymphocytes PWM   56.3   Lung fibroblast IFN   48.3               gamma       B lymphocytes CD40L   36.9   Dermal fibroblast   28.5       and IL-4       CCD1070 rest       EOL-1 dbcAMP   23.5   Dermal fibroblast   38.7               CCD1070 TNF alpha       EOL-1 dbcAMP   20.0   Dermal fibroblast   11.8       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   10.1   Dermal fibroblast IFN   9.9               gamma       Dendritic cells LPS   9.7   Dermal fibroblast IL-4   15.7       Dendritic cells anti-   10.2   IBD Colitis 2   6.6       CD40       Monocytes rest   12.0   IBD Crohn&#39;s   6.2       Monocytes LPS   12.5   Colon   46.0       Macrophages rest   13.3   Lung   12.6       Macrophages LPS   7.4   Thymus   21.8       HUVEC none   24.3   Kidney   18.3       HUVEC starved   33.4                    
     [1885] CNS_neurodegeneration_v1.0 Summary: Ag3476 This panel confirms the expression of the CG59572-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1886] General_screening_panel_v1.4 Summary: Ag3476 Highest expression of the CG59572-01 gene is detected in a breast cancer cell line sample (CT=27.4). Furthermore, moderate to high expression of this gene is detected in CNS cancer, colon cancer, gastric cancer, pancreatic cancer, lung cancer, ovarian cancer, and prostate cancer. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.  
     [1887] This gene is expressed at low to moderate levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1888] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [1889] In addition, this gene is expressed at much higher levels in fetal lung and liver tissue (CTs=30) when compared to expression in the adult counterpart (CTs=33). Thus, expression of this gene may be used to differentiate between the fetal and adult source of these tissues.  
     [1890] Panel 4D Summary: Ag3476 Highest expression of the CG59572-01 gene is detected in TNFalpha+IL-1 beta treated keratinocytes (CT=27.2). Expression of this gene appears to be stimulated in activated secondary Th1, Th2 and Tr1 cells, PWM treated PBMCs, PWM treated 13-lymphocytes, IL-2/IL-2+IL-12/IL-2+IFN gamma/IL-2+IL-18 treated LAK cells, and TNFalpha+IL-1beta treated small airway epithelium (CTs=28-30). Thus, this gene may be important in the activation of T and B cells or the function of activated T and B cells. Therefore, small molecules that antagonize the function of this gene product may reduce or eliminate the symptoms in patients with autoimmune and inflammatory diseases in which B and T cells play a part in the initiation or progression of the disease process, such as systemic lupus erythematosus, Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.  
     [1891] BX. CG59522-01: Myosin I  
     [1892] Expression of gene CG59522-01 was assessed using the primer-probe set Ag3456, described in Table BXA. Results of the RTQ-PCR runs are shown in Table BXB.  
                   TABLE BXA                          Probe Name 3456                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-atgaactgcacttggagagaaa-3′   22   664   629                   Probe   TET-5′-aatttcacacaccagggagcaggact-3′-TAMRA   26   699   630               Reverse   5′-ctctgctcatcactcacagtca-3′   22   730   631                  
 
     [1893]               TABLE BXB                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3456, Run       Ag3456, Run       Tissue Name   166397214   Tissue Name   166397214                                     Secondary Th1 act   20.2   HUVEC IL-1beta   0.0       Secondary Th2 act   19.6   HUVEC IFN gamma   0.0       Secondary Tr1 act   35.4   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   34.2   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   17.3   HUVEC IL-11   0.0       Secondary Tr1 rest   20.7   Lung Microvascular EC   0.0               none       Primary Th1 act   10.6   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   13.3   Microvascular Dermal   0.0               EC none       Primary Tr1 act   25.2   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   100.0   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   35.1   Small airway epithelium   0.0               none       Primary Tr1 rest   25.9   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   9.9   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   28.9   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   27.5   Astrocytes rest   0.0       Secondary CD8   15.6   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   26.6   KU-812 (Basophil) rest   2.2       lymphocyte act       CD4 lymphocyte none   5.0   KU-812 (Basophil)   5.2               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   31.2   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   4.7   CCD1106   1.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   41.5   Liver cirrhosis   0.8       LAK cells IL-2 + IL-12   22.4   Lupus kidney   0.4       LAK cells IL-2 + IFN   29.5   NCI-H292 none   0.3       gamma       LAK cells IL-2 + IL-18   25.7   NCI-H292 IL-4   0.1       LAK cells   4.4   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   22.2   NCI-H292 IL-13   0.0       Two Way MLR 3 day   14.2   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   16.0   HPAEC none   0.0       Two Way MLR 7 day   17.2   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   7.5   Lung fibroblast none   0.0       PBMC PWM   33.9   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   12.7   Lung fibroblast IL-4   0.0       Ramos (B cell) none   4.7   Lung fibroblast IL-9   0.0       Ramos (B cell)   8.5   Lung fibroblast IL-13   0.1       ionomycin       B lymphocytes PWM   25.5   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   18.8   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   17.3   Dermal fibroblast   43.5               CCD1070 TNF alpha       EOL-1 dbcAMP   9.9   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   2.1   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   16.4   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   1.6   IBD Colitis 2   0.3       CD40       Monocytes rest   20.9   IBD Crohn&#39;s   0.1       Monocytes LPS   45.7   Colon   4.2       Macrophages rest   1.3   Lung   2.5       Macrophages LPS   16.3   Thymus   0.0       HUVEC none   0.0   Kidney   11.3       HUVEC starved   0.0                    
     [1894] CNS_neurodegeneration_v1.0 Summary: Ag3456 Expression of CG59522-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1895] General_screening_panel_v1.4 Summary: Ag3456 Expression of CG59522-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1896] Panel 4D Summary: Ag3456 Highest expression of the CG59522-01 gene is detected in sample derived from resting primary Th1 cells (CT=29.8). Thus, expression of this gene can be used to distinguish this sample from other samples in this panel. This gene is also expressed at low but significant levels in T cells prepared under a number of conditions, LAK cells, macrophages and dendritic cells also express the transcript. The only non-hematopoietic cell type that expresses the transcript detected by this primer and probe at significant levels is dermal fibroblasts. Colon and kidney also express low levels of the transcript. Thus, this transcript or the protein it encodes could be used to detect hematopoietically-derived cells. Furthermore, therapeutics designed with the protein encoded by this transcript could be important in the regulation the function of antigen presenting cells (macrophages and dendritic cells) or T cells and be important in the treatment of asthma, emphysema, psoriasis, arthritis, and IBD. Therefore, therapeutics designed with the protein encoded for by this transcript could be important in regulating T cell function and treating T and B cell mediated diseases such as asthma, arthritis, psoriasis, IBD, and systemic lupus erythematosus.  
     [1897] BY. CG59520-01: Farnesyl Pyrophosphate Synthetase  
     [1898] Expression of gene CG59520-01 was assessed using the primer-probe set Ag5923, described in Table BYA. Results of the RTQ-PCR runs are shown in Tables BYB and BYC.  
                   TABLE BYA                          Probe Name Ag5923                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:                                             Forward   5′-gaatgggaaaccagaaatcag-3′   21   5   632                   Probe   TET-5′-tttatgcccaagcaaagcaggatttc-3′-TAMRA   26   29   633               Reverse   5′-accctaacgatctgggagtagt-3′   22   62   634                  
 
     [1899]               TABLE BYB                          General_screening panel v1.5                                 Rel. Exp.       Rel. Exp.           (%) Ag5923,       (%) Ag5923,           Run       Run       Tissue Name   247608956   Tissue Name   247608956                                     Adipose   0.6   Renal ca. TK-10   12.1       Melanoma*   1.9   Bladder   7.1       Hs688(A).T       Melanoma*   2.9   Gastric ca. (liver met.)   26.2       Hs688(B).T       NCI-N87       Melanoma* M14   8.9   Gastric ca. KATO III   31.0       Melanoma*   3.9   Colon ca. SW-948   6.8       LOXIMVI       Melanoma* SK-   2.4   Colon ca. SW480   15.3       MEL-5       Squamous cell   1.8   Colon ca.* (SW480   8.2       carcinoma SCC-4       met) SW620       Testis Pool   15.1   Colon ca. HT29   1.9       Prostate ca.* (bone   5.6   Colon ca. HCT-116   9.3       met) PC-3       Prostate Pool   2.3   Colon ca. CaCo-2   6.4       Placenta   2.3   Colon cancer tissue   7.3       Uterus Pool   0.0   Colon ca. SW1116   7.1       Ovarian ca.   6.7   Colon ca. Colo-205   9.5       OVCAR-3       Ovarian ca. SK-   14.8   Colon ca. SW-48   3.8       OV-3       Ovarian ca.   4.2   Colon Pool   5.6       OVCAR-4       Ovarian ca.   23.0   Small Intestine Pool   7.0       OVCAR-5       Ovarian ca.   4.1   Stomach Pool   0.6       IGROV-1       Ovarian ca.   0.7   Bone Marrow Pool   2.1       OVCAR-8       Ovary   12.1   Fetal Heart   4.1       Breast ca. MCF-7   4.4   Heart Pool   1.1       Breast ca. MDA-   6.8   Lymph Node Pool   7.3       MB-231       Breast ca. BT 549   17.8   Fetal Skeletal Muscle   1.0       Breast ca. T47D   5.6   Skeletal Muscle Pool   5.3       Breast ca. MDA-N   2.5   Spleen Pool   2.0       Breast Pool   9.5   Thymus Pool   8.0       Trachea   14.1   CNS cancer   1.7               (glio/astro) U87-MG       Lung   13.9   CNS cancer   10.2               (glio/astro) U-118-MG       Fetal Lung   16.7   CNS cancer   2.8               (neuro; met) SK-N-AS       Lung ca. NCI-N417   1.7   CNS cancer (astro)   2.8               SF-539       Lung ca. LX-1   12.8   CNS cancer (astro)   14.2               SNB-75       Lung ca. NCI-H146   1.6   CNS cancer (glio)   3.9               SNB-19       Lung ca. SHP-77   1.5   CNS cancer (glio) SF-   10.8               295       Lung ca. A549   11.0   Brain (Amygdala)   1.8               Pool       Lung ca. NCI-H526   0.5   Brain (cerebellum)   4.0       Lung ca. NCI-H23   10.9   Brain (fetal)   4.6       Lung ca. NCI-H460   4.1   Brain (Hippocampus)   3.3               Pool       Lung ca. HOP-62   2.3   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   5.2   Brain (Substantia   3.2               nigra) Pool       Liver   0.5   Brain (Thalamus) Pool   1.6       Fetal Liver   4.3   Brain (whole)   1.8       Liver ca. HepG2   0.3   Spinal Cord Pool   1.7       Kidney Pool   13.6   Adrenal Gland   1.7       Fetal Kidney   7.1   Pituitary gland Pool   0.0       Renal ca. 786-0   11.7   Salivary Gland   1.2       Renal ca. A498   5.6   Thyroid (female)   0.5       Renal ca. ACHN   6.2   Pancreatic ca.   100.0               CAPAN2       Renal ca. UO-31   14.0   Pancreas Pool   15.3                    
     [1900]               TABLE BYC                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag5923, Run       Ag5923, Run       Tissue Name   247579946   Tissue Name   247579946                                     Secondary Th1 act   14.6   HUVEC IL-1beta   5.3       Secondary Th2 act   36.6   HUVEC IFN gamma   12.1       Secondary Tr1 act   5.6   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   10.5   HUVEC IL-11   6.7       Secondary Tr1 rest   0.0   Lung Microvascular EC   15.5               none       Primary Th1 act   0.0   Lung Microvascular EC   2.4               TNF alpha + IL-1beta       Primary Th2 act   11.1   Microvascular Dermal   0.0               EC none       Primary Tr1 act   11.0   Microsvasular Dermal   5.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   13.5               TNF alpha + IL1beta       Primary Th2 rest   1.5   Small airway epithelium   7.2               none       Primary Tr1 rest   1.3   Small airway epithelium   44.8               TNF alpha + IL-1beta       CD45RA CD4   13.5   Coronery artery SMC rest   1.6       lymphocyte act       CD45RO CD4   12.9   Coronery artery SMC   6.7       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   1.8   Astrocytes rest   1.5       Secondary CD8   3.6   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   15.3               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   21.5       CD95 CH11       (Keratinocytes) none       LAK cells rest   15.9   CCD1106   31.9               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   3.5   Liver cirrhosis   4.0       LAK cells IL-2 + IL-12   0.0   NCI-H292 none   61.1       LAK cells IL-2 + IFN   2.3   NCI-H292 IL-4   100.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-9   45.1       LAK cells   13.0   NCI-H292 IL-13   47.0       PMA/ionomycin       NK Cells IL-2 rest   37.1   NCI-H292 IFN gamma   14.5       Two Way MLR 3 day   4.9   HAPEC none   0.0       Two Way MLR 5 day   0.0   HPAEC TNF alpha + IL-   24.1               1beta       Two Way MLR 7 day   1.2   Lung fibroblast none   6.0       PBMC rest   0.0   Lung fibroblast TNF   3.7               alpha + IL-1beta       PBMC PWM   0.0   Lung fibroblast IL-4   1.0       PBMC PHA-L   0.0   Lung fibroblast IL-9   8.7       Ramos (B cell) none   0.0   Lung fibroblast IL-13   0.0       Ramos (B cell)   17.7   Lung fibroblast IFN   3.8       ionomycin       gamma       B lymphocytes PWM   11.4   Dermal fibroblast   5.8               CCD1070 rest       B lymphocytes CD40L   23.2   Dermal fibroblast   21.3       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   21.0   Dermal fibroblast   8.6               CCD1070 IL-1beta       EOL-1 dbcAMP   3.5   Dermal fibroblast IFN   12.9       PMA/ionomycin       gamma       Dendritic cells none   11.7   Dermal fibroblast IL-4   13.8       Dendritic cells LPS   8.4   Dermal Fibroblasts rest   0.0       Dendritic cells anti-   3.8   Neutrophils TNFa + LPS   1.5       CD40       Monocytes rest   0.0   Neutrophils rest   18.0       Monocytes LPS   57.8   Colon   0.0       Macrophages rest   1.7   Lung   0.0       Macrophages LPS   9.8   Thymus   8.8       HUVEC none   3.1   Kidney   4.0       HUVEC starved   2.5                    
     [1901] CNS_neurodegeneration_v1.0 Summary: Ag5923 Expression of the CG59520-01 gene is low/undetectable (CTs&gt;34.5) across all of the samples on this panel (data not shown).  
     [1902] General_screening_panel_v1.5 Summary: Ag5923 Highest expression of the CG59520-01 gene is detected in sample derived from a pancreatic cancer cell line (CT=31.5). Thus, expression of this gene can be used in distinguishing this sample from other samples from the panel and as a marker for pancreatic cancer. In addition low levels of expression of this gene are associated with samples derived from CNS, colon, gastric, renal, lung, breast, ovarian and melanoma cnacer cell lines. This gene encodes a farnesyl pyrophosphate synthetase, which is involved in cholesterol biosynthesis. It has been suggested that in several types of cancer, activation of p21 would be aided by continuous farnesylation due to stimulation of the cholesterol biosynthetic pathway in tumors (Rao, 1995). Therefore, therapeutic modulation of the activity of protein encoded by this gene may be beneficial in the treatment of these cancers.  
     [1903] In addition, low but significant levels of expression in the pancreas suggest that this gene product may be useful in the treatment of type II diabetes.  
     REFERENCES  
     [1904] 1. Rao K N. (1995) The significance of the cholesterol biosynthetic pathway in cell growth and carcinogenesis (review). Anticancer Res March-April 1995;15(2):309-14  
     [1905] Panel 4.1D Summary: Ag5923 High expression of the CG59520-01 gene is detected in sample derived from untreated and IL4 treated NCI-H292 cells (CTs=33). Thus, expression of this gene could be used to distinguish these samples from other samples from the panel. Also, therapeutic modulation of the activity of this gene product may be beneficial in the treatment asthma and emphysema.  
     [1906] Panel 5 Islet Summary: Ag5923 Expression of the CG59520-01 gene is low/undetectable (CTs&gt;34.5) across all of the samples on this panel (data not shown).  
     [1907] BZ. CG-59704-01: Serine/Threonine Kinase  
     [1908] Expression of gene CG59704-01 was assessed using the primer-probe set Ag3509, described in Table BZA. Results of the RTQ-PCR runs are shown in Tables BZB, BZC and BZD.  
                   TALE BZA                          Probe Name Ag3509                                                     Start               Primers   Sequences   Length   Position   SEQ ID NO:               Forward   5′-gacttccctcacctagcttctg-3′   22   4228   635                   Probe   TET-5′-actgcatgccaccactgctgagta-3′-TAMRA   24   4257   636               Reverse   5′-caccaacctagcaaacaaacag-3′   22   4281   637                  
 
     [1909]               TABLE BZB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3509,           Ag3509, Run       Run       Tissue Name   210499481   Tissue Name   210499481                                     AD 1 Hippo   20.2   Control (Path) 3   24.1               Temporal Ctx       AD 2 Hippo   20.2   Control (Path) 4   20.7               Temporal Ctx       AD 3 Hippo   23.3   AD 1 Occipital Ctx   16.4       AD 4 Hippo   13.5   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   66.4   AD 3 Occipital Ctx   9.9       AD 6 Hippo   84.7   AD 4 Occipital Ctx   4.6       Control 2 Hippo   18.0   AD 5 Occipital Ctx   30.4       Control 4 Hippo   0.4   AD 6 Occipital Ctx   0.0       Control (Path) 3   0.3   Control 1 Occipital   10.0       Hippo       Ctx       AD 1 Temporal   23.7   Control 2 Occipital   35.6       Ctx       Ctx       AD 2 Temporal   15.4   Control 3 Occipital   16.3       Ctx       Ctx       AD 3 Temporal   10.8   Control 4 Occipital   25.2       Ctx       Ctx       AD 4 Temporal   18.8   Control (Path) 1   57.4       Ctx       Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   8.1       Ctx       Occipital Ctx       AD 5 Sup   72.2   Control (Path) 3   5.4       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   21.9   Control (Path) 4   30.4       Ctx       Occipital Ctx       AD 6 Sup   62.4   Control 1 Parietal   12.1       Temporal Ctx       Ctx       Control 1   5.4   Control 2 Parietal   54.0       Temporal Ctx       Ctx       Control 2   30.6   Control 3 Parietal   12.0       Temporal Ctx       Ctx       Control 3   6.0   Control (Path) 1   51.4       Temporal Ctx       Parietal Ctx       Control 3   12.2   Control (Path) 2   16.0       Temporal Ctx       Parietal Ctx       Control (Path) 1   40.9   Control (Path) 3   2.1       Temporal Ctx       Parietal Ctx       Control (Path) 2   31.9   Control (Path) 4   29.7       Temporal Ctx       Parietal Ctx                    
     [1910]               TABLE BZC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3509,       (%) Ag3509,           Run       Run       Tissue Name   217240617   Tissue Name   217240617                                     Adipose   9.5   Renal ca. TK-10   20.4       Melanoma*   8.7   Bladder   16.6       Hs688(A).T       Melanoma*   4.5   Gastric ca. (liver met.)   37.6       Hs688(B).T       NCI-N87       Melanoma* M14   12.0   Gastric ca. KATO III   23.3       Melanoma*   3.1   Colon ca. SW-948   6.9       LOXIMVI       Melanoma* SK-   11.0   Colon ca. SW480   35.8       MEL-5       Squamous cell   9.5   Colon ca.* (SW480   24.7       carcinoma SCC-4       met) SW620       Testis Pool   5.4   Colon ca. HT29   9.3       Prostate ca.* (bone   24.1   Colon ca. HCT-116   62.4       met) PC-3       Prostate Pool   4.5   Colon ca. CaCo-2   8.8       Placenta   1.9   Colon cancer tissue   10.9       Uterus Pool   1.8   Colon ca. SW1116   3.7       Ovarian ca.   43.2   Colon ca. Colo-205   1.2       OVCAR-3       Ovarian ca. SK-   42.3   Colon ca. SW-48   2.8       OV-3       Ovarian ca.   1.1   Colon Pool   9.2       OVCAR-4       Ovarian ca.   19.1   Small Intestine Pool   8.2       OVCAR-5       Ovarian ca.   8.7   Stomach Pool   3.7       IGROV-1       Ovarian ca.   7.5   Bone Marrow Pool   4.6       OVCAR-8       Ovary   3.4   Fetal Heart   7.3       Breast ca. MCF-7   20.7   Heart Pool   5.6       Breast ca. MDA-   32.8   Lymph Node Pool   10.1       MB-231       Breast ca. BT 549   35.1   Fetal Skeletal Muscle   6.7       Breast ca. T47D   34.4   Skeletal Muscle Pool   3.6       Breast ca. MDA-N   18.6   Spleen Pool   7.7       Breast Pool   15.7   Thymus Pool   11.0       Trachea   6.8   CNS cancer   27.4               (glio/astro) U87-MG       Lung   15.3   CNS cancer   45.4               (glio/astro) U-118-MG       Fetal Lung   17.6   CNS cancer   16.3               (neuro; met) SK-N-AS       Lung ca. NCI-N417   11.8   CNS cancer (astro)   9.9               SF-539       Lung ca. LX-1   29.5   CNS cancer (astro)   50.7               SNB-75       Lung ca. NCI-H146   5.6   CNS cancer (glio)   7.0               SNB-19       Lung ca. SHP-77   19.1   CNS cancer (glio) SF-   25.7               295       Lung ca. A549   17.2   Brain (Amygdala)   4.9               Pool       Lung ca. NCI-H526   4.2   Brain (cerebellum)   13.7       Lung ca. NCI-H23   100.0   Brain (fetal)   14.8       Lung ca. NCI-H460   27.2   Brain (Hippocampus)   3.7               Pool       Lung ca. HOP-62   16.2   Cerebral Cortex Pool   3.0       Lung ca. NCI-H522   29.9   Brain (Substantia   1.7               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   5.6       Fetal Liver   10.1   Brain (whole)   6.1       Liver ca. HepG2   17.7   Spinal Cord Pool   2.0       Kidney Pool   26.1   Adrenal Gland   8.8       Fetal Kidney   24.3   Pituitary gland Pool   3.4       Renal ca. 786-0   19.8   Salivary Gland   4.9       Renal ca. A498   2.4   Thyroid (female)   3.4       Renal ca. ACHN   8.2   Pancreatic ca.   34.2               CAPAN2       Renal ca. UO-31   9.5   Pancreas Pool   16.7                    
     [1911]               TABLE BZD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3509, Run       Ag3509, Run       Tissue Name   166407201   Tissue Name   166407201                                     Secondary Th1 act   50.0   HUVEC IL-1beta   4.7       Secondary Th2 act   45.4   HUVEC IFN gamma   4.8       Secondary Tr1 act   87.7   HUVEC TNF alpha +   10.0               IFN gamma       Secondary Th1 rest   17.4   HUVEC TNF alpha +   19.9               IL4       Secondary Th2 rest   21.9   HUVEC IL-11   13.4       Secondary Tr1 rest   32.5   Lung Microvascular EC   14.1               none       Primary Th1 act   40.9   Lung Microvascular EC   24.8               TNF alpha + IL-1beta       Primary Th2 act   83.5   Microvascular Dermal   22.1               EC none       Primary Tr1 act   100.0   Microsvasular Dermal   12.2               EC TNF alpha + IL-1beta       Primary Th1 rest   75.8   Bronchial epithelium   9.9               TNF alpha + IL1beta       Primary Th2 rest   31.0   Small airway epithelium   7.7               none       Primary Tr1 rest   41.5   Small airway epithelium   23.0               TNF alpha + IL-1beta       CD45RA CD4   21.9   Coronery artery SMC rest   7.6       lymphocyte act       CD45RO CD4   56.6   Coronery artery SMC   2.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   58.6   Astrocytes rest   25.5       Secondary CD8   51.4   Astrocytes TNF alpha +   28.5       lymphocyte rest       IL-1beta       Secondary CD8   52.1   KU-812 (Basophil) rest   25.5       lymphocyte act       CD4 lymphocyte none   21.0   KU-812 (Basophil)   68.8               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   41.8   CCD1106   17.4       CD95 CH11       (Keratinocytes) none       LAK cells rest   27.9   CCD1106   36.6               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   58.6   Liver cirrhosis   57.8       LAK cells IL-2 + IL-12   61.1   Lupus kidney   24.3       LAK cells IL-2 + IFN   85.3   NCI-H292 none   20.0       gamma       LAK cells IL-2 + IL-18   61.1   NCI-H292 IL-4   21.6       LAK cells   49.3   NCI-H292 IL-9   24.5       PMA/ionomycin       NK Cells IL-2 rest   43.2   NCI-H292 IL-13   24.8       Two Way MLR 3 day   50.0   NCI-H292 IFN gamma   14.8       Two Way MLR 5 day   39.5   HPAEC none   9.5       Two Way MLR 7 day   37.1   HPAEC TNF alpha + IL-   25.9               1beta       PBMC rest   15.1   Lung fibroblast none   19.6       PBMC PWM   44.8   Lung fibroblast TNF   21.3               alpha + IL-1beta       PBMC PHA-L   14.8   Lung fibroblast IL-4   18.8       Ramos (B cell) none   75.3   Lung fibroblast IL-9   17.8       Ramos (B cell)   17.8   Lung fibroblast IL-13   21.9       ionomycin       B lymphocytes PWM   33.4   Lung fibroblast IFN   21.3               gamma       B lymphocytes CD40L   42.3   Dermal fibroblast   46.7       and IL-4       CCD1070 rest       EOL-1 dbcAMP   25.3   Dermal fibroblast   69.3               CCD1070 TNF alpha       EOL-1 dbcAMP   18.9   Dermal fibroblast   20.3       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   10.7   Dermal fibroblast IFN   17.4               gamma       Dendritic cells LPS   13.6   Dermal fibroblast IL-4   21.8       Dendritic cells anti-   12.2   IBD Colitis 2   7.1       CD40       Monocytes rest   10.0   IBD Crohn&#39;s   5.5       Monocytes LPS   25.3   Colon   53.6       Macrophages rest   29.3   Lung   5.6       Macrophages LPS   7.2   Thymus   27.5       HUVEC none   24.1   Kidney   51.4       HUVEC starved   33.9                    
     [1912] CNS_neurodegeneration_v1.0 Summary: Ag3509 This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment.  
     [1913] General_screening_panel_v1.4 Summary: Ag3509 Highest expression of the CG59704-01 gene is detected in a sample derived from a lung cancer cell line (CT=31.69). Thus, expression of this gene can be used in distinguishing this sample from other samples in this panel. Furthermore, moderate expression of this gene is associated with cell lines derived from pancreatic, brain, colon, gastric, renal, lung, breast and ovarian cancers. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, or antibodies, might be beneficial in the treatment of these cancers.  
     [1914] Panel 4D Summary: Ag3509 Expression of the CG59704-01 gene is stimulated in T cells, LAK cells and B cells, with highest expression in primary activated Tr1 cells (CT=32). Therefore, therapeutics designed with the protein encoded for by this transcript could be important in regulating T and B cell function and treating T cell/B cell mediated diseases such as asthma, arthritis, psoriasis, IBD, allergies, hypersensitivity reactions, microbial and viral infections systemic lupus erythematosus, multiple sclerosis, chronic obstructive pulmonary disease and systemic lupus erythematosus.  
     [1915] Furthermore, expression of this gene is decreased in colon samples from patients with IBD colitis and Crohn&#39;s disease relative to normal colon. Therefore, therapeutic modulation of the activity of this gene product may be useful in the treatment of inflammatory bowel disease.  
     [1916] Panel 5 Islet Summary: Ag3509 Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [1917] CA. CG59628-01: Short-Chain Dehydrogenase Like  Homo Sapiens    
     [1918] Expression of gene CG59628-01 was assessed using the primer-probe set Ag3500, described in Table CAA. Results of the RTQ-PCR runs are shown in Tables CAB and CAC.  
                   TABLE CCA                          Probe Name Ag3500                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-gcagatgtggtgatgagtatga-3′   22   1159   638                   Probe   TET-5′-tcaggtaaactaaaaccaacaatggca-3′-TAMRA   27   1207   639               Reverse   5′-atcttcaatttccctgacatga-3′   22   1235   640                  
 
     [1919]               TABLE CAB                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3500,       (%) Ag3500,           Run       Run       Tissue Name   217131378   Tissue Name   217131378                                     Adipose   25.0   Renal ca. TK-10   82.4       Melanoma*   19.3   Bladder   15.6       Hs688(A).T       Melanoma*   18.3   Gastric ca. (liver met.)   36.3       Hs688(B).T       NCI-N87       Melanoma* M14   33.9   Gastric ca. KATO III   51.1       Melanoma*   36.3   Colon ca. SW-948   17.8       LOXIMVI       Melanoma* SK-   61.1   Colon ca. SW480   66.4       MEL-5       Squamous cell   17.0   Colon ca.* (SW480   36.1       carcinoma SCC-4       met) SW620       Testis Pool   11.4   Colon ca. HT29   31.6       Prostate ca.* (bone   35.1   Colon ca. HCT-116   46.0       met) PC-3       Prostate Pool   3.9   Colon ca. CaCo-2   58.6       Placenta   1.2   Colon cancer tissue   24.1       Uterus Pool   1.9   Colon ca. SW1116   6.7       Ovarian ca.   12.2   Colon ca. Colo-205   12.1       OVCAR-3       Ovarian ca. SK-   55.9   Colon ca. SW-48   25.0       OV-3       Ovarian ca.   7.2   Colon Pool   16.2       OVCAR-4       Ovarian ca.   47.6   Small Intestine Pool   9.9       OVCAR-5       Ovarian ca.   23.8   Stomach Pool   6.2       IGROV-1       Ovarian ca.   16.5   Bone Marrow Pool   4.6       OVCAR-8       Ovary   31.2   Fetal Heart   27.0       Breast ca. MCF-7   9.7   Heart Pool   12.9       Breast ca. MDA-   33.2   Lymph Node Pool   13.1       MB-231       Breast ca. BT 549   42.0   Fetal Skeletal Muscle   13.7       Breast ca. T47D   90.8   Skeletal Muscle Pool   40.9       Breast ca. MDA-N   18.9   Spleen Pool   11.6       Breast Pool   14.1   Thymus Pool   13.4       Trachea   7.7   CNS cancer   27.0               (glio/astro) U87-MG       Lung   8.1   CNS cancer   39.0               (glio/astro) U-118-MG       Fetal Lung   27.7   CNS cancer   20.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   4.4   CNS cancer (astro)   15.0               SF-539       Lung ca. LX-1   30.1   CNS cancer (astro)   100.0               SNB-75       Lung ca. NCI-H146   1.7   CNS cancer (glio)   22.5               SNB-19       Lung ca. SHP-77   27.4   CNS cancer (glio) SF-   20.6               295       Lung ca. A549   24.5   Brain (Amygdala)   4.5               Pool       Lung ca. NCI-H526   5.6   Brain (cerebellum)   1.8       Lung ca. NCI-H23   23.8   Brain (fetal)   2.0       Lung ca. NCI-H460   22.2   Brain (Hippocampus)   9.2               Pool       Lung ca. HOP-62   14.4   Cerebral Cortex Pool   11.7       Lung ca. NCI-H522   24.0   Brain (Substantia   7.7               nigra) Pool       Liver   1.2   Brain (Thalamus) Pool   10.1       Fetal Liver   28.7   Brain (whole)   2.8       Liver ca. HepG2   36.6   Spinal Cord Pool   17.2       Kidney Pool   10.8   Adrenal Gland   18.6       Fetal Kidney   13.6   Pituitary gland Pool   2.4       Renal ca. 786-0   44.1   Salivary Gland   1.7       Renal ca. A498   13.7   Thyroid (female)   11.3       Renal ca. ACHN   19.1   Pancreatic ca.   34.9               CAPAN2       Renal ca. UO-31   37.4   Pancreas Pool   22.8                    
     [1920]               TABLE CAC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3500, Run       Ag3500, Run       Tissue Name   166441942   Tissue Name   166441942                                     Secondary Th1 act   6.0   HUVEC IL-1beta   6.8       Secondary Th2 act   10.1   HUVEC IFN gamma   17.1       Secondary Tr1 act   14.0   HUVEC TNF alpha +   5.6               IFN gamma       Secondary Th1 rest   4.1   HUVEC TNF alpha +   6.2               IL4       Secondary Th2 rest   2.4   HUVEC IL-11   7.2       Secondary Tr1 rest   3.1   Lung Microvascular EC   6.0               none       Primary Th1 act   1.7   Lung Microvascular EC   4.5               TNF alpha + IL-1beta       Primary Th2 act   6.4   Microvascular Dermal   20.0               EC none       Primary Tr1 act   10.5   Microsvasular Dermal   5.9               EC TNF alpha + IL-1beta       Primary Th1 rest   20.3   Bronchial epithelium   6.8               TNF alpha + IL1beta       Primary Th2 rest   9.8   Small airway epithelium   11.2               none       Primary Tr1 rest   18.0   Small airway epithelium   50.7               TNF alpha + IL-1beta       CD45RA CD4   11.5   Coronery artery SMC rest   6.8       lymphocyte act       CD45RO CD4   8.5   Coronery artery SMC   5.7       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   13.2   Astrocytes rest   17.9       Secondary CD8   6.9   Astrocytes TNF alpha +   26.2       lymphocyte rest       IL-1beta       Secondary CD8   6.2   KU-812 (Basophil) rest   13.2       lymphocyte act       CD4 lymphocyte none   2.1   KU-812 (Basophil)   23.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   3.2   CCD1106   14.5       CD95 CH11       (Keratinocytes) none       LAK cells rest   2.5   CCD1106   68.8               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   12.2   Liver cirrhosis   20.4       LAK cells IL-2 + IL-12   9.8   Lupus kidney   13.5       LAK cells IL-2 + IFN   11.7   NCI-H292 none   47.0       gamma       LAK cells IL-2 + IL-18   8.0   NCI-H292 IL-4   21.8       LAK cells   2.0   NCI-H292 IL-9   29.5       PMA/ionomycin       NK Cells IL-2 rest   6.3   NCI-H292 IL-13   13.3       Two Way MLR 3 day   6.4   NCI-H292 IFN gamma   12.3       Two Way MLR 5 day   12.3   HPAEC none   10.5       Two Way MLR 7 day   6.3   HPAEC TNF alpha + IL-   7.3               1beta       PBMC rest   3.3   Lung fibroblast none   10.1       PBMC PWM   11.6   Lung fibroblast TNF   15.1               alpha + IL-1beta       PBMC PHA-L   5.7   Lung fibroblast IL-4   9.1       Ramos (B cell) none   6.1   Lung fibroblast IL-9   9.3       Ramos (B cell)   8.3   Lung fibroblast IL-13   8.1       ionomycin       B lymphocytes PWM   27.4   Lung fibroblast IFN   24.5               gamma       B lymphocytes CD40L   15.0   Dermal fibroblast   39.8       and IL-4       CCD1070 rest       EOL-1 dbcAMP   20.7   Dermal fibroblast   47.3               CCD1070 TNF alpha       EOL-1 dbcAMP   4.7   Dermal fibroblast   12.4       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   6.9   Dermal fibroblast IFN   11.4               gamma       Dendritic cells LPS   11.6   Dermal fibroblast IL-4   48.3       Dendritic cells anti-   3.8   IBD Colitis 2   2.2       CD40       Monocytes rest   6.0   IBD Crohn&#39;s   8.4       Monocytes LPS   2.3   Colon   100.0       Macrophages rest   12.2   Lung   14.0       Macrophages LPS   5.4   Thymus   73.2       HUVEC none   19.2   Kidney   25.0       HUVEC starved   31.9                    
     [1921] CNS_neurodegeneration_v1.0 Summary: Ag3500 Results from one experiment with the CG59628-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [1922] General_screening_panel_v1.4 Summary: Ag3500 Highest expression of the CG59628-01 gene is detected in a sample derived from a CNS cancer cell line (CT=31.1). Therefore, expression of this gene may be used to distinguish this sample from the other samples on this panel. In addition, significant expression of this gene is associated with samples derived from colon, ovarian, breast, renal, lung, melanoma, and brain cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product might be beneficial in the treatment of these cancers.  
     [1923] Among tissues with metabolic function, this gene is expressed at low but significant levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [1924] This molecule is also expressed at low levels in the CNS, including the hippocampus, thalamus, substantia nigra and cerebral cortex. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurologic disorders, such as Alzheimer&#39;s disease, Parkinson&#39;s disease, schizophrenia, multiple sclerosis, stroke and epilepsy.  
     [1925] Panel 4.1D Summary: Ag3500 Highest expression of the CG59628-01 gene is detected in colon (CT=30.3). Therefore, expression of this gene may be used to distinguish colon from the other tissues on this panel. Furthermore, expression of this gene is decreased in colon samples from patients with IBD colitis and Crohn&#39;s disease relative to normal colon. Therefore, therapeutic modulation of the activity of the GPCR encoded by this gene may be useful in the treatment of inflammatory bowel disease.  
     [1926] CB. CG59671-02: Acetyl-Coenzyme A Synthetase  
     [1927] Expression of gene CG59671-02 was assessed using the primer-probe sets Ag3506 and Ag3581, described in Tables CBA and CBB. Results of the RTQ-PCR runs are shown in Tables CBC, CBD, CBE and CBF.  
                   TABLE CBA                          Probe Name Ag3506                                                         SEQ ID           Primers   Sequences   Length   Start Position   NO:               Forward   5′-aggacacagctacgtggtgtat-3′   22   1072   641                   Probe   TET-5′-cctctctgcaatggtgccaccag-3′-TAMRA   23   1097   642               Reverse   5′-gataaactggggtgctctcaa-3′   21   1128   643                  
 
     [1928]                   TABLE CBB                          Probe Name Ag3581                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-aggacacagctacgtggtgtat-3′   22   1072   644                   Probe   TET-5′-cctctctgcaatggtgccaccag-3′-TAMRA   23   1097   645               Reverse   5′-gataaactggggtgctctcaa-3′   21   1128   646t                    
     [1929]               TABLE CBC                          CNS_neurodegeneration_v1.0                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)       Tissue   Ag3506, Run   Ag3581, Run   Tissue   Ag3506, Run   Ag3581, Run       Name   210497900   210643840   Name   210497900   210643840                                             AD 1 Hippo   30.1   36.9   Control   15.8   21.5                   (Path) 3                   Temporal                   Ctx       AD 2 Hippo   87.7   89.5   Control   42.6   53.6                   (Path) 4                   Temporal                   Ctx       AD 3 Hippo   12.5   12.5   AD 1   35.6   31.4                   Occipital                   Ctx       AD 4 Hippo   29.1   38.4   AD 2   0.0   0.0                   Occipital                   Ctx                   (Missing)       AD 5 Hippo   55.5   69.3   AD 3   17.8   18.7                   Occipital                   Ctx       AD 6 Hippo   24.1   33.4   AD 4   47.0   38.4                   Occipital                   Ctx       Control 2   42.3   56.3   AD 5   42.9   26.1       Hippo           Occipital                   Ctx       Control 4   42.6   60.3   AD 6   24.3   51.1       Hippo           Occipital                   Ctx       Control   19.8   23.0   Control 1   20.3   16.2       (Path) 3           Occipital       Hippo           Ctx       AD 1   63.7   48.3   Control 2   71.2   63.7       Temporal           Occipital       Ctx           Ctx       AD 2   60.7   87.7   Control 3   35.4   41.5       Temporal           Occipital       Ctx           Ctx       AD 3   15.9   15.6   Control 4   20.0   27.9       Temporal           Occipital       Ctx           Ctx       AD 4   47.0   57.0   Control   81.2   100.0       Temporal           (Path) 1       Ctx           Occipital                   Ctx       AD 5 Inf   68.3   72.2   Control   18.9   26.4       Temporal           (Path) 2       Ctx           Occipital                   Ctx       AD 5 Sup   65.5   57.8   Control   15.7   10.1       Temporal           (Path) 3       Ctx           Occipital                   Ctx       AD 6 Inf   29.5   35.6   Control   24.8   26.8       Temporal           (Path) 4       Ctx           Occipital                   Ctx       AD 6 Sup   31.2   31.9   Control 1   21.9   33.7       Temporal           Parietal Ctx       Ctx       Control 1   22.5   29.3   Control 2   51.8   79.0       Temporal           Parietal Ctx       Ctx       Control 2   55.1   58.6   Control 3   31.4   38.4       Temporal           Parietal Ctx       Ctx       Control 3   26.4   34.6   Control   100.0   93.3       Temporal           (Path) 1       Ctx           Parietal Ctx       Control 3   35.6   35.8   Control   51.1   57.4       Temporal           (Path) 2       Ctx           Parietal Ctx       Control   62.9   73.7   Control   17.1   17.2       (Path) 1           (Path) 3       Temporal           Parietal Ctx       Ctx       Control   54.0   55.1   Control   54.3   55.9       (Path) 2           (Path) 4       Temporal           Parietal Ctx       Ctx                    
     [1930]               TABLE CBD                          General_screening_panel_v1.4                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3506, Run   Ag3581, Run       Ag3506, Run   Ag3581, Run       Tissue Name   217236187   217423588   Tissue Name   217236187   217423588                                             Adipose   3.6   3.5   Renal ca. TK-10   4.1   3.4       Melanoma*   1.8   1.0   Bladder   16.5   12.2       Hs688(A).T       Melanoma*   0.6   0.6   Gastric ca. (liver   21.5   17.3       Hs688(B).T           met.) NCI-N87       Melanoma*   100.0   30.4   Gastric ca.   63.3   53.2       M14           KATO III       Melanoma*   0.0   0.0   Colon ca. SW-   8.0   5.0       LOXIMVI           948       Melanoma*   7.5   100.0   Colon ca.   20.7   16.6       SK-MEL-5           SW480       Squamous   10.9   6.3   Colon ca.*   0.0   0.1       cell           (SW480 met)       carcinoma           SW620       SCC-4       Testis Pool   11.9   9.8   Colon ca. HT29   24.7   15.7       Prostate ca.*   2.0   2.3   Colon ca. HCT-   0.0   0.0       (bone met)           116       PC-3       Prostate Pool   13.0   7.5   Colon ca. CaCo-2   60.3   40.1       Placenta   87.1   50.3   Colon cancer   30.8   18.8                   tissue       Uterus Pool   7.0   4.5   Colon ca.   5.3   2.4                   SW1116       Ovarian ca.   28.5   14.4   Colon ca. Colo-   1.9   1.9       OVCAR-3           205       Ovarian ca.   7.7   4.2   Colon ca. SW-48   33.2   16.8       SK-OV-3       Ovarian ca.   2.6   1.0   Colon Pool   14.3   15.1       OVCAR-4       Ovarian ca.   28.3   14.1   Small Intestine   15.0   7.4       OVCAR-5           Pool       Ovarian ca.   0.5   0.2   Stomach Pool   8.3   4.8       IGROV-1       Ovarian ca.   1.4   1.1   Bone Marrow   7.3   4.7       OVCAR-8           Pool       Ovary   7.9   7.3   Fetal Heart   16.0   12.8       Breast ca.   3.8   2.1   Heart Pool   13.1   10.1       MCF-7       Breast ca.   8.2   6.0   Lymph Node   16.3   9.2       MDA-MB-           Pool       231       Breast ca. BT   1.6   1.2   Fetal Skeletal   6.9   3.7       549           Muscle       Breast ca.   62.9   31.2   Skeletal Muscle   18.9   15.1       T47D           Pool       Breast ca.   29.7   15.4   Spleen Pool   8.8   6.9       MDA-N       Breast Pool   12.5   8.8   Thymus Pool   19.6   11.6       Trachea   12.4   8.2   CNS cancer   0.6   0.3                   (glio/astro) U87-                   MG       Lung   1.7   0.8   CNS cancer   0.4   0.2                   (glio/astro) U-                   118-MG       Fetal Lung   29.7   18.0   CNS cancer   3.4   2.2                   (neuro; met) SK-                   N-AS       Lung ca.   0.1   0.0   CNS cancer   0.1   0.0       NCI-N417           (astro) SF-539       Lung ca. LX-1   0.1   0.1   CNS cancer   10.4   2.1                   (astro) SNB-75       Lung ca.   0.3   0.1   CNS cancer   1.0   0.2       NCI-H146           (glio) SNB-19       Lung ca.   7.8   5.0   CNS cancer   1.3   0.6       SHP-77           (glio) SF-295       Lung ca.   7.8   5.1   Brain   10.3   5.9       A549           (Amygdala) Pool       Lung ca.   10.2   2.5   Brain   32.3   21.0       NCI-H526           (cerebellum)       Lung ca.   3.4   3.2   Brain (fetal)   9.7   4.7       NCI-H23       Lung ca.   1.9   0.8   Brain   15.5   10.6       NCI-H460           (Hippocampus)                   Pool       Lung ca.   0.9   0.6   Cerebral Cortex   20.7   14.5       HOP-62           Pool       Lung ca.   0.1   0.1   Brain (Substantia   18.8   9.9       NCI-H522           nigra) Pool       Liver   0.8   0.5   Brain   15.9   10.4                   (Thalamus) Pool       Fetal Liver   37.1   22.4   Brain (whole)   20.3   14.3       Liver ca.   1.8   0.8   Spinal Cord Pool   14.8   9.0       HepG2       Kidney Pool   18.7   14.9   Adrenal Gland   5.6   3.8       Fetal Kidney   6.2   6.0   Pituitary gland   1.6   1.0                   Pool       Renal ca.   0.3   0.1   Salivary Gland   15.3   8.6       786-0       Renal ca.   1.8   1.1   Thyroid (female)   11.0   11.4       A498       Renal ca.   4.3   1.4   Pancreatic ca.   0.3   0.2       ACHN           CAPAN2       Renal ca.   9.3   2.5   Pancreas Pool   16.7   16.5       UO-31                    
     [1931]               TABLE CBE                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3581, Run       Ag3581, Run       Tissue Name   169910402   Tissue Name   169910402                                     Secondary Th1 act   36.6   HUVEC IL-1beta   4.0       Secondary Th2 act   38.2   HUVEC IFN gamma   19.5       Secondary Tr1 act   45.1   HUVEC TNF alpha +   5.3               IFN gamma       Secondary Th1 rest   72.2   HUVEC TNF alpha +   2.6               IL4       Secondary Th2 rest   58.2   HUVEC IL-11   11.5       Secondary Tr1 rest   79.0   Lung Microvascular EC   27.9               none       Primary Th1 act   23.2   Lung Microvascular EC   28.1               TNF alpha + IL-1beta       Primary Th2 act   48.6   Microvascular Dermal   7.9               EC none       Primary Tr1 act   38.4   Microsvasular Dermal   10.6               EC TNF alpha + IL-1beta       Primary Th1 rest   90.8   Bronchial epithelium   6.9               TNF alpha + IL1beta       Primary Th2 rest   99.3   Small airway epithelium   1.7               none       Primary Tr1 rest   90.8   Small airway epithelium   3.2               TNF alpha + IL-1beta       CD45RA CD4   15.2   Coronery artery SMC rest   0.3       lymphocyte act       CD45RO CD4   45.1   Coronery artery SMC   0.3       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   36.3   Astrocytes rest   0.0       Secondary CD8   27.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   41.2   KU-812 (Basophil) rest   100.0       lymphocyte act       CD4 lymphocyte none   31.0   KU-812 (Basophil)   25.2               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   77.4   CCD1106   13.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   40.6   CCD1106   19.3               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   66.0   Liver cirrhosis   8.9       LAK cells IL-2 + IL-12   28.3   NCI-H292 none   0.5       LAK cells IL-2 + IFN   34.9   NCI-H292 IL-4   0.8       gamma       LAK cells IL-2 + IL-18   32.1   NCI-H292 IL-9   0.8       LAK cells   9.3   NCI-H292 IL-13   1.2       PMA/ionomycin       NK Cells IL-2 rest   82.4   NCI-H292 IFN gamma   3.0       Two Way MLR 3 day   59.9   HPAEC none   8.6       Two Way MLR 5 day   28.7   HPAEC TNF alpha + IL-   7.7               1beta       Two Way MLR 7 day   27.4   Lung fibroblast none   1.9       PBMC rest   45.1   Lung fibroblast TNF   0.1               alpha + IL-1beta       PBMC PWM   19.5   Lung fibroblast IL-4   1.2       PBMC PHA-L   28.1   Lung fibroblast IL-9   0.3       Ramos (B cell) none   47.0   Lung fibroblast IL-13   0.6       Ramos (B cell)   37.4   Lung fibroblast IFN   2.6       ionomycin       gamma       B lymphocytes PWM   16.4   Dermal fibroblast   3.6               CCD1070 rest       B lymphocytes CD40L   48.6   Dermal fibroblast   73.7       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   0.3   Dermal fibroblast   3.5               CCD1070 IL-1beta       EOL-1 dbcAMP   0.0   Dermal fibroblast IFN   8.3       PMA/ionomycin       gamma       Dendritic cells none   24.0   Dermal fibroblast IL-4   6.1       Dendritic cells LPS   6.5   Dermal Fibroblasts rest   23.0       Dendritic cells anti-   24.1   Neutrophils TNFa + LPS   2.1       CD40       Monocytes rest   44.8   Neutrophils rest   8.7       Monocytes LPS   10.7   Colon   69.3       Macrophages rest   38.7   Lung   27.7       Macrophages LPS   9.5   Thymus   75.3       HUVEC none   2.9   Kidney   84.7       HUVEC starved   3.3                    
     [1932]               TABLE CBF                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3506, Run       Ag3506, Run       Tissue Name   166407188   Tissue Name   166407188                                     Secondary Th1 act   8.4   HUVEC IL-1beta   0.4       Secondary Th2 act   7.2   HUVEC IFN gamma   6.7       Secondary Tr1 act   11.4   HUVEC TNF alpha +   1.1               IFN gamma       Secondary Th1 rest   31.6   HUVEC TNF alpha +   1.0               IL4       Secondary Th2 rest   13.7   HUVEC IL-11   2.3       Secondary Tr1 rest   22.5   Lung Microvascular EC   3.8               none       Primary Th1 act   3.9   Lung Microvascular EC   4.0               TNF alpha + IL-1beta       Primary Th2 act   14.6   Microvascular Dermal   3.4               EC none       Primary Tr1 act   14.3   Microsvasular Dermal   2.8               EC TNF alpha + IL-1beta       Primary Th1 rest   69.7   Bronchial epithelium   0.9               TNF alpha + IL1beta       Primary Th2 rest   44.1   Small airway epithelium   0.2               none       Primary Tr1 rest   28.9   Small airway epithelium   1.2               TNF alpha + IL-1beta       CD45RA CD4   3.2   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   12.3   Coronery artery SMC   0.3       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   8.7   Astrocytes rest   0.1       Secondary CD8   9.5   Astrocytes TNF alpha +   0.1       lymphocyte rest       IL-1beta       Secondary CD8   12.0   KU-812 (Basophil) rest   18.3       lymphocyte act       CD4 lymphocyte none   9.6   KU-812 (Basophil)   14.9               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   23.8   CCD1106   2.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   6.8   CCD1106   11.7               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   21.2   Liver cirrhosis   5.4       LAK cells IL-2 + IL-12   8.5   Lupus kidney   12.2       LAK cells IL-2 + IFN   12.2   NCI-H292 none   0.2       gamma       LAK cells IL-2 + IL-18   12.0   NCI-H292 IL-4   0.2       LAK cells   1.8   NCI-H292 IL-9   0.2       PMA/ionomycin       NK Cells IL-2 rest   16.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   16.6   NCI-H292 IFN gamma   0.1       Two Way MLR 5 day   7.2   HPAEC none   2.9       Two Way MLR 7 day   9.6   HPAEC TNF alpha + IL-   2.8               1beta       PBMC rest   8.5   Lung fibroblast none   0.5       PBMC PWM   3.5   Lung fibroblast TNF   0.6               alpha + IL-1beta       PBMC PHA-L   2.8   Lung fibroblast IL-4   0.1       Ramos (B cell) none   11.3   Lung fibroblast IL-9   0.1       Ramos (B cell)   5.6   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   6.2   Lung fibroblast IFN   0.5               gamma       B lymphocytes CD40L   12.2   Dermal fibroblast   1.1       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.1   Dermal fibroblast   21.8               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   1.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   4.3   Dermal fibroblast IFN   2.1               gamma       Dendritic cells LPS   1.4   Dermal fibroblast IL-4   1.8       Dendritic cells anti-   4.6   IBD Colitis 2   2.6       CD40       Monocytes rest   11.9   IBD Crohn&#39;s   5.5       Monocytes LPS   1.7   Colon   100.0       Macrophages rest   9.3   Lung   5.9       Macrophages LPS   1.6   Thymus   37.9       HUVEC none   0.9   Kidney   24.7       HUVEC starved   1.7                    
     [1933] CNS_neurodegeneration_v1.0 Summary: Ag3506/Ag3581 This panel confirms the expression of the CG59671-02 gene at significant levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment.  
     [1934] This gene is expressed at moderate levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord as observed in panel 1.4. Therefore, this gene may play a role in other central nervous system disorders such as, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression  
     [1935] General_screening_panel_v1.4 Summary: Ag3506/Ag3581 Two experiments produce results that are in very good agreement. Highest expression of the CG59671-02 gene is observed in samples derived from melanoma cell lines (CTs=23-35). Thus, expression of this gene can be used in distinguishing these samples from other samples in the panel. In addition, significant levels of expression of this gene are also associated with colon cancer, ovarian cancer, breast cancer, and lung cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product might be beneficial in the treatment of these cancers.  
     [1936] This gene is also expressed at low to moderate levels in a number of tissues with metabolic or endocrine function, including adipose, adrenal gland, gastrointestinal tract, pancreas, skeletal muscle and thyroid. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [1937] This gene is also expressed at high to moderate levels in all regions of the CNS examined. Please see Panel CNS_neurodegeneration_v1.0 for discussion of utility of this gene in the central nervous system.  
     [1938] Panel 4.1D Summary: Ag3581 Highest expression of the CG59671-02 gene is observed in the resting KU-812 sample (CT=29.18). In addition, high expression of this gene is detected in colon, lung, thymus and kidney. Therefore, therapies designed with the protein encoded for by this gene could be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, lung and kidney including, asthma, allergies, lupus and glomerulonephritis. Expression of this gene is decreased in colon samples from patients with IBD colitis and Crohn&#39;s disease relative to normal colon. Therefore, therapeutic modulation of the activity of the protein encoded by this gene may also be useful in the treatment of inflammatory bowel disease.  
     [1939] Expression of this gene appears to be down-regulated in activated primary and secondary Th1, Th2, and Tr1 cells. Also, TNF alpha stimulates the expression of this gene in resting dermal fibroblasts. Therefore, therapeutics designed with the protein encoded by this transcript could be important in regulating T cell function and treating diseases such as asthma, arthritis, psoriasis, IBD, and systemic lupus erythematosus.  
     [1940] Panel 4D Summary: Ag3506 Highest expression of CG59671-02 is observed colon sample (CT=27.3). Overall, the expression pattern using this probe is in excellent agreement with results in panel 4.1 D for Ag3581. Please see that panel for discussion of utility of this gene in inflammation.  
     [1941] CC. CG56870-01: NDR3  
     [1942] Expression of gene CG56870-01 was assessed using the primer-probe set Ag2075, described in Table CCA. Results of the RTQ-PCR runs are shown in Tables CCB, CCC, CCD and CCE. Please note that CG56870-02 represents a full-length physical clone of the CG56870-01 gene, validating the prediction of the gene sequence.  
     [1943] Table CCA. Probe Name Ag2075 
               TABLE CCA                          Probe Name Ag2075                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-catggatgaacttcaggatgtt-3′   22   70   647               Probe   TET-5′-cagctcacagagatcaaaccacttct-3′-TAMRA   26   92   648               Reverse   5′-tgacagtcaaagtcctggaagt-3′   22   141   649                  
 
     [1944]               TABLE CCB                          Panel 1.3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag2075,       Ag2075,       Tissue Name   Run 152355202   Tissue Name   Run 152355202                                     Liver adenocarcinoma   11.9   Kidney (fetal)   1.4       Pancreas   0.8   Renal ca. 786-0   3.5       Pancreatic ca. CAPAN2   1.6   Renal ca. A498   12.9       Adrenal gland   2.4   Renal ca. RXF 393   1.5       Thyroid   1.8   Renal ca. ACHN   1.7       Salivary gland   1.2   Renal ca. UO-31   6.8       Pituitary gland   2.4   Renal ca. TK-10   2.8       Brain (fetal)   3.2   Liver   0.4       Brain (whole)   25.2   Liver (fetal)   0.8       Brain (amygdala)   14.1   Liver ca.   6.7               (hepatoblast) HepG2       Brain (cerebellum)   10.8   Lung   2.1       Brain (hippocampus)   39.8   Lung (fetal)   3.2       Brain (substantia nigra)   2.7   Lung ca. (small cell)   4.1               LX-1       Brain (thalamus)   12.4   Lung ca. (small cell)   3.8               NCI-H69       Cerebral Cortex   100.0   Lung ca. (s.cell var.)   3.8               SHP-77       Spinal cord   3.5   Lung ca. (large   0.6               cell)NCI-H460       glio/astro U87-MG   6.4   Lung ca. (non-sm.   3.0               cell) A549       glio/astro U-118-MG   10.4   Lung ca. (non-s.cell)   7.7               NCI-H23       astrocytoma SW1783   5.1   Lung ca. (non-s.cell)   3.1               HOP-62       neuro*; met SK-N-AS   6.2   Lung ca. (non-s.cl)   6.3               NCI-H522       astrocytoma SF-539   5.4   Lung ca. (squam.)   1.4               SW 900       astrocytoma SNB-75   6.7   Lung ca. (squam.)   1.4               NCI-H596       glioma SNB-19   3.1   Mammary gland   2.4       glioma U251   2.0   Breast ca.* (pl.ef)   1.8               MCF-7       glioma SF-295   3.4   Breast ca.* (pl.ef)   11.6               MDA-MB-231       Heart (fetal)   6.7   Breast ca.* (pl.ef)   9.0               T47D       Heart   1.4   Breast ca. BT-549   4.8       Skeletal muscle (fetal)   18.0   Breast ca. MDA-N   4.2       Skeletal muscle   0.7   Ovary   13.4       Bone marrow   0.9   Ovarian ca.   1.8               OVCAR-3       Thymus   0.9   Ovarian ca.   1.6               OVCAR-4       Spleen   3.7   Ovarian ca.   1.8               OVCAR-5       Lymph node   1.9   Ovarian ca.   4.9               OVCAR-8       Colorectal   3.3   Ovarian ca. IGROV-1   1.6       Stomach   2.7   Ovarian ca.*   5.8               (ascites) SK-OV-3       Small intestine   2.5   Uterus   2.4       Colon ca. SW480   10.4   Placenta   1.2       Colon ca.*   3.7   Prostate   6.0       SW620(SW480 met)       Colon ca. HT29   4.6   Prostate ca.* (bone   4.5               met)PC-3       Colon ca. HCT-116   3.6   Testis   1.7       Colon ca. CaCo-2   10.3   Melanoma   3.8               Hs688(A).T       Colon ca.   3.2   Melanoma* (met)   4.4       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   2.6   Melanoma UACC-   1.4               62       Gastric ca.* (liver met)   3.1   Melanoma M14   1.8       NCI-N87       Bladder   0.8   Melanoma LOX   3.3               IMVI       Trachea   2.0   Melanoma* (met)   2.4               SK-MEL-5       Kidney   1.3   Adipose   1.2                    
     [1945]               TABLE CCC                          Panel 2.2                                 Rel. Exp.       Rel. Exp.           (%) Ag2075,       (%) Ag2075,           Run       Run       Tissue Name   174255357   Tissue Name   174255357                                     Normal Colon   27.7   Kidney Margin   46.3               (OD04348)       Colon cancer   52.9   Kidney malignant   19.2       (OD06064)       cancer (OD06204B)       Colon Margin   30.1   Kidney normal   14.3       (OD06064)       adjacent tissue               (OD06204E)       Colon cancer   5.5   Kidney Cancer   66.0       (OD06159)       (OD04450-01)       Colon Margin   21.0   Kidney Margin   19.8       (OD06159)       (OD04450-03)       Colon cancer   22.2   Kidney Cancer   3.0       (OD06297-04)       8120613       Colon Margin   41.8   Kidney Margin   11.0       (OD06297-05)       8120614       CC Gr.2 ascend colon   4.0   Kidney Cancer   6.8       (ODO3921)       9010320       CC Margin   6.7   Kidney Margin   9.7       (OD03921)       9010321       Colon cancer metastasis   11.1   Kidney Cancer   35.6       (OD06104)       8120607       Lung Margin   42.6   Kidney Margin   13.7       (OD06104)       8120608       Colon mets to lung   17.8   Normal Uterus   59.5       (OD04451-01)       Lung Margin   9.3   Uterine Cancer 064011   9.7       (OD04451-02)       Normal Prostate   51.4   Normal Thyroid   8.8       Prostate Cancer   23.0   Thyroid Cancer   11.2       (OD04410)       064010       Prostate Margin   19.3   Thyroid Cancer   17.9       (OD04410)       A302152       Normal Ovary   22.8   Thyroid Margin   5.5               A302153       Ovarian cancer   9.9   Normal Breast   33.2       (OD06283-03)       Ovarian Margin   17.1   Breast Cancer   8.5       (OD06283-07)       (OD04566)       Ovarian Cancer 064008   18.0   Breast Cancer 1024   36.1       Ovarian cancer   6.6   Breast Cancer   18.4       (OD06145)       (OD04590-01)       Ovarian Margin   12.5   Breast Cancer Mets   31.9       (OD06145)       (OD04590-03)       Ovarian cancer   14.7   Breast Cancer   45.4       (OD06455-03)       Metastasis (OD0465505)       Ovarian Margin   21.8   Breast Cancer 064006   11.5       (OD06455-07)       Normal Lung   21.9   Breast Cancer   20.9       Invasive poor diff. lung   17.6   9100266 Breast   35.1       adeno (OD04945-01)       Margin 9100265       Lung Margin   12.2   Breast Cancer   9.7       (ODO4945-03)       A209073       Lung Malignant Cancer   8.7   Breast Margin   22.2       (OD03126)       A2090734       Lung Margin   7.4   Breast cancer   100.0       (OD03126)       (OD06083)       Lung Cancer   9.9   Breast cancer node   63.7       (OD05014A)       metastasis (OD06083)       Lung Margin   21.8   Normal Liver   9.9       (OD05014B)       Lung cancer   5.1   Liver Cancer 1026   5.6       (OD06081)       Lung Margin   7.9   Liver Cancer 1025   13.5       (OD06081)       Lung Cancer   17.4   Liver Cancer 6004-T   4.8       (OD04237-01)       Lung Margin   24.0   Liver Tissue 6004-N   9.3       (OD04237-02)       Ocular Melanoma   9.7   Liver Cancer 6005-T   15.7       Metastasis       Ocular Melanoma   4.6   Liver Tissue 6005-N   20.4       Margin (Liver)       Melanoma Metastasis   19.8   Liver Cancer 064003   10.7       Melanoma Margin   21.6   Normal Bladder   8.0       (Lung)       Normal Kidney   11.0   Bladder Cancer 1023   10.5       Kidney Ca, Nuclear   37.6   Bladder Cancer   17.3       grade 2 (OD04338)       A302173       Kidney Margin   22.1   Normal Stomach   37.9       (OD04338)       Kidney Ca Nuclear   21.6   Gastric Cancer   11.1       grade 1/2 (OD04339)       9060397       Kidney Margin   12.9   Stomach Margin   20.6       (OD04339)       9060396       Kidney Ca, Clear   6.5   Gastric Cancer   22.7       cell type (OD04340)       9060395       Kidney Margin   18.4   Stomach Margin   36.1       (OD04340)       9060394       Kidney Ca, Nuclear   12.9   Gastric Cancer 064005   8.1       grade 3 (OD04348)                    
     [1946]               TABLE CCD                          Panel 3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag2075, Run       Ag2075, Run       Tissue Name   164750734   Tissue Name   164750734                                     Daoy-Medulloblastoma   6.7   Ca Ski-Cervical epidermoid   50.3               carcinoma (metastasis)       TE671-   9.0   ES-2-Ovarian clear cell   13.9       Medulloblastoma       carcinoma       D283 Med-   35.4   Ramos-Stimulated with   2.7       Medulloblastoma       PMA/ionomycin 6 h       PFSK-1-Primitive   15.4   Ramos-Stimulated with   3.3       Neuroectodermal       PMA/ionomycin 14 h       XF-498-CNS   4.4   MEG-01-Chronic   3.4               myelogenous leukemia               (megokaryoblast)       SNB-78-Glioma   23.3   Raji-Burkitt&#39;s Lymphoma   3.7       SF-268-Glioblastoma   13.6   Daudi-Burkitt&#39;s lymphoma   6.5       T98G-Glioblastoma   18.6   U266-B-cell plasmacytoma   8.4       SK-N-SH-   17.0   CA46-Burkitt&#39;s lymphoma   7.2       Neuroblastoma       (metastasis)       SF-295-Glioblastoma   8.4   RL-non-Hodgkin&#39;s B-cell   3.5               lymphoma       Cerebellum   74.7   JM1-pre-B-cell lymphoma   3.1       Cerebellum   62.4   Jurkat-T cell leukemia   11.6       NCI-H292-   45.7   TF-1-Erythroleukemia   13.4       Mucoepidermoid lung       carcinoma       DMS-114-Small cell   10.9   HUT 78-T-cell lymphoma   10.0       lung cancer       DMS-79-Small cell   100.0   U937-Histiocytic lymphoma   18.2       lung cancer       NCI-H146-Small cell   30.6   KU-812-Myelogenous   6.0       lung cancer       leukemia       NCI-H526-Small cell   57.4   769-P-Clear cell renal   11.3       lung cancer       carcinoma       NCI-N417-Small cell   15.2   Caki-2-Clear cell renal   10.4       lung cancer       carcinoma       NCI-H82-Small cell   36.9   SW 839-Clear cell renal   2.2       lung cancer       carcinoma       NCI-H157-Squamous   51.1   G401-Wilms&#39; tumor   6.2       cell lung cancer       (metastasis)       NCI-H1155-Large cell   26.6   Hs766T-Pancreatic   42.9       lung cancer       carcinoma (LN metastasis)       NCI-H1299-Large cell   44.4   CAPAN-1-Pancreatic   5.0       lung cancer       adenocarcinoma (liver               metastasis)       NCI-H727-Lung   47.0   SU86.86-Pancreatic   28.1       carcinoid       carcinoma (liver metastasis)       NCI-UMC-11-Lung   60.3   BxPC-3-Pancreatic   6.3       carcinoid       adenocarcinoma       LX-1-Small cell lung   23.5   HPAC-Pancreatic   7.4       cancer       adenocarcinoma       Colo-205-Colon cancer   29.5   MIA PaCa-2-Pancreatic   3.6               carcinoma       KM12-Colon cancer   24.0   CFPAC-1-Pancreatic ductal   40.9               adenocarcinoma       KM20L2-Colon cancer   8.4   PANC-1-Pancreatic   20.9               epithelioid ductal carcinoma       NCI-H716-Colon   23.3   T24-Bladder carcinma   13.1       cancer       (transitional cell)       SW-48-Colon   27.0   5637-Bladder carcinoma   11.0       adenocarcinoma       SW1116-Colon   10.0   HT-1197-Bladder   9.2       adenocarcinoma       carcinoma       LS 174T-Colon   9.9   UM-UC-3-Bladder   7.2       adenocarcinoma       carcinma (transitional cell)       SW-948-Colon   1.1   A204-Rhabdomyosarcoma   7.0       adenocarcinoma       SW-480-Colon   8.8   HT-1080-Fibrosarcoma   16.6       adenocarcinoma       NCI-SNU-5-Gastric   7.2   MG-63-Osteosarcoma   16.7       carcinoma       KATO III-Gastric   32.8   SK-LMS-1-   26.4       carcinoma       Leiomyosarcoma (vulva)       NCI-SNU-16-Gastric   13.6   SJRH30-   16.8       carcinoma       Rhabdomyosarcoma (met to               bone marrow)       NCI-SNU-1-Gastric   16.0   A431-Epidermoid   9.8       carcinoma       carcinoma       RF-1-Gastric   2.1   WM266-4-Melanoma   12.0       adenocarcinoma       RF-48-Gastric   4.0   DU 145-Prostate carcinoma   0.1       adenocarcinoma       (brain metastasis)       MKN-45-Gastric   28.7   MDA-MB-468-Breast   14.7       carcinoma       adenocarcinoma       NCI-N87-Gastric   13.3   SCC-4-Squamous cell   0.9       carcinoma       carcinoma of tongue       OVCAR-5-Ovarian   2.6   SCC-9-Squamous cell   0.3       carcinoma       carcinoma of tongue       RL95-2-Uterine   7.2   SCC-15-Squamous cell   0.5       carcinoma       carcinoma of tongue       HelaS3-Cervical   13.4   CAL 27-Squamous cell   21.2       adenocarcinoma       carcinoma of tongue                    
     [1947]               TABLE CCE                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag2075, Run       Ag2075, Run       Tissue Name   152787491   Tissue Name   152787491                                     Secondary Th1 act   46.3   HUVEC IL-1beta   25.0       Secondary Th2 act   39.2   HUVEC IFN gamma   33.0       Secondary Tr1 act   31.9   HUVEC TNF alpha +   13.1               IFN gamma       Secondary Th1 rest   11.7   HUVEC TNF alpha +   20.7               IL4       Secondary Th2 rest   13.9   HUVEC IL-11   20.0       Secondary Tr1 rest   21.6   Lung Microvascular EC   22.7               none       Primary Th1 act   30.1   Lung Microvascular EC   15.0               TNF alpha + IL-1beta       Primary Th2 act   39.2   Microvascular Dermal   26.8               EC none       Primary Tr1 act   54.7   Microsvasular Dermal   16.6               EC TNF alpha + IL-1beta       Primary Th1 rest   84.1   Bronchial epithelium   4.9               TNF alpha + IL1beta       Primary Th2 rest   48.6   Small airway epithelium   19.9               none       Primary Tr1 rest   39.0   Small airway epithelium   72.7               TNF alpha + IL-1beta       CD45RA CD4   21.8   Coronery artery SMC rest   27.9       lymphocyte act       CD45RO CD4   33.0   Coronery artery SMC   19.6       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   25.5   Astrocytes rest   26.4       Secondary CD8   21.5   Astrocytes TNF alpha +   13.2       lymphocyte rest       IL-1beta       Secondary CD8   29.3   KU-812 (Basophil) rest   6.3       lymphocyte act       CD4 lymphocyte none   12.7   KU-812 (Basophil)   16.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   25.5   CCD1106   46.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   26.1   CCD1106   4.3               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   30.6   Liver cirrhosis   2.7       LAK cells IL-2 + IL-12   18.2   Lupus kidney   3.0       LAK cells IL-2 + IFN   31.0   NCI-H292 none   76.8       gamma       LAK cells IL-2 + IL-18   31.2   NCI-H292 IL-4   94.6       LAK cells   9.5   NCI-H292 IL-9   97.3       PMA/ionomycin       NK Cells IL-2 rest   37.4   NCI-H292 IL-13   59.5       Two Way MLR 3 day   24.0   NCI-H292 IFN gamma   51.8       Two Way MLR 5 day   23.0   HPAEC none   23.3       Two Way MLR 7 day   19.6   HPAEC TNF alpha + IL-   15.8               1beta       PBMC rest   11.4   Lung fibroblast none   18.4       PBMC PWM   72.2   Lung fibroblast TNF   12.0               alpha + IL-1beta       PBMC PHA-L   33.9   Lung fibroblast IL-4   35.8       Ramos (B cell) none   19.6   Lung fibroblast IL-9   25.5       Ramos (B cell)   100.0   Lung fibroblast IL-13   18.7       ionomycin       B lymphocytes PWM   81.8   Lung fibroblast IFN   38.4               gamma       B lymphocytes CD40L   42.3   Dermal fibroblast   48.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   23.7   Dermal fibroblast   83.5               CCD1070 TNF alpha       EOL-1 dbcAMP   13.5   Dermal fibroblast   13.6       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   20.9   Dermal fibroblast IFN   13.1               gamma       Dendritic cells LPS   11.5   Dermal fibroblast IL-4   36.6       Dendritic cells anti-   23.2   IBD Colitis 2   1.8       CD40       Monocytes rest   19.2   IBD Crohn&#39;s   2.4       Monocytes LPS   6.5   Colon   26.8       Macrophages rest   36.1   Lung   21.3       Macrophages LPS   13.3   Thymus   41.5       HUVEC none   37.6   Kidney   24.3       HUVEC starved   58.6                    
     [1948] Panel 1.3D Summary: Ag2075 Highest expression of the CG56870-01 gene is detected in the cerebral cortex (CT=24.2). Thus expression of this gene can be used in distinguishing this sample from other samples in the panel. Furthermore, significant expression of this gene is observed throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. The CG56870-01 gene encodes an Ndr3 homolog which is a putative member of Ndr family. This family consists of proteins from different gene families: Ndr1/RTP/Drg1/NDRG1, Ndr2, and Ndr3 (PFAM: IPR004142). NDRG1 is a cytoplasmic protein involved in stress responses, hormone responses, cell growth, and differentiation. Mutation of this gene was reported to be causative for hereditary motor and sensory neuropathy-Lom. Recently, NDRG4, another memember of Ndr family, was shown to be expressed in neurons of the brain and spinal cord. Its expression was markedly decreased in the brain of Alzheimer&#39;s disease patient (Zhou et al., 2001). Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1949] This gene also has moderate levels of expression in adipose, adrenal, thyroid, liver, heart, thyroid and skeletal muscle. Thus, this gene product may be important in the pathogenesis, diagnosis and/or treatment of metabolic and endocrine disease, including Types 1 and 2 diabetes and obesity.  
     [1950] In addition, there appears to be substantial expression in other samples derived from breast cancer cell lines, lung cancer cell lines, renal cancer cell lines and colon cancer cell lines. Thus, therapeutic modulation of this gene could be of benefit in the treatment of breast, lung, renal or colon cancer.  
     REFERENCES  
     [1951] 1. Zhou R H, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T. (2001) Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 73(1):86-97  
     [1952] Ag2075 The expression of this gene appears to be highest in a sample derived from a normal brain tissue. In addition, there appears to be substantial expression in other samples derived from breast cancer cell lines, lung cancer cell lines, renal cancer cell lines and colon cancer cell lines. Thus, the expression of this gene could be used to distinguish normal brain tissue from other samples in the panel. Moreover, therapeutic modulation of this gene could be of benefit in the treatment of breast, lung, renal or colon cancer.  
     [1953] Panel 2.2 Summary: Ag2075 Highest expression of CG56870-01 is detected in breast cancer sample (CT=29.89). Thus expression of this gene can be used in distinguishing this sample from other samples in the panel. In addition, there appears to be substantial expression in other samples derived from breast cancers, kidney cancers and colon cancers. Therefore, therapeutic modulation of this could be of benefit in the treatment of breast, kidney or colon cancer.  
     [1954] Panel 3D Summary: Ag2075 The expression of this gene appears to be highest in a sample derived from a lung cancer cell line (DMS-79)(CT=26.4). In addition, there appears to be substantial expression in other samples derived from pancreatic cancer cell lines, lung cancer cell lines, brain cancer cell lines and cervical cancer cell lines. Thus, the expression of this gene could be used to distinguish DMS-79 cells from other samples in the panel. Moreover, therapeutic modulation of this gene could be of benefit in the treatment of pancreatic, lung, brain or cervical cancer.  
     [1955] Panel 4D Summary: Ag2075 Expression of the CG56870-01 gene is ubiquitous througout this panel, with highest in samples derived from ionomycin treated Ramos (B cell) cells (CT=26.1). Furthermore, expression of this gene is also detected in PWM treated PBMC cells and PWM treated B lymphocytes. Therefore, therapeutic modulation of the express ion or function of this gene may reduce or eliminate the symptoms in patients with autoimmune and inflammatory diseases in which B cells play a part in the initiation or progression of the disease process, such as systemic lupus erythematosus, Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.  
     [1956] CD. CG56870-04: N-myc Downstream-Regulated Gene 3  
     [1957] Expression of gene CG56870-04 was assessed using the primer-probe sets Ag5279 and Ag2075, described in Tables CDA and CDB. Results of the RTQ-PCR runs are shown in Tables CDC, CDD, CDE, CDF, CDG, CDH and CDI.  
     [1958] Table CDA. Probe Name Ag5279 
               TABLE CDA                          Probe Name Ag5279                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-aggctgtgatggcggact-3′   18   873   650               Probe   TET-5′-ttcagcctgggaagttcaccgaggcc-3′-TAMRA   26   912   651               Reverse   5′-gccgagtcatgctggcagat-3′20   973   652                  
 
     [1959] Table CDB. Probe Name Ag2075 
               TABLE CDB                          Probe Name Ag2075                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-catggatgaacttcaggatgtt-3′   22   70   653               Probe   TET-5′-cagctcacagagatcaaaccacttct-3′-TAMRA   26   92   654               Reverse   5′-tgacagtcaaagtcctggaagt-3′   22   141   655                  
 
     [1960]               TABLE CDC                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag5279,           Ag5279, Run       Run       Tissue Name   230512909   Tissue Name   230512909                                     AD 1 Hippo   7.7   Control (Path) 3   1.0               Temporal Ctx       AD 2 Hippo   8.4   Control (Path) 4   13.2               Temporal Ctx       AD 3 Hippo   3.4   AD 1 Occipital   7.2               Ctx       AD 4 Hippo   2.8   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   100.0   AD 3 Occipital   2.1               Ctx       AD 6 Hippo   32.8   AD 4 Occipital   13.1               Ctx       Control 2 Hippo   32.3   AD 5 Occipital   15.6               Ctx       Control 4 Hippo   2.7   AD 6 Occipital   54.7               Ctx       Control (Path) 3   1.2   Control 1 Occipital   1.1       Hippo       Ctx       AD 1 Temporal Ctx   6.4   Control 2 Occipital   81.2               Ctx       AD 2 Temporal Ctx   17.1   Control 3 Occipital   8.1               Ctx       AD 3 Temporal Ctx   2.3   Control 4 Occipital   2.5               Ctx       AD 4 Temporal Ctx   8.7   Control (Path) 1   66.0               Occipital Ctx       AD 5 Inf Temporal   79.0   Control (Path) 2   5.6       Ctx       Occipital Ctx       AD 5 SupTemporal   6.4   Control (Path) 3   1.5       Ctx       Occipital Ctx       AD 6 Inf Temporal   25.7   Control (Path) 4   7.6       Ctx       Occipital Ctx       AD 6 Sup Temporal   24.1   Control 1 Parietal   2.4       Ctx       Ctx       Control 1 Temporal   2.0   Control 2 Parietal   10.7       Ctx       Ctx       Control 2 Temporal   41.2   Control 3 Parietal   16.6       Ctx       Ctx       Control 3 Temporal   4.6   Control (Path) 1   75.3       Ctx       Parietal Ctx       Control 4 Temporal   2.7   Control (Path) 2   13.7       Ctx       Parietal Ctx       Control (Path) 1   35.4   Control (Path) 3   1.6       Temporal Ctx       Parietal Ctx       Control (Path) 2   27.7   Control (Path) 4   19.3       Temporal Ctx       Parietal Ctx                    
     [1961]               TABLE CDD                          General_screening_panel_v1.5                                 Rel. Exp.       Rel. Exp.           (%) Ag5279,       (%) Ag5279,           Run       Run       Tissue Name   230509998   Tissue Name   230509998                                     Adipose   1.3   Renal ca. TK-10   9.2       Melanoma*   7.6   Bladder   2.4       Hs688(A).T       Melanoma*   8.0   Gastric ca. (liver met.)   8.7       Hs688(B).T       NCI-N87       Melanoma* M14   12.2   Gastric ca. KATO III   21.8       Melanoma*   13.8   Colon ca. SW-948   4.6       LOXIMVI       Melanoma* SK-   8.2   Colon ca. SW480   14.1       MEL-5       Squamous cell   6.5   Colon ca.* (SW480   10.4       carcinoma SCC-4       met) SW620       Testis Pool   8.2   Colon ca. HT29   12.3       Prostate ca.* (bone   2.3   Colon ca. HCT-116   12.2       met) PC-3       Prostate Pool   6.2   Colon ca. CaCo-2   17.8       Placenta   3.5   Colon cancer tissue   4.9       Uterus Pool   1.4   Colon ca. SW1116   2.6       Ovarian ca.   8.8   Colon ca. Colo-205   7.3       OVCAR-3       Ovarian ca. SK-   20.4   Colon ca. SW-48   5.9       OV-3       Ovarian ca.   5.6   Colon Pool   5.1       OVCAR-4       Ovarian ca.   10.9   Small Intestine Pool   3.9       OVCAR-5       Ovarian ca.   6.0   Stomach Pool   2.3       IGROV-1       Ovarian ca.   5.5   Bone Marrow Pool   1.5       OVCAR-8       Ovary   5.7   Fetal Heart   7.5       Breast ca. MCF-7   5.0   Heart Pool   3.3       Breast ca. MDA-   23.0   Lymph Node Pool   5.1       MB-231       Breast ca. BT 549   21.9   Fetal Skeletal Muscle   3.1       Breast ca. T47D   10.6   Skeletal Muscle Pool   4.0       Breast ca. MDA-N   5.8   Spleen Pool   2.2       Breast Pool   5.9   Thymus Pool   2.9       Trachea   5.0   CNS cancer   20.4               (glio/astro) U87-MG       Lung   2.5   CNS cancer   16.8               (glio/astro) U-118-MG       Fetal Lung   8.7   CNS cancer   10.7               (neuro; met) SK-N-AS       Lung ca. NCI-N417   3.7   CNS cancer (astro)   7.0               SF-539       Lung ca. LX-1   12.1   CNS cancer (astro)   21.3               SNB-75       Lung ca. NCI-H146   5.8   CNS cancer (glio)   5.8               SNB-19       Lung ca. SHP-77   7.9   CNS cancer (glio) SF-   12.2               295       Lung ca. A549   14.1   Brain (Amygdala)   19.3               Pool       Lung ca. NCI-H526   5.1   Brain (cerebellum)   100.0       Lung ca. NCI-H23   11.2   Brain (fetal)   20.0       Lung ca. NCI-H460   2.9   Brain (Hippocampus)   17.4               Pool       Lung ca. HOP-62   4.6   Cerebral Cortex Pool   23.7       Lung ca. NCI-H522   13.6   Brain (Substantia   17.9               nigra) Pool       Liver   0.5   Brain (Thalamus) Pool   34.2       Fetal Liver   3.2   Brain (whole)   46.3       Liver ca. HepG2   5.3   Spinal Cord Pool   9.5       Kidney Pool   7.1   Adrenal Gland   11.8       Fetal Kidney   5.7   Pituitary gland Pool   2.9       Renal ca. 786-0   6.3   Salivary Gland   3.5       Renal ca. A498   11.0   Thyroid (female)   2.0       Renal ca. ACHN   6.0   Pancreatic ca.   5.6               CAPAN2       Renal ca. UO-31   8.0   Pancreas Pool   6.2                    
     [1962]               TABLE CDE                          Panel 1.3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag2075, Run       Ag2075,       Tissue Name   Run 152355202   Tissue Name   Run 152355202                                     Liver adenocarcinoma   11.9   Kidney (fetal)   1.4       Pancreas   0.8   Renal ca. 786-0   3.5       Pancreatic ca. CAPAN 2   1.6   Renal ca. A498   12.9       Adrenal gland   2.4   Renal ca. RXF 393   1.5       Thyroid   1.8   Renal ca. ACHN   1.7       Salivary gland   1.2   Renal ca. UO-31   6.8       Pituitary gland   2.4   Renal ca. TK-10   2.8       Brain (fetal)   3.2   Liver   0.4       Brain (whole)   25.2   Liver (fetal)   0.8       Brain (amygdala)   14.1   Liver ca.   6.7               (hepatoblast) HepG2       Brain (cerebellum)   10.8   Lung   2.1       Brain (hippocampus)   39.8   Lung (fetal)   3.2       Brain (substantia nigra)   2.7   Lung ca. (small cell)   4.1               LX-1       Brain (thalamus)   12.4   Lung ca. (small cell)   3.8               NCI-H69       Cerebral Cortex   100.0   Lung ca. (s.cell var.)   3.8               SHP-77       Spinal cord   3.5   Lung ca. (large   0.6               cell)NCI-H460       glio/astro U87-MG   6.4   Lung ca. (non-sm.   3.0               cell) A549       glio/astro U-118-MG   10.4   Lung ca. (non-s.cell)   7.7               NCI-H23       astrocytoma SW1783   5.1   Lung ca. (non-s.cell)   3.1               HOP-62       neuro*; met SK-N-AS   6.2   Lung ca. (non-s.cl)   6.3               NCI-H522       astrocytoma SF-539   5.4   Lung ca. (squam.)   1.4               SW 900       astrocytoma SNB-75   6.7   Lung ca. (squam.)   1.4               NCI-H596       glioma SNB-19   3.1   Mammary gland   2.4       glioma U251   2.0   Breast ca.* (pl.ef)   1.8               MCF-7       glioma SF-295   3.4   Breast ca.* (pl.ef)   11.6               MDA-MB-231       Heart (fetal)   6.7   Breast ca.* (pl.ef)   9.0               T47D       Heart   1.4   Breast ca. BT-549   4.8       Skeletal muscle (fetal)   18.0   Breast ca. MDA-N   4.2       Skeletal muscle   0.7   Ovary   13.4       Bone marrow   0.9   Ovarian ca.   1.8               OVCAR-3       Thymus   0.9   Ovarian ca.   1.6               OVCAR-4       Spleen   3.7   Ovarian ca.   1.8               OVCAR-5       Lymph node   1.9   Ovarian ca.   4.9               OVCAR-8       Colorectal   3.3   Ovarian ca. IGROV-1   1.6       Stomach   2.7   Ovarian ca.*   5.8               (ascites) SK-OV-3       Small intestine   2.5   Uterus   2.4       Colon ca. SW480   10.4   Placenta   1.2       Colon ca.*   3.7   Prostate   6.0       SW620(SW480 met)       Colon ca. HT29   4.6   Prostate ca.* (bone   4.5               met)PC-3       Colon ca. HCT-116   3.6   Testis   1.7       Colon ca. CaCo-2   10.3   Melanoma   3.8               Hs688(A).T       Colon ca.   3.2   Melanoma* (met)   4.4       tissue(ODO3866)       Hs688(B).T       Colon ca. HCC-2998   2.6   Melanoma UACC-   1.4               62       Gastric ca.* (liver met)   3.1   Melanoma M14   1.8       NCI-N87       Bladder   0.8   Melanoma LOX   3.3               IMVI       Trachea   2.0   Melanoma* (met)   2.4               SK-MEL-5       Kidney   1.3   Adipose   1.2                    
     [1963]               TABLE CDF                          Panel 2.2                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag2075, Run       Ag2075,       Tissue Name   174255357   Tissue Name   Run 174255357                                     Normal Colon   27.7   Kidney Margin   46.3               (OD04348)       Colon cancer   52.9   Kidney malignant   19.2       (OD06064)       cancer (OD06204B)       Colon Margin   30.1   Kidney normal   14.3       (OD06064)       adjacent tissue               (OD06204E)       Colon cancer   5.5   Kidney Cancer   66.0       (OD06159)       (OD04450-01)       Colon Margin   21.0   Kidney Margin   19.8       (OD06159)       (OD04450-03)       Colon cancer   22.2   Kidney Cancer   3.0       (OD06297-04)       8120613       Colon Margin   41.8   Kidney Margin   11.0       (OD06297-05)       8120614       CC Gr.2 ascend colon   4.0   Kidney Cancer   6.8       (ODO3921)       9010320       CC Margin (ODO3921)   6.7   Kidney Margin   9.7               9010321       Colon cancer metastasis   11.1   Kidney Cancer   35.6       (OD06104)       8120607       Lung Margin   42.6   Kidney Margin   13.7       (OD06104)       8120608       Colon mets to lung   17.8   Normal Uterus   59.5       (OD04451-01)       Lung Margin   9.3   Uterine Cancer 064011   9.7       (OD04451-02)       Normal Prostate   51.4   Normal Thyroid   8.8       Prostate Cancer   23.0   Thyroid Cancer   11.2       (OD04410)       064010       Prostate Margin   19.3   Thyroid Cancer   17.9       (OD04410)       A302152       Normal Ovary   22.8   Thyroid Margin   5.5               A302153       Ovarian cancer   9.9   Normal Breast   33.2       (OD06283-03)       Ovarian Margin   17.1   Breast Cancer   8.5       (OD06283-07)       (OD04566)       Ovarian Cancer 064008   18.0   Breast Cancer 1024   36.1       Ovarian cancer   6.6   Breast Cancer   18.4       (OD06145)       (OD04590-01)       Ovarian Margin   12.5   Breast Cancer Mets   31.9       (OD06145)       (OD04590-03)       Ovarian cancer   14.7   Breast Cancer   45.4       (OD06455-03)       Metastasis (OD04655-               05)       Ovarian Margin   21.8   Breast Cancer 064006   11.5       (OD06455-07)       Normal Lung   21.9   Breast Cancer 9100266   20.9       Invasive poor diff. lung   17.6   Breast Margin   35.1       adeno (ODO4945-01)       9100265       Lung Margin   12.2   Breast Cancer   9.7       (ODO4945-03)       A209073       Lung Malignant Cancer   8.7   Breast Margin   22.2       (OD03126)       A2090734       Lung Margin   7.4   Breast cancer   100.0       (OD03126)       (OD06083)       Lung Cancer   9.9   Breast cancer node   63.7       (OD05014A)       metastasis (OD06083)       Lung Margin   21.8   Normal Liver   9.9       (OD05014B)       Lung cancer   5.1   Liver Cancer 1026   5.6       (OD06081)       Lung Margin   7.9   Liver Cancer 1025   13.5       (OD06081)       Lung Cancer   17.4   Liver Cancer 6004-T   4.8       (OD04237-01)       Lung Margin   24.0   Liver Tissue 6004-N   9.3       (OD04237-02)       Ocular Melanoma   9.7   Liver Cancer 6005-T   15.7       Metastasis       Ocular Melanoma   4.6   Liver Tissue 6005-N   20.4       Margin (Liver)       Melanoma Metastasis   19.8   Liver Cancer 064003   10.7       Melanoma Margin   21.6   Normal Bladder   8.0       (Lung)       Normal Kidney   11.0   Bladder Cancer 1023   10.5       Kidney Ca, Nuclear   37.6   Bladder Cancer   17.3       grade 2 (OD04338)       A302173       Kidney Margin   22.1   Normal Stomach   37.9       (OD04338)       Kidney Ca Nuclear   21.6   Gastric Cancer   11.1       grade 1/2 (OD04339)       9060397       Kidney Margin   12.9   Stomach Margin   20.6       (OD04339)       9060396       Kidney Ca, Clear cell   6.5   Gastric Cancer   22.7       type (OD04340)       9060395       Kidney Margin   18.4   Stomach Margin   36.1       (OD04340)       9060394       Kidney Ca, Nuclear   12.9   Gastric Cancer 064005   8.1       grade 3 (OD04348)                    
     [1964]               TABLE CDG                          Panel 3D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag2075, Run       Ag2075, Run       Tissue Name   164750734   Tissue Name   164750734                                     Daoy-Medulloblastoma   6.7   Ca Ski-Cervical epidermoid   50.3               carcinoma (metastasis)       TE671-   9.0   ES-2-Ovarian clear cell   13.9       Medulloblastoma       carcinoma       D283 Med-   35.4   Ramos-Stimulated with   2.7       Medulloblastoma       PMA/ionomycin 6 h       PFSK-1-Primitive   15.4   Ramos-Stimulated with   3.3       Neuroectodermal       PMA/ionomycin 14 h       XF-498-CNS   4.4   MEG-01-Chronic   3.4               myelogenous leukemia               (megokaryoblast)       SNB-78-Glioma   23.3   Raji-Burkitt&#39;s lymphoma   3.7       SF-268-Glioblastoma   13.6   Daudi-Burkitt&#39;s lymphoma   6.5       T98G-Glioblastoma   18.6   U266-B-cell plasmacytoma   8.4       SK-N-SH-   17.0   CA46-Burkitt&#39;s lymphoma   7.2       Neuroblastoma       (metastasis)       SF-295-Glioblastoma   8.4   RL-non-Hodgkin&#39;s B-cell   3.5               lymphoma       Cerebellum   74.7   JM1-pre-B-cell lymphoma   3.1       Cerebellum   62.4   Jurkat-T cell leukemia   11.6       NCI-H292-   45.7   TF-1-Erythroleukemia   13.4       Mucoepidermoid lung       carcinoma       DMS-114-Small cell   10.9   HUT 78-T-cell lymphoma   10.0       lung cancer       DMS-79-Small cell   100.0   U937-Histiocytic lymphoma   18.2       lung cancer       NCI-H146-Small cell   30.6   KU-812-Myelogenous   6.0       lung cancer       leukemia       NCI-H526-Small cell   57.4   769-P-Clear cell renal   11.3       lung cancer       carcinoma       NCI-N417-Small cell   15.2   Caki-2-Clear cell renal   10.4       lung cancer       carcinoma       NCI-H82-Small cell   36.9   SW 839-Clear cell renal   2.2       lung cancer       carcinoma       NCI-H157-Squamous   51.1   G401-Wilms&#39; tumor   6.2       cell lung cancer       (metastasis)       NCI-H1155-Large cell   26.6   Hs766T-Pancreatic   42.9       lung cancer       carcinoma (LN metastasis)       NCI-H1299-Large cell   44.4   CAPAN-1-Pancreatic   5.0       lung cancer       adenocarcinoma (liver               metastasis)       NCI-H727-Lung   47.0   SU86.86-Pancreatic   28.1       carcinoid       carcinoma (liver metastasis)       NCI-UMC-11-Lung   60.3   BxPC-3-Pancreatic   6.3       carcinoid       adenocarcinoma       LX-1-Small cell lung   23.5   HPAC-Pancreatic   7.4       cancer       adenocarcinoma       Colo-205-Colon cancer   29.5   MIA PaCa-2-Pancreatic   3.6               carcinoma       KM12-Colon cancer   24.0   CFPAC-1-Pancreatic ductal   40.9               adenocarcinoma       KM20L2-Colon cancer   8.4   PANC-1-Pancreatic   20.9               epithelioid ductal carcinoma       NCI-H716-Colon   23.3   T24-Bladder carcinma   13.1       cancer       (transitional cell)       SW-48-Colon   27.0   5637-Bladder carcinoma   11.0       adenocarcinoma       SW1116-Colon   10.0   HT-1197-Bladder   9.2       adenocarcinoma       carcinoma       LS 174T-Colon   9.9   UM-UC-3-Bladder   7.2       adenocarcinoma       carcinma (transitional cell)       SW-948-Colon   1.1   A204-Rhabdomyosarcoma   7.0       adenocarcinoma       SW-480-Colon   8.8   HT-1080-Fibrosarcoma   16.6       adenocarcinoma       NCI-SNU-5-Gastric   7.2   MG-63-Osteosarcoma   16.7       carcinoma       KATO III-Gastric   32.8   SK-LMS-1-   26.4       carcinoma       Leiomyosarcoma (vulva)       NCI-SNU-16-Gastric   13.6   SJRH30-   16.8       carcinoma       Rhabdomyosarcoma (met to               bone marrow)       NCI-SNU-1-Gastric   16.0   A431-Epidermoid   9.8       carcinoma       carcinoma       RF-1-Gastric   2.1   WM266-4-Melanoma   12.0       adenocarcinoma       RF-48-Gastric   4.0   DU 145-Prostate carcinoma   0.1       adenocarcinoma       (brain metastasis)       MKN-45-Gastric   28.7   MDA-MB-468-Breast   14.7       carcinoma       adenocarcinoma       NCI-N87-Gastric   13.3   SCC-4-Squamous cell   0.9       carcinoma       carcinoma of tongue       OVCAR-5-Ovarian   2.6   SCC-9-Squamous cell   0.3       carcinoma       carcinoma of tongue       RL95-2-Uterine   7.2   SCC-15-Squamous cell   0.5       carcinoma       carcinoma of tongue       HelaS3-Cervical   13.4   CAL 27-Squamous cell   21.2       adenocarcinoma       carcinoma of tongue                    
     [1965]               TABLE CDH                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag5279, Run       Ag5279, Run       Tissue Name   230472927   Tissue Name   230472927                                     Secondary Th1 act   59.0   HUVEC IL-1beta   41.5       Secondary Th2 act   91.4   HUVEC IFN gamma   71.7       Secondary Tr1 act   27.5   HUVEC TNF alpha +   17.4               IFN gamma       Secondary Th1 rest   7.5   HUVEC TNF alpha +   20.7               IL4       Secondary Th2 rest   8.4   HUVEC IL-11   32.3       Secondary Tr1 rest   2.6   Lung Microvascular EC   57.4               none       Primary Th1 act   26.8   Lung Microvascular EC   14.6               TNF alpha + IL-1beta       Primary Th2 act   55.1   Microvascular Dermal   10.9               EC none       Primary Tr1 act   55.5   Microsvasular Dermal   13.2               EC TNF alpha + IL-1beta       Primary Th1 rest   3.2   Bronchial epithelium   17.4               TNF alpha + IL1beta       Primary Th2 rest   13.7   Small airway epithelium   18.8               none       Primary Tr1 rest   7.6   Small airway epithelium   56.3               TNF alpha + IL-1beta       CD45RA CD4   31.9   Coronery artery SMC rest   31.9       lymphocyte act       CD45RO CD4   48.3   Coronery artery SMC   37.1       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   21.2   Astrocytes rest   28.3       Secondary CD8   36.1   Astrocytes TNF alpha +   15.8       lymphocyte rest       IL-1beta       Secondary CD8   8.0   KU-812 (Basophil) rest   15.2       lymphocyte act       CD4 lymphocyte none   8.4   KU-812 (Basophil)   17.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   8.9   CCD1106   71.2       CD95 CH11       (Keratinocytes) none       LAK cells rest   26.1   CCD1106   42.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   16.3   Liver cirrhosis   15.5       LAK cells IL-2 + IL-12   2.0   NCI-H292 none   45.4       LAK cells IL-2 + IFN   12.5   NCI-H292 IL-4   63.7       gamma       LAK cells IL-2 + IL-18   7.5   NCI-H292 IL-9   70.7       LAK cells   21.9   NCI-H292 IL-13   99.3       PMA/ionomycin       NK Cells IL-2 rest   44.4   NCI-H292 IFN gamma   45.4       Two Way MLR 3 day   21.9   HPAEC none   25.9       Two Way MLR 5 day   13.5   HPAEC TNF alpha + IL-   34.9               1beta       Two Way MLR 7 day   11.3   Lung fibroblast none   37.9       PBMC rest   11.0   Lung fibroblast TNF   21.2               alpha + IL-1beta       PBMC PWM   4.5   Lung fibroblast IL-4   31.6       PBMC PHA-L   18.4   Lung fibroblast IL-9   36.3       Ramos (B cell) none   14.0   Lung fibroblast IL-13   9.0       Ramos (B cell)   42.9   Lung fibroblast IFN   58.6       ionomycin       gamma       B lymphocytes PWM   18.9   Dermal fibroblast   43.2               CCD1070 rest       B lymphocytes CD40L   31.0   Dermal fibroblast   100.0       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   37.9   Dermal fibroblast   23.5               CCD1070 IL-1beta       EOL-1 dbcAMP   14.7   Dermal fibroblast IFN   31.4       PMA/ionomycin       gamma       Dendritic cells none   26.2   Dermal fibroblast IL-4   45.4       Dendritic cells LPS   13.2   Dermal Fibroblasts rest   61.6       Dendritic cells anti-   17.0   Neutrophils TNFA + LPS   4.2       CD40       Monocytes rest   11.6   Neutrophils rest   31.4       Monocytes LPS   8.5   Colon   1.0       Macrophages rest   12.9   Lung   1.6       Macrophages LPS   2.6   Thymus   4.5       HUVEC none   36.1   Kidney   32.5       HUVEC starved   36.9                    
     [1966]               TABLE CDI                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag2075, Run       Ag2075, Run       Tissue Name   152787491   Tissue Name   152787491                                     Secondary Th1 act   46.3   HUVEC IL-1beta   25.0       Secondary Th2 act   39.2   HUVEC IFN gamma   33.0       Secondary Tr1 act   31.9   HUVEC TNF alpha +   13.1               IFN gamma       Secondary Th1 rest   11.7   HUVEC TNF alpha +   20.7               IL4       Secondary Th2 rest   13.9   HUVEC IL-11   20.0       Secondary Tr1 rest   21.6   Lung Microvascular EC   22.7               none       Primary Th1 act   30.1   Lung Microvascular EC   15.0               TNF alpha + IL-1beta       Primary Th2 act   39.2   Microvascular Dermal   26.8               EC none       Primary Tr1 act   54.7   Microsvasular Dermal   16.6               EC TNF alpha + IL-1beta       Primary Th1 rest   84.1   Bronchial epithelium   4.9               TNF alpha + IL1beta       Primary Th2 rest   48.6   Small airway epithelium   19.9               none       Primary Tr1 rest   39.0   Small airway epithelium   72.7               TNF alpha + IL-1beta       CD45RA CD4   21.8   Coronery artery SMC rest   27.9       lymphocyte act       CD45RO CD4   33.0   Coronery artery SMC   19.6       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   25.5   Astrocytes rest   26.4       Secondary CD8   21.5   Astrocytes TNF alpha +   13.2       lymphocyte rest       IL-1beta       Secondary CD8   29.3   KU-812 (Basophil) rest   6.3       lymphocyte act       CD4 lymphocyte none   12.7   KU-812 (Basophil)   16.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   25.5   CCD1106   46.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   26.1   CCD1106   4.3               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   30.6   Liver cirrhosis   2.7       LAK cells IL-2 + IL-12   18.2   Lupus kidney   3.0       LAK cells IL-2 + IFN   31.0   NCI-H292 none   76.8       gamma       LAK cells IL-2 + IL-18   31.2   NCI-H292 IL-4   94.6       LAK cells   9.5   NCI-H292 IL-9   97.3       PMA/ionomycin       NK Cells IL-2 rest   37.4   NCI-H292 IL-13   59.5       Two Way MLR 3 day   24.0   NCI-H292 IFN gamma   51.8       Two Way MLR 5 day   23.0   HPAEC none   23.3       Two Way MLR 7 day   19.6   HPAEC TNF alpha + IL-   15.8               1beta       PBMC rest   11.4   Lung fibroblast none   18.4       PBMC PWM   72.2   Lung fibroblast TNF   12.0               alpha + IL-1beta       PBMC PHA-L   33.9   Lung fibroblast IL-4   35.8       Ramos (B cell) none   19.6   Lung fibroblast IL-9   25.5       Ramos (B cell)   100.0   Lung fibroblast IL-13   18.7       ionomycin       B lymphocytes PWM   81.8   Lung fibroblast IFN   38.4               gamma       B lymphocytes CD40L   42.3   Dermal fibroblast   48.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   23.7   Dermal fibroblast   83.5               CCD1070 TNF alpha       EOL-1 dbcAMP   13.5   Dermal fibroblast   13.6       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   20.9   Dermal fibroblast IFN   13.1               gamma       Dendritic cells LPS   11.5   Dermal fibroblast IL-4   36.6       Dendritic cells anti-   23.2   IBD Colitis 2   1.8       CD40       Monocytes rest   19.2   IBD Crohn&#39;s   2.4       Monocytes LPS   6.5   Colon   26.8       Macrophages rest   36.1   Lung   21.3       Macrophages LPS   13.3   Thymus   41.5       HUVEC none   37.6   Kidney   24.3       HUVEC starved   58.6                    
     [1967] CNS_neurodegeneration_v1.0 Summary: Ag5279 This panel confirms the expression of the CG56870-04 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.5 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1968] General_screening_panel_v1.5 Summary: Ag5279 Highest expression of the CG56870-01 is detected in cerebral cortex (CT=25.02). Thus, expression of this gene can be used in distinguishing this sample from other samples in the panel. Furthermore, significant expression of this gene is observed throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. The CG56870-01 gene encodes a Ndr3 protein homolog. The Ndr family is comprised of members from different gene families: Ndr1/RTP/Drg1/NDRG1, Ndr2, and Ndr3 (PFAM: IPR004142). NDRG1 is a cytoplasmic protein involved in stress responses, hormone responses, cell growth, and differentiation. Mutation of this gene was reported to be causative for hereditary motor and sensory neuropathy-Lom. Recently, NDRG4, another memember of Ndr family, was shown to be expressed in neurons of the brain and spinal cord. Its expression was markedly decreased in the brain of Alzheimer&#39;s disease patient (Zhou et al., 2001). Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1969] Among metabolic tissues, this gene is moderately expressed in adipose, adrenal, heart, thyroid, liver, pancreas, pituitary, and skeletal muscle. Thus, this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine disease, including Types 1 and 2 diabetes and obesity.  
     [1970] In addition, there appears to be substantial expression in other samples derived from brain cancer cell lines, colon cancer cell lines, breast cancer cell lines and ovarian cancer cell lines. Moreover, therapeutic modulation of this gene could be of benefit in the treatment of brain, colon, breast or ovarian cancer.  
     REFERENCES  
     [1971] 1. Zhou R H, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T. (2001) Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 73(1):86-97  
     [1972] Panel 1.3D Summary: Ag2075 Highest expression of the CG56870-01 gene is detected in the cerebral cortex (CT=24.2). This expression is consistent with expression in Panel 1.5. Please see that panel for discussion of utility of this gene in the central nervous system.  
     [1973] This gene also has moderate levels of expression in adipose, adrenal, thyroid, liver, heart, thyroid and skeletal muscle. Thus, this gene product may be important in the pathogenesis, diagnosis and/or treatment of metabolic and endocrine disease, including Types 1 and 2 diabetes and obesity.  
     [1974] In addition, there appears to be substantial expression in other samples derived from breast cancer cell lines, lung cancer cell lines, renal cancer cell lines and colon cancer cell lines. Thus, therapeutic modulation of this gene could be of benefit in the treatment of breast, lung, renal or colon cancer.  
     [1975] Panel 2.2 Summary: Ag2075 Highest expression of CG56870-01 is detected in breast cancer sample (CT=29.89). Thus expression of this gene can be used in distinguishing this sample from other samples in the panel. In addition, there appears to be substantial expression in other samples derived from breast cancers, kidney cancers and colon cancers. Therefore, therapeutic modulation of this gene could be of benefit in the treatment of breast, kidney or colon cancer.  
     [1976] Panel 3D Summary: Ag2075 The expression of this gene appears to be highest in a sample derived from a lung cancer cell line (DMS-79)(CT=26.4). In addition, there appears to be substantial expression in other samples derived from pancreatic cancer cell lines, lung cancer cell lines, brain cancer cell lines and cervical cancer cell lines. Thus, the expression of this gene could be used to distinguish DMS-79 cells from other samples in the panel. Moreover, therapeutic modulation of this gene could be of benefit in the treatment of pancreatic, lung, brain or cervical cancer.  
     [1977] Panel 4.1D Summary: Ag5279 Expression of the CG56870-01 gene is highest in samples derived from TNF alpha treated dermal fibroblast CCD1070 cells (CT=30.6). Expression of this gene is also prominent in activated secondary and primarey Th1, Th2 and Tr1 cells when compared expression in the corresponding resting cell lines. Thus, this gene may be involved in T lymphocyte function. Therefore, therapeutic modulation to the expression or function of this gene may be as anti-inflammatory therapeutics for T cell-mediated autoimmune and inflammatory diseases, such as asthma, athritis, psoriasis, IBD, and lupus.  
     [1978] Panel 4D Summary: Ag2075 Expression of the CG56870-01 gene is ubiquitous throughout this panel, with highest in samples derived from ionomycin treated Ramos (B cell) cells (CT=26.1). Furthermore, expression of this gene is also detected in PWM treated PBMC cells and PWM treated B lymphocytes. Therefore, therapeutic modulation of the expression or function of this gene may reduce or eliminate the symptoms in patients with autoimmune and inflammatory diseases in which B cells play a part in the initiation or progression of the disease process, such as systemic lupus erythematosus, Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.  
     [1979] CE. CG!56870-05: N-myc Downstream-Regulated Gene 3  
     [1980] Expression of gene CG56870-05 was assessed using the primer-probe set Ag5265, described in Table CEA. Results of the RTQ-PCR runs are shown in Tables CEB and CEC.  
     [1981] Table CEA. Probe Name Ag5265 
               TABLE CEA                          Probe Name Ag5265                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tgttcagctcacagagatcaaa-3′   22   18   656               Probe   TET-5′-caagaaacttccaggactttgactgtca-3′-TAMRA   28   65   657               Reverse   5′-catccattgtggggtactga-3′   20   96   658                  
 
     [1982]               TABLE CEB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag5265,           Ag5265, Run       Run        Tissue Name   230512714   Tissue Name   230512714                                     AD 1 Hippo   7.2   Control (Path) 3   2.4               Temporal Ctx       AD 2 Hippo   15.2   Control (Path) 4   10.3               Temporal Ctx       AD 3 Hippo   2.0   AD 1 Occipital Ctx   11.5       AD 4 Hippo   3.3   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   59.9   AD 3 Occipital Ctx   7.0       AD 6 Hippo   22.1   AD 4 Occipital Ctx   6.9       Control 2 Hippo   14.5   AD 5 Occipital Ctx   54.7       Control 4 Hippo   2.6   AD 6 Occipital Ctx   12.2       Control (Path) 3   3.9   Control 1 Occipital   1.2       Hippo       Ctx       AD 1 Temporal   12.7   Control 2 Occipital   60.3       Ctx       Ctx       AD 2 Temporal   16.0   Control 3 Occipital   8.2       Ctx       Ctx       AD 3 Temporal   5.5   Control 4 Occipital   1.7       Ctx       Ctx       AD 4 Temporal   13.9   Control (Path) 1   53.6       Ctx       Occipital Ctx       AD 5 Inf Temporal   64.6   Control (Path) 2   5.9       Ctx       Occipital Ctx       AD 5 Sup   28.9   Control (Path) 3   2.2       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   27.0   Control (Path) 4   5.5       Ctx       Occipital Ctx       AD 6 Sup   100.0   Control 1 Parietal   3.0       Temporal Ctx       Ctx       Control 1   2.6   Control 2 Parietal   19.6       Temporal Ctx       Ctx       Control 2   38.2   Control 3 Parietal   18.8       Temporal Ctx       Ctx       Control 3   9.7   Control (Path) 1   56.6       Temporal Ctx       Parietal Ctx       Control 3   1.5   Control (Path) 2   14.2       Temporal Ctx       Parietal Ctx       Control (Path) 1   31.4   Control (Path) 3   2.6       Temporal Ctx       Parietal Ctx       Control (Path) 2   18.3   Control (Path) 4   25.0       Temporal Ctx       Parietal Ctx                    
     [1983]               TABLE CEC                          General_screening_panel_v1.5                                 Rel. Exp.       Rel. Exp.           (%) Ag5265,       (%) Ag5265,           Run       Run       Tissue Name   232936652   Tissue Name   232936652                                     Adipose   1.1   Renal ca. TK-10   14.8       Melanoma*   7.9   Bladder   2.5       Hs688(A).T       Melanoma*   10.1   Gastric ca. (liver met.)   7.3       Hs688(B).T       NCI-N87       Melanorna* M14   12.4   Gastric ca. KATO III   17.8       Melanoma*   13.7   Colon ca. SW-948   1.8       LOXIMVI       Melanoma* SK-   9.9   Colon ca. SW480   16.0       MEL-5       Squamous cell   8.3   Colon ca.* (SW480   8.2       carcinoma SCC-4       met) SW620       Testis Pool   2.2   Colon ca. HT29   6.7       Prostate ca.* (bone   18.0   Colon ca. HCT-116   15.8       met) PC-3       Prostate Pool   4.4   Colon ca. CaCo-2   25.5       Placenta   2.1   Colon cancer tissue   2.5       Uterus Pool   1.9   Colon ca. SW1116   2.3       Ovarian ca.   9.0   Colon ca. Colo-205   4.8       OVCAR-3       Ovarian ca. SK-   16.0   Colon ca. SW-48   5.1       OV-3       Ovarian ca.   4.5   Colon Pool   2.8       OVCAR-4       Ovarian ca.   10.4   Small Intestine Pool   2.4       OVCAR-5       Ovarian ca.   12.0   Stomach Pool   1.8       IGROV-1       Ovarian ca.   4.5   Bone Marrow Pool   1.2       OVCAR-8       Ovary   2.8   Fetal Heart   2.3       Breast ca. MCF-7   4.9   Heart Pool   1.5       Breast ca. MDA-   30.1   Lymph Node Pool   3.0       MB-231       Breast ca. BT 549   18.9   Fetal Skeletal Muscle   0.9       Breast ca. T47D   4.0   Skeletal Muscle Pool   1.8       Breast ca. MDA-N   8.4   Spleen Pool   2.2       Breast Pool   3.6   Thymus Pool   1.9       Trachea   3.2   CNS cancer   18.3               (glio/astro) U87-MG       Lung   1.7   CNS cancer   19.5               (glio/astro) U-118-MG       Fetal Lung   4.8   CNS cancer   8.4               (neuro; met) SK-N-AS       Lung ca. NCI-N417   2.0   CNS cancer (astro)   8.8               SF-539       Lung ca. LX-1   8.5   CNS cancer (astro)   29.1               SNB-75       Lung ca. NCI-H146   9.2   CNS cancer (glio)   10.9               SNB-19       Lung ca. SHP-77   8.2   CNS cancer (glio) SF-   17.2               295       Lung ca. A549   15.2   Brain (Amygdala)   14.0               Pool       Lung ca. NCI-H526   3.2   Brain (cerebellum)   100.0       Lung ca. NCI-H23   16.2   Brain (fetal)   10.7       Lung ca. NCI-H460   2.7   Brain (Hippocampus)   11.4               Pool       Lung ca. HOP-62   5.6   Cerebral Cortex Pool   15.5       Lung ca. NCI-H522   13.0   Brain (Substantia   14.7               nigra) Pool       Liver   0.9   Brain (Thalamus) Pool   17.9       Fetal Liver   2.4   Brain (whole)   25.9       Liver ca. HepG2   6.2   Spinal Cord Pool   9.0       Kidney Pool   6.9   Adrenal Gland   5.0       Fetal Kidney   3.1   Pituitary gland Pool   1.5       Renal ca. 786-0   9.0   Salivary Gland   2.3       Renal ca. A498   7.6   Thyroid (female)   2.0       Renal ca. ACHN   6.0   Pancreatic ca.   6.5               CAPAN2       Renal ca. UO-31   6.3   Pancreas Pool   3.2                    
     [1984] CNS_neurodegeneration_v1.0 Summary: Ag5265 This panel confirms the expression of the CG56870-04 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.5 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1985] General_screening_panel_v1.5 Summary: Ag5265 Highest expression of the CG56870-05 gene is detected in cerebral cortex (CT=28.86). Thus, expression of this gene can be used in distinguishing this sample from other samples in the panel. Furthermore, significant expression of this gene is observed throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. The CG56870-05 gene encodes a putative Ndr3 protein. This family consists of proteins from different gene families: Ndr1/RTP/Drg1/NDRG1, Ndr2, and Ndr3 (PFAM: IPR004142). NDRG1 is a cytoplasmic protein involved in stress responses, hormone responses, cell growth, and differentiation. Mutation of this gene was reported to be causative for hereditary motor and sensory neuropathy-Lom. Recently, NDRG4, another memember of Ndr family, was shown to be expressed in neurons of the brain and spinal cord. Its expression was markedly decreased in the brain of Alzheimer&#39;s disease patient (Zhou et al., 2001). Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [1986] Among metabolic tissues, this gene has low levels of expression in heart, skeletal muscle, adrenal, thyroid, pancreas and pituitary. Therefore, this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine disease, including Types 1 and 2 diabetes and obesity.  
     [1987] Overall, this gene is expressed in all the samples on this panel, with slightly higher levels of expression in the cancer cell lines compared to expression in the normal tissues samples.  
     [1988] Panel 4.1D Summary: Ag5265 Expression of this gene is low/undetectable (CTs&gt;34.5) across all of the samples on this panel (data not shown).  
     [1989] sCF. CG59764-01: Ferritin Heavy Chain Like Protein  
     [1990] Expression of gene CG59764-01 was assessed using the primer-probe set Ag3578, described in Table CFA. Results of the RTQ-PCR runs are shown in Tables CFB and CFC.  
     [1991] Table CFA. Probe Name Ag3578 
               TABLE CFA                          Probe Name Ag3578                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ctgcgacttcctggagaac-3′   19   430   659               Probe   TET-5′-agcaggccaagaccatcaaagagct-3′-TAMRA   25   462   660               Reverse   5′-tgtgcaggttgctcaggta-3′   19   494   661                  
 
     [1992]               TABLE CFB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3578,           Ag3578, Run       Run       Tissue Name   210642348   Tissue Name   210642348                                     AD 1 Hippo   14.0   Control (Path) 3   3.2               Temporal Ctx       AD 2 Hippo   8.2   Control (Path) 4   52.9               Temporal Ctx       AD 3 Hippo   6.7   AD 1 Occipital Ctx   22.8       AD 4 Hippo   2.3   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   83.5   AD 3 Occipital Ctx   7.3       AD 6 Hippo   29.1   AD 4 Occipital Ctx   14.9       Control 2 Hippo   1.6   AD 5 Occipital Ctx   11.4       Control 4 Hippo   3.1   AD 6 Occipital Ctx   19.8       Control (Path) 3   8.0   Control 1 Occipital   9.0       Hippo       Ctx       AD 1 Temporal   19.5   Control 2 Occipital   29.5       Ctx       Ctx       AD 2 Temporal   22.8   Control 3 Occipital   24.0       Ctx       Ctx       AD 3 Temporal   17.0   Control 4 Occipital   7.4       Ctx       Ctx       AD 4 Temporal   16.8   Control (Path) 1   38.4       Ctx       Occipital Ctx       AD 5 Inf Temporal   50.3   Control (Path) 2   10.3       Ctx       Occipital Ctx       AD 5 Sup   40.6   Control (Path) 3   0.0       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   63.7   Control (Path) 4   46.0       Ctx       Occipital Ctx       AD 6 Sup   100.0   Control 1 Parietal   9.2       Temporal Ctx       Ctx       Control 1   9.2   Control 2 Parietal   44.1       Temporal Ctx       Ctx       Control 2   13.3   Control 3 Parietal   21.0       Temporal Ctx       Ctx       Control 3   21.3   Control (Path) 1   20.2       Temporal Ctx       Parietal Ctx       Control 3   14.2   Control (Path) 2   16.7       Temporal Ctx       Parietal Ctx       Control (Path) 1   35.1   Control (Path) 3   0.0       Temporal Ctx       Parietal Ctx       Control (Path) 2   25.3   Control (Path) 4   45.4       Temporal Ctx       Parietal Ctx                    
     [1993]               TABLE CFC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3578,       (%) Ag3578,           Run       Run       Tissue Name   217423081   Tissue Name   217423081                                     Adipose   8.6   Renal ca. TK-10   19.9       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   15.3       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   16.4       Melanoma*   0.0   Colon ca. SW-948   22.8       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   5.6       MEL-5       Squamous cell   8.3   Colon ca.* (SW480   42.0       carcinoma SCC-4       met) SW620       Testis Pool   27.4   Colon ca. HT29   2.6       Prostate ca.* (bone   11.0   Colon ca. HCT-116   39.2       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   13.5       Placenta   15.3   Colon cancer tissue   4.8       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   4.2       OVCAR-3       Ovarian ca. SK-   14.4   Colon ca. SW-48   9.3       OV-3       Ovarian ca.   8.8   Colon Pool   27.5       OVCAR-4       Ovarian ca.   16.6   Small Intestine Pool   11.2       OVCAR-5       Ovarian ca.   13.0   Stomach Pool   11.3       IGROV-1       Ovarian ca.   4.3   Bone Marrow Pool   8.7       OVCAR-8       Ovary   0.0   Fetal Heart   17.7       Breast ca. MCF-7   0.0   Heart Pool   9.9       Breast ca. MDA-   5.7   Lymph Node Pool   22.4       MB-231       Breast ca. BT 549   47.3   Fetal Skeletal Muscle   10.2       Breast ca. T47D   8.0   Skeletal Muscle Pool   100.0       Breast ca. MDA-N   0.0   Spleen Pool   0.0       Breast Pool   7.6   Thymus Pool   3.5       Trachea   0.0   CNS cancer   0.0               (glio/astro) U87-MG       Lung   3.1   CNS cancer   8.1               (glio/astro) U-118-MG       Fetal Lung   7.1   CNS cancer   22.4               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   8.2               SF-539       Lung ca. LX-1   49.7   CNS cancer (astro)   25.2               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   10.1               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   24.5               295       Lung ca. A549   0.0   Brain (Amygdala)   7.8               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   20.3       Lung ca. NCI-H23   11.9   Brain (fetal)   18.7       Lung ca. NCI-H460   2.7   Brain (Hippocampus)   14.9               Pool       Lung ca. HOP-62   10.9   Cerebral Cortex Pool   26.2       Lung ca. NCI-H522   0.0   Brain (Substantia   35.4               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   19.1       Fetal Liver   0.0   Brain (whole)   17.3       Liver ca. HepG2   3.2   Spinal Cord Pool   9.2       Kidney Pool   21.5   Adrenal Gland   3.7       Fetal Kidney   21.2   Pituitary gland Pool   0.0       Renal ca. 786-0   11.7   Salivary Gland   0.0       Renal ca. A498   9.2   Thyroid (female)   6.7       Renal ca. ACHN   11.5   Pancreatic ca.   48.3               CAPAN2       Renal ca. UO-31   10.3   Pancreas Pool   5.5                    
     [1994] CNS_neurodegeneration_v1.0 Summary: Ag3578 This panel confirms the expression of the CG59764-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [1995] General_screening_panel_v1.4 Summary: Ag3578 Highest expression of the CG59764-01 gene is detected in sample derived from skeletal muscle (CT=31.2). Thus expression of this gene can be used to distinguish skeletal muscle sample from other samples used in this panel. This gene is also expressed at low but significant levels in heart and adipose. Thus, this gene product may be useful in the treatment of metabolic disorders that involve these tissues, including obesity.  
     [1996] Significant expression of this gene is also associated with samples derived from breast cancer, pancreatic cancer, colon cancer and lung cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product might be beneficial in the treatment of these cancers.  
     [1997] In addition, this gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. The CG59764-01 gene encodes a homologue of ferritin heavy chain protein (H-feritin). It has been hypothesized that the up-regulation of the H-ferritin mRNA is part of a mechanism protecting the hippocampus, a seizure-prone area, against a possible overactivation during absence seizures (Lakaye et al., 2000). Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of seizure disorders, such as epilepsy. Furthermore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, multiple sclerosis, schizophrenia and depression.  
     REFERENCES  
     [1998] 1. Lakaye B, de Borman B, Minet A, Arckens L, Vergnes M, Marescaux C, Grisar T. (2000) Increased expression of mRNA encoding ferritin heavy chain in brain structures of a rat model of absence epilepsy. Exp Neurol 162(1):112-20.  
     [1999] Panel 4.1D Summary: Ag3578 Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2000] CG. CG59710-01: P14  
     [2001] Expression of gene CG59710-01 was assessed using the primer-probe set Ag3512, described in Table CGA. Results of the RTQ-PCR runs are shown in Tables CGB and CGC.  
     [2002] Table CGA. Probe Name Ag3512 
               TABLE CGA                          Probe Name Ag3512                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ctttgttctccagcacatctg-3′   21   211   662               Probe   TET-5′-ctacatcatggccgagatctgcaatg-3′-TAMRA   26   232   663               Reverse   5′-cctcgcatytttaggatctg-3′   20   290   664                  
 
     [2003]               TABLE CGB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3512,           Ag3512, Run       Run       Tissue Name   211004862   Tissue Name   211004862                                     AD 1 Hippo   23.0   Control (Path) 3   7.2               Temporal Ctx       AD 2 Hippo   31.2   Control (Path) 4   37.1               Temporal Ctx       AD 3 Hippo   9.8   AD 1 Occipital   20.0               Ctx       AD 4 Hippo   10.0   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 Hippo   85.9   AD 3 Occipital   9.0               Ctx       AD 6 Hippo   56.6   AD 4 Occipital   21.3               Ctx       Control 2 Hippo   41.5   AD 5 Occipital   15.2               Ctx       Control 4 Hippo   21.6   AD 6 Occipital   49.0               Ctx       Control (Path) 3   12.5   Control 1 Occipital   6.0       Hippo       Ctx       AD 1 Temporal Ctx   31.9   Control 2 Occipital   77.4               Ctx       AD 2 Temporal Ctx   41.2   Control 3 Occipital   22.1               Ctx       AD 3 Temporal Ctx   11.3   Control 4 Occipital   9.8               Ctx       AD 4 Temporal Ctx   21.0   Control (Path) 1   77.9               Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   12.6       Ctx       Occipital Ctx       AD 5 SupTemporal   42.6   Control (Path) 3   5.4       Ctx       Occipital Ctx       AD 6 Inf Temporal   35.1   Control (Path) 4   21.6       Ctx       Occipital Ctx       AD 6 Sup Temporal   56.6   Control 1 Parietal   11.4       Ctx       Ctx       Control 1 Temporal   10.1   Control 2 Parietal   52.5       Ctx       Ctx       Control 2 Temporal   53.2   Control 3 Parietal   21.5       Ctx       Ctx       Control 3 Temporal   17.2   Control (Path) 1   68.8       Ctx       Parietal Ctx       Control 4 Temporal   15.9   Control (Path) 2   29.7       Ctx       Parietal Ctx       Control (Path) 1   55.1   Control (Path) 3   10.2       Temporal Ctx       Parietal Ctx       Control (Path) 2   39.5   Control (Path) 4   48.3       Temporal Ctx       Parietal Ctx                    
     [2004]               TABLE CGC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3512,       (%) Ag3512,           Run       Run       Tissue Name   217240776   Tissue Name   217240776                                     Adipose   3.3   Renal ca. TK-10   21.8       Melanoma*   9.7   Bladder   5.5       Hs688(A).T       Melanoma*   10.5   Gastric ca. (liver met.)   37.1       Hs688(B).T       NCI-N87       Melanoma* M14   26.4   Gastric ca. KATO III   48.6       Melanoma*   35.4   Colon ca. SW-948   7.2       LOXIMVI       Melanoma* SK-   14.4   Colon ca. SW480   62.4       MEL-5       Squamous cell   14.9   Colon ca.* (SW480   29.7       carcinoma SCC-4       met) SW620       Testis Pool   6.7   Colon ca. HT29   14.6       Prostate ca.* (bone   17.2   Colon ca. HCT-116   24.1       met) PC-3       Prostate Pool   4.8   Colon ca. CaCo-2   46.0       Placenta   4.4   Colon cancer tissue   13.9       Uterus Pool   3.1   Colon ca. SW1116   2.1       Ovarian ca.   20.0   Colon ca. Colo-205   10.8       OVCAR-3       Ovarian ca. SK-   31.6   Colon ca. SW-48   11.9       OV-3       Ovarian ca.   19.6   Colon Pool   13.4       OVCAR-4       Ovarian ca.   30.8   Small Intestine Pool   7.0       OVCAR-5       Ovarian ca.   10.2   Stomach Pool   4.0       IGROV-1       Ovarian ca.   14.0   Bone Marrow Pool   2.4       OVCAR-8       Ovary   3.6   Fetal Heart   3.3       Breast ca. MCF-7   18.2   Heart Pool   4.1       Breast ca. MDA-   33.7   Lymph Node Pool   7.5       MB-231       Breast ca. BT 549   24.8   Fetal Skeletal Muscle   1.8       Breast ca. T47D   100.0   Skeletal Muscle Pool   6.3       Breast ca. MDA-N   24.8   Spleen Pool   10.8       Breast Pool   7.3   Thymus Pool   5.9       Trachea   2.8   CNS cancer   33.7               (glio/astro) U87-MG       Lung   3.1   CNS cancer   30.1               (glio/astro) U-118-MG       Fetal Lung   7.0   CNS cancer   13.3               (neuro; met) SK-N-AS       Lung ca. NCI-N417   7.3   CNS cancer (astro)   16.2               SF-539       Lung ca. LX-1   17.6   CNS cancer (astro)   46.3               SNB-75       Lung ca. NCI-H146   13.1   CNS cancer (glio)   10.6               SNB-19       Lung ca. SHP-77   21.0   CNS cancer (glio) SF-   27.5               295       Lung ca. A549   25.7   Brain (Amygdala)   4.1               Pool       Lung ca. NCI-H526   15.0   Brain (cerebellum)   6.7       Lung ca. NCI-H23   30.8   Brain (fetal)   6.7       Lung ca. NCI-H460   9.3   Brain (Hippocampus)   4.4               Pool       Lung ca. HOP-62   6.7   Cerebral Cortex Pool   6.3       Lung ca. NCI-H522   15.2   Brain (Substantia   6.1               nigra) Pool       Liver   1.3   Brain (Thalamus) Pool   5.6       Fetal Liver   7.7   Brain (whole)   4.7       Liver ca. HepG2   11.2   Spinal Cord Pool   4.5       Kidney Pool   12.9   Adrenal Gland   3.3       Fetal Kidney   4.2   Pituitary gland Pool   2.6       Renal ca. 786-0   11.8   Salivary Gland   2.5       Renal ca. A498   6.1   Thyroid (female)   3.5       Renal ca. ACHN   10.5   Pancreatic ca.   15.3               CAPAN2       Renal ca. UO-31   18.2   Pancreas Pool   7.6                    
     [2005] CNS_neurodegeneration_v1.0 Summary: Ag3512 This panel confirms the expression of the CG59710-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. However, as seen in panel 1.4, this gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in other central nervous system disorders such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2006] General_screening_panel_v1.4 Summary: Ag3512 Highest expression of the CG59710-01 gene is detected in a sample derived from a breast cancer cell line (CT=25.3). Therefore, expression of this gene could be used in distinguishing this sample from other samples in the panel. Overall, expression of this gene appears to be associated with the cancer cell lines suggesting a role for this gene product in cellular growth and proliferation. Specifically, significant expression of this gene is associated with CNS cancer, colon cancer, gastric cancer, renal cancer, lung cancer, breast cancer, ovarian cancer, and melanoma cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product might be beneficial in the treatment of these cancers.  
     [2007] Panel 4.1D Summary: Ag3512 Results from one experiment with the CG59710-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [2008] CH. CG59754-02 and CG59754-01: Down Syndrome Cell Adhesion Molecule  
     [2009] Expression of gene CG59754-02 and variant CG59754-01 was assessed using the primer-probe set Ag1305, described in Table CHA.  
     [2010] Table CHA. Probe Name Ag1305 
               TABLE CHA                          Probe Name Ag1305                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5-′-gtgagcattgtgtctccagaa-3′   21   291   665               Probe   TET-5′-tttattacctaccacggcgggctgta-3′-TAMRA   26   321   666               Reverse   5′-tcctccttctgtacgtcagaga-3′   22   349   667                  
 
     [2011] Panel 4D Summary: Ag1305 Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2012] CI. CG59800-01: Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase-3B  
     [2013] Expression of gene CG59800-01 was assessed using the primer-probe set Ag3589, described in Table CIA.  
     [2014] Table CIA. Probe Name Ag3589 
               TABLE CIA                          Probe Name Ag3589                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tacatacctgccctgtccatac-3′   22   88   668               Probe   TET-5′-ctacatacctgccccgtccatacctg-3′-TAMRA   26   117   669               Reverse   5′-gtatggacggggcaggtat-3′   19   121   670                  
 
     [2015] Results from Panels CNS_neurodegeneration_v1.0, 1.4, 2.2, and 4.1D are not included. The amp plots corresponding to these runs suggest that there were experimental difficulties with these runs.  
     [2016] CJ. CG59761-01: AXIN 1 (Axis Inhibition Protein 1) (Haxin)—Isoform1, Submitted to Study DDSMT on Mar. 21, 2001 by Cmiller; Clone Status=FIS; Novelty=Novel; ORF Start=97, ORF Stop=2833, Frame=1; 2949 bp.  
     [2017] Expression of gene CG59761-01 was assessed using the primer-probe set Ag3577, described in Table CJA. Results of the RTQ-PCR runs are shown in Tables CJB, CJC and CJD.  
     [2018] Table CJA. Probe Name Ag3577 
               TABLE CJA                          Probe Name Ag3577                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atacttgaagtgggctgagtca-3′   22   486   671               Probe   TET-5′-cattccctgctggatgaccaagatg-3′-TAMRA   25   511   672               Reverse   5′-aggaaagtcctgaacaggctta-3′   22   539   673                  
 
     [2019]               TABLE CJB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3577,           Ag3577, Run       Run       Tissue Name   210642177   Tissue Name   210642177                                     AD 1 Hippo   26.1   Control (Path) 3   7.5               Temporal Ctx       AD 2 Hippo   20.6   Control (Path) 4   26.8               Temporal Ctx       AD 3 Hippo   10.8   AD 1 Occipital   23.5               Ctx       AD 4 Hippo   9.1   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   86.5   AD 3 Occipital   12.3               Ctx       AD 6 Hippo   48.3   AD 4 Occipital   18.9               Ctx       Control 2 Hippo   21.8   AD 5 Occipital   24.3               Ctx       Control 4 Hippo   16.6   AD 6 Occipital   34.4               Ctx       Control (Path) 3   4.7   Control 1 Occipital   6.2       Hippo       Ctx       AD 1 Temporal Ctx   25.7   Control 2 Occipital   57.4               Ctx       AD 2 Temporal Ctx   28.3   Control 3 Occipital   13.4               Ctx       AD 3 Temporal Ctx   14.5   Control 4 Occipital   8.7               Ctx       AD 4 Temporal Ctx   19.8   Control (Path) 1   62.4               Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   10.5       Ctx       Occipital Ctx       AD 5 SupTemporal   44.1   Control (Path) 3   5.3       Ctx       Occipital Ctx       AD 6 Inf Temporal   48.3   Control (Path) 4   20.4       Ctx       Occipital Ctx       AD 6 Sup Temporal   47.0   Control 1 Parietal   15.9       Ctx       Ctx       Control 1 Temporal   11.6   Control 2 Parietal   54.3       Ctx       Ctx       Control 2 Temporal   35.1   Control 3 Parietal   15.5       Ctx       Ctx       Control 3 Temporal   14.6   Control (Path) 1   43.5       Ctx       Parietal Ctx       Control 4 Temporal   12.9   Control (Path) 2   21.3       Ctx       Parietal Ctx       Control (Path) 1   47.0   Control (Path) 3   7.0       Temporal Ctx       Parietal Ctx       Control (Path) 2   28.5   Control (Path) 4   39.0       Temporal Ctx       Parietal Ctx                    
     [2020]               TABLE CJC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3577,       (%) Ag3577,           Run       Run       Tissue Name   217343282   Tissue Name   217343282                                     Adipose   2.8   Renal ca. TK-10   35.4       Melanoma*   13.9   Bladder   13.3       Hs688(A).T       Melanoma*   13.7   Gastric ca. (liver met.)   70.7       Hs688(B).T       NCI-N87       Melanoma* M14   28.5   Gastric ca. KATO III   100.0       Melanoma*   21.2   Colon ca. SW-948   15.0       LOXIMVI       Melanoma* SK-   24.3   Colon ca. SW480   43.5       MEL-5       Squamous cell   23.2   Colon ca.* (SW480   47.6       carcinoma SCC-4       met) SW620       Testis Pool   6.4   Colon ca. HT29   26.2       Prostate ca.* (bone   32.3   Colon ca. HCT-116   27.2       met) PC-3       Prostate Pool   5.1   Colon ca. CaCo-2   35.4       Placenta   6.2   Colon cancer tissue   13.1       Uterus Pool   2.8   Colon ca. SW1116   14.2       Ovarian ca.   12.5   Colon ca. Colo-205   10.1       OVCAR-3       Ovarian ca. SK-   56.6   Colon ca. SW-48   21.8       OV-3       Ovarian ca.   11.4   Colon Pool   10.7       OVCAR-4       Ovarian ca.   42.0   Small Intestine Pool   10.4       OVCAR-5       Ovarian ca.   12.9   Stomach Pool   5.6       IGROV-1       Ovarian ca.   13.1   Bone Marrow Pool   5.2       OVCAR-8       Ovary   7.3   Fetal Heart   3.5       Breast ca. MCF-7   29.3   Heart Pool   4.0       Breast ca. MDA-   32.3   Lymph Node Pool   12.7       MB-231       Breast ca. BT 549   30.1   Fetal Skeletal Muscle   3.6       Breast ca. T47D   75.3   Skeletal Muscle Pool   10.6       Breast ca. MDA-N   21.8   Spleen Pool   7.3       Breast Pool   12.3   Thymus Pool   13.9       Trachea   10.8   CNS cancer   10.7               (glio/astro) U87-MG       Lung   1.8   CNS cancer   42.9               (glio/astro) U-118-MG       Fetal Lung   16.0   CNS cancer   25.3               (neuro; met) SK-N-AS       Lung ca. NCI-N417   7.0   CNS cancer (astro)   6.0               SF-539       Lung ca. LX-1   79.0   CNS cancer (astro)   34.2               SNB-75       Lung ca. NCI-H146   12.3   CNS cancer (glio)   13.8               SNB-19       Lung ca. SHP-77   29.1   CNS cancer (glio) SF-   28.1               295       Lung ca. A549   29.1   Brain (Amygdala)   5.3               Pool       Lung ca. NCI-H526   7.4   Brain (cerebellum)   34.9       Lung ca. NCI-H23   28.3   Brain (fetal)   21.5       Lung ca. NCI-H460   23.3   Brain (Hippocampus)   5.4               Pool       Lung ca. HOP-62   7.8   Cerebral Cortex Pool   6.3       Lung ca. NCI-H522   28.5   Brain (Substantia   6.6               nigra) Pool       Liver   0.9   Brain (Thalamus) Pool   8.1       Fetal Liver   12.5   Brain (whole)   11.6       Liver ca. HepG2   26.8   Spinal Cord Pool   5.1       Kidney Pool   14.1   Adrenal Gland   10.1       Fetal Kidney   7.2   Pituitary gland Pool   0.0       Renal ca. 786-0   13.6   Salivary Gland   5.9       Renal ca. A498   7.9   Thyroid (female)   5.3       Renal ca. ACHN   22.1   Pancreatic ca.   30.8               CAPAN2       Renal ca. UO-31   17.7   Pancreas Pool   13.9                    
     [2021]               TABLE CJD                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3577, Run       Ag3577, Run       Tissue Name   169851850   Tissue Name   169851850                                     Secondary Th1 act   50.0   HUVEC IL-1beta   37.9       Secondary Th2 act   57.0   HUVEC IFN gamma   25.5       Secondary Tr1 act   71.2   HUVEC TNF alpha +   35.8               IFN gamma       Secondary Th1 rest   29.5   HUVEC TNF alpha +   36.9               IL4       Secondary Th2 rest   58.2   HUVEC IL-11   14.6       Secondary Tr1 rest   55.1   Lung Microvascular EC   48.0               none       Primary Th1 act   62.9   Lung Microvascular EC   45.7               TNF alpha + IL-1beta       Primary Th2 act   61.6   Microvascular Dermal   27.5               EC none       Primary Tr1 act   60.7   Microvascular Dermal   24.1               EC TNF alpha + IL-1beta       Primary Th1 rest   50.3   Bronchial epithelium   39.2               TNF alpha + IL1beta       Primary Th2 rest   61.1   Small airway epithelium   20.4               none       Primary Tr1 rest   85.3   Small airway epithelium   57.8               TNF alpha + IL-1beta       CD45RA CD4   47.6   Coronery artery SMC rest   13.9       lymphocyte act       CD45RO CD4   58.6   Coronery artery SMC   12.9       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   55.5   Astrocytes rest   16.8       Secondary CD8   51.4   Astrocytes TNF alpha +   18.7       lymphocyte rest       IL-1beta       Secondary CD8   31.0   KU-812 (Basophil) rest   37.1       lymphocyte act       CD4 lymphocyte none   33.2   KU-812 (Basophil)   64.2               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   54.3   CCD1106   48.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   52.1   CCD1106   43.8               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   50.3   Liver cirrhosis   7.5       LAK cells IL-2 + IL-12   47.0   NCI-H292 none   30.6       LAK cells IL-2 + IFN   62.9   NCI-H292 IL-4   60.3       gamma       LAK cells IL-2 + IL-18   61.1   NCI-H292 IL-9   72.2       LAK cells   95.9   NCI-H292 IL-13   57.8       PMA/ionomycin       NK Cells IL-2 rest   100.0   NCI-H292 IFN gamma   85.9       Two Way MLR 3 day   74.7   HPAEC none   23.0       Two Way MLR 5 day   50.7   HPAEC TNF alpha + IL-   33.4               1beta       Two Way MLR 7 day   27.9   Lung fibroblast none   15.3       PBMC rest   58.2   Lung fibroblast TNF   17.4               alpha + IL-1beta       PBMC PWM   46.7   Lung fibroblast IL-4   23.7       PBMC PHA-L   29.9   Lung fibroblast IL-9   29.3       Ramos (B cell) none   39.2   Lung fibroblast IL-13   30.4       Ramos (B cell)   42.6   Lung fibroblast IFN   36.3       ionomycin       gamma       B lymphocytes PWM   31.9   Dermal fibroblast   47.3               CCD1070 rest       B lymphocytes CD40L   49.7   Dermal fibroblast   94.6       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   59.5   Dermal fibroblast   20.6               CCD1070 IL-1beta       EOL-1 dbcAMP   55.1   Dermal fibroblast IFN   25.0       PMA/ionomycin       gamma       Dendritic cells none   47.6   Dermal fibroblast IL-4   34.6       Dendritic cells LPS   41.2   Dermal Fibroblasts rest   22.4       Dendritic cells anti-   62.4   Neutrophils TNFa + LPS   10.2       CD40       Monocytes rest   50.3   Neutrophils rest   28.9       Monocytes LPS   63.7   Colon   20.2       Macrophages rest   46.0   Lung   21.9       Macrophages LPS   27.7   Thymus   57.0       HUVEC none   15.8   Kidney   15.8       HUVEC starved   29.9                    
     [2022] CNS_neurodegeneration_v1.0 Summary: Ag3577 This panel confirms the expression of the CG59671-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. As seen in panel 1.4, this gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in other central nervous system disorders such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2023] General_screening_panel_v1.4 Summary: Ag3577 Highest expression of the CG59671-01 gene is detected in a gastric cancer cell line sample (CTs=27.3). In addition, significant expression of this gene is associated with clusters of cell lines derived from ovarian cancer, breast cancer, and gastric cancer. Therefore, expression of this gene might be used to differentiate between these samples and other samples on this panel and as a marker for these cancers. The CG59671-01 gene encodes an Axin 1 protein, which is known play an important role in Wnt signalling transduction pathway. The Wnt/Wingless signaling transduction pathway plays an important role in both embryonic development and tumorigenesis. Beta-Catenin, a key component of the Wnt signaling pathway, interacts with the TCF/LEF family of transcription factors and activates transcription of Wnt target genes. A number of proteins such as the tumor suppressor APC and Axin are also involved in the regulation of the Wnt signaling pathway. Furthermore, mutations in APC or beta-catenin have been found to be responsible for the genesis of human cancers (Akiyama T, 2000). Recently, Dahmen et al. (2001) have shown presence of a single somatic point mutation in exon 1 (Pro255Ser) and deletion of seven large of AXIN1 (12%) in 86 medulloblastoma (MB) samples and 11 MB cell lines. Therefore, AXIN1 may play a role as tumor suppressor gene in MBs. Furthermore, therapeutic modulation of the activity of this gene or its protein product might be beneficial in the treatment of these cancers.  
     [2024] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [2025] This gene is also expressed in all regions of the CNS examined. Please see Panel CNS_neurodegeneration_v1.0 for discussion of utility of this gene in the central nervous system.  
     REFERENCES  
     [2026] 1. Akiyama T. (2000) Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 11(4):273-82.  
     [2027] 2. Dahmen R P, Koch A, Denkhaus D, Tonn J C, Sorensen N, Berthold F, Behrens J, Birchmeier W, Wiestler O D, Pietsch T. (2001) Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res Oct. 1, 2001;61(19):7039-43  
     [2028] Panel 4.1D Summary: Ag3577 Highest expression of the CG59671-01 gene is detected in resting NK Cells IL-2 cells (CTs=28.3). In addition, this gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [2029] CK. CG59708-01 and CG59708-02 and CG59708-03: Ubiquitin Carboxyl-Terminal Hydrolase 21  
     [2030] Expression of gene CG59708-01, full length clone CG59708-03 and variant CG59708-02 was assessed using the primer-probe set Ag3511, described in Table CKA. Results of the RTQ-PCR runs are shown in Tables CKB, CKC and CKD. Please note that CG59708-03 represents a full-length physical clone of the CG59708-01 gene, validating the prediction of the gene sequence.  
     [2031] Table CKA. Probe Name Ag3511 
               TABLE CKA                          Probe Name Ag3511                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-acccaaaagggtagtagaacga-3′   22   2431   674               Probe   TET-5′-cccttctggaacagtttgcagataaa-3′-TAMRA   26   2454   675               Reverse   5′-gccaccttcataatgctgatt-3′   21   2503   676                  
 
     [2032]               TABLE CKB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3511,           Ag3511, Run       Run       Tissue Name   210499621   Tissue Name   210499621                                     AD 1 Hippo   8.2   Control (Path) 3   4.1               Temporal Ctx       AD 2 Hippo   17.9   Control (Path) 4   32.1               Temporal Ctx       AD 3 Hippo   6.0   AD 1 Occipital Ctx   17.7       AD 4 Hippo   4.1   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   87.1   AD 3 Occipital Ctx   3.1       AD 6 Hippo   52.5   AD 4 Occipital Ctx   20.0       Control 2 Hippo   13.0   AD 5 Occipital Ctx   22.4       Control 4 Hippo   6.4   AD 6 Occipital Ctx   21.6       Control (Path) 3   3.4   Control 1 Occipital   2.5       Hippo       Ctx       AD 1 Temporal   15.0   Control 2 Occipital   39.5       Ctx       Ctx       AD 2 Temporal   22.7   Control 3 Occipital   18.6       Ctx       Ctx       AD 3 Temporal   4.5   Control 4 Occipital   3.8       Ctx       Ctx       AD 4 Temporal   20.0   Control (Path) 1   61.6       Ctx       Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   10.4       Ctx       Occipital Ctx       AD 5 Sup   36.6   Control (Path) 3   2.4       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   46.7   Control (Path) 4   14.1       Ctx       Occipital Ctx       AD 6 Sup   58.6   Control 1 Parietal   5.3       Temporal Ctx       Ctx       Control 1   5.6   Control 2 Parietal   47.0       Temporal Ctx       Ctx       Control 2   20.2   Control 3 Parietal   14.7       Temporal Ctx       Ctx       Control 3   15.8   Control (Path) 1   57.4       Temporal Ctx       Parietal Ctx       Control 3   6.1   Control (Path) 2   27.4       Temporal Ctx       Parietal Ctx       Control (Path) 1   50.0   Control (Path) 3   2.2       Temporal Ctx       Parietal Ctx       Control (Path) 2   33.2   Control (Path) 4   37.1       Temporal Ctx       Parietal Ctx                    
     [2033]               TABLE CKC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3511,       (%) Ag3511,           Run       Run       Tissue Name   217240774   Tissue Name   217240774                                     Adipose   4.9   Renal ca. TK-10   18.4       Melanoma*   15.9   Bladder   9.3       Hs688(A).T       Melanoma*   12.8   Gastric ca. (liver met.)   24.3       Hs688(B).T       NCI-N87       Melanoma* M14   20.6   Gastric ca. KATO III   100.0       Melanoma*   9.1   Colon ca. SW-948   4.7       LOXIMVI       Melanoma* SK-   26.6   Colon ca. SW480   63.7       MEL-5       Squamous cell   14.3   Colon ca.*(SW480   26.1       carcinoma SCC-4       met) SW620       Testis Pool   6.3   Colon ca. HT29   17.4       Prostate ca.* (bone   43.5   Colon ca. HCT-116   24.3       met) PC-3       Prostate Pool   6.6   Colon ca. CaCo-2   54.7       Placenta   0.7   Colon cancer tissue   6.5       Uterus Pool   4.4   Colon ca. SW1116   4.8       Ovarian ca.   11.7   Colon ca. Colo-205   2.0       OVCAR-3       Ovarian ca. SK-   45.1   Colon ca. SW-48   4.0       OV-3       Ovarian ca.   17.9   Colon Pool   13.0       OVCAR-4       Ovarian ca.   26.1   Small Intestine Pool   14.1       OVCAR-5       Ovarian ca.   12.5   Stomach Pool   7.2       IGROV-1       Ovarian ca.   10.2   Bone Marrow Pool   6.5       OVCAR-8       Ovary   7.5   Fetal Heart   73.2       Breast ca. MCF-7   9.7   Heart Pool   19.1       Breast ca. MDA-   47.0   Lymph Node Pool   14.5       MB-231       Breast ca. BT 549   58.2   Fetal Skeletal Muscle   34.9       Breast ca. T47D   44.1   Skeletal Muscle Pool   45.1       Breast ca. MDA-N   12.9   Spleen Pool   9.8       Breast Pool   15.2   Thymus Pool   13.0       Trachea   7.1   CNS cancer   2.6               (glio/astro) U87-MG       Lung   3.8   CNS cancer   33.4               (glio/astro) U-118-MG       Fetal Lung   27.5   CNS cancer   8.5               (neuro; met) SK-N-AS       Lung ca. NCI-N417   2.5   CNS cancer (astro)   11.6               SF-539       Lung ca. LX-1   24.0   CNS cancer (astro)   31.6               SNB-75       Lung ca. NCI-H146   3.2   CNS cancer (glio)   12.1               SNB-19       Lung ca. SHP-77   13.0   CNS cancer (glio) SF-   40.9               295       Lung ca. A549   18.9   Brain (Amygdala)   4.7               Pool       Lung ca. NCI-H526   20.6   Brain (cerebellum)   12.0       Lung ca. NCI-H23   23.5   Brain (fetal)   10.7       Lung ca. NCI-H460   10.5   Brain (Hippocampus)   3.8               Pool       Lung ca. HOP-62   10.2   Cerebral Cortex Pool   7.5       Lung ca. NCI-H522   21.8   Brain (Substantia   3.2               nigra) Pool       Liver   1.6   Brain (Thalamus) Pool   8.0       Fetal Liver   10.9   Brain (whole)   5.0       Liver ca. HepG2   7.2   Spinal Cord Pool   3.8       Kidney Pool   16.3   Adrenal Gland   5.0       Fetal Kidney   16.3   Pituitary gland Pool   3.0       Renal ca. 786-0   11.3   Salivary Gland   3.1       Renal ca. A498   4.2   Thyroid (female)   3.1       Renal ca. ACHN   10.2   Pancreatic ca.   25.0               CAPAN2       Renal ca. UO-31   17.1   Pancreas Pool   13.0                    
     [2034]               TABLE CKD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3511, Run       Ag3511, Run       Tissue Name   166407112   Tissue Name   166407112                                     Secondary Th1 act   26.6   HUVEC IL-1beta   14.8       Secondary Th2 act   31.6   HUVEC IFN gamma   16.8       Secondary Tr1 act   33.7   HUVEC TNF alpha +   9.7               IFN gamma       Secondary Th1 rest   22.8   HUVEC TNF alpha +   9.1               IL4       Secondary Th2 rest   17.2   HUVEC IL-11   9.9       Secondary Tr1 rest   20.3   Lung Microvascular EC   13.2               none       Primary Th1 act   10.4   Lung Microvascular EC   8.3               TNF alpha + IL-1beta       Primary Th2 act   17.2   Microvascular Dermal   22.7               EC none       Primary Tr1 act   25.7   Microsvasular Dermal   11.9               EC TNF alpha + IL-1beta       Primary Th1 rest   57.4   Bronchial epithelium   8.0               TNF alpha + IL1beta       Primary Th2 rest   28.1   Small airway epithelium   3.7               none       Primary Tr1 rest   15.6   Small airway epithelium   24.3               TNF alpha + IL-1beta       CD45RA CD4   11.0   Coronery artery SMC rest   11.9       lymphocyte act       CD45RO CD4   28.1   Coronery artery SMC   7.6       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   19.2   Astrocytes rest   10.6       Secondary CD8   15.3   Astrocytes TNF alpha +   12.4       lymphocyte rest       IL-1beta       Secondary CD8   20.3   KU-812 (Basophil) rest   20.2       lymphocyte act       CD4 lymphocyte none   8.4   KU-812 (Basophil)   46.7               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   24.8   CCD1106   12.6       CD95 CH11       (Keratinocytes) none       LAK cells rest   12.2   CCD1106   53.2               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   49.3   Liver cirrhosis   7.7       LAK cells IL-2 + IL-12   27.5   Lupus kidney   9.7       LAK cells IL-2 + IFN   47.6   NCI-H292 none   59.5       gamma       LAK cells IL-2 + IL-18   35.4   NCI-H292 IL-4   100.0       LAK cells   3.6   NCI-H292 IL-9   69.7       PMA/ionomycin       NK Cells IL-2 rest   46.0   NCI-H292 IL-13   46.7       Two Way MLR 3 day   24.7   NCI-H292 IFN gamma   36.6       Two Way MLR 5 day   22.1   HPAEC none   11.8       Two Way MLR 7 day   13.9   HPAEC TNF alpha + IL-   12.9               1beta       PBMC rest   13.0   Lung fibroblast none   13.3       PBMC PWM   17.3   Lung fibroblast TNF   31.9               alpha + IL-1beta       PBMC PHA-L   11.7   Lung fibroblast IL-4   9.6       Ramos (B cell) none   19.8   Lung fibroblast IL-9   7.4       Ramos (B cell)   18.2   Lung fibroblast IL-13   6.3       ionomycin       B lymphocytes PWM   37.1   Lung fibroblast IFN   10.4               gamma       B lymphocytes CD40L   34.6   Dermal fibroblast   23.7       and IL-4       CCD1070 rest       EOL-1 dbcAMP   14.4   Dermal fibroblast   75.8               CCD1070 TNF alpha       EOL-1 dbcAMP   21.6   Dermal fibroblast   18.7       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   10.8   Dermal fibroblast IFN   5.6               gamma       Dendritic cells LPS   13.5   Dermal fibroblast IL-4   11.3       Dendritic cells anti-   14.4   IBD Colitis 2   5.3       CD40       Monocytes rest   11.6   IBD Crohn&#39;s   6.0       Monocytes LPS   7.6   Colon   52.9       Macrophages rest   20.3   Lung   9.7       Macrophages LPS   15.0   Thymus   16.3       HUVEC none   16.8   Kidney   19.9       HUVEC starved   29.9                    
     [2035] CNS_neurodegeneration_v1.0 Summary: Ag3511 This panel confirms the expression of CG59708-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. However, as seen in panel 1.4, this gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in other central nervous system disorders such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2036] General_screening_panel_v1.4 Summary: Ag3511 Highest expression of the CG59708-01 is detected in a gastric cancer cell line sample (CT=27.1). Thus, expression of this gene can be used to distinguish this sample from other samples in this panel. In addition, high levels of expression of this gene are associated with breast cancer, ovarian cancer, and gastric cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product might be beneficial in the treatment of these cancers.  
     [2037] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [2038] This gene is also expressed at moderate to low levels in all regions of the CNS examined. Please see Panel CNS_neurodegeneration_v1.0 for discussion of utility of this gene in the central nervous system.  
     [2039] Panel 4D Summary: Ag3511 Highest expression of the CG59708-01 gene is detected in a IL-4 treated NCI-H292 sample (CT=26.4). In addition, this gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [2040] CL. CG59559-01: CPSase-Related  
     [2041] Expression of gene CG59559-01 was assessed using the primer-probe set Ag3469, described in Table CLA. Results of the RTQ-PCR runs are shown in Tables CLB, CLC and CLD.  
     [2042] Table CLA. Probe Name Ag3469 
               TABLE CLA                          Probe Name Ag3469                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tccagtcggatcaattctattg-3′   22   1213   677               Probe   TET-5′-attcagatgtcccctcatcagcccat-3′-TAMRA   26   1237   678               Reverse   5′-aattgtcttcgacgaagaaacc-3′   22   1266   679                  
 
     [2043]               TABLE CLB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3469,           Ag3469, Run       Run       Tissue Name   210376662   Tissue Name   210376662                                     AD 1 Hippo   23.5   Control (Path) 3   13.9               Temporal Ctx       AD 2 Hippo   31.0   Control (Path) 4   35.6               Temporal Ctx       AD 3 Hippo   17.1   AD 1 Occipital Ctx   8.1       AD 4 Hippo   23.0   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   21.0   AD 3 Occipital Ctx   2.0       AD 6 Hippo   69.3   AD 4 Occipital Ctx   25.9       Control 2 Hippo   56.6   AD 5 Occipital Ctx   31.9       Control 4 Hippo   52.5   AD 6 Occipital Ctx   10.4       Control (Path) 3   7.5   Control 1 Occipital   3.3       Hippo       Ctx       AD 1 Temporal   39.8   Control 2 Occipital   42.6       Ctx       Ctx       AD 2 Temporal   35.8   Control 3 Occipital   10.7       Ctx       Ctx       AD 3 Temporal   12.2   Control 4 Occipital   17.6       Ctx       Ctx       AD 4 Temporal   30.1   Control (Path) 1   59.0       Ctx       Occipital Ctx       AD 5 Inf Temporal   37.6   Control (Path) 2   14.6       Ctx       Occipital Ctx       AD 5 Sup   33.4   Control (Path) 3   0.0       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   52.1   Control (Path) 4   10.6       Ctx       Occipital Ctx       AD 6 Sup   31.0   Control 1 Parietal   9.1       Temporal Ctx       Ctx       Control 1   12.7   Control 2 Parietal   28.5       Temporal Ctx       Ctx       Control 2   31.4   Control 3 Parietal   17.2       Temporal Ctx       Ctx       Control 3   36.3   Control (Path) 1   64.2       Temporal Ctx       Parietal Ctx       Control 3   16.8   Control (Path) 2   25.7       Temporal Ctx       Parietal Ctx       Control (Path) 1   100.0   Control (Path) 3   1.3       Temporal Ctx       Parietal Ctx       Control (Path) 2   62.4   Control (Path) 4   55.9       Temporal Ctx       Parietal Ctx                    
     [2044]               TABLE CLC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3469,       (%) Ag3469,           Run       Run       Tissue Name   217119419   Tissue Name   217119419                                     Adipose   3.8   Renal ca. TK-10   7.1       Melanoma*   9.2   Bladder   5.7       Hs688(A).T       Melanoma*   4.7   Gastric ca. (liver met.)   4.9       Hs688(B).T       NCI-N87       Melanorna* M14   0.1   Gastric ca. KATO III   1.0       Melanoma*   0.8   Colon ca. SW-948   0.8       LOXIMVI       Melanoma* SK-   2.3   Colon ca. SW480   0.0       MEL-5       Squamous cell   1.9   Colon ca.* (SW480   5.1       carcinoma SCC-4       met) SW620       Testis Pool   5.1   Colon ca. HT29   8.9       Prostate ca.* (bone   3.6   Colon ca. HCT-116   0.7       met) PC-3       Prostate Pool   1.8   Colon ca. CaCo-2   8.1       Placenta   1.4   Colon cancer tissue   8.2       Uterus Pool   2.7   Colon ca. SW1116   0.3       Ovarian ca.   7.9   Colon ca. Colo-205   1.6       OVCAR-3       Ovarian ca. SK-   11.3   Colon ca. SW-48   0.9       OV-3       Ovarian ca.   0.8   Colon Pool   10.4       OVCAR-4       Ovarian ca.   9.2   Small Intestine Pool   3.6       OVCAR-5       Ovarian ca.   5.5   Stomach Pool   2.7       IGROV-1       Ovarian ca.   2.0   Bone Marrow Pool   6.3       OVCAR-8       Ovary   16.7   Fetal Heart   0.9       Breast ca. MCF-7   31.6   Heart Pool   3.8       Breast ca. MDA-   4.0   Lymph Node Pool   11.9       MB-231       Breast ca. BT 549   3.7   Fetal Skeletal Muscle   0.4       Breast ca. T47D   20.9   Skeletal Muscle Pool   0.5       Breast ca. MDA-N   0.1   Spleen Pool   10.7       Breast Pool   11.3   Thymus Pool   7.5       Trachea   3.8   CNS cancer   10.2               (glio/astro) U87-MG       Lung   9.3   CNS cancer   1.3               (glio/astro) U-118-MG       Fetal Lung   3.8   CNS cancer   0.1               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   3.0               SF-539       Lung ca. LX-1   13.8   CNS cancer (astro)   10.8               SNB-75       Lung ca. NCI-H146   0.1   CNS cancer (glio)   4.9               SNB-19       Lung ca. SHP-77   6.0   CNS cancer (glio) SF-   21.0               295       Lung ca. A549   100.0   Brain (Amygdala)   1.1               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   2.0       Lung ca. NCI-H23   0.1   Brain (fetal)   1.2       Lung ca. NCI-H460   8.9   Brain (Hippocampus)   1.1               Pool       Lung ca. HOP-62   45.4   Cerabral Cortex Pool   1.2       Lung ca. NCI-H522   4.2   Brain (Substantia   1.3               nigra) Pool       Liver   0.6   Brain (Thalamus) Pool   1.2       Fetal Liver   1.8   Brain (whole)   1.1       Liver ca. HepG2   1.5   Spinal Cord Pool   1.9       Kidney Pool   8.8   Adrenal Gland   26.8       Fetal Kidney   3.7   Pituitary gland Pool   0.5       Renal ca. 786-0   3.9   Salivary Gland   1.3       Renal ca. A498   10.5   Thyroid (female)   0.7       Renal ca. ACHN   6.2   Pancreatic ca.   20.2               CAPAN2       Renal ca. UO-31   6.3   Pancreas Pool   9.6                    
     [2045]               TABLE CLD                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3469, Run       Ag3469, Run       Tissue Name   169839390   Tissue Name   169839390                                     Secondary Th1 act   19.2   HUVEC IL-1beta   1.3       Secondary Th2 act   25.2   HUVEC IFN gamma   6.2       Secondary Tr1 act   14.4   HUVEC TNF alpha +   1.3               IFN gamma       Secondary Th1 rest   26.1   HUVEC TNF alpha +   1.1               IL4       Secondary Th2 rest   46.3   HUVEC IL-11   1.1       Secondary Tr1 rest   36.6   Lung Microvascular EC   0.7               none       Primary Th1 act   13.6   Lung Microvascular EC   0.4               TNF alpha + IL-1beta       Primary Th2 act   27.7   Microvascular Dermal   0.1               EC none       Primary Tr1 act   15.2   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   46.0   Bronchial epithelium   5.8               TNF alpha + IL1beta       Primary Th2 rest   44.4   Small airway epithelium   2.0               none       Primary Tr1 rest   45.1   Small airway epithelium   6.9               TNF alpha + IL-1beta       CD45RA CD4   25.2   Coronery artery SMC rest   3.1       lymphocyte act       CD45RO CD4   67.8   Coronery artery SMC   3.4       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   59.5   Astrocytes rest   1.4       Secondary CD8   47.0   Astrocytes TNF alpha +   3.2       lymphocyte rest       IL-1beta       Secondary CD8   38.4   KU-812 (Basophil) rest   3.0       lymphocyte act       CD4 lymphocyte none   61.1   KU-812 (Basophil)   6.4               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   27.2   CCD1106   3.8       CD95 CH11       (Keratinocytes) none       LAK cells rest   50.7   CCD1106   5.2               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   36.9   Liver cirrhosis   3.0       LAK cells IL-2 + IL-12   49.0   NCI-H292 none   5.0       LAK cells IL-2 + IFN   59.5   NCI-H292 IL-4   5.5       gamma       LAK cells IL-2 + IL-18   58.2   NCI-H292 IL-9   6.8       LAK cells   65.5   NCI-H292 IL-13   6.7       PMA/ionomycin       NK Cells IL-2 rest   47.0   NCI-H292 IFN gamma   8.0       Two Way MLR 3 day   54.0   HPAEC none   2.7       Two Way MLR 5 day   25.2   HPAEC TNF alpha + IL-   3.3               1beta       Two Way MLR 7 day   42.6   Lung fibroblast none   1.5       PBMC rest   23.5   Lung fibroblast TNF   1.1               alpha + IL-1beta       PBMC PWM   37.4   Lung fibroblast IL-4   0.7       PBMC PHA-L   59.5   Lung fibroblast IL-9   3.1       Ramos (B cell) none   1.8   Lung fibroblast IL-13   0.7       Ramos (B cell)   2.5   Lung fibroblast IFN   0.3       ionomycin       gamma       B lymphocytes PWM   26.8   Dermal fibroblast   7.7               CCD1070 rest       B lymphocytes CD40L   100.0   Dermal fibroblast   36.9       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   2.7   Dermal fibroblast   5.5               CCD1070 IL-1beta       EOL-1 dbcAMP   0.5   Dermal fibroblast IFN   0.7       PMA/ionomycin       gamma       Dendritic cells none   10.4   Dermal fibroblast IL-4   3.7       Dendritic cells LPS   3.2   Dermal Fibroblasts rest   0.2       Dendritic cells anti-   4.2   Neutrophils TNFa + LPS   0.8       CD40       Monocytes rest   1.7   Neutrophils rest   3.2       Monocytes LPS   2.6   Colon   4.4       Macrophages rest   5.6   Lung   5.0       Macrophages LPS   2.6   Thymus   6.9       HUVEC none   0.7   Kidney   2.0       HUVEC starved   1.6                    
     [2046] CNS_neurodegeneration_v1.0 Summary: Ag3469 This panel confirms the expression of the CG59559-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. However, as seen in panel 1.4, this gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in other central nervous system disorders such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2047] General_screening_panel_v1.4 Summary: Ag3469 Highest expression of the CG59559-01 gene is detected in sample derived from a lung cancer cell line (CT=25.6). Thus, expression of this gene can be used to distinguish this sample from other samples used in this panel. Furthermore, significant expression of this gene is associated with pancreatic cancer, CNS cancer and breast cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product might be beneficial in the treatment of these cancers.  
     [2048] Among tissues with metabolic function, this gene is expressed in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [2049] This gene is also expressed at low but significant levels in all regions of the CNS examined. Please see Panel CNS_neurodegeneration_v1.0 for discussion of utility of this gene in the central nervous system.  
     [2050] Panel 4.1D Summary: Ag3469 Highest expression of the CG59559-01 gene is detected in sample derived CD40L and IL-4 treated B lymphocytes (CT=27.2). Fur5hermore, this gene is expressed at significant levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [2051] CM. CG59669-01: Carbonyl Reductase  
     [2052] Expression of gene CG59669-01 was assessed using the primer-probe set Ag3505, described in Table CMA.  
     [2053] Table CMA. Probe Name Ag3505 
               TABLE CMA                          Probe Name Ag3505                                                 SEQ ID       Primers   Sequences   Length   Start Position   NO:                                         Forward   5′-ccgggtcccagaatctagt-3′   19   4   680               Probe   TET-5′-cctacgccacggttttgaccacg-3′-TAMRA   23   23   681               Reverse   5′-gacacacggaccacctgat-3′   19   74   682                  
 
     [2054] CNS_neurodegeneration_v1.0 Summary: Ag3505 Expression of the CG59669-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2055] General_screening_panel_v1.4 Summary: Ag3505 Results from one experiment with the CG59669-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [2056] Panel 4.1D Summary: Ag3505 Expression of the CG59669-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel due to a probable probe or chemistry failure (data not shown).  
     [2057] Panel 5 Islet Summary: Ag3505 Expression of the CG59669-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2058] CN. CG59679-01: Carbonyl Reductase  
     [2059] Expression of gene CG59679-01 was assessed using the primer-probe set Ag3507, described in Table CNA.  
     [2060] Table CNA. Probe Name Ag3507 
               TABLE CNA                          Probe Name Ag3507                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gactggagctaataagggcatt-3′   22   130   683               Probe   TET-5′-tcgtgacctgtgtcagcaattctcag-3′-TAMRA   26   166   684               Reverse   5′-gtgcagtgagcaccacatc-3′   19   194   685                  
 
     [2061] CNS_neurodegeneration_v1.0 Summary: Ag3507 Expression of the CG59679-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2062] General_screening_panel_v1.4 Summary: Ag3507 Expression of the CG59679-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2063] Panel 4.1D Summary: Ag3507 Expression of the CG59679-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown). The data suggest that there may have been experimental difficulties with this run.  
     [2064] Panel 5 Islet Summary: Ag3507 Expression of CG59679-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2065] CO. CG59644-01: Putative Protein Phosphatase  
     [2066] Expression of gene CG59644-01 was assessed using the primer-probe set Ag3503, described in Table COA. Results of the RTQ-PCR runs are shown in Tables COB, COC and COD.  
     [2067] Table COA. Probe Name Ag3503 
               TABLE COA                          Probe Name Ag3503                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tcgtacctagtaatcccattgg-3′   22   410   763               Probe   TET-5′-ccacaagctactgtgagttgctgcaa-3′-TAMRA   26   440   764               Reverse   5′-ctaccgagcaaagggactttat-3′   22   467   765                  
 
     [2068]               TABLE COB                          CNS_neurodegeneration_v1.0                                         Rel. Exp.           Rel. Exp. (%)       (%) Ag3503,           Ag3503, Run       Run        Tissue Name   210938272   Tissue Name   210938272                                     AD 1 Hippo   22.1   Control (Path) 3   5.7               Temporal Ctx       AD 2 Hippo   29.1   Control (Path) 4   25.3               Temporal Ctx       AD 3 Hippo   10.8   AD 1 Occipital   21.8               Ctx       AD 4 Hippo   9.4   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   100.0   AD 3 Occipital   8.9               Ctx       AD 6 Hippo   80.7   AD 4 Occipital   22.8               Ctx       Control 2 Hippo   27.0   AD 5 Occipital   26.8               Ctx       Control 4 Hippo   11.4   AD 6 Occipital   56.6               Ctx       Control (Path) 3   11.3   Control 1 Occipital   5.6       Hippo       Ctx       AD 1 Temporal Ctx   18.9   Control 2 Occipital   93.3               Ctx       AD 2 Temporal Ctx   29.5   Control 3 Occipital   15.8               Ctx       AD 3 Temporal Ctx   7.2   Control 4 Occipital   6.1               Ctx       AD 4 Temporal Ctx   19.3   Control (Path) 1   80.1               Occipital Ctx       AD 5 Inf Temporal   73.2   Control (Path) 2   7.5       Ctx       Occipital Ctx       AD 5 Sup Temporal   49.0   Control (Path) 3   5.9       Ctx       Occipital Ctx       AD 6 Inf Temporal   68.8   Control (Path) 4   14.5       Ctx       Occipital Ctx       AD 6 Sup Temporal   66.0   Control 1 Parietal   7.6       Ctx       Ctx       Control 1 Temporal   4.4   Control 2 Parietal   29.1       Ctx       Ctx       Control 2 Temporal   53.2   Control 3 Parietal   26.6       Ctx       Ctx       Control 3 Temporal   9.7   Control (Path) 1   95.9       Ctx       Parietal Ctx       Control 4 Temporal   11.3   Control (Path) 2   22.5       Ctx       Parietal Ctx       Control (Path) 1   48.0   Control (Path) 3   6.8       Temporal Ctx       Parietal Ctx       Control (Path) 2   22.2   Control (Path) 4   49.7       Temporal Ctx       Parietal Ctx                    
     [2069]               TABLE COC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3503,       (%) Ag3503,           Run       Run       Tissue Name   217131685   Tissue Name   217131685                                     Adipose   12.9   Renal ca. TK-10   26.8       Melanoma*   7.7   Bladder   22.1       Hs688(A).T       Melanoma*   11.0   Gastric ca. (liver met.)   63.7       Hs688(B).T       NCI-N87       Melanoma* M14   25.0   Gastric ca. KATO III   66.0       Melanoma*   25.9   Colon ca. SW-948   16.4       LOXIMVI       Melanoma* SK-   69.3   Colon ca. SW480   37.4       MEL-5       Squamous cell   18.9   Colon ca.* (SW480   24.8       carcinoma SCC-4       met) SW620       Testis Pool   13.0   Colon ca. HT29   13.7       Prostate ca.* (bone   51.8   Colon ca. HCT-116   60.3       met) PC-3       Prostate Pool   6.9   Colon ca. CaCo-2   25.7       Placenta   7.1   Colon cancer tissue   34.9       Uterus Pool   5.9   Colon ca. SW1116   8.2       Ovarian ca.   14.0   Colon ca. Colo-205   9.2       OVCAR-3       Ovarian ca. SK-   90.8   Colon ca. SW-48   5.8       OV-3       Ovarian ca.   12.5   Colon Pool   17.4       OVCAR-4       Ovarian ca.   34.2   Small Intestine Pool   15.7       OVCAR-5       Ovarian ca.   33.0   Stomach Pool   6.6       IGROV-1       Ovarian ca.   17.6   Bone Marrow Pool   6.4       OVCAR-8       Ovary   7.8   Fetal Heart   12.1       Breast ca. MCF-7   15.9   Heart Pool   17.7       Breast ca. MDA-   55.1   Lymph Node Pool   17.6       MB-231       Breast ca. BT 549   19.8   Fetal Skeletal Muscle   4.8       Breast ca. T47D   66.9   Skeletal Muscle Pool   100.0       Breast ca. MDA-N   12.2   Spleen Pool   12.5       Breast Pool   17.6   Thymus Pool   14.2       Trachea   28.7   CNS cancer   42.9               (glio/astro) U87-MG       Lung   3.0   CNS cancer   55.1               (glio/astro) U-118-MG       Fetal Lung   18.8   CNS cancer   30.6               (neuro; met) SK-N-AS       Lung ca. NCI-N417   9.1   CNS cancer (astro)   12.2               SF-539       Lung ca. LX-1   41.2   CNS cancer (astro)   22.4               SNB-75       Lung ca. NCI-H146   7.0   CNS cancer (glio)   36.3               SNB-19       Lung ca. SHP-77   26.8   CNS cancer (glio) SF-   50.7               295       Lung ca. A549   24.8   Brain (Amygdala)   12.4               Pool       Lung ca. NCI-H526   8.0   Brain (cerebellum)   14.6       Lung ca. NCI-H23   26.6   Brain (fetal)   10.2       Lung ca. NCI-H460   29.7   Brain (Hippocampus)   13.8               Pool       Lung ca. HOP-62   8.0   Cerebral Cortex Pool   17.2       Lung ca. NCI-H522   19.9   Brain (Substantia   19.1               nigra) Pool       Liver   2.9   Brain (Thalamus) Pool   18.4       Fetal Liver   10.4   Brain (whole)   15.7       Liver ca. HepG2   14.2   Spinal Cord Pool   10.9       Kidney Pool   23.8   Adrenal Gland   25.7       Fetal Kidney   10.4   Pituitary gland Pool   3.9       Renal ca. 786-0   12.3   Salivary Gland   11.1       Renal ca. A498   3.7   Thyroid (female)   4.4       Renal ca. ACHN   27.9   Pancreatic ca.   15.0               CAPAN2       Renal ca. UO-31   12.0   Pancreas Pool   17.1                    
     [2070]               TABLE COD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3503, Run       Ag3503, Run       Tissue Name   166441943   Tissue Name   166441943                                     Secondary Th1 act   54.3   HUVEC IL-1beta   20.4       Secondary Th2 act   52.5   HUVEC IFN gamma   14.6       Secondary Tr1 act   61.1   HUVEC TNF alpha +   16.0               IFN gamma       Secondary Th1 rest   34.6   HUVEC TNF alpha +   24.8               IL4       Secondary Th2 rest   20.0   HUVEC IL-11   6.6       Secondary Tr1 rest   23.0   Lung Microvascular EC   12.9               none       Primary Th1 act   39.5   Lung Microvascular EC   17.4               TNF alpha + IL-1beta       Primary Th2 act   59.9   Microvascular Dermal   21.6               EC none       Primary Tr1 act   92.7   Microsvasular Dermal   20.2               EC TNF alpha + IL-1beta       Primary Th1 rest   94.6   Bronchial epithelium   17.7               TNF alpha + IL1beta       Primary Th2 rest   31.4   Small airway epithelium   7.9               none       Primary Tr1 rest   32.8   Small airway epithelium   53.6               TNF alpha + IL-1beta       CD45RA CD4   44.1   Coronery artery SMC rest   7.7       lymphocyte act       CD45RO CD4   65.5   Coronery artery SMC   8.3       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   68.3   Astrocytes rest   11.7       Secondary CD8   68.8   Astrocytes TNF alpha +   21.9       lymphocyte rest       IL-1beta       Secondary CD8   40.1   KU-812 (Basophil) rest   12.1       lymphocyte act       CD4 lymphocyte none   20.9   KU-812 (Basophil)   42.6               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   40.9   CCD1106   21.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   22.7   CCD1106   72.2               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   46.7   Liver cirrhosis   12.8       LAK cells IL-2 + IL-12   38.2   Lupus Kidney   16.7       LAK cells IL-2 + IFN   68.8   NCI-H292 none   33.0       gamma       LAK cells IL-2 + IL-18   57.8   NCI-H292 IL-4   35.1       LAK cells   100.0   NCI-H292 IL-9   35.4       PMA/ionomycin       NK Cells IL-2 rest   32.8   NCI-H292 IL-13   24.8       Two Way MLR 3 day   42.9   NCI-H292 IFN gamma   22.5       Two Way MLR 5 day   39.8   HPAEC none   11.2       Two Way MLR 7 day   33.7   HPAEC TNF alpha + IL-   27.9               1beta       PBMC rest   22.5   Lung fibroblast none   10.6       PBMC PWM   54.0   Lung fibroblast TNF   25.5               alpha + IL-1beta       PBMC PHA-L   20.6   Lung fibroblast IL-4   11.6       Ramos (B cell) none   56.3   Lung fibroblast IL-9   5.4       Ramos (B cell)   38.4   Lung fibroblast IL-13   8.5       ionomycin       B lymphocytes PWM   44.8   Lung fibroblast IFN   11.7               gamma       B lymphocytes CD40L   42.9   Dermal fibroblast   16.4       and IL-4       CCD1070 rest       EOL-1 dbcAMP   18.2   Dermal fibroblast   56.3               CCD1070 TNF alpha       EOL-1 dbcAMP   30.4   Dermal fibroblast   14.4       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   31.2   Dermal fibroblast IFN   14.5               gamma       Dendritic cells LPS   40.9   Dermal fibroblast IL-4   29.1       Dendritic cells anti-   31.2   IBD Colitis 2   13.7       CD40       Monocytes rest   50.0   IBD Crohn&#39;s   11.6       Monocytes LPS   31.0   Colon   70.7       Macrophages rest   26.4   Lung   17.1       Macrophages LPS   28.9   Thymus   29.3       HUVEC none   22.2   Kidney   40.1       HUVEC starved   25.3                    
     [2071] CNS_neurodegeneration_v1.0 Summary: Ag3503 This panel confirms the expression of this gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [2072] General_screening_panel_v1.4 Summary: Ag3503 Expression of the CG59644-01 gene is highest in adult skeletal muscle (CT=25.5). Interestingly, expression of this gene is much lower in fetal skeletal muscle (CT=29.9), suggesting that expression of this gene may be used to distinguish adult and fetal skeletal muscle.  
     [2073] The CG59644-01 gene encodes a protein with homology to protein phosphatases. This gene is expressed at high to moderate levels in the majority of samples on this panel. However, expression of this gene appears to be higher in cancer cell lines when compared to normal adult tissues. This observation is consistent with the potential role for this gene product in cell survival and proliferation.  
     [2074] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2075] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [2076] Panel 4D Summary: Ag3503 This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include T cells, B cells, endothelial cells, macrophages, monocytes, dendritic cells, basophils, eosinophils and peripheral blood mononuclear cells, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also suggests a role for the gene product in cell survival and proliferation. Therefore, therapeutic modulation of the activity of this gene or its protein product may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis., and osteoarthritis.  
     [2077] CP. CG59662-01: Cyclophilin  
     [2078] Expression of gene CG59662-01 was assessed using the primer-probe set Ag3504, described in Table CPA. Results of the RTQ-PCR runs are shown in Tables CPB and CPC.  
     [2079] Table CPA. Probe Name Ag3504 
               TABLE CPA                          Probe Name Ag3504                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-ggtcaaccacaccatgttctt-3′   21   22   686               Probe   TET-5′-cttggaccacgtctcctttgagctg-3′-TAMRA   25   67   687               Reverse   5′-tctttggaaacttttctgcaaa-3′   22   92   688                  
 
     [2080] Table CPB. General_screening_panel_v1.4 
               TABLE CPB                          General_screening_panel_v1.4                                 Ref. Exp. (%)       Rel. Exp. (%)           Ag3504, Run       Ag3504, Run       Tissue Name   217236170   Tissue Name   217236170                                     Adipose   0.5   Renal ca. TK-10   0.4       Melanoma*   1.0   Bladder   0.6       Hs688(A).T       Melanoma*   0.4   Gastric ca. (liver met.)   4.8       Hs688(B).T       NCI-N87       Melanoma* M14   100.0   Gastric ca. KATO III   14.2       Melanoma*   3.9   Colon ca. SW-948   2.3       LOXIMVI       Melanoma* SK-   4.9   Colon ca. SW480   12.9       MEL-5       Squamous Cell   47.6   Colon ca.* (SW480   0.3       carcinoma SCC-4       met) SW620       Testis Pool   2.7   Colon ca. HT29   3.5       Prostate ca.* (bone   3.1   Colon ca. HCT-116   1.1       met) PC-3       Prostate Pool   5.7   Colon ca. CaCo-2   11.6       Placenta   5.0   Colon cancer tissue   7.6       Uterus Pool   2.2   Colon ca. SW1116   1.5       Ovarian ca.   20.6   Colon ca. Colo-205   11.7       OVCAR-3       Ovarian ca. SK-   6.3   Colon ca. SW-48   6.2       OV-3       Ovarian ca.   1.5   Colon Pool   4.7       OVCAR-4       Ovarian ca.   10.2   Small Intestine Pool   2.5       OVCAR-5       Ovarian ca.   0.6   Stomach Pool   5.8       IGROV-1       Ovarian ca.   0.7   Bone Marrow Pool   1.2       OVCAR-8       Ovary   2.2   Fetal Heart   3.3       Breast ca. MCF-7   2.9   Heart Pool   2.2       Breast ca. MDA-   4.0   Lymph Node Pool   11.8       MB-231       Breast ca. BT 549   5.6   Fetal Skeletal Muscle   0.9       Breast ca. T47D   15.0   Skeletal Muscle Pool   32.3       Breast ca. MDA-N   17.7   Spleen Pool   2.0       Breast Pool   0.9   Thymus Pool   9.3       Trachea   2.0   CNS cancer   1.0               (glio/astro) U87-MG       Lung   16.3   CNS cancer   3.3               (glio/astro) U-118-MG       Fetal Lung   42.0   CNS cancer   6.2               (neuro;met) SK-N-AS       Lung ca. NCI-N417   3.6   CNS cancer (astro) SF-   2.3               539       Lung ca. LX-1   0.7   CNS cancer (astro)   12.7               SNB-75       Lung ca. NCI-H146   5.1   CNS cancer (glio)   4.1               SNB-19       Lung ca. SHP-77   17.6   CNS cancer (glio) SF-   0.7               295       Lung ca. A549   19.9   Brain (Amygdala) Pool   3.3       Lung ca. NCI-H526   4.3   Brain (cerebellum)   2.3       Lung ca. NCI-H23   3.3   Brain (fetal)   0.9       Lung ca. NCI-H460   3.8   Brain (Hippocampus)   16.3               Pool       Lung ca. HOP-62   0.7   Cerebral Cortex Pool   0.5       Lung ca. NCI-H522   1.5   Brain (Substantia   4.6               nigra) Pool       Liver   1.2   Brain (Thalamus) Pool   9.0       Fetal Liver   17.2   Brain (whole)   1.4       Liver ca. HepG2   1.2   Spinal Cord Pool   11.6       Kidney Pool   5.1   Adrenal Gland   0.3       Fetal Kidney   7.1   Pituitary gland Pool   3.9       Renal ca. 786-0   1.2   Salivary Gland   1.2       Renal ca. A498   2.4   Thyroid (female)   5.5       Renal ca. ACHN   1.2   Pancreatic ca.   0.6               CAPAN2       Renal ca. UO-31   2.5   Pancreas Pool   8.8                  
 
     [2081] CNS_neurodegeneration_v1.0 Summary: Ag3504 Expression of the CG59662-01 gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2082] General_screening_panel_v1.4 Summary: Ag3504 The CG59662-01 gene is expressed at low le,vels in the majority of samples on this panel, with highest expression in a melanoma cell line (CT=30). The CG59662-01 gene encodes a protein with homology to cyclophilin, a specific high-affinity binding protein for the immunosuppressant agent cyclosporin A.  
     [2083] Among tissues with metabolic or endocrine function, this gene is expressed at low levels in pancreas, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes. Interestingly, this gene is expressed at higher levels in fetal liver (CT=32.5) than in adult liver (CT=36.4), suggesting that expression of this gene can be used to distinguish fetal and adult liver.  
     [2084] In addition, this gene is expressed at low levels in some regions of the central nervous system, including amygdala, hippocampus, substantia nigra, thalamus, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2085] Panel 4D Summary: Ag3504 Significant expression of this gene is detected in a liver cirrhosis sample (CT=34.4). Furthermore, expression of this gene is not detected at significant levels in normal adult liver in Panel 1.4, suggesting that its expression is unique to liver cirrhosis. This gene encodes a putative cyclophilin; therefore, small molecule therapeutics could reduce or inhibit fibrosis that occurs in liver cirrhosis. In addition, expression of this putative cyclophilin could also be used for the diagnosis of liver cirrhosis.  
     [2086] CQ. CG59773-01: Splice Variant Of Myomegalin  
     [2087] Expression of gene CG59773-01 was assessed using the primer-probe set Ag3580, described in Table CQA. Results of the RTQ-PCR runs are shown in Tables CQB, CQC and CQD.  
               TABLE DDA                          Probe Name Ag3591                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cactgctccacttttgtcttg-3′   21   1195   728               Probe   TET-5′-cataaaaggacccacacaggagaaaa-3′-TAMRA   26   1216   729               Reverse   5′-cttttccacattctttgcattc-3′   22   1249   730                  
 
     [2088]               TABLE DGD                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3635, Run       Ag3635, Run       Tissue Name   169960385   Tissue Name   169960385                                     Secondary Th1 act   26.1   HUVEC IL-1beta   12.5       Secondary Th2 act   19.1   HUVEC IFN gamma   34.6       Secondary Tr1 act   12.7   HUVEC TNF alpha +   3.2               IFN gamma       Secondary Th1 rest   2.0   HUVEC TNF alpha +   5.3               IL4       Secondary Th2 rest   8.2   HUVEC IL-11   29.3       Secondary Tr1 rest   4.8   Lung Microvascular EC   12.7               none       Primary Th1 act   16.0   Lung Microvascular EC   3.0               TNF alpha + IL-1beta       Primary Th2 act   17.8   Microvascular Dermal   6.0               EC none       Primary Tr1 act   13.1   Microsvasular Dermal   4.3               EC TNF alpha + IL-1beta       Primary Th1 rest   3.4   Bronchial epithelium   12.5               TNF alpha + IL-1beta       Primary Th2 rest   6.3   Small airway epithelium   4.5               none       Primary Tr1 rest   5.4   Small airway epithelium   11.0               TNF alpha + IL-1beta       CD45RA CD4   17.1   Coronery artery SMC rest   20.4       lymphocyte act       CD45RO CD4   44.1   Coronery artery SMC   21.8       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   23.3   Astrocytes rest   6.4       Secondary CD8   42.9   Astrocytes TNF alpha +   9.9       lymphocyte rest       IL-1beta       Secondary CD8   7.4   KU-812 (Basophil) rest   0.2       lymphocyte act       CD4 lymphocyte none   11.5   KU-812 (Basophil)   0.8               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   2.4   CCD1106   11.2       CD95 CH11       (Keratinocytes) none       LAK cells rest   36.3   CCD1106   22.8               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   9.1   Liver cirrhosis   7.4       LAK cells IL-2 + IL-12   22.8   NCI-H292 none   14.3       LAK cells IL-2 + IFN   21.8   NCI-H292 IL-4   20.9       gamma       LAK cells IL-2 + IL-18   21.2   NCI-H292 IL-9   26.1       LAK cells   21.0   NCI-H292 IL-13   25.5       PMA/ionomycin       NK Cells IL-2 rest   8.7   NCI-H292 IFN gamma   13.2       Two Way MLR 3 day   24.8   HPAEC none   32.5       Two Way MLR 5 day   18.7   HPAEC TNF alpha + IL-   14.3               1beta       Two Way MLR 7 day   21.6   Lung fibroblast none   1.3       PBMC rest   23.0   Lung fibroblast TNF   0.8               alpha + IL-1beta       PBMC PWM   71.2   Lung fibroblast IL-4   1.5       PBMC PHA-L   46.7   Lung fibroblast IL-9   2.9       Ramos (B cell) none   1.8   Lung fibroblast IL-13   1.4       Ramos (B cell)   1.5   Lung fibroblast IFN   1.2       ionomycin       gamma       B lymphocytes PWM   49.7   Dermal fibroblast   33.7               CCD1070 rest       B lymphocytes CD40L   68.8   Dermal fibroblast   22.5       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   22.7   Dermal fibroblast   10.1               CCD1070 IL-1beta       EOL-1 dbcAMP   40.3   Dermal fibroblast IFN   6.1       PMA/ionomycin       gamma       Dendritic cells none   54.0   Dermal fibroblast IL-4   10.4       Dendritic cells LPS   73.7   Dermal Fibroblasts rest   9.9       Dendritic cells anti-   100.0   Neutrophils TNFa + LPS   0.8       CD40       Monocytes rest   66.0   Neutrophils rest   2.8       Monocytes LPS   22.4   Colon   6.7       Macrophages rest   86.5   Lung   34.6       Macrophages LPS   13.4   Thymus   51.1       HUVEC none   8.6   Kidney   90.8       HUVEC starved   11.3                    
     [2089]               TABLE CQC                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp.       Exp.           (%)       (%)           Ag3580,       Ag3580,           Run       Run       Tissue Name   217423587   Tissue Name   217423587                                     Adipose   20.7   Renal ca. TK-10   20.7       Melanoma*   76.8   Bladder   15.7       Hs688(A).T       Melanoma*   38.7   Gastric ca. (liver met.)   50.0       Hs688(B).T       NCI-N87       Melanoma* M14   7.6   Gastric ca. KATO III   13.1       Melanoma*   81.2   Colon ca. SW-948   5.8       LOXIMVI       Melanoma* SK-   14.9   Colon ca. SW480   12.9       MEL-5       Squamous cell   10.2   Colon ca.* (SW480   2.6       carcinoma SCC-4       met) SW620       Testis Pool   4.5   Colon ca. HT29   4.5       Prostate ca.* (bone   29.1   Colon ca. HCT-116   15.0       met) PC-3       Prostate Pool   6.1   Colon ca. CaCo-2   29.7       Placenta   8.2   Colon cancer tissue   8.4       Uterus Pool   7.7   Colon ca. SW1116   2.5       Ovarian ca.   24.0   Colon ca. Colo-205   2.9       OVCAR-3       Ovarian ca.   15.4   Colon ca. SW-48   7.1       SK-OV-3       Ovarian ca.   17.0   Colon Pool   18.8       OVCAR-4       Ovarian ca.   19.8   Small Intestine Pool   18.0       OVCAR-5       Ovarian ca.   15.1   Stomach Pool   7.4       IGROV-1       Ovarian ca.   6.7   Bone Marrow Pool   9.9       OVCAR-8       Ovary   4.4   Fetal Heart   9.0       Breast ca. MCF-7   28.9   Heart Pool   8.2       Breast ca. MDA-   39.8   Lymph Node Pool   22.8       MB-231       Breast ca. BT 549   13.9   Fetal Skeletal Muscle   6.8       Breast ca. T47D   49.0   Skeletal Muscle Pool   22.7       Breast ca. MDA-N   7.6   Spleen Pool   12.1       Breast Pool   9.5   Thymus Pool   19.9       Trachea   15.0   CNS cancer   35.1               (glio/astro)               U87-MG       Lung   4.0   CNS cancer   28.9               (glio/astro)               U-118-MG       Fetal Lung   30.6   CNS cancer   3.4               (neuro; met)               SK-N-AS       Lung ca. NCI-N417   5.4   CNS cancer   13.4               (astro)               SF-539       Lung ca. LX-1   6.6   CNS cancer (astro)   57.4               SNB-75       Lung ca. NCI-H146   15.8   CNS cancer (glio)   9.0               SNB-19       Lung ca. SHP-77   25.9   CNS cancer (glio)   49.7               SF-295       Lung ca. A549   4.2   Brain (Amygdala)   15.9               Pool       Lung ca. NCI-H526   7.6   Brain (cerebellum)   100.0       Lung ca. NCI-H23   50.0   Brain (fetal)   69.3       Lung ca. NCI-H460   4.8   Brain (Hippocampus)   16.0               Pool       Lung ca. HOP-62   24.3   Cerebral Cortex Pool   26.1       Lung ca. NCI-H522   4.5   Brain   22.7               ( Substantia nigra )               Pool       Liver   4.9   Brain (Thalamus) Pool   37.4       Fetal Liver   12.0   Brain (whole)   33.4       Liver ca. HepG2   11.1   Spinal Cord Pool   34.4       Kidney Pool   54.0   Adrenal Gland   5.2       Fetal Kidney   40.3   Pituitary gland Pool   9.7       Renal ca. 786-0   13.9   Salivary Gland   3.4       Renal ca. A498   15.0   Thyroid (female)   5.3       Renal ca. ACHN   1.6   Pancreatic ca.   16.4               CAPAN2       Renal ca. UO-31   10.2   Pancreas Pool   17.2                    
     [2090]               TABLE CQD                          Panel 4.1D                                 Rel.       Rel.           Exp.       Exp.           (%)       (%)           Ag3580,       Ag3580,           Run       Run       Tissue Name   169910382   Tissue Name   169910382                                     Secondary Th1 act   28.3   HUVEC IL-1beta   28.5       Secondary Th2 act   32.8   HUVEC IFN gamma   8.0       Secondary Tr1 act   34.2   HUVEC TNF alpha +   30.1               IFN gamma       Secondary Th1 rest   23.7   HUVEC TNF alpha +   27.2               IL4       Secondary Th2 rest   26.4   HUVEC IL-11   8.8       Secondary Tr1 rest   34.2   Lung Microvascular   42.9               EC none       Primary Th1 act   11.2   Lung Microvascular   33.2               EC TNFalpha +               IL-1beta       Primary Th2 act   10.8   Microvascular Dermal   24.8               EC none       Primary Tr1 act   11.0   Microvascular Dermal   20.7               EC TNFalpha +               IL-1beta       Primary Th1 rest   32.3   Bronchial epithelium   18.6               TNFalpha + IL1beta       Primary Th2 rest   31.2   Small airway   8.2               epithelium none       Primary Tr1 rest   24.1   Small airway   10.7               epithelium               TNFalpha + IL-beta       CD45RA CD4   50.0   Coronery artery   10.7       lymphocyte act       SMC rest       CD45RO CD4   25.5   Coronery artery   15.6       lymphocyte act       SMC TNFalpha +               IL-1beta       CD8 lymphocyte act   18.8   Astrocytes rest   14.1       Secondary CD8   16.3   Astrocytes   13.0       lymphocyte rest       TNFalpha +               IL-1beta       Secondary CD8   16.3   KU-812 (Basophil)   4.0       lynphocyte act       rest       CD4 lymphocyte   22.4   KU-812 (Basophil)   7.8       none       PMA/ionomycin       2ry Th1/Th2/   47.6   CCD1106   24.3       Tr1_anti-       (Keratinocytes)       CD95 CH11       none       LAK cells rest   24.1   CCD1106   26.4               (Keratinocytes)               TNFalpha + IL-1beta       LAK cells IL-2   21.8   Liver cirrhosis   12.0       LAK cells IL-2 +   23.2   NCI-H292 none   9.6       IL-12       LAK cells IL-2 +   29.1   NCI-H292 IL-4   15.5       IFN gamma       LAK cells IL-2 +   32.5   NCI-H292 IL-9   26.2       IL-18       LAK cells   35.8   NCI-H292 IL-13   15.3       PMA/ionomycin       NK Cells IL-2 rest   26.1   NCI-H292 IFN gamma   14.0       Two Way MLR   35.8   HPAEC none   8.2       3 day       Two Way MLR   19.5   HPAEC TNF alpha +   31.9       5 day       IL-1beta       Two Way MLR   46.0   Lung fibroblast none   51.8       7 day       PBMC rest   15.8   Lung fibroblast   44.8               TNF alpha +               IL-1beta       PBMC PWM   16.0   Lung fibroblast IL-4   32.8       PBMC PHA-L   13.3   Lung fibroblast IL-9   51.4       Ramos (B cell) none   16.8   Lung fibroblast IL-13   29.9       Ramos (B cell)   15.9   Lung fibroblast IFN   27.7       ionomycin       gamma       B lymphocytes   14.4   Dermal fibroblast   38.4       PMW       CCD1070 rest       B lymphocytes   16.3   Dermal fibroblast   100.0       CD40L and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   5.6   Dermal fibroblast   48.3               CCD1070 IL-1beta       EOL-1 dbcAMP   29.3   Dermal fibroblast IFN   11.0       PMA/ionomycin       gamma       Dendritic cells none   13.6   Dermal fibroblast IL-4   22.7       Dendritic cells LPS   14.4   Dermal Fibroblasts   18.8               rest       Dendritic cells anti-   13.5   Neutrophils TNFa +   1.7       CD40       LPS       Monocytes rest   12.3   Neutrophils rest   2.6       Monocytes LPS   62.9   Colon   15.8       Macrophages rest   18.4   Lung   15.6       Macrophages LPS   15.3   Thymus   21.8       HUVEC none   12.6   Kidney   46.3       HUVEC starved   17.0                    
     [2091] CNS_neurodegeneration_v1.0 Summary: Ag3580 Results from two experiments using the same probe/primer set are in excellent agreement. This panel confirms the expression of this gene at high to moderate levels in the brains of an independent group of individuals. This gene is found to be upregulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, therapeutic modulation of this gene or its protein product may be used to decrease neuronal death and treat Alzheimer&#39;s disease.  
     [2092] General_screening_panel_v1.4 Summary: Ag3580 The CG59773-01 gene encodes a splice variant of the myomegalin protein, which is a component of the golgi/centrosome and interacts with a cyclic nucleotide phosphodiesterase (ref. 1). Expression of the CG59773-01 gene is highest in the cerebellum (CT=23.8). In addition, this gene is expressed at high levels in all other regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2093] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [2094] This gene is also expressed at very high levels in a number of melanoma cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product may be of benefit in the treatment of melanoma.  
     References  
     [2095] 1. Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D, Onuffer J, Jin S L, Conti M. Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem Apr. 6, 2001;276(14): 11189-98  
     [2096] Panel 4.1D Summary: Ag3580 This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include T cells, B cells, endothelial cells, macrophages, monocytes, dendritic cells, basophils, eosinophils and peripheral blood mononuclear cells, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also suggests a role for the gene product in cell survival and proliferation. Therefore, therapeutic modulation of the activity of this gene or its protein product may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [2097] CR. CG57460-01: N-Acetyltransferase Camello 2  
     [2098] Expression of gene CG57460-01 was assessed using the primer-probe set Ag3273, described in Table CRA. Results of the RTQ-PCR runs are shown in Tables CRB, CRC and CRD.  
               TABLE CRA                          Probe Name Ag3273                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cgctactactacagccgcaa-3′   20   205   692       Probe   TET-5′-gtgatccgcgcctacctggagtg-3′-   23   226   693           TAMRA       Reverse   5′-gggcggcttcatgtagtact-3′   20   281   694                  
 
     [2099]               TABLE CRB                          CNS_neurodegeneration_v1.0                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)       Tissue   Ag3273, Run   Ag3273, Run   Tissue   Ag3273, Run   Ag3273, Run       Name   210038591   230512515   Name   210038591   230512515                                             AD 1 Hippo   15.7   18.6   Control   12.2   12.7                   (Path) 3                   Temporal                   Ctx       AD 2 Hippo   28.9   23.2   Control   40.3   35.4                   (Path) 4                   Temporal                   Ctx       AD 3 Hippo   11.0   11.0   AD 1   20.9   18.8                   Occipital                   Ctx       AD 4 Hippo   10.2   13.8   AD 2   0.0   0.0                   Occipital                   Ctx                   (Missing)       AD 5 hippo   100.0   100.0   AD 3   15.2   13.1                   Occipital                   Ctx       AD 6 Hippo   21.8   22.4   AD 4   22.1   23.2                   Occipital                   Ctx       Control 2   27.0   27.9   AD 5   18.4   18.4       Hippo           Occipital                   Ctx       Control 4   22.5   21.8   AD 6   46.3   48.3       Hippo           Occipital                   Ctx       Control (Path)   8.4   9.0   Control 1   8.0   11.2       3 Hippo           Occipital                   Ctx       AD 1 Temporal   16.5   15.1   Control 2   80.1   82.4       Ctx           Occipital                   Ctx       AD 2 Temporal   29.3   26.2   Control 3   26.2   27.2       Ctx           Occipital                   Ctx       AD 3 Temporal   10.9   12.9   Control 4   14.8   14.1       Ctx           Occipital                   Ctx       AD 4 Temporal   22.5   20.3   Control   70.2   68.8       Ctx           (Path) 1                   Occipital                   Ctx       AD 5 Inf   57.0   59.5   Control   21.6   20.6       Temporal Ctx           (Path) 2                   Occipital                   Ctx       AD 5   30.6   26.8   Control   8.8   7.4       Sup Temporal           (Path) 3       Ctx           Occipital                   Ctx       AD 6 Inf   27.2   30.1   Control   36.1   34.2       Temporal Ctx           (Path) 4                   Occipital                   Ctx       AD 6 Sup   34.2   37.4   Control 1   14.1   13.7       Temporal Ctx           Parietal Ctx       Control 1   12.2   11.1   Control 2   33.9   36.9       Temporal Ctx           Parietal Ctx       Control 2   43.2   39.8   Control 3   33.0   28.7       Temporal Ctx           Parietal Ctx       Control 3   16.7   18.3   Control   63.7   67.8       Temporal Ctx           (Path) 1                   Parietal Ctx       Control 4   18.3   19.8   Control   30.6   30.4       Temporal Ctx           (Path) 2                   Parietal Ctx       Control (Path)   51.4   48.0   Control   8.1   9.7       1 Temporal Ctx           (Path) 3                   Parietal Ctx       Control (Path)   39.2   45.7   Control   64.2   59.5       2 Temporal Ctx           (Path) 4                   Parietal Ctx                    
     [2100]               TABLE CRC                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp.       Exp.           (%)       (%)           Ag3273,       Ag3273,           Run       Run       Tissue Name   215775405   Tissue Name   215775405                                     Adipose   7.1   Renal ca. TK-10   4.9       Melanoma*   0.0   Bladder   0.9       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   2.4       Hs688(B).T       NCI-N87       Melanoma* M14   17.6   Gastric ca. KATO III   0.0       Melanoma*   0.9   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   4.2   Colon ca. SW480   2.7       MEL-5       Squamous cell   0.2   Colon ca.* (SW480   1.0       carcinoma SCC-4       met) SW620       Testis Pool   13.5   Colon ca. HT29   0.1       Prostate ca.* (bone   2.7   Colon ca. HCT-116   6.0       met) PC-3       Prostate Pool   0.2   Colon ca. CaCo-2   2.0       Placenta   0.0   Colon cancer tissue   0.6       Uterus Pool   0.0   Colon ca. SW1116   0.4       Ovarian ca.   5.4   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca.   6.8   Colon ca. SW-48   0.0       SK-OV-3       Ovarian ca.   1.6   Colon Pool   0.4       OVCAR-4       Ovarian ca.   2.1   Small Intestine Pool   0.1       OVCAR-5       Ovarian ca.   7.7   Stomach Pool   0.3       IGROV-1       Ovarian ca.   9.6   Bone Marrow Pool   0.1       OVCAR-8       Ovary   0.8   Fetal Heart   100.0       Breast ca. MCF-7   1.7   Heart Pool   0.2       Breast ca. MDA-   0.8   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   7.7   Fetal Skeletal Muscle   0.3       Breast ca. T47D   9.3   Skeletal Muscle Pool   1.3       Breast ca. MDA-N   0.0   Spleen Pool   0.0       Breast Pool   0.4   Thymus Pool   0.4       Trachea   0.2   CNS cancer   0.0               (glio/astro)               U87-MG       Lung   0.0   CNS cancer   0.0               (glio/astro)               U-118-MG       Fetal Lung   0.3   CNS cancer   0.0               (neuro; met)               SK-N-AS       Lung ca. NCI-N417   5.1   CNS cancer   0.2               (astro)               SF-539       Lung ca. LX-1   0.4   CNS cancer (astro)   0.6               SNB-75       Lung ca. NCI-H146   12.2   CNS cancer (glio)   7.1               SNB-19       Lung ca. SHP-77   2.4   CNS cancer (glio)   1.8               SF-295       Lung ca. A549   3.4   Brain (Amygdala)   31.4               Pool       Lung ca. NCI-H526   12.0   Brain (cerebellum)   32.3       Lung ca. NCI-H23   5.8   Brain (fetal)   9.3       Lung ca. NCI-H460   2.3   Brain (Hippocampus)   22.5               Pool       Lung ca. HOP-62   1.0   Cerebral Cortex Pool   40.3       Lung ca. NCI-H522   7.4   Brain   57.4               ( Substantia nigra )               Pool       Liver   0.0   Brain (Thalamus) Pool   36.6       Fetal Liver   0.1   Brain (whole)   24.8       Liver ca. HepG2   0.3   Spinal Cord Pool   20.2       Kidney Pool   0.2   Adrenal Gland   0.0       Fetal Kidney   0.7   Pituitary gland Pool   2.2       Renal ca. 786-0   0.2   Salivary Gland   0.2       Renal ca. A498   1.0   Thyroid (female)   1.1       Renal ca. ACHN   4.5   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   3.7   Pancreas Pool   0.6                    
     [2101]               TABLE CRD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3273, Run       Ag3273, Run       Tissue Name   165338992   Tissue Name   165338992                                     Secondary Th1 act   1.0   HUVEC IL-1beta   0.0       Secondary Th2 act   2.5   HUVEC IFN gamma   0.0       Secondary Tr1 act   3.7   HUVEC TNF alpha+   0.0               IFN gamma       Secondary Th1 rest   5.0   HUVEC TNF alpha+   0.0               IL4       Secondary Th2 rest   0.9   HUVEC IL-11   0.0       Secondary Th1 rest   6.9   Lung Microvascular EC   0.0               none       Primary Th1 act   6.2   Lung Microvascular EC   0.0               TNFalpha + IL-1beta       Primary Th2 act   5.9   Microvascular Dermal   0.0               EC none       Primary Tr1 act   9.5   Microsvasular Dermal   0.0               EC TNFalpha + IL-1beta       Primary Th1 rest   3.1   Bronchial epithelium   0.0               TNFalpha + IL-1beta       Primary Th2 rest   0.0   Small airway epithelium   2.9               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNFalpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   1.8       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNFalpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   16.5       Secondary CD8   0.0   Astrocytes TNFalpha +   10.4       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   19.1   CCD1106   0.0       CD95 CH11       (Keratinocytes) none               CCD1106       LAK cells rest   0.0   (Keratinocytes)   0.0               TNFalpha + IL-1beta       LAK cells IL-2   1.2   liver cirrhosis   12.7       LAK cells IL-2 + IL-12   2.5   Lupus kidney   3.9       LAK cells IL-2 + IFN   4.1   NCI-H292 none   10.8       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   23.2       LAK cells   0.0   NCI-H292 IL-9   22.4       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   10.3       Two Way MLR 3 day   1.1   NCI-H292 IFN gamma   18.0       Two Way MLR 5 day   0.0   AHPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1 beta       PBMC rest   0.0   Lung fibroblast none   1.9       PBMC PWM   1.2   Lung fibroblast TNF   0.0               alpha + IL-1 beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   3.8       Ramos (B cell) none A   0.0   Lung fibroblast IL-9   0.5       Ramos (B cell)   0.0   Lung fibroblast IL-13   5.7       ionomycin       B lymphocytes PWM   3.5   Lung fibroblast IFN   2.9               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   0.0       and IL-4       CCD1070 rest       EOL-1 dbcAMP   100.0   Dermal fibroblast   0.0               CCD1070 TNF alpha   0.0       EOL-1 dbcAMP   25.9   Dermal fibroblast       PMA/ionomycin       CCD1070 IL-1 beta       Dendritic cells none   3.8   Dermal fibroblast IFN   2.8               gamma       Dendritic cells LPS   2.6   Dermal fibroblast IL-4   4.8       Dendritic cells anti-   5.0   IBD Colitis 2   0.0       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   0.0       Monocytes LPS   0.0   Colon   37.4       Macrophages rest   4.2   Lung   8.4       Macrophages LPS   0.0   Thymus   40.9       HUVEC none   0.0   Kidney   6.3       HUVEC starved   0.0                    
     [2102] CNS_neurodegeneration_v1.0 Summary: Ag3273 Two experiments with the same probe and primer set produce results that are in excellent agreement. This panel confirms the expression of this gene at low to moderate levels in the brains of an independent group of individuals. Expression of this gene is found to be down-regulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, up-regulation of this gene or its protein product, or treatment with specific agonists for this protein, may be of use in reversing the dementia/memory loss associated with Alzheimer&#39;s disease and neuronal death.  
     [2103] General_screening_panel_v1.4 Summary: Ag3273 Highest expression of the CG57460-01 gene is seen in fetal heart (CT=28.6). In addition, this gene is expressed at much higher levels in fetal heart when compared to expression in the adult heart (CT=38). Thus, expression of this gene may be used to differentiate between the fetal and adult source of this tissue. In addition, the higher expression in fetal heart suggests that this protein product may be involved in the development of this organ. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of heart disease.  
     [2104] This gene also shows highly specific brain expression. Please see Panel CNS_neurodegeneration for discussion of utility of this gene in the central nervous system.  
     [2105] In addition, expression of this gene appears to be upregulated in a number of cancer cell lines when compared to the normal tissues. Specifically, expression of this gene appears to be higher in ovarian, breast, lung and renal cancer cell lines when compared to their respective normal tissues. Therefore, therapeutic modulation of the activity of this gene or its protein may be of benefit in the treatment of ovarian, breast, lung and renal cancer. The CG57460-01 gene encodes a transmembrane protein with homology to N-acetyltransferase Camello 2, a protein involved in cellular adhesion (ref. 1).  
     REFERENCES  
     [2106] 1. Popsueva A E, Luchinskaya N N, Ludwig A V, Zinovjeva O Y, Poteryaev D A, Feigelman M M, Ponomarev M B, Berekelya L, Belyavsky A V. Overexpression of camello, a member of a novel protein family, reduces blastomere adhesion and inhibits gastrulation in  Xenopus laevis . Dev Biol Jun. 15, 2001;234(2):483-96  
     [2107] Panel 4.1D Summary: Ag3273 Highest expression of the CG57460-01 is seen in eosinophils. In addition, differential expression is observed in the eosinophil cell line EOL-1 under resting conditions over that in EOL-1 cells stimulated by phorbol ester and ionomycin. Thus, this gene may be involved in eosinophil function. Therefore, therapeutic modulation of the expression or function of this gene may reduce eosinophil activation and be useful in the treatment of asthma and allergies.  
     [2108] In addition, significant expression in normal colon and thymus suggest a role for this gene in the normal homeostasis of these tissues. Therefore, therapeutic modulation of the expression or function of this gene may modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitution. Furthermore, since expression of this gene is decreased in colon samples from patients with IBD colitis and Crohn&#39;s disease relative to normal colon, therapeutic modulation of the activity of the protein encoded by this gene may be useful in the treatment of inflammatory bowel disease.  
     [2109] CS. CG57464-01  
     [2110] Expression of gene CG57464-01 was assessed using the primer-probe set Ag3248, described in Table CSA. Results of the RTQ-PCR runs are shown in Tables CSB, CSC, CSD and CSE.  
               TABLE CSA                          Probe Name Ag3248                                                 SEQ                   Start   ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cctccctggtagaggtcaac-3′   20   929   695       Probe   TET-5′-ctactcagtgcccagcagccaggt-3′-   24   954   696           TAMRA       Reverse   5′-tgtctgcatgcagcctatg-3′   19   996   697                  
 
     [2111]               TABLE CSB                          CNS_neurodegeneration_v1.0                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)       Tissue   Ag3248, Run   Ag3248, Run   Tissue   Ag3248, Run   Ag3248, Run       Name   210037962   224063124   Name   210037962   224063124                                             AD 1 Hippo   26.4   4.8   Control   28.5   39.2                   (Path) 3                   Temporal                   Ctx       AD 2 Hippo   73.2   71.7   Control   57.8   61.1                   (Path) 4                   Temporal                   Ctx       AD 3 Hippo   21.6   5.6   AD 1   19.1   21.2                   Occipital                   Ctx       AD 4 Hippo   28.3   28.9   AD 2   0.0   0.0                   Occipital                   Ctx                   (Missing)       AD 5 hippo   85.3   100.0   AD 3   13.0   15.9                   Occipital                   Ctx       AD 6 Hippo   70.2   72.7   AD 4   37.4   28.7                   Occipital                   Ctx       Control 2   64.6   49.3   AD 5   33.9   85.3       Hippo           Occipital                   Ctx       Control 4   55.5   64.2   AD 6   58.6   14.4       Hippo           Occipital                   Ctx       Control (Path)   46.3   0.9   Control 1   17.3   22.7       3 Hippo           Occipital                   Ctx       AD 1 Temporal   28.9   24.1   Control 2   89.5   81.2       Ctx           Occipital                   Ctx       AD 2 Temporal   57.4   62.4   Control 3   68.3   62.0       Ctx           Occipital                   Ctx       AD 3 Temporal   18.9   16.7   Control 4   29.3   34.2       Ctx           Occipital                   Ctx       AD 4 Temporal   42.3   29.9   Control   100.0   92.7       Ctx           (Path) 1                   Occipital                   Ctx       AD 5 Inf   77.4   97.3   Control   36.3   15.1       Temporal Ctx           (Path) 2                   Occipital                   Ctx       AD 5   69.7   87.7   Control   32.5   25.2       Sup Temporal           (Path) 3       Ctx           Occipital                   Ctx       AD 6 Inf   39.2   87.1   Control   70.2   66.9       Temporal Ctx           (Path) 4                   Occipital                   Ctx       AD 6 Sup   73.2   70.7   Control 1   24.8   32.3       Temporal Ctx           Parietal Ctx       Control 1   25.3   26.1   Control 2   70.7   94.0       Temporal Ctx           Parietal Ctx       Control 2   43.5   77.4   Control 3   59.0   0.0       Temporal Ctx           Parietal Ctx       Control 3   74.2   49.3   Control   42.6   80.7       Temporal Ctx           (Path) 1                   Parietal Ctx       Control 4   45.7   68.8   Control   67.4   59.9       Temporal Ctx           (Path) 2                   Parietal Ctx       Control (Path)   63.3   58.6   Control   25.3   24.1       1 Temporal Ctx           (Path) 3                   Parietal Ctx       Control (Path)   55.9   55.1   Control   78.5   79.0       2 Temporal Ctx           (Path) 4                   Parietal Ctx                    
     [2112]               TABLE CSC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3248,       (%) Ag3248,           Run       Run       Tissue Name   214693634   Tissue Name   214693634                                     Adipose   1.5   Renal ca. TK-10   3.6       Melanoma*   6.2   Bladder   7.6       Hs688(A).T       Melanoma*   5.8   Gastric ca. (liver met.)   16.8       Hs688(B).T       NCI-N87       Melanoma* M14   4.9   Gastric ca. KATO III   14.5       Melanoma*   5.3   Colon ca. SW-948   6.4       LOXIMVI       Melanoma* SK-   4.3   Colon ca. SW480   15.6       MEL-5       Squamous cell   3.3   Colon ca.* (SW480   9.1       carcinoma SCC-4       met) SW620       Testis Pool   1.5   Colon ca. HT29   7.1       Prostate ca.* (bone   2.3   Colon ca. HCT-116   7.5       met) PC-3       Prostate Pool   3.1   Colon ca. CaCo-2   8.7       Placenta   3.0   Colon cancer tissue   4.9       Uterus Pool   0.9   Colon ca. SW1116   10.2       Ovarian ca.   24.0   Colon ca. Colo-205   6.2       OVCAR-3       Ovarian ca. SK-   18.7   Colon ca. SW-48   7.5       OV-3       Ovarian ca.   4.1   Colon Pool   4.2       OVCAR-4       Ovarian ca.   33.0   Small Intestine Pool   4.5       OVCAR-5       Ovarian ca.   16.0   Stomach Pool   2.7       IGROV-1       Ovarian ca.   20.9   Bone Marrow Pool   1.3       OVCAR-8       Ovary   3.1   Fetal Heart   3.2       Breast ca. MCF-7   4.5   Heart Pool   2.6       Breast ca. MDA-   12.2   Lymph Node Pool   4.6       MB-231       Breast ca. BT 549   12.0   Fetal Skeletal Muscle   1.2       Breast ca. T47D   100.0   Skeletal Muscle Pool   4.0       Breast ca. MDA-N   9.7   Spleen Pool   4.1       Breast Pool   5.2   Thymus Pool   5.3       Trachea   3.1   CNS cancer   12.1               (glio/astro) U87-MG       Lung   0.4   CNS cancer   10.9               (glio/astro) U-118-MG       Fetal Lung   4.4   CNS cancer   16.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   3.1   CNS cancer (astro)   6.2               SF-539       Lung ca. LX-1   12.5   CNS cancer (astro)   15.3               SNB-75       Lung ca. NCI-H146   5.1   CNS cancer (glio)   13.2               SNB-19       Lung ca. SHP-77   1.5   CNS cancer (glio) SF-   25.9               295       Lung ca. A549   5.4   Brain (Amygdala)   4.7               Pool       Lung ca. NCI-H526   7.4   Brain (cerebellum)   8.5       Lung ca. NCI-H23   4.4   Brain (fetal)   2.1       Lung ca. NCI-H460   4.5   Brain (Hippocampus)   6.1               Pool       Lung ca. HOP-62   6.3   Cerebral Cortex Pool   6.0       Lung ca. NCI-H522   5.5   Brain (Substantia   8.1               nigra) Pool       Liver   3.2   Brain (Thalamus) Pool   7.8       Fetal Liver   2.3   Brain (whole)   3.4       Liver ca. HepG2   5.4   Spinal Cord Pool   6.6       Kidney Pool   4.5   Adrenal Gland   3.0       Fetal Kidney   3.1   Pituitary gland Pool   3.4       Renal ca. 786-0   7.4   Salivary Gland   4.3       Renal ca. A498   5.8   Thyroid (female)   6.1       Renal ca. ACHN   5.6   Pancreatic ca.   11.3               CAPAN2       Renal ca. UO-31   6.1   Pancreas Pool   5.2                    
     [2113]               TABLE CSD                          Panel 2.2                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3248, Run       Ag3248,       Tissue Name   174441298   Tissue Name   Run 174441298                                     Normal Colon   14.4   Kidney Margin   100.0               (OD04348)       Colon cancer   6.3   Kidney malignant   6.3       (OD06064)       cancer (OD06204B)       Colon Margin   7.5   Kidney normal   9.3       (OD06064)       adjacent tissue               (OD06204E)       Colon cancer   8.0   Kidney Cancer   57.8       (OD06159)       (OD04450-01)       Colon Margin   5.3   Kidney Margin   16.2       (OD06159)       (OD04450-03)       Colon cancer   2.4   Kidney Cancer   10.8       (OD06297-04)       8120613       Colon Margin   6.3   Kidney Margin   16.7       (OD06297-05)       8120614       CC Gr.2 ascend colon   14.1   Kidney Cancer   9.0       (ODO3921)       9010320       CC Margin (ODO3921)   12.8   Kidney Margin   19.5               9010321       Colon cancer metastasis   4.4   Kidney Cancer   34.2       (OD06104)       8120607       Lung Margin   4.8   Kidney Margin   27.7       (OD06104)       8120608       Colon mets to lung   15.0   Normal Uterus   3.8       (OD04451-01)       Lung Margin   6.7   Uterine Cancer 064011   10.5       (OD04451-02)       Normal Prostate   9.0   Normal Thyroid   4.6       Prostate Cancer   7.5   Thyroid Cancer   18.6       (OD04410)       064010       Prostate Margin   11.6   Thyroid Cancer   24.0       (OD04410)       A302152       Normal Ovary   28.7   Thyroid Margin   13.3               A302153       Ovarian cancer   3.1   Normal Breast   4.0       (OD06283-03)       Ovarian Margin   1.1   Breast Cancer   9.3       (OD06283-07)       (OD04566)       Ovarian Cancer 064008   6.8   Breast Cancer 1024   6.9       Ovarian cancer   8.6   Breast Cancer   86.5       (OD06145)       (OD04590-01)       Ovarian Margin   17.8   Breast Cancer Mets   22.4       (OD06145)       (OD04590-03)       Ovarian cancer   2.0   Breast Cancer   47.3       (OD06455-03)       Metastasis (OD04655-               05)       Ovarian Margin   2.5   Breast Cancer 064006   9.8       (OD06455-07)       Normal Lung   4.7   Breast Cancer 9100266   5.8       Invasive poor diff. lung   9.0   Breast Margin   3.3       adeno (ODO4945-01)       9100265       Lung Margin   4.5   Breast Cancer   7.3       (ODO4945-03)       A209073       Lung Malignant Cancer   10.6   Breast Margin   17.0       (OD03126)       A2090734       Lung Margin   8.4   Breast cancer   8.6       (OD03126)       (OD06083)       Lung Cancer   8.7   Breast cancer node   8.2       (OD05014A)       metastasis (OD06083)       Lung Margin   8.6   Normal Liver   33.4       (OD05014B)       Lung cancer   6.3   Liver Cancer 1026   20.6       (OD06081)       Lung Margin   4.4   Liver Cancer 1025   29.1       (OD06081)       Lung Cancer   2.7   Liver Cancer 6004-T   27.4       (OD04237-01)       Lung Margin   16.7   Liver Tissue 6004-N   2.5       (OD04237-02)       Ocular Melanoma   25.0   Liver Cancer 6005-T   26.2       Metastasis       Ocular Melanoma   15.8   Liver Tissue 6005-N   58.2       Margin (Liver)       Melanoma Metastasis   3.8   Liver Cancer 064003   52.5       Melanoma Margin   2.6   Normal Bladder   10.7       (Lung)       Normal Kidney   12.4   Bladder Cancer 1023   6.8       Kidney Ca, Nuclear   32.3   Bladder Cancer   3.8       grade 2 (OD04338)       A302173       Kidney Margin   7.1   Normal Stomach   16.8       (OD04338)       Kidney Ca Nuclear   71.7   Gastric Cancer   9.2       grade 1/2 (OD04339)       9060397       Kidney Margin   14.6   Stomach Margin   10.4       (OD04339)       9060396       Kidney Ca, Clear cell   8.4   Gastric Cancer   1.7       type (OD04340)       9060395       Kidney Margin   31.2   Stomach Margin   7.5       (OD04340)       9060394       Kidney Ca, Nuclear   7.5   Gastric Cancer 064005   10.7       grade 3 (OD04348)                    
     [2114]               TABLE CSE                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3248, Run       Ag3248, Run       Tissue Name   164390952   Tissue Name   164390952                                     Secondary Th1 act   15.3   HUVEC IL-1beta   1.7       Secondary Th2 act   16.5   HUVEC IFN gamma   16.0       Secondary Tr1 act   15.5   HUVEC TNF alpha +   7.8               IFN gamma       Secondary Th1 rest   8.0   HUVEC TNF alpha +   9.2               IL4       Secondary Th2 rest   8.8   HUVEC IL-11   12.8       Secondary Tr1 rest   12.8   Lung Microvascular EC   19.1               none       Primary Th1 act   8.4   Lung Microvascular EC   13.8               TNF alpha + IL-1beta       Primary Th2 act   9.3   Microvascular Dermal   18.0               EC none       Primary Tr1 act   15.1   Microsvasular Dermal   6.9               EC TNF alpha + IL-1beta       Primary Th1 rest   12.3   Bronchial epithelium   21.3               TNF alpha + IL1beta       Primary Th2 rest   4.6   Small airway epithelium   13.5               none       Primary Tr1 rest   5.6   Small airway epithelium   45.4               TNF alpha + IL-1beta       CD45RA CD4   12.1   Coronery artery SMC rest   12.9       lymphocyte act       CD45RO CD4   12.0   Coronery artery SMC   15.2       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   12.5   Astrocytes rest   18.6       Secondary CD8   13.7   Astrocytes TNF alpha +   17.2       lymphocyte rest       IL-1beta       Secondary CD8   9.9   KU-812 (Basophil) rest   8.7       lymphocyte act       CD4 lymphocyte none   6.8   KU-812 (Basophil)   8.6               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   9.5   CCD1106   10.9       CD95 CH11       (Keratinocytes) none       LAK cells rest   15.2   CCD1106   12.2               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   13.6   Liver cirrhosis   7.4       LAK cells IL-2 + IL-12   9.1   Lupus kidney   10.7       LAK cells IL-2 + IFN   13.9   NCI-H292 none   42.6       gamma       LAK cells IL-2 + IL-18   9.7   NCI-H292 IL-4   48.3       LAK cells   1.5   NCI-H292 IL-9   54.3       PMA/ionomycin       NK Cells IL-2 rest   12.9   NCI-H292 IL-13   37.1       Two Way MLR 3 day   19.8   NCI-H292 IFN gamma   48.3       Two Way MLR 5 day   6.3   HPAEC none   17.9       Two Way MLR 7 day   9.7   HPAEC TNF alpha + IL-   5.0               1beta       PBMC rest   10.7   Lung fibroblast none   21.5       PBMC PWM   27.0   Lung fibroblast TNF   27.9               alpha + IL-1beta       PBMC PHA-L   12.0   Lung fibroblast IL-4   31.9       Ramos (B cell) none   27.9   Lung fibroblast IL-9   35.4       Ramos (B cell)   100.0   Lung fibroblast IL-13   18.6       ionomycin       B lymphocytes PWM   21.0   Lung fibroblast IFN   37.4               gamma       B lymphocytes CD40L   8.9   Dermal fibroblast   17.7       and IL-4       CCD1070 rest       EOL-1 dbcAMP   19.8   Dermal fibroblast   21.2               CCD1070 TNF alpha       EOL-1 dbcAMP   1.4   Dermal fibroblast   8.4       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   18.3   Dermal fibroblast IFN   16.8               gamma       Dendritic cells LPS   20.0   Dermal fibroblast IL-4   27.7       Dendritic cells anti-   22.1   IBD Colitis 2   3.0       CD40       Monocytes rest   12.6   IBD Crohn&#39;s   4.2       Monocytes LPS   2.6   Colon   28.5       Macrophages rest   20.6   Lung   12.0       Macrophages LPS   10.4   Thymus   53.6       HUVEC none   11.9   Kidney   20.0       HUVEC starved   15.6                    
     [2115] CNS_neurodegeneration_v1.0 Summary: Ag3248 Results from two experiments using the same probe/primer set gave results that are in excellent agreement. This panel confirms the expression of this gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [2116] General_screening_panel_v1.4 Summary: Ag3248 Expression of the CG57464-01 gene is highest in a breast cancer cell line (CT=27). This also gene appears to be overexpressed in ovarian and CNS cancer cell lines when compared to the normal tissue controls. Thus, therapeutic modulation of the activity of this gene or its protein may be of benefit in the treatment of breast, ovarian and CNS cancer.  
     [2117] In addition, this gene is expressed at low levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2118] Among tissues with metabolic or endocrine function, this gene is expressed at low levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [2119] Panel 2.2 Summary: Ag3248 This gene is expressed at low to moderate levels in the majority of samples on this panel, with highest expression detected in a sample derived from normal kidney (CT=28.6). Expression of the CG57464-01 gene appears to be upregulated in a number of breast cancer samples when compared to normal breast. Thus, therapeutic modulation of the activity of this gene or its protein product may be of benefit in the treatment of breast cancer.  
     [2120] Panel 4D Summary: Ag3248 Expression of the CG57464-01 gene is highest in Ramos B cells treated with ionomycin (CT=29). Therefore, expression of this gene may be used as a marker of activated B cells. In addition, this gene is expressed at relatively high levels in lung fibroblasts as well as in the mucoepidermoid cell line NCI-H292 independent of treatment (CTs=30), suggesting that therapeutic modulation of the activity of this gene or its protein product may be of benefit in the treatment of asthma and emphysema.  
     [2121] This gene is also expressed at low to moderate levels in a wide range of other cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues.  
     [2122] This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also suggests a role for the gene product in cell survival and proliferation.  
     [2123] Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [2124] CT. CG57466-01: Acetylglucosaminyltransferase  
     [2125] Expression of gene CG57466-01 was assessed using the primer-probe set Ag3249, described in Table CTA. Results of the RTQ-PCR runs are shown in Tables CTB, CTC and CTD.  
               TABLE CTA                          Probe Name Ag3249                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-accactaactgctcagccaata-3′   22   156   698               Probe   TET-5′-aacttgacccaccagccctggtt-3′-TAMRA   23   180   699               Reverse   5′-tagaagagaaactgccggaact-3′   22   220   700                  
 
     [2126]               TABLE CTB                          CNS_neurodegeneration_v1.0                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3249,       Ag3249,           Run       Run       Tissue Name   210037963   Tissue Name   210037963                                     AD 1 Hippo   8.4   Control (Path) 3   5.6               Temporal Ctx       AD 2 Hippo   41.5   Control (Path) 4   27.2               Temporal Ctx       AD 3 Hippo   14.0   AD 1 Occipital Ctx   6.6       AD 4 Hippo   26.1   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   29.9   AD 3 Occipital Ctx   8.5       AD 6 Hippo   100.0   AD 4 Occipital Ctx   25.2       Control 2 Hippo   42.0   AD 5 Occipital Ctx   48.0       Control 4 Hippo   29.3   AD 6 Occipital Ctx   22.4       Control (Path) 3   5.6   Control 1 Occipital   6.1       Hippo       Ctx       AD 1 Temporal   10.7   Control 2 Occipital   51.4       Ctx       Ctx       AD 2 Temporal   25.5   Control 3 Occipital   22.1       Ctx       Ctx       AD 3 Temporal   9.9   Control 4 Occipital   15.8       Ctx       Ctx       AD 4 Temporal   29.9   Control (Path) 1   92.7       Ctx       Occipital Ctx       AD 5 Inf Temporal   25.5   Control (Path) 2   18.7       Ctx       Occipital Ctx       AD 5 Sup   27.4   Control (Path) 3   0.7       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   87.1   Control (Path) 4   29.9       Ctx       Occipital Ctx       AD 6 Sup   5.0   Control 1 Parietal   13.7       Temporal Ctx       Ctx       Control 1   24.5   Control 2 Parietal   29.1       Temporal Ctx       Ctx       Control 2   41.2   Control 3 Parietal   25.7       Temporal Ctx       Ctx       Control 3   33.7   Control (Path) 1   64.2       Temporal Ctx       Parietal Ctx       Control 3   21.9   Control (Path) 2   25.9       Temporal Ctx       Parietal Ctx       Control (Path) 1   69.7   Control (Path) 3   1.9       Temporal Ctx       Parietal Ctx       Control (Path) 2   26.4   Control (Path) 4   39.8       Temporal Ctx       Parietal Ctx                    
     [2127]               TABLE CTC                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3249,       Ag3249,           Run       Run       Tissue Name   214693635   Tissue Name   214693635                                     Adipose   5.6   Renal ca. TK-10   2.7       Melanoma*   0.4   Bladder   59.5       Hs688(A).T       Melanoma*   0.5   Gastric ca. (liver met.)   78.5       Hs688(B).T       NCI-N87       Melanoma* M14   8.8   Gastric ca. KATO III   60.3       Melanoma*   0.1   Colon ca. SW-948   0.5       LOXIMVI       Melanoma* SK-   15.2   Colon ca. SW480   4.4       MEL-5       Squamous cell   50.7   Colon ca.* (SW480   0.9       carcinoma SCC-4       met) SW620       Testis Pool   1.7   Colon ca. HT29   0.8       Prostate ca.* (bone   9.0   Colon ca. HCT-116   13.2       met) PC-3       Prostate Pool   1.8   Colon ca. CaCo-2   6.6       Placenta   10.9   Colon cancer tissue   26.6       Uterus Pool   0.9   Colon ca. SW1116   3.6       Ovarian ca.   3.8   Colon ca. Colo-205   0.1       OVCAR-3       Ovarian ca. SK-   6.1   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   1.3   Colon Pool   6.2       OVCAR-4       Ovarian ca.   22.1   Small Intestine Pool   11.3       OVCAR-5       Ovarian ca.   7.5   Stomach Pool   6.7       IGROV-1       Ovarian ca.   1.4   Bone Marrow Pool   2.3       OVCAR-8       Ovary   24.5   Fetal Heart   11.6       Breast ca. MCF-7   0.7   Heart Pool   2.7       Breast ca. MDA-   1.4   Lymph Node Pool   7.1       MB-231       Breast ca. BT 549   1.8   Fetal Skeletal Muscle   0.4       Breast ca. T47D   37.9   Skeletal Muscle Pool   0.8       Breast ca. MDA-N   100.0   Spleen Pool   13.3       Breast Pool   4.0   Thymus Pool   3.7       Trachea   65.5   CNS cancer   0.0               (glio/astro) U87-MG       Lung   5.8   CNS cancer   0.7               (glio/astro) U-118-MG       Fetal Lung   87.7   CNS cancer   21.3               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.1               SF-539       Lung ca. LX-1   29.5   CNS cancer (astro)   12.2               SNB-75       Lung ca. NCI-H146   0.6   CNS cancer (glio)   6.5               SNB-19       Lung ca. SHP-77   0.2   CNS cancer (glio) SF-   6.2               295       Lung ca. A549   12.9   Brain (Amygdala)   5.1               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   6.8       Lung ca. NCI-H23   2.3   Brain (fetal)   4.5       Lung ca. NCI-H460   0.2   Brain (Hippocampus)   6.7               Pool       Lung ca. HOP-62   5.0   Cerebral Cortex Pool   6.7       Lung ca. NCI-H522   0.4   Brain (Substantia   7.6               nigra) Pool       Liver   0.8   Brain (Thalamus) Pool   9.0       Fetal Liver   4.8   Brain (whole)   7.5       Liver ca. HepG2   0.0   Spinal Cord Pool   4.6       Kidney Pool   11.7   Adrenal Gland   40.6       Fetal Kidney   4.5   Pituitary gland Pool   10.5       Renal ca. 786-0   2.5   Salivary Gland   5.7       Renal ca. A498   1.4   Thyroid (female)   5.8       Renal ca. ACHN   22.2   Pancreatic ca.   43.8               CAPAN2       Renal ca. UO-31   32.8   Pancreas Pool   11.3                    
     [2128]               TABLE CTD                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3249, Run       Ag3249, Run       Tissue Name   164390953   Tissue Name   164390953                                     Secondary Th1 act   0.2   HUVEC IL-1beta   0.4       Secondary Th2 act   0.0   HUVEC IFN gamma   1.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.5               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.6               IL4       Secondary Th2 rest   0.1   HUVEC IL-11   0.9       Secondary Tr1 rest   0.0   Lung Microvascular EC   1.4               none       Primary Th1 act   0.2   Lung Microvascular EC   4.5               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.9               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   7.7               EC TNF alpha + IL-1beta       Primary Th1 rest   0.1   Bronchial epithelium   3.6               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.2               none       Primary Tr1 rest   0.1   Small airway epithelium   5.8               TNF alpha + IL-1beta       CD45RA CD4   0.5   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.1   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.6   Astrocytes rest   0.8       Secondary CD8   0.0   Astrocytes TNF alpha +   3.1       lymphocyte rest       IL-1beta       Secondary CD8   0.1   KU-812 (Basophil) rest   2.7       lymphocyte act       CD4 lymphocyte none   1.1   KU-812 (Basophil)   3.8               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.1   CCD1106   1.6       CD95 CH11       (Keratinocytes) none       LAK cells rest   1.9   CCD1106   1.3               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   5.0   Liver cirrhosis   3.2       LAK cells IL-2 + IL-12   1.6   Lupus kidney   1.3       LAK cells IL-2 + IFN   5.0   NCI-H292 none   100.0       gamma       LAK cells IL-2 + IL-18   4.3   NCI-H292 IL-4   87.7       LAK cells   6.1   NCI-H292 IL-9   96.6       PMA/ionomycin       NK Cells IL-2 rest   12.7   NCI-H292 IL-13   54.0       Two Way MLR 3 day   0.6   NCI-H292 IFN gamma   25.2       Two Way MLR 5 day   1.6   HPAEC none   0.4       Two Way MLR 7 day   0.9   HPAEC TNF alpha + IL-   6.3               1beta       PBMC rest   9.4   Lung fibroblast none   0.1       PBMC PWM   3.7   Lung fibroblast TNF   0.3               alpha + IL-1beta       PBMC PHA-L   0.7   Lung fibroblast IL-4   0.7       Ramos (B cell) none   0.1   Lung fibroblast IL-9   0.0       Ramos (B cell)   2.0   Lung fibroblast IL-13   0.3       ionomycin       B lymphocytes PWM   2.7   Lung fibroblast IFN   0.4               gamma       B lymphocytes CD40L   5.8   Dermal fibroblast   0.1       and IL-4       CCD1070 rest       EOL-1 dbcAMP   26.6   Dermal fibroblast   0.8               CCD1070 TNF alpha       EOL-1 dbcAMP   8.4   Dermal fibroblast   0.0       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   3.2   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   2.5   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   1.3   IBD Colitis 2   1.4       CD40       Monocytes rest   0.4   IBD Crohn&#39;s   4.2       Monocytes LPS   10.5   Colon   48.6       Macrophages rest   1.1   Lung   19.5       Macrophages LPS   17.9   Thymus   2.5       HUVEC none   0.8   Kidney   3.9       HUVEC starved   1.1                    
     [2129] CNS_neurodegeneration_v1.0 Summary: Ag3249 This panel confirms the expression of this gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [2130] General_screening_panel_v1.4 Summary: Ag3249 The CG57466-01 gene encodes a protein with homology to beta-1,3-galactosyltransferases, which catalyze the formation of type I oligosaccharides (ref. 1). Expression of this gene is highest in a breast cancer cell line (CT=28.1). In addition, expression of this gene appears to be upregulated in pancreatic and gastric cancer cell lines when compared to their respective normal tissues. Thus, therapeutic modulation of the activity of this gene or its protein product may be of benefit in the treatment of breast, pancreatic and gastric cancer.  
     [2131] This gene also shows significant levels of expression in trachea, bladder and fetal lung. Interestingly, CG57466-01 gene expression is much higher in fetal lung (CT=28.3) than in adult lung (CT=32.2), suggesting that expression of this gene can be used to distinguish adult from fetal lung.  
     [2132] In addition, this gene is expressed at low levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2133] Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, heart, fetal liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     REFERENCES  
     [2134] 1. Shiraishi N, Natsume A, Togayachi A, Endo T, Akashima T, Yamada Y, Imai N, Nakagawa S, Koizumi S, Sekine S, Narimatsu H, Sasaki K. Identification and characterization of three novel beta 1,3-N-acetylglucosaminyltransferases structurally related to the beta 1,3-galactosyltransferase family. J Biol Chem Feb. 2, 2001;276(5):3498  
     [2135] Panel 4D Summary: Ag3249 This transcript is most highly expressed in a cluster of treated and untreated samples derived from the NCI-H292 cell line, a human airway epithelial cell line that produces mucins (CTs=30-32). Mucus overproduction is an important feature of bronchial asthma and chronic obstructive pulmonary disease samples. The transcript is also expressed at lower but still significant levels in small airway epithelium treated with IL-1 beta and TNF-alpha. The expression of the transcript in this mucoepidermoid cell line that is often used as a model for airway epithelium (NCI-H292 cells) suggests that this transcript may be important in the proliferation or activation of airway epithelium. Therefore, therapeutics designed with the protein encoded by the transcript may reduce or eliminate symptoms caused by inflammation in lung epithelia in chronic obstructive pulmonary disease, asthma, allergy, and emphysema.  
     [2136] CU. CG57468-01: Multidrug Resistance Protein 1  
     [2137] Expression of gene CG57468-01 was assessed using the primer-probe set Ag3250, described in Table CUA. Results of the RTQ-PCR runs are shown in Tables CUB.  
               TABLE CUA                          Probe Name Ag3250                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-agcaggggaaattttaacgat-3′   21   2391   701               Probe   TET-5′-agacacttggccttcaaagccatgtt-3′-TAMRA   26   2419   702               Reverse   5′-caaaccaggcaatatcctgata-3′   22   2446   703                  
 
     [2138]               TABLE CUB                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3250,       Ag3250,           Run       Run       Tissue Name   214693636   Tissue Name   214693636                                     Adipose   0.1   Renal ca. TK-10   0.0       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   11.9       LOXIMVI       Melanoma* SK-   0.6   Colon ca. SW480   0.0       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   0.0   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   0.1       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.7       Breast ca. MDA-   0.0   Lymph Node Pool   0.8       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.3   Spleen Pool   0.0       Breast Pool   100.0   Thymus Pool   0.0       Trachea   0.0   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   0.1   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.0   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   0.0   Brain (fetal)   0.0       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   0.0   Brain (Substantia   0.0               nigra) Pool       Liver   9.5   Brain (Thalamus) Pool   0.0       Fetal Liver   21.0   Brain (whole)   0.0       Liver ca. HepG2   0.0   Spinal Cord Pool   0.0       Kidney Pool   17.4   Adrenal Gland   0.0       Fetal Kidney   6.5   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.0                    
     [2139] CNS_neurodegeneration v1.0 Summary: Ag3250 Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2140] General_screening_panel_v1.4 Summary: Ag3250 Expression of the CG57468-01 gene is highest in normal breast (CT=23.8). In addition, this gene is highly expressed in fetal/adult kidney and fetal/adult liver (CTs=26-27). Thus, expression of this gene may be used to distinguish these tissues from the other samples on this panel. Strikingly, expression of this gene is much lower in breast, kidney, and liver cancer cell lines. Therapeutic modulation of the activity of this gene or its protein product may be of benefit in the treatment of these types of cancers.  
     [2141] Panel 4D Summary: Ag3250 Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2142] CV. CG59609-01: Peptidyl-Prolyl Cis-Trans Isomerase A  
     [2143] Expression of gene CG59609-01 was assessed using the primer-probe set Ag3494, described in Table CVA. Results of the RTQ-PCR runs are shown in Tables CVB and CVC.  
                               TABLE CVA                       phc,1 Probe Name Ag3494                   Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                                    Forward   5′-ccgttctatcagccatggt-3′   19   3   704               Probe   TET-5′-ccccaccaggttcttagacatcatcg-3′-TAMRA   26   25   705               Reverse   5′-aaggagacacgtcccaagag-3′   20   62   706                  
 
     [2144]               TABLE CVB                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3494,       Ag3494,           Run       Run       Tissue Name   217215292   Tissue Name   217215292                                     Adipose   0.0   Renal ca.TK-10   0.0       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   25.5   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.0       MEL-5       Squamous cell   33.4   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   100.0   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.0   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   0.0       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   79.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   41.8   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   86.5   Spleen Pool   0.0       Breast Pool   0.0   Thymus Pool   0.0       Trachea   0.0   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.0   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   0.0   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   40.6   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.0   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   0.0   Brain (fetal)   0.0       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   0.0   Brain (Substantia   0.0               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   0.0       Fetal Liver   0.0   Brain (whole)   0.0       Liver ca. HepG2   0.0   Spinal Cord Pool   0.0       Kidney Pool   47.0   Adrenal Gland   0.0       Fetal Kidney   0.0   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.0                    
     [2145]               TABLE CVC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3494, Run       Ag3494, Run       Tissue Name   166441744   Tissue Name   166441744                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular EC   0.0               none       Primary Th1 act   0.0   Lung Microvascular EC   0.0               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes TNF alpha +   0.0       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   100.0       LAK cells IL-2 + IL-12   5.6   Lupus Kidney   4.6       LAK cells IL-2 + IFN   0.0   NCI-H292 none   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-4   0.0       LAK cells   0.0   NCI-H292 IL-9   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IL-13   0.0       Two Way MLR 3 day   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 5 day   0.0   HPAEC none   0.0       Two Way MLR 7 day   0.0   HPAEC TNF alpha + IL-   0.0               1beta       PBMC rest   0.0   Lung fibroblast none   0.0       PBMC PWM   0.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PHA-L   0.0   Lung fibroblast IL-4   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell)   0.0   Lung fibroblast IL-13   0.0       ionomycin       B lymphocytes PWM   0.0   Lung fibroblast IFN   0.0               gamma       B lymphocytes CD40L   0.0   Dermal fibroblast   7.7       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   1.4       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.0   Dermal fibroblast IFN   0.0               gamma       Dendritic cells LPS   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells anti-   0.0   IBD Colitis 2   26.2       CD40       Monocytes rest   0.0   IBD Crohn&#39;s   13.8       Monocytes LPS   0.0   Colon   17.6       Macrophages rest   0.0   Lung   8.1       Macrophages LPS   0.0   Thymus   16.5       HUVEC none   0.0   Kidney   0.0       HUVEC starved   0.0                    
     [2146] CNS_neurodegeneration_v1.0 Summary: Ag3494 Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2147] General_screening_panel_v1.4 Summary: Ag3494 Expression of the CG59609-01 gene is highest in testis (CT=34.3). In addition, low but significant expression of this gene is detected in a breast cancer cell line and an ovarian cancer cell line. Thus, expression of this gene may be used to distinguish these samples from the other samples on this panel. Furthermore, therapeutic modulation of the activity of this gene may be of benefit in the treatment of fertility, breast cancer, and ovarian cancer.  
     [2148] Panel 4D Summary: Ag3494 Expression of the CG59609-01 gene is highest in a liver cirrhosis sample (CT=34.3). In addition, low but significant expression of this gene is detected in samples from thymus as well as from normal and IBD colon. Thus, expression of this gene may be used to distinguish these samples from the other samples on this panel. Furthermore, therapies designed with the protein encoded for by this gene may potentially modulate liver function and play a role in the identification and treatment of inflammatory or autoimmune diseases which effect the liver including liver cirrhosis and fibrosis.  
     [2149] CW. CG59613-01: Proliferating Cell Nuclear Antigen  
     [2150] Expression of gene CG59613-01 was assessed using the primer-probe set Ag3496, described in Table CWA. Results of the RTQ-PCR runs are shown in Tables CWB and  
               TABLE CWA                          Probe Name Ag3496                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cacataccactgtgaccacaac-3′   22   238   707               Probe   TET-5′-cctcaccagcatgtccaaaatgctaa-3′-TAMRA   26   277   708               Reverse   5′-tgtcttcactgccattgttgta-3′   22   305   709                  
 
     [2151]               TABLE CWB                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3496,       Ag3496,           Run       Run       Tissue Name   217217871   Tissue Name   217217871                                     Adipose   9.6   Renal ca. TK-10   21.8       Melanoma*   25.2   Bladder   11.4       Hs688(A).T       Melanoma*   20.4   Gastric ca. (liver met.)   3.9       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   1.1       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   1.5   Colon ca. SW480   1.7       MEL-5       Squamous cell   5.4   Colon ca.* (SW480   2.0       carcinoma SCC-4       met) SW620       Testis Pool   56.3   Colon ca. HT29   3.9       Prostate ca.* (bone   2.6   Colon ca. HCT-116   12.9       met) PC-3       Prostate Pool   37.6   Colon ca. CaCo-2   8.4       Placenta   0.0   Colon cancer tissue   1.4       Uterus Pool   21.5   Colon ca. SW1116   0.0       Ovarian ca.   18.3   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   1.9   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   8.0   Colon Pool   29.9       OVCAR-4       Ovarian ca.   2.9   Small Intestine Pool   57.8       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   38.7       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   6.3       OVCAR-8       Ovary   4.9   Fetal Heart   6.2       Breast ca. MCF-7   4.3   Heart Pool   12.3       Breast ca. MDA-   6.4   Lymph Node Pool   64.6       MB-231       Breast ca. BT 549   4.7   Fetal Skeletal Muscle   31.6       Breast ca. T47D   12.9   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   1.7       Breast Pool   47.6   Thymus Pool   47.3       Trachea   26.1   CNS cancer   2.3               (glio/astro) U87-MG       Lung   7.7   CNS cancer   22.5               (glio/astro) U-118-MG       Fetal Lung   82.9   CNS cancer   0.9               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   1.8               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   35.4               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   3.7   CNS cancer (glio) SF-   9.2               295       Lung ca. A549   0.0   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   46.0   Brain (fetal)   23.8       Lung ca. NCI-H460   0.5   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   7.5   Cerebral Cortex Pool   1.6       Lung ca. NCI-H522   2.1   Brain (Substantia   3.8               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   3.2       Fetal Liver   7.9   Brain (whole)   4.2       Liver ca. HepG2   0.0   Spinal Cord Pool   1.9       Kidney Pool   80.7   Adrenal Gland   1.7       Fetal Kidney   100.0   Pituitary gland Pool   0.7       Renal ca. 786-0   13.3   Salivary Gland   6.2       Renal ca. A498   0.0   Thyroid (female)   2.6       Renal ca. ACHN   23.8   Pancreatic ca.   5.5               CAPAN2       Renal ca. UO-31   13.7   Pancreas Pool   48.6                    
     [2152]               TABLE CWC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3496, Run       Ag3496, Run       Tissue Name   166441888   Tissue Name   166441888                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.7       Secondary Th2 act   0.7   HUVEC IFN gamma   1.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.7   HUVEC TNF alpha +   0.6               IL4       Secondary Th2 rest   1.2   HUVEC IL-11   0.4       Secondary Tr1 rest   0.4   Lung Microvascular EC   1.0               none       Primary Th1 act   0.3   Lung Microvascular EC   1.0               TNF alpha + IL-1beta       Primary Th2 act   1.2   Microvascular Dermal   0.4               EC none       Primary Tr1 act   0.8   Microsvasular Dermal   0.2               EC TNF alpha + IL-1beta       Primary Th1 rest   1.5   Bronchial epithelium   5.2               TNF alpha + IL1beta       Primary Th2 rest   1.0   Small airway epithelium   6.6               none       Primary Tr1 rest   1.5   Small airway epithelium   100.0               TNF alpha + IL-1beta       CD45RA CD4   2.1   Coronery artery SMC rest   2.6       lymphocyte act       CD45RO CD4   0.9   Coronery artery SMC   1.5       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   2.1   Astrocytes rest   13.1       Secondary CD8   0.0   Astrocytes TNF alpha +   7.4       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   4.2       lymphocyte act       CD4 lymphocyte none   1.8   KU-812 (Basophil)   5.2               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.7   CCD1106   17.9       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   82.4               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   2.3   Liver cirrhosis   17.2       LAK cells IL-2 + IL-12   1.7   Lupus Kidney   9.3       LAK cells IL-2 + IFN   2.3   NCI-H292 none   0.3       gamma       LAK cells IL-2 + IL-18   3.1   NCI-H292 IL-4   0.8       LAK cells   0.2   NCI-H292 IL-9   3.0       PMA/ionomycin       NK Cells IL-2 rest   2.7   NCI-H292 IL-13   1.9       Two Way MLR 3 day   3.3   NCI-H292 IFN gamma   0.5       Two Way MLR 5 day   0.0   HPAEC none   0.3       Two Way MLR 7 day   0.2   HPAEC TNF alpha + IL-   0.6               1beta       PBMC rest   1.0   Lung fibroblast none   12.3       PBMC PWM   1.7   Lung fibroblast TNF   2.9               alpha + IL-1beta       PBMC PHA-L   0.7   Lung fibroblast IL-4   11.0       Ramos (B cell) none   0.0   Lung fibroblast IL-9   5.3       Ramos (B cell)   0.0   Lung fibroblast IL-13   10.4       ionomycin       B lymphocytes PWM   0.9   Lung fibroblast IFN   11.9               gamma       B lymphocytes CD40L   2.8   Dermal fibroblast   11.7       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.0   Dermal fibroblast   5.8               CCD1070 TNF alpha       EOL-1 dbcAMP   0.9   Dermal fibroblast   2.3       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   0.1   Dermal fibroblast IFN   8.8               gamma       Dendritic cells LPS   0.7   Dermal fibroblast IL-4   11.3       Dendritic cells anti-   0.6   IBD Colitis 2   2.6       CD40       Monocytes rest   0.7   IBD Crohn&#39;s   1.3       Monocytes LPS   0.0   Colon   11.4       Macrophages rest   0.0   Lung   1.9       Macrophages LPS   0.0   Thymus   3.8       HUVEC none   1.0   Kidney   7.2       HUVEC starved   1.4                    
     [2153] CNS_neurodegeneration_v1.0 Summary: Ag3496 Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2154] General_screening_panel_v1.4 Summary: Ag3496 Expression of the CG59613-01 gene is highest in fetal and adult kidney (CTs=31). This gene is also expressed at higher levels in fetal lung (CT=31.4) than in adult lung (CT=34.8), suggesting that expression of this gene can be used to distinguish adult and fetal lung and that this gene may play a role in lung development and regeneration. Differentially higher expression in fetal tissues also occurs in brain and skeletal muscle.  
     [2155] In general, expression of this gene is associated with normal tissues rather than cancer cell lines. Specifically, CG59613-01 gene expression is downregulated in pancreatic, colon, gastric, renal, lung, breast and prostate cancer cell lines when compared to their respective normal tissues. Therefore, therapeutic modulation of the activity of this gene may be of benefit in the treatment of these cancers.  
     [2156] Among tissues with metabolic or endocrine function, this gene is expressed at low levels in pancreas, adipose, adrenal gland, fetal skeletal muscle, and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [2157] Panel 4D Summary: Ag3496 Expression of the CG59613-01 gene is highest in small airway epithelium treated with TNF alpha and IL-1 beta (CT=29.4). In addition, this gene is substantially upregulated in keratinocytes treated with TNF alpha and IL-1 beta. Low expression of this gene is also seen in lung and dermal fibroblasts independent of treatment. Therefore, therapeutics designed with the protein encoded by the transcript may reduce or eliminate symptoms caused by inflammation of the lung and skin in chronic obstructive pulmonary disease, asthma, allergy, emphysema, and psoriasis.  
     [2158] CX. CG59619-01: Actin, Cytoplasmic 2  
     [2159] Expression of gene CG59619-01 was assessed using the primer-probe set Ag3498, described in Table CXA. Results of the RTQ-PCR runs are shown in Tables CXB and CXC.  
               TABLE CXA                          Probe Name Ag3498                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tgatatggacatccccaaag-3′   20   860   710               Probe   TET-5′-acctgtacgccaacacagtgctgtct-3′-TAMRA   26   880   711               Reverse   5′-atctccttctgcatcctattgg-3′   22   934   712                  
 
     [2160]               TABLE CXB                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3498,       Ag3498,           Run       Run       Tissue Name   217217873   Tissue Name   217217873                                     Adipose   4.7   Renal ca. TK-10   0.0       Melanoma*   0.0   Bladder   3.3       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.0       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   55.1   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   8.7       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   4.9       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   6.6   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   9.5   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   18.3       OVCAR-4       Ovarian ca.   17.9   Small Intestine Pool   26.2       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   7.2       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   2.9   Fetal Heart   6.4       Breast ca. MCF-7   0.0   Heart Pool   11.2       Breast ca. MDA-   0.0   Lymph Node Pool   34.2       MB-231       Breast ca. BT 549   8.4   Fetal Skeletal Muscle   12.9       Breast ca. T47D   2.5   Skeletal Muscle Pool   10.8       Breast ca. MDA-N   0.0   Spleen Pool   4.7       Breast Pool   13.7   Thymus Pool   27.0       Trachea   5.4   CNS cancer   0.0               (glio/astro) U87-MG       Lung   7.0   CNS cancer   2.2               (glio/astro) U-118-MG       Fetal Lung   7.9   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   3.1   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio) SF-   0.0               295       Lung ca. A549   0.0   Brain (Amygdala)   12.9               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   3.2       Lung ca. NCI-H23   0.0   Brain (fetal)   12.9       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   6.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   4.9       Lung ca. NCI-H522   0.0   Brain (Substantia   26.6               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   37.9       Fetal Liver   0.0   Brain (whole)   0.0       Liver ca. HepG2   0.0   Spinal Cord Pool   0.0       Kidney Pool   100.0   Adrenal Gland   0.0       Fetal Kidney   4.4   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   6.5               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   6.3                    
     [2161]               TABLE CXC                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3498, Run       Ag3498, Run       Tissue Name   169839576   Tissue Name   169839576                                     Secondary Th1 act   78.5   HUVEC IL-1beta   11.3       Secondary Th2 act   17.0   HUVEC IFN gamma   12.4       Secondary Tr1 act   17.9   HUVEC TNF alpha +   15.7               IFN gamma       Secondary Th1 rest   5.2   HUVEC TNF alpha +   12.5               IL4       Secondary Th2 rest   7.0   HUVEC IL-11   5.4       Secondary Tr1 rest   5.5   Lung Microvascular EC   17.2               none       Primary Th1 act   14.8   Lung Microvascular EC   7.6               TNF alpha + IL-1beta       Primary Th2 act   16.0   Microvascular Dermal   8.1               EC none       Primary Tr1 act   13.3   Microsvasular Dermal   8.0               EC TNF alpha + IL-1beta       Primary Th1 rest   8.2   Bronchial epithelium   5.3               TNF alpha + IL 1beta       Primary Th2 rest   7.1   Small airway epithelium   4.3               none       Primary Tr1 rest   8.1   Small airway epithelium   6.4               TNF alpha + IL-1beta       CD45RA CD4   15.8   Coronery artery SMC rest   5.8       lymphocyte act       CD45RO CD4   15.9   Coronery artery SMC   5.9       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   19.6   Astrocytes rest   6.2       Secondary CD8   14.0   Astrocytes TNF alpha +   4.6       lymphocyte rest       IL-1beta       Secondary CD8   9.7   KU-812 (Basophil) rest   34.4       lymphocyte act       CD4 lymphocyte none   4.3   KU-812 (Basophil)   31.9               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   6.1   CCD1106   28.9       CD95 CH11       (Keratinocytes) none       LAK cells rest   12.6   CCD1106   34.2               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   9.9   Liver cirrhosis   1.4       LAK cells IL-2 + IL-12   12.6   NCI-H292 none   9.3       LAK cells IL-2 + IFN   9.4   NCI-H292 IL-4   13.1       gamma       LAK cells IL-2 + IL-18   12.5   NCI-H292 IL-9   17.7       LAK cells   13.9   NCI-H292 IL-13   13.6       PMA/ionomycin       NK Cells IL-2 rest   15.5   NCI-H292 IFN gamma   22.2       Two Way MLR 3 day   13.0   HPAEC none   4.4       Two Way MLR 5 day   14.4   HPAEC TNF alpha + IL-   12.4               1beta       Two Way MLR 7 day   8.8   Lung fibroblast none   5.7       PBMC rest   6.6   Lung fibroblast TNF   14.6               alpha + IL-1beta       PBMC PWM   16.8   Lung fibroblast IL-4   8.8       PBMC PHA-L   15.1   Lung fibroblast IL-9   13.0       Ramos (B cell) none   13.0   Lung fibroblast IL-13   10.2       Ramos (B cell)   11.4   Lung fibroblast IFN   17.8       ionomycin       gamma       B lymphocytes PWM   13.7   Dermal fibroblast   9.8               CCD1070 rest       B lymphocytes CD40L   13.8   Dermal fibroblast   10.8       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   11.1   Dermal fibroblast   11.2               CCD1070 IL-1beta       EOL-1 dbcAMP   100.0   Dermal fibroblast IFN   19.8       PMA/ionomycin       gamma       Dendritic cells none   14.4   Dermal fibroblast IL-4   9.7       Dendritic cells LPS   9.8   Dermal Fibroblast rest   7.7       Dendritic cells anti-   13.2   Neutrophils TNFa + LPS   0.7       CD40       Monocytes rest   8.9   Neutrophils rest   1.1       Monocytes LPS   32.5   Colon   4.4       Macrophages rest   12.6   Lung   5.1       Macrophages LPS   17.3   Thymus   7.3       HUVEC none   6.2   Kidney   4.9       HUVEC starved   10.0                    
     [2162] CNS_neurodegeneration_v1.0 Summary: Ag3498 Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2163] General_screening_panel_v1.4 Summary: Ag3498 The CG59619-01 gene is only expressed at detectable levels in the adult kidney (CT=34.2). Thus, expression of this gene can be used to distinguish kidney from the other samples on this panel. In addition, expression of this gene is much lower in fetal kidney (CT=38.7), suggesting that this gene can be used to distinguish between the fetal and adult source of this tissue. Furthermore, this gene is not expressed at detectable levels in renal cancer cell lines. Therefore, therapeutic modulation of this gene may be of use in the treatment of renal cell carcinoma.  
     [2164] Panel 4.1D Summary: Ag3498 Expression of the CG59619-01 gene is highest in activated eosinophils (CT=25.7), displaying 10-fold upregulation when compared to the control eosinophils. Therefore, therapies designed with the protein encoded for by this gene could block or inhibit inflammation or tissue damage due to eosinophil activation in response to asthma, ulcerative colitis and parasitic diseases.  
     [2165] The CG59619-01 gene is expressed at moderate levels in the majority of samples on this panel, including T cells, B cells, endothelial cells, macrophages, monocytes, dendritic cells, basophils and peripheral blood mononuclear cells, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [2166] CY. CG59621-01: Selenide, Water Dikinase 1  
     [2167] Expression of gene CG59621-01 was assessed using the primer-probe set Ag3764, described in Table CYA.  
               TABLE CYA                          Probe Name Ag3764                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-catgttcagcctcatgcat-3′   19   925   713               Probe   TET-5′-agacctcaggcggccttctgatct-3′-TAMRA   24   957   714               Reverse   5′-ctgcttgctgacatggtaaac-3′   21   981   715                  
 
     [2168] General_screening_panel_v1.4 Summary: Ag3764 Results from one experiment with the CG59621-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [2169] Panel 4.1D Summary: Ag3764 Expression of this gene is low/undetectable (CTs&gt;35) across all of the samples on this panel (data not shown).  
     [2170] CZ. CG59625-01: Glucose Transporter Type 3  
     [2171] Expression of gene CG59625-01 was assessed using the primer-probe set Ag3499, described in Table CZA. Results of the RTQ-PCR runs are shown in Tables CZB and CZC.  
               TABLE CZA                          Probe Name Ag3499                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cttcccctctgctgcttactat-3′   22   1298   716               Probe   TET-5′-ttttattatcttcaccggcttcctca-3′-TAMRA   26   1334   717               Reverse   5′-gaaggtaaaggccaagaaggta-3′   22   1361   718                  
 
     [2172]               TABLE CZB                          CNS_neurodegeneration_v1.0                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3499,   Ag3499,           Run       Run       Tissue Name   210935864   Tissue Name   210935864                                     AD 1 Hippo   5.8   Control (Path) 3   4.9               Temporal Ctx       AD 2 Hippo   25.9   Control (Path) 4   32.3               Temporal Ctx       AD 3 Hippo   5.8   AD 1 Occipital   11.6               Ctx       AD 4 Hippo   1.5   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   100.0   AD 3 Occipital   5.1               Ctx       AD 6 Hippo   29.7   AD 4 Occipital   4.5               Ctx       Control 2 Hippo   31.9   AD 5 Occipital   39.2               Ctx       Control 4 Hippo   0.0   AD 6 Occipital   72.2               Ctx       Control (Path) 3   6.6   Control 1 Occipital   13.5       Hippo       Ctx       AD 1 Temporal Ctx   7.0   Control 2 Occipital   82.4               Ctx       AD 2 Temporal Ctx   49.3   Control 3 Occipital   8.8               Ctx       AD 3 Temporal Ctx   2.9   Control 4 Occipital   0.0               Ctx       AD 4 Temporal Ctx   5.6   Control (Path) 1   64.6               Occipital Ctx       AD 5 Inf Temporal   83.5   Control (Path) 2   4.0       Ctx       Occipital Ctx       AD 5 SupTemporal   37.6   Control (Path) 3   4.0       Ctx       Occipital Ctx       AD 6 Inf Temporal   23.0   Control (Path) 4   13.2       Ctx       Occipital Ctx       AD 6 Sup Temporal   24.8   Control 1 Parietal   9.9       Ctx       Ctx       Control 1 Temporal   11.0   Control 2 Parietal   33.2       Ctx       Ctx       Control 2 Temporal   50.7   Control 3 Parietal   12.1       Ctx       Ctx       Control 3 Temporal   6.0   Control (Path) 1   57.8       Ctx       Parietal Ctx       Control 4 Temporal   0.1   Control (Path) 2   25.2       Ctx       Parietal Ctx       Control (Path) 1   28.9   Control (Path) 3   5.6       Temporal Ctx       Parietal Ctx       Control (Path) 2   13.9   Control (Path) 4   60.3       Temporal Ctx       Parietal Ctx                    
     [2173]               TABLE CZC                          Panel 4D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3499, Run       Ag3499, Run       Tissue Name   166441940   Tissue Name   166441940                                     Secondary Th1 act   12.1   HUVEC IL-1beta   0.1       Secondary Th2 act   3.2   HUVEC IFN gamma   3.2       Secondary Tr1 act   3.6   HUVEC TNF alpha +   0.1               IFN gamma       Secondary Th1 rest   7.5   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   5.3   HUVEC IL-11   0.9       Secondary Tr1 rest   6.0   Lung Microvascular EC   2.0               none       Primary Th1 act   2.4   Lung Microvascular EC   1.2               TNF alpha + IL-1beta       Primary Th2 act   7.5   Microvascular Dermal   0.1               EC none       Primary Tr1 act   10.1   Microsvasular Dermal   0.1               EC TNF alpha + IL-1beta       Primary Th1 rest   14.9   Bronchial epithelium   0.3               TNF alpha + IL-1beta       Primary Th2 rest   5.1   Small airway epithelium   0.3               none       Primary Tr1 rest   5.8   Small airway epithelium   1.9               TNF alpha + IL1beta       CD45RA CD4   2.9   Coronery artery SMC rest   2.4       lymphocyte act       CD45RO CD4   12.3   Coronery artery SMC   1.3       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   4.1   Astrocytes rest   0.3       Secondary CD8   4.3   Astrocytes TNF alpha +   0.5       lymphocyte rest       IL-1beta       Secondary CD8   2.9   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   3.2   KU-812 (Basophil)   0.3               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   6.4   CCD1106   1.9       CD95 CH11       (Keratinocytes) none       LAK cells rest   8.9   CCD1106   30.6               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   14.1   Liver cirrhosis   19.2       LAK cells IL-2 + IL-12   7.1   Lupus Kidney   1.5       LAK cells IL-2 + IFN   8.2   NCI-H292 none   0.5       gamma       LAK cells IL-2 + IL-18   6.3   NCI-H292 IL-4   0.8       LAK cells   100.0   NCI-H292 IL-9   0.2       PMA/ionomycin       NK Cells IL-2 rest   4.8   NCI-H292 IL-13   0.3       Two Way MLR 3 day   7.4   NCI-H292 IFN gamma   0.2       Two Way MLR 5 day   7.6   HPAEC none   1.7       Two Way MLR 7 day   3.8   HPAEC TNF alpha + IL-   1.5               1beta       PBMC rest   0.1   Lung fibroblast none   3.2       PBMC PWM   10.9   Lung fibroblast TNF   2.7               alpha + IL-1beta       PBMC PHA-L   9.2   Lung fibroblast IL-4   4.7       Ramos (B cell) none   0.3   Lung fibroblast IL-9   2.4       Ramos (B cell)   0.2   Lung fibroblast IL-13   3.0       ionomycin       B lymphocytes PWM   3.8   Lung fibroblast IFN   5.5               gamma       B lymphocytes CD40L   2.6   Dermal fibroblast   3.7       and IL-4       CCD1070 rest       EOL-1 dbcAMP   0.1   Dermal fibroblast   15.1               CCD1070 TNF alpha       EOL-1 dbcAMP   0.6   Dermal fibroblast   2.5       PMA/ionomycin       CCD1070 IL-1beta       Dendritic cells none   30.4   Dermal fibroblast IFN   0.1               gamma       Dendritic cells LPS   14.2   Dermal fibroblast IL-4   0.1       Dendritic cells anti-   15.1   IBD Colitis 2   0.0       CD40       Monocytes rest   5.8   IBD Crohn&#39;s   1.1       Monocytes LPS   12.1   Colon   3.3       Macrophages rest   0.3   Lung   7.9       Macrophages LPS   12.9   Thymus   0.6       HUVEC none   0.1   Kidney   9.4       HUVEC starved   0.1                    
     [2174] CNS_neurodegeneration_v1.0 Summary: Ag3499 This panel confirms the expression of this gene at moderate levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [2175] Panel 4D Summary: Ag3499 Expression of the CG59625-01 gene is highest in PMA/ionomycin-treated lymphokine activated killer (LAK) cells (CT=24.3). Since these cells are involved in tumor immunology and tumor cell clearance, as well as virally and bacterial infected cells, therapeutic modulation of this gene product may alter the functions of these cells and lead to improvement in cancer cell killing as well as host immunity to microbial and viral infections.  
     [2176] This gene is also expressed at high levels in stimulated keratinocytes, dendritic cells, monocytes and macrophages, suggesting that small molecule therapeutics designed against the CG59625-01 protein could reduce or inhibit inflammation in asthma, emphysema, allergy, psoriasis, arthritis, or any other condition in which localizalion/activation of these cell types is important.  
     [2177] This gene is also expressed at moderate levels in a number of other cell types of significance in the immune response in health and disease.  
     [2178] DA. CG59887-01 and CG59887-02: Amino Acid/Metabolite Permease  
     [2179] Expression of gene CG59887-01 and full length clone CG59887-02 was assessed using the primer-probe set Ag4715, described in Table DAA. Please note that CG59887-02 represents a full-length physical clone of the CG59887-02 gene, validating the prediction of the gene sequence.  
               TABLE DAA                          Probe Name Ag4715                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-cgtgttgtggtggttgtttt-3′   20   1362   719               Probe   TET-5′-actgcgcacgcgccttaacaatg-3′-TAMRA   23   1383   720               Reverse   5′-ggctagtggtcgagcaattt-3′   20   1426   721                  
 
     [2180] General_screening_panel_v1.4 Summary: Ag4715 Expression of the CG59887-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure.  
     [2181] DB. CG59857-01: Rhotekin  
     [2182] Expression of gene CG59857-01 was assessed using the primer-probe set Ag3622, described in Table DBA. Results of the RTQ-PCR runs are shown in Tables DBB, DBC and DBD.  
               TABLE DBA                          Probe Name Ag3622                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-acatcctggaggacctgaatat-3′   22   84   722               Probe   TET-5′-ctctacattcggcagatggcactcag-3′-TAMRA   26   107   723               Reverse   5′-ggatctcatggtctagcttcct-3′   22   155   724                  
 
     [2183]               TABLE DBB                          CNS_neurodegeneration_v1.0                                 Rel.       Rel.           Exp. (%)       Exp. (%)           Ag3622,       Ag3622,           Run       Run       Tissue Name   211005293   Tissue Name   211005293                                     AD 1 Hippo   10.7   Control (Path) 3   3.9               Temporal Ctx       AD 2 Hippo   42.9   Control (Path) 4   9.2               Temporal Ctx       AD 3 Hippo   6.9   AD 1 Occipital Ctx   10.1       AD 4 Hippo   13.2   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   40.6   AD 3 Occipital Ctx   7.1       AD 6 Hippo   38.4   AD 4 Occipital Ctx   23.3       Control 2 Hippo   29.9   AD 5 Occipital Ctx   28.5       Control 4 Hippo   13.6   AD 6 Occipital Ctx   0.1       Control (Path) 3   0.8   Control 1 Occipital   4.9       Hippo       Ctx       AD 1 Temporal   17.8   Control 2 Occipital   51.4       Ctx       Ctx       AD 2 Temporal   27.7   Control 3 Occipital   12.2       Ctx       Ctx       AD 3 Temporal   6.3   Control 4 Occipital   8.2       Ctx       Ctx       AD 4 Temporal   19.5   Control (Path) 1   58.6       Ctx       Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   10.2       Ctx       Occipital Ctx       AD 5 Sup   47.3   Control (Path) 3   5.7       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   49.0   Control (Path) 4   7.9       Ctx       Occipital Ctx       AD 6 Sup   29.7   Control 1 Parietal   7.6       Temporal Ctx       Ctx       Control 1   5.6   Control 2 Parietal   44.4       Temporal Ctx       Ctx       Control 2   34.9   Control 3 Parietal   16.2       Temporal Ctx       Ctx       Control 3   13.7   Control (Path) 1   32.1       Temporal Ctx       Parietal Ctx       Control 3   8.2   Control (Path) 2   15.6       Temporal Ctx       Parietal Ctx       Control (Path) 1   18.8   Control (Path) 3   2.4       Temporal Ctx       Parietal Ctx       Control (Path) 2   16.0   Control (Path) 4   17.6       Temporal Ctx       Parietal Ctx                    
     [2184]               TABLE DBC                          General_screening_panel_v1.4                                         Rel. Exp. (%)   Rel. Exp. (%)       Rel. Exp. (%)   Rel. Exp. (%)           Ag3622, Run   Ag3622, Run       Ag3622, Run   Ag3622, Run                                             Tissue Name   218211380   218307304   Tissue Name   218211380   218307304       Adipose   0.7   1.1   Renal ca. TK-10   4.7   4.0       Melanoma*   4.6   7.6   Bladder   10.2   3.5       Hs688(A).T       Melanoma*   7.2   6.4   Gastric ca. (liver   6.0   9.0       Hs688(B).T           met.) NCI-N87       Melanoma*   29.9   37.9   Gastric ca.   7.8   7.7       M14           KATO III       Melanoma*   15.1   17.2   Colon ca. SW-   1.9   1.3       LOXIMVI           948       Melanoma*   19.3   22.7   Colon ca.   11.0   15.1       SK-MEL-5           SW480       Squamous   0.4   1.5   Colon ca.*   5.9   10.4       cell           (SW480 met)       carcinoma           SW620       SCC-4       Testis Pool   2.0   1.7   Colon ca. HT29   5.4   6.8       Prostate ca.*    3.3   3.4   Colon ca. HCT-   5.6   6.7       (bone met)           116       PC-3       Prostate Pool   0.8   2.3   Colon ca. CaCo-2   4.2   3.2       Placenta   2.2   3.0   Colon cancer   2.3   3.5                   tissue       Uterus Pool   0.8   0.7   Colon ca.    1.1   2.9                   SW1116       Ovarian ca.   19.5   18.7   Colon ca. Colo-   1.0   0.3       OVCAR-3           205       Ovarian ca.   9.0   8.0   Colon ca. SW-48   1.2   1.2       SK-OV-3       Ovarian ca.   1.1   2.2   Colon Pool   16.0   5.8       OVCAR-4       Ovarian ca.   6.4   9.0   Small Intestine   1.7   3.3       OVCAR-5           Pool       Ovarian ca.   10.7   10.7   Stomach Pool   2.7   3.8       IGROV-1       Ovarian ca.   7.1   20.3   Bone Marrow   1.2   1.8       OVCAR-8           Pool       Ovary   3.2   4.3   Fetal Heart   5.1   6.5       Breast ca.   1.1   1.4   Heart Pool   1.5   3.0       MCF-7       Breast ca.   8.8   10.9   Lymph Node   4.9   6.5       MDA-MB-           Pool       231       Breast ca. BT   4.7   8.4   Fetal Skeletal   69.7   11.3       549           Muscle       Breast ca.   17.0   15.2   Skeletal Muscle   2.7   1.5       T47D           Pool       Breast ca.   23.8   21.0   Spleen Pool   2.8   1.8       MDA-N       Breast Pool   4.4   5.0   Thymus Pool   2.8   5.9       Trachea   3.8   5.8   CNS cancer   17.7   25.0                   (glio/astro) U87-                   MG       Lung   0.7   0.8   CNS cancer   46.0   57.4                   (glio/astro) U-                   118-MG       Fetal Lung   8.2   9.3   CNS cancer   26.8   35.6                   (neuro; met) SK-                   N-AS       Lung ca.   0.4   0.5   CNS cancer   9.7   9.8       NCI-N417           (astro) SF-539       Lung ca. LX-1   9.3   10.7   CNS cancer   22.5   34.4                   (astro) SNB-75       Lung ca.   8.4   6.7   CNS cancer   9.0   13.0       NCI-H146           (glio) SNB-19       Lung ca.   7.4   6.4   CNS cancer   33.2   37.1       SHP-77           (glio) SF-295       Lung ca.   13.3   23.3   Brain   86.5   82.9       A549           (Amygdala) Pool       Lung ca.   1.3   1.4   Brain   22.5   30.8       NCI-H526           (cerebellum)       Lung ca.   5.1   6.0   Brain (fetal)   5.1   6.5       NCI-H23       Lung ca.    5.2   4.9   Brain   45.4   52.1       NCI-H460           (Hippocampus)                   Pool       Lung ca.   5.1   7.4   Cerebral Cortex   27.4   40.3       HOP-62           Pool       Lung ca.   6.7   9.8   Brain (Substantia   46.7   54.7       NCI-H522           nigra) Pool       Liver   0.5   0.9   Brain   51.4   90.1                   (Thalamus) Pool       Fetal Liver   1.7   1.5   Brain (whole)   23.8   32.8       Liver ca.   2.9   4.5   Spinal Cord Pool   100.0   100.0       HepG2       Kidney Pool   5.3   6.4   Adrenal Gland   1.5   3.5       Fetal Kidney   7.0   11.7   Pituitary gland   0.3   2.5                   Pool       Renal ca.   2.8   3.0   Salivary Gland   1.4   3.2       786-0       Renal ca.   4.9   5.6   Thyroid (female)   2.8   2.1       A498       Renal ca.   4.2   4.0   Pancreatic ca.   1.7   0.6       ACHN           CAPAN2       Renal ca.   10.4   7.7   Pancreas Pool   5.2   6.2       UO-31                    
     [2185]               TABLE DBD                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3622, Run       Ag3622, Run       Tissue Name   169944131   Tissue Name   169944131                                     Secondary Th1 act   0.0   HUVEC IL-1beta   14.7       Secondary Th2 act   2.9   HUVEC IFN gamma   25.2       Secondary Tr1 act   7.3   HUVEC TNF alpha +   2.5               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   5.8               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   19.2       Secondary Tr1 rest   0.0   Lung Microvascular EC   49.0               none       Primary Th1 act   6.5   Lung Microvascular EC   11.3               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   7.7               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   10.9               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   21.5               TNF alpha + IL1beta       Primary Th2 rest   0.0   Small airway epithelium   7.2               none       Primary Tr1 rest   0.0   Small airway epithelium   27.9               TNF alpha + IL-1beta       CD45RA CD4   0.8   Coronery artery SMC rest   22.5       lymphocyte act       CD45RO CD4   3.5   Coronery artery SMC   31.4       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   1.8   Astrocytes rest   17.0       Secondary CD8   1.6   Astrocytes TNF alpha +   25.3       lymphocyte rest       IL-1beta       Secondary CD8   0.2   KU-812 (Basophil) rest   8.0       lymphocyte act       CD4 lymphocyte none   0.0   KU-812 (Basophil)   3.4               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   4.2   CCD1106   44.8       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.4   CCD1106   61.6               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   6.0   Liver cirrhosis   0.0       LAK cells IL-2 + IL-12   0.0   NCI-H292 none   5.3       LAK cells IL-2 + IFN   1.5   NCI-H292 IL-4   9.9       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-9   14.4       LAK cells   0.0   NCI-H292 IL-13   1.4       PMA/ionomycin       NK Cells IL-2 rest   13.9   NCI-H292 IFN gamma   11.4       Two Way MLR 3 day   3.6   HPAEC none   20.9       Two Way MLR 5 day   3.8   HPAEC TNF alpha + IL-   10.2               1beta       Two Way MLR 7 day   0.0   Lung fibroblast none   38.2       PBMC rest   1.7   Lung fibroblast TNF   25.0               alpha + IL-1beta       PBMC PWM   3.6   Lung fibroblast IL-4   35.8       PBMC PHA-L   1.3   Lung fibroblast IL-9   100.0       Ramos (B cell) none   0.2   Lung fibroblast IL-13   69.7       Ramos (B cell)   1.1   Lung fibroblast IFN   58.2       ionomycin       gamma       B lymphocytes PWM   0.5   Dermal fibroblast   39.2               CCD1070 rest       B lymphocytes CD40L   7.9   Dermal fibroblast   5.7       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   17.4               CCD1070 IL-1beta       EOL-1 dbcAMP   0.0   Dermal fibroblast IFN   31.2       PMA/ionomycin       gamma       Dendritic cells none   9.9   Dermal fibroblast IL-4   44.8       Dendritic cells LPS   2.4   Dermal Fibroblasts rest   19.1       Dendritic cells anti-   24.7   Neutrophils TNFa + LPS   0.0       CD40       Monocytes rest   0.0   Neutrophils rest   0.0       Monocytes LPS   6.3   Colon   10.3       Macrophages rest   8.8   Lung   13.6       Macrophages LPS   3.4   Thymus   2.4       HUVEC none   11.1   Kidney   23.8       HUVEC starved   28.5                    
     [2186] CNS_neurodegeneration_v1.0 Summary: Ag3622 This panel confirms the expression of the CG59857-01 gene at significant levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [2187] General_screening_panel_v1.4 Summary: Ag3622 Two experiments with the same probe and primer set show highest expression of the CG59857-01 gene in spinal cord samples (CTs=26-28). In addition, high levels of expression of this gene are seen in brain derived tissue, including samples from amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and CNS cancer cell lines. Therefore, expression of this gene could be used to distinguish between brain derived samples and other samples used in this panel. Furthermore, this gene may play a role in central nervous system disorders such as Alzheinier&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2188] Significant expression is also detected in fetal skeletal muscle (CTs=27-31). Interestingly, this gene is expressed at much higher levels in fetal when compared to adult skeletal muscle (CTs=32-34). This observation suggests that expression of this gene can be used to distinguish fetal from adult skeletal muscle. In addition, the relative overexpression of this gene in fetal skeletal muscle suggests that the protein product may enhance muscular growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of muscle related diseases. More specifically, treatment of weak or dystrophic muscle with the protein encoded by this gene could restore muscle mass or function.  
     [2189] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [2190] Panel 4.1D Summary: Ag3622 Highest expression of the CG59857-01 gene is seen in IL-9/IL-13 treated lung fibroblasts (CT=31). In addition, significant expression is seen in clusters of treated and untreated lung and dermal fibroblasts, epithelium and endothelium. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, and psoriasis.  
     [2191] DC. CG59855-01 and CG59855-02: ATP Synthase Subunit C  
     [2192] Expression of gene CG59855-01 and full length clone CG59855-02 was assessed using the primer-probe set Ag3621, described in Table DCA. Results of the RTQ-PCR runs are shown in Tables DCB and DCC. Please note that CG59855-02 represents a full-length physical clone of the CG59855-02 gene, validating the prediction of the gene sequence.  
               TABLE DCA                          Probe Name Ag3621                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gggtctaatcaggcctgtgt-3′   20   73   725               Probe   TET-5′-tgccttctccttgaatagcccagaga-3′-TAMRA   26   94   726               Reverse   5′-ctgctgtaggaaggctgtttag-3′   22   126   727                  
 
     [2193]               TABLE DCB                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3621,       (%) Ag3621,           Run       Run       Tissue Name   217702346   Tissue Name   217702346                                     Adipose   0.0   Renal ca. TK-10   0.0       Melanoma*   0.0   Bladder   7.5       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.0       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   35.1   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   3.5   Colon ca. CaCo-2   0.0       Placenta   2.9   Colon cancer tissue   0.0       Uterus Pool   5.9   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   47.6   Colon ca. SW-48   0.0       OV-3       Ovarian ca.   0.0   Colon Pool   57.0       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   42.9       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   7.5       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   7.0       OVCAR-8       Ovary   12.9   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   0.0   Lymph Node Pool   8.1       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   13.2       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   27.4       Breast Pool   49.0   Thymus Pool   25.9       Trachea   46.3   CNS cancer   0.0               (glio/astro) U87-MG       Lung   38.4   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   100.0   CNS cancer   0.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio)   0.0               SF-295       Lung ca. A549   0.0   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   6.7   Brain (fetal)   0.0       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   0.0   Brain (Substantia   0.0               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   0.0       Fetal Liver   0.0   Brain (whole)   0.0       Liver ca. HepG2   0.0   Spinal Cord Pool   6.1       Kidney Pool   57.8   Adrenal Gland   0.0       Fetal Kidney   10.7   Pituitary gland Pool   12.4       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.0       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   63.3                    
     [2194]               TABLE DCC                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3621, Run       Ag3621, Run       Tissue Name   169944096   Tissue Name   169944096                                     Secondary Th1 act   1.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   1.0       Secondary Tr1 act   16.5   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   7.5   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   2.6   HUVEC IL-11   7.8       Secondary Tr1 rest   0.0   Lung Microvascular EC   1.0               none       Primary Th1 act   0.0   Lung Microvascular EC   6.7               TNF alpha + IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microsvasular Dermal   0.0               EC TNF alpha + IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNF alpha + IL-1beta       Primary Th2 rest   1.5   Small airway epithelium   0.0               none       Primary Tr1 rest   0.0   Small airway epithelium   0.0               TNF alpha + IL-1beta       CD45RA CD4   0.0   Coronery artery SMC rest   0.0       lymphocyte act       CD45RO CD4   0.0   Coronery artery SMC   0.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   1.1       Secondary CD8   0.0   Astrocytes TNF alpha +   0.9       lymphocyte rest       IL-1beta       Secondary CD8   0.0   KU-812 (Basophil) rest   0.0       lymphocyte act       CD4 lymphocyte none   8.6   KU-812 (Basophil)   0.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   0.0   CCD1106   0.0       CD95 CH11       (Keratinocytes) none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   0.0       LAK cells IL-2 + IL-12   0.0   NCI-H292 none   4.5       LAK cells IL-2 + IFN   0.0   NCI-H292 IL-4   0.0       gamma       LAK cells IL-2 + IL-18   0.0   NCI-H292 IL-9   1.5       LAK cells   2.3   NCI-H292 IL-13   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR 3 day   1.3   HPAEC none   2.9       Two Way MLR 5 day   0.0   HPAEC TNF alpha + IL-   2.3               1beta       Two Way MLR 7 day   0.9   Lung fibroblast none   5.1       PBMC rest   1.0   Lung fibroblast TNF   0.0               alpha + IL-1beta       PBMC PWM   0.0   Lung fibroblast IL-4   0.0       PBMC PHA-L   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-13   0.0       Ramos (B cell)   0.0   Lung fibroblast IFN   0.0       ionomycin       gamma       B lymphocytes PWM   0.0   Dermal fibroblast   9.0               CCD1070 rest       B lymphocytes CD40L   0.0   Dermal fibroblast   1.1       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 IL-1beta       EOL-1 dbcAMP   0.0   Dermal fibroblast IFN   0.0       PMA/ionomycin       gamma       Dendritic cells none   2.0   Dermal fibroblast IL-4   2.8       Dendritic cells LPS   17.6   Dermal Fibroblasts rest   0.0       Dendritic cells anti-   2.7   Neutrophils TNFa + LPS   0.0       CD40       Monocytes rest   100.0   Neutrophils rest   20.0       Monocytes LPS   6.1   Colon   0.8       Macrophages rest   2.8   Lung   0.0       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   0.0   Kidney   9.3       HUVEC starved   0.0                    
     [2195] CNS_neurodegeneration_v1.0 Summary: Ag3621 Expression of the CG59855-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [2196] General_screening_panel_v1.4 Summary: Ag3621 Expression of the CG59855-01 gene is restricted to samples from fetal lung and adult pancrease(CTs=34.5-35). Thus, expression of this gene can be used to distinguish this sample from other samples in the panel.  
     [2197] The CG59855-01 gene encodes a homologue of ATP synthase subunit c, mitochondrial precursor. Subunit c is an intrinsic membrane component of ATP synthase, and in mammals it is encoded by two expressed nuclear genes, P1 and P2. Both genes encode the same mature c subunit, but the mitochondrial import pre-sequences in the precursors of subunit c are different (ref. 1). Each ATP synthase complex has multiple copies of subunit C. The mitochondrial ATP synthase uses energy derived from a proton gradient to synthesize ATP. The structure of this complex has been referred to as a ‘lollipop,’ as the soluble F1 catalytic unit is attached to the mitochondrial inner membrane via the F0 unit containing subunit c. F0 subunit C transports protons across the mitochondrial inner membrane to the F1-ATPase (ref. 2).  
     [2198] Subunit C of the F0 region of the ATP synthase complex of the inner mitochondrial membrane is found in high concentrations in lysosomes in late infantile neuronal ceroid lipofuscinosis (Batten&#39;s disease). Kominami et al. (1995, Ref 3) found marked delay of degradation of subunit C in patient fibroblasts with no significant differences between control and patient cells with regard to degradation of cytochrome oxidase subunit IV. Furthermore, accumulation of labeled subunit C in the mitochondrial fraction was detected before Lysosomal appearance of the radiolabeled subunit, suggesting to the authors a specific failure in the degradation of subunit C after its normal inclusion in mitochondria and its consequent accumulation in lysosomes. Jolly (1995, ref 4) reported that subunit C represents more than 50% of the accumulated metabolites in the ovine form of the disease and also accumulates significantly in late infantile and juvenile forms of the human disease and several other animal forms. The author suggested that the extreme hydrophobicity and lipophilicity of subunit C may be in part responsible.  
     REFERENCES  
     [2199] 1. Dyer M R, Walker J E. (1993) Sequences of members of the human gene family for the c subunit of mitochondrial ATP synthase. Biochem J 293 (Pt 1):51-64  
     [2200] 2. OMIM 603192  
     [2201] 3. Kominami E, Ezaki J, Wolfe L S. (1995) New insight into lysosomal protein storage disease: delayed catabolism of ATP synthase subunit c in Batten disease. Neuroctiem Res 20(11):1305-9  
     [2202] 4. Jolly R D. (1995) Batten disease (ceroid-lipofuscinosis): the enigma of subunit c of mitochondrial ATP synthase accumulation. Neurochem Res 20(11):1301-4  
     [2203] Panel 4.1D Summary: Ag3621 Expression of the CG59855-01 gene is exclusively seen in resting monocytes (CT=32). Thus, expression of this gene can be used to distinguish this sample from other samples in the panel. In addition, expression of this gene in monocytes suggests a role for the gene product in their function as antigen-presenting cells. This suggests that antibodies or small molecule therapeutics that block the function of this protein nay be useful as anti-inflammatory therapeutics for the treatment of autoimmune and inflammatory diseases and for the treatment of immunosupressed individuals.  
     [2204] DD. CG59807-01: Nuclear Hormone Receptor/Zinc Finger  
     [2205] Expression of gene CG59807-01 was assessed using the primer-probe set Ag3591, described in Table DDA. Results of the RTQ-PCR runs are shown in Tables DDB and DDC.  
                   TABLE DDA                          Probe Name Ag3591                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:                                             Forward   5′-cactgctccacttttgtcttg-3′   21   1195   728                   Probe   TET-5′-cataaaaggacccacacaggagaaaa-3′-TAMRA   26   1216   729               Reverse   5′-cttttccacattctttgcattc-3′   22   1249   730                  
 
     [2206]               TABLE DDB                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3591,       (%) Ag3591,           Run       Run       Tissue Name   217479278   Tissue Name   217479278                                     Adipose   13.9   Renal ca. TK-10   22.2       Melanoma*   18.6   Bladder   27.5       Hs688(A).T       Melanoma*   17.6   Gastric ca. (liver met.)   100.0       Hs688(B).T       NCI-N87       Melanoma* M14   22.8   Gastric ca. KATO III   63.7       Melanoma*   12.5   Colon ca. SW-948   4.9       LOXIMVI       Melanoma* SK-   10.4   Colon ca. SW480   41.2       MEL-5       Squamous cell   27.9   Colon ca.* (SW480   17.1       carcinoma SCC-4       met) SW620       Testis Pool   14.9   Colon ca. HT29   19.3       Prostate ca.* (bone   51.4   Colon ca. HCT-116   52.9       met) PC-3       Prostate Pool   12.7   Colon ca. CaCo-2   13.5       Placenta   8.7   Colon cancer tissue   7.4       Uterus Pool   5.0   Colon ca. SW1116   11.3       Ovarian ca.   29.9   Colon ca. Colo-205   8.3       OVCAR-3       Ovarian ca. SK-   49.7   Colon ca. SW-48   3.2       OV-3       Ovarian ca.   9.1   Colon Pool   18.8       OVCAR-4       Ovarian ca.   14.6   Small Intestine Pool   19.2       OVCAR-5       Ovarian ca.   26.2   Stomach Pool   15.1       IGROV-1       Ovarian ca.   14.4   Bone Marrow Pool   7.5       OVCAR-8       Ovary   12.7   Fetal Heart   24.5       Breast ca. MCF-7   9.5   Heart Pool   10.9       Breast ca. MDA-   42.0   Lymph Node Pool   33.9       MB-231       Breast ca. BT 549   66.0   Fetal Skeletal Muscle   24.0       Breast ca. T47D   40.3   Skeletal Muscle Pool   19.9       Breast ca. MDA-N   13.7   Spleen Pool   30.4       Breast Pool   25.5   Thymus Pool   30.6       Trachea   14.5   CNS cancer   19.2               (glio/astro) U87-MG       Lung   14.6   CNS cancer   51.1               (glio/astro) U-118-MG       Fetal Lung   72.7   CNS cancer   49.0               (neuro; met) SK-N-AS       Lung ca. NCI-N417   2.6   CNS cancer (astro)   18.7               SF-539       Lung ca. LX-1   21.2   CNS cancer (astro)   48.6               SNB-75       Lung ca. NCI-H146   24.5   CNS cancer (glio)   26.6               SNB-19       Lung ca. SHP-77   33.7   CNS cancer (glio)   80.1               SF-295       Lung ca. A549   16.6   Brain (Amygdala)   10.6               Pool       Lung ca. NCI-H526   14.7   Brain (cerebellum)   65.5       Lung ca. NCI-H23   35.4   Brain (fetal)   50.0       Lung ca. NCI-H460   33.0   Brain (Hippocampus)   15.3               Pool       Lung ca. HOP-62   10.4   Cerebral Cortex Pool   18.6       Lung ca. NCI-H522   30.6   Brain (Substantia   19.9               nigra) Pool       Liver   2.0   Brain (Thalamus) Pool   26.6       Fetal Liver   21.6   Brain (whole)   25.9       Liver ca. HepG2   16.4   Spinal Cord Pool   16.3       Kidney Pool   27.7   Adrenal Gland   25.0       Fetal Kidney   28.1   Pituitary gland Pool   8.2       Renal ca. 786-0   25.2   Salivary Gland   7.0       Renal ca. A498   12.9   Thyroid (female)   9.2       Renal ca. ACHN   23.5   Pancreatic ca.   12.5               CAPAN2       Renal ca. UO-31   32.1   Pancreas Pool   16.8                    
     [2207]               TABLE DDC                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3591, Run       Ag3591, Run       Tissue Name   169908857   Tissue Name   169908857                                     Secondary Th1 act   38.4   HUVEC IL-1beta   24.7       Secondary Th2 act   37.4   HUVEC IFN gamma   23.5       Secondary Tr1 act   48.6   HUVEC TNF alpha +   17.3               IFN gamma       Secondary Th1 rest   22.7   HUVEC TNF alpha +   20.6               IL4       Secondary Th2 rest   34.9   HUVEC IL-11   19.6       Secondary Tr1 rest   35.1   Lung Microvascular EC   36.6               none       Primary Th1 act   47.0   Lung Microvascular EC   39.5               TNF alpha + IL-1beta       Primary Th2 act   43.5   Microvascular Dermal   22.1               EC none       Primary Tr1 act   50.3   Microsvasular Dermal   21.9               EC TNF alpha + IL-1beta       Primary Th1 rest   43.5   Bronchial epithelium   35.4               TNF alpha + IL-1beta       Primary Th2 rest   40.6   Small airway epithelium   14.0               none       Primary Tr1 rest   51.1   Small airway epithelium   31.0               TNF alpha + IL-1beta       CD45RA CD4   22.2   Coronery artery SMC rest   14.5       lymphocyte act       CD45RO CD4   38.4   Coronery artery SMC   12.0       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   39.8   Astrocytes rest   24.1       Secondary CD8   22.5   Astrocytes TNF alpha +   20.0       lymphocyte rest       IL-1beta       Secondary CD8   31.0   KU-812 (Basophil) rest   57.8       lymphocyte act       CD4 lymphocyte none   15.8   KU-812 (Basophil)   98.6               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   57.8   CCD1106   28.7       CD95 CH11       (Keratinocytes) none       LAK cells rest   28.9   CCD1106   24.1               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   44.4   Liver cirrhosis   8.6       LAK cells IL-2 + IL-12   35.4   NCI-H292 none   40.1       LAK cells IL-2 + IFN   44.8   NCI-H292 IL-4   80.7       gamma       LAK cells IL-2 + IL-18   52.5   NCI-H292 IL-9   79.0       LAK cells   18.3   NCI-H292 IL-13   100.0       PMA/ionomycin       NK Cells IL-2 rest   44.1   NCI-H292 IFN gamma   100.0       Two Way MLR 3 day   42.0   HPAEC none   21.6       Two Way MLR 5 day   25.7   HPAEC TNF alpha + IL-   32.8               1beta       Two Way MLR 7 day   20.4   Lung fibroblast none   28.5       PBMC rest   11.2   Lung fibroblast TNF   13.9               alpha + IL-1beta       PBMC PWM   21.3   Lung fibroblast IL-4   28.1       PBMC PHA-L   24.7   Lung fibroblast IL-9   49.3       Ramos (B cell) none   61.1   Lung fibroblast IL-13   37.9       Ramos (B cell)   66.9   Lung fibroblast IFN   29.5       ionomycin       gamma       B lymphocytes PWM   24.1   Dermal fibroblast   29.9               CCD1070 rest       B lymphocytes CD40L   56.6   Dermal fibroblast   45.1       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   69.7   Dermal fibroblast   11.0               CCD1070 IL-1beta       EOL-1 dbcAMP   54.0   Dermal fibroblast IFN   8.7       PMA/ionomycin       gamma       Dendritic cells none   26.6   Dermal fibroblast IL-4   29.7       Dendritic cells LPS   10.2   Dermal Fibroblast rest   12.2       Dendritic cells anti-   23.2   Neutrophils TNFa + LPS   1.3       CD40       Monocytes rest   12.2   Neutrophils rest   3.3       Monocytes LPS   16.5   Colon   8.8       Macrophages rest   18.6   Lung   33.4       Macrophages LPS   8.1   Thymus   82.9       HUVEC none   17.4   Kidney   23.8       HUVEC starved   27.2                    
     [2208] General_screening_panel_v1.4 Summary: Ag3591 Highest expression of the CG59807-01 gene is detected in the gastric cancer cell line (CT=28). In addition, high expression of this gene is seen in samples derived from CNS cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer cell lines (CTs=28-31). Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.  
     [2209] In addition, expression of this gene is higher in fetal liver (CT=31) as compared to the corresponding adult tissues (CTs=34). Thus, expression of this gene can be used to distinguish between the fetal and adults source of this tissue.  
     [2210] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [2211] This gene is also expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2212] Panel 4.1D Summary: Ag3591 Highest expression of the CG59807-01 gene is detected in treated mucoepidermoid NCI-H292 cells. In addition, this gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [2213] DE. CG59805-01: Nuclear Hormone Receptor/Zinc Finger  
     [2214] Expression of gene CG59805-01 was assessed using the primer-probe set Ag3590, described in Table DEA. Results of the RTQ-PCR runs are shown in Tables DEB, DEC and DED.  
               TABLE DEA                          Probe Name Ag3590                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-atgagtgcagtgaatgtggaa-3′   21   1620   731               Probe   TET-5′-cttcagtcgcagctcgtccctcact-3′-TAMRA   25   1645   732               Reverse   5′-atttctcccagtatgcatcctt-3′   22   1678   733                  
 
     [2215]               TABLE DEB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.       Rel. Exp.           (%) Ag3590,       (%) Ag3590,           Run       Run       Tissue Name   211006692   Tissue Name   211006692                                     AD 1 Hippo   16.7   Control (Path) 3   5.8               Temporal Ctx       AD 2 Hippo   22.1   Control (Path) 4   42.6               Temporal Ctx       AD 3 Hippo   8.2   AD 1 Occipital Ctx   17.7       AD 4 Hippo   7.9   AD 2 Occipital Ctx   0.0               (Missing)       AD 5 Hippo   73.2   AD 3 Occipital Ctx   3.9       AD 6 Hippo   87.7   AD 4 Occipital Ctx   23.3       Control 2 Hippo   25.7   AD 5 Occipital Ctx   32.5       Control 4 Hippo   17.0   AD 6 Occipital Ctx   31.2       Control (Path) 3   7.4   Control 1 Occipital   5.2       Hippo       Ctx       AD 1 Temporal   25.2   Control 2 Occipital   39.2       Ctx       Ctx       AD 2 Temporal   34.2   Control 3 Occipital   20.0       Ctx       Ctx       AD 3 Temporal   10.1   Control 4 Occipital   8.1       Ctx       Ctx       AD 4 Temporal   28.3   Control (Path) 1   80.7       Ctx       Occipital Ctx       AD 5 Inf Temporal   71.7   Control (Path) 2   11.1       Ctx       Occipital Ctx       AD 5 Sup   35.4   Control (Path) 3   6.1       Temporal Ctx       Occipital Ctx       AD 6 Inf Temporal   98.6   Control (Path) 4   17.9       Ctx       Occipital Ctx       AD 6 Sup   100.0   Control 1 Parietal   8.8       Temporal Ctx       Ctx       Control 1   8.2   Control 2 Parietal   39.0       Temporal Ctx       Ctx       Control 2   29.1   Control 3 Parietal   18.3       Temporal Ctx       Ctx       Control 3   17.3   Control (Path) 1   55.5       Temporal Ctx       Parietal Ctx       Control 3   10.2   Control (Path) 2   26.8       Temporal Ctx       Parietal Ctx       Control (Path) 1   50.7   Control (Path) 3   7.4       Temporal Ctx       Parietal Ctx       Control (Path) 2   34.6   Control (Path) 4   46.0       Temporal Ctx       Parietal Ctx                    
     [2216]               TABLE DEC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3590,       (%) Ag3590,           Run       Run       Tissue Name   217474417   Tissue Name   217474417                                     Adipose   12.8   Renal ca. TK-10   28.9       Melanoma*   33.7   Bladder   28.5       Hs688(A).T       Melanoma*   25.3   Gastric ca. (liver met.)   82.4       Hs688(B).T       NCI-N87       Melanoma* M14   16.3   Gastric ca. KATO III   24.5       Melanoma*   19.6   Colon ca. SW-948   5.8       LOXIMVI       Melanoma* SK-   16.5   Colon ca. SW480   28.1       MEL-5       Squamous cell   29.5   Colon ca.* (SW480   10.7       carcinoma SCC-4       met) SW620       Testis Pool   16.0   Colon ca. HT29   13.6       Prostate ca.* (bone   57.4   Colon ca. HCT-116   26.2       met) PC-3       Prostate Pool   14.6   Colon ca. CaCo-2   28.5       Placenta   7.7   Colon cancer tissue   13.0       Uterus Pool   6.0   Colon ca. SW1116   4.8       Ovarian ca.   18.9   Colon ca. Colo-205   3.4       OVCAR-3       Ovarian ca. SK-   38.2   Colon ca. SW-48   2.3       OV-3       Ovarian ca.   15.4   Colon Pool   27.0       OVCAR-4       Ovarian ca.   17.4   Small Intestine Pool   24.1       OVCAR-5       Ovarian ca.   12.2   Stomach Pool   14.3       IGROV-1       Ovarian ca.   12.5   Bone Marrow Pool   11.7       OVCAR-8       Ovary   14.2   Fetal Heart   21.8       Breast ca. MCF-7   29.1   Heart Pool   10.7       Breast ca. MDA-   28.3   Lymph Node Pool   29.5       MB-231       Breast ca. BT 549   100.0   Fetal Skeletal Muscle   10.7       Breast ca. T47D   34.4   Skeletal Muscle Pool   14.7       Breast ca. MDA-N   12.5   Spleen Pool   26.2       Breast Pool   40.6   Thymus Pool   26.8       Trachea   16.3   CNS cancer   32.3               (glio/astro) U87-MG       Lung   4.6   CNS cancer   57.0               (glio/astro) U-118-MG       Fetal Lung   66.4   CNS cancer   33.2               (neuro; met) SK-N-AS       Lung ca. NCI-N417   2.0   CNS cancer (astro)   14.4               SF-539       Lung ca. LX-1   15.9   CNS cancer (astro)   46.7               SNB-75       Lung ca. NCI-H146   3.3   CNS cancer (glio)   14.9               SNB-19       Lung ca. SHP-77   24.5   CNS cancer (glio)   82.9               SF-295       Lung ca. A549   17.2   Brain (Amygdala)   7.2               Pool       Lung ca. NCI-H526   5.4   Brain (cerebellum)   13.2       Lung ca. NCI-H23   26.4   Brain (fetal)   26.8       Lung ca. NCI-H460   22.5   Brain (Hippocampus)   10.3               Pool       Lung ca. HOP-62   10.6   Cerebral Cortex Pool   14.6       Lung ca. NCI-H522   18.9   Brain (Substantia   13.9               nigra) Pool       Liver   1.6   Brain (Thalamus) Pool   18.2       Fetal Liver   26.1   Brain (whole)   16.5       Liver ca. HepG2   19.8   Spinal Cord Pool   9.1       Kidney Pool   43.5   Adrenal Gland   30.8       Fetal Kidney   26.2   Pituitary gland Pool   7.3       Renal ca. 786-0   26.1   Salivary Gland   7.7       Renal ca. A498   19.8   Thyroid (female)   6.5       Renal ca. ACHN   14.6   Pancreatic ca.   13.3               CAPAN2       Renal ca. UO-31   27.0   Pancreas Pool   25.2                    
     [2217]               TABLE DED                          Panel 4.1D                                 Rel. Exp. (%)       Rel. Exp. (%)           Ag3590, Run       Ag3590, Run       Tissue Name   169908854   Tissue Name   169908854                                     Secondary Th1 act   33.9   HUVEC IL-1beta   31.0       Secondary Th2 act   42.6   HUVEC IFN gamma   30.6       Secondary Tr1 act   52.1   HUVEC TNF alpha +   18.9               IFN gamma       Secondary Th1 rest   20.3   HUVEC TNF alpha +   18.2               IL4       Secondary Th2 rest   28.1   HUVEC IL-11   17.4       Secondary Tr1 rest   26.6   Lung Microvascular EC   39.5               none       Primary Th1 act   44.1   Lung Microvascular EC   54.0               TNF alpha + IL-1beta       Primary Th2 act   38.7   Microvascular Dermal   25.9               EC none       Primary Tr1 act   45.7   Microsvasular Dermal   36.6               EC TNF alpha + IL-1beta       Primary Th1 rest   23.3   Bronchial epithelium   51.1               TNF alpha + IL-1beta       Primary Th2 rest   27.7   Small airway epithelium   22.1               none       Primary Tr1 rest   30.4   Small airway epithelium   33.0               TNF alpha + IL-1beta       CD45RA CD4   24.8   Coronery artery SMC rest   38.4       lymphocyte act       CD45RO CD4   42.9   Coronery artery SMC   29.1       lymphocyte act       TNF alpha + IL-1beta       CD8 lymphocyte act   39.2   Astrocytes rest   34.9       Secondary CD8   32.8   Astrocytes TNF alpha +   26.2       lymphocyte rest       IL-1beta       Secondary CD8   19.5   KU-812 (Basophil) rest   56.6       lymphocyte act       CD4 lymphocyte none   37.4   KU-812 (Basophil)   100.0               PMA/ionomycin       2ry Th1/Th2/Tr1_anti-   39.8   CCD1106   29.3       CD95 CH11       (Keratinocytes) none       LAK cells rest   43.8   CCD1106   34.9               (Keratinocytes)               TNF alpha + IL-1beta       LAK cells IL-2   38.2   Liver cirrhosis   12.9       LAK cells IL-2 + IL-12   39.5   NCI-H292 none   22.2       LAK cells IL-2 + IFN   50.3   NCI-H292 IL-4   38.7       gamma       LAK cells IL-2 + IL-18   51.1   NCI-H292 IL-9   41.2       LAK cells   50.0   NCI-H292 IL-13   36.1       PMA/ionomycin       NK Cells IL-2 rest   41.5   NCI-H292 IFN gamma   56.3       Two Way MLR 3 day   50.7   HPAEC none   19.3       Two Way MLR 5 day   28.5   HPAEC TNF alpha + IL-   50.3               1beta       Two Way MLR 7 day   19.5   Lung fibroblast none   37.6       PBMC rest   33.2   Lung fibroblast TNF   24.0               alpha + IL-1beta       PBMC PWM   25.7   Lung fibroblast IL-4   49.3       PBMC PHA-L   16.3   Lung fibroblast IL-9   56.6       Ramos (B cell) none   42.3   Lung fibroblast IL-13   43.5       Ramos (B cell)   33.4   Lung fibroblast IFN   42.9       ionomycin       gamma       B lymphocytes PWM   24.3   Dermal fibroblast   38.7               CCD1070 rest       B lymphocytes CD40L   36.9   Dermal fibroblast   43.8       and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   40.3   Dermal fibroblast   22.8               CCD1070 IL-1beta       EOL-1 dbcAMP   37.9   Dermal fibroblast IFN   12.3       PMA/ionomycin       gamma       Dendritic cells none   33.7   Dermal fibroblast IL-4   55.1       Dendritic cells LPS   18.9   Dermal Fibroblasts rest   23.2       Dendritic cells anti-   26.8   Neutrophils TNFa + LPS   1.4       CD40       Monocytes rest   33.7   Neutrophils rest   16.5       Monocytes LPS   31.4   Colon   8.8       Macrophages rest   19.8   Lung   41.2       Macrophages LPS   6.6   Thymus   82.9       HUVEC none   16.0   Kidney   30.8       HUVEC starved   20.0                    
     [2218] CNS_neurodegeneration_v1.0 Summary: Ag3590 This panel confirms the expression of the CG59805-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [2219] General_screening_panel_v1.4 Summary: Ag3590 Highest expression of the CG59805-01 gene is detected in one of the breast cancer cell line BT 549 (CT=26). In addition, expression of this gene is high in CNS cancer, gastric cancer, and prostate cancer cell lines. Therefore, expression of this gene can be used to distinguish these samples from other samples in this panel and it can be used as marker for detection of these cancers. Furthermore, therapeutic modulation of the activity of the protein encoded by this gene may be beneficial in the treatment of these cancers.  
     [2220] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases. such as obesity and diabetes.  
     [2221] In addtion, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [2222] Panel 4.1D Summary: Ag3590 Highest expression of the CG59805-01 gene is detected in PMA/ionomycin treated Ku-812 (basophil) cells (CT=29). In addition, this gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [2223] DF. CG59928-01: Novel Universal Stress (USP) Domain Containg Protein  
     [2224] Expression of gene CG59928-01 was assessed using the primer-probe set Ag3636, described in Table DFA. Please note that this sequence is represented by a full length clone.  
               TABLE DFA                          Probe Name Ag3636                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gaagccttcgacaagctgat-3′   20   1268   734               Probe   TET-5′-atcgatagagcacaggcccacctgtt-3′-TAMRA   26   1301   735               Reverse   5′-gatgacttcctcggcaaaac-3′   20   1332   736                  
 
     [2225] CNS_neurodegeneration_v1.0 Summary: Ag3636 Expression of the CG59928-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure.  
     [2226] General_screening_panel_v1.4 Summary: Ag3636 Expression of the CG59928-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure.  
     [2227] Panel 4.1D Summary: Ag3636 Expression of the CG59928-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure.  
     [2228] DG. CG59947-01: Voltage-Gated Potassium Channel Protein KV3.3  
     [2229] Expression of gene CG59947-01 was assessed using the primer-probe set Ag3635, described in Table DGA. Results of the RTQ-PCR runs are shown in Tables DGB, DGC, DGD and DGE.  
               TABLE DGA                          Probe Name Ag3635                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tacttcaagaacatccccattg-3′   22   1326   737               Probe   TET-5′-ctgtggtcaccatgacgaccctg-3′-TAMRA   23   1360   738               Reverse   5′-tcttggggtacatgtctccata-3′   22   1386   739                  
 
     [2230]               TABLE DGB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.       Rel. Exp.           (%) Ag3635,       (%) Ag3635,           Run       Run       Tissue Name   211020704   Tissue Name   211020704                                     AD 1 Hippo   8.7   Control (Path) 3   2.8               Temporal Ctx       AD 2 Hippo   14.3   Control (Path) 4   23.8               Temporal Ctx       AD 3 Hippo   5.1   AD 1 Occipital   0.9               Ctx       AD 4 Hippo   4.8   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   100.0   AD 3 Occipital   4.2               Ctx       AD 6 Hippo   23.7   AD 4 Occipital   13.0               Ctx       Control 2 Hippo   22.4   AD 5 Occipital   18.4               Ctx       Control 4 Hippo   4.9   AD 6 Occipital   47.3               Ctx       Control (Path) 3   2.7   Control 1 Occipital   2.0       Hippo       Ctx       AD 1 Temporal Ctx   6.8   Control 2 Occipital   99.3               Ctx       AD 2 Temporal Ctx   18.3   Control 3 Occipital   11.3               Ctx       AD 3 Temporal Ctx   4.6   Control 4 Occipital   2.6               Ctx       AD 4 Temporal Ctx   11.5   Control (Path) 1   80.7               Occipital Ctx       AD 5 Inf Temporal   68.8   Control (Path) 2   10.4       Ctx       Occipital Ctx       AD 5 SupTemporal   23.5   Control (Path) 3   2.5       Ctx       Occipital Ctx       AD 6 Inf Temporal   21.6   Control (Path) 4   18.4       Ctx       Occipital Ctx       AD 6 Sup Temporal   31.0   Control 1 Parietal   3.9       Ctx       Ctx       Control 1 Temporal   3.8   Control 2 Parietal   20.2       Ctx       Ctx       Control 2 Temporal   30.8   Control 3 Parietal   20.3       Ctx       Ctx       Control 3 Temporal   8.3   Control (Path) 1   66.4       Ctx       Parietal Ctx       Control 4 Temporal   4.9   Control (Path) 2   21.2       Ctx       Parietal Ctx       Control (Path) 1   46.7   Control (Path) 3   1.8       Temporal Ctx       Parietal Ctx       Control (Path) 2   16.8   Control (Path) 4   51.4       Temporal Ctx       Parietal Ctx                    
     [2231]               TABLE DGC                          Panel 2.2                                 Rel. Exp.       Rel. Exp.           (%) Ag3635,       (%) Ag3635,           Run       Run       Tissue Name   173764364   Tissue Name   173764364                                     Normal Colon   5.4   Kidney Margin   100.0               (OD04348)       Colon cancer   5.0   Kidney malignant   5.0       (OD06064)       cancer (OD06204B)       Colon Margin   3.0   Kidney normal   19.2       (OD06064)       adjacent tissue               (OD06204E)       Colon cancer   1.0   Kidney Cancer   5.7       (OD06159)       (OD04450-01)       Colon Margin   2.8   Kidney Margin   23.3       (OD06159)       (OD04450-03)       Colon cancer   2.0   Kidney Cancer   1.2       (OD06297-04)       8120613       Colon Margin   5.0   Kidney Margin   23.5       (OD06297-05)       8120614       CC Gr.2 ascend colon   4.4   Kidney Cancer   3.6       (ODO3921)       9010320       CC Margin   0.7   Kidney Margin   12.9       (ODD3921)       9010321       Colon cancer   1.8   Kidney Cancer   13.3       metastasis (OD06104)       8120607       Lung Margin   0.6   Kidney Margin   16.3       (OD06104)       8120608       Colon mets to lung   1.6   Normal Uterus   6.3       (OD04451-01)       Lung Margin   6.1   Uterine Cancer   20.3       (OD04451-02)       064011       Normal Prostate   8.2   Normal Thyroid   6.7       Prostate Cancer   2.2   Thyroid Cancer   4.8       (OD04410)       064010       Prostate Margin   3.4   Thyroid Cancer   33.7       (OD04410)       A302152       Normal Ovary   5.4   Thyroid Margin   7.0               A302153       Ovarian cancer   9.9   Normal Breast   23.7       (OD06283-03)       Ovarian Margin   5.6   Breast Cancer   3.2       (OD06283-07)       (OD04566)       Ovarian Cancer   8.0   Breast Cancer 1024   63.3       064008       Ovarian cancer   13.1   Breast Cancer   8.7       (OD06145)       (OD04590-01)       Ovarian Margin   15.7   Breast Cancer Mets   4.0       (OD06145)       (OD04590-03)       Ovarian cancer   24.7   Breast Cancer   78.5       (OD06455-03)       Metastasis               (OD04655-05)       Ovarian Margin   3.5   Breast Cancer   16.3       (OD06455-07)       064006       Normal Lung   8.2   Breast Cancer   5.2               9100266       Invasive poor diff.   5.4   Breast Margin   5.4       lung adeno       9100265       (ODO4945-01)       Lung Margin   7.7   Breast Cancer   2.2       (ODO4945-03)       A209073       Lung Malignant   3.7   Breast Margin   20.3       Cancer (OD03126)       A2090734       Lung Margin   3.1   Breast cancer   9.1       (OD03126)       (OD06083)       Lung Cancer   8.8   Breast cancer node   7.6       (OD05014A)       metastasis               (OD06083)       Lung Margin   12.6   Normal Liver   7.4       (OD05014B)       Lung cancer   11.0   Liver Cancer 1026   4.5       (OD06081)       Lung Margin   6.7   Liver Cancer 1025   9.7       (OD06081)       Lung Cancer   1.0   Liver Cancer   7.4       (OD04237-01)       6004-T       Lung Margin   10.4   Liver Tissue   7.4       (OD04237-02)       6004-N       Ocular Melanoma   5.1   Liver Cancer   5.2       Metastasis       6005-T       Ocular Melanoma   6.1   Liver Tissue   8.8       Margin (Liver)       6005-N       Melanoma Metastasis   1.6   Liver Cancer   5.9               064003       Melanoma Margin   5.1   Normal Bladder   6.1       (Lung)       Normal Kidney   11.3   Bladder Cancer   4.6               1023       Kidney Ca, Nuclear   51.8   Bladder Cancer   7.9       grade 2 (OD04338)       A302173       Kidney Margin   4.7   Normal Stomach   8.6       (OD04338)       Kidney Ca Nuclear   24.5   Gastric Cancer   1.2       grade 1/2 (OD04339)       9060397       Kidney Margin   21.5   Stomach Margin   4.3       (OD04339)       9060396       Kidney Ca, Clear cell   2.3   Gastric Cancer   1.9       type (OD04340)       9060395       Kidney Margin   14.8   Stomach Margin   6.8       (OD04340)       9060394       Kidney Ca, Nuclear   1.1   Gastric Cancer   3.1       grade 3 (OD04348)       064005                    
     [2232]               TABLE DGE                          Panel CNS_1                                 Rel. Exp. (%)       Rel. Exp.           Ag3635, Run       Ag3635, Run       Tissue Name   171648701   Tissue Name   171648701                                     BA4 Control   16.7   BA17 PSP   27.0       BA4 Control2   39.2   BA17 PSP2   8.9       BA4   5.0   Sub Nigra Control   1.1       Alzheimer&#39;s2       BA4 Parkinson&#39;s   28.5   Sub Nigra Control2   16.5       BA4   100.0   Sub Nigra   4.1       Parkinson&#39;s2       Alzheimer&#39;s2       BA4   24.7   Sub Nigra   26.1       Huntington&#39;s       Parkinson&#39;s2       BA4   9.7   Sub Nigra   25.3       Huntington&#39;s2       Huntington&#39;s       BA4 PSP   11.7   Sub Nigra   9.3               Huntington&#39;s2       BA4 PSP2   36.6   Sub Nigra PSP2   2.4       BA4 Depression   14.9   Sub Nigra   2.0               Depression       BA4   8.8   Sub Nigra   4.5       Depression2       Depression2       BA7 Control   25.3   Glob Palladus   3.3               Control       BA7 Control2   42.6   Glob Palladus   4.9               Control2       BA7   4.5   Glob Palladus   4.5       Alzheimer&#39;s2       Alzheimer&#39;s       BA7 Parkinson&#39;s   10.4   Glob Palladus   1.2               Alzheimer&#39;s2       BA7   29.5   Glob Palladus   21.6       Parkinson&#39;s2       Parkinson&#39;s       BA7   25.3   Glob Palladus   2.0       Huntington&#39;s       Parkinson&#39;s2       BA7   12.9   Glob Palladus PSP   1.6       Huntington&#39;s2       BA7 PSP   30.6   Glob Palladus PSP2   2.1       BA7 PSP2   12.1   Glob Palladus   1.4               Depression       BA7 Depression   10.1   Temp Pole Control   7.3       BA9 Control   15.0   Temp Pole Control2   27.4       BA9 Control2   47.0   Temp Pole   4.2               Alzheimer&#39;s       BA9 Alzheimer&#39;s   4.7   Temp Pole   2.5               Alzheimer&#39;s2       BA9   9.2   Temp Pole   15.1       Alzheimer&#39;s2       Parkinson&#39;s       BA9 Parkinson&#39;s   28.9   Temp Pole   14.2               Parkinson&#39;s2       BA9   34.4   Temp Pole   19.2       Parkinson&#39;s2       Huntington&#39;s       BA9   24.1   Temp Pole PSP   3.4       Huntington&#39;s       BA9   9.5   Temp Pole PSP2   3.0       Huntington&#39;s2       BA9 PSP   10.2   Temp Pole   4.8               Depression2       BA9 PSP2   6.2   Cing Gyr Control   20.9       BA9 Depression   5.6   Cing Gyr Control2   25.9       BA9   8.3   Cing Gyr   5.6       Depression2       Alzheimer&#39;s       BA17 Control   33.2   Cing Gyr   6.3               Alzheimer&#39;s2       BA17 Control2   64.6   Cing Gyr   9.1               Parkinson&#39;s       BA17   7.2   Cing Gyr   13.1       Alzheimer&#39;s2       Parkinson&#39;s2       BA17   18.3   Cing Gyr   22.1       Parkinson&#39;s       Huntington&#39;s       BA17   35.1   Cing Gyr   6.0       Parkinson&#39;s2       Huntington&#39;s2       BA17   32.1   Cing Gyr PSP   6.5       Huntington&#39;s       BA17   8.8   Cing Gyr PSP2   2.6       Huntington&#39;s2       BA17   7.3   Cing Gyr   2.6       Depression       Depression       BA17   25.7   Cing Gyr   6.1       Depression2       Depression2                    
     [2233] CNS_neurodegeneration_v1.0 Summary: Ag3635 This panel confirms the expression of CG59947-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. This gene encodes a potassium channel protein homolog. The significant levels of expression in the brain may indicate a role for this protein in signal processing in the central nervous system.  
     REFERENCES  
     [2234] 1. Rudy B, Chow A, Lau D, Amarillo Y, Ozaita A, Saganich M, Moreno H, Nadal M S, Hernandez-Pineda R, Hernandez-Cruz A, Erisir A, Leonard C, Vega-Saenz de Miera E.  
     [2235] 2. Contributions of Kv3 channels to neuronal excitability. Ann NY Acad Sci Apr. 30, 1999;868:304-43  
     [2236] General_screening_panel_v1.4 Summary: Ag3635 Results from one experiment with the CG59947-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [2237] Panel 2.2 Summary: Ag3635 Highest expression of the CG59447-01 gene is seen in normal kidney tissue adjacent to a tumor (CT=28). In addition, expression appears to be higher in normal kidney tissue than in the adjacent tumor in six out of nine matched pairs. Conversely expression appears to be higher in breast cancer than in matched normal breast tissue. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker for kidney and breast cancers. Furthermore, therapeutic modulation of the expression or function of this protein may be effective in the treatment of breast and kidney cancer.  
     [2238] Panel 4.1D Summary: Ag3635 This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease, with highest expression in anti CD40 dendritic cells (CT=28.1). Other cells that express this protein include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [2239] Panel CNS — 1 Summary: Ag3635 Expression in this panel confirms expression of the CG59947-01 gene in the brain. Please see Panel CNS_neurodegeneration_v1.0 for discussion of utility of this gene in the central nervous system.  
     [2240] DH. CG59938-01: Arylsulfatase  
     [2241] Expression of gene CG59938-01 was assessed using the primer-probe set Ag3634, described in Table DHA.  
               TABLE DHA                          Probe Name Ag3634                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-agccaatgaaagaggagaaagt-3′   22   870   740               Probe   TET-5′-cttccctcatgctgaaggaggcactt-3′-TAMRA   26   894   741               Reverse   5′-cccttttgtacctttcaatgaa-3′   22   923   742                  
 
     [2242] CNS_neurodegeneration_v1.0 Summary: Ag3634 Expression of the CG55938-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [2243] General_screening_panel_v1.4 Summary: Ag3634 Expression of the CG55938-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [2244] Panel 2.2 Summary: Ag3634 Expression of the CG55938-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [2245] Panel 4.1D Summary: Ag3634 Expression of the CG55938-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [2246] DI. CG!59746-01: Ubiquitin Carboxyl-Terminal Hydrolase  
     [2247] Expression of gene CG59746-01 was assessed using the primer-probe set Ag3574, described in Table DIA.  
               TABLE DIA                          Probe Name Ag3574                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-agcacaacacagaaggaaatca-3′   22   461   743               Probe   TET-5′-tcattccacaaagttgatgagaaatca-3′-TAMRA   27   491   744               Reverse   5′-gtcccacttccttttgctatct-3′   22   534   745                  
 
     [2248] CNS_neurodegeneration_v1.0 Summary: Ag3574 Expression of the CG59746-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [2249] General_screening_panel_v1.4 Summary: Ag3574 Expression of the CG59746-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [2250] Panel 2.2 Summary: Ag3574 Expression of the CG59746-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [2251] Panel 4.1D Summary: Ag3574 Expression of the CG59746-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [2252] Panel CNS — 1 Summary: Ag3574 Expression of the CG59746-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown.)  
     [2253] DJ. CG8613-01: Inositol 1,4,5-Trisphosphate 3-Kinase Isoenzyme  
     [2254] Expression of gene CG88613-01 was assessed using the primer-probe set Ag3647, described in Table DJA. Results of the RTQ-PCR runs are shown in Tables DJB, DJC and DJD.  
               TABLE DJA                          Probe Name Ag3647                                             Start   SEQ ID       Primer   Sequences   Length   Position   NO:                                         Forward   5′-actggagcaggtgacaaaagt-3′   21   1731   766               Probe   TET-5′-accacgtcatcctgcaaaagtacgtg-3′-TAMRA   26   1775   767               Reverse   5′-cagagcttcacgaagttcttct-3′   22   1809   768                  
 
     [2255]               TABLE DJB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.       Rel. Exp.           (%) Ag3647,       (%) Ag3647,           Run       Run       Tissue Name   211019283   Tissue Name   211019283                                     AD 1 Hippo   44.8   Control (Path) 3   16.3               Temporal Ctx       AD 2 Hippo   28.1   Control (Path) 4   20.7               Temporal Ctx       AD 3 Hippo   10.2   AD 1 Occipital   30.1               Ctx       AD 4 Hippo   10.7   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   98.6   AD 3 Occipital   17.1               Ctx       AD 6 Hippo   75.3   AD 4 Occipital   17.9               Ctx       Control 2 Hippo   33.4   AD 5 Occipital   39.8               Ctx       Control 4 Hippo   29.1   AD 6 Occipital   42.6               Ctx       Control (Path) 3   14.9   Control 1 Occipital   8.0       Hippo       Ctx       AD 1 Temporal Ctx   19.5   Control 2 Occipital   67.4               Ctx       AD 2 Temporal Ctx   29.1   Control 3 Occipital   29.3               Ctx       AD 3 Temporal Ctx   14.2   Control 4 Occipital   16.6               Ctx       AD 4 Temporal Ctx   23.8   Control (Path) 1   57.4               Occipital Ctx       AD 5 Inf Temporal   100.0   Control (Path) 2   12.9       Ctx       Occipital Ctx       AD 5 SupTemporal   69.7   Control (Path) 3   14.6       Ctx       Occipital Ctx       AD 6 Inf Temporal   73.2   Control (Path) 4   12.5       Ctx       Occipital Ctx       AD 6 Sup Temporal   57.8   Control 1 Parietal   11.7       Ctx       Ctx       Control 1 Temporal   17.3   Control 2 Parietal   50.0       Ctx       Ctx       Control 2 Temporal   47.6   Control 3 Parietal   39.0       Ctx       Ctx       Control 3 Temporal   32.5   Control (Path) 1   41.8       Ctx       Parietal Ctx       Control 4 Temporal   20.9   Control (Path) 2   18.4       Ctx       Parietal Ctx       Control (Path) 1   35.6   Control (Path) 3   16.0       Temporal Ctx       Parietal Ctx       Control (Path) 2   28.3   Control (Path) 4   20.4       Temporal Ctx       Parietal Ctx                    
     [2256]               TABLE DJC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3647,       (%) Ag3647,           Run       Run       Tissue Name   218342103   Tissue Name   218342103                                     Adipose   37.9   Renal ca. TK-10   23.3       Melanoma*   15.7   Bladder   24.1       Hs688(A).T       Melanoma*   20.2   Gastric ca. (liver met.)   100.0       Hs688(B).T       NCI-N87       Melanoma* M14   11.3   Gastric ca. KATO III   25.2       Melanoma*   8.5   Colon ca. SW-948   11.2       LOXIMVI       Melanoma* SK-   13.0   Colon ca. SW480   38.7       MEL-5       Squamous cell   35.6   Colon ca.* (SW480   11.7       carcinoma SCC-4       met) SW620       Testis Pool   6.4   Colon ca. HT29   17.2       Prostate ca.* (bone   11.7   Colon ca. HCT-116   24.1       met) PC-3       Prostate Pool   12.7   Colon ca. CaCo-2   78.5       Placenta   31.6   Colon cancer tissue   37.1       Uterus Pool   4.5   Colon ca. SW1116   8.0       Ovarian ca.   21.2   Colon ca. Colo-205   4.6       OVCAR-3       Ovarian ca. SK-   22.2   Colon ca. SW-48   9.3       OV-3       Ovarian ca.   22.2   Colon Pool   13.5       OVCAR-4       Ovarian ca.   32.5   Small Intestine Pool   13.0       OVCAR-5       Ovarian ca.   32.8   Stomach Pool   11.7       IGROV-1       Ovarian ca.   14.3   Bone Marrow Pool   5.7       OVCAR-8       Ovary   7.9   Fetal Heart   5.0       Breast ca. MCF-7   50.0   Heart Pool   6.4       Breast ca. MDA-   25.7   Lymph Node Pool   11.2       MB-231       Breast ca. BT 549   61.1   Fetal Skeletal Muscle   4.4       Breast ca. T47D   87.7   Skeletal Muscle Pool   11.6       Breast ca. MDA-N   7.4   Spleen Pool   6.0       Breast Pool   10.6   Thymus Pool   8.3       Trachea   24.5   CNS cancer   14.9               (glio/astro) U87-MG       Lung   3.5   CNS cancer   16.6               (glio/astro) U-118-MG       Fetal Lung   95.3   CNS cancer   15.7               (neuro; met) SK-N-AS       Lung ca. NCI-N417   3.9   CNS cancer (astro)   11.3               SF-539       Lung ca. LX-1   16.4   CNS cancer (astro)   34.4               SNB-75       Lung ca. NCI-H146   6.0   CNS cancer (glio)   48.0               SNB-19       Lung ca. SHP-77   23.3   CNS cancer (glio)   45.4               SF-295       Lung ca. A549   25.0   Brain (Amygdala)   12.6               Pool       Lung ca. NCI-H526   6.4   Brain (cerebellum)   37.1       Lung ca. NCI-H23   10.2   Brain (fetal)   13.6       Lung ca. NCI-H460   8.7   Brain (Hippocampus)   15.3               Pool       Lung ca. HOP-62   11.3   Cerebral Cortex Pool   15.6       Lung ca. NCI-H522   16.8   Brain (Substantia   27.0               nigra) Pool       Liver   2.5   Brain (Thalamus) Pool   17.0       Fetal Liver   6.6   Brain (whole)   8.9       Liver ca. HepG2   16.3   Spinal Cord Pool   19.9       Kidney Pool   24.0   Adrenal Gland   9.9       Fetal Kidney   8.0   Pituitary gland Pool   6.3       Renal ca. 786-0   11.4   Salivary Gland   7.2       Renal ca. A498   21.2   Thyroid (female)   12.1       Renal ca. ACHN   10.2   Pancreatic ca.   35.1               CAPAN2       Renal ca. UO-31   18.3   Pancreas Pool   23.3                    
     [2257]               TABLE DJD                          Panel 4.1D                                         Rel.   Rel.       Rel.   Rel.           Exp. (%)   Exp. (%)       Exp. (%)   Exp. (%)           Ag3647,   Ag3647,       Ag3647,   Ag3647,           Run   Run       Run   Run       Tissue Name   169975750   197444046   Tissue Name   169975750   197444046                                             Secondary Th1 act   7.7   7.1   HUVEC IL-1beta   20.4   22.1       Secondary Th2 act   10.7   8.7   HUVEC IFN   21.5   21.6                   gamma       Secondary Tr1 act   9.1   7.9   HUVEC TNF   39.2   26.2                   alpha + IFN                   gamma       Secondary Th1 rest   4.2   2.7   HUVEC TNF   20.9   16.6                   alpha + IL4       Secondary Th2 rest   6.0   6.2   HUVEC IL-11   8.5   8.8       Secondary Tr1 rest   5.0   4.0   Lung   29.9   31.0                   Microvascular EC                   none       Primary Th1 act   8.1   6.3   Lung   37.4   24.1                   Microvascular EC                   TNF alpha + IL-                   1beta       Primary Th2 act   9.0   9.5   Microvascular   17.9   12.4                   Dermal EC none       Primary Tr1 act   10.1   10.7   Microsvasular   20.0   15.6                   Dermal EC                   TNF alpha + IL-                   1beta       Primary Th1 rest   6.0   2.3   Bronchial   41.5   34.6                   epithelium                   TNF alpha +                   IL-1beta       Primary Th2 rest   4.3   1.1   Small airway   37.4   33.2                   epithelium none       Primary Tr1 rest   7.4   5.4   Small airway   58.2   43.8                   epithelium                   TNF alpha + IL-                   1beta       CD45RA CD4   4.2   4.2   Coronery artery   6.3   8.0       lymphocyte act           SMC rest       CD45RO CD4   7.1   5.7   Coronery artery   9.7   7.8       lymphocyte act           SMC TNF alpha +                   IL-1beta       CD8 lymphocyte   6.2   4.5   Astrocytes rest   11.7   4.2       act       Secondary CD8   9.7   8.5   Astrocytes   11.1   7.2       lymphocyte rest           TNF alpha + IL-                   1beta       Secondary CD8   6.5   3.7   KU-812   10.0   7.9       lymphocyte act           (Basophil) rest       CD4 lymphocyte   1.8   1.7   KU-812   14.4   13.3       none           (Basophil)                   PMA/ionomycin       2ry   3.1   2.9   CCD1106   42.0   46.7       Th1/Th2/Tr1_anti-           (Keratinocytes)       CD95 CH11           none       LAK cells rest   9.9   5.9   CCD1106   100.0   100.0                   (Keratinocytes)                   TNF alpha + IL-                   1beta       LAK cells IL-2   5.3   4.5   Liver cirrhosis   14.7   16.2       LAK cells IL-   9.2   3.2   NCI-H292 none   17.1   16.2       2 + IL-12       LAK cells IL-   6.1   3.8   NCI-H292 IL-4   19.1   25.0       2 + IFN gamma       LAK cells IL-2 +   11.3   5.5   NCI-H292 IL-9   25.7   23.8       IL-18       LAK cells   20.9   16.2   NCI-H292 IL-13   20.6   18.8       PMA/ionomycin       NK Cells IL-2 rest   8.2   12.1   NCI-H292 IFN   42.6   28.3                   gamma       Two Way MLR 3   9.2   11.4   HPAEC none   13.6   11.7       day       Two Way MLR 5   8.4   4.9   HPAEC TNF   20.3   22.1       day           alpha + IL-1beta       Two Way MLR 7   8.7   5.8   Lung fibroblast   16.4   17.3       day           none       PBMC rest   3.0   2.2   Lung fibroblast   11.6   13.6                   TNF alpha + IL-                   1beta       PBMC PWM   11.0   7.6   Lung fibroblast   14.6   28.3                   IL-4       PBMC PHA-L   9.1   4.6   Lung fibroblast   16.3   23.8                   IL-9       Ramos (B cell)   5.2   3.6   Lung fibroblast   14.7   12.9       none           IL-13       Ramos (B cell)   5.1   4.9   Lung fibroblast   22.7   23.8       ionomycin           IFN gamma       B lymphocytes   4.1   3.8   Dermal fibroblast   12.0   13.6       PWM           CCD1070 rest       B lymphocytes   8.4   4.9   Dermal fibroblast   10.9   14.7       CD40L and IL-4           CCD1070 TNF                   alpha       EOL-1 dbcAMP   7.3   5.5   Dermal fibroblast   10.0   4.4                   CCD1070 IL-1beta       EOL-1 dbcAMP   8.4   7.8   Dermal fibroblast   9.2   7.7       PMA/ionomycin           IFN gamma       Dendritic cells   7.5   8.0   Dermal fibroblast   9.7   7.5       none           IL-4       Dendritic cells LPS   5.7   4.6   Dermal   10.1   8.5                   Fibroblasts rest       Dendritic cells   7.7   6.9   Neutrophils   11.4   5.8       anti-CD40           TNFa + LPS       Monocytes rest   8.5   7.5   Neutrophils rest   3.0   3.0       Monocytes LPS   24.8   25.9   Colon   13.0   9.6       Macrophages rest   8.4   5.6   Lung   16.4   8.4       Macrophages LPS   12.2   5.9   Thymus   10.9   8.8       HUVEC none   8.7   12.8   Kidney   6.3   4.7       HUVEC starved   11.8   11.7                    
     [2258] CNS_neurodegeneration_v1.0 Summary: Ag3647 This panel confirms the expression of this gene at moderate levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.  
     [2259] General_screening_panel_v1.4 Summary: Ag3647 Expression of the CG88613-01 gene is highest in a gastric cancer cell line (CT=28). Expression of this gene appears to be upregulated in a number of cancer cell lines when compared to normal tissues. Specifically, CG88613-01 gene expression is somewhat higher in breast and ovarian cancers when compared to their respective normal tissues. Thus, therapeutic modulation of the activity of this gene or its protein product, using small molecule drugs, antibodies or protein therapeutics, may be of benefit in the treatment of gastric, breast and ovarian cancer.  
     [2260] In addition, this gene is expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. The CG88613-01 gene encodes a protein that is identical to a protein now known in the public domain as inositol 1,4,5-triphosphate 3-kinase C (ref. 1). Inositol 1,4,5-trisphosphate 3-kinase (ITPK) catalyzes the phosphorylation of Ins(1,4,5)P3 to Ins(1,4,5)P4, both of which are modulators of calcium homeostasis. Calcium is one of the most important intracellular messengers in the brain, being essential for neuronal development, synaptic transmission and plasticity, and the regulation of various metabolic pathways (ref. 2). Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression. Furthermore, this gene is also expressed in tissues with metabolic or endocrine function, including pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     REFERENCES  
     [2261] 1. Dewaste V, Pouillon V, Moreau C, Shears S, Takazawa K, Erneux C. Cloning and expression of a cDNA encoding human inositol 1,4,5-trisphosphate 3-kinase C. Biochem J Dec. 1, 2000;352 Pt 2:343-51  
     [2262] 2. Mattson M P, Chan S L. Dysregulation of cellular calcium homeostasis in Alzheimer&#39;s disease: bad genes and bad habits. J Mol Neurosci October 2001;17(2):205-24  
     [2263] Panel 4.1D Summary: Ag3647 Results from two experiments using the same probe/primer set are in excellent agreement. Expression of the CG88613-01 gene is highest in keratinocytes treated with the inflammatory cytokines TNF-a and IL-1b(CT=29.5). Therefore, modulation of the expression or activity of this protein through the application of small molecule therapeutics may be useful in the treatment of psoriasis and wound healing.  
     [2264] This gene is also expressed at moderate levels in small airway epithelial cells, bronchial epithelium, and lung microvascular endothelial cells. Endothelial cells are known to play important roles in inflammatory responses by altering the expression of surface proteins that are involved in activation and recruitment of effector inflammatory cells (ref. 1). Expression in small airway epithelial cells, bronchial epithelium, lung microvascular endothelial cells suggests that the protein encoded by this transcript may be involved in lung disorders including asthma, allergies, chronic obstructive pulmonary disease, and emphysema. This gene is homologoust o PI-3-kinase which is involved in cell survival and receptor signaling of a number of cells of importance in the immune response in health and disease, including lung pathologies. Therefore, Small molecule antagonists of this gene product may lead to amelioration of symptoms associated with asthma, allergies, chronic obstructive pulmonary disease, and emphysema.  
     [2265] This gene is expressed at low levels in the remainder of the samples on this panel, suggesting that the gene product may play an important role in homeostasis of a number of cell types.  
     REFERENCES  
     [2266] 1. Siddiqui R A, English D. Phosphatidylinositol 3′-kinase-mediated calcium mobilization regulates chemotaxis in phosphatidic acid-stimulated human neutrophils. Biochim Biophys Acta Jan. 3, 2000;1483(1):161-73  
     [2267] 2. Condliffe A M, Cadwallader K A, Walker T R, Rintoul R C, Cowburn A S, Chilvers E R. Phosphoinositide 3-kinase: a critical signalling event in pulmonary cells. Respir Res 2000;1(1):24-9  
     [2268] DK. CG59993-01 and CG59993-02: Synaptotagmin II  
     [2269] Expression of gene CG59993-01 and variant CG59993-02 was assessed using the primer-probe set Ag3645, described in Table DKA. Results of the RTQ-PCR runs are shown in Tables DKB, DKC and DKD.  
                   TABLE DKA                          Probe Name Ag3645                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO:               Forward   5′-gaagaagaccctgaacccatac-3′   22   1056   746                   Probe   TET-5′-agctttgagatccccttcgagcagat-3′-TAMRA   26   1093   747               Reverse   5′-tgaccactacctggactttctg-3′   22   1120   748                  
 
     [2270]               TABLE DKB                          CNS_neurodegeneration_v1.0                                 Rel. Exp.       Rel. Exp.           (%) Ag3645,       (%) Ag3645           Run       Run       Tissue Name   211019104   Tissue Name   211019104                                     AD 1 Hippo   0.4   Control (Path) 3   0.2               Temporal Ctx       AD 2 Hippo   0.2   Control (Path) 4   7.2               Temporal Ctx       AD 3 Hippo   0.0   AD 1 Occipital   8.7               Ctx       AD 4 Hippo   0.1   AD 2 Occipital   0.0               Ctx (Missing)       AD 5 hippo   100.0   AD 3 Occipital   0.6               Ctx       AD 6 Hippo   1.5   AD 4 Occipital   10.7               Ctx       Control 2 Hippo   0.9   AD 5 Occipital   19.2               Ctx       Control 4 Hippo   0.1   AD 6 Occipital   57.8               Ctx       Control (Path) 3   0.0   Control 1 Occipital   0.3       Hippo       Ctx       AD 1 Temporal Ctx   0.8   Control 2 Occipital   81.8               Ctx       AD 2 Temporal Ctx   2.8   Control 3 Occipital   11.0               Ctx       AD 3 Temporal Ctx   0.3   Control 4 Occipital   0.5               Ctx       AD 4 Temporal Ctx   2.6   Control (Path) 1   29.1               Occipital Ctx       AD 5 Inf Temporal   50.0   Control (Path) 2   8.5       Ctx       Occipital Ctx       AD 5 SupTemporal   0.9   Control (Path) 3   0.7       Ctx       Occipital Ctx       AD 6 Inf Temporal   2.8   Control (Path) 4   12.8       Ctx       Occipital Ctx       AD 6 Sup Temporal   8.2   Control 1 Parietal   0.4       Ctx       Ctx       Control 1 Temporal   0.1   Control 2 Parietal   2.3       Ctx       Ctx       Control 2 Temporal   7.2   Control 3 Parietal   28.7       Ctx       Ctx       Control 3 Temporal   1.5   Control (Path) 1   33.2       Ctx       Parietal Ctx       Control 4 Temporal   0.7   Control (Path) 2   21.8       Ctx       Parietal Ctx       Control (Path) 1   4.7   Control (Path) 3   0.5       Temporal Ctx       Parietal Ctx       Control (Path) 2   6.8   Control (Path) 4   68.3       Temporal Ctx       Parietal Ctx                    
     [2271]               TABLE DKC                          General_screening_panel_v1.4                                 Rel. Exp.       Rel. Exp.           (%) Ag3645,       (%) Ag3645,           Run       Run       Tissue Name   218341901   Tissue Name   218341901                                     Adipose   0.0   Renal ca. TK-10   0.1       Melanoma*   0.1   Bladder   0.1       Hs688(A).T       Melanoma*   0.1   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.0       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.4   Colon ca. SW480   0.0       MEL-5       Squamous cell   0.1   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   1.0   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.0       met) PC-3       Prostate Pool   0.1   Colon ca. CaCo-2   0.6       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.2   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca. SK-   0.0   Colon ca. SW-48   0.2       OV-3       Ovarian ca.   0.2   Colon Pool   0.2       OVCAR-4       Ovarian ca.   0.1   Small Intestine Pool   0.1       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.1       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.7   Fetal Heart   0.1       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   1.4   Lymph Node Pool   1.0       MB-231       Breast ca. BT 549   0.2   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.1   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   0.1       Breast Pool   0.2   Thymus Pool   0.5       Trachea   0.2   CNS cancer   0.0               (glio/astro) U87-MG       Lung   0.3   CNS cancer   0.0               (glio/astro) U-118-MG       Fetal Lung   0.5   CNS cancer   0.2               (neuro; met) SK-N-AS       Lung ca. NCI-N417   0.5   CNS cancer (astro)   0.0               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.2               SNB-75       Lung ca. NCI-H146   0.1   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   0.3   CNS cancer (glio)   0.1               SF-295       Lung ca. A549   0.0   Brain (Amygdala)   5.9               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   100.0       Lung ca. NCI-H23   0.2   Brain (fetal)   0.9       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   2.1               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   19.3       Lung ca. NCI-H522   0.0   Brain (Substantia   19.5               nigra) Pool       Liver   0.0   Brain (Thalamus) Pool   14.1       Fetal Liver   0.0   Brain (whole)   10.0       Liver ca. HepG2   0.0   Spinal Cord Pool   15.9       Kidney Pool   0.1   Adrenal Gland   0.9       Fetal Kidney   0.6   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.1       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.8                    
     [2272]               TABLE DKD                          Panel 4.1D                                 Rel.       Rel.           Exp.       Exp.           (%)       (%)           Ag3645,       Ag3645,           Run       Run       Tissue Name   169975206   Tissue Name   169975206                                     Secondary Th1 act   0.0   HUVEC IL-1beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular   0.0               EC none       Primary Th1 act   0.0   Lung Microvascular   0.0               EC TNFalpha +               IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microvasular Dermal   0.0               EC TNFalpha +               IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNFalpha + IL1beta       Primary Th2 rest   0.0   Small airway   0.0               epithelium none       Primary Tr1 rest   0.0   Small airway   0.0               epithelium               TNFalpha + IL-beta       CD45RA CD4   0.0   Coronery artery   0.0       lymphocyte act       SMC rest       CD45RO CD4   0.0   Coronery artery   0.0       lymphocyte act       SMC TNFalpha +               IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes   100.0       lymphocyte rest       TNFalpha +               IL-1beta       Secondary CD8   0.0   KU-812 (Basophil)   0.0       lymphocyte act       rest       CD4 lymphocyte   0.0   KU-812 (Basophil)   0.0       none       PMA/ionomycin       2ry Th1/Th2/   0.0   CCD1106   0.0       Tr1_anti-       (Keratinocytes)       CD95 CH11       none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNFalpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   0.0       LAK cells IL-2 +   0.0   NCI-H292 none   15.0       IL-12       LAK cells IL-2 +   8.3   NCI-H292 IL-4   0.0       IFN gamma       LAK cells IL-2 +   0.0   NCI-H292 IL-9   22.5       IL-18       LAK cells   0.0   NCI-H292 IL-13   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR   0.0   HPAEC none   0.0       3 day       Two Way MLR   0.0   HPAEC TNF alpha +   0.0       5 day       IL-1beta       Two Way MLR   0.0   Lung fibroblast none   0.0       7 day       PBMC rest   0.0   Lung fibroblast   4.3               TNF alpha +               IL-1beta       PBMC PWM   0.0   Lung fibroblast IL-4   0.0       PBMC PHA-L   12.9   Lung fibroblast IL-9   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-13   36.9       Ramos (B cell)   0.0   Lung fibroblast IFN   0.0       ionomycin       gamma       B lymphocytes   0.0   Dermal fibroblast   0.0       PMW       CCD1070 rest       B lymphocytes   0.0   Dermal fibroblast   0.0       CD40L and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 IL-1beta       EOL-1 dbcAMP   48.6   Dermal fibroblast IFN   0.0       PMA/ionomycin       gamma       Dendritic cells none   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells LPS   0.0   Dermal Fibroblasts   0.0               rest       Dendritic cells anti-   20.9   Neutrophils TNFa +   0.0       CD40       LPS       Monocytes rest   0.0   Neutrophils rest   0.0       Monocytes LPS   0.0   Colon   25.7       Macrophages rest   0.0   Lung   28.7       Macrophages LPS   0.0   Thymus   43.2       HUVEC none   0.0   Kidney   25.9       HUVEC starved   0.0                    
     [2273] CNS_nturodegeneration_v1.0 Summary: Ag3645 While no association between the expression of the CG59993-01 gene and the presence of Alzheimer&#39;s disease is detected in this panel, these results confirm the expression of this gene in areas that degenerate in Alzheimer&#39;s disease, including the cortex and hippocampus. Synaptotagmin expression is altered in the brain of Alzheimer&#39;s patients, possibly explaining impaired synaptogenesis and/or synaptosomal loss secondary to neuronal loss observed in the neurodegenerative disorder. It may also represent, reflect or account for the impaired neuronal transmission in Alzheimer&#39;s disease (AD), caused by deterioration of the exocytic machinery. Since the this gene is a homolog of synaptotagmin, agents that potentiate the expression or function of the protein encoded by the this gene may be useful in the treatment of Alzheimer&#39;s disease.  
     [2274] General_screening_panel_v1.4 Summary: Ag3645 The CG59993-01 gene is a homolog of synaptotagmin, and shows high to moderate expression across all brain regions with highest expression in the cerebellum (CT=26.4) Synaptotagmin is a presynaptic protein involved in synaptic vesicle release, making this an ideal drug target for diseases such as epilepsy, in which reduction of neurotransmission is beneficial. Selective inhibition of this gene or its protein product may therefore be useful in the treatment of seizure disorders. Furthermore, selective inhibition of neural transmission through antagonism of the protein encoded by this gene may show therapeutic benefit in psychiatric diseases where it is believed that inappropriate neural connections have been established, such as schizophrenia and bipolar disorder. In addition, antibodies against synaptotagmin may cause Lambert-Eaton myasthenic syndrome. Therefore, peptide fragments of the protein encoded by this gene may serve to block the action of these antibodies and treat Lambert-Eaton myasthenic syndrome.  
     [2275] Panel 4.1D Summary: Ag3645 Expression of the CG59993-01 gene is restricted to a sample derived from astrocytes treated with TNF-alpha and IL-1 beta (CT=33.9). This expression in samples related to the central nervous system is consistent with results of the previous panels and suggests that modulation of this protein could be beneficial in the treatment of CNS disease-associated inflammation or neurodegeneration, including mutliple sclerosis.  
     [2276] DL. CG59991-01: Ooplasm Specific Protein  
     [2277] Expression of gene CG59991-01 was assessed using the primer-probe set Ag3644, described in Table DLA. Results of the RTQ-PCR runs are shown in Tables DLB and DLC.  
               TABLE DLA                          Probe Name Ag3644                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-gggagtaatgcctctcagtga-3′   21   2294   749               Probe   TET-5′-cttgagagtctcccagtgcgccct-3′-TAMRA   24   2318   750               Reverse   5′-atgccacagtcctccagtatc-3′   21   2351   751                  
 
     [2278]               TABLE DLB                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp.       Exp.           (%)       (%)           Ag3644,       Ag3644,           Run       Run       Tissue Name   218306573   Tissue Name   218306573                                     Adipose   0.0   Renal ca. TK-10   0.0       Melanoma*   0.0   Bladder   0.0       Hs688(A).T       Melanoma*   0.0   Gastric ca. (liver met.)   0.0       Hs688(B).T       NCI-N87       Melanoma* M14   0.0   Gastric ca. KATO III   0.1       Melanoma*   0.0   Colon ca. SW-948   0.0       LOXIMVI       Melanoma* SK-   0.0   Colon ca. SW480   0.0       MEL-5       Squamous cell   0.0   Colon ca.* (SW480   0.0       carcinoma SCC-4       met) SW620       Testis Pool   0.5   Colon ca. HT29   0.0       Prostate ca.* (bone   0.0   Colon ca. HCT-116   0.1       met) PC-3       Prostate Pool   0.0   Colon ca. CaCo-2   0.0       Placenta   0.0   Colon cancer tissue   0.0       Uterus Pool   0.0   Colon ca. SW1116   0.0       Ovarian ca.   0.0   Colon ca. Colo-205   0.0       OVCAR-3       Ovarian ca.   0.0   Colon ca. SW-48   0.0       SK-OV-3       Ovarian ca.   0.6   Colon Pool   0.0       OVCAR-4       Ovarian ca.   0.0   Small Intestine Pool   0.0       OVCAR-5       Ovarian ca.   0.0   Stomach Pool   0.0       IGROV-1       Ovarian ca.   0.0   Bone Marrow Pool   0.0       OVCAR-8       Ovary   0.0   Fetal Heart   0.0       Breast ca. MCF-7   0.0   Heart Pool   0.0       Breast ca. MDA-   0.0   Lymph Node Pool   0.0       MB-231       Breast ca. BT 549   0.0   Fetal Skeletal Muscle   0.0       Breast ca. T47D   0.0   Skeletal Muscle Pool   0.0       Breast ca. MDA-N   0.0   Spleen Pool   0.0       Breast Pool   0.0   Thymus Pool   0.0       Trachea   0.0   CNS cancer   0.0               (glio/astro)               U87-MG       Lung   0.0   CNS cancer   0.0               (glio/astro)               U-118-MG       Fetal Lung   0.0   CNS cancer   0.0               (neuro; met)               SK-N-AS       Lung ca. NCI-N417   0.0   CNS cancer   0.0               (astro)               SF-539       Lung ca. LX-1   0.0   CNS cancer (astro)   0.0               SNB-75       Lung ca. NCI-H146   0.0   CNS cancer (glio)   0.0               SNB-19       Lung ca. SHP-77   100.0   CNS cancer (glio)   0.3               SF-295       Lung ca. A549   0.0   Brain (Amygdala)   0.0               Pool       Lung ca. NCI-H526   0.0   Brain (cerebellum)   0.0       Lung ca. NCI-H23   0.0   Brain (fetal)   0.0       Lung ca. NCI-H460   0.0   Brain (Hippocampus)   0.0               Pool       Lung ca. HOP-62   0.0   Cerebral Cortex Pool   0.0       Lung ca. NCI-H522   0.0   Brain   0.0               ( Substantia nigra )               Pool       Liver   0.0   Brain (Thalamus) Pool   0.0       Fetal Liver   0.0   Brain (whole)   0.0       Liver ca. HepG2   0.0   Spinal Cord Pool   0.0       Kidney Pool   0.0   Adrenal Gland   0.0       Fetal Kidney   0.0   Pituitary gland Pool   0.0       Renal ca. 786-0   0.0   Salivary Gland   0.0       Renal ca. A498   0.0   Thyroid (female)   0.1       Renal ca. ACHN   0.0   Pancreatic ca.   0.0               CAPAN2       Renal ca. UO-31   0.0   Pancreas Pool   0.1                    
     [2279]               TABLE DLC                          Panel 4.1D                                 Rel.       Rel.           Exp.       Exp.           (%)       (%)           Ag3644,       Ag3644,           Run       Run       Tissue Name   169975188   Tissue Name   169975188                                     Secondary Th1 act   0.0   HUVEC IL-beta   0.0       Secondary Th2 act   0.0   HUVEC IFN gamma   0.0       Secondary Tr1 act   0.0   HUVEC TNF alpha +   0.0               IFN gamma       Secondary Th1 rest   0.0   HUVEC TNF alpha +   0.0               IL4       Secondary Th2 rest   0.0   HUVEC IL-11   0.0       Secondary Tr1 rest   0.0   Lung Microvascular   0.0               EC none       Primary Th1 act   0.0   Lung Microvascular   0.0               EC TNFalpha +               IL-1beta       Primary Th2 act   0.0   Microvascular Dermal   0.0               EC none       Primary Tr1 act   0.0   Microvasular Dermal   0.0               EC TNFalpha +               IL-1beta       Primary Tr1 act   0.0   Microvascular Dermal   0.0               EC TNFalpha +               IL-1beta       Primary Th1 rest   0.0   Bronchial epithelium   0.0               TNFalpha + IL1beta       Primary Th2 rest   0.0   Small airway   0.0               epithelium none       Primary Tr1 rest   0.0   Small airway   0.0               epithelium               TNFalpha + IL-beta       CD45RA CD4   0.0   Coronery artery   0.0       lymphocyte act       SMC rest       CD45RO CD4   0.0   Coronery artery   0.0       lymphocyte act       SMC TNFalpha +               IL-1beta       CD8 lymphocyte act   0.0   Astrocytes rest   0.0       Secondary CD8   0.0   Astrocytes   0.0       lymphocyte rest       TNFalpha +               IL-1beta       Secondary CD8   0.0   KU-812 (Basophil)   48.3       lynphocyte act       rest       CD4 lymphocyte   0.0   KU-812 (Basophil)   100.0       none       PMA/ionomycin       2ry Th1/Th2/   0.0   CCD1106   0.0       Tr1_anti-       (Keratinocytes)       CD95 CH11       none       LAK cells rest   0.0   CCD1106   0.0               (Keratinocytes)               TNFalpha + IL-1beta       LAK cells IL-2   0.0   Liver cirrhosis   0.0       LAK cells IL-2 +   0.0   NCI-H292 none   0.0       IL-12       LAK cells IL-2 +   0.0   NCI-H292 IL-4   0.0       IFN gamma       LAK cells IL-2 +   0.0   NCI-H292 IL-9   0.0       IL-18       LAK cells   0.0   NCI-H292 IL-13   0.0       PMA/ionomycin       NK Cells IL-2 rest   0.0   NCI-H292 IFN gamma   0.0       Two Way MLR   0.0   HPAEC none   0.0       3 day       Two Way MLR   0.0   HPAEC TNF alpha +   0.0       5 day       IL-1beta       Two Way MLR   0.0   Lung fibroblast none   0.0       7 day       PBMC rest   0.0   Lung fibroblast   0.0               TNF alpha +               IL-1beta       PBMC PWM   0.0   Lung fibroblast IL-4   0.0       PBMC PHA-L   0.0   Lung fibroblast IL-9   0.0       Ramos (B cell) none   0.0   Lung fibroblast IL-13   0.0       Ramos (B cell)   0.0   Lung fibroblast IFN   0.0       ionomycin       gamma       B lymphocytes   0.0   Dermal fibroblast   0.0       PMW       CCD1070 rest       B lymphocytes   0.0   Dermal fibroblast   0.0       CD40L and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   0.0               CCD1070 IL-1beta       EOL-1 dbcAMP   0.0   Dermal fibroblast IFN   0.0       PMA/ionomycin       gamma       Dendritic cells none   0.0   Dermal fibroblast IL-4   0.0       Dendritic cells LPS   0.0   Dermal Fibroblasts   0.0               rest       Dendritic cells anti-   0.0   Neutrophils TNFa +   0.0       CD40       LPS       Monocytes rest   0.0   Neutrophils rest   0.0       Monocytes LPS   0.0   Colon   0.0       Macrophages rest   0.0   Lung   0.0       Macrophages LPS   0.0   Thymus   0.0       HUVEC none   0.0   Kidney   0.0       HUVEC starved   0.0                    
     [2280] CNS_neurodegeneration — 1.0 Summary: Ag3644 Expression of the CG59991-01 gene is low/undetectable in all samples on this panel (CTs&gt;35). (Data not shown).  
     [2281] General_screening_panel_v1.4 Summary: Ag3644 Expression of the CG59991-01 gene is restricted to a sample derived from a lung cancer cell line (CT=27.2). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of lung cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung cancer.  
     [2282] Panel 4.1D Summary: Ag3644 Expression of the CG59991-01 gene is restricted to samples derived from the basophil cell line KU-812 (CTs=32). Thus, expression of this gene could be used as a marker of this cell type. Basophils release histamines and other biological modifiers in repose to allergens and play an important role in the pathology of asthma and hypersensitivity reactions. Therefore, the specific pattern of expression of this gene suggests that therapeutic modulation of the expression or function of the protein encoded by this gene may block or inhibit inflammation or tissue damage due to basophil activation in response to asthma, allergies, hypersensitivity reactions, psoriasis, and viral infections.  
     [2283] DM. CG59987-01 and CG59987-02: Rhophilin  
     [2284] Expression of gene CG59987-01 and full length clone CG59987-02 was assessed using the primer-probe set Ag3643, described in Table DMA. Results of the RTQ-PCR runs are shown in Tables DMB and DMC. Please note that CG59987-02 represents a full-length physical clone of the CG59987-01 gene, validating the prediction of the gene sequence.  
     [2285] Table DMA. Probe Name Ag3643 
               TABLE DMA                          Probe Name Ag3643                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′-tactttcggaagggctgtaatc-3′   22   103   752               Probe   TET-5′-cttgcacaaaccggccggagtaaatt-3′-TAMRA   26   127   753               Reverse   5′-tgattcaaagcagctctttgat-3′   22   158   754                  
 
     [2286]               TABLE DMB                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp.       Exp.           (%)       (%)           Ag3643,       Ag3643,           Run       Run       Tissue Name   218306426   Tissue Name   218306426                                     Adipose   1.4   Renal ca. TK-10   17.2       Melanoma*   0.5   Bladder   9.1       Hs688(A).T       Melanoma*   0.6   Gastric ca. (liver met.)   46.7       Hs688(B).T       NCI-N87       Melanoma* M14   6.3   Gastric ca. KATO III   39.2       Melanoma*   1.7   Colon ca. SW-948   16.6       LOXIMVI       Melanoma* SK-   8.7   Colon ca. SW480   7.0       MEL-5       Squamous cell   5.4   Colon ca.* (SW480   0.4       carcinoma SCC-4       met) SW620       Testis Pool   0.5   Colon ca. HT29   24.8       Prostate ca.* (bone   7.7   Colon ca. HCT-116   26.8       met) PC-3       Prostate Pool   6.6   Colon ca. CaCo-2   34.2       Placenta   3.3   Colon cancer tissue   13.0       Uterus Pool   0.4   Colon ca. SW1116   4.5       Ovarian ca.   44.1   Colon ca. Colo-205   5.5       OVCAR-3       Ovarian ca.   36.9   Colon ca. SW-48   6.5       SK-OV-3       Ovarian ca.   58.6   Colon Pool   0.9       OVCAR-4       Ovarian ca.   50.7   Small Intestine Pool   1.9       OVCAR-5       Ovarian ca.   20.3   Stomach Pool   2.3       IGROV-1       Ovarian ca.   7.9   Bone Marrow Pool   0.3       OVCAR-8       Ovary   1.6   Fetal Heart   0.7       Breast ca. MCF-7   17.4   Heart Pool   0.4       Breast ca. MDA-   13.7   Lymph Node Pool   1.0       MB-231       Breast ca. BT 549   8.2   Fetal Skeletal Muscle   0.1       Breast ca. T47D   100.0   Skeletal Muscle Pool   0.2       Breast ca. MDA-N   4.7   Spleen Pool   0.2       Breast Pool   1.9   Thymus Pool   1.5       Trachea   8.4   CNS cancer   1.0               (glio/astro)               U87-MG       Lung   0.3   CNS cancer   1.3               (glio/astro)               U-118-MG       Fetal Lung   6.9   CNS cancer   5.2               (neuro; met)               SK-N-AS       Lung ca. NCI-N417   0.9   CNS cancer   2.5               (astro)               SF-539       Lung ca. LX-1   0.2   CNS cancer (astro)   6.0               SNB-75       Lung ca. NCI-H146   1.9   CNS cancer (glio)   21.6               SNB-19       Lung ca. SHP-77   0.0   CNS cancer (glio)   14.7               SF-295       Lung ca. A549   54.3   Brain (Amygdala)   1.0               Pool       Lung ca. NCI-H526   3.7   Brain (cerebellum)   5.2       Lung ca. NCI-H23   3.2   Brain (fetal)   0.7       Lung ca. NCI-H460   1.2   Brain (Hippocampus)   1.9               Pool       Lung ca. HOP-62   6.5   Cerebral Cortex Pool   2.3       Lung ca. NCI-H522   3.7   Brain   2.1               ( Substantia nigra )               Pool       Liver   1.5   Brain (Thalamus) Pool   2.7       Fetal Liver   5.6   Brain (whole)   3.5       Liver ca. HepG2   7.0   Spinal Cord Pool   3.6       Kidney Pool   1.4   Adrenal Gland   0.2       Fetal Kidney   3.4   Pituitary gland Pool   1.3       Renal ca. 786-0   12.2   Salivary Gland   6.7       Renal ca. A498   8.8   Thyroid (female)   1.2       Renal ca. ACHN   9.1   Pancreatic ca.   21.3               CAPAN2       Renal ca. UO-31   9.9   Pancreas Pool   12.2                    
     [2287]               TABLE CMD                          Panel 4.1D                                 Rel.       Rel.           Exp.       Exp.           (%)       (%)           Ag3643,       Ag3643,           Run       Run       Tissue Name   169975145   Tissue Name   169975145                                     Secondary Th1 act   3.8   HUVEC IL-1beta   6.9       Secondary Th2 act   1.1   HUVEC IFN gamma   4.4       Secondary Tr1 act   0.9   HUVEC TNF alpha +   2.6               IFN gamma       Secondary Th1 rest   0.5   HUVEC TNF alpha +   4.0               IL4       Secondary Th2 rest   0.9   HUVEC IL-11   2.5       Secondary Tr1 rest   0.6   Lung Microvascular   4.3               EC none       Primary Th1 act   1.8   Lung Microvascular   1.5               EC TNFalpha +               IL-1beta       Primary Th2 act   5.0   Microvascular Dermal   6.7               EC none       Primary Tr1 act   3.4   Microvascular Dermal   7.7               EC TNFalpha +               IL-1beta       Primary Th1 rest   1.0   Bronchial epithelium   17.7               TNFalpha + IL1beta       Primary Th2 rest   0.8   Small airway   13.7               epithelium none       Primary Tr1 rest   0.9   Small airway   23.3               epithelium               TNFalpha + IL-beta       CD45RA CD4   3.5   Coronery artery   6.7       lymphocyte act       SMC rest       CD45RO CD4   3.0   Coronery artery   4.3       lymphocyte act       SMC TNFalpha +               IL-1beta       CD8 lymphocyte act   6.2   Astrocytes rest   35.4       Secondary CD8   3.4   Astrocytes   24.3       lymphocyte rest       TNFalpha +               IL-1beta       Secondary CD8   0.0   KU-812 (Basophil)   0.5       lynphocyte act       rest       CD4 lymphocyte   0.0   KU-812 (Basophil)   2.3       none       PMA/ionomycin       2ry Th1/Th2/   0.0   CCD1106   39.8       Tr1_anti-       (Keratinocytes)       CD95 CH11       none       LAK cells rest   0.7   CCD1106   32.5               (Keratinocytes)               TNFalpha + IL-1beta       LAK cells IL-2   0.4   Liver cirrhosis   41.2       LAK cells IL-2 +   1.3   NCI-H292 none   49.3       IL-12       LAK cells IL-2 +   2.2   NCI-H292 IL-4   45.1       IFN gamma       LAK cells IL-2 +   2.0   NCI-H292 IL-9   100.0       IL-18       LAK cells   1.7   NCI-H292 IL-13   51.8       PMA/ionomycin       NK Cells IL-2 rest   0.5   NCI-H292 IFN gamma   53.6       Two Way MLR   0.4   HPAEC none   8.0       3 day       Two Way MLR   0.8   HPAEC TNF alpha +   6.1       5 day       IL-1beta       Two Way MLR   1.5   Long fibroblast none   13.3       7 day       PBMC rest   0.6   Lung fibroblast   7.1               TNF alpha +               IL-1beta       PBMC PWM   4.3   Lung fibroblast IL-4   3.6       PBMC PHA-L   3.6   Lung fibroblast IL-9   8.5       Ramos (B cell) none   14.8   Lung fibroblast IL-13   3.3       Ramos (B cell)   15.7   Lung fibroblast IFN   10.5       ionomycin       gamma       B lymphocytes   6.3   Dermal fibroblast   5.1       PMW       CCD1070 rest       B lymphocytes   6.5   Dermal fibroblast   5.6       CD40L and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   0.0   Dermal fibroblast   7.7               CCD1070 IL-1beta       EOL-1 dbcAMP   0.0   Dermal fibroblast IFN   5.5       PMA/ionomycin       gamma       Dendritic cells none   0.5   Dermal fibroblast IL-4   3.7       Dendritic cells LPS   0.0   Dermal Fibroblasts   1.5               rest       Dendritic cells anti-   41.8   Neutrophils TNFa +   0.0       CD40       LPS       Monocytes rest   100.0   Neutrophils rest   0.0       Monocytes LPS   77.4   Colon   34.6       Macrophages rest   62.4   Lung   4.3       Macrophages LPS   15.9   Thymus   9.9       HUVEC none   20.0   Kidney   51.4       HUVEC starved   30.6                    
     [2288] CNS_neurodegeneration_v1.0 Summary: Ag3643 Results from one experiment with the CG59987-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [2289] General_screening_panel_v1.4 Summary: Ag3643 Expression of the CG59987-01 gene is highest in a breast cancer cell line (CT=25.3). In addition, significant levels of expression are seen in clusters of cell lines derived from brain, gastric, colon, lung, and ovarian cancers. In addition, expression overall appears to be higher in samples derived from cancer cell lines than in normal tissues. Thus, expression of this gene could be used as a marker to detect the presence of cancer. This gene encodes a homolog of rhophilin, a rho GTPase that is involved in a signaling pathway that regulates cell adhesion, among other functions. Therefore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.  
     [2290] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, skeletal muscle, and adult and fetal heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [2291] This gene is also expressed at moderate to low levels in the CNS and may be a small molecule target for the treatment of neurologic diseases.  
     [2292] Panel 4.1D Summary: Ag3643 Expression of the CG59987-01 gene is highest in NCI-H292 cells stimulated by IL-9(CT=29.2). The gene is also expressed in a cluster of treated and untreated NCI-H292 mucoepidermoid cell line samples. The transcript is also expressed at lower but still significant levels in both small airway and bronchial epithelium treated with IL-1 beta and TNF-alpha. In comparison, expression in the normal lung is relatively low. The expression of the transcript in activated normal epithelium as well as a cell line that is often used as a model for airway epithelium (NCI-H292 cells) suggests that this transcript may be important in the proliferation or activation of airway epithelium. Therefore, therapuetics designed with the protein encoded by this transcript could be important in the treatment of diseases which include lung airway inflammation such as asthma and COPD.  
     [2293] DN. CG59971-01 and CG59971-02: Leucine Rich Repeat Protein  
     [2294] Expression of gene CG59971-01 and variant CG59971-02 was assessed using the primer-probe set Ag3639, described in Table DNA. Results of the RTQ-PCR runs are shown in Tables DNB and DNC.  
               TABLE DNA                          Probe Name Ag3639                                             Start   SEQ ID       Primers   Sequences   Length   Position   NO:                                         Forward   5′ttctgaacttcagctacaat-3′   22   510   755               Probe   TET-5′-cttagacagctccctgcgcctcttgt-3′-TAMRA   26   543   756               Reverse   5′-acttgattgtggcttaggttca-3′   22   584   757                  
 
     [2295]               TABLE DNB                          General_screening_panel_v1.4                                 Rel.       Rel.           Exp.       Exp.           (%)       (%)           Ag3639,       Ag3639,           Run       Run       Tissue Name   218234144   Tissue Name   218234144                                     Adipose   3.2   Renal ca. TK-10   24.0       Melanoma*   17.9   Bladder   11.8       Hs688(A).T       Melanoma*   12.6   Gastric ca. (liver met.)   35.6       Hs688(B).T       NCI-N87       Melanoma* M14   64.6   Gastric ca. KATO III   35.8       Melanoma*   15.5   Colon ca. SW-948   8.0       LOXIMVI       Melanoma* SK-   25.2   Colon ca. SW480   55.5       MEL-5       Squamous cell   10.5   Colon ca.* (SW480   32.8       carcinoma SCC-4       met) SW620       Testis Pool   8.9   Colon ca. HT29   13.7       Prostate ca.* (bone   19.3   Colon ca. HCT-116   34.9       met) PC-3       Prostate Pool   3.2   Colon ca. CaCo-2   15.4       Placenta   16.3   Colon cancer tissue   14.3       Uterus Pool   1.0   Colon ca. SW1116   7.9       Ovarian ca.   19.9   Colon ca. Colo-205   13.3       OVCAR-3       Ovarian ca.   30.1   Colon ca. SW-48   8.8       SK-OV-3       Ovarian ca.   14.8   Colon Pool   8.2       OVCAR-4       Ovarian ca.   60.7   Small Intestine Pool   7.7       OVCAR-5       Ovarian ca.   15.1   Stomach Pool   3.9       IGROV-1       Ovarian ca.   9.5   Bone Marrow Pool   2.7       OVCAR-8       Ovary   12.6   Fetal Heart   7.2       Breast ca. MCF-7   54.0   Heart Pool   3.7       Breast ca. MDA-   31.2   Lymph Node Pool   10.4       MB-231       Breast ca. BT 549   27.2   Fetal Skeletal Muscle   4.0       Breast ca. T47D   100.0   Skeletal Muscle Pool   3.6       Breast ca. MDA-N   20.4   Spleen Pool   8.4       Breast Pool   8.9   Thymus Pool   15.3       Trachea   10.3   CNS cancer   37.9               (glio/astro)               U87-MG       Lung   1.1   CNS cancer   26.2               (glio/astro)               U-118-MG       Fetal Lung   21.9   CNS cancer   22.4               (neuro; met)               SK-N-AS       Lung ca. NCI-N417   4.5   CNS cancer   15.7               (astro)               SF-539       Lung ca. LX-1   32.8   CNS cancer (astro)   46.7               SNB-75       Lung ca. NCI-H146   7.7   CNS cancer (glio)   12.2               SNB-19       Lung ca. SHP-77   33.2   CNS cancer (glio)   31.4               SF-295       Lung ca. A549   30.83   Brain (Amygdala)   7.9               Pool       Lung ca. NCI-H526   8.7   Brain (cerebellum)   27.4       Lung ca. NCI-H23   23.2   Brain (fetal)   24.3       Lung ca. NCI-H460   18.0   Brain (Hippocampus)   6.8               Pool       Lung ca. HOP-62   9.2   Cerebral Cortex Pool   8.0       Lung ca. NCI-H522   22.5   Brain   8.3               ( Substantia nigra )               Pool       Liver   0.8   Brain (Thalamus) Pool   10.7       Fetal Liver   8.8   Brain (whole)   13.8       Liver ca. HepG2   19.3   Spinal Cord Pool   7.6       Kidney Pool   12.9   Adrenal Gland   14.1       Fetal Kidney   8.4   Pituitary gland Pool   6.6       Renal ca. 786-0   20.0   Salivary Gland   3.0       Renal ca. A498   5.2   Thyroid (female)   4.9       Renal ca. ACHN   34.4   Pancreatic ca.   20.9               CAPAN2       Renal ca. UO-31   15.5   Pancreas Pool   10.7                    
     [2296]               TABLE DNC                          Panel 4.1D                                 Rel.       Rel.           Exp.       Exp.           (%)       (%)           Ag3639,       Ag3639,           Run       Run       Tissue Name   169975065   Tissue Name   169975065                                     Secondary Th1 act   51.8   HUVEC IL-beta   27.0       Secondary Th2 act   68.8   HUVEC IFN gamma   31.2       Secondary Tr1 act   74.7   HUVEC TNF alpha +   28.9               IFN gamma       Secondary Th1 rest   26.4   HUVEC TNF alpha +   26.4               IL4       Secondary Th2 rest   41.5   HUVEC IL-11   22.4       Secondary Tr1 rest   24.1   Lung Microvascular   55.5               EC none       Primary Th1 act   50.3   Lung Microvascular   36.1               EC TNFalpha +               IL-1beta       Primary Th2 act   75.8   Microvascular Dermal   23.5               EC none       Primary Tr1 act   66.4   Microvascular Dermal   33.0               EC TNFalpha +               IL-1beta       Primary Th1 rest   19.8   Bronchial epithelium   22.8               TNFalpha + IL1beta       Primary Th2 rest   33.9   Small airway   23.2               epithelium none       Primary Tr1 rest   64.2   Small airway   37.1               epithelium               TNFalpha + IL-beta       CD45RA CD4   35.4   Coronery artery   21.2       lymphocyte act       SMC rest       CD45RO CD4   59.5   Coronery artery   13.4       lymphocyte act       SMC TNFalpha +               IL-1beta       CD8 lymphocyte act   64.6   Astrocytes rest   23.3       Secondary CD8   36.1   Astrocytes   25.2       lymphocyte rest       TNFalpha +               IL-1beta       Secondary CD8   45.1   KU-812 (Basophil)   22.4       lynphocyte act       rest       CD4 lymphocyte   20.0   KU-812 (Basophil)   32.8       none       PMA/ionomycin       2ry Th1/Th2/   44.1   CCD1106   61.6       Tr1_anti-       (Keratinocytes)       CD95 CH11       none       LAK cells rest   53.2   CCD1106   49.0               (Keratinocytes)               TNFalpha + IL-1beta       LAK cells IL-2   57.4   Liver cirrhosis   8.1       LAK cells IL-2 +   54.0   NCI-H292 none   46.7       IL-12       LAK cells IL-2 +   59.0   NCI-H292 IL-4   45.1       IFN gamma       LAK cells IL-2 +   61.6   NCI-H292 IL-9   58.6       IL-18       LAK cells   39.0   NCI-H292 IL-13   35.6       PMA/ionomycin       NK Cells IL-2 rest   60.7   NCI-H292 IFN gamma   28.9       Two Way MLR   55.1   HPAEC none   18.3       3 day       Two Way MLR   36.6   HPAEC TNF alpha +   44.8       5 day       IL-1beta       Two Way MLR   36.6   Lung fibroblast none   28.3       7 day       PBMC rest   22.2   Lung fibroblast   20.2               TNF alpha +               IL-1beta       PBMC PWM   62.4   Lung fibroblast IL-4   29.1       PBMC PHA-L   42.9   Lung fibroblast IL-9   50.7       Ramos (B cell) none   43.5   Lung fibroblast IL-13   40.3       Ramos (B cell)   46.3   Lung fibroblast IFN   37.4       ionomycin       gamma       B lymphocytes   40.9   Dermal fibroblast   60.3       PMW       CCD1070 rest       B lymphocytes   78.5   Dermal fibroblast   92.7       CD40L and IL-4       CCD1070 TNF alpha       EOL-1 dbcAMP   34.2   Dermal fibroblast   22.7               CCD1070 IL-1beta       EOL-1 dbcAMP   62.0   Dermal fibroblast IFN   24.0       PMA/ionomycin       gamma       Dendritic cells none   65.1   Dermal fibroblast IL-4   35.6       Dendritic cells LPS   25.3   Dermal Fibroblasts   21.8               rest       Dendritic cells anti-   41.8   Neutrophils TNFa +   1.7       CD40       LPS       Monocytes rest   100.0   Neutrophils rest   18.3       Monocytes LPS   77.4   Colon   11.2       Macrophages rest   62.4   Lung   17.7       Macrophages LPS   15.9   Thymus   81.8       HUVEC none   20.0   Kidney   18.6       HUVEC starved   30.6                    
     [2297] CNS_neurodegeneration_v1.0 Summary: Ag3639 Results from one experiment with the CG59971-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.  
     [2298] General_screening_panel_v1.4 Summary: Ag3639 Expression of the CG59971-02 gene is ubiquitous in this panel, with highest expression in a breast cancer cell line (CT=26.6). Overall, expression of this gene appears to be higher in samples derived from cancer cell lines than in normal tissues. This widespread expression suggests that this gene product is involved in cell growth and prolideration. Thus, expression of this gene could be used as a marker to detect the presence of cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of cancer.  
     [2299] In addition, this gene is expressed at much higher levels in fetal lung and liver (CTs=29-30) when compared to expression in the adult counterpart (CTs=33). Thus, expression of this gene may be used to differentiate between the fetal and adult sources of these tissue.  
     [2300] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.  
     [2301] This gene is also highly expressed in the brain, with highest expression in the cerebellum (CT=28.5), with moderate expression in other CNS regions as well including, amygdala, hippocampus, cerebral cortex, substantia nigra and thalamus. This gene encodes a leucine-rich repeat protein. Leucine rich repeats (LRR) mediate reversible protein-protein interactions and have diverse cellular functions, including cellular adhesion and signaling. Several of these proteins, such as connectin, slit, chaoptin, and Toll have pivotal roles in neuronal development in Drosophila and may play significant but distinct roles in neural development and in the adult nervous system of humans (Ref. 1). In Drosophilia, the LRR region of axon guidance proteins has been shown to be critical for their function (especially in axon this gene shows high expression in the brain, it is an excellent candidate neuronal guidance protein for axons, dendrites and/or growth cones in general. Therefore, therapeutic modulation of the levels of this protein, or possible signaling via this protein, may be of utility in enhancing/directing compensatory synaptogenesis and fiber growth in the CNS in response to neuronal death (stroke, head trauma), axon lesion (spinal cord injury), or neurodegeneration (Alzheimer&#39;s, Parkinson&#39;s, Huntington&#39;s, vascular dementia or any neurodegenerative disease).  
     REFERENCES  
     [2302] 1. Battye R., Stevens A., Perry R. L., Jacobs J. R. (2001) Repellent signaling by Slit requires the leucine-rich repeats. J. Neurosci. 21: 4290-4298.  
     [2303] Panel 4.1D Summary: Ag3639 The CG59971-01 gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. Highest expression of the gene is seen in resting monocytes (CT=28.6). Significant levels of expression are also seen in members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     Example D  
     Identification of Single Nucleotide Polymorphisms in NOVX Nucleic Acid Sequences  
     [2304] Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a “cSNP” to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.  
     [2305] SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for similarity to the known DNA and protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.  
     [2306] Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fragment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation&#39;s human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraTools™ program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.  
     [2307] The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein. When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence (Alderborn et al., Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. Genome Research. 10 (8) 1249-1265, 2000).  
     [2308] Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.  
     [2309] NOV5a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:13 and 14, respectively. The nucleotide sequence of the NOV5a variant differs as shown in Table SNP1.  
               TABLE SNP1                          NOV5a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13376274   143   A   T   47   Gln   Leu                  
 
     [2310] NOV9a has eight SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:21 and 22, respectively. The nucleotide sequence of the NOV9a variant differs as shown in Table SNP2.  
               TABLE SNP2                          NOV9a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13376043   230   G   T   72   Glu   End               13376044   341   G   A   109   Gly   Arg               13376045   441   A   C   142   Gln   Pro               13376046   532   C   T   172   His   His               13376050   1680   T   C   555   Leu   Ser               13376O49   1762   G   T   582   Leu   Phe               13376048   1818   C   T   601   Ser   Leu               13376047   1900   A   G   628   Thr   Thr                  
 
     [2311] NOV14a has five SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:43 and 44, respectively. The nucleotide sequence of the NOV14a variant differs as shown in Table SNP3.  
               TABLE SNP3                          NOV14a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13376438   1307   T   C   431   Val   Ala               13376437   1571   A   G   519   His   Arg               13376436   1625   T   C   537   Val   Ala               13376435   1646   T   C   544   Val   Ala               13376434   1667   T   C   551   Ile   Thr                  
 
     [2312] NOV15a has twelve SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:53 and 54, respectively. The nucleotide sequence of the NOV14a variant differs as shown in Table SNP4.  
               TABLE SNP4                          NOV15a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13376083   154   A   G   45   Pro   Pro               13376082   194   T   C   59   Ser   Pro               13376081   253   G   A   78   Arg   Arg               13376080   280   G   A   87   Gln   Gln               13376079   327   C   T   103   Ala   Val               13376078   338   C   T   107   Pro   Ser               13376077   366   T   C   116   Ile   Thr               13376076   502   A   G   161   Lys   Lys               13376069   1069   A   G   350   Pro   Pro               13376072   1137   A   G   373   Glu   Gly               13376071   1264   T   C   415   Leu   Leu               13376070   1367   T   C   450   Ser   Pro                  
 
     [2313] NOV17a has four SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:61 and 62, respectively. The nucleotide sequence of the NOV17a variant differs as shown in Table SNP5.  
               TABLE SNP5                          NOV17a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13377433   175   T   C   55   His   His               13377432   223   C   G   71   Pro   Pro               13377431   538   G   A   176   Thr   Thr               13377430   680   T   C   224   Phe   Leu                  
 
     [2314] NOV19a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:71 and 72, respectively. The nucleotide sequence of the NOV19a variant differs as shown in Table SNP6.  
               TABLE SNP6                          NOV19a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13377434   1777   T   A   586   Thr   Thr                  
 
     [2315] NOV21a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:75 and 76, respectively. The nucleotide sequence of the NOV21a variant differs as shown in Table SNP7.  
               TABLE SNP7                          NOV21a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13377435   7503   T   A   2482   Ala   Ala                  
 
     [2316] NOV38a has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:123 and 124, respectively. The nucleotide sequence of the NOV38a variant differs as shown in Table SNP8.  
                   TABLE SNP8                          NOV38a variants.                                     Nucleotides   Amino Acids                                                 Variant   Position   Initial   Modified   Position   Initial   Modified                                                     13377439   801   G   A   232   Ser   Ser                   13377441   1595   C   G   497   Pro   Arg                  
 
     [2317] NOV39a has three SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:125 and 126, respectively. The nucleotide sequence of the NOV39a variant differs as shown in Table SNP9.  
               TABLE SNP9                          NOV39a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13375670   183   C   G   57   His   Gln               13375669   187   C   T   59   Leu   Phe               13377389   1385   A   G   458   His   Arg                  
 
     [2318] NOV46a has four SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:143 and 144, respectively. The nucleotide sequence of the NOV46a variant differs as shown in Table SNP10.  
               TABLE SNP10                          NOV46a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13377442   177   T   C   27   Val   Ala               13377443   590   A   G   165   Thr   Ala               13377444   799   A   G   234   Gln   Gln               13377445   977   T   C   294   Tyr   His                  
 
     [2319] NOV49a has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:151 and 152, respectively. The nucleotide sequence of the NOV49a variant differs as shown in Table SNP11.  
               TABLE SNP11                          NOV49a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13377450   119   A   G   7   Arg   Gly               13377448   1556   G   A   486   Ala   Thr                  
 
     [2320] NOV50a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:153 and 154, respectively. The nucleotide sequence of the NOV50a variant differs as shown in Table SNP 12.  
               TABLE SNP12                          NOV50a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13377451   2371   G   A   791   Ala   Thr                  
 
     [2321] NOV51a has five SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:155 and 156, respectively. The nucleotide sequence of the NOV51a variant differs as shown in Table SNP13.  
               TABLE SNP13                          NOV51a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13374492   765   G   A   243   Ala   Thr               13374491   924   T   C   296   Phe   Leu               13377453   1028   C   T   330   Pro   Pro               13377454   1052   A   C   338   Ala   Ala               13377455   1205   C   T   389   His   His                  
 
     [2322] NOV52a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:157 and 158, respectively. The nucleotide sequence of the NOV52a variant differs as shown in Table SNP14.  
               TABLE SNP14                          NOV52a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13377458   221   C   T   37   Arg   Trp                  
 
     [2323] NOV55a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:163 and 164, respectively. The nucleotide sequence of the NOV55a variant differs as shown in Table SNP15.  
               TABLE SNP15                          NOV55a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13377462   514   C   T   165   Arg   Trp               13377461   993   T   C   324   Ser   Ser                  
 
     [2324] NOV60a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:183 and 184, respectively. The nucleotide sequence of the NOV55a variant differs as shown in Table SNP16.  
               TABLE SNP16                          NOV60a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13377463   453   T   C   111   Gly   Gly                  
 
     [2325] NOV65a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:195 and 196, respectively. The nucleotide sequence of the NOV65a variant differs as shown in Table SNP17.  
               TABLE SNP17                          NOV65a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13377464   75   C   A   25   Gln   Lys                  
 
     [2326] NOV68a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:201 and 202, respectively. The nucleotide sequence of the NOV68a variant differs as shown in Table SNP 18.  
               TABLE SNP18                          NOV68a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13377465   438   C   G   145   Gly   Gly                  
 
     [2327] NOV72a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:209 and 210, respectively. The nucleotide sequence of the NOV72a variant differs as shown in Table SNP19.  
               TABLE SNP19                          NOV72a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13377466   839   C   T   271   Pro   Ser                  
 
     [2328] NOV80a has four SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:225 and 226, respectively. The nucleotide sequence of the NOV80a variant differs as shown in Table SNP20.  
               TABLE SNP20                          NOV80a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13377471   166   G   T   46   Ala   Ser               13377470   482   C   T   151   Ala   Val               13377469   685   A   G   219   Thr   Ala               13377468   1410   G   C   460   Glu   Asp                  
 
     [2329] NOV81a has four SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:229 and 230, respectively. The nucleotide sequence of the NOV81a variant differs as shown in Table SNP21.  
               TABLE SNP21                          NOV81a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13377472   285   C   T   91   His   Tyr               13377473   553   A   G   180   His   Arg               13377474   554   C   T   180   His   His               13377475   2581   A   G   856   Gln   Arg                  
 
     [2330] NOV89a has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:249 and 250, respectively. The nucleotide sequence of the NOV89a variant differs as shown in Table SNP22.  
               TABLE SNP22                          NOV89a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13377477   425   A   G   119   Met   Val               13377478   1162   C   A   364   Val   Val                  
 
     [2331] NOV94a has one SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:269 and 270, respectively. The nucleotide sequence of the NOV94a variant differs as shown in Table SNP23.  
               TABLE SNP23                          NOV94a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied               13377479   1005   T   C   303   Asp   Asp                  
 
     [2332] NOV96a has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:273 and 274, respectively. The nucleotide sequence of the NOV96a variant differs as shown in Table SNP24.  
               TABLE SNP24                          NOV96a variants.                                 Nucleotides       Amino Acids                                             Posi-       Modi-   Posi-       Modi-       Variant   tion   Initial   fied   tion   Initial   fied                                                 13377480   150   A   G   45   Lys   Arg               13377482   2221   A   G   735   Ser   Ser                  
 
     [2333] NOV99a has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:283 and 284, respectively. The nucleotide sequence of the NOV99a variant differs as shown in Table SNP25.  
                   TABLE SNP25                          NOV99a variants.                                     Nucleotides   Amino Acids                                                     Posi-       Modi-   Posi-       Modi-               Variant   tion   Initial   fied   tion   Initial   fied                                                     13377485   274   T   C   78   Thr   Thr                  
 
     [2334] NOV105a has three SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:299 and 300, respectively. The nucleotide sequence of the NOV105a variant differs as shown in Table SNP26.  
                   TABLE SNP26                          NOV105a variants.                                     Nucleotides   Amino Acids                                                     Posi-       Modi-   Posi-       Modi-           Variant   tion   Initial   fied   tion   Initial   fied               13377488   453   C   T   145   Ile   Ile                   13377487   828   T   G   270   Thr   Thr               13377486   924   A   G   302   Thr   Thr                  
 
     [2335] NOV113a has three SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:315 and 316, respectively. The nucleotide sequence of the NOV113a variant differs as shown in Table SNP27.  
                   TABLE SNP27                          NOV113a variants.                             Nucleotides   Amino Acids                                                     Posi-       Modi-   Posi-       Modi-           Variant   tion   Initial   fied   tion   Initial   fied               13377490    340   G   A   100   Ala   Thr                   13377491    659   C   T   206   Pro   Leu               13377492    726   C   T   228   Arg   Arg               13377493    915   T   C   291   Ala   Ala               13377494   1058   T   C   339   Ile   Thr               13377495   1088   T   C   349   Leu   Pro                  
 
     [2336] NOV114a has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:319 and 320, respectively. The nucleotide sequence of the NOV114a variant differs as shown in Table SNP28.  
                   TABLE SNP28                          NOV114a variants.                                     Nucleotides   Amino Acids                                                     Posi-       Modi-   Posi-       Modi-           Variant   tion   Initial   fied   tion   Initial   fied               13375633   185   T   C    54   Val   Ala                   13375632   689   A   G   222   Gln Arg                  
 
     [2337] NOV116a has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:325 and 326, respectively. The nucleotide sequence of the NOV116a variant differs as shown in Table SNP29.  
                   TABLE SNP29                          NOV116a variants.                             Nucleotides   Amino Acids                                                     Posi-       Modi-   Posi-       Modi-           Variant   tion   Initial   fied   tion   Initial   fied               13374815   203   A   G    63   Thr   Ala                   13374814   384   T   C   123   Leu   Pro                  
 
     [2338] NOV117a has three SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:329 and 330, respectively. The nucleotide sequence of the NOV117a variant differs as shown in Table SNP30.  
                   TABLE SNP30                          NOV117a variants.                                     Nucleotides   Amino Acids                                                     Posi-       Modi-   Posi-       Modi-           Variant   tion   Initial   fied   tion   Initial   fied               13377507    453   A   G   149   Pro   Pro                   13377506    755   A   T   250   Glu   Val               13377505   1128   G   A   374   Lys   Lys                  
 
     [2339] NOV124a has six SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:343 and 344, respectively. The nucleotide sequence of the NOV124a variant differs as shown in Table SNP31.  
               TABLE SNIP31                          NOV124a variants.                                 Nucleotides   Amino Acids                                                     Posi-       Modi-   Posi-       Modi-           Variant   tion   Initial   fied   tion   Initial   fied               13377511    186   C   T    39   Ser   Ser                   13377512    372   C   T   101   Gly   Gly               13377513    970   G   T   301   Asp   Tyr               13377514   1051   G   A   328   Val   Met               13377515   1266   C   T   399   Ile   Ile               13377516   1304   A   G   412   Asp   Gly                  
 
     [2340] NOV126a has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:349 and 350, respectively. The nucleotide sequence of the NOV126a variant differs as shown in Table SNP32.  
                   TABLE SNP32                          NOV126a variants.                                     Nucleotides   Amino Acids                                                     Posi-       Modi-   Posi-       Modi-           Variant   tion   Initial   fied   tion   Initial   fied               13377517   747   T   C   234   Cys   Cys                  
 
     Other Embodiments  
     [2341] Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. Applicants reserve the right to pursue such inventions in later claims.